<SEC-DOCUMENT>0001657312-21-000004.txt : 20210225
<SEC-HEADER>0001657312-21-000004.hdr.sgml : 20210225
<ACCEPTANCE-DATETIME>20210225082946
ACCESSION NUMBER:		0001657312-21-000004
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		89
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210225
DATE AS OF CHANGE:		20210225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Verona Pharma plc
		CENTRAL INDEX KEY:			0001657312
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38067
		FILM NUMBER:		21676570

	BUSINESS ADDRESS:	
		STREET 1:		3 MORE LONDON RIVERSIDE
		CITY:			LONDON
		STATE:			X0
		ZIP:			SE1 2RE
		BUSINESS PHONE:		011-44-0-2032834200

	MAIL ADDRESS:	
		STREET 1:		3 MORE LONDON RIVERSIDE
		CITY:			LONDON
		STATE:			X0
		ZIP:			SE1 2RE
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>vrna-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:0ccc0c69-9480-4ff0-8704-1a461378680d,g:39118e12-eba9-4fb3-8b93-ef28b95cf059,d:d4dd95a68a65415aa5f2e21bd87d1189--><html xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vrna="http://veronapharma.com/20201231" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vrna-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MzkvZnJhZzo4ODA3ZThjZDlmZTI0N2Y4OWQ2OTIzY2ZlZWVlNTNiOS90YWJsZTpmMDAwZmNiYjFiNWM0ZWExODU4N2VlODM2ODIzYTRmNy90YWJsZXJhbmdlOmYwMDBmY2JiMWI1YzRlYTE4NTg3ZWU4MzY4MjNhNGY3XzMtMS0xLTEtMTQxNzc_09fa92c4-f4f4-4328-94d6-6353d565356b">false</ix:nonNumeric><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MzkvZnJhZzo4ODA3ZThjZDlmZTI0N2Y4OWQ2OTIzY2ZlZWVlNTNiOS90YWJsZTpmMDAwZmNiYjFiNWM0ZWExODU4N2VlODM2ODIzYTRmNy90YWJsZXJhbmdlOmYwMDBmY2JiMWI1YzRlYTE4NTg3ZWU4MzY4MjNhNGY3XzQtMS0xLTEtMTQxNzc_3c05f58b-8cfb-4541-9ed7-b11314262828">2020</ix:nonNumeric><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MzkvZnJhZzo4ODA3ZThjZDlmZTI0N2Y4OWQ2OTIzY2ZlZWVlNTNiOS90YWJsZTpmMDAwZmNiYjFiNWM0ZWExODU4N2VlODM2ODIzYTRmNy90YWJsZXJhbmdlOmYwMDBmY2JiMWI1YzRlYTE4NTg3ZWU4MzY4MjNhNGY3XzUtMS0xLTEtMTQxNzc_3a395176-fd6f-423e-8157-6c4635e1453d">FY</ix:nonNumeric><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MzkvZnJhZzo4ODA3ZThjZDlmZTI0N2Y4OWQ2OTIzY2ZlZWVlNTNiOS90YWJsZTpmMDAwZmNiYjFiNWM0ZWExODU4N2VlODM2ODIzYTRmNy90YWJsZXJhbmdlOmYwMDBmY2JiMWI1YzRlYTE4NTg3ZWU4MzY4MjNhNGY3XzYtMS0xLTEtMTQxNzc_38dc6d2a-2e3a-4dbc-883a-abe61d91b445">0001657312</ix:nonNumeric><ix:nonNumeric contextRef="i51bd538a85ce40bb90149ddc83f13568_D20180101-20181231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzMtMC0xLTEtMTk5NTI_cdbb0f1c-034b-4cc5-a4ab-bf0b4180f75c">us-gaap:AccountingStandardsUpdate201602Member</ix:nonNumeric><ix:nonNumeric contextRef="if9ab2cee3ac140aa8c75e12ed71b0cf2_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNjc4_366b91a1-c260-4eab-9b78-d6ac9d5b8954">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="i0c63e739a8e547e990aedd5fb7ed7cf4_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcyNjkw_00bc9b5e-059e-48bb-806a-540b915c41a7">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vrna-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ia1877ba50aad4b8b8bb262f25baa012d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i87a26c2d1e064e0b89d02c718f6a3154_I20210219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idecac34827ce472182dc1492d400ffdf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbpPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i7cd52ee77a7948f196f2eb3dd03b56a8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c68faae09684ddba54ea78663480657_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ia7bb2db7aeed4fe28f6502081a2b3fb2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad4673fe986541979acd434b04d81115_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i670b119a86454681a09079c9b183ec50_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1448e425ab1943f8ae8c4d34c3c75f39_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89de9796f5344884bc5b430e67f6af27_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc6502e2d84744a1a4f122e93a5bbedc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51bd538a85ce40bb90149ddc83f13568_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7144fbaaf53a410eb5a86ca2c38da7d6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bffa5795b9245b9b6367166015c8f55_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i218678a6acb04250abe3f3a39f5ced25_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48d5ccc6c4d54da9843cb1e12f96b89a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9796b77433d84134a9500d1119aa6875_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4209fc83abb4e68a86d37c119722d62_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d652bbdead0408181aff2dd02b415f6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cfc9b650e8f4111a9282e4577094d50_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33ee67ddc86e47f4b9ee46c176ae9f52_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67b3a7b2ab5743e8ab134b4311cd3357_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc88e7e39c7041c7aec47904740a5ffa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ee4138b94f24a3fb37c3a49fc55fbf0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id772c24a98d045f687a38be7f9204a60_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4bdef42e0964c40a84e61be80f90c28_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfd1b77b4c11404ab36abf3475f7fdf7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie991833e533a42c1bb4590e7c40b875d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia30de411faa549d8a507b268ebbff4e6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ab5f2cf37f34ce1822987a9a032bfe3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2906e285538640d2ba863cc6f7be6d7f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i382c3abae01044dfaf69a5a01cfc1c00_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if62ffe34397d4178bfe3a160fb777109_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib24f80c535f0403a800a6d65d53720d3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2cc9b6147bc414a87f7dd9652e152aa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff1f3d0564a142dbb860c4d8ca0a33d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie91783fe6f4743229a237427eba95bbe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="subsidiary"><xbrli:measure>vrna:subsidiary</xbrli:measure></xbrli:unit><xbrli:context id="i9dd30f2681444b31a30cecbb105a8d12_D20200717-20200717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-17</xbrli:startDate><xbrli:endDate>2020-07-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84e00d94b1de4386a6170826d98862d2_D20200717-20200717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-17</xbrli:startDate><xbrli:endDate>2020-07-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f3b17ae809741d291cfb524e558c10e_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46b0f32ad5df416e83423bbabba5a3b9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9ab2cee3ac140aa8c75e12ed71b0cf2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94c8c6508a314e10be6ed1a9414e5627_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>vrna:segment</xbrli:measure></xbrli:unit><xbrli:context id="i87d649c393ad4d1b95b36d916dbd127f_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06f7637896b74a8e922bb5f0526d2b57_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c561e8d91b04a3eb8a0bb1c609295ce_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vrna:LondonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d00a9e878d548fb96619548564db190_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i433bd94d277a4aaca4429c549dceb814_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie038220275954e62811afea2defe4cd3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30a26c5ea22f48a09788808b52ec5291_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i1934261cb6744a68b1f3c1ac28b455f2_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia00163949ecb43ad94978f60f9da30cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie527217d2eb345ecb87bd45f62bc6551_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9d34c4d3648482ca9398caf5933c3fc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vrna:MeasurementInputAnnualizedVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15dd5dffacd24b789e1a47ff62cf2c12_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vrna:MeasurementInputAnnualizedVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic846b25fc9864471980143616fd3554b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i798475f69cfd4d4cae668edfa84dcee9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie41a5e71b1994eee9bbaacc09238aab0_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a160b4682334bfdb2a585dd96fe5385_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermBLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f6a1d485e244da9a9515d7aeca27d8b_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermCLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4a9630a9c2e4c549a9169a0cdb89d7c_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11218b759beb41eeb8f443403c8f9195_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vrna:DebtPrepaymentPeriodAxis">vrna:DebtPrepaymentPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermCLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37571b3be78b4c2bb25afe43255bbd52_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermCLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="vrna:DebtPrepaymentPeriodAxis">vrna:DebtPrepaymentPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14b92f6c922045ebb4b765d2692f0b26_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vrna:DebtPrepaymentPeriodAxis">vrna:DebtPrepaymentPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermCLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a56eccf381d4490ab23ba0ce2602ed8_I20201119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifff034be4ded4bcb8670b2917c2d0bd5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bcfa5910fbe4e2ca7f076edd714a549_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52c90d5f0c46487fb88765d553f1b65b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9935563a347240e5a3824eaba4a823a6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c70e119f5364bafabd0f2b4cf13c8cb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c63e739a8e547e990aedd5fb7ed7cf4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia47baec57d49425a9f307369903c9687_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15364ff1d68341ec805494f64c383003_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bd04de9015c48df9fe3e3bef6ce4e5d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i465329a24eeb4cefbb25e840bfa5bc80_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc6a3a52eb8741acb78a572b648649d0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38dd4fa39df844e6af7ab7270ee1dc55_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac60289acf4d49a68397763e265d6cf1_I20060918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:EMIOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2006-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c19fa116eb54bf28428386737d1542d_I20120724"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:PreIPOOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-07-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia61b9dcc76d44330a7872e53c1b77d1a_D20170401-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:PreIPOOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-04-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafc15080cb714e279a2a7b822b3d58d6_D20170401-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:EMIOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-04-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i747d51980c684daaa52f9e04f16b0666_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:PreIPOOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i210506e1747a4dcab92bcdbad863492a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:EMIOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e33e5ffa3934ca7a4c7048a96c317a9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:A2017IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="rate"><xbrli:measure>utr:Rate</xbrli:measure></xbrli:unit><xbrli:context id="if3ed89efc5e44f55be2b1d1c803d1f72_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75308170234746af98ca1381553d9120_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44675776f6c54a54a40dc4ccde2d3c52_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c77df9054424edb9685cd91224a73df_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35514ffd7c034b0e8ce21b1da270c038_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i844f6711369540ba826df75f6b6a22dd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bc3d048b42b479595d7e0e6de32ce57_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c41d3b6c046482b826d8cdf888acde0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idce44936200646a39eb2e2ac020a3b66_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:RestrictedStockUnitTimeBasedVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idffe8ebf902f434a94b6fcaa44362bd1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:RestrictedStockUnitTimeBasedVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie67bf5c881684176b281b06cfe0628ed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:RestrictedStockUnitMilestoneBasedVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cb4743b3dc645c38fc5bff065067b3c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:RestrictedStockUnitMilestoneBasedVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaed0afb2f5ac4a73bc91d4c2a32c115e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vrna:ConsultancyServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia323b627bb0e4dfda11f8e943e75767d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vrna:DirectorOrOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:DrEbsworthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="i14e765c2f7c2471cac03f164f5c1521e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vrna:DirectorOrOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:DrZaccardelliMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b7fe6a0bec54714ba0212643a952e53_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vrna:DirectorOrOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:MrSinhaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf836d4ae04748dd8b1be54f7881b5a8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vrna:DirectorOrOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:DrUllmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05bb837cdc2e4bab8740f004c4754b5d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vrna:DirectorOrOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:DrEdwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6ee6389e25345f08e3512dcfb211a54_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vrna:DirectorOrOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:MrHahnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_204"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Washington, D.C. 20549 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjI4_7c2f6607-4559-41b9-a2c6-a3fe2688de61">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjM0_c505206c-440d-4bca-ad2b-15dece4310c7">&#9746;</ix:nonNumeric>&#160;&#160;&#160;&#160;ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNTM0_176188d2-b281-4954-9f46-5771cad99e65"><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNTM0_06599b25-6810-4dfb-8c31-148cb4c8f7c7">December 31</ix:nonNumeric>, 2020</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OR </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjM5_c163e170-a994-4d07-bf6d-86f3bae9b378">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FOR THE TRANSITION PERIOD FROM __________ TO __________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjQw_fef6545f-eed1-4a46-8b03-ec0b9197fd86">001-38067</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjQx_7e4bb365-bd20-4ad6-a0fa-2df933fd2e46">Verona Pharma plc</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its Charter) </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90YWJsZTozMGJiMGFhOTk5Njc0ZjQyOWM4NTZiZWQyMDUwNTkxMy90YWJsZXJhbmdlOjMwYmIwYWE5OTk2NzRmNDI5Yzg1NmJlZDIwNTA1OTEzXzAtMC0xLTEtMTg2MTU_58a3e921-7184-49bc-bc51-e30c602c857e">United Kingdom</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90YWJsZTozMGJiMGFhOTk5Njc0ZjQyOWM4NTZiZWQyMDUwNTkxMy90YWJsZXJhbmdlOjMwYmIwYWE5OTk2NzRmNDI5Yzg1NmJlZDIwNTA1OTEzXzAtMy0xLTEtMTg2MTM_2d9f39e0-00c4-43c8-9486-1ec0a0b0e76f">98-1489389</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer Identification No.)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90YWJsZTozMGJiMGFhOTk5Njc0ZjQyOWM4NTZiZWQyMDUwNTkxMy90YWJsZXJhbmdlOjMwYmIwYWE5OTk2NzRmNDI5Yzg1NmJlZDIwNTA1OTEzXzMtMC0xLTEtMTg2MDIvdGV4dHJlZ2lvbjpiMjIwYWRiMDNhY2Y0MWEyYWFjZGQ2M2MyZmYxYTZhOV8yMDg5MDcyMDkyNzg2Mg_b12c74ae-7443-4dde-893f-623492883df6">3 More London Riverside</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90YWJsZTozMGJiMGFhOTk5Njc0ZjQyOWM4NTZiZWQyMDUwNTkxMy90YWJsZXJhbmdlOjMwYmIwYWE5OTk2NzRmNDI5Yzg1NmJlZDIwNTA1OTEzXzMtMC0xLTEtMTg2MDIvdGV4dHJlZ2lvbjpiMjIwYWRiMDNhY2Y0MWEyYWFjZGQ2M2MyZmYxYTZhOV8yMDg5MDcyMDkyNzg3MQ_a6fbcaea-a4f7-4f9b-9d07-6dd871dfc7f8">London</ix:nonNumeric> <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90YWJsZTozMGJiMGFhOTk5Njc0ZjQyOWM4NTZiZWQyMDUwNTkxMy90YWJsZXJhbmdlOjMwYmIwYWE5OTk2NzRmNDI5Yzg1NmJlZDIwNTA1OTEzXzMtMC0xLTEtMTg2MDIvdGV4dHJlZ2lvbjpiMjIwYWRiMDNhY2Y0MWEyYWFjZGQ2M2MyZmYxYTZhOV8yMDg5MDcyMDkyNzg4MQ_9fa023d9-e900-462e-8347-6d84076106ac">SE1 2RE</ix:nonNumeric> <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90YWJsZTozMGJiMGFhOTk5Njc0ZjQyOWM4NTZiZWQyMDUwNTkxMy90YWJsZXJhbmdlOjMwYmIwYWE5OTk2NzRmNDI5Yzg1NmJlZDIwNTA1OTEzXzMtMC0xLTEtMTg2MDIvdGV4dHJlZ2lvbjpiMjIwYWRiMDNhY2Y0MWEyYWFjZGQ2M2MyZmYxYTZhOV8yMDM0MDk2NTExNDA2Ng_87662dcc-9ca2-4cae-98a5-2a0208354725">United Kingdom</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Zip Code)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: +<ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="dei:CountryRegion" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTYxOTEx_8d4c97ec-ff30-4741-b7b4-09c615bbf968">44</ix:nonNumeric> <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjQ0_2e5579ad-f987-4bf8-80ee-a6f793e859f8">203</ix:nonNumeric> <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjQ4_2c2d82aa-b36c-4f72-a3fa-6a046edb7517">283 4200</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:42.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90YWJsZTpiMDJhZTU2YTg5Zjc0NjdjYTRhZjQwZmM1MDBkYzljNS90YWJsZXJhbmdlOmIwMmFlNTZhODlmNzQ2N2NhNGFmNDBmYzUwMGRjOWM1XzEtMC0xLTEtMTY3ODI_529bf9c4-4b7e-42de-a441-01a05c58d886">Ordinary shares, nominal value &#163;0.05 per share*</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90YWJsZTpiMDJhZTU2YTg5Zjc0NjdjYTRhZjQwZmM1MDBkYzljNS90YWJsZXJhbmdlOmIwMmFlNTZhODlmNzQ2N2NhNGFmNDBmYzUwMGRjOWM1XzEtMS0xLTEtMTg2MTc_cea1aba3-6398-44fc-b43f-452df59c07a4">VRNA</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Nasdaq Stock Market LLC (<ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90YWJsZTpiMDJhZTU2YTg5Zjc0NjdjYTRhZjQwZmM1MDBkYzljNS90YWJsZXJhbmdlOmIwMmFlNTZhODlmNzQ2N2NhNGFmNDBmYzUwMGRjOWM1XzEtMi0xLTEtMTg2MTcvdGV4dHJlZ2lvbjo1MGJkMDFjYjVjNWM0MDExOTBkMzc0NGQzOWY5MDMyN18yMDM0MDk2NTExMzkzMA_32e12288-33ca-49d6-a829-ced2da95a4c1">Nasdaq Global Market</ix:nonNumeric>)</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* The ordinary shares are represented by American Depositary Shares (each representing 8 ordinary shares), which are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">None</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjY0_8480c7a8-69ac-47f0-b6b7-f26fbd94a939">No</ix:nonNumeric> &#9746;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes &#9744; <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjY1_27af857d-e1c3-4345-b250-aa9688f6d505">No</ix:nonNumeric> &#9746;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjY2_ade9ca35-9241-4661-9d2d-6c03b1d74c7a">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjY3_010cf5b2-9b2f-402c-83b6-dda04c03ad82">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.397%"><tr><td style="width:1.0%"></td><td style="width:43.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.812%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90YWJsZTphNmI2Yzc0MGU5NTI0MTAxYjVmZjFkYzQzNTAwNzVlNy90YWJsZXJhbmdlOmE2YjZjNzQwZTk1MjQxMDFiNWZmMWRjNDM1MDA3NWU3XzEtMC0xLTEtMTg2MjA_c5f093ed-b52d-4b5e-98e2-45572a99afea">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Small reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90YWJsZTphNmI2Yzc0MGU5NTI0MTAxYjVmZjFkYzQzNTAwNzVlNy90YWJsZXJhbmdlOmE2YjZjNzQwZTk1MjQxMDFiNWZmMWRjNDM1MDA3NWU3XzEtNC0xLTEtMTY4Mzc_4a4ddec7-5838-4662-89a9-00e351e105b8">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90YWJsZTphNmI2Yzc0MGU5NTI0MTAxYjVmZjFkYzQzNTAwNzVlNy90YWJsZXJhbmdlOmE2YjZjNzQwZTk1MjQxMDFiNWZmMWRjNDM1MDA3NWU3XzItNC0xLTEtMTY4NDE_dc2f5570-df7e-42c5-8ee4-6eb21abca9a6">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjc0_83787c8a-21b1-4660-bdc5-f06fdcdc42d1">&#9746;</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTYxODkx_3a82b628-73e8-4bc6-b52f-420d2489cb64">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjc1_df8a3e94-f848-4437-aa61-50157ffba68a">&#9744;</ix:nonNumeric>    No &#9746;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The aggregate market value of the registrant's voting and non-voting common equity held by non-affiliates was approximately $<ix:nonFraction unitRef="usd" contextRef="ia1877ba50aad4b8b8bb262f25baa012d_I20200630" decimals="-5" name="dei:EntityPublicFloat" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTYxODc4_b742d294-3da1-4c46-a6f8-802da9288071">37.5</ix:nonFraction> million as of June 30, 2020, the last business day of the registrant's most recently completed second fiscal quarter. Solely for purposes of this disclosure, shares held by executive officers, directors and certain shareholders of the registrant as of such date have been excluded because such persons or entities may be deemed to be affiliates of the registrant. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of February 19, 2021, the registrant had <ix:nonFraction unitRef="shares" contextRef="i87a26c2d1e064e0b89d02c718f6a3154_I20210219" decimals="0" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzU0OTc1NTg2MjQ2Ng_267e2a74-d4f4-4c0c-95c8-c2cd2c62351a">463,478,446</ix:nonFraction> ordinary shares, nominal value &#163;0.05 per share, outstanding, which if all held in ADS form, would be represented by 57,934,805 American Depositary Shares, each representing eight (8) ordinary shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjc2_ac965a8a-d843-4d6c-ae6d-f7a9fd0565e9" escape="true">Portions of the registrant&#8217;s definitive proxy statement that the registrant intends to file with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant&#8217;s 2021 Annual Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</ix:nonNumeric> </span></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_209"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">GENERAL INFORMATION</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">All references in this Annual Report on Form 10-K (the &#8220;Annual Report&#8221;), to &#8220;Verona,&#8221; the &#8220;company,&#8221; the "group", &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Verona Pharma plc and its consolidated subsidiaries. In this Annual Report, the U.S. Securities and Exchange Commission is referred to as the &#8220;SEC&#8221;, the Securities Act of 1933, as amended, is referred to as the &#8220;Securities Act&#8221; and the Securities Exchange Act of 1934, as amended, is referred to as the &#8220;Exchange Act.&#8221;</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">TRADEMARKS, TRADENAMES AND SERVICE MARKS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">This Annual Report may include trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, trademarks and tradenames referred to in this Annual Report appear without the &#174; and &#8482; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and tradenames.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">This Annual Report contains statements that constitute forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. All statements other than statements of historical facts contained in this Annual Report, including without limitation statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, the development of ensifentrine or any other product candidates, including statements regarding the expected initiation, timing, progress and availability of data from our clinical trials and potential regulatory approvals, research and development costs, timing and likelihood of success, potential collaborations, the duration of our patent portfolio, our estimates regarding expenses, future revenues, capital requirements, debt service obligations and our need for additional financing, the funding we expect to become available under the Term Loan and from cash receipts from U.K. tax credits, and the sufficiency of our cash and cash equivalents to fund operations, are forward-looking statements. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The forward-looking statements in this Annual Report are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report and are subject to a number of known and unknown risks, uncertainties and assumptions, including the important factors described under the sections in this Annual Report entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and in our other filings with the SEC.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. We intend the forward-looking statements contained in this Annual Report to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">This Annual Report contains market data and industry forecasts that were obtained from industry publications. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified any third-party information. While we believe the market position, market opportunity and market size information included in this Annual Report is generally reliable, such information is inherently imprecise.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">SUMMARY RISK FACTORS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our business is subject to numerous risks and uncertainties, including those described in Part I, Item 1A. &#8220;Risk Factors&#8221; in this Annual Report. You should carefully consider these risks and uncertainties when investing in our ADSs. The principal risks and uncertainties affecting our business include the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We have a limited operating history and have never generated any product revenue;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We will need additional funding to complete development of any future product candidates, or development of other formulations or target indications of ensifentrine, and to commercialize our products, including ensifentrine, if approved;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Changes in our tax rates, unavailability of certain tax credits or reliefs or exposure to additional tax liabilities or assessments could affect our profitability, and audits by tax authorities could result in additional tax payments for prior periods;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We depend heavily on the success of ensifentrine, our only product candidate under development;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">The COVID-19 pandemic has and may continue to adversely impact our business;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Ensifentrine may have serious adverse, undesirable or unacceptable side effects which may delay or prevent marketing approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">If we are unable to enroll patients in our clinical trials, or enrollment is slower than anticipated, our research and development efforts could be adversely affected;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We may become exposed to costly and damaging liability claims, either when testing ensifentrine in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Regulatory approval processes are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for ensifentrine, our business will be substantially harmed;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize ensifentrine and may affect the prices we may set;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We operate in a highly competitive and rapidly changing industry, which may result in others discovering, developing or commercializing competing products before or more successfully than we do;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We may be unable to obtain orphan drug designation from the FDA or EU for ensifentrine for the treatment of cystic fibrosis, and even if we do obtain such designations, we may be unable to obtain or maintain the benefits associated with orphan drug designation, including the potential for orphan drug exclusivity;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We rely, and expect to continue to rely, on third parties, including independent clinical investigators and clinical research organizations, to conduct our pre-clinical studies and clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">If we fail to enter into new strategic relationships for ensifentrine, our business, research and development and commercialization prospects could be adversely affected;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We currently rely on third-party manufacturers and suppliers for production of the active pharmaceutical ingredient ensifentrine and its derived formulated products. Our dependence on these third parties may impair the advancement of our research and development programs and the development of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We rely on patents and other intellectual property rights to protect ensifentrine, the enforcement, defense and maintenance of which may be challenging and costly;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect our ability to develop, manufacture and market ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We may be involved in lawsuits to protect or enforce patents covering ensifentrine, which could be expensive, time consuming and unsuccessful, and issued patents could be found invalid or unenforceable if challenged in court;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Our future growth and ability to compete depends on our ability to retain our key personnel and recruit additional qualified personnel;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We expect to expand our development, regulatory and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">The price of our American Depositary Shares may be volatile and may fluctuate due to factors beyond our control; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We will continue to incur increased costs as a result of operating as a public company in the United States, and our senior management are required to devote substantial time to new compliance initiatives and corporate governance practices.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_32"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.516%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Table of Contents</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part I</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_38">Item 1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_38">Business</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_38">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_43">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_43">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_43">22</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_48">Item 1B.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_48">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_48">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_66">Item 2.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_66">Properties</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_66">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_61">Item 3.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_61">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_61">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_56">Item 4.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_56">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_56">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part II</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_86">Item 5.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_86">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_86">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_121">Item 6.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_121">Selected Financial Data</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_121">66</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_116">Item 7.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_116">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_116">66</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_111">Item 7A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_111">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_106">Item 8.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_106">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_106">76</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_101">Item 9.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_101">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_101">76</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_96">Item 9A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_96">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_96">76</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_91">Item 9B.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_91">Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_91">77</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part III</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_149">Item 10.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_149">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_149">77</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_144">Item 11.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_144">Executive Compensation</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_144">77</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_164">Item 12.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_164">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_164">77</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_159">Item 13.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_159">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_159">77</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_154">Item 14.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_154">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_154">77</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part IV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_169">Item 15.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_169">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_169">78</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_732">Item 16.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_191">Form 10-K Summary</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_732">80</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_191">Signatures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_191">81</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_38"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 1.&#160;&#160;&#160;&#160;Business</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">OVERVIEW</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Our product candidate, ensifentrine, is a first-in-class, inhaled, dual inhibitor of the phosphodiesterase (&#8220;PDE&#8221;) 3 and PDE4 enzymes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In Phase 2 clinical trials, ensifentrine has demonstrated positive results in chronic obstructive pulmonary disease (&#8220;COPD&#8221;), asthma and cystic fibrosis (&#8220;CF&#8221;). In addition, we believe that based on its unique profile, it could be beneficial in the treatment of COVID-19 and it is currently under evaluation in a pilot clinical study. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are developing ensifentrine in three formulations for the most widely used inhalation devices: nebulizer, dry powder inhaler (&#8220;DPI&#8221;) and pressurized metered-dose inhaler (&#8220;pMDI&#8221;). Ensifentrine has shown positive Phase 2 data in COPD trials when delivered by each of these formulations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Initially, we are targeting COPD, a common, chronic, progressive, and life-threatening respiratory disease without a cure. If successfully developed, ensifentrine would be the first therapeutic with a novel mode of action for COPD in a decade. We made substantial progress in 2020, including reporting positive data from a large 4-week Phase 2b trial, receiving guidance from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) on our Phase 3 ENHANCE (&#8220;Ensifentrine as a Novel inHAled Nebulized COPD thErapy&#8221;) program and commencing enrollment in the pivotal Phase 3 clinical trials. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our near term operating focus is the ongoing ENHANCE program, related chemistry, manufacturing and controls, regulatory efforts and early pre-commercial activities. We believe that our cash and cash equivalents as of December 31, 2020, together with funding expected to become available under the Term Loan and from cash receipts from U.K. tax credits, will enable us to fund our planned operating expenses and capital expenditure requirements into 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Overview of COPD and current treatments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">COPD is a common, chronic, progressive, and life-threatening respiratory disease without a cure. It damages the airways and lungs, leading to debilitating breathlessness, hospitalizations, and death. COPD has a major impact on everyday life. Patients struggle with basic activities such as getting out of bed, showering, eating, and walking. Worldwide, COPD affects approximately 384 million people and is the third leading cause of death, according to the World Health Organization.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The goal of COPD pharmacological therapy is to improve patients&#8217; quality of life by reducing symptoms, reducing the quantity and severity of exacerbations (often an escalation of symptoms) and to improve patients&#8217; ability to function (GOLD 2020).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For approximately 40 years, the treatment of COPD has been dominated by three classes of inhaled therapies approved for use by the FDA and the European Medicines Agency (&#8220;EMA&#8221;): anti-muscarinics, beta-agonists and inhaled corticosteroids (&#8220;ICSs&#8221;). COPD patients are frequently treated with bronchodilators, including long acting anti-muscarinics (&#8220;LAMAs&#8221;) and long acting beta-agonists (&#8220;LABAs&#8221;), to relieve airway constriction and make it easier to breathe. In addition, they receive ICSs to prevent exacerbations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Certain COPD patients are treated with the oral PDE4 inhibitor, roflumilast (Daliresp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">), which has demonstrated a reduction in exacerbation risk in patients with severe chronic bronchitis. However, oral PDE4 therapy has been associated with unfavorable gastrointestinal side-effects such as nausea, emesis, diarrhea, abdominal pain, loss of appetite and weight loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">COPD treatments are often combined in patients who remain uncontrolled on one or two therapies. These include LAMA/LABA combinations or LAMA/LABA/ICS combinations. Unfortunately, clinical data suggests that 40-60% of patients on dual or triple therapy still experience significant symptoms of COPD, including breathlessness. These chronic recurring symptoms limit their daily activities and impair quality of life. Despite receiving maximum therapy, it is estimated that more than 1.2 million patients in the U.S. alone remain symptomatic. For these patients, there are no available inhaled therapies that offer treatment options beyond standard LAMA / LABA and ICS combinations. New treatment options are urgently needed to help improve lung function, symptoms, and overall quality of life in these patients.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Ensifentrine</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ensifentrine is a first-in-class, inhaled, dual PDE3 and PDE4 inhibitor. This dual inhibition enables it to act as a bronchodilator and an anti-inflammatory agent in a single compound. Importantly, this therapeutic profile differentiates it from existing classes of bronchodilator and anti-inflammatory treatments. We are not aware of any other single compound in clinical development or approved by the FDA nor the EMA for the treatment of respiratory diseases that acts both as a bronchodilator and anti-inflammatory agent. If successfully developed and approved, ensifentrine has the potential to be the first novel class of bronchodilator in COPD in over 40 years and the only bronchodilator option as an add-on to existing dual / triple therapy. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ensifentrine has demonstrated significant and clinically meaningful improvements in both lung function and COPD symptoms, including breathlessness, in our prior Phase 2 clinical studies in patients with moderate to severe COPD. In addition, ensifentrine showed further improved lung function and reduced lung volumes in patients taking standard short- and long-acting bronchodilator therapy, including maximum bronchodilator treatment with dual/triple therapy. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Safety profile</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ensifentrine has demonstrated a safety profile similar to placebo in clinical trials involving more than 1,300 people to date. It is delivered directly to the lungs by inhalation to maximize pulmonary exposure to ensifentrine while minimizing systemic exposure. This feature minimizes any systemic side-effects such as the gastrointestinal disturbance associated with oral PDE4 inhibitors. In addition, in non-clinical trials ensifentrine has demonstrated high selectivity for PDE3 and PDE4 over other enzymes and receptors, which is believed to minimize off-target effects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Differentiated profile</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">By inhibiting PDE3 and PDE4, ensifentrine impacts three key mechanisms in respiratory disease: bronchodilation, inflammation and mucociliary clearance. Ensifentrine is designed to increase the levels of cellular cAMP and cGMP in smooth muscle cells and inflammatory cells, resulting in bronchodilator and anti-inflammatory effects. Ensifentrine is also designed to stimulate the cystic fibrosis transmembrane conductance regulator (&#8220;CFTR&#8221;), which is an ion channel in the epithelial cells lining the airways. Mutations in the CFTR protein result in poorly or non-functioning ion channels, which cause CF and are potentially important in COPD. CFTR stimulation leads to improved electrolyte balance in the lung and thinning of the mucus, which facilitates mucociliary clearance and leads to improved lung function and potentially a reduction in lung infections. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Dual inhibition of PDE3 and PDE4 has shown enhanced or synergistic effects compared with inhibition of either PDE alone on contraction of airway smooth muscle and suppression of inflammatory mediator release in several preclinical studies. We believe these enhanced effects may increase the utility of ensifentrine in the treatment of respiratory diseases including COPD, asthma and CF. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><img src="vrna-20201231_g1.gif" alt="vrna-20201231_g1.gif" style="height:376px;margin-bottom:5pt;vertical-align:text-bottom;width:700px"/></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We believe ensifentrine has the potential to address the large unmet need in treating COPD with its improvement in COPD symptoms and meaningful improvement in quality of life.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Clinical data</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ensifentrine has demonstrated improvements in lung function, symptoms and quality of life with or without background therapy in two 4-week, Phase 2b dose-ranging clinical trials in moderate to severe COPD patients. In both studies ensifentrine was well tolerated at all doses with an adverse event profile similar to placebo:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">In March 2018, we reported positive top-line results with ensifentrine as monotherapy from our first Phase 2b trial in 403 patients. The trial evaluated four doses of nebulized ensifentrine (0.75 mg, 1.5 mg, 3 mg and 6 mg) or placebo twice daily over 4 weeks. Patients withheld use of regular long-acting bronchodilator therapy for the duration of the study. The trial met its primary endpoint of improved lung function with ensifentrine demonstrating a clinically and statistically significant increase in peak forced expiratory volume in 1 second (&#8220;FEV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:1.41pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221;) at week 4 compared to placebo. In addition, clinically relevant secondary endpoints were met including significant progressive improvements in COPD symptoms. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">In January 2020, we reported positive top-line results with ensifentrine added on to background therapy from our second Phase 2b trial in 413 patients. This trial evaluated four doses of nebulized ensifentrine (0.375 mg, 0.75 mg, 1.5 mg and 3 mg) or placebo added on to treatment with once-daily tiotropium (Spiriva</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> Respimat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">), a commonly used LAMA bronchodilator, in symptomatic patients with moderate to severe COPD who required additional treatment. The trial met its primary endpoint of improved lung function, with ensifentrine plus tiotropium demonstrating a clinically and statistically significant dose-dependent improvement in peak FEV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:1.41pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> and FEV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:1.41pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> over 12 hours with ensifentrine at week 4, compared to placebo plus tiotropium. Additionally, clinically meaningful and statistically significant improvements in health-related quality of life were observed with ensifentrine added on to tiotropium. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><img src="vrna-20201231_g2.jpg" alt="vrna-20201231_g2.jpg" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:700px"/></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In May 2020, the FDA provided guidance on key features of our pivotal Phase 3 clinical program in response to our End-of-Phase 2 briefing package for nebulized ensifentrine as a maintenance treatment for COPD. This included clarity on the dose, primary and secondary endpoints, patient population and program design.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In September 2020, we initiated our ENHANCE Phase 3 trials to evaluate the efficacy and safety of nebulized ensifentrine in patients with moderate to severe COPD. The two randomized, double-blind, placebo-controlled studies (ENHANCE-1 and ENHANCE-2) will evaluate ensifentrine as monotherapy and added onto a single bronchodilator. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Each study is expected to enroll approximately 800 moderate to severe, symptomatic COPD patients at sites primarily in the U.S. and Europe. The two study designs will replicate measurements of efficacy and safety data over 24 weeks but ENHANCE-1 will also evaluate longer-term safety in 400 patients over 48 weeks. The primary endpoint is improvement in lung function measured by FEV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:1.41pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> over 12 hours with ensifentrine after 12 weeks of treatment. Key secondary endpoints include measurements of COPD symptoms and health-related quality of life through 24 weeks assessed via the validated patient reported outcome tools, E-RS: COPD and SGRQ. Additional lung function endpoints including peak and morning trough FEV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:1.41pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> will also be assessed. Exacerbations will be analyzed by individual study and in a pooled analysis.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are in the early stages of recruiting patients and based on our recruitment projections, we expect to complete enrollment in both Phase 3 studies in the second half of 2021. Longer term, based on forecasted recruitment, we expect to report top-line data from ENHANCE-2 in the first half of 2022 and ENHANCE-1 in the second half of 2022. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><img src="vrna-20201231_g3.jpg" alt="vrna-20201231_g3.jpg" style="height:403px;margin-bottom:5pt;vertical-align:text-bottom;width:700px"/></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Formulations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Verona Pharma has developed formulations of ensifentrine for the three most widely used inhalation devices: nebulizer, DPI and pMDI. The nebulized formulation of ensifentrine is designed to be suitable for use in a standard jet nebulizer, not a proprietary device. Delivery of COPD medications by nebulizer is important because such medications can be used by adults of almost any age and dexterity and regardless of peak inspiratory flow, offering advantages to patients who may struggle to operate handheld inhaler devices or have low peak inspiratory flow. DPI and pMDI handheld inhaler formats are relatively portable and convenient and are also important delivery mechanisms in the approximately $9.6 billion U.S. market for maintenance COPD therapies. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">While we continue to focus on development of the nebulized formulation of ensifentrine, we believe the development of pMDI and DPI formulations of ensifentrine provides additional lifecycle opportunities including new potential indications, formulation combinations and collaborations.While we continue to focus on development of the nebulized formulation of ensifentrine, we believe the development of pMDI and DPI formulations of ensifentrine provides additional lifecycle opportunities including new potential indications, formulation combinations and collaborations. In February 2021, we reported positive results from the second, multiple dose part of a Phase 2 trial with pMDI ensifentrine in patients with moderate to severe COPD. Ensifentrine delivered by pMDI met all of the primary and secondary lung function endpoints. The improvement in lung function was dose-ordered and statistically significant at peak and over the 12-hour dosing interval compared with placebo, and supports twice-daily dosing of ensifentrine via pMDI for the treatment of COPD. Data from the single dose part of the study were reported in March 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Verona Pharma has successfully demonstrated proof of concept in Phase 2 COPD trials with all three formulations. In addition, the data from Phase 2 trials were consistent across the three formulations. All three dosing forms have demonstrated statistically significant and clinically meaningful improvements in lung function and duration of action, supporting twice-daily dosing and a safety profile similar to placebo. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Pipeline</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table summarizes our development programs.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><img src="vrna-20201231_g4.jpg" alt="vrna-20201231_g4.jpg" style="height:324px;margin-bottom:5pt;vertical-align:text-bottom;width:700px"/></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Potential additional indications for ensifentrine</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">COVID-19</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">While our initial focus is COPD, we are also evaluating ensifentrine as a potential treatment option for COVID-19. Clinical data from prior studies of ensifentrine in other respiratory diseases demonstrated that ensifentrine improved lung function, reduced cellular markers of inflammation in the lungs and reduced symptoms of cough and sputum. We believe these results, if replicated in COVID-19 patients, could improve patient outcomes from COVID-19 by reducing dyspnea, targeting viral-induced inflammation in the lung, improving patient&#8217;s oxygen levels and preventing secondary infections related to mucus hypersecretion. </span></div><div style="text-align:center"><img src="vrna-20201231_g5.jpg" alt="vrna-20201231_g5.jpg" style="height:341px;margin-bottom:5pt;vertical-align:text-bottom;width:700px"/></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In January 2021, we completed enrollment (n=45) in a pilot study to evaluate pMDI ensifentrine in a randomized, double-blind, placebo-controlled pilot clinical study for the treatment of U.S. patients hospitalized with COVID-19. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The study will evaluate the effect of ensifentrine on key outcomes in patients hospitalized with COVID-19 including facilitation of recovery from the viral infection, clinical status improvement, reduction in supplemental oxygen use and progression to mechanical ventilation. We expect to report top-line results in the second quarter of 2021.</span></div><div style="text-align:center"><img src="vrna-20201231_g6.jpg" alt="vrna-20201231_g6.jpg" style="height:392px;margin-bottom:5pt;vertical-align:text-bottom;width:700px"/></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Cystic fibrosis and asthma</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition to COPD and COVID-19, we believe ensifentrine has potential applications in other respiratory diseases including CF and asthma. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">CF is a progressive, fatal genetic disease without a cure and a median age of death of 46 years. The condition is characterized by thick, sticky mucus that damages many of the body&#8217;s organs. It causes repeat and persistent lung infections that result in frequent exacerbations and hospitalizations. Other symptoms include malnutrition, constipation and diarrhea, and some adults develop diabetes, arthritis and liver problems.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">CF is the most common fatal inherited disease in the U.S. and Europe. More than 70,000 people worldwide are living with CF and approximately 1,000 new cases are diagnosed each year, according to the Cystic Fibrosis Foundation. The U.S. and European regulatory authorities consider CF to be a rare, or orphan, disease and provide incentives to encourage development of effective new treatments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">CF patients endure multiple daily medications, taking an average of seven per day, including inhaled and injected treatments to clear mucus and fight infections as well as enzyme pills to digest food. Ultimately, selected patients have lung transplants.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In a Phase 2a clinical trial, a single dose of nebulized ensifentrine demonstrated an improvement in lung function in patients with CF. In addition, in preclinical studies, ensifentrine activated the Cystic Fibrosis Transmembrane Conductance Regulator, which is beneficial in reducing mucous viscosity and improving mucociliary clearance. We believe these data support the continued development of ensifentrine as a potential therapy for CF.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Asthma is a common lung condition that causes sporadic breathing difficulties. The disease causes narrowing and swelling of the airways leading to symptoms including difficulty breathing, wheezing, coughing and tightness in the chest. Exposure to triggers such as allergens or irritants can lead to asthma attacks.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Asthma attacks vary in severity and frequency. More than 300 million people worldwide suffer from asthma and it is the most common chronic disease among children, according to the World Health Organization.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Although there is no cure, symptoms may be prevented by avoiding triggers and through established maintenance therapies including bronchodilators, ICS, anti-IgE agents and leukotriene inhibitors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ensifentrine has shown potential in a Phase 2a clinical trial in asthma. The data from this trial, published in October 2019 in the journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Pulmonary Pharmacology &amp; Therapeutic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">s, demonstrated that ensifentrine produced dose-dependent improvements in bronchodilation that were comparable current rescue medication, high dose nebulized albuterol. Importantly, ensifentrine was well tolerated and patients experienced fewer systemic effects than those receiving albuterol.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Our team</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our expert team has decades of experience in developing and commercializing respiratory therapeutics including the following COPD therapeutics: Advair</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">; Anoro Ellipta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">; Breo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">; Flovent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">; Flutiform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">; Incruse Ellipta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">; Serevent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">; Symbicort</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">; Tudorza Pressair</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> and Ventolin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">MANUFACTURING </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We do not have manufacturing facilities and rely on, and expect to continue to rely on, third-party contract manufacturing organizations (&#8220;CMOs&#8221;) for the supply of current good manufacturing practices (&#8220;cGMP&#8221;) compliant clinical trial materials of ensifentrine, and any future product candidates, as well as for commercial quantities of ensifentrine and any future product candidates, if approved. We currently do not have any agreements for the commercial production of ensifentrine. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">While we may contract with other CMOs in the future, we currently have one CMO for the manufacture of ensifentrine drug substance and one CMO for each formulation of ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">All of our current CMOs have commercial scale manufacturing capabilities. We believe that the ensifentrine drug substance and drug product manufacturing processes can be transferred to other CMOs to produce clinical and commercial supplies in the ordinary course of business.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">COMMERCIALIZATION</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">United States</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the United States, we are preparing to commercialize nebulized ensifentrine ourselves, if approved. Despite the availability of current therapies, it is estimated that 1.2 million patients remain symptomatic following treatment with maximum therapy. These patients need therapies that can help improve their lung function and symptoms. In addition to the number of patients that remain symptomatic, COPD places a tremendous burden on the U.S. healthcare system with approximately $50 billion in direct and indirect costs. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Based on our market research, which was conducted with U.S. healthcare providers and payers, we anticipate ensifentrine would be used primarily as an add-on to dual or triple therapy regimens and we anticipate the majority of ensifentrine usage would be initiated by pulmonologists. Due to this focused prescriber base, we anticipate needing a field sales force of approximately 100 representatives. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">International</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">COPD effects over 384 million people worldwide with many patients remaining undiagnosed. Our strategy outside of the U.S. including Asia, Europe and Latin America, is to establish partnerships with leading companies that can support the further development and commercialization of ensifentrine in those regions. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">COMPETITION</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The pharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary drugs. We face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. If successfully developed and commercialized, ensifentrine will compete with existing treatments and new treatments that may become available in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ensifentrine is a unique, first-in-class therapeutic candidate with both bronchodilator and anti-inflammatory properties in a single compound. As far as we are aware, no other dual PDE3 and PDE4 inhibitor is on the market nor in clinical development. Based on our market research, we expect ensifentrine to be used mainly in addition to existing dual and triple therapies, LAMA / LABA / ICS where no additional treatment options exist for patients who </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">are symptomatic. Some healthcare providers have indicated that they would use it as earlier line therapy based on ensifentrine&#8217;s clinical profile. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Consequently, we believe that, if approved, nebulized ensifentrine&#8217;s unique profile will enable it to compete with all approved COPD therapies including nebulized and handheld inhaler formulations, DPI and MDI. Furthermore, because ensifentrine&#8217;s mechanism of action is complementary to available therapies, we believe it could be used in addition to these treatments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Within the currently approved nebulizers for the maintenance treatment of COPD, we consider ensifentrine's potential competitors in the U.S. market to be LABAs (Brovana</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> and Perforomist</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">) and LAMAs (Yupelri</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> and Lonhala</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Magnair</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">). </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the DPI/MDI maintenance treatment of COPD market, ensifentrine&#8217;s current closest potential competitors are Symbicort</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, a combination of a long-acting beta2-agonist bronchodilator and ICS marketed by AstraZeneca plc, Spiriva</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, a long-acting anti-muscarinic bronchodilator marketed by Boehringer Ingelheim GmbH, Advair</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, a combination of a long-acting beta2-agonist bronchodilator and ICS marketed by GlaxoSmithKline plc, Utibron Neohaler</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, a combination of a long-acting beta2-agonist and long-acting anti-muscarinic bronchodilator marketed by Novartis International AG, Breo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, a combination of a long-acting beta2-agonist bronchodilator and ICS marketed by GlaxoSmithKline, and Anoro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, a combination of a long-acting beta2-agonist bronchodilator and long-acting anti-muscarinic bronchodilator marketed by GlaxoSmithKline. A triple-combination therapy of a LAMA, a LABA and ICS, developed by GlaxoSmithKline and Chiesi Farmaceutici S.p.A., Trelegy Ellipta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, has been approved in the U.S. and the European Union and AstraZeneca also has a triple-therapy combination product (LAMA / LABA / ICS), Breztri Aerosphere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> that was approved in the U.S. in July 2020, in the European Union in December 2020 and in China in December 2019. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other potential therapies in clinical development for the prevention of COPD exacerbations include injectable biologics. Sanofi&#8217;s anti-IL4, Dupixent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, AstraZeneca&#8217;s anti-IL5, Fasenra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, and GlaxoSmithKline&#8217;s anti-IL5, Nucala</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, are in Phase 3 trials. We are also aware of several anti-inflammatories and bronchodilators that are in Phase 2 clinical trials for the treatment of COPD.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">INTELLECTUAL PROPERTY</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We hold rights in the major markets relating to ensifentrine for treating respiratory disorders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We strive to protect and enhance the proprietary technologies, inventions and improvements that we believe are important to our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the U.S. and in jurisdictions outside of the U.S. related to our proprietary technology, inventions, improvements, platforms and our product candidates that are important to the development and implementation of our business. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of December 31, 2020, our patent portfolio consisted of eleven issued U.S. patents, three pending U.S. patent applications, forty-six issued foreign patents and forty-three pending foreign applications including two patent applications made under the Patent Cooperation Treaty. These patents and patent applications include claims directed to new dosage formulations comprising ensifentrine and a crystalline polymorph, as well as methods of making and using ensifentrine in the treatment of respiratory diseases, with expected expiry dates up to 2041. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Individual patents extend for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, patents issued for regularly filed applications in the United States are granted a term of 20 years from the earliest effective non&#8209;provisional filing date. In addition, in certain instances, a patent term can be extended to recapture a portion of the U.S. Patent and Trademark Office, or the USPTO, delay in issuing the patent as well as a portion of the term effectively lost as a result of the FDA regulatory review period. However, as to the FDA component, the restoration period cannot be longer than five years and the total patent term including the restoration period must not exceed 14 years following FDA approval. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a product-by-product basis, from country to country and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory&#8209;related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Furthermore, we rely upon trade secrets and know&#8209;how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">agreements with our collaborators, employees and consultants and invention assignment agreements with our employees. We also have confidentiality agreements or invention assignment agreements with our collaborators and selected consultants. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know&#8209;how and inventions. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our commercial success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third&#8209;party patent would require us to alter our development or commercial strategies, or our drugs or processes, obtain licenses or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future drugs may have an adverse impact on us. If third parties have prepared and filed patent applications prior to March 16, 2013 in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the USPTO, to determine priority of invention. For more information, please see &#8220;Item 1A. Risk Factors - Risks Related to Intellectual Property and Information Technology.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">License agreement with Ligand (formerly Vernalis)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In February 2005, Rhinopharma Limited (&#8220;Rhinopharma&#8221;) entered into an assignment and license agreement with Ligand UK Development Limited (formerly Vernalis Development Limited) (&#8220;Ligand&#8221;), which since October 2018 has been a wholly owned subsidiary of Ligand Pharmaceuticals, Inc. We refer to the assignment and license agreement as the Ligand Agreement. In 2006, we acquired Rhinopharma and all its rights and liabilities under the Ligand Agreement. Pursuant to the Ligand Agreement, Ligand has assigned to us all its rights to certain patents and patent applications relating to ensifentrine and related compounds, or the Ligand Patents. We cannot further assign the Ligand Patents to a third party without Ligand's prior consent. Ligand also granted to us an exclusive, worldwide, royalty-bearing license under certain Ligand know-how to develop, manufacture and commercialize products, or the Licensed Products, based on PDE inhibitors developed using Ligand Patents, Ligand know-how and the physical stock of certain compounds, including ensifentrine, which we refer to as the Program IP, in the treatment of human or animal allergic or inflammatory disorders. Pursuant to the Ligand Agreement, we must maintain the Ligand Patents and use commercially reasonable and diligent efforts to develop and commercialize the Licensed Products. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the Ligand Agreement, we are obligated to pay Ligand a milestone payment of &#163;5.0 million upon the first approval of any regulatory authority for the commercialization of any Licensed Product, and a portion equal to a percentage in the mid-twenties of any consideration received from any of our sublicensees for Ligand Patents or Ligand know-how, excluding royalties. We must also pay Ligand, on a Licensed Product-by-Licensed Product and country-by-country basis, a low single digit percentage royalty based on net sales of each Licensed Product for a period beginning with the first commercial sale of such Licensed Product in a country and ending on the later of the expiration of a certain number of years after such first commercial sale and if applicable the expiration of the last to expire valid claim in the Ligand Patents covering the development, manufacture or commercialization of such Licensed Product in such country. Prior to the first commercial sale of each Licensed Product, such royalties also are due in the same percentages for any named patient sales. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Ligand Agreement continues until terminated by either party in accordance with its terms. Either party may terminate the Ligand Agreement for an uncured material breach, bankruptcy or insolvency of the other party. We may terminate the Ligand Agreement upon 90 days' prior written notice. Ligand may terminate the Ligand Agreement if we notify Ligand of our intention to abandon any Ligand Patents or allow any Ligand Patents to lapse. Upon termination of the Ligand Agreement, we must cease use of any Program IP and assign the Ligand Patents and any improvements thereto back to Ligand.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">GOVERNMENT REGULATION</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the clinical development, manufacture, marketing and distribution of drugs such as those we are developing. These agencies and other federal, state and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and import of our product candidates.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">FDA drug approval process </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the U.S., the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA's refusal to file an application for assessment or non approval of a pending new drug applications (&#8220;NDA&#8221;), withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The process required by the FDA before a drug may be marketed in the United States generally involves the following: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Completion of non-clinical laboratory tests, animal studies and formulation studies in compliance with the FDA's good laboratory practice (&#8220;GLP&#8221;) regulations; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Submission to the FDA of an investigational new drug application (&#8220;IND&#8221;), which must become effective before human clinical trials may begin;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Approval by an independent institutional review board (&#8220;IRB&#8221;) or ethics committee at each clinical site before each trial may be initiated; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Performance of adequate and well-controlled human clinical trials in accordance with good clinical practice (&#8220;GCP&#8221;) requirements to establish the safety and efficacy of the proposed drug product for each indication;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Submission to the FDA of an NDA after completion of all pivotal trials; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Completion of an FDA advisory committee review, if required by the FDA;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practice (&#8220;cGMP&#8221;) requirements and to assure that the facilities, methods and controls are adequate to preserve the drug's identity, strength, quality and purity, and of selected clinical investigation sites to assess compliance with GCP; and </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">FDA review and approval of the NDA and U.S. Prescribing Information to permit commercial marketing of the product for particular indications for use in the U.S..</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Non-clinical Studies </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Non-clinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the non-clinical tests, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to ship in interstate commerce and administer an investigational new drug product to humans. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Clinical Trials </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects or a legal representative provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives or endpoints of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which reviews the data and recommends whether or not a study may move forward at designated checkpoints. It may halt the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">clinical trial if it determines that there is an unacceptable safety risk or on other grounds, such as no demonstration of efficacy. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their www.clinicaltrials.gov website. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Human clinical trials are typically conducted in three phases, which may overlap or be combined: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Phase 1: The drug candidate is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Phase 2: The drug candidate is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Phase 3: The drug candidate is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Post-approval trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 trial to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new drug. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">While the IND is active and before approval, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Marketing Approval </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Assuming successful completion of the required clinical testing, the results of the pre-clinical studies and clinical trials, together with detailed information relating to the product's chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product's continued safety, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">quality and purity. Under the Prescription Drug User Fee Act guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221;of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision after it the application is submitted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or pre-clinical testing in order for FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA's satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the NDA with a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. The FDA may also require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, the Pediatric Research Equity Act (&#8220;PREA&#8221;) requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver from the FDA. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The FDA offers a number of expedited development and review programs for qualifying product candidates. For example, the fast track program is intended to expedite or facilitate the process for reviewing new products that are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a fast track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once an NDA is submitted, the product candidate may be eligible for priority review. A fast track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product candidate can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Any marketing application for a drug submitted to the FDA for approval, including a product candidate with a fast track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product candidate is eligible for priority review if it is designed to treat a serious or life-threatening disease or condition, and if approved, would provide a significant improvement in safety or effectiveness compared to available alternatives for such disease or condition. For new molecular entity NDAs, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date (as compared to ten months under standard review). </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Additionally, product candidates studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Fast track designation, breakthrough therapy designation, priority review, and accelerated approval do not change the standards for approval but may expedite the development or approval process. Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Orphan drug designation and exclusivity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 individuals in the United States and when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full NDA, to market the same drug for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA application user fee.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">A designated orphan drug many not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if a second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Post-Approval Requirements </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products under which NDA applicants must pay a substantial &#8220;program fee&#8221; for each prescription drug product approved in an NDA. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Fines, warning letters or holds on post-approval clinical trials; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Product seizure or detention, or refusal to permit the import or export of products; or </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Injunctions or the imposition of civil or criminal penalties. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Drug Product Marketing Exclusivity </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Market exclusivity provisions authorized under the FDCA can delay the submission or the approval of certain marketing applications. For example, the FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application (&#8220;ANDA&#8221;) or an NDA submitted under Section 505(b)(2) (a &#8220;505(b)(2) NDA&#8221;), submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to any preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Foreign regulation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In order to market any pharmaceutical product outside of the U.S., similar regulatory requirements, including adherence to GLP, Good Clinical Practices (&#8220;GCP&#8221;) and Good Manufacturing Practice (&#8220;GMP&#8221;), to initiate clinical trials and, subsequently, to obtain marketing approval of a new pharmaceutical product are in place in each jurisdiction. Each jurisdiction will apply these regulations in their assessment of clinical trial applications and marketing authorization applications. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another. In addition, a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In order to market our future products in the EEA (which is comprised of the 27 Member States of the EU plus Norway, Iceland and Liechtenstein) and many other foreign jurisdictions, we must obtain separate regulatory approvals. With respect to the United-Kingdom, the transition period, during which EU pharmaceutical laws continued to apply to the United Kingdom expired on December 31, 2020. The EU and the United Kingdom have concluded a trade and cooperation agreement (&#8220;TCA&#8221;), which is provisionally applicable since January 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the EEA, a clinical trial application (&#8220;CTA&#8221;) must be submitted to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and the IRB, respectively. Once the CTA is approved by the national health authority and the ethics committee has granted a positive opinion in relation to the conduct of the trial in the relevant EU Member State(s), clinical study development may proceed. The requirements and process governing the conduct of clinical studies are to a significant extent harmonized at EU level but could vary from country to country. In all cases, the clinical studies must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. The way clinical trials are conducted in the EU will undergo a major change when the Clinical Trial Regulation (Regulation (EU) No 536/2014) comes into application, probably in 2022. The Regulation harmonizes the assessment and supervision processes for clinical trials throughout the EU via a Clinical Trials Information System, which will contain a centralized EU portal and database. During the development of a pharmaceutical product, the European Medicines Agency (&#8220;EMA&#8221;) and national regulators within the EU provide the opportunity for dialogue and guidance on the development program. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the EEA, medicinal products can only be placed on the market after obtaining a Marketing Authorization (&#8220;MA&#8221;). There are two types of MAs:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">The Union MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) of the EMA, and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of human medicinal products, such as medicines derived from biotechnology processes, advanced therapy medicinal products (such as gene therapy, somatic cell therapy and tissue engineered products), orphan designated medicinal products, products that contain a new active substance indicated for the treatment of certain diseases such as HIV/AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU. Under the centralized procedure the maximum timeframe for the evaluation of a or MA application, by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP; and </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this national MA can be recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a national MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure. Under the Decentralized Procedure an identical dossier is submitted to the NCA of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the above described procedures, in order to grant the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">criteria concerning its quality, safety and efficacy. MAs have an initial duration of five years. After these five years, the authorization may be renewed on the basis of a reevaluation of the risk-benefit balance. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the PRIME scheme, which provides incentives similar to the breakthrough therapy designation in the U.S. Such products are generally eligible for accelerated assessment (according to which the timeframe for the evaluation of a MA application is reduced to 150 days, excluding clock stops) and may also benefit from different types of fast track approvals, such as a conditional marketing authorization or a marketing authorization under exceptional circumstances granted on the basis of less comprehensive clinical data than normally required (respectively in the likelihood that the sponsor will provide such data within an agreed timeframe or when comprehensive data cannot be obtained even after authorization). </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the EEA, new products authorized for marketing, or reference products, qualify for eight years of data exclusivity and an additional two years of market exclusivity upon MA. The data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial authorization of the reference product in the EU. The overall 10-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those 10 years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the EEA, MA applications for new medicinal products have to include the results of studies conducted in the pediatric population, in compliance with a pediatric investigation plan (&#8220;PIP&#8221;), agreed with the EMA's Pediatric Committee (&#8220;PDCO&#8221;). The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data is not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. We have received a waiver for pediatric data in COPD. Once the MA is obtained in all Member States of the EU and study results are included in the product information, even when negative, the product is eligible for six months' supplementary extension of the protection under a supplementary protection certificate (if any is in effect at the time of the approval) or, in the case of orphan pharmaceutical products, a two year extension of the orphan market exclusivity is granted. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The criteria for designating an &#8220;orphan medicinal product&#8221; in the European Union are similar in principle to those in the United States. A medicinal product may be designated as orphan if (1) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2) either (a) such condition affects no more than five in 10,000 persons in the European Union when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the European Union to justify investment; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the European Union, or if such a method exists, the product will be of significant benefit to those affected by the condition. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. The application for orphan drug designation must be submitted before the application for MA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, MA may be granted to a similar product for the same indication at any time if (1) the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior; (2) the applicant consents to a second orphan medicinal product application; or (3) the applicant cannot supply enough orphan medicinal product.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Similar to the United States, both marketing authorization holders and manufacturers of pharmaceutical products are subject to comprehensive regulatory oversight by the EMA, the European Commission and/or the competent regulatory authorities of the EU Member States. Failure by us or by any of our third-party partners, including suppliers, manufacturers and distributors to comply with EU and EU Member State laws that apply to the conduct of clinical trials, manufacturing approval, MA of pharmaceutical products and marketing of such products, both before </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">and after grant of the MA, manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the marketing authorization, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are also subject to privacy laws in the jurisdictions in which we are established or in which we sell or market our products or run clinical trials. For example, in Europe, we are subject to Regulation (EU) 2016/679 (General Data Protection Regulation (&#8220;GDPR&#8221;) in relation to our collection, control, processing and other use of personal data (i.e. data relating to an identifiable living individual). We process personal data in relation to participants in our clinical trials in the EEA., including the health and medical information of these participants. The GDPR is directly applicable in each EU Member State, however, it provides that EU Member States may introduce further conditions, including limitations which could limit our ability to collect, use and share personal data (including health and medical information), or could cause our compliance costs to increase, ultimately having an adverse impact on our business. The GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain a record of their data processing and implement policies as part of its mandated privacy governance framework. It also requires data controllers to be transparent and disclose to data subjects (in a concise, intelligible and easily accessible form) how their personal information is to be used, imposes limitations on retention of personal data; defines for the first time pseudonymized (i.e., key-coded) data; introduces mandatory data breach notification requirements; and sets higher standards for data controllers to demonstrate that they have obtained valid consent for certain data processing activities. We are also subject to EU rules with respect to cross-border transfers of personal data out of the EU and EEA. We are subject to the supervision of local data protection authorities in those EU jurisdictions where we are established or otherwise subject to the GDPR. Fines for certain breaches of the GDPR are significant: up to the greater of &#8364;20 million or 4% of total global annual turnover. In addition to the foregoing, a breach of the GDPR could result in regulatory investigations, reputational damage, orders to cease/change our use of data, enforcement notices, as well potential civil claims including class action type litigation where individuals suffer harm. Following the United Kingdom&#8217;s formal departure from the European Union on January 31, 2020 and the end of the transition period on December 31, 2020, the United Kingdom has become a &#8220;third country&#8221; for the purposes of EU data protection law. However, the TCA includes a provision, whereby the transfer of personal data from the EU to the United Kingdom will not be considered as a transfer to a &#8220;third country&#8221; for a period of four months starting from the entry into force of the TCA. This period will be extended by two further months, unless the EU or the United Kingdom objects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Following the United Kingdom&#8217;s formal departure from the European Union on January 31, 2020 and the end of the transition period on December 31, 2020, the United Kingdom has become a &#8220;third country&#8221; for the purposes of EU data protection law. However, the TCA includes a provision, whereby the transfer of personal data from the EU to the United Kingdom will not be considered as a transfer to a &#8220;third country&#8221; for a period of four months starting from the entry into force of the TCA. This period will be extended by two further months, unless the EU or the United Kingdom objects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Other U.S. Healthcare Laws </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition to FDA restrictions on marketing of pharmaceutical and biological products, other U.S. federal and state healthcare regulatory laws restrict business practices in the pharmaceutical industry, which include, but are not limited to, state and federal anti-kickback, false claims, data privacy and security and physician payment and drug pricing transparency laws. Similar laws exist in foreign jurisdictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The U.S. federal Anti-Kickback Statute prohibits, among other things, any person or entity from knowingly and willfully offering, paying, soliciting, receiving or providing any remuneration, directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order of any good, facility, item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term "remuneration" has been broadly interpreted to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, formulary managers and beneficiaries on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases, or recommendations may be subject to scrutiny if they do not meet the requirements of a statutory or regulatory exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the U.S. federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">a case-by-case basis based on a cumulative review of all its facts and circumstances. Several courts have interpreted the statute's intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. The majority of states also have anti-kickback laws, which establish similar prohibitions and in some cases may apply to items or services reimbursed by any third-party payor, including commercial insurers. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The federal false claims and civil monetary penalties laws, including the civil False Claims Act, prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false, fictitious or fraudulent claim for payment to, or approval by, the federal government, knowingly making, using, or causing to 67 be made or used a false record or statement material to a false or fraudulent claim to the federal government, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. A claim includes "any request or demand" for money or property presented to the U.S. government. Actions under the civil False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Violations of the civil False Claims Act can result in very significant monetary penalties and treble damages. Several pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies' marketing of products for unapproved, or off-label, uses. Moreover, a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statue constitutes a false or fraudulent claim for the purposes of the federal civil False Claims Act. In addition, the civil monetary penalties statute imposes penalties against any person who is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. Many states also have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Violations of fraud and abuse laws, including federal and state anti-kickback and false claims laws, may be punishable by criminal and civil sanctions, including fines and civil monetary penalties, the possibility of exclusion from federal healthcare programs (including Medicare and Medicaid), disgorgement and corporate integrity agreements, which impose, among other things, rigorous operational and monitoring requirements on companies. Similar sanctions and penalties, as well as imprisonment, also can be imposed upon executive officers and employees of such companies. Given the significant size of actual and potential settlements, it is expected that the government authorities will continue to devote substantial resources to investigating healthcare providers' and manufacturers' compliance with applicable fraud and abuse laws. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, the ACA broadened the reach of certain criminal healthcare fraud statutes created under HIPAA by amending the intent requirement such that a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and certain other healthcare providers. The ACA imposed, among other things, new annual reporting requirements through the Physician Payments Sunshine Act for covered manufacturers for certain payments and "transfers of value" provided to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure to submit timely, accurately and completely the required information for all payments, transfers of value and ownership or investment interests may result in significant civil monetary penalties and additional penalties for "knowing failures." Covered manufacturers must submit reports by the 90th day of each subsequent calendar year. In addition, certain states require implementation of compliance programs and compliance with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, impose restrictions on marketing practices and/or tracking and reporting of gifts, compensation and other remuneration or items of value provided to physicians and other healthcare professionals and entities. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We may also be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and their respective implementing regulations impose obligations relating to the privacy, security and transmission of individually identifiable health information held by covered entities and their business associates. Entities that are found to be in violation of HIPAA, whether as the result of a breach of unsecured PHI, a complaint about privacy practices, or an audit by HHS, may be subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same requirements, thus complicating compliance efforts. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Coverage and Reimbursement </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological products for which we obtain regulatory approval. In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products. Sales of any products for which we receive regulatory approval for commercial sale will therefore depend, in part, on the availability of coverage and adequate reimbursement from third-party payors. Third-party payors include government authorities, managed care plans, private health insurers and other organizations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the United States, the process for determining whether a third-party payor will provide coverage for a pharmaceutical or biological product typically is separate from the process for setting the price of such product or for establishing the reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the FDA-approved products for a particular indication. A decision by a third-party payor not to cover our product candidates could reduce physician utilization of our products once approved and have a material adverse effect on our sales, results of operations and financial condition. Moreover, a third-party payor's decision to provide coverage for a pharmaceutical or biological product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Additionally, coverage and reimbursement for products can differ significantly from payor to payor. One third-party payor's decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service, or will provide coverage at an adequate reimbursement rate. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payor separately and will be a time-consuming process. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the EEA, governments influence the price of products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Member States are free to restrict the range of pharmaceutical products for which their national health insurance systems provide reimbursement, and to control the prices and reimbursement levels of pharmaceutical products for human use. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed to by the government. Member States may approve a specific price or level of reimbursement for the pharmaceutical product, or alternatively adopt a system of direct or indirect controls on the profitability of the company responsible for placing the pharmaceutical product on the market, including volume-based arrangements, caps and reference pricing mechanisms.To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. Other Member States allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription products, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross border imports from low-priced markets exert a commercial pressure on pricing within a country. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of pharmaceutical or biological products have been a focus in this effort. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost-effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after FDA approval or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Healthcare Reform </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, was enacted, which, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; introduced a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care plans; imposed mandatory discounts for certain Medicare Part D beneficiaries as a condition for manufacturers' outpatient drugs coverage under Medicare Part D.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Since its enactment, the U.S. federal government has delayed or suspended implementation of certain provisions of the ACA. In addition, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. In addition, Congress could consider subsequent legislation to replace those elements of the ACA if so repealed. Further, on December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, ruled that the entire ACA is invalid based primarily on the fact that the Tax Cuts and Jobs Act of 2017 repealed the tax-based shared responsibility payment imposed by the ACA, on certain individuals who fail to maintain qualifying health coverage for all or part of a year, which is commonly referred to as the &#8220;individual mandate&#8221;. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The United States Supreme Court is currently reviewing this case, although it is unclear when a will be made. It is also unclear how other efforts to challenge or replace the ACA will impact the law. The ultimate content, timing or effect of any healthcare reform legislation on the U.S. healthcare industry is unclear. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and additional downward pressure on the price that we receive for any approved product. In particular, we anticipate that Medicare Part B will play an important role in the reimbursement of ensifentrine. Changes in how products are reimbursed through Medicare Part B may effect the overall coverage for ensifentrine, if approved. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. Moreover, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Additionally, on August 2, 2011, the Budget Control Act of 2011 created measures for spending reductions was enacted, which, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will stay in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2020, unless additional action is taken by Congress. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. More recently, there has been heightened governmental scrutiny recently over the manner in which manufacturers set prices for their marketed products, which have resulted in several recent Congressional inquiries and proposed and enacted legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products one approved or additional price increases. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Additional regulation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservation and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern the use, handling and disposal of various biologic, chemical and radioactive substances used in, and wastes generated by, operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">and governmental fines. Equivalent laws have been adopted in certain other countries that impose similar obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">U.S. Foreign Corrupt Practices Act</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The U.S. Foreign Corrupt Practices Act ("FCPA"), prohibits U.S. corporations and individuals from engaging in certain activities to obtain or retain business abroad or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. The scope of the FCPA includes interactions with certain healthcare professionals in many countries. Equivalent laws have been adopted in other foreign countries that impose similar obligations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">EMPLOYEES</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of December 31, 2020, we had 25 full-time and 2 part time employees. None of our employees is party to a collective bargaining agreement or represented by a trade union or labor union. We consider our relationship with our employees to be good.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">ADDITIONAL INFORMATION</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We were incorporated in February 2005 as Isis Resources plc under the laws of England and Wales. In September 2006, we acquired Rhinopharma Limited, a private company incorporated in Canada, and changed our name to Verona Pharma plc. Our principal office is located at 3 More London Riverside, London, SE1 2RE, United Kingdom. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We make available our public filings, including annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to those reports, with the SEC free of charge through our website at www.veronapharma.com in the &#8220;Investors&#8221; section as soon as reasonably practicable after we electronically file such material with, or furnish such material to, the SEC. The information contained in, or accessible through, our website does not constitute a part of this Annual Report.</span></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_43"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Investing in our ADSs involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report, including our consolidated financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;. The occurrence of any of the events or developments described below could adversely affect our business, financial condition, results of operations and growth prospects. In such an event, the market price of our ADSs could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Our Business and Industry</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We have a limited operating history and have never generated any product revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are a clinical-stage biopharmaceutical company with a limited operating history, and have incurred significant operating losses since our inception. We had net losses of $65.1 million and $40.6 million for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, we had an accumulated deficit of $207.1 million. Our losses have resulted principally from expenses incurred in research and development of ensifentrine, our only product candidate, and from general and administrative costs that we have incurred while building our business infrastructure. We expect to continue to incur significant operating losses for the foreseeable future as we expand our research and development efforts, advance our clinical development of ensifentrine, and seek to obtain regulatory approval for and commercialize ensifentrine. We anticipate that our expenses will increase substantially as we:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">conduct Phase 3 clinical trials of nebulized ensifentrine for the treatment of chronic obstructive pulmonary disease (&#8220;COPD&#8221;);</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">initiate and conduct clinical trials of ensifentrine for the treatment of cystic fibrosis (&#8220;CF&#8221;), asthma, COVID-19 or other indications;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">initiate and conduct other future clinical trials in other formulations, for the treatment of COPD or other indications;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">initiate and conduct clinical pharmacology studies with any formulation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">seek to discover and develop or in-license additional respiratory product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">conduct pre-clinical studies to support ensifentrine and potentially other future product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">develop the manufacturing processes and produce clinical and commercial supplies of the ensifentrine active pharmaceutical ingredient and formulated drug products derived from it;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">seek regulatory approvals of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">potentially establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize ensifentrine, if approved;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">secure, maintain or obtain freedom to operate for our in-licensed technologies and products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our product development and potential future commercialization efforts; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">expand our operations in the United States, the United Kingdom and possibly elsewhere.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our expenses may also increase substantially if we experience any delays or encounter any issues with any of the above, including, but not limited to, failed pre-clinical studies or clinical trials, complex results, safety issues or regulatory challenges.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have devoted substantially all of our financial resources and efforts to the research and development and pre-clinical studies and clinical trials of ensifentrine. We are continuing development of ensifentrine, and we have not completed development of any product candidate or any drugs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To become and remain profitable, we must succeed in developing, and eventually commercializing, products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing clinical trials of ensifentrine, discovering and developing additional product candidates, obtaining regulatory approval for ensifentrine and any future product candidates that successfully complete clinical trials, establishing manufacturing and marketing capabilities and ultimately selling any products for which we may obtain regulatory approval. We are only in the preliminary stages of many of these activities. We may never succeed in these activities and, even if we do, we may never generate revenue that is significant enough to achieve profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the FDA, the EMA, or other regulatory authorities to perform studies in addition to those we currently anticipate, or if there are any delays in completing our clinical trials or the development of ensifentrine or any other product candidates, our expenses could increase and revenue could be further delayed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Even if we do generate product royalties or product sales, we may never achieve or sustain profitability on a quarterly or annual basis. Our failure to sustain profitability would depress the market price of our ADSs and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations. A decline in the market price of our ADSs also could cause our ADS holders to lose all or a part of their investment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We will need additional funding to complete development of any future product candidates, or development of other formulations or target indications of ensifentrine, and to commercialize our products, including ensifentrine, if approved. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We expect our expenses to increase in connection with our ongoing and planned activities, particularly as we conduct our ongoing Phase 2 and Phase 3 clinical trials of ensifentrine, and develop ensifentrine for other indications. In addition, if we obtain regulatory approval for ensifentrine or any other product candidates, we expect to incur significant commercialization expenses related to activities including product positioning studies, product manufacturing, medical affairs, marketing, sales and distribution. Furthermore, we expect to incur ongoing costs associated with operating as a public company in the United States and maintaining a listing on the Nasdaq Global Market, or Nasdaq. Accordingly, we will need to obtain substantial additional funding in connection with our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we obtain regulatory approval for ensifentrine, we estimate that our existing cash resources and short-term investments will not be sufficient to commercialize ensifentrine. We will require additional funds to conduct any post-marketing studies to support the commercial positioning of ensifentrine for the treatment of COPD, if regulatory approval is received. We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner than we currently expect. In addition, our operating plan may change as a result of many factors unknown to us. These factors, among others, may necessitate that we seek additional capital sooner than currently planned. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the costs, progress and results of our ongoing Phase 3 clinical trials for the maintenance treatment of COPD;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the costs, timing and outcome of the regulatory review of ensifentrine, including any post-marketing studies that could be required by regulatory authorities, if regulatory approval is received;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the cost, progress and results of any other studies required to support the commercial positioning of ensifentrine for the treatment of COPD, if regulatory approval is received;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the cost, progress and results of any clinical trials for the treatment of CF, asthma, COVID-19 or other indications;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the cost of manufacturing clinical and, if approved, commercial supplies of the ensifentrine active ingredient and derived formulated drug products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the scope, progress, results and costs of pre-clinical development, laboratory testing and clinical trials for ensifentrine in other indications and of the development of DPI and pMDI formulations of ensifentrine for the maintenance treatment of COPD and potentially asthma and other respiratory diseases;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the costs, timing and outcome of potential future commercialization activities, including manufacturing, marketing, sales and distribution, for ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the timing and amount of revenue, if any, received from commercial sales of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the sales price and availability of adequate third-party coverage and reimbursement for ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the effect of competing technological and market developments; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for ensifentrine, although we currently have no commitments or agreements to complete any such transactions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize ensifentrine. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect our business, the holdings or the rights of our shareholders, or the value of our ordinary shares or ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue our research and development programs relating to ensifentrine or any commercialization efforts, be unable to expand our operations, or be unable to otherwise capitalize on our business opportunities, as desired, which could harm our business and potentially cause us to discontinue operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We depend heavily on the success of ensifentrine, our only product candidate under development. We cannot give any assurance that ensifentrine will receive regulatory approval for any indication, which is necessary before it can be commercialized. If we, and any collaborators with whom we may enter into agreements for the development and commercialization of ensifentrine, are unable to commercialize ensifentrine, or experience </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">significant delays in doing so, our ability to generate revenue and our financial condition will be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We do not currently generate any revenues from sales of any products, and we may never be able to develop or commercialize a marketable product. We have invested substantially all of our efforts and financial resources in the development of ensifentrine, and we do not have any other product candidate currently under development. Our ability to generate royalty and product revenues, which we do not expect will occur for at least the next several years, if ever, will depend heavily on the successful development and eventual commercialization of ensifentrine, if approved, which may never occur. Ensifentrine will require additional clinical development, management of clinical, pre-clinical and manufacturing activities, regulatory approval in multiple jurisdictions, procurement of manufacturing supply, commercialization, substantial additional investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote ensifentrine or any product candidates in the United States, Europe or other countries before we receive regulatory approval from the FDA, the EMA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for ensifentrine or any future product candidate. We have not submitted an NDA to the FDA, a Marketing Authorization Application to the EMA or comparable applications to other regulatory authorities and do not expect to be in a position to do so in the foreseeable future. The success of ensifentrine will depend on many factors, including the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may not be able to demonstrate that ensifentrine is safe and effective as a treatment for our targeted indications to the satisfaction of the applicable regulatory authorities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the applicable regulatory authorities may require additional pre-clinical or clinical trials, which would increase our costs and prolong our development;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the results of clinical trials of ensifentrine may not meet the level of statistical or clinical significance required by the applicable regulatory authorities for marketing approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the applicable regulatory authorities may disagree with the number, design, size, conduct or implementation of our planned clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the contract research organizations(&#8220;CROs&#8221;) that we retain to conduct clinical trials may take actions outside of our control that materially adversely impact our clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the applicable regulatory authorities may not find the data from pre-clinical studies and clinical trials sufficient to demonstrate that the clinical and other benefits of ensifentrine outweigh its safety risks or may disagree with our interpretation of data;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">our ability to demonstrate a non-clinical safety profile that is acceptable to the applicable regulatory authorities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">unexpected operational or clinical issues may prevent completion or interpretation of clinical study results;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">unexpected manufacturing issues, product performance issues or stability issues may delay or otherwise adversely affect the progress of our clinical development program;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the applicable regulatory authorities may not accept data generated at our clinical trial sites;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">if we submit an NDA to the FDA, and it is reviewed by an advisory committee, the FDA may have difficulties scheduling an advisory committee meeting in a timely manner or the advisory committee may recommend against approval of our application or may recommend that the FDA require, as a condition of approval, additional pre-clinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the applicable regulatory authorities may require development of a risk evaluation and mitigation strategy, or REMS, as a condition of approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the applicable regulatory authorities may identify deficiencies in the manufacturing processes or facilities of our third-party manufacturers;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the applicable regulatory authorities may change their approval policies or adopt new regulations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">if we license ensifentrine to others, the efforts of those parties in completing clinical trials of, receiving regulatory approval for, and commercializing ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">through our clinical trials, we may discover factors that limit the commercial viability of ensifentrine or make the commercialization of ensifentrine unfeasible;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">if we retain rights under a collaboration agreement for ensifentrine, our efforts in completing pre-clinical studies and clinical trials of, receiving marketing approvals for, establishing commercial manufacturing capabilities for, and commercializing ensifentrine; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">if approved, acceptance of ensifentrine by patients, the medical community and third-party payors, effectively competing with other therapies, a continued acceptable safety profile following approval and qualifying for, maintaining, enforcing and defending our intellectual property rights and claims.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">An unfavorable outcome in any of these factors could result in our experiencing significant delays or an inability to successfully commercialize ensifentrine. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We cannot be certain that ensifentrine or any future product candidates will be successful in clinical trials or receive regulatory approval. Further, ensifentrine or any future product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for ensifentrine or any future product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approvals to manufacture and market ensifentrine or any future product candidates, our revenues will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets for patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, if approved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We plan to seek regulatory approval to commercialize ensifentrine both in the United States and the EU, and potentially in additional foreign countries. While the scope of regulatory approval is similar in many countries, to obtain separate regulatory approval in multiple countries requires us to comply with the numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of ensifentrine, and we cannot predict success in these jurisdictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The COVID-19 pandemic has and may continue to adversely impact our business, including our preclinical studies and clinical trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The COVID-19 pandemic has spread to multiple countries, including countries where we have operations or planned or ongoing preclinical studies and clinical trials. Governments from many countries have established stay at home measures including, among other things, the prohibition of public gatherings and restrictions on domestic and international travel. The pandemic and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. In response to the spread of COVID-19, we have closed our principal office in the U.K. and our office in the U.S. with all employees continuing their work outside of our offices. In addition, whilst we successfully initiated our Phase 3 program in the third quarter of 2020, we are investigating the potential impact of the COVID-19 pandemic on the program cost and timelines.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">If the COVID-19 pandemic continues for a significant length of time, we may experience additional disruptions that could severely impact our business, preclinical studies and clinical trials, including in particular the cost and timelines of our Phase 3 program and:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials in certain countries;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays or difficulties in enrolling patients in our clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">disruption to manufacturers that could affect the supply of drug product for our clinical trials or difficulty sourcing key components necessary for the manufacture of ensifentrine drug substance and drug product;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including the potential for COVID-19 test shortages and interruption in global shipping that may affect the transport of clinical trial materials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">changes in local regulations as part of a response to the COVID-19 pandemic which may require us to undertake additional testing or change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue such clinical trials altogether;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others, or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">risk that participants enrolled in our clinical trials will contract COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">interruptions or delays in preclinical studies due to restricted or limited operations at our third party research and development services;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">diversion of or limitations on employee resources that would otherwise be focused on the operations of our business and the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">higher clinical trial insurance costs and/or delays in operations at insurance agencies, which may impact timelines for the issuance of insurance coverage policies and local coverage determinations delays; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">refusal of the FDA, the EMA or comparable foreign regulatory authorities to accept data from clinical trials in affected geographies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Health regulatory agencies globally may also experience disruptions in their operations as a result of the COVID-19 pandemic. The FDA, EMA and comparable foreign regulatory agencies may have slower response times or be under-resourced to review or meet to discuss our regulatory submissions, or to continue to monitor our clinical trials and, as a result, review, inspection and other timelines may be materially delayed. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The COVID-19 pandemic continues to rapidly evolve. The extent to which the pandemic impacts our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, travel restrictions and social distancing, business closures or business disruptions, the availability and efficacy of vaccines, and the effectiveness of other actions taken to contain and treat the disease.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">While the potential economic impact brought by and the duration of the COVID-19 pandemic may be difficult to assess or predict, the widespread pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, the recession or market correction resulting from the spread of COVID-19 could materially affect our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Our limited operating history may make it difficult for investors to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Since our inception in 2005, we have devoted substantially all of our resources to developing ensifentrine, building our intellectual property portfolio, developing our supply chain, planning our business, raising capital and providing general and administrative support for these operations. We have completed multiple Phase 1 and 2 clinical trials for ensifentrine, but we have not yet demonstrated our ability to successfully complete any Phase 3 or other pivotal clinical trials, obtain regulatory approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary for successful product commercialization. Additionally, we are not profitable and have incurred losses in each year since our inception, and we expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Consequently, any predictions investors make about our future success or viability may not be as accurate as they could be if we had a longer operating history.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The terms of our credit facility place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In November 2020, we and Verona Pharma, Inc. (&#8220;Verona U.S.&#8221;) entered into a loan and security agreement (the &#8220;Loan Agreement&#8221;), with Silicon Valley Bank (&#8220;SVB&#8221;), pursuant to which a term loan facility in an aggregate </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">amount of up to $30.0 million (the &#8220;Term Loan&#8221;) is available to us in three tranches. We received the first tranche of $5.0 million at closing. Only upon satisfaction of certain clinical milestones relating to ensifentrine and subject to customary terms and conditions will the following be available to the Company: (i) the second tranche will allow us to borrow an additional amount up to $10.0 million through June 30, 2022, and (ii) the third tranche will allow us to borrow an additional amount up to $15.0 million through June 30, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Term Loan is secured by a lien on substantially all of our and Verona U.S.&#8217;s assets, other than the equity interests of Verona U.S. and other than intellectual property, provided that such lien on substantially all assets includes any rights to payments and proceeds from the sale, licensing or disposition of intellectual property. We have also granted SVB a negative pledge with respect to our intellectual property.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Loan Agreement contains customary covenants and representations, including but not limited to financial reporting obligations and limitations on dividends, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. The Loan Agreement also contains other customary provisions, such as expense reimbursement, non-disclosure obligations as well as indemnification rights for the benefit of SVB. The Loan Agreement includes a minimum cash covenant triggered when our consolidated cash and cash equivalents drop below $45.0 million at any time after the occurrence of certain clinical and/or regulatory event. Upon such trigger, we would be required cash collateralize an amount equal to the outstanding obligations to SVB plus the amount of any prepayment penalty and a final payment which would be due in the event the Loan Agreement were prepaid in full with respect to the Term Loans advanced as of such time. Any such cash collateralization could have a material adverse impact on our liquidity and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The events of default under the Loan Agreement include, but are not limited to: (i) insolvency, liquidation, bankruptcy or similar events; (ii) failure to pay any debts due under the Loan Agreement or other loan documents on a timely basis; (iii) failure to observe certain covenants under the Loan Agreement; (iv) occurrence of a material adverse effect; (v) material misrepresentation by us; (vi) occurrence of any default under any other agreement involving material indebtedness; and (vii) certain material money judgments. If we default under the Loan Agreement, SVB may accelerate all of our repayment obligations and take control of our and Verona U.S.&#8217;s pledged assets, potentially requiring us to renegotiate our agreement on terms less favorable to us or to immediately cease operations. Further, if we are liquidated, the lenders&#8217; right to repayment would be senior to the rights of our ADS holders or shareholders to receive any proceeds from the liquidation. Any declaration by SVB of an event of default could significantly harm our business and prospects and could cause the price of our ADSs to decline. If we raise any additional debt financing, the terms of such additional debt could further restrict our operating and financial flexibility.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Raising additional capital may cause dilution to our holders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of securities offerings, debt financings, license and collaboration agreements and research grants. If we raise capital through securities offerings, the ownership interest of our ADS holders and shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect these holders&#8217; rights as holders of our ADSs. Debt financing, if available, could result in fixed payment obligations, and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, to acquire, sell or license intellectual property rights, to make capital expenditures, or to declare dividends, or other operating restrictions. If we raise additional funds through collaboration or licensing agreements, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. In addition, we could also be required to seek funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable. If we raise funds through research grants, we may be subject to certain requirements, which may limit our ability to use the funds or require us to share information from our research and development. Raising additional capital through any of these or other means could adversely affect our business and the holdings or rights of our ADS holders and shareholders, and may cause the market price of our ADSs to decline.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Our business may become subject to economic, political, regulatory and other risks associated with international operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As a company based in the United Kingdom, our business is subject to risks associated with conducting business internationally. Many of our suppliers and collaborative and clinical trial relationships are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular non-U.S. economies and markets;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">differing regulatory requirements for drug approvals in non-U.S. countries;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">differing jurisdictions could present different issues for securing, maintaining or obtaining freedom to operate in such jurisdictions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">potentially reduced protection for intellectual property rights;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">difficulties in compliance with non-U.S. laws and regulations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">changes in non-U.S. regulations and customs, tariffs and trade barriers;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">changes in non-U.S. currency exchange rates of the euro and currency controls;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">changes in a specific country&#8217;s or region&#8217;s political or economic environment, including the withdrawal of the United Kingdom from the EU;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">differing reimbursement regimes and price controls in certain non-U.S. markets;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">negative consequences from changes in tax laws;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">difficulties associated with staffing and managing international operations, including differing labor relations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires, or public health emergencies, such as the COVID-19 pandemic.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The United Kingdom&#8217;s withdrawal from the EU may have a negative effect on global economic conditions, financial markets and our business, which could reduce the price of our ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Following a national referendum and enactment of legislation by the government of the United Kingdom, the United Kingdom formally withdrew from the EU on January 31, 2020 and entered into a transition period during which it continued its ongoing and complex negotiations with the EU relating to the future trading relationship between the parties. The transition period ended on December 31, 2020, before which the United Kingdom and the European Commission reached an agreement on the future trading relationship between the parties (the &#8220;UK-EU Trade and Cooperation Agreement&#8221; or &#8220;TCA&#8221;). On December 30, 2020, the U.K. Parliament approved the European Union (Future Relationship) Bill, thereby ratifying the TCA. The TCA is subject to formal approval by the European Parliament and the Council of the European Union before it comes into effect and has been applied provisionally since January 1, 2021. Significant political and economic uncertainty remains about whether the terms of the relationship will differ materially from the terms before withdrawal.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">These developments, or the perception that any of them could occur, have had and may continue to have a significant adverse effect on global economic conditions and the stability of global financial markets, and could significantly reduce global market liquidity and restrict the ability of key market participants to operate in certain financial markets. Asset valuations, currency exchange rates and credit ratings may be especially subject to increased market volatility. Any of these factors could have a significant adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Further, the United Kingdom&#8217;s withdrawal from the EU has resulted in the relocation of the EMA from the United Kingdom to the Netherlands. This relocation has caused, and may continue to cause, disruption in the administrative and medical scientific links between the EMA and the U.K. Medicines and Healthcare products Regulatory Agency, including delays in granting clinical trial authorization or marketing authorization, disruption of importation and export of active substance and other components of new drug formulations, and disruption of the supply chain for clinical trial product and final authorized formulations. The cumulative effects of the disruption to the regulatory framework may add considerably to the development lead time to marketing authorization and commercialization of products in the EU and/or the United Kingdom.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Exchange rate fluctuations may materially affect our results of operations and financial condition.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Owing to the international scope of our operations, fluctuations in exchange rates, particularly between the pound sterling and the U.S. dollar, may adversely affect us. Although we are based in the United Kingdom, we source research and development, manufacturing, consulting and other services from the United States and the EU. Further, potential future revenue may be derived from abroad, particularly from the United States. As a result, our business and the price of our ADSs may be affected by fluctuations in foreign exchange rates not only between the pound sterling and the U.S. dollar, but also the currencies of other countries, which may have a significant impact on our results of operations and cash flows from period to period. Currently, we do not have any exchange rate hedging arrangements in place.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Development, Clinical Testing and Regulatory Approval</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our only product candidate, ensifentrine, is in clinical development. Clinical drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes. If clinical trials of ensifentrine are prolonged or delayed, or if ensifentrine in later stage clinical trials fails to show the desired safety and efficacy, we or our collaborators may be unable to obtain required regulatory approvals and be unable to commercialize ensifentrine on a timely basis, or at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To obtain the requisite regulatory approvals to market and sell ensifentrine, we or any collaborator for ensifentrine must demonstrate through extensive pre-clinical studies and clinical trials that ensifentrine is safe and effective in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of pre-clinical studies and early-stage clinical trials of ensifentrine may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through pre-clinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Our future clinical trial results may not be successful.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We may experience delays in our ongoing clinical trials and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Our clinical trials can be delayed, suspended, or terminated, or the utility of data from these trials may be compromised, for a variety of reasons, including the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation or continuation of clinical trials; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays in or failure to obtain regulatory agreement on clinical trial design or implementation, including dose and frequency of administration;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays in or failure to obtain regulatory authorization to commence a trial;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays in or failure to reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays in or failure to obtain institutional review board (&#8220;IRB&#8221;), or ethics committee approval at each site;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays in or failure to recruit suitable patients to participate in a trial;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">failure to have patients complete a trial or return for post-treatment follow-up;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">clinical sites deviating from trial protocol or dropping out of a trial or committing gross misconduct or fraud;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays to the addition of new clinical trial sites;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">inability to achieve or maintain double blinding of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">unexpected technical issues during manufacture of ensifentrine and the corresponding drug products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">variability in drug product performance and/or stability;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">discoveries that may reduce the commercial viability of ensifentrine;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">inability to manufacture sufficient quantities of ensifentrine for use in clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the quality or stability of ensifentrine falling below acceptable standards for either safety or efficacy;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">third-party actions claiming infringement by ensifentrine in clinical trials and obtaining injunctions interfering with our progress;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">safety or tolerability concerns causing us or our collaborators, as applicable, to suspend or terminate a trial if we or our collaborators find that the participants are being exposed to unacceptable health risks;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">changes in regulatory requirements, policies and guidelines;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">lower than anticipated retention rates of patients and volunteers in clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">failure of our third-party research contractors to comply with regulatory requirements or to meet their contractual obligations to us in a timely manner, or at all; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">difficulty in certain countries in identifying the sub-populations that we are trying to treat in a particular trial, which may delay enrollment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Review Committee or Data Safety Monitoring Board for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, failure of our clinical trials to demonstrate adequate efficacy and safety, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or other regulatory authority. The FDA or other regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or other regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or other regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we experience delays in the completion of any clinical trial of ensifentrine or any clinical trial of ensifentrine is terminated, the commercial prospects of ensifentrine may be harmed, and our ability to generate product revenues from ensifentrine, if any, will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down the development and approval process of ensifentrine and jeopardize our ability to commence product sales and generate revenue, if any. Significant clinical trial delays could also allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right to commercialize ensifentrine and could impair our ability to commercialize ensifentrine. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Clinical trials must be conducted in accordance with the laws and regulations of the FDA, EU rules and regulations and other applicable regulatory authorities&#8217; legal requirements, regulations or guidelines, and are subject to oversight by these governmental agencies and IRBs (or other Ethics Committees) at the medical institutions where the clinical trials are conducted. In addition, clinical trials must be conducted with supplies of ensifentrine produced under current good manufacturing practice, or cGMP, requirements and other regulations. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and while we have agreements governing their committed activities, we have limited influence over their actual performance. We depend on our collaborators and on medical institutions and CROs to conduct our clinical trials in compliance with good clinical practice, or GCP, requirements. To the extent our collaborators or the CROs fail to enroll participants for our clinical trials, fail to conduct the study to GCP standards or are delayed for a significant time in the execution of trials, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">including achieving full enrollment, we may be affected by increased costs, program delays or both. In addition, clinical trials that are conducted in countries outside the EU and the United States may subject us to further delays and expenses as a result of increased shipment costs, additional regulatory requirements and the engagement of non-EU and non-U.S. CROs, as well as expose us to risks associated with clinical investigators who are unknown to the FDA or the EMA, and different standards of diagnosis, screening and medical care.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Ensifentrine may have serious adverse, undesirable or unacceptable side effects which may delay or prevent marketing approval. If such side effects are identified during the development of ensifentrine or following approval, if any, we may need to abandon our development of ensifentrine, the commercial profile of any approved label may be limited, or we may be subject to other significant negative consequences following marketing approval, if any.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Undesirable side effects that may be caused by ensifentrine could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, EMA or other comparable foreign authorities. During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries, and discomforts, to their study doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. It is possible that as we test our product candidates in larger, longer and more extensive clinical trials, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in previous trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. Many times, side effects are only detectable after investigational products are tested in large-scale clinical trials or, in some cases, after they are made available to patients on a commercial scale following approval. We have completed 17 Phase 1 and 2 clinical trials of ensifentrine. In these trials, some patients have experienced mild to moderate adverse reactions, including headache, cough, worsening of COPD, nasopharyngitis and hypertension.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Results of our future clinical trials could reveal a high and unacceptable severity and prevalence of adverse side effects. In such an event, our trials could be suspended or terminated and the FDA, EMA or other comparable foreign regulatory authorities could order us to cease further development of or deny approval of ensifentrine for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Additionally, if ensifentrine receives marketing approval and we or others later identify undesirable or unacceptable side effects caused by ensifentrine, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">regulatory authorities may withdraw approvals of such products and require us to take ensifentrine off the market;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">regulatory authorities may require a medication guide outlining the risks of such side effects for distribution to patients, or that we implement a REMS plan to ensure that the benefits of ensifentrine outweigh its risks;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may be required to change the way ensifentrine is administered, conduct additional clinical trials or change the labeling of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may be subject to limitations on how we may promote ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">sales of ensifentrine may decrease significantly;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may be subject to litigation or product liability claims; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Any of these events could prevent us or any collaborators from achieving or maintaining market acceptance of ensifentrine or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may not be successful in our efforts to develop ensifentrine for multiple indications, including asthma, CF, COVID-19 or other respiratory diseases.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Part of our strategy is to continue to develop ensifentrine in indications other than COPD, such as CF, asthma and COVID-19. Although our research and development efforts to date have suggested that ensifentrine has the potential to treat CF, asthma and COVID-19, we may not be able to develop ensifentrine in these indications or any other disease, or development may not be successful. In addition, the potential use of ensifentrine in other diseases may </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">not be suitable for clinical development, including as a result of difficulties enrolling patients in any clinical studies we plan to initiate or the potential for harmful side effects or other characteristics that might suggest marketing approval and market acceptance are unlikely. If we do not continue to successfully develop and begin to commercialize ensifentrine for multiple indications, we will face difficulty in obtaining product revenues in future periods, which could significantly harm our financial position.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We depend on enrollment of patients in our clinical trials for ensifentrine. If we are unable to enroll patients in our clinical trials, or enrollment is slower than anticipated, our research and development efforts could be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Successful and timely completion of clinical trials for ensifentrine will require that we enroll a sufficient number of patient candidates. Trials may be subject to delays as a result of patient enrollment taking longer than anticipated or patient withdrawal and other external factors including COVID-19. Patient enrollment depends on many factors, including the size and nature of the patient population, the severity of the disease under investigation, eligibility criteria for the trial, the proximity of patients to clinical sites, the design of the clinical protocol, the ability to obtain and maintain patient consents, the risk that enrolled patients will drop out of a trial, the availability of competing clinical trials, the availability of new drugs approved for the indication the clinical trial is investigating and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies. These factors may make it difficult for us to enroll enough patients to complete our clinical trials in a timely and cost-effective manner. Higher than expected numbers of patients could also discontinue participation in the clinical trials. Delays in the completion of any clinical trial of ensifentrine will increase our costs, slow down our development and approval of ensifentrine and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may become exposed to costly and damaging liability claims, either when testing ensifentrine in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of pharmaceutical products. Currently, we have no products that have been approved for commercial sale; however, the current and future use of ensifentrine by us and any collaborators in clinical trials, and the sale of ensifentrine, if approved, in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies, our collaborators or others selling ensifentrine. Any claims against us, regardless of their merit, could be difficult and costly to defend and could adversely affect the market for ensifentrine or any prospects for commercialization of ensifentrine. In addition, regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">decreased demand for ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">injury to our reputation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">costs to defend related litigation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">diversion of management&#8217;s time and our resources;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">regulatory investigation, product recalls or withdrawals, or labeling, marketing or promotional restrictions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">loss of revenue; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the inability to commercialize or promote ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If ensifentrine were to cause adverse side effects during clinical trials or after approval, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Although we maintain product liability insurance for ensifentrine, it is possible that our liabilities could exceed our insurance coverage. We intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for ensifentrine. However, we may not be able to maintain insurance coverage at a </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The regulatory approval processes of the FDA, the EMA and comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for ensifentrine, our business will be substantially harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The time required to obtain approval by the FDA, the EMA and comparable foreign regulatory authorities is unpredictable, but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for ensifentrine and it is possible that ensifentrine or any product candidates we may develop in the future will never obtain regulatory approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such product candidate is safe and effective for its intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for our product candidate are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. The FDA may also require us to conduct additional preclinical studies or clinical trials for ensifentrine either prior to or post-approval, or it may object to elements of our clinical development program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ensifentrine could fail to receive regulatory approval for many reasons, including the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA, the EMA or comparable foreign regulatory authorities that ensifentrine is safe and effective, with the required level of statistical significance, for its proposed indication;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may be unable to demonstrate that ensifentrine&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the FDA, the EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from pre-clinical studies or clinical trials or may find the data to be unacceptable;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the FDA, the EMA or comparable foreign regulatory authorities may find that the dose or doses evaluated in Phase 3 clinical trials or the way in which double blinding was effected to be unacceptable;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the data collected from clinical trials of ensifentrine may, for other reasons, not be sufficient to support the submission of an NDA in the United States, an MMA in the EU, or other comparable submission to obtain regulatory approval in other countries;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the FDA, the EMA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the approval policies or regulations of the FDA, the EMA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the FDA, the EMA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the FDA, the EMA or comparable foreign regulatory authorities may disagree with our proposed product specifications and performance characteristics.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market ensifentrine. The FDA, the EMA and other regulatory authorities have substantial discretion in the approval process, and determining when or whether regulatory approval will be obtained for ensifentrine. Even if we believe the data collected from clinical trials of ensifentrine are promising, such data may not be sufficient to support approval by the FDA, the EMA or any other regulatory authority.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, even if we were to obtain approval for any jurisdiction, regulatory authorities may approve ensifentrine for fewer or more limited indications than we request, may not approve the price we intend to charge for ensifentrine, may grant approval contingent on the performance of costly post-marketing clinical trials, or may </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">approve ensifentrine with a label that does not include the labeling claims necessary or desirable for the successful commercialization of ensifentrine. Any of the foregoing scenarios could materially harm the commercial prospects for ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs or modifications to cleared or approved drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Separately, in response to the COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July 10, 2020 the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Even if ensifentrine obtains regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, ensifentrine, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If the FDA, the EMA or a comparable foreign regulatory authority approves ensifentrine, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and record keeping for ensifentrine will be subject to extensive and ongoing regulatory requirements. These requirements include payment of annual user fees, submissions of safety and other post-marketing information and reports, facility registration and drug listing, as well as continued compliance with cGMP requirements for the manufacture of ensifentrine and GCP requirements for any clinical trials that we conduct post-approval, all of which may result in significant expense and limit our ability to commercialize ensifentrine. In addition, any approval we may obtain for ensifentrine may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We and our contract manufacturers will also be subject to periodic inspection by the FDA, the EMA and other regulatory authorities to monitor compliance with these requirements and the terms of any product approval we may obtain. If we or a regulatory authority discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. In addition, failure to comply with FDA and other comparable foreign regulatory requirements may subject our company to administrative or judicially imposed sanctions, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays in or the rejection of product approvals;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">restrictions on the products, manufacturers or manufacturing process;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">warning or untitled letters;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">civil and criminal penalties;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">injunctions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">suspension or withdrawal of regulatory approvals;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">product seizures, detentions or import bans;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">voluntary or mandatory product recalls and publicity requirements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">total or partial suspension of production; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">imposition of restrictions on operations, including costly new manufacturing requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The occurrence of any event or penalty described above may inhibit our ability to commercialize ensifentrine and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, the policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, the results of the 2020 U.S. Presidential election may impact our business and industry. Namely, the Trump administration took several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict whether or how these orders will be implemented, or whether they will be rescinded and replaced under a Biden administration. The policies and priorities of an incoming presidential administration are unknown and could materially impact the regulations governing our product candidate. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If ensifentrine is approved for any indication and we are found to have improperly promoted off-label uses for ensifentrine, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of ensifentrine, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In Europe, off-label use is not per se regulated by the EU pharmaceutical legislation and a difference is made between the strict regulation of medicinal product and the use of medicinal products in medical practice. Off-label use is deferred to national regulation and may vary depending on the EU Member State(s).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Even if we obtain marketing approval of ensifentrine for any indication in a major pharmaceutical market such as the United States or EU, we may never obtain approval or commercialize ensifentrine in other major markets, which would limit our ability to realize its full market potential.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In order to market any products in a country or territory, we must establish and comply with numerous and varying regulatory requirements of such country or territory regarding safety and efficacy. Clinical trials conducted in one </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking regulatory approvals in all major markets could result in significant delays, difficulties and costs for us and may require additional pre-clinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of ensifentrine in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We currently do not have any product candidates approved for sale in any jurisdiction, whether in the EU, the United States or any other international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the full market potential of ensifentrine will be compromised.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Our employees and independent contractors, including principal investigators, consultants, vendors and collaboration partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are exposed to the risk that our employees and independent contractors, including principal investigators, consultants, vendors and collaboration partners may engage in fraudulent conduct or other illegal activities. Misconduct by these parties could include intentional, reckless or negligent conduct or unauthorized activities that violate: (i) the laws and regulations of the FDA and other similar regulatory bodies and the EU, including those laws that require the reporting of true, complete and accurate information to such authorities; (ii) manufacturing standards; (iii) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad; or (iv) laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creating fraudulent data in our pre-clinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Interim, &#8220;top-line,&#8221; or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">From time to time, we may publicly disclose top-line or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the top-line or preliminary data we previously published. As a result, top-line and preliminary data should be viewed with caution until the final data are available.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">materially change as patient enrollment continues and more patient data become available. Adverse differences between interim data and final data could significantly harm our business prospects. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If the interim, top-line or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Healthcare Laws and Other Legal Compliance Matters</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize ensifentrine and may affect the prices we may set.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the United States, the EU and other foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted, which substantially changes the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents, which is apportioned among these entities according to their market share in certain government healthcare programs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">establishment of a Center for Medicare Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. The current presidential administration and Congress will likely continue to seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the ACA. Further, on December 14, 2018, a U.S. District Court Judge in the Northern District of Texas ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the 2017 Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court&#8217;s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">remaining provisions of the ACA are invalid as well. The United States Supreme Court is currently reviewing this case, although it is unclear when a decision will be made. It is also unclear how other efforts to challenge, repeal or replace the ACA will impact the law.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, the Budget Control Act of 2011 has, among other things, led to aggregate reductions of Medicare payments to providers of 2% per fiscal year, which, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2021, unless additional action is taken by Congress. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws and any laws enacted in the future may result in additional reductions in Medicare and other health care funding, which could have a material adverse effect on our customers and accordingly, our financial operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for ensifentrine or additional pricing pressures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for ensifentrine or put pressure on our product pricing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the EU, similar political, economic and regulatory developments may affect our ability to profitably commercialize ensifentrine, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of health care in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU Member States have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of ensifentrine, restrict or regulate post-approval activities and affect our ability to commercialize ensifentrine, if approved. In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we or our collaborators are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or our collaborators are not able to maintain regulatory compliance, ensifentrine may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute ensifentrine, if approved. Such laws include:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the U.S. federal false claims and civil monetary penalties laws, including the civil False Claims Act, which, among other things, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and regulations implemented thereunder, which also imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization by covered entities subject to the rule, such as health plans, healthcare clearinghouses and healthcare providers as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the U.S. federal legislation commonly referred to as Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain health care professionals beginning in 2022, and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">analogous state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state laws governing the privacy and security of health-related and other personal information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. For example, California recently enacted the California Consumer Privacy Act, or CCPA, which went into effect on January 1, 2020. The CCPA, among other things, creates data privacy obligations for covered companies and provides expanded privacy rights to California residents, including rights to access and delete their information, to opt out of certain information sharing, and receive detailed information about how their personal information is used. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. Although the law includes limited exceptions, including for &#8220;protected health </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">information&#8221; maintained by a covered entity or business associate, it may regulate or impact our processing of personal information depending on the context; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">in the European Union, interactions between pharmaceutical companies and health care professionals and health care organizations, are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct both at EU level and in the individual EU Member States. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of pharmaceutical products is prohibited in the European Union. Relationships with healthcare professionals and associations are subject to stringent anti-gift statutes and anti-bribery laws, the scope of which differs across the EU. In addition, national &#8220;Sunshine Acts&#8221; may require pharmaceutical companies to report/publish transfers of value provided to health care professionals and associations on a regular (e.g. annual) basis. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">European and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to healthcare providers and laws governing the privacy and security of certain personal data, such as the European Union General Data Protection Regulation, or GDPR, which imposes obligations and restrictions on the collection and use of personal data relating to individuals located in the EEA (including health data). Relatedly, following the United Kingdom&#8217;s withdrawal from the EEA and the EU, and the expiry of the transition period, companies have to comply with both the GDPR and the GDPR as incorporated into United Kingdom national law, the latter regime having the ability to separately fine up to the greater of &#163;17.5 million or 4% of global turnover. The relationship between the United Kingdom and the EU in relation to certain aspects of data protection law remains unclear, for example around how data can lawfully be transferred between each jurisdiction, which exposes us to further compliance risk.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ensuring that our internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations involves substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We are subject to governmental regulation and other legal obligations in the EU and European Economic Area, or EEA, related to privacy, data protection and data security. Our actual or perceived failure to comply with such obligations could harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are subject to diverse laws and regulations relating to data privacy and security in the EU and the EEA, including the GDPR. The GDPR went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the EEA. The GDPR imposes strict obligations on the ability to process health-related and other personal data of individuals within the EEA, including in relation to use, collection, analysis, and transfer (including cross-border transfer) of such personal data. The law is also developing rapidly and, in July 2020, the Court of Justice of the EU limited how organizations could lawfully transfer personal data from the EEA to the U.S. In addition, EU and EEA member states may impose further obligations relating to the processing of genetic, biometric or health data, which could further add to our compliance costs and limit how we process this information. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Relatedly, following the United Kingdom&#8217;s withdrawal from the EEA and the European Union, and the expiry of the transition period, companies have to comply with both the GDPR and the GDPR as incorporated into United Kingdom national law, the latter regime having the ability to separately fine up to the greater of &#163;17.5 million or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">law remains unclear, for example around how data can lawfully be transferred between each jurisdiction, which exposes us to further compliance risk. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Pursuant to the EU-UK Trade and Cooperation Agreement of December 24, 2020, transfers of personal data from the European Union to the United Kingdom may continue to take place without a need for additional safeguards during a further transition period, to expire on (1) the date on which an adequacy decision with respect to the United Kingdom is adopted by the EU Commission; or (2) the expiry of four months, which shall be extended by a further two months unless either the European Union or the United Kingdom objects. It remains unclear whether the EU Commission will adopt an adequacy decision with respect to the United Kingdom. In the absence of such decision after the expiry of the additional transition period, companies may need to put in place additional safeguards for transfers of personal data from the European Union to the United Kingdom, such as standard contractual clauses approved by the EU Commission. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are also subject to evolving European privacy laws on cookies, and if we commence any EU marketing campaigns, also on e-marketing. The EU is in the process of replacing the e-Privacy Directive (2002/58/EC) with a new set of rules taking the form of a regulation, which will be directly implemented in the laws of each European Member State. The draft e-Privacy Regulation imposes strict opt-in marketing rules with limited exceptions for business-to-business communications, alters rules on third-party cookies, web beacons and similar technology and significantly increases fining powers to the greater of &#8364;20 million or 4% of total global annual revenue. While the e-Privacy Regulation was originally intended to be adopted on May 25, 2018 (alongside the GDPR), it is still going through the European legislative process.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Compliance with applicable data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure by us or our collaborators and third-party providers to comply with applicable data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose such information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend, could result in adverse publicity and could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our operations, including our research, development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, our production and development efforts may be interrupted or delayed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our operations are subject to anti-corruption laws, including the U.K. Bribery Act 2010, or Bribery Act, the U.S. Foreign Corrupt Practices Act, or FCPA, and other anti-corruption laws that apply in countries where we do business and may do business in the future. The Bribery Act, FCPA and these other laws generally prohibit us, our officers and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We may in the future operate in jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and we may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the Bribery Act, FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">of future regulatory requirements to which any of our international operations might be subject or the manner in which existing laws might be administered or interpreted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We also are subject to other laws and regulations governing any international operations, including regulations administered by the governments of the United Kingdom and the United States, and authorities in the EU, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, or, collectively, the Trade Control laws.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the Bribery Act, the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures and legal expenses. Any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control laws by U.K., U.S. or other authorities, even if it is ultimately determined that we did not violate such laws, could be costly and time consuming, require significant personnel resources and harm our reputation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We will seek to build and continuously improve our systems of internal controls and to remedy any weaknesses identified. There can be no assurance, however, that the policies and procedures will be followed at all times or effectively detect and prevent violations of the applicable laws by one or more of our employees, consultants, agents or collaborators and, as a result, we could be subject to fines, penalties or prosecution.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Commercialization</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We operate in a highly competitive and rapidly changing industry, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The biopharmaceutical and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to discover, develop and obtain marketing approval for new products on a cost-effective basis and to market them successfully. If ensifentrine is approved for any indication, we will face intense competition from a variety of businesses, including large, fully integrated pharmaceutical companies, specialty pharmaceutical companies and biopharmaceutical companies, academic institutions, government agencies and other private and public research institutions in Europe, the United States and other jurisdictions. These organizations may have significantly greater resources than we do and conduct similar research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and marketing of products that may compete with ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Given the number of products already on the market to treat COPD, asthma and CF, we expect to face intense competition if ensifentrine is approved for these indications. Companies including Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Mylan, Novartis, Vertex, Mylan, Gilead, Genentech and Sunovion currently have treatments on the market for COPD, CF and asthma, and we anticipate that new companies will enter these markets in the future. If we successfully develop and commercialize ensifentrine, it will compete with existing therapies and new therapies that may become available in the future. The highly competitive nature of, and rapid technological changes in, the biopharmaceutical and pharmaceutical industries could render ensifentrine obsolete, less competitive or uneconomical. Our competitors may, among other things:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">have significantly greater name recognition, financial, manufacturing, marketing, drug development, technical and human resources than we do, and future mergers and acquisitions in the biopharmaceutical and pharmaceutical industries may result in even more resources being concentrated in our competitors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">develop and commercialize products that are safer, more effective, less expensive, more convenient or easier to administer, or have fewer or less severe side effects;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">obtain quicker regulatory approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">establish superior proprietary positions covering our products and technologies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">implement more effective approaches to sales and marketing; or</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">form more advantageous strategic alliances.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">any collaborators we may have may decide to market and sell products that compete with ensifentrine. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side effects, are more convenient or are less expensive than ensifentrine. Our competitors may also obtain FDA or other regulatory approval for their product candidates more rapidly than we may obtain approval for ours, which could result in our competitors establishing or strengthening their market position before we are able to enter the market.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may be unable to obtain orphan drug designation from the FDA or EU for ensifentrine for the treatment of CF, and even if we do obtain such designations, we may be unable to obtain or maintain the benefits associated with orphan drug designation, including the potential for orphan drug exclusivity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is intended to treat a rare disease or condition, defined as one occurring in a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the EU, orphan drug designation may be granted to promote the development of products that are intended for the diagnosis, prevention or treatment that is life-threatening or chronically debilitating affecting not more than five in 10,000 persons in the EU and for which no satisfactory method of diagnosis, prevention or treatment of the condition concerned can be authorized, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition. Additionally, designation is granted for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary investment in developing the drug or biological product or where there is no satisfactory method of diagnosis, prevention or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding toward clinical trial costs, tax credits for qualified clinical testing and application fee waivers. In addition, if a product receives the first FDA approval of that drug for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the rare disease or condition. Under the FDA&#8217;s regulations, the FDA will deny orphan drug exclusivity to a designated drug upon approval if the FDA has already approved another drug with the same active ingredient for the same indication, unless the drug is demonstrated to be clinically superior to the previously approved drug. In the EU, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following approval. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We plan to seek orphan drug designation from the FDA and the EMA for ensifentrine for the treatment of CF. Even if we are able to obtain orphan designation for ensifentrine in the United States and/or the EU, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products, which could prevent us from marketing ensifentrine if another company is able to obtain orphan drug exclusivity before we do. In addition, exclusive marketing rights in the United States may be unavailable if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition following approval. Further, even if we obtain orphan drug exclusivity for ensifentrine, that exclusivity may not effectively protect ensifentrine from competition because different drugs with different active moieties can be approved for the same condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, the FDA or the EMA can subsequently approve products with the same active moiety for the same condition if the FDA or the EMA concludes that the later drug is clinically superior on the basis of greater safety, greater effectiveness, or a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. In addition, while we intend to seek orphan drug designation for ensifentrine for the treatment of CF, we may never receive such designation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The successful commercialization of ensifentrine will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies for </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">ensifentrine. Failure to obtain or maintain adequate coverage and reimbursement for ensifentrine, if approved, could limit our ability to market ensifentrine and decrease our ability to generate revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as ensifentrine, assuming approval. Our ability to achieve acceptable levels of coverage and reimbursement by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize ensifentrine. Assuming we obtain coverage for ensifentrine by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Moreover, for drugs and biologics administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such products. We cannot be sure that coverage and reimbursement in the United States, the EU or elsewhere will be available for ensifentrine or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider ensifentrine as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with ensifentrine, pricing of existing drugs may limit the amount we will be able to charge for ensifentrine. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in ensifentrine. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize ensifentrine, and may not be able to obtain a satisfactory financial return on ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Obtaining and maintaining reimbursement status is time consuming and costly. No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of ensifentrine to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely. Specifically, we anticipate that Medicare Part B will play an important role in the reimbursement of ensifentrine. Changes within how products are reimbursed through Medicare Part B are likely to occur and those changes may effect the overall coverage of ensifentrine in the future. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of ensifentrine. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for ensifentrine. Accordingly, in markets outside the United States, the reimbursement for ensifentrine may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for ensifentrine. We expect to experience pricing pressures in connection with the sale of ensifentrine due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, even if a pharmaceutical product obtains a marketing authorization in the European Union, there can be no assurance that reimbursement for such product will be secured on a timely basis or at all. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Ensifentrine may not gain market acceptance, in which case our ability to generate product revenues will be compromised.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Even if the FDA, the EMA or any other regulatory authority approves the marketing of ensifentrine, whether developed on our own or with a collaborator, physicians, healthcare providers, patients or the medical community may not accept or use ensifentrine. If ensifentrine does not achieve an adequate level of acceptance, we may not generate significant product revenues or any profits from operations. The degree of market acceptance of ensifentrine will depend on a variety of factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the timing of market introduction;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the number and clinical profile of competing products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the clinical indications for which ensifentrine is approved;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">our ability to provide acceptable evidence of safety and efficacy;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the prevalence and severity of any side effects;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">relative convenience, frequency, and ease of administration;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">cost effectiveness;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">marketing and distribution support;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">availability of adequate coverage, reimbursement and adequate payment from health maintenance organizations and other insurers, both public and private; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">other potential advantages over alternative treatment methods</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If ensifentrine fails to gain market acceptance, this will adversely impact our ability to generate revenues. Even if ensifentrine achieves market acceptance, the market may prove not to be large enough to allow us to generate significant revenues.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We currently have no marketing, sales or distribution infrastructure. If we are unable to develop sales, marketing and distribution capabilities on our own or through collaborations, we may not be successful in commercializing ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have no marketing, sales or distribution capabilities and we have no experience with marketing, selling or distributing pharmaceutical products. If ensifentrine is approved, we intend either to establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize ensifentrine, or to outsource this function to a third party. Either of these options would be expensive and time consuming. Some or all of these costs may be incurred in advance of any approval of ensifentrine. In addition, we may not be able to hire a sales force that is sufficient in size or has adequate expertise in the medical markets that we intend to target. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To the extent that we enter into collaboration agreements with respect to marketing, sales or distribution, our product revenue may be lower than if we directly marketed or sold ensifentrine, if approved. In addition, any revenue we receive will depend in whole or in part upon the efforts of these third-party collaborators, which may not be successful and are generally not within our control. If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize ensifentrine. If we are not successful in commercializing ensifentrine, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct our pre-clinical studies and clinical trials. If these third parties do not successfully carry out their </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize ensifentrine and our business could be substantially harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and CROs, to conduct our pre-clinical studies and clinical trials and to monitor and manage data for our ongoing pre-clinical and clinical programs. We rely on these parties for execution of our pre-clinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the EEA and comparable foreign regulatory authorities for all of our products in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we fail to exercise adequate oversight over any of our CROs or if we or any of our CROs fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot provide assurance that upon a regulatory inspection of us or our CROs or other third parties performing services in connection with our clinical trials, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under applicable cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Further, these investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to ensifentrine and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of ensifentrine, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of ensifentrine. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our existing and future CROs have or may have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. Switching or adding CROs involves additional cost and requires management&#8217;s time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays could occur, which could materially impact our ability to meet our desired clinical development timelines. In addition, if our CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for, or commercialize, ensifentrine. As a result, our results of operations and the commercial prospects for ensifentrine would be harmed, our costs could increase and our ability to generate revenues could be delayed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">If we fail to enter into new strategic relationships for ensifentrine, our business, research and development and commercialization prospects could be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our development program for ensifentrine and the potential commercialization of ensifentrine will require substantial additional cash to fund expenses. Therefore, we may decide to enter into collaborations with pharmaceutical or biopharmaceutical companies for the development and potential commercialization of ensifentrine. For example, we may seek a collaborator for development of our DPI or MDI formulation of ensifentrine for the maintenance treatment of COPD and potentially asthma and other respiratory diseases.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We face significant competition in seeking appropriate collaborators. Collaborations are complex and time consuming to negotiate and document. We may also be restricted under existing and future collaboration agreements from entering into agreements on certain terms with other potential collaborators. We may not be able to negotiate collaborations on acceptable terms, or at all. If that were to occur, we may have to curtail the development of ensifentrine, reduce or delay its development program, delay its potential commercialization or reduce the scope of our sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">terms or at all. If we do not have sufficient funds, we will not be able to bring ensifentrine to market and generate product revenue. If we do enter into a collaboration agreement, we could be subject to the following risks, among others, any of which could adversely affect our ability to develop and commercialize ensifentrine:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may not be able to control the amount and timing of resources that the collaborator devotes to the development of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the collaborator may experience financial difficulties;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may be required to relinquish important rights such as marketing, distribution and intellectual property rights;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">a collaborator could move forward with a competing product developed either independently or in collaboration with third parties, including our competitors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">business combinations or significant changes in a collaborator&#8217;s business strategy may adversely affect our willingness to complete our obligations under any arrangement; or</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the collaboration may not provide sufficient funds to be profitable for us after we fulfill our payment liabilities under our agreement with Ligand Pharmaceuticals, Inc., or Ligand, which acquired Vernalis Development Limited, or Vernalis, in October 2018.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We currently rely on third-party manufacturers and suppliers for production of the active pharmaceutical ingredient ensifentrine and its derived formulated products. Our dependence on these third parties may impair the advancement of our research and development programs and the development of ensifentrine. Moreover, we intend to rely on third parties to produce commercial supplies of ensifentrine, if approved, and commercialization could be stopped, delayed or made less profitable if those third parties fail to obtain the necessary approvals from the FDA or comparable regulatory authorities, fail to provide us with sufficient quantities of product in a timely manner or fail to do so at acceptable quality levels or prices or fail to otherwise complete their duties in compliance with their obligations to us or other parties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have limited personnel with experience in manufacturing, and we do not own facilities for manufacturing ensifentrine and its derived formulated products. Instead, we rely on and expect to continue to rely on third-party contract manufacturing organizations, or CMOs, for the supply of cGMP-grade clinical trial materials and commercial quantities of ensifentrine and its derived formulated products, if approved. While we may contract with other CMOs in the future, we currently have one CMO for the manufacture of ensifentrine drug substance and one CMO for each formulation of ensifentrine. The facilities used to manufacture ensifentrine and its derived formulated products must be approved by the FDA pursuant to inspections that will be conducted after we submit an NDA to the FDA, and by comparable foreign regulatory authorities for approvals outside the United States. While we provide sponsor oversight of manufacturing activities, we do not and will not directly control the manufacturing process of, and are or will be essentially dependent on, our CMOs for compliance with cGMP requirements for the manufacture of ensifentrine and its derived formulated products. If a CMO cannot successfully manufacture material that conforms to our specifications and the regulatory requirements of the FDA or a comparable foreign regulatory authority, it will not be able to secure or maintain regulatory approval for the manufacture of ensifentrine and its derived formulated products in its manufacturing facilities. In addition, we have little direct control over the ability of a CMO to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of ensifentrine and its derived formulated products or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would delay our development program and significantly impact our ability to develop, obtain regulatory approval for or market ensifentrine and its derived formulated products, if approved. In addition, any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacture of ensifentrine and its derived formulated products or that obtained approvals could be revoked. Furthermore, third-party providers may breach existing agreements they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement because of their own financial difficulties or business priorities, at a time that is costly or otherwise inconvenient for us. If we were unable to find an adequate replacement or another acceptable solution in time, our clinical trials could be delayed or our commercial activities could be harmed. In addition, the fact that we are dependent on our suppliers, CMOs and other third parties for the manufacture, storage and distribution of ensifentrine and its derived formulated products means that we are subject to the risk that ensifentrine and its derived formulated products may have manufacturing defects that we have limited ability to prevent, detect or control.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We rely on and will continue to rely on CMOs to purchase from third-party suppliers the materials necessary to produce ensifentrine and its derived formulated products and the inhalation and nebulization devices to deliver </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">ensifentrine. We do not and will not have any direct control over the process or timing of the acquisition of these supplies by any CMO or its third-party suppliers, or the quality or quantity of such supplies. Moreover, we currently do not have any agreements for the commercial production of these supplies. These supplies could be interrupted from time to time and, if interrupted, we cannot be certain that alternative supplies could be obtained within a reasonable timeframe, at an acceptable cost or quality, or at all. There are a limited number of suppliers for the raw materials that we may use to manufacture ensifentrine and for the drug delivery devices (e.g. nebulizers) that we use for clinical trials with ensifentrine, and we will need to assess alternate suppliers to prevent a possible disruption to our clinical trials, and if approved, ultimately to commercial sales. Although we generally do not begin a clinical trial unless we believe we have on hand, or will be able to obtain, a sufficient supply of ensifentrine to complete the clinical trial, any significant delay in the supply of ensifentrine drug products, or the raw material components needed to produce, or devices needed to deliver, ensifentrine, for an ongoing clinical trial due to our CMOs or their third-party suppliers could considerably delay completion of our clinical trials, product testing and potential regulatory approval of ensifentrine. If our CMOs, their third-party supplies, or we are unable to purchase these supplies after regulatory approval has been obtained for ensifentrine, the commercial launch of ensifentrine would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of ensifentrine. In addition, growth in the costs and expenses of these supplies may impair our ability to cost-effectively manufacture ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We rely and will continue to rely on CMOs and third-party suppliers to comply with and respect the proprietary rights of others in conducting their contractual obligations for us. If a CMO or third-party suppliers fails to acquire the proper licenses or otherwise infringes third-party proprietary rights in the course of providing services to us, we may have to find alternative CMOs or third-party suppliers, or defend against claims of infringement, either of which would significantly impact our ability to develop, obtain regulatory approval for, or market ensifentrine and any of its derived formulated products, if approved.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Intellectual Property and Information Technology</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We rely on patents and other intellectual property rights to protect ensifentrine, the enforcement, defense and maintenance of which may be challenging and costly. Failure to enforce or protect these rights adequately could harm our ability to compete and impair our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our commercial success depends in part on obtaining and maintaining patents and other forms of intellectual property rights for ensifentrine, formulations of ensifentrine, polymorphs, salts and analogs of ensifentrine, methods used to manufacture ensifentrine, methods for manufacturing of final drug product for different inhalation devices such as nebulizer, DPI, MDI, and the methods for treating patients with respiratory diseases using ensifentrine alone or in combination with other available products, or on in-licensing such rights. Our ensifentrine development program relies on the patents and patent applications assigned and know-how licensed from Ligand. The registrations of the assignment of each of these patents and patent applications with the relevant authorities in certain jurisdictions in which the patent and patent applications are registered have been granted, but there is no assurance that any additional registrations will be effected in a timely manner or at all. Failure to protect or to obtain, maintain or extend adequate patent and other intellectual property rights could adversely affect our ability to develop and market ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The patent prosecution process is expensive and time-consuming, and we or our licensors, licensees or collaborators may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions. It is also possible that we or our licensors, licensees or collaborators will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Moreover, depending on the terms of any future in-licenses to which we may become a party, in some circumstances we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology in-licensed from third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. Further, the issuance, scope, validity, enforceability and commercial value of our and our current or future licensors&#8217;, licensees&#8217; or collaborators&#8217; patent rights are highly uncertain. Our and our licensors&#8217; pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. The patent examination process may require us or our licensors, licensees or collaborators to narrow the scope of the claims of our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; pending and future patent applications, which may limit the scope of patent protection that may be obtained. We cannot provide assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">successfully issue and even if such patents cover ensifentrine, third parties may initiate an opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices, or similar proceedings challenging the validity, enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated. Our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover the technology.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Because patent applications are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were the first to file any patent application related to ensifentrine. Furthermore, if third parties have filed such patent applications on or before March 15, 2013, the date on which the U.S. patent filing system changed from a first-to-invent to a first-to-file standard, an interference proceeding can be initiated by such third parties to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. If third parties have filed such applications after March 15, 2013, a derivation proceeding can be initiated by such third parties to determine whether our invention was derived from theirs. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect our ability to develop, manufacture and market ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We cannot guarantee that any of our or our licensors&#8217; patent searches or analyses, including but not limited to the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of ensifentrine in any jurisdiction. For example, U.S. applications filed before November 29, 2000 and certain U.S. applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering ensifentrine could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover ensifentrine or the use of ensifentrine. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market ensifentrine. We may incorrectly determine that ensifentrine is not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market ensifentrine. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we fail to identify and correctly interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing ensifentrine. We might, if possible, also be forced to redesign ensifentrine so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may be involved in lawsuits to protect or enforce patents covering ensifentrine, which could be expensive, time consuming and unsuccessful, and issued patents could be found invalid or unenforceable if challenged in court.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To protect our competitive position, we may from time to time need to resort to litigation in order to enforce or defend any patents or other intellectual property rights owned by or licensed to us, or to determine or challenge the scope or validity of patents or other intellectual property rights of third parties. As enforcement of intellectual property rights is difficult, unpredictable, time consuming and expensive, we may fail in enforcing our rights&#8201;&#8212;&#8201;in which case our competitors may be permitted to use our technology without being required to pay us any license fees. In addition, however, litigation involving our patents carries the risk that one or more of our patents will be held invalid (in whole or in part, on a claim-by-claim basis) or held unenforceable. Such an adverse court ruling could allow third parties to commercialize ensifentrine, and then compete directly with us, without payment to us. If we in-license intellectual property rights, our agreements may give our licensors the first right to control claims of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">third-party infringement, or to defend validity challenges. Therefore, these patents and patent applications may not be enforced or defended in a manner consistent with the best interests of our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we were to initiate legal proceedings against a third party to enforce a patent covering one of our products, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States or in Europe, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the U.S. Patent and Trademark Office, or USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on ensifentrine. Patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without infringing our patents or other intellectual property rights.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts, industry commentators or investors perceive these results to be negative, it could have an adverse effect on the price of our ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our commercial success depends, in part, upon our ability, and the ability of our future collaborators, to develop, manufacture, market and sell our product candidates without alleged or actual infringement, misappropriation or other violation of the patents and proprietary rights of third parties. There have been many lawsuits and other proceedings involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and reexamination proceedings before the USPTO and corresponding foreign patent offices. The various markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. In addition, many companies in intellectual property-dependent industries, including the biopharmaceutical and pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage over their competitors. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing ensifentrine. Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that ensifentrine may be subject to claims of infringement of the intellectual property rights of third parties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to ensifentrine and any future product candidates, including interference or derivation proceedings, post grant review and inter partes review before the USPTO or similar adversarial proceedings or litigation in other jurisdictions. Similarly, we or our licensors or collaborators may initiate such proceedings or litigation against third parties, for example, to challenge the validity or scope of intellectual property rights controlled by third parties. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our compositions, formulations, or methods of treatment, prevention or use, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires or is finally determined to be invalid or unenforceable. Such licenses may not be available on reasonable terms, or at all, or may be non-exclusive thereby giving our competitors access to the same technologies licensed to us.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we fail in any such dispute, we may be forced to pay damages, including the possibility of treble damages in a patent case if a court finds us to have willfully infringed certain intellectual property rights. We or our licensees may be temporarily or permanently prohibited from commercializing ensifentrine or from selling, incorporating, manufacturing or using our products in the United States and/or other jurisdictions that use the subject intellectual property. We might, if possible, also be forced to redesign ensifentrine so that we no longer infringe the third-party intellectual property rights, which may result in significant cost or delay to us, or which redesign could be technically infeasible. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, if the breadth or strength of protection provided by our or our licensors&#8217; or collaborators&#8217; patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Although we are not currently experiencing any claims challenging the inventorship of our patents or ownership of our intellectual property, we may in the future be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. While it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. For example, the assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, or we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, such perceptions could have a substantial adverse effect on the price of our ADSs. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have an adverse effect on our ability to compete in the marketplace.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">If we fail to comply with our obligations under our existing and any future intellectual property licenses with third parties, we could lose license rights that are important to our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are party to a license agreement with Ligand, under which we in-license certain intellectual property and were assigned certain patents and patent applications related to our business. We may enter into additional license agreements in the future. We expect that any future license agreements would impose various diligence, milestone payment, royalty, insurance and other obligations on us. Any uncured, material breach under these license agreements could result in our loss of rights to practice the patent rights and other intellectual property licensed to us under these agreements, and could compromise our development and commercialization efforts for ensifentrine or any future product candidates. Under our agreement with Ligand, we may not abandon any of the assigned patents or allow any of the assigned patents to lapse without consent from Ligand, which is not to be unreasonably delayed or withheld. If we do not obtain such consent in a timely manner or at all and such assigned patent rights lapse or are abandoned, our agreement with Ligand may be terminated in its entirety. For example, if we decide for commercial reasons to let an assigned patent lapse in a country of little commercial importance, but Ligand does not provide consent and such patent rights lapse, we may lose all intellectual property rights covering ensifentrine in multiple markets. Moreover, our future licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may not be successful in maintaining the necessary rights to ensifentrine or obtaining other intellectual property rights important to our business through acquisitions and in-licenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We currently own and have in-licensed rights to intellectual property, including patents, patent applications and know-how, relating to ensifentrine, and our success will likely depend on maintaining these rights. Because our programs may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license, maintain or use these proprietary rights. In addition, ensifentrine may require specific formulations to work effectively and the rights to these formulations may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property rights that we identify as necessary for ensifentrine. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies also are pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We may also be unable to license or acquire third-party intellectual property rights on a timely basis, on terms that would allow us to make an appropriate return on our investment, or at all. Even if we are able to obtain a license to intellectual property of interest, we may not be able to secure exclusive rights, in which case others could use the same rights and compete with us. If we are unable to successfully obtain a license to third-party intellectual property rights necessary for the development of ensifentrine or a development program on acceptable terms, we may have to abandon development of ensifentrine or that development program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our competitive position may be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We do not currently own any registered trademarks. We may not be able to obtain trademark protection in territories that we consider of significant importance to us. If we register trademarks, our trademark applications may be rejected during trademark registration proceedings. Although we will be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, any of our trademarks or trade names, whether registered or unregistered, may be challenged, opposed, infringed, cancelled, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential collaborators or customers in our markets of interest. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. If other entities use trademarks similar to ours in different jurisdictions, or have senior rights to ours, it could interfere with our use of our current trademarks throughout the world.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">If we do not obtain protection under the Hatch-Waxman Amendments and similar non-U.S. legislation for extending the term of patents covering ensifentrine and any other product candidates, our ability to compete effectively could be impaired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. The issued patents covering the composition of matter for ensifentrine expired in 2020, and our other issued patents will expire in 2031 to 2041, subject to any patent extensions that may be available for such patents. If patents are issued on our pending patent applications, the resulting patents are projected to expire on dates ranging from 2031 to 2036. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering ensifentrine are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including generic medications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Depending upon the timing, duration and conditions of the FDA marketing approval of ensifentrine, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and similar legislation in the EU. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We enjoy only limited geographical protection with respect to certain patents and may face difficulties in certain jurisdictions, which may diminish the value of our intellectual property rights in those jurisdictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We generally file our first patent application, or priority filing, at the United Kingdom Intellectual Property Office. International applications under the Patent Cooperation Treaty, or PCT, are usually filed within 12 months after the priority filing. Based on the PCT filing, national and regional patent applications may be filed in additional jurisdictions where we believe a product candidate may be marketed or manufactured. We have so far not filed for patent protection for ensifentrine in all national and regional jurisdictions where such protection may be available. Filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, we may decide to abandon national and regional patent applications before grant. The grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant patent offices, while granted by others. For example, unlike other countries, China has a heightened requirement for patentability, and specifically requires a detailed description of medical uses of a claimed drug. Furthermore, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors&#8217; patents, requiring us or our licensors to engage in complex, lengthy and costly litigation or other proceedings. Generic drug manufacturers may develop, seek approval for and launch generic versions of our products. It is also quite common that depending on the country, the scope of patent protection may vary for the same product candidate or technology.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Competitors may use our or our licensors&#8217; or collaborators&#8217; technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we or our licensors or collaborators have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our and our licensors&#8217; or collaborators&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or rules and regulations in the United States and the EU, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Some countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Others may be able to make compounds that are the same as or similar to our product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">The patents of third parties may impair our ability to develop or commercialize our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We or our licensors or any future strategic collaborators might not have been the first to conceive or reduce to practice the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We or our licensors or any future collaborators might not have been the first to file patent applications covering certain of our inventions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">It is possible that our pending patent applications will not lead to issued patents.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Third parties performing manufacturing or testing for us using our product candidates or technologies could use the intellectual property of others without obtaining a proper license.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We may not develop additional technologies that are patentable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect ensifentrine or any future product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological complexity and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. In addition, the America Invents Act, or the AIA, which was passed on September 16, 2011, resulted in significant changes to the U.S. patent system.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">An important change introduced by the AIA is that, as of March 16, 2013, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO, after that date but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. This requires us to be cognizant of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#8217; or collaboration partners&#8217; patent applications and the enforcement or defense of our or our licensors&#8217; or collaboration partners&#8217; issued patents.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. Similarly, the complexity and uncertainty of European patent laws has also increased in recent years. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and protect other proprietary information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We consider proprietary trade secrets and confidential know-how and unpatented know-how to be important to our business. We may rely on trade secrets or confidential know-how to protect our technology, especially where patent protection is believed to be of limited value. However, trade secrets and confidential know-how are difficult to maintain as confidential.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To protect this type of information against disclosure or appropriation by competitors, our policy is to require our employees, consultants, contractors and advisors to enter into confidentiality agreements with us. We also seek to preserve the integrity and confidentiality of our data, trade secrets and know-how by maintaining physical security of our premises and physical and electronic security of our information technology systems. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. We cannot guarantee that our trade secrets and other proprietary and confidential information will not be disclosed or that competitors will not otherwise gain access to our trade secrets. However, current or former employees, consultants, contractors and advisors may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Enforcing a claim that a third party obtained illegally and is using trade secrets and/or confidential know-how is expensive, time consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. Furthermore, if a competitor lawfully obtained or independently developed any of our trade secrets, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Failure to obtain or maintain trade secrets and confidential know-how trade protection could adversely affect our competitive position. Moreover, our competitors may independently develop substantially equivalent proprietary information and may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, our competitors could limit our use of our trade secrets and/or confidential know-how.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Many of our employees, including our senior management, were previously employed at universities or at other biopharmaceutical companies, including our competitors or potential competitors. Some of these employees executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. Litigation may be necessary to defend against these claims.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we successfully prosecute or defend against such claims, litigation could result in substantial costs and distract management.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors or collaboration partners fail to maintain the patents and patent applications covering our product candidates, our competitors might be able to enter the market, which would hurt our competitive position and could impair our ability to successfully commercialize any product candidate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Our proprietary information, or that of our manufacturers, suppliers and other parties that we use to conduct our pre-clinical and clinical trials and any future collaborators, may be lost or we may suffer security breaches.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the ordinary course of our business, we and our manufacturers, suppliers and third parties that we use to conduct our pre-clinical and clinical trials, collect and store sensitive data, including intellectual property, clinical trial data, proprietary business information and personally identifiable information of our clinical trial subjects and employees, in our and third-party data centers and on our and third-party networks. The secure processing, maintenance and transmission of this information is critical to our operations. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Although to our knowledge we have not experienced any such material security breach to date, any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal data including the GDPR, regulatory penalties, disrupt our operations, damage our reputation, and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our reputation and delay clinical development of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Our information technology systems, and that of our manufacturers, suppliers and other third parties that we use to conduct our pre-clinical and clinical trials, could experience serious disruptions that could distract our operations and cause delays in our research and development work.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection to the Internet, and that of our manufacturers, suppliers and other third parties that we use to conduct our pre-clinical and clinical trials, face the risk of systemic failure that could disrupt our operations. A significant disruption in the availability of these information technology and other internal infrastructure systems could cause interruptions in our collaborations and delays in our research and development work.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Employee Matters and Managing Growth</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Our future growth and ability to compete depends on the successful transition of our CEO and CFO roles, retaining our key personnel and recruiting additional qualified personnel.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our success depends upon the contributions of our key management, scientific and technical personnel, many of whom have been instrumental for us and have substantial experience with ensifentrine and related technologies. On February 3, 2020 we announced the appointment of David Zaccardelli as chief executive officer with effect from February 1, 2020, following the retirement of Jan-Anders Karlsson, PhD. We also announced the appointment of Mark Hahn as chief financial officer with effect from March 1, 2020, as successor to Piers Morgan. We anticipate that we will experience a transitional period until our new chief executive officer and chief financial officer are fully integrated into their new roles and the transition may not be successful. Moreover, we cannot provide any assurance that the transition in leadership will not result in a disruption that adversely impacts our business and employee morale, or that successful working relationships between our other key management individuals and the new chief executive officer and chief financial officer will be developed.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our other key management individuals include our general counsel, Claire Poll, our chief medical officer, Kathleen Rickard, our senior vice president, chemistry manufacturing and controls, Peter Spargo, our vice president, regulatory affairs, Desiree Luthman, our vice president of commercial, Christopher Martin, and our vice president, R&amp;D operations, Tara Rheault. The loss of key managers and senior scientists could delay our research and development activities. In addition, the competition for qualified personnel in the biopharmaceutical and pharmaceutical field is intense, and our future success depends upon our ability to attract, retain and motivate highly skilled scientific, technical and managerial employees. We face competition for personnel from other companies, universities, public and private research institutions and other organizations. If our recruitment and retention efforts are unsuccessful in the future, it may be difficult for us to achieve our product candidate development objectives, raise additional capital and implement our business strategy.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We expect to expand our development, regulatory and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Our ADSs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Certain of our shareholders, members of our board of directors, and senior management own a majority of our ordinary shares (including ordinary shares represented by ADSs) and as a result, are be able to exercise significant control over us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of December 31, 2020, our senior management, board of directors and greater than 5% shareholders and their respective affiliates, in the aggregate, owned approximately 21% of our ordinary shares (including ordinary shares represented by ADSs) assuming no exercise of outstanding options or warrants, and approximately 33% of our ordinary shares, assuming exercise of all options available for exercise and outstanding warrants. Depending on the level of attendance at our general meetings of shareholders, these shareholders either alone or voting together as a group may be in a position to determine or significantly influence the outcome of decisions taken at any such general meeting. Any shareholder or group of shareholders controlling more than 50% of the share capital present and voting at our general meetings of shareholders may control any shareholder resolution requiring a simple majority, including the appointment of board members, certain decisions relating to our capital structure, and the approval of certain significant corporate transactions. Among other consequences, this concentration of ownership may have the effect of delaying or preventing a change in control and might therefore negatively affect the market price of our ADSs and ordinary shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Because we do not anticipate paying any cash dividends on our ADSs or ordinary shares in the foreseeable future, capital appreciation, if any, will be our ADS holders&#8217; and shareholders&#8217; sole source of gains and they may never receive a return on their investment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under current English law, a company&#8217;s accumulated realized profits must exceed its accumulated realized losses (on a non-consolidated basis) before dividends can be paid. Therefore, we must have distributable profits before issuing a dividend. We have not paid dividends in the past on our ordinary shares. We intend to retain earnings, if any, for use in our business and do not anticipate paying any cash dividends in the foreseeable future. As a result, capital appreciation, if any, on our ADSs or ordinary shares will be our ADS holders&#8217; and shareholders&#8217; sole source of gain for the foreseeable future, and they will suffer a loss on their investment if they are unable to sell their ADSs or ordinary shares at or above the price at which they were purchased. Investors seeking cash dividends should not purchase our ADSs or ordinary shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Holders of our ADSs may not have the same voting rights as the holders of our ordinary shares and may not receive voting materials in time to be able to exercise their right to vote.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Holders of our ADSs are not be able to exercise voting rights attaching to the ordinary shares evidenced by our ADSs on an individual basis. Holders of our ADSs have appointed a depositary as their representative to exercise the voting rights attaching to the ordinary shares represented by their ADSs. Holders of our ADSs may not receive </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">voting materials in time to instruct the depositary to vote, and it is possible that they,or persons who hold their ADSs through brokers, dealers or other third parties, will not have the opportunity to exercise a right to vote. Furthermore, the depositary will not be liable for any failure to carry out any instructions to vote, for the manner in which any vote is cast or for the effect of any such vote. As a result, holders of our ADSs may not be able to exercise voting rights and may lack recourse if their ADSs are not voted as requested. In addition, holders of our ADSs will not be able to call a shareholders&#8217; meeting.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Holders of our ADSs may not receive distributions on our ordinary shares represented by our ADSs or any value for them if it is illegal or impractical to make them available to them.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The depositary for our ADSs has agreed to pay to holders of our ADSs the cash dividends or other distributions it or the custodian receives on our ordinary shares or other deposited securities after deducting its fees and expenses. Holders of our ADSs will receive these distributions in proportion to the number of our ordinary shares their ADSs represent. However, in accordance with the limitations set forth in the deposit agreement entered into with the depositary, it may be unlawful or impractical to make a distribution available to holders of our ADSs. We have no obligation to take any other action to permit the distribution of our ADSs, ordinary shares, rights or anything else to holders of our ADSs. This means that holders of our ADSs may not receive the distributions we make on our ordinary shares or any value from them if it is unlawful or impractical to make the distributions available to them. These restrictions may have a material adverse effect on the value of our ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Holders of our ADSs may be subject to limitations on transfer of their ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">ADSs are transferable on the books of the depositary. However, the depositary may close its transfer books at any time or from time to time when it deems expedient in connection with the performance of its duties. In addition, the depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary deems it advisable to do so because of any requirement of law or of any government or governmental body, or under any provision of the deposit agreement, or for any other reason in accordance with the terms of the deposit agreement. These limitations on transfer may have a material adverse effect on the value of our ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are incorporated under English law. The rights of holders of ordinary shares and, therefore, certain of the rights of holders of ADSs, are governed by English law, including the provisions of the Companies Act 2006, and by our Articles of Association. These rights differ in certain material respects from the rights of shareholders in typical U.S. corporations. As a result, investors in our ordinary shares or ADSs may not have the same protections or rights as they would if they had invested in a U.S. corporation. This may make our ADSs less attractive to such investors, which could harm the value of our ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Claims of U.S. civil liabilities may not be enforceable against us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are incorporated under English law. Substantially all of our assets are located outside the United States. The majority of our senior management and board of directors reside outside the United States. As a result, it may not be possible for investors to effect service of process within the United States upon such persons or to enforce judgments obtained in U.S. courts against them or us, including judgments predicated upon the civil liability provisions of the U.S. federal securities laws.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The United States and the United Kingdom do not currently have a treaty providing for recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters. Consequently, a final judgment for payment given by a court in the United States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in the United Kingdom. In addition, uncertainty exists as to whether U.K. courts would entertain original actions brought in the United Kingdom against us or our directors or senior management predicated upon the securities laws of the United States or any state in the United States. Any final and conclusive monetary judgment for a definite sum obtained against us in U.S. courts would be treated by the courts of the United Kingdom as a cause of action in itself and sued upon as a debt at common law so that no retrial of the issues would be necessary, provided that certain requirements are met. Whether these requirements are met in respect of a judgment based upon the civil liability provisions of the U.S. securities laws, including whether the award of monetary damages under such laws would constitute a penalty, is an issue for the court making such decision. If an English court gives judgment for the sum payable under a U.S. judgment, the English judgment will be enforceable by methods generally available for this purpose. These methods generally permit the English court discretion to prescribe the manner of enforcement.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As a result, U.S. investors may not be able to enforce against us or our senior management, board of directors or certain experts named herein who are residents of the United Kingdom or countries other than the United States any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">As of January 1, 2021, we were no longer a foreign private issuer and we are required to comply with the provisions of the Exchange Act, and the rules of Nasdaq, applicable to U.S. domestic issuers, which will continue to require us to incur significant expenses and expend time and resources.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of January 1, 2021, we were no longer a foreign private issuer, and we are required to comply with all of the provisions applicable to a U.S. domestic issuer under the Exchange Act, including filing an annual report on Form 10-K, quarterly periodic reports and current reports for certain events, complying with the sections of the Exchange Act regulating the solicitation of proxies, requiring insiders to file public reports of their share ownership and trading activities and insiders being liable for profit from trades made in a short period of time. We are also no longer exempt from the requirements of Regulation FD promulgated under the Exchange Act related to selective disclosures. We are also no longer permitted to follow our home country&#8217;s rules in lieu of the corporate governance obligations imposed by Nasdaq, and are required to comply with the governance practices required by U.S. domestic issuers listed on Nasdaq. We are also required to comply with all other rules of Nasdaq applicable to U.S. domestic issuers, including that our articles of association specify a quorum of no less than one-third of our outstanding voting common shares for meetings of our common shareholders, the solicitation of proxies and the approval by our shareholders in connection with certain events such as the acquisition of stock or assets of another company, the establishment of or amendments to equity-based compensation plans for employees, a change of control and certain private placements. In addition, we are required to report our financial results under U.S. generally accepted accounting principles, including our historical financial results, which have previously been prepared in accordance with IFRS.The regulatory and compliance costs associated with the reporting and governance requirements applicable to U.S. domestic issuers may be significantly higher than the costs we previously incurred as a foreign private issuer. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The regulatory and compliance costs associated with the reporting and governance requirements applicable to U.S. domestic issuers may be significantly higher than the costs we previously incurred as a foreign private issuer. We expect to continue to incur significant legal, accounting, insurance and other expenses and to expend greater time and resources to comply with these requirements. In addition, we may need to develop our reporting and compliance infrastructure and may face challenges in complying with the new requirements applicable to us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We are an &#8220;emerging growth company,&#8221; and we cannot be certain if the reduced reporting requirements applicable to &#8220;emerging growth companies&#8221; will make our ADSs less attractive to investors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For as long as we continue to be an EGC, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not EGCs, including not being required to comply with the auditor attestation requirements of Section 404, not being required to present selected financial data for any period prior to the earliest audited period presented in our first registration statement, and exemptions from the requirement of holding a shareholder nonbinding advisory vote on executive compensation and golden parachute payments and from having to disclose the ratio of compensation of our chief executive officer to the median compensation of our employee. We may take advantage of these exemptions until we are no longer an EGC. We could be an EGC for up to five years, although circumstances could cause us to lose that status earlier, including if the aggregate market value of our ADSs and ordinary shares held by non-affiliates exceeds $700 million as of any June 30 (the end of our second fiscal quarter), in which case we would no longer be an emerging growth company as of the following December 31 (our fiscal year-end). We cannot predict if investors will find our ADSs less attractive because we may rely on these exemptions. If some investors find our ADSs less attractive as a result, there may be a less active trading market for our ADSs and the price of our ADSs may be more volatile.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inadequate internal controls </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Management will be required to assess the effectiveness of our internal controls annually. However, for as long as we are an EGC, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404. An independent assessment of the effectiveness of our internal controls could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements requiring us to incur the expense of remediation and could also result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may have inadvertently violated Section 13(k) of the Exchange Act (implementing Section 402 of the Sarbanes-Oxley Act of 2002) and may be subject to sanctions as a result.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Section 13(k) of the Exchange Act provides that it is unlawful for a company, such as ours, that has a class of securities registered under Section 12 of the Exchange Act to, directly or indirectly, including through any subsidiary, extend or maintain credit in the form of a personal loan to or for any director or executive officer of the company. In August 2018, a receivable arose with respect to taxes due upon the vesting of restricted share units held by one of our directors and two of our executive officers, which may have violated Section 13(k) of the Exchange Act. The receivable was repaid, with interest, in March 2019, as soon as management became aware of the possible violation. Issuers that are found to have violated Section 13(k) of the Exchange Act may be subject to civil sanctions, including injunctive remedies and monetary penalties, as well as criminal sanctions. The imposition of any of such sanctions on us could have a material adverse effect on our business, financial position, results of operations or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Changes in our tax rates, unavailability of certain tax credits or reliefs or exposure to additional tax liabilities or assessments could affect our profitability, and audits by tax authorities could result in additional tax payments for prior periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We carry out research and development activities including, but not limited to, developing ensifentrine for various indications and delivery methods, and as a result we benefit in the U.K. from the HM Revenue and Customs, or HMRC, small and medium sized enterprises research and development relief, or SME R&amp;D Relief, which provides relief against U.K. Corporation Tax.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Broadly, SME R&amp;D Relief comprises two elements, (a) allowing qualifying SMEs to deduct a total of 230% (an additional 130% deduction plus the usual 100% deduction) of their qualifying expenditure from their yearly profit for U.K. Corporation Tax purposes, or the SME R&amp;D Additional Deduction and, (b) where there are not sufficient profits for U.K. Corporation Tax purposes to fully utilize the SME R&amp;D Additional Deduction, the excess (&#8220;surrenderable losses&#8221;) can be carried forward to offset against future taxable profits, or a tax credit currently equal to 14.5% of such surrenderable loss can be claimed in cash, or the SME R&amp;D Tax Credit.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Based on criteria established by HMRC a portion of expenditure incurred in relation to our research and development activities including, but not limited to, operating clinical trials, manufacturing, consultant and salary and related costs, is eligible for the SME R&amp;D Additional Deduction. Our consequential surrenderable losses are currently eligible for the SME R&amp;D Tax Credit, in accordance with HMRC criteria.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the financial statements for the year ended December 31, 2019, we recorded an SME R&amp;D Tax Credit of $9.3 million which was subsequently received in cash in the year ended December 31, 2020. For the year ended December 31, 2020, we recorded an SME R&amp;D Tax Credit of $8.3 million, which we expect to receive in the year ended December 31, 2021. We estimate that in the financial years 2021-2023 we could be eligible to receive $25 million&#8201;&#8211;&#8201;$35 million in cash from HMRC in SME R&amp;D Tax Credits (including the 2020 tax credit).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Legislation has been proposed that will, if enacted, limit the amount of SME R&amp;D Tax Credit a company can claim in a period to &#163;20,000 plus 300% of such company&#8217;s liability for Pay As You Earn (&#8220;PAYE&#8221;) and national insurance contributions, from 1 April 2021. There can be no assurance that the U.K. Government will not amend the program further, impacting the timing or amount of credits, or discontinue it entirely.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are currently reviewing recent clarifications to the proposed legislation to evaluate the effect on our financing strategy. It is possible that our tax credit for the 2021 financial year, payable in 2022, will be impacted by the cap. If the legislation is enacted as currently drafted, we estimate the cash receivable under this program could be approximately $15 million lower than currently anticipated for 2021 and $6 million lower for 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Taxation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We believe we will likely be classified as a passive foreign investment company for U.S. federal income tax purposes for the taxable year ended December 31, 2020, which could result in adverse U.S. federal income tax consequences to U.S. investors in our ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Because we do not earn revenue from our business operations, and because our sole source of income currently is interest on bank accounts held by us, we believe we will likely be classified as a &#8220;passive foreign investment company,&#8221; or PFIC, for the taxable year ended December 31, 2020. A non-U.S. company will be considered a PFIC for any taxable year if (i) at least 75% of its gross income is passive income (including interest income), or (ii) at least 50% of the value of its assets (based on an average of the quarterly values of the assets during a taxable year) is attributable to assets that produce or are held for the production of passive income. If we are classified as a PFIC in any year with respect to which a U.S. Holder (as defined below) owns our ordinary shares or ADSs, we will continue to be treated as a PFIC with respect to such U.S. Holder in all succeeding years during which the U.S. Holder owns our ordinary shares or ADSs, regardless of whether we continue to meet the PFIC test described above, unless the U.S. Holder makes a specified election once we cease to be a PFIC. If we are classified as a PFIC for any taxable year during which a U.S. Holder holds our ordinary shares or ADSs, certain adverse U.S. federal income tax consequences could apply to such U.S. Holder, including (i) the treatment of all or a portion of any gain on disposition as ordinary income, (ii) the application of a deferred interest charge on such gain and the receipt of certain dividends and (iii) the obligation to comply with certain reporting requirements. A &#8220;U.S. Holder&#8221; is a holder who, for U.S. federal income tax purposes, is a beneficial owner of our ordinary shares or ADSs who is a citizen or individual resident of the United States, a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the District of Columbia; or an estate or trust the income of which is subject to U.S. federal income taxation regardless of its source. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">If a U.S. Holder is treated as owning at least 10% of our ordinary shares or ADSs, such holder may be subject to adverse U.S. federal income tax consequences.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If a U.S. Holder (as defined above) is treated as owning, directly, indirectly or constructively, at least 10% of the value or voting power of our ordinary shares or ADSs, such U.S. Holder may be treated as a &#8220;United States shareholder&#8221; with respect to each &#8220;controlled foreign corporation&#8221; or &#8220;CFC&#8221; in our group, if any. Because our group includes one or more U.S. subsidiaries, certain of our non-U.S. subsidiaries could be treated as CFCs, regardless of whether we are treated as a CFC. A United States shareholder of a controlled foreign corporation may be required to annually report and include in its U.S. taxable income its pro rata share of &#8220;Subpart F income,&#8221; &#8220;global intangible low-taxed income&#8221; and investments in U.S. property by CFCs, regardless of whether we make any distributions. An individual that is a United States shareholder with respect to a CFC generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a United States shareholder that is a U.S. corporation. Failure to comply with these reporting obligations may subject a United States shareholder to significant monetary penalties and may prevent the statute of limitations with respect to such shareholder&#8217;s U.S. federal income tax return for the year for which reporting was due from starting. We cannot provide any assurances that we will assist our investors in determining whether any of our non-U.S. subsidiaries are treated as a CFC or whether such investor is treated as a United States shareholder with respect to any of such CFCs. Further, we cannot provide any assurances that we will furnish to any United States shareholder information that may be necessary to comply with the reporting and tax paying obligations described in this risk factor. U.S. Holders should consult their tax advisors regarding the potential application of these rules to their investment in our ordinary shares or ADSs.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">General Risks</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The price of our ADSs may be volatile and may fluctuate due to factors beyond our control.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The trading market for publicly traded emerging biopharmaceutical and drug discovery and development companies has been highly volatile and is likely to remain highly volatile in the future. The market price of our ADSs may fluctuate significantly due to a variety of factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">positive or negative results from, or delays in, clinical trials of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">developments in our competitors&#8217; businesses;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays in entering into collaborations and strategic relationships with respect to development or commercialization of ensifentrine or entry into collaborations and strategic relationships on terms that are not deemed to be favorable to us;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">technological innovations or commercial product introductions by us or competitors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">changes in government regulations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">developments concerning proprietary rights, including patents and litigation matters;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">public concern relating to the commercial value or safety of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">financing or other corporate transactions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">publication of research reports or comments by securities or industry analysts or commentators;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">general market conditions in the pharmaceutical industry or in the economy as a whole;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the loss of any of our key scientific or senior management personnel;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">sales of our ADSs by us, our senior management or board members, and significant holders of our ADSs; or</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">other events and factors, many of which are beyond our control.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">These and other market and industry factors may cause the market price and demand for our ADSs to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from readily selling their ADSs and may otherwise negatively affect the liquidity of our ADSs. In addition, the stock market in general, and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the issuer. If any of the holders of our ADSs were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the attention of our senior management would be diverted from the operation of our business. Any adverse determination in litigation could also subject us to significant liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Future sales, or the possibility of future sales, of a substantial number of our ADSs or ordinary shares could adversely affect the price of our ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Future sales of a substantial number of our ADSs or ordinary shares, or the perception that such sales will occur, could cause a decline in the market price of our ADSs. Sales in the United States of our ADSs and ordinary shares held by our directors, officers and affiliated shareholders are subject to restrictions. If these shareholders sell substantial amounts of ordinary shares or ADSs in the public market, or the market perceives that such sales may occur, the market price of our ADSs and our ability to raise capital through an issue of equity securities in the future could be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If securities or industry analysts or commentators publish inaccurate or unfavorable research, about our business, the price of our ADSs and ordinary shares and our trading volume could decline.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The trading market for our ADSs and ordinary shares depends in part on the research and reports that securities or industry analysts or commentators publish about us or our business. If one or more of the analysts who cover us downgrade our ADSs or if they or other industry commentators publish inaccurate or unfavorable research or comments about our business, the price of our ADSs and ordinary shares would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our ADSs could decrease, which might cause the price of our ADSs and ordinary shares and trading volume to decline.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We have incurred and expect to continue to incur increased costs as a result of operating as a public company in the United States, and our senior management are required to devote substantial time to new compliance initiatives and corporate governance practices.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As a U.S. public company, and particularly after we no longer qualify as an emerging growth company, or EGC, we have incurred and expect to continue to incur significant legal, accounting and other expenses that we did not incur prior to becoming a U.S. public company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq and other applicable securities rules and regulations impose various requirements on non-U.S. reporting public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our senior management and other personnel have devoted and will need to continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, we are required to furnish a report by our senior management on our internal control over financial reporting. However, while we remain an EGC, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To prepare for eventual compliance with Section 404, once we no longer qualify as an EGC, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed time frame or at all, that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_48"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 1B.&#160;&#160;&#160;&#160;Unresolved Staff Comments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">None.</span></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_66"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 2.&#160;&#160;&#160;&#160;Properties</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our corporate headquarters is in leased office space at 3 More London Riverside, London, U.K. The leases on the offices expire in the first quarter of 2022. We also have office space at 8045 Arco Corporate Drive, Suite 130, Raleigh, NC 27617, USA, that expires in the second quarter of 2024. We have vacated premises in New York after consolidating our U.S. operations in North Carolina but continue to hold the lease until the third quarter of 2021. We believe that these facilities are adequate to meet our current and near term needs.</span></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_61"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 3.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently subject to any material legal proceedings.</span></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_56"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 4.&#160;&#160;&#160;&#160;Mine Safety Disclosures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Not applicable.</span></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_79"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART II</span></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_86"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 5.&#160;&#160;&#160;&#160;Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Market Information and Holders</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Prior to October 30, 2020, our ordinary shares were traded on the AIM Market of the London Stock Exchange under the symbol &#8220;VRP&#8221;. We canceled the admission of the ordinary shares to trading on AIM on October 30, 2020 and our ordinary shares are now not publicly traded. Our American Depositary Shares (&#8220;ADSs&#8221;) have been publicly traded on the Nasdaq Global Market under the symbol &#8220;VRNA&#8221; since April 27, 2017.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Each ADS represents eight ordinary shares of Verona Pharma plc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of February 19, 2021, 94.5% of our ordinary shares are held in ADS form, between 73 holders. The 5.5% balance of our ordinary shares are held as unlisted ordinary shares between 436 holders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Dividends</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have never declared or paid any dividends on our common stock. We anticipate that we will retain all of our future earnings, if any, for use in the operation and expansion of our business and do not anticipate paying cash dividends in the foreseeable future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Recent Sales of Unregistered Securities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On July 17, 2020, we issued securities in a private placement (&#8220;Private Placement&#8221;) with new and existing institutional and accredited investors. The Private Placement comprised a placement, in reliance upon the exemption from securities registration afforded by the provisions of Section 4(a)(2) of Regulation D of the Securities Act, of 38,440,009 ADSs, each representing eight Ordinary Shares or non-voting Ordinary Shares of the Company, at a price of $4.50 per ADS, and 48,088,896 of the Company&#8217;s Ordinary Shares at the equivalent price per Ordinary Share of $0.5625.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The net proceeds of the Private Placement were approximately $185.5 million after deducting fees paid to Jefferies LLC in its role as placement agent and associated expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The securities were subsequently registered on a registration statement on Form F-1 filed with the SEC on August 17, 2020 (File No. 333-247928), as amended.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Use of Proceeds</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In May 2017, we completed the initial public offering of our ADSs in the United States and a private placement of our ordinary shares in Europe, or the global offering. In the global offering we issued and sold 6,501,738 ADSs, including 733,738 ADSs issued and sold upon the partial exercises by the underwriters pursuant to their overallotment option to purchase additional ADSs, at a public offering price of $13.50 per ADS, and 1,225,001 ordinary shares at an offering price of &#163;1.32 per share. We received aggregate gross proceeds from the global offering of approximately $89.9 million, and aggregate net proceeds of approximately $80.8 million after deducting underwriting discounts and commissions of approximately $6.3 million and offering expenses of approximately $3.2 million. No payments for such expenses were made directly or indirectly to (i) any of our officers, members of our board of directors, or their associates, (ii) any persons owning 10% or more of any class of our equity securities or (iii) any of our affiliates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The offer and sale of the ADSs and ordinary shares in the global offering were registered under the Securities Act pursuant to a registration statement on Form F-1 (File No. 333-217124) to register ordinary shares, which was declared effective by the SEC on April 26, 2017, a registration statement on Form F-1 to register additional ordinary shares (File No. 333-217487), which was immediately effective upon filing on April 26, 2017, and a registration statement on Form F-6 (File No. 333-217353) to register the ADSs, which was declared effective by the SEC on April 26, 2017, or, collectively, the Registration Statements. Under the Registration Statements, we registered an aggregate offering price of approximately $91.7 million of ordinary shares and 100,000,000 ADSs for a registered aggregate offering price of $5.0 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">There has been no material change in our planned use of the net proceeds from the global offering as described in our final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on April 28, 2017. As of December 31, 2018, we had used all of the net proceeds from the global offering.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_121"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 6.&#160;&#160;&#160;&#160;Selected Financial Data</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this Item 6.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_116"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 7.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the consolidated financial statements and the related notes to those statements included later in this Annual Report on Form 10-K. In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, beliefs and expectations that involve risks and uncertainties. Our actual results and the timing of events could differ materially from those discussed in these forward-looking statements. Important factors that could cause or contribute to these differences include those discussed below and elsewhere in this Annual Report on Form 10-K, particularly in Part I, Item 1A. &#8220;Risk Factors&#8221; and the section entitled &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221;</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical need. Our product candidate, ensifentrine, is an investigational, potential first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4, or PDE3 and PDE4, that is designed to act as both a bronchodilator and an anti-inflammatory agent. In the third quarter of 2020 we commenced our Phase 3 ENHANCE trials and, if approved, we intend to commercialize ensifentrine for the maintenance treatment of COPD for the nebulized formation in the U.S.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have incurred recurring losses and negative cash flows from operations since inception, and have an accumulated deficit of $207.1 million as of December 31, 2020. We expect to incur additional losses and negative cash flows from operations until our product candidates potentially gain regulatory approval and reach commercial profitability, if at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">continue to invest in the clinical development of ensifentrine for the treatment of COPD;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">manufacture ensifentrine and engage in other Chemistry, Manufacturing and Control activities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">maintain, expand and protect our intellectual property portfolio; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">enhance our commercial insights and capabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On July 17, 2020, we raised $200 million in a private placement (the "Private Placement"), with net proceeds after transaction related fees and expenses of $185.5 million. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In November 2020, we and Verona Pharma, Inc. ("Verona U.S.") entered into a term loan facility of up to $30.0 million (the &#8220;Term Loan&#8221;), consisting of term loan advances in an aggregate amount of $5.0 million funded at closing, a term loan advance available subject to certain terms and conditions in an aggregate amount of $10.0 million, and a term loan advance available subject to certain terms and conditions in an aggregate amount of $15.0 million with Silicon Valley Bank (&#8220;SVB&#8221;). See &#8220;Indebtedness&#8221; below.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We believe that our cash and cash equivalents as of December 31, 2020, together with funding expected to become available under the Term Loan and from cash receipts from U.K. tax credits, will enable us to fund our planned operating expenses and capital expenditure requirements into 2023. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">COVID-19 impact and business continuity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To help protect the health and safety of the patients, caregivers and healthcare professionals involved in its ongoing clinical trials of ensifentrine, as well as our employees and independent contractors, we continue to follow guidance from the FDA and other health regulatory authorities regarding the conduct of clinical trials during the COVID-19 pandemic to ensure the safety of study participants, minimize risks to study integrity, and maintain compliance with good clinical practice. We continue to review this guidance and the effect of the COVID-19 pandemic on our operations and clinical trials and will provide an update if we become aware of any meaningful disruption caused by the pandemic to our clinical trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are closely monitoring activities at our contract manufacturers associated with clinical supply for our ongoing clinical trials, and are satisfied that appropriate plans and procedures are in place to ensure uninterrupted future supply of ensifentrine to the clinical trial sites, subject to potential limitations on their operations and on the supply chain due to the COVID-19 pandemic. We continue to monitor this situation and will provide an update if we become aware of any meaningful disruption caused by the pandemic to the clinical supply of ensifentrine for our clinical trials.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Significant contracts</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Ligand agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In 2006 we acquired Rhinopharma and assumed contingent liabilities owed to Ligand UK Development Limited (&#8220;Ligand&#8221;) (formerly Vernalis Development Limited). We refer to the assignment and license agreement as the Ligand Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ligand&#160;assigned to us all of its rights to certain patents and patent applications relating to ensifentrine and related compounds (the "Ligand Patents") and an exclusive, worldwide, royalty-bearing license under certain Ligand know-how to develop, manufacture and commercialize products (the "Licensed Products") developed using Ligand Patents, Ligand know-how and the physical stock of certain compounds.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The contingent liability comprises a milestone payment on obtaining the first approval of any regulatory authority for the commercialization of a Licensed Product, low single digit royalties based on the future sales performance of all Licensed Products and a portion equal to a mid-twenty percent of any consideration received from any sub-licensees for the Ligand Patents and for Ligand know-how.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At time of the acquisition the contingent liability was not recognized as part of the acquisition accounting as it was immaterial. We will therefore record as an R&amp;D expense the milestone payment or royalties when they are payable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Warrants</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On July 29, 2016, as part of a placement we issued warrants to investors. The warrant holders can subscribe for an ordinary share at a per share exercise price of &#163;1.7238. They can also opt for a cashless exercise of their warrants whereby they can choose to exchange the warrants held for a reduced number of warrants exercisable at nil consideration.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If, after a transaction, should the warrants be exercisable for unlisted securities, the warrant holders may demand a cash payment instead of the delivery of the underlying securities. Accordingly, they are accounted for as a liability under ASC 480 &#8220;Distinguishing Liabilities from Equity&#8221; and recorded at fair value </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">using the Black-Scholes valuation methodology, on recognition and at each reporting date. The warrants are currently exercisable and may be exercised by the holders until April 2022 when the warrant instruments may either be exercised, cashlessly exercised, or expire. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Loan and security agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In November, 2020, we entered into the Term Loan. See &#8220;Indebtedness&#8221; for additional information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Critical accounting policies and significant judgments and estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP"). The preparation of these financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities as of the dates of the balance sheets and the reported amounts of expenses during the reporting periods. In accordance with US GAAP, we evaluate our estimates and judgments on an ongoing basis.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">While our significant accounting policies are described in more detail in the notes to our financial statements appearing elsewhere in this Annual Report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Stock-based compensation and warrants</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have share-based compensation plans under which various types of equity-based awards may be granted, including stock options and restricted stock units (RSUs). The fair value of share options and RSUs is recognized as compensation expense using the cliff vesting method; f</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">orfeitures are recognized as they occur. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We use the fair-value based method to determine compensation for all arrangements under which employees receive shares, using the Black-Scholes methodology. The warrants are recorded at fair value, also using this methodology.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Black-Scholes valuation methodology uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Expected volatility for options is based on the historical volatility of our ordinary shares. For warrants, it is based on a basket of the Company&#8217;s and similar entities&#8217; share or ADS prices.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The expected term of options granted is derived using the simplified method, which computes the expected term as the average of the sum of the vesting term plus the contract term. For the warrants the expected term is assumed to be until expiry of the instruments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Historically the risk-free rate has been based on the appropriate U.K. government debt yield. After delisting its Ordinary shares from AIM on October 30, 2020, the Company began using U.S. government debt yields.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Research and development costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Research and development (&#8220;R&amp;D&#8221;) costs are charged to the consolidated statements of operations and comprehensive loss, as incurred. As part of the process of preparing financial statements we are required to estimate our expenses resulting from our obligation under contracts with vendors and consultants and clinical site agreements in connection with our R&amp;D efforts. The financial terms of these contracts are subject to negotiations which vary contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. Our objective is to reflect the appropriate clinical trial expenses in our financial statements by matching those expenses with the period in which services and efforts are expended. We account for these expenses according to the progress of the trials and other development activities measured by patient progression and the timing of various aspects of the trial. We also determine prepaid and accrual estimates through discussions with applicable personnel and outside service providers as to the progress of clinical trials, or other services completed. During the course of a clinical trial, we may adjust our rate of clinical trial expense recognition if actual results differ from its estimates. We make estimates of its prepaid and accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known at that time. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low for any particular period. Our clinical trial prepaid and accrual expense is dependent upon the timely and accurate reporting of study recruitment from contract research organizations and activities carried out by other third-party vendors as well as the timely processing of any change orders from the contract research organizations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Components of results of operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We anticipate that our expenses will increase substantially if and as we:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">conduct our ongoing Phase 3 clinical trials for ensifentrine for the maintenance treatment of COPD;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">continue the clinical development of our DPI and pMDI formulations of ensifentrine and research and develop other formulations of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">initiate and conduct further clinical trials for ensifentrine for the treatment of acute COPD, CF or any other indication;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">initiate and progress pre-clinical studies relating to other potential indications of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">seek to discover and develop additional product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">seek regulatory approvals for any of our product candidates that successfully complete clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">potentially establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any products for which we may obtain regulatory approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our product development and potential future commercialization efforts and to support our continuing operations as a U.S. public company; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">experience any delays or encounter any issues from any of the above, including but not limited to failed studies, complex results, safety issues or other regulatory challenges.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Operating expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">R&amp;D costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">R&amp;D costs consist of salary and personnel related costs and third party costs for our research and development activities for ensifentrine. Personnel related costs include a share based compensation charge relating to our stock option plan. The largest component of third party costs is for clinical trials, as well as manufacturing for clinical supplies and associated development, and pre-clinical studies. Research and development costs are expensed as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We expect our research and development costs to significantly increase in the near future as we progress our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">ENHANCE program. Due to the nature of research and development, the expected costs are inherently uncertain and may vary significantly from our current expectations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">General and administrative costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">General and administrative costs consist of salary and personnel related costs, including share based expense, expenses relating to operating as a public company, including professional fees, insurance and commercial related costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We expect commercial costs to increase as we continue to develop our potential commercial operations and, in the event of successful regulatory approval, we expect to incur sales force, marketing and other launch related costs. As we develop our knowledge of the market and refine our commercialization plans, expected costs may vary significantly from our current expectations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Other income / (expense)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other income / (expense) are driven by interest income and foreign exchange movements on cash and cash equivalents, interest income and the U.K. tax credits.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are entitled to participate in the U.K. Small and Medium Enterprises R&amp;D tax relief program. The tax credits are calculated as a percentage of qualifying research and development expenditure and are payable in cash by the U.K. government to the Company. Credits recorded in the 2020 financial year are expected to be received in the 2021 financial year.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The U.K. tax authorities have reviewed legislation and have proposed to cap the amount payable in the program to a multiple of employment taxes a company pays in the year in question, from April 1, 2021. We are currently reviewing recent clarifications to these proposed changes to review the effect on our financing strategy. It is possible that our tax credit for the 2021 financial year, payable in 2022, will be impacted by the cap. If the legislation is enacted as currently drafted, we estimate the potential cash received under this program could be approximately $15 million and $6 million lower than currently anticipated in 2022 and 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Taxation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are subject to corporate taxation in the United States and the United Kingdom. We have generated losses since inception and have therefore not paid United Kingdom corporation tax. The income taxes presented in our consolidated statements of operations and comprehensive loss represents the tax impact from our operating activities in the United States, which generates taxable income based on intercompany service arrangements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">United Kingdom losses may be carried forward indefinitely to be offset against future taxable profits, subject to various utilization criteria and restrictions. The amount that can be offset each year is limited to &#163;5.0 million plus an incremental 50% of U.K. taxable profits.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Results of Operations for the years ended December 31, 2020 and 2019</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In prior periods, we prepared our financial information in accordance with IFRS. As a consequence of becoming a U.S. domestic issuer as of January 1, 2021, we are required to present our financial information in accordance with US GAAP and expressed in U.S. dollars from that date. The below financial information has been prepared in accordance with US GAAP. The financial information should not be expected to correspond to figures we have previously presented under IFRS.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows our statements of operations for the years ended December 31, 2020 and 2019, (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Variance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,277&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,403&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,874&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,403)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,874)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income / (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from R&amp;D tax credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(843)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value movement on warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,136)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gain / (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(399)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,277&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,914&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,637)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,489)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,511)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,146)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,561)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,585)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Research and development costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Research and development costs were $44.5 million for the year ended December 31, 2020, compared to $42.4 million for the year ended December 31, 2020, an increase of $2.1 million. This increase was primarily due to a $7.7 million increase in share-based compensation charges and a $1.0 million increase in salary and related costs as we increased the development team in 2019 and 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Offsetting this, clinical trial costs fell by $5.2 million from 2019 to 2020. There were seven clinical trials (ongoing, in preparation or closing down) in 2020 compared to five in 2019, but the costs related to the Phase 2b four-week clinical study with ensifentrine added on to tiotropium in 2019 were significantly higher than the start-up costs of the ENHANCE program in 2020. Additionally, travel, manufacturing and development related consulting expenses were $1.4 million lower in 2020 compared to 2019.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">General and administrative costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">General and administrative costs were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">$29.8 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> for the year ended 2020 compared to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">$10.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> for the year ended 2019, an increase of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">$19.8 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. This increase was driven primarily by an $11.4 million increase in s</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">hare-based compensation charges, $3.0 million related to severance and other executive change costs, a $2.5 million increase in Directors&#8217; and Officers&#8217; insurance, $1.9 million of expenses relating to the Private Placement and a $1.0 million increase in professional fees, office close down costs and foreign exchange movements, partially offset by lower travel and other expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Other income / (expense)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The R&amp;D tax credit for 2020 was $8.3 million compared to a credit of $9.3 million for the year ended December 31, 2019, a decrease of $1.0 million.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> This reduction is attributable to our lower qualifying expenditure on research and development in 2020 compared to 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Interest received on cash and short term investments decreased by $0.8 million due to lower overall interest rates and a change in our investment policy to use lower yielding government debt money market funds compared to term deposits previously utilized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The foreign exchange gain of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">$2.1 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> in 2020 and loss of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">$0.4 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> in 2019 relate to the foreign exchange movements on the cash and short term investments the Company holds in pounds sterling.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Net loss</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Net loss was $65.1 million for the year ended December 31, 2020, compared to $40.6 million for the year ended December 31, 2019. The increase in net loss was primarily the result of the increase in operating costs and the fall in other income, net, discussed above.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Cash flows</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table summarizes our cash flows for the years ended December 31, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Variance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at beginning of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,076)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,868)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,604)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of the year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,986&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,428&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,558&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Operating activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Net cash used in operating activities increased to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">$45.1 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> 2020, from </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">$42.9 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> in 2019, an increase of $2.2 million. Operating expenses increased by $19.8 million, however $19.1 million of this was the non-cash share based compensation expense. The remaining variance of $1.5 million is due to the timing of supplier payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Investing activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Net cash provided by investing activities decreased to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">$9.7 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> for 2020, from </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">$47.3 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> in 2019 due to less movement of funds from short term investments to cash in 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Financing activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Net cash provided by financing activities was $192.3 million for 2020 driven by net proceeds from the Private Placement and the first advance received under the Term Loan. We received $185.5 million after costs in the Private Placement. Of the costs, $1.9 million were recorded in the statement of operations and comprehensive loss and therefore included in net cash used in operating activities. Financing activities also includes a net $4.9 million receipt from the term loan facility. There was no cash provided by financing activities during the year ended December 31, 2019.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Liquidity and capital resources</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We do not currently have any approved products and have never generated any revenue from product sales or otherwise. To date, we have financed our operations primarily through the issuances of our equity securities, including warrants, and in 2020 from borrowings under the Term Loan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have incurred recurring losses since inception, including net losses of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">$65.1 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">$40.6 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">for the years ended December 31, 2020, and 2019, respectively. In addition, as of December 31, 2020, we had an accumulated deficit of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">$207.1 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. We expect to continue to generate operating losses for the foreseeable future.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In July 2020, we raised approximately $200 million in the Private Placement with new and existing institutional and accredited investors. The Private Placement comprised a placement of 38,440,009 ADSs, each representing eight Ordinary Shares or non-voting Ordinary Shares of the Company, at a price of $4.50 per ADS, and 48,088,896 of the Company&#8217;s Ordinary Shares at the equivalent price per Ordinary Share of $0.5625.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The net proceeds of the Private Placement </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">were</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> approximately $185.5 million after deducting placement agent fees and associated expenses (including costs recorded to both equity and as expense in the consolidated statement of operations and comprehensive loss).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have no ongoing material financing commitments, such as lines of credit or guarantees, that are expected to affect our liquidity over the next five years, other than leases and the Term Loan with Silicon Valley Bank.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Indebtedness</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In November, 2020, we and Verona Pharma, Inc. (the &#8220;Borrowers&#8221;) entered into the Term Loan facility of up to $30.0 million, consisting of term loan advances in an aggregate amount of $5.0 million funded at closing, a term loan advance available subject to certain terms and conditions in an aggregate amount of $10.0 million (the &#8220;Term B Loan&#8221;) and a term loan advance available subject to certain terms and conditions in an aggregate amount of $15.0 million (the &#8220;Term C Loan&#8221;), with Silicon Valley Bank, a California corporation (&#8220;SVB&#8221;), the proceeds of which will be used for general corporate and working capital purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Term Loan is governed by a loan and security agreement, dated as of November 19, 2020, between the Borrowers and SVB (the &#8220;Loan Agreement&#8221;). The Term B Loan will be available, subject to and customary terms and conditions, during the period commencing upon the achievement of a specific clinical milestone relating to ensifentrine through and including June 30, 2022. The Term C Loan will be available, subject to customary terms and conditions, during the period commencing upon the achievement of an additional specific clinical milestone relating to ensifentrine through and including June 30, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Term Loan will mature on November 1, 2024. Each advance under the Term Loan accrues interest at a floating per annum rate equal to the greater of (a) the sum of the prime rate reported in The Wall Street Journal plus 1.00% and (b) four and one-quarter of one percent (4.25%). The Term Loan provides for interest-only payments on a monthly basis until the payment date immediately preceding December 1, 2023. Thereafter, amortization payments will be payable monthly in equal installments of principal plus monthly payments of accrued interest. Upon repayment (whether at maturity, upon acceleration or by prepayment or otherwise), the Borrowers shall make a final payment to SVB in the amount of 10% of the aggregate Term Loans advanced (the "Final Payment"). The Borrowers may prepay the Term Loan in full but not in part provided that the Borrowers (i) provide ten days prior written notice to SVB, (ii) pays on the date of such prepayment (A) all outstanding principal plus accrued and unpaid interest, (B) a prepayment fee of $450,000 plus 3.0% of the Term C Loans advanced if paid on or before the first anniversary of the closing date; $300,000 plus 2.00% of the Term C Loans advanced if paid after the first anniversary of the closing date and on or before the second anniversary of the closing date; and $150,000 plus 1.00% of the Term C Loans advanced if paid thereafter and prior to maturity, (C) the Final Payment and (D) all other sums, if any, that shall become due and payable with respect to the Term Loan Advances, including interest at the Default Rate with respect to any past due amounts. Amounts outstanding during an event of default are payable upon SVB's demand and shall accrue interest at an additional rate of 3.0% per annum.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Term Loan is secured by a lien on substantially all of the assets of the Borrowers, other than the equity interests of Verona U.S. and other than intellectual property, provided that such lien on substantially all assets includes any rights to payments and proceeds from the sale, licensing or disposition of intellectual property. The Borrowers have also granted SVB a negative pledge with respect to its intellectual property.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Loan Agreement contains customary covenants and representations, including but not limited to financial reporting obligations and limitations on dividends, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. The Loan Agreement also contains other customary provisions, such as expense reimbursement, non-disclosure obligations as well as indemnification rights for the benefit of SVB. The Loan Agreement includes a minimum cash covenant triggered when Borrowers' consolidated cash and cash equivalents drop below $45.0 million at any time after the earliest to occur of any of the following: (i) the release of negative data from Enhance 2 and/or Enhance 1, which in the reasonable business discretion of Borrowers&#8217; senior management, would be considered insufficient to support submission of an NDA to the FDA, (ii) the FDA issues a complete response letter with respect to an NDA submitted for ensifentrine, or (iii) failure to achieve a specific regulatory milestone relating to ensifentrine by June 30, 2023 (extendable to March 31, 2024 upon the Borrowers receiving a specified amount of new cash proceeds after </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">September 8, 2020 from the sale of equity securities in one or more public financings or other bona fide equity financings, subordinated debt and/or upfront/milestone payments from one or more collaboration agreements not prohibited in the Loan Agreement). Upon such trigger, Borrowers must cash collateralize an amount equal to the outstanding obligations to SVB plus the amount of any prepayment penalty and Final Payment which would be due in the event the Loan Agreement were prepaid in full with respect to the Term Loans advanced as of such time.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The events of default under the Loan Agreement include, but are not limited to, the Borrowers&#8217; failure to make any payments of principal or interest under the Loan Agreement or other transaction documents, the Borrowers&#8217; breach or default in the performance of any covenant under the Loan Agreement or other transaction documents, the occurrence of a material adverse change, any Borrower making a false or misleading representation or warranty in any material respect under the Loan Agreement, any Borrower&#8217;s insolvency or bankruptcy, any attachment or judgment on any Borrower&#8217;s assets of at least $500,000, or the occurrence of any default under any agreement or obligation of any Borrower involving indebtedness in excess of $500,000. If an event of default occurs, SVB is entitled to take enforcement action, including acceleration of amounts due under the Loan Agreement.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Funding requirements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We initiated our Phase 3 ENHANCE program for the maintenance treatment of COPD in the third quarter of 2020 after raising funds in the Private Placement that we estimated to be the required funds to complete this program. We believe that our cash and cash equivalents as of December 31, 2020, together with funding expected to become available under the Term Loan and from cash receipts from U.K. tax credits, will enable us to fund our planned operating expenses and capital expenditure requirements into 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We will require significant additional capital to further advance clinical and regulatory activities, to fund prelaunch and launch related costs and to create an effective sales and marketing organization to commercialize ensifentrine. We will need to seek additional funding through public or private financings, debt financing, collaboration or licensing agreements and other arrangements. However, there is no guarantee that we will be successful in securing additional finance on acceptable terms, or at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our shareholders and ADS holders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect such holders&#8217; rights as a shareholder or ADS holder. Any future debt financing or preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute our security holders&#8217; ownership interests.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our future capital requirements for ensifentrine or any future product candidates will depend on many factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the progress, timing and completion of pre-clinical testing and clinical trials for ensifentrine or any future product candidates and the potential that we may be required to conduct additional clinical trials for ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the number of potential new product candidates we decide to in-license and develop;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the costs involved in growing our organization to the size needed to allow for the research, development and potential commercialization of ensifentrine or any future product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the costs involved in filing patent applications and maintaining and enforcing patents or defending against claims or infringements raised by third parties;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the time and costs involved in obtaining regulatory approvals for ensifentrine or any future product candidate we develop and any delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to ensifentrine or any future product candidates;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">any licensing or milestone fees we might have to pay during future development of ensifentrine or any future product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">selling and marketing activities undertaken in connection with the anticipated commercialization of ensifentrine or any future product candidates, if approved, and costs involved in the creation of an effective sales and marketing organization; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the amount of revenues, if any, we may derive either directly or in the form of royalty payments from future sales of ensifentrine or any future product candidates, if approved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if ever. Accordingly, we will need to obtain substantial additional funds to achieve our business objective.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Off-balance sheet arrangements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We do not have any relationships with unconsolidated entities or financial partnerships, including entities sometimes referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. We do not engage in off-balance sheet financing arrangements. In addition, we do not engage in trading activities involving non-exchange traded contracts. We therefore believe that we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these relationships.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Recent accounting pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For a discussion of pending and recently adopted accounting pronouncements, see Note 2 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K</span></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_310"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Conversion from IFRS to US GAAP</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As the Company no longer qualifies as a Foreign Private Issuer, its consolidated financial statements have been retroactively converted from IFRS to US GAAP.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The significant differences between IFRS and US GAAP as they relate to the Company are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(a) Rhinopharma acquisition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In connection with the Rhinopharma acquisition in 2006, an in-process R&amp;D (&#8220;IP R&amp;D&#8221;) asset was recognized at fair value under both IFRS (IFRS 3 &#8220;Business Combinations&#8221;) and US GAAP (FAS 141 &#8220;Business Combinations&#8221;). Under US GAAP the IP R&amp;D asset was expensed immediately after its recognition in the business combination.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Also as part of the acquisition, and under both IFRS and US GAAP, an assumed contingent liability was identified but was not recognized as the fair value was immaterial. Under IFRS the assumed contingent liability was subsequently measured at amortized cost as the discounted expected value of the milestone payment and estimated royalty payments. It was re-measured for changes in these estimated cash flows or when the probability of achieving regulatory approval and commercial revenue changed. Re-measurements relating to changes in estimated cash flows and probabilities of success were recognized in the IP R&amp;D asset. Under US GAAP, the contingent consideration will be recognized at the time each element of the contingency is resolved, and will be charged to R&amp;D expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(b) Patents</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under IFRS the Company recognized the cost of patent applications and associated legal costs as intangible fixed assets. Under US GAAP, in the absence of regulatory approval, these costs are expensed as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(c) Social security costs on share based compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under IFRS the Company accrued the cost of the Company&#8217;s social security contributions on share-based compensation. Under US GAAP this cost is recognized when RSUs vest or options are exercised.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The significant differences in the Consolidated Statements of Operations and Comprehensive Loss were as follows (in thousands):</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss - IFRS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,511)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reversal of accounting for contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reversal of patent amortization and current period patent costs, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss - US GAAP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,561)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(d) Research and development tax credit - reclassification</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The U.K R&amp;D tax credit receivable is an estimate of the amount expected to be received in cash from the U.K. government in the following fiscal year relating to the Small and Medium Enterprise Program (the &#8220;R&amp;D Tax Credit&#8221;). It relates to the estimated research and development tax credit receivable on qualifying expenditure incurred in the year. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under IFRS the Company recorded the R&amp;D Tax Credit in income taxes. Under US GAAP the credit is considered to be akin to a government grant and is recorded as other income.</span></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_111"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 7A.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this Item 7A.</span></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_106"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 8.&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The information required by this Item is set forth in the consolidated financial statements and notes thereto in Item 15 of Part IV of this Annual Report.</span></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_101"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 9.&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">None</span></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_96"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 9A.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Limitations on Effectiveness of Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a- 15(e) and 15d- 15(e) under the Exchange Act), as of the end of the period covered by this Annual Report. Based on such evaluation, our principal executive officer and principal financial officer have concluded that as of December 31, 2020, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth in &#8220;Internal Control &#8211; Integrated Framework (2013)&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Based on this assessment, our management concluded that, as of December&#160;31, 2020, our internal control over financial reporting was effective.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Attestation Report of the Registered Public Accounting Firm</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">This Annual Report does not include an attestation report of our registered public accounting firm due to an exemption established by the JOBS Act for &#8220;emerging growth companies.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our consolidated financial statements for the year ended December 31, 2020, were prepared in compliance with generally accepted accounting principles in the U.S. which represents a change in accounting principles previously applied in financial statements prepared by us for prior periods that were prepared in accordance with International Financial Reporting Standards. We have added to or updated the functioning of our existing internal controls over financial reporting to accommodate the necessary changes to continue to provide reasonable assurance to prevent or detect misstatements in the preparation and presentation of our financial statements. Except as described herein, there was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) under the Exchange Act) that occurred during the fourth quarter of fiscal year ended December 31, 2020, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_91"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 9B.&#160;&#160;&#160;&#160;Other Information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">None</span></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_134"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_149"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 10.&#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Code of Ethics</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our board of directors has adopted a written Code of Business Conduct and Ethics applicable to all officers, directors and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. We have posted a current copy of our Code of Business Conduct and Ethics on our website at www.veronapharma.com in the &#8220;Investors&#8221; section under &#8220;Corporate Governance.&#8221; We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding amendment to, or waiver from, a provision of our Code of Business Conduct and Ethics, as well as Nasdaq&#8217;s requirement to disclose waivers with respect to directors and executive officers, by posting such information on our website at the address and location specified above. The information contained on our website is not incorporated by reference into this Annual Report.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The remaining information required by this item will be included in our definitive proxy statement for the 2021 Annual General Meeting of Stockholders and is incorporated herein by reference to such proxy statement.</span></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_144"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 11. Executive Compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The information required by this item will be included in our definitive proxy statement for the 2021 Annual General Meeting of Shareholders and is incorporated herein by reference to such proxy statement.</span></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_164"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The information required by this item will be included in our definitive proxy statement for the 2021 General Meeting of Shareholders and is incorporated herein by reference to such proxy statement.</span></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_159"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The information required by this item will be included in our definitive proxy statement for the 2021 General Meeting of Shareholders and is incorporated herein by reference to such proxy statement.</span></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_154"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 14.&#160;&#160;&#160;&#160;Principal Accountant Fees and Services</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The information required by this item will be included in our definitive proxy statement for the 2021 General Meeting of Shareholders and is incorporated herein by reference to such proxy statement.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_197"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART IV</span></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_169"></div><div style="-sec-extract:summary;margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 15. Exhibits and Financial Statement Schedule</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">s</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">(a)(1) Financial Statements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As part of this Annual Report on Form 10-K, the consolidated financial statements are listed in the accompanying index to financial statements on page F-1.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">(a)(2) Financial Statement Schedules.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">(a)(3) Exhibits.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following is a list of exhibits filed as part of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:8.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by Reference to Filings Indicated </span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit&#160;Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">File No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit No. </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filing date</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed / Furnished Herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000110465920140541/tm2039594d1_ex1.htm">Articles of Association, as amended and as currently in effect</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/30/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731218000006/exhibit21depositagreemen.htm">Deposit Agreement</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/2018</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731218000006/exhibit21depositagreemen.htm">Form of American Depositary Receipt (included in Exhibit 4.1)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/2018</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000104746917002313/a2231519zex-4_3.htm">Form of Warrant issued to each of the investors named in Schedule A thereto</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-217124</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/3/2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000104746917002313/a2231519zex-4_4.htm">Warrant Instrument issued to NPlus1 Singer LLP</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-217124</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/3/2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vrna-descriptionofsecuriti.htm">Description of Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000104746917002313/a2231519zex-10_1.htm">Registration Rights Agreement, dated July 29, 2016, by and among Verona Pharma plc and the investors set forth therein</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-217124</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/3/2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000110465920085620/tm2025101d2_ex2.htm">Registration Rights Agreement, dated July 16, 2020, by and among Verona Pharma plc and the investors set forth therein</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/22/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000104746917002313/a2231519zex-10_2.htm">Intellectual Property Assignment and Licence Agreement between Vernalis Development Limited and Rhinopharma Limited, as predecessor to Verona Pharma plc, dated February 7, 2005</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-217124</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/3/2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731219000007/renewalagreementnovember.htm">Renewal Agreement to Lease by and between the Verona Pharma plc and Regus Management (UK) Limited dated October 19, 2017</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/19/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731219000007/renewalagreementnovember.htm">Renewal Agreement to Lease by and between the Verona Pharma plc and Regus Management (UK) Limited dated November 8, 2017</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/19/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731219000007/renewalagreementapril320.htm">Renewal Agreement to Lease by and between the Verona Pharma plc and Regus Management (UK) Limited dated April 3, 2018</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/19/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731220000019/ex433reguslease13914316s.htm">Renewal Agreement to Lease by and between the Verona Pharma plc and Regus Management (UK) Limited dated September 16, 2017#1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731220000019/ex434reguslease14214416s.htm">Renewal Agreement to Lease by and between the Verona Pharma plc and Regus Management (UK) Limited dated September 16, 2017#2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731220000019/ex435reguslease145a15116.htm">Renewal Agreement to Lease by and between the Verona Pharma plc and Regus Management (UK) Limited dated September 16, 2017#3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731220000019/ex436regushudsonyardslea.htm">Renewal Agreement to Lease by and between the Verona Pharma Inc. and Regus Management Group LLC dated July 16, 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000104746917002313/a2231519zex-10_4.htm">EMI Option Scheme</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-217124</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/3/2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000104746917002313/a2231519zex-10_5.htm">Unapproved Share Option Scheme, as amended</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-217124</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/3/2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:8.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731218000006/exhibit462017plan.htm">2017 Incentive Award Plan and forms of award agreements thereunder</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/2018</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731220000019/a47dzaccarrelliemploymen.htm">Employment Agreement, dated January 28, 2020, between Verona Pharma Inc. and David Zaccardelli, Pharm. D.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731219000007/kathyrickardemploymentag.htm">Employment Agreement, dated December 21, 2019, between Verona Pharma plc and Kathleen Rickard</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/19/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000104746917002313/a2231519zex-10_9.htm">Employment Agreement, dated October 1, 2016, between Verona Pharma plc and Claire Poll</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-217124</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/3/2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000110465920095810/tm2027314d2_ex10-12.htm">Employment Agreement, dated February 1, 2020, between Verona Pharma Inc. </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000110465920095810/tm2027314d2_ex10-12.htm">and Mark Hahn</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-247928</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/17/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000104746917002697/a2231786zex-10_111.htm">Form of Indemnification Agreement for board members</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-217124</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/18/2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000104746917002697/a2231786zex-10_112.htm">Form of Indemnification Agreement for executive officers</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-217124</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/18/2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000104746917002313/a2231519zex-10_12.htm">Relationship Agreement relating to Verona Pharma plc, dated July 29, 2016, by and among the Verona Pharma plc, OrbiMed Private Investments VI, LP and NPlus1 Singer Advisory LLP</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-217124</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/3/2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000104746917002313/a2231519zex-10_13.htm">Relationship Agreement relating to Verona Pharma plc, dated July 29, 2016, by and among the Verona Pharma plc, Abingworth Bioventures VI LP and NPlus1 Singer Advisory LLP</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-217124</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/3/2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000104746917002313/a2231519zex-10_14.htm">Relationship Agreement relating to Verona Pharma plc, dated July 29, 2016, by and among the Verona Pharma plc, Vivo Ventures Fund VII, L.P., Vivo Ventures VII Affiliates Fund, L.P., Vivo Ventures Fund VI, L.P., Vivo Ventures VI Affiliates Fund, L.P. and NPlus1 Singer Advisory LLP</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-217124</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/3/2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000110465920085620/tm2025101d2_ex1.htm">Relationship Agreement relating to Verona Pharma plc, dated July 29, 2016, by and among the Verona Pharma plc, Vivo Ventures Fund VII, L.P., Vivo Ventures VII Affiliates Fund, L.P., Vivo Ventures Fund VI, L.P., Vivo Ventures VI Affiliates Fund, L.P. and NPlus1 Singer Advisory LLP</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/22/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000110465920128643/tm2036424d1_ex1-1.htm">Loan and Security Agreement, dated as of November 19, 2020, by and among Silicon Valley Bank, Verona Pharma plc and Verona Pharma, Inc.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/24/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="svb-firstamendmenttoloan.htm">First Amendment to Loan and Security Agreement, dated as of November 19, 2020, by and among Silicon Valley Bank, Verona Pharma plc and Verona Pharma, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="non-executicedirectorappoi.htm">Form of Non-Executive Director letter of appointment</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000104746917002313/a2231519zex-21_1.htm">List of Subsidiaries of Verona Pharma plc </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-217124</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/3/2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="consentletter-fy20vrp_sx4x.htm">Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311.htm">Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312.htm">Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321.htm">Section 1350 Certification of Chief Executive Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322.htm">Section 1350 Certification of Chief Financial Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">*        Filed herewith.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">**      Furnished herewith.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">#         Indicates management contract or compensatory plan.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_732"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 16.&#160;&#160;&#160;&#160;Form 10-K Summary</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">None</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_191"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.664%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">VERONA PHARMA PLC</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: February 25, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ David Zaccardelli</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">David Zaccardelli, Pharm. D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">President and Chief Executive Officer</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:30.029%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.934%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ David Zaccardelli</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">President and Chief Executive Officer</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(principal executive officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 25, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">David Zaccardelli, Pharm. D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Mark W. Hahn</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(principal financial and accounting officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 25, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Mark W. Hahn</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ David Ebsworth, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chairperson of the Board of Directors</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 25, 2021</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">David Ebsworth, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Ken Cunningham, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 25, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Ken Cunningham, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Martin Edwards, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 25, 2021</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Martin Edwards, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Rishi Gupta</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 25, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Rishi Gupta</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Mahendra Shah, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 25, 2021</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Mahendra Shah, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Andrew Sinclair, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 25, 2021</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Andrew Sinclair, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Vikas Sinha</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 25, 2021</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Vikas Sinha</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Anders Ullman, M.D., Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 25, 2021</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Anders Ullman, M.D., Ph.D.</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_687"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Index</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_555">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_555">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_370">Consolidated Balance Sheets as of December 31, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_370">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_378">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_378">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_385">Consolidated Statements of Changes in Shareholders&#8217; Equity for the years ended December 31, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_385">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_392">Consolidated Statements of Cash Flows for the years ended December 31, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_392">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_321">Notes to</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4dd95a68a65415aa5f2e21bd87d1189_321"> Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id4dd95a68a65415aa5f2e21bd87d1189_321">7</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-1</span></div></div></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_555"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Shareholders of Verona Pharma Plc</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Verona Pharma Plc and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2020 and 2019, and the related consolidated statements of operations and comprehensive loss, of shareholders&#8217; equity and of cash flows for the years then ended, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ PricewaterhouseCoopers LLP </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reading, United Kingdom</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 25, 2021</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2015.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-2</span></div></div></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_370"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands,  except per share amounts and par value of shares)</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzUtMi0xLTEtMzg0Mw_2e59ec01-818e-41f0-9192-654f83ab58de">187,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzUtNC0xLTEtMzg0Mw_af83dc9d-b146-4d54-97d2-ac40257f8cda">30,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzYtMi0xLTEtMzg0Mw_64b9d5f2-4f7e-4521-b1c1-63852c82bfc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzYtNC0xLTEtMzg0Mw_2b9943a3-5157-4b72-831f-0b538c83a1dc">10,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzctMi0xLTEtMzg0Mw_0cbd3eb0-496b-4e77-8791-e6408888a1fd">4,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzctNC0xLTEtMzg0Mw_3c948cd7-c267-481e-9e44-f49f8204403d">1,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax and tax incentive receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="vrna:TaxCreditAndIncomeTaxesReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzgtMi0xLTEtMzg0Mw_95baeac1-c9cb-44b1-9158-f7a9a346673c">8,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="vrna:TaxCreditAndIncomeTaxesReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzgtNC0xLTEtMzg0Mw_62defcfb-323e-433d-be45-fdf89cd48d8b">9,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzktMi0xLTEtMzg0Mw_bf4409b7-96d0-4721-810d-4b3149bd7618">1,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzktNC0xLTEtMzg0Mw_933c730a-52b9-4bb7-beb0-cdbde6fb2a2a">2,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzktMi0xLTEtNDc5Mw_8fb2da62-cc8c-467b-8946-9bde91b9c5ce">202,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzktNC0xLTEtNDc5Mw_835d758f-0104-4408-92d6-b1a28d412239">54,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzEyLTItMS0xLTM4NDM_a12f40e7-40e4-4cea-b9cf-34d6c7c8e157">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzEyLTQtMS0xLTM4NDM_85474781-f71c-4181-995c-33f2748c39d8">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzEzLTItMS0xLTM4NDM_c18fe2fa-f3fd-4824-b5ce-8286e62ee185">545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzEzLTQtMS0xLTM4NDM_b7698176-a9f0-48ec-a94a-580d6fd230df">585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzE0LTItMS0xLTM4NDM_d746f07a-6abe-4884-ad3d-6a51ee4d0635">1,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzE0LTQtMS0xLTM4NDM_f08d8cca-2bf1-49c9-8da9-61b8a8db1cd4">1,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzE1LTItMS0xLTM4NDM_3d4b3073-7698-4ad6-bc53-c5cdf4f3c27e">1,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzE1LTQtMS0xLTM4NDM_3e0601bf-2c1f-49ec-864c-f164420c1bfa">1,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzE2LTItMS0xLTQ3OTM_b92856ec-d507-46f7-a1f5-f3fe510236d5">204,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzE2LTQtMS0xLTQ3OTM_c55ef3aa-f644-40b6-b23e-7afaf6aaadab">56,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzIwLTItMS0xLTM4NDM_ae598a7b-94b7-410f-ad6c-54b2fc269361">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzIwLTQtMS0xLTM4NDM_0164023a-2ead-4028-9173-f0d834957175">1,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzIxLTItMS0xLTM4NDM_99e1b8ed-7b03-4252-bb97-2f81a045267c">10,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzIxLTQtMS0xLTM4NDM_3d2b0c3d-05da-4991-b4a1-b69423dd15c1">8,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzIzLTItMS0xLTM4NDM_33f2cf54-73ea-426b-b3e0-8413ca2b803f">798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzIzLTQtMS0xLTM4NDM_1795716f-404b-4a38-b09a-58867a302e1f">611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="vrna:WarrantLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzI0LTItMS0xLTExMDI4_1e3521a8-4c34-4f5a-8f97-25d7228a05d6">2,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="vrna:WarrantLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzI0LTQtMS0xLTExMDI4_f6778f44-ac89-4e7a-949f-8eafce386fec">1,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzI0LTItMS0xLTQ3OTM_00955cd0-0733-4ae6-a48e-9981997c340d">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzI0LTQtMS0xLTQ3OTM_58fc5b3d-ae8e-4981-8707-5efcfca48dd0">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzI1LTItMS0xLTM4NDM_c84e7a9f-a7bb-4e82-b214-325e12b7f950">14,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzI1LTQtMS0xLTM4NDM_787bb612-27f2-4fc3-8cdd-cc7167740987">12,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMwLTItMS0xLTEyMDIw_900c8222-e994-4449-b0e3-468f4f3dcfef">4,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMwLTQtMS0xLTEyMDIz_9a34d0b3-507d-472b-9aad-1eee3bedd14b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzI5LTItMS0xLTQ3OTM_d87ebeca-bf93-4548-ac96-b7fd51d847d5">514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzI5LTQtMS0xLTQ3OTM_47c34d48-be87-4509-bd71-17748c1ee691">652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMwLTItMS0xLTQ3OTM_e8ee1cc1-b0d4-451a-b4b9-c6ad8d8fa916">5,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMwLTQtMS0xLTQ3OTM_ec55f7eb-204f-468e-a043-3ef741404b74">652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMxLTItMS0xLTQ3OTM_2491568c-1878-4d69-890c-d0cb6c043c9b">19,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMxLTQtMS0xLTQ3OTM_2fac3c39-2d93-4dc1-9c34-4a108a4ff743">13,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitments and contingencies </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzM1LTItMS0xLTE5MDIy_354c0e7b-c6ee-4485-8bf2-1891e375c779"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzM1LTQtMS0xLTE5MDIy_e90cfe37-0897-4485-be96-b87af81e02d9"></ix:nonFraction></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordinary &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzM4LTAtMS0xLTg4MTQvdGV4dHJlZ2lvbjo4OGFlYmZmNGMyMGE0NjE5OTk4MTY4NTRjMDE3YTM5MV8yMDM0MDk2NTExNDM5NA_70554a27-7271-4830-ae31-8d0d9228b0dd"><ix:nonFraction unitRef="gbpPerShare" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzM4LTAtMS0xLTg4MTQvdGV4dHJlZ2lvbjo4OGFlYmZmNGMyMGE0NjE5OTk4MTY4NTRjMDE3YTM5MV8yMDM0MDk2NTExNDM5NA_d6e93802-a8e5-466b-a351-2b8bdf433df1">0.05</ix:nonFraction></ix:nonFraction> par value shares; <ix:nonFraction unitRef="shares" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzM4LTAtMS0xLTg4MTQvdGV4dHJlZ2lvbjo4OGFlYmZmNGMyMGE0NjE5OTk4MTY4NTRjMDE3YTM5MV8yMDM0MDk2NTExNDM2Nw_ba2a8224-3f95-44b3-ad52-5d4885df77d2">488,304,446</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7cd52ee77a7948f196f2eb3dd03b56a8_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzM4LTAtMS0xLTg4MTQvdGV4dHJlZ2lvbjo4OGFlYmZmNGMyMGE0NjE5OTk4MTY4NTRjMDE3YTM5MV81NDk3NTU4MTQ0NDc_d5560b71-702b-44a9-98d7-fd4b20ce2b4c">105,326,638</ix:nonFraction> issued, and <ix:nonFraction unitRef="shares" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzM4LTAtMS0xLTg4MTQvdGV4dHJlZ2lvbjo4OGFlYmZmNGMyMGE0NjE5OTk4MTY4NTRjMDE3YTM5MV82NTk3MDY5NzY3MDYz_80eeb2d7-ac35-4ec9-bf7b-1fe265c42244">463,304,446</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzM4LTAtMS0xLTg4MTQvdGV4dHJlZ2lvbjo4OGFlYmZmNGMyMGE0NjE5OTk4MTY4NTRjMDE3YTM5MV82NTk3MDY5NzY3MDY5_0ee86cb1-6302-4e3c-968f-cabed2a36c95">105,326,638</ix:nonFraction> outstanding, at December 31, 2020 and 2019,  respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzM4LTItMS0xLTQ3OTM_b7e459ae-b164-4fef-a8ec-233bd500928f">31,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzM4LTQtMS0xLTQ3OTM_42274bc4-94d3-46b5-8f39-c820831f3389">7,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzI5LTItMS0xLTM4NDM_b0fe4b93-3d1c-4329-a421-5dca5a8cf6d8">366,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzI5LTQtMS0xLTM4NDM_2f20951c-e3a0-4ad1-be3d-7695bbbebd10">179,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordinary shares held in treasury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzM5LTItMS0xLTEyMDA0_8cb0ad22-a108-4830-b87f-2c50adc95829">1,700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzM5LTQtMS0xLTEyMDA4_d02a0b77-7585-433c-a1de-d8a07785bf17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMwLTItMS0xLTM4NDM_e4169321-4a5e-494d-b1ac-164c6d45e11e">4,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMwLTQtMS0xLTM4NDM_eacfc111-391f-4f16-85ab-aaaaff37524b">2,280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMxLTItMS0xLTM4NDM_96034322-787e-49a8-9023-d0cfcd1209ad">207,050</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMxLTQtMS0xLTM4NDM_54776477-a599-4564-8737-b79fcbcbf0f4">141,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shareholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMyLTItMS0xLTM4NDM_4fe1ebcb-e9d5-4aca-80af-fa687afef6aa">184,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMyLTQtMS0xLTM4NDM_8302b777-2c7a-4a6b-be32-afaca4f90e39">42,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and shareholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMzLTItMS0xLTM4NDM_bf73101e-1711-4275-afcc-6c8928288bb4">204,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMzLTQtMS0xLTM4NDM_289f46c3-eb2f-4c4d-82ee-6d330d6c06ac">56,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-3</span></div></div></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_378"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzMtMi0xLTEtMzkyOA_9b809355-daef-4d95-bbc9-5487bb594295">44,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzMtNC0xLTEtMzkyOA_d5be59e3-7350-4521-a984-99da3ae1f2c8">42,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzQtMi0xLTEtMzkyOA_2d4ffa7f-ae94-4e30-901f-9c1ff8db54b2">29,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzQtNC0xLTEtMzkyOA_1bf59991-87a2-45ba-b731-e5ef814f8416">9,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzUtMi0xLTEtMzkyOA_4c7c002a-18da-4b8d-a522-e9d9860f4275">74,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzUtNC0xLTEtMzkyOA_f3dc878c-3cde-404c-bc8b-59f4046b10b0">52,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzYtMi0xLTEtMzkyOA_13761d1d-3bed-4a21-9810-26065224f288">74,277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzYtNC0xLTEtMzkyOA_1253d4a3-3fef-4cac-97f8-373485ef21fd">52,403</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income / (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from R&amp;D tax credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="vrna:GainLossFromResearchAndDevelopmentTaxCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzktMi0xLTEtODk4NA_e1a2d316-89b9-468b-be7e-b8da4481cd78">8,267</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="vrna:GainLossFromResearchAndDevelopmentTaxCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzktNC0xLTEtODk4NA_4d5b8e49-5bdc-4db6-bbfa-177b5da5dce9">9,283</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzgtMi0xLTEtMzkyOA_bc5b33cc-39a3-4c59-8e63-44a572c97bdf">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzgtNC0xLTEtMzkyOA_576a81bf-25bc-4c41-9367-992daa9fab1c">964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzktMi0xLTEtMzkyOA_bdad4dfd-6f9a-4c66-b694-8538d0c9c67c">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzktNC0xLTEtMzkyOA_d6c19bb9-576a-490d-a1f0-425735dbc530">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value movement on warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="vrna:UnrealizedGainLossOnWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzExLTItMS0xLTExMjI1_122346ff-8d15-427e-95d1-fbde581583c0">1,136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="vrna:UnrealizedGainLossOnWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzExLTQtMS0xLTExMjI1_6eccb012-0a73-49fc-805a-14c6761d33c2">2,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gain / (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzEwLTItMS0xLTM5Mjg_5facb47b-14c6-4c24-850c-b3513219921c">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzEwLTQtMS0xLTM5Mjg_1a845639-6aed-4a68-b431-735533fccb34">399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzEyLTItMS0xLTM5Mjg_b329a4f7-6a74-4647-9a0a-3e4a2e687031">9,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzEyLTQtMS0xLTM5Mjg_93407228-935c-4436-bc93-93493858bd66">11,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzEzLTItMS0xLTM5Mjg_eff17340-60df-4e71-a970-7f74a8d18e2a">65,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzEzLTQtMS0xLTM5Mjg_3589c0f8-8edb-425a-9923-67fca8152762">40,489</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzE0LTItMS0xLTM5Mjg_ad06c86a-6424-4f18-885b-c89774fa0a90">146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzE0LTQtMS0xLTM5Mjg_8d136bde-c2c1-407f-8427-b7a7465b3109">72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzE1LTItMS0xLTM5Mjg_fa5e342c-4d54-4d91-b3cd-57cdb01342ce">65,146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzE1LTQtMS0xLTM5Mjg_8f872b94-ccc1-4060-8c70-bd305436d882">40,561</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive (loss) / income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzE3LTItMS0xLTM5Mjg_95b485eb-16dd-41d9-a93d-d0d0689f7535">2,321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzE3LTQtMS0xLTM5Mjg_d1861811-591d-4b07-a770-324f208c6089">1,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total comprehensive loss attributable to shareholders of the Company</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzE4LTItMS0xLTM5Mjg_fef8ed60-73f7-4001-bbc8-bee07a937ec1">67,467</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzE4LTQtMS0xLTM5Mjg_3223f51e-7f88-4e6c-988f-5c728b2d4e52">39,213</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per ordinary share &#8212; basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzE5LTItMS0xLTM5MzI_1b72646d-e556-44e5-a75a-7974c4e8b298">0.25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzE5LTQtMS0xLTM5MzI_31947bf6-f608-460b-96d9-a90f2cfa7481">0.39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-4</span></div></div></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_385"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Shareholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands except share data)</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.282%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ordinary shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ordinary shares held in treasury</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total shareholders' equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7bb2db7aeed4fe28f6502081a2b3fb2_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEwLTItMS0xLTQxMDA_f3cbdd08-43a7-4681-a7c8-46fb91caffa2">105,326,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7bb2db7aeed4fe28f6502081a2b3fb2_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEwLTQtMS0xLTQxMDA_de3ef8da-ff0e-430b-88a4-2cf0ca5f7362">7,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad4673fe986541979acd434b04d81115_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEwLTYtMS0xLTQxMDA_c15db197-f2b1-4ba7-a6c9-713e2b5446a9">176,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i670b119a86454681a09079c9b183ec50_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzItOC0xLTEtMTM0NzM_78814d3d-2fa1-4e30-b251-9b7d40e5e643">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1448e425ab1943f8ae8c4d34c3c75f39_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEwLTgtMS0xLTQxMDA_da8cf25e-2129-4476-a0c2-d45de6057255">3,628</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89de9796f5344884bc5b430e67f6af27_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEwLTEwLTEtMS00MTAw_38877b67-abcd-4347-98a8-f13181c58e61">101,192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6502e2d84744a1a4f122e93a5bbedc_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEwLTEyLTEtMS00MTAw_6bf70775-1b11-4e28-bcef-f6aeec5d25ab">78,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzMtMC0xLTEtMTk5NTI_cdbb0f1c-034b-4cc5-a4ab-bf0b4180f75c">Cumulative effect adjustment for ASU 2016-02 adoption</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7144fbaaf53a410eb5a86ca2c38da7d6_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzExLTEwLTEtMS00MTAw_d4cd132e-47f4-43a7-8bb4-4bb21e555a0b">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7bffa5795b9245b9b6367166015c8f55_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzExLTEyLTEtMS00MTAw_d0db9d21-0b74-4a9a-9a11-454200694ba5">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted balance at January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i218678a6acb04250abe3f3a39f5ced25_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEyLTItMS0xLTQxMDA_c38f72a7-526f-4b4b-bd56-5bd8b92f5773">105,326,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i218678a6acb04250abe3f3a39f5ced25_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEyLTQtMS0xLTQxMDA_ccb43d70-cd97-4e1d-aee4-a7393a22d1f1">7,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48d5ccc6c4d54da9843cb1e12f96b89a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEyLTYtMS0xLTQxMDA_49f55738-046b-497e-b1fe-59696901e4aa">176,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9796b77433d84134a9500d1119aa6875_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzQtOC0xLTEtMTM0NzM_c14e5c5b-4026-4fab-933a-f183c28c2fc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4209fc83abb4e68a86d37c119722d62_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEyLTgtMS0xLTQxMDA_4133ff52-0733-4913-8a58-ce4a28176b4c">3,628</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d652bbdead0408181aff2dd02b415f6_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEyLTEwLTEtMS00MTAw_b86c2b27-57ee-44ba-beca-cac96fe20c40">101,218</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cfc9b650e8f4111a9282e4577094d50_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEyLTEyLTEtMS00MTAw_62a4ee84-7753-4ad4-87bf-2ca58abd064f">78,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33ee67ddc86e47f4b9ee46c176ae9f52_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEzLTEwLTEtMS00MTAw_f87efa84-7bdf-44b6-936a-ee53c9d38e54">40,561</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEzLTEyLTEtMS00MTAw_4cbdafb0-9edb-405d-a62d-c37672c7446d">40,561</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b3a7b2ab5743e8ab134b4311cd3357_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE1LTgtMS0xLTQxMDA_c6567cc3-56c6-454d-8117-bf40bd356a5a">1,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE1LTEyLTEtMS00MTAw_6284564f-c38e-4a73-a719-d56ba4f45ee0">1,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc88e7e39c7041c7aec47904740a5ffa_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE4LTYtMS0xLTQxMDA_ed448803-db3a-4359-b590-591fd49ec401">3,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE4LTEyLTEtMS00MTAw_eb8dc4b1-6784-4bad-a2b8-e56aef635802">3,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7cd52ee77a7948f196f2eb3dd03b56a8_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE5LTItMS0xLTQxMDA_d5560b71-702b-44a9-98d7-fd4b20ce2b4c">105,326,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cd52ee77a7948f196f2eb3dd03b56a8_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE5LTQtMS0xLTQxMDA_540c8daf-946b-407f-b41c-a0c4571e1309">7,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ee4138b94f24a3fb37c3a49fc55fbf0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE5LTYtMS0xLTQxMDA_3854f2ec-9512-49e6-9d49-bc584225584d">179,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id772c24a98d045f687a38be7f9204a60_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzktOC0xLTEtMTM0Nzc_08e6a74e-63eb-4b3e-97f5-d8242d8cc7ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4bdef42e0964c40a84e61be80f90c28_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE5LTgtMS0xLTQxMDA_7f9bb10a-01db-419e-81eb-c16855248cbe">2,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfd1b77b4c11404ab36abf3475f7fdf7_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE5LTEwLTEtMS00MTAw_81bed40a-eb55-4254-b3fe-cffd3b8bea6c">141,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE5LTEyLTEtMS00MTAw_c9d7b1d4-5c63-451d-989b-d8698ebea87d">42,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie991833e533a42c1bb4590e7c40b875d_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzIwLTEwLTEtMS00MTAw_aa7472e0-8cb2-4a40-bfc7-f71130b2787d">65,146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzIwLTEyLTEtMS00MTAw_7f085370-f491-4990-b57f-37b0c407714c">65,146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia30de411faa549d8a507b268ebbff4e6_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzIyLTgtMS0xLTQxMDA_dc2825bf-ad9e-482b-9350-8d33ddd8bfe4">2,321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzIyLTEyLTEtMS00MTAw_298f8206-2e61-4e7c-aa33-63ea0ae0dc2e">2,321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of ordinary shares, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1ab5f2cf37f34ce1822987a9a032bfe3_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI0LTItMS0xLTQxMDA_8d563de9-3a92-41eb-8847-30cc6bf091da">355,831,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ab5f2cf37f34ce1822987a9a032bfe3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI0LTQtMS0xLTQxMDA_51932485-c9cf-447b-8de3-bd094f512df2">22,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2906e285538640d2ba863cc6f7be6d7f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI0LTYtMS0xLTQxMDA_cf48279b-1a68-4e0e-9648-34f52f0ab6c8">164,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI0LTEyLTEtMS00MTAw_fb28faeb-4e92-4ac2-9bd0-9d6a50eb70ad">187,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of ordinary shares to treasury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1ab5f2cf37f34ce1822987a9a032bfe3_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="vrna:StockIssuedDuringPeriodSharesHeldInTreasury" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE1LTItMS0xLTEyMDM4_ee308189-97a0-4db3-8532-56c818d5900c">25,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ab5f2cf37f34ce1822987a9a032bfe3_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="vrna:StockIssuedDuringPeriodValueHeldInTreasury" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE1LTQtMS0xLTEyMDM4_852b1560-fb15-4994-acf7-04680eeb71b0">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i382c3abae01044dfaf69a5a01cfc1c00_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="vrna:StockIssuedDuringPeriodValueHeldInTreasury" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE0LTgtMS0xLTEzNDgx_c9fd44b9-cdd5-4fb8-873e-3369ffc59379">1,700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="vrna:StockIssuedDuringPeriodValueHeldInTreasury" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE1LTEyLTEtMS0xMjAzOA_d10b02ff-86cd-49e5-ae70-5f342ddbe67a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of ordinary shares from restricted share units and share options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1ab5f2cf37f34ce1822987a9a032bfe3_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI2LTItMS0xLTQxMDA_7c5e03f6-1bc2-4359-92c7-1aa82e81f7ef">2,146,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ab5f2cf37f34ce1822987a9a032bfe3_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI2LTQtMS0xLTQxMDA_c86296fb-a634-4b94-90ed-9e6e30552d8c">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2906e285538640d2ba863cc6f7be6d7f_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI2LTYtMS0xLTQxMDA_290f54db-9ef5-423a-8498-a96dfac045c5">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie991833e533a42c1bb4590e7c40b875d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI2LTEwLTEtMS00MTAw_36e2a568-c31d-4387-9b3c-32595493543b">125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI2LTEyLTEtMS00MTAw_22b51f81-64a9-40d4-ba5e-c8ad244df61d">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2906e285538640d2ba863cc6f7be6d7f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI3LTYtMS0xLTQxMDA_34d4285b-508d-49e6-a320-45b677500e75">22,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI3LTEyLTEtMS00MTAw_e1009bf5-11c0-4f4c-be4a-56bffcc171c1">22,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if62ffe34397d4178bfe3a160fb777109_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI4LTItMS0xLTQxMDA_493342f6-bba5-41c2-b1e4-2ffc1b25da9d">488,304,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62ffe34397d4178bfe3a160fb777109_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI4LTQtMS0xLTQxMDA_e86448f4-4700-42d6-928a-5aff18e4adbb">31,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib24f80c535f0403a800a6d65d53720d3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI4LTYtMS0xLTQxMDA_07c2b302-6b07-4116-a567-e40c6565e6e7">366,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2cc9b6147bc414a87f7dd9652e152aa_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE3LTgtMS0xLTEzNDgx_862b9f09-47df-4818-bf65-93dba87e1f1f">1,700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff1f3d0564a142dbb860c4d8ca0a33d1_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI4LTgtMS0xLTQxMDA_7af98a36-d2a4-4cc7-aeb7-ef6c0fadf56c">4,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie91783fe6f4743229a237427eba95bbe_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI4LTEwLTEtMS00MTAw_fc697b7d-09f8-41c8-a9b7-b6078955c47d">207,050</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI4LTEyLTEtMS00MTAw_ffe08f78-90f7-47d2-bf57-43a11ee61209">184,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-5</span></div></div></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_392"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzItMi0xLTEtNDgyOQ_fb8120ad-28fa-4d35-845e-5e3d22c83ff5">65,146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzItNC0xLTEtNDgyOQ_23df8b8d-05d4-4458-aca5-2816a5e0a04e">40,561</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange (gain) / loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzQtMi0xLTEtNDgyOQ_9e600696-02af-40a2-8c3d-b6500561ed3f">2,060</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzQtNC0xLTEtNDgyOQ_8c26d6eb-23a1-4741-bc4d-cafd2c6b63c3">399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issue costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzYtMi0xLTEtMTI4MjM_58cddd78-7d00-4653-8b04-8e52f2879fd2">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzYtNC0xLTEtMTI4MjM_a204a2d5-7c2e-4b02-bd51-0f4e1d30a01c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of redemption premium on debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzctMi0xLTEtMTI4MjM_9473a4ce-ed82-4698-8aed-a58633a7de72">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzctNC0xLTEtMTI4MjM_cfde3933-8a62-48d6-aee9-a2e1aebf5e09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value movement on warrants </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzYtMi0xLTEtMTEyMDU_f2902be9-735d-4e94-9e49-1ba0a317e043">1,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzYtNC0xLTEtMTEyMDU_8aa17878-065f-44ed-bd49-6eca24f14885">2,066</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of right-of-use asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzUtMi0xLTEtNTE4OQ_79ea4177-6b21-4a31-9baa-2bff11f3878b">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeaseImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzUtNC0xLTEtNTE4OQ_70fc75a5-2dfd-4b0f-ace7-c6a5d1860933">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzUtMi0xLTEtNDgyOQ_3821f482-db6a-464b-b932-201fa991df76">22,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzUtNC0xLTEtNDgyOQ_f42d3881-eb56-431b-9aa8-be2348192a24">3,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzYtMi0xLTEtNDgyOQ_eaeb691b-4d2f-437b-a49a-c24ad079f401">623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzYtNC0xLTEtNDgyOQ_59f7a60c-9877-475e-a67c-a418a710717b">510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzgtMi0xLTEtNDgyOQ_da81ed9d-1638-41aa-ae08-96d294cd0ec5">3,065</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzgtNC0xLTEtNDgyOQ_6f353225-7ff8-492f-8ca0-7df3957b360b">158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax and tax incentive receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" sign="-" name="vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzktMi0xLTEtNDgyOQ_3c87dd8d-3e7b-4474-80f7-07644625f2da">768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzktNC0xLTEtNDgyOQ_577c15b5-a560-4204-ac76-225d4f253d27">3,929</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzEwLTItMS0xLTQ4Mjk_d650ef00-6f6c-437a-8b01-8c1d7a0e2d8c">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzEwLTQtMS0xLTQ4Mjk_cd07ba64-0531-4f29-a781-f3718185ba8b">289</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzE3LTItMS0xLTIxMTM5_cc55ccb9-34c1-4bed-b870-59dd1fbef7c9">703</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzE3LTQtMS0xLTIxMTM5_d3a96f5d-600b-4aaf-ba8c-dba38c8fcb6a">1,325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzExLTItMS0xLTQ4Mjk_0790c668-6bea-4a67-944b-faa380d415bb">1,398</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzExLTQtMS0xLTQ4Mjk_af5d4ae0-4add-4cd9-8232-3c3c316b7b45">1,734</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzEyLTItMS0xLTQ4Mjk_80cc249e-23c8-472a-9a02-a636e65a507e">1,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzEyLTQtMS0xLTQ4Mjk_7c5da896-cc20-46f2-8597-330511af4c9e">2,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" name="vrna:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzE0LTItMS0xLTQ4Mjk_468c0173-b204-4b21-afc5-6040aa87c007">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" name="vrna:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzE0LTQtMS0xLTQ4Mjk_43f39439-10cc-4a06-ac91-ea863fdd90cb">849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzE1LTItMS0xLTQ4Mjk_94e4e810-0767-4809-a929-e5fc13805113">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzE1LTQtMS0xLTQ4Mjk_bc4ee346-2b4e-475d-a652-a97270cdd24f">137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzE2LTItMS0xLTQ4Mjk_250d30ae-5f18-45fb-9289-958f4273f851">45,076</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzE2LTQtMS0xLTQ4Mjk_75e716e3-3daf-4d33-840d-2fd05ad82039">42,868</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of furniture and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzE4LTItMS0xLTQ4Mjk_81b50cc2-2ccb-428e-8f15-751dac6504d7">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzE4LTQtMS0xLTQ4Mjk_db58e4a0-4062-47a3-9636-32ebdc7e2bca">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzIwLTItMS0xLTQ4Mjk_6cd6e8b0-9ec9-4dfc-b909-a1f27beb248b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzIwLTQtMS0xLTQ4Mjk_a3ffea3c-c38f-40cb-9147-204fc8657492">9,777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzIxLTItMS0xLTQ4Mjk_b6f5fbe8-b84f-4adc-9159-df1234419479">9,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzIxLTQtMS0xLTQ4Mjk_997119f9-e646-40a4-9349-da47b66629fa">57,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzIyLTItMS0xLTQ4Mjk_433e65f2-50f5-4471-a43c-5f081188a208">9,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzIyLTQtMS0xLTQ4Mjk_2071c419-c346-4d00-bd3a-05d5d631ff54">47,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of ordinary shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzI0LTItMS0xLTQ4Mjk_86b2c339-8e94-4eaf-9a91-c222f6e73428">200,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzI0LTQtMS0xLTQ4Mjk_acbce34c-6f4e-415b-99d0-bdb08a6f70fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of offering costs in connection with the issuance of ordinary shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzI1LTItMS0xLTQ4Mjk_4f69ed02-e1eb-4038-b366-0aebd1d65931">12,748</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzI1LTQtMS0xLTQ4Mjk_58e48738-7112-479a-897b-3f1d249f2a5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the issuance of term loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzI5LTItMS0xLTEyMDUx_2e2c210d-0349-4dcc-ac3b-7247fbc6d964">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzI5LTQtMS0xLTEyMDUx_306fba86-cb6b-47b1-8b1e-c64214cf1d26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzMwLTItMS0xLTEyMDUx_9a60252b-4a39-4bab-a826-6067e2fa93bf">108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzMwLTQtMS0xLTEyMDUx_747b6f69-0164-4c5d-bb7f-117df4ed2dfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of share options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzMxLTItMS0xLTEyMDUx_cc397431-fced-473a-b4ff-dd5ee51dbef6">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzMxLTQtMS0xLTEyMDUx_7da37945-c0b1-4c81-8388-0e129594ebc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzI3LTItMS0xLTQ4Mjk_53f76e54-1632-437e-b714-c0a4cc2bcad9">192,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzI3LTQtMS0xLTQ4Mjk_f865e34d-8c0f-40ba-a4b4-d6984c9c8356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzI4LTItMS0xLTQ4Mjk_777f942f-e6df-44f3-aff7-41226006a6ab">581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzI4LTQtMS0xLTQ4Mjk_16d1472a-ab64-4482-8700-a48daddefd91">739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzI5LTItMS0xLTQ4Mjk_205ce423-3255-40ed-aeaa-596f95d17978">157,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzI5LTQtMS0xLTQ4Mjk_55be8210-9712-416d-9348-8cb08af43300">5,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at beginning of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzMwLTItMS0xLTQ4Mjk_4403b9fc-063a-410e-96ce-a4fe87a2ad9e">30,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6502e2d84744a1a4f122e93a5bbedc_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzMwLTQtMS0xLTQ4Mjk_0ce5da92-6c2f-4e49-b45b-8d2e5b1a2f24">25,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of the year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzMxLTItMS0xLTQ4Mjk_06afa7dd-8b97-4be3-804f-9a553d3bf166">187,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzMxLTQtMS0xLTQ4Mjk_cdaf27f8-69b4-40ee-b58e-e7f8c26a2df2">30,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzMzLTItMS0xLTQ4Mjk_436fe6a0-1314-407a-b90e-9fbb5b8ed015">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzMzLTQtMS0xLTQ4Mjk_fbc024c8-3311-44f3-a697-c368ea4c5402">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzQyLTItMS0xLTEyODMw_0bf5719e-70b4-403d-9321-46246e85e9b8">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzQyLTQtMS0xLTEyODMw_5fa02ec9-aabf-4ea3-9cd7-f543b47ff948">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-6</span></div></div></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_321"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 1 - <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="vrna:OrganizationAndBusinessDescriptionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMjEvZnJhZzowMDU4MjEzMTY4Yzc0ODNiODg3YTVhMDYzNTg1ZTRhMy90ZXh0cmVnaW9uOjAwNTgyMTMxNjhjNzQ4M2I4ODdhNWEwNjM1ODVlNGEzXzIxNDQwNDc2NzU5MjI1_71ecb317-dbb1-4634-84ae-c5edfecf3174" continuedAt="ibae3109cd2294e47a2c9fe94a6efe4dc" escape="true">Organization and description of business operations </ix:nonNumeric></span></div><ix:continuation id="ibae3109cd2294e47a2c9fe94a6efe4dc" continuedAt="icb62fe459d534294990c4857f75e4951"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Verona Pharma plc (the "Company") is incorporated and domiciled in the United Kingdom. Verona Pharma plc has <ix:nonFraction unitRef="subsidiary" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="vrna:NumberOfWhollyOwnedSubsidiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMjEvZnJhZzowMDU4MjEzMTY4Yzc0ODNiODg3YTVhMDYzNTg1ZTRhMy90ZXh0cmVnaW9uOjAwNTgyMTMxNjhjNzQ4M2I4ODdhNWEwNjM1ODVlNGEzXzIxNDQwNDc2NzU5MjMx_f46a1986-08f7-4105-84d7-258c4f0541dc">two</ix:nonFraction> wholly-owned subsidiaries, Verona Pharma, Inc., a Delaware corporation and Rhinopharma Limited ("Rhinopharma"), a Canadian company. The address of the registered office is 1 Central Square, Cardiff, CF10 1FS, United Kingdom.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company is a clinical-stage biopharmaceutical group focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The Company listed its American Depositary Shares ("ADSs") on Nasdaq in April, 2017, which trade under the symbol &#8220;VRNA". The Company&#8217;s ordinary shares were also listed on the Alternative Investment Market of the London Stock Exchange (&#8220;AIM&#8221;) until October 30, 2020, when the shares were delisted from AIM in an effort to enhance liquidity of trading by combining all transactions on Nasdaq and to reduce costs through removing duplicative listing and compliance fees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has incurred recurring losses and negative cashflows from operations since inception, and has an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMjEvZnJhZzowMDU4MjEzMTY4Yzc0ODNiODg3YTVhMDYzNTg1ZTRhMy90ZXh0cmVnaW9uOjAwNTgyMTMxNjhjNzQ4M2I4ODdhNWEwNjM1ODVlNGEzXzIwMzQwOTY1MTM0Nzky_c1f0da2e-b5da-482b-9e99-4ec98ddaf138">207.1</ix:nonFraction>&#160;million as of December 31, 2020. The Company expects to incur additional losses and negative cash flows from operations until its products potentially gain regulatory approval and reach commercial profitability, if at all.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"><ix:continuation id="icb62fe459d534294990c4857f75e4951">In July, 2020, the Company raised $<ix:nonFraction unitRef="usd" contextRef="i9dd30f2681444b31a30cecbb105a8d12_D20200717-20200717" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMjEvZnJhZzowMDU4MjEzMTY4Yzc0ODNiODg3YTVhMDYzNTg1ZTRhMy90ZXh0cmVnaW9uOjAwNTgyMTMxNjhjNzQ4M2I4ODdhNWEwNjM1ODVlNGEzXzIwMzQwOTY1MTM0ODE4_d67b4ea1-f1eb-4ae9-aef9-d3115c2e5552">200</ix:nonFraction>&#160;million in a private placement (the "Private Placement"), with net proceeds after transaction related fees and expenses of $<ix:nonFraction unitRef="usd" contextRef="i84e00d94b1de4386a6170826d98862d2_D20200717-20200717" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMjEvZnJhZzowMDU4MjEzMTY4Yzc0ODNiODg3YTVhMDYzNTg1ZTRhMy90ZXh0cmVnaW9uOjAwNTgyMTMxNjhjNzQ4M2I4ODdhNWEwNjM1ODVlNGEzXzIwMzQwOTY1MTM0ODMy_1e88e6b6-3761-456d-80da-2048da0fc0d5">185.5</ix:nonFraction>&#160;million. Additionally, in November, 2020, the Company entered into a term loan facility with Silicon Valley Bank for up to $<ix:nonFraction unitRef="usd" contextRef="i2f3b17ae809741d291cfb524e558c10e_I20201130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMjEvZnJhZzowMDU4MjEzMTY4Yzc0ODNiODg3YTVhMDYzNTg1ZTRhMy90ZXh0cmVnaW9uOjAwNTgyMTMxNjhjNzQ4M2I4ODdhNWEwNjM1ODVlNGEzXzIwMzQwOTY1MTM0ODQ4_596e76f1-fe15-4383-b0fa-636c72e4f6a0">30</ix:nonFraction>&#160;million (the &#8220;Term Loan&#8221;). As of December 31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i46b0f32ad5df416e83423bbabba5a3b9_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMjEvZnJhZzowMDU4MjEzMTY4Yzc0ODNiODg3YTVhMDYzNTg1ZTRhMy90ZXh0cmVnaW9uOjAwNTgyMTMxNjhjNzQ4M2I4ODdhNWEwNjM1ODVlNGEzXzIwMzQwOTY1MTM0ODYx_009083fa-ab07-4796-ac05-2ce9f4c3c482">5</ix:nonFraction>&#160;million had been drawn down.</ix:continuation> The Company expects that its cash and cash equivalents as of December 31, 2020, will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance.</span></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_242"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 2 - <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNjY0_81b0f732-900f-40c3-8c35-5ea741009086" continuedAt="i2ac22ceaa24f4afe95bc77bd6d897d0f" escape="true">Basis of Presentation and Summary of Significant Accounting policies</ix:nonNumeric></span></div><ix:continuation id="i2ac22ceaa24f4afe95bc77bd6d897d0f" continuedAt="i55c995b3b5ab40789936d3d3de958bf4"><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNjY1_d24a4efc-39e7-4c2a-828d-75461626bb3f" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Basis of presentation and consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The consolidated financial statements include the accounts of Verona Pharma plc and its wholly-owned subsidiaries Verona Pharma, Inc. and Rhinopharma. All inter-company balances and transactions have been eliminated. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. ("US GAAP") and the following accounting policies have been consistently applied.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Previously, the Company prepared its consolidated financial statements in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS").</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At the end of the second quarter of 2020, the Company determined that it no longer qualified as a Foreign Private Issuer under SEC rules. As a result, beginning January 1, 2020, the Company is required to report with the SEC on domestic forms and comply with domestic company rules in the United States. The transition to US GAAP was made retrospectively for all periods from the Company&#8217;s inception.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNjY2_0432018e-7a84-4e9c-ac89-ac3bb11cc46c" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses, the fair value of share-based compensation and the fair value of warrants. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company&#8217;s estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNjY3_85387915-ef26-4f2d-beb4-2346fd86a952" continuedAt="ie80a4de4c85949d1b3fd5777f643a7d8" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Business combinations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company applies the acquisition method to account for business combinations. The consideration transferred for the acquisition of a subsidiary is the fair value of the assets transferred, the liabilities incurred to the former owners of the acquiree and the equity interests issued by the Company. The consideration transferred includes the </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="i55c995b3b5ab40789936d3d3de958bf4" continuedAt="i4100b54a79eb4c6c8b8f5527e4bf9bc7"><ix:continuation id="ie80a4de4c85949d1b3fd5777f643a7d8"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">fair value of any asset or liability resulting from a contingent consideration arrangement. The excess of the cost of acquisition over the fair value of the Company's share of the identifiable net assets acquired is recorded as goodwill. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Identifiable ass</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">ets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date. Acquisition-related costs are expensed as incurred and included in administrative expenses.</span></div></ix:continuation><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNjY4_98ee18d0-7410-4280-bcf4-6b2a04053da1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Cash and cash equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company considers all highly liquid investments purchased with original maturities of ninety days or less at acquisition to be cash equivalents. Cash and cash equivalents includes deposits held at call with banks, term deposits with maturities of less than three months at inception, and in money market funds investing in U.S. and U.K. government debt and liquid securities from highly rated institutions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNjY5_fb20f96f-2de2-4390-8cba-8bcfe9c87612" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Short-term investments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Short-term investments include fixed term deposits held at banks with original maturities between three months and a year. They are classified as loans and receivables and are measured at amortized cost using the effective interest method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNjcw_5a53147b-b0c5-4fb6-9c3e-b802db58aaa9" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Furniture and equipment, net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Furniture and equipment comprise office furniture and computer equipment and are stated at cost less accumulated depreciation, which is calculated on a straight-line basis over the expected useful economic lives, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNjc4_366b91a1-c260-4eab-9b78-d6ac9d5b8954">two</span> to <ix:nonNumeric contextRef="i94c8c6508a314e10be6ed1a9414e5627_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNjk2_689dd258-bf83-451b-bde5-d35cffe01131">five years</ix:nonNumeric>.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzIy_2a6a587c-2e8c-4417-94f5-906828893856" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Goodwill consists of goodwill related to the acquisition of Rhinopharma. Goodwill is not amortized but periodically tested for impairment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzIz_e760aca7-c8aa-4394-b5de-570698801ad0" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Impairment of long-lived assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company reviews long lived assets for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of assets may not be fully recoverable. The Company initially compares the market capitalization of the Company to the book value of its assets. If the value of the market capitalization does not support the valuation of the assets, the Company reviews estimates of the cash flows over the remaining lives of its other intangible assets, or related group of assets where applicable, in measuring whether the assets to be held and used will be realizable. In the event of impairment, the Company would discount the future cash flows using its then estimated incremental borrowing rate to estimate the amount of the impairment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzI0_0a5a7c14-7517-4f52-84a0-5eef678091b0" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Effective January 1, 2019, the Company adopted ASC 842, Leases (&#8220;ASC842&#8221;) using the modified retrospective transition approach and did not restate comparative periods. The Company determines if an arrangement is a lease at inception. Leases are classified as operating or finance leases in accordance with the recognition criteria in ASC 842-20-25. The Company&#8217;s lease portfolio consists entirely of operating leases as of December 31, 2020. The Company&#8217;s leases do not contain any material residual value guarantees or material restrictive covenants.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="i4100b54a79eb4c6c8b8f5527e4bf9bc7" continuedAt="i6be62ec17bf043ef90a2a43d365f58cc"><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzI1_e3c25a1d-2ea7-407e-b79c-70be520ae539" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Ligand agreement </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In 2006 the Company acquired Rhinopharma and assumed contingent liabilities owed to Ligand UK Development Limited (&#8220;Ligand&#8221;) (formerly Vernalis Development Limited). The Company refers to the assignment and license agreement as the Ligand Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ligand assigned to the Company all of its rights to certain patents and patent applications relating to ensifentrine and related compounds (the "Ligand Patents") and an exclusive, worldwide, royalty-bearing license under certain Ligand know-how to develop, manufacture and commercialize products (the "Licensed Products") developed using Ligand Patents, Ligand know-how and the physical stock of certain compounds.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company is obligated to pay a milestone payment on obtaining the first approval of any regulatory authority for the commercialization of a Licensed Product, low single digit royalties based on the future sales performance of all Licensed Products and a portion equal to a mid-twenty percent of any consideration received from any sub-licensees for the Ligand Patents and for Ligand know-how. Royalties payable are based on the future sales performance so the amount payable is unlimited.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At the time each contingency is resolved, the Company will record the contingent consideration payment (or payable) in connection with the Ligand Agreement as an expense and will classify it within R&amp;D expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzI2_707c0406-a345-4712-9956-8ff5b8124f60" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Research and development costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. Research and development expenses include salaries, share-based compensation and benefits of employees, and other costs related to the Company&#8217;s R&amp;D activities, including contracts with clinical research organizations and contract manufacturers. As part of the process of preparing financial statements the Company is required to estimate its expenses resulting from its obligation under contracts with vendors and consultants and clinical site agreements in connection with its R&amp;D efforts. The financial terms of these contracts are subject to negotiations which vary contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company&#8217;s objective is to reflect the appropriate clinical trial expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the trials and other development activities measured by patient progression and the timing of various aspects of the trial. The Company determines prepaid and accrual estimates through discussions with applicable personnel and outside service providers as to the progress of clinical trials, or other services completed. During the course of a clinical trial, the Company adjusts its rate of clinical trial expense recognition if actual results differ from its estimates. The Company makes estimates of its prepaid and accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. The Company&#8217;s clinical trial prepaid and accrual expense is dependent upon the timely and accurate reporting of study recruitment from contract research organizations and activities carried out by other third-party vendors as well as the timely processing of any change orders from the contract research organizations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzI3_b00a8528-00f7-4b76-adcf-02262dc7d2b8" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Share-based compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has a share-based compensation plan under which various types of equity-based awards may be granted, including stock options and restricted stock units (RSUs). The fair value of share options and RSUs, which are subject to service conditions with graded vesting, are recognized as compensation expense using the cliff vesting method; f</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">orfeitures are recognized as they occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company uses the fair-value based method to determine compensation for all arrangements under which employees receive shares. The fair value of each option and RSU is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatility is based on the historical volatility of the Company&#8217;s ordinary shares over the expected term of the options. The expected term of options granted is derived using the simplified method, which computes the expected term as the average of the sum of the vesting term plus the contract term. Historically the risk-free rate has been based on the appropriate U.K. government debt yield. After delisting its Ordinary shares from AIM on October 30, 2020, the Company began using U.S. government debt yields.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Details of the assumptions used are set out in note 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">to the consolidated financial statements.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="i6be62ec17bf043ef90a2a43d365f58cc" continuedAt="i3acace060c204cbe862a8a09077a423f"><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="vrna:GovernmentTaxCreditsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzMw_0906c519-34c7-45ac-9230-4650adfda985" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Other income - United Kingdom R&amp;D tax credits </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other operating income relates to R&amp;D tax credits receivable in the UK. As a company that carries out extensive research and development activities, Verona is subject to the UK R&amp;D Small and Medium Enterprise (&#8220;SME&#8221;) Program. Qualifying expenditures largely comprise employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which it does not receive income. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Tax credits related to the SME Program are received as cash and are recorded as other income, as they are akin to grant income, in the consolidated statements of operations and comprehensive loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzI4_287e7d0d-a48d-4852-a80f-b333a4ebdfa4" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Income taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company accounts for income taxes in accordance with ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). This Topic prescribes the use of the liability method, whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. ASC 740 establishes a single model to address accounting for uncertain tax positions. ASC 740 clarified the accounting for income taxes by prescribing the minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. The Company has no uncertain tax positions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzMx_fb66e492-ad9f-4652-bece-f9c228d6fe6f" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Comprehensive loss</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company accounts for comprehensive loss in accordance with ASC 220, &#8220;Income Statement - Reporting Comprehensive Income&#8221;. Comprehensive income represents all changes in stockholders&#8217; equity during the period except those resulting from investments by, or distributions to, stockholders.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzMy_f7cd402e-c7d0-4ab0-b554-90e1f1ef4e80" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Segment Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has <ix:nonFraction unitRef="segment" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzg3_813c9345-417c-4828-8089-f4977da28705"><ix:nonFraction unitRef="segment" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzg3_ee5fcb2d-1e02-4b13-8112-8b66579bca9a">one</ix:nonFraction></ix:nonFraction> operating and reportable segment, pharmaceutical development. The Company&#8217;s long-lived assets are held in the United Kingdom.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzMz_162acff9-3c16-4772-94b8-84bb216ebbcc" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Foreign Currencies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Reporting currency</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s reporting currency is U.S. dollars. Prior to July 1, 2020, Verona Pharma plc&#8217;s functional currency was pounds sterling and its financial statements were translated to U.S. dollars. The statement of comprehensive income was translated at average rates for the period, assets and liabilities at the balance sheet date exchange rate and equity balances at historical rates. Translation differences were recorded in accumulated other comprehensive income / (loss).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Functional currency</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company's consolidated financial statements are measured using the currency of the primary economic environment in which the entity operates, which was pounds sterling for Verona Pharma plc until June 30, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the six months to June 30, 2020, management changes resulted in lower people costs being paid in pounds sterling. Following the Private Placement the Company entered into contracts to commence Phase 3 trials for ensifentrine and the majority of the costs are incurred in U.S. dollars. Management reviewed budgeted activities over the next five years and identified that the majority of costs from the second half of 2020 onwards will be incurred in U.S. dollars. Furthermore, the Private Placement in July, 2020, raised funds in U.S. dollars and having delisted from AIM any future fundraises will be in U.S. dollars. Also, the commercial focus of Company is the U.S. market.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As a consequence, management determined the Company's functional currency changed from pounds sterling to U.S. dollars and this has been accounted for prospectively from July 1, 2020. To convert Verona Pharma plc&#8217;s books and records into U.S. dollars income and expenses were translated at average rates, assets and liabilities at the June 30, 2020, exchange rate and equity balances at historical rates. Translation differences were recorded in accumulated other comprehensive income / (loss).</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:StockholdersEquityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwODkwNzIxMDkxNjk5_76417b82-ef7e-4119-bb5b-f51ac72752f4" continuedAt="i14d74219127d4c20b9f121d4fa05d067" escape="true">Treasury shares</ix:nonNumeric></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="i3acace060c204cbe862a8a09077a423f" continuedAt="i690d1cd8e3ee4ba5bc97beb2c42da446"><ix:continuation id="i14d74219127d4c20b9f121d4fa05d067"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the year ended December 31, 2020, the Company incorporated a trust to facilitate the acquisition of shares, by or for the benefit of employees and former employees. The Company issued <ix:nonFraction unitRef="shares" contextRef="i1ab5f2cf37f34ce1822987a9a032bfe3_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="vrna:StockIssuedDuringPeriodSharesHeldInTreasury" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwODkwNzIxMDkxNzI2_c9c47e73-0594-4ea8-91f0-30beb1d176d0">25</ix:nonFraction>&#160;million ordinary shares (equivalent to <ix:nonFraction unitRef="shares" contextRef="i1ab5f2cf37f34ce1822987a9a032bfe3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="vrna:StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwODkwNzIxMDkxNzM4_5e71e9f5-d958-4752-84ea-759705968343">3.125</ix:nonFraction>&#160;million ADSs) to cover expected shares issued upon the vesting of share awards to employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has the indirect ability to control the trust as trustees are required to act in accordance with the trust deed and because the Company controls the issuance of shares to cover awards. As a consequence, the trust is consolidated into the Company&#8217;s consolidated financial statements. The shares that were issued to the trust that have not been issued to employees to satisfy vesting of share awards are included in the Consolidated Balance Sheet as treasury shares.</span></div></ix:continuation><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzM0_43f3caa2-a594-4ec4-b8a3-e44e80430a48" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Fair value of financial instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">US GAAP defines fair value and requires companies to establish a framework for measuring fair value and disclosure about fair value measurements using a three-tier approach. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our financial instruments include cash equivalents, short-term investments, other assets, accounts payable and accrued expenses and other liabilities. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgement and therefore cannot be determined with precision. The carrying amounts of these instruments are considered to be representative of their fair values because of their short-term nature.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzM1_5e64a9e1-461b-47c8-a7fd-4244f78a59e7" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Concentration of credit risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Financial instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents, bank deposits and certain receivables. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company holds cash and cash equivalents with highly rated financial institutions and in highly rated money market funds and the Company has not experienced any significant credit losses in these accounts and does not believe the Company is exposed to any significant credit risk on these instruments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzM3_cdc601ec-0951-41ea-9771-d3be3103cb8d" continuedAt="ie6fdc93d62bc40e6b1be0a525c91fce7" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Recently adopted accounting pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In February 2016, the FASB issued ASU No. 2016-02, &#8220;Leases&#8221; (Topic 842) (&#8220;ASC 842&#8221;). The standard requires lessees to recognize almost all leases on the balance sheet as right-of-use (&#8220;ROU&#8221;) assets and lease liabilities, and requires leases to be classified as either an operating or a finance type lease. The standard excludes leases of intangible assets or inventory. The standard became effective for the Company beginning January 1, 2019. The Company adopted ASC 842 using the modified retrospective approach, by applying the new standard to all leases existing at the date of initial application. Results and disclosure requirements for reporting periods beginning after January 1, 2019, are presented under ASC 842, while prior period amounts have not been adjusted and continue to be reported in accordance with our historical accounting under ASC 840 &#8220;Leases&#8221;. The Company elected the package of practical expedients permitted under ASC 842, which also allowed the Company to carry forward historical lease classifications. The Company also elected the practical expedient related to treating lease and non-lease components as a single lease component for all equipment leases as well as electing a policy exclusion permitting leases with an original lease term of less than one year to be excluded from the ROU assets and lease liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As a result of the adoption of ASC 842 on January 1, 2019, the Company recorded an operating lease ROU asset of $<ix:nonFraction unitRef="usd" contextRef="i87d649c393ad4d1b95b36d916dbd127f_I20190101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzU0_10a4abe2-84ee-499a-9cd9-ca7074faaecb">415</ix:nonFraction>&#160;thousand and an operating lease liability of $<ix:nonFraction unitRef="usd" contextRef="i87d649c393ad4d1b95b36d916dbd127f_I20190101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzM5_42fca009-735e-4044-bd83-212596b5880d">441</ix:nonFraction>&#160;thousand. The adoption increased opening accumulated losses by $<ix:nonFraction unitRef="usd" contextRef="i06f7637896b74a8e922bb5f0526d2b57_I20190101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzY5_d2b2e282-aff9-4673-a728-7d32b3496c46">26</ix:nonFraction>&#160;thousand but did not impact the Company's prior year financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under ASC 842, the Company determines if an arrangement is a lease at inception. ROU ass</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">ets and liabilities are recognized at the commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As the Company's leases do not provide an implicit rate, the Company determined the incremental borrowing rate in determining the present value of lease payments. The ROU assets also include any lease payments made prior to commencement and are recorded net of any lease incentives received. </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="i690d1cd8e3ee4ba5bc97beb2c42da446"><ix:continuation id="ie6fdc93d62bc40e6b1be0a525c91fce7"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s lease terms may include options to extend or terminate the lease. When it is reasonably certain the Company will exercise such options the lease will be recognized as a liability and a corresponding ROU asset also recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Operating leases are included in operating lease ROU assets and current and non-current operating lease liabilities, on the Company's consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The FASB issued ASU 2020-04 to provide optional expedients and exceptions for applying US GAAP to contract modifications, hedging relationships, and other transactions affected by the anticipated transition away from LIBOR. There is no material impact of the adoption of ASU 2020-04 on our consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Recently issued accounting pronouncements, not yet adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (&#8220;ASU 2019-10&#8221;). The purpose of this amendment is to create a two tier rollout of major updates, staggering the effective dates between larger public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies (&#8220;SRCs&#8221;), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies will have an effective date for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until the earlier of fiscal periods beginning after December 15, 2022. Under the current SEC definitions, we meet the definition of an SRC as of the ASU 2019-10 issuance date and are deferring adoption for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. We are currently evaluating the impact of the adoption of ASU 2016-13 on our consolidated financial statements, but do not believe the adoption of this standard will have a material impact on our consolidated financial statements.</span></div></ix:continuation></ix:continuation><div id="id4dd95a68a65415aa5f2e21bd87d1189_279"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 3 - <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="vrna:PrepaidExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNzkvZnJhZzplODQ4NzQ0NGE1Mzg0ZmFjYWQxMTAzYTg4Zjc3MDc4NS90ZXh0cmVnaW9uOmU4NDg3NDQ0YTUzODRmYWNhZDExMDNhODhmNzcwNzg1XzIxNDQwNDc2NzQyNTcx_50a0b6e0-705a-4128-a392-f5f1d110fef7" continuedAt="ide000978d2e7416499e32999dfa1edb3" escape="true">Prepaid expenses </ix:nonNumeric></span></div><ix:continuation id="ide000978d2e7416499e32999dfa1edb3"><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNzkvZnJhZzplODQ4NzQ0NGE1Mzg0ZmFjYWQxMTAzYTg4Zjc3MDc4NS90ZXh0cmVnaW9uOmU4NDg3NDQ0YTUzODRmYWNhZDExMDNhODhmNzcwNzg1XzIxNDQwNDc2NzQyNTcy_5e856a41-f5c7-467e-a5e4-e21b02e1eac5" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Prepaid expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and other development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="vrna:PrepaidResearchAndDevelopmentFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNzkvZnJhZzplODQ4NzQ0NGE1Mzg0ZmFjYWQxMTAzYTg4Zjc3MDc4NS90YWJsZTo1YzQxYmU0M2E4MGY0NzQzOWNkNjljOTAzOTdhZDhhMS90YWJsZXJhbmdlOjVjNDFiZTQzYTgwZjQ3NDM5Y2Q2OWM5MDM5N2FkOGExXzItMi0xLTEtMTIxMzk_1eb65228-99c7-4f4a-995b-190be5c6e3fa">2,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" name="vrna:PrepaidResearchAndDevelopmentFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNzkvZnJhZzplODQ4NzQ0NGE1Mzg0ZmFjYWQxMTAzYTg4Zjc3MDc4NS90YWJsZTo1YzQxYmU0M2E4MGY0NzQzOWNkNjljOTAzOTdhZDhhMS90YWJsZXJhbmdlOjVjNDFiZTQzYTgwZjQ3NDM5Y2Q2OWM5MDM5N2FkOGExXzItNC0xLTEtMTIxMzk_926177d3-172f-467d-b09d-cb7612cf1765">874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNzkvZnJhZzplODQ4NzQ0NGE1Mzg0ZmFjYWQxMTAzYTg4Zjc3MDc4NS90YWJsZTo1YzQxYmU0M2E4MGY0NzQzOWNkNjljOTAzOTdhZDhhMS90YWJsZXJhbmdlOjVjNDFiZTQzYTgwZjQ3NDM5Y2Q2OWM5MDM5N2FkOGExXzItMi0xLTEtODc0NA_ef92a558-d1ec-45e6-9799-e84fbe2d7b2f">1,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNzkvZnJhZzplODQ4NzQ0NGE1Mzg0ZmFjYWQxMTAzYTg4Zjc3MDc4NS90YWJsZTo1YzQxYmU0M2E4MGY0NzQzOWNkNjljOTAzOTdhZDhhMS90YWJsZXJhbmdlOjVjNDFiZTQzYTgwZjQ3NDM5Y2Q2OWM5MDM5N2FkOGExXzItNC0xLTEtODc0NA_5abfd2f6-55fb-4519-a799-16dc4f3464e1">534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNzkvZnJhZzplODQ4NzQ0NGE1Mzg0ZmFjYWQxMTAzYTg4Zjc3MDc4NS90YWJsZTo1YzQxYmU0M2E4MGY0NzQzOWNkNjljOTAzOTdhZDhhMS90YWJsZXJhbmdlOjVjNDFiZTQzYTgwZjQ3NDM5Y2Q2OWM5MDM5N2FkOGExXzQtMi0xLTEtNDgxMQ_c3538e20-4a58-4fc5-9462-8cd602149188">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNzkvZnJhZzplODQ4NzQ0NGE1Mzg0ZmFjYWQxMTAzYTg4Zjc3MDc4NS90YWJsZTo1YzQxYmU0M2E4MGY0NzQzOWNkNjljOTAzOTdhZDhhMS90YWJsZXJhbmdlOjVjNDFiZTQzYTgwZjQ3NDM5Y2Q2OWM5MDM5N2FkOGExXzQtNC0xLTEtNDgxMQ_7e12ced4-6cad-4a35-b1ae-cd546abd4127">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNzkvZnJhZzplODQ4NzQ0NGE1Mzg0ZmFjYWQxMTAzYTg4Zjc3MDc4NS90YWJsZTo1YzQxYmU0M2E4MGY0NzQzOWNkNjljOTAzOTdhZDhhMS90YWJsZXJhbmdlOjVjNDFiZTQzYTgwZjQ3NDM5Y2Q2OWM5MDM5N2FkOGExXzUtMi0xLTEtMzU1Ng_d72cad1f-750c-487d-abf1-78851079a980">4,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNzkvZnJhZzplODQ4NzQ0NGE1Mzg0ZmFjYWQxMTAzYTg4Zjc3MDc4NS90YWJsZTo1YzQxYmU0M2E4MGY0NzQzOWNkNjljOTAzOTdhZDhhMS90YWJsZXJhbmdlOjVjNDFiZTQzYTgwZjQ3NDM5Y2Q2OWM5MDM5N2FkOGExXzUtNC0xLTEtMzU1Ng_2cd24c12-a112-4b2a-a013-0788e7b6aeac">1,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="id4dd95a68a65415aa5f2e21bd87d1189_421"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 4 - <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV80MjEvZnJhZzo2OTA3NGIwZGY4ZWY0OTg0YTg1NWY0NWJjMWExYmIzZi90ZXh0cmVnaW9uOjY5MDc0YjBkZjhlZjQ5ODRhODU1ZjQ1YmMxYTFiYjNmXzIwMzQwOTY1MTE3NDc2_18db0d7f-c18f-4b1f-b83d-986e6995308a" continuedAt="i4680faeb6d7c4bdaa0c837bbc17d7b10" escape="true">Tax and tax incentive receivables</ix:nonNumeric></span></div><ix:continuation id="i4680faeb6d7c4bdaa0c837bbc17d7b10"><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="vrna:ScheduleOfNontradeReceivablesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV80MjEvZnJhZzo2OTA3NGIwZGY4ZWY0OTg0YTg1NWY0NWJjMWExYmIzZi90ZXh0cmVnaW9uOjY5MDc0YjBkZjhlZjQ5ODRhODU1ZjQ1YmMxYTFiYjNmXzIwMzQwOTY1MTE3NDc3_6916da73-08f1-4a76-9f55-da886cdd2ea1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Taxes receivable consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D tax credit receivable - U.K.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="vrna:ResearchAndDevelopmentTaxCreditReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV80MjEvZnJhZzo2OTA3NGIwZGY4ZWY0OTg0YTg1NWY0NWJjMWExYmIzZi90YWJsZToyNmM4NzdmMWUyMzA0NjUxYTZiOGE5ODE5MDRlMTBhZS90YWJsZXJhbmdlOjI2Yzg3N2YxZTIzMDQ2NTFhNmI4YTk4MTkwNGUxMGFlXzItMi0xLTEtNDgxNQ_d5256533-9e5a-4739-955d-07f581f1542c">8,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="vrna:ResearchAndDevelopmentTaxCreditReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV80MjEvZnJhZzo2OTA3NGIwZGY4ZWY0OTg0YTg1NWY0NWJjMWExYmIzZi90YWJsZToyNmM4NzdmMWUyMzA0NjUxYTZiOGE5ODE5MDRlMTBhZS90YWJsZXJhbmdlOjI2Yzg3N2YxZTIzMDQ2NTFhNmI4YTk4MTkwNGUxMGFlXzItNC0xLTEtNDgxNQ_27aaf064-b4dc-42b6-a35b-54d7813a46e5">9,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax receivable - U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" name="us-gaap:IncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV80MjEvZnJhZzo2OTA3NGIwZGY4ZWY0OTg0YTg1NWY0NWJjMWExYmIzZi90YWJsZToyNmM4NzdmMWUyMzA0NjUxYTZiOGE5ODE5MDRlMTBhZS90YWJsZXJhbmdlOjI2Yzg3N2YxZTIzMDQ2NTFhNmI4YTk4MTkwNGUxMGFlXzMtMi0xLTEtNDgxNQ_d8686a4a-1bbd-4d9e-a6d7-342c0a1321c2">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" name="us-gaap:IncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV80MjEvZnJhZzo2OTA3NGIwZGY4ZWY0OTg0YTg1NWY0NWJjMWExYmIzZi90YWJsZToyNmM4NzdmMWUyMzA0NjUxYTZiOGE5ODE5MDRlMTBhZS90YWJsZXJhbmdlOjI2Yzg3N2YxZTIzMDQ2NTFhNmI4YTk4MTkwNGUxMGFlXzMtNC0xLTEtNDgxNQ_9c47bc14-7755-44c0-932e-89a6e5e78bc2">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total tax receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="vrna:TaxCreditAndIncomeTaxesReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV80MjEvZnJhZzo2OTA3NGIwZGY4ZWY0OTg0YTg1NWY0NWJjMWExYmIzZi90YWJsZToyNmM4NzdmMWUyMzA0NjUxYTZiOGE5ODE5MDRlMTBhZS90YWJsZXJhbmdlOjI2Yzg3N2YxZTIzMDQ2NTFhNmI4YTk4MTkwNGUxMGFlXzQtMi0xLTEtNDgxNQ_327e14dd-4dea-41cf-92b4-a3b1ac4eab38">8,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="vrna:TaxCreditAndIncomeTaxesReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV80MjEvZnJhZzo2OTA3NGIwZGY4ZWY0OTg0YTg1NWY0NWJjMWExYmIzZi90YWJsZToyNmM4NzdmMWUyMzA0NjUxYTZiOGE5ODE5MDRlMTBhZS90YWJsZXJhbmdlOjI2Yzg3N2YxZTIzMDQ2NTFhNmI4YTk4MTkwNGUxMGFlXzQtNC0xLTEtNDgxNQ_8b605a08-49c0-4621-bab3-7c382db50865">9,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="id4dd95a68a65415aa5f2e21bd87d1189_284"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 5 - <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90ZXh0cmVnaW9uOjk4MjgwNjE0ODNhZTRkYjg4NDM2YWY1MzI5MjgyZDBmXzIwMzQwOTY1MTIzNDM2_e5ce51e5-7e86-42fe-9600-f149efddfafa" continuedAt="if75e707eaee3454f95bdec71be3b0f2b" escape="true">Property leases</ix:nonNumeric></span></div><ix:continuation id="if75e707eaee3454f95bdec71be3b0f2b"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The right-of-use assets (&#8220;ROU&#8221;) relate to rented office space in London and North Carolina, with leases ending in 2022 and 2024, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the year ended December 31, 2019, the Company determined that it was reasonably likely to extend its existing London lease. As a consequence it modified its accounting for the lease and recorded an additional $<ix:nonFraction unitRef="usd" contextRef="i9c561e8d91b04a3eb8a0bb1c609295ce_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90ZXh0cmVnaW9uOjk4MjgwNjE0ODNhZTRkYjg4NDM2YWY1MzI5MjgyZDBmXzIwMzQwOTY1MTIzMzA1_68bbf444-6418-4b54-9405-47ffb63c04e9">0.7</ix:nonFraction>&#160;million ROU and associated liability. The Company has the option to further extend this lease but is not reasonably certain to do so and therefore has not recognized this extension as an asset and liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the year ended December 31, 2019, the Company entered in&#160;&#160;&#160;&#160;to a lease arrangement in New York for serviced offices and recognized a right of use asset and corresponding lease liability of $<ix:nonFraction unitRef="usd" contextRef="i8d00a9e878d548fb96619548564db190_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90ZXh0cmVnaW9uOjk4MjgwNjE0ODNhZTRkYjg4NDM2YWY1MzI5MjgyZDBmXzIwMzQwOTY1MTIzMjkx_52de9087-b52a-45a0-ae7b-69b6d5e8fbbc">0.4</ix:nonFraction>&#160;million. In the year ended December 31, 2020, the Company&#8217;s New York office was closed and the related ROU asset of $<ix:nonFraction unitRef="usd" contextRef="i433bd94d277a4aaca4429c549dceb814_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90ZXh0cmVnaW9uOjk4MjgwNjE0ODNhZTRkYjg4NDM2YWY1MzI5MjgyZDBmXzIwMzQwOTY1MTIzMzM0_9ef59987-2de3-4b20-a65e-d56bbd2e76ff">290</ix:nonFraction>&#160;thousand was subsequently expensed in the consolidated statements of operations and comprehensive loss. The Company retains a liability of $<ix:nonFraction unitRef="usd" contextRef="ie038220275954e62811afea2defe4cd3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90ZXh0cmVnaW9uOjk4MjgwNjE0ODNhZTRkYjg4NDM2YWY1MzI5MjgyZDBmXzIwMzQwOTY1MTIzMzE5_0eb5bafb-a460-40b1-a6cd-27af3ec2fdb6">195</ix:nonFraction>&#160;thousand relating to this lease arrangement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the year ended December 31, 2020, the Company entered into a lease arrangement in North Carolina for office space and recognized an ROU asset and corresponding lease liability of $<ix:nonFraction unitRef="usd" contextRef="i30a26c5ea22f48a09788808b52ec5291_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90ZXh0cmVnaW9uOjk4MjgwNjE0ODNhZTRkYjg4NDM2YWY1MzI5MjgyZDBmXzIwMzQwOTY1MTIzMzUz_fd5797d1-b5ee-4e20-9db9-bdab24943694">0.7</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To calculate lease liabilities the Company used a weighted average discount rate of <ix:nonFraction unitRef="number" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="2" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90ZXh0cmVnaW9uOjk4MjgwNjE0ODNhZTRkYjg4NDM2YWY1MzI5MjgyZDBmXzIwMzQwOTY1MTIzMzQ5_668b24df-21fd-4001-8473-b9b334507af3">8</ix:nonFraction>%. The weighted average remaining lease term is <ix:nonNumeric contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90ZXh0cmVnaW9uOjk4MjgwNjE0ODNhZTRkYjg4NDM2YWY1MzI5MjgyZDBmXzU0OTc1NTgyNTM3OQ_e621f8d0-3a0c-4467-92d0-cb80de0e7f6d">2.2</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90ZXh0cmVnaW9uOjk4MjgwNjE0ODNhZTRkYjg4NDM2YWY1MzI5MjgyZDBmXzIwMzQwOTY1MTIzNDM4_885ae978-3746-44e8-8658-2c31fc1792e8" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Minimum annual payments over the remaining lease periods as of December 31, 2020 are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90YWJsZTo1MTcyNmUxNjc0Y2Q0OTk5YjY5ZTM5OTM2NTA2NTMwMC90YWJsZXJhbmdlOjUxNzI2ZTE2NzRjZDQ5OTliNjllMzk5MzY1MDY1MzAwXzMtMi0xLTEtMzUxOQ_f7395080-8d25-4878-9d5c-79a77f8c36da">862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90YWJsZTo1MTcyNmUxNjc0Y2Q0OTk5YjY5ZTM5OTM2NTA2NTMwMC90YWJsZXJhbmdlOjUxNzI2ZTE2NzRjZDQ5OTliNjllMzk5MzY1MDY1MzAwXzQtMi0xLTEtMzUxOQ_fa00269b-0b49-43af-b9b4-bb9798a32e99">281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90YWJsZTo1MTcyNmUxNjc0Y2Q0OTk5YjY5ZTM5OTM2NTA2NTMwMC90YWJsZXJhbmdlOjUxNzI2ZTE2NzRjZDQ5OTliNjllMzk5MzY1MDY1MzAwXzUtMi0xLTEtMzUxOQ_052197d4-71bb-4ebc-87b8-6e281d4d2802">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90YWJsZTo1MTcyNmUxNjc0Y2Q0OTk5YjY5ZTM5OTM2NTA2NTMwMC90YWJsZXJhbmdlOjUxNzI2ZTE2NzRjZDQ5OTliNjllMzk5MzY1MDY1MzAwXzYtMi0xLTEtMzUxOQ_69c76273-c2a3-4153-879b-5c96a1b71ddb">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum future lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90YWJsZTo1MTcyNmUxNjc0Y2Q0OTk5YjY5ZTM5OTM2NTA2NTMwMC90YWJsZXJhbmdlOjUxNzI2ZTE2NzRjZDQ5OTliNjllMzk5MzY1MDY1MzAwXzgtMi0xLTEtMzUxOQ_e5226a19-fe4f-4055-b481-a6f21d0afc7d">1,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90YWJsZTo1MTcyNmUxNjc0Y2Q0OTk5YjY5ZTM5OTM2NTA2NTMwMC90YWJsZXJhbmdlOjUxNzI2ZTE2NzRjZDQ5OTliNjllMzk5MzY1MDY1MzAwXzgtMi0xLTEtNTk5NQ_bc68705c-227e-47d3-b6f8-5da0c33488ea">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90YWJsZTo1MTcyNmUxNjc0Y2Q0OTk5YjY5ZTM5OTM2NTA2NTMwMC90YWJsZXJhbmdlOjUxNzI2ZTE2NzRjZDQ5OTliNjllMzk5MzY1MDY1MzAwXzktMi0xLTEtNTk5NQ_91372cc1-5397-423a-81fb-c02403afb69b">1,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The total operating lease expense included in general and administrative costs was $<ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90ZXh0cmVnaW9uOjk4MjgwNjE0ODNhZTRkYjg4NDM2YWY1MzI5MjgyZDBmXzIwMzQwOTY1MTI2NTc3_e11acad8-50e8-4d8a-a341-787e94f5109f">692,000</ix:nonFraction>.</span></div><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90ZXh0cmVnaW9uOjk4MjgwNjE0ODNhZTRkYjg4NDM2YWY1MzI5MjgyZDBmXzI0NzM5MDExNjM4NjQ1_cf37f6e9-f057-4a95-945c-319595a27767" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the prior lease accounting guidance minimum rental commitments under non-cancelable leases,  for each of the five years and total thereafter as of December 31, 2019, were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90YWJsZTpmOWM0YzA1YjI0Zjc0Y2IyYjMwMTJhMjM4Y2I1ODc2ZC90YWJsZXJhbmdlOmY5YzRjMDViMjRmNzRjYjJiMzAxMmEyMzhjYjU4NzZkXzEtMi0xLTEtMjUwNzE_2e7b4e8b-14c7-4918-9db8-9bc28ea6c8c7">680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90YWJsZTpmOWM0YzA1YjI0Zjc0Y2IyYjMwMTJhMjM4Y2I1ODc2ZC90YWJsZXJhbmdlOmY5YzRjMDViMjRmNzRjYjJiMzAxMmEyMzhjYjU4NzZkXzEtNC0xLTEtMjQ5NDU_5a9623b6-9465-4ec6-8d4a-d263ac1b79ba">862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90YWJsZTpmOWM0YzA1YjI0Zjc0Y2IyYjMwMTJhMjM4Y2I1ODc2ZC90YWJsZXJhbmdlOmY5YzRjMDViMjRmNzRjYjJiMzAxMmEyMzhjYjU4NzZkXzEtNi0xLTEtMjQ5NDI_4e8973ec-7e52-40dd-90ee-2f576457fd3d">281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90YWJsZTpmOWM0YzA1YjI0Zjc0Y2IyYjMwMTJhMjM4Y2I1ODc2ZC90YWJsZXJhbmdlOmY5YzRjMDViMjRmNzRjYjJiMzAxMmEyMzhjYjU4NzZkXzEtOC0xLTEtMjQ5Mzk_3e239c69-1f93-4f4e-b107-ab33c2e2bd72">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90YWJsZTpmOWM0YzA1YjI0Zjc0Y2IyYjMwMTJhMjM4Y2I1ODc2ZC90YWJsZXJhbmdlOmY5YzRjMDViMjRmNzRjYjJiMzAxMmEyMzhjYjU4NzZkXzEtMTAtMS0xLTI0OTM2_8eba82ab-0003-40cf-ae76-56979c9c9279">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="id4dd95a68a65415aa5f2e21bd87d1189_259"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 6 - <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNTkvZnJhZzo4NjA1NjFiNWIxZWE0MzVkOTBlMzE5ZjZkMjI0YzQxZi90ZXh0cmVnaW9uOjg2MDU2MWI1YjFlYTQzNWQ5MGUzMTlmNmQyMjRjNDFmXzIwMzQwOTY1MTE0NzI0_43462080-1aaa-4f95-90bc-ac1d9f13140c" continuedAt="iaf383a21e593450992ece1b24041fe0f" escape="true">Accrued expenses</ix:nonNumeric></span></div><ix:continuation id="iaf383a21e593450992ece1b24041fe0f"><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNTkvZnJhZzo4NjA1NjFiNWIxZWE0MzVkOTBlMzE5ZjZkMjI0YzQxZi90ZXh0cmVnaW9uOjg2MDU2MWI1YjFlYTQzNWQ5MGUzMTlmNmQyMjRjNDFmXzIwMzQwOTY1MTE0NzI1_8c22767a-001f-486b-ab9b-c4c89247cfe2" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and other development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="vrna:AccruedResearchAndDevelopmentFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNTkvZnJhZzo4NjA1NjFiNWIxZWE0MzVkOTBlMzE5ZjZkMjI0YzQxZi90YWJsZTpjZmU4ZjQxZjU4MWE0MDZhYTJkYTRlYzc5YmQzNGNkZS90YWJsZXJhbmdlOmNmZThmNDFmNTgxYTQwNmFhMmRhNGVjNzliZDM0Y2RlXzMtMi0xLTEtMzcwOA_1ecb21e8-e39d-487a-b11c-4db6cbbaabe5">8,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="vrna:AccruedResearchAndDevelopmentFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNTkvZnJhZzo4NjA1NjFiNWIxZWE0MzVkOTBlMzE5ZjZkMjI0YzQxZi90YWJsZTpjZmU4ZjQxZjU4MWE0MDZhYTJkYTRlYzc5YmQzNGNkZS90YWJsZXJhbmdlOmNmZThmNDFmNTgxYTQwNmFhMmRhNGVjNzliZDM0Y2RlXzMtNC0xLTEtMzcwOA_8a5a6c71-f8de-433d-b2e7-237cd4c9e963">6,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees, listing and general corporate costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNTkvZnJhZzo4NjA1NjFiNWIxZWE0MzVkOTBlMzE5ZjZkMjI0YzQxZi90YWJsZTpjZmU4ZjQxZjU4MWE0MDZhYTJkYTRlYzc5YmQzNGNkZS90YWJsZXJhbmdlOmNmZThmNDFmNTgxYTQwNmFhMmRhNGVjNzliZDM0Y2RlXzMtMi0xLTEtMjUxNzQ_62b3ea5f-0cbf-4533-ad62-7f8526728981">2,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNTkvZnJhZzo4NjA1NjFiNWIxZWE0MzVkOTBlMzE5ZjZkMjI0YzQxZi90YWJsZTpjZmU4ZjQxZjU4MWE0MDZhYTJkYTRlYzc5YmQzNGNkZS90YWJsZXJhbmdlOmNmZThmNDFmNTgxYTQwNmFhMmRhNGVjNzliZDM0Y2RlXzMtNC0xLTEtMjUxNzQ_21b48942-866a-46d9-bce3-d037f1ca1041">2,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNTkvZnJhZzo4NjA1NjFiNWIxZWE0MzVkOTBlMzE5ZjZkMjI0YzQxZi90YWJsZTpjZmU4ZjQxZjU4MWE0MDZhYTJkYTRlYzc5YmQzNGNkZS90YWJsZXJhbmdlOmNmZThmNDFmNTgxYTQwNmFhMmRhNGVjNzliZDM0Y2RlXzQtMi0xLTEtMzcwOA_ae1c055e-506a-4352-b76d-1df04f6b56c9">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNTkvZnJhZzo4NjA1NjFiNWIxZWE0MzVkOTBlMzE5ZjZkMjI0YzQxZi90YWJsZTpjZmU4ZjQxZjU4MWE0MDZhYTJkYTRlYzc5YmQzNGNkZS90YWJsZXJhbmdlOmNmZThmNDFmNTgxYTQwNmFhMmRhNGVjNzliZDM0Y2RlXzQtNC0xLTEtMzcwOA_305739fe-4cc5-4785-9655-6e31a8b5bd52">386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNTkvZnJhZzo4NjA1NjFiNWIxZWE0MzVkOTBlMzE5ZjZkMjI0YzQxZi90YWJsZTpjZmU4ZjQxZjU4MWE0MDZhYTJkYTRlYzc5YmQzNGNkZS90YWJsZXJhbmdlOmNmZThmNDFmNTgxYTQwNmFhMmRhNGVjNzliZDM0Y2RlXzYtMi0xLTEtMzcwOA_b0a635f0-0cd1-4599-8081-ad377632d861">10,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNTkvZnJhZzo4NjA1NjFiNWIxZWE0MzVkOTBlMzE5ZjZkMjI0YzQxZi90YWJsZTpjZmU4ZjQxZjU4MWE0MDZhYTJkYTRlYzc5YmQzNGNkZS90YWJsZXJhbmdlOmNmZThmNDFmNTgxYTQwNmFhMmRhNGVjNzliZDM0Y2RlXzYtNC0xLTEtMzcwOA_3d050f84-4daf-4679-a2b3-a3fd235cf030">8,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other expenses include people costs, professional fees and other accrued costs.</span></div></ix:continuation><div id="id4dd95a68a65415aa5f2e21bd87d1189_264"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 7 - <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="vrna:WarrantAndRightsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzIwMzQwOTY1MTIxMjA3_18f0508c-4d8a-44ad-a38b-b0fd37113afb" continuedAt="ib27df441863a4db3a4d73fbbfcd27442" escape="true">Warrants</ix:nonNumeric></span></div><ix:continuation id="ib27df441863a4db3a4d73fbbfcd27442"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In 2016, the Company issued <ix:nonFraction unitRef="shares" contextRef="i1934261cb6744a68b1f3c1ac28b455f2_I20161231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzIwMzQwOTY1MTIxMjA5_24c17df1-bfec-4875-a31e-d7914fda36c3">31,115,926</ix:nonFraction> units to new and existing investors at the placing price of &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="i1934261cb6744a68b1f3c1ac28b455f2_I20161231" decimals="4" name="vrna:ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzIwMzQwOTY1MTIxMjIx_cda85977-ae23-4885-bb27-c2dc4384e3e5">1.4365</ix:nonFraction> per unit. Each unit comprised one ordinary share and one warrant. The warrant holders can subscribe for <ix:nonFraction unitRef="shares" contextRef="i1934261cb6744a68b1f3c1ac28b455f2_I20161231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzIwMzQwOTY1MTIxMjMw_bfe6e97f-a90e-4856-857a-668e2146666d">0.4</ix:nonFraction> of an ordinary share at a per share exercise price of &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="i1934261cb6744a68b1f3c1ac28b455f2_I20161231" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzIwMzQwOTY1MTIxMjM1_21d8ad3c-e7ef-43cb-b37d-da40526975fd">1.7238</ix:nonFraction> until May 2, 2022. The warrant holders can opt for a cashless exercise of their warrants, whereby the warrant holders can choose to exchange the warrants held for a reduced number of warrants exercisable at nil consideration. The reduced number of warrants is calculated based on a formula considering the share price and the exercise price of the warrants.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At December 31, 2020, <ix:nonFraction unitRef="shares" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzU0OTc1NTgxNzE0MQ_e27da514-3fdd-4386-b1ca-07f85c803c49">31,003,155</ix:nonFraction> warrants remain outstanding and entitle the investors to subscribe for, in aggregate, a maximum of <ix:nonFraction unitRef="shares" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzIwMzQwOTY1MTIxMjQ2_f8ea50bc-bdcd-416d-816d-50420fafed4b">12,401,262</ix:nonFraction> ordinary shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If, after a transaction, should the warrants be exercisable for unlisted securities, the warrant holders may demand a cash payment instead of the delivery of the underlying securities. Accordingly, the warrants are accounted for as a liability under ASC 480 &#8220;Distinguishing Liabilities from Equity&#8221;.The warrants are measured at fair value, Level 3 in the fair value hierarchy, with movements recorded in finance income / (expense) in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the years ended December 31, 2020, and 2019, <ix:nonFraction unitRef="shares" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="0" format="ixt-sec:numwordsen" name="vrna:ClassOfWarrantOrRightNumberOfExercisedOrForfeited" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzIwMzQwOTY1MTIxMjY1_42505124-86bc-4bc3-802a-d16f90608d26"><ix:nonFraction unitRef="shares" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="0" format="ixt-sec:numwordsen" name="vrna:ClassOfWarrantOrRightNumberOfExercisedOrForfeited" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzIwMzQwOTY1MTIxMjY1_6b985ca1-0dcd-439f-9b96-8ff6f42e91be">no</ix:nonFraction></ix:nonFraction> warrants were exercised or forfeited.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The warrants had <ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="vrna:ClassOfWarrantOrRightIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzIwMzQwOTY1MTIzMzEz_9fda51b7-5387-4efc-9909-b03fe4a69674">no</ix:nonFraction> intrinsic value as at December 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">There have been no changes in valuation techniques or transfers between fair value measurement levels during the years ended December 31, 2020 and 2019. <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzIwMzQwOTY1MTIyODg2_7a0795a7-49a2-44d7-8459-cb14c857cd99" continuedAt="ibae801a7082843e699313e681c5842b4" escape="true">The warrants are valued using the Black-Scholes model and the table below presents the assumptions used:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><ix:continuation id="ibae801a7082843e699313e681c5842b4"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares potentially issued under warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzItMi0xLTEtNjkzMQ_65489030-78aa-486e-8a02-c205532adca0">12,401,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzItNC0xLTEtNjkzMQ_e6bcf89b-8921-476c-b64c-e5f53b31f492">12,401,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price in pounds sterling</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="gbpPerShare" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzMtMi0xLTEtNjkzMQ_50b199f7-5204-483d-bb39-9684ec6f0bb1">1.7238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="gbpPerShare" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzMtNC0xLTEtNjkzMQ_ab11031c-6167-4bc4-b6fd-9357b2f7b378">1.7238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equivalent price of ordinary share (ADS price divided by eight)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="2" name="vrna:ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzQtMi0xLTEtMTIyNDc_390ac764-495c-4153-a0e4-b445be1dc562">0.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="2" name="vrna:ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzQtNC0xLTEtMTIyNDc_4c216e73-56fd-4bf3-b6f3-1217da66ed4a">0.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia00163949ecb43ad94978f60f9da30cc_I20201231" decimals="4" format="ixt:zerodash" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzUtMi0xLTEtMTIyNDc_d1b39aa4-d7b3-4fee-a3f0-66e7830eb5cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie527217d2eb345ecb87bd45f62bc6551_I20191231" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzUtNC0xLTEtMTIyNDc_80b2ebd0-8af4-457a-8f67-738922a4c2ca">0.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term to exercise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzYtMi0xLTEtMTIyNDc_a08864c8-af1d-49f9-b4df-7b9fb887a233">1.33</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzYtNC0xLTEtMTIyNDc_3a80b36c-a8c7-4593-b4f1-0ab76fd12813">2.34</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic9d34c4d3648482ca9398caf5933c3fc_I20201231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzctMi0xLTEtMTIyNDc_6a4bb0c6-b09e-43e6-b934-fb6c568320b4">105.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15dd5dffacd24b789e1a47ff62cf2c12_I20191231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzctNC0xLTEtMTIyNDc_fbf5ee1b-6dfd-425b-926f-8ca5b619359e">65.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic846b25fc9864471980143616fd3554b_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzQtMi0xLTEtNjkzMQ_a090d62c-2550-4658-85ec-b922851c8f7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i798475f69cfd4d4cae668edfa84dcee9_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzQtNC0xLTEtNjkzMQ_228068b6-44df-44c0-a263-899f64bd0ac8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Calculated value of the warrants, in thousands of U.S. dollars</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="vrna:WarrantLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzUtMi0xLTEtNjkzMQ_dcd1d22e-040e-46b8-9a5e-0ff0b11ae6f3">2,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="vrna:WarrantLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzUtNC0xLTEtNjkzMQ_c5abd579-e977-4a57-bd35-7c67dc656ef6">1,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzIwMzQwOTY1MTIxMjU3_e4648427-2202-4a39-ae8d-73fd2fae37fc" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows the movement of the value of the warrants (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTowOGQwYmI1MmFkYjE0ZGViODI3MGMwYTgzMTA1OGE3OC90YWJsZXJhbmdlOjA4ZDBiYjUyYWRiMTRkZWI4MjcwYzBhODMxMDU4YTc4XzItMS0xLTEtMTIyMTU_9b049d69-389e-4a27-be3c-33f785a633e1">1,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6502e2d84744a1a4f122e93a5bbedc_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTowOGQwYmI1MmFkYjE0ZGViODI3MGMwYTgzMTA1OGE3OC90YWJsZXJhbmdlOjA4ZDBiYjUyYWRiMTRkZWI4MjcwYzBhODMxMDU4YTc4XzItMy0xLTEtMTIyNDE_5c5caaad-f19b-40fa-ad27-4da8001a4dea">3,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTowOGQwYmI1MmFkYjE0ZGViODI3MGMwYTgzMTA1OGE3OC90YWJsZXJhbmdlOjA4ZDBiYjUyYWRiMTRkZWI4MjcwYzBhODMxMDU4YTc4XzQtMS0xLTEtMTIyMzc_7c4ddcb0-df4a-4994-a156-f6538ee64767">1,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTowOGQwYmI1MmFkYjE0ZGViODI3MGMwYTgzMTA1OGE3OC90YWJsZXJhbmdlOjA4ZDBiYjUyYWRiMTRkZWI4MjcwYzBhODMxMDU4YTc4XzQtMy0xLTEtMTIyNDE_3c4cd362-eec6-4a7c-8cee-3d431218add9">2,066</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange differences recognized in loss for the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" name="vrna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTowOGQwYmI1MmFkYjE0ZGViODI3MGMwYTgzMTA1OGE3OC90YWJsZXJhbmdlOjA4ZDBiYjUyYWRiMTRkZWI4MjcwYzBhODMxMDU4YTc4XzUtMS0xLTEtMTIyMzc_9150c85b-bd6c-412e-90ce-864339db13d3">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="vrna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTowOGQwYmI1MmFkYjE0ZGViODI3MGMwYTgzMTA1OGE3OC90YWJsZXJhbmdlOjA4ZDBiYjUyYWRiMTRkZWI4MjcwYzBhODMxMDU4YTc4XzUtMy0xLTEtMTIyNDE_bbc096fa-19ca-4f71-8a77-444477259eab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation differences recognized in other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTowOGQwYmI1MmFkYjE0ZGViODI3MGMwYTgzMTA1OGE3OC90YWJsZXJhbmdlOjA4ZDBiYjUyYWRiMTRkZWI4MjcwYzBhODMxMDU4YTc4XzYtMS0xLTEtMTIyMzc_f94df147-a210-40db-a1db-9c2624945c96">78</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTowOGQwYmI1MmFkYjE0ZGViODI3MGMwYTgzMTA1OGE3OC90YWJsZXJhbmdlOjA4ZDBiYjUyYWRiMTRkZWI4MjcwYzBhODMxMDU4YTc4XzYtMy0xLTEtMTIyNDE_b06a405f-82fc-4d9b-a4cc-c73c083a4df0">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At December 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTowOGQwYmI1MmFkYjE0ZGViODI3MGMwYTgzMTA1OGE3OC90YWJsZXJhbmdlOjA4ZDBiYjUyYWRiMTRkZWI4MjcwYzBhODMxMDU4YTc4XzUtMS0xLTEtMTIyMTA_a18459e2-b54f-45d1-a41b-876f12991769">2,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTowOGQwYmI1MmFkYjE0ZGViODI3MGMwYTgzMTA1OGE3OC90YWJsZXJhbmdlOjA4ZDBiYjUyYWRiMTRkZWI4MjcwYzBhODMxMDU4YTc4XzctMy0xLTEtMTIyNDE_c9c1be7c-54d0-46d7-a38a-459b28ef66c9">1,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="vrna:FairValueImpactOfIncreaseOrDecreaseInVolatilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzIwMzQwOTY1MTIyODg4_5a1b9c35-b899-4803-b1b5-c7a09be08d01" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For the amount recognized at December 31, 2020, the effect when the following parameter deviates up or down is presented in the below table (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10% volatility increase</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="vrna:SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTo1Zjc3OGYyMWE0NmQ0MGFjYmJmNzQ3NTM4MGM3YjM5Zi90YWJsZXJhbmdlOjVmNzc4ZjIxYTQ2ZDQwYWNiYmY3NDc1MzgwYzdiMzlmXzEtMS0xLTEtMTIyNzA_0127a248-ed36-42c9-ac47-dfcc53333b86">2,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Base case, reported fair value</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="vrna:WarrantLiabilityFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTo1Zjc3OGYyMWE0NmQ0MGFjYmJmNzQ3NTM4MGM3YjM5Zi90YWJsZXJhbmdlOjVmNzc4ZjIxYTQ2ZDQwYWNiYmY3NDc1MzgwYzdiMzlmXzItMS0xLTEtMTIyNzA_2c9bc920-9766-4b77-9c25-d705e02870fb">2,246</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10% volatility decrease</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="vrna:SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTo1Zjc3OGYyMWE0NmQ0MGFjYmJmNzQ3NTM4MGM3YjM5Zi90YWJsZXJhbmdlOjVmNzc4ZjIxYTQ2ZDQwYWNiYmY3NDc1MzgwYzdiMzlmXzMtMS0xLTEtMTIyNzA_96fba689-98f4-496a-88ed-03cf214f9e4e">1,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="id4dd95a68a65415aa5f2e21bd87d1189_508"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 8 - <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTM3MTg3_ea98e98d-3b1a-4d94-8ae6-c4c0474a500e" continuedAt="iefdbc7dac1654476a54504632386ceeb" escape="true">Term loan</ix:nonNumeric></span></div><ix:continuation id="iefdbc7dac1654476a54504632386ceeb" continuedAt="i114f58c8153640f3a230ebfe4b09ee54"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In November 2020, the Company and its wholly owned subsidiary, Verona Pharma, Inc. (the &#8220;Borrowers&#8221;) entered into a term loan facility of up to $<ix:nonFraction unitRef="usd" contextRef="i2f3b17ae809741d291cfb524e558c10e_I20201130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwNzM5_2bffa798-f730-48f6-84c3-3cd202cc4b2b">30.0</ix:nonFraction>&#160;million (the &#8220;Term Loan&#8221;), consisting of term loan advances in an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="ie41a5e71b1994eee9bbaacc09238aab0_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwNzU0_c0ece4e4-4a4d-47a8-9a83-b4c28841a200">5.0</ix:nonFraction>&#160;million funded at closing, a term loan advance available subject to certain terms and conditions in an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i7a160b4682334bfdb2a585dd96fe5385_I20201130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwNzY4_1a46e45e-0003-46c2-8ae9-5322e32e8987">10.0</ix:nonFraction>&#160;million (the &#8220;Term B Loan&#8221;) and a term loan advance available subject to certain terms and conditions in an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i5f6a1d485e244da9a9515d7aeca27d8b_I20201130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwNzgz_436ba53b-035b-4959-a2c2-c9c2f32ca42e">15.0</ix:nonFraction>&#160;million (the &#8220;Term C Loan&#8221;), with Silicon Valley Bank, a California corporation (&#8220;SVB&#8221;), the proceeds of which will be used for general corporate and working capital purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Term Loan is governed by a loan and security agreement, dated as of November 19, 2020, between the Borrowers and SVB (the &#8220;Loan Agreement&#8221;). The Term B Loan will be available, subject to and customary terms and conditions, only during the period commencing upon the achievement of a specific clinical milestone relating to ensifentrine through and including June 30, 2022. The Term C Loan will be available, subject to customary terms and conditions, only during the period commencing upon the achievement of an additional specific clinical milestone relating to ensifentrine through and including June 30, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Term Loan will mature on November 1, 2024. Each advance under the Term Loan accrues interest at a floating per annum rate equal to the greater of (a) the sum of the prime rate reported in The Wall Street Journal plus <ix:nonFraction unitRef="number" contextRef="if4a9630a9c2e4c549a9169a0cdb89d7c_D20201101-20201130" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwODA1_4f5ddfe8-26ac-4066-8165-5a443d94f10c">1.00</ix:nonFraction>% and (b) four and one-quarter of one percent (<ix:nonFraction unitRef="number" contextRef="i2f3b17ae809741d291cfb524e558c10e_I20201130" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwNzk4_bf8807d3-3087-473b-afc5-569849ee63cd">4.25</ix:nonFraction>%). The Term Loan provides for interest-only payments on a monthly basis until the payment date immediately preceding December 1, 2023. Thereafter, amortization payments will be payable monthly in equal installments of principal plus monthly payments of accrued interest. Upon repayment (whether at maturity, upon acceleration or by prepayment or otherwise), the Borrowers shall make a final payment to SVB in the amount of <ix:nonFraction unitRef="number" contextRef="i2f3b17ae809741d291cfb524e558c10e_I20201130" decimals="2" name="vrna:DebtInstrumentFinalPaymentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwODEy_39977871-30a7-40df-a4a0-46ddb6966d68">10</ix:nonFraction>% of the aggregate Term Loans advanced (the "Final Payment"). The Borrowers may prepay the Term Loan in full but not in part provided that the Borrowers (i) provide <ix:nonNumeric contextRef="ie41a5e71b1994eee9bbaacc09238aab0_D20201101-20201130" format="ixt-sec:durwordsen" name="vrna:DebtInstrumentPrepaymentTermOfPriorWrittenNotice" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwODI5_197addeb-593d-4f5c-8598-aea56b3252a3">ten days</ix:nonNumeric>&#8217; prior written notice to SVB, (ii) pays on the date of such prepayment (A) all outstanding principal plus accrued and unpaid interest, (B) a prepayment fee of $<ix:nonFraction unitRef="usd" contextRef="i11218b759beb41eeb8f443403c8f9195_I20201130" decimals="0" format="ixt:numdotdecimal" name="vrna:DebtInstrumentEarlyRepaymentPenaltyAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwODM2_17a878ac-ec63-4e61-813c-c5290a8f7611">450,000</ix:nonFraction> plus <ix:nonFraction unitRef="number" contextRef="i11218b759beb41eeb8f443403c8f9195_I20201130" decimals="3" name="vrna:DebtInstrumentEarlyRepaymentPenaltyPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwODQ2_6a06517e-7661-4636-a821-dd99d0333298">3.0</ix:nonFraction>% of the Term C Loans advanced if paid on or before the first anniversary of the closing date; $<ix:nonFraction unitRef="usd" contextRef="i37571b3be78b4c2bb25afe43255bbd52_I20201130" decimals="0" format="ixt:numdotdecimal" name="vrna:DebtInstrumentEarlyRepaymentPenaltyAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwODUy_cb4f4bb6-fa0a-4fe5-b125-1bee735ae601">300,000</ix:nonFraction> plus <ix:nonFraction unitRef="number" contextRef="i37571b3be78b4c2bb25afe43255bbd52_I20201130" decimals="4" name="vrna:DebtInstrumentEarlyRepaymentPenaltyPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwODYy_e37c901f-6679-474c-85df-d9d23a95d9c1">2.00</ix:nonFraction>% of the Term C Loans advanced if paid after the first anniversary of the closing date and on or before the second anniversary of the closing date; and $<ix:nonFraction unitRef="usd" contextRef="i14b92f6c922045ebb4b765d2692f0b26_I20201130" decimals="0" format="ixt:numdotdecimal" name="vrna:DebtInstrumentEarlyRepaymentPenaltyAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwODY5_ac56e6b3-b0c2-47f7-b4f3-fc9f8cc01824">150,000</ix:nonFraction> plus <ix:nonFraction unitRef="number" contextRef="i14b92f6c922045ebb4b765d2692f0b26_I20201130" decimals="4" name="vrna:DebtInstrumentEarlyRepaymentPenaltyPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwODc5_9de1db7c-eb75-447e-882e-4b16a9acc5ea">1.00</ix:nonFraction>% of the Term C Loans advanced if paid thereafter and prior to maturity, (C) the Final Payment and (D) all other sums, if any, that shall become due and payable with respect to the Term Loan Advances, including interest at the Default Rate with respect to any past due amounts. Amounts outstanding during an event of default are payable upon SVB's demand and shall accrue interest at an additional rate of <ix:nonFraction unitRef="number" contextRef="i2f3b17ae809741d291cfb524e558c10e_I20201130" decimals="2" name="vrna:DebtInstrumentDebtDefaultInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwODg2_22a28394-10c9-4452-9a08-952f8cd85f27">3.0</ix:nonFraction>% per annum.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Term Loan is secured by a lien on substantially all of the assets of the Borrowers, other than the equity interests of Verona U.S. and other than intellectual property, provided that such lien on substantially all assets includes any rights to payments and proceeds from the sale, licensing or disposition of intellectual property. The Borrowers have also granted SVB a negative pledge with respect to its intellectual property.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Loan Agreement contains customary covenants and representations, including but not limited to financial reporting obligations and limitations on dividends, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. The Loan Agreement also contains other customary provisions, such as expense reimbursement, non-disclosure obligations as well as indemnification rights for the benefit of SVB. The Loan Agreement includes a minimum cash covenant triggered when Borrowers' consolidated cash and cash equivalents drop below $<ix:nonFraction unitRef="usd" contextRef="ie41a5e71b1994eee9bbaacc09238aab0_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="vrna:DebtInstrumentCovenantCashAndCashEquivalentsMinimum" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwODky_32264118-66f1-4eac-8ff2-6ad7447f028b">45.0</ix:nonFraction>&#160;million at any time after the earliest to occur of any of the following: (i) the release of negative data from Enhance 2 and/or Enhance 1, which in the reasonable business discretion Borrowers&#8217; senior management, would be considered insufficient to support submission of an NDA to the FDA, (ii) the FDA issues a complete response letter with respect to an NDA submitted for ensifentrine, or (iii) failure to achieve a specific regulatory milestone relating to ensifentrine by June 30, 2023 (extendable to March 31, 2024 upon the Borrowers receiving a specified amount of new cash proceeds after September 8, 2020 from the sale of equity securities in one or more public financings or other bona fide equity financings, subordinated debt and/or upfront/milestone payments from one or more collaboration agreements not prohibited in the Loan Agreement). Upon such trigger, Borrowers must cash collateralize an amount equal to the outstanding obligations to SVB plus the amount of any prepayment penalty and Final Payment which would be due in the event the Loan Agreement were prepaid in full with respect to the Term Loans advanced as of such time.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The events of default under the Loan Agreement include, but are not limited to, the Borrowers&#8217; failure to make any payments of principal or interest under the Loan Agreement or other transaction documents, the Borrowers&#8217; breach or default in the performance of any covenant under the Loan Agreement or other transaction documents, the occurrence of a material adverse change, any Borrower making a false or misleading representation or warranty in any material respect under the Loan Agreement, any Borrower&#8217;s insolvency or bankruptcy, any attachment or judgment on any Borrower&#8217;s assets of at least $<ix:nonFraction unitRef="usd" contextRef="ie41a5e71b1994eee9bbaacc09238aab0_D20201101-20201130" decimals="0" format="ixt:numdotdecimal" name="vrna:DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwOTA3_e0b3d21a-e5d9-4f02-8cb0-6f81b919ce72">500,000</ix:nonFraction>, or the occurrence of any default under any agreement or </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="i114f58c8153640f3a230ebfe4b09ee54"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">obligation of any Borrower involving indebtedness in excess of $<ix:nonFraction unitRef="usd" contextRef="ie41a5e71b1994eee9bbaacc09238aab0_D20201101-20201130" decimals="0" format="ixt:numdotdecimal" name="vrna:DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwOTE3_e011f38d-89f2-4b5b-9b1e-1ab2a2a994de">500,000</ix:nonFraction>. If an event of default occurs, SVB is entitled to take enforcement action, including acceleration of amounts due under the Loan Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In connection with the Term Loan the Company incurred debt issuance costs totaling approximate</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">ly $<ix:nonFraction unitRef="usd" contextRef="i6a56eccf381d4490ab23ba0ce2602ed8_I20201119" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTM3MTU4_d4a0c8a2-f553-4b1d-a5cd-f3bcb30e9075">400</ix:nonFraction>&#160;thousand </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">which were deducted from the carrying amount of the debt and are being amortized over the estimated term of the debt using the effective interest method.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of December 31, 2020, the carrying value of the Term Loan was approximately $<ix:nonFraction unitRef="usd" contextRef="i46b0f32ad5df416e83423bbabba5a3b9_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTQwMjQ4_e0f268bb-97aa-485a-a742-a934ff64e810">4.6</ix:nonFraction>&#160;million, of which all was due in greater than 12 months. The debt balance has been categorized within Level 3 of the fair value hierarchy. The carrying amount of the debt approximates its fair value based on prevailing interest rates as of the balance sheet date.</span></div></ix:continuation><div id="id4dd95a68a65415aa5f2e21bd87d1189_329"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 9 - <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:DefinedContributionPlanTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMjkvZnJhZzo3MjRiZjBhM2Y1MGI0MzczODhmMjE3Y2E3MGM1OTg5Mi90ZXh0cmVnaW9uOjcyNGJmMGEzZjUwYjQzNzM4OGYyMTdjYTcwYzU5ODkyXzIwMzQwOTY1MTE2MTQw_a6cabd6a-d775-41bc-b921-52fc994fd616" continuedAt="i1e64fecc8e864285b77fd4baf569fd41" escape="true">Benefit plans</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"><ix:continuation id="i1e64fecc8e864285b77fd4baf569fd41" continuedAt="iffe6af9a88d64d949e30674de2304da7">The Company maintains a 401(k) defined contribution retirement plan in the U.S. and a defined contribution plan in the U.K. for its employees and executive director. The assets of the plans are held separately from those of the Company in independently administered funds. </ix:continuation></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"><ix:continuation id="iffe6af9a88d64d949e30674de2304da7">The retirement plan cost charge represents the contributions payable by the Company to the plans during the year. Defined contribution costs during the years ended December 31, 2020 and 2019 amounted to $<ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMjkvZnJhZzo3MjRiZjBhM2Y1MGI0MzczODhmMjE3Y2E3MGM1OTg5Mi90ZXh0cmVnaW9uOjcyNGJmMGEzZjUwYjQzNzM4OGYyMTdjYTcwYzU5ODkyXzMyOTg1MzQ4ODQyNzM_411bd366-5416-4c9b-8626-b8a8e09bc9ec">315</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMjkvZnJhZzo3MjRiZjBhM2Y1MGI0MzczODhmMjE3Y2E3MGM1OTg5Mi90ZXh0cmVnaW9uOjcyNGJmMGEzZjUwYjQzNzM4OGYyMTdjYTcwYzU5ODkyXzMyOTg1MzQ4ODQyODI_94f90a15-e242-4740-86c1-4674c11e2014">203</ix:nonFraction> thousand, respectively.</ix:continuation> </span></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_299"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 10 - <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI0MTcy_c7336ddc-0fea-49f1-908a-7daa00bce991" continuedAt="i466d0b9cab8a482091da64cffddf14ad" escape="true">Taxation</ix:nonNumeric></span></div><ix:continuation id="i466d0b9cab8a482091da64cffddf14ad" continuedAt="ic4857c3cc25841d6b4930ce62476a679"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Verona Pharma plc operates in the United Kingdom and Verona Pharma, Inc. in the United States and they are subject to income taxes in those countries. U.K. corporation tax is charged at 19% and the U.S. Federal Income tax rate is 21%.</span></div><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI0MTcz_a80deb3a-0c1e-41c6-9ae7-23c3ba988980" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The components of loss before income taxes are as follows (in thousands): </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTpmYzRiMjFkNTdkNjM0NWI2ODY4YjMyODA1M2NlZjc1Mi90YWJsZXJhbmdlOmZjNGIyMWQ1N2Q2MzQ1YjY4NjhiMzI4MDUzY2VmNzUyXzMtMi0xLTEtMzMzMg_7917f80f-1979-46a6-afd3-a521171a9686">3,191</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTpmYzRiMjFkNTdkNjM0NWI2ODY4YjMyODA1M2NlZjc1Mi90YWJsZXJhbmdlOmZjNGIyMWQ1N2Q2MzQ1YjY4NjhiMzI4MDUzY2VmNzUyXzMtNC0xLTEtMzMzMg_2dbdc9aa-ce6a-4ce8-81a5-866cd5df86a8">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTpmYzRiMjFkNTdkNjM0NWI2ODY4YjMyODA1M2NlZjc1Mi90YWJsZXJhbmdlOmZjNGIyMWQ1N2Q2MzQ1YjY4NjhiMzI4MDUzY2VmNzUyXzMtMi0xLTEtMTQ1NzQ_916f731c-5b30-4b25-a463-af1afdba5483">68,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTpmYzRiMjFkNTdkNjM0NWI2ODY4YjMyODA1M2NlZjc1Mi90YWJsZXJhbmdlOmZjNGIyMWQ1N2Q2MzQ1YjY4NjhiMzI4MDUzY2VmNzUyXzMtNC0xLTEtMTQ1NzQ_41dc19c8-0a8a-48a4-9ddc-d1f01c6b6f58">40,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTpmYzRiMjFkNTdkNjM0NWI2ODY4YjMyODA1M2NlZjc1Mi90YWJsZXJhbmdlOmZjNGIyMWQ1N2Q2MzQ1YjY4NjhiMzI4MDUzY2VmNzUyXzYtMi0xLTEtMzMzMg_79aca95d-cff2-4dbf-801f-53ce28c5c7b2">65,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTpmYzRiMjFkNTdkNjM0NWI2ODY4YjMyODA1M2NlZjc1Mi90YWJsZXJhbmdlOmZjNGIyMWQ1N2Q2MzQ1YjY4NjhiMzI4MDUzY2VmNzUyXzYtNC0xLTEtMzMzMg_f5aa1595-2598-4b5c-a77e-f85f03eec308">40,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI0MTc0_f3cdb9b4-9445-4d3c-bae4-7d04f851258d" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The components of income tax expense are as follows </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzQtMi0xLTEtMzMzOQ_3baacf26-bbc2-4300-857b-2a4ba8f6203c">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzQtNC0xLTEtMzMzOQ_c988b089-a1d4-42e7-bc8b-3ac631a11d05">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzUtMi0xLTEtMzMzOQ_abcf7734-a285-4509-9a4b-954fe173fe71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzUtNC0xLTEtMzMzOQ_5e67d7d3-5795-4f08-9a36-41d2d0fbd3b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzctMi0xLTEtMzMzOQ_89113d8a-85f8-436e-bd91-130d8daf51f1">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzctNC0xLTEtMzMzOQ_da78afad-cb10-4fbe-b74c-b4d9606066ea">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzYtMi0xLTEtMTcxMTU_8a8da82f-59cd-468a-af52-351e485b16fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzYtNC0xLTEtMTcxMTU_6016fa0d-f27d-4c9b-989d-f7c735059a15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzEwLTItMS0xLTMzMzk_4dd5da3e-59ab-4e4d-a17c-0d0379b191a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzEwLTQtMS0xLTMzMzk_05fbff4a-f4cb-49aa-bf50-07fc7bc39c5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzEzLTItMS0xLTMzMzk_e063a913-e617-4dd7-8ea5-97aa81b3ecd3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzEzLTQtMS0xLTMzMzk_39c2296b-4a26-4daa-81f9-f610cce4074a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total income tax expense </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzE0LTItMS0xLTMzMzk_77806262-26bb-4918-bdec-712c0f849cb7">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzE0LTQtMS0xLTMzMzk_8211ba4e-4345-48f9-968b-9ba7c925e497">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI0MTc1_46dd257d-f838-4b79-a4b9-527461d9dd56" continuedAt="i07cb89bcb7244c4a8e4da7ca5b7f7c87" escape="true">A reconciliation of the U.K. statutory income tax rate to our effective income tax rate is as follows (in percentages):</ix:nonNumeric></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="ic4857c3cc25841d6b4930ce62476a679"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><ix:continuation id="i07cb89bcb7244c4a8e4da7ca5b7f7c87"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.K. tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzItMi0xLTEtMTcxMTk_fabbab7b-62c8-47a9-b271-8d2d93213dda">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzItNC0xLTEtMTcxMTk_c469bf76-40c3-4114-a8ca-ed64705fe91f">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzctMi0xLTEtMzM1MA_f40a87a0-6505-4947-8be6-e1b430b96c60">8.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzctNC0xLTEtMzM1MA_17d63b82-42b1-44db-9a11-8ab863297a6e">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development incentive</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzgtMi0xLTEtMzM1MA_049a5d2c-fc9e-4ff1-b576-e2164df5d57b">4.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzgtNC0xLTEtMzM1MA_3a9cc7a6-ff71-4bf7-a375-710fa7c672d6">8.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzktMi0xLTEtMzM1MA_140f86ab-1dcf-4641-99ed-cfd31e61b330">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzktNC0xLTEtMzM1MA_9b75672e-afcb-43e0-b6b8-e52b3c7433a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred tax valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzEwLTItMS0xLTMzNTA_46534683-5798-44b1-8fad-ca4adec2609c">5.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzEwLTQtMS0xLTMzNTA_e472523b-3e07-418d-ac93-1780dec2b231">9.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Difference in overseas statutory tax rates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzctMi0xLTEtMjQ0NTU_9aedb0e6-0de7-4fd5-9c38-deff7f44563c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzctNC0xLTEtMjQ0NTU_37287ed6-4574-4131-80f1-3a7a618cda74">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzExLTItMS0xLTMzNTA_63a7873c-87ec-4987-b719-dd2225664205">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzExLTQtMS0xLTMzNTA_df9361d2-5d9f-4f9f-8cba-8b44136dc69d">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI0MTc2_99d8a22d-7926-4567-a8b3-a2da2231f77f" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Significant components of the Company&#8217;s deferred tax assets and liabilities were as follows (in thousands): </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="vrna:DeferredTaxLiabilitiesContingentLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzUtMi0xLTEtMzQzOA_62453d38-8e42-4e84-8cf7-1975d192de64">5,860</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" name="vrna:DeferredTaxLiabilitiesContingentLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzUtNC0xLTEtMzQzOA_3640ff11-a35c-4a9f-9b27-fae35d147fa0">95</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzctMi0xLTEtMzQzOA_68f15f6a-907c-4623-8fbc-f71b3ebf3c15">5,860</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzctNC0xLTEtMzQzOA_f3a29dec-7da2-455a-9b9f-f5a06209eb4a">95</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzgtMi0xLTEtMTgxMTM_5074996d-4265-4e54-bbc6-f0eee86b0ec7">19,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzgtNC0xLTEtMTgxMTM_4918812a-d574-40e9-8c02-a5e58b8839de">12,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzEyLTItMS0xLTM0Mzg_e93ba706-243e-4d89-9f1f-b2cf29397d1c">5,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzEyLTQtMS0xLTM0Mzg_0e69b34d-4134-42dd-a1c8-d6a9d5961102">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future exercisable shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzEzLTItMS0xLTM0Mzg_356ca178-80c4-4596-ac04-cd52fc649c4e">10,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzEzLTQtMS0xLTM0Mzg_a4983ec9-65aa-4c6d-853e-3aa287c79433">273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzExLTItMS0xLTE4MTEz_ffc931ed-ff85-4c98-8a69-ee502b75b9e6">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzExLTQtMS0xLTE4MTEz_63f0eab6-5b4f-4b3b-a669-775bdf599ed0">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzEyLTItMS0xLTE4MTEz_d1e92b2c-f491-4a12-98d6-33ab112c65a8">36,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzEyLTQtMS0xLTE4MTEz_48cb0003-d38c-4a35-bcd6-510197a8ad57">13,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzEzLTItMS0xLTE4MTEz_dfb9dc6a-626c-4023-ba4f-c38be2b5809e">30,321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzEzLTQtMS0xLTE4MTEz_4bfdba9b-b7d1-4cd1-9c79-3fe37aaac1af">13,504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzE0LTItMS0xLTE4MTEz_3003ae16-8e6c-416f-ba6e-d44e6ff6953f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzE0LTQtMS0xLTE4MTEz_404736d5-7166-4c37-9b68-7b14e80f90af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Movements in the deferred tax valuation allowance </span></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation allowance at January 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifff034be4ded4bcb8670b2917c2d0bd5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzE4LTItMS0xLTE4MTIx_a83f2e3b-ed03-4784-8d06-e4a68a719890">13,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bcfa5910fbe4e2ca7f076edd714a549_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzE4LTQtMS0xLTE4MTIx_9d6e5e43-7ce2-4a53-ab92-eb9732767fcf">9,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52c90d5f0c46487fb88765d553f1b65b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="vrna:SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzE5LTItMS0xLTE4MTIx_90269403-f5d6-4778-9c31-29aa13e1d68f">1,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9935563a347240e5a3824eaba4a823a6_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="vrna:SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzE5LTQtMS0xLTE4MTMw_63917326-e73b-422b-9963-018b85906a17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52c90d5f0c46487fb88765d553f1b65b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="vrna:SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzIwLTItMS0xLTE4MTIx_d6db43ee-e3b0-42b1-a092-fcf63354c177">14,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9935563a347240e5a3824eaba4a823a6_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="vrna:SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzIwLTQtMS0xLTE4MTIx_ca89f198-7ed8-4b7c-8762-fe8ae562b295">3,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52c90d5f0c46487fb88765d553f1b65b_D20200101-20201231" decimals="-3" name="vrna:SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzIxLTItMS0xLTE4MTIx_061b539d-bb29-4115-80fc-4805444bee92">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9935563a347240e5a3824eaba4a823a6_D20190101-20191231" decimals="-3" name="vrna:SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzIxLTQtMS0xLTE4MTIx_1448a3ab-5efd-4b7f-80d9-6bbf220ae198">380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation allowance at December 31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c70e119f5364bafabd0f2b4cf13c8cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzIyLTItMS0xLTE4MTIx_7b02ea86-fa23-4a02-8393-e822f389dd01">30,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifff034be4ded4bcb8670b2917c2d0bd5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzIyLTQtMS0xLTE4MTIx_69703363-3c0d-499c-9ad4-449a79466bff">13,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline"> (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">These relate to the difference in the tax base of the IP R&amp;D asset and assumed contingent liability and the accounting base, which is nil under US GAAP.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Management has reviewed cumulative tax losses and projections of future taxable losses and determined that it is not more likely than not that they will be realized. Accordingly, valuation allowances have been provided over deferred tax assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At December 31, 2020 and December 31, 2019, the Company had U.K. net operating losses (&#8220;NOLs&#8221;) of $<ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI4MjUy_1977fb07-104c-4c5b-a48a-b73f50f14f2c">95.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI4MjY5_49bb699f-0ceb-4707-8d5c-e935b5571aea">75.5</ix:nonFraction>&#160;million, respectively. The NOLs can be carried forward indefinitely to be offset against future taxable profits, but this is restricted to an annual &#163;5&#160;million allowance after which there will be a 50% restriction in the profits that can be covered by losses brought forward.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company files separate income tax returns in the U.K. and the U.S. All necessary income tax filings have been completed for all years up to and including December 31, 2019, and there are no ongoing tax examinations in any jurisdiction. <ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationPenaltiesAccrued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI0MTgy_2cf26bf2-636e-4c09-a6d3-46631d2ae0ae"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationInterestAccrued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI0MTgy_4785d40b-9e21-4622-9113-13321d533c9f"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationInterestAccrued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI0MTgy_5420d7ab-fde1-417c-b019-4d213daab429"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationPenaltiesAccrued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI0MTgy_5807b9dd-bb44-4bc8-a5e6-180be2365443"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI0MTgy_b4699813-1329-4803-b087-bcbf34cb8cae"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI0MTgy_f8060b0c-e139-4cb6-b6b5-57b86388a862">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> interest or penalties were recognized in the consolidated statements of operations or consolidated balance sheets. As of December 31, 2020, the Company has no uncertain tax positions.</span></div></ix:continuation><div id="id4dd95a68a65415aa5f2e21bd87d1189_269"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 11 - <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwODkwNzIwOTg0ODUx_25d5b187-e826-432d-9fac-a287bba00ed9" continuedAt="i4207b6753bff4a5fa9e7ad4fef4523d9" escape="true">Share-based compensation</ix:nonNumeric></span></div><ix:continuation id="i4207b6753bff4a5fa9e7ad4fef4523d9" continuedAt="id235cd7811e547bd91495362e8371478"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company operates various share based incentive plans for its staff and issues ordinary shares or ADSs when share-based awards are exercised.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company records share-based compensation expense related to share options and RSUs granted to employees and directors. The expense is included in R&amp;D and general and administrative costs, based on the nature of individual employees&#8217; functions, and represents the relevant year's allocation of the expense. The costs of share-based compensation to employees are recognized in the consolidated statements of operations and comprehensive loss, together with a corresponding increase in equity over the vesting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Options are issued with an exercise price of the market price on the day of grant and generally vest over a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcyNjkw_00bc9b5e-059e-48bb-806a-540b915c41a7">one</span> to <ix:nonNumeric contextRef="ia47baec57d49425a9f307369903c9687_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcyNjc4_93e364a0-6a9d-45ad-ae72-f45e1de096de">four years</ix:nonNumeric> and the contractual life of all options is <ix:nonNumeric contextRef="i15364ff1d68341ec805494f64c383003_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcyNjcx_0c0f0557-f3bc-49da-a461-d56718af14c7">ten years</ix:nonNumeric>. </span></div><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwMzc2_8c9a7fe8-4d21-4639-9a2c-cbdd19ffb7a3" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows the allocation of share-based compensation between R&amp;D and general and administrative costs (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bd04de9015c48df9fe3e3bef6ce4e5d_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo1NmM5M2ZhYzg5N2Q0ZTQxYjRjODZlNDY1NjU0OGZlNC90YWJsZXJhbmdlOjU2YzkzZmFjODk3ZDRlNDFiNGM4NmU0NjU2NTQ4ZmU0XzItMi0xLTEtMjA0MjM_5975779c-a433-4bc4-9c8f-28a591b4848b">9,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i465329a24eeb4cefbb25e840bfa5bc80_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo1NmM5M2ZhYzg5N2Q0ZTQxYjRjODZlNDY1NjU0OGZlNC90YWJsZXJhbmdlOjU2YzkzZmFjODk3ZDRlNDFiNGM4NmU0NjU2NTQ4ZmU0XzItNC0xLTEtMjA0MjU_46177f5a-e92a-4bc3-9855-8173dd738e09">1,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6a3a52eb8741acb78a572b648649d0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo1NmM5M2ZhYzg5N2Q0ZTQxYjRjODZlNDY1NjU0OGZlNC90YWJsZXJhbmdlOjU2YzkzZmFjODk3ZDRlNDFiNGM4NmU0NjU2NTQ4ZmU0XzMtMi0xLTEtMjA0MjM_b72daef2-df02-44ef-a1eb-56e82c550894">12,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38dd4fa39df844e6af7ab7270ee1dc55_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo1NmM5M2ZhYzg5N2Q0ZTQxYjRjODZlNDY1NjU0OGZlNC90YWJsZXJhbmdlOjU2YzkzZmFjODk3ZDRlNDFiNGM4NmU0NjU2NTQ4ZmU0XzMtNC0xLTEtMjA0MjU_1537417f-9d26-4c76-b704-ff10d3712cc3">1,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo1NmM5M2ZhYzg5N2Q0ZTQxYjRjODZlNDY1NjU0OGZlNC90YWJsZXJhbmdlOjU2YzkzZmFjODk3ZDRlNDFiNGM4NmU0NjU2NTQ4ZmU0XzQtMi0xLTEtMjA0MjM_e37a0995-8fbc-4e79-a7cf-d37caf7944da">22,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo1NmM5M2ZhYzg5N2Q0ZTQxYjRjODZlNDY1NjU0OGZlNC90YWJsZXJhbmdlOjU2YzkzZmFjODk3ZDRlNDFiNGM4NmU0NjU2NTQ4ZmU0XzQtNC0xLTEtMTAzMjg_0214fbb1-61b6-4b99-9496-70f44746861e">3,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">EMI Option Plan and Pre-IPO Option Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The EMI Option Plan and the Pre-IPO Option Plan were adopted by our board of directors on September 18, 2006, and July 24, 2012, respectively. The total number of shares that may be issued under these plans is the current number of outstanding options, or <ix:nonFraction unitRef="shares" contextRef="iac60289acf4d49a68397763e265d6cf1_I20060918" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwMzc4_aedca137-796c-494a-90c3-25d771f01ad8">114,000</ix:nonFraction> ordinary shares, or <ix:nonFraction unitRef="shares" contextRef="iac60289acf4d49a68397763e265d6cf1_I20060918" decimals="0" format="ixt:numdotdecimal" name="vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwMzg3_880e15cd-3a14-474a-8368-4861ef694ef2">14,250</ix:nonFraction> ADSs, for the EMI Option Plan and <ix:nonFraction unitRef="shares" contextRef="i3c19fa116eb54bf28428386737d1542d_I20120724" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwMzk1_eb965709-39af-488d-b4ca-eeaf81c8c647">1,860,000</ix:nonFraction> ordinary shares, or <ix:nonFraction unitRef="shares" contextRef="i3c19fa116eb54bf28428386737d1542d_I20120724" decimals="0" format="ixt:numdotdecimal" name="vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNDE0_f4500176-4b3e-444a-85cc-455e17c4f777">232,500</ix:nonFraction> ADSs, for the Pre-IPO Option Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"><ix:nonFraction unitRef="shares" contextRef="ia61b9dcc76d44330a7872e53c1b77d1a_D20170401-20201231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNDI2_9e670cb9-ab72-455c-9fa9-18a47efa0274"><ix:nonFraction unitRef="shares" contextRef="iafc15080cb714e279a2a7b822b3d58d6_D20170401-20201231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNDI2_c05d8407-1507-447c-838a-3e6826f0843c">No</ix:nonFraction></ix:nonFraction> further awards have been granted since the 2017 Incentive Plan was adopted, and <ix:nonFraction unitRef="shares" contextRef="i747d51980c684daaa52f9e04f16b0666_I20201231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNDM1_78f2668a-319a-44ac-a93e-32721f6f4dde"><ix:nonFraction unitRef="shares" contextRef="i210506e1747a4dcab92bcdbad863492a_I20201231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNDM1_fe7c3939-774b-4250-8cf3-eea6f58bf308">no</ix:nonFraction></ix:nonFraction> further awards will be granted under them.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">2017 Incentive Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The 2017 Incentive Plan was adopted by our board of directors and became effective on April 26, 2017, in order to grant share based compensation to certain of the Company&#8217;s directors and employees. It provides for the grant of stock options, RSUs, and other share-based awards to Company&#8217;s directors, officers, employees and non-employee directors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the year ended December 31, 2019, the Company modified the terms of all RSUs issued prior to January 1, 2019 to include a market based condition, which was also included in the terms of RSUs issued during 2019. The Company's stock price must be maintained above the equivalent of &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="i7e33e5ffa3934ca7a4c7048a96c317a9_D20190101-20191231" decimals="2" name="vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNDcx_b02ffbe8-a69c-4cc2-bba7-98d113a69533">2</ix:nonFraction> per ordinary share for <ix:nonNumeric contextRef="i7e33e5ffa3934ca7a4c7048a96c317a9_D20190101-20191231" format="ixt-sec:durwordsen" name="vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNTEz_cdd16053-91ee-4c6c-aa6c-f2f3da9d42a0">thirty days</ix:nonNumeric> for the RSUs to vest, in addition to the existing service condition. The RSUs vest <ix:nonNumeric contextRef="i7e33e5ffa3934ca7a4c7048a96c317a9_D20190101-20191231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNDky_b4ccfb66-290c-4bc1-bd4d-3773a6cfe6fa">five years</ix:nonNumeric> after the date of grant irrespective of whether the &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="i7e33e5ffa3934ca7a4c7048a96c317a9_D20190101-20191231" decimals="2" name="vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNDc1_a4592031-5c0d-4e97-bb00-2986b404b45d">2</ix:nonFraction> market condition was met. This modification did not result in an increase in the fair value of the RSUs. </span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="id235cd7811e547bd91495362e8371478" continuedAt="ie345cd95659742d2a271a6d6f89d7710"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Share option activity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The number of options, the weighted average grant date fair value per stock option, and the weighted average exercise price are all shown below on a per ordinary shares basis. The Company&#8217;s ADSs that are listed on the Nasdaq Global Market each represent <ix:nonFraction unitRef="rate" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="0" format="ixt-sec:numwordsen" name="dei:EntityListingDepositoryReceiptRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwODkwNzIwOTg0ODM5_fe52a3c5-62dc-4a2e-ad13-9ad1f5f55820">eight</ix:nonFraction> ordinary shares.</span></div><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNTE5_79c098d0-b774-4a98-adec-069c68c04c22" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows share option activity and includes the options outstanding from all three plans :</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.244%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of share options outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average exercise price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate intrinsic value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc6502e2d84744a1a4f122e93a5bbedc_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzEtMi0xLTEtMzY0Ng_2d036b6d-eb8d-4c25-ac94-207a59124255">8,752,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc6502e2d84744a1a4f122e93a5bbedc_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzEtNC0xLTEtMzY0Ng_8e66e596-e13a-438c-92f7-a26444ba4e9d">2.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzItMi0xLTEtMzY0Ng_391fe287-8021-40f0-9499-1a9755a32133">5,569,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzItNC0xLTEtMzY0Ng_613f9cc3-837e-4e62-bdf9-677906382286">0.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzMtMi0xLTEtMzY0Ng_270355f2-ee4c-4580-a7ec-41f8e064a499">121,970</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzMtNC0xLTEtMzY0Ng_19436ae2-dde4-4887-b13a-ff078052254a">1.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzQtMi0xLTEtMzY0Ng_1cb84cf7-108f-4218-b9b8-8f7779ddbe10">19,998</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzQtNC0xLTEtMzY0Ng_0ad207e7-ce8b-4c62-82db-d1fe645fdc17">2.65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzUtMi0xLTEtMzY0Ng_302cfbd5-78ab-4809-a294-2a7c9b8f8ef4">14,179,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzUtNC0xLTEtMzY0Ng_87120c53-8d05-4fc6-90a8-0dce38fd9433">1.53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzUtNi0xLTEtMzY0Ng_ccf5c944-d62a-4dc3-8cc5-9ffcd0cc3de7">7.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzUtOC0xLTEtMjA1NzI_2fd5ada0-2988-4ef6-a10b-28cf014492f9">933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzYtMi0xLTEtMzY0Ng_fbfbc52f-ad48-4013-89ec-c8ecef758b2c">2,096,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzYtNC0xLTEtMzY0Ng_88ef8828-e012-4f20-bf3f-adad189ebff7">0.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzctMi0xLTEtMzY0Ng_b1763c5d-4ba7-4310-a961-6b66c9065363">2,506,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzctNC0xLTEtMzY0Ng_4a7596ee-962e-40f1-ac9e-ebe7e47ba557">1.53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzgtMi0xLTEtMzY0Ng_a14336e9-2b91-404d-ba59-d82dff287b8f">589,128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzgtNC0xLTEtMzY0Ng_e1ba4bb2-079e-4c98-8d40-dd02448f415a">1.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzktMi0xLTEtMTIyOTE_47ee7143-f09f-458b-98ad-accf3a92bd1e">54,664</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzktNC0xLTEtMTIyOTE_638f8fcf-90e8-41f0-ad2c-01a5a6c5c331">0.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzktMi0xLTEtMzY0Ng_8a3980b0-7d9a-4abb-bb06-7e93af3ffff2">13,125,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzktNC0xLTEtMzY0Ng_4fb5e658-7f95-4512-b236-bb9b6cd27041">1.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzktNi0xLTEtMzY0Ng_c7d3129e-2da0-4abc-b886-991c4a6c55c1">7.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzEwLTgtMS0xLTIwNTc0_8729a66b-4730-4ab9-ac92-fc992e18c374">914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzEwLTItMS0xLTM2NTc_205149da-ccc2-497a-b7ef-149e4282a277">7,749,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzEwLTQtMS0xLTM2NTc_9e664506-9e9d-4006-aa3e-017f39ac961a">1.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzEwLTYtMS0xLTM2NTc_c9e1bc4a-6b17-407b-a46c-031cd4bc2bcd">6.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzExLTgtMS0xLTIwNTc0_6e90e79a-7ddc-4f52-b956-dfb3e52e1fa4">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline"> (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The exercise prices relate to the equivalent price for an ordinary share, calculated as one <ix:nonFraction unitRef="rate" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="0" format="ixt-sec:numwordsen" name="dei:EntityListingDepositoryReceiptRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwOTcx_4fee5e99-ed77-4742-8b25-cd5970cb07c0">eight</ix:nonFraction>h of the ADS price.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Determining the fair value of share options and RSUs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The total fair values of the options and RSUs were estimated using the Black-Scholes option-pricing model for equity-settled compensation, amounted to $<ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNTIy_2ff1886f-17ef-4a7e-af56-6bc5c08ca5e5">62.1</ix:nonFraction>&#160;million for instruments granted in the year ended December 31, 2020 (2019: $<ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNTM4_4b8130e6-e97e-4f89-8bce-60ceebaf457e">3.1</ix:nonFraction>&#160;million). The cost is amortized over the vesting period of the options and RSUs on a straight-line basis using the cliff-vesting method.The following assumptions were used for the Black-Scholes valuation of share options granted in 2020 and 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Expected volatility</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Volatility is calculated using historical weekly averages of the Company's share price over a period that is in line with the expected life of the options and RSUs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Fair value of ordinary shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The fair value of ordinary shares has been based on the share price of the Company&#8217;s shares on AIM on the evening before the date of grant, as the Company&#8217;s primary listing was previously on this market.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Risk-free interest rate</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The risk-free interest rate has been based on the U.K. Government debt yield for the relevant term at the time of grant, as the Company&#8217;s primary listing was previously on AIM. Effective from the delisting from AIM the Company will use appropriate U.S Government debt yields.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Expected term.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The expected term is determined using the simplified method.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Expected dividend</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">There are no expected dividends.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwODkwNzIwOTg0ODUw_bed61fd1-0f0e-41bc-8ad2-dc534a598e6e" continuedAt="i313d2787492a4538a0daaee4e05de645" escape="true">A summary of the weighted-average assumptions applicable to the share options granted in the applicable years is as follows:</ix:nonNumeric></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="ie345cd95659742d2a271a6d6f89d7710"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><ix:continuation id="i313d2787492a4538a0daaee4e05de645"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15364ff1d68341ec805494f64c383003_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzEtMi0xLTEtMzY4My90ZXh0cmVnaW9uOmJkMWY5MDhjZDhhYTQyZjdhMTYwMDQ1Y2MyYTNlNzQ2XzIwMzQwOTY1MTEzODcy_18210e56-6a56-4bc2-9e14-439c7952ba0a">0</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i15364ff1d68341ec805494f64c383003_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzEtMi0xLTEtMzY4My90ZXh0cmVnaW9uOmJkMWY5MDhjZDhhYTQyZjdhMTYwMDQ1Y2MyYTNlNzQ2XzIwMzQwOTY1MTEzODgw_c957ec56-20b7-4f9f-8a6d-42e0e14d808f">0.21</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3ed89efc5e44f55be2b1d1c803d1f72_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzEtNC0xLTEtMzY4My90ZXh0cmVnaW9uOjgxNzY4ZjE3NGE0YzQzYjA5Yzg0NGExOGNlZDBlZDEzXzIwMzQwOTY1MTEzODc4_974726af-712c-4463-a0f2-75dcb868c44b">0.39</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="if3ed89efc5e44f55be2b1d1c803d1f72_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzEtNC0xLTEtMzY4My90ZXh0cmVnaW9uOjgxNzY4ZjE3NGE0YzQzYjA5Yzg0NGExOGNlZDBlZDEzXzIwMzQwOTY1MTEzODg2_584fa5fd-b764-4367-8926-c023523eec9e">0.82</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected lives (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c63e739a8e547e990aedd5fb7ed7cf4_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzItMi0xLTEtMzY4My90ZXh0cmVnaW9uOjBhNDc5YjE2MmU3YjRlMGFiY2Q4ZWM0ZDQ5ZTM5YWMwXzIwMzQwOTY1MTEzODcy_413c0c90-bc6b-4e9a-bba9-058611125000">5.05</ix:nonNumeric> - <ix:nonNumeric contextRef="ia47baec57d49425a9f307369903c9687_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzItMi0xLTEtMzY4My90ZXh0cmVnaW9uOjBhNDc5YjE2MmU3YjRlMGFiY2Q4ZWM0ZDQ5ZTM5YWMwXzIwMzQwOTY1MTEzODc2_a2378533-7d87-4a94-97f9-7c7562772378">7</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i75308170234746af98ca1381553d9120_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzItNC0xLTEtMzY4My90ZXh0cmVnaW9uOmQ1MTBlMGFhZWFhZTQ1OTg5OTUzYTlhMDIwNWU5MGIyXzIwMzQwOTY1MTEzODcw_60ea6c31-0f06-4c8a-9fc0-f9f44679fa50">5.5</ix:nonNumeric> - <ix:nonNumeric contextRef="i44675776f6c54a54a40dc4ccde2d3c52_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzItNC0xLTEtMzY4My90ZXh0cmVnaW9uOmQ1MTBlMGFhZWFhZTQ1OTg5OTUzYTlhMDIwNWU5MGIyXzIwMzQwOTY1MTEzODc0_74e631cf-0afe-4968-8fe1-b60268b01d42">7</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15364ff1d68341ec805494f64c383003_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzMtMi0xLTEtMzY4My90ZXh0cmVnaW9uOjEyNTk0NGE2OTE5YzQyZTc4MzJkOGI5NWFkNDQ5MzNlXzIwMzQwOTY1MTEzODgx_559b809e-814a-4c4f-afe2-ae289e6aafd3">65.83</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i15364ff1d68341ec805494f64c383003_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzMtMi0xLTEtMzY4My90ZXh0cmVnaW9uOjEyNTk0NGE2OTE5YzQyZTc4MzJkOGI5NWFkNDQ5MzNlXzIwMzQwOTY1MTEzODkw_f5d13401-7ba6-4f0b-9319-4293de78c8d7">75.40</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3ed89efc5e44f55be2b1d1c803d1f72_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzMtNC0xLTEtMzY4My90ZXh0cmVnaW9uOjIyNDEzMmFhMjAzNzQ2ZDA4NWI4ZjcyYmZkMDQ1MDUxXzIwMzQwOTY1MTEzODgx_5af6f56a-323b-4204-9dc2-e6b767e6b469">67.98</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="if3ed89efc5e44f55be2b1d1c803d1f72_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzMtNC0xLTEtMzY4My90ZXh0cmVnaW9uOjIyNDEzMmFhMjAzNzQ2ZDA4NWI4ZjcyYmZkMDQ1MDUxXzIwMzQwOTY1MTEzODkw_34e67f02-9ac9-4983-abe2-b8a6982d5f02">68.71</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15364ff1d68341ec805494f64c383003_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzQtMi0xLTEtMzY4Mw_d51d87b1-00d6-4861-884d-a21ab1e951ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3ed89efc5e44f55be2b1d1c803d1f72_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzQtNC0xLTEtMzY4Mw_80797c53-d6fa-4a82-91f7-cd05740998e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant date fair value (per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i0c63e739a8e547e990aedd5fb7ed7cf4_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzUtMi0xLTEtMzY4My90ZXh0cmVnaW9uOjI2NzgxZmJkM2U1ZTRkNjY5ZjAyZmEwM2NhNTNiZTdmXzIwMzQwOTY1MTEzODc4_aeeed79b-0f6a-4429-be07-c962d33a41e5">0.40</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="ia47baec57d49425a9f307369903c9687_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzUtMi0xLTEtMzY4My90ZXh0cmVnaW9uOjI2NzgxZmJkM2U1ZTRkNjY5ZjAyZmEwM2NhNTNiZTdmXzIwMzQwOTY1MTEzODg2_d96e23d8-a225-48fd-aa3d-2da1ce350a67">0.62</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i75308170234746af98ca1381553d9120_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzUtNC0xLTEtMzY4My90ZXh0cmVnaW9uOjhjNzUwOTc1MDQwYzRmYjU4YmUxNDVjNDFmZjcwOGY0XzIwMzQwOTY1MTEzODc4_0daff27d-da3e-40d2-a9c4-529c8c984684">0.31</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i44675776f6c54a54a40dc4ccde2d3c52_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzUtNC0xLTEtMzY4My90ZXh0cmVnaW9uOjhjNzUwOTc1MDQwYzRmYjU4YmUxNDVjNDFmZjcwOGY0XzIwMzQwOTY1MTEzODg2_65f40a04-b81b-45c6-9ebb-e3950525217c">0.49</ix:nonFraction></span></div></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Restricted stock units activity</span></div><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNTUy_572354c9-9847-4706-ad04-da736ea67673" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows RSU activity:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of RSUs outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c77df9054424edb9685cd91224a73df_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTphOTVjMzAyMDRhOTE0NjQ2OTQyOWFlNGRkYWEzMDJhYi90YWJsZXJhbmdlOmE5NWMzMDIwNGE5MTQ2NDY5NDI5YWU0ZGRhYTMwMmFiXzEtMi0xLTEtMTM3MjU_007db3ef-7010-4fb0-b115-31d76e8b97c8">862,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i35514ffd7c034b0e8ce21b1da270c038_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTphOTVjMzAyMDRhOTE0NjQ2OTQyOWFlNGRkYWEzMDJhYi90YWJsZXJhbmdlOmE5NWMzMDIwNGE5MTQ2NDY5NDI5YWU0ZGRhYTMwMmFiXzItMi0xLTEtMTM3MjU_37c3eedf-7db9-4598-bbe1-84a30a41d1eb">740,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i844f6711369540ba826df75f6b6a22dd_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTphOTVjMzAyMDRhOTE0NjQ2OTQyOWFlNGRkYWEzMDJhYi90YWJsZXJhbmdlOmE5NWMzMDIwNGE5MTQ2NDY5NDI5YWU0ZGRhYTMwMmFiXzUtMi0xLTEtMTM3MjU_b3e9bfa6-157c-438f-b11c-76608a827f77">1,602,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i35514ffd7c034b0e8ce21b1da270c038_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTphOTVjMzAyMDRhOTE0NjQ2OTQyOWFlNGRkYWEzMDJhYi90YWJsZXJhbmdlOmE5NWMzMDIwNGE5MTQ2NDY5NDI5YWU0ZGRhYTMwMmFiXzUtNC0xLTEtMjEzNjU_5656bca0-dea5-4d4f-84b4-acc04c82bffd">3.4</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3bc3d048b42b479595d7e0e6de32ce57_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTphOTVjMzAyMDRhOTE0NjQ2OTQyOWFlNGRkYWEzMDJhYi90YWJsZXJhbmdlOmE5NWMzMDIwNGE5MTQ2NDY5NDI5YWU0ZGRhYTMwMmFiXzYtMi0xLTEtMTM3MjU_29d9a172-6764-4a08-8083-dbb9b951498c">62,566,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3bc3d048b42b479595d7e0e6de32ce57_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTphOTVjMzAyMDRhOTE0NjQ2OTQyOWFlNGRkYWEzMDJhYi90YWJsZXJhbmdlOmE5NWMzMDIwNGE5MTQ2NDY5NDI5YWU0ZGRhYTMwMmFiXzctMi0xLTEtMTM3MjU_c39e0daf-c25d-4332-898e-105dcde05552">84,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3bc3d048b42b479595d7e0e6de32ce57_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTphOTVjMzAyMDRhOTE0NjQ2OTQyOWFlNGRkYWEzMDJhYi90YWJsZXJhbmdlOmE5NWMzMDIwNGE5MTQ2NDY5NDI5YWU0ZGRhYTMwMmFiXzgtMi0xLTEtMTM3MjU_e6339cbc-0a46-4322-aac8-e1e3c5267ce4">2,091,960</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c41d3b6c046482b826d8cdf888acde0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTphOTVjMzAyMDRhOTE0NjQ2OTQyOWFlNGRkYWEzMDJhYi90YWJsZXJhbmdlOmE5NWMzMDIwNGE5MTQ2NDY5NDI5YWU0ZGRhYTMwMmFiXzktMi0xLTEtMTM3MjU_c934801b-c348-48ec-a0ab-60f530ee295c">61,992,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3bc3d048b42b479595d7e0e6de32ce57_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTphOTVjMzAyMDRhOTE0NjQ2OTQyOWFlNGRkYWEzMDJhYi90YWJsZXJhbmdlOmE5NWMzMDIwNGE5MTQ2NDY5NDI5YWU0ZGRhYTMwMmFiXzktNC0xLTEtMjE1MDU_1ac1f9e1-6e47-44b2-8b6c-977cc1afae93">1.5</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of RSUs outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining vesting Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Period in which the target must be achieved</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs subject to time based vesting</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idce44936200646a39eb2e2ac020a3b66_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTpiZmExZTZiZmFjMDk0YmRmOThiZWM4MDFmYzAyMWI4Mi90YWJsZXJhbmdlOmJmYTFlNmJmYWMwOTRiZGY5OGJlYzgwMWZjMDIxYjgyXzEtMi0xLTEtMzY5OQ_6954ea2d-0d5b-452a-abf7-b4aa5f310205">61,416,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idffe8ebf902f434a94b6fcaa44362bd1_D20200101-20201231" format="ixt-sec:duryear" name="vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTpiZmExZTZiZmFjMDk0YmRmOThiZWM4MDFmYzAyMWI4Mi90YWJsZXJhbmdlOmJmYTFlNmJmYWMwOTRiZGY5OGJlYzgwMWZjMDIxYjgyXzEtNC0xLTEtMzY5OQ_50e0af21-9b41-43af-a7f7-60cf3860375c">1.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs subject to milestone based vesting</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie67bf5c881684176b281b06cfe0628ed_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTpiZmExZTZiZmFjMDk0YmRmOThiZWM4MDFmYzAyMWI4Mi90YWJsZXJhbmdlOmJmYTFlNmJmYWMwOTRiZGY5OGJlYzgwMWZjMDIxYjgyXzItMi0xLTEtMzY5OQ_2d33067c-ee33-4276-bd48-111ebf50b276">576,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0cb4743b3dc645c38fc5bff065067b3c_D20200101-20201231" format="ixt-sec:duryear" name="vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTpiZmExZTZiZmFjMDk0YmRmOThiZWM4MDFmYzAyMWI4Mi90YWJsZXJhbmdlOmJmYTFlNmJmYWMwOTRiZGY5OGJlYzgwMWZjMDIxYjgyXzItNC0xLTEtMzY5OQ_beaeec8e-b652-469a-a463-f728da35242f">2.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 - 2024</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The intrinsic and fair value of RSUs that vested in the year ended December 31, 2020, was $<ix:nonFraction unitRef="usd" contextRef="i3bc3d048b42b479595d7e0e6de32ce57_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNTU1_047e3834-34da-493a-b3a8-718f059598ff">1.5</ix:nonFraction>&#160;million (2019: $<ix:nonFraction unitRef="usd" contextRef="i35514ffd7c034b0e8ce21b1da270c038_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNTcz_b961de6a-5fe6-4415-9a1b-815507b8ad2c">nil</ix:nonFraction>).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of December 31, 2020, total compensation cost related to share options and RSUs granted but not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="idecac34827ce472182dc1492d400ffdf_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNjI5_8f692089-1177-4a4a-a13f-0552a6acbb63">41.8</ix:nonFraction>&#160;million. This cost will be amortized to expense over a weighted average remaining period of <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzU0OTc1NTg3MDkxMg_6ac5db54-901f-4a9e-b70e-2cdb1d773abd">1.5</ix:nonNumeric> years and will be adjusted for subsequent forfeitures.</span></div></ix:continuation><div id="id4dd95a68a65415aa5f2e21bd87d1189_304"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 12 - <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90ZXh0cmVnaW9uOmNhMGRhMjE3ZjBjNTQ4MjE5YzI2YjFmZTk0MzBjNzQ0XzIwMzQwOTY1MTE5NjA0_edc81351-96c0-460e-b1f4-a6f9a7c33f8b" continuedAt="i8eb13599c1824001bdb0ffdbb5a42e9e" escape="true">Net loss per share </ix:nonNumeric></span></div><ix:continuation id="i8eb13599c1824001bdb0ffdbb5a42e9e" continuedAt="i29a4bf9fe5bd446eaeba19fe08207b85"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Net loss per share is calculated on an ordinary share basis. The Company&#8217;s ADSs that are listed on the Nasdaq Global Market each represent eight ordinary shares.<ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90ZXh0cmVnaW9uOmNhMGRhMjE3ZjBjNTQ4MjE5YzI2YjFmZTk0MzBjNzQ0XzIwMzQwOTY1MTE5NjA1_a79fe95a-0690-407b-a40e-9a5cca19d126" continuedAt="i5ade9c257fda4041bbbd7063d2fac5da" escape="true">The following table shows the computation of basic and diluted earnings per share for 2020 and 2019 (net loss in thousands, loss per share in cents):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><ix:continuation id="i5ade9c257fda4041bbbd7063d2fac5da"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90YWJsZTo5MjQ3ZGY2NmQ5Mjk0YmJiODkxM2IxMzViYzc2Njk0Ny90YWJsZXJhbmdlOjkyNDdkZjY2ZDkyOTRiYmI4OTEzYjEzNWJjNzY2OTQ3XzQtMi0xLTEtMzMxNw_8fc43d04-b910-4889-8955-88156185a64d">65,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90YWJsZTo5MjQ3ZGY2NmQ5Mjk0YmJiODkxM2IxMzViYzc2Njk0Ny90YWJsZXJhbmdlOjkyNDdkZjY2ZDkyOTRiYmI4OTEzYjEzNWJjNzY2OTQ3XzQtNC0xLTEtMzMxNw_9ba2b235-1181-4e8f-a039-49ba3a507a27">40,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available to ordinary shareholders - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90YWJsZTo5MjQ3ZGY2NmQ5Mjk0YmJiODkxM2IxMzViYzc2Njk0Ny90YWJsZXJhbmdlOjkyNDdkZjY2ZDkyOTRiYmI4OTEzYjEzNWJjNzY2OTQ3XzUtMi0xLTEtMzMxNw_191abda8-7778-4b77-8975-dfbb2ed77533"><ix:nonFraction unitRef="usd" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90YWJsZTo5MjQ3ZGY2NmQ5Mjk0YmJiODkxM2IxMzViYzc2Njk0Ny90YWJsZXJhbmdlOjkyNDdkZjY2ZDkyOTRiYmI4OTEzYjEzNWJjNzY2OTQ3XzUtMi0xLTEtMzMxNw_98542997-ccce-4b05-98bd-9f79bd01ce85">65,146</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90YWJsZTo5MjQ3ZGY2NmQ5Mjk0YmJiODkxM2IxMzViYzc2Njk0Ny90YWJsZXJhbmdlOjkyNDdkZjY2ZDkyOTRiYmI4OTEzYjEzNWJjNzY2OTQ3XzUtNC0xLTEtMzMxNw_4386ef0d-c03b-48c8-a6a6-fd726c889b38"><ix:nonFraction unitRef="usd" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90YWJsZTo5MjQ3ZGY2NmQ5Mjk0YmJiODkxM2IxMzViYzc2Njk0Ny90YWJsZXJhbmdlOjkyNDdkZjY2ZDkyOTRiYmI4OTEzYjEzNWJjNzY2OTQ3XzUtNC0xLTEtMzMxNw_c0d13325-1746-4225-9324-be0de78ae19f">40,561</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90YWJsZTo5MjQ3ZGY2NmQ5Mjk0YmJiODkxM2IxMzViYzc2Njk0Ny90YWJsZXJhbmdlOjkyNDdkZjY2ZDkyOTRiYmI4OTEzYjEzNWJjNzY2OTQ3XzctMi0xLTEtMzMxNw_f78f6444-ab95-4ed2-a0d1-f6abcf64dd06">262,932,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90YWJsZTo5MjQ3ZGY2NmQ5Mjk0YmJiODkxM2IxMzViYzc2Njk0Ny90YWJsZXJhbmdlOjkyNDdkZjY2ZDkyOTRiYmI4OTEzYjEzNWJjNzY2OTQ3XzctNC0xLTEtMzMxNw_650966fc-d3a6-4971-b26f-f1b2cd80b300">105,326,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90YWJsZTo5MjQ3ZGY2NmQ5Mjk0YmJiODkxM2IxMzViYzc2Njk0Ny90YWJsZXJhbmdlOjkyNDdkZjY2ZDkyOTRiYmI4OTEzYjEzNWJjNzY2OTQ3XzgtMi0xLTEtMzMxNw_1b72646d-e556-44e5-a75a-7974c4e8b298">0.25</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90YWJsZTo5MjQ3ZGY2NmQ5Mjk0YmJiODkxM2IxMzViYzc2Njk0Ny90YWJsZXJhbmdlOjkyNDdkZjY2ZDkyOTRiYmI4OTEzYjEzNWJjNzY2OTQ3XzgtNC0xLTEtMzMxNw_31947bf6-f608-460b-96d9-a90f2cfa7481">0.39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"><ix:continuation id="i29a4bf9fe5bd446eaeba19fe08207b85">During the years ended December 31, 2020 and 2019, outstanding share options, RSUs and warrants of <ix:nonFraction unitRef="shares" contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90ZXh0cmVnaW9uOmNhMGRhMjE3ZjBjNTQ4MjE5YzI2YjFmZTk0MzBjNzQ0XzIwMzQwOTY1MTIyMDUz_b9d8ef38-e8a9-4fdc-be29-b0aabef2414b">87,519,294</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90ZXh0cmVnaW9uOmNhMGRhMjE3ZjBjNTQ4MjE5YzI2YjFmZTk0MzBjNzQ0XzIwMzQwOTY1MTIyMDY1_6d7fbbe5-2eac-4b50-880a-58fdcad9ee14">28,183,427</ix:nonFraction>, respectively, were not included in the computation of diluted earnings per ordinary share, because to do so would be antidilutive.</ix:continuation></span></div><div id="id4dd95a68a65415aa5f2e21bd87d1189_249"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 13 - <ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90ZXh0cmVnaW9uOjZjMTgyMGJkZGQ3NjQ2NjJhMDg5M2NkYzQ0MDVjM2U5XzIwMzQwOTY1MTE1NjU4_0e2b55a5-507c-46cb-8991-8097187535be" continuedAt="icdbb9a2aafc1424b9a3378a4af23bd58" escape="true">Related party transactions and other shareholder matters</ix:nonNumeric></span></div><ix:continuation id="icdbb9a2aafc1424b9a3378a4af23bd58"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the year ended December 31, 2019, Anders Ullman, a director of the Company, provided consultancy services to the Company for which the Company paid him $<ix:nonFraction unitRef="usd" contextRef="iaed0afb2f5ac4a73bc91d4c2a32c115e_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90ZXh0cmVnaW9uOjZjMTgyMGJkZGQ3NjQ2NjJhMDg5M2NkYzQ0MDVjM2U5XzIwMzQwOTY1MTE1NjQ1_c22886e0-d172-4f90-9023-396515d7ec37">33</ix:nonFraction>&#160;thousand.</span></div><ix:nonNumeric contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90ZXh0cmVnaW9uOjZjMTgyMGJkZGQ3NjQ2NjJhMDg5M2NkYzQ0MDVjM2U5XzIwMzQwOTY1MTE1NjU5_381a1364-3825-4920-a01b-a001e0ac9e1b" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the year ended December 31, 2020, certain directors and officers participated in the Private Placement, summarized below (in thousands, except for number of shares acquired):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"></td><td style="width:58.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.542%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Participation in Private Placement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ordinary Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Consideration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Ebsworth</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia323b627bb0e4dfda11f8e943e75767d_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90YWJsZTpmOGI3NDZkOWZlYWM0MTNjYjg3NDg2M2RmMzY5MDExNS90YWJsZXJhbmdlOmY4Yjc0NmQ5ZmVhYzQxM2NiODc0ODYzZGYzNjkwMTE1XzEtMi0xLTEtMTY0OTk_51805f37-51c1-4b53-b939-905df4ebba80">222,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="gbp" contextRef="ia323b627bb0e4dfda11f8e943e75767d_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90YWJsZTpmOGI3NDZkOWZlYWM0MTNjYjg3NDg2M2RmMzY5MDExNS90YWJsZXJhbmdlOmY4Yjc0NmQ5ZmVhYzQxM2NiODc0ODYzZGYzNjkwMTE1XzEtNC0xLTEtMTY1MDE_601e1bb1-14f4-4e06-adc5-2476c275d124">100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Zaccardelli</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i14e765c2f7c2471cac03f164f5c1521e_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90YWJsZTpmOGI3NDZkOWZlYWM0MTNjYjg3NDg2M2RmMzY5MDExNS90YWJsZXJhbmdlOmY4Yjc0NmQ5ZmVhYzQxM2NiODc0ODYzZGYzNjkwMTE1XzItMi0xLTEtMTY0OTk_cc856b34-4a44-44f0-9c73-9e140d31aeca">444,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14e765c2f7c2471cac03f164f5c1521e_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90YWJsZTpmOGI3NDZkOWZlYWM0MTNjYjg3NDg2M2RmMzY5MDExNS90YWJsZXJhbmdlOmY4Yjc0NmQ5ZmVhYzQxM2NiODc0ODYzZGYzNjkwMTE1XzItNC0xLTEtMTY1MDE_69bf1a86-841d-4a9c-9fca-3b80c17c27c5">249,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Sinha (through connected persons)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b7fe6a0bec54714ba0212643a952e53_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90YWJsZTpmOGI3NDZkOWZlYWM0MTNjYjg3NDg2M2RmMzY5MDExNS90YWJsZXJhbmdlOmY4Yjc0NmQ5ZmVhYzQxM2NiODc0ODYzZGYzNjkwMTE1XzMtMi0xLTEtMTY0OTk_6e262410-0984-4702-8f95-d9939911a584">533,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b7fe6a0bec54714ba0212643a952e53_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90YWJsZTpmOGI3NDZkOWZlYWM0MTNjYjg3NDg2M2RmMzY5MDExNS90YWJsZXJhbmdlOmY4Yjc0NmQ5ZmVhYzQxM2NiODc0ODYzZGYzNjkwMTE1XzMtNC0xLTEtMTY1MDE_8c0f6827-5a35-4b41-bb55-69f55afc19a4">299,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Ullman</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf836d4ae04748dd8b1be54f7881b5a8_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90YWJsZTpmOGI3NDZkOWZlYWM0MTNjYjg3NDg2M2RmMzY5MDExNS90YWJsZXJhbmdlOmY4Yjc0NmQ5ZmVhYzQxM2NiODc0ODYzZGYzNjkwMTE1XzQtMi0xLTEtMTY0OTk_dc1d6948-20ba-48ec-a716-35262359e0d6">266,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf836d4ae04748dd8b1be54f7881b5a8_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90YWJsZTpmOGI3NDZkOWZlYWM0MTNjYjg3NDg2M2RmMzY5MDExNS90YWJsZXJhbmdlOmY4Yjc0NmQ5ZmVhYzQxM2NiODc0ODYzZGYzNjkwMTE1XzQtNC0xLTEtMTY1MDE_e3d973ab-f0de-443e-96f0-81cceecff162">149,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Edwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i05bb837cdc2e4bab8740f004c4754b5d_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90YWJsZTpmOGI3NDZkOWZlYWM0MTNjYjg3NDg2M2RmMzY5MDExNS90YWJsZXJhbmdlOmY4Yjc0NmQ5ZmVhYzQxM2NiODc0ODYzZGYzNjkwMTE1XzUtMi0xLTEtMTY0OTk_48ba3753-c873-4a24-a569-ab9dc3e97a33">53,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05bb837cdc2e4bab8740f004c4754b5d_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90YWJsZTpmOGI3NDZkOWZlYWM0MTNjYjg3NDg2M2RmMzY5MDExNS90YWJsZXJhbmdlOmY4Yjc0NmQ5ZmVhYzQxM2NiODc0ODYzZGYzNjkwMTE1XzUtNC0xLTEtMTY1MDE_00f14a62-9d89-45a2-b87f-7a1387064b26">29,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Hahn</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6ee6389e25345f08e3512dcfb211a54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90YWJsZTpmOGI3NDZkOWZlYWM0MTNjYjg3NDg2M2RmMzY5MDExNS90YWJsZXJhbmdlOmY4Yjc0NmQ5ZmVhYzQxM2NiODc0ODYzZGYzNjkwMTE1XzYtMi0xLTEtMTY0OTk_35dbe698-3ae4-4ea4-b4da-eefa593ef6c3">177,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ee6389e25345f08e3512dcfb211a54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90YWJsZTpmOGI3NDZkOWZlYWM0MTNjYjg3NDg2M2RmMzY5MDExNS90YWJsZXJhbmdlOmY4Yjc0NmQ5ZmVhYzQxM2NiODc0ODYzZGYzNjkwMTE1XzYtNC0xLTEtMTY1MDE_b64e6f72-0a50-478c-872b-b529f2bd0455">100,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-21</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>2
<FILENAME>vrna-descriptionofsecuriti.htm
<DESCRIPTION>EX-4.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i1c3777cd89c9436ca9437784e0056ede_1"></div><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">DESCRIPTION OF SECURITIES</font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:144%">DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Set forth below is a summary of certain information concerning the share capital of Verona Pharma plc (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) as well as a description of certain provisions of our articles of association and relevant provisions of English law. Because the following is only a summary, it does not contain all of the information that may be important to you. The summary includes certain references to and descriptions of material provisions of our articles of association and English law in effect as of the date of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020 (the &#8220;Annual Report&#8221;). The summary below does not purport to be complete and is qualified in its entirety by reference to applicable English law and our articles of association, which have been publicly filed with the Securities and Exchange Commission. </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:206%">&#160;</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">General </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">We were incorporated as a public limited company with the legal name Isis Resources plc under the laws of England and Wales on February 24, 2005 with the company number 5375156. In September 2006, we acquired Rhinopharma Limited, a company incorporated under the laws of the province of British Columbia, Canada and changed our name to Verona Pharma plc. Our registered office is One Central Square, Cardiff, CF10 1FS, Wales. The principal legislation under which we operate and our shares are issued is the Companies Act 2006. </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Articles of Association</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Set forth below is a summary of relevant information concerning our share capital and material provisions of our Articles of Association and applicable UK law. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:144%">Ordinary Shares </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">In accordance with the Articles, the following summarizes the rights of holders of our ordinary shares&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:14.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.050%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.126%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.165%"></td><td style="width:0.0%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each holder of our voting ordinary shares is entitled to one vote per ordinary share on all matters to be voted on by shareholders generally&#59;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the holders of our voting ordinary shares shall be entitled to receive notice of, attend, speak and vote at our general meetings&#59; and</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">holders of our voting and non-voting ordinary shares are entitled to receive such dividends as are recommended by our directors and declared by our shareholders.</font></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:144%">Registered Shares </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">We are required by the Companies Act 2006 to keep a register of our shareholders. Under English law, the ordinary shares are deemed to be issued when the name of the shareholder is entered in our share register. The share register therefore is prima facie evidence of the identity of our shareholders, and the shares that they hold. The share register generally provides limited, or no, information regarding the ultimate beneficial owners of our ordinary shares. Our share register is maintained by our registrar, Computershare Investor Services plc. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Holders of our ADSs will not be treated as one of our shareholders and their names will therefore not be entered in our share register. The depositary, the custodian or their nominees will be the holder of the shares underlying our ADSs. For discussion on our ADSs and ADS holder rights see &#34;Description of American Depository Shares&#34; below. Holders of our ADSs have a right to receive the ordinary shares underlying their ADSs as discussed in &#34;Description of American Depository Shares&#34; below. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Under the Companies Act 2006, we must enter an allotment of shares in our share register as soon as practicable and in any event within two months of the allotment. We also are required by the Companies Act 2006 to register a transfer of shares (or give the transferee notice of and reasons for refusal) as soon as practicable and in any event within two months of receiving notice of the transfer. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">We, any of our shareholders or any other affected person may apply to the court for rectification of the share register if&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:14.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.128%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the name of any person, without sufficient cause, is wrongly entered in or omitted from our register of members&#59; or</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">there is a default or unnecessary delay in entering on the register the fact of any person having ceased to be a member or on which we have a lien, provided that such refusal does not prevent dealings in the shares taking place on an open and proper basis.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:144%">Preemptive Rights </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">English law generally provides shareholders with preemptive rights when new shares are issued for cash&#59; however, it is possible for the articles of association, or shareholders in general meeting, to exclude preemptive rights. Such an exclusion of preemptive rights may be for a maximum period of up to five years from the date of adoption of the articles of association, if the exclusion is contained in the articles of association, or from the date of the shareholder resolution, if the exclusion is by shareholder resolution. In either case, this exclusion would need to be renewed by our shareholders upon its expiration (i.e., at least every five years). On April 16, 2020, our shareholders approved the exclusion of preemptive rights up to an aggregate nominal amount of &#163;21,065,327.60 which shall expire on June 1, 2021 unless renewed, revoked or varied sooner.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:144%">Shares and Rights Attaching to Them </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Objects </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The objects of our company are unrestricted. </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Share Rights </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Subject to any special rights attaching to shares already in issue, our shares may be issued with or have attached to them any preferred, deferred or other special rights or privileges or be subject to such restrictions as we may resolve by ordinary resolution of the shareholders or decision of our board. </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Voting Rights </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Without prejudice to any special rights, privileges or restrictions as to voting rights attached to any shares forming part of our share capital from time to time, the voting rights attaching to voting ordinary shares are as follows&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:14.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.213%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.163%"></td><td style="width:0.0%"></td><td style="width:0.0%"></td><td style="width:0.165%"></td><td style="width:0.0%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on a show of hands, every shareholder who (being an individual) is present in person and (being a corporation) is present by a duly authorized representative shall have one vote&#59;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on a show of hands, each proxy present in person has one vote for and one vote against a resolution if the proxy has been duly appointed by more than one shareholder and the proxy has been instructed by one or more of those shareholders to vote for the resolution and by one or more other of those shareholders to vote against it&#59;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on a show of hands, each proxy present in person has one vote for and one vote against a resolution if the proxy has been duly appointed by more than one shareholder entitled to vote on the resolution and either&#58; (1) the proxy has been instructed by one or more of those shareholders to vote for the resolution and has been given any discretion by one or more other of those shareholders to vote and the proxy exercises that discretion to vote against it&#59; or (2) the proxy has been instructed by one or more of those shareholders to vote against the resolution and has been given any discretion by one or more other of those shareholders to vote and the proxy exercises that discretion to vote for it&#59; and</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on a poll every shareholder who is present in person or by proxy shall have one vote for each share of which he is the holder.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">At any general meeting a resolution put to the vote of the meeting shall be decided on a show of hands unless a poll is demanded. Subject to the provisions of the Companies Act 2006, as described in &#34;Differences in Corporate Law - Voting Rights&#34; below, a poll may be demanded by&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.922%"><tr><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.089%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the chairman of the meeting&#59;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at least five shareholders present in person or by proxy and entitled to vote&#59;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any shareholder(s) present in person or by proxy and representing in the aggregate not less than one-tenth of the total voting rights of all shareholders having the right to attend and vote at the meeting (excluding the shares held in treasury)&#59; or</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any shareholder(s) present in person or by proxy and holding shares conferring a right to attend and vote at the meeting on which there have been paid up sums in the aggregate equal to not less than one-tenth of the total sums paid up on all shares conferring that right (excluding the shares held in treasury).</font></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Restrictions on Voting </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">No shareholder shall be entitled to vote at any general meeting or at any separate class meeting in respect of any share held by him unless all calls or other sums payable by him in respect of that share have been paid. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The board may from time to time make calls upon the shareholders in respect of any money unpaid on their shares and each shareholder shall (subject to at least 14 days' notice specifying the time or times and place of payment) pay at the time or times so specified the amount called on his shares. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">No holders of non-voting ordinary shares shall be entitled to receive notice of, attend or vote at any general meeting.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Dividends </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">We may by ordinary resolution of shareholders declare dividends out of profits available for distribution in accordance with the respective rights of shareholders but no such dividend shall exceed the amount recommended by the directors. The board may from time to time pay shareholders such interim dividends as appear to the board to be justified by our profits and, if at any time, our share capital is divided into different classes the board may pay such interim dividends in respect of those shares which confer on the holders thereof deferred or non-preferential rights with regard to dividends. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Subject to any special rights attaching to or the terms of issue of any share, all dividends shall be declared and paid according to the amounts paid up on the shares and shall be apportioned and paid pro rata according to the amounts paid up on the shares during any part or parts of the period in respect of which the dividend is paid. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">No dividend or other moneys payable by us on or in respect of any share shall bear interest against us. Any dividend unclaimed after a period of 12 years from the date such dividend became due for payment shall, if the Board so resolved, be forfeited and shall revert to us. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Dividends may be declared or paid in any currency and the board may decide the rate of exchange for any currency conversions that may be required, and how any costs involved are to be met, in relation to the currency of any dividend. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Any general meeting declaring a dividend may by ordinary resolution of shareholders, upon the recommendation of the board, direct payment or satisfaction of such dividend wholly or in part by the distribution of specific assets other than cash, and in particular of paid up shares or debentures of any other company. The directors may, if authorized by ordinary resolution of shareholders, offer any holders of ordinary shares the right to elect to receive in lieu of a dividend an allotment of ordinary shares credited as fully paid up, subject to such exclusions as the Board may deem necessary or desirable. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:137%">No shareholder shall be entitled to receive any dividend or other distribution in respect of any share held by him unless all calls or other sums payable by him in respect of that share have been paid. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:137%">&#160;&#160;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Change of Control </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">There is no specific provision in our articles of association that would have the effect of delaying, deferring or preventing a change of control. </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Distributions on Winding Up </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">On a winding up, the liquidator may, with the consent by a special resolution of shareholders and any other resolution of the shareholders (excluding us to the extent we are a shareholder by virtue only of our holding of shares as treasury shares) in proportion to their shareholdings in specie or in kind or sanction of the court required by the Companies Act 2006 and&#47;or the Insolvency Act 1986, divide amongst the shareholders the whole </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">or any part of our assets (whether they shall consist of property of the same kind or not) and may set such values as he deems fair upon any property to be divided and may determine how such division shall be carried out as between the shareholders or different classes of shareholder. The liquidator may vest the whole or any part of such assets in trustees upon such trusts for the benefit of the shareholders as the liquidator shall think fit, but no shareholder shall be compelled to accept any shares or other assets upon which there is any liability or potential liability. </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Variation of Rights </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">All or any of the rights and restrictions attached to any class of shares issued may be altered, added to or revoked with the consent in writing of the holders of not less than three-fourths in nominal value of the issued shares of that class (excluding any shares held as treasury shares) or by special resolution passed at a separate general meeting of the holders of such shares, subject to the Companies Act 2006 and the terms of their issue. The Companies Act 2006 provides a right to object to the variation of the share capital by the shareholders who did not vote in favor of the variation. Should an aggregate of 15% of the shareholders of the issued shares in question apply to the court to have the variation cancelled, the variation shall have no effect unless and until it is confirmed by the court. </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Alteration to Share Capital </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">We may, by ordinary resolution of shareholders, consolidate and divide all or any of our share capital into shares of larger amount than our existing shares, or sub-divide our shares or any of them into shares of a smaller amount. We may, by special resolution of shareholders, confirmed by the court, reduce our share capital or any capital redemption reserve or any share premium account in any manner authorized by the Companies Act 2006. We may redeem or purchase all or any of our shares as described in &#34;-Other U.K. Law Considerations - Purchase of Own Shares.&#34; </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Preemption Rights </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">In certain circumstances, our shareholders may have statutory preemption rights under the Companies Act 2006 in respect of the allotment of new shares as described in &#34;- Preemptive Rights&#34; and &#34;- Differences in Corporate Law - Preemptive Rights&#34; below. </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:144%">Transfer of Shares </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Any certificated shareholder may transfer all or any of his shares by an instrument of transfer in the usual common form or in any other manner which is permitted by the Companies Act 2006 and approved by the board. Any written instrument of transfer shall be signed by or on behalf of the transferor and (in the case of a partly paid share) the transferee. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">All transfers of uncertificated shares shall be made in accordance with and subject to the provisions of the Uncertificated Securities Regulations 2001 and the facilities and requirements of its relevant system. The Uncertificated Securities Regulations 2001 permit shares to be issued and held in uncertificated form and transferred by means of a computer-based system. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The board may decline to register any transfer of any share&#58;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.220%"><tr><td style="width:1.0%"></td><td style="width:14.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.702%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.129%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which is not a fully paid share&#59;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to a person known to be a minor, bankrupt or person who is mentally disordered or a patient for the purpose of any statute relating to mental health&#59;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to an entity which is not a natural or legal person&#59;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unless any written instrument of transfer, duly stamped, is lodged with us at our registered office or such other place as the board may appoint accompanied by the certificate for the shares to which it relates&#59;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unless there is provided such evidence as the board may reasonably require to show the right of the transferor to make the transfer and if the instrument of transfer is executed by some other person on his behalf, the authority of that person to do so&#59;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">where the transfer is in respect of more than one class of share&#59; and</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the case of a transfer to joint holders, the number of joint holders to whom the share is to be transferred exceeds four.</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">If the board declines to register a transfer it shall, as soon as practicable and in any event within two months after the date on which the transfer is lodged, send to the transferee notice of the refusal, together with reasons for the refusal. </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:144%">Shareholder Meetings </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Annual General Meetings </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">In accordance with the Companies Act 2006, we are required in each year to hold an annual general meeting in addition to any other general meetings in that year and to specify the meeting as such in the notice convening it. The annual general meeting shall be convened whenever and wherever the board sees fit, subject to the requirements of the Companies Act 2006, as described in &#34;- Differences in Corporate Law - Annual General Meeting&#34; and &#34;- Differences in Corporate Law - Notice of General Meetings&#34; below. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The arrangements for the calling of general meetings are described in &#34;- Differences in Corporate Law - Notice of General Meetings&#34; below. </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Quorum of General Meetings </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">No business shall be transacted at any general meeting unless a quorum is present. At least two shareholders present in person or by proxy and entitled to vote, holding or representing at least 33 1&#47;3% of the issued and outstanding shares of the Company&#8217;s ordinary voting shares present at such general meeting in person or by proxy, shall be a quorum for all purposes. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Class Meetings </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The provisions in the Articles of Association relating to general meetings apply to every separate general meeting of the holders of a class of shares except that&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.922%"><tr><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.188%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.163%"></td><td style="width:0.0%"></td><td style="width:0.0%"></td><td style="width:0.165%"></td><td style="width:0.0%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the quorum for such class meeting shall be two holders in person or by proxy representing not less than 33 1&#47;3% in nominal value of the issued shares of the class (excluding any shares held in treasury)&#59;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at the class meeting, a holder of shares of the class present in person or by proxy may demand a poll and shall on a poll be entitled to one vote for every share of the class held by him&#59; and</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if at any adjourned meeting of such holders a quorum is not present at the meeting, one holder of shares of the class present in person or by proxy at an adjourned meeting constitutes a quorum.</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:144%">Directors </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Number of Directors </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">We may not have less than two directors on the board of directors. We may, by ordinary resolution of the shareholders, vary the minimum and maximum number of directors from time to time. </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Appointment of Directors </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Subject to the provisions of the Articles of Association, we may, by ordinary resolution of the shareholders, elect any person to be a director, either to fill a casual vacancy or as an addition to the existing board. However, any person that is not a director retiring from the existing board must be recommended by a shareholder not less than seven and not more than 21 days before the day of the appointment in order to be eligible for election. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Without prejudice to the power to appoint any person to be a director by shareholder resolution, the board has power to appoint any person to be a director, either to fill a casual vacancy or as an addition to the existing board but so that the total number of directors does not exceed the maximum number fixed by or in accordance with the Articles of Association. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Any director appointed by the board will hold office only until the earlier to occur of the close of the next following annual general meeting and someone being appointed in his stead at that meeting. Such a director is eligible for re-election at that meeting but shall not be taken into account in determining the directors or the number of directors who are to retire by rotation at such meeting. </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Rotation of Directors </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">At every annual general meeting, one-third of the directors or, if their number is not a multiple of three, then the number nearest to and not exceeding one-third, shall retire from office. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The directors to retire on each occasion shall be those subject to retirement by rotation who have been longest in office since their last election, but as between persons who became or were re-elected directors on the same day those to retire shall (unless they otherwise agree amongst themselves) be determined by lot. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">A director who retires at the annual general meeting shall be eligible for re-election. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shareholders may, at the meeting at which a director retires, fill the vacated office by electing a person and in default the retiring director shall, if willing to continue to act, be deemed to have been re-elected, unless at such meeting it is expressly resolved not to fill such vacated office or unless a resolution for the re-election of such director shall have been put to the meeting and lost. </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Directors' Interests </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The directors may authorize, to the fullest extent permitted by law, any matter proposed to them which would otherwise result in a director infringing his duty to avoid a situation in which he has, or can have, a direct or indirect interest that conflicts, or possibly may conflict, with our interests. A director shall not, save as otherwise agreed by him, be accountable to us for any benefit which he derives from any matter authorized by the directors and any contract, transaction or arrangement relating thereto shall not be liable to be avoided on the grounds of any such benefit. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Subject to the requirements under sections 175, 177 and 182 of the Companies Act 2006, a director who is any way, whether directly or indirectly, interested in a proposed or existing transaction or arrangement with us shall declare the nature of his interest at a meeting of the directors. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">In the case of interests arising where a director is in any way, directly or indirectly, interested in (a) a proposed transaction or arrangement with us or (b) a transaction or arrangement that has been entered into by us and save as otherwise provided by the Articles of Association, such director shall not vote at a meeting of the board or of a committee of the board on any resolution concerning such matter in which he has a material interest (otherwise than by virtue of his interest in shares, debentures or other securities of, or otherwise in or through, us) unless his interest or duty arises only because the case falls within one or more of the following paragraphs&#58;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:14.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.128%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the resolution relates to the giving of any security, guarantee or indemnity to the director in respect of money lent or obligations incurred by the director at the request of or for the benefit of us or our subsidiaries&#59;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the resolution relates to the giving to a third party of a security or indemnity in respect of a debt or obligation of ours or any of our subsidiaries for which the director or a person connected with him has assumed responsibility in whole or part under a guarantee or indemnity or by the giving of security&#59;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">his interest arises by virtue of any offer of shares or debentures or other securities by us or our subsidiaries for subscription or purchase in which offer the director is or may be entitled to participate as a holder of securities or in the director is interested as a participant in the underwriting or sub-underwriting thereof&#59;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">the resolution relates in any way to any other company in which he is interested, directly or indirectly and whether as an officer or shareholder or otherwise howsoever, provided that he and any persons connected with him do not to his knowledge hold an interest in shares representing one per cent or more of any class of the equity share capital of such company or of the voting rights available to shareholders of such company&#59; </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the resolution relates in any way to an arrangement in whole or in part for the benefit of our employees or any employees of our subsidiaries which does not award him as such any privilege or benefit not generally awarded to the employees to whom such arrangement relates&#59;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the resolution relates to the adoption, modification or operation of a superannuation fund or retirement, death or disability benefits scheme or employees' share scheme under which he may benefit and which has been approved by or is subject to and conditional upon approval by the U.K. tax authorities for taxation purposes and which does not award him any privilege or benefit not awarded to the employee to whom the scheme relates&#59; or</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the resolution relates in any way to the purchase or maintenance for the directors of insurance against any liability which by virtue of any rule of law would otherwise attach to all or any of them in respect of any negligence, default, breach of duty or breach of trust in relation to us or any of our subsidiaries.</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">A director shall not be counted in the quorum present at a meeting in relation to a resolution on which he is not entitled to vote. </font></div><div><font><br></font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">If a question arises at a meeting of the board or of a committee of the board as to the right of a director to vote or be counted in the quorum, and such question is not resolved by his voluntarily agreeing to abstain from voting or not to be counted in the quorum, the question shall be determined by a majority of votes of the remaining directors present at the meeting or if there is an equality of votes, the Chairman shall have a second or casting vote and his ruling in relation to any director other than himself shall be final and conclusive except in a case where the nature or extent of the interest of the director concerned has not been fairly disclosed. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Directors' Fees and Remuneration </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Each of the directors shall be paid a fee at such rate as may from time to time be determined by the board (or for the avoidance of doubt any duly authorized committee of the board) provided that the aggregate of all such fees so paid to directors shall not exceed &#163;500,000 per annum, or such higher amount as may from time to time be determined by ordinary resolution of shareholders. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Each director may be paid his traveling, hotel and incidental expenses of attending and returning from meetings of the board or committees of the board or general meetings or separate meetings of the holders class of shares or of debentures and shall be paid all expenses properly incurred by him in the conduct of our business or in the discharge of his duties as a director. Any director who, by request, performs special or extra services which in the opinion of the board go beyond the ordinary duties of a director may be paid such extra remuneration as the board may determine. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">An executive director shall receive such remuneration as the board may determine, and either in addition to or in lieu of his remuneration as a director as detailed above. </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Borrowing Powers </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The board may exercise all the powers to borrow money and to mortgage or charge our undertaking, property and assets (present or future) and uncalled capital or any part thereof and to issue debentures and other securities, whether outright or as collateral security for any debt, liability or obligation of us or of any third party. </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Indemnity </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Every director, alternate director, other officer or auditor of our group may be indemnified against all costs, charges, expenses, losses and liabilities incurred by him in connection with any negligence, default, breach of duty or breach of trust by him in relation to us or in relation to the actual or purported execution or discharge of his duties or the exercise or purported exercise of his powers or otherwise in relation to such members of our group. </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:144%">Other U.K. Law Considerations </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Mandatory Purchases and Acquisitions </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Pursuant to Sections 979 to 991 of the Companies Act 2006, where a takeover offer has been made for us and the offeror has acquired or unconditionally contracted to acquire not less than 90% in value of the shares to which the offer relates and not less than 90% of the voting rights carried by those shares, the offeror may give notice to the holder of any shares to which the offer relates which the offeror has not acquired or unconditionally contracted to acquire that he wishes to acquire, and is entitled to so acquire, those shares on the same terms as the general offer. The offeror would do so by sending a notice to the outstanding minority shareholders telling them that it will compulsorily acquire their shares. Such notice must be sent within three months of the last day on which the offer can be accepted in the prescribed manner. The squeeze-out of the minority shareholders can be completed at the end of six weeks from the date the notice has been given, subject to the minority shareholders failing to successfully lodge an application to the court to prevent such squeeze-out any time prior to the end of those six weeks following which the offeror can execute a transfer of the outstanding shares in its favor and pay the consideration to us, which would hold the consideration on trust for the outstanding minority shareholders. The consideration offered to the outstanding minority shareholders whose shares are compulsorily acquired under the </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Companies Act 2006 must, in general, be the same as the consideration that was available under the takeover offer. </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Sell Out </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The Companies Act 2006 also gives our minority shareholders a right to be bought out in certain circumstances by an offeror who has made a takeover offer for all of our shares. The holder of shares to which the offer relates, and who has not otherwise accepted the offer, may require the offeror to acquire his shares if, prior to the expiry of the acceptance period for such offer, (i) the offeror has acquired or unconditionally agreed to acquire not less than 90% in value of the voting shares, and (ii) not less than 90% of the voting rights carried by those shares. The offeror may impose a time limit on the rights of minority shareholders to be bought out that is not less than three months after the end of the acceptance period. If a shareholder exercises his rights to be bought out, the offeror is required to acquire those shares on the terms of this offer or on such other terms as may be agreed. </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Disclosure of Interest in Shares </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Pursuant to Part 22 of the Companies Act 2006, we are empowered by notice in writing to any person whom we know or have reasonable cause to believe to be interested in our shares, or at any time during the three years immediately preceding the date on which the notice is issued has been so interested, within a reasonable time to disclose to us particulars of that person's interest and (so far as is within his knowledge) particulars of any other interest that subsists or subsisted in those shares. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Under the Articles of Association, if a person defaults in supplying us with the required particulars in relation to the shares in question, or default shares within the prescribed period, the directors may by notice direct that&#58;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:160%">&#167;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%"> in respect of the default shares, the relevant member shall not be entitled to attend or vote (either in person or by proxy) at any general meeting or of a general meeting of the holders of a class of shares or upon any poll or to exercise any right conferred by the default shares&#59; </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:160%">&#167;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%"> where the default shares represent at least 0.25% of their class, (a) any dividend or other money payable in respect of the default shares shall be retained by us without liability to pay interest, and&#47;or (b) no transfers by the relevant member of any default shares may be registered (unless the member himself is not in default and the member proves to the satisfaction of the Board that no person in default as regards supplying such information is interested in any of the default shares)&#59; and&#47;or </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:160%">&#167;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%"> any shares held by the relevant member in uncertificated form shall be converted into certificated form and that member shall not after that be entitled to convert all or any shares held by him into uncertificated form (unless the member himself is not in default as regards supplying the information required and the member proves to the satisfaction of the board that, after due and careful inquiry, the member is satisfied that none of the shares he is proposing to convert into uncertificated form is a default share). </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Purchase of Own Shares </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Under English law, a limited company may only purchase its own shares out of the distributable profits of the company or the proceeds of a fresh issue of shares made for the purpose of financing the purchase, provided that they are not restricted from doing so by their articles. A limited company may not purchase its own shares if, as a result of the purchase, there would no longer be any issued shares of the company other than redeemable shares or shares held as treasury shares. Shares must be fully paid in order to be repurchased. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Subject to the above, we may purchase our own shares in the manner prescribed below. We may make a market purchase of our own fully paid shares pursuant to an ordinary resolution of shareholders. The resolution authorizing the purchase must&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:14.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.749%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.660%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specify the maximum number of shares authorized to be acquired&#59;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determine the maximum and minimum prices that may be paid for the shares&#59; and</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specify a date, not being later than five years after the passing of the resolution, on which the authority to purchase is to expire.</font></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">We may purchase our own fully paid shares otherwise than on a recognized investment exchange pursuant to a purchase contract authorized by resolution of shareholders before the purchase takes place. Any authority will not be effective if any shareholder from whom we propose to purchase shares votes on the resolution and the resolution would not have been passed if he had not done so. The resolution authorizing the purchase must specify a date, not being later than five years after the passing of the resolution, on which the authority to purchase is to expire. </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Distributions and Dividends </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Under the Companies Act 2006, before a company can lawfully make a distribution or dividend, it must ensure that it has sufficient distributable reserves (on a non-consolidated basis). The basic rule is that a company's profits available for the purpose of making a distribution are its accumulated, realized profits, so far as not previously utilized by distribution or capitalization, less its accumulated, realized losses, so far as not previously written off in a reduction or reorganization of capital duly made. The requirement to have sufficient distributable reserves before a distribution or dividend can be paid applies to us and to each of our subsidiaries that has been incorporated under English law. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">It is not sufficient that we, as a public company, have made a distributable profit for the purpose of making a distribution. An additional capital maintenance requirement is imposed on us to ensure that the net worth of the company is at least equal to the amount of its capital. A public company can only make a distribution&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:14.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.128%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if, at the time that the distribution is made, the amount of its net assets (that is, the total excess of assets over liabilities) is not less than the total of its called up share capital and undistributable reserves&#59; and</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if, and to the extent that, the distribution itself, at the time that it is made, does not reduce the amount of the net assets to less than that total.</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Takeovers and Mergers </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Following our delisting from AIM, the U.K. Panel on Takeovers and Mergers has confirmed to us that the U.K. City Code on Takeovers and Mergers or the Code will not apply to us. However, we may become subject to the Code in the future if any changes to the board composition results in the majority of our directors being resident in the </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">United Kingdom, Channel Islands or the Isle of Man. We have incorporated certain takeover protections in our articles of association so that we are able to defend ourselves and our shareholders from hostile takeovers. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Differences in Corporate Law </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">The applicable provisions of the Companies Act 2006 differ from laws applicable to U.S. corporations and their shareholders. Set forth below is a summary of certain differences between the provisions of the Companies Act 2006 applicable to us and the General Corporation Law of the State of Delaware relating to shareholders' rights and protections. This summary is not intended to be a complete discussion of the respective rights and it is qualified in its entirety by reference to Delaware law and English law.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.220%"><tr><td style="width:1.0%"></td><td style="width:20.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.890%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">England and Wales</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Number of Directors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the Companies Act 2006, a public limited company must have at least two directors and the number of directors may be fixed by or in the manner provided in a company&#8217;s articles of association.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under Delaware law, a corporation must have at least one director and the number of directors shall be fixed by or in the manner provided in the bylaws.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Removal of Directors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the Companies Act 2006, shareholders may remove a director without cause by an ordinary resolution (which is passed by a simple majority of those voting in person or by proxy at a general meeting) irrespective of any provisions of any service contract the director has with the company, provided 28 clear days&#8217; notice of the resolution has been given to the company and its shareholders. On receipt of notice of an intended resolution to remove a director, the company must forthwith send a copy of the notice to the director concerned. Certain other procedural requirements under the Companies Act 2006 must also be followed such as allowing the director to make representations against his or her removal either at the meeting or in writing.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under Delaware law, any director or the entire board of directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors, except (a) unless the certificate of incorporation provides otherwise, in the case of a corporation whose board of directors is classified, shareholders may effect such removal only for cause, or (b) in the case of a corporation having cumulative voting, if less than the entire board of directors is to be removed, no director may be removed without cause if the votes cast against his removal would be sufficient to elect him if then cumulatively voted at an election of the entire board of directors, or, if there are classes of directors, at an election of the class of directors of which he is a part.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">19</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.220%"><tr><td style="width:1.0%"></td><td style="width:20.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.890%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.220%"><tr><td style="width:1.0%"></td><td style="width:20.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vacancies on the Board of Directors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under English law, the procedure by which directors, other than a company&#8217;s initial directors, are appointed is generally set out in a company&#8217;s articles of association, provided that where two or more persons are appointed as directors of a public limited company by resolution of the shareholders, resolutions appointing each director must be voted on individually.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under Delaware law, vacancies and newly created directorships may be filled by a majority of the directors then in office (even though less than a quorum) or by a sole remaining director unless (a) otherwise provided in the certificate of incorporation or by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8209;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">laws of the corporation or (b) the certificate of incorporation directs that a particular class of stock is to elect such director, in which case a majority of the other directors elected by such class, or a sole remaining director elected by such class, will fill such vacancy.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Annual General Meeting</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the Companies Act 2006, a public limited company must hold an annual general meeting in each six</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8209;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">month period following the company&#8217;s annual accounting reference date.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under Delaware law, the annual meeting of stockholders shall be held at such place, on such date and at such time as may be designated from time to time by the board of directors or as provided in the certificate of incorporation or by the bylaws.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General Meeting</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the Companies Act 2006, a general meeting of the shareholders of a public limited company may be called by the directors.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under Delaware law, special meetings of the stockholders may be called by the board of directors or by such person or persons as may be authorized by the certificate of incorporation or by the bylaws.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shareholders holding at least 5% of the paid</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8209;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">up capital of the company carrying voting rights at general meetings (excluding nay paid up capital held as treasury shares) can require the directors to call a general meeting and, if the directors fail to do so within a certain period, may themselves convene a general meeting.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.220%"><tr><td style="width:1.0%"></td><td style="width:20.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Notice of General Meetings</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the Companies Act 2006, 21 clear days&#8217; notice must be given for an annual general meeting and any resolutions to be proposed at the meeting. Subject to a company&#8217;s articles of association providing for a longer period, at least 14 clear days&#8217; notice is required for any other general meeting. In addition, certain matters, such as the removal of directors or auditors, require special notice, which is 28 clear days&#8217; notice. The shareholders of a company may in all cases consent to a shorter notice period, the proportion of shareholders&#8217; consent required being 100% of those entitled to attend and vote in the case of an annual general meeting and, in the case of any other general meeting, a majority in number of the members having a right to attend and vote at the meeting, being a majority who together hold not less than 95% in nominal value of the shares giving a right to attend and vote at the meeting.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under Delaware law, unless otherwise provided in the certificate of incorporation or bylaws, written notice of any meeting of the stockholders must be given to each stockholder entitled to vote at the meeting not less than ten nor more than 60 days before the date of the meeting and shall specify the place, date, hour, and purpose or purposes of the meeting.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proxy</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the Companies Act 2006, at any meeting of shareholders, a shareholder may designate another person to attend, speak and vote at the meeting on their behalf by proxy.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under Delaware law, at any meeting of stockholders, a stockholder may designate another person to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. A director of a Delaware corporation may not issue a proxy representing the director&#8217;s voting rights as a director.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.220%"><tr><td style="width:1.0%"></td><td style="width:20.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.890%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8209;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">emptive Rights</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the Companies Act 2006, &#8220;equity securities&#8221;, being (i) shares in the company other than shares that, with respect to dividends and capital, carry a right to participate only up to a specified amount in a distribution (&#8220;ordinary shares&#8221;) or (ii) rights to subscribe for, or to convert securities into, ordinary shares, proposed to be allotted for cash must be offered first to the existing equity shareholders in the company in proportion to the respective nominal value of their holdings, unless an exception applies or a special resolution to the contrary has been passed by shareholders in a general meeting or the articles of association provide otherwise in each case in accordance with the provisions of the Companies Act 2006.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under Delaware law, shareholders have no preemptive rights to subscribe to additional issues of stock or to any security convertible into such stock unless, and except to the extent that, such rights are expressly provided for in the certificate of incorporation.</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.220%"><tr><td style="width:1.0%"></td><td style="width:20.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Authority to Allot</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the Companies Act 2006, the directors of a company must not allot shares or grant of rights to subscribe for or to convert any security into shares unless an exception applies or an ordinary resolution to the contrary has been passed by shareholders in a general meeting or the articles of association provide otherwise in each case in accordance with the provisions of the Companies Act 2006.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under Delaware law, if the corporation&#8217;s charter or certificate of incorporation so provides, the board of directors has the power to authorize the issuance of stock. It may authorize capital stock to be issued for consideration consisting of cash, any tangible or intangible property or any benefit to the corporation or any combination thereof. It may determine the amount of such consideration by approving a formula. In the absence of actual fraud in the transaction, the judgment of the directors as to the value of such consideration is conclusive.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Liability of Directors and Officers</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the Companies Act 2006, any provision, whether contained in a company&#8217;s articles of association or any contract or otherwise, that purports to exempt a director of a company, to any extent, from any liability that would otherwise attach to him in connection with any negligence, default, breach of duty or breach of trust in relation to the company is void.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under Delaware law, a corporation&#8217;s certificate of incorporation may include a provision eliminating or limiting the personal liability of a director to the corporation and its stockholders for damages arising from a breach of fiduciary duty as a director. However, no provision can limit the liability of a director for&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any provision by which a company directly or indirectly provides an indemnity, to any extent, for a director of the company or of an associated company against any liability attaching to him in connection with any negligence, default, breach of duty or breach of trust in relation to the company of which he is a director is also void except as permitted by the Companies Act 2006, which provides exceptions for the company to (a) purchase and maintain insurance against such liability&#59; (b) provide a &#8220;qualifying third party indemnity&#8221; (being an indemnity against liability incurred by the director to a person other than the company or an associated company or criminal proceedings in which he is convicted)&#59; and (c) provide a &#8220;qualifying pension scheme indemnity&#8221; (being an indemnity against liability incurred in connection with the company&#8217;s activities as trustee of an occupational pension plan).</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders&#59;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law&#59;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">intentional or negligent payment of unlawful dividends or stock purchases or redemptions&#59; or</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">any transaction from which the director derives an improper personal benefit.</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.220%"><tr><td style="width:1.0%"></td><td style="width:20.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.890%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.220%"><tr><td style="width:1.0%"></td><td style="width:20.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Voting Rights</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under English law, unless a poll is demanded by the shareholders of a company or is required by the chairman of the meeting or the company&#8217;s articles of association, shareholders shall vote on all resolutions on a show of hands. Under the Companies Act 2006, a poll may be demanded by (a) not fewer than five shareholders having the right to vote on the resolution&#59; (b) any shareholder(s) representing not less than 10% of the total voting rights of all the shareholders having the right to vote on the resolution (excluding any voting rights attaching to treasury shares)&#59; or (c) any shareholder(s) holding shares in the company conferring a right to vote on the resolution (excluding any voting rights attaching to treasury shares) being shares on which an aggregate sum has been paid up equal to not less than 10% of the total sum paid up on all the shares conferring that right. A company&#8217;s articles of association may provide more extensive rights for shareholders to call a poll.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Delaware law provides that, unless otherwise provided in the certificate of incorporation, each stockholder is entitled to one vote for each share of capital stock held by such stockholder.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under English law, an ordinary resolution is passed on a show of hands if it is approved by a simple majority (more than 50%) of the votes cast by shareholders present (in person or by proxy) and entitled to vote. If a poll is demanded, an ordinary resolution is passed if it is approved by holders representing a simple majority of the total voting rights of shareholders present, in person or by proxy,</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">who, being entitled to vote, vote on the resolution. Special resolutions require the affirmative vote of not less than 75% of the votes cast by shareholders present, in person or by proxy, at the meeting.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shareholder Vote on Certain Transactions</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Companies Act 2006 provides for schemes of arrangement, which are arrangements or compromises between a company and any class of shareholders or creditors and used in certain types of reconstructions, amalgamations, capital reorganizations or takeovers. These arrangements require&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">the approval at a shareholders&#8217; or creditors&#8217; meeting convened by order of the court, of a majority in number of shareholders or creditors representing 75% in value of the capital held by, or debt owed to, the class of shareholders or creditors, or class thereof present and voting, either in person or by proxy&#59; and</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">the approval of the court.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Generally, under Delaware law, unless the certificate of incorporation provides for the vote of a larger portion of the stock, completion of a merger, consolidation, sale, lease or exchange of all or substantially all of a corporation&#8217;s assets or dissolution requires&#58;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">the approval of the board of directors&#59; and</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">approval by the vote of the holders of a majority of the outstanding stock or, if the certificate of incorporation provides for more or less than one vote per share, a majority of the votes of the outstanding stock of a corporation entitled to vote on the matter.</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.220%"><tr><td style="width:1.0%"></td><td style="width:20.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.890%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Standard of Conduct for Directors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under English law, a director owes various statutory and fiduciary duties to the company, including&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to act in the way he considers, in good faith, would be most likely to promote the success of the company for the benefit of its members as a whole&#59;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to avoid a situation in which he has, or can have, a direct or indirect interest that conflicts, or possibly conflicts, with the interests of the company&#59;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to act in accordance with the company&#8217;s constitution and only exercise his powers for the purposes for which they are conferred&#59;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to exercise independent judgment&#59;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to exercise reasonable care, skill and diligence&#59;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">not to accept benefits from a third party conferred by reason of his being a director or doing, or not doing, anything as a director&#59; and</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">a duty to declare any interest that he has, whether directly or indirectly, in a proposed or existing transaction or arrangement with the company.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Delaware law does not contain specific provisions setting forth the standard of conduct of a director. The scope of the fiduciary duties of directors is generally determined by the courts of the State of Delaware. In general, directors have a duty to act without self</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8209;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">interest, on a well</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8209;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">informed basis and in a manner they reasonably believe to be in the best interest of the stockholders.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors of a Delaware corporation owe fiduciary duties of care and loyalty to the corporation and to its shareholders. The duty of care generally requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself of all material information reasonably available regarding a significant transaction. The duty of loyalty requires that a director act in a manner he reasonably believes to be in the best interests of the corporation. He must not use his corporate position for personal gain or advantage. In general, but subject to certain exceptions, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Delaware courts have also imposed a heightened standard of conduct upon directors of a Delaware corporation who take any action designed to defeat a threatened change in control of the corporation.</font></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.220%"><tr><td style="width:1.0%"></td><td style="width:20.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, under Delaware law, when the board of directors of a Delaware corporation approves the sale or break</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8209;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">up of a corporation, the board of directors may, in certain circumstances, have a duty to obtain the highest value reasonably available to the shareholders.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stockholder Suits</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under English law, generally, the company, rather than its shareholders, is the proper claimant in an action in respect of a wrong done to the company or where there is an irregularity in the company&#8217;s internal management. Notwithstanding this general position, the Companies Act 2006 provides that (i) a court may allow a shareholder to bring a derivative claim (that is, an action in respect of and on behalf of the company) in respect of a cause of action arising from a director&#8217;s negligence, default, breach of duty or breach of trust and (ii) a shareholder may bring a claim for a court order where the company&#8217;s affairs have been or are being conducted in a manner that is unfairly prejudicial to some of its shareholders.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under Delaware law, a stockholder may initiate a derivative action to enforce a right of a corporation if the corporation fails to enforce the right itself. The complaint must&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff complains or that the plaintiffs shares thereafter devolved on the plaintiff by operation of law&#59; and</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">allege with particularity the efforts made by the plaintiff to obtain the action the plaintiff desires from the directors and the reasons for the plaintiff&#8217;s failure to obtain the action&#59; or</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">state the reasons for not making the effort.</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.220%"><tr><td style="width:1.0%"></td><td style="width:20.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.890%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, the plaintiff must remain a stockholder through the duration of the derivative suit. The action will not be dismissed or compromised without the approval of the Delaware Court of Chancery.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#160;</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><div id="i1c3777cd89c9436ca9437784e0056ede_4"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:144%">DESCRIPTION OF AMERICAN DEPOSITARY SHARES </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">American Depositary Shares </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">We are providing you with a summary description of the material terms of our ADSs and of the material rights of owners of our ADSs. Please remember that summaries by their nature lack the precision of the information summarized and that the rights and obligations of an owner of ADSs will be determined by reference to the terms of the deposit agreement and not by this summary. We urge you to review the deposit agreement in its entirety. We have registered 100,000,000 of our ADSs with the SEC under a registration statement on Form F-6 (Reg. No. 333-217353), or the F-6 Registration Statement.</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Citibank, N.A., or Citibank, has agreed to act as the depositary for our ADSs. Citibank's depositary offices are located at 388 Greenwich Street, New York, New York 10013. ADSs represent ownership interests in securities that are on deposit with the depositary. ADSs may be represented by certificates that are commonly known as American Depositary Receipts, or ADRs. The depositary typically appoints a custodian to safekeep the securities on deposit. In this case, the custodian is Citibank, N.A., London Branch, located at 25 Canada Square, Canary Wharf, London, E14 5LB, United Kingdom. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">We have appointed Citibank as depositary pursuant to a deposit agreement. A copy of the deposit agreement is on file with the SEC under cover of the F-6 Registration Statement. You may obtain a copy of the deposit agreement from the SEC's website (www.sec.gov). Please refer to registration number 333-217353 when retrieving such copy. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Each ADS represents the right to receive, and to exercise the beneficial ownership interests in, eight of our ordinary shares that are on deposit with the depositary and&#47;or custodian. An ADS also represents the right to receive, and to exercise the beneficial interests in, any other property received by the depositary or the custodian on behalf of the owner of the ADS but that has not been distributed to the owners of ADSs because of legal restrictions or practical considerations. We and the depositary may agree to change the ADS-to-ordinary share ratio by amending the deposit agreement. This amendment may give rise to, or change, the depositary fees payable by ADS owners. The custodian, the depositary and their respective nominees will hold all deposited property for the benefit of the holders and beneficial owners of ADSs. The deposited property does not constitute the proprietary assets of the depositary, the custodian or their nominees. Beneficial ownership in the deposited property will, under the terms of the deposit agreement, be vested in the beneficial owners of the ADSs. The depositary, the custodian and their respective nominees will be the record holders of the deposited property represented by the ADSs for the benefit of the holders and beneficial owners of the corresponding ADSs. A beneficial owner of ADSs may or may not be the holder of ADSs. Beneficial owners of ADSs will be able to receive, and to exercise beneficial ownership interests in, the deposited property only through the registered holders of the ADSs, the registered holders of the ADSs (on behalf of the applicable ADS owners) only through the depositary, and the depositary (on behalf of the owners of the corresponding ADSs) directly, or indirectly, through the custodian or their respective nominees, in each case upon the terms of the deposit agreement. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">If you become an owner of ADSs, you will become a party to the deposit agreement and therefore will be bound to its terms and to the terms of any ADR that represents your ADSs. The deposit agreement and the ADR specify our rights and obligations as well as your rights and obligations as owner of ADSs and those of the depositary. As an ADS holder you appoint the depositary to act on your behalf in certain circumstances. The deposit agreement and the ADRs are governed by New York law. However, our obligations to the holders of ordinary shares will continue to be governed by the laws of England and Wales, which may be different from the laws in the United States. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">In addition, applicable laws and regulations may require you to satisfy reporting requirements and obtain regulatory approvals in certain circumstances. You are solely responsible for complying with such reporting requirements and obtaining such approvals. Neither the depositary, the custodian, us or any of their or our respective agents or affiliates shall be required to take any actions whatsoever on your behalf to satisfy such reporting requirements or obtain such regulatory approvals under applicable laws and regulations. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">As an owner of ADSs, we will not treat you as one of our shareholders and you will not have direct shareholder rights. The depositary will hold on your behalf the shareholder rights attached to the ordinary shares underlying your ADSs. As an owner of ADSs you will be able to exercise the shareholders rights for the ordinary shares represented by your ADSs through the depositary only to the extent contemplated in the deposit agreement. To exercise any shareholder rights not contemplated in the deposit agreement you will, as an ADS owner, need to arrange for the cancellation of your ADSs and become a direct shareholder. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">As an owner of ADSs, you may hold your ADSs either by means of an ADR registered in your name, through a brokerage or safekeeping account, or through an account established by the depositary in your name reflecting the registration of uncertificated ADSs directly on the books of the depositary (commonly referred to as the direct registration system, or DRS). The DRS reflects the uncertificated (book-entry) registration of ownership of ADSs by the depositary. Under the DRS, ownership of ADSs is evidenced by periodic statements issued by the depositary to the holders of the ADSs. The DRS includes automated transfers between the depositary and The Depository Trust Company, or DTC, the central book-entry clearing and settlement system for equity securities in the United States. If you decide to hold your ADSs through your brokerage or safekeeping account, you must rely on the procedures of your broker or bank to assert your rights as an ADS owner. Banks and brokers typically hold securities such as the ADSs through clearing and settlement systems such as DTC. The procedures of such clearing and settlement systems may limit your ability to exercise your rights as an owner of ADSs. Please consult with your broker or bank if you have any questions concerning these limitations and procedures. All ADSs held through DTC will be registered in the name of a nominee of DTC. This summary description assumes you have opted to own the ADSs directly by means of an ADS registered in your name and, as such, we will refer to you as the &#34;holder.&#34; When we refer to &#34;you,&#34; we assume the reader owns ADSs and will own ADSs at the relevant time. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The registration of the ordinary shares in the name of the depositary or the custodian shall, to the maximum extent permitted by applicable law, vest in the depositary or the custodian the record ownership in the applicable ordinary shares with the beneficial ownership rights and interests in such ordinary shares being at all times vested with the beneficial owners of the ADSs representing the ordinary shares. The depositary or the custodian shall at all times be entitled to exercise the beneficial ownership rights in all deposited property, in each case only on behalf of the holders and beneficial owners of the ADSs representing the deposited property. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Dividends and Other Distributions </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">As a holder of ADSs, you generally have the right to receive the distributions we make on the ordinary shares deposited with the custodian. Your receipt of these distributions may be limited, however, by practical considerations and legal limitations. Holders of ADSs will receive such distributions under the terms of the deposit agreement in proportion to the number of ADSs held as of the specified record date, after deducting the applicable fees, taxes and expenses. </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:144%">Distributions of Cash </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Whenever we make a cash distribution for the ordinary shares on deposit with the custodian, we will deposit the funds with the custodian. Upon receipt of confirmation of the deposit of the requisite funds, the depositary will arrange for the funds to be converted into U.S. dollars and for the distribution of the U.S. dollars to the holders, subject to the laws and regulations of England and Wales. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The conversion into U.S. dollars will take place only if practicable and if the U.S. dollars are transferable to the United States. The depositary will apply the same method for distributing the proceeds of the sale of any property (such as undistributed rights) held by the custodian in respect of ordinary shares on deposit. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The distribution of cash will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. The depositary will hold any cash amounts it is unable to distribute in a non-interest bearing account for the benefit of the applicable holders and beneficial owners of ADSs until the distribution can be effected or the funds that the depositary holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distributions of Shares </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Whenever we make a free distribution of ordinary shares for the ordinary shares on deposit with the custodian, we will deposit the applicable number of ordinary shares with the custodian. Upon receipt of confirmation of such deposit, the depositary will either distribute to holders new ADSs representing the ordinary shares deposited or modify the ADS-to-ordinary shares ratio, in which case each ADS you hold will represent rights and interests in the additional ordinary shares so deposited. Only whole new ADSs will be distributed. Fractional entitlements will be sold and the proceeds of such sale will be distributed as in the case of a cash distribution. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The distribution of new ADSs or the modification of the ADS-to-ordinary shares ratio upon a distribution of ordinary shares will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. In order to pay such taxes or governmental charges, the depositary may sell all or a portion of the new ordinary shares so distributed. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">No such distribution of new ADSs will be made if it would violate a law (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">e.g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">, the U.S. securities laws) or if it is not operationally practicable. If the depositary does not distribute new ADSs as described above, it may sell the ordinary shares received upon the terms described in the deposit agreement and will distribute the proceeds of the sale as in the case of a distribution of cash. </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:144%">Distributions of Rights </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Whenever we intend to distribute rights to purchase additional ordinary shares, we will give prior notice to the depositary and we will assist the depositary in determining whether it is lawful and reasonably practicable to distribute rights to purchase additional ADSs to holders. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The depositary will establish procedures to distribute rights to purchase additional ADSs to holders and to enable such holders to exercise such rights if it is lawful and reasonably practicable to make the rights available to holders of ADSs, and if we provide all of the documentation contemplated in the deposit agreement (such as opinions to address the lawfulness of the transaction). You may have to pay fees, expenses, taxes and other governmental charges to subscribe for the new ADSs upon the exercise of your rights. The depositary is not obligated to establish procedures to facilitate the distribution and exercise by holders of rights to purchase new ordinary shares other than in the form of ADSs. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The depositary will </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">not</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%"> distribute the rights to you if&#58;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:14.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.762%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.922%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we do not timely request that the rights be distributed to you or we request that the rights not be distributed to you&#59; or</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we fail to deliver satisfactory documents to the depositary&#59; or</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it is not reasonably practicable to distribute the rights.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The depositary will sell the rights that are not exercised or not distributed if such sale is lawful and reasonably practicable. The proceeds of such sale will be distributed to holders as in the case of a cash distribution. If the depositary is unable to sell the rights, it will allow the rights to lapse. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:144%">Elective Distributions </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Whenever we intend to distribute a dividend payable at the election of shareholders either in cash or in additional shares, we will give prior notice thereof to the depositary and will indicate whether we wish the elective distribution to be made available to you. In such case, we will assist the depositary in determining whether such distribution is lawful and reasonably practicable. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The depositary will make the election available to you only if it is reasonably practicable and if we have provided all of the documentation contemplated in the deposit agreement. In such case, the depositary will establish procedures to enable you to elect to receive either cash or additional ADSs, in each case as described in the deposit agreement. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">If the election is not made available to you, you will receive either cash or additional ADSs, depending on what a shareholder in England and Wales would receive upon failing to make an election, as more fully described in the deposit agreement. </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:144%">Other Distributions </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Whenever we intend to distribute property other than cash, ordinary shares or rights to purchase additional ordinary shares, we will notify the depositary in advance and will indicate whether we wish such distribution to be made to you. If so, we will assist the depositary in determining whether such distribution to holders is lawful and reasonably practicable. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">If it is reasonably practicable to distribute such property to you and if we provide all of the documentation contemplated in the deposit agreement, the depositary will distribute the property to the holders in a manner it deems practicable. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The distribution will be made net of fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. In order to pay such taxes and governmental charges, the depositary may sell all or a portion of the property received. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The depositary will </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">not</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%"> distribute the property to you and will sell the property if&#58;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:14.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.756%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.165%"></td><td style="width:0.0%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we do not request that the property be distributed to you or if we ask that the property not be distributed to you&#59; or</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we do not deliver satisfactory documents to the depositary&#59; or</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the depositary determines that all or a portion of the distribution to you is not reasonably practicable.</font></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The proceeds of such a sale will be distributed to holders as in the case of a cash distribution. </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:144%">Redemption </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Whenever we decide to redeem any of the ordinary shares on deposit with the custodian, we will notify the depositary in advance. If it is practicable and if we provide all of the documentation contemplated in the deposit agreement, the depositary will provide notice of the redemption to the holders. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The custodian will be instructed to surrender the shares being redeemed against payment of the applicable redemption price. The depositary will convert the redemption funds received into U.S. dollars upon the terms of the deposit agreement and will establish procedures to enable holders to receive the net proceeds from the redemption upon surrender of their ADSs to the depositary. You may have to pay fees, expenses, taxes and other governmental charges upon the redemption of your ADSs. If less than all ADSs are being redeemed, the ADSs to be retired will be selected by lot or on a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">pro rata</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%"> basis, as the depositary may determine. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Changes Affecting Ordinary Shares </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The ordinary shares held on deposit for your ADSs may change from time to time. For example, there may be a change in nominal or par value, split-up, cancellation, consolidation or any other reclassification of such ordinary shares or a recapitalization, reorganization, merger, consolidation or sale of assets of Verona. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">If any such change were to occur, your ADSs would, to the extent permitted by law, represent the right to receive the property received or exchanged in respect of the ordinary shares held on deposit. The depositary may in such circumstances deliver new ADSs to you, amend the deposit agreement, the ADRs and the applicable registration statement(s) on Form F-6, call for the exchange of your existing ADSs for new ADSs and take any other actions that are appropriate to reflect as to the ADSs the change affecting the Shares. If the depositary may not lawfully distribute such property to you, the depositary may sell such property and distribute the net proceeds to you as in the case of a cash distribution. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Issuance of ADSs upon Deposit of Ordinary Shares </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The depositary may create ADSs on your behalf if you or your broker deposit ordinary shares with the custodian. The depositary will deliver these ADSs to the person you indicate only after you pay any applicable issuance fees and any charges and taxes payable for the transfer of the ordinary shares to the custodian. Your ability to deposit ordinary shares and receive ADSs may be limited by U.S. and England and Wales legal considerations applicable at the time of deposit. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The issuance of ADSs may be delayed until the depositary or the custodian receives confirmation that all required approvals have been given and that the ordinary shares have been duly transferred to the custodian. The depositary will only issue ADSs in whole numbers. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">When you make a deposit of ordinary shares, you will be responsible for transferring good and valid title to the depositary. As such, you will be deemed to represent and warrant that&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:13.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.126%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.602%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the ordinary shares are duly authorized, validly issued, fully paid, non-assessable and legally obtained&#59;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">all preemptive (and similar) rights, if any, with respect to such ordinary shares have been validly waived or exercised&#59;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">you are duly authorized to deposit the ordinary shares&#59;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the ordinary shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge, mortgage or adverse claim, and are not, and the ADSs issuable upon such deposit will not be, &#34;restricted securities&#34; (as defined in the deposit agreement)&#59; and</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the ordinary shares presented for deposit have not been stripped of any rights or entitlements.</font></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">If any of the representations or warranties are incorrect in any way, we and the depositary may, at your cost and expense, take any and all actions necessary to correct the consequences of the misrepresentations. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Transfer, Combination and Split Up of ADRs </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">As an ADR holder, you will be entitled to transfer, combine or split up your ADRs and the ADSs evidenced thereby. For transfers of ADRs, you will have to surrender the ADRs to be transferred to the depositary and also must&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:13.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.214%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ensure that the surrendered ADR is properly endorsed or otherwise in proper form for transfer&#59;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#8226;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">provide such proof of identity and genuineness of signatures as the depositary deems appropriate&#59; </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.220%"><tr><td style="width:1.0%"></td><td style="width:14.071%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.758%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provide any transfer stamps required by the State of New York or the United States&#59; and</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pay all applicable fees, charges, expenses, taxes and other government charges payable by ADR holders pursuant to the terms of the deposit agreement, upon the transfer of ADRs.</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">To have your ADRs either combined or split up, you must surrender the ADRs in question to the depositary with your request to have them combined or split up, and you must pay all applicable fees, charges and expenses payable by ADR holders, pursuant to the terms of the deposit agreement, upon a combination or split up of ADRs. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Withdrawal of Ordinary Shares Upon Cancellation of ADSs </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">As a holder, you will be entitled to present your ADSs to the depositary for cancellation and then receive the corresponding number of underlying ordinary shares at the custodian's offices. Your ability to withdraw the ordinary shares held in respect of the ADSs may be limited by U.S. and England and Wales considerations applicable at the time of withdrawal. In order to withdraw the ordinary shares represented by your ADSs, you will be required to pay to the depositary the fees for cancellation of ADSs and any charges and taxes payable upon the transfer of the ordinary shares. You assume the risk for delivery of all funds and securities upon withdrawal. Once canceled, the ADSs will not have any rights under the deposit agreement. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">If you hold ADSs registered in your name, the depositary may ask you to provide proof of identity and genuineness of any signature and such other documents as the depositary may deem appropriate before it will cancel your ADSs. The withdrawal of the ordinary shares represented by your ADSs may be delayed until the depositary receives satisfactory evidence of compliance with all applicable laws and regulations. Please keep in mind that the depositary will only accept ADSs for cancellation that represent a whole number of securities on deposit. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">You will have the right to withdraw the securities represented by your ADSs at any time except as a result of&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:14.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.350%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.165%"></td><td style="width:0.0%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">temporary delays that may arise because (i) the transfer books for the ordinary shares or ADSs are closed, or (ii) ordinary shares are immobilized on account of a shareholders' meeting or a payment of dividends&#59;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obligations to pay fees, taxes and similar charges&#59; and&#47;or</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">restrictions imposed because of laws or regulations applicable to ADSs or the withdrawal of securities on deposit.</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The deposit agreement may not be modified to impair your right to withdraw the securities represented by your ADSs except to comply with mandatory provisions of law. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Voting Rights </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">As a holder, you generally have the right under the deposit agreement to instruct the depositary to exercise the voting rights for the ordinary shares represented by your ADSs. The voting rights of holders of ordinary shares are described in &#34;Description of Share Capital and Articles of Association - Articles of Association&#34; above. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">At our request, the depositary will distribute to you any notice of shareholders' meeting received from us together with information explaining how to instruct the depositary to exercise the voting rights of the securities represented by ADSs. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">If the depositary timely receives voting instructions from a holder of ADSs, it will endeavor to vote the securities (in person or by proxy) represented by the holder's ADSs as follows&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:15.476%"><tr><td style="width:1.0%"></td><td style="width:91.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.593%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%"> In the event of voting by show of hands</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">, the depositary will vote (or cause the custodian to vote) all ordinary held on deposit at that time in accordance with the voting instructions received from a majority of holders of ADSs who provide timely voting instructions. </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:15.476%"><tr><td style="width:1.0%"></td><td style="width:91.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.593%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%"> In the event of voting by poll</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">, the depositary will vote (or cause the custodian to vote) the ordinary shares held on deposit in accordance with the voting instructions received from the holders of ADSs. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Securities for which no voting instructions have been received will not be voted (except as otherwise contemplated herein). Please note that the ability of the depositary to carry out voting instructions may be limited by practical and legal limitations and the terms of the securities on deposit. We cannot assure you that you will receive voting materials in time to enable you to return voting instructions to the depositary in a timely manner. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Fees and Charges </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">As an ADS holder, you will be required to pay the following fees under the terms of the deposit agreement&#58; </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.714%"><tr><td style="width:1.0%"></td><td style="width:61.573%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.144%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Service</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fee</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of ADSs (e.g., an issuance of ADS upon a deposit of ordinary shares or upon a change in the ADS(s)-to-ordinary shares ratio), excluding ADS issuances as a result of distributions of ordinary shares</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up to $0.05 per ADS issued</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancellation of ADSs (e.g., a cancellation of ADSs for delivery of deposited property or upon a change in the ADS(s)-to-ordinary shares ratio)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up to $0.05 per ADS cancelled</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distribution of cash dividends or other cash distributions (e.g., upon a sale of rights and other entitlements)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:7.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up to $0.05 per ADS held</font></div><div><font><br></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distribution of ADSs pursuant to (i) stock dividends or other free stock distributions, or (ii) exercise of rights to purchase additional ADSs</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:7.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up to $0.05 per ADS held</font></div><div><font><br></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distribution of securities other than ADSs or rights to purchase additional ADSs (e.g., upon a spin-off)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:7.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up to $0.05 per ADS held</font></div><div><font><br></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADS Services</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up to $0.05 per ADS held on the applicable record date(s) established by the depositary</font></td></tr></table></div><div style="margin-top:7.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">As an ADS holder you will also be responsible to pay certain charges such as&#58;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.414%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.163%"></td><td style="width:0.0%"></td><td style="width:1.0%"></td><td style="width:3.151%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">taxes (including applicable interest and penalties) and other governmental charges&#59;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the registration fees as may from time to time be in effect for the registration of ordinary shares on the share register and applicable to transfers of ordinary shares to or from the name of the custodian, the depositary or any nominees upon the making of deposits and withdrawals, respectively&#59;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain cable, telex and facsimile transmission and delivery expenses&#59;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the expenses and charges incurred by the depositary in the conversion of foreign currency&#59;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the fees and expenses incurred by the depositary in connection with compliance with exchange control regulations and other regulatory requirements applicable to ordinary shares, ADSs and ADRs&#59; and</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the fees and expenses incurred by the depositary, the custodian, or any nominee in connection with the servicing or delivery of deposited property.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">ADS fees and charges payable upon (i) the issuance of ADSs, and (ii) the cancellation of ADSs are charged to the person to whom the ADSs are issued (in the case of ADS issuances) and to the person whose ADSs are cancelled (in the case of ADS cancellations). In the case of ADSs issued by the depositary into DTC, the ADS issuance and cancellation fees and charges may be deducted from distributions made through DTC, and may be charged to the DTC participant(s) receiving the ADSs being issued or the DTC participant(s) holding the ADSs being cancelled, as the case may be, on behalf of the beneficial owner(s) and will be charged by the DTC participant(s) to the account of the applicable beneficial owner(s) in accordance with the procedures and practices of the DTC participants as in effect at the time. ADS fees and charges in respect of distributions and the ADS service fee are charged to the holders as of the applicable ADS record date. In the case of distributions of cash, the amount of the applicable ADS fees and charges is deducted from the funds being distributed. In the case of (i) distributions other than cash and (ii) the ADS service fee, holders as of the ADS record date will be invoiced for the amount of the ADS fees and charges and such ADS fees and charges may be deducted from distributions made to holders of ADSs. For ADSs held through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted from distributions made through DTC, and may be charged to the DTC participants in accordance with the procedures and practices prescribed by DTC and the DTC participants in turn charge the amount of such ADS fees and charges to the beneficial owners for whom they hold ADSs. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">In the event of refusal to pay the depositary fees, the depositary may, under the terms of the deposit agreement, refuse the requested service until payment is received or may set off the amount of the depositary fees from any distribution to be made to the ADS holder. Certain of the depositary fees and charges (such as the ADS services fee) may become payable shortly after the closing of any applicable ADS offering. Note that the fees and charges you may be required to pay may vary over time and may be changed by us and by the depositary. You will receive prior notice of such changes. The depositary may reimburse us for certain expenses incurred by us in respect of the ADR program, by making available a portion of the ADS fees charged in respect of the ADR program or otherwise, upon such terms and conditions as we and the depositary agree from time to time. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Amendments and Termination </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">We may agree with the depositary to modify the deposit agreement at any time without your consent. We undertake to give holders 30 days' prior notice of any modifications that would materially prejudice any of their substantial rights under the deposit agreement. We will not consider to be materially prejudicial to your substantial rights any modifications or supplements that are reasonably necessary for the ADSs to be registered under the Securities Act of 1933, as amended, or the Securities Act, or to be eligible for book-entry settlement, in each case without imposing or increasing the fees and charges you are required to pay. In addition, we may not be able to provide you with prior notice of any modifications or supplements that are required to accommodate compliance with applicable provisions of law. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">You will be bound by the modifications to the deposit agreement if you continue to hold your ADSs after the modifications to the deposit agreement become effective. The deposit agreement cannot be amended to prevent you from withdrawing the ordinary shares represented by your ADSs (except as permitted by law). </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">We have the right to direct the depositary to terminate the deposit agreement. Similarly, the depositary may in certain circumstances on its own initiative terminate the deposit agreement. In either case, the depositary must give notice to the holders at least 30 days before termination. Until termination, your rights under the deposit agreement will be unaffected. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Termination </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">After termination, the depositary will continue to collect distributions received (but will not distribute any such property until you request the cancellation of your ADSs) and may sell the securities held on deposit. After the sale, the depositary will hold the proceeds from such sale and any other funds then held for the holders of ADSs in a non-interest bearing account. At that point, the depositary will have no further obligations to holders other than to account for the funds then held for the holders of ADSs still outstanding (after deduction of applicable fees, taxes and expenses). </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">In connection with the termination of the deposit agreement, the depositary may, independently and without the need for any action by us, make available to holders a means to withdraw the ordinary shares and other deposited securities represented by their ADSs and to direct the deposit of such ordinary shares and other deposited securities into an unsponsored American depositary shares program established by the depositary, upon such terms and conditions as the depositary may deem reasonably appropriate, subject however, in each case, to satisfaction of the applicable registration requirements by the unsponsored American depositary shares program under the Securities Act, and to receipt by the depositary of payment of the applicable fees and charges of, and reimbursement of the applicable expenses incurred by, the depositary. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Books of Depositary </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The depositary will maintain ADS holder records at its depositary office. You may inspect such records at such office during regular business hours but solely for the purpose of communicating with other holders in the interest of business matters relating to the ADSs and the deposit agreement. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The depositary will maintain in New York facilities to record and process the issuance, cancellation, combination, split-up and transfer of ADSs. These facilities may be closed from time to time, to the extent not prohibited by law. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Transmission of Notices, Reports and Proxy Soliciting Material </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The depositary will make available for your inspection at its office all communications that it receives from us as a holder of deposited securities that we make generally available to holders of deposited securities. Subject to the terms of the deposit agreement, the depositary will send you copies of those communications or otherwise make those communications available to you if we ask it to. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitations on Obligations and Liabilities </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The deposit agreement limits our obligations and the depositary's obligations to you. Please note the following&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.922%"><tr><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.188%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.163%"></td><td style="width:0.0%"></td><td style="width:0.0%"></td><td style="width:0.165%"></td><td style="width:0.0%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the depositary are obligated only to take the actions specifically stated in the deposit agreement without negligence or bad faith.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depositary disclaims any liability for any failure to carry out voting instructions, for any manner in which a vote is cast or for the effect of any vote, provided it acts in good faith and in accordance with the terms of the deposit agreement.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depositary disclaims any liability for any failure to determine the lawfulness or practicality of any action, for the content of any document forwarded to you on our behalf or for the accuracy of any translation of such a document, for the investment risks associated with investing in ordinary shares, for the validity or worth of the ordinary shares, for any tax consequences that result from the ownership of ADSs, for the credit-worthiness of any third party, for allowing any rights to lapse under the terms of the deposit agreement, for the timeliness of any of our notices or for our failure to give notice.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the depositary will not be obligated to perform any act that is inconsistent with the terms of the deposit agreement.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the depositary disclaim any liability if we or the depositary are prevented or forbidden from or subject to any civil or criminal penalty or restraint on account of, or delayed in, doing or performing any act or thing required by the terms of the deposit agreement, by reason of any provision, present or future of any law or regulation, or by reason of present or future provision of any provision of our Articles of Association, or any provision of or governing the securities on deposit, or by reason of any act of God or war or other circumstances beyond our control.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the depositary disclaim any liability by reason of any exercise of, or failure to exercise, any discretion provided for in the deposit agreement or in our Articles of Association or in any provisions of or governing the securities on deposit.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the depositary further disclaim any liability for any action or inaction in reliance on the advice or information received from legal counsel, accountants, any person presenting Shares for deposit, any holder of ADSs or authorized representatives thereof, or any other person believed by either of us in good faith to be competent to give such advice or information.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the depositary also disclaim liability for the inability by a holder to benefit from any distribution, offering, right or other benefit that is made available to holders of ordinary shares but is not, under the terms of the deposit agreement, made available to you.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.922%"><tr><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.188%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.163%"></td><td style="width:0.0%"></td><td style="width:0.0%"></td><td style="width:0.165%"></td><td style="width:0.0%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the depositary may rely without any liability upon any written notice, request or other document believed to be genuine and to have been signed or presented by the proper parties.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the depositary also disclaim liability for any consequential or punitive damages for any breach of the terms of the deposit agreement.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No disclaimer of any Securities Act liability is intended by any provision of the deposit agreement.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Pre-Release Transactions </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Subject to the terms and conditions of the deposit agreement, the depositary may issue to broker&#47;dealers ADSs before receiving a deposit of ordinary shares or release ordinary shares to broker&#47;dealers before receiving ADSs for cancellation. These transactions are commonly referred to as &#34;pre-release transactions,&#34; and are entered into between the depositary and the applicable broker&#47;dealer. The deposit agreement limits the aggregate size of pre-release transactions (not to exceed 30% of the ordinary shares on deposit in the aggregate) and imposes a number of conditions on such transactions (e.g., the need to receive collateral, the type of collateral required, the representations required from brokers, etc.). The depositary may retain the compensation received from the pre-release transactions. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Taxes </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">You will be responsible for the taxes and other governmental charges payable on the ADSs and the securities represented by the ADSs. We, the depositary and the custodian may deduct from any distribution the taxes and governmental charges payable by holders and may sell any and all property on deposit to pay the taxes and governmental charges payable by holders. You will be liable for any deficiency if the sale proceeds do not cover the taxes that are due. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The depositary may refuse to issue ADSs, to deliver, transfer, split and combine ADRs or to release securities on deposit until all taxes and charges are paid by the applicable holder. The depositary and the custodian may take reasonable administrative actions to obtain tax refunds and reduced tax withholding for any distributions on your behalf. However, you may be required to provide to the depositary and to the custodian proof of taxpayer status and residence and such other information as the depositary and the custodian may require to fulfill legal obligations. You are required to indemnify us, the depositary and the custodian for any claims with respect to taxes based on any tax benefit obtained for you. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Foreign Currency Conversion </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The depositary will arrange for the conversion of all foreign currency received into U.S. dollars if such conversion is practical, and it will distribute the U.S. dollars in accordance with the terms of the deposit agreement. You may have to pay fees and expenses incurred in converting foreign currency, such as fees and expenses incurred in complying with currency exchange controls and other governmental requirements. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">If the conversion of foreign currency is not practical or lawful, or if any required approvals are denied or not obtainable at a reasonable cost or within a reasonable period, the depositary may take the following actions in its discretion&#58;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:13.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.417%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convert the foreign currency to the extent practical and lawful and distribute the U.S. dollars to the holders for whom the conversion and distribution is lawful and practical.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distribute the foreign currency to holders for whom the distribution is lawful and practical.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hold the foreign currency (without liability for interest) for the applicable holders.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Governing Law&#47;Waiver of Jury Trial </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The deposit agreement and the ADRs will be interpreted in accordance with the laws of the State of New York. The rights of holders of ordinary shares (including ordinary shares represented by ADSs) is governed by the laws of England and Wales. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">AS A PARTY TO THE DEPOSIT AGREEMENT, YOU WAIVE YOUR RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF THE DEPOSIT AGREEMENT OR THE ADRs AGAINST US AND&#47;OR THE DEPOSITARY. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#124;US-DOCS&#92;121028032.3&#124;&#124;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>3
<FILENAME>non-executicedirectorappoi.htm
<DESCRIPTION>EX-10.20
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i6f21978527104000918c3cf60cea586c_1"></div><div style="min-height:62.35pt;width:100%"><div><img alt="image_01a.jpg" src="image_01a.jpg" style="height:99px;margin-bottom:5pt;vertical-align:text-bottom;width:203px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">DRAFT&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PRIVATE AND CONFIDENTIAL</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Name&#93;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Address&#93; </font></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Date&#93;</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dear &#91;Name&#93;,</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Letter of appointment as a non-executive director</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On behalf of the board of directors (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Board&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) of Verona Pharma plc (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Company&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), it is with pleasure that I confirm your appointment as a non-executive director of the Company, with effect from &#91;Date&#93; (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and to set out your duties, terms of appointment and remuneration. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By accepting this appointment, you agree that this letter is a contract for services and is not a contract of employment and you confirm that you are not subject to any restrictions which prevent you from holding office as a director. </font></div><div style="margin-top:16pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.5pt">Appointment</font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.97pt">Subject to the remaining provisions of this letter, your appointment shall commence on the Effective Date and shall continue subject to&#58;</font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-37.53pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">your election or re-election at the Company&#8217;s annual general meetings at which you are standing for election or re-election and otherwise to the provisions of the Company&#8217;s articles of association, as amended from time to time (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Articles</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-40.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">prior termination, which shall be at the discretion of either party upon three months&#8217; written notice&#59; and</font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-42.57pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">prior termination at any time without notice in accordance with the provisions of paragraph 1.3 below. </font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.46pt">You may be required to serve on one or more Board committees from time to time, and will be provided with the relevant terms of reference on your appointment to such committees. With effect from the Effective Date, you will serve on the Nominations and Corporate Governance Committee. You also may be asked to serve as a non-executive director on the board of any of the Company's subsidiaries. </font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.58pt">Notwithstanding paragraph 1.1 above, the Company may terminate your appointment with immediate effect if you have&#58;</font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-37.53pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">committed a material breach of your obligations under this letter&#59; </font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-40.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">been found guilty of fraud, gross misconduct and&#47;or any serious or persistent negligence or misconduct in respect of your obligations under this letter, or otherwise in respect of your fiduciary duties owed to the Company&#59;</font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-top:16pt;text-align:justify"><font><br></font></div><div style="height:70.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.457%"><tr><td style="width:1.0%"></td><td style="width:79.236%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Registered office&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">One Central Square, </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cardiff CF10 1FS </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">United Kingdom</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Company number 5375156</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Principal office&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3 More London Riverside</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">London SE1 2RE</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">United Kingdom</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">T&#58; +44 (0) 20 3283 4200</font></div></td></tr></table></div><div style="text-indent:36pt"><font><br></font></div></div></div><div id="i6f21978527104000918c3cf60cea586c_4"></div><hr style="page-break-after:always"><div style="min-height:121.9pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-33.64pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">committed any serious or repeated breach or non-observance of your obligations to the Company (which include an obligation not to breach your statutory, fiduciary or common-law duties)&#59; </font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-36.16pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">been guilty of any fraud or dishonesty or acted in any manner which, in the Company's opinion, brings or is likely to bring you or the Company into disrepute or is materially adverse to the Company's interests&#59; </font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-38.68pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">been convicted of an arrestable criminal offence other than a road traffic offence for which a fine or non-custodial penalty is imposed (including if you are convicted of the criminal offence of insider dealing under the Criminal Justice Act 1993 or any similar conviction in the United States)&#59; </font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-38.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">been declared bankrupt or have made an arrangement with or for the benefit of your creditors, or if you are the subject of insolvency or similar proceedings, whether in a state or federal court, or any jurisdiction&#59; </font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-36.08pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">v.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">been disqualified from acting as a director for any reason&#59; or </font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-38.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">vi.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">not complied with the Company&#8217;s Code of Business Conduct and Ethics, as amended from time to time, available on Verona Pharma&#8217;s website at </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.veronapharma.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.97pt">On termination of your appointment, you shall, at the Company's request, resign from your office as non-executive director of the Company and any offices you hold in any of the Company's group companies without any claim for compensation or damages. If you fail to resign, you irrevocably appoint any member of the Board as  your attorney in your name and on your behalf to sign any documents and take such other steps as are necessary to give effect to those resignations.</font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.46pt">If matters arise which cause you concern about your role, you should discuss these matters with the chairperson of the Board.</font></div><div style="margin-top:16pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.5pt">Time commitment</font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.97pt">You will be expected to devote such time as is necessary for the proper performance of your duties. We envisage that, on average, you will spend a minimum of two days a month on work for the Company, recognising however that particular events may from time to time require you to devote to the Company more time than this. </font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.46pt">You will be expected to attend scheduled and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">ad hoc </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Board meetings, the annual general meeting, Board strategic planning sessions, meetings with the chairperson, the chief executive officer and other directors and meetings with major shareholders. Board meetings normally take place in London, but some meetings may be held in the US or by electronic means, as required. </font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.58pt">By accepting this appointment, you confirm that, taking into account all of your other commitments, you are able to allocate sufficient time to the Company to discharge your responsibilities effectively. </font></div><div style="height:28.35pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:121.9pt;width:100%"><div><font><br></font></div></div><div style="margin-top:16pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.5pt">Role and duties</font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.97pt">The Board as a whole is collectively responsible for the success of the Company. The Board's role is to&#58;</font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-33.64pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">provide entrepreneurial leadership of the Company within a framework of prudent and effective controls which enable risk to be assessed and managed&#59;</font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-36.16pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">set the Company&#8217;s strategic aims, ensure that the necessary financial and human resources are in place for the Company to meet its objectives, and review management performance&#59; and</font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-38.68pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">set the Company&#8217;s values and standards and ensure that its obligations to its shareholders and others are understood and met.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All directors must take decisions objectively in the interests of the Company.</font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.46pt">As a non-executive director you shall have the same general legal responsibilities to the Company as any other director. You are expected to perform your duties (whether statutory, fiduciary or common law) faithfully, diligently and to a standard commensurate with the functions of your role and your knowledge, skills and experience.</font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.58pt">You shall exercise your powers in your role as a non-executive director having regard to relevant obligations under prevailing law and regulation, including the Companies Act 2006 and the relevant rules and requirements of the US Securities and Exchange Commission and of Nasdaq. </font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.46pt">You shall have particular regard to the general duties of directors in the Companies Act 2006, including the duty to promote the success of the Company under which all directors must act in the way they consider, in good faith, would be most likely to promote the success of the Company for the benefit of its members as a whole. In doing so, as a director, you must have regard (among other matters) to&#58;</font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-33.64pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:136%">i.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:136%;padding-left:28.35pt">the likely consequences of any decision in the long term&#59;</font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-36.16pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:136%">ii.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:136%;padding-left:28.35pt">the interests of the Company&#8217;s employees&#59;</font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-38.68pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:136%">iii.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:136%;padding-left:28.35pt">the need to foster the Company&#8217;s business relationships with suppliers, customers and others&#59;</font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-38.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:136%">iv.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:136%;padding-left:28.35pt">the impact of the Company&#8217;s operations on the community and the environment&#59;</font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-36.08pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:136%">v.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:136%;padding-left:28.35pt">the desirability of the Company maintaining a reputation for high standards of business conduct&#59; and </font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-38.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:136%">vi.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:136%;padding-left:28.35pt">the need to act fairly as between the members of the Company. </font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.76pt">In your role as a non-executive director, you shall also be required to&#58;</font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-33.64pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">constructively challenge and help develop proposals on strategy&#59;</font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-36.16pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">scrutinise the performance of management in meeting agreed goals and objectives and monitor the reporting of performance&#59;</font></div><div style="height:28.35pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:121.9pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-38.68pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">satisfy yourself on the integrity of financial information and that financial controls and systems of risk management are robust and defensible&#59;</font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-38.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">be responsible for determining appropriate levels of remuneration of executive directors and have a prime role in appointing and, where necessary, removing senior management and in succession planning&#59;</font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-36.08pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">v.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">uphold high standards of integrity and probity and support the executive directors in instilling the appropriate culture, values and behaviours in the boardroom and beyond&#59;</font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-38.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">vi.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">take into account the views of shareholders and other stakeholders where appropriate&#59;</font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-41.12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">vii.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">make sufficient time available to discharge your responsibilities effectively&#59;</font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-43.64pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">viii.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">exercise relevant powers under, and abide by, the Articles&#59;</font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-38.4pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ix.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">disclose the nature and extent of any direct or indirect interest you may have in any matter being considered at a Board or committee meeting and, except as permitted under the Articles, you will not vote on any resolution of the Board, or of one of its committees, on any matter where you have any direct or indirect interest&#59;</font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-35.88pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">x.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">immediately report your own wrongdoing or the wrongdoing or proposed wrongdoing of any employee of other director of the Company of which you become aware to the chairperson&#59;</font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-38.4pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">xi.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">exercise your powers as a director in accordance with the Company's policies and procedures, including but not limited to the Company&#8217;s Code of Business Conduct and Ethics&#59; and </font></div><div style="margin-bottom:6pt;padding-left:77.95pt;text-align:justify;text-indent:-40.92pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">xii.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.35pt">not do anything that would cause you to be disqualified from acting as a director.</font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:29.88pt">Unless the Board specifically authorises you to do so, you shall not enter into any legal or other commitment or contract on behalf of the Company. </font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.06pt">Subject to paragraph 7, you shall be entitled to request all relevant information about the Company's affairs as is reasonably necessary to enable you to discharge your duties as a non-executive director.</font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.46pt">You shall not, at any time after the termination of your appointment, either personally or by an agent, directly or indirectly represent yourself as being in any way connected with or interested in the business of the Company (except in your capacity as a shareholder, if applicable).</font></div><div style="margin-top:16pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.5pt">Fees and expenses</font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.97pt">With effect from the Effective Date, you shall be paid a fee of &#163;&#91;amount&#93; per annum for acting as a non-executive director and a fee of &#163;&#91;amount&#93; per annum as a member of the Nominations and Corporate Governance Committee. The fees shall be paid monthly in arrears in equal instalments after deduction of any taxes and other amounts that are required by law. The fees will be subject to annual review by the Board, the first such review to take place with effect from January 1, &#91;date&#93;.</font></div><div style="height:28.35pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:121.9pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.46pt">The Company shall reimburse you for all reasonable and properly documented expenses that you incur in performing your duties, including reimbursement of business class air travel, but on the basis that these will also be shared on a fair basis with other companies of which you are a non-executive director, consultant or employee, where appropriate. </font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.58pt">Additional work outside your normal non-executive director duties will be remunerated separately upon approval of the Board.</font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.46pt">You will be eligible to participate in the long term incentive plan of the Company, subject to the discretion of the Company&#8217;s Board of Directors.  </font></div><div style="margin-top:16pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.5pt">Independent professional advice</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In order to enable you to carry out your duties as a non-executive director you will, after consultation with the chief executive officer if that is practicable (and, if appropriate, jointly with any other non-executive directors whose interests are the same as yours), be entitled to seek advice from independent advisers at the Company&#8217;s expense. </font></div><div style="margin-top:16pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.5pt">Outside interests</font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.97pt">It is accepted and acknowledged that you have business interests other than those of the Company. In the event that you become aware of any direct or indirect potential conflicts of interest, these should be promptly disclosed to the chief executive officer as soon as you become aware of them and you may have to seek the agreement of the Board. You will not vote on any resolutions of the Board or the Board committees, or on any matters, in each case where you have any direct or indirect conflict of interest, except as permitted by the Articles.</font></div><div style="margin-top:16pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.5pt">Confidentiality</font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.97pt">You acknowledge that all information acquired during your appointment is confidential to the Company and should not be released, communicated or disclosed to third parties, including shareholders of the Company, or used for any reason other than in the interests of the Company, either during your appointment or following termination (by whatever means), without prior clearance from the chief executive officer. This restriction shall cease to apply to any confidential information which may (other than by reason of your breach) become available to the public generally.</font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.46pt">You acknowledge the need to hold and retain Company information (in whatever format you may receive it) under appropriately secure conditions.</font></div><div style="margin-top:16pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.5pt">Inside information and dealing in the Company's shares</font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.97pt">Your attention is drawn to the requirements under both law and regulation as to the disclosure of price-sensitive information. You should avoid making any statements that might risk a breach of these requirements in any circumstance whatsoever. </font></div><div style="height:28.35pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:121.9pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.46pt">During your period of appointment you are required to comply with the provisions of the Company's Insider Trading Compliance Policy in relation to dealing in the Company&#8217;s publicly traded or quoted securities, and any such other code as the Company may adopt from time to time which sets out the terms for dealings by directors in the Company&#8217;s publicly traded or quoted securities. A copy of the current Insider Trading Compliance Policy adopted by the Company will be provided to you separately. </font></div><div style="margin-top:16pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.5pt">Insurance and indemnity</font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company shall maintain directors&#8217; and officers&#8217; liability insurance for your benefit during and after your appointment in respect of any matter occurring or alleged to have occurred while you are or were a director of the Company in such amount and on such terms considered reasonable by the Board. A copy of the policy document is available from the chief financial officer.</font></div><div style="margin-top:16pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.5pt">Return of property</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On termination of your appointment with the Company however arising, or at any time at the Board's request, you shall immediately return to the Company all documents, records, papers or other property belonging to the Company which may be in your possession or under your control, and which relate in any way to the Company's  business affairs and you shall not retain any copies thereof.</font></div><div style="margin-top:16pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:21.93pt">Moral rights</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You hereby irrevocably waive any moral rights in all works prepared by you, in the provision of your services to the Company, to which you are now or may at any future time be entitled under Chapter IV of the Copyright Designs and Patents Act 1988 or any similar provisions of law in any jurisdiction, including (but without limitation) the right to be identified, the right of integrity and the right against false attribution, and agree not to institute, support, maintain or permit any action or claim to the effect that any treatment, exploitation or use of such works or other materials, infringes your moral rights.</font></div><div style="margin-top:16pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:21.93pt">Data protection</font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.97pt">By signing this letter you consent to the Company holding and processing data about you for legal, personnel, administrative and management purposes and in particular to the processing of any sensitive personal data (as defined in the Data Protection Act 1998) relating to you.</font></div><div style="margin-bottom:6pt;margin-top:14pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.46pt">You consent to the Company making such information available to those who provide products or services to the Company or any company in the Company's group, including employees, professional advisers, shareholders, regulatory authorities, governmental or quasi-governmental organisations and potential purchasers of the Company.</font></div><div style="margin-top:16pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:21.93pt">Entire agreement</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.97pt">This letter and any document referred to in it constitutes the entire terms and conditions of your appointment and supersedes and extinguishes all previous </font></div><div style="height:28.35pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:121.9pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">agreements, promises, assurances, warranties, representations and understandings between you and the Company, whether written or oral, relating to its subject matter. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.46pt">You agree that you shall have no remedies in respect of any representation, assurance or warranty (whether made innocently or negligently) that is not set out in this letter and you shall not have any claim for innocent or negligent misrepresentation or negligent misstatement based on any statement in this letter. </font></div><div style="margin-top:16pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:21.93pt">Variation</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No variation of this letter shall be effective unless it is in writing and signed by you and the Company (or respective authorised representatives). </font></div><div style="margin-top:16pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:21.93pt">Governing law and jurisdiction</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This letter of appointment shall be governed by and construed in accordance with the law of England and Wales and you and the Company submit to the exclusive jurisdiction of the courts and tribunals of England and Wales. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Please indicate your acceptance of these terms by signing and returning the attached copy of this letter to Ms. Claire Poll at claire.poll&#64;veronapharma.com. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Yours sincerely,</font></div><div style="padding-right:22.95pt"><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. David Ebsworth</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Non-Executive Chairperson</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For and on behalf of Verona Pharma plc </font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I agree to the above terms of my appointment as a non-executive director of Verona Pharma plc as set out in this letter.</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_________________________________</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Name&#93;</font></div><div style="height:28.35pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19.2
<SEQUENCE>4
<FILENAME>svb-firstamendmenttoloan.htm
<DESCRIPTION>EX-10.19.2
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>svb-firstamendmenttoloan</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- svb-firstamendmenttoloan001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="svb-firstamendmenttoloan001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This First Amendment to Loan and Security Agreement (this &#8220;Amendment&#8221;) is entered  into this 28th day of January, 2021, by and between SILICON VALLEY BANK, a California  corporation (&#8220;Bank&#8221;) and VERONA PHARMA PLC., a company registered under the laws of  England and Wales with company number 05375156 (&#8220;Parent&#8221; or &#8220;UK Borrower&#8221;) and VERONA  PHARMA, INC., a Delaware corporation (&#8220;US Borrower&#8221; and together with UK Borrower, each  a &#8220;Co-Borrower&#8221; and collectively &#8220;Co-Borrowers&#8221;). RECITALS A. Bank and Co-Borrowers have entered into that certain Loan and Security  Agreement dated as of November 19, 2020 (as the same may from time to time be amended,  modified, supplemented or restated, collectively, the &#8220;Loan Agreement&#8221;).   B. Bank has extended credit to Co-Borrowers for the purposes permitted in the Loan  Agreement.   C. Co-Borrowers have requested that Bank amend the Loan Agreement to the Loan  Agreement as more fully set forth herein. D. Bank has agreed to so amend certain provisions of the Loan Agreement, but only  to the extent, in accordance with the terms, subject to the conditions and in reliance upon the  representations and warranties set forth below. AGREEMENT NOW, THEREFORE, in consideration of the foregoing recitals and other good and valuable  consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be  legally bound, the parties hereto agree as follows: 1. Definitions.  Capitalized terms used but not defined in this Amendment shall have  the meanings given to them in the Loan Agreement. 2. Amendments to Loan Agreement. 2.1 Section 3.5 (Conditions Precedent to Term B Loan Advance). New  Section 3.5 is hereby added to the Loan Agreement as follows: &#8220;3.5 Conditions Precedent to Term B Loan Advance.  Bank&#8217;s  obligations to make the Term B Loan Advance is further subject to Co-Borrowers&#8217;  maintaining a balance of unrestricted cash with Bank and Bank&#8217;s Affiliates not less  than Forty Five Million Dollars ($45,000,000) at such time the Term Loan B  Advance is requested.&#8221; </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- svb-firstamendmenttoloan002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="svb-firstamendmenttoloan002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">2   2.2 Section 6.5 (Operating Accounts).  Section 6.5(a) of the Loan Agreement  hereby is amended and restated in its entirety and replaced with the following: &#8220;(a) Starting February 1, 2021, Co-Borrowers shall at all times maintain  all their and all of their Subsidiaries&#8217; consolidated cash and Cash Equivalents with  Bank and Bank&#8217;s Affiliates; provided however, so long as Co-Borrowers&#8217; maintain  a balance of unrestricted cash with Bank and Bank&#8217;s Affiliates not less than Forty  Five Million Dollars ($45,000,000), Co-Borrowers&#8217; may maintain cash and Cash  Equivalents in accounts outside of Bank and Bank&#8217;s Affiliates subject to a Control  Agreement or subject to the UK Security Documents with aggregate balances not  to exceed Twenty Five Million Dollars ($25,000,000); provided further that within  five (5) Business Days of Bank's written request following an Event of Default that  is continuing or a Cash Collateralization Event, Co-Borrowers shall maintain all  their and all of their Subsidiaries&#8217; consolidated cash and Cash Equivalents with  Bank and Bank&#8217;s Affiliates.&#8221; 2.3 Section 6.13 (Cash Collateralization Trigger).  Section 6.13 of the Loan  Agreement hereby is amended and restated in its entirety and replaced with the following: &#8220;6.13 Cash Collateralization Trigger. If a Cash Collateralization Event  occurs at any time prior to repayment in full of all Obligations (other than inchoate  indemnity obligations),  (i)  US Borrower hereby authorizes and directs Bank to  immediately transfer to account number XXX-XXX-2119 held at Bank (from any  one or a combination  of US Borrower&#8217;s accounts at Bank) and (ii) UK Borrower  hereby authorizes and directs Bank to immediately transfer to account number  XXX-XXX-2123 held at Bank (from any one or a combination UK Borrower&#8217;s  accounts at Bank), an aggregate amount of cash and/or Cash Equivalents equal to  the sum of (i) the then-outstanding principal balance of and interest accrued on the  Term Loan Advances, plus (ii) an amount equal to the Final Payment, plus (iii) an  amount equal to the applicable Prepayment Fee, in order to cash collateralize all  amounts owing from Co-Borrowers to Bank in connection with the Term Loan  Advances, the Final Payment and the Prepayment Fee (if applicable) (a &#8220;Cash  Collateralization&#8221;), it being understood that the foregoing authorization shall  constitute an immediate Cash Collateralization of the Obligations, irrespective of  any delay by Bank in effecting such transfer.  For purposes hereof &#8220;Cash  Collateralization Event&#8221; means Co-Borrowers&#8217; consolidated cash and Cash  Equivalents at Bank or Bank&#8217;s Affiliates drops below Forty Five Million Dollars  ($45,000,000) at any time after the earliest to occur of any of the following: (i) the  release of Negative Data from Enhance 2 and/or Enhance 1, which in the reasonable  business discretion of Co-Borrowers&#8217; senior management, would be considered  insufficient to  support submission of an NDA to the FDA, (ii) the FDA issues a  complete response letter with respect to an NDA submitted for Ensifentrine, or (iii)  Ensifentrine has not received FDA approval for any indication by June 30, 2023,  provided however if Co-Borrowers receive at least One Hundred Fifty Million  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- svb-firstamendmenttoloan003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="svb-firstamendmenttoloan003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">3   Dollars ($150,000,000) in  new cash proceeds after September 8, 2020 from the  sale of equity securities in one or more public financings or other bona fide equity  financings, Subordinated Debt and/or upfront/milestone payments from one or  more collaboration agreements not prohibited herein, then such date shall be  automatically extended to March 31, 2024.&#8221; 2.4 Bank hereby acknowledges that effective as of the date on which the  conditions precedent set forth in Section 8 of this Amendment have been satisfied, Bank is agreeing  to include unrestricted cash maintained at Bank Affiliates for purposes of the covenant set forth in  Section 6.5(a) of the Loan Agreement and, for the avoidance of doubt, to the extent that  unrestricted cash was required to be held at Bank but not Bank Affiliates pursuant to Section 6.5(a)  of the Loan Agreement and failure to do so would have resulted in a default under the Agreement  as in effect prior to the date hereof, any such default is hereby deemed waived by Bank 3. Limitation of Amendments. 3.1 The amendments set forth in Section 2, above, are effective for the purposes  set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent  to any amendment, waiver or modification of any other term or condition of any Loan Document,  or (b) otherwise prejudice any right or remedy which Bank may now have or may have in the  future under or in connection with any Loan Document. 3.2 This Amendment shall be construed in connection with and as part of the  Loan Documents and all terms, conditions, representations, warranties, covenants and agreements  set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed and  shall remain in full force and effect. 4. Representations and Warranties.  To induce Bank to enter into this Amendment,  Co-Borrowers hereby represent and warrant to Bank as follows: 4.1 Immediately after giving effect to this Amendment (a) the representations  and warranties contained in the Loan Documents are true, accurate and complete in all material  respects as of the date hereof (except to the extent such representations and warranties relate to an  earlier date, in which case they are true and correct as of such date), and (b) no Event of Default  has occurred and is continuing; 4.2 Co-Borrowers have the power and authority to execute and deliver this  Amendment and to perform its obligations under the Loan Agreement, as amended by this  Amendment; 4.3 Except as has been delivered to Bank pursuant to Section 6.2(e), the  organizational documents of each Co-Borrower delivered to Bank on the Effective Date remain  true, accurate and complete and have not been amended, supplemented or restated and are and  continue to be in full force and effect;   </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- svb-firstamendmenttoloan004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="svb-firstamendmenttoloan004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">4   4.4 The execution and delivery by Co-Borrowers of this Amendment and the  performance by Co-Borrowers of its obligations under the Loan Agreement, as amended by this  Amendment, have been duly authorized;   4.5 The execution and delivery by Co-Borrowers of this Amendment and the  performance by Co-Borrowers of its obligations under the Loan Agreement, as amended by this  Amendment, do not and will not contravene (a) any material law or regulation binding on or  affecting Co-Borrowers, (b) any material contractual restriction with a Person binding on Co- Borrowers, (c) any order, judgment or decree of any court or other governmental or public body  or authority, or subdivision thereof, binding on Co-Borrowers, or (d) the organizational documents  of Co-Borrowers;  4.6 The execution and delivery by Co-Borrowers of this Amendment and the  performance by Co-Borrowers of its obligations under the Loan Agreement, as amended by this  Amendment, do not require any order, consent, approval, license, authorization or validation of,  or filing, recording or registration with, or exemption by any governmental or public body or  authority, or subdivision thereof, binding on Co-Borrowers, except as already has been obtained  or made; and 4.7 This Amendment has been duly executed and delivered by Co-Borrowers  and is the binding obligation of Co-Borrowers, enforceable against Co-Borrowers in accordance  with its terms, except as such enforceability may be limited by bankruptcy, insolvency,  reorganization, liquidation, moratorium or other similar laws of general application and equitable  principles relating to or affecting creditors&#8217; rights. 5. [Reserved].   6. Integration.  This Amendment and the Loan Documents represent the entire  agreement about this subject matter and supersede prior negotiations or agreements.  All prior  agreements, understandings, representations, warranties, and negotiations between the parties  about the subject matter of this Amendment and the Loan Documents merge into this Amendment  and the Loan Documents. 7. Counterparts.  This Amendment may be executed in any number of counterparts  and all of such counterparts taken together shall be deemed to constitute one and the same  instrument. 8. Effectiveness.  This Amendment shall be deemed effective upon (a) the due  execution and delivery to Bank of this Amendment by each party hereto and (b) Co-Borrowers&#8217;  payment of Bank&#8217;s legal fees and expenses incurred in connection with this Amendment. [Signature page follows.] </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- svb-firstamendmenttoloan005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="svb-firstamendmenttoloan005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly  executed and delivered as of the date first written above. BANK: SILICON VALLEY BANK By:   Name:   Title:   BORROWER: VERONA PHARMA, INC. By:   Name:   Title:   Executed as a deed, but not delivered until  the first date specified on page 1 by  VERONA PHARMA PLC. acting by: By Name: Title: Director Witness signature: Witness name: Witness address:  ___________________________________ ____________________________________ ____________________________________ </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>consentletter-fy20vrp_sx4x.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if95abd984746410b94b94161ac7e8483_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-248199, 333-237926, 333-217521) of Verona Pharma Plc of our report dated February 25, 2021 relating to the financial statements, which appears in this Form 10-K.</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font><br></font></div><div><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; PricewaterhouseCoopers LLP</font></div><div><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">Reading, United Kingdom</font></div><div><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">February 25, 2021</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic921f44cab384a26a8060652be4283b8_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David Zaccardelli, Pharm.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Verona Pharma plc&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in&#160;Exchange Act Rules 13a-15(e)&#160;and&#160;15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February 25, 2021</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47;&#160;David Zaccardelli, Pharm.D.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David Zaccardelli, Pharm.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(principal executive officer)</font></div></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ibcc986832ffc4a42ac2ed1aa3da31206_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark W. Hahn, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Verona Pharma plc&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in&#160;Exchange Act Rules 13a-15(e)&#160;and&#160;15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February 25, 2021</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47;&#160;Mark W. Hahn</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mark W. Hahn</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">principal financial officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i744097b5dd1a4f0cbdda457a34f19503_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Verona Pharma plc (the &#8220;Company&#8221;) for the period ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.457%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February 25, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; David Zaccardelli, Pharm.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David Zaccardelli, Pharm.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">principal executive officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>exhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i38bba2ad64834e41be2c62184623f0d7_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Verona Pharma plc (the &#8220;Company&#8221;) for the period ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.457%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February 25, 2021</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47;&#160;Mark W. Hahn</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mark W. Hahn</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">principal financial officer)</font></div></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>vrna-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0ccc0c69-9480-4ff0-8704-1a461378680d,g:39118e12-eba9-4fb3-8b93-ef28b95cf059-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vrna="http://veronapharma.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://veronapharma.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrna-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrna-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrna-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrna-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://veronapharma.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersEquity" roleURI="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity">
        <link:definition>1004005 - Statement - Consolidated Statements of Shareholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organizationanddescriptionofbusinessoperations" roleURI="http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations">
        <link:definition>2101101 - Disclosure - Organization and description of business operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationConsolidationandPresentationofFinancialStatementsDetails" roleURI="http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails">
        <link:definition>2402401 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingpolicies" roleURI="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpolicies">
        <link:definition>2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies" roleURI="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies">
        <link:definition>2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails" roleURI="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails">
        <link:definition>2405402 - Disclosure - Basis of Presentation and Summary of Significant Accounting policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Prepaidexpenses" roleURI="http://veronapharma.com/role/Prepaidexpenses">
        <link:definition>2106103 - Disclosure - Prepaid expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidexpensesTables" roleURI="http://veronapharma.com/role/PrepaidexpensesTables">
        <link:definition>2307301 - Disclosure - Prepaid expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidexpensesDetails" roleURI="http://veronapharma.com/role/PrepaidexpensesDetails">
        <link:definition>2408403 - Disclosure - Prepaid expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Taxandtaxincentivereceivable" roleURI="http://veronapharma.com/role/Taxandtaxincentivereceivable">
        <link:definition>2109104 - Disclosure - Tax and tax incentive receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxandtaxincentivereceivableTables" roleURI="http://veronapharma.com/role/TaxandtaxincentivereceivableTables">
        <link:definition>2310302 - Disclosure - Tax and tax incentive receivable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxandtaxincentivereceivableDetails" roleURI="http://veronapharma.com/role/TaxandtaxincentivereceivableDetails">
        <link:definition>2411404 - Disclosure - Tax and tax incentive receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Propertyleases" roleURI="http://veronapharma.com/role/Propertyleases">
        <link:definition>2112105 - Disclosure - Property leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyleasesTables" roleURI="http://veronapharma.com/role/PropertyleasesTables">
        <link:definition>2313303 - Disclosure - Property leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyleasesNarrativeDetails" roleURI="http://veronapharma.com/role/PropertyleasesNarrativeDetails">
        <link:definition>2414405 - Disclosure - Property leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyleasesMaturityDetails" roleURI="http://veronapharma.com/role/PropertyleasesMaturityDetails">
        <link:definition>2415406 - Disclosure - Property leases - Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyleasesMaturityDetails_1" roleURI="http://veronapharma.com/role/PropertyleasesMaturityDetails_1">
        <link:definition>2415406 - Disclosure - Property leases - Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyleasesMaturityUnderASC840Details" roleURI="http://veronapharma.com/role/PropertyleasesMaturityUnderASC840Details">
        <link:definition>2416407 - Disclosure - Property leases Maturity Under ASC 840 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Accruedexpenses" roleURI="http://veronapharma.com/role/Accruedexpenses">
        <link:definition>2117106 - Disclosure - Accrued expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedexpensesTables" roleURI="http://veronapharma.com/role/AccruedexpensesTables">
        <link:definition>2318304 - Disclosure - Accrued expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedexpensesDetails" roleURI="http://veronapharma.com/role/AccruedexpensesDetails">
        <link:definition>2419408 - Disclosure - Accrued expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Warrants" roleURI="http://veronapharma.com/role/Warrants">
        <link:definition>2120107 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsTables" roleURI="http://veronapharma.com/role/WarrantsTables">
        <link:definition>2321305 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsNarrativeDetails" roleURI="http://veronapharma.com/role/WarrantsNarrativeDetails">
        <link:definition>2422409 - Disclosure - Warrants - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsFairValueAssumptionsDetails" roleURI="http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails">
        <link:definition>2423410 - Disclosure - Warrants - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsMovementinValueDetails" roleURI="http://veronapharma.com/role/WarrantsMovementinValueDetails">
        <link:definition>2424411 - Disclosure - Warrants - Movement in Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsEffectofChangeinVolatilityDetails" roleURI="http://veronapharma.com/role/WarrantsEffectofChangeinVolatilityDetails">
        <link:definition>2425412 - Disclosure - Warrants - Effect of Change in Volatility (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Termloan" roleURI="http://veronapharma.com/role/Termloan">
        <link:definition>2126108 - Disclosure - Term loan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TermloanDetails" roleURI="http://veronapharma.com/role/TermloanDetails">
        <link:definition>2427413 - Disclosure - Term loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Benefitplans" roleURI="http://veronapharma.com/role/Benefitplans">
        <link:definition>2128109 - Disclosure - Benefit plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BenefitplansDetails" roleURI="http://veronapharma.com/role/BenefitplansDetails">
        <link:definition>2429414 - Disclosure - Benefit plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Taxation" roleURI="http://veronapharma.com/role/Taxation">
        <link:definition>2130110 - Disclosure - Taxation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxationTables" roleURI="http://veronapharma.com/role/TaxationTables">
        <link:definition>2331306 - Disclosure - Taxation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxationLossBeforeTaxDetails" roleURI="http://veronapharma.com/role/TaxationLossBeforeTaxDetails">
        <link:definition>2432415 - Disclosure - Taxation - Loss Before Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxationTaxExpenseBenefitDetails" roleURI="http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails">
        <link:definition>2433416 - Disclosure - Taxation - Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxationReconciliationofStatutoryRateDetails" roleURI="http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails">
        <link:definition>2434417 - Disclosure - Taxation - Reconciliation of Statutory Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxationDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>2435418 - Disclosure - Taxation - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxationNarrativeDetails" roleURI="http://veronapharma.com/role/TaxationNarrativeDetails">
        <link:definition>2436419 - Disclosure - Taxation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Sharebasedcompensation" roleURI="http://veronapharma.com/role/Sharebasedcompensation">
        <link:definition>2137111 - Disclosure - Share based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationTables" roleURI="http://veronapharma.com/role/SharebasedcompensationTables">
        <link:definition>2338307 - Disclosure - Share based compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationShareBasedCompensationExpenseDetails" roleURI="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails">
        <link:definition>2439420 - Disclosure - Share based compensation - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationNarrativeDetails" roleURI="http://veronapharma.com/role/SharebasedcompensationNarrativeDetails">
        <link:definition>2440421 - Disclosure - Share based compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationShareOptionActivityDetails" roleURI="http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails">
        <link:definition>2441422 - Disclosure - Share based compensation - Share Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationWeightedAverageAssumptionsDetails" roleURI="http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails">
        <link:definition>2442423 - Disclosure - Share based compensation - Weighted-Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationRSUActivityDetails" roleURI="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails">
        <link:definition>2443424 - Disclosure - Share based compensation - RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Netlosspershare" roleURI="http://veronapharma.com/role/Netlosspershare">
        <link:definition>2144112 - Disclosure - Net loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetlosspershareTables" roleURI="http://veronapharma.com/role/NetlosspershareTables">
        <link:definition>2345308 - Disclosure - Net loss per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetlosspershareComputationDetails" roleURI="http://veronapharma.com/role/NetlosspershareComputationDetails">
        <link:definition>2446425 - Disclosure - Net loss per share - Computation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Relatedpartytransactionsandothershareholdermatters" roleURI="http://veronapharma.com/role/Relatedpartytransactionsandothershareholdermatters">
        <link:definition>2147113 - Disclosure - Related party transactions and other shareholder matters</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartytransactionsandothershareholdermattersTables" roleURI="http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersTables">
        <link:definition>2348309 - Disclosure - Related party transactions and other shareholder matters (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartytransactionsandothershareholdermattersDetails" roleURI="http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails">
        <link:definition>2449426 - Disclosure - Related party transactions and other shareholder matters (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="vrna_DrEbsworthMember" abstract="true" name="DrEbsworthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vrna_DebtInstrumentEarlyRepaymentPenaltyPercent" abstract="false" name="DebtInstrumentEarlyRepaymentPenaltyPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vrna_PrepaidExpenseDisclosureTextBlock" abstract="false" name="PrepaidExpenseDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="vrna_EMIOptionPlanMember" abstract="true" name="EMIOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vrna_DeferredTaxLiabilitiesContingentLiability" abstract="false" name="DeferredTaxLiabilitiesContingentLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited" abstract="false" name="ClassOfWarrantOrRightNumberOfExercisedOrForfeited" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vrna_RestrictedStockUnitTimeBasedVestingMember" abstract="true" name="RestrictedStockUnitTimeBasedVestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vrna_DebtPrepaymentPeriodOneMember" abstract="true" name="DebtPrepaymentPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vrna_UnrealizedGainLossOnWarrants" abstract="false" name="UnrealizedGainLossOnWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_OrganizationAndBusinessDescriptionTextBlock" abstract="false" name="OrganizationAndBusinessDescriptionTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="vrna_FairValueImpactOfIncreaseOrDecreaseInVolatilityTableTextBlock" abstract="false" name="FairValueImpactOfIncreaseOrDecreaseInVolatilityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="vrna_DrEdwardsMember" abstract="true" name="DrEdwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vrna_DebtInstrumentEarlyRepaymentPenaltyAmount" abstract="false" name="DebtInstrumentEarlyRepaymentPenaltyAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates" abstract="false" name="SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_PreIPOOptionPlanMember" abstract="true" name="PreIPOOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent" abstract="false" name="ResearchAndDevelopmentTaxCreditReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_LondonMember" abstract="true" name="LondonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vrna_StockIssuedDuringPeriodSharesHeldInTreasury" abstract="false" name="StockIssuedDuringPeriodSharesHeldInTreasury" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate" abstract="false" name="SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_DebtPrepaymentPeriodAxis" abstract="true" name="DebtPrepaymentPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="vrna_GovernmentTaxCreditsPolicyPolicyTextBlock" abstract="false" name="GovernmentTaxCreditsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="vrna_ClassOfWarrantOrRightIntrinsicValue" abstract="false" name="ClassOfWarrantOrRightIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_WarrantAndRightsDisclosureTextBlock" abstract="false" name="WarrantAndRightsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="vrna_WarrantLiabilityFairValue" abstract="false" name="WarrantLiabilityFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_A2017IncentivePlanMember" abstract="true" name="A2017IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vrna_DirectorOrOfficerMember" abstract="true" name="DirectorOrOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" abstract="false" name="IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_NumberOfWhollyOwnedSubsidiaries" abstract="false" name="NumberOfWhollyOwnedSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vrna_DebtPrepaymentPeriodThreeMember" abstract="true" name="DebtPrepaymentPeriodThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vrna_DebtPrepaymentPeriodTwoMember" abstract="true" name="DebtPrepaymentPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vrna_DebtInstrumentPrepaymentTermOfPriorWrittenNotice" abstract="false" name="DebtInstrumentPrepaymentTermOfPriorWrittenNotice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vrna_DebtInstrumentCovenantCashAndCashEquivalentsMinimum" abstract="false" name="DebtInstrumentCovenantCashAndCashEquivalentsMinimum" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_DebtPrepaymentPeriodDomain" abstract="true" name="DebtPrepaymentPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vrna_TermLoanFacilityMember" abstract="true" name="TermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vrna_MrSinhaMember" abstract="true" name="MrSinhaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage" abstract="false" name="DebtInstrumentDebtDefaultInterestRateStatedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="vrna_ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare" abstract="false" name="ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="vrna_DrZaccardelliMember" abstract="true" name="DrZaccardelliMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vrna_TermCLoanMember" abstract="true" name="TermCLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vrna_DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold" abstract="false" name="DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate" abstract="false" name="SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_ScheduleOfNontradeReceivablesTableTextBlock" abstract="false" name="ScheduleOfNontradeReceivablesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="vrna_MrHahnMember" abstract="true" name="MrHahnMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vrna_StockIssuedDuringPeriodValueHeldInTreasury" abstract="false" name="StockIssuedDuringPeriodValueHeldInTreasury" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_RestrictedStockUnitMilestoneBasedVestingMember" abstract="true" name="RestrictedStockUnitMilestoneBasedVestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vrna_SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments" abstract="false" name="SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_MeasurementInputAnnualizedVolatilityMember" abstract="true" name="MeasurementInputAnnualizedVolatilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" abstract="false" name="AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance" abstract="false" name="SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_TermBLoanMember" abstract="true" name="TermBLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vrna_DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness" abstract="false" name="DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_GainLossFromResearchAndDevelopmentTaxCredit" abstract="false" name="GainLossFromResearchAndDevelopmentTaxCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_PrepaidResearchAndDevelopmentFeesCurrent" abstract="false" name="PrepaidResearchAndDevelopmentFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_DrUllmanMember" abstract="true" name="DrUllmanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vrna_AccruedResearchAndDevelopmentFeesCurrent" abstract="false" name="AccruedResearchAndDevelopmentFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_DebtInstrumentFinalPaymentPercent" abstract="false" name="DebtInstrumentFinalPaymentPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares" abstract="false" name="StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vrna_ConsultancyServicesMember" abstract="true" name="ConsultancyServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vrna_TaxCreditAndIncomeTaxesReceivableCurrent" abstract="false" name="TaxCreditAndIncomeTaxesReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vrna_WarrantLiabilityCurrent" abstract="false" name="WarrantLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>vrna-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0ccc0c69-9480-4ff0-8704-1a461378680d,g:39118e12-eba9-4fb3-8b93-ef28b95cf059-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://veronapharma.com/role/Cover" xlink:type="simple" xlink:href="vrna-20201231.xsd#Cover"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vrna-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_96eb12fc-060b-4570-b6f8-a238e6b79b56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_36e39fd5-1b54-4fa2-a64a-0a82b9bd1eb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_96eb12fc-060b-4570-b6f8-a238e6b79b56" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_36e39fd5-1b54-4fa2-a64a-0a82b9bd1eb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a98c03b1-c7d9-4fcf-a0c1-f080ed9001d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_96eb12fc-060b-4570-b6f8-a238e6b79b56" xlink:to="loc_us-gaap_Goodwill_a98c03b1-c7d9-4fcf-a0c1-f080ed9001d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1f2dd137-96cc-4df8-81ff-500b0884db68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_96eb12fc-060b-4570-b6f8-a238e6b79b56" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1f2dd137-96cc-4df8-81ff-500b0884db68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_81020e6b-506a-4ca8-8962-d228727c4b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e7878a41-7465-4571-94d3-9256259104e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_81020e6b-506a-4ca8-8962-d228727c4b9e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e7878a41-7465-4571-94d3-9256259104e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_554f930a-5f67-40df-af95-03ee440d3a92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_81020e6b-506a-4ca8-8962-d228727c4b9e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_554f930a-5f67-40df-af95-03ee440d3a92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_a7a5c5ae-fabf-4d48-9fbb-37e9b01cf680" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_81020e6b-506a-4ca8-8962-d228727c4b9e" xlink:to="loc_us-gaap_TreasuryStockValue_a7a5c5ae-fabf-4d48-9fbb-37e9b01cf680" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d69294bb-8ce2-43af-a565-d034adbde3a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_81020e6b-506a-4ca8-8962-d228727c4b9e" xlink:to="loc_us-gaap_CommonStockValue_d69294bb-8ce2-43af-a565-d034adbde3a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_090b5ce8-7cb8-465a-9ef9-d5a00f3f17e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_81020e6b-506a-4ca8-8962-d228727c4b9e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_090b5ce8-7cb8-465a-9ef9-d5a00f3f17e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f78a875a-2d15-40fd-886a-f9c65f394434" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_57d06383-6b84-4e2b-ab23-0a3422957e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f78a875a-2d15-40fd-886a-f9c65f394434" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_57d06383-6b84-4e2b-ab23-0a3422957e5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_df140f68-83db-4b7f-9fde-6cfa2df13cae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f78a875a-2d15-40fd-886a-f9c65f394434" xlink:to="loc_us-gaap_OtherAssetsCurrent_df140f68-83db-4b7f-9fde-6cfa2df13cae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_1e73a2e2-a79c-455e-94d5-42fb63c960d5" xlink:href="vrna-20201231.xsd#vrna_TaxCreditAndIncomeTaxesReceivableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f78a875a-2d15-40fd-886a-f9c65f394434" xlink:to="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_1e73a2e2-a79c-455e-94d5-42fb63c960d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_bcd6424f-ef39-4c05-95d8-d7d0f49c0ef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f78a875a-2d15-40fd-886a-f9c65f394434" xlink:to="loc_us-gaap_ShortTermInvestments_bcd6424f-ef39-4c05-95d8-d7d0f49c0ef7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_42c5c0f5-9f71-40c0-bc93-1088d28e8731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f78a875a-2d15-40fd-886a-f9c65f394434" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_42c5c0f5-9f71-40c0-bc93-1088d28e8731" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f9d0493b-a880-48df-9741-440765648efb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4bbbaba3-2288-4300-bc0e-4a281881f639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f9d0493b-a880-48df-9741-440765648efb" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_4bbbaba3-2288-4300-bc0e-4a281881f639" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_WarrantLiabilityCurrent_158c11bd-5be4-48cd-bc5a-d6d91404cd66" xlink:href="vrna-20201231.xsd#vrna_WarrantLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f9d0493b-a880-48df-9741-440765648efb" xlink:to="loc_vrna_WarrantLiabilityCurrent_158c11bd-5be4-48cd-bc5a-d6d91404cd66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_24d1aa8c-511e-4e95-b328-fd133c7e2bc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f9d0493b-a880-48df-9741-440765648efb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_24d1aa8c-511e-4e95-b328-fd133c7e2bc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6a29ff38-4ef1-4728-9b88-855ce2d25f7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f9d0493b-a880-48df-9741-440765648efb" xlink:to="loc_us-gaap_AccountsPayableCurrent_6a29ff38-4ef1-4728-9b88-855ce2d25f7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f4811c04-b297-454c-98e0-a52cc1a02897" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f9d0493b-a880-48df-9741-440765648efb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f4811c04-b297-454c-98e0-a52cc1a02897" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_9a6822e7-9331-49b4-b86f-749a3cb3af10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2220355e-029f-409d-ae85-1f3c1c68475b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_9a6822e7-9331-49b4-b86f-749a3cb3af10" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2220355e-029f-409d-ae85-1f3c1c68475b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0e0f283f-84f3-4003-95ba-d20672b23cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_9a6822e7-9331-49b4-b86f-749a3cb3af10" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0e0f283f-84f3-4003-95ba-d20672b23cdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_99656372-3120-4a9a-8116-276cb9c367f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_32a6810d-6660-4ae6-9a21-bfa0e7d364f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_99656372-3120-4a9a-8116-276cb9c367f0" xlink:to="loc_us-gaap_AssetsNoncurrent_32a6810d-6660-4ae6-9a21-bfa0e7d364f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7dd4a587-e63a-4e88-8ad2-a824c6bc1617" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_99656372-3120-4a9a-8116-276cb9c367f0" xlink:to="loc_us-gaap_AssetsCurrent_7dd4a587-e63a-4e88-8ad2-a824c6bc1617" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_229dd18e-17e9-4dcb-a976-ee4966600e76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_46b1f315-8154-40a1-a7b3-50345336569a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_229dd18e-17e9-4dcb-a976-ee4966600e76" xlink:to="loc_us-gaap_Liabilities_46b1f315-8154-40a1-a7b3-50345336569a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2ed344ca-803a-432a-8f9f-24611841b38f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_229dd18e-17e9-4dcb-a976-ee4966600e76" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2ed344ca-803a-432a-8f9f-24611841b38f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ad37b6b8-18eb-4592-a0c5-13ada31ad4b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_229dd18e-17e9-4dcb-a976-ee4966600e76" xlink:to="loc_us-gaap_StockholdersEquity_ad37b6b8-18eb-4592-a0c5-13ada31ad4b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a0ff380b-950c-41b0-af78-400244e65d37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_b9dc316c-aeb3-4a1a-a570-8aec0aec7954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a0ff380b-950c-41b0-af78-400244e65d37" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_b9dc316c-aeb3-4a1a-a570-8aec0aec7954" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3766d8a7-54c7-47a8-9446-5b24f7f662b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a0ff380b-950c-41b0-af78-400244e65d37" xlink:to="loc_us-gaap_LiabilitiesCurrent_3766d8a7-54c7-47a8-9446-5b24f7f662b3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="vrna-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="vrna-20201231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_17ed015b-5fe5-47c5-9906-6bf9a2280c8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ccc425a6-22d6-4c6c-abfa-14314c7f17ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_17ed015b-5fe5-47c5-9906-6bf9a2280c8f" xlink:to="loc_us-gaap_OperatingExpenses_ccc425a6-22d6-4c6c-abfa-14314c7f17ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1456d4b7-cec1-4960-bd54-b99947dca9aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e2c1b747-024b-4541-b391-f900c282b07c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1456d4b7-cec1-4960-bd54-b99947dca9aa" xlink:to="loc_us-gaap_NetIncomeLoss_e2c1b747-024b-4541-b391-f900c282b07c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4cc5f150-1c1a-49be-8516-317a983b8c51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1456d4b7-cec1-4960-bd54-b99947dca9aa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4cc5f150-1c1a-49be-8516-317a983b8c51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9ad978af-877d-49ca-a77b-3041482bedb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_962ac156-b0cc-4be6-af0d-f25ae996fd4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_9ad978af-877d-49ca-a77b-3041482bedb7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_962ac156-b0cc-4be6-af0d-f25ae996fd4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b9417b37-7819-4949-a048-859defc99574" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_9ad978af-877d-49ca-a77b-3041482bedb7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b9417b37-7819-4949-a048-859defc99574" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3da5f86c-eff7-4269-b4e5-243e709d212f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0f96299d-ddd9-4f8e-a5db-5d7c98014594" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3da5f86c-eff7-4269-b4e5-243e709d212f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0f96299d-ddd9-4f8e-a5db-5d7c98014594" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_40b333d5-6cae-476c-941b-10f828964fc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3da5f86c-eff7-4269-b4e5-243e709d212f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_40b333d5-6cae-476c-941b-10f828964fc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1650d6b2-604e-46e4-bdfc-2889da3dacb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_22e84001-fc71-4ffe-9e85-bdba6c2e8b07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1650d6b2-604e-46e4-bdfc-2889da3dacb6" xlink:to="loc_us-gaap_InvestmentIncomeNet_22e84001-fc71-4ffe-9e85-bdba6c2e8b07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit_a30ec71f-16e2-487d-bee1-5cc76da5c939" xlink:href="vrna-20201231.xsd#vrna_GainLossFromResearchAndDevelopmentTaxCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1650d6b2-604e-46e4-bdfc-2889da3dacb6" xlink:to="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit_a30ec71f-16e2-487d-bee1-5cc76da5c939" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_UnrealizedGainLossOnWarrants_79b401ef-3b4d-41fc-9087-1f0195509a96" xlink:href="vrna-20201231.xsd#vrna_UnrealizedGainLossOnWarrants"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1650d6b2-604e-46e4-bdfc-2889da3dacb6" xlink:to="loc_vrna_UnrealizedGainLossOnWarrants_79b401ef-3b4d-41fc-9087-1f0195509a96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9459772f-3a5a-44d6-aea1-fb173f160478" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1650d6b2-604e-46e4-bdfc-2889da3dacb6" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9459772f-3a5a-44d6-aea1-fb173f160478" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_30df2573-4ff9-4c5f-aa3d-1241bdc67b5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1650d6b2-604e-46e4-bdfc-2889da3dacb6" xlink:to="loc_us-gaap_InterestExpense_30df2573-4ff9-4c5f-aa3d-1241bdc67b5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_300896d4-cfa2-4328-aa5e-c31f10f24b03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6b8b270c-5bf6-4ba7-aa32-0c6925a73984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_300896d4-cfa2-4328-aa5e-c31f10f24b03" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6b8b270c-5bf6-4ba7-aa32-0c6925a73984" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_21b257b2-e43c-463f-956c-998be2bbc32f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_300896d4-cfa2-4328-aa5e-c31f10f24b03" xlink:to="loc_us-gaap_OperatingIncomeLoss_21b257b2-e43c-463f-956c-998be2bbc32f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="vrna-20201231.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="vrna-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1f07c8ab-3e74-4bce-b765-695c1de0dc03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d0b1031-141c-4964-b725-91bf9b9ddba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1f07c8ab-3e74-4bce-b765-695c1de0dc03" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d0b1031-141c-4964-b725-91bf9b9ddba6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_af550548-60b6-46e3-92b8-8bd46090c9a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1f07c8ab-3e74-4bce-b765-695c1de0dc03" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_af550548-60b6-46e3-92b8-8bd46090c9a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b653bc38-a350-4a8c-ac07-c846b6ff52af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1f07c8ab-3e74-4bce-b765-695c1de0dc03" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b653bc38-a350-4a8c-ac07-c846b6ff52af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_02f600f1-fe82-4a79-9424-02d72731ffc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1f07c8ab-3e74-4bce-b765-695c1de0dc03" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_02f600f1-fe82-4a79-9424-02d72731ffc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4ad566b3-cfcc-4406-a0b2-fa1f96fb8653" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_eb6271f7-80a5-4991-a276-c616d3f717ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4ad566b3-cfcc-4406-a0b2-fa1f96fb8653" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_eb6271f7-80a5-4991-a276-c616d3f717ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_8ae18a25-626f-46aa-91be-38979df8ca86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4ad566b3-cfcc-4406-a0b2-fa1f96fb8653" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_8ae18a25-626f-46aa-91be-38979df8ca86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b16f947f-fb4e-4c57-9a3a-7c1e0d188e3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4ad566b3-cfcc-4406-a0b2-fa1f96fb8653" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b16f947f-fb4e-4c57-9a3a-7c1e0d188e3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7c8016ca-79a4-465e-b788-f71a4e97ff64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_461c9dce-4da7-4b74-868e-1b9e22483280" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7c8016ca-79a4-465e-b788-f71a4e97ff64" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_461c9dce-4da7-4b74-868e-1b9e22483280" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_cfb455cd-5d25-4264-83ad-2caf7017c815" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7c8016ca-79a4-465e-b788-f71a4e97ff64" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_cfb455cd-5d25-4264-83ad-2caf7017c815" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_62de0c79-7264-44fa-8dba-e7bec2a0816d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7c8016ca-79a4-465e-b788-f71a4e97ff64" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_62de0c79-7264-44fa-8dba-e7bec2a0816d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6e63a752-46d3-4dff-b800-1ba873959741" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7c8016ca-79a4-465e-b788-f71a4e97ff64" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_6e63a752-46d3-4dff-b800-1ba873959741" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_55c0b54a-5b1f-48e0-a9bc-99e1b7a39211" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7c8016ca-79a4-465e-b788-f71a4e97ff64" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_55c0b54a-5b1f-48e0-a9bc-99e1b7a39211" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59529e9d-2844-4855-9962-6cb9e8fb05c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_d71daba6-3759-4741-8a42-d65fb0b7ebfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59529e9d-2844-4855-9962-6cb9e8fb05c5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_d71daba6-3759-4741-8a42-d65fb0b7ebfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_3bd1d084-e2af-4ee5-bfe4-675eff8a3a9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59529e9d-2844-4855-9962-6cb9e8fb05c5" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_3bd1d084-e2af-4ee5-bfe4-675eff8a3a9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_f85b09a5-bea6-427d-b4bd-94651cb508bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59529e9d-2844-4855-9962-6cb9e8fb05c5" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_f85b09a5-bea6-427d-b4bd-94651cb508bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_12adfa2c-1303-4944-8251-c2f62725b226" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59529e9d-2844-4855-9962-6cb9e8fb05c5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_12adfa2c-1303-4944-8251-c2f62725b226" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_3afeb180-8cd3-4b54-90b4-28673c6ec327" xlink:href="vrna-20201231.xsd#vrna_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59529e9d-2844-4855-9962-6cb9e8fb05c5" xlink:to="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_3afeb180-8cd3-4b54-90b4-28673c6ec327" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_755e2f3c-4975-479c-82ba-23c1dab2dd82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59529e9d-2844-4855-9962-6cb9e8fb05c5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_755e2f3c-4975-479c-82ba-23c1dab2dd82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_417dc4f9-863f-42a4-a331-b72cf129d920" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59529e9d-2844-4855-9962-6cb9e8fb05c5" xlink:to="loc_us-gaap_ShareBasedCompensation_417dc4f9-863f-42a4-a331-b72cf129d920" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_a6440a39-f409-4d51-8f4b-3275967f638e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59529e9d-2844-4855-9962-6cb9e8fb05c5" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_a6440a39-f409-4d51-8f4b-3275967f638e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_27ef2df7-3b08-4d48-ac62-2c78c83afa57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59529e9d-2844-4855-9962-6cb9e8fb05c5" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_27ef2df7-3b08-4d48-ac62-2c78c83afa57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_1ffc7167-d7bb-4b25-be48-acb16121fc70" xlink:href="vrna-20201231.xsd#vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59529e9d-2844-4855-9962-6cb9e8fb05c5" xlink:to="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_1ffc7167-d7bb-4b25-be48-acb16121fc70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_13c027c0-62fa-4818-a487-f78a3bd2e720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59529e9d-2844-4855-9962-6cb9e8fb05c5" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_13c027c0-62fa-4818-a487-f78a3bd2e720" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_54bf55bb-2bd7-4852-b401-f541f565804f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59529e9d-2844-4855-9962-6cb9e8fb05c5" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_54bf55bb-2bd7-4852-b401-f541f565804f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b90e4300-0495-4a87-98a3-8583be1312af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59529e9d-2844-4855-9962-6cb9e8fb05c5" xlink:to="loc_us-gaap_NetIncomeLoss_b90e4300-0495-4a87-98a3-8583be1312af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_8bd4d673-2934-407a-802d-1ee52d4e1783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59529e9d-2844-4855-9962-6cb9e8fb05c5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_8bd4d673-2934-407a-802d-1ee52d4e1783" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_bba17b7a-a533-4532-acdb-b04a123c4837" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59529e9d-2844-4855-9962-6cb9e8fb05c5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_bba17b7a-a533-4532-acdb-b04a123c4837" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_7238a528-e7cc-43fa-b4a9-5fba848f2c3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59529e9d-2844-4855-9962-6cb9e8fb05c5" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_7238a528-e7cc-43fa-b4a9-5fba848f2c3e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations" xlink:type="simple" xlink:href="vrna-20201231.xsd#Organizationanddescriptionofbusinessoperations"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#OrganizationConsolidationandPresentationofFinancialStatementsDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpolicies" xlink:type="simple" xlink:href="vrna-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingpolicies"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies" xlink:type="simple" xlink:href="vrna-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/Prepaidexpenses" xlink:type="simple" xlink:href="vrna-20201231.xsd#Prepaidexpenses"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/Prepaidexpenses" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/PrepaidexpensesTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#PrepaidexpensesTables"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/PrepaidexpensesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/PrepaidexpensesDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#PrepaidexpensesDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/PrepaidexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_bf4450ff-c7c0-4240-b4bc-b7cbd7b3e67f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_65b1827a-0c91-465b-9e23-caeb461f7fc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_bf4450ff-c7c0-4240-b4bc-b7cbd7b3e67f" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_65b1827a-0c91-465b-9e23-caeb461f7fc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PrepaidResearchAndDevelopmentFeesCurrent_a9222e40-23cf-4d21-a853-000c8ba244fa" xlink:href="vrna-20201231.xsd#vrna_PrepaidResearchAndDevelopmentFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_bf4450ff-c7c0-4240-b4bc-b7cbd7b3e67f" xlink:to="loc_vrna_PrepaidResearchAndDevelopmentFeesCurrent_a9222e40-23cf-4d21-a853-000c8ba244fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_e1fff444-8bf0-47fc-b774-b6c1a2854e9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_bf4450ff-c7c0-4240-b4bc-b7cbd7b3e67f" xlink:to="loc_us-gaap_PrepaidInsurance_e1fff444-8bf0-47fc-b774-b6c1a2854e9e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Taxandtaxincentivereceivable" xlink:type="simple" xlink:href="vrna-20201231.xsd#Taxandtaxincentivereceivable"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/Taxandtaxincentivereceivable" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxandtaxincentivereceivableTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#TaxandtaxincentivereceivableTables"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/TaxandtaxincentivereceivableTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxandtaxincentivereceivableDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#TaxandtaxincentivereceivableDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/TaxandtaxincentivereceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_fedf0466-1ac8-4909-886f-741f011b09da" xlink:href="vrna-20201231.xsd#vrna_TaxCreditAndIncomeTaxesReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent_aa4f523b-2065-4022-b1d2-58aa6deda7ea" xlink:href="vrna-20201231.xsd#vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_fedf0466-1ac8-4909-886f-741f011b09da" xlink:to="loc_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent_aa4f523b-2065-4022-b1d2-58aa6deda7ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_35b19046-7eb0-4613-91f9-56160b7670e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_fedf0466-1ac8-4909-886f-741f011b09da" xlink:to="loc_us-gaap_IncomeTaxesReceivable_35b19046-7eb0-4613-91f9-56160b7670e7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Propertyleases" xlink:type="simple" xlink:href="vrna-20201231.xsd#Propertyleases"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/Propertyleases" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/PropertyleasesTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#PropertyleasesTables"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/PropertyleasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/PropertyleasesNarrativeDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#PropertyleasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/PropertyleasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/PropertyleasesMaturityDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#PropertyleasesMaturityDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/PropertyleasesMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7a007954-41f5-4f38-9f71-9b9e789680c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c7b995b0-a851-4820-824b-2078f241d80d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7a007954-41f5-4f38-9f71-9b9e789680c9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c7b995b0-a851-4820-824b-2078f241d80d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_deaf8e9a-d8a5-4ae4-9858-2e3c3b642202" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7a007954-41f5-4f38-9f71-9b9e789680c9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_deaf8e9a-d8a5-4ae4-9858-2e3c3b642202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_12518ad1-56ba-4129-8f5d-5e8cbba8d9aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7a007954-41f5-4f38-9f71-9b9e789680c9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_12518ad1-56ba-4129-8f5d-5e8cbba8d9aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9cea8cab-e8b3-4972-9a7b-f7608ff6c5d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7a007954-41f5-4f38-9f71-9b9e789680c9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9cea8cab-e8b3-4972-9a7b-f7608ff6c5d0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/PropertyleasesMaturityDetails_1" xlink:type="simple" xlink:href="vrna-20201231.xsd#PropertyleasesMaturityDetails_1"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/PropertyleasesMaturityDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_03be0b11-2d3f-40a6-917d-fecbac05e2b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1b29d3be-d0e5-4567-a03e-d25786802ed5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_03be0b11-2d3f-40a6-917d-fecbac05e2b9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1b29d3be-d0e5-4567-a03e-d25786802ed5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_68bf7809-9979-47de-9534-7e4273feaf98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_03be0b11-2d3f-40a6-917d-fecbac05e2b9" xlink:to="loc_us-gaap_OperatingLeaseLiability_68bf7809-9979-47de-9534-7e4273feaf98" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/PropertyleasesMaturityUnderASC840Details" xlink:type="simple" xlink:href="vrna-20201231.xsd#PropertyleasesMaturityUnderASC840Details"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/PropertyleasesMaturityUnderASC840Details" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/Accruedexpenses" xlink:type="simple" xlink:href="vrna-20201231.xsd#Accruedexpenses"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/Accruedexpenses" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/AccruedexpensesTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#AccruedexpensesTables"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/AccruedexpensesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/AccruedexpensesDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#AccruedexpensesDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/AccruedexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a25b9ff8-f9c3-46f2-abac-c8cdd73aed37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_fd7eea57-83a3-4164-a7ca-40f6c3786e5a" xlink:href="vrna-20201231.xsd#vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_a25b9ff8-f9c3-46f2-abac-c8cdd73aed37" xlink:to="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_fd7eea57-83a3-4164-a7ca-40f6c3786e5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent_3980805d-6246-4115-9415-863f3ff8b964" xlink:href="vrna-20201231.xsd#vrna_AccruedResearchAndDevelopmentFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_a25b9ff8-f9c3-46f2-abac-c8cdd73aed37" xlink:to="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent_3980805d-6246-4115-9415-863f3ff8b964" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_01cfb267-1610-4494-9fe3-9984e98fe688" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_a25b9ff8-f9c3-46f2-abac-c8cdd73aed37" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_01cfb267-1610-4494-9fe3-9984e98fe688" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Warrants" xlink:type="simple" xlink:href="vrna-20201231.xsd#Warrants"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/Warrants" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/WarrantsTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#WarrantsTables"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/WarrantsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/WarrantsNarrativeDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#WarrantsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/WarrantsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#WarrantsFairValueAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/WarrantsMovementinValueDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#WarrantsMovementinValueDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/WarrantsMovementinValueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/WarrantsEffectofChangeinVolatilityDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#WarrantsEffectofChangeinVolatilityDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/WarrantsEffectofChangeinVolatilityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/Termloan" xlink:type="simple" xlink:href="vrna-20201231.xsd#Termloan"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/Termloan" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/TermloanDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#TermloanDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/TermloanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/Benefitplans" xlink:type="simple" xlink:href="vrna-20201231.xsd#Benefitplans"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/Benefitplans" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/BenefitplansDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#BenefitplansDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/BenefitplansDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/Taxation" xlink:type="simple" xlink:href="vrna-20201231.xsd#Taxation"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/Taxation" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#TaxationTables"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/TaxationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationLossBeforeTaxDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#TaxationLossBeforeTaxDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/TaxationLossBeforeTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5fb8f5d3-76fc-45fb-97b8-6a95b40ad1c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_772cb730-a92b-4bd3-9b8c-0e50faaf61af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5fb8f5d3-76fc-45fb-97b8-6a95b40ad1c6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_772cb730-a92b-4bd3-9b8c-0e50faaf61af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_fa968875-3d37-482a-a52e-8bb579a64118" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5fb8f5d3-76fc-45fb-97b8-6a95b40ad1c6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_fa968875-3d37-482a-a52e-8bb579a64118" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#TaxationTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_14c4c6a4-d851-4a35-a814-837b750e1c79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_c72dc384-7f37-4e0d-93ef-d71dddd06642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_14c4c6a4-d851-4a35-a814-837b750e1c79" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_c72dc384-7f37-4e0d-93ef-d71dddd06642" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2a31a6f9-9175-4c9a-ac93-6e6df05e73ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_14c4c6a4-d851-4a35-a814-837b750e1c79" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2a31a6f9-9175-4c9a-ac93-6e6df05e73ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a1dc1bf6-565f-4d95-a620-04ac4fdbbd66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_530d5d0d-9062-4533-be95-8a968f7a30a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a1dc1bf6-565f-4d95-a620-04ac4fdbbd66" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_530d5d0d-9062-4533-be95-8a968f7a30a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_cff66899-8c5b-4923-9dab-7ffff944c8df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a1dc1bf6-565f-4d95-a620-04ac4fdbbd66" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_cff66899-8c5b-4923-9dab-7ffff944c8df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_975b6fb5-0498-4a37-a521-afd4921e4a73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_da899164-2de0-4059-8795-0e7e74d7e851" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_975b6fb5-0498-4a37-a521-afd4921e4a73" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_da899164-2de0-4059-8795-0e7e74d7e851" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b65b6d4a-2dc4-4f75-8d46-74509b2fc1bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_975b6fb5-0498-4a37-a521-afd4921e4a73" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b65b6d4a-2dc4-4f75-8d46-74509b2fc1bb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#TaxationReconciliationofStatutoryRateDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_33c4e6e9-c28e-425b-8ca0-af906e282ce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_9468f44a-7203-4334-a95c-0928da5f00f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_33c4e6e9-c28e-425b-8ca0-af906e282ce3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_9468f44a-7203-4334-a95c-0928da5f00f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0e5d1cbd-5f1d-49f1-aade-6fc9dfbb6caf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_33c4e6e9-c28e-425b-8ca0-af906e282ce3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0e5d1cbd-5f1d-49f1-aade-6fc9dfbb6caf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_4e3a95cd-0de6-4dfe-af61-f8f1e57a0b0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_33c4e6e9-c28e-425b-8ca0-af906e282ce3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_4e3a95cd-0de6-4dfe-af61-f8f1e57a0b0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_e00aea9d-6765-4b44-a0ea-e7d33e370e50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_33c4e6e9-c28e-425b-8ca0-af906e282ce3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_e00aea9d-6765-4b44-a0ea-e7d33e370e50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_be1c5175-236d-4a14-8871-67c695594357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_33c4e6e9-c28e-425b-8ca0-af906e282ce3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_be1c5175-236d-4a14-8871-67c695594357" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_79bee1f2-c4d5-4a74-93f0-e8fb04aa2312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_33c4e6e9-c28e-425b-8ca0-af906e282ce3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_79bee1f2-c4d5-4a74-93f0-e8fb04aa2312" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#TaxationDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_f7072571-e91a-4316-8387-8839e8e09b89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_0f41851e-3bba-4296-9ce8-8006921dc9b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_f7072571-e91a-4316-8387-8839e8e09b89" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_0f41851e-3bba-4296-9ce8-8006921dc9b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0862fb4f-6a7e-4510-bf98-149fbee9ad69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_f7072571-e91a-4316-8387-8839e8e09b89" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0862fb4f-6a7e-4510-bf98-149fbee9ad69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_f3f45d79-b800-4e51-82fc-74c5b196c8dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_f7072571-e91a-4316-8387-8839e8e09b89" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_f3f45d79-b800-4e51-82fc-74c5b196c8dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_3ebecdeb-b783-4a25-a523-14afb555f11b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DeferredTaxLiabilitiesContingentLiability_51f4eeb7-31e8-4a10-8c85-b9d0a21fbe12" xlink:href="vrna-20201231.xsd#vrna_DeferredTaxLiabilitiesContingentLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_3ebecdeb-b783-4a25-a523-14afb555f11b" xlink:to="loc_vrna_DeferredTaxLiabilitiesContingentLiability_51f4eeb7-31e8-4a10-8c85-b9d0a21fbe12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6cfa5896-1a47-4f17-af64-6d9f9b322a8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_f2cf896e-24bf-4c33-b50c-f0516f9bfac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6cfa5896-1a47-4f17-af64-6d9f9b322a8f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_f2cf896e-24bf-4c33-b50c-f0516f9bfac8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b699bd28-a51b-4ec7-8730-c7d16880eeaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6cfa5896-1a47-4f17-af64-6d9f9b322a8f" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b699bd28-a51b-4ec7-8730-c7d16880eeaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_d807e912-5dcd-4afa-8903-74ba5fe963e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6cfa5896-1a47-4f17-af64-6d9f9b322a8f" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_d807e912-5dcd-4afa-8903-74ba5fe963e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5a75f74d-5164-4d8a-a44f-553cb5a49227" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6cfa5896-1a47-4f17-af64-6d9f9b322a8f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5a75f74d-5164-4d8a-a44f-553cb5a49227" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationNarrativeDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#TaxationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/TaxationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/Sharebasedcompensation" xlink:type="simple" xlink:href="vrna-20201231.xsd#Sharebasedcompensation"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/Sharebasedcompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#SharebasedcompensationTables"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#SharebasedcompensationShareBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationNarrativeDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#SharebasedcompensationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#SharebasedcompensationShareOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#SharebasedcompensationWeightedAverageAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#SharebasedcompensationRSUActivityDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/Netlosspershare" xlink:type="simple" xlink:href="vrna-20201231.xsd#Netlosspershare"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/Netlosspershare" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/NetlosspershareTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#NetlosspershareTables"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/NetlosspershareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/NetlosspershareComputationDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#NetlosspershareComputationDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/NetlosspershareComputationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/Relatedpartytransactionsandothershareholdermatters" xlink:type="simple" xlink:href="vrna-20201231.xsd#Relatedpartytransactionsandothershareholdermatters"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/Relatedpartytransactionsandothershareholdermatters" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#RelatedpartytransactionsandothershareholdermattersTables"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#RelatedpartytransactionsandothershareholdermattersDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>vrna-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0ccc0c69-9480-4ff0-8704-1a461378680d,g:39118e12-eba9-4fb3-8b93-ef28b95cf059-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://veronapharma.com/role/Cover" xlink:type="simple" xlink:href="vrna-20201231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/Cover" xlink:type="extended" id="i3dbb2d921d1745afaf07754e9275ac4b_Cover"/>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vrna-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="i1ee091ea7c2243dd8c291c469df2c6c1_ConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="vrna-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i404352fe923a4ee68008f103482ed83d_ConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="vrna-20201231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="i40cbf9b4ad374b71adfa408644880aa9_ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="vrna-20201231.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended" id="id7c9285e7ed645bdbd8527bca6964428_ConsolidatedStatementsofShareholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f1ace001-aafd-4bd0-9e89-11d8d09f5f68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f1ace001-aafd-4bd0-9e89-11d8d09f5f68" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9dd17d54-b0f4-4e2a-8e96-80db16c99c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9dd17d54-b0f4-4e2a-8e96-80db16c99c7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_345d463c-5c05-429f-9489-eb0bd48f35c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_us-gaap_StockholdersEquity_345d463c-5c05-429f-9489-eb0bd48f35c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_0584cfcc-0096-4d93-bc98-b4e0e807a328" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_0584cfcc-0096-4d93-bc98-b4e0e807a328" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_509122af-4ecc-486e-af2e-4d189c735893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_us-gaap_NetIncomeLoss_509122af-4ecc-486e-af2e-4d189c735893" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d460215f-f630-4677-afbc-985a8a38bc0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d460215f-f630-4677-afbc-985a8a38bc0e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ce9c2f7b-8cb8-4075-bcc2-2848751c8a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ce9c2f7b-8cb8-4075-bcc2-2848751c8a4c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1da1af13-82ab-4f7f-930f-72bb5ac38979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1da1af13-82ab-4f7f-930f-72bb5ac38979" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasury_1b946d32-3d63-4faa-8dae-04a769f9fe58" xlink:href="vrna-20201231.xsd#vrna_StockIssuedDuringPeriodSharesHeldInTreasury"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasury_1b946d32-3d63-4faa-8dae-04a769f9fe58" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_StockIssuedDuringPeriodValueHeldInTreasury_d4b7293f-bc35-4b17-8c32-d5ab574d4a5a" xlink:href="vrna-20201231.xsd#vrna_StockIssuedDuringPeriodValueHeldInTreasury"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_vrna_StockIssuedDuringPeriodValueHeldInTreasury_d4b7293f-bc35-4b17-8c32-d5ab574d4a5a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_1c04b6d0-cfb5-4a11-b2eb-0b512488d588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_1c04b6d0-cfb5-4a11-b2eb-0b512488d588" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_b90b0c75-6f82-4573-bf29-b5536fd82dd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_b90b0c75-6f82-4573-bf29-b5536fd82dd3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9c3e0fdd-9001-4e1f-a4f4-457ccaa2692d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9c3e0fdd-9001-4e1f-a4f4-457ccaa2692d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_87f5c6d8-9cc3-40ee-9589-f55fc55210ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5812cedd-c1e6-4615-a108-72f6dc0c930f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_37305858-1143-4f78-8375-da16843687ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f1ace001-aafd-4bd0-9e89-11d8d09f5f68" xlink:to="loc_us-gaap_StatementTable_37305858-1143-4f78-8375-da16843687ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_6c3bb5e8-db2f-4922-9652-6bfadfc915b9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_37305858-1143-4f78-8375-da16843687ca" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_6c3bb5e8-db2f-4922-9652-6bfadfc915b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_6c3bb5e8-db2f-4922-9652-6bfadfc915b9_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_6c3bb5e8-db2f-4922-9652-6bfadfc915b9" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_6c3bb5e8-db2f-4922-9652-6bfadfc915b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_86a4ea81-cc34-40ff-87bf-a73c1cf65f45" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_6c3bb5e8-db2f-4922-9652-6bfadfc915b9" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_86a4ea81-cc34-40ff-87bf-a73c1cf65f45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_a5c92bc6-22f9-4a12-bc61-ce9e1177d4a0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_86a4ea81-cc34-40ff-87bf-a73c1cf65f45" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_a5c92bc6-22f9-4a12-bc61-ce9e1177d4a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_5b9a6f77-0be3-46ed-9242-b611f49cd0ab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_86a4ea81-cc34-40ff-87bf-a73c1cf65f45" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_5b9a6f77-0be3-46ed-9242-b611f49cd0ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_356901aa-7358-49b4-bfb0-84fef5ac4df7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_37305858-1143-4f78-8375-da16843687ca" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_356901aa-7358-49b4-bfb0-84fef5ac4df7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_356901aa-7358-49b4-bfb0-84fef5ac4df7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_356901aa-7358-49b4-bfb0-84fef5ac4df7" xlink:to="loc_us-gaap_EquityComponentDomain_356901aa-7358-49b4-bfb0-84fef5ac4df7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_42525acd-7dc5-4985-b59a-7fd413bf4478" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_356901aa-7358-49b4-bfb0-84fef5ac4df7" xlink:to="loc_us-gaap_EquityComponentDomain_42525acd-7dc5-4985-b59a-7fd413bf4478" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_72c6c31f-51cf-4c2c-a13b-c847dcce3f58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_42525acd-7dc5-4985-b59a-7fd413bf4478" xlink:to="loc_us-gaap_CommonStockMember_72c6c31f-51cf-4c2c-a13b-c847dcce3f58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_cb8f94dc-4dc0-40db-b703-c0fae7241e90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_42525acd-7dc5-4985-b59a-7fd413bf4478" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_cb8f94dc-4dc0-40db-b703-c0fae7241e90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_0f7a5873-84c3-44bb-8111-6825e50ff750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_42525acd-7dc5-4985-b59a-7fd413bf4478" xlink:to="loc_us-gaap_TreasuryStockMember_0f7a5873-84c3-44bb-8111-6825e50ff750" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fb141f81-573f-4e0f-bb74-ac92548dacb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_42525acd-7dc5-4985-b59a-7fd413bf4478" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fb141f81-573f-4e0f-bb74-ac92548dacb3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_43ca5579-2b2c-4138-b59e-2acc612ed6cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_42525acd-7dc5-4985-b59a-7fd413bf4478" xlink:to="loc_us-gaap_RetainedEarningsMember_43ca5579-2b2c-4138-b59e-2acc612ed6cc" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="vrna-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="ie02994c1b4fd4891b19d9f82a2160c46_ConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations" xlink:type="simple" xlink:href="vrna-20201231.xsd#Organizationanddescriptionofbusinessoperations"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations" xlink:type="extended" id="i679150aed5a64c56a44da2e81f0db248_Organizationanddescriptionofbusinessoperations"/>
  <link:roleRef roleURI="http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#OrganizationConsolidationandPresentationofFinancialStatementsDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails" xlink:type="extended" id="i1b5e55a90420464fa98c30ea8bccb143_OrganizationConsolidationandPresentationofFinancialStatementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_515584c9-cfd5-47e7-a624-a179f4a9e59a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d2dc8325-3d36-4af3-8cc0-3c7f43305072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_515584c9-cfd5-47e7-a624-a179f4a9e59a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d2dc8325-3d36-4af3-8cc0-3c7f43305072" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_4e8ef1b5-8b34-49f5-976f-e1589a811c0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_515584c9-cfd5-47e7-a624-a179f4a9e59a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_4e8ef1b5-8b34-49f5-976f-e1589a811c0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1e2ba75d-8b7c-4de3-bd98-73a41bfc6594" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_515584c9-cfd5-47e7-a624-a179f4a9e59a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1e2ba75d-8b7c-4de3-bd98-73a41bfc6594" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_73a4aff9-ee48-441a-9eec-06b4d51f0e5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_515584c9-cfd5-47e7-a624-a179f4a9e59a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_73a4aff9-ee48-441a-9eec-06b4d51f0e5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_f5100456-1a0a-48ff-a06f-5655bc14a6b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_515584c9-cfd5-47e7-a624-a179f4a9e59a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_f5100456-1a0a-48ff-a06f-5655bc14a6b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_86386497-140d-4525-893a-0674698e089b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_515584c9-cfd5-47e7-a624-a179f4a9e59a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_86386497-140d-4525-893a-0674698e089b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_baa4c513-0008-47af-b08f-dee054fe3736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86386497-140d-4525-893a-0674698e089b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_baa4c513-0008-47af-b08f-dee054fe3736" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_baa4c513-0008-47af-b08f-dee054fe3736_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_baa4c513-0008-47af-b08f-dee054fe3736" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_baa4c513-0008-47af-b08f-dee054fe3736_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e33b50b3-bc44-4a1d-a0d2-28cf21b2bd84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_baa4c513-0008-47af-b08f-dee054fe3736" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e33b50b3-bc44-4a1d-a0d2-28cf21b2bd84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_e5de81be-f0f5-4ff4-be31-d5155fca5a5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e33b50b3-bc44-4a1d-a0d2-28cf21b2bd84" xlink:to="loc_us-gaap_PrivatePlacementMember_e5de81be-f0f5-4ff4-be31-d5155fca5a5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fe5817dc-fb37-4351-b1e5-c220a2f32bd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86386497-140d-4525-893a-0674698e089b" xlink:to="loc_us-gaap_DebtInstrumentAxis_fe5817dc-fb37-4351-b1e5-c220a2f32bd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fe5817dc-fb37-4351-b1e5-c220a2f32bd8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_fe5817dc-fb37-4351-b1e5-c220a2f32bd8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fe5817dc-fb37-4351-b1e5-c220a2f32bd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_74d567ab-19ad-4b8d-b13e-d1a448ef9032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_fe5817dc-fb37-4351-b1e5-c220a2f32bd8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_74d567ab-19ad-4b8d-b13e-d1a448ef9032" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermLoanFacilityMember_8f52258f-d388-4970-a7f1-7dec41aed896" xlink:href="vrna-20201231.xsd#vrna_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_74d567ab-19ad-4b8d-b13e-d1a448ef9032" xlink:to="loc_vrna_TermLoanFacilityMember_8f52258f-d388-4970-a7f1-7dec41aed896" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d31bab14-980f-4e12-b74d-4c2d67055dc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86386497-140d-4525-893a-0674698e089b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d31bab14-980f-4e12-b74d-4c2d67055dc0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d31bab14-980f-4e12-b74d-4c2d67055dc0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d31bab14-980f-4e12-b74d-4c2d67055dc0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d31bab14-980f-4e12-b74d-4c2d67055dc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_db2b87e6-b168-4b03-a061-0a171cad9bf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d31bab14-980f-4e12-b74d-4c2d67055dc0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_db2b87e6-b168-4b03-a061-0a171cad9bf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_256ca969-8573-4723-a1ad-8a55b5405224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_db2b87e6-b168-4b03-a061-0a171cad9bf5" xlink:to="loc_us-gaap_SecuredDebtMember_256ca969-8573-4723-a1ad-8a55b5405224" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpolicies" xlink:type="simple" xlink:href="vrna-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingpolicies"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpolicies" xlink:type="extended" id="i58d5301c95314427978c0544b4528bc2_BasisofPresentationandSummaryofSignificantAccountingpolicies"/>
  <link:roleRef roleURI="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies" xlink:type="simple" xlink:href="vrna-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies" xlink:type="extended" id="ic0e4e6ba4c6d4fa796e993b60d94721c_BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"/>
  <link:roleRef roleURI="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails" xlink:type="extended" id="i93a66c77f2ab4df2982575b7f044310b_BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d5e46da4-07cd-4ed2-824f-d54720d7dd8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a5e4ee52-9e8a-4c53-8fc0-54fb81ac3798" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d5e46da4-07cd-4ed2-824f-d54720d7dd8d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a5e4ee52-9e8a-4c53-8fc0-54fb81ac3798" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_557bbc5e-9bfe-43cb-a8e0-2b37226b9c80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d5e46da4-07cd-4ed2-824f-d54720d7dd8d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_557bbc5e-9bfe-43cb-a8e0-2b37226b9c80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_9506de5e-23e7-47c6-a18b-c45344fcee27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d5e46da4-07cd-4ed2-824f-d54720d7dd8d" xlink:to="loc_us-gaap_NumberOfReportableSegments_9506de5e-23e7-47c6-a18b-c45344fcee27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d9a139dd-7fa9-40bb-aace-5cbb66020d90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d5e46da4-07cd-4ed2-824f-d54720d7dd8d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d9a139dd-7fa9-40bb-aace-5cbb66020d90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8028661e-083d-493c-b37b-d5bb734cce68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d5e46da4-07cd-4ed2-824f-d54720d7dd8d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8028661e-083d-493c-b37b-d5bb734cce68" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ebd2a180-ae03-4c29-a8f9-bfb16c3c6d22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d5e46da4-07cd-4ed2-824f-d54720d7dd8d" xlink:to="loc_us-gaap_OperatingLeaseLiability_ebd2a180-ae03-4c29-a8f9-bfb16c3c6d22" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_567e85a0-0fa3-4ea6-906b-d85ff388ea42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d5e46da4-07cd-4ed2-824f-d54720d7dd8d" xlink:to="loc_us-gaap_StockholdersEquity_567e85a0-0fa3-4ea6-906b-d85ff388ea42" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasury_b40ac2b2-179e-41b8-8988-55e26a28f6cb" xlink:href="vrna-20201231.xsd#vrna_StockIssuedDuringPeriodSharesHeldInTreasury"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d5e46da4-07cd-4ed2-824f-d54720d7dd8d" xlink:to="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasury_b40ac2b2-179e-41b8-8988-55e26a28f6cb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares_d8469201-a6d5-479a-9a66-e7682f5d2b5c" xlink:href="vrna-20201231.xsd#vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d5e46da4-07cd-4ed2-824f-d54720d7dd8d" xlink:to="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares_d8469201-a6d5-479a-9a66-e7682f5d2b5c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_431e74f2-989f-471f-9adf-a3025c23a4cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d5e46da4-07cd-4ed2-824f-d54720d7dd8d" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_431e74f2-989f-471f-9adf-a3025c23a4cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aab74a1e-aac5-4eb6-9a31-7187336e0d6d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_431e74f2-989f-471f-9adf-a3025c23a4cf" xlink:to="loc_srt_RangeAxis_aab74a1e-aac5-4eb6-9a31-7187336e0d6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aab74a1e-aac5-4eb6-9a31-7187336e0d6d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_aab74a1e-aac5-4eb6-9a31-7187336e0d6d" xlink:to="loc_srt_RangeMember_aab74a1e-aac5-4eb6-9a31-7187336e0d6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_abc5a851-7b45-4277-84a7-f21ab4c3dfab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_aab74a1e-aac5-4eb6-9a31-7187336e0d6d" xlink:to="loc_srt_RangeMember_abc5a851-7b45-4277-84a7-f21ab4c3dfab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_57623773-5625-4b44-ad45-506a21ea8401" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_abc5a851-7b45-4277-84a7-f21ab4c3dfab" xlink:to="loc_srt_MinimumMember_57623773-5625-4b44-ad45-506a21ea8401" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a90d5f12-b9c9-477b-8720-9a644171fab8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_abc5a851-7b45-4277-84a7-f21ab4c3dfab" xlink:to="loc_srt_MaximumMember_a90d5f12-b9c9-477b-8720-9a644171fab8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c3d38855-a2a0-4a28-b168-fce1b8fea26b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_431e74f2-989f-471f-9adf-a3025c23a4cf" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c3d38855-a2a0-4a28-b168-fce1b8fea26b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c3d38855-a2a0-4a28-b168-fce1b8fea26b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c3d38855-a2a0-4a28-b168-fce1b8fea26b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c3d38855-a2a0-4a28-b168-fce1b8fea26b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5220d107-1703-4239-8cfa-1b231c44af9a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c3d38855-a2a0-4a28-b168-fce1b8fea26b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5220d107-1703-4239-8cfa-1b231c44af9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_0a9e871c-c3f5-4bc3-bf86-a497d434ceeb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5220d107-1703-4239-8cfa-1b231c44af9a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_0a9e871c-c3f5-4bc3-bf86-a497d434ceeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c1fb700c-4a05-4193-a522-8d1c87c0a643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_431e74f2-989f-471f-9adf-a3025c23a4cf" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c1fb700c-4a05-4193-a522-8d1c87c0a643" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c1fb700c-4a05-4193-a522-8d1c87c0a643_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c1fb700c-4a05-4193-a522-8d1c87c0a643" xlink:to="loc_us-gaap_EquityComponentDomain_c1fb700c-4a05-4193-a522-8d1c87c0a643_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_747701e7-f4cb-4d95-b7e2-ed1283508953" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c1fb700c-4a05-4193-a522-8d1c87c0a643" xlink:to="loc_us-gaap_EquityComponentDomain_747701e7-f4cb-4d95-b7e2-ed1283508953" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0eadf9de-cf0f-426f-beb7-de25a0249f77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_747701e7-f4cb-4d95-b7e2-ed1283508953" xlink:to="loc_us-gaap_RetainedEarningsMember_0eadf9de-cf0f-426f-beb7-de25a0249f77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f808ac4a-16df-47c5-9d6a-b3058b4327a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_747701e7-f4cb-4d95-b7e2-ed1283508953" xlink:to="loc_us-gaap_CommonStockMember_f808ac4a-16df-47c5-9d6a-b3058b4327a4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Prepaidexpenses" xlink:type="simple" xlink:href="vrna-20201231.xsd#Prepaidexpenses"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/Prepaidexpenses" xlink:type="extended" id="i94f5fd16f8164e3abf769f7485a34a0b_Prepaidexpenses"/>
  <link:roleRef roleURI="http://veronapharma.com/role/PrepaidexpensesTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#PrepaidexpensesTables"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/PrepaidexpensesTables" xlink:type="extended" id="i960cfd8dcc834351aee462cb497e064c_PrepaidexpensesTables"/>
  <link:roleRef roleURI="http://veronapharma.com/role/PrepaidexpensesDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#PrepaidexpensesDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/PrepaidexpensesDetails" xlink:type="extended" id="id895a3c36ff346bd8d7df2d03ed55d96_PrepaidexpensesDetails"/>
  <link:roleRef roleURI="http://veronapharma.com/role/Taxandtaxincentivereceivable" xlink:type="simple" xlink:href="vrna-20201231.xsd#Taxandtaxincentivereceivable"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/Taxandtaxincentivereceivable" xlink:type="extended" id="i989a2dfe395e433ab76754f930f197e3_Taxandtaxincentivereceivable"/>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxandtaxincentivereceivableTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#TaxandtaxincentivereceivableTables"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/TaxandtaxincentivereceivableTables" xlink:type="extended" id="i37370598dd224ae6bf30d692dfe0db73_TaxandtaxincentivereceivableTables"/>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxandtaxincentivereceivableDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#TaxandtaxincentivereceivableDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/TaxandtaxincentivereceivableDetails" xlink:type="extended" id="i84abd126ca264c758a6fea21ae75db2b_TaxandtaxincentivereceivableDetails"/>
  <link:roleRef roleURI="http://veronapharma.com/role/Propertyleases" xlink:type="simple" xlink:href="vrna-20201231.xsd#Propertyleases"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/Propertyleases" xlink:type="extended" id="i65afca9d3bb04d7e9efdca08fc4f4dc0_Propertyleases"/>
  <link:roleRef roleURI="http://veronapharma.com/role/PropertyleasesTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#PropertyleasesTables"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/PropertyleasesTables" xlink:type="extended" id="i5b37ea5597f14d30b8986bcba1197098_PropertyleasesTables"/>
  <link:roleRef roleURI="http://veronapharma.com/role/PropertyleasesNarrativeDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#PropertyleasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/PropertyleasesNarrativeDetails" xlink:type="extended" id="i9a3fb914372a47a58736f985c1e26c80_PropertyleasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_91b1b30a-0151-4efe-bfb1-35e159fb45f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_45370b39-2b59-490e-86e8-fa73bd583b2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91b1b30a-0151-4efe-bfb1-35e159fb45f0" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_45370b39-2b59-490e-86e8-fa73bd583b2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_93e78898-ecea-447d-ae00-65dce6866d48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91b1b30a-0151-4efe-bfb1-35e159fb45f0" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_93e78898-ecea-447d-ae00-65dce6866d48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f8b192e6-920a-48b0-bfd2-2a239a59b752" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91b1b30a-0151-4efe-bfb1-35e159fb45f0" xlink:to="loc_us-gaap_OperatingLeaseLiability_f8b192e6-920a-48b0-bfd2-2a239a59b752" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_c1e64e5e-1b82-4d8a-a153-d365cb5cdbcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91b1b30a-0151-4efe-bfb1-35e159fb45f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_c1e64e5e-1b82-4d8a-a153-d365cb5cdbcd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ef97b778-9ac0-4231-9ad1-0ebb510d838e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91b1b30a-0151-4efe-bfb1-35e159fb45f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ef97b778-9ac0-4231-9ad1-0ebb510d838e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_16a4e994-8b4a-41c0-b665-bafe9a4441d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91b1b30a-0151-4efe-bfb1-35e159fb45f0" xlink:to="loc_us-gaap_OperatingLeaseExpense_16a4e994-8b4a-41c0-b665-bafe9a4441d7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f71cdd92-2e70-431a-82ef-bf9eb9fddc8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91b1b30a-0151-4efe-bfb1-35e159fb45f0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f71cdd92-2e70-431a-82ef-bf9eb9fddc8f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3a341cce-af64-4d1a-80f0-89781e7539eb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f71cdd92-2e70-431a-82ef-bf9eb9fddc8f" xlink:to="loc_srt_StatementGeographicalAxis_3a341cce-af64-4d1a-80f0-89781e7539eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3a341cce-af64-4d1a-80f0-89781e7539eb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_3a341cce-af64-4d1a-80f0-89781e7539eb" xlink:to="loc_srt_SegmentGeographicalDomain_3a341cce-af64-4d1a-80f0-89781e7539eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7be423ee-552e-4d64-be07-dc08e1743afc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_3a341cce-af64-4d1a-80f0-89781e7539eb" xlink:to="loc_srt_SegmentGeographicalDomain_7be423ee-552e-4d64-be07-dc08e1743afc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_LondonMember_d1c1b374-d0ed-49bf-bc38-608b57415c65" xlink:href="vrna-20201231.xsd#vrna_LondonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7be423ee-552e-4d64-be07-dc08e1743afc" xlink:to="loc_vrna_LondonMember_d1c1b374-d0ed-49bf-bc38-608b57415c65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_169779be-3609-4593-bb4d-3c1342c15929" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7be423ee-552e-4d64-be07-dc08e1743afc" xlink:to="loc_stpr_NY_169779be-3609-4593-bb4d-3c1342c15929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3162bd16-2323-4d7c-8e84-dec835564f72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f71cdd92-2e70-431a-82ef-bf9eb9fddc8f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3162bd16-2323-4d7c-8e84-dec835564f72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3162bd16-2323-4d7c-8e84-dec835564f72_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3162bd16-2323-4d7c-8e84-dec835564f72" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3162bd16-2323-4d7c-8e84-dec835564f72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e8ea4f28-0eb1-4dd9-aa7e-263171bff5c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3162bd16-2323-4d7c-8e84-dec835564f72" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e8ea4f28-0eb1-4dd9-aa7e-263171bff5c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_4d3fbce5-acd1-44cb-b677-491394b5443b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e8ea4f28-0eb1-4dd9-aa7e-263171bff5c9" xlink:to="loc_us-gaap_BuildingMember_4d3fbce5-acd1-44cb-b677-491394b5443b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/PropertyleasesMaturityDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#PropertyleasesMaturityDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/PropertyleasesMaturityDetails" xlink:type="extended" id="i24e6831e75c94cfe86bec58afa626757_PropertyleasesMaturityDetails"/>
  <link:roleRef roleURI="http://veronapharma.com/role/PropertyleasesMaturityUnderASC840Details" xlink:type="simple" xlink:href="vrna-20201231.xsd#PropertyleasesMaturityUnderASC840Details"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/PropertyleasesMaturityUnderASC840Details" xlink:type="extended" id="icb5c9d8d18054d01a2996dc8dbb7e384_PropertyleasesMaturityUnderASC840Details"/>
  <link:roleRef roleURI="http://veronapharma.com/role/Accruedexpenses" xlink:type="simple" xlink:href="vrna-20201231.xsd#Accruedexpenses"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/Accruedexpenses" xlink:type="extended" id="i24ff3a183a9b4878be34c91639720e83_Accruedexpenses"/>
  <link:roleRef roleURI="http://veronapharma.com/role/AccruedexpensesTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#AccruedexpensesTables"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/AccruedexpensesTables" xlink:type="extended" id="i7db7a81873f24c008ef1e5f2ab8604d4_AccruedexpensesTables"/>
  <link:roleRef roleURI="http://veronapharma.com/role/AccruedexpensesDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#AccruedexpensesDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/AccruedexpensesDetails" xlink:type="extended" id="iafe4ad2bf8be4c86804fda9cfecddf4b_AccruedexpensesDetails"/>
  <link:roleRef roleURI="http://veronapharma.com/role/Warrants" xlink:type="simple" xlink:href="vrna-20201231.xsd#Warrants"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/Warrants" xlink:type="extended" id="idf9b5daae92849128589cad63b431e33_Warrants"/>
  <link:roleRef roleURI="http://veronapharma.com/role/WarrantsTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#WarrantsTables"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/WarrantsTables" xlink:type="extended" id="i03e43dbb092b4e37b363ff6f6ffc8bd1_WarrantsTables"/>
  <link:roleRef roleURI="http://veronapharma.com/role/WarrantsNarrativeDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#WarrantsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/WarrantsNarrativeDetails" xlink:type="extended" id="i6958ead96b0944aeb5b5ad6bef831ba4_WarrantsNarrativeDetails"/>
  <link:roleRef roleURI="http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#WarrantsFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails" xlink:type="extended" id="i5900caa35f4b446283d8d456b37b4d79_WarrantsFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_b41b8943-ca12-4230-92e2-32524bced7f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_aa92fdc8-32b1-4268-b5f9-f7eb07415e2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_b41b8943-ca12-4230-92e2-32524bced7f4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_aa92fdc8-32b1-4268-b5f9-f7eb07415e2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c013be28-9cdb-4f3d-adbf-66983fbaf5e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_b41b8943-ca12-4230-92e2-32524bced7f4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c013be28-9cdb-4f3d-adbf-66983fbaf5e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare_86d5f4a6-43b7-46a6-b627-d9411cf35e26" xlink:href="vrna-20201231.xsd#vrna_ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_b41b8943-ca12-4230-92e2-32524bced7f4" xlink:to="loc_vrna_ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare_86d5f4a6-43b7-46a6-b627-d9411cf35e26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_3c6207ab-a8af-467b-82a6-4ce7ed8d6efa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_b41b8943-ca12-4230-92e2-32524bced7f4" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_3c6207ab-a8af-467b-82a6-4ce7ed8d6efa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_6b1b23d1-ffa6-4a03-a5b7-5caa25aee262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_b41b8943-ca12-4230-92e2-32524bced7f4" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_6b1b23d1-ffa6-4a03-a5b7-5caa25aee262" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_WarrantLiabilityCurrent_f5c2c03f-129a-41c3-aebb-e6f4b8135ffb" xlink:href="vrna-20201231.xsd#vrna_WarrantLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_b41b8943-ca12-4230-92e2-32524bced7f4" xlink:to="loc_vrna_WarrantLiabilityCurrent_f5c2c03f-129a-41c3-aebb-e6f4b8135ffb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_912d4240-2a76-4fd9-9a95-bfc3fc4697a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_b41b8943-ca12-4230-92e2-32524bced7f4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_912d4240-2a76-4fd9-9a95-bfc3fc4697a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_7c89d676-efa2-4d34-8d31-684aa6ff8d88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_912d4240-2a76-4fd9-9a95-bfc3fc4697a0" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_7c89d676-efa2-4d34-8d31-684aa6ff8d88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7c89d676-efa2-4d34-8d31-684aa6ff8d88_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7c89d676-efa2-4d34-8d31-684aa6ff8d88" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7c89d676-efa2-4d34-8d31-684aa6ff8d88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_fdfb9f14-ea7a-4bc9-96ff-885e39adfbfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7c89d676-efa2-4d34-8d31-684aa6ff8d88" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_fdfb9f14-ea7a-4bc9-96ff-885e39adfbfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_dee8a959-c399-42f9-b203-f29ecfacf316" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_fdfb9f14-ea7a-4bc9-96ff-885e39adfbfc" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_dee8a959-c399-42f9-b203-f29ecfacf316" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_MeasurementInputAnnualizedVolatilityMember_8b80d170-5f66-4ecd-a911-e8b8ae2d69bc" xlink:href="vrna-20201231.xsd#vrna_MeasurementInputAnnualizedVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_fdfb9f14-ea7a-4bc9-96ff-885e39adfbfc" xlink:to="loc_vrna_MeasurementInputAnnualizedVolatilityMember_8b80d170-5f66-4ecd-a911-e8b8ae2d69bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_374c4c64-b219-4330-8a96-7b25cf825d8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_fdfb9f14-ea7a-4bc9-96ff-885e39adfbfc" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_374c4c64-b219-4330-8a96-7b25cf825d8b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/WarrantsMovementinValueDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#WarrantsMovementinValueDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/WarrantsMovementinValueDetails" xlink:type="extended" id="i4332fc91cd204215b9516d19c2274e0d_WarrantsMovementinValueDetails"/>
  <link:roleRef roleURI="http://veronapharma.com/role/WarrantsEffectofChangeinVolatilityDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#WarrantsEffectofChangeinVolatilityDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/WarrantsEffectofChangeinVolatilityDetails" xlink:type="extended" id="i54e4edf6c01245ceb649c25c171cdfcd_WarrantsEffectofChangeinVolatilityDetails"/>
  <link:roleRef roleURI="http://veronapharma.com/role/Termloan" xlink:type="simple" xlink:href="vrna-20201231.xsd#Termloan"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/Termloan" xlink:type="extended" id="i5d3b72d8cac642edb434a69ac767ed7a_Termloan"/>
  <link:roleRef roleURI="http://veronapharma.com/role/TermloanDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#TermloanDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/TermloanDetails" xlink:type="extended" id="i3b88419d24374313ba4cc606313880ba_TermloanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_44451c69-e2a2-4c59-868c-c3f4615ae1fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_44451c69-e2a2-4c59-868c-c3f4615ae1fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5181748c-0fc6-464d-817c-1c0f09e440b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5181748c-0fc6-464d-817c-1c0f09e440b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e65d8bd7-0b29-45e8-9f4c-cd563f23ad07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e65d8bd7-0b29-45e8-9f4c-cd563f23ad07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f4d8dcc6-0e42-4add-a36e-057f898f4d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f4d8dcc6-0e42-4add-a36e-057f898f4d4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentFinalPaymentPercent_32cde366-5d22-4caf-9d55-4aee7de255fb" xlink:href="vrna-20201231.xsd#vrna_DebtInstrumentFinalPaymentPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_vrna_DebtInstrumentFinalPaymentPercent_32cde366-5d22-4caf-9d55-4aee7de255fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentPrepaymentTermOfPriorWrittenNotice_b3d8079e-d1e8-4c04-862d-7cc903eb5409" xlink:href="vrna-20201231.xsd#vrna_DebtInstrumentPrepaymentTermOfPriorWrittenNotice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_vrna_DebtInstrumentPrepaymentTermOfPriorWrittenNotice_b3d8079e-d1e8-4c04-862d-7cc903eb5409" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentEarlyRepaymentPenaltyAmount_be0ee350-1052-4119-9104-0b06012cd80c" xlink:href="vrna-20201231.xsd#vrna_DebtInstrumentEarlyRepaymentPenaltyAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_vrna_DebtInstrumentEarlyRepaymentPenaltyAmount_be0ee350-1052-4119-9104-0b06012cd80c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent_929487f2-8790-4b3e-ad33-1d5dd214b65b" xlink:href="vrna-20201231.xsd#vrna_DebtInstrumentEarlyRepaymentPenaltyPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent_929487f2-8790-4b3e-ad33-1d5dd214b65b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage_c3e7f946-39dc-480a-8d9c-929497605a38" xlink:href="vrna-20201231.xsd#vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage_c3e7f946-39dc-480a-8d9c-929497605a38" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentCovenantCashAndCashEquivalentsMinimum_0692a1f7-20ae-45b3-84fc-d07c967b2444" xlink:href="vrna-20201231.xsd#vrna_DebtInstrumentCovenantCashAndCashEquivalentsMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_vrna_DebtInstrumentCovenantCashAndCashEquivalentsMinimum_0692a1f7-20ae-45b3-84fc-d07c967b2444" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold_677ffd5d-bf08-4dd5-be83-baef4085f9bf" xlink:href="vrna-20201231.xsd#vrna_DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_vrna_DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold_677ffd5d-bf08-4dd5-be83-baef4085f9bf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness_42301d8e-56a6-4622-84a5-74440eebc8b6" xlink:href="vrna-20201231.xsd#vrna_DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_vrna_DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness_42301d8e-56a6-4622-84a5-74440eebc8b6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_94bdc2b0-a19a-43a6-8aae-8ecd0db3cb28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_94bdc2b0-a19a-43a6-8aae-8ecd0db3cb28" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0e5114fe-a08f-49d8-9490-a4cb2fa5bf99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_us-gaap_LongTermDebt_0e5114fe-a08f-49d8-9490-a4cb2fa5bf99" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f4da39b1-5bdc-48e4-b2a8-2ff4edd6591f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_us-gaap_DebtInstrumentTable_f4da39b1-5bdc-48e4-b2a8-2ff4edd6591f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e0749d1b-dc08-4246-8da8-307a8581e7cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f4da39b1-5bdc-48e4-b2a8-2ff4edd6591f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e0749d1b-dc08-4246-8da8-307a8581e7cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e0749d1b-dc08-4246-8da8-307a8581e7cf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e0749d1b-dc08-4246-8da8-307a8581e7cf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e0749d1b-dc08-4246-8da8-307a8581e7cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c3372507-b1ac-4c81-848c-972164726592" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e0749d1b-dc08-4246-8da8-307a8581e7cf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c3372507-b1ac-4c81-848c-972164726592" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_9bf6bf1f-ccfd-4ba8-a278-8cfb4de9228f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c3372507-b1ac-4c81-848c-972164726592" xlink:to="loc_us-gaap_SecuredDebtMember_9bf6bf1f-ccfd-4ba8-a278-8cfb4de9228f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bfebf910-9b29-44e4-a0f8-2e9a7bfdda84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f4da39b1-5bdc-48e4-b2a8-2ff4edd6591f" xlink:to="loc_us-gaap_DebtInstrumentAxis_bfebf910-9b29-44e4-a0f8-2e9a7bfdda84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bfebf910-9b29-44e4-a0f8-2e9a7bfdda84_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_bfebf910-9b29-44e4-a0f8-2e9a7bfdda84" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bfebf910-9b29-44e4-a0f8-2e9a7bfdda84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e6426fd2-8757-45b0-b7d0-d7e7e99748cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_bfebf910-9b29-44e4-a0f8-2e9a7bfdda84" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e6426fd2-8757-45b0-b7d0-d7e7e99748cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermLoanFacilityMember_3dc5ba7b-0a7d-4ac4-90f5-acaff14c1f5f" xlink:href="vrna-20201231.xsd#vrna_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e6426fd2-8757-45b0-b7d0-d7e7e99748cb" xlink:to="loc_vrna_TermLoanFacilityMember_3dc5ba7b-0a7d-4ac4-90f5-acaff14c1f5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermBLoanMember_33330232-6f6d-480b-9aa7-a569182266c1" xlink:href="vrna-20201231.xsd#vrna_TermBLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrna_TermLoanFacilityMember_3dc5ba7b-0a7d-4ac4-90f5-acaff14c1f5f" xlink:to="loc_vrna_TermBLoanMember_33330232-6f6d-480b-9aa7-a569182266c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermCLoanMember_55e3efd4-04bc-4399-82e8-13d4d60dbb0c" xlink:href="vrna-20201231.xsd#vrna_TermCLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrna_TermLoanFacilityMember_3dc5ba7b-0a7d-4ac4-90f5-acaff14c1f5f" xlink:to="loc_vrna_TermCLoanMember_55e3efd4-04bc-4399-82e8-13d4d60dbb0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_d9761d11-41b2-4da6-8354-41a4af799581" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f4da39b1-5bdc-48e4-b2a8-2ff4edd6591f" xlink:to="loc_us-gaap_VariableRateAxis_d9761d11-41b2-4da6-8354-41a4af799581" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_d9761d11-41b2-4da6-8354-41a4af799581_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_d9761d11-41b2-4da6-8354-41a4af799581" xlink:to="loc_us-gaap_VariableRateDomain_d9761d11-41b2-4da6-8354-41a4af799581_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e490fcdb-e184-4762-b36e-2b783a8582a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_d9761d11-41b2-4da6-8354-41a4af799581" xlink:to="loc_us-gaap_VariableRateDomain_e490fcdb-e184-4762-b36e-2b783a8582a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_8512ae59-6bfb-4c14-8c32-23c9ebea8a82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_e490fcdb-e184-4762-b36e-2b783a8582a0" xlink:to="loc_us-gaap_PrimeRateMember_8512ae59-6bfb-4c14-8c32-23c9ebea8a82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodAxis_23381838-677a-499c-bc1b-945eefb17243" xlink:href="vrna-20201231.xsd#vrna_DebtPrepaymentPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f4da39b1-5bdc-48e4-b2a8-2ff4edd6591f" xlink:to="loc_vrna_DebtPrepaymentPeriodAxis_23381838-677a-499c-bc1b-945eefb17243" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodDomain_23381838-677a-499c-bc1b-945eefb17243_default" xlink:href="vrna-20201231.xsd#vrna_DebtPrepaymentPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_vrna_DebtPrepaymentPeriodAxis_23381838-677a-499c-bc1b-945eefb17243" xlink:to="loc_vrna_DebtPrepaymentPeriodDomain_23381838-677a-499c-bc1b-945eefb17243_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodDomain_453afeb9-e49e-44cc-8e30-bacaf3dfedb5" xlink:href="vrna-20201231.xsd#vrna_DebtPrepaymentPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_vrna_DebtPrepaymentPeriodAxis_23381838-677a-499c-bc1b-945eefb17243" xlink:to="loc_vrna_DebtPrepaymentPeriodDomain_453afeb9-e49e-44cc-8e30-bacaf3dfedb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodOneMember_2151c19b-c083-4116-a8e4-ff60d1a5ac71" xlink:href="vrna-20201231.xsd#vrna_DebtPrepaymentPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrna_DebtPrepaymentPeriodDomain_453afeb9-e49e-44cc-8e30-bacaf3dfedb5" xlink:to="loc_vrna_DebtPrepaymentPeriodOneMember_2151c19b-c083-4116-a8e4-ff60d1a5ac71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodTwoMember_3522e23c-bfc1-42b2-8f4e-ed65bea36be5" xlink:href="vrna-20201231.xsd#vrna_DebtPrepaymentPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrna_DebtPrepaymentPeriodDomain_453afeb9-e49e-44cc-8e30-bacaf3dfedb5" xlink:to="loc_vrna_DebtPrepaymentPeriodTwoMember_3522e23c-bfc1-42b2-8f4e-ed65bea36be5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodThreeMember_cd128199-aeab-4565-b94e-d89838d89976" xlink:href="vrna-20201231.xsd#vrna_DebtPrepaymentPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrna_DebtPrepaymentPeriodDomain_453afeb9-e49e-44cc-8e30-bacaf3dfedb5" xlink:to="loc_vrna_DebtPrepaymentPeriodThreeMember_cd128199-aeab-4565-b94e-d89838d89976" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Benefitplans" xlink:type="simple" xlink:href="vrna-20201231.xsd#Benefitplans"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/Benefitplans" xlink:type="extended" id="ie579379dc2df4f4a92c7bb37a8e9520c_Benefitplans"/>
  <link:roleRef roleURI="http://veronapharma.com/role/BenefitplansDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#BenefitplansDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/BenefitplansDetails" xlink:type="extended" id="i953e83382dfe407bb8537f0b4c6dcdb0_BenefitplansDetails"/>
  <link:roleRef roleURI="http://veronapharma.com/role/Taxation" xlink:type="simple" xlink:href="vrna-20201231.xsd#Taxation"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/Taxation" xlink:type="extended" id="ie6510c9f58e54d7e944ca5e5d5a75125_Taxation"/>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#TaxationTables"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/TaxationTables" xlink:type="extended" id="i23a19df243314dc697e7069f4994ec9a_TaxationTables"/>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationLossBeforeTaxDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#TaxationLossBeforeTaxDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/TaxationLossBeforeTaxDetails" xlink:type="extended" id="i6ca3197e933b4cb88db437f06eaec42e_TaxationLossBeforeTaxDetails"/>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#TaxationTaxExpenseBenefitDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails" xlink:type="extended" id="ifddd3a2ad6da443ba839e230c8ec8582_TaxationTaxExpenseBenefitDetails"/>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#TaxationReconciliationofStatutoryRateDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails" xlink:type="extended" id="ic6f4ee284498493fb5e22dd99d0b5107_TaxationReconciliationofStatutoryRateDetails"/>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#TaxationDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended" id="i3eeb6f5975a346489bba2f88c3da540d_TaxationDeferredTaxAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_32230278-27e5-480d-b59f-f7074a25a059" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_64f8a187-3cb2-4dfc-931f-507a5ad92582" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_32230278-27e5-480d-b59f-f7074a25a059" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_64f8a187-3cb2-4dfc-931f-507a5ad92582" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_05af4aa7-16bc-4984-915d-3797cda9262f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_64f8a187-3cb2-4dfc-931f-507a5ad92582" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_05af4aa7-16bc-4984-915d-3797cda9262f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates_bc656a17-0ab6-427a-9d0e-cea29890527c" xlink:href="vrna-20201231.xsd#vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_64f8a187-3cb2-4dfc-931f-507a5ad92582" xlink:to="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates_bc656a17-0ab6-427a-9d0e-cea29890527c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance_081a6f60-47ae-494b-b0d3-32349a83cf1e" xlink:href="vrna-20201231.xsd#vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_64f8a187-3cb2-4dfc-931f-507a5ad92582" xlink:to="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance_081a6f60-47ae-494b-b0d3-32349a83cf1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments_7369f637-d6bc-4390-85a2-8e11658b1218" xlink:href="vrna-20201231.xsd#vrna_SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_64f8a187-3cb2-4dfc-931f-507a5ad92582" xlink:to="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments_7369f637-d6bc-4390-85a2-8e11658b1218" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_ecefd14b-59bf-440d-896f-b3064c0b22da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ad100f57-f571-4f84-806d-20aac1f681c8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_32230278-27e5-480d-b59f-f7074a25a059" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ad100f57-f571-4f84-806d-20aac1f681c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_080de793-e1c7-4a8c-8298-720a28cca7a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ad100f57-f571-4f84-806d-20aac1f681c8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_080de793-e1c7-4a8c-8298-720a28cca7a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_080de793-e1c7-4a8c-8298-720a28cca7a1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_080de793-e1c7-4a8c-8298-720a28cca7a1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_080de793-e1c7-4a8c-8298-720a28cca7a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_0773c831-4e13-45c8-90d3-a54adf4b1eb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_080de793-e1c7-4a8c-8298-720a28cca7a1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_0773c831-4e13-45c8-90d3-a54adf4b1eb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_8430463f-1295-43c3-97ae-4ecce731c8a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_0773c831-4e13-45c8-90d3-a54adf4b1eb7" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_8430463f-1295-43c3-97ae-4ecce731c8a4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationNarrativeDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#TaxationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/TaxationNarrativeDetails" xlink:type="extended" id="ia2d70c5714644e74a70c828dfe2ddcc7_TaxationNarrativeDetails"/>
  <link:roleRef roleURI="http://veronapharma.com/role/Sharebasedcompensation" xlink:type="simple" xlink:href="vrna-20201231.xsd#Sharebasedcompensation"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/Sharebasedcompensation" xlink:type="extended" id="iccbfc278814747df9b3d81781585cf83_Sharebasedcompensation"/>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#SharebasedcompensationTables"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/SharebasedcompensationTables" xlink:type="extended" id="i7f925c76a0d740318b0236593351c471_SharebasedcompensationTables"/>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#SharebasedcompensationShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails" xlink:type="extended" id="ic4ce88b97ee34a85b530e75891e62875_SharebasedcompensationShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_78c4e820-9f07-408a-b79c-7ea5b9d44f57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a6dcda96-082c-47c1-8c0f-a41a46ce26f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_78c4e820-9f07-408a-b79c-7ea5b9d44f57" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a6dcda96-082c-47c1-8c0f-a41a46ce26f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f454f9c9-8f9d-452e-a3e0-5619318c5879" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_78c4e820-9f07-408a-b79c-7ea5b9d44f57" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f454f9c9-8f9d-452e-a3e0-5619318c5879" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_efd6f5d5-82f3-4c4c-bc92-ba15543b4537" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f454f9c9-8f9d-452e-a3e0-5619318c5879" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_efd6f5d5-82f3-4c4c-bc92-ba15543b4537" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_efd6f5d5-82f3-4c4c-bc92-ba15543b4537_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_efd6f5d5-82f3-4c4c-bc92-ba15543b4537" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_efd6f5d5-82f3-4c4c-bc92-ba15543b4537_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_587e6192-5011-4223-8e4d-a6e1f84080ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_efd6f5d5-82f3-4c4c-bc92-ba15543b4537" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_587e6192-5011-4223-8e4d-a6e1f84080ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3d5b8084-8e68-4491-bdaa-cb2665320311" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_587e6192-5011-4223-8e4d-a6e1f84080ad" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3d5b8084-8e68-4491-bdaa-cb2665320311" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ab852847-e525-4780-a100-37647f892930" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_587e6192-5011-4223-8e4d-a6e1f84080ad" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ab852847-e525-4780-a100-37647f892930" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationNarrativeDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#SharebasedcompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/SharebasedcompensationNarrativeDetails" xlink:type="extended" id="ib9011da83243420ca860e93f9087619c_SharebasedcompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9e0d788f-2b34-4c6c-8567-e567de8e170a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9e0d788f-2b34-4c6c-8567-e567de8e170a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_547a218d-4977-44e1-9103-866d8d1271c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_547a218d-4977-44e1-9103-866d8d1271c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c2b2ff00-c699-44e5-8c5f-d09816ebf95b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c2b2ff00-c699-44e5-8c5f-d09816ebf95b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized_48edda27-cafc-4087-a615-1d0b6e711097" xlink:href="vrna-20201231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized_48edda27-cafc-4087-a615-1d0b6e711097" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ee560a1b-4899-415f-96cf-7aaf137935e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ee560a1b-4899-415f-96cf-7aaf137935e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e035c998-e833-416c-b3e3-65f85e8b8fc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e035c998-e833-416c-b3e3-65f85e8b8fc6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired_f0e28dfc-7eaa-40d2-ba0b-7baa61131f6b" xlink:href="vrna-20201231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired_f0e28dfc-7eaa-40d2-ba0b-7baa61131f6b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod_20bdb0b7-5f16-4ccc-a8bc-bf7fdbd3adbe" xlink:href="vrna-20201231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod_20bdb0b7-5f16-4ccc-a8bc-bf7fdbd3adbe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingDepositoryReceiptRatio_1cd5a81a-bceb-4f7c-9af6-ce40f8e94d3d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingDepositoryReceiptRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_dei_EntityListingDepositoryReceiptRatio_1cd5a81a-bceb-4f7c-9af6-ce40f8e94d3d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue_3055f280-9d45-4f79-99d4-f05fbbd5652b" xlink:href="vrna-20201231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue_3055f280-9d45-4f79-99d4-f05fbbd5652b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_1e9cfda6-741e-4dcc-8528-65c0326449f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_1e9cfda6-741e-4dcc-8528-65c0326449f0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_dbe0a287-53bf-4824-8117-19da95f5dbd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_dbe0a287-53bf-4824-8117-19da95f5dbd6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b7c6b7a4-0275-438b-a9ef-735e9cf0e3d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b7c6b7a4-0275-438b-a9ef-735e9cf0e3d1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a930cef-04ea-46a2-a0f9-abd38a507f97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a930cef-04ea-46a2-a0f9-abd38a507f97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2c8c781d-38aa-45ad-af10-b2484f561767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a930cef-04ea-46a2-a0f9-abd38a507f97" xlink:to="loc_us-gaap_AwardTypeAxis_2c8c781d-38aa-45ad-af10-b2484f561767" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c8c781d-38aa-45ad-af10-b2484f561767_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2c8c781d-38aa-45ad-af10-b2484f561767" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c8c781d-38aa-45ad-af10-b2484f561767_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6307e45f-4de6-46d1-a56c-e53576966d2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2c8c781d-38aa-45ad-af10-b2484f561767" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6307e45f-4de6-46d1-a56c-e53576966d2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7738f20f-f97a-4560-8135-31461a18d7da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6307e45f-4de6-46d1-a56c-e53576966d2f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7738f20f-f97a-4560-8135-31461a18d7da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_951651cf-e19e-4fdf-9ce3-c78afd71006a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6307e45f-4de6-46d1-a56c-e53576966d2f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_951651cf-e19e-4fdf-9ce3-c78afd71006a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b97d11bd-13fa-459f-aba4-306d699d34e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a930cef-04ea-46a2-a0f9-abd38a507f97" xlink:to="loc_us-gaap_PlanNameAxis_b97d11bd-13fa-459f-aba4-306d699d34e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b97d11bd-13fa-459f-aba4-306d699d34e5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_b97d11bd-13fa-459f-aba4-306d699d34e5" xlink:to="loc_us-gaap_PlanNameDomain_b97d11bd-13fa-459f-aba4-306d699d34e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d20d9041-6030-4b2d-8b28-26a2462d2dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_b97d11bd-13fa-459f-aba4-306d699d34e5" xlink:to="loc_us-gaap_PlanNameDomain_d20d9041-6030-4b2d-8b28-26a2462d2dd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_EMIOptionPlanMember_703829ca-671b-4a04-9ae0-af4c08e80b29" xlink:href="vrna-20201231.xsd#vrna_EMIOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d20d9041-6030-4b2d-8b28-26a2462d2dd0" xlink:to="loc_vrna_EMIOptionPlanMember_703829ca-671b-4a04-9ae0-af4c08e80b29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PreIPOOptionPlanMember_db5eafaa-8667-44f8-9708-3e98dbdf5bb9" xlink:href="vrna-20201231.xsd#vrna_PreIPOOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d20d9041-6030-4b2d-8b28-26a2462d2dd0" xlink:to="loc_vrna_PreIPOOptionPlanMember_db5eafaa-8667-44f8-9708-3e98dbdf5bb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2017IncentivePlanMember_0dc5cfad-eb94-4753-934d-ac3da2567266" xlink:href="vrna-20201231.xsd#vrna_A2017IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d20d9041-6030-4b2d-8b28-26a2462d2dd0" xlink:to="loc_vrna_A2017IncentivePlanMember_0dc5cfad-eb94-4753-934d-ac3da2567266" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_37e55207-b8c8-485a-98ff-a93153740037" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a930cef-04ea-46a2-a0f9-abd38a507f97" xlink:to="loc_srt_RangeAxis_37e55207-b8c8-485a-98ff-a93153740037" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_37e55207-b8c8-485a-98ff-a93153740037_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_37e55207-b8c8-485a-98ff-a93153740037" xlink:to="loc_srt_RangeMember_37e55207-b8c8-485a-98ff-a93153740037_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_094f2497-e43c-4ded-bba1-8782acfe4280" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_37e55207-b8c8-485a-98ff-a93153740037" xlink:to="loc_srt_RangeMember_094f2497-e43c-4ded-bba1-8782acfe4280" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e0349d22-9034-40b1-9728-d87263b3c40e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_094f2497-e43c-4ded-bba1-8782acfe4280" xlink:to="loc_srt_MinimumMember_e0349d22-9034-40b1-9728-d87263b3c40e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_267c6bcb-a9c7-4202-8fd0-815ebf1cd944" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_094f2497-e43c-4ded-bba1-8782acfe4280" xlink:to="loc_srt_MaximumMember_267c6bcb-a9c7-4202-8fd0-815ebf1cd944" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#SharebasedcompensationShareOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails" xlink:type="extended" id="ibc958bf13d6b4d40b5e163359c27526b_SharebasedcompensationShareOptionActivityDetails"/>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#SharebasedcompensationWeightedAverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails" xlink:type="extended" id="i499de9aa10dc4ad9b03a956c0acd5071_SharebasedcompensationWeightedAverageAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47e815d5-2d13-4c60-9593-e597ad3ec611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_322a3212-0577-4709-a41d-067555b6ab51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47e815d5-2d13-4c60-9593-e597ad3ec611" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_322a3212-0577-4709-a41d-067555b6ab51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_873b4877-6d87-44a6-a26d-7b38a75b776a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47e815d5-2d13-4c60-9593-e597ad3ec611" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_873b4877-6d87-44a6-a26d-7b38a75b776a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2e449f04-d342-401e-9225-86d2e2094aba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47e815d5-2d13-4c60-9593-e597ad3ec611" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2e449f04-d342-401e-9225-86d2e2094aba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2f9f1075-fe11-43ec-94e7-a5577d60758f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47e815d5-2d13-4c60-9593-e597ad3ec611" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2f9f1075-fe11-43ec-94e7-a5577d60758f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_a3fe5959-1bbc-4615-b21a-9f4f43502f28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47e815d5-2d13-4c60-9593-e597ad3ec611" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_a3fe5959-1bbc-4615-b21a-9f4f43502f28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_65ea8221-90a5-4450-a447-621e375de162" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47e815d5-2d13-4c60-9593-e597ad3ec611" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_65ea8221-90a5-4450-a447-621e375de162" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_921b0af3-ee13-4e37-b5eb-cc40dc081ff5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47e815d5-2d13-4c60-9593-e597ad3ec611" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_921b0af3-ee13-4e37-b5eb-cc40dc081ff5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89a2f412-7b70-44ab-826d-a9bd611dd66d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47e815d5-2d13-4c60-9593-e597ad3ec611" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89a2f412-7b70-44ab-826d-a9bd611dd66d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0e36ee19-ff16-412f-b021-ae14bfd4161e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89a2f412-7b70-44ab-826d-a9bd611dd66d" xlink:to="loc_us-gaap_AwardTypeAxis_0e36ee19-ff16-412f-b021-ae14bfd4161e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e36ee19-ff16-412f-b021-ae14bfd4161e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0e36ee19-ff16-412f-b021-ae14bfd4161e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e36ee19-ff16-412f-b021-ae14bfd4161e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebc0b3a0-a313-4838-9869-e2b914bd88ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0e36ee19-ff16-412f-b021-ae14bfd4161e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebc0b3a0-a313-4838-9869-e2b914bd88ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3c957a55-8e81-46d2-89d7-13f54d1aaccb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebc0b3a0-a313-4838-9869-e2b914bd88ea" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3c957a55-8e81-46d2-89d7-13f54d1aaccb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cb8987ef-7512-4e38-9a26-521d5d9d60ce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89a2f412-7b70-44ab-826d-a9bd611dd66d" xlink:to="loc_srt_RangeAxis_cb8987ef-7512-4e38-9a26-521d5d9d60ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb8987ef-7512-4e38-9a26-521d5d9d60ce_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cb8987ef-7512-4e38-9a26-521d5d9d60ce" xlink:to="loc_srt_RangeMember_cb8987ef-7512-4e38-9a26-521d5d9d60ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e5294fbc-45a3-4bba-83e2-f2f819f61ab5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cb8987ef-7512-4e38-9a26-521d5d9d60ce" xlink:to="loc_srt_RangeMember_e5294fbc-45a3-4bba-83e2-f2f819f61ab5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7578542d-7217-4b89-8465-54d3040f9441" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e5294fbc-45a3-4bba-83e2-f2f819f61ab5" xlink:to="loc_srt_MinimumMember_7578542d-7217-4b89-8465-54d3040f9441" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f4dd1e5d-fd3a-4de7-a36b-badb023a5eb1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e5294fbc-45a3-4bba-83e2-f2f819f61ab5" xlink:to="loc_srt_MaximumMember_f4dd1e5d-fd3a-4de7-a36b-badb023a5eb1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#SharebasedcompensationRSUActivityDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails" xlink:type="extended" id="ib80fefd70103427ba83264868f44a272_SharebasedcompensationRSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c049ea8-a918-44da-9c14-480d40847679" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0b1f1bc4-af86-416e-be65-29647406023f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c049ea8-a918-44da-9c14-480d40847679" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0b1f1bc4-af86-416e-be65-29647406023f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2060f83a-ace7-4c4e-912f-17dfa7f212f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0b1f1bc4-af86-416e-be65-29647406023f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2060f83a-ace7-4c4e-912f-17dfa7f212f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_490c977f-9dcd-4a8a-b262-19163369a52c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0b1f1bc4-af86-416e-be65-29647406023f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_490c977f-9dcd-4a8a-b262-19163369a52c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cd76fc0b-8657-4475-8d26-c8d704e30484" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0b1f1bc4-af86-416e-be65-29647406023f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cd76fc0b-8657-4475-8d26-c8d704e30484" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8508577f-d62c-4087-83cf-52696f5c5cdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0b1f1bc4-af86-416e-be65-29647406023f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8508577f-d62c-4087-83cf-52696f5c5cdf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8a8a1b98-b43e-4f79-bf26-ad03a93a4963" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_2af8494e-4aa5-4142-af48-8f3262360c97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c049ea8-a918-44da-9c14-480d40847679" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_2af8494e-4aa5-4142-af48-8f3262360c97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e1788ef8-6afd-41aa-b98b-253598f323b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod_05affb8b-80a4-4054-876f-cb4080e602eb" xlink:href="vrna-20201231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c049ea8-a918-44da-9c14-480d40847679" xlink:to="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod_05affb8b-80a4-4054-876f-cb4080e602eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee48cad5-b81e-4466-a5ab-4294ed8385eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c049ea8-a918-44da-9c14-480d40847679" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee48cad5-b81e-4466-a5ab-4294ed8385eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4c07ced2-8fa4-45ed-a18d-c30b54400944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee48cad5-b81e-4466-a5ab-4294ed8385eb" xlink:to="loc_us-gaap_AwardTypeAxis_4c07ced2-8fa4-45ed-a18d-c30b54400944" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c07ced2-8fa4-45ed-a18d-c30b54400944_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4c07ced2-8fa4-45ed-a18d-c30b54400944" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c07ced2-8fa4-45ed-a18d-c30b54400944_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7b8081ab-b25f-442a-ad25-65611fa7c43b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4c07ced2-8fa4-45ed-a18d-c30b54400944" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7b8081ab-b25f-442a-ad25-65611fa7c43b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_035ac1e4-4c2a-4d58-a501-dfc28486d2df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7b8081ab-b25f-442a-ad25-65611fa7c43b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_035ac1e4-4c2a-4d58-a501-dfc28486d2df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RestrictedStockUnitTimeBasedVestingMember_81c79a74-2209-45c8-bdbb-c04e328a1d08" xlink:href="vrna-20201231.xsd#vrna_RestrictedStockUnitTimeBasedVestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_035ac1e4-4c2a-4d58-a501-dfc28486d2df" xlink:to="loc_vrna_RestrictedStockUnitTimeBasedVestingMember_81c79a74-2209-45c8-bdbb-c04e328a1d08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RestrictedStockUnitMilestoneBasedVestingMember_b6326be0-eddb-480b-b3e8-9f195cebdd4f" xlink:href="vrna-20201231.xsd#vrna_RestrictedStockUnitMilestoneBasedVestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_035ac1e4-4c2a-4d58-a501-dfc28486d2df" xlink:to="loc_vrna_RestrictedStockUnitMilestoneBasedVestingMember_b6326be0-eddb-480b-b3e8-9f195cebdd4f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Netlosspershare" xlink:type="simple" xlink:href="vrna-20201231.xsd#Netlosspershare"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/Netlosspershare" xlink:type="extended" id="if4e36c25e57740ca96b217c4eeaf8808_Netlosspershare"/>
  <link:roleRef roleURI="http://veronapharma.com/role/NetlosspershareTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#NetlosspershareTables"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/NetlosspershareTables" xlink:type="extended" id="i9c13d5cf05254b3fadc03cb0c18f350d_NetlosspershareTables"/>
  <link:roleRef roleURI="http://veronapharma.com/role/NetlosspershareComputationDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#NetlosspershareComputationDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/NetlosspershareComputationDetails" xlink:type="extended" id="i71c6c5798a494659892115824f6a380a_NetlosspershareComputationDetails"/>
  <link:roleRef roleURI="http://veronapharma.com/role/Relatedpartytransactionsandothershareholdermatters" xlink:type="simple" xlink:href="vrna-20201231.xsd#Relatedpartytransactionsandothershareholdermatters"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/Relatedpartytransactionsandothershareholdermatters" xlink:type="extended" id="i6695e97b032547c3a203e4bd464d7429_Relatedpartytransactionsandothershareholdermatters"/>
  <link:roleRef roleURI="http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#RelatedpartytransactionsandothershareholdermattersTables"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersTables" xlink:type="extended" id="i9154fa74becc48448d40a8c1abdf6b62_RelatedpartytransactionsandothershareholdermattersTables"/>
  <link:roleRef roleURI="http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#RelatedpartytransactionsandothershareholdermattersDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails" xlink:type="extended" id="ic9ff527490a7477b8a34f112d25d2599_RelatedpartytransactionsandothershareholdermattersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_6bd408c1-677c-44e6-aaec-2bac67aa4113" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_6cc9f92f-ada2-4e8b-8630-596a08127e76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6bd408c1-677c-44e6-aaec-2bac67aa4113" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_6cc9f92f-ada2-4e8b-8630-596a08127e76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fe5f08d2-b5e5-4a01-87c1-8cae5b45c918" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6bd408c1-677c-44e6-aaec-2bac67aa4113" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fe5f08d2-b5e5-4a01-87c1-8cae5b45c918" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_80d7bbb8-1203-4bd1-bdaa-43e65248ffa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6bd408c1-677c-44e6-aaec-2bac67aa4113" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_80d7bbb8-1203-4bd1-bdaa-43e65248ffa0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7dc7c622-ad07-4c15-a825-6b6505a883e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6bd408c1-677c-44e6-aaec-2bac67aa4113" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7dc7c622-ad07-4c15-a825-6b6505a883e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_39cfce9e-7865-450d-90dc-d75f863ca8f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7dc7c622-ad07-4c15-a825-6b6505a883e3" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_39cfce9e-7865-450d-90dc-d75f863ca8f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_39cfce9e-7865-450d-90dc-d75f863ca8f6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_39cfce9e-7865-450d-90dc-d75f863ca8f6" xlink:to="loc_us-gaap_RelatedPartyDomain_39cfce9e-7865-450d-90dc-d75f863ca8f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5ea636da-2217-42de-bdd8-577127e0637d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_39cfce9e-7865-450d-90dc-d75f863ca8f6" xlink:to="loc_us-gaap_RelatedPartyDomain_5ea636da-2217-42de-bdd8-577127e0637d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_1567caa8-46f0-4312-a883-9e9e9012e2d1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5ea636da-2217-42de-bdd8-577127e0637d" xlink:to="loc_srt_DirectorMember_1567caa8-46f0-4312-a883-9e9e9012e2d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DirectorOrOfficerMember_2c157dfc-9a13-40d9-9fbd-fc623c67d0cb" xlink:href="vrna-20201231.xsd#vrna_DirectorOrOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5ea636da-2217-42de-bdd8-577127e0637d" xlink:to="loc_vrna_DirectorOrOfficerMember_2c157dfc-9a13-40d9-9fbd-fc623c67d0cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7b0ccd4e-6b10-46d1-808b-485014fcffd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7dc7c622-ad07-4c15-a825-6b6505a883e3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7b0ccd4e-6b10-46d1-808b-485014fcffd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7b0ccd4e-6b10-46d1-808b-485014fcffd8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7b0ccd4e-6b10-46d1-808b-485014fcffd8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7b0ccd4e-6b10-46d1-808b-485014fcffd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_24f59505-c036-47fd-9a09-911e7a877990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7b0ccd4e-6b10-46d1-808b-485014fcffd8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_24f59505-c036-47fd-9a09-911e7a877990" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_faa4d9e3-e0bf-4316-9025-e1ace1ad096a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_24f59505-c036-47fd-9a09-911e7a877990" xlink:to="loc_us-gaap_PrivatePlacementMember_faa4d9e3-e0bf-4316-9025-e1ace1ad096a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_8bc0486c-b68e-4d00-bc7d-94c72d8fd436" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7dc7c622-ad07-4c15-a825-6b6505a883e3" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_8bc0486c-b68e-4d00-bc7d-94c72d8fd436" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_8bc0486c-b68e-4d00-bc7d-94c72d8fd436_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_8bc0486c-b68e-4d00-bc7d-94c72d8fd436" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_8bc0486c-b68e-4d00-bc7d-94c72d8fd436_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_f4529ff1-eb32-4be9-a145-9ec9f46ac85c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_8bc0486c-b68e-4d00-bc7d-94c72d8fd436" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_f4529ff1-eb32-4be9-a145-9ec9f46ac85c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ConsultancyServicesMember_b0bd4774-0a81-409a-998c-c28ab548c93d" xlink:href="vrna-20201231.xsd#vrna_ConsultancyServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f4529ff1-eb32-4be9-a145-9ec9f46ac85c" xlink:to="loc_vrna_ConsultancyServicesMember_b0bd4774-0a81-409a-998c-c28ab548c93d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c13b8b96-5eb4-4bdf-a7e5-3f9221760b22" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7dc7c622-ad07-4c15-a825-6b6505a883e3" xlink:to="loc_srt_CounterpartyNameAxis_c13b8b96-5eb4-4bdf-a7e5-3f9221760b22" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c13b8b96-5eb4-4bdf-a7e5-3f9221760b22_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c13b8b96-5eb4-4bdf-a7e5-3f9221760b22" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c13b8b96-5eb4-4bdf-a7e5-3f9221760b22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d8392c98-6560-4a39-bd54-39ad42778703" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c13b8b96-5eb4-4bdf-a7e5-3f9221760b22" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d8392c98-6560-4a39-bd54-39ad42778703" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DrEbsworthMember_99c06815-c47f-4515-974d-61ea550a11ee" xlink:href="vrna-20201231.xsd#vrna_DrEbsworthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d8392c98-6560-4a39-bd54-39ad42778703" xlink:to="loc_vrna_DrEbsworthMember_99c06815-c47f-4515-974d-61ea550a11ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DrZaccardelliMember_c310912e-8b40-45b2-ad40-b4861b383668" xlink:href="vrna-20201231.xsd#vrna_DrZaccardelliMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d8392c98-6560-4a39-bd54-39ad42778703" xlink:to="loc_vrna_DrZaccardelliMember_c310912e-8b40-45b2-ad40-b4861b383668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_MrSinhaMember_a4093502-6e14-4bfa-898e-c8645e763c27" xlink:href="vrna-20201231.xsd#vrna_MrSinhaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d8392c98-6560-4a39-bd54-39ad42778703" xlink:to="loc_vrna_MrSinhaMember_a4093502-6e14-4bfa-898e-c8645e763c27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DrUllmanMember_6626b051-c121-4f9e-8730-67fa2cf9971d" xlink:href="vrna-20201231.xsd#vrna_DrUllmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d8392c98-6560-4a39-bd54-39ad42778703" xlink:to="loc_vrna_DrUllmanMember_6626b051-c121-4f9e-8730-67fa2cf9971d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DrEdwardsMember_5d59274e-94a6-4363-87b6-88b1a3430009" xlink:href="vrna-20201231.xsd#vrna_DrEdwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d8392c98-6560-4a39-bd54-39ad42778703" xlink:to="loc_vrna_DrEdwardsMember_5d59274e-94a6-4363-87b6-88b1a3430009" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_MrHahnMember_b281af6e-91b1-40e3-b275-598cdf13e4b9" xlink:href="vrna-20201231.xsd#vrna_MrHahnMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d8392c98-6560-4a39-bd54-39ad42778703" xlink:to="loc_vrna_MrHahnMember_b281af6e-91b1-40e3-b275-598cdf13e4b9" xlink:type="arc" order="5"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>vrna-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0ccc0c69-9480-4ff0-8704-1a461378680d,g:39118e12-eba9-4fb3-8b93-ef28b95cf059-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_8f37688e-d85f-4373-8502-a4cd5624c2a7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_65268a1f-da87-4ad9-837f-78dc22f7a2fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_cc645cad-2f27-4084-ae14-99ced6f7cdd8_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_7577a9d4-5e01-4943-a30c-787d3d39a001_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_65a51b1b-ed9b-480d-b558-9bc444683d07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Aggregate intrinsic value (in dollars)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b444b300-14a9-4249-ad63-33b78c7acb0b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e2fa281f-6d24-429e-adf5-be9ba935ef4f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_399fdbc2-14f9-496f-a323-1ca1b0047e41_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_199f0035-cfb3-40ca-89d3-04930d8378fe_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of redemption premium on debt</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_612f7b9c-10c8-43cb-8b7f-76df34995547_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares held in treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_538fcebd-e1a7-4f9e-aced-a33114844465_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_a78b36b1-2663-40e1-b2c1-b933de1531b9_negatedTerseLabel_en-US" xlink:label="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax and tax incentive receivables</link:label>
    <link:label id="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_label_en-US" xlink:label="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Tax And Tax Credit Receivables, Current</link:label>
    <link:label id="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_documentation_en-US" xlink:label="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Tax And Tax Credit Receivables, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:href="vrna-20201231.xsd#vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:to="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_b4f22be3-137e-44bb-80c9-d7a96bf5a3ae_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_8e81aaf3-abd2-40d8-ac29-f9ad4518ca90_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount paid to related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired_60710e25-5a24-4bf9-b077-9cc5ea0f14ea_terseLabel_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum stock price required to vest (in pound sterling per share)</link:label>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired_label_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Minimum Stock Price Required</link:label>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired_documentation_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Minimum Stock Price Required</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired" xlink:href="vrna-20201231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired" xlink:to="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_a89cd7b7-aa63-4160-83d3-b98ad56141d2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs incurred</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_1f49f19f-b585-4ece-8b72-43df595a8e50_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5bd52a3d-b0d1-4b68-b13a-b2d68626f718_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_942403cf-f32d-4233-892c-f41d28c463db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates_faf1e464-8e71-4b19-ae10-02ce52781a7a_terseLabel_en-US" xlink:label="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in tax rates</link:label>
    <link:label id="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates_label_en-US" xlink:label="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule 12-09, Valuation Allowances and Reserves, Change In Tax Rates</link:label>
    <link:label id="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates_documentation_en-US" xlink:label="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule 12-09, Valuation Allowances and Reserves, Change In Tax Rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates" xlink:href="vrna-20201231.xsd#vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates" xlink:to="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_62401c6c-5d0c-41a6-b6b9-857e0ef23bbe_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized_edb28010-f6f8-4e59-846e-c18064951c85_terseLabel_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of American Depository Shares authorized</link:label>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized_label_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of American Depositary Shares Authorized</link:label>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized_documentation_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of American Depositary Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized" xlink:href="vrna-20201231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized" xlink:to="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_cf363bc1-e3e3-4d6b-aca5-d3ae7c7310fb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of term loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_da98dbdd-7424-4568-8b42-ad9a0daf9e94_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded advances</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_17c49e27-ab5a-4452-a37f-e549a03d8f5a_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_3380f401-bf8b-4a74-a0b4-47def62f947b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_f17a63eb-286c-422c-8f90-1e1e77ee5638_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_081ac071-15b4-4f21-87e1-db76b2fb17b0_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DrEdwardsMember_6aa74874-2f25-4881-baab-64a860f404dd_terseLabel_en-US" xlink:label="lab_vrna_DrEdwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Edwards</link:label>
    <link:label id="lab_vrna_DrEdwardsMember_label_en-US" xlink:label="lab_vrna_DrEdwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Edwards [Member]</link:label>
    <link:label id="lab_vrna_DrEdwardsMember_documentation_en-US" xlink:label="lab_vrna_DrEdwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Edwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DrEdwardsMember" xlink:href="vrna-20201231.xsd#vrna_DrEdwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DrEdwardsMember" xlink:to="lab_vrna_DrEdwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_df601ce7-3a1f-4f9f-9b17-fb33b3f0950d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_7b810fb9-462d-474f-bdb0-fe69b7b35f95_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_67562b18-d779-4661-868e-1ec13ee27e94_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_552f52f8-f835-459c-8c2c-bc4c409f023f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in deferred tax valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_e0938867-6d53-4dda-8f0e-8a4c4550a377_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares from restricted share units and share options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_46cd389a-1f36-4514-8798-6593d2b6949c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4eba5eaa-c426-4588-902d-75cdc8ea6ea6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_92b23469-0058-4af5-b22f-b60799d75a3d_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_498f549e-33b4-4e51-8b0e-03bca6f386e7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanTextBlock_e34918d4-4125-404b-b33c-91225b56772a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits plans</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTextBlock_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTextBlock" xlink:to="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1f082686-e4f2-4b8c-a5ef-b6db7b2a2e6a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5e9e7e86-4cd9-458a-8374-d9e30bbbc414_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4cae0fce-1db1-4f2d-9401-1a4c7d132e1c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_76c0e52b-6d27-4bd5-8453-3becee802c1e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_75aae3d2-9770-4cbf-963d-44b841c995da_terseLabel_en-US" xlink:label="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:label id="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="vrna-20201231.xsd#vrna_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_d60d5f72-f2ea-4c7e-8ef1-d349af49b12e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a07a9ea6-e817-4c01-b050-1e1bf52d6806_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_69f90221-d9f2-4929-a065-22ed7d533089_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dd8b24df-9cca-4394-91e3-4a9dbbf0a16d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5c77686c-d637-4385-bb41-1bac56f744d6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_024c310c-eef2-4ca1-b6cc-d53ce2df338d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost related to share options and RSUs granted but not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_58de6a58-3588-4316-954d-e715cb7624d2_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_EMIOptionPlanMember_f7def84c-2bdb-41a6-9f9e-17c5e5b3d020_terseLabel_en-US" xlink:label="lab_vrna_EMIOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMI Option Plan</link:label>
    <link:label id="lab_vrna_EMIOptionPlanMember_label_en-US" xlink:label="lab_vrna_EMIOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMI Option Plan [Member]</link:label>
    <link:label id="lab_vrna_EMIOptionPlanMember_documentation_en-US" xlink:label="lab_vrna_EMIOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMI Option Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_EMIOptionPlanMember" xlink:href="vrna-20201231.xsd#vrna_EMIOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_EMIOptionPlanMember" xlink:to="lab_vrna_EMIOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_946d9ef2-4269-4724-9196-e196d2715d53_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Held-to-maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:to="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_c7a5de6a-e66f-4052-af33-779f90146192_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_f84b34c0-2ad7-4f65-b882-c4ec5a69ead9_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_3fb51763-7c06-4200-9afc-608502471348_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a9650181-ba54-41cb-958a-d9426a80df75_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_8825bca0-967a-461f-8ab2-46d4f1068104_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in pounds sterling per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_RestrictedStockUnitTimeBasedVestingMember_90806479-a66d-44ad-812d-ed151694af47_terseLabel_en-US" xlink:label="lab_vrna_RestrictedStockUnitTimeBasedVestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-Based Vesting</link:label>
    <link:label id="lab_vrna_RestrictedStockUnitTimeBasedVestingMember_label_en-US" xlink:label="lab_vrna_RestrictedStockUnitTimeBasedVestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit, Time-Based Vesting [Member]</link:label>
    <link:label id="lab_vrna_RestrictedStockUnitTimeBasedVestingMember_documentation_en-US" xlink:label="lab_vrna_RestrictedStockUnitTimeBasedVestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit, Time-Based Vesting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RestrictedStockUnitTimeBasedVestingMember" xlink:href="vrna-20201231.xsd#vrna_RestrictedStockUnitTimeBasedVestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_RestrictedStockUnitTimeBasedVestingMember" xlink:to="lab_vrna_RestrictedStockUnitTimeBasedVestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_74e50a68-555e-47a1-8737-90cdef40a6ae_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_3f3c9fcd-1e98-4fb6-b7ee-0b06259dba92_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f9e6bdb3-73c4-4d87-be59-1e88ea34e9c2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_e6a06745-5adc-4e98-b8a3-ad463282796c_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjusted Balance</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjusted Balance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage_e95158f6-b9f3-49eb-9577-7e0d096f3414_terseLabel_en-US" xlink:label="lab_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate in the event of default</link:label>
    <link:label id="lab_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage_label_en-US" xlink:label="lab_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Debt Default, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage_documentation_en-US" xlink:label="lab_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Debt Default, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage" xlink:href="vrna-20201231.xsd#vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage" xlink:to="lab_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_20898a63-5625-4b85-925f-bcfca53436cb_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_1087fd6f-79fd-4c62-84fa-4d30a7dfff92_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Shares</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference_64c315b9-dcfe-4f80-80dc-7dd3805c9f5c_terseLabel_en-US" xlink:label="lab_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange differences recognized in loss for the period</link:label>
    <link:label id="lab_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference_label_en-US" xlink:label="lab_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Exchange Difference</link:label>
    <link:label id="lab_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference_documentation_en-US" xlink:label="lab_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Exchange Difference</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference" xlink:href="vrna-20201231.xsd#vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference" xlink:to="lab_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_f3381a44-ace9-458c-be2c-0c0db3ac7ffe_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_031fab30-8a8a-4961-9bcd-1617432dd7ba_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_OrganizationAndBusinessDescriptionTextBlock_cf23d0fa-cced-46fd-9e65-002ecebc58d3_terseLabel_en-US" xlink:label="lab_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Business Description</link:label>
    <link:label id="lab_vrna_OrganizationAndBusinessDescriptionTextBlock_label_en-US" xlink:label="lab_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Business Description [Text Block]</link:label>
    <link:label id="lab_vrna_OrganizationAndBusinessDescriptionTextBlock_documentation_en-US" xlink:label="lab_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Business Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:href="vrna-20201231.xsd#vrna_OrganizationAndBusinessDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:to="lab_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a70c5e29-12d0-49b0-9382-73fe24887cd3_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_2877de0e-ff13-4691-8018-60efd8f6ca36_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_b2b5ba23-97b2-4a3f-b36f-218a4088cd42_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_453329ed-2917-471b-8cea-ed262f897cc8_terseLabel_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax and tax incentive receivable</link:label>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_47fd32aa-b8d5-4a35-921c-fe002b67d016_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_c102464e-0942-497f-827b-04949d7a719d_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_3cf8a616-fca4-4f75-a163-ab9581a8aa87_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_3f7b335e-0d82-43bd-b5f2-a9c6886d370e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_5a30b610-b754-4910-b28e-01fd025b659d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and penalties recognized</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent_63b4c536-5d37-4cd8-bbcc-bae6a785f951_terseLabel_en-US" xlink:label="lab_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D tax credit receivable - U.K.</link:label>
    <link:label id="lab_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent_label_en-US" xlink:label="lab_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit Receivable, Current</link:label>
    <link:label id="lab_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent_documentation_en-US" xlink:label="lab_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:href="vrna-20201231.xsd#vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:to="lab_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_aecf13e8-cea0-45cb-8e08-c7aecd8f6cec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a8336585-11fa-4e4e-9f9f-994308cf0a4d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of stock warrant (in pound sterling per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_411bb000-0346-4927-9ef5-13a6e50aba12_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_1940e920-85a1-4e77-8080-1b870b38cd5c_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share - basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_7514c128-b38b-4a52-8ae9-f4a6f9f082f0_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_e58d1b70-d740-471a-960a-9e7952e07352_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation and consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_70c61b09-4b5d-446f-b7fb-e65544f0c197_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingDepositoryReceiptRatio_f616cfb7-cf07-4f9f-8a30-4ae8a4cd1ea8_terseLabel_en-US" xlink:label="lab_dei_EntityListingDepositoryReceiptRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ordinary shares per ADS</link:label>
    <link:label id="lab_dei_EntityListingDepositoryReceiptRatio_label_en-US" xlink:label="lab_dei_EntityListingDepositoryReceiptRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listing, Depository Receipt Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingDepositoryReceiptRatio" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingDepositoryReceiptRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingDepositoryReceiptRatio" xlink:to="lab_dei_EntityListingDepositoryReceiptRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e0960bea-093d-4de7-87b7-f6e94bb8e5d7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in sale</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_56f0be56-9f28-4a94-a628-e57e4e73a6cd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_12013d91-ce67-4bbb-a428-51768cad6716_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Held-to-maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:to="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f39f8397-74d0-4703-8f0d-1f3ad6c5adf8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Weighted average remaining contractual term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_7ca27494-f607-4013-800e-5f02a80a3dee_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_723eeffd-4fcf-47ab-8e6e-1e22f6aaff88_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_eada7aab-9f3a-447f-90cf-17cdad40c509_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of ordinary shares</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c07df557-bb85-4de3-94cd-e0c8772cb075_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_131e2390-d08f-4acf-a249-0a5d666f55f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of Basic and Diluted Earning Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_WarrantAndRightsDisclosureTextBlock_d617b520-8546-4d94-97eb-7e744144e4e2_terseLabel_en-US" xlink:label="lab_vrna_WarrantAndRightsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_vrna_WarrantAndRightsDisclosureTextBlock_label_en-US" xlink:label="lab_vrna_WarrantAndRightsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant And Rights Disclosure [Text Block]</link:label>
    <link:label id="lab_vrna_WarrantAndRightsDisclosureTextBlock_documentation_en-US" xlink:label="lab_vrna_WarrantAndRightsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant And Rights Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_WarrantAndRightsDisclosureTextBlock" xlink:href="vrna-20201231.xsd#vrna_WarrantAndRightsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_WarrantAndRightsDisclosureTextBlock" xlink:to="lab_vrna_WarrantAndRightsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c3ef796d-3806-4384-82b7-0075e4842691_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At January 1</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6654cc56-6c91-4e3e-a26c-18480fd6fb54_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At December 31</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c260e4df-0b50-4842-abb6-a33e0791ae30_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_7eb140b7-f73f-41c1-b786-2f6faf8cb1e1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_b35702d1-de57-4143-ad31-cbca5eaadccc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d7188d32-5fee-45e6-b4de-58cab2e90fbe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Further awards to be granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_TermCLoanMember_1666c49c-db1c-49ef-856c-b7b6f256e2e3_terseLabel_en-US" xlink:label="lab_vrna_TermCLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term C Loan</link:label>
    <link:label id="lab_vrna_TermCLoanMember_label_en-US" xlink:label="lab_vrna_TermCLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term C Loan [Member]</link:label>
    <link:label id="lab_vrna_TermCLoanMember_documentation_en-US" xlink:label="lab_vrna_TermCLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term C Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermCLoanMember" xlink:href="vrna-20201231.xsd#vrna_TermCLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_TermCLoanMember" xlink:to="lab_vrna_TermCLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_18272f55-72f4-49ad-84bf-21fde20479e5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e4a5e98-f607-41f5-9d19-c20629358eca_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e4ed8065-3b78-4d93-9a40-f7e73297c952_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_33c99b3f-f567-4f78-8fbd-5cafac99fec5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_f5df044d-2d61-401e-9bcd-777398490d60_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_a24c271c-ce01-499d-9ad3-b05519c3b940_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax receivable - U.S.</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DeferredTaxLiabilitiesContingentLiability_b109022c-648f-4824-8327-3a6d5a659838_negatedTerseLabel_en-US" xlink:label="lab_vrna_DeferredTaxLiabilitiesContingentLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liability</link:label>
    <link:label id="lab_vrna_DeferredTaxLiabilitiesContingentLiability_label_en-US" xlink:label="lab_vrna_DeferredTaxLiabilitiesContingentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Contingent Liability</link:label>
    <link:label id="lab_vrna_DeferredTaxLiabilitiesContingentLiability_documentation_en-US" xlink:label="lab_vrna_DeferredTaxLiabilitiesContingentLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Contingent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DeferredTaxLiabilitiesContingentLiability" xlink:href="vrna-20201231.xsd#vrna_DeferredTaxLiabilitiesContingentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DeferredTaxLiabilitiesContingentLiability" xlink:to="lab_vrna_DeferredTaxLiabilitiesContingentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_a430c49c-1be3-461f-bf4e-3412d0af1d85_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtPrepaymentPeriodThreeMember_7e25fc8c-c82f-4f1a-b08d-418932c0b13c_terseLabel_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After Second Anniversary and Prior to Maturity</link:label>
    <link:label id="lab_vrna_DebtPrepaymentPeriodThreeMember_label_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Prepayment Period Three [Member]</link:label>
    <link:label id="lab_vrna_DebtPrepaymentPeriodThreeMember_documentation_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Prepayment Period Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodThreeMember" xlink:href="vrna-20201231.xsd#vrna_DebtPrepaymentPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtPrepaymentPeriodThreeMember" xlink:to="lab_vrna_DebtPrepaymentPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_b1e060bd-5bf6-43fa-9299-8c5e227edd3e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustment</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_86c6451e-44ad-4309-ae39-a9a612230fb7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ligand agreement</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1f725ed2-712c-4251-b687-04bd934aacdb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_2987e19e-a304-47a2-94e0-8bd0ef67e284_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_b92cdeca-87fc-482f-91d4-b0e7bbbc172e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance at January 1</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_fe9b2508-766d-4c96-b34c-c247cd37ddc6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance at December 31</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b30957f6-ea72-426e-9407-5703ba28346b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_bc1bd585-369d-47df-9ff3-5d4bc59e6165_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_8aca88de-735d-42c9-a1ac-8ce654e490b2_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_222fa231-e2af-4fc5-aa64-7da9705c9c95_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share options exercised</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a40f242a-b419-48c7-88ed-4060cf86b27a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7276b558-8976-4776-8dcb-97e5743307c7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_51e0a1eb-2457-4d55-aa61-b93251250bba_terseLabel_en-US" xlink:label="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees, listing and general corporate costs</link:label>
    <link:label id="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_label_en-US" xlink:label="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Listing, And General Corporate Costs, Current</link:label>
    <link:label id="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_documentation_en-US" xlink:label="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Listing, And General Corporate Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:href="vrna-20201231.xsd#vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:to="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_75f5fbc2-1d61-4c97-b83f-86df300b9360_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_cdf36eda-47c9-4e10-b052-bafe3e4cd186_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Prepaid Expenses</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtInstrumentPrepaymentTermOfPriorWrittenNotice_31699a81-5498-44c4-86e1-fe9a6d3baf03_terseLabel_en-US" xlink:label="lab_vrna_DebtInstrumentPrepaymentTermOfPriorWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of prior written notice</link:label>
    <link:label id="lab_vrna_DebtInstrumentPrepaymentTermOfPriorWrittenNotice_label_en-US" xlink:label="lab_vrna_DebtInstrumentPrepaymentTermOfPriorWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment, Term of Prior Written Notice</link:label>
    <link:label id="lab_vrna_DebtInstrumentPrepaymentTermOfPriorWrittenNotice_documentation_en-US" xlink:label="lab_vrna_DebtInstrumentPrepaymentTermOfPriorWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment, Term of Prior Written Notice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentPrepaymentTermOfPriorWrittenNotice" xlink:href="vrna-20201231.xsd#vrna_DebtInstrumentPrepaymentTermOfPriorWrittenNotice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtInstrumentPrepaymentTermOfPriorWrittenNotice" xlink:to="lab_vrna_DebtInstrumentPrepaymentTermOfPriorWrittenNotice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_225aab67-d55b-4e1a-a3ae-a23fcf97205d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_9988bd52-4956-4fb1-b136-b534fcc0e597_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_b836d1fe-ed7d-49f5-9430-f63cf379503e_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_12a8368c-2c31-4504-b5d5-ea064cb4d2a7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares from restricted share units and share options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_0d95c3ab-4151-4194-aa6c-75ec849bc166_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_747d0eaf-a5ef-4b58-9cec-603bd685e83c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transactions and other shareholder matters</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_LondonMember_22a64a53-6b90-4a5c-a50c-49975f782ee3_terseLabel_en-US" xlink:label="lab_vrna_LondonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London</link:label>
    <link:label id="lab_vrna_LondonMember_label_en-US" xlink:label="lab_vrna_LondonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London [Member]</link:label>
    <link:label id="lab_vrna_LondonMember_documentation_en-US" xlink:label="lab_vrna_LondonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_LondonMember" xlink:href="vrna-20201231.xsd#vrna_LondonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_LondonMember" xlink:to="lab_vrna_LondonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6198d76d-f7f9-4bc2-bea0-7474c99d8da0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6aff8fa1-ff9d-4cb2-be5d-25f2de43bec0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3a978dd8-9bfb-47d1-949e-9db4ca507bd2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSUs outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0bddd68d-5491-4b96-8daa-e202f460a6b3_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c9592842-954e-4e1b-9f4f-7dddd4fae61a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_26334d1c-674f-4274-8593-2f3a9e569b47_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_a32adf64-ad2e-4b93-9b87-60108a71d6de_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of credit risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_7e5b7ac3-e427-4aeb-b318-1bdca4c34a52_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7bb04647-8f8c-48cc-8f3e-e930e4e5fac9_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_4f9ee380-9f3d-417f-b798-1954842e4249_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_4e8af820-0942-472a-aee3-ba0594813f76_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of income tax expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_92d870b2-bd41-4e4a-be2d-1e5277fd6cbb_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3a779945-c544-4306-80ef-5b07e7f030da_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_78be80b3-0686-48b6-a834-2fac41328f26_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DirectorOrOfficerMember_ba5d790d-56d0-4500-9f78-f2c4c97e44b9_terseLabel_en-US" xlink:label="lab_vrna_DirectorOrOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director or Officer</link:label>
    <link:label id="lab_vrna_DirectorOrOfficerMember_label_en-US" xlink:label="lab_vrna_DirectorOrOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director Or Officer [Member]</link:label>
    <link:label id="lab_vrna_DirectorOrOfficerMember_documentation_en-US" xlink:label="lab_vrna_DirectorOrOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director Or Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DirectorOrOfficerMember" xlink:href="vrna-20201231.xsd#vrna_DirectorOrOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DirectorOrOfficerMember" xlink:to="lab_vrna_DirectorOrOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a78e3750-2522-4001-8d8e-de7de44b4612_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_502f80f0-fc0d-4f4a-8866-020a251ff7d7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss available to ordinary shareholders - basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_deb0a06a-e949-4e3e-9f32-bb3324c5c6da_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2d4e5b4a-bfc3-45ad-b5cd-e865b2cb1b99_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_bfff752f-6013-40e9-862d-f921f6c1aca3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_3924bbf3-066b-4e0c-a4fa-0c6dbd57a69f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_8c2e920c-6f18-4492-8690-54da692834c9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_3ad0b63a-2be4-4db5-ad71-d4a8d31d82bf_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ecb21089-57fc-47fb-b287-036ce6a91674_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_7a88ba95-6596-4667-b5a0-cb1d7b8b67ed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of financial instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1f17841f-6f28-4427-8f6b-99ee655293df_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_586ddfec-57df-498e-9cfc-ba2679cc034f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8038932c-75bd-48cb-975b-f0ede93ff5ab_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5c5ef1cd-b6d5-4131-a85a-1fe9bf481620_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_769ab089-6687-441f-b6e1-a9d2fb5054c9_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_583d1b8f-0fa6-47e7-bb9b-f636a9c831e8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f91227c8-5fce-4b04-a4cc-dd96fa791b46_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning Balance, Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_56a4d74f-ac6a-4d8b-b897-ef7dc15c8ea6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending Balance, Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_c79c335c-2296-4f19-ba42-bbb6f73884c9_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_2c230e8d-a929-4086-a9ff-399533fdbbce_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of share options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_7a01b6aa-1b67-45ec-96a4-cfe3c13e7938_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NY_96777b41-a740-46da-8071-ddfcb1e8927e_terseLabel_en-US" xlink:label="lab_stpr_NY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York</link:label>
    <link:label id="lab_stpr_NY_label_en-US" xlink:label="lab_stpr_NY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NY" xlink:to="lab_stpr_NY" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent_17a931f3-6498-43a5-88e5-294f21822b5b_terseLabel_en-US" xlink:label="lab_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment fee (in percent)</link:label>
    <link:label id="lab_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent_label_en-US" xlink:label="lab_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, Early Repayment Penalty, Percent</link:label>
    <link:label id="lab_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent_documentation_en-US" xlink:label="lab_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, Early Repayment Penalty, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent" xlink:href="vrna-20201231.xsd#vrna_DebtInstrumentEarlyRepaymentPenaltyPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent" xlink:to="lab_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_079a4666-2aad-49f8-bdc0-0baf2dd42123_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_aacb1e8a-0757-408e-aa82-8f27e7ca20da_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_474bbad0-e081-4961-8e81-9d156dc4b17a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_6657b08e-1503-40f6-81af-85fa0f3b91fb_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_0dbff4e2-d397-4c4c-b59b-bedc8e6f54a4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development incentive</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_76395644-f591-4927-88c8-87cc30a4376d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasury_a2fb9c7d-2c5f-4af1-b9fe-90d80dd9a2fd_terseLabel_en-US" xlink:label="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasury" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares to treasury (in shares)</link:label>
    <link:label id="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasury_label_en-US" xlink:label="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasury" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Held In Treasury</link:label>
    <link:label id="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasury_documentation_en-US" xlink:label="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasury" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Held In Treasury</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasury" xlink:href="vrna-20201231.xsd#vrna_StockIssuedDuringPeriodSharesHeldInTreasury"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasury" xlink:to="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasury" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_26eb8f12-9532-4bf4-b028-272e4ceac5f6_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss attributable to shareholders of the Company</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0cd710d1-cb89-4ef6-b85d-c2ccad475224_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights_080854fb-7117-49c0-be65-5a91ca4f7892_terseLabel_en-US" xlink:label="lab_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue price of warrants (in pounds sterling per share)</link:label>
    <link:label id="lab_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights_label_en-US" xlink:label="lab_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Issue Price of Warrants or Rights</link:label>
    <link:label id="lab_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights_documentation_en-US" xlink:label="lab_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Issue Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights" xlink:href="vrna-20201231.xsd#vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights" xlink:to="lab_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_3c03fdcf-3175-49ed-b9f6-ef1e82b441dc_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_abbbfe3a-d1e7-4a36-b986-7304f6661132_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the U.K. statutory income tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DrZaccardelliMember_684abf36-1c26-4283-8f92-3a58fc493935_terseLabel_en-US" xlink:label="lab_vrna_DrZaccardelliMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Zaccardelli</link:label>
    <link:label id="lab_vrna_DrZaccardelliMember_label_en-US" xlink:label="lab_vrna_DrZaccardelliMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Zaccardelli [Member]</link:label>
    <link:label id="lab_vrna_DrZaccardelliMember_documentation_en-US" xlink:label="lab_vrna_DrZaccardelliMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Zaccardelli</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DrZaccardelliMember" xlink:href="vrna-20201231.xsd#vrna_DrZaccardelliMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DrZaccardelliMember" xlink:to="lab_vrna_DrZaccardelliMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_fbd2b61d-3f00-45d0-829e-b898f05b0572_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_01f214b1-1625-481b-9363-f7af9b960f79_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of furniture and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d8657e0f-8551-4c04-8b66-03c3fbc88810_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DrEbsworthMember_ed42a7b8-0f5e-4764-8e95-0e9b0d02d925_terseLabel_en-US" xlink:label="lab_vrna_DrEbsworthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Ebsworth</link:label>
    <link:label id="lab_vrna_DrEbsworthMember_label_en-US" xlink:label="lab_vrna_DrEbsworthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Ebsworth [Member]</link:label>
    <link:label id="lab_vrna_DrEbsworthMember_documentation_en-US" xlink:label="lab_vrna_DrEbsworthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Ebsworth</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DrEbsworthMember" xlink:href="vrna-20201231.xsd#vrna_DrEbsworthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DrEbsworthMember" xlink:to="lab_vrna_DrEbsworthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_be58ff81-db34-4578-b932-09c7372e310a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_e48d901e-9627-4b75-be61-e2882a1e7f97_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_MrHahnMember_4555c6ad-a022-4f4f-9358-5b9830ae7452_terseLabel_en-US" xlink:label="lab_vrna_MrHahnMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mr. Hahn</link:label>
    <link:label id="lab_vrna_MrHahnMember_label_en-US" xlink:label="lab_vrna_MrHahnMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mr. Hahn [Member]</link:label>
    <link:label id="lab_vrna_MrHahnMember_documentation_en-US" xlink:label="lab_vrna_MrHahnMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mr. Hahn</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_MrHahnMember" xlink:href="vrna-20201231.xsd#vrna_MrHahnMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_MrHahnMember" xlink:to="lab_vrna_MrHahnMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_e4dc6184-7574-46b3-8e41-05e2f39b696e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod_409fa091-5ea7-4864-be87-3bed96f148df_terseLabel_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period to maintain minimum stock price</link:label>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod_label_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Minimum Stock Price Required, Period</link:label>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod_documentation_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Minimum Stock Price Required, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod" xlink:href="vrna-20201231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod" xlink:to="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_4690afb5-09a7-480b-8779-c9d0fe67a6fb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtPrepaymentPeriodDomain_3eb54b6d-b4a1-40d2-a1ce-37f284618c4e_terseLabel_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Prepayment Period [Domain]</link:label>
    <link:label id="lab_vrna_DebtPrepaymentPeriodDomain_label_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Prepayment Period [Domain]</link:label>
    <link:label id="lab_vrna_DebtPrepaymentPeriodDomain_documentation_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Prepayment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodDomain" xlink:href="vrna-20201231.xsd#vrna_DebtPrepaymentPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtPrepaymentPeriodDomain" xlink:to="lab_vrna_DebtPrepaymentPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_c10854a0-38a6-4c4a-a2e7-51e596a82067_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_ea2d77d0-2426-42ad-984f-f8695c691c30_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_NumberOfWhollyOwnedSubsidiaries_c4164372-8f9e-4e93-9dac-c19f5085c6be_terseLabel_en-US" xlink:label="lab_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of wholly owned subsidiaries</link:label>
    <link:label id="lab_vrna_NumberOfWhollyOwnedSubsidiaries_label_en-US" xlink:label="lab_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholly Owned Subsidiaries</link:label>
    <link:label id="lab_vrna_NumberOfWhollyOwnedSubsidiaries_documentation_en-US" xlink:label="lab_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholly Owned Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:href="vrna-20201231.xsd#vrna_NumberOfWhollyOwnedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:to="lab_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_d98b166b-1484-4629-b53a-4a6ba49e2283_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_d8613670-2988-42c7-a4c3-d3ab4f4660a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate_30b1e956-c5df-4cdd-ac4c-0e1a17a3cdcc_terseLabel_en-US" xlink:label="lab_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">10% volatility decrease</link:label>
    <link:label id="lab_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate_label_en-US" xlink:label="lab_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis Of Fair Value, Warrant Liability, Impact of 10 Percent Decrease In Volatility Rate</link:label>
    <link:label id="lab_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate_documentation_en-US" xlink:label="lab_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis Of Fair Value, Warrant Liability, Impact of 10 Percent Decrease In Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate" xlink:href="vrna-20201231.xsd#vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate" xlink:to="lab_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtInstrumentFinalPaymentPercent_eb78a23e-ea10-4a27-842c-b4158f51f51e_terseLabel_en-US" xlink:label="lab_vrna_DebtInstrumentFinalPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final payment (in percent)</link:label>
    <link:label id="lab_vrna_DebtInstrumentFinalPaymentPercent_label_en-US" xlink:label="lab_vrna_DebtInstrumentFinalPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Final Payment, Percent</link:label>
    <link:label id="lab_vrna_DebtInstrumentFinalPaymentPercent_documentation_en-US" xlink:label="lab_vrna_DebtInstrumentFinalPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Final Payment, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentFinalPaymentPercent" xlink:href="vrna-20201231.xsd#vrna_DebtInstrumentFinalPaymentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtInstrumentFinalPaymentPercent" xlink:to="lab_vrna_DebtInstrumentFinalPaymentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ConsultancyServicesMember_7d1c0794-5e49-4631-81a2-b55678ddfd32_terseLabel_en-US" xlink:label="lab_vrna_ConsultancyServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consultancy Services</link:label>
    <link:label id="lab_vrna_ConsultancyServicesMember_label_en-US" xlink:label="lab_vrna_ConsultancyServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consultancy Services [Member]</link:label>
    <link:label id="lab_vrna_ConsultancyServicesMember_documentation_en-US" xlink:label="lab_vrna_ConsultancyServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consultancy Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ConsultancyServicesMember" xlink:href="vrna-20201231.xsd#vrna_ConsultancyServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ConsultancyServicesMember" xlink:to="lab_vrna_ConsultancyServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_0769ee70-e27f-4acd-83ee-4fea8dd1dba9_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_2412ed99-ed4e-4d4f-ba9c-afaa210de488_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of loss before income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_b58c0477-89c3-40af-9f6e-f214201fe0df_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_caf61f69-9b79-4d14-bbd8-f9c3a787bffe_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carry value of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_1147b1b8-9f69-4883-a0e5-fb5786dd15e3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_3dc1e658-de9b-4014-ac04-3b994293f5a9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1aa98d41-3cc1-44b5-b677-33a39cce37de_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_1027119e-b168-4cd0-b4d8-c20e5e266db2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ba6b4c25-c706-4c3b-8f7b-0011e43cf9f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_77c23a69-3c30-4d1f-8177-322910ffab7c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_376887d1-c10e-48e3-b3aa-6a85ced5ac7a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_82bea2c8-91c5-4f78-ba17-aad574c45b67_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_54256ab8-32f4-4514-9720-5ca9e591c2f6_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a9fd0b78-60ed-43e0-9166-70288a9d6180_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_PrepaidExpenseDisclosureTextBlock_0eb8087c-4033-40bd-bc35-60fed7ce438a_terseLabel_en-US" xlink:label="lab_vrna_PrepaidExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_vrna_PrepaidExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_vrna_PrepaidExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Disclosure [Text Block]</link:label>
    <link:label id="lab_vrna_PrepaidExpenseDisclosureTextBlock_documentation_en-US" xlink:label="lab_vrna_PrepaidExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PrepaidExpenseDisclosureTextBlock" xlink:href="vrna-20201231.xsd#vrna_PrepaidExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_PrepaidExpenseDisclosureTextBlock" xlink:to="lab_vrna_PrepaidExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_cd132976-31f8-4923-8fb5-e662d5eab4f0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-Average Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_WarrantLiabilityCurrent_26c98f9a-718f-474c-b07c-bd54121ae0be_terseLabel_en-US" xlink:label="lab_vrna_WarrantLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_vrna_WarrantLiabilityCurrent_5e83f325-4061-4375-a50c-1e0b35ed0674_verboseLabel_en-US" xlink:label="lab_vrna_WarrantLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Calculated value of the warrants, in thousands of U.S. dollars</link:label>
    <link:label id="lab_vrna_WarrantLiabilityCurrent_label_en-US" xlink:label="lab_vrna_WarrantLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability, Current</link:label>
    <link:label id="lab_vrna_WarrantLiabilityCurrent_documentation_en-US" xlink:label="lab_vrna_WarrantLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_WarrantLiabilityCurrent" xlink:href="vrna-20201231.xsd#vrna_WarrantLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_WarrantLiabilityCurrent" xlink:to="lab_vrna_WarrantLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_68efc3e8-6832-4ef7-88fc-e4e9f7241b43_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7d7ae3e5-4c66-40b4-a162-ee92a7bd20dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised, Weight average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent_6a9377cf-ac26-4e28-9deb-51b4e5682c04_terseLabel_en-US" xlink:label="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial and other development costs</link:label>
    <link:label id="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent_label_en-US" xlink:label="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Fees, Current</link:label>
    <link:label id="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent_documentation_en-US" xlink:label="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:href="vrna-20201231.xsd#vrna_AccruedResearchAndDevelopmentFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:to="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares_dfbbf241-8085-4166-80ee-41966a4dd3f8_terseLabel_en-US" xlink:label="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares to treasury as ADS equivalent (in shares)</link:label>
    <link:label id="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares_label_en-US" xlink:label="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Held In Treasury (American Depository Shares)</link:label>
    <link:label id="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares_documentation_en-US" xlink:label="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Held In Treasury (American Depository Shares)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares" xlink:href="vrna-20201231.xsd#vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares" xlink:to="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c2f8349c-9dbb-4e7f-b713-9a5a66b23135_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ac555b53-8793-4c07-bfba-7d01ad009499_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_92830ae6-6cff-43d2-a0c4-50122046fcf8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7ea611b4-0981-40e3-b67c-78dfc319b0c5_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_bb0801d8-b5f4-437f-8f5c-0c7f818e2bf2_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_d085861a-436e-4b18-881d-c23a6f0f11bf_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_15186202-d05c-4499-a7c5-9b6745ee8652_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness_1d64b8ff-088a-46c7-b732-13637c15104f_terseLabel_en-US" xlink:label="lab_vrna_DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Default indebtedness threshold for default of any agreement or obligation</link:label>
    <link:label id="lab_vrna_DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness_label_en-US" xlink:label="lab_vrna_DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Debt Default, Default of Other Agreement Or Obligation, Threshold of Indebtedness</link:label>
    <link:label id="lab_vrna_DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness_documentation_en-US" xlink:label="lab_vrna_DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Debt Default, Default of Other Agreement Or Obligation, Threshold of Indebtedness</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness" xlink:href="vrna-20201231.xsd#vrna_DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness" xlink:to="lab_vrna_DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_bf9d9181-40a1-412d-8792-5c92ad6a0f7a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_c35e8a45-bfc1-47d1-b458-494942c90765_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtInstrumentEarlyRepaymentPenaltyAmount_024c5264-3a43-4b90-9f64-8f59e7785c81_terseLabel_en-US" xlink:label="lab_vrna_DebtInstrumentEarlyRepaymentPenaltyAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment fee</link:label>
    <link:label id="lab_vrna_DebtInstrumentEarlyRepaymentPenaltyAmount_label_en-US" xlink:label="lab_vrna_DebtInstrumentEarlyRepaymentPenaltyAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, Early Repayment Penalty, Amount</link:label>
    <link:label id="lab_vrna_DebtInstrumentEarlyRepaymentPenaltyAmount_documentation_en-US" xlink:label="lab_vrna_DebtInstrumentEarlyRepaymentPenaltyAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, Early Repayment Penalty, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentEarlyRepaymentPenaltyAmount" xlink:href="vrna-20201231.xsd#vrna_DebtInstrumentEarlyRepaymentPenaltyAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtInstrumentEarlyRepaymentPenaltyAmount" xlink:to="lab_vrna_DebtInstrumentEarlyRepaymentPenaltyAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit_03ef18e8-25f7-40a6-8b37-11153a2e2cb0_terseLabel_en-US" xlink:label="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from R&amp;D tax credit</link:label>
    <link:label id="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit_label_en-US" xlink:label="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) From Research And Development Tax Credit</link:label>
    <link:label id="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit_documentation_en-US" xlink:label="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) From Research And Development Tax Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:href="vrna-20201231.xsd#vrna_GainLossFromResearchAndDevelopmentTaxCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:to="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4a34c107-22a8-4f19-a154-74647302644d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_54430d67-d7ea-4698-98a4-9cbbffb7761f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_19000f65-93b0-4c2f-9fa5-ea65024a9e94_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare_ac067f01-2466-48aa-92dd-fd06a2c02f1a_terseLabel_en-US" xlink:label="lab_vrna_ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equivalent price of ordinary share (ADS price divided by eight)</link:label>
    <link:label id="lab_vrna_ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare_label_en-US" xlink:label="lab_vrna_ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Equivalent Price Per Ordinary Share</link:label>
    <link:label id="lab_vrna_ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare_documentation_en-US" xlink:label="lab_vrna_ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Equivalent Price Per Ordinary Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare" xlink:href="vrna-20201231.xsd#vrna_ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare" xlink:to="lab_vrna_ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_fe21a1e9-1e58-46a8-80e2-7d7f8219c709_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_46a66aa4-9e58-4878-80e1-b354b3d983db_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_85c5fc6b-863c-4ffc-b653-11882a446f70_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8c440734-997e-41c9-84c3-0078b2044772_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum future lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_696963d0-8645-4a55-8286-6e9096dbf9e0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b5f64ebd-01d5-46fd-9817-1124b3c6d883_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_827eb6e3-3d5b-46b8-aed9-dc33eba508ee_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currencies</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_abf0f89f-e1b9-4677-854f-f6545cdd257f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_775ed0c5-d35a-4c72-bcb3-fc888a07c3cb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_bdd7907d-c9d5-4400-9be4-618d972eacca_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding - basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_ee644ab3-d0d4-4b5b-affc-b32d897d4644_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net of valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_615874a0-f89a-4e27-96a9-9bf6ba655d0d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a9e60782-678e-42a2-b04e-0b99991e2110_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_5be72677-f6b1-4b7c-8661-d2e3e8d37bf9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_32ec51d2-deb2-49b7-9bbf-2cf8e57c4271_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited_f51c7964-4201-4e97-a7f4-0c7ab1e3cf27_terseLabel_en-US" xlink:label="lab_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants exercised and forfeited</link:label>
    <link:label id="lab_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited_label_en-US" xlink:label="lab_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Exercised Or Forfeited</link:label>
    <link:label id="lab_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited_documentation_en-US" xlink:label="lab_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Exercised Or Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited" xlink:href="vrna-20201231.xsd#vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited" xlink:to="lab_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_41f1d608-0be2-4aea-8489-d850fad30655_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Valuation Assumptions of Warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_b119bb48-c283-4b2b-bcd6-5cdac3f26755_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c1c41afd-16a0-442f-9853-cb5a2cbe2d78_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_69becbaf-685b-4599-9065-794819918ae6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of outstanding warrants</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_c40651b3-5824-4dcf-baf6-c2cbb6989e99_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_c908dcde-b1cc-4a50-83aa-b2e6d8bba267_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_d867fbaa-0b1a-49ee-912f-cf11ca1ca99f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments_7a34f558-550d-4915-8896-c927a2f4cd34_terseLabel_en-US" xlink:label="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments_label_en-US" xlink:label="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule 12-09, Valuation Allowances and Reserves, Foreign Currency Translation Adjustments</link:label>
    <link:label id="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments_documentation_en-US" xlink:label="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule 12-09, Valuation Allowances and Reserves, Foreign Currency Translation Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments" xlink:href="vrna-20201231.xsd#vrna_SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments" xlink:to="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_7843ce63-3630-4094-a357-c7fa4132361d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CountryRegion_88456efd-1ccb-493e-b395-0b4c36382194_terseLabel_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Country Region</link:label>
    <link:label id="lab_dei_CountryRegion_label_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Country Region</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CountryRegion" xlink:to="lab_dei_CountryRegion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e1540e70-8473-423a-add2-70348196bad1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_88e5125e-a6a3-4314-90a0-5396c89100f0_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_StockIssuedDuringPeriodValueHeldInTreasury_ee045c10-78ce-450a-a046-5b96992c61a7_negatedTerseLabel_en-US" xlink:label="lab_vrna_StockIssuedDuringPeriodValueHeldInTreasury" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares to treasury</link:label>
    <link:label id="lab_vrna_StockIssuedDuringPeriodValueHeldInTreasury_label_en-US" xlink:label="lab_vrna_StockIssuedDuringPeriodValueHeldInTreasury" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Held In Treasury</link:label>
    <link:label id="lab_vrna_StockIssuedDuringPeriodValueHeldInTreasury_documentation_en-US" xlink:label="lab_vrna_StockIssuedDuringPeriodValueHeldInTreasury" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Held In Treasury</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_StockIssuedDuringPeriodValueHeldInTreasury" xlink:href="vrna-20201231.xsd#vrna_StockIssuedDuringPeriodValueHeldInTreasury"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_StockIssuedDuringPeriodValueHeldInTreasury" xlink:to="lab_vrna_StockIssuedDuringPeriodValueHeldInTreasury" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_ebc3f1aa-a9c2-4f76-8845-d2367caa0ac6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d59d2c5d-74a3-4c40-862f-65e925b348f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, Weight average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_17db50b9-2eb1-42a7-95f3-37a7e28b33f4_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_b8a33a27-81d9-45ca-a2dc-0e0d95fe8a3f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income / (expense)</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6d890026-bee6-4987-9bca-1c94fffc819c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected lives (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_WarrantLiabilityFairValue_9f7ba843-ea54-4d5a-9b16-10d96c71b303_terseLabel_en-US" xlink:label="lab_vrna_WarrantLiabilityFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base case, reported fair value</link:label>
    <link:label id="lab_vrna_WarrantLiabilityFairValue_label_en-US" xlink:label="lab_vrna_WarrantLiabilityFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability, Fair Value</link:label>
    <link:label id="lab_vrna_WarrantLiabilityFairValue_documentation_en-US" xlink:label="lab_vrna_WarrantLiabilityFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_WarrantLiabilityFairValue" xlink:href="vrna-20201231.xsd#vrna_WarrantLiabilityFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_WarrantLiabilityFairValue" xlink:to="lab_vrna_WarrantLiabilityFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_0921b705-8426-4f1a-8217-e62db250ddad_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_21779164-32e2-412b-9f4a-216f4ac29a5b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_def37c75-5e18-4e54-aff0-68d3c2363b59_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5777c2ce-283a-4d1b-910e-ebbedead2f89_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DrUllmanMember_f4a45678-356a-454a-a68d-adc8942f32cd_terseLabel_en-US" xlink:label="lab_vrna_DrUllmanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Ullman</link:label>
    <link:label id="lab_vrna_DrUllmanMember_label_en-US" xlink:label="lab_vrna_DrUllmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Ullman [Member]</link:label>
    <link:label id="lab_vrna_DrUllmanMember_documentation_en-US" xlink:label="lab_vrna_DrUllmanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Ullman</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DrUllmanMember" xlink:href="vrna-20201231.xsd#vrna_DrUllmanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DrUllmanMember" xlink:to="lab_vrna_DrUllmanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_f6220c4a-f473-4567-9984-128b1d8610cd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_e2251608-c770-43fb-81aa-baad1d183d67_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationInterestAccrued_b49e5502-fca8-410a-879e-be6ad1bfa5b8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest accrued</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationInterestAccrued_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationInterestAccrued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationInterestAccrued" xlink:to="lab_us-gaap_IncomeTaxExaminationInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_f1da4330-dfe1-48d9-9316-00e47f4f44b3_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_TermBLoanMember_62f5236e-9017-4b61-b799-eea75ed43eb0_terseLabel_en-US" xlink:label="lab_vrna_TermBLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B Loan</link:label>
    <link:label id="lab_vrna_TermBLoanMember_label_en-US" xlink:label="lab_vrna_TermBLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B Loan [Member]</link:label>
    <link:label id="lab_vrna_TermBLoanMember_documentation_en-US" xlink:label="lab_vrna_TermBLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermBLoanMember" xlink:href="vrna-20201231.xsd#vrna_TermBLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_TermBLoanMember" xlink:to="lab_vrna_TermBLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_ff5aeba5-9c9d-4427-8e81-6bca7d641e16_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary &#163;0.05 par value shares; 488,304,446 and 105,326,638 issued, and 463,304,446 and 105,326,638 outstanding, at December 31, 2020 and 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_8ff9e11b-a2c5-4409-befa-4a2df419d960_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_55829fbf-8998-443e-89d1-76bb1874ae12_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_1cdad43a-912d-4e3f-a709-b543aa0a9a96_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_48ab6cf2-6396-45fa-a1c1-dba1940d35d5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Aggregate intrinsic value (in dollars)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_9980548d-8e5e-4397-a750-1fd09d079cfc_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d806a35c-70c8-49d6-8537-f0071e546852_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustment</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtPrepaymentPeriodTwoMember_4982b7c6-88d3-485e-a650-5cfa9a86353f_terseLabel_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Anniversary</link:label>
    <link:label id="lab_vrna_DebtPrepaymentPeriodTwoMember_label_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Prepayment Period Two [Member]</link:label>
    <link:label id="lab_vrna_DebtPrepaymentPeriodTwoMember_documentation_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Prepayment Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodTwoMember" xlink:href="vrna-20201231.xsd#vrna_DebtPrepaymentPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtPrepaymentPeriodTwoMember" xlink:to="lab_vrna_DebtPrepaymentPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_71bbd83b-4968-457f-8a8f-590f332de9dd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_aa5f4242-2822-4c38-b4c2-e042e1215775_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02715c4e-164f-4deb-9aad-44c7ac4e6fac_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d231aa44-2161-4542-b816-49314f6e2c46_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e6bc0a52-b08b-4a36-bdc3-47d690d6a53d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_15382bf0-2c3f-4f98-9d46-fb6678ea5604_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_MeasurementInputAnnualizedVolatilityMember_5969c260-0e30-4e6b-9d08-76cca2477bdb_terseLabel_en-US" xlink:label="lab_vrna_MeasurementInputAnnualizedVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annualized volatility</link:label>
    <link:label id="lab_vrna_MeasurementInputAnnualizedVolatilityMember_label_en-US" xlink:label="lab_vrna_MeasurementInputAnnualizedVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Annualized Volatility [Member]</link:label>
    <link:label id="lab_vrna_MeasurementInputAnnualizedVolatilityMember_documentation_en-US" xlink:label="lab_vrna_MeasurementInputAnnualizedVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Annualized Volatility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_MeasurementInputAnnualizedVolatilityMember" xlink:href="vrna-20201231.xsd#vrna_MeasurementInputAnnualizedVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_MeasurementInputAnnualizedVolatilityMember" xlink:to="lab_vrna_MeasurementInputAnnualizedVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod_657572ed-8ad0-49b9-8a71-79f3eb8881b0_terseLabel_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining vesting Period</link:label>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod_label_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Vesting Period</link:label>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod_documentation_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod" xlink:href="vrna-20201231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod" xlink:to="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_7e536f6a-871d-4c0c-a1a6-332f92e5f540_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_9e59504e-e992-4262-91c9-8480d5e861e2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_b03adf6a-481d-41fc-9d39-9f80e9209806_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_534a54ed-8991-4f61-aef1-dce7863fa15b_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_a6d6be54-6b9f-4825-9cf0-9aaa20e3ff4a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_7fe5b4a5-43fd-4fc0-820a-36466abafd08_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1f21c019-07ea-470f-abbc-ed35bca7dceb_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_5e193664-2f81-484c-af10-45240bee4c04_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_8e030d8d-6d68-4d72-9203-768f76375c57_negatedLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_df1fd826-4b3e-4a32-a4bb-bc69cbf431c5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of offering costs in connection with the issuance of ordinary shares</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_MrSinhaMember_7cdca97e-ddf5-4ffd-8c2b-a49b4dba5c65_terseLabel_en-US" xlink:label="lab_vrna_MrSinhaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mr. Sinha</link:label>
    <link:label id="lab_vrna_MrSinhaMember_label_en-US" xlink:label="lab_vrna_MrSinhaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mr. Sinha [Member]</link:label>
    <link:label id="lab_vrna_MrSinhaMember_documentation_en-US" xlink:label="lab_vrna_MrSinhaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mr. Sinha</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_MrSinhaMember" xlink:href="vrna-20201231.xsd#vrna_MrSinhaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_MrSinhaMember" xlink:to="lab_vrna_MrSinhaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_60860cd2-123d-401e-9180-8bf6d26cbb86_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_a81a953d-9cb1-4d46-8799-473c96819881_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3583f505-9b34-4aca-904d-d255d5a983c1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_2722e4c7-7a65-4d14-b39b-0a461252123c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_3aa36f90-9cf2-4fff-8e21-5459d09fe1e5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b6eeb3a8-9110-4066-8314-e38aaf175fa7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_945ac5a5-7cb8-4593-8574-b1a83588830b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">People related costs</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ScheduleOfNontradeReceivablesTableTextBlock_f5f05479-4f66-41d6-bdfc-21ba608ed8a1_terseLabel_en-US" xlink:label="lab_vrna_ScheduleOfNontradeReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Taxes Receivable</link:label>
    <link:label id="lab_vrna_ScheduleOfNontradeReceivablesTableTextBlock_label_en-US" xlink:label="lab_vrna_ScheduleOfNontradeReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Nontrade Receivables [Table Text Block]</link:label>
    <link:label id="lab_vrna_ScheduleOfNontradeReceivablesTableTextBlock_documentation_en-US" xlink:label="lab_vrna_ScheduleOfNontradeReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Nontrade Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ScheduleOfNontradeReceivablesTableTextBlock" xlink:href="vrna-20201231.xsd#vrna_ScheduleOfNontradeReceivablesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ScheduleOfNontradeReceivablesTableTextBlock" xlink:to="lab_vrna_ScheduleOfNontradeReceivablesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_5a1e27ce-bbfd-485f-9ce8-8189a216ef91_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold_ff75e800-7d97-4f1f-8e66-0c75213ed416_terseLabel_en-US" xlink:label="lab_vrna_DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Default threshold of attachment or judgment on any of borrower&#8217;s assets</link:label>
    <link:label id="lab_vrna_DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold_label_en-US" xlink:label="lab_vrna_DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Debt Default, Attachment Or Judgment On Any Borrower&#8217;s Assets Threshold</link:label>
    <link:label id="lab_vrna_DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold_documentation_en-US" xlink:label="lab_vrna_DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Debt Default, Attachment Or Judgment On Any Borrower&#8217;s Assets Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold" xlink:href="vrna-20201231.xsd#vrna_DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold" xlink:to="lab_vrna_DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_PrepaidResearchAndDevelopmentFeesCurrent_f63487a0-72e9-418f-b7f2-a92379f316d1_terseLabel_en-US" xlink:label="lab_vrna_PrepaidResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial and other development costs</link:label>
    <link:label id="lab_vrna_PrepaidResearchAndDevelopmentFeesCurrent_label_en-US" xlink:label="lab_vrna_PrepaidResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research And Development Fees, Current</link:label>
    <link:label id="lab_vrna_PrepaidResearchAndDevelopmentFeesCurrent_documentation_en-US" xlink:label="lab_vrna_PrepaidResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research And Development Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PrepaidResearchAndDevelopmentFeesCurrent" xlink:href="vrna-20201231.xsd#vrna_PrepaidResearchAndDevelopmentFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_PrepaidResearchAndDevelopmentFeesCurrent" xlink:to="lab_vrna_PrepaidResearchAndDevelopmentFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_089fdaa2-66a3-4d5b-bb23-4b4d4c0d0d67_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_0d45dab3-5607-45b2-89b8-2300fc19fef2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c23fed04-d607-48a7-b3bc-10f57cecc7fc_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_1bb7251a-e191-4568-8184-36a628a4fadb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_5664f8fb-3af8-46be-be1a-25f1f4fe97eb_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_1ba2c496-689e-4a9b-8500-36bc533b4e20_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_1e042993-28c7-42bd-9239-ef8434da3923_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_83f0db1c-33b1-4160-89bc-2d75871d7f95_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_TermLoanFacilityMember_412242e6-453d-462b-866e-f162b80f2074_terseLabel_en-US" xlink:label="lab_vrna_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility</link:label>
    <link:label id="lab_vrna_TermLoanFacilityMember_label_en-US" xlink:label="lab_vrna_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:label id="lab_vrna_TermLoanFacilityMember_documentation_en-US" xlink:label="lab_vrna_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermLoanFacilityMember" xlink:href="vrna-20201231.xsd#vrna_TermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_TermLoanFacilityMember" xlink:to="lab_vrna_TermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_b0df76aa-9f66-438f-af9a-036a18da0305_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b17b6184-8120-4fc3-8e19-51e34bd12a34_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f9ca56f8-67c6-44a9-b29a-d4238cc3af0e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_3056e956-2ab1-4f1c-b738-343bde8fd573_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_df0d0bfd-2d06-4af9-bbfa-f4361dd306cf_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term to exercise</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_e8cd39e7-5555-4e37-9ed7-4ad2bf92e283_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7e6daf52-fe75-4659-8152-3d15aab0f861_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_78ebd03f-eb1f-4913-b7cc-06d4478a656b_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_931d24e5-2317-440c-b807-6a4e8fed5d5c_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_445900ba-fab5-4958-b4ca-f252352040e9_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e99ea088-e674-4583-9f63-80dea4e6ddc1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_81c449af-b766-408a-a989-3ecfc17b6f3c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_3b775905-a8d7-4b23-9f05-a64e4e6b9b28_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_af24ded7-359a-46aa-84f6-92bbc2fa02cc_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_146ce644-b06c-4f2c-851a-6b57989a307d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_7a702398-80ce-48e9-91ec-fa9553796ad1_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_3bf05783-0562-4eba-abb1-4490778ecb13_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_520b0749-bc2a-45f8-82c4-d36f7cfcdbd2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ab03b892-c7f2-4f2e-ae61-1b08ef6a6005_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_99facbfb-6660-418d-be6a-aec683497ea7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock_3f097193-22d8-4545-b105-6e258d1431fe_terseLabel_en-US" xlink:label="lab_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income - U.K. R&amp;D tax credits</link:label>
    <link:label id="lab_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Tax Credits, Policy [Policy Text Block]</link:label>
    <link:label id="lab_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Tax Credits, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock" xlink:href="vrna-20201231.xsd#vrna_GovernmentTaxCreditsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock" xlink:to="lab_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_00029502-04ab-45ff-a244-678efd35fcd8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0ddde80f-842a-4f50-9ddd-4eadf7e992de_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_UnrealizedGainLossOnWarrants_27c3c802-c872-4602-a864-4b1b959d8967_terseLabel_en-US" xlink:label="lab_vrna_UnrealizedGainLossOnWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value movement on warrants</link:label>
    <link:label id="lab_vrna_UnrealizedGainLossOnWarrants_label_en-US" xlink:label="lab_vrna_UnrealizedGainLossOnWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) On Warrants</link:label>
    <link:label id="lab_vrna_UnrealizedGainLossOnWarrants_documentation_en-US" xlink:label="lab_vrna_UnrealizedGainLossOnWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) On Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_UnrealizedGainLossOnWarrants" xlink:href="vrna-20201231.xsd#vrna_UnrealizedGainLossOnWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_UnrealizedGainLossOnWarrants" xlink:to="lab_vrna_UnrealizedGainLossOnWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b618567e-720d-4a90-8eaa-dd605b1daea6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_eed0a2ed-fffa-4b87-8333-42bdfbf8b164_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_0e373d1c-dae2-4067-9b87-d98bee8888b0_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_fd03a328-abbd-4fb4-8647-bce2665211e4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss available to ordinary shareholders - diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_e48106dc-9f21-4289-aa65-92ad06dfc921_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic and fair value, vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_2f427614-1f09-4421-b4cc-e59fb143e426_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_fa5cf2ee-5f08-44c7-ad6b-247868d4880c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible expenses</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c8234a6a-1529-43c1-a56f-99960ca4bff2_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_198c40ee-4110-4ed5-b40f-67ae20cb7584_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocation of Share Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_e781231c-85a7-4e0f-a884-3e888e2ba80f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_518105bb-dff6-43d4-b745-c6e679d6dcb7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_RestrictedStockUnitMilestoneBasedVestingMember_23be46f7-22eb-45fe-b9c6-f809dc0be352_terseLabel_en-US" xlink:label="lab_vrna_RestrictedStockUnitMilestoneBasedVestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone-Based Vesting</link:label>
    <link:label id="lab_vrna_RestrictedStockUnitMilestoneBasedVestingMember_label_en-US" xlink:label="lab_vrna_RestrictedStockUnitMilestoneBasedVestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit, Milestone-Based Vesting [Member]</link:label>
    <link:label id="lab_vrna_RestrictedStockUnitMilestoneBasedVestingMember_documentation_en-US" xlink:label="lab_vrna_RestrictedStockUnitMilestoneBasedVestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit, Milestone-Based Vesting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RestrictedStockUnitMilestoneBasedVestingMember" xlink:href="vrna-20201231.xsd#vrna_RestrictedStockUnitMilestoneBasedVestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_RestrictedStockUnitMilestoneBasedVestingMember" xlink:to="lab_vrna_RestrictedStockUnitMilestoneBasedVestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_f6bff7a7-c27d-4fd2-aee6-aefcb37a10d8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate (in percent)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_d2a2ef9f-2d8c-4aaa-a8c4-8b90651130a5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Difference in overseas statutory tax rates</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_d57bb192-ae19-4a3f-8010-0d2dca42f00f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_0935d985-aab2-435c-90e0-51a92b95e2b9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation differences recognized in other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_c631ce83-fef9-476c-8d99-26f0673fbe48_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution cost</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate_198e494f-03ad-4424-9dbf-85323e6aa918_terseLabel_en-US" xlink:label="lab_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">10% volatility increase</link:label>
    <link:label id="lab_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate_label_en-US" xlink:label="lab_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis Of Fair Value, Warrant Liability, Impact of 10 Percent Increase In Volatility Rate</link:label>
    <link:label id="lab_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate_documentation_en-US" xlink:label="lab_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis Of Fair Value, Warrant Liability, Impact of 10 Percent Increase In Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate" xlink:href="vrna-20201231.xsd#vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate" xlink:to="lab_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ClassOfWarrantOrRightIntrinsicValue_29f345ae-6be9-4fc6-9e41-4519ffb5042a_terseLabel_en-US" xlink:label="lab_vrna_ClassOfWarrantOrRightIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value</link:label>
    <link:label id="lab_vrna_ClassOfWarrantOrRightIntrinsicValue_label_en-US" xlink:label="lab_vrna_ClassOfWarrantOrRightIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Intrinsic Value</link:label>
    <link:label id="lab_vrna_ClassOfWarrantOrRightIntrinsicValue_documentation_en-US" xlink:label="lab_vrna_ClassOfWarrantOrRightIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ClassOfWarrantOrRightIntrinsicValue" xlink:href="vrna-20201231.xsd#vrna_ClassOfWarrantOrRightIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ClassOfWarrantOrRightIntrinsicValue" xlink:to="lab_vrna_ClassOfWarrantOrRightIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_62c5b531-a524-49b6-ad1f-6bc605e51c10_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_b328ecac-8e87-49f0-8ec7-3dfbc8f3514a_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_23eee888-40ca-42a2-8697-2e87c8256406_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_541f70ab-0deb-4d51-8ce5-75053523b41b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance_0f331e81-f2b2-4aa9-b7d7-8ab199571924_terseLabel_en-US" xlink:label="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in valuation allowance</link:label>
    <link:label id="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance_label_en-US" xlink:label="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule 12-09, Valuation Allowances and Reserves, Increase In Valuation Allowance</link:label>
    <link:label id="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance_documentation_en-US" xlink:label="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule 12-09, Valuation Allowances and Reserves, Increase In Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance" xlink:href="vrna-20201231.xsd#vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance" xlink:to="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_FairValueImpactOfIncreaseOrDecreaseInVolatilityTableTextBlock_6df8580e-11ab-413a-9a36-12e990c3f755_terseLabel_en-US" xlink:label="lab_vrna_FairValueImpactOfIncreaseOrDecreaseInVolatilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Impact Of Increase Or Decrease in Volatility</link:label>
    <link:label id="lab_vrna_FairValueImpactOfIncreaseOrDecreaseInVolatilityTableTextBlock_label_en-US" xlink:label="lab_vrna_FairValueImpactOfIncreaseOrDecreaseInVolatilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Impact Of Increase Or Decrease in Volatility [Table Text Block]</link:label>
    <link:label id="lab_vrna_FairValueImpactOfIncreaseOrDecreaseInVolatilityTableTextBlock_documentation_en-US" xlink:label="lab_vrna_FairValueImpactOfIncreaseOrDecreaseInVolatilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Impact Of Increase Or Decrease in Volatility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_FairValueImpactOfIncreaseOrDecreaseInVolatilityTableTextBlock" xlink:href="vrna-20201231.xsd#vrna_FairValueImpactOfIncreaseOrDecreaseInVolatilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_FairValueImpactOfIncreaseOrDecreaseInVolatilityTableTextBlock" xlink:to="lab_vrna_FairValueImpactOfIncreaseOrDecreaseInVolatilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3c88ebdb-6226-4c10-9a53-88b549ed1423_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_59da3f1a-29b6-4290-8ff6-b26f4832716e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Private Placement to Related Parties</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_be291191-6855-4369-ba34-2ddf0e168f98_verboseLabel_en-US" xlink:label="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax and tax incentive receivables</link:label>
    <link:label id="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_903e7aef-6722-4ebf-b793-0b40643d894d_totalLabel_en-US" xlink:label="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total tax receivable</link:label>
    <link:label id="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_label_en-US" xlink:label="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit And Income Taxes Receivable, Current</link:label>
    <link:label id="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_documentation_en-US" xlink:label="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit And Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:href="vrna-20201231.xsd#vrna_TaxCreditAndIncomeTaxesReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:to="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f64f1a95-aadc-4187-aca9-84f56bf56836_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_3790fa1e-d056-4085-baf9-6e5f925bc59e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_08c5292d-40fc-4526-8924-41fc4d13a683_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_ec985efe-9d3e-4ad8-bea4-72da599470df_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7c891c80-3dd0-4906-94c9-1436bd945c64_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Annual Operating Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_f7ef093f-de70-4b72-abbd-5a749151ff65_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_eff4cba0-166c-420a-ad48-538a3d50b40b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ad165024-ee6c-4523-819b-995276f1a292_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited, Weight average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_6e41ff24-cdff-4cff-a3d3-13f02cef1917_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_113a9a65-139b-4ef8-9844-32660d6e6853_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Rental Commitments Under Non-cancelable Leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_A2017IncentivePlanMember_409f99c8-b1f7-4309-8ea6-2aab298bd235_terseLabel_en-US" xlink:label="lab_vrna_A2017IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Incentive Plan</link:label>
    <link:label id="lab_vrna_A2017IncentivePlanMember_label_en-US" xlink:label="lab_vrna_A2017IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Incentive Plan [Member]</link:label>
    <link:label id="lab_vrna_A2017IncentivePlanMember_documentation_en-US" xlink:label="lab_vrna_A2017IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2017IncentivePlanMember" xlink:href="vrna-20201231.xsd#vrna_A2017IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_A2017IncentivePlanMember" xlink:to="lab_vrna_A2017IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_d8f91560-3509-493a-abc2-7aa6ea593927_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1803efb8-0cfe-4963-86ca-ef4ae5081286_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_ba4cfd90-6907-4773-ac96-369732eb87f0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares called by each warrant</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_31b88c22-0501-4bb0-93d2-26e210e5e19d_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_3805c31a-3cfb-4ff5-a652-ecc5d2b5297b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_a376016c-7dbd-4c7c-8b64-7b4ef526275f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_afe37178-3eef-4b8a-b92b-42d4b5bc6537_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_0a44c000-58ba-4b0f-bd77-6d55f327d70a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) / income:</link:label>
    <link:label id="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Other Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_8434574b-d260-4650-af3b-447d1566f666_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets recognized with associated liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_859f8da4-70c7-4ee3-b0f8-bf0ec02817a4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_51394335-2d7e-4343-8de8-06a4f17bd7c7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_351b65fa-823e-460e-b893-4677572c3370_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_66c0603f-7ce9-4b44-922c-a5f8c3e1db1d_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange gain / (loss)</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_de9c7aab-df9a-4eb0-8202-b3087aaa82a4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange (gain) / loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_47044dbf-3a88-4476-bb1d-4e403f7c7e0f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_bb6abddf-4b80-46e4-8f8e-fb37b28617ed_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_ae14e8a5-4315-4641-9e1f-a015f9229b54_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_7a88f947-4443-4d81-88e7-da281ddc7261_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3ab786fe-6a55-4f13-b7ae-be5981c023ce_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f0c48974-31b5-4547-8883-efa30edf4759_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_fa19eb04-71b5-4728-bef4-ed1db7292a7b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAccrued_2baf1de2-d5f9-46f2-8782-fe5cc95daf8b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Penalties accrued</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAccrued_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Penalties Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAccrued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAccrued" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_605cb227-c2ca-4686-97ce-3684a023cb3b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_509841e0-3277-4411-b6f2-038b9f65666c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e69f3eef-c8b1-462a-a08f-46b5c978d656_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_0a10a097-ace6-4441-b38a-48f8809619e0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8aa67376-b8c1-4fd0-9dd4-260c79b534ba_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_854af221-03c7-457a-9456-7fd877c12167_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_b1458252-ba6b-4604-9054-228d012a3b23_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtPrepaymentPeriodOneMember_936fd000-ebeb-4ac6-999e-03515b66e489_terseLabel_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Anniversary</link:label>
    <link:label id="lab_vrna_DebtPrepaymentPeriodOneMember_label_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Prepayment Period One [Member]</link:label>
    <link:label id="lab_vrna_DebtPrepaymentPeriodOneMember_documentation_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Prepayment Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodOneMember" xlink:href="vrna-20201231.xsd#vrna_DebtPrepaymentPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtPrepaymentPeriodOneMember" xlink:to="lab_vrna_DebtPrepaymentPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_dfb7f784-f6bf-4deb-b43c-e749d481f6c9_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_cdcef70d-e74b-471e-996e-d6be1e414ef6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Movement of the Value of the Warrants</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_7960e44f-e77d-4a1f-8438-2db6e7d70050_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b32752ff-4664-4696-b565-a9487dada7ee_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Activity</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_5214dfc4-7f0f-4014-bbe9-fd5532b975fa_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_2885eb44-1db2-44db-bcc9-e90c89d93e42_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount drawn down</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f71f95a9-7840-4c85-8a30-cb03af59e824_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_PreIPOOptionPlanMember_15afc5df-8a36-438c-b223-3c8ee9f16899_terseLabel_en-US" xlink:label="lab_vrna_PreIPOOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-IPO Option Plan</link:label>
    <link:label id="lab_vrna_PreIPOOptionPlanMember_label_en-US" xlink:label="lab_vrna_PreIPOOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-IPO Option Plan [Member]</link:label>
    <link:label id="lab_vrna_PreIPOOptionPlanMember_documentation_en-US" xlink:label="lab_vrna_PreIPOOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-IPO Option Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PreIPOOptionPlanMember" xlink:href="vrna-20201231.xsd#vrna_PreIPOOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_PreIPOOptionPlanMember" xlink:to="lab_vrna_PreIPOOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_402e807f-af6e-4637-ba25-a4149499aae1_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_5ebd89dd-8745-4b35-98f8-73998fce7687_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_5ed6fbc0-7666-4e93-b714-b0c77ab7d1a2_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_44ac69c9-880b-4ed7-8922-7773cf820130_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue_a5b1aff9-5709-40f9-a5d9-be73c7e3a4e7_terseLabel_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value for instruments granted during period</link:label>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue_label_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Grant Date Fair Value</link:label>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue_documentation_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue" xlink:href="vrna-20201231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue" xlink:to="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_1e93d715-4bae-4915-8d2f-dc0afac8fb48_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_7443c301-8023-465d-b057-f0277c579cdd_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_a09cb131-e9f3-4009-9ff0-67dec628e841_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issue costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8832afeb-96f8-4d80-9744-4a289fcd4ade_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future exercisable shares</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_6518cafd-2c5d-4da5-9707-dd75c95a17ec_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7a74c2bc-b32b-45ca-a454-41d84b729a0f_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_e480ad92-cd73-4d09-96d5-89d7253f6caf_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9a6954fb-619b-4fde-9b86-78feb5ece59e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option activity, additional disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e055b1fe-c11c-422b-b0bc-1a472262b4d7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Weighted average remaining contractual term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_56cf383c-db8c-43a2-a1a6-4ebaaed6308b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc2c9359-2eaa-4650-b8e2-cfd3ee5f0f62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_9f69d926-cd04-436a-b3e3-8706002d9231_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_fabc092c-c2f6-401a-a819-8c5c74bd307b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_82e04dff-e1f2-4806-9d45-8ccad65eaae3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_bba13f5c-9033-48f6-b384-1b9f57cb1628_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Weight average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtPrepaymentPeriodAxis_9d87d00e-b61f-4dd7-b6c0-ce5356b8f582_terseLabel_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Prepayment Period</link:label>
    <link:label id="lab_vrna_DebtPrepaymentPeriodAxis_label_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Prepayment Period [Axis]</link:label>
    <link:label id="lab_vrna_DebtPrepaymentPeriodAxis_documentation_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Prepayment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodAxis" xlink:href="vrna-20201231.xsd#vrna_DebtPrepaymentPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtPrepaymentPeriodAxis" xlink:to="lab_vrna_DebtPrepaymentPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_40e3cac1-3609-45e7-94ac-e1d215cef32c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtInstrumentCovenantCashAndCashEquivalentsMinimum_d314f81c-73a2-40f4-a838-8dea67173619_terseLabel_en-US" xlink:label="lab_vrna_DebtInstrumentCovenantCashAndCashEquivalentsMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan covenant, minimum cash and cash equivalents</link:label>
    <link:label id="lab_vrna_DebtInstrumentCovenantCashAndCashEquivalentsMinimum_label_en-US" xlink:label="lab_vrna_DebtInstrumentCovenantCashAndCashEquivalentsMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Cash and Cash Equivalents, Minimum</link:label>
    <link:label id="lab_vrna_DebtInstrumentCovenantCashAndCashEquivalentsMinimum_documentation_en-US" xlink:label="lab_vrna_DebtInstrumentCovenantCashAndCashEquivalentsMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Cash and Cash Equivalents, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentCovenantCashAndCashEquivalentsMinimum" xlink:href="vrna-20201231.xsd#vrna_DebtInstrumentCovenantCashAndCashEquivalentsMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtInstrumentCovenantCashAndCashEquivalentsMinimum" xlink:to="lab_vrna_DebtInstrumentCovenantCashAndCashEquivalentsMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_c4f61c67-5916-427c-9c18-8c49bc54ea80_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares held in treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_6e7a2634-f276-4e32-99be-ca8f4d6caa60_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_7d210fed-5eeb-49e9-b3ad-7355dd1c8f4b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_afc23f5c-d0e8-406b-adea-b3669cee394e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e771c5d1-fd24-4a01-8df2-6cfead4ccdf3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.K. tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_5516ea0d-47d3-4685-8db5-53dde04296ce_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_779d28ec-6c81-4192-baea-a541e194e685_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_78745f44-7da6-40dc-b5be-585356e904d4_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_42bf7f84-e97a-4d0d-8204-9038f7ee618a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired, Weight average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_844667ca-c768-4576-bf4b-4ec344c22c64_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently adopted accounting pronouncements and Recently issued accounting pronouncements, not yet adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_868563ed-a330-455f-9855-c19cc4cee5a5_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_1b63acaa-fdca-48fa-9b27-f9ede77792b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>vrna-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0ccc0c69-9480-4ff0-8704-1a461378680d,g:39118e12-eba9-4fb3-8b93-ef28b95cf059-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://veronapharma.com/role/Cover" xlink:type="simple" xlink:href="vrna-20201231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8a03a288-b199-4c74-9a27-455c5cfad417" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_DocumentType_8a03a288-b199-4c74-9a27-455c5cfad417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_a1cca9e5-4968-4d15-ab12-fe98961b4b0d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_DocumentAnnualReport_a1cca9e5-4968-4d15-ab12-fe98961b4b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3ec1f335-e034-489f-bcd6-432de363efbd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_DocumentPeriodEndDate_3ec1f335-e034-489f-bcd6-432de363efbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a7c4e1f3-db2f-4dad-9c6d-5dbccc2cafca" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_CurrentFiscalYearEndDate_a7c4e1f3-db2f-4dad-9c6d-5dbccc2cafca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_8249a933-d463-4641-ab26-221609355934" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_DocumentTransitionReport_8249a933-d463-4641-ab26-221609355934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ed96b725-ea5a-466d-95f2-2c87182b61f0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_EntityFileNumber_ed96b725-ea5a-466d-95f2-2c87182b61f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b5b268f0-5c50-46ad-90f1-b428317d069a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_EntityRegistrantName_b5b268f0-5c50-46ad-90f1-b428317d069a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9ab4d15d-fdaa-4215-938b-e7bd5cb01010" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9ab4d15d-fdaa-4215-938b-e7bd5cb01010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_9d16710a-7c81-42ef-a450-8ff34ff2f58f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_EntityTaxIdentificationNumber_9d16710a-7c81-42ef-a450-8ff34ff2f58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3d2130e5-b404-4f89-80b6-90829efbee1e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_EntityAddressAddressLine1_3d2130e5-b404-4f89-80b6-90829efbee1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_98aa4c23-2b3c-4a81-969e-e70e8e56bb86" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_EntityAddressCityOrTown_98aa4c23-2b3c-4a81-969e-e70e8e56bb86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ca471243-82c5-45f3-8f48-8457929970f9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_EntityAddressPostalZipCode_ca471243-82c5-45f3-8f48-8457929970f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_c3cecfcb-fcf6-47ba-9536-4eed98a2a359" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_EntityAddressCountry_c3cecfcb-fcf6-47ba-9536-4eed98a2a359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion_c757a6d3-436a-4afb-8ae4-b3393b3f5a93" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_CountryRegion_c757a6d3-436a-4afb-8ae4-b3393b3f5a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_008ecf82-63d8-423f-8907-966658bd63f6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_CityAreaCode_008ecf82-63d8-423f-8907-966658bd63f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5c88e7c9-c721-4983-bacb-1c60788d2229" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_LocalPhoneNumber_5c88e7c9-c721-4983-bacb-1c60788d2229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c7d402f1-2233-4e8b-9ecf-5a3a321c7078" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_Security12bTitle_c7d402f1-2233-4e8b-9ecf-5a3a321c7078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d24609fb-f809-4b6b-bb3e-41d8b8453ea2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_TradingSymbol_d24609fb-f809-4b6b-bb3e-41d8b8453ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_db27b91f-8bab-4f46-8ca7-522f621a382c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_SecurityExchangeName_db27b91f-8bab-4f46-8ca7-522f621a382c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_b58f5dac-62ed-41ea-a166-117dfd822ce8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_b58f5dac-62ed-41ea-a166-117dfd822ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_307f49a4-b180-468d-859b-a3da7d447dc1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_EntityVoluntaryFilers_307f49a4-b180-468d-859b-a3da7d447dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_f7c73162-d73c-4177-9f77-cdd7efb8e2a8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_EntityCurrentReportingStatus_f7c73162-d73c-4177-9f77-cdd7efb8e2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_d8edf7d3-46a3-4309-a1f8-0a23d2fbf8ea" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_EntityInteractiveDataCurrent_d8edf7d3-46a3-4309-a1f8-0a23d2fbf8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e25564cb-1645-4b6d-b2ad-4a3de8fb738f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_EntityFilerCategory_e25564cb-1645-4b6d-b2ad-4a3de8fb738f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_9a176dc9-32bb-4b4a-9d2b-33be08f16f9b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_EntitySmallBusiness_9a176dc9-32bb-4b4a-9d2b-33be08f16f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6fbe23da-7c68-4b6c-9b82-80b5364cdb57" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_EntityEmergingGrowthCompany_6fbe23da-7c68-4b6c-9b82-80b5364cdb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_cc550fed-2304-4ddd-8b13-3261ab4bd055" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_EntityExTransitionPeriod_cc550fed-2304-4ddd-8b13-3261ab4bd055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_fad9d728-7c52-4534-885d-51a26a6d1698" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_EntityShellCompany_fad9d728-7c52-4534-885d-51a26a6d1698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_34d6a07f-3078-4340-85de-0b5a1f5285dd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_IcfrAuditorAttestationFlag_34d6a07f-3078-4340-85de-0b5a1f5285dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_50d6e423-bdab-4e11-b2d3-409abbebe074" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_EntityPublicFloat_50d6e423-bdab-4e11-b2d3-409abbebe074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_283ce147-c065-4c1e-824c-44f0c2a50cea" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_283ce147-c065-4c1e-824c-44f0c2a50cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_c1805cee-2aa9-4a1d-beed-fda651aba089" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_c1805cee-2aa9-4a1d-beed-fda651aba089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_404127be-7719-40e5-a4e7-7d98b95caf8a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_AmendmentFlag_404127be-7719-40e5-a4e7-7d98b95caf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f6f6fc7c-7ace-4f6b-9064-f2a11299c0c7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_DocumentFiscalYearFocus_f6f6fc7c-7ace-4f6b-9064-f2a11299c0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_85fc85c0-ac45-4f8d-be45-7147ef39bf57" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_85fc85c0-ac45-4f8d-be45-7147ef39bf57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f3d7eb41-b4a3-43cd-b174-219ea5ab785b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01499b78-5e0d-490b-a6dc-a8eeb89bc2f4" xlink:to="loc_dei_EntityCentralIndexKey_f3d7eb41-b4a3-43cd-b174-219ea5ab785b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vrna-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ff902c04-90cf-44e9-a53f-d7fe19ad1984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_2eca72a0-68ef-4f92-867d-96a5ab7bf7ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ff902c04-90cf-44e9-a53f-d7fe19ad1984" xlink:to="loc_us-gaap_AssetsAbstract_2eca72a0-68ef-4f92-867d-96a5ab7bf7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f712859b-d03c-41f0-b063-8689b2266b88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2eca72a0-68ef-4f92-867d-96a5ab7bf7ad" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f712859b-d03c-41f0-b063-8689b2266b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b57c69ad-52f0-4507-8966-dcb86c9652be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f712859b-d03c-41f0-b063-8689b2266b88" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b57c69ad-52f0-4507-8966-dcb86c9652be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_ac122bd3-94ab-482f-860d-3aa8b9ddd7e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f712859b-d03c-41f0-b063-8689b2266b88" xlink:to="loc_us-gaap_ShortTermInvestments_ac122bd3-94ab-482f-860d-3aa8b9ddd7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_bcde9485-0ca4-445d-a8d0-399f63d2da86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f712859b-d03c-41f0-b063-8689b2266b88" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_bcde9485-0ca4-445d-a8d0-399f63d2da86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_b50adbf3-00d9-4970-992d-493635eba1db" xlink:href="vrna-20201231.xsd#vrna_TaxCreditAndIncomeTaxesReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f712859b-d03c-41f0-b063-8689b2266b88" xlink:to="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_b50adbf3-00d9-4970-992d-493635eba1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_458ec022-39ff-4641-ba89-2ffbb11e91a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f712859b-d03c-41f0-b063-8689b2266b88" xlink:to="loc_us-gaap_OtherAssetsCurrent_458ec022-39ff-4641-ba89-2ffbb11e91a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5a3a7027-7222-4383-8342-cb69d81fc9f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f712859b-d03c-41f0-b063-8689b2266b88" xlink:to="loc_us-gaap_AssetsCurrent_5a3a7027-7222-4383-8342-cb69d81fc9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_bf3929cc-b7b1-4e31-9b90-19690baafc29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2eca72a0-68ef-4f92-867d-96a5ab7bf7ad" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_bf3929cc-b7b1-4e31-9b90-19690baafc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a511889f-d948-4e32-99af-7f1d27b31da2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bf3929cc-b7b1-4e31-9b90-19690baafc29" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a511889f-d948-4e32-99af-7f1d27b31da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a9c2e21f-8375-4be6-814d-a762d2bb2a3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bf3929cc-b7b1-4e31-9b90-19690baafc29" xlink:to="loc_us-gaap_Goodwill_a9c2e21f-8375-4be6-814d-a762d2bb2a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e99b6d5b-5d77-45ee-8d7f-3b809bb62dea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bf3929cc-b7b1-4e31-9b90-19690baafc29" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e99b6d5b-5d77-45ee-8d7f-3b809bb62dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_90bd1db2-0120-4649-9cd3-a7025b5eabe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bf3929cc-b7b1-4e31-9b90-19690baafc29" xlink:to="loc_us-gaap_AssetsNoncurrent_90bd1db2-0120-4649-9cd3-a7025b5eabe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_dfc5c203-aba6-4f2f-87f7-81cc332f71c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2eca72a0-68ef-4f92-867d-96a5ab7bf7ad" xlink:to="loc_us-gaap_Assets_dfc5c203-aba6-4f2f-87f7-81cc332f71c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_be2cc475-5b10-48d2-85dd-2989d470e59c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ff902c04-90cf-44e9-a53f-d7fe19ad1984" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_be2cc475-5b10-48d2-85dd-2989d470e59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5d291981-6fe6-47ff-a610-a9ea3215c581" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_be2cc475-5b10-48d2-85dd-2989d470e59c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5d291981-6fe6-47ff-a610-a9ea3215c581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0ace75fd-08a2-4f25-895a-fe768ea16d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5d291981-6fe6-47ff-a610-a9ea3215c581" xlink:to="loc_us-gaap_AccountsPayableCurrent_0ace75fd-08a2-4f25-895a-fe768ea16d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1c0f89ac-7a4d-45f3-a509-b591f9525e13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5d291981-6fe6-47ff-a610-a9ea3215c581" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1c0f89ac-7a4d-45f3-a509-b591f9525e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7ef4311c-1566-4bb9-954f-f096b04c849d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5d291981-6fe6-47ff-a610-a9ea3215c581" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7ef4311c-1566-4bb9-954f-f096b04c849d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_WarrantLiabilityCurrent_2439b7e4-2954-421a-a12e-28d21ba3146f" xlink:href="vrna-20201231.xsd#vrna_WarrantLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5d291981-6fe6-47ff-a610-a9ea3215c581" xlink:to="loc_vrna_WarrantLiabilityCurrent_2439b7e4-2954-421a-a12e-28d21ba3146f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_b15bae1c-c6fc-482e-a710-7dabec9433f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5d291981-6fe6-47ff-a610-a9ea3215c581" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_b15bae1c-c6fc-482e-a710-7dabec9433f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2d8e3df9-efb2-48c2-ad48-47e935da3cc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5d291981-6fe6-47ff-a610-a9ea3215c581" xlink:to="loc_us-gaap_LiabilitiesCurrent_2d8e3df9-efb2-48c2-ad48-47e935da3cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a25cdc2-7e41-4782-af0d-45a03fef0b67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_be2cc475-5b10-48d2-85dd-2989d470e59c" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a25cdc2-7e41-4782-af0d-45a03fef0b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_47ebf209-9c56-4e5b-adbd-f70782c30da8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a25cdc2-7e41-4782-af0d-45a03fef0b67" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_47ebf209-9c56-4e5b-adbd-f70782c30da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b7db2a55-a8d9-4e2a-9741-1381a1f7d5d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a25cdc2-7e41-4782-af0d-45a03fef0b67" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b7db2a55-a8d9-4e2a-9741-1381a1f7d5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_5cb9d9a7-a48c-4166-b206-6b3075bd3050" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a25cdc2-7e41-4782-af0d-45a03fef0b67" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_5cb9d9a7-a48c-4166-b206-6b3075bd3050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9d06dfef-8605-450a-856b-d64818058019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_be2cc475-5b10-48d2-85dd-2989d470e59c" xlink:to="loc_us-gaap_Liabilities_9d06dfef-8605-450a-856b-d64818058019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_75c47f73-df4c-49d2-a499-76d125c7110c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_be2cc475-5b10-48d2-85dd-2989d470e59c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_75c47f73-df4c-49d2-a499-76d125c7110c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_727280b2-bcc8-44a4-9f4b-d50a7cbd8343" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_be2cc475-5b10-48d2-85dd-2989d470e59c" xlink:to="loc_us-gaap_StockholdersEquityAbstract_727280b2-bcc8-44a4-9f4b-d50a7cbd8343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_59c3df09-35e6-4207-9753-b05fd994bcb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_727280b2-bcc8-44a4-9f4b-d50a7cbd8343" xlink:to="loc_us-gaap_CommonStockValue_59c3df09-35e6-4207-9753-b05fd994bcb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_0f5c14ce-67db-49f6-b551-a4109c71a254" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_727280b2-bcc8-44a4-9f4b-d50a7cbd8343" xlink:to="loc_us-gaap_AdditionalPaidInCapital_0f5c14ce-67db-49f6-b551-a4109c71a254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_74869193-d97b-41a6-89f0-1db5d4f37ef1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_727280b2-bcc8-44a4-9f4b-d50a7cbd8343" xlink:to="loc_us-gaap_TreasuryStockValue_74869193-d97b-41a6-89f0-1db5d4f37ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_41199881-68de-44ab-b212-9090730161c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_727280b2-bcc8-44a4-9f4b-d50a7cbd8343" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_41199881-68de-44ab-b212-9090730161c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_308791db-830e-40ea-a272-3c8918543b47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_727280b2-bcc8-44a4-9f4b-d50a7cbd8343" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_308791db-830e-40ea-a272-3c8918543b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_88f746c3-bd5b-4fb2-b040-9ae4f2912256" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_727280b2-bcc8-44a4-9f4b-d50a7cbd8343" xlink:to="loc_us-gaap_StockholdersEquity_88f746c3-bd5b-4fb2-b040-9ae4f2912256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7a38e47a-1a4a-4012-93ba-6e825821e229" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_be2cc475-5b10-48d2-85dd-2989d470e59c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_7a38e47a-1a4a-4012-93ba-6e825821e229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="vrna-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_18e6f065-58f2-49f3-a0f2-057ef70888f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9b34251e-8969-4880-b9af-1a4d10ad8e5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_18e6f065-58f2-49f3-a0f2-057ef70888f6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9b34251e-8969-4880-b9af-1a4d10ad8e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_47105da7-fc13-4dde-818e-ef7468278b90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_18e6f065-58f2-49f3-a0f2-057ef70888f6" xlink:to="loc_us-gaap_CommonStockSharesIssued_47105da7-fc13-4dde-818e-ef7468278b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_82be2ddd-1847-4961-8da8-e03e40e5907b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_18e6f065-58f2-49f3-a0f2-057ef70888f6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_82be2ddd-1847-4961-8da8-e03e40e5907b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="vrna-20201231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_e31b34f7-00af-43c4-a35e-197d4c0f292c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2f32999d-cdd6-4ea0-a279-79ee470011b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e31b34f7-00af-43c4-a35e-197d4c0f292c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2f32999d-cdd6-4ea0-a279-79ee470011b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_fc30ff8b-df63-4e75-a24f-8cb52b24d907" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2f32999d-cdd6-4ea0-a279-79ee470011b8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_fc30ff8b-df63-4e75-a24f-8cb52b24d907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8c3b2239-c84c-49d7-9f2f-17aa1e53ef44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2f32999d-cdd6-4ea0-a279-79ee470011b8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8c3b2239-c84c-49d7-9f2f-17aa1e53ef44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_cf903c01-a86e-430b-86a4-8cf6b8a7893b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2f32999d-cdd6-4ea0-a279-79ee470011b8" xlink:to="loc_us-gaap_OperatingExpenses_cf903c01-a86e-430b-86a4-8cf6b8a7893b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0615c450-9816-419c-848f-3afe78e283d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2f32999d-cdd6-4ea0-a279-79ee470011b8" xlink:to="loc_us-gaap_OperatingIncomeLoss_0615c450-9816-419c-848f-3afe78e283d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_cc1403ba-edd0-4450-a105-fd5dae4d9bc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e31b34f7-00af-43c4-a35e-197d4c0f292c" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_cc1403ba-edd0-4450-a105-fd5dae4d9bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit_74c9307e-b6db-40d4-9815-fa681e0f4f47" xlink:href="vrna-20201231.xsd#vrna_GainLossFromResearchAndDevelopmentTaxCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_cc1403ba-edd0-4450-a105-fd5dae4d9bc1" xlink:to="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit_74c9307e-b6db-40d4-9815-fa681e0f4f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_eb5004df-56c8-492c-a332-81b0c80f1e07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_cc1403ba-edd0-4450-a105-fd5dae4d9bc1" xlink:to="loc_us-gaap_InvestmentIncomeNet_eb5004df-56c8-492c-a332-81b0c80f1e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_306a2d1f-48c7-4390-9b5c-1275e86f2cb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_cc1403ba-edd0-4450-a105-fd5dae4d9bc1" xlink:to="loc_us-gaap_InterestExpense_306a2d1f-48c7-4390-9b5c-1275e86f2cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_UnrealizedGainLossOnWarrants_b45eda9b-310f-4689-ba7e-999af940bcee" xlink:href="vrna-20201231.xsd#vrna_UnrealizedGainLossOnWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_cc1403ba-edd0-4450-a105-fd5dae4d9bc1" xlink:to="loc_vrna_UnrealizedGainLossOnWarrants_b45eda9b-310f-4689-ba7e-999af940bcee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0f6e0887-2f30-4793-9582-0da4ff7a9111" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_cc1403ba-edd0-4450-a105-fd5dae4d9bc1" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0f6e0887-2f30-4793-9582-0da4ff7a9111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b6340604-7dfc-47cd-a933-df5cdfd3e40a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_cc1403ba-edd0-4450-a105-fd5dae4d9bc1" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_b6340604-7dfc-47cd-a933-df5cdfd3e40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2aaee1f7-3aa4-4b6d-9f56-e9c56c1c3941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e31b34f7-00af-43c4-a35e-197d4c0f292c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2aaee1f7-3aa4-4b6d-9f56-e9c56c1c3941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5c710a03-e1a6-4dcf-a595-5146d1fa36c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e31b34f7-00af-43c4-a35e-197d4c0f292c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5c710a03-e1a6-4dcf-a595-5146d1fa36c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2f2d1e28-fbf7-45cf-a665-fd1d2cd1cc4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e31b34f7-00af-43c4-a35e-197d4c0f292c" xlink:to="loc_us-gaap_NetIncomeLoss_2f2d1e28-fbf7-45cf-a665-fd1d2cd1cc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_ba4a0a1e-1ed3-4d2d-8a26-c5cad9c7ca8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e31b34f7-00af-43c4-a35e-197d4c0f292c" xlink:to="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_ba4a0a1e-1ed3-4d2d-8a26-c5cad9c7ca8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_99997c00-2edf-49b6-ac79-e2a6567e90f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_ba4a0a1e-1ed3-4d2d-8a26-c5cad9c7ca8e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_99997c00-2edf-49b6-ac79-e2a6567e90f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_19284ba0-eef1-4a4f-991d-1ef1277b2e8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_ba4a0a1e-1ed3-4d2d-8a26-c5cad9c7ca8e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_19284ba0-eef1-4a4f-991d-1ef1277b2e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_4603bfa9-51fd-4ad6-8d09-c778517bcd16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e31b34f7-00af-43c4-a35e-197d4c0f292c" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_4603bfa9-51fd-4ad6-8d09-c778517bcd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="vrna-20201231.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_77d95486-6f55-45e6-bec4-68641fef74dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_37305858-1143-4f78-8375-da16843687ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_77d95486-6f55-45e6-bec4-68641fef74dc" xlink:to="loc_us-gaap_StatementTable_37305858-1143-4f78-8375-da16843687ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_6c3bb5e8-db2f-4922-9652-6bfadfc915b9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_37305858-1143-4f78-8375-da16843687ca" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_6c3bb5e8-db2f-4922-9652-6bfadfc915b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_86a4ea81-cc34-40ff-87bf-a73c1cf65f45" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_6c3bb5e8-db2f-4922-9652-6bfadfc915b9" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_86a4ea81-cc34-40ff-87bf-a73c1cf65f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_a5c92bc6-22f9-4a12-bc61-ce9e1177d4a0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_86a4ea81-cc34-40ff-87bf-a73c1cf65f45" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_a5c92bc6-22f9-4a12-bc61-ce9e1177d4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_5b9a6f77-0be3-46ed-9242-b611f49cd0ab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_86a4ea81-cc34-40ff-87bf-a73c1cf65f45" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_5b9a6f77-0be3-46ed-9242-b611f49cd0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_356901aa-7358-49b4-bfb0-84fef5ac4df7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_37305858-1143-4f78-8375-da16843687ca" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_356901aa-7358-49b4-bfb0-84fef5ac4df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_42525acd-7dc5-4985-b59a-7fd413bf4478" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_356901aa-7358-49b4-bfb0-84fef5ac4df7" xlink:to="loc_us-gaap_EquityComponentDomain_42525acd-7dc5-4985-b59a-7fd413bf4478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_72c6c31f-51cf-4c2c-a13b-c847dcce3f58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_42525acd-7dc5-4985-b59a-7fd413bf4478" xlink:to="loc_us-gaap_CommonStockMember_72c6c31f-51cf-4c2c-a13b-c847dcce3f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_cb8f94dc-4dc0-40db-b703-c0fae7241e90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_42525acd-7dc5-4985-b59a-7fd413bf4478" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_cb8f94dc-4dc0-40db-b703-c0fae7241e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_0f7a5873-84c3-44bb-8111-6825e50ff750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_42525acd-7dc5-4985-b59a-7fd413bf4478" xlink:to="loc_us-gaap_TreasuryStockMember_0f7a5873-84c3-44bb-8111-6825e50ff750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fb141f81-573f-4e0f-bb74-ac92548dacb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_42525acd-7dc5-4985-b59a-7fd413bf4478" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fb141f81-573f-4e0f-bb74-ac92548dacb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_43ca5579-2b2c-4138-b59e-2acc612ed6cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_42525acd-7dc5-4985-b59a-7fd413bf4478" xlink:to="loc_us-gaap_RetainedEarningsMember_43ca5579-2b2c-4138-b59e-2acc612ed6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f1ace001-aafd-4bd0-9e89-11d8d09f5f68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_37305858-1143-4f78-8375-da16843687ca" xlink:to="loc_us-gaap_StatementLineItems_f1ace001-aafd-4bd0-9e89-11d8d09f5f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f1ace001-aafd-4bd0-9e89-11d8d09f5f68" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9dd17d54-b0f4-4e2a-8e96-80db16c99c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9dd17d54-b0f4-4e2a-8e96-80db16c99c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_345d463c-5c05-429f-9489-eb0bd48f35c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_us-gaap_StockholdersEquity_345d463c-5c05-429f-9489-eb0bd48f35c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_0584cfcc-0096-4d93-bc98-b4e0e807a328" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_0584cfcc-0096-4d93-bc98-b4e0e807a328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_509122af-4ecc-486e-af2e-4d189c735893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_us-gaap_NetIncomeLoss_509122af-4ecc-486e-af2e-4d189c735893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d460215f-f630-4677-afbc-985a8a38bc0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d460215f-f630-4677-afbc-985a8a38bc0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ce9c2f7b-8cb8-4075-bcc2-2848751c8a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ce9c2f7b-8cb8-4075-bcc2-2848751c8a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1da1af13-82ab-4f7f-930f-72bb5ac38979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1da1af13-82ab-4f7f-930f-72bb5ac38979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasury_1b946d32-3d63-4faa-8dae-04a769f9fe58" xlink:href="vrna-20201231.xsd#vrna_StockIssuedDuringPeriodSharesHeldInTreasury"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasury_1b946d32-3d63-4faa-8dae-04a769f9fe58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_StockIssuedDuringPeriodValueHeldInTreasury_d4b7293f-bc35-4b17-8c32-d5ab574d4a5a" xlink:href="vrna-20201231.xsd#vrna_StockIssuedDuringPeriodValueHeldInTreasury"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_vrna_StockIssuedDuringPeriodValueHeldInTreasury_d4b7293f-bc35-4b17-8c32-d5ab574d4a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_1c04b6d0-cfb5-4a11-b2eb-0b512488d588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_1c04b6d0-cfb5-4a11-b2eb-0b512488d588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_b90b0c75-6f82-4573-bf29-b5536fd82dd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_b90b0c75-6f82-4573-bf29-b5536fd82dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9c3e0fdd-9001-4e1f-a4f4-457ccaa2692d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9c3e0fdd-9001-4e1f-a4f4-457ccaa2692d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_87f5c6d8-9cc3-40ee-9589-f55fc55210ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_87f5c6d8-9cc3-40ee-9589-f55fc55210ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5812cedd-c1e6-4615-a108-72f6dc0c930f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1935cf5d-0caf-4213-8bcb-8748bc1efb8b" xlink:to="loc_us-gaap_StockholdersEquity_5812cedd-c1e6-4615-a108-72f6dc0c930f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="vrna-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_d5279419-4552-446e-97e8-05151407e808" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c5afcea3-39d8-41b6-aefb-aff1ea3603b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d5279419-4552-446e-97e8-05151407e808" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c5afcea3-39d8-41b6-aefb-aff1ea3603b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1e990721-66b4-407e-913e-ee729edc7181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c5afcea3-39d8-41b6-aefb-aff1ea3603b2" xlink:to="loc_us-gaap_NetIncomeLoss_1e990721-66b4-407e-913e-ee729edc7181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb82be99-427e-4921-a528-8fffc2ddeec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c5afcea3-39d8-41b6-aefb-aff1ea3603b2" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb82be99-427e-4921-a528-8fffc2ddeec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_06967305-60b0-4f12-9ed2-929a354c6241" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb82be99-427e-4921-a528-8fffc2ddeec9" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_06967305-60b0-4f12-9ed2-929a354c6241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_0ec27473-b666-4f59-9bdd-30623ed4e9e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb82be99-427e-4921-a528-8fffc2ddeec9" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_0ec27473-b666-4f59-9bdd-30623ed4e9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_bb611308-5c6f-491a-a6bd-bc6dddfac4ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb82be99-427e-4921-a528-8fffc2ddeec9" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_bb611308-5c6f-491a-a6bd-bc6dddfac4ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_38393203-3bb4-4f14-a144-5787c3c76cb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb82be99-427e-4921-a528-8fffc2ddeec9" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_38393203-3bb4-4f14-a144-5787c3c76cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_cbe39d88-6f9c-45ab-8642-bb2f1503b9ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb82be99-427e-4921-a528-8fffc2ddeec9" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_cbe39d88-6f9c-45ab-8642-bb2f1503b9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3472888f-dbad-4b0b-827e-abef3bcbb7e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb82be99-427e-4921-a528-8fffc2ddeec9" xlink:to="loc_us-gaap_ShareBasedCompensation_3472888f-dbad-4b0b-827e-abef3bcbb7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5a95bcf0-3a75-40ec-8359-cd3484955974" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb82be99-427e-4921-a528-8fffc2ddeec9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5a95bcf0-3a75-40ec-8359-cd3484955974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0df4402c-9017-4d1d-960b-732adba94ad2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb82be99-427e-4921-a528-8fffc2ddeec9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0df4402c-9017-4d1d-960b-732adba94ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_590dc247-ba21-4962-bffc-43aac97827c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0df4402c-9017-4d1d-960b-732adba94ad2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_590dc247-ba21-4962-bffc-43aac97827c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_ae65baf5-4408-49ad-9a96-995f91f96b4d" xlink:href="vrna-20201231.xsd#vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0df4402c-9017-4d1d-960b-732adba94ad2" xlink:to="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_ae65baf5-4408-49ad-9a96-995f91f96b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_708cec0e-c787-4c50-9d83-5f6d331a675a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0df4402c-9017-4d1d-960b-732adba94ad2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_708cec0e-c787-4c50-9d83-5f6d331a675a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1bdd98cc-f326-468c-868f-0820b30c03f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0df4402c-9017-4d1d-960b-732adba94ad2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1bdd98cc-f326-468c-868f-0820b30c03f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_728740f8-252d-4512-b986-c27b9bfbb2aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0df4402c-9017-4d1d-960b-732adba94ad2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_728740f8-252d-4512-b986-c27b9bfbb2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a3fc71a3-fdd0-4c3f-8fb8-d58e060e2981" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0df4402c-9017-4d1d-960b-732adba94ad2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a3fc71a3-fdd0-4c3f-8fb8-d58e060e2981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_89c9c340-3807-4a1c-b97d-cac576e0d27e" xlink:href="vrna-20201231.xsd#vrna_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0df4402c-9017-4d1d-960b-732adba94ad2" xlink:to="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_89c9c340-3807-4a1c-b97d-cac576e0d27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1cd20098-5e23-4b56-a088-e0fc47b1b034" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0df4402c-9017-4d1d-960b-732adba94ad2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1cd20098-5e23-4b56-a088-e0fc47b1b034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6636e2fc-de1c-460b-a104-48ffa3f86151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c5afcea3-39d8-41b6-aefb-aff1ea3603b2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6636e2fc-de1c-460b-a104-48ffa3f86151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_077dea50-48d0-4a62-887b-154fd49b3b07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d5279419-4552-446e-97e8-05151407e808" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_077dea50-48d0-4a62-887b-154fd49b3b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4fea2d9c-a8b1-400d-b5cc-21d89042b77a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_077dea50-48d0-4a62-887b-154fd49b3b07" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4fea2d9c-a8b1-400d-b5cc-21d89042b77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_c6de9d7e-bf8d-49f5-a1d0-34bbde36d14b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_077dea50-48d0-4a62-887b-154fd49b3b07" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_c6de9d7e-bf8d-49f5-a1d0-34bbde36d14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_ebb6556a-6c97-49ba-ab18-2f9c1f4df8c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_077dea50-48d0-4a62-887b-154fd49b3b07" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_ebb6556a-6c97-49ba-ab18-2f9c1f4df8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dc66ed6a-e3d4-41be-9217-ad4efc675348" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_077dea50-48d0-4a62-887b-154fd49b3b07" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dc66ed6a-e3d4-41be-9217-ad4efc675348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bd842233-8d9b-4fd2-a97c-8378bc92764d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d5279419-4552-446e-97e8-05151407e808" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bd842233-8d9b-4fd2-a97c-8378bc92764d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c9d3efaf-0d95-4899-89d8-daf16487ca8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bd842233-8d9b-4fd2-a97c-8378bc92764d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c9d3efaf-0d95-4899-89d8-daf16487ca8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_c8aaf6ab-5ec7-4920-80f0-52c78701ecad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bd842233-8d9b-4fd2-a97c-8378bc92764d" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_c8aaf6ab-5ec7-4920-80f0-52c78701ecad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8437f1af-1bdd-4862-ae0d-3141c39b1581" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bd842233-8d9b-4fd2-a97c-8378bc92764d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8437f1af-1bdd-4862-ae0d-3141c39b1581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_91cd09d0-acd8-4ffe-8323-15935f8b48a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bd842233-8d9b-4fd2-a97c-8378bc92764d" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_91cd09d0-acd8-4ffe-8323-15935f8b48a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_bab571b7-74ae-4e4e-bab6-5ffebe39178b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bd842233-8d9b-4fd2-a97c-8378bc92764d" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_bab571b7-74ae-4e4e-bab6-5ffebe39178b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7982bff0-18d9-41d9-9617-e31a126dd7f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bd842233-8d9b-4fd2-a97c-8378bc92764d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7982bff0-18d9-41d9-9617-e31a126dd7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9c75a793-56d8-4f91-9b16-ab4c21f9acf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d5279419-4552-446e-97e8-05151407e808" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9c75a793-56d8-4f91-9b16-ab4c21f9acf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a8691d3e-4818-4264-a065-da4f5cbe7e4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d5279419-4552-446e-97e8-05151407e808" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a8691d3e-4818-4264-a065-da4f5cbe7e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1a48dedc-09f2-41f8-afe9-f0887b42c179" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d5279419-4552-446e-97e8-05151407e808" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1a48dedc-09f2-41f8-afe9-f0887b42c179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6e8af4d1-a3ed-4fd6-84eb-9035dab19d52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d5279419-4552-446e-97e8-05151407e808" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6e8af4d1-a3ed-4fd6-84eb-9035dab19d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_2a5fa402-0119-48e5-b4ef-9f12e77d71a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d5279419-4552-446e-97e8-05151407e808" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_2a5fa402-0119-48e5-b4ef-9f12e77d71a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_9147d9a8-62aa-4656-a9af-77e34b6ea2e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_2a5fa402-0119-48e5-b4ef-9f12e77d71a8" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_9147d9a8-62aa-4656-a9af-77e34b6ea2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_4f14d72c-0efb-4036-bccf-6e1df5d71371" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_2a5fa402-0119-48e5-b4ef-9f12e77d71a8" xlink:to="loc_us-gaap_InterestPaidNet_4f14d72c-0efb-4036-bccf-6e1df5d71371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations" xlink:type="simple" xlink:href="vrna-20201231.xsd#Organizationanddescriptionofbusinessoperations"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_704dde79-b5cf-45cc-91f5-17c1365f1334" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OrganizationAndBusinessDescriptionTextBlock_44a7254d-b018-46ea-8640-ed614096ac0f" xlink:href="vrna-20201231.xsd#vrna_OrganizationAndBusinessDescriptionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_704dde79-b5cf-45cc-91f5-17c1365f1334" xlink:to="loc_vrna_OrganizationAndBusinessDescriptionTextBlock_44a7254d-b018-46ea-8640-ed614096ac0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#OrganizationConsolidationandPresentationofFinancialStatementsDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cbd99c08-5bed-4640-87fa-c07433d6473c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_NumberOfWhollyOwnedSubsidiaries_2932e64d-4396-43b8-b4cb-077e763bd5aa" xlink:href="vrna-20201231.xsd#vrna_NumberOfWhollyOwnedSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cbd99c08-5bed-4640-87fa-c07433d6473c" xlink:to="loc_vrna_NumberOfWhollyOwnedSubsidiaries_2932e64d-4396-43b8-b4cb-077e763bd5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_86386497-140d-4525-893a-0674698e089b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cbd99c08-5bed-4640-87fa-c07433d6473c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_86386497-140d-4525-893a-0674698e089b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_baa4c513-0008-47af-b08f-dee054fe3736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86386497-140d-4525-893a-0674698e089b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_baa4c513-0008-47af-b08f-dee054fe3736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e33b50b3-bc44-4a1d-a0d2-28cf21b2bd84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_baa4c513-0008-47af-b08f-dee054fe3736" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e33b50b3-bc44-4a1d-a0d2-28cf21b2bd84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_e5de81be-f0f5-4ff4-be31-d5155fca5a5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e33b50b3-bc44-4a1d-a0d2-28cf21b2bd84" xlink:to="loc_us-gaap_PrivatePlacementMember_e5de81be-f0f5-4ff4-be31-d5155fca5a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fe5817dc-fb37-4351-b1e5-c220a2f32bd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86386497-140d-4525-893a-0674698e089b" xlink:to="loc_us-gaap_DebtInstrumentAxis_fe5817dc-fb37-4351-b1e5-c220a2f32bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_74d567ab-19ad-4b8d-b13e-d1a448ef9032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_fe5817dc-fb37-4351-b1e5-c220a2f32bd8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_74d567ab-19ad-4b8d-b13e-d1a448ef9032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermLoanFacilityMember_8f52258f-d388-4970-a7f1-7dec41aed896" xlink:href="vrna-20201231.xsd#vrna_TermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_74d567ab-19ad-4b8d-b13e-d1a448ef9032" xlink:to="loc_vrna_TermLoanFacilityMember_8f52258f-d388-4970-a7f1-7dec41aed896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d31bab14-980f-4e12-b74d-4c2d67055dc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86386497-140d-4525-893a-0674698e089b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d31bab14-980f-4e12-b74d-4c2d67055dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_db2b87e6-b168-4b03-a061-0a171cad9bf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d31bab14-980f-4e12-b74d-4c2d67055dc0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_db2b87e6-b168-4b03-a061-0a171cad9bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_256ca969-8573-4723-a1ad-8a55b5405224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_db2b87e6-b168-4b03-a061-0a171cad9bf5" xlink:to="loc_us-gaap_SecuredDebtMember_256ca969-8573-4723-a1ad-8a55b5405224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_515584c9-cfd5-47e7-a624-a179f4a9e59a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86386497-140d-4525-893a-0674698e089b" xlink:to="loc_us-gaap_ClassOfStockLineItems_515584c9-cfd5-47e7-a624-a179f4a9e59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d2dc8325-3d36-4af3-8cc0-3c7f43305072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_515584c9-cfd5-47e7-a624-a179f4a9e59a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d2dc8325-3d36-4af3-8cc0-3c7f43305072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_4e8ef1b5-8b34-49f5-976f-e1589a811c0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_515584c9-cfd5-47e7-a624-a179f4a9e59a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_4e8ef1b5-8b34-49f5-976f-e1589a811c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1e2ba75d-8b7c-4de3-bd98-73a41bfc6594" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_515584c9-cfd5-47e7-a624-a179f4a9e59a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1e2ba75d-8b7c-4de3-bd98-73a41bfc6594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_73a4aff9-ee48-441a-9eec-06b4d51f0e5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_515584c9-cfd5-47e7-a624-a179f4a9e59a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_73a4aff9-ee48-441a-9eec-06b4d51f0e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_f5100456-1a0a-48ff-a06f-5655bc14a6b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_515584c9-cfd5-47e7-a624-a179f4a9e59a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_f5100456-1a0a-48ff-a06f-5655bc14a6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpolicies" xlink:type="simple" xlink:href="vrna-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingpolicies"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4e02a180-7548-4025-aaa6-ef3a484d5e6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_8d978007-c1c8-430f-b597-e0608aba3b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4e02a180-7548-4025-aaa6-ef3a484d5e6b" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_8d978007-c1c8-430f-b597-e0608aba3b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies" xlink:type="simple" xlink:href="vrna-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9dd85927-dbca-4674-bf54-6a2a468cf3fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_271c066c-8ac9-4748-8f06-1932d68f2fb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dd85927-dbca-4674-bf54-6a2a468cf3fa" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_271c066c-8ac9-4748-8f06-1932d68f2fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_df7d9ed4-ac67-4ccb-b982-c51368a710cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dd85927-dbca-4674-bf54-6a2a468cf3fa" xlink:to="loc_us-gaap_UseOfEstimates_df7d9ed4-ac67-4ccb-b982-c51368a710cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_bbccced4-fd08-4015-901c-e976c22a4c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dd85927-dbca-4674-bf54-6a2a468cf3fa" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_bbccced4-fd08-4015-901c-e976c22a4c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_a1e4e175-00d4-42a9-b7c1-036596eb059f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dd85927-dbca-4674-bf54-6a2a468cf3fa" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_a1e4e175-00d4-42a9-b7c1-036596eb059f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_a5ce4ab2-a97a-4596-a485-525cfeaa22c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dd85927-dbca-4674-bf54-6a2a468cf3fa" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_a5ce4ab2-a97a-4596-a485-525cfeaa22c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_40847e44-726e-46da-90f3-b66fb5cc486c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dd85927-dbca-4674-bf54-6a2a468cf3fa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_40847e44-726e-46da-90f3-b66fb5cc486c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_ad2ebfb3-b32a-4eaa-9784-c288410f64a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dd85927-dbca-4674-bf54-6a2a468cf3fa" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_ad2ebfb3-b32a-4eaa-9784-c288410f64a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_a221407d-71b4-4113-9edf-f615bfa87943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dd85927-dbca-4674-bf54-6a2a468cf3fa" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_a221407d-71b4-4113-9edf-f615bfa87943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_1873e0d1-6e47-4ed0-b0dd-f7b12065382c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dd85927-dbca-4674-bf54-6a2a468cf3fa" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_1873e0d1-6e47-4ed0-b0dd-f7b12065382c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_cf165553-5545-4c60-93e7-60aa2b225d3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dd85927-dbca-4674-bf54-6a2a468cf3fa" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_cf165553-5545-4c60-93e7-60aa2b225d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_443b7037-1cb6-40d4-8f72-88ee59ff70e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dd85927-dbca-4674-bf54-6a2a468cf3fa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_443b7037-1cb6-40d4-8f72-88ee59ff70e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_cd4565c1-82d8-479f-a530-7390ca9d6bdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dd85927-dbca-4674-bf54-6a2a468cf3fa" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_cd4565c1-82d8-479f-a530-7390ca9d6bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock_e26cc60b-8ea0-418c-a2e1-8c1ae308e518" xlink:href="vrna-20201231.xsd#vrna_GovernmentTaxCreditsPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dd85927-dbca-4674-bf54-6a2a468cf3fa" xlink:to="loc_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock_e26cc60b-8ea0-418c-a2e1-8c1ae308e518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_c793f3d1-f0b1-4ab2-ba41-10255b394574" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dd85927-dbca-4674-bf54-6a2a468cf3fa" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_c793f3d1-f0b1-4ab2-ba41-10255b394574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_bdd05938-a4b4-463b-a988-50b752a108c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dd85927-dbca-4674-bf54-6a2a468cf3fa" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_bdd05938-a4b4-463b-a988-50b752a108c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_ad81c674-e5a7-4b8f-92e9-a6aa5e249492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dd85927-dbca-4674-bf54-6a2a468cf3fa" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_ad81c674-e5a7-4b8f-92e9-a6aa5e249492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_5cecc1dd-72f0-4f98-825c-518890737851" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dd85927-dbca-4674-bf54-6a2a468cf3fa" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_5cecc1dd-72f0-4f98-825c-518890737851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_02eec786-9360-4304-90f8-4b405e800b56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dd85927-dbca-4674-bf54-6a2a468cf3fa" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_02eec786-9360-4304-90f8-4b405e800b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_2ab95d41-51cd-4f6c-b760-1527d2a69d54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dd85927-dbca-4674-bf54-6a2a468cf3fa" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_2ab95d41-51cd-4f6c-b760-1527d2a69d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_51af0343-c4d8-4f52-b388-ea9b526ea863" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dd85927-dbca-4674-bf54-6a2a468cf3fa" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_51af0343-c4d8-4f52-b388-ea9b526ea863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1650688d-d0b3-4a62-ad7b-b58b25600380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dd85927-dbca-4674-bf54-6a2a468cf3fa" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1650688d-d0b3-4a62-ad7b-b58b25600380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2ac41915-4793-48eb-8889-97c52d764d94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_431e74f2-989f-471f-9adf-a3025c23a4cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ac41915-4793-48eb-8889-97c52d764d94" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_431e74f2-989f-471f-9adf-a3025c23a4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aab74a1e-aac5-4eb6-9a31-7187336e0d6d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_431e74f2-989f-471f-9adf-a3025c23a4cf" xlink:to="loc_srt_RangeAxis_aab74a1e-aac5-4eb6-9a31-7187336e0d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_abc5a851-7b45-4277-84a7-f21ab4c3dfab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_aab74a1e-aac5-4eb6-9a31-7187336e0d6d" xlink:to="loc_srt_RangeMember_abc5a851-7b45-4277-84a7-f21ab4c3dfab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_57623773-5625-4b44-ad45-506a21ea8401" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_abc5a851-7b45-4277-84a7-f21ab4c3dfab" xlink:to="loc_srt_MinimumMember_57623773-5625-4b44-ad45-506a21ea8401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a90d5f12-b9c9-477b-8720-9a644171fab8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_abc5a851-7b45-4277-84a7-f21ab4c3dfab" xlink:to="loc_srt_MaximumMember_a90d5f12-b9c9-477b-8720-9a644171fab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c3d38855-a2a0-4a28-b168-fce1b8fea26b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_431e74f2-989f-471f-9adf-a3025c23a4cf" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c3d38855-a2a0-4a28-b168-fce1b8fea26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5220d107-1703-4239-8cfa-1b231c44af9a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c3d38855-a2a0-4a28-b168-fce1b8fea26b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5220d107-1703-4239-8cfa-1b231c44af9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_0a9e871c-c3f5-4bc3-bf86-a497d434ceeb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5220d107-1703-4239-8cfa-1b231c44af9a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_0a9e871c-c3f5-4bc3-bf86-a497d434ceeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c1fb700c-4a05-4193-a522-8d1c87c0a643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_431e74f2-989f-471f-9adf-a3025c23a4cf" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c1fb700c-4a05-4193-a522-8d1c87c0a643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_747701e7-f4cb-4d95-b7e2-ed1283508953" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c1fb700c-4a05-4193-a522-8d1c87c0a643" xlink:to="loc_us-gaap_EquityComponentDomain_747701e7-f4cb-4d95-b7e2-ed1283508953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0eadf9de-cf0f-426f-beb7-de25a0249f77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_747701e7-f4cb-4d95-b7e2-ed1283508953" xlink:to="loc_us-gaap_RetainedEarningsMember_0eadf9de-cf0f-426f-beb7-de25a0249f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f808ac4a-16df-47c5-9d6a-b3058b4327a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_747701e7-f4cb-4d95-b7e2-ed1283508953" xlink:to="loc_us-gaap_CommonStockMember_f808ac4a-16df-47c5-9d6a-b3058b4327a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d5e46da4-07cd-4ed2-824f-d54720d7dd8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_431e74f2-989f-471f-9adf-a3025c23a4cf" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d5e46da4-07cd-4ed2-824f-d54720d7dd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a5e4ee52-9e8a-4c53-8fc0-54fb81ac3798" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d5e46da4-07cd-4ed2-824f-d54720d7dd8d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a5e4ee52-9e8a-4c53-8fc0-54fb81ac3798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_557bbc5e-9bfe-43cb-a8e0-2b37226b9c80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d5e46da4-07cd-4ed2-824f-d54720d7dd8d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_557bbc5e-9bfe-43cb-a8e0-2b37226b9c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_9506de5e-23e7-47c6-a18b-c45344fcee27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d5e46da4-07cd-4ed2-824f-d54720d7dd8d" xlink:to="loc_us-gaap_NumberOfReportableSegments_9506de5e-23e7-47c6-a18b-c45344fcee27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d9a139dd-7fa9-40bb-aace-5cbb66020d90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d5e46da4-07cd-4ed2-824f-d54720d7dd8d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d9a139dd-7fa9-40bb-aace-5cbb66020d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8028661e-083d-493c-b37b-d5bb734cce68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d5e46da4-07cd-4ed2-824f-d54720d7dd8d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8028661e-083d-493c-b37b-d5bb734cce68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ebd2a180-ae03-4c29-a8f9-bfb16c3c6d22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d5e46da4-07cd-4ed2-824f-d54720d7dd8d" xlink:to="loc_us-gaap_OperatingLeaseLiability_ebd2a180-ae03-4c29-a8f9-bfb16c3c6d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_567e85a0-0fa3-4ea6-906b-d85ff388ea42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d5e46da4-07cd-4ed2-824f-d54720d7dd8d" xlink:to="loc_us-gaap_StockholdersEquity_567e85a0-0fa3-4ea6-906b-d85ff388ea42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasury_b40ac2b2-179e-41b8-8988-55e26a28f6cb" xlink:href="vrna-20201231.xsd#vrna_StockIssuedDuringPeriodSharesHeldInTreasury"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d5e46da4-07cd-4ed2-824f-d54720d7dd8d" xlink:to="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasury_b40ac2b2-179e-41b8-8988-55e26a28f6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares_d8469201-a6d5-479a-9a66-e7682f5d2b5c" xlink:href="vrna-20201231.xsd#vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d5e46da4-07cd-4ed2-824f-d54720d7dd8d" xlink:to="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares_d8469201-a6d5-479a-9a66-e7682f5d2b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Prepaidexpenses" xlink:type="simple" xlink:href="vrna-20201231.xsd#Prepaidexpenses"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Prepaidexpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_b9f883fd-467d-4fe1-b204-fd2bbe91a9ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PrepaidExpenseDisclosureTextBlock_d06a3d4a-1405-4868-a93d-8139e31fb505" xlink:href="vrna-20201231.xsd#vrna_PrepaidExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_b9f883fd-467d-4fe1-b204-fd2bbe91a9ad" xlink:to="loc_vrna_PrepaidExpenseDisclosureTextBlock_d06a3d4a-1405-4868-a93d-8139e31fb505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/PrepaidexpensesTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#PrepaidexpensesTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/PrepaidexpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0be5bdf0-9d55-475d-b1cd-0d15d2976098" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_ca1ece28-56b7-438d-ade2-44515c181131" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0be5bdf0-9d55-475d-b1cd-0d15d2976098" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_ca1ece28-56b7-438d-ade2-44515c181131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/PrepaidexpensesDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#PrepaidexpensesDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/PrepaidexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_56c2d5c0-c025-4518-afcf-63f26f657787" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PrepaidResearchAndDevelopmentFeesCurrent_77bd7ee8-2cd0-45cb-b250-ff0eabc272d4" xlink:href="vrna-20201231.xsd#vrna_PrepaidResearchAndDevelopmentFeesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_56c2d5c0-c025-4518-afcf-63f26f657787" xlink:to="loc_vrna_PrepaidResearchAndDevelopmentFeesCurrent_77bd7ee8-2cd0-45cb-b250-ff0eabc272d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_5742fdc6-3628-480e-af3e-8ca501f4ba96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_56c2d5c0-c025-4518-afcf-63f26f657787" xlink:to="loc_us-gaap_PrepaidInsurance_5742fdc6-3628-480e-af3e-8ca501f4ba96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_18fc0ec0-14e1-4e63-b82d-f94b1f6c5cbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_56c2d5c0-c025-4518-afcf-63f26f657787" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_18fc0ec0-14e1-4e63-b82d-f94b1f6c5cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_445aded7-69dc-46d8-a07e-d7ff887041a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_56c2d5c0-c025-4518-afcf-63f26f657787" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_445aded7-69dc-46d8-a07e-d7ff887041a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Taxandtaxincentivereceivable" xlink:type="simple" xlink:href="vrna-20201231.xsd#Taxandtaxincentivereceivable"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Taxandtaxincentivereceivable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_6cd0eb0c-ac61-43b2-a487-7a8bf2b1874f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_5ca82ced-3d22-454a-b79b-361ebe9ee09a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_6cd0eb0c-ac61-43b2-a487-7a8bf2b1874f" xlink:to="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_5ca82ced-3d22-454a-b79b-361ebe9ee09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxandtaxincentivereceivableTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#TaxandtaxincentivereceivableTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/TaxandtaxincentivereceivableTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_41f8a584-3d10-4572-9a89-33237df0a41f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ScheduleOfNontradeReceivablesTableTextBlock_0f897a7a-ab25-405f-bee1-a5578d6544b6" xlink:href="vrna-20201231.xsd#vrna_ScheduleOfNontradeReceivablesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_41f8a584-3d10-4572-9a89-33237df0a41f" xlink:to="loc_vrna_ScheduleOfNontradeReceivablesTableTextBlock_0f897a7a-ab25-405f-bee1-a5578d6544b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxandtaxincentivereceivableDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#TaxandtaxincentivereceivableDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/TaxandtaxincentivereceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_8181b8a8-8463-4665-9076-b3cbdc1a97ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent_c7046281-3507-4cd5-baa1-a61dd07492a7" xlink:href="vrna-20201231.xsd#vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_8181b8a8-8463-4665-9076-b3cbdc1a97ae" xlink:to="loc_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent_c7046281-3507-4cd5-baa1-a61dd07492a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_a49ce138-125b-474a-97d2-bfc81c7a009f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_8181b8a8-8463-4665-9076-b3cbdc1a97ae" xlink:to="loc_us-gaap_IncomeTaxesReceivable_a49ce138-125b-474a-97d2-bfc81c7a009f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_1b398822-2ff8-4889-b6f9-3890e9ca62ff" xlink:href="vrna-20201231.xsd#vrna_TaxCreditAndIncomeTaxesReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_8181b8a8-8463-4665-9076-b3cbdc1a97ae" xlink:to="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_1b398822-2ff8-4889-b6f9-3890e9ca62ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Propertyleases" xlink:type="simple" xlink:href="vrna-20201231.xsd#Propertyleases"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Propertyleases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ac3847e2-05f2-4f43-88bd-bccd32f9b16d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_29e1db4c-4240-4b28-b40a-77e6407d1f4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ac3847e2-05f2-4f43-88bd-bccd32f9b16d" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_29e1db4c-4240-4b28-b40a-77e6407d1f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/PropertyleasesTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#PropertyleasesTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/PropertyleasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6cf9119b-304b-4224-b4fb-242ef87ebed7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0167b74c-b4c0-4e79-90b7-19690a1bdabf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6cf9119b-304b-4224-b4fb-242ef87ebed7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0167b74c-b4c0-4e79-90b7-19690a1bdabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_fc68a859-1603-4489-b048-be505176741d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6cf9119b-304b-4224-b4fb-242ef87ebed7" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_fc68a859-1603-4489-b048-be505176741d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/PropertyleasesNarrativeDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#PropertyleasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/PropertyleasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_abd162bf-61e0-42c1-983a-bfb61e055223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f71cdd92-2e70-431a-82ef-bf9eb9fddc8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_abd162bf-61e0-42c1-983a-bfb61e055223" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f71cdd92-2e70-431a-82ef-bf9eb9fddc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3a341cce-af64-4d1a-80f0-89781e7539eb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f71cdd92-2e70-431a-82ef-bf9eb9fddc8f" xlink:to="loc_srt_StatementGeographicalAxis_3a341cce-af64-4d1a-80f0-89781e7539eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7be423ee-552e-4d64-be07-dc08e1743afc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_3a341cce-af64-4d1a-80f0-89781e7539eb" xlink:to="loc_srt_SegmentGeographicalDomain_7be423ee-552e-4d64-be07-dc08e1743afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_LondonMember_d1c1b374-d0ed-49bf-bc38-608b57415c65" xlink:href="vrna-20201231.xsd#vrna_LondonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7be423ee-552e-4d64-be07-dc08e1743afc" xlink:to="loc_vrna_LondonMember_d1c1b374-d0ed-49bf-bc38-608b57415c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_169779be-3609-4593-bb4d-3c1342c15929" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7be423ee-552e-4d64-be07-dc08e1743afc" xlink:to="loc_stpr_NY_169779be-3609-4593-bb4d-3c1342c15929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3162bd16-2323-4d7c-8e84-dec835564f72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f71cdd92-2e70-431a-82ef-bf9eb9fddc8f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3162bd16-2323-4d7c-8e84-dec835564f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e8ea4f28-0eb1-4dd9-aa7e-263171bff5c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3162bd16-2323-4d7c-8e84-dec835564f72" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e8ea4f28-0eb1-4dd9-aa7e-263171bff5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_4d3fbce5-acd1-44cb-b677-491394b5443b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e8ea4f28-0eb1-4dd9-aa7e-263171bff5c9" xlink:to="loc_us-gaap_BuildingMember_4d3fbce5-acd1-44cb-b677-491394b5443b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_91b1b30a-0151-4efe-bfb1-35e159fb45f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f71cdd92-2e70-431a-82ef-bf9eb9fddc8f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_91b1b30a-0151-4efe-bfb1-35e159fb45f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_45370b39-2b59-490e-86e8-fa73bd583b2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91b1b30a-0151-4efe-bfb1-35e159fb45f0" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_45370b39-2b59-490e-86e8-fa73bd583b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_93e78898-ecea-447d-ae00-65dce6866d48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91b1b30a-0151-4efe-bfb1-35e159fb45f0" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_93e78898-ecea-447d-ae00-65dce6866d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f8b192e6-920a-48b0-bfd2-2a239a59b752" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91b1b30a-0151-4efe-bfb1-35e159fb45f0" xlink:to="loc_us-gaap_OperatingLeaseLiability_f8b192e6-920a-48b0-bfd2-2a239a59b752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_c1e64e5e-1b82-4d8a-a153-d365cb5cdbcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91b1b30a-0151-4efe-bfb1-35e159fb45f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_c1e64e5e-1b82-4d8a-a153-d365cb5cdbcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ef97b778-9ac0-4231-9ad1-0ebb510d838e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91b1b30a-0151-4efe-bfb1-35e159fb45f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ef97b778-9ac0-4231-9ad1-0ebb510d838e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_16a4e994-8b4a-41c0-b665-bafe9a4441d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91b1b30a-0151-4efe-bfb1-35e159fb45f0" xlink:to="loc_us-gaap_OperatingLeaseExpense_16a4e994-8b4a-41c0-b665-bafe9a4441d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/PropertyleasesMaturityDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#PropertyleasesMaturityDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/PropertyleasesMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8a29ce00-9e13-43ab-a2ec-ec23ccc2b9f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_feea481e-c348-4d18-8d0f-3ae09b102585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8a29ce00-9e13-43ab-a2ec-ec23ccc2b9f2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_feea481e-c348-4d18-8d0f-3ae09b102585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0fd93017-7e44-4073-b199-425f14f12638" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8a29ce00-9e13-43ab-a2ec-ec23ccc2b9f2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0fd93017-7e44-4073-b199-425f14f12638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bbef8d6c-c0c1-45cb-bead-05dab28fd9ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8a29ce00-9e13-43ab-a2ec-ec23ccc2b9f2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bbef8d6c-c0c1-45cb-bead-05dab28fd9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7ad67b8d-d8c6-4883-9039-5e8df492d9de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8a29ce00-9e13-43ab-a2ec-ec23ccc2b9f2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7ad67b8d-d8c6-4883-9039-5e8df492d9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fe6bbab3-515c-4476-81d0-1b71477f0b11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8a29ce00-9e13-43ab-a2ec-ec23ccc2b9f2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fe6bbab3-515c-4476-81d0-1b71477f0b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5acd5ad0-21c4-485a-a0fa-8470e2851f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8a29ce00-9e13-43ab-a2ec-ec23ccc2b9f2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5acd5ad0-21c4-485a-a0fa-8470e2851f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_586a1585-03c9-4872-a952-6b98f3e5912c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8a29ce00-9e13-43ab-a2ec-ec23ccc2b9f2" xlink:to="loc_us-gaap_OperatingLeaseLiability_586a1585-03c9-4872-a952-6b98f3e5912c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/PropertyleasesMaturityDetails_1" xlink:type="simple" xlink:href="vrna-20201231.xsd#PropertyleasesMaturityDetails_1"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/PropertyleasesMaturityDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/PropertyleasesMaturityUnderASC840Details" xlink:type="simple" xlink:href="vrna-20201231.xsd#PropertyleasesMaturityUnderASC840Details"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/PropertyleasesMaturityUnderASC840Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_156290e5-eee5-4f65-9c84-a3512c012163" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_8715c586-95c8-483a-820a-d84f0ff70f53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_156290e5-eee5-4f65-9c84-a3512c012163" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_8715c586-95c8-483a-820a-d84f0ff70f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2bf0d5bf-84a4-41d2-935e-e486e7aa89d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_8715c586-95c8-483a-820a-d84f0ff70f53" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2bf0d5bf-84a4-41d2-935e-e486e7aa89d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_72bec4e3-b6bc-45ce-8804-02556905309b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_8715c586-95c8-483a-820a-d84f0ff70f53" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_72bec4e3-b6bc-45ce-8804-02556905309b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_721be736-1fb6-43e9-a50b-e0dd14778b64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_8715c586-95c8-483a-820a-d84f0ff70f53" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_721be736-1fb6-43e9-a50b-e0dd14778b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_4dcd0d83-75ea-4090-8150-612bb59bb4c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_8715c586-95c8-483a-820a-d84f0ff70f53" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_4dcd0d83-75ea-4090-8150-612bb59bb4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_1d6f5d9f-d62e-4d40-a4d2-a13a174ef465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_8715c586-95c8-483a-820a-d84f0ff70f53" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_1d6f5d9f-d62e-4d40-a4d2-a13a174ef465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Accruedexpenses" xlink:type="simple" xlink:href="vrna-20201231.xsd#Accruedexpenses"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Accruedexpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_4c469363-ead0-40fc-a4e6-e7b48ae72f23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_a46b41cb-507a-45f6-b656-a6e631885114" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4c469363-ead0-40fc-a4e6-e7b48ae72f23" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_a46b41cb-507a-45f6-b656-a6e631885114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/AccruedexpensesTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#AccruedexpensesTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/AccruedexpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_dbce4a16-23d5-4876-b6c8-0f997ea298c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0aea14e6-99d8-4cf3-8839-59c7fbbda99c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_dbce4a16-23d5-4876-b6c8-0f997ea298c6" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0aea14e6-99d8-4cf3-8839-59c7fbbda99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/AccruedexpensesDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#AccruedexpensesDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/AccruedexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_b292f2bb-d0ed-40bc-b59d-bfb1214fe27e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent_bb8b9356-a1cc-44c2-b42a-b17f61839a32" xlink:href="vrna-20201231.xsd#vrna_AccruedResearchAndDevelopmentFeesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b292f2bb-d0ed-40bc-b59d-bfb1214fe27e" xlink:to="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent_bb8b9356-a1cc-44c2-b42a-b17f61839a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_c342b215-ff9e-4e5f-bae5-12137fc59904" xlink:href="vrna-20201231.xsd#vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b292f2bb-d0ed-40bc-b59d-bfb1214fe27e" xlink:to="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_c342b215-ff9e-4e5f-bae5-12137fc59904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1727f5a0-8f30-47ce-982b-b072b53b06c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b292f2bb-d0ed-40bc-b59d-bfb1214fe27e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1727f5a0-8f30-47ce-982b-b072b53b06c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_be6e6a9e-544e-4276-9606-7673062aeda6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b292f2bb-d0ed-40bc-b59d-bfb1214fe27e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_be6e6a9e-544e-4276-9606-7673062aeda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Warrants" xlink:type="simple" xlink:href="vrna-20201231.xsd#Warrants"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Warrants" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b5047a2c-2a3e-4ed2-907a-7c0a6929bcd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_WarrantAndRightsDisclosureTextBlock_31174ef3-71b0-4296-ba0d-22853bceca3b" xlink:href="vrna-20201231.xsd#vrna_WarrantAndRightsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b5047a2c-2a3e-4ed2-907a-7c0a6929bcd5" xlink:to="loc_vrna_WarrantAndRightsDisclosureTextBlock_31174ef3-71b0-4296-ba0d-22853bceca3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/WarrantsTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#WarrantsTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/WarrantsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_2992575e-f812-4e3f-acd2-cf5884ef982f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_b9fee0dd-5cff-469b-95d2-d3a1b33e649f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_2992575e-f812-4e3f-acd2-cf5884ef982f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_b9fee0dd-5cff-469b-95d2-d3a1b33e649f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_65239ace-0586-43f3-b5fc-1eddb14779a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_2992575e-f812-4e3f-acd2-cf5884ef982f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_65239ace-0586-43f3-b5fc-1eddb14779a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_FairValueImpactOfIncreaseOrDecreaseInVolatilityTableTextBlock_c74a2c8b-465d-49b1-b06a-9a17d6e28f42" xlink:href="vrna-20201231.xsd#vrna_FairValueImpactOfIncreaseOrDecreaseInVolatilityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_2992575e-f812-4e3f-acd2-cf5884ef982f" xlink:to="loc_vrna_FairValueImpactOfIncreaseOrDecreaseInVolatilityTableTextBlock_c74a2c8b-465d-49b1-b06a-9a17d6e28f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/WarrantsNarrativeDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#WarrantsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/WarrantsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_1d501cfe-cee5-45f3-8e01-d9eb1753226b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a0b1dd57-88bd-4d8a-9062-7b65ba6db473" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_1d501cfe-cee5-45f3-8e01-d9eb1753226b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a0b1dd57-88bd-4d8a-9062-7b65ba6db473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights_21051188-acaf-424c-bef1-f93161d45ef7" xlink:href="vrna-20201231.xsd#vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_1d501cfe-cee5-45f3-8e01-d9eb1753226b" xlink:to="loc_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights_21051188-acaf-424c-bef1-f93161d45ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_945f966b-31e4-457c-a6ba-ec32f790f0f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_1d501cfe-cee5-45f3-8e01-d9eb1753226b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_945f966b-31e4-457c-a6ba-ec32f790f0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a3786008-63ab-41eb-b654-907c905c0432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_1d501cfe-cee5-45f3-8e01-d9eb1753226b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a3786008-63ab-41eb-b654-907c905c0432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1e26a62e-18bc-48f3-9d99-72b6e9d054b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_1d501cfe-cee5-45f3-8e01-d9eb1753226b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1e26a62e-18bc-48f3-9d99-72b6e9d054b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited_30df7ac1-507d-49af-842b-f3ddd01537e3" xlink:href="vrna-20201231.xsd#vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_1d501cfe-cee5-45f3-8e01-d9eb1753226b" xlink:to="loc_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited_30df7ac1-507d-49af-842b-f3ddd01537e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ClassOfWarrantOrRightIntrinsicValue_f52183a3-4eee-4d6b-9f77-d7e315ac365e" xlink:href="vrna-20201231.xsd#vrna_ClassOfWarrantOrRightIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_1d501cfe-cee5-45f3-8e01-d9eb1753226b" xlink:to="loc_vrna_ClassOfWarrantOrRightIntrinsicValue_f52183a3-4eee-4d6b-9f77-d7e315ac365e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#WarrantsFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_794a7929-44e7-4ee8-bed7-9df5e55541ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_912d4240-2a76-4fd9-9a95-bfc3fc4697a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_794a7929-44e7-4ee8-bed7-9df5e55541ba" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_912d4240-2a76-4fd9-9a95-bfc3fc4697a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_7c89d676-efa2-4d34-8d31-684aa6ff8d88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_912d4240-2a76-4fd9-9a95-bfc3fc4697a0" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_7c89d676-efa2-4d34-8d31-684aa6ff8d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_fdfb9f14-ea7a-4bc9-96ff-885e39adfbfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7c89d676-efa2-4d34-8d31-684aa6ff8d88" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_fdfb9f14-ea7a-4bc9-96ff-885e39adfbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_dee8a959-c399-42f9-b203-f29ecfacf316" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_fdfb9f14-ea7a-4bc9-96ff-885e39adfbfc" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_dee8a959-c399-42f9-b203-f29ecfacf316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_MeasurementInputAnnualizedVolatilityMember_8b80d170-5f66-4ecd-a911-e8b8ae2d69bc" xlink:href="vrna-20201231.xsd#vrna_MeasurementInputAnnualizedVolatilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_fdfb9f14-ea7a-4bc9-96ff-885e39adfbfc" xlink:to="loc_vrna_MeasurementInputAnnualizedVolatilityMember_8b80d170-5f66-4ecd-a911-e8b8ae2d69bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_374c4c64-b219-4330-8a96-7b25cf825d8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_fdfb9f14-ea7a-4bc9-96ff-885e39adfbfc" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_374c4c64-b219-4330-8a96-7b25cf825d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_b41b8943-ca12-4230-92e2-32524bced7f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_912d4240-2a76-4fd9-9a95-bfc3fc4697a0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_b41b8943-ca12-4230-92e2-32524bced7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_aa92fdc8-32b1-4268-b5f9-f7eb07415e2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_b41b8943-ca12-4230-92e2-32524bced7f4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_aa92fdc8-32b1-4268-b5f9-f7eb07415e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c013be28-9cdb-4f3d-adbf-66983fbaf5e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_b41b8943-ca12-4230-92e2-32524bced7f4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c013be28-9cdb-4f3d-adbf-66983fbaf5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare_86d5f4a6-43b7-46a6-b627-d9411cf35e26" xlink:href="vrna-20201231.xsd#vrna_ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_b41b8943-ca12-4230-92e2-32524bced7f4" xlink:to="loc_vrna_ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare_86d5f4a6-43b7-46a6-b627-d9411cf35e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_3c6207ab-a8af-467b-82a6-4ce7ed8d6efa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_b41b8943-ca12-4230-92e2-32524bced7f4" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_3c6207ab-a8af-467b-82a6-4ce7ed8d6efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_6b1b23d1-ffa6-4a03-a5b7-5caa25aee262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_b41b8943-ca12-4230-92e2-32524bced7f4" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_6b1b23d1-ffa6-4a03-a5b7-5caa25aee262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_WarrantLiabilityCurrent_f5c2c03f-129a-41c3-aebb-e6f4b8135ffb" xlink:href="vrna-20201231.xsd#vrna_WarrantLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_b41b8943-ca12-4230-92e2-32524bced7f4" xlink:to="loc_vrna_WarrantLiabilityCurrent_f5c2c03f-129a-41c3-aebb-e6f4b8135ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/WarrantsMovementinValueDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#WarrantsMovementinValueDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/WarrantsMovementinValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_720fcf4d-25e7-4510-ad31-9403f0154316" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6ea2a16e-a5a2-4da0-8920-1bbf0cb3deda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_720fcf4d-25e7-4510-ad31-9403f0154316" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6ea2a16e-a5a2-4da0-8920-1bbf0cb3deda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9e7ca316-affd-4c93-8b21-f924431eb8d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6ea2a16e-a5a2-4da0-8920-1bbf0cb3deda" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9e7ca316-affd-4c93-8b21-f924431eb8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_544aa51b-a230-4e73-8661-8b8254556839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6ea2a16e-a5a2-4da0-8920-1bbf0cb3deda" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_544aa51b-a230-4e73-8661-8b8254556839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference_607f9669-2eec-4ef7-83d7-63cd6130e569" xlink:href="vrna-20201231.xsd#vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6ea2a16e-a5a2-4da0-8920-1bbf0cb3deda" xlink:to="loc_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference_607f9669-2eec-4ef7-83d7-63cd6130e569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_530ffba0-9f42-488e-ae43-7f41216c56ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6ea2a16e-a5a2-4da0-8920-1bbf0cb3deda" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_530ffba0-9f42-488e-ae43-7f41216c56ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_bfc3e8ae-a2fc-42a0-a7b3-de7db3c56d4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6ea2a16e-a5a2-4da0-8920-1bbf0cb3deda" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_bfc3e8ae-a2fc-42a0-a7b3-de7db3c56d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/WarrantsEffectofChangeinVolatilityDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#WarrantsEffectofChangeinVolatilityDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/WarrantsEffectofChangeinVolatilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_7f6d96d4-210f-447a-bafe-aa3c3276671d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate_a267029f-5ac0-4e81-b766-03654b853332" xlink:href="vrna-20201231.xsd#vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_7f6d96d4-210f-447a-bafe-aa3c3276671d" xlink:to="loc_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate_a267029f-5ac0-4e81-b766-03654b853332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_WarrantLiabilityFairValue_f6c2fcbe-aabc-4477-9aed-f394c6684f28" xlink:href="vrna-20201231.xsd#vrna_WarrantLiabilityFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_7f6d96d4-210f-447a-bafe-aa3c3276671d" xlink:to="loc_vrna_WarrantLiabilityFairValue_f6c2fcbe-aabc-4477-9aed-f394c6684f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate_76610232-13b6-41fa-9a1e-3706348bfe3e" xlink:href="vrna-20201231.xsd#vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_7f6d96d4-210f-447a-bafe-aa3c3276671d" xlink:to="loc_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate_76610232-13b6-41fa-9a1e-3706348bfe3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Termloan" xlink:type="simple" xlink:href="vrna-20201231.xsd#Termloan"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Termloan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2f4eb336-9716-4f1c-b24e-5fd97705a94f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_7b20c447-0668-47d7-b000-37344082027c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2f4eb336-9716-4f1c-b24e-5fd97705a94f" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_7b20c447-0668-47d7-b000-37344082027c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TermloanDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#TermloanDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/TermloanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_aeaa5a3c-4238-4de1-b2bb-970ea6001fb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f4da39b1-5bdc-48e4-b2a8-2ff4edd6591f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_aeaa5a3c-4238-4de1-b2bb-970ea6001fb9" xlink:to="loc_us-gaap_DebtInstrumentTable_f4da39b1-5bdc-48e4-b2a8-2ff4edd6591f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e0749d1b-dc08-4246-8da8-307a8581e7cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f4da39b1-5bdc-48e4-b2a8-2ff4edd6591f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e0749d1b-dc08-4246-8da8-307a8581e7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c3372507-b1ac-4c81-848c-972164726592" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e0749d1b-dc08-4246-8da8-307a8581e7cf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c3372507-b1ac-4c81-848c-972164726592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_9bf6bf1f-ccfd-4ba8-a278-8cfb4de9228f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c3372507-b1ac-4c81-848c-972164726592" xlink:to="loc_us-gaap_SecuredDebtMember_9bf6bf1f-ccfd-4ba8-a278-8cfb4de9228f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bfebf910-9b29-44e4-a0f8-2e9a7bfdda84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f4da39b1-5bdc-48e4-b2a8-2ff4edd6591f" xlink:to="loc_us-gaap_DebtInstrumentAxis_bfebf910-9b29-44e4-a0f8-2e9a7bfdda84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e6426fd2-8757-45b0-b7d0-d7e7e99748cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_bfebf910-9b29-44e4-a0f8-2e9a7bfdda84" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e6426fd2-8757-45b0-b7d0-d7e7e99748cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermLoanFacilityMember_3dc5ba7b-0a7d-4ac4-90f5-acaff14c1f5f" xlink:href="vrna-20201231.xsd#vrna_TermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e6426fd2-8757-45b0-b7d0-d7e7e99748cb" xlink:to="loc_vrna_TermLoanFacilityMember_3dc5ba7b-0a7d-4ac4-90f5-acaff14c1f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermBLoanMember_33330232-6f6d-480b-9aa7-a569182266c1" xlink:href="vrna-20201231.xsd#vrna_TermBLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_TermLoanFacilityMember_3dc5ba7b-0a7d-4ac4-90f5-acaff14c1f5f" xlink:to="loc_vrna_TermBLoanMember_33330232-6f6d-480b-9aa7-a569182266c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermCLoanMember_55e3efd4-04bc-4399-82e8-13d4d60dbb0c" xlink:href="vrna-20201231.xsd#vrna_TermCLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_TermLoanFacilityMember_3dc5ba7b-0a7d-4ac4-90f5-acaff14c1f5f" xlink:to="loc_vrna_TermCLoanMember_55e3efd4-04bc-4399-82e8-13d4d60dbb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_d9761d11-41b2-4da6-8354-41a4af799581" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f4da39b1-5bdc-48e4-b2a8-2ff4edd6591f" xlink:to="loc_us-gaap_VariableRateAxis_d9761d11-41b2-4da6-8354-41a4af799581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e490fcdb-e184-4762-b36e-2b783a8582a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_d9761d11-41b2-4da6-8354-41a4af799581" xlink:to="loc_us-gaap_VariableRateDomain_e490fcdb-e184-4762-b36e-2b783a8582a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_8512ae59-6bfb-4c14-8c32-23c9ebea8a82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_e490fcdb-e184-4762-b36e-2b783a8582a0" xlink:to="loc_us-gaap_PrimeRateMember_8512ae59-6bfb-4c14-8c32-23c9ebea8a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodAxis_23381838-677a-499c-bc1b-945eefb17243" xlink:href="vrna-20201231.xsd#vrna_DebtPrepaymentPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f4da39b1-5bdc-48e4-b2a8-2ff4edd6591f" xlink:to="loc_vrna_DebtPrepaymentPeriodAxis_23381838-677a-499c-bc1b-945eefb17243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodDomain_453afeb9-e49e-44cc-8e30-bacaf3dfedb5" xlink:href="vrna-20201231.xsd#vrna_DebtPrepaymentPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_DebtPrepaymentPeriodAxis_23381838-677a-499c-bc1b-945eefb17243" xlink:to="loc_vrna_DebtPrepaymentPeriodDomain_453afeb9-e49e-44cc-8e30-bacaf3dfedb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodOneMember_2151c19b-c083-4116-a8e4-ff60d1a5ac71" xlink:href="vrna-20201231.xsd#vrna_DebtPrepaymentPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_DebtPrepaymentPeriodDomain_453afeb9-e49e-44cc-8e30-bacaf3dfedb5" xlink:to="loc_vrna_DebtPrepaymentPeriodOneMember_2151c19b-c083-4116-a8e4-ff60d1a5ac71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodTwoMember_3522e23c-bfc1-42b2-8f4e-ed65bea36be5" xlink:href="vrna-20201231.xsd#vrna_DebtPrepaymentPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_DebtPrepaymentPeriodDomain_453afeb9-e49e-44cc-8e30-bacaf3dfedb5" xlink:to="loc_vrna_DebtPrepaymentPeriodTwoMember_3522e23c-bfc1-42b2-8f4e-ed65bea36be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodThreeMember_cd128199-aeab-4565-b94e-d89838d89976" xlink:href="vrna-20201231.xsd#vrna_DebtPrepaymentPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_DebtPrepaymentPeriodDomain_453afeb9-e49e-44cc-8e30-bacaf3dfedb5" xlink:to="loc_vrna_DebtPrepaymentPeriodThreeMember_cd128199-aeab-4565-b94e-d89838d89976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f4da39b1-5bdc-48e4-b2a8-2ff4edd6591f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_44451c69-e2a2-4c59-868c-c3f4615ae1fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_44451c69-e2a2-4c59-868c-c3f4615ae1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5181748c-0fc6-464d-817c-1c0f09e440b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5181748c-0fc6-464d-817c-1c0f09e440b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e65d8bd7-0b29-45e8-9f4c-cd563f23ad07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e65d8bd7-0b29-45e8-9f4c-cd563f23ad07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f4d8dcc6-0e42-4add-a36e-057f898f4d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f4d8dcc6-0e42-4add-a36e-057f898f4d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentFinalPaymentPercent_32cde366-5d22-4caf-9d55-4aee7de255fb" xlink:href="vrna-20201231.xsd#vrna_DebtInstrumentFinalPaymentPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_vrna_DebtInstrumentFinalPaymentPercent_32cde366-5d22-4caf-9d55-4aee7de255fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentPrepaymentTermOfPriorWrittenNotice_b3d8079e-d1e8-4c04-862d-7cc903eb5409" xlink:href="vrna-20201231.xsd#vrna_DebtInstrumentPrepaymentTermOfPriorWrittenNotice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_vrna_DebtInstrumentPrepaymentTermOfPriorWrittenNotice_b3d8079e-d1e8-4c04-862d-7cc903eb5409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentEarlyRepaymentPenaltyAmount_be0ee350-1052-4119-9104-0b06012cd80c" xlink:href="vrna-20201231.xsd#vrna_DebtInstrumentEarlyRepaymentPenaltyAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_vrna_DebtInstrumentEarlyRepaymentPenaltyAmount_be0ee350-1052-4119-9104-0b06012cd80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent_929487f2-8790-4b3e-ad33-1d5dd214b65b" xlink:href="vrna-20201231.xsd#vrna_DebtInstrumentEarlyRepaymentPenaltyPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent_929487f2-8790-4b3e-ad33-1d5dd214b65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage_c3e7f946-39dc-480a-8d9c-929497605a38" xlink:href="vrna-20201231.xsd#vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage_c3e7f946-39dc-480a-8d9c-929497605a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentCovenantCashAndCashEquivalentsMinimum_0692a1f7-20ae-45b3-84fc-d07c967b2444" xlink:href="vrna-20201231.xsd#vrna_DebtInstrumentCovenantCashAndCashEquivalentsMinimum"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_vrna_DebtInstrumentCovenantCashAndCashEquivalentsMinimum_0692a1f7-20ae-45b3-84fc-d07c967b2444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold_677ffd5d-bf08-4dd5-be83-baef4085f9bf" xlink:href="vrna-20201231.xsd#vrna_DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_vrna_DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold_677ffd5d-bf08-4dd5-be83-baef4085f9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness_42301d8e-56a6-4622-84a5-74440eebc8b6" xlink:href="vrna-20201231.xsd#vrna_DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_vrna_DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness_42301d8e-56a6-4622-84a5-74440eebc8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_94bdc2b0-a19a-43a6-8aae-8ecd0db3cb28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_94bdc2b0-a19a-43a6-8aae-8ecd0db3cb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0e5114fe-a08f-49d8-9490-a4cb2fa5bf99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4ca2aef-f1cd-4cf3-bd85-7ae2130dec2d" xlink:to="loc_us-gaap_LongTermDebt_0e5114fe-a08f-49d8-9490-a4cb2fa5bf99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Benefitplans" xlink:type="simple" xlink:href="vrna-20201231.xsd#Benefitplans"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Benefitplans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8cd3974f-b75c-4188-a20f-42dc778f01a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTextBlock_fe4465ab-bf1e-4d23-9947-ee8809f73241" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8cd3974f-b75c-4188-a20f-42dc778f01a2" xlink:to="loc_us-gaap_DefinedContributionPlanTextBlock_fe4465ab-bf1e-4d23-9947-ee8809f73241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/BenefitplansDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#BenefitplansDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/BenefitplansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3a6aebf3-7b47-4e5c-bb71-b5dbac8b5bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_d83d7881-24ca-49fc-bfdb-f556a355f157" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3a6aebf3-7b47-4e5c-bb71-b5dbac8b5bf3" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_d83d7881-24ca-49fc-bfdb-f556a355f157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Taxation" xlink:type="simple" xlink:href="vrna-20201231.xsd#Taxation"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Taxation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f8aa94bc-37f6-4cf6-a06f-84a27c76e2be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_2c83edbe-421a-47ba-b54e-7192e3fe777d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f8aa94bc-37f6-4cf6-a06f-84a27c76e2be" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_2c83edbe-421a-47ba-b54e-7192e3fe777d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#TaxationTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/TaxationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_79e745df-8e11-441a-a75c-ad7337c8e0bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_01aeb6b7-31d3-4a98-b19a-be63f814012f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_79e745df-8e11-441a-a75c-ad7337c8e0bd" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_01aeb6b7-31d3-4a98-b19a-be63f814012f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2e205dc6-bda2-46b9-9263-32e00a73d5bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_79e745df-8e11-441a-a75c-ad7337c8e0bd" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2e205dc6-bda2-46b9-9263-32e00a73d5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_56390769-c26c-4e4a-99eb-6ac1c81fb860" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_79e745df-8e11-441a-a75c-ad7337c8e0bd" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_56390769-c26c-4e4a-99eb-6ac1c81fb860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_dc8b9247-4fd4-4781-b317-16a0339040f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_79e745df-8e11-441a-a75c-ad7337c8e0bd" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_dc8b9247-4fd4-4781-b317-16a0339040f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationLossBeforeTaxDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#TaxationLossBeforeTaxDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/TaxationLossBeforeTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_17ada128-c39d-4064-b8b9-b33696fd3e8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6892e070-4aa6-46ab-aebe-1312ae750b08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_17ada128-c39d-4064-b8b9-b33696fd3e8b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6892e070-4aa6-46ab-aebe-1312ae750b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_890264df-a4f7-441e-8d14-d973968cf192" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_17ada128-c39d-4064-b8b9-b33696fd3e8b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_890264df-a4f7-441e-8d14-d973968cf192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a15a2752-5b08-44db-9465-d81f0ce35b3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_17ada128-c39d-4064-b8b9-b33696fd3e8b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a15a2752-5b08-44db-9465-d81f0ce35b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#TaxationTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_dd727140-2017-4ef2-bc08-42f1cf8dc06e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_5221f334-631a-4666-a64f-281e170ce44e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dd727140-2017-4ef2-bc08-42f1cf8dc06e" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_5221f334-631a-4666-a64f-281e170ce44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_52a379a5-2aa4-4459-8002-9c9f73018c70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dd727140-2017-4ef2-bc08-42f1cf8dc06e" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_52a379a5-2aa4-4459-8002-9c9f73018c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_518fb7ff-8dd4-4b4f-8fac-15fa4824c44f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dd727140-2017-4ef2-bc08-42f1cf8dc06e" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_518fb7ff-8dd4-4b4f-8fac-15fa4824c44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_833092c9-1d8b-4649-ad75-a3c8255478f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dd727140-2017-4ef2-bc08-42f1cf8dc06e" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_833092c9-1d8b-4649-ad75-a3c8255478f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_35953e5c-7cd2-4a3b-b8e3-5a3f55a8578a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dd727140-2017-4ef2-bc08-42f1cf8dc06e" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_35953e5c-7cd2-4a3b-b8e3-5a3f55a8578a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2b19378f-ce47-40c5-8511-c2ae59b7f703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dd727140-2017-4ef2-bc08-42f1cf8dc06e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2b19378f-ce47-40c5-8511-c2ae59b7f703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_96a36adc-0852-44a0-a73c-cdfeb6f44e37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dd727140-2017-4ef2-bc08-42f1cf8dc06e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_96a36adc-0852-44a0-a73c-cdfeb6f44e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#TaxationReconciliationofStatutoryRateDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d25b2dbc-4620-4e98-a4da-b4861f6c04b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5175ab80-9d1f-4d3b-932a-4d2ee6123040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d25b2dbc-4620-4e98-a4da-b4861f6c04b4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5175ab80-9d1f-4d3b-932a-4d2ee6123040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_b31bd1af-196d-4d3e-a97b-952fc2c24137" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d25b2dbc-4620-4e98-a4da-b4861f6c04b4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_b31bd1af-196d-4d3e-a97b-952fc2c24137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_afc673ad-d2aa-4395-b251-157059585a38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d25b2dbc-4620-4e98-a4da-b4861f6c04b4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_afc673ad-d2aa-4395-b251-157059585a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_864baa6b-9ebf-481f-a247-2250eb941f0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d25b2dbc-4620-4e98-a4da-b4861f6c04b4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_864baa6b-9ebf-481f-a247-2250eb941f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_73e1d146-91ed-40d4-8563-2b9e9b9f8a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d25b2dbc-4620-4e98-a4da-b4861f6c04b4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_73e1d146-91ed-40d4-8563-2b9e9b9f8a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_8f22a377-284f-4a18-911f-49283486d65d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d25b2dbc-4620-4e98-a4da-b4861f6c04b4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_8f22a377-284f-4a18-911f-49283486d65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cc744b94-4d1d-41c6-ac7e-2585805483df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d25b2dbc-4620-4e98-a4da-b4861f6c04b4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cc744b94-4d1d-41c6-ac7e-2585805483df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#TaxationDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d3e549e8-605e-41f5-b248-f197627e515b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_5890c6cf-0828-471c-9ea6-5824a9daeb54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d3e549e8-605e-41f5-b248-f197627e515b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_5890c6cf-0828-471c-9ea6-5824a9daeb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DeferredTaxLiabilitiesContingentLiability_e8c2409f-9fb4-4b0d-a1a3-21d04ae8730b" xlink:href="vrna-20201231.xsd#vrna_DeferredTaxLiabilitiesContingentLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_5890c6cf-0828-471c-9ea6-5824a9daeb54" xlink:to="loc_vrna_DeferredTaxLiabilitiesContingentLiability_e8c2409f-9fb4-4b0d-a1a3-21d04ae8730b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_68cbab34-325f-4187-9ed1-eb943ece7060" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_5890c6cf-0828-471c-9ea6-5824a9daeb54" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_68cbab34-325f-4187-9ed1-eb943ece7060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_2c295f1e-2683-4d4b-87b8-7ef674bcf629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d3e549e8-605e-41f5-b248-f197627e515b" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_2c295f1e-2683-4d4b-87b8-7ef674bcf629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_21b1f9ca-71dc-4ef3-87ba-894d6cde0c5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_2c295f1e-2683-4d4b-87b8-7ef674bcf629" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_21b1f9ca-71dc-4ef3-87ba-894d6cde0c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_c5df2835-c828-4baa-ba4e-12d7e4529fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_2c295f1e-2683-4d4b-87b8-7ef674bcf629" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_c5df2835-c828-4baa-ba4e-12d7e4529fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9618ffd1-741b-4622-93a1-4fb3fa938c1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_2c295f1e-2683-4d4b-87b8-7ef674bcf629" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9618ffd1-741b-4622-93a1-4fb3fa938c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_f3e8b379-984b-4188-9cbf-9be46fec1cee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_2c295f1e-2683-4d4b-87b8-7ef674bcf629" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_f3e8b379-984b-4188-9cbf-9be46fec1cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6f4e5e17-299c-4e54-973c-aa3a407e3e3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_2c295f1e-2683-4d4b-87b8-7ef674bcf629" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_6f4e5e17-299c-4e54-973c-aa3a407e3e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_cbfef7b9-4994-4fe5-911c-c666018371d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d3e549e8-605e-41f5-b248-f197627e515b" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_cbfef7b9-4994-4fe5-911c-c666018371d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_8311b66b-af26-4c26-bd48-054b7b311b81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d3e549e8-605e-41f5-b248-f197627e515b" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_8311b66b-af26-4c26-bd48-054b7b311b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ad100f57-f571-4f84-806d-20aac1f681c8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d3e549e8-605e-41f5-b248-f197627e515b" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ad100f57-f571-4f84-806d-20aac1f681c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_080de793-e1c7-4a8c-8298-720a28cca7a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ad100f57-f571-4f84-806d-20aac1f681c8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_080de793-e1c7-4a8c-8298-720a28cca7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_0773c831-4e13-45c8-90d3-a54adf4b1eb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_080de793-e1c7-4a8c-8298-720a28cca7a1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_0773c831-4e13-45c8-90d3-a54adf4b1eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_8430463f-1295-43c3-97ae-4ecce731c8a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_0773c831-4e13-45c8-90d3-a54adf4b1eb7" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_8430463f-1295-43c3-97ae-4ecce731c8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_32230278-27e5-480d-b59f-f7074a25a059" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ad100f57-f571-4f84-806d-20aac1f681c8" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_32230278-27e5-480d-b59f-f7074a25a059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_64f8a187-3cb2-4dfc-931f-507a5ad92582" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_32230278-27e5-480d-b59f-f7074a25a059" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_64f8a187-3cb2-4dfc-931f-507a5ad92582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_05af4aa7-16bc-4984-915d-3797cda9262f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_64f8a187-3cb2-4dfc-931f-507a5ad92582" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_05af4aa7-16bc-4984-915d-3797cda9262f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates_bc656a17-0ab6-427a-9d0e-cea29890527c" xlink:href="vrna-20201231.xsd#vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_64f8a187-3cb2-4dfc-931f-507a5ad92582" xlink:to="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates_bc656a17-0ab6-427a-9d0e-cea29890527c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance_081a6f60-47ae-494b-b0d3-32349a83cf1e" xlink:href="vrna-20201231.xsd#vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_64f8a187-3cb2-4dfc-931f-507a5ad92582" xlink:to="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance_081a6f60-47ae-494b-b0d3-32349a83cf1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments_7369f637-d6bc-4390-85a2-8e11658b1218" xlink:href="vrna-20201231.xsd#vrna_SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_64f8a187-3cb2-4dfc-931f-507a5ad92582" xlink:to="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments_7369f637-d6bc-4390-85a2-8e11658b1218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_ecefd14b-59bf-440d-896f-b3064c0b22da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_64f8a187-3cb2-4dfc-931f-507a5ad92582" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_ecefd14b-59bf-440d-896f-b3064c0b22da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationNarrativeDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#TaxationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/TaxationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c875690d-b6d2-4797-8644-b37e17f62a68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_c959b076-86a2-4f5f-b3b6-a9c848c41a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c875690d-b6d2-4797-8644-b37e17f62a68" xlink:to="loc_us-gaap_OperatingLossCarryforwards_c959b076-86a2-4f5f-b3b6-a9c848c41a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_a4f406a6-b3cc-4950-a499-3d46f03ab8b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c875690d-b6d2-4797-8644-b37e17f62a68" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_a4f406a6-b3cc-4950-a499-3d46f03ab8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationInterestAccrued_c2ce172a-b7db-4790-b34f-33b332fffc68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationInterestAccrued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c875690d-b6d2-4797-8644-b37e17f62a68" xlink:to="loc_us-gaap_IncomeTaxExaminationInterestAccrued_c2ce172a-b7db-4790-b34f-33b332fffc68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAccrued_3c2af053-3d17-44d8-9db8-f522ae19d6e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAccrued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c875690d-b6d2-4797-8644-b37e17f62a68" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAccrued_3c2af053-3d17-44d8-9db8-f522ae19d6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Sharebasedcompensation" xlink:type="simple" xlink:href="vrna-20201231.xsd#Sharebasedcompensation"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Sharebasedcompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_02cc0ea0-a68b-4329-b5e4-0e4f3540e2f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8f5ed399-64d6-4d99-bdc8-09f9e2edd9ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_02cc0ea0-a68b-4329-b5e4-0e4f3540e2f9" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8f5ed399-64d6-4d99-bdc8-09f9e2edd9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#SharebasedcompensationTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9f5cfb6-1207-430c-8b1f-0eada7d51d27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_dd2f944e-f046-45aa-9afe-3fae1ab8d3ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9f5cfb6-1207-430c-8b1f-0eada7d51d27" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_dd2f944e-f046-45aa-9afe-3fae1ab8d3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_34304614-66ef-4822-8c67-df8a7fe6b745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9f5cfb6-1207-430c-8b1f-0eada7d51d27" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_34304614-66ef-4822-8c67-df8a7fe6b745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8889932a-d69b-4750-874d-7a9737505ed6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9f5cfb6-1207-430c-8b1f-0eada7d51d27" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8889932a-d69b-4750-874d-7a9737505ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_0c97ecd4-86a8-48df-a791-9f30cee3018c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9f5cfb6-1207-430c-8b1f-0eada7d51d27" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_0c97ecd4-86a8-48df-a791-9f30cee3018c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#SharebasedcompensationShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8b8fe716-6755-4867-bee2-167ee4cc8dd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f454f9c9-8f9d-452e-a3e0-5619318c5879" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8b8fe716-6755-4867-bee2-167ee4cc8dd3" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f454f9c9-8f9d-452e-a3e0-5619318c5879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_efd6f5d5-82f3-4c4c-bc92-ba15543b4537" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f454f9c9-8f9d-452e-a3e0-5619318c5879" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_efd6f5d5-82f3-4c4c-bc92-ba15543b4537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_587e6192-5011-4223-8e4d-a6e1f84080ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_efd6f5d5-82f3-4c4c-bc92-ba15543b4537" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_587e6192-5011-4223-8e4d-a6e1f84080ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3d5b8084-8e68-4491-bdaa-cb2665320311" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_587e6192-5011-4223-8e4d-a6e1f84080ad" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3d5b8084-8e68-4491-bdaa-cb2665320311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ab852847-e525-4780-a100-37647f892930" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_587e6192-5011-4223-8e4d-a6e1f84080ad" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ab852847-e525-4780-a100-37647f892930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_78c4e820-9f07-408a-b79c-7ea5b9d44f57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f454f9c9-8f9d-452e-a3e0-5619318c5879" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_78c4e820-9f07-408a-b79c-7ea5b9d44f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a6dcda96-082c-47c1-8c0f-a41a46ce26f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_78c4e820-9f07-408a-b79c-7ea5b9d44f57" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a6dcda96-082c-47c1-8c0f-a41a46ce26f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationNarrativeDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#SharebasedcompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71ea7e4a-6137-4d29-8cba-195be5a79233" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a930cef-04ea-46a2-a0f9-abd38a507f97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71ea7e4a-6137-4d29-8cba-195be5a79233" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a930cef-04ea-46a2-a0f9-abd38a507f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2c8c781d-38aa-45ad-af10-b2484f561767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a930cef-04ea-46a2-a0f9-abd38a507f97" xlink:to="loc_us-gaap_AwardTypeAxis_2c8c781d-38aa-45ad-af10-b2484f561767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6307e45f-4de6-46d1-a56c-e53576966d2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2c8c781d-38aa-45ad-af10-b2484f561767" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6307e45f-4de6-46d1-a56c-e53576966d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7738f20f-f97a-4560-8135-31461a18d7da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6307e45f-4de6-46d1-a56c-e53576966d2f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7738f20f-f97a-4560-8135-31461a18d7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_951651cf-e19e-4fdf-9ce3-c78afd71006a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6307e45f-4de6-46d1-a56c-e53576966d2f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_951651cf-e19e-4fdf-9ce3-c78afd71006a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b97d11bd-13fa-459f-aba4-306d699d34e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a930cef-04ea-46a2-a0f9-abd38a507f97" xlink:to="loc_us-gaap_PlanNameAxis_b97d11bd-13fa-459f-aba4-306d699d34e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d20d9041-6030-4b2d-8b28-26a2462d2dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_b97d11bd-13fa-459f-aba4-306d699d34e5" xlink:to="loc_us-gaap_PlanNameDomain_d20d9041-6030-4b2d-8b28-26a2462d2dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_EMIOptionPlanMember_703829ca-671b-4a04-9ae0-af4c08e80b29" xlink:href="vrna-20201231.xsd#vrna_EMIOptionPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d20d9041-6030-4b2d-8b28-26a2462d2dd0" xlink:to="loc_vrna_EMIOptionPlanMember_703829ca-671b-4a04-9ae0-af4c08e80b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PreIPOOptionPlanMember_db5eafaa-8667-44f8-9708-3e98dbdf5bb9" xlink:href="vrna-20201231.xsd#vrna_PreIPOOptionPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d20d9041-6030-4b2d-8b28-26a2462d2dd0" xlink:to="loc_vrna_PreIPOOptionPlanMember_db5eafaa-8667-44f8-9708-3e98dbdf5bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2017IncentivePlanMember_0dc5cfad-eb94-4753-934d-ac3da2567266" xlink:href="vrna-20201231.xsd#vrna_A2017IncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d20d9041-6030-4b2d-8b28-26a2462d2dd0" xlink:to="loc_vrna_A2017IncentivePlanMember_0dc5cfad-eb94-4753-934d-ac3da2567266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_37e55207-b8c8-485a-98ff-a93153740037" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a930cef-04ea-46a2-a0f9-abd38a507f97" xlink:to="loc_srt_RangeAxis_37e55207-b8c8-485a-98ff-a93153740037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_094f2497-e43c-4ded-bba1-8782acfe4280" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_37e55207-b8c8-485a-98ff-a93153740037" xlink:to="loc_srt_RangeMember_094f2497-e43c-4ded-bba1-8782acfe4280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e0349d22-9034-40b1-9728-d87263b3c40e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_094f2497-e43c-4ded-bba1-8782acfe4280" xlink:to="loc_srt_MinimumMember_e0349d22-9034-40b1-9728-d87263b3c40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_267c6bcb-a9c7-4202-8fd0-815ebf1cd944" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_094f2497-e43c-4ded-bba1-8782acfe4280" xlink:to="loc_srt_MaximumMember_267c6bcb-a9c7-4202-8fd0-815ebf1cd944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a930cef-04ea-46a2-a0f9-abd38a507f97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9e0d788f-2b34-4c6c-8567-e567de8e170a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9e0d788f-2b34-4c6c-8567-e567de8e170a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_547a218d-4977-44e1-9103-866d8d1271c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_547a218d-4977-44e1-9103-866d8d1271c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c2b2ff00-c699-44e5-8c5f-d09816ebf95b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c2b2ff00-c699-44e5-8c5f-d09816ebf95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized_48edda27-cafc-4087-a615-1d0b6e711097" xlink:href="vrna-20201231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized_48edda27-cafc-4087-a615-1d0b6e711097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ee560a1b-4899-415f-96cf-7aaf137935e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ee560a1b-4899-415f-96cf-7aaf137935e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e035c998-e833-416c-b3e3-65f85e8b8fc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e035c998-e833-416c-b3e3-65f85e8b8fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired_f0e28dfc-7eaa-40d2-ba0b-7baa61131f6b" xlink:href="vrna-20201231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired_f0e28dfc-7eaa-40d2-ba0b-7baa61131f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod_20bdb0b7-5f16-4ccc-a8bc-bf7fdbd3adbe" xlink:href="vrna-20201231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod_20bdb0b7-5f16-4ccc-a8bc-bf7fdbd3adbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingDepositoryReceiptRatio_1cd5a81a-bceb-4f7c-9af6-ce40f8e94d3d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingDepositoryReceiptRatio"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_dei_EntityListingDepositoryReceiptRatio_1cd5a81a-bceb-4f7c-9af6-ce40f8e94d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue_3055f280-9d45-4f79-99d4-f05fbbd5652b" xlink:href="vrna-20201231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue_3055f280-9d45-4f79-99d4-f05fbbd5652b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_1e9cfda6-741e-4dcc-8528-65c0326449f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_1e9cfda6-741e-4dcc-8528-65c0326449f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_dbe0a287-53bf-4824-8117-19da95f5dbd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_dbe0a287-53bf-4824-8117-19da95f5dbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b7c6b7a4-0275-438b-a9ef-735e9cf0e3d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b88936d-1201-4ead-a771-f6c715387b2d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b7c6b7a4-0275-438b-a9ef-735e9cf0e3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#SharebasedcompensationShareOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_72ce11c0-b6a3-4fed-b113-5864de5ef24a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingDepositoryReceiptRatio_e12bd5b9-7c9c-4f15-8ff8-9b666022eedf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingDepositoryReceiptRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_72ce11c0-b6a3-4fed-b113-5864de5ef24a" xlink:to="loc_dei_EntityListingDepositoryReceiptRatio_e12bd5b9-7c9c-4f15-8ff8-9b666022eedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7ffbd44d-d3e6-46b7-af67-25c605d1b107" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_72ce11c0-b6a3-4fed-b113-5864de5ef24a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7ffbd44d-d3e6-46b7-af67-25c605d1b107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c7cb32b3-c594-4f12-8876-790a90cdbd8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7ffbd44d-d3e6-46b7-af67-25c605d1b107" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c7cb32b3-c594-4f12-8876-790a90cdbd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6a5b8b4e-b701-4e01-959f-aa20cfb116a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7ffbd44d-d3e6-46b7-af67-25c605d1b107" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6a5b8b4e-b701-4e01-959f-aa20cfb116a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_34b051d2-01fd-49fd-8b22-9f8b90dd9170" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7ffbd44d-d3e6-46b7-af67-25c605d1b107" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_34b051d2-01fd-49fd-8b22-9f8b90dd9170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1438a1c3-d9f9-4c9e-b894-a1ea02ca378f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7ffbd44d-d3e6-46b7-af67-25c605d1b107" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1438a1c3-d9f9-4c9e-b894-a1ea02ca378f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d719ed9a-ad05-4135-b9cd-68da720142ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7ffbd44d-d3e6-46b7-af67-25c605d1b107" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d719ed9a-ad05-4135-b9cd-68da720142ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9ab6ae41-4009-4670-b285-b1d2ac43875a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7ffbd44d-d3e6-46b7-af67-25c605d1b107" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9ab6ae41-4009-4670-b285-b1d2ac43875a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_bbd408a2-e3c1-4d69-ac56-f41aaaf528c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_72ce11c0-b6a3-4fed-b113-5864de5ef24a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_bbd408a2-e3c1-4d69-ac56-f41aaaf528c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4964c60f-52e2-4b5d-8ac1-67da58f7863a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_72ce11c0-b6a3-4fed-b113-5864de5ef24a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4964c60f-52e2-4b5d-8ac1-67da58f7863a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9fcce6b2-c3f5-4608-8c65-2eddec0d64a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4964c60f-52e2-4b5d-8ac1-67da58f7863a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9fcce6b2-c3f5-4608-8c65-2eddec0d64a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bc77d6eb-4164-4868-9f62-4453f10c4590" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4964c60f-52e2-4b5d-8ac1-67da58f7863a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bc77d6eb-4164-4868-9f62-4453f10c4590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c2988512-b186-4b7a-92dd-cc36787ad171" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4964c60f-52e2-4b5d-8ac1-67da58f7863a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c2988512-b186-4b7a-92dd-cc36787ad171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4ebebc7a-04cd-441d-a0cd-a427446046a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4964c60f-52e2-4b5d-8ac1-67da58f7863a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4ebebc7a-04cd-441d-a0cd-a427446046a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_27d73636-ae8f-49b5-a52b-a83ed9086a24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4964c60f-52e2-4b5d-8ac1-67da58f7863a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_27d73636-ae8f-49b5-a52b-a83ed9086a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_acf029c2-3d29-438b-bb92-f74c9cd42e9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4964c60f-52e2-4b5d-8ac1-67da58f7863a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_acf029c2-3d29-438b-bb92-f74c9cd42e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_fb392c14-cb5f-4820-8e84-1c85afc6d6c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_72ce11c0-b6a3-4fed-b113-5864de5ef24a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_fb392c14-cb5f-4820-8e84-1c85afc6d6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_efa57a67-ea80-457d-93ae-5193d2fdcda6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_72ce11c0-b6a3-4fed-b113-5864de5ef24a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_efa57a67-ea80-457d-93ae-5193d2fdcda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b8db46b9-8c6d-4743-8650-8533556ea69b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_efa57a67-ea80-457d-93ae-5193d2fdcda6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b8db46b9-8c6d-4743-8650-8533556ea69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a71821e9-69e7-4cba-b528-2fe618d01520" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_efa57a67-ea80-457d-93ae-5193d2fdcda6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a71821e9-69e7-4cba-b528-2fe618d01520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2a4a0079-8d4d-4140-9eb6-4250e07d47d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_efa57a67-ea80-457d-93ae-5193d2fdcda6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2a4a0079-8d4d-4140-9eb6-4250e07d47d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3b9f907c-546f-428b-b6e8-09c076b6756a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_efa57a67-ea80-457d-93ae-5193d2fdcda6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3b9f907c-546f-428b-b6e8-09c076b6756a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#SharebasedcompensationWeightedAverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ad4254de-f959-409d-b3cb-4ad5fdb19a55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89a2f412-7b70-44ab-826d-a9bd611dd66d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ad4254de-f959-409d-b3cb-4ad5fdb19a55" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89a2f412-7b70-44ab-826d-a9bd611dd66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0e36ee19-ff16-412f-b021-ae14bfd4161e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89a2f412-7b70-44ab-826d-a9bd611dd66d" xlink:to="loc_us-gaap_AwardTypeAxis_0e36ee19-ff16-412f-b021-ae14bfd4161e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebc0b3a0-a313-4838-9869-e2b914bd88ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0e36ee19-ff16-412f-b021-ae14bfd4161e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebc0b3a0-a313-4838-9869-e2b914bd88ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3c957a55-8e81-46d2-89d7-13f54d1aaccb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebc0b3a0-a313-4838-9869-e2b914bd88ea" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3c957a55-8e81-46d2-89d7-13f54d1aaccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cb8987ef-7512-4e38-9a26-521d5d9d60ce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89a2f412-7b70-44ab-826d-a9bd611dd66d" xlink:to="loc_srt_RangeAxis_cb8987ef-7512-4e38-9a26-521d5d9d60ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e5294fbc-45a3-4bba-83e2-f2f819f61ab5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cb8987ef-7512-4e38-9a26-521d5d9d60ce" xlink:to="loc_srt_RangeMember_e5294fbc-45a3-4bba-83e2-f2f819f61ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7578542d-7217-4b89-8465-54d3040f9441" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e5294fbc-45a3-4bba-83e2-f2f819f61ab5" xlink:to="loc_srt_MinimumMember_7578542d-7217-4b89-8465-54d3040f9441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f4dd1e5d-fd3a-4de7-a36b-badb023a5eb1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e5294fbc-45a3-4bba-83e2-f2f819f61ab5" xlink:to="loc_srt_MaximumMember_f4dd1e5d-fd3a-4de7-a36b-badb023a5eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47e815d5-2d13-4c60-9593-e597ad3ec611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89a2f412-7b70-44ab-826d-a9bd611dd66d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47e815d5-2d13-4c60-9593-e597ad3ec611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_322a3212-0577-4709-a41d-067555b6ab51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47e815d5-2d13-4c60-9593-e597ad3ec611" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_322a3212-0577-4709-a41d-067555b6ab51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_873b4877-6d87-44a6-a26d-7b38a75b776a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47e815d5-2d13-4c60-9593-e597ad3ec611" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_873b4877-6d87-44a6-a26d-7b38a75b776a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2e449f04-d342-401e-9225-86d2e2094aba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47e815d5-2d13-4c60-9593-e597ad3ec611" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2e449f04-d342-401e-9225-86d2e2094aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2f9f1075-fe11-43ec-94e7-a5577d60758f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47e815d5-2d13-4c60-9593-e597ad3ec611" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2f9f1075-fe11-43ec-94e7-a5577d60758f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_a3fe5959-1bbc-4615-b21a-9f4f43502f28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47e815d5-2d13-4c60-9593-e597ad3ec611" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_a3fe5959-1bbc-4615-b21a-9f4f43502f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_65ea8221-90a5-4450-a447-621e375de162" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47e815d5-2d13-4c60-9593-e597ad3ec611" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_65ea8221-90a5-4450-a447-621e375de162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_921b0af3-ee13-4e37-b5eb-cc40dc081ff5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47e815d5-2d13-4c60-9593-e597ad3ec611" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_921b0af3-ee13-4e37-b5eb-cc40dc081ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#SharebasedcompensationRSUActivityDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5f08f6dd-7b70-4f3d-af3c-35f40320b46a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee48cad5-b81e-4466-a5ab-4294ed8385eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5f08f6dd-7b70-4f3d-af3c-35f40320b46a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee48cad5-b81e-4466-a5ab-4294ed8385eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4c07ced2-8fa4-45ed-a18d-c30b54400944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee48cad5-b81e-4466-a5ab-4294ed8385eb" xlink:to="loc_us-gaap_AwardTypeAxis_4c07ced2-8fa4-45ed-a18d-c30b54400944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7b8081ab-b25f-442a-ad25-65611fa7c43b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4c07ced2-8fa4-45ed-a18d-c30b54400944" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7b8081ab-b25f-442a-ad25-65611fa7c43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_035ac1e4-4c2a-4d58-a501-dfc28486d2df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7b8081ab-b25f-442a-ad25-65611fa7c43b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_035ac1e4-4c2a-4d58-a501-dfc28486d2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RestrictedStockUnitTimeBasedVestingMember_81c79a74-2209-45c8-bdbb-c04e328a1d08" xlink:href="vrna-20201231.xsd#vrna_RestrictedStockUnitTimeBasedVestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_035ac1e4-4c2a-4d58-a501-dfc28486d2df" xlink:to="loc_vrna_RestrictedStockUnitTimeBasedVestingMember_81c79a74-2209-45c8-bdbb-c04e328a1d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RestrictedStockUnitMilestoneBasedVestingMember_b6326be0-eddb-480b-b3e8-9f195cebdd4f" xlink:href="vrna-20201231.xsd#vrna_RestrictedStockUnitMilestoneBasedVestingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_035ac1e4-4c2a-4d58-a501-dfc28486d2df" xlink:to="loc_vrna_RestrictedStockUnitMilestoneBasedVestingMember_b6326be0-eddb-480b-b3e8-9f195cebdd4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c049ea8-a918-44da-9c14-480d40847679" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee48cad5-b81e-4466-a5ab-4294ed8385eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c049ea8-a918-44da-9c14-480d40847679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0b1f1bc4-af86-416e-be65-29647406023f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c049ea8-a918-44da-9c14-480d40847679" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0b1f1bc4-af86-416e-be65-29647406023f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2060f83a-ace7-4c4e-912f-17dfa7f212f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0b1f1bc4-af86-416e-be65-29647406023f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2060f83a-ace7-4c4e-912f-17dfa7f212f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_490c977f-9dcd-4a8a-b262-19163369a52c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0b1f1bc4-af86-416e-be65-29647406023f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_490c977f-9dcd-4a8a-b262-19163369a52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cd76fc0b-8657-4475-8d26-c8d704e30484" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0b1f1bc4-af86-416e-be65-29647406023f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cd76fc0b-8657-4475-8d26-c8d704e30484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8508577f-d62c-4087-83cf-52696f5c5cdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0b1f1bc4-af86-416e-be65-29647406023f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8508577f-d62c-4087-83cf-52696f5c5cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8a8a1b98-b43e-4f79-bf26-ad03a93a4963" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0b1f1bc4-af86-416e-be65-29647406023f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8a8a1b98-b43e-4f79-bf26-ad03a93a4963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_2af8494e-4aa5-4142-af48-8f3262360c97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c049ea8-a918-44da-9c14-480d40847679" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_2af8494e-4aa5-4142-af48-8f3262360c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e1788ef8-6afd-41aa-b98b-253598f323b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c049ea8-a918-44da-9c14-480d40847679" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e1788ef8-6afd-41aa-b98b-253598f323b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod_05affb8b-80a4-4054-876f-cb4080e602eb" xlink:href="vrna-20201231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c049ea8-a918-44da-9c14-480d40847679" xlink:to="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod_05affb8b-80a4-4054-876f-cb4080e602eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Netlosspershare" xlink:type="simple" xlink:href="vrna-20201231.xsd#Netlosspershare"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Netlosspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3e7ab772-c012-41c0-bedb-873f8eb36a22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_85abf601-a93f-4f0e-ac5d-48d572583882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3e7ab772-c012-41c0-bedb-873f8eb36a22" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_85abf601-a93f-4f0e-ac5d-48d572583882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/NetlosspershareTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#NetlosspershareTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/NetlosspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d8dca47a-95f1-4c63-b717-b59a6f4bbf21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a0fccb68-f004-420a-8db6-3d237465e1da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d8dca47a-95f1-4c63-b717-b59a6f4bbf21" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a0fccb68-f004-420a-8db6-3d237465e1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/NetlosspershareComputationDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#NetlosspershareComputationDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/NetlosspershareComputationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_da368de9-17f0-4949-887d-d3bab06e1593" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_c5cb83c0-d00d-47ee-8af9-00e236659279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_da368de9-17f0-4949-887d-d3bab06e1593" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_c5cb83c0-d00d-47ee-8af9-00e236659279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f53c0cc5-1fbc-4976-a031-9ae16741b888" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_c5cb83c0-d00d-47ee-8af9-00e236659279" xlink:to="loc_us-gaap_NetIncomeLoss_f53c0cc5-1fbc-4976-a031-9ae16741b888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9e357c65-9020-4725-9ae6-b303912f26bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_c5cb83c0-d00d-47ee-8af9-00e236659279" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9e357c65-9020-4725-9ae6-b303912f26bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_3ca084f3-6655-4a52-90e7-0a40fc9a61c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_c5cb83c0-d00d-47ee-8af9-00e236659279" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_3ca084f3-6655-4a52-90e7-0a40fc9a61c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_055991f0-8746-438c-85c9-0e1f62175f0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_da368de9-17f0-4949-887d-d3bab06e1593" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_055991f0-8746-438c-85c9-0e1f62175f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c7e3fdce-a807-464d-a383-fc7711deb521" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_055991f0-8746-438c-85c9-0e1f62175f0f" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c7e3fdce-a807-464d-a383-fc7711deb521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_d1250535-66c3-408f-9c09-114f72d42be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_da368de9-17f0-4949-887d-d3bab06e1593" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_d1250535-66c3-408f-9c09-114f72d42be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7180a9f6-b856-4a61-92e1-ad63c1b31d27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_da368de9-17f0-4949-887d-d3bab06e1593" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7180a9f6-b856-4a61-92e1-ad63c1b31d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Relatedpartytransactionsandothershareholdermatters" xlink:type="simple" xlink:href="vrna-20201231.xsd#Relatedpartytransactionsandothershareholdermatters"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Relatedpartytransactionsandothershareholdermatters" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_c4cd03bd-55a6-4314-b806-a66ad640d486" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_919ffe87-df0f-4f01-99b9-2e35f7b65855" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_c4cd03bd-55a6-4314-b806-a66ad640d486" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_919ffe87-df0f-4f01-99b9-2e35f7b65855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersTables" xlink:type="simple" xlink:href="vrna-20201231.xsd#RelatedpartytransactionsandothershareholdermattersTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_817a8f19-a007-48f5-a168-00418f89662d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_dfe4ccd9-2adc-4b6b-b144-b5ff84b6b0fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_817a8f19-a007-48f5-a168-00418f89662d" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_dfe4ccd9-2adc-4b6b-b144-b5ff84b6b0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails" xlink:type="simple" xlink:href="vrna-20201231.xsd#RelatedpartytransactionsandothershareholdermattersDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_74ed9d71-3f0c-4ad4-869b-3da5d792ecae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7dc7c622-ad07-4c15-a825-6b6505a883e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_74ed9d71-3f0c-4ad4-869b-3da5d792ecae" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7dc7c622-ad07-4c15-a825-6b6505a883e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_39cfce9e-7865-450d-90dc-d75f863ca8f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7dc7c622-ad07-4c15-a825-6b6505a883e3" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_39cfce9e-7865-450d-90dc-d75f863ca8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5ea636da-2217-42de-bdd8-577127e0637d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_39cfce9e-7865-450d-90dc-d75f863ca8f6" xlink:to="loc_us-gaap_RelatedPartyDomain_5ea636da-2217-42de-bdd8-577127e0637d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_1567caa8-46f0-4312-a883-9e9e9012e2d1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_5ea636da-2217-42de-bdd8-577127e0637d" xlink:to="loc_srt_DirectorMember_1567caa8-46f0-4312-a883-9e9e9012e2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DirectorOrOfficerMember_2c157dfc-9a13-40d9-9fbd-fc623c67d0cb" xlink:href="vrna-20201231.xsd#vrna_DirectorOrOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_5ea636da-2217-42de-bdd8-577127e0637d" xlink:to="loc_vrna_DirectorOrOfficerMember_2c157dfc-9a13-40d9-9fbd-fc623c67d0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7b0ccd4e-6b10-46d1-808b-485014fcffd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7dc7c622-ad07-4c15-a825-6b6505a883e3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7b0ccd4e-6b10-46d1-808b-485014fcffd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_24f59505-c036-47fd-9a09-911e7a877990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7b0ccd4e-6b10-46d1-808b-485014fcffd8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_24f59505-c036-47fd-9a09-911e7a877990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_faa4d9e3-e0bf-4316-9025-e1ace1ad096a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_24f59505-c036-47fd-9a09-911e7a877990" xlink:to="loc_us-gaap_PrivatePlacementMember_faa4d9e3-e0bf-4316-9025-e1ace1ad096a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_8bc0486c-b68e-4d00-bc7d-94c72d8fd436" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7dc7c622-ad07-4c15-a825-6b6505a883e3" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_8bc0486c-b68e-4d00-bc7d-94c72d8fd436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_f4529ff1-eb32-4be9-a145-9ec9f46ac85c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_8bc0486c-b68e-4d00-bc7d-94c72d8fd436" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_f4529ff1-eb32-4be9-a145-9ec9f46ac85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ConsultancyServicesMember_b0bd4774-0a81-409a-998c-c28ab548c93d" xlink:href="vrna-20201231.xsd#vrna_ConsultancyServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f4529ff1-eb32-4be9-a145-9ec9f46ac85c" xlink:to="loc_vrna_ConsultancyServicesMember_b0bd4774-0a81-409a-998c-c28ab548c93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c13b8b96-5eb4-4bdf-a7e5-3f9221760b22" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7dc7c622-ad07-4c15-a825-6b6505a883e3" xlink:to="loc_srt_CounterpartyNameAxis_c13b8b96-5eb4-4bdf-a7e5-3f9221760b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d8392c98-6560-4a39-bd54-39ad42778703" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c13b8b96-5eb4-4bdf-a7e5-3f9221760b22" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d8392c98-6560-4a39-bd54-39ad42778703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DrEbsworthMember_99c06815-c47f-4515-974d-61ea550a11ee" xlink:href="vrna-20201231.xsd#vrna_DrEbsworthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d8392c98-6560-4a39-bd54-39ad42778703" xlink:to="loc_vrna_DrEbsworthMember_99c06815-c47f-4515-974d-61ea550a11ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DrZaccardelliMember_c310912e-8b40-45b2-ad40-b4861b383668" xlink:href="vrna-20201231.xsd#vrna_DrZaccardelliMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d8392c98-6560-4a39-bd54-39ad42778703" xlink:to="loc_vrna_DrZaccardelliMember_c310912e-8b40-45b2-ad40-b4861b383668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_MrSinhaMember_a4093502-6e14-4bfa-898e-c8645e763c27" xlink:href="vrna-20201231.xsd#vrna_MrSinhaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d8392c98-6560-4a39-bd54-39ad42778703" xlink:to="loc_vrna_MrSinhaMember_a4093502-6e14-4bfa-898e-c8645e763c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DrUllmanMember_6626b051-c121-4f9e-8730-67fa2cf9971d" xlink:href="vrna-20201231.xsd#vrna_DrUllmanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d8392c98-6560-4a39-bd54-39ad42778703" xlink:to="loc_vrna_DrUllmanMember_6626b051-c121-4f9e-8730-67fa2cf9971d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DrEdwardsMember_5d59274e-94a6-4363-87b6-88b1a3430009" xlink:href="vrna-20201231.xsd#vrna_DrEdwardsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d8392c98-6560-4a39-bd54-39ad42778703" xlink:to="loc_vrna_DrEdwardsMember_5d59274e-94a6-4363-87b6-88b1a3430009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_MrHahnMember_b281af6e-91b1-40e3-b275-598cdf13e4b9" xlink:href="vrna-20201231.xsd#vrna_MrHahnMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d8392c98-6560-4a39-bd54-39ad42778703" xlink:to="loc_vrna_MrHahnMember_b281af6e-91b1-40e3-b275-598cdf13e4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_6bd408c1-677c-44e6-aaec-2bac67aa4113" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7dc7c622-ad07-4c15-a825-6b6505a883e3" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_6bd408c1-677c-44e6-aaec-2bac67aa4113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_6cc9f92f-ada2-4e8b-8630-596a08127e76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6bd408c1-677c-44e6-aaec-2bac67aa4113" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_6cc9f92f-ada2-4e8b-8630-596a08127e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fe5f08d2-b5e5-4a01-87c1-8cae5b45c918" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6bd408c1-677c-44e6-aaec-2bac67aa4113" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fe5f08d2-b5e5-4a01-87c1-8cae5b45c918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_80d7bbb8-1203-4bd1-bdaa-43e65248ffa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6bd408c1-677c-44e6-aaec-2bac67aa4113" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_80d7bbb8-1203-4bd1-bdaa-43e65248ffa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_01a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_01a.jpg
MB5!.1PT*&@H    -24A$4@  "!P   /T" 8    #,;VC    !&=!34$  +&/
M"_QA!0   #AE6$EF34T *@    @  8=I  0    !    &@       J "  0
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M^']1OE_[LS2LP44$$$   0000  !!!!   $$$$   0000  !!!!   $$$$
M 000&&D!KVX0/VP0]M<=:14&CP " R<P=N!Z3(<10  !!!!   $$$$   000
M0  !!!!   $$$$   000&&R!207=O[O@/*<10 "!6@KPP$$M;PN=0@ !!!!
M  $$$$   0000  !!!!   $$$$   000&&*!W ,'3VJ\-PWQF!D: @@,H0 /
M' SA365("""   ((((   @@@@  """"   ((((   @@@@  "M1;(/7#P)_7X
MQ5KWFLXA@  "B<"XY)A#!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!"H5B#WP,$5U39)= 0&3F 5]7@MY4>4+U*^59F$  ((((   @@@@  """"
M  ((((   @@@@  """"   ((C*S HAKY_\ODS496A($C\%J!:75XDG+\=_*T
MCG=^;3&.$$   0000  !!!!   $$$$   0000  !!!!   $$$$  @=$2>+^&
M&T^DAOT%1XN!T2)0*+"/KH2_BWC[G,XO7UB+"P@@@  """"   ((((   @@@
M@  """"   ((((   @@@@,"0"QRJ\<63J-Z_:\C'S/ 0:%5@9A5\2#G]&PG'
M7VDU$.5Z(S"V-\W0"@((((   @@@@  """"   ((((   @@@@  """" P(@+
M+*#Q_T3Y-N6SE)=4'L4T*3/HOV;.<0J!413818.>L\' _?\("0$$$$   000
M0  !!!!   $$$$   0000  !!!!   $$1DS@SQIO>$O9VUN4_:WV44OW:\"Q
M@_?W&S4$QHM 1F"\SMVAG/Y]Q,=[9.IQJGR!F11R!^7CE ]17E:9A  """"
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MTY4;?:(B^*;;AU3OZ\J+*Y,00  !!!!   $$$$   0000  !!!!   $$$$
M 000J)W /NI1.LEU9>UZ64V'%LR,W1;+5M,<41&HO< $]7"J<OI_@H_]EOU*
MRJ36!/R0P(G*SROG/!N=NTIU=E3FTQ5"("&   ((((   @@@@  """"   ((
M((   @@@@  ""-178"=U+9WXNJ6^W2VU9YMDQOZ4SHTKM16"(3 X ONKJ^G_
M!^'X^,$91E][ZD]2'*?<Z+,4P33>NKQ70EA#F80  @@@@  """"   ((((
M @@@@  """"   ((((# 0 A\0+V,)[V\_^! ]+S[3AZD$.G8)W<?E@@(#*3
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M'HV&[(>Q/J?\D'(P:K:]567]H(M70R A@  """"   ((((   @@@@  """"
M  ((((   @@@,#0"GCS+398M,S0CS ]DX\RX'\@7Y>P0"$RO,>0FB%<9@K&5
M,82_*TCN_X%SRP@^)#'\&_JD\G^4<U;I.3_<\EOE391934,() 000  !!!!
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M6RG?J)S^9M+CYU7F+.5UE$D(((   @@@@  """"   ((((   @@@@  """"
M  ((C*3 )1IU.I&V\Q!+^*WV=+P^GF^(QSS*0_,$\H/*Z3T_?)117A[[3S(N
M=MIQ1&TVU;BO+C")?S_WJ\Q7E!=1)B&   ((((   @@@@  """"   ((((
M @@@@  """ PT@+G:/3Q9)KW]QYBD8TRX[UYB,<;AO9F[1RH?)#RJLJCDI;3
M0-/?MX_7&Q6 @G$NH?-^0S^U^9O.C2VH,ZRGO;K)7Y53B_3X"I7YF/+TRB0$
M$$   0000  !!!!   $$$$   0000  !!!!   $$$)# B<KIQ-HA0RQS0&:\
MIPWQ>#VT;93CR>47=;R?+XQ VE5C3'_?3^K<#",P]D9#/"[C8J<U&E4:LFOO
MU'C^J)S^/N+CIW7]%.55E$D(((   @@@@  """"   ((((   @@@@  """"
M  ((() ('*GC>(+-^\<F98;I\.S,>#\U3 -,QC))Q\]DQNP'$)9)R@[CX8\S
M8__=, ZTC3'Y\R%/95R&_<&;0.05/L[/C#_^?_!.7=]?V9]@(2&   ((((
M @@@@  """"   ((((   @@@@  """" 0(& )]7BB3;OGU10=AA.>R(Q'>\P
MO]5]7F:\8?Q^^W_8TQ0-,(PW;#\S[(-N,KXO9TR>T+E%FM0;],LK:@"_4@Z_
M@]QVLJYOKCRM,@D!!!!   $$$$   0000  !!!!   $$$$   0000  !!)H(
M?%S7TXDWKP(PC&D>#2H=J]_TGW48!ZLQO5G9GT](QQR._3WZ84X+:7!AK/%V
MA6$>=).Q^;?^2,;EBTWJ#?+E9=7Y,Y6+_A8>US5_8F)Y91(""""   ((((
M @@@@  """"   ((((   @@@@  ""+0AL)7*QI.QWI_<1OU!*OK>S%BO&J0!
MM-G7GV;&&^ZUWVB?N\UX@U9\Z\SX[]6Y:09M("7VUZL[A-] V$[1N1E+;*,N
MH9901TY1?D$YC#7>WJ3S_IS*[,HD!!!   $$$$   0000  !!!!   $$$$
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MJ3^JZ3(-//XM/*+CN4<58]C'/8Q/40W[/6-\"""   ((((   @@@@  """"
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M,\8P5J\B,4\?^];+IOW;#>,.VPMZV8$:M;6<^O)BXK%!C?I'5Q!   $$$$
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MR:NQI.G\],0('.^N,<X<C?/SVI\:';,[Q (\<##$-Y>A(8   @@@@  """"
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M^M6I/K:[1<;#JW>,4MI*@PV_ :],L_ H#9ZQ(H   @@@@  """"   ((((
M @@@@  """"   ((U%?@#>J:)[#"9%:\]9O6I,$5\)OP\?WT_I45#2>WXD#<
M]LPEMQN_[>UV7E2>M>0V^A'NO6HT=HOW'].UN?K1J3ZW>4QB\HR.R_X]]7F(
M39OWB@[AM_#%IJ4I@  """"   ((((   @@@@  """"   ((((   @@@@$ /
M!3ZAML)D5KS]C\[/V<-^T%2Y EZ&/;Z?WK^EW"9>B798IJW0MB?*RTQS*%B(
M';;7EME 'V/],3.V,,917-W MR)=\>'"/MZ??C7]1C7LW\8/E*?K5R=H%P$$
M$$   0000  !!!!   $$$$   0000  !!!!  (&<@#^M<)%RF-B,MR?G*G!N
M8 0>3>[K@Q7U_+M)._%OJ.R''-;+M/7#BL;5R[#OR(PK./JA#:]8,6II%@WX
M>>7@X.U^HX; >!&PP%@8$$   0000  !!!!   $$$$   0000  !!!!  (&:
M"G@2;P=E?UHA3=OHQ/KI28X'1N#AI*=5?79@0M).?'A??%#"_J1,C"LRYP;M
MU/X-.GRLKE7UL$B#9OM^Z>WJ@5?JB-/OXP/V$4   0000  !!!!   $$$$
M 0000  !!!!   $$$$"@'@*[J1OQF\1A?XK.^TUCTN )_$U=#O<Q;&>N8!B_
MS;03VCN[Y/9^FFEKY9+;Z'6X%3-C"GY>W6"N7G>H)NT=G+CXH0M>]*[)S:$;
M"""   ((((   @@@@  """"   ((((   @@@@  "",0"_K2"OX\>)CKCK9?,
MKTORA.,RRF]3'E^73M6T'WX;/+Z/WE^P@K[^.=-.:/=[);?G3S2$V-X^HSQ]
MR6WT.MQ9:C >4[S_Y5YWID;M_2%Q.:-&?:,K"""   ((((   @@@@  """"
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M#<JIQ=31K0HZZP=ICBJX-@JGUTP&Z54T[DS.<8C R CPP,'(W&H&B@ """"
M  ((((   @@@@  """"   ((((# P OX;>(=E+V<>9KVU(DJWI!/V\D=SYD[
M^?(Y+[5>Q41Z@R8'XM(CF5Z6[>25)V;-M!-.5?W P16AH0'<?EY]]J<#<NE8
MG7PH=V%$SJ4/')P_(N-FF @@@  """"   ((((   @@@@  """"   ((((
M @@,A<#.&D58RCS>7J_ST_5AA NIS><*^N3^[=N'/M6]R>TS7KZO9:;Y%2S^
M?:3[RY78F#_K$<?W Q6#^N+O@NK[T\EXPMBFZGRC!VQT>>C3?1IA\/!VXZ$?
M,0-$  $$$$   0000  !!!!   $$$$   0000  !!!! 8(@$IM%8+E".)_W"
M?K^^+?_#@OZX7W<ICU<FO2JPJ7;#/0O;O5^]7,K>&S-MA+:\G;N45L:,F4UQ
M7DS:^GU)L?L1YAO)6&*S0_K1H1JUZ4^GQ![/ZMB?3B$A@  """"   ((((
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MI_>JH.A0GUXS&5WN_YRD"(<(((   @@@@  """"   ((((   @@@@  """"
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M>Y00MY<AKLZ,P5:/*D_H94=JWI8_RQ)^0_ZTPFPU[R_=0P !!!!   $$$$
M 0000  !!!!   $$$$   0000. U COK*$QXQ5LO0__AUY3DP +G*<=.8?^C
M/>3Q0R(W%_3#_=F^AWVI8U.?R]@L4V)'[\W$#[^#F4IH9Z],_#)63BBA:RV%
M:/39CX-:BC :A?QW[,^@A-_.I:,Q;$:)  ((((   @@@@  """"   ((((
M @@@@  """ P3 *G:3!APBO=>EGWCP_38$L82]&G%>Y7[+E+B-]JB!U5,+U?
MX?B:5H,,:;G<0S2KE3C6IPKL'RNIC5.3^,_K>,:28O<BS&5)_\/OTJL;S-&+
M#@Q(&RLG3OZ\ @D!!!!   $$$$   0000  !!!!   $$$$   0000 "!@1+X
MH7H;)@2+MOL/U(BJ[^PV!69G5M_T*RU,I[V["OKA^[CA*R5';^>#&9<-2F(8
MFXD=_FYN*:F-&Y,V_EI2W%Z$63?I>[#Q]J!>=&" VMA3?8U]WCY ?:>K"""
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M91(W;F//$MJX/HE_80DQ>Q'BC*3?P875#?+Z)T1>M^2+<!8!!!!   $$$$
M 0000  !!!!   $$$$   0000 "!P11XJ[I]OW*8-"S:7J<R"P[F$$OM]8<+
MK(XKM97B8//HDM^$S]VGJ3KO51!&+?U' XX]ROK,Q2Y)W+B-K;I$]@,J+R3Q
M#^\R9B^J^^W\YY-^!Y<#>M&! 6SCALCKNP/8?[J,  ((((   @@@@  """"
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M?D\FKFU/[3+V24G<?W<9K\KJ_OS#_4E_P^^K[I^!J-*EE=B_B=QV;Z4"91!
M  $$$$   0000  !!!!   $$$$   0000  !!! 85H%)&MA]RF&RL6A[@LJ,
M'5:$!N/:HL!FWP9URKKTVX*VG]/Y1<MJI,9QWIT9_S(E]/?)3%S_[H_J,O9U
M2=S3NHQ79?6]DKZ&O_N'=7ZV*AL>\-C^/S#^#,52 SX>NH\  @@@@  """"
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MTU<;L+I!<W5_0B'\7K[7O#@E$$   0000  !!!!   $$$$   0000  !!!!
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M\5W$JJJJ_ZZO3?H9^LSJ!LW5)T9V5S0O3@D$$$   0000  !!!!   $$$$
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M>9!.T^ZJ&.)X^Y2R[U>=T@;J3-S'L.^'A6:M4T=KW)?K7C;TPRGC:]Q/NH8
M @@@@  """"   ((((   @@@@  """"   ((((! [0165(_N50X3E;GM,[KN
M)>M'(;U?@\P9?+C"P>]6T*;[,:G"=OL9^M1DS&=WV9DO)_'"/;R\B[@_3&)>
MTD6LJJJZ3V&L\9;5#5H7O_-EPRH?+&J]-Y1$  $$$$   0000  !!!!   $$
M$$   0000  !!!! 8, $)JJ__U*.)RS3_>=UW<O6CT)*)\-M\8#R/!4-?GK%
MO4<Y-??QZ16UV>^PWTS&.[G+#GT[B1<LS^DB[M5)S".[B%5%U363_H4QL[I!
M>]IKJ_BWE">V5XW2"""   ((((   @@@@  """"   ((((   @@@@  """ 0
M!#R9?H5RF+0LVNX=*@SQ=BZ-[3\9BY]4..;/9-KS/7A.>=$*V\V%'J^3RRC/
MDKM8TKF#%2?^C5W99=S<0R*._[T.X\Z@>K:/^[A5A[&JJI9^EB+T=;^J&B0N
M @@@@  """"   ((((   @@@@  """"   ((((   @@@4"0PDRZ<JQPF+HNV
MAQ4%&*+SFQ4X^'P5R9/[#RKGS(^NHL&"F'[;._1CJO;?75"NV].?5(!XK+=V
M&?"\)%Z(?6B'<5?-Q%N\PUA55%LYTS^/V?=NUBH:)"8""""   ((((   @@@
M@  """"   ((((   @@@@  """#03,!OMY^H'"9LB[9^<WQLLV #?OW'&0=_
M^F!"1>/Z8J8]^S]689OQ4'P_TY4=[M>Y.>-")>U_3''BWY8_ ]!-NDR5XWAA
M?\\.@WXBB>>)_#JEGZDS88SQEM4-ZG27JN_+&]3$(<H_5?Z:\M+*) 000  !
M!!!   $$$$   0000  !!!!   $$$$   03Z*C"-6O<J!O%$9F[?GQCP PK#
MFCS1?J]R.O83*QKP'(KK5072]GS<BXGD^0O:_HC.EYTV4L!XG/Y\03?IGZH<
MQPO[6W<8] =)O%]W&*>*:O[<Q0M)_SQ>5C>H0KN^,3^@KOEAI/!;]_99Y?<J
MDQ!   $$$$   0000  !!!!   $$$$   0000  !!!#HNX#?#G]1.9[02O=_
MJ^LS];VGU75@TX+Q5_6I@:('/;RRPG35#?-_D<?IW]P##\=5T.[;%3/]+<W<
M13MW9^(YOC\1T4GZARK%_3NHDR 5U3DYZ5OHY[X5M4?8^@GX_Q\_7!#N?;SU
M0U+^6R8A@  """"   ((((   @@@@  """"   ((((   @@@T'<!OR'^C'(\
MH97N7ZKK57UFH.\ ZD!N@O=6G>]F@KQH7//IPE/*J;&/MR^J5.+Y<S-M7U=B
M_!#J39EV%@P7.]@^D8EGL^4ZB#6]ZJ23N5Z1H0YI,74B[9O'R>H&=;@[O>G#
M*FKF<67?]Z+\MMYTA5800  !!!!   $$$$   0000  !!!!   $$$$   000
M:"ZPKHKDWGR/)[O\1K@GRX<QS:E!Y3ZM\.V*!GNLXL:V8?_:BMJ+P^Z5:=O+
M]Y?]0,F\F7;\J8!.TEA5"D;I=IX. GJR-HTS?P=QJJCBU2;2OOF8U0VJT*Y?
M3#^HXX=+<K^!^-RJ]>LZ/4(  0000  !!!!   $$$$   0000  !!!!   $$
M$!AE@;=H\+E)]WB2ZV:566Q(D3;1N.*Q>M\3\6M5,-Y%%3/W%KO;W+""]N*0
M*^H@':>/WQ<7*F%_?*:=U3J,ZX<*<GWV_?'#".VFW50ACG=;NP$J*N\'>IY.
M^N9^>@)Z%F72< LLK.'=H1S_-G/[_!Z&^W? Z!!   $$$$   0000  !!!!
M  $$$$   0000 "!@1587#V_43DWR17.W:7KG2QC/P@H)V7&?I/.>0G^LM,/
M%#"8QMO)93>4Q/,$_4.9MK^>E"OC,%TU8X,.@RZ9Z:_-_M-AO!.2>#_I,$[9
MU8Y(^A5^%Y\KNR'BU4Y@+O7H>N5PSQMM>_'IE=H!T2$$$$   0000  !!!!
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MX['&\=[109RRJQR<]"GTC]4-RI:N5SQ_>J39_[7^+?C_H(_6J^OT!@$$$$
M 0000  !!!!   $$$$   0000  !!!!  (%B@7&ZE/O$0)@(]=;?F]^L.,3
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M;E0.8PG;^W6NJM4-?I*TY\GO-RB3JA?PPR[^9$FXS[FM/_<Q=_5=H04$$$
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M:H4?X(JMP_[M.K_4B'DP7 000  !!!!   $$$$   0000  !!!!   $$$$
M@2$2\#?%B]YV#I-BUZK,\GT:\R?4KB>-0U_2[61=F[5/?>NT6;\U[\GL>"RW
MZKB,M]@]:1S'#?N3=+ZLY'ZF$^-^T*';!U.V4(S07V]/4FXG?5.%X_K>OZ^-
M 'X+/:Y_0QMURRCJAWOB]KU?]NH&.V?:<#O_5)Y1F52NP'P*=[-R>E]]?*/R
M(LHD!!!   $$$$   0000  !!!!   $$$$   0000  !! 9:8%[U)(2*JP
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M9T_E84I+:S!>G<)C"]D/5?B!DEZE&=30Q<JA_7CKSX_X8002 @@@@  """"
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M_W2<\7$O5G/X04$?SM1Y_]V0$$   0000  !!!!   $$$$   0000  !!!!
M  $$$'A%H.AMVC#)=8M*;JW<S43L*XWU>,??=;]&.8PEM[U1UU?L<;_F5'M_
M:M O3WROU>,^==J<']CP;R2V?5['GB3N)DU2Y3AFV-^OFZ!)W=]GVNCV80]_
M^B'T]:&DO6:'=T9U0XQ6Q^O?>JCC[17-&BOINA\JN%\Y;MO[GRHIOA^:^&<F
MOE? >'=);=0AC/\/\LHKJ6-Z?$#%G3VLH ]^",$K'Y 00  !!!!   $$$$
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M/CY1,,9XO-X_4;G;SY,H1#9YA87XM^/VGE?>3IF$  ((((   @@@@  """"
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M^72%@YVHV'<KQVT_H>-W*Y,00  !!!!   $$$$   0000  !!!!   $$$$
M 000Z%K $^Q;*U^O'$]*M;+OB:M#E =E@G!Q]?72)N.\6-<75>Y%\IO'=RD7
M69^E:]/WHB,=MN&')EY0COM_D8X]4=U)<KW<[_",3H(E=1S[0>6XKWY@HM-T
M@"K&L;9L,5#NH8I;6ZQ[;-*F8U69-E/P>(S>OT=YABX;];WXG7(:VRNH^#<U
MZ,DK!SRKG(XO/7:9#U<XV'D4^Z:D'X_J>/4*VR0T @@@@  """"   ((((
M @@@@  """"   ((((# B KXP8-ME6]43B?&FAW[3>5]E/W6>]V3Q[F_LE=I
M*!J75Q[HU7+CBZBMW"1[Z-L%NCZ+<EW3-]2QT->PW;V+SGXT$\^K3RS61<Q0
M]<Q,['G#Q3:W>R2Q=FZQ_@Y)/9M=WF+=RY*Z_NU4F?ZLX.&>ANV>)33H&"%>
MO#VXA-C]#N&'M_Q[C<>5V_=J*^M7V-E9%?MO23_NT_&*%;9): 000  !!!!
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M]V<(!CGMKLZ_J!S&4[3U;VW^B@?ZW:0?_]!QIY\-J;BKA$<  0000  !!!!
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MSU"Y;A^4:3;6E9*^_%['=B<A@  """"   ((((   @@@@  """"   ((((
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M:4#5\[V*K</^/EW$['?5KQ2,*8PM;+T"0B_3>FIL$^5>/.#0RW'1%@((((
M @@@@  """"   ((((   @@@@  """" P @(^(U:OPE]FW*8<&MEZTGS;RHO
MJ%S'Y <B_JA<-!9/T/H->7]JHJJTG +?H9SK@]O?M:J&.XR[FNJE$]>=3I)_
M5;'2<4_NL%^AVO>3F$_JN),WPF^)XO@AAE92[C[.TZ3B-KH>&WRR2?E.+_\H
M:<=M[M%I,-6;6_E>Y;COWK] N9M5*E2];^D;:CD=3WK\O,ILU[<>TC """"
M  ((((   @@@@  """"   ((((   @@@@  " RS@B5M/B-ZEG$[$-3KVI*_?
M')Y#N6[);PQ[>?]GE(O&<(6N+:5<55I8@?TY@:+VZ_;&^.&9OF[8 <Z\JN/?
M1CIN+R'?:?JP*J;QO))$N\GW/,1YJ,7*Z8H-?C!CVB9UCX[:<7NK-RG?R>5%
M5<D/_X3Q>.O5#;QB1:?)2_O'\;S_@')='RYJ-$X_('&L<CJ>]-B_5:\R0$(
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M0;EV3K\SBA?ZT.[J!NE*$([CAQC\($*=T]+JW%W*8=SI]D5=V[O. Z!O"""
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MNJ8UU;&IRO&8X_U_Z-H"=>T\_4(  0000  !!!!   $$$$   0000  !!!!
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M>K\ZU>AOTRMED*H5\$,^NRO_4SG]W>2.SZ^V.T1'  $$$$   0000  !!!!
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MU:'@DVYOT+5%Z];A >S/BNKST<H/*:?&S8[_KCJ?5IY;F80  @@@@  """"
M  ((((   @@@@  """"   ((((   AT(+*TZGNA/)W!SDW5>_OUSRLW>U%>1
MCM,'5+/H>^M_TS4_*-%)VDZ5_"9S.JZK=&Y>Y5:3)\G3!PE"S#.3(,OI^&GE
M<-W&;T_*I(>_CLJ[WN2T0.;8$]>A#6^],D*C=(0NAO(>?RX]JI.AC+>K9@K%
MD[R'9JXW.Y5.R-^F"LT>*IE%96Y1COMVEX[G4JY3VD>=B?L8[_])U^K6WSK9
M->O+ BKP667_SF/75O:]TLA!RDLJDQ!   $$$$   0000  !!!!   $$$$
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MJMGJ?W=.!A7'.&S !FS !FS !FS !FS !FS !FS !FS !FS !FS !FS !FS
M!IK @-XNK2;1T](<+4NO-^+WA"5 B59'US&@PH-KH9K" \U;L,Z/KC>A3RQS
M_2_I_VV-UYN4^9=#_KW^AKYJD]H]F!N3_?%<&S&60@41*F9(X_J9A7)%$DID
MY^<\A+Y*<0J#Z=S:KE)F\ES9O/P>-LC&;\C.TRL;7SD;K[2[?G;LZ^Q/7.&
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MX OF_!&F@WJ%?@[D \BOK<*9O\)D4&ULQ\2BH@']+2B!VE+H)QWR^]#^)>'
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MN>_8G8Q-W9$WU\'7GHKK;P-#0(4^\;.KU%:AT.F@[X?#!FS !FS !FS !FS
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MSH'/(?=0;O\=YOX5^H/#!FS !FS !FS !FS !FS !FS !FS !FS !FS !FS
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M5:2DGP?1<1VY$@67=]B #=B #=B #=B #=B #=B #=B #=B #=B #=B #=B
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MKJ3[(U#IGI3X_QVT)E$Z#\<]6'!^)>,/!25ORX6.'0;YO55*Z!U;,/\5^GI
M'XBK3KS!_M00XS)VXO7T-G,>M]*1YCR3#<X8QC1GRM*XWF9/QVB[4ZE_MJQ_
M]E)_T>;P;.YV!9-^G\UYBOW6?&X%IZZIJR^S1T%\9K7/ A4N=<:8EYL^!O2]
MR9^KW+Y6$U'QU/3@:$X#^AM<$PZ&2^$YB(5'Y3[;<OWZWT"M\N*P 1NP 1NP
M 1NP 1NP 1NP 1NP 1NP 1NP 1NP 1NP 1NP 1MHA0&]N;PR*)FL0@&M6% N
M,=.:?KU=?AOH#7$E<3LBF<IEVQ1Z<_9DR-_@;\F'WH0_ 1:">L=ZG/!1J'0/
M2K3N"+4FC#5?10(JGLC/KS>'>T&YF)F!)R _3F_M3UAP4#?Z;BR8KZ(-Q1X0
MSW7&#[W__<_"-+620IHS]+]#_VGM'\8U=[K_C/SH)AX_:VEL_7",SJU]1>P?
M_6-7X7]5N/ !I/MZE7;^.6CUD9@H57'%?-#>,3\7+/J[/ZJ];Z0.UYN6<_P:
M[H/DOJ7MB\S5L\X-CN8Q, FWLCAL#<?#'1#_IEKZ7&L97X=S.VS !FS !FS
M!FS !FS !FS !FS !FS !FS !FS !FS !FS !NID0 G('>%,4#*NUI\7J)3H
M&<OYE+3^ ZP.4T%GB8FY4:U<\$_0<U1ZSGSL,>;_%F*RF]TVAQ+@.G=^O;C_
M,N.;0E'"G^ZRL00CST,\E]H?PQ90+K0*P9V0'W<^?7G27>?0?+VEG,_?CS[=
M\] PIN* @1!#A3+Q6!6(Q.C/3AQ7L4:,3]A)X_KN*[:%U*>MB@,42DRG_NM_
MZ"G^CU;X2/.TU?EBJ"#A%8ASE"AO[U#!QKL0[T-_[[NV]XVTX7HJ6M$;[Y?
M5Q"?I5S[/>;]#0: H^,-S,@MK KZF[\0GH2B@J=RGV=;^_7]<=B #=B #=B
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M8$>8&ASM9T#?Z17A=W ./ 8J:"GW675$O[X?FX##!FS !FS !FS !FS !FS
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M-F #-M"I#$S!W>HMVD/@5O@0VII\&\DY+H:=85YH[QC !4^'6A*,*@XX#.:
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MV( -V( -V( -V( -V( -V( -V( -V( -V( -V( -V( -V( -V( -R( 2\9O
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ML0]$/^F9\NUPYAT#^AOH2J&5&9:"G> 4N!?&0/[\C=[_@FNJ*.D2.!0V@OE
MA40.&[ !&[ !&[ !&[ !&[ !&[ !&[ !&[ !&[ !&[ !&[ !&[ !&["!+FA
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MB+$AS =%A35T.VS !FS !FS !FS !FS !FS !FS !FS !FS !FS !FS !FS
M!FR@\QK0F^G+P\J@A._,,!$X.K^!J7@$O<4_&&Z!F/BN-LFJHH7'0(ERK2B@
MGP>H)69G\O[P%%1SS7\S;W>8'F),R<X!4*[PX$[&EBH=,"M;K6R07T^)]%_
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ML3$POH2^#TKHJ_A A0A+P91036C)^\=!*P&H .%^^!@4"X,*#S:'N:!<?,G
M-7 =+ Y[0/YV_:?T30VU)L8_YQC=D^YO).A:DX&NLP3\'*:"&%K1844H^BF)
M.*_:MEQN!(-@92B77WN%,:UD<"F\#FT)%1@M *FX(&WUMUV/T(H$(Z"HL$#%
M0 X;L $;J,I N7\0JSK8DVS !FS !FS !FS !FS !FS !FS !FS !FS !FS
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M#=B #70U RXXZ&J?J)_'!FS !FS !FS !FS !FS !FS !FS !FS !FS !FS
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MA3N<WE&% 17IZ.].?X^.3F3 !0>=Z,/RK=J #=B #=B #=B #=B #=B #=B
M#=B #=B #=B #=B #325@:FY&Q4/J%@@%0S$;2HFT%8)T_8()>U&0RHF4'([
M;VM<OR7?VEB0 ]<$%0DL!^5^JD'%"OHI B5T>T&EO)02_HO")]#6T.?R(LA[
MK3&* ZZ!)^!]T.?9%U2$H.U<T /:$BHV& &I "&ND*#^M&($34<[&=!W4]_3
M2<LP20OCY8Y+_;6L$*%KJ1"BTM\+PUTNWN.)]/?FZ&0&QK<O:B?[>'R[-F #
M-F #-F #-F #-F #-F #-F #-F #-F #-F #-F #[6Q "<)8**""@EGA9Y 7
M$^CM[/:*L5RHJ' @+RCXH@$WI*7X5X)U0:L8S GEXC,&[H*'0*L?; V5YC/\
MG[B6UJ^@+;_CKD3M=:#[K!1?,JC$?J6B!-W' W /#(7[X!O0]Z$?](4^I:W:
M\X"2UFT-W5=<%4$%"=I7@8(*,\;WU1%0T.5#.=Q4K*!M+04+\;C4CL>KH"'N
MISF5MCJFT7GEO;G&2>#H9 8:_<7H9#I\NS9@ S9@ S9@ S9@ S9@ S9@ S9@
M S9@ S9@ S9@ S9@ UW0@))KJ6! R>*>I?U82*!B B6?E5QOSU#R^%UX&]XJ
M;5-[=.C[B'9[AE8DV!!6@U5!#LN%[E<_AR >A9U@+VC-V\I:76!+^!IJ#25,
M+X)-JSSP/>:I.$*)_)_#BJ#$:KGXG($[X$%0<80* 6(H[Z;BBE2(,!_MN4';
MWE#IW Q7%2J"& FZ=EHA(6W5IV(%APTTPD"E@H26QO3O1[DY^EN_I40C[MOG
M;+ !%QPT6+!/;P,V8 ,V8 ,V8 ,V8 ,V8 ,V8 ,V8 ,V8 ,V8 ,V8 ,VT! #
M2EYI]0$5#RBQ+5([;5-!@7X7O+WC_[C@AQ"+")283_O:C@85&WP/'1U*AB\+
M6AE A09Z6[]<Z-F>!Q487 7Z^8'IX;>P'TP#;0D5+>P"3]5P$OW,PS]@X1J.
M25._HG$NG .]83U8"V:'2J'/3JLIW E:_4 %#.5B(@94C*#B Q4D]"MMU9X#
M)H9ZQ*><1(4'6A%!VXA61] *#0X;L $;J)L!%QS43:5/9 ,V8 ,V8 ,V8 ,V
M8 ,V8 ,V8 ,V8 ,V8 ,V8 ,V8 ,VT$8#W3E>A0-I-8)4.*"M5A^8 5*?VAT5
M8[BPB@=B 4'>5C'!N(ZZP2JOJX3ZZK !:!6#2JL[Z"<('H1_PLV@YU6HJ&,?
M^ U,"?4*O<E_/J@0X.$*)UV,,5U_<]#WIYK0&]7O0UY0\#U]6KG@!- U%X%U
M0#\EL0Q4*@I0$<9CH,(#%6*H+6?5A.Y;!1Y]H"_,"_U*^RI&J%<^3TY'P7#(
MBQ+4]P$X;, &;* F _7Z!ZJFBWJR#=B #=B #=B #=B #=B #=B #=B #=B
M#=B #=B #=C >&- 25JM1!!7(9B%?14.J+! 6^VK+3HRQG)Q)=(3;X6V^M+^
M%[0[8TS$32\)*C!0(GU1J!3O,*CD^4UP%\0$>F_V#X5M8%*(H;?HNX&N5X\8
MP4FTVL%+H"*.R: W+ \J>&A-Z-EN@*5@\8(3/$C?\: Y*D28%M8 %1^L!3-!
MI=!WZ7[X%\CA"Z"BA%I#SZI"A/D@_3R#BA+Z@?ZFZAF?<;)4B) 7)8QDK-D+
M:.KIPN>R 1NHTH +#JH4Y6DV8 ,V8 ,V8 ,V8 ,V8 ,V8 ,V8 ,V8 ,V8 ,V
M8 ,V8 /_,:!$\@R@A*<*!F(Q@1+ *AQ(8VIW=#[B6^Y!R]_'HH&\K?V/H*N%
MBCU6@_5A39@>*H62^E?"'?  Y$GR^>D[&+8 %9/$^(H=)=9[@[X?S1;ZN8%I
MLILZB_U[0*LDJ!@CCU?I^ M<!'H^A;[/FJNB#?W\0G]HZ3O^/G-4?' SW GZ
M/K8UIN0$6@TA%22H$"%1;_\JNG@35)"@8H1AI;;VA9[/80,V,!X::.D?O_%0
MB1_9!FS !FS !FS !FS !FS !FS !FS !FS !FS !FS !L9+ WHC7<EHK3:@
MM[=3P4#<IK;&-;^C0\EP+0/_%HR&HB("C;T'2IB.#Z'<C][85W&!$N++0J7/
M2F^MWPTJ,+@:WH"B4()]7]@,\OS25_3=!E/!ZM"L\34W]D]0D<!TX29?H[U=
MJ>\PMLN$L=140OU4. /RY+K^'M8&^=;SQW.S6Q@J[$C%!X_2_KAP5NL[M2*#
MBA'ZENC'5H4)VM=8O>,+3I@7(:@00<4)(V L.&S !KJ@@?Q_$+K@(_J1;, &
M;, &;, &;, &;, &;, &;, &;, &;, &;, &;&"\-: \@)*?/4'% B*UXU9%
M!EJ)0"L7-$N,X4;*%1"D?A49:/G^\3UZ(& 54,);*QGH<ZX42ICK+?L;X0;X
M$LK%SQDX"E3 D(>*%2X!?1Y[0%P]0)^+DM!Y<OM%^N8 %2=4"A4^S%EI0BO'
M5'2P.VP%*T&*[VC\&8Z$E> (6 [R^(J."^"O\"KDH;^A :"B!GT>"T-+H6L_
M!*D X2G:ZFM4S,B)]1,-J1A!6Q4DS TM?2Y,J3E4&*3OR#!0$4)./59[X+0.
M&["!CC#@@H..L.YKVH -V( -V( -V( -V( -V( -V( -V( -V( -V( -V$#;
M#"B)&PL&E& 6>9_V\V7OZ>K0&,O5E7Q,O!7:ZDO[2E8[RAOHQY 2VNO"0.@.
ME4+)<148B'OA>Z@4JS!X)*Q0,.D;^BX%G>M@T.H',9YE1XGW!4*GDLX7@>ZU
M-U0*W=O%L%VE26T8TW=P(^@/A\,DD.)I&MN GF$U. **'.@>KX?C0<4"Y6)V
M!O0YB56AFH3^I\R['>XL,9)M>\5L7*@OZ/NE;4+%")-!(T(%+Z^7803]*O)P
MV( --*D!%QPTZ0?CV[(!&[ !&[ !&[ !&[ !&[ !&[ !&[ !&[ !&[ !&QCO
M#.CM\$J% W$L)DB;1=2WW(C>5'X+W@[D^Q\QYJC=P.0<LB(H<:U5#'I#I=#J
M P^#B@+T4PG#H:7HQ@05, P&)>/ST&=\.>CM_AU@5] Q*3ZF<2VL KTAA3[S
M ^$ 4 *[I3B?"?J^ZUD;%2HZV #>@TMA 4BA51!4B/ 74&'!0)"3E:$H5'"@
MP@,5(&A^N=#?K<ZEYUH;YH5J8B23TNH']]'^L)J#ZCQG0L[7"_3YB5B0H/Y&
M_9OT?YQ[-!05) POC6F.PP9LH(,,Z!\'APW8@ W8@ W8@ W8@ W8@ W8@ W8
M@ W8@ W8@ W8@ W80&,,3,UIE3C52@.Q8"#UI7YM)X5F#"7S/H!41/!6F;82
MMY62K0P[:C0P%_/7!"7&5X*6WC#7YW0W_!/T=KQ^EJ*:T"H8F\!1H$1R'M_1
M<14< LO!"3 3Q+B,G3=@7^@>!AZGO1MHQ0(EJA4J7!!%SZ-" "7_GX&IH%RH
MB&'Z<H-E^O4F_3<P36E<A04;PA X#O: F#N[G_UM08EMA9Y],*RNG8(81M]?
MX$+0M5J*N9F@ @\Q$(I\T/V3^#_VG@05DN@S_C?H.3HR)N+BO4&?KXHHM-7W
M2-LY0..-"GU?]/FH($'^M4V,H.V54I#@L $;L $;L $;L $;L $;L $;L $;
ML $;L $;L $;L $;L $;:!X#4W(K?6!9T++L>LO[2#@#KH4'00DO)1R5'&QF
MM'3["W 77 1_ B5=-X8!T NZ@Z-]#,CUJJ#D][-0S7?G.>:=!#JNUL2N$MR_
M 7U?BZZE0H-+04GD!6$HY/->H6]S4 (\'_L[?;WA^3"F0H.'P[Z.4:%".O98
MVBN&_=2?;V^O,$?WG<]/^X\PIN*8M/\5[35 L1:\"6E,V\]@9XBAOXU;(,Z+
M[0\8^SW,!-7&%$Q<#TZ#X1#/5ZFMA+I65M@=%H-FBTFXH?E!13/[P5GP+]!G
M_CU4>K9ZC(WF&@_ Q7 4# )]OV:'"<%A S9@ S9@ S9@ S9@ S9@ S9@ S9@
M S9@ S9@ S9@ S9@ S9@ VTV,#EGZ W+@!)CN\ 1<#I<#4I8O0:?0SV28(T^
MAY*H>MOW/K@<3@0E^[:$@= 75#CAZ'@#LW +.X!6)="*!"U]-_2&_A X$.:!
MUH0^^WW@;2BZGA+!5X**##3W3S .XESM_P%6AU'9F+Y_VX$2[K%P0N=5$4(\
MUX/L?PPZMQ+UTX&2]>E:>M[4CEM]KU\J,S:2_GC<6]F\4]G_,/1]23L5'<Q(
M^ZHPEJYY$WT](<92[!056J1CY.%,F"\>5&5;[O>'NR'Z2N<NMU6"_5S8!O3=
M:N;0O[N+P,9P,.B^]6_6.U#N^>K9/Y;KO @WPRFP-_P2%H:IP&$#-F #-F #
M-F #-F #-F #-F #-F #-F #-F #-F #-F #-F #$\R-@_5A9S@,E&Q4,E6)
MK5>@FB1O/9-<;3F7DJA*[NHM;:VF<!H< H- "=.%0 E;1_,:Z,:M#8"CX5%0
M$KZE[X02\I?!%C MM#9FX,##08G]<M=4LEU)8,6&H.1]/O=>^A: 0T$K%L1Q
M%>8L"DK</YN-'<'^VZ%/W^6+P_[O:"L>@G3.UT/[W=!6(= Y83\FY>54!0+I
M'!_1?CSLJ\! _QZD0@?-BT4'[$ZP(WP*Z1S:RMLFD,?B=%P'Y3Y+]5\/*T!K
MH@<':365\R OGHCW5]1^@F-.A+5!JRATEIB:&^T/FX/^W=;W1-^+#Z'H.1O1
MI^^;KGDIJ+AF>U@)Y@#]'3MLP 9LP 9LP 9LP 9LP 9LP 9LP 9LP 9LP 9L
MP 9LP 9LP :ZL $EA"Z"1B2BZGU.)23?@Z= ;]N>#4?!+K >+ %ZN]I)+B1T
MPIB>>U:QP(50*=D?OU>O,E=O7:\,$T-;8A8.5L+T,XC7B&TEZ)4X5\P%,6&?
MYBG9NQ/H?'="ZD_;&^A3082>5XGNU*_MOG!/Z%.APB!(A0(C:$\*2C1_ ^G8
MNT/[L=!6 G_[L#^"]G=A_T+:[X=]%>B,#OO#:"L)_VGH4]'!:I"B#XT'(=U+
MVBKYK>?,0X46*MC0WW.:FV\?8>Q7,!&T)B;D('U.2L(_ /&9\VOE^_)Z!^P/
M2T)G_?=$[I>!;>#W\ _X-\3/,G_V>N]_S?5>@5M!A5_Z?F\(BX$*1!PV8 ,V
M8 ,V8 ,V8 ,V8 ,V8 ,V8 ,V8 ,V8 ,V8 ,V8 ,V8 .=W,"FW'^]DTRM.=\G
MW,<+<!>H .)8V ,VA@$P)W0'1]<RH,3C@7 O*+G>TG='<S3W4&C-$OP<]C\Q
M%SUZNUV)]'+7OXVQI4$Q">CZ1?,OH7\F4$(^7_)>26\=IV3X=! + W3=@^$$
MB/=P$/O7A;XM:"LV@#1/;Y@KH9OVKPGM6VCW"_M* -\?]K5ZP=YA7W[WA)B@
MUSF6@\\A74//OBJDF)C&D9!_AJ/HDXNB6(C.*R!>*YT_;8<QOCM,"6V)&3AX
M*[@$/H!T_FJV*B#1V_L[PVS0%6)F'F)YV 'T;^V5\#1\ =4XJ=<<%;NHN$3%
M$,? 3K R](+6%IMPJ,,&;, &;, &;, &;, &;, &;, &;, &;, &;, &;, &
M;, &;*"]#/R!"]4K>51T'B4FE314DOAR4&)W/U#B="#TA;8F$SF%HY,8F(K[
MU!O.9\);4/2=R?L^9=X_0<E1)8[K%2I8. O2Z@'Y=;5_%RP+*90\?QGRN7J+
M6V-*DNIO*D^B:V4.C2NF@8<AGN,H]C?*^NYD7\G7-.\)VBI64)P*J5]_5\^'
M_9-#6^?0,4KLIOGGA[;Z=H.G0I]6*S@X[&O.8!@(,2&M]BH00V_4RX6.26@E
M@[_!Y% 4\]-Y*>3.TO':*NE_-/2$MD8W3C  ]#D]#I566HCWD-JO<HP<ZWNL
MS[(KA;XKLX.^=[^&$T %+R_ 6$@.VF.KOTNYOAW.@/U!!6A+P+3@L $;L $;
ML $;L $;L $;L $;L $;L $;L $;L $;L $;L $;: (#ZW$/K4D>?<-Q>GM9
M;Z=>"TJ '@*#8 U8$*8#APW,BX*]0(G#KZ&:[]OKS%-2=VWH#O6,Q3G9)5 I
MP7T/XRN&B\Y*^S+([UU)426N)P,E:E58D\]YB+XY0-$#'H XYR_LR]&GH7\T
M[5E "?$T=U7:*5ZBD?IWI1U7'U!!3QH;4CI ?Z.I3]?[+.P_2WN%L*]Y*NZX
M+?3)E?ZN=0]?A?ZBH@,5E9P;YJ3KZIZ7AG+1CX&+X%M(Q^1;);W/A@6@7M&3
M$^EYKX3X&>37+MK7O>HS/QR6AXFAJT8W'FPNT/= 12HGP<V@H@#][T&1GT;V
M?<@U'X,KX%C8&?3]U#UVY<^!QW/8@ W8@ W8@ W8@ W8@ W8@ W8@ W8@ W8
M@ W8@ W8@ W80',94+(F)?GTMJ_>QGX2E$Q2<N\H^#6H.$%OERI!I^23PP:*
M#"CYOCKHK?9A4$W240EM)0\/!A4$-"(&<-(;H=+]J!@@%AI,Q+Y^8J H$3V4
M_I3XUM_&!Y"?6X4XDX!B2LB+#4XK]3_'-ATK%TJ<;AOZ]),)*6:CD>9JJ_N-
M^YN%_?MI*_:%-$<)\O/#OOI7@G^$OG=HSPUOA+[W:?>"M2 6CA05'3!E@O4A
M=Z+$M/X]J900GH?Q\Z!2$OM[QF^"@5#/T'VM#'^&YT%N:F$,\Z^!/4#/,;Z$
MO/6%=4'%1?I>WP$C0-_G6AS68ZZ^._JWYTXX"PZ$7T%_F X<-F #-F #-F #
M-F #-F #-F #-F #-F #-F #-F #-F #-F #=38P%>>;$[K7^;P^W?AAH!>/
MJ:(4)?25@*XF:?@9\VZ G6$&:%0,Y,1#H=(]::6.-2'&,NRH\"8_[B/Z=H()
M07\O6C% "? X3PZV@A23TQ@*<<ZY[.L<EV;]1[*O^:-*_3KW8I!B>QKI/$KH
M+QGV/Z:]3MC7<RGT+.F8L;15-)#VM;T:]/>OGT!)_2?37@Z4O$U].I\**'X!
M6MTA]>MY!T(>*DZZ'=*\M/TW??/GD[/]N=@_!^)UTO%QJW-M"BH.J7?(R:Z@
MXH9JO]?QWM[F."6\-X&?P?@8D_+0*LS9 /:'O\,0>!/ROYOHKI%M_9T\#E?"
M<; +K Y]0'_3#ANP 1NP 1NP 1NP 1NP 1NP 1NP 1NP 1NP 1NP 1NP 1NP
M 1NP@08:T!O-*X#>!'\.JDT.ZHWYTT );R4B&Q5*Y.L-^\>@TKTI@:ZWLF-,
MS\[94)0,O83^E#C6"@"/0G[^E^A;$%),1F,(Q'DJ,N@&>V;]FJ?$^1&A_P+:
M,2YC)YU+"=.-PKX^BUA,H*2J0D4"\:<05F5_.*3S:(63V>'PK&\A]O<)?9JO
MA+%B0XC%"%^POQ+DH<]B-XC7UWFT_SO0>*50TO\,B*LJI/N.VQ',V0NF@D:$
M/D<5I:@0XU6(UZZFK>_3DZ"_F95 YQO?8PH$+ (JR#@8SH/[X5VHQFDCYNAO
M83CH;VLI<-B #=B #=B #=B #=B #=B #=B #=B #=B #=B #=B #=B #=B
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M04K&ZTWN:=498E_:Z9Q:B4'/<VWH^SWM5<+^J[13Z+-)QXZEK>*"^T.?QI3
M50R!-/<MVO*\%"B)G_I?HST-* ;!]Y#&/J,]$,J%?+T!:7[:ZEE^5NZ@K+\G
M^_KLOH!T?-%6]W4+R$M[A0I8#H1[H.B[572?>=^S''L*K 4]P%&= 7TO5H =
M0']75X-6^FBI0"7WG_;WYEB'#=B #=B #=B #=B #=B #=B #=B #=B #=B
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M(WP"E>[U=<:W@Z+$[#STWU[F^(OHCV_8R]4%9>:>2'^>N-;U5 @0[^T1]GN
MXI<0D_)ZCCDU0*P'Z;CAM"=39XA):,>D^EZEL8_8IN/6I:TD?]I_LS0G;9X-
M8X-I3P/Z7--\;9<&Q6F0^I60G5^=Q)60^K4]5)VEV(UM'!O#ONZG4FS.H'Y2
M(1ZG]GF0O-%L,=)W0]?,SY7OCV3./C!UBV>M[P0EO9>$P:#BCEC4D=]CI7U]
M;_0]VQ5Z@Z-M!O1W.Q>L"2JJ.1[T76[O[P>7=-B #=B #=B #=B #=B #=B
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M4:'/4\4BQT+^72FZYW)]6C7A(?@]Z'SE_B88<MB #=B #=B #=B #=B #=B
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MV( -V( -C"<&M-2]DJ"7035+Q<>$HQ*52BRO"-V@F6)Y;N96B/=;U/Z .8?
ME% N=*YGH.CX2^F7PSSVI.-KR(]YD[YE\\FE?14;G GQF+?8[U,:UV9IR,^[
M91CO37LLZ!S?PQ)0%!O1&:^CX@A%+%:X]\>N"52TD>:J2"&/?]*1QO]5&EPX
M]*6QC<.!*@))_2IBF+LTIF*5E\.8YBB1'2/>H\95=*"BB&IB72:IN"1=.VT?
MIJ]?-2<HF*/OSOY0=-YT_K@=Q=Q]044?S1+RKQ4+]#>CSR/>;ZUMK;:ASVAU
MF (<-F #-F #-F #-F #-F #-F #-F #-F #-F #-F #-F #-F #-F #7<2
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M9YE^?XKC7.DNTF6DPXV)4D8@  $(0  "$(  !"   0A   (0@  $(  !"$
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MXW6Z?D3VWY'.(AVNXL4B'Y;^4GJ7M--\J_1Y4<;/I>M+IY<B$(  !"   0A
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M_R8^(.TT]RI]7OARJM3W;B$I @$(0  "$(  !"   0A   (0@  $(  !"$
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M23/85'J,]%_2,BS*V/@W?)7T!U+_1J:2(A"   0@  $(0  "$(  !"   0A
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M+TG+\BIK=[MB'BSU;A(S2A$(0  "$(  !"   0A   (0@  $(  !"$   A"
M  0@ ($!)+"$<OJZ] )I6A@N6QARP>TXZ:>D+J:.1O%N$"=)_29^66[_D*V+
MY75D*CGM(2TJ]-VAOK1P7C2.W]#_H[0H[SO5MW21<X?V==47%^H=_S)IIP+W
MWNI/\YB@-A?+<^*WKN^2!I\).:,.;5Y,X.<W^'NA2)J?"_JAW\<?2&-Q,33N
MWRKN+#C_>^3SK,[3^7D;^SAF.']O0;Q=$_OC"^P\%R\8"/%\]'/;21959[H
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MB5>=/B_2.4/J'186ER(0@  $(  !"$   A"   0@  $(0  "$(  !"   0A
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M*4UWRBC+L9O=_>_$WU3'HM^'NA (0  "$(  !"   0A   (0@  $(  !"$
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M?T-&NRPG +M++Y?67<A1Q-GM7JCDOR?[23\H]=\7! (0@  $(  !"$   A"
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MS^_%(?W[THUQE?Y;%/\7TH]*IY<B$(  !"   0A   (0@  $(  !"$   A"
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MP6$^IO_/6E/J'3]NDN:X-M'VFF)/D.XA75GJWS8" 0A   (0@  $(  !"$
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MO)CD2FD\UW#^M-H_T^;@Q!Y6!+RP9A/IT=)T(55X9KH=67 PK&XYR4(  A"
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MH02\XX=_7WM*O6#%OZGXN<V=>W>7^:4(!"   0A   (0@  $(  !"$   A"
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M^['HP/?PR,SX(1_O$F(;! )%!"97QVK2[TM/DWK1TZI2! (0@  $(  !"$
M A"   0@  $(0  "$(  !"   0BT3L %TR](CY;N)?66S46%1'4A%0CXN_1^
MP]1O2X?B8=FCM^4_7+J M"GQ??6]=N&W*(^+U+>$M(ZX0'^BM"BVV\UB)6D3
M,I^"W"U-Q]NI9'#S.#/C[UT]7/@N(U^143S^'F6<NM@X1ASSA@[V2R6VWHVD
M2.+[?FJ148?V>&&%\RM:".#%,?&B@7@NWBFEFWB!3>QS>3<'];]'ZEU 8K\;
M=5UEP=3.B;]C^7GMQZ(##3/))Z1/2.,YA/-[U>X=21 (0  "$(  !"   0A
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MR\@1,HK]?/Z#,HZ)36Z1BN>U0&+7]N4L&N T:3JG<'VN^N9M.PGB0P "$(
M!"   0A   (0@  $(  !"$   A"   0@  $(0  "U0CX3>USI*&P5_7X%_FN
M5&W(TM9C9>F">:><CE'_;-+A*"Z@7R5-Y^="=Y7OUR\E>[\)GL;Q6^,NY):5
M=-&"%Z T)5LH4)K?7!V">P>)>('"<QULW16_(7]M%]NB[E74$>?H3RQ,6F2L
M]KT3^]C7NV&4D>_)*/;SPHGI2CAZQX]_)K[FM7X)W]C$\_NU-,[!YT.QZ,!Y
M;25]5IKFX^M_2S>3(A"   0@  $(0  "$(  !"   0A   (0@  $(  !"$
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MM4Q.GN/#T@]+$0A   (0@  $(  !"$   A"   0@  $(0  "$(  !"   0A
MH&4"4RC^9Z0NQ,:%S2KGE\MW;6E;,I<"'R_ME--%ZF_RK?NVYM(IKK?"OUB:
MSM,+$,ILI1_'_E8FCN.>*_7BDK(RAPSC;>S]UKSO1U.RA *E\W61O9-LK\[8
MYYA.QNJ[*[+WC@]UY4=RC,?M]EF)[1+[V/?H"DE<EL3Q9T[*BA>'Q./Z_(BR
MSI'=Y#K_G32-9;;S17;]//6B#>]FDN84K@]57]7?33_S9RP(0  "$(  !"
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M7<X/3/P]OA>[U/E=>W>%OV;B^3GQWYJA%"\">5$:<P[G_AOR#6G5WX-<$ A
M  (0@  $(  !"$   A"   0@  $(0  "$(  !"   0B,7@)[:^JAZ%;V>*M\
M-I/6*4A6(;V4C"^1=LK+1?/%JP0=<%L7[_\H3><\46WSU\C=]RF-Y6LOX*BZ
M>,'%V'\F\3ZAZZ9E3P5,<^XV=^\(\'KB-U>7Q.*Y/-O%MEOW9Y*Q_9F);O)C
M&:3S#-<7=G..^OW,W)+$\H*5LN(%+E=*P]CAN'?9 (G==+J>( UQPG$0%ATL
MIKRNR>06<O3?FW%2! (0@  $(  !"$   A"   0@  $(0  "$(  !"   0A
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MS,RZB#F'N?FW/ B+#F90'L=*0U[IT;_!C:4(!"   0A   (0@  $(  !"$
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M=-!V.E!*DRPL[;2@ZAGU;VU#! (0@  $(  !"$   A"   0@  $(0  "$(
M!"   0A   (0*$?@4S)[6)H6#>/KV]2_9KEP(\9JKP(FN_8XPZ\5Q#7O7C[1
MX(4*KR6QU]!UFS*Y@KM(&S\KCU08\)#$]ZR2ON<E?LN4].MFMED2U_,JNWBB
M6^PZ_1_-Y.-%&E7%Q7\OGHCOD\\/JQHH8V_VN<^O>-'!("Y.\C.[M[33XJH_
MJ'\0%TPH+00"$(  !"   0A   (0@  $(  !"$   A"   0@  $(0  "@T%@
M,:61%F[3@N0KLG'AO=<WH0=CQN6S\**"E(6OS:(764W.Z:* ,,Z1O026[YG2
M$,O'/_88KXS[^Y,Q/6Z5SQ!X@4&<\^%E!I7-N8G?\B7]NIDMF,1U;CMT<VJY
M/YWKLQIO[AIC^E[EBNQ;UHB5NIA_^BD/L_/G009QT8'S7UF:[B 1/XO_4O_'
M;8A   (0@  $(  !"$   A"   0@  $(0  "$(  !"   0A   +_(3"-3K\G
M]6*"N,"6GON;YEZ4,-ID%TTX9>'KG_0(8D[Y%^TD<8OZINLA_GCYQCF_H6MO
M=]^V[*,!XG%]_OD*@_XS\?]N2=\_)WXN'C<E]RE0/*<3F@I<,XX_%Y$N4CFI
M9JQORB^>F\]?E"Y=,U[LMI(NTMTN'-^?R9@U-AR@\S'*Q0M]4B;QM?MG&*"<
M204"$(  !"   0A   (0@  $(  !"$   A"   0@  $(0  "0T9@?8U\MS0N
MJ*7GCZM_ZR'+<&@'_FH!FX-Z3,O;N%]4$/LEM?=2\)U4_M<EL<ON%""WGN1R
M>:?/SQ(5(OIM_=A_VY*^9R=^?GN_*?$.#7%.#S85N(<X!R0Y.;_5:\3SL_*G
M3"R_Z3]CC7BIRZIJ>$X:\_/Y("\Z\!P^(7U"FN8=KB>J[P-2! (0@  $(  !
M"$   A"   0@  $(0  "$(  !"   0A   *CDL#\FO5ITE! RQW?4O]1TD%]
M&UFIM2H[*GJ.RQ%J=Z&V%]E?SKG8;MNNE\#RW48:Q_8;Z_-(VY;I-4#ZYOUC
M%0:=1;9QWCY?MZ1_6C1?LZ1?&;,OR2C-:Y$RCBW:S*389AOGY<\5>"%+53'W
M^Z1Q+)^?+FU"UE"0%Z1I_.O5-LA_6_R9BG,R>8=YO*F^GTJGEB(0@  $(  !
M"$   A"   0@  $(0  "$(  !"   0A   (0&!4$IM LO8WZ\])0.,L=;U/_
M:'Z#UY\!\(*+E,WQ:IM,VHML).<T;KBNNS5^R,>?87@HB?^]T-GRT=^W#_,(
MQU,JC+E<QG_)DOYG)+X?*NE7QNP]26S/;?LRCBW;>&%*X!R.7ZLYIC]!D2X6
M<<QOUXR7NJVE!N_<$?(,1^_$X04/@RP[*;E<[F$.-ZM_^4&> +E!  (0@  $
M(  !"$   A"   0@  $(0  "$(  !"   0A H D"?M/X)FDHE.6.KZA_+^E4
MTM$J+N3F%AN<JO8Z;Y#''!?3Q;/2'/N[U#Y#;%SC?.\D]N,-Q"R;QB^3L3U'
M[PY05KR-?<K%;_*7$;^-'_NN5\:II(T7F*3W[+B2OFV:.2\7[.-Y/ZWK.6H.
MZL)Z',OG;TC'2YL0[U;AOR_I&)[#+$T,T&*,=RNV=V1(<P_77JRQN[37OP\*
M@4   A"   0@  $(0  "$(  !"   0A   (0@  $(  !"$!@L BX 'FT-%=$
M#P4S'R^4NB ^FF5K3=Y;I<=<?'Z6=$II+^+=!XH6?+@0NWPOP>7KSR:D6]?O
MV&/,*NZWRCCE5G:' H_SU<3?<RDKZ>=!/E[6L:3=N;*+YW9_2;^VS=Z?Y.4<
MC^UAT)2CX_G3#?/V$#-V_8@N7I7&+'U^K71FZ2"+?__[2W-_'\)\KE3_:/\;
M.LCWD-P@  $(0  "$(  !"   0A   (0@  $(  !"$   A"   0J$/ ;T%^0
M/B4-!;'<\7'UN] ^VF5+ <@5$\]7>Q/?:3]!<7+\W;:CM%<Y2@'B^'?KNM=%
M$F5S\F*'>&R?/R&=M&P V?U,&L>XO8+O[Q/?C2OXEC'];A+?>2Y4QK$/-NES
MY85%J]0<USM*^+F)[X//KY V]2QY)POO")".<8W:!GW1@5*<9$VI%YRD^8?K
M%]5796</F2,0@  $(  !"$   A"   0@  $(0  "$(  !"   0A   (0&"P"
M*RB=JZ6A")8[NC#Y6^FLTM$NFPF MX]/.5VBMND:@/.53.PPUA\:B+^L8J2+
M)39I(&[9$)^589A/./H3%%7$'(*OCQ=6<#XE\=VT@F\9T_%)?.>W;1G'/MC,
MIS'2G2V\8X 7'-41[[21^_3!076"%?CXV<S]WH;+H@,OS#A9&C^OZ?E?U.][
M@T   A"   0@  $(0  "$(  !"   0A   (0@  $(  !"$!@V!!P(<R%P5PQ
M+RZ(>?O[#PR;6;6;Z"<5_G5IS,?GWAY]!FFO\CX%R&TC[S$F2IMXJ]O%^3A_
M+S;IIQROP>+Q?>Y%%E7$1?(XQK$5G$]*?+U;19,R1L'29Z1*?DWFDHNUNQIC
M=C[O9=<,[XR2QO/UIZ5-R>8*E"Z2\1A_E_KOV' 0S^%I:8Z5V[R[C&T0"$
M A"   0@  $(0  "$(  !"   0A   (0@  $(  !" P\@2V4X:/2HN*7VU^6
M[BF=2HI,,LF&@I#;WOUZM3>Q$& .Q7E0FKLG'K?NUO=R_3_YN,[2^&O^7V]_
M3A[.Y+!,Q:&?2&+L6\'_Q,1WFPJ^94W3'4/N*^O8![MI-,:]TO@Y^+>N9^MA
M['01AV-[)X4E>XB9NFZMAMRB [,>+HL.%E2N$Z0Q^_3<.W"PDXP@(!"   0@
M  $(0  "$(  !"   0A   (0@  $(  !"$   H-'X%U**7W#/2UX^?JOTL4&
M+_TAR^AC&CFWV. FM?=2J T3FEPG9IZ[%V[;)1CV<)Q"OK=)XS'.["%>'=>E
MD_&=BXO=DU8(YL]6Q'/P^9<K^*<[+.Q0P;>LZ8$R3',<5]:Y#W9>/)/F=T0/
MXTXOW]LS,=TV0P]Q4]?MU?"6-,U]."TZ\.<K=I,6[63BN3TB74^*0  "$(
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MB1R[,$<O'OJ6M*F_#QX3@0 $(  !"$   A"   0@  $(0  "$(  !"   0A
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M3AM+<W^OXKD>+YN9;8Q   (0@  $(  !"$   A"   0@  $(0  "$(  !"
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M.A=?>X[328>S^/?^#VEN?J'M=O77V4UD.',A=PA   (0@  $(  !"$   A"
M  0@  $(0  "$(  !"  @0P!%VE#$<E'O]WZ7:G?'$;*$5A,9BYNQAS#^9?+
MA:AD=53!6![S:>G82M&Z&Z?/R$MR&>JWZ?^E' +C<-RM^U2R%A<GL9[(6G5N
M_'$2X\3.YCWW;I",9P9']!RUW0#+*KQWQ@CWR\='I--+>Y4<#\>?(/6N!$W+
ME IXIC2>2SB?H/;AONC ?_^]:X<73(5YI<?7U?<]:9U=1>2&0  "$(  !"
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M:A\IBPZ\ &IWZ6L%<PWS_J/ZYY B$(  !"   0A   (0@  $(  !"$   A"
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M5-JFC%7P^Z3Q_,+YN6H?B8L.O/N&G\TWDWD?HFL$ A"   0@  $(0  "$(
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MPWG-K'CW2M/GR]<_:'BLHG"KJ.,Y:2Z',]3.HH,B<K1#  (0@  $(  !"$
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M<I\&<2'^_2U-;FO%39\57WO'@7XL%HJG]86"7)S/*5(6'<2T.(< !"   0A
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MH0\KR,EY'2MET4$W@O1#  (0@  $(  !"$   A"   0@  $(0  "$(  !"
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M(W&R7>;D10>G%O PF]]*1]M"#$T9@0 $(  !"$   A"   0@  $(0  "$(
M!"   0A   (0&&T$7&S.O;GOHMG=TGE'&Y#,?+V+05Q@]?E;TC:WD\^DT5/3
M8O).YQ"NY^DI\G\[WY,9YZO_;5+K:K5,W"_4BM2LDW?<"!S#T;^GH?S\2+,S
M_.]H%V?F^YC:^KG;R']G-'174VKH,Z3AOJ?'(]7'HH.ANS^,# $(0  "$(
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M3:.OHQV:F;,7(7@QPFB4J37I\Z3IWXEP?83ZV.E@-#X9S!D"$(  !"   0A
M  (0@  $(  !"$   A"   0@  $(C% "'].\BA8;/*Z^=X_0>5>=U@QR\';Q
MH7 8C@=6#33$]MYYX*G,/#R?+1K,;;6",>9O8(SW9F)_JX&X382X*Y/;WYL(
M/* Q9E->N>?IL@'-MQ]I3:M!+I*&OQ'I\3?J8]%!/^X$8T   A"   0@  $(
M0  "$(  !"   0A   (0@  $(  !"+1*8'U%]QOZ:4',U_^6CM:WE#7U_Y%]
MU9)R>D9M+K@.)\GM#A#FU<1B@,!B<YV$N.'H-]_]68I>904%"#'#<?=>@S;D
M?TPF-\_;"U9&JOAS%N$^Q,>M1NJ$2\QKC&PN+>!B1MY-A$4'@H!   (0@  $
M(  !"$   A"   0@  $(0  "$(  !"   0@,3P+K*NV7I7&!,)P_JW:_18[\
M?P(+ZI!CM=LP!+2'<@[W.3[ZS?PFY3L*%L?WN3_/T80LIR!I[+V:"-Q C!TR
MN3E7+^X9J>)%)#=)TWORJ-IF'*F3+C$O+S+YFS3E$JX/5Q^+#DJ Q 0"$(
M!"   0A   (0@  $(  !"$   A"   0@  $(0&"P"'Q0Z;PD#86O^/B"VM\_
M6.D.>38G9E@]I#9OG3[<Y&(E'-_O<'YDPQ-Q,37$#L>K&QK#.V^$F.'X@X9B
M]QKFW9G<G.-/>@T\X/YK%\S[P '/N^WT9M( _J1&>$[3XZ_4QZ*#MN\"\2$
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M9?/,W'V__)D-9)))YA.$NZ7I,QRN!VFW#NX7!"   0A   (0@  $(  !"$
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MVP]HSIW2\G;TZ7S^T,EA"/K\68XT1U]?,02Y#-60<VK@9Z0I!^^J,=U0)36
MX_KW>:\T<+I1Y],/8)ZD! $(0  "$(  !"   0A   (0@  $(  !"$   A"
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MKHR8C_YI>YZHQM=[).G1#B._7U^-&.2,  ((((   @@@@  """"   ((((
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M9QM*-#@>>ZG#.T(J2,I[Q&3DI^VUXI6EKISR$4   0000  !!!!   $$$$
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MYCG=\>2LO]WWQL9M_WVJX[&7*[QL0X)LEP#LWS,O!!!P4,"V%N*%  ((((
M @@@@  """"   ((((   @@@@  ""$1-X"N2D+T)/_9UJ4RPX\5'[;58$LK6
M]?QZF1=$*.$P0RYU&::Y-,GZWYHEH,59IE?;Y(V2\,H,24^5:5_.,)U)"""
M  ((((   @@@@  """"   ((((   @@@@  """" 0-$%7BLEIN4]]FGR)V5:
M4]%K<Z/ ;V7(=R3_?X]\[Z4  $  241!5'(CQ*)%87ML&,EMY.=!12N]= 5]
M*4/<-OX_E*Y*[TJVV[%/WB/;=>3GX]YE0L (((   @@@@  """"   ((((
M @@@@  """"   (((."EP&\EZI$;E:-_?LC+;,87]'U9<K;YGS"^(KQ9:EN&
M7&=Y$/V2#'';[=,O[WH/XB]7B/\L%8W^N[6_9^L=HEPQ40\""""   ((((
M @@@@  """"   ((((   @@@@  ""%2!P)F2X]B;E?;?#\@[VY #OK,<F"5G
MF_<.>=?XGN"8^)^7?X_=QH>-6<;%?S9+4.D,L=M<%K@8<(5BFB3UKI/WR#9.
MR>_V[YH7 @@@@  """"   ((((   @@@@  """"   ((((   @@@4%*!JZ3T
MD1N5HW^>4]):*UOX>[+D;//_365#*TGMSV;(=TY):BI^H7=FB-UNI\\7ORJO
M2ZR3Z#OD_8_R/M+K3 @> 0000  !!!!   $$$$   0000  !!!!   $$$$
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M=HS[D1O68W_^+J(N?\N0\P*/<GTT0_QVVWW.HQP(%0$$$!@6B.&   ((((
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M;SR/_?VR,L;B4E5G2C WROLF><=="JR 6&;+NF.W[\B_?UY N:R*  ((((
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M@  """"P5X&#90G;Z"#;JSO;#*9[*[ Q1^2+<LQC%@((((   @@@@  """"
M  ((((   @@@@  """"   ((((   B\)S)+?LG6O;Z>_XZ4E^24J G622)^\
M,VWWYV2ZCDJBY($  @@@@  """"   ((((   @@@@  """"   ((((   @@@
M4%J!35)\IIO/3\GTAM)63>D5$DA(O9FVN9WVV@K%1+4(((! 1@&&5,C(PD0$
M$$   0000  !!!!   $$$$   0000  !!!! P F!\R2*9\9$,BC_MM.'QDSG
MG]$0R#6LPNQHI$@6"""   ((((   @@@@  """"   ((((   @@@@  """"
M  +E$)@JE7Q*WBOE_6_RGB5O7M$5>(.DEJV'@\7139O,$$   0000  !!!!
M  $$$$   0000  !!!!   $$$$   0000* 0 =M#^5WR'MOHX$\RK::0@ED7
M 0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !!*(M<("D=[V\
MD_(.Y'V=O ^4-R\$$$   0000  !!!!   $$$$   0000  !!!!   $$$$
M 0000&"O K6R1/U>EV(!!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!!!   $$$$   0000  !
M!!!   $$$$   0000  !!!!   $$$$  @3P$=![KL H""""   ((((   @@@
M@  """"   )["!AC]&W-R_?;8X8#$\)IZ1WSMW8..! *(2"   ((((   @@@
M@  "D1&HC4PF)((  @@@@  """"   ((((   @@@4%&!35/>,[W?I)^J:!!9
M*M<OQ#X@LWZ893:3$4   0000  !!!!   $$\A"(Y;$.JR"   ((((   @@@
M@  """"   ((((   @@@@  """"   ((((! E0O0X*#*=P#21P !!!!   $$
M$$   0000  !!!!   $$$$   0000  !!!! (!\!&ASDH\8Z"""   ((((
M @@@@  """"   ((((   @@@@  """"   ((5+D #0ZJ? <@?0000  !!!!
M  $$$$   0000  !!!!   $$$$   0000  !!/(1H,%!/FJL@P """"   ((
M((   @@@@  """"   ((((   @@@@  """" 0)4+T."@RG< TD<  0000  !
M!!!   $$$$   0000  !!!!   $$$$   0000" ? 1H<Y*/&.@@@@  """"
M  ((((   @@@@  """"   ((((   @@@@  ""%2Y  T.JGP'('T$$$   000
M0  !!!!   $$$$   0000  !!!!   $$$$   03R$:B]>9_X@4.F7N>S<KG7
M:4@G^^?OZ'RAW/527WX"MTX_;\J 4E/R6[O$:PTETVU]G4^5N!:*1P !!!!
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M^3.L@MS0/B+1W/%:3XRK*DRY@'* W-0_U=6D8S5FI:NQ$1<""""   ((((
M @@@4$R![I:E\].I]-U&F0_+<_<OG?\7LP[*&K^ 7,LXRH3FNZI?/='5V/YM
M&8[PB/&OS9((((   @@@@  """"   ((N"GPT@6'YBE3?RUCV_>Z&>:>46D5
MTLO!GBP5GZ)U3+:+LQ>R_KIHQ[6W5AR) !!   $$$$   0000 "!$@H8:06>
M:&K_=!@$W=+8X%4EK(JB\Q"0A@<MH3(?,4'Z7AENX4?=TY>RC?)P9!4$$$
M 0000  !!!!   $W!%YJ<##OB1_T*ZVO=R.LO4<AUT]H<+!WIK(O(4]K.#N<
M@NS?5VNMI1=17@@@@  """"   ((((! - 5N/B@^61H;7"^-#KXF)S^UT<PR
M,EG5R' +[PT&@RVRS;Y^\Y3X],AD1B((((   @@@@  """"   )5(_!2@P.;
ML38^#:M@YFQH7C:W:K:4!XG>O$_\0.G=8+ZKH<J5'(93<'7C$!<""""   ((
M((   @@4++!^ZO)I@R^H/TA!9Q=<& 644Z!!&HA</!3H!V7XR*7EK)BZ$$
M 0000  !!!!   $$$"A48+<&!\USIOY!:?5\H866:_V4"NCEH%S8XZAG<%!U
MR!,T,C*'>R^MU0.+^CK_[%YD1(0  @@@@  """"   ((%"Z0F'[>0:ET:H.4
MY&PC\,*SC'8)TNA@A@G#E8G&^/7K&M_UBFAG2W8(((   @@@@  """"   )1
M$=BMP<&\.W^0DEX..GU)3D[&:7#@TL8RRMGA%&0(CBM=HB(6!!!   $$$$
M 0000*!8 NN:X_NJH>1:9=21Q2J3<BHG( WYWQ;HH?L2S?%S*Q<%-2.   ((
M((   @@@@  """ P/H'=&AS856(QY4^W\W(Q97U+Q^'C2Y6E2BFPL77Y3.G:
MX(12UE%(V36UM=XTI"DD3]9%  $$$$   0000 "!ZA)([!MO3H?J-\:HPZHK
M\VAG*]NSU82J<VU3_!(3C]=$.UNR0P !!!!   $$$$   000\%E@CP8'"WM6
MKY<;QUM]22H=F&6^Q!KE.).I]%)GAU-0ZK9%.Z[9$F5_<D,  0000  !!!!
M ('J$]@\-UZO^O7/)?/CJR_[*LG8J'_J6J-^FVA9-J-*,B9-!!!   $$$$
M 0000  !SP3V:'"@M39*ZU6^Y&$TPRJXL*VDL4&["W%DBL'$]#69IC,- 000
M0  !!!!   $$$/!9X-G']*4RU. 2GW,@]KT+2&\'IZL@O6G]U.6OWOO2+($
M @@@@  """"   ((((! >07V:'!@JZ\QVJ=A%>8FIL1GEY>-VD8+;)S:<:@R
MYKC1T]SY78>3&LQU[L1#) @@@  """"   ((((! X0)=+?&WA\;\0^$E48(/
M M+(_Y!T.K5A0_.RN3[$2XP(((   @@@@  """"   +5(Y"QP<'"_M5_E%X.
M'O*%0:<UPRI4<&,E4^'2"E:?LVKIL",Q__G._\NY$#,10  !!!!   $$$$
M 8\$NJ?&#S&A^I%'(1-J$02DIX-7)$UZW;HI\1.+4!Q%((   @@@@  """"
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M(H   @@@@  """"   (."]@GV;4Q'W8X1$*K@(#T>''"UB>>_F8%JJ9*!!!
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MMIZ5S\FP"K_U)=,@I1E6H0P;*]3&V=X-Y$+<M7,W=R;+P$ 5"""   ((((
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MB0 """"   ((((   @A40L!H?7@EZJ7.Z AH9?YQR^R+&J*3$9D@@  """"
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M85K\X.20.E-K=8[T@O!&Z4S/#MD0B5=HU <D$1H<1&)KD@0""""   ((((
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MO_9?#GKE ;.55A?+^WEWH]U[9$:92>D@[6S/A7O/@"400  !!!!   $$$$
M 01<%<BKP8%-1GO2RX$\F:^3J32]'!2P!QIMG+TH$5,,IU# IF55!!!   $$
M$$   000<%3 Q$R#HZ&]%);6^JZ7_A'17^S0"Z?U=?[GE'IUJ*3X Z_3-.9<
MK^,G> 000  !!!!   $$$$   2<%\F]P4&M6.9E1AJ",,30XR. RGDF;Y\;K
M9=S*MXUGV0HL,]14']Y0@7JI$@$$$$   0000  !!!"H>@%CU(YJ09BWK?-%
M&6[A0[%8K%V>P'C1R[R-6G1;R[N=[+W02T^"1@ !!!!   $$$$   000&!;(
MN\'!HA<['Y7N$[T8JU'B/(%A%?+;XY_[JSI3+B*UYK=V:=>27C9^92_ZE+86
M2D<  0000  !!!!   $$$,@HH%5OQND1GKBX=W5G72QVHJ3X?[ZE*3U U@Z$
M0V?[%C?Q(H   @@@@  """"   ((N"V0=X,#FY:.^=&=_:YA%>@Z,(]],0B5
MN\,IQ/0U>:3$*@@@@  """"   ((((   L40,*:O&,7X5L:I/:L?JJFM:Y.X
M_6MT8,S;??,F7@000  !!!!   $$$$   ;<%"FIP,,G$KI7T K=3W!4=PRI,
M>#,E9ETP27J'>.N$5RS#"EJKGG#&Y#5EJ(HJ$$   0000  !!!!   $$,@C(
M^:(?UP,RQ%[HI$4[KME27Z-.M^>FA995UO6U69Q8O**VK'52&0((((   @@@
M@  """" 0*0%"FIP<'+?RJ?EY'JM)T(GWKQ/_$!/8G4B3/-<_YME.(46)X+9
M(PC]OVV/73&XQV0F((   @@@@  """"   (((% &@04]G0\J%;NP#%45K8KA
M<_P_WC^O: 52$ ((((   @@@@  """" 0-4+%-3@P.IIY<^P"H.#[@X/X.2>
M:%2[DW%)4#),QDI78R,N!!!   $$$$   0000 "!ZA!HZUM]M5P8N=*G;$W:
MG.93O,2*  ((((   @@@@  """#@MD#!#0Y,W>2?2XI#;J>Y,SIMU+D^Q.E"
MC'>\\H.-<E?_S2[$,C8&K?5S^H0C;QH[G7\C@  """"   ((((   @@@4&Z!
M6JTNEN$E>LM=;[[U24^5;?FNRWH(((   @@@@  """"   ((C!4H>-R^MNU7
M;$\TMO_&*'/.V,(=_/?)B>GG'=3VPM5;'8S-J9!Z=FQ[JP34Y%10(\$8M;JM
M:T5ZY)_\S"RP9?9%#4\^]=0475/7(D^P-!L=IF(U-4.Z+ARL&ZH?FM1H!H]Y
M^LJ^S&LS%0'W!<R*%;%[OON7R2_TIR?7U:8;55I-#NIJ^A>]L.IO[D=?^0B-
M,;IKO_8FU:^:ZVMC34%:WC&55'6QWMK ]$V>W=P[[\X?I"H?*1$@,#$!NV]O
MW/?OFL/^9+.I#9MU8"8'->G^FG1#7ZRQOO>4CQ[<IU>L""=6*DM7@X =T[SN
MWK].3@T---0UF/H@%32$86U#;1@V&!4SL5AZR'Y.UM6J9'I()1OK5+)G:M,0
MPWQ5P]Y1F1RUTM)F7OIVX^6\P,+>SF<3S?%OJE!]WOE@)4#9JTZTWY?R8@=S
M=(,E9ETPJ?'YL"E5.] 4I&)-<N!2HVIU;V-0WS-]_ZF]ASU\N1</_CC*&ZFP
M-L^-U_<\63\IF4PV!/7U#?5!NB$(PH; J'JE8VEI$)5,U^CAXY?4D$Y.KHLE
M6UZ1')R[N3,9*0B206"4P!W'?[ N_6C?9#443AZH,Y-KTD%C?7W]UI-?N'K'
MJ,7X-8> B<=KNFZLG5:KPNEI^3RIKU$#0:JN/ZBO'3AH1LL WT.[XUFO6]:J
M U*#:KH<PD\+M9H>"]3T0)M6^7<Z9G2/](C5:TS8HV*JMS:,]:C:FK^>^N(U
MVW8OB7]5FX ]YFMYL:]A*#6I(5V?:@C304.=7(=(F71=G:Y-!3&=K)7K$$$R
MEFRHB253#;7)U&L/'N#^6+7M*7[D*XWP"W]U-[>W!Z%977A)I2]!Z]@_2I>'
MEY6^)K]KD$8D/W>V$4F-7G!:S[4;_1;./WI[T-SWX(NSI80Y81C.D8.6.7+%
M:);29HHRNL7(3VU_*E,WCEJ2\B'PC%QE>EK*>5J6?UHN.3VN8OI!9<('6J9.
M>VC>$S_H'T<Y+() T02&;X1/6S93IX+#9-\\4/;K@Z3P V4?MS^'?Y>Q9Z?(
M[PUC*Y6+IC]IZ[OV@K'3J^G?MB%&UV4/'*Q2X6PYF9DMGP_R-K/EDO(L;<P4
MHZ4QF5'-\K<_67SE1\Y74DS[9/G>X1,C99Z4WQ^6:5OD!.EAV38/-[2&?YF_
MM7,@9RG,1*"( HG6"UIKPK[#PT ?*I\%AX[LY_*]-TMVZ5:M3./>]FVYB3<H
MWY<[9']^3-9_6+X#_R+??W^1>\I_J3'J07OCJ(@A4U2%!>[>__RFGK[TK" ,
M9LK)^BPYQIDE^\!^<LMMANP#,R2\?>2S<5_Y?6J>H<I-'_V\W+=[7M9_7LIY
MSOY;/B>?C87J41.3=VWLT<5G!'_3G9U!GG6P6A4*=#6W_VL8FL^YG'I,JW<O
M[NOT:CB!4GG:[R>3ZGNL@,^24H66L=R:VKK#%^VX9DO&F05.O*WEW?OT!0/R
M6>C>2X8%_4!;_^H?5C*R#3/>UY),]A^I0W.(_4Z28^I9<CPR2XY?#I&X#I!C
M=_OP1TVN&.4@/BWKV%XUGI+UM\CO#\GQS!8Y#GJHOL$\-/_YSO_+M3[SW!>X
M>4I\>CH=FQ76A#-5J.W^<;!$O:^\9\@YLSU^D;>6]_#^DD="<IZGY-C%]B)J
M?]IC%R/',7:?TOK16$P_JH/:1T_MN_(I&B?EP<LJ)1&P#U<]]>0S1X2Q<&9@
M8@?%E#DP-.H@V8</E+\1N5ZD7R'7/>SYX!X/6<KG_UOE\_]7)0G,XT)O/B@^
M.?FB>IVT0SQ.SJ^/E\\%>6M[_4BN+<NW2]:7#F7NL[+<%KG>]) L^%!,OH>D
M@=Q#BS\YY[XH-_(?OFXY9?EK5!A:KWGRO3W/*'UL/I_'TNO4L_+9^Z!8/BB&
M#QH3NU_53]Y@'_+-2L\,+P1N;5JV?W^-F543VL\K9?^F7B7?K[N^OT>N1>@9
M<BUK4EX):;U#RMQY#4++=[A2\GVNGI?RGI2_Q4>,?(_+_O1H6\]*)X_)\\J9
ME9P7R/&E,?[8[1?3T#;UM'PIM8Q_K8HM>?-I_9VG5*QV#RJV)[^I_EZY"9WG
MAUUI<WQ<;B8>4BTG.W9HB[[MVQ>',3/?A&J.Y&T;%\R6;3.>Q@0%;PGY@) _
M:_57*>AN.0"Z1;ZL;FZ:TGH'C1 *IJ6 70+KIRZ?%@;IH^2$Y"AY(NPHV>6.
MEH/LU^;[?2)_(U75X, V0.K9\N+Q)C +Y:_U%+%[C7Q&'"*\]>7:R79]3CPA
MGQ%R@5-O"HU9-Z5!;9BWK?/%<L5 /=$5L$^<QS8]<)2)!2>'1I\LF9XL)U2V
M,5)1CF&SR=G]62X8K)<+5^OE<O^&MAV=#V=;ENGN"&R8%C\X/12;*XU)CI1]
M9*[L*T?*";TT3!F^*%_Q0&6G34L0?Y.]]Q'YK+X_IO1=2L7NFG%(L)FG#"N^
M>9P,0)Z8_ZJ< SC]Q#P-#G;?==8VQK\C4R[<?:J;_](QM;2MM[,D#X[0X.#E
M;6[/Z7?T;#]6&A?,D\,7>:OCY5SG-7+>4_ 0IR_7LN=O\IVS51K3)6JD4[-8
M76V7/$'YR)Y+,:72 O:)V(TWJMERXW2N"8T<PRA[##-'CD%?G>\Y<;%SL@UU
MY=CE48GK4=EI[Y4;BW?5Z?"N4RZ>NR7*-Q2+[4AY$Q=(M"Z=I8/PJ#!01TG#
MWJ-E'SQ*&HD?+C_W:$PPGM)I</"RDOV>[@\'WR+G).?(->8WR)S&E^<6_IN<
M3V^7S["UL9CZ@X[5_:%4#1P+CW3\)=C>9)YY-/8&I<VYLM;9<HXY;?QK3W1)
M+1TDJ#NEKIN,JOF#WG?21GK5FZAA>98?[F'ZR>=>$ZK 7H>8*]>V[36((^0:
M[2SYK)I<GBARUR)_CSWV.UP>4'U$Q\P]]GN\OJ;VKE.V7_-X[C69B\#$!>2S
MJSBO1%/[E?)!^Z[BE%:Z4B1AHR;5'\RP"MF-95N^2[:EDT^IR,W$_Y &!Y_)
M'KW_<[J;XG+S5;]1=M4SY>!L@62TQU/<E<Q2_H;LQ?(_R9?G37*)Y)=M%Q]Y
M"R>9E=PB?M6]8<;25Z8&S4(3A@OEHL4B^40^LI@91+W!P7 #O^TU)YDP6"@'
MC OE,^+UXE?4$\/B; \Y.=+F;KFHVBT'L^N,JEU/B]KBR%9#*1N:E\U-F> L
MN?!QEGQ&V$8&%=_'Y>_M*6F L$:>H%FUZ$UJ+4^I5WY/M,.DJ63R9'FJ4]ZR
MG]B+D'XT?MX#3R[DIR3^S;*/W27'5W?((ZV)1;VK[]]C0294G0 -#OS;Y(F6
M^ (3J/5>1*[5I:?U=7ZJ%+%6<X,#>P.Y^T89LB+0<@/'O%$N\)XHQCE[*RC%
M-AA;IGS7_$W.WV^40*Y:V+-ZO9PW26B\RBD@U]GTNI:E1X0F/&GX^$6;D^38
MQ9X/EZVQ>#'SE6M#O;(3W2/[UEVR.]U6/TFMI6>-8@I75UGV[V-]\_*C0ATN
MLM>+I/&-/%2AI$>RXKVJO<'!KN^GLZ4QZX7RV7.:R);SN^FO\EGQRUJM_^?4
MOM5RK<B/EWW(9\=#+[Y)&@W&Y?/NK7(3V?:V6O:7V U*I3?J&O6C16>:-5R/
M*/LF&*[0/A!3L^G^H],QN?Y@0GNMZD3YG+*]4)?S;ZEXR6OU@A3V)_L]+I^Y
MMTR*F<3\'9UV&B\$\A8H6H.#KL:.LT(5KLD[DC*N*!>-/][6U_G-,E;I556)
MIO@OY<#C+2X&7:=CK_/IP&0\ACMO(*JSY0OJ3%G^C6+_BO&LY\PR>KC+O37R
M=_4+-:/I5[2XS+YE$HT=[U<ZO#C[$I68H_\LC7C:2U6S[5I6I_KE^T$MD2=-
M%\H!NCT0*]DKB@T.$OO&FW6_>KO<B#I/3L+;!,^["U)RL&%'";Y+?JYLF&16
M<B$J]Y_ NN;XD8'1/\N]5/GGMDQMG5>*'F[LDW^]/=M/EQLT;Y)&!F^2S XN
M?W83J%&K9Z1E>*>J,:L6[[AV(Q?L)V"7YZ([]Y$=QZLP.%D^3$Z2[Q)I;&5>
MF6=QGJRF;<\Q:R7/FV(--3<M>F'5WSP)G#"+*,"0"D7$+%-1]H:)-.!_5*J;
M6:8J\ZY&/F-NE.LB9^5=0(X5JZW!@1R[[1N&^IQ0'AH0U]/DG+XU!X\+LQZ7
M[O*OE@O,5]' K72;PPZ)D$S'3E*Q4'KJDEZZY,:$!_M&82#2);B,4WZ3CNF;
MZF)A%S<NQL\IWQW7RG&?]/KHT$O'+FOK7?W]4D74/67Y829(OT7^+MKD@90%
M\AU:PB?&;1=YXQM286/S^?L-F<%$J?+.MUSIL>8;B_JO_=%$UT^T+)NAP^ #
MTAOEAV7=BI]KRW?/[?)Y^#^FR:QL>[:S=Z+YE&/YG<-D]7]0KF3]@]1W8#GJ
M'&\=<ISQI.S-/ZV-Z1^=VK/ZH?&NQW(3%[AYG_B!J:'828$T+I!]UC[H($-G
MN-%KP<2S&<\:P\.D_,E>@Y!][*8I4UO7E^(:X'@B81E_!?+J@BA3NN;$.;_7
MM]_WG!P<S,@TWZEI1L<E'AH<9-@HPU^HR3[;E9)S+[F@?W^4&AMT-W?,D9;M
M'Y+A2-[C]4FG4?O(SG*^Y'"^?K9ONW0CNC)6&_OQXAVK;W=N)ZIP0-*UTG0Y
M.#FBPF'L5KUTU5CT@_N-K<MGIM*!="\6ODTE^Q:%N[J[DX,R7N,4L*VH>Q_:
M?J9TJWF>ZE-GBZ%TP^6OH$0NNYHY3GX>-SB@_V-M4[Q+3I:O;FHPUS'T0H:=
M(HQ-,BJ<DV%.12?UI+85K>O?X>% [G_QC4:'RW9LW_XVV;_M6,5^O.1)&VD8
M\?<J4'^?:.KX2Z*Y_>MJ1N,5-+@KWN:SO1?HH62;??I/^I(\N6?[-MN%ZJ[S
M%G\_"R<F9%XIQU:V][AW!8.!6MO4;B\F75>K:E8M[%MYS\3*8FE?!>2SIEIV
M>%\WT1YQVT9H<M/HYW)=Y.-[S'1MPLXGLER+RIMXAH>&2Z7?'FJS-!W:)T7-
M\--MGOS5S@Q#\SF)^7.)QOAMJD9_3<[?;Z 196&[GVTT+.=MBT:& 1M,F\.5
M]*UL_[.OJOA E^%"I.&-C&MN/A+(H^IR?>@.V:\Z8PVQU32>W+D?9/V_4;-D
M'W'K>I$)BWJ-7[X;==?4I2>I0*X5*?VV()UZ^9S7H3\0W3!8IP:*VQMGUNT^
M@1F!5A/:'G=,BT_M3>E/R3"F'Q?>BO<:.)*J'-^>(/&<H/O4?R8:VW\B/;U]
M51I /C4ROY(_Y;O]U4$Z_3&3['N?Q-%<R5BRU2W'&?*@HOET*C"?EF/.W^H:
M_06NP6?3&O]TLV)%;/U_;IX7!/I4.06SO1></#B@#AKY$G?H(VK\24UX2>D+
MRZCC9#5YFW_:L7U;4AY,7B\/W*R>7#/I?T_J^>GS$RZ2%:I.H&@-#MJZ5J3E
M2\(^C6=;RSG^,O-MM]X+GEOUA..!ECT\G1J0IVC=?'I6.OQ;67:0(E<X/-[3
MX[%W2+<['P["<%&1BZ]X<7+08Y_DN#!,AQ?*0<^]<HOQ>PVMYD?SMW8.5#PX
M BBI@&V9'H9I>0)?G3.43!U3TLHB7'ABZM)Y*A6^?\<#V^)RD#<]FJD.'\">
M%BAS6L^0_K9<Y/R5?.]<(3UM2$\I=.T:S6V^,RM[@2G1TKY0+KHNEWW\7)EJ
M&V'):_A_.Q?R[O_F4.F2\KOJV;XOR[[\K=JZNN_(&,G;O$NCP@';BV$[TK'%
M,D;K$CEV6&(&DT?LW"OD_SO_JW"$#E1O[$T+]=FT2G]63OH?D,88J^JDEXT%
M/9T/.A =(2" P"@!.9ZYV8L&!TK/M-TKTRWOJ(VWEU]'G<^?ETJE[(,:]5X?
MQD@"\C4K-__,S[N:.^Z5X1W_?>&;U&KVB;WL"+MFV^N*P8!9$JAPB3SYN$0:
MGLA-(/O:>12S\_=J_K^<]PWWZF!.# >#2Z3QP2VQ6&R5/)C0Z<K-Q6K>.N7*
MW=[$2USZ0)O6X=)$<X?MDG[_G77S=U*J;6![TAW<IB_J2:K/R/%(27N-*"0'
MV0/DAKXTY#?Z FG$_U^3Z^LN/?F%JW<44F:^Z]HGV8<&];^F4NGS)::B/6B1
M;SSC74^V[QM-VKQ1KD7<4*-KOTC#]/'*[5QNN)>5,+4D#-62KDLW[^JABL^F
M48KU<IW_=&DD='I_,/ =N0[Q^YB*K6IHJ+V^4G^KHV+C5T<%BM;@P.:G:V+7
MF"!POL&!?&SHY&!H+W1_R]'M4K&PY .DHV*5[Z5B4VN\;7 P/,[P4.JCSSQF
MWB<G5_ON)=5(S):#GM?*>?9_2P\.7Y(#GV^J^J9[5T(<  !  $E$051OMVV_
M8GLDDLLS";D($:F[J;9'%)4>Z%!A^!YIF?[Z/%E8302DR^0V.8C[G$D%2X9!
MJN3X5KYS)DF^]OOX7#'XLUR ^+?%GYQSK5ZQ8M=S0,,:_,]S@5N;ENT_H-+O
M[6IJ_Z"D<LAP.E';QX=[/5!?3:=2GY$GT2_?I[GA7X]Y^LH^SS==R<*W-VR>
M?ER]7KK37"(-4);L&#(GR),#-<.[1=3VC1(HRO?%$7(A;$4R4"ODI/\NZ;KX
MO\/]&J^AEXT28%,D GD(F/K:6]1@,H\UR[N*'(?5K?O=<-?*CY:W9O]JVSBU
MX]"A=/BA9Q[3[Y7S^0D]8>I+MO;\/5#JZJY?JR]W-<6_LKBO\TI?8B]7G+=.
M/V_*8"JU* S4&=*E]9)D?_#2T]D<ON3>"N(CET/4_# ,Y\NOE\GQRTUR3^];
MB_M6_9I&Y[GM?)TKW?@?8<+@W5V7W"<]=IE7R?$KKS((R-_6F8,OJ.^)^4Q_
MR&5PA5#]\\!0ZL,2_U?WFZ6^.W=S9UD.I.[>__RF;7V#GY(GV3\I9L[T C'1
M746V]=L"DSY;'OY;+3W*?(H>93(+VN%24F;H=+G@N$0:/RV1:]D'CRS)9]2(
M1.:?LH_5RGV>LZ21Y5G]@\DA^5N]7L?4-Q?W=-Z2>0VF5JM 41L<+-JQ<H-<
M3-XJ.Z!T-^+V2X?&#JM @X-1F\F.L]@?#$I7@.Z][/A.;3NN?=B]R')'9$](
M!X:2GY4+3A^3OPOI$KWZ7O*%;1M8?%6G^FQ73]]IJ3?_7JU=J,L^(/_Y_;)/
M077].G:6-)UXMW0Q=K9DT^!W1I6+7B[JZ>XI'6\Q@?FL=&E:]0TVY+/B*.G]
M9:6T*OY*=V/[UYKFM%XY[\X?I"JWA:BY$ &[?R>:EYVF5?BA 1.<(Q]^=864
MY\NZDF>SG+A^]OF>P7<GFN,7M_5VKO8E]E+'.?Q4Z&/Z(ODJ//WI1_5"^=DD
M-[M*76WDRY?/SF.EQYC_)\-:?6UM<_OWM#'?X:G!R&]V$G1<H.V%J[=*[X]_
MD\^X5SD>J@K3^E")\5'7XZQ$?/:\9]UO8F^381 _G$Q)#SS#C<>C_[TE&<Z6
M[Y:?2@/*]]?KFH\LZ%VYN1+^KM2YKO%=KPAC0Q^V3S\.#"9/%)_AZZABQ"MO
M 1,3OS.DL>D9TNA\BQPS?TNNEEWAZECN>:=9A2O:H6920;#,/I1B@O2)EH _
ME?+L"-+ 8X8*@\OD//R\\M18_%HD=MN@[[*G'U,?6-_4<5XIAU6V/6^LN^2^
M"U[H'?RJ?![MZIVF^#F5LT3Y6[-#F2X-AL(W)1H[+F[K7_W#<M;O:EUVN*/
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MPX-_2P[TV._Q"^WG4U02(X^)"12]P<&B_E5W2<<D#TXLC,HL+6/OV2=T>8F
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M@-9>-#B07AY[LN; # 0*%WAU:J#G6X470PD(3$Q SOW>WMW4\>Z)K<72"""
M  )R;#AMR Q=A@0"E120QMN?73MEZ4F5C(&Z\Q,H2X.#N9L[DQ+>=?F%6.:U
M3!CY816ZFSOFR)?':\LL.Z[J=$Q?,ZX%B[Q08O&*VIZDZI1>+KRX,%3D]+TM
M3O;CMJXUZJO>)D#@7@A(=]+34J'YI3WH]B)@@LPH(#?-6E-A^(M$ZP7.CZE,
M#P<9-V%U3C3JR&<?TW]?G<F3M2L"\OUW45=S>YLK\1 ' JX+V"Y I?'@T:['
M:>.+J=C??(B3&/T5D&/P"Q+-2Q?[FP&1^RH0J/!;B>GG'>1K_,2-  ((5$S
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MF.*F%NI4X^F->D[O3C=+Y;(R(^"ZPX%6#S^696CUDG8X2&&44J=5"(3#@1X
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M9]T/>@  0 !)1$%4(6:A&ZP/@0O,H"<I!KP//2^?]DAYS^R.QLWY9#+;.HQ
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M)A4KJ<4@O7(MM4:Z6L*)CMQ*Q71USZ?CX'0J_SZQ]MC>7C@56.C0PYE KQ1
MV_6TYELVG()G5#$<"W"K&7 J./@FGS"QK4R "=A P##$=ZO;&Y^P012+"!H!
M*3?A04/2X2 9DKH]PPX'Q*XYG;:T\-F-)\63?4X%.EH!FL6IR8CVC6U3H&Y(
MJZR4U3<4EVJ^X#_>F  3R'L"O>6E>\2!KKSGD!L RY7YE*QTY @'66%S^R2]
M ._-'3M.36K'0#S#,2Z!YS@6-^"U=Z\X3@F,3*24@FO@P<?WP3=NJ\OE!8
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MR1[KL\AY^'%(Q0H";!3;P"G%^#\FP 28@',$I!!_%$>5S#OGE24]SI7"DID
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M!##(QQ$.@E6E!ZUYZXU2ZAZK/*A\L+9&?$.6#^X;CEY;"#M(+HK1B#7$.YE
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M"?B)@.\<#FKV-;P"P&NH0[8L:7M:!=-4--,I"/'H[/U+O5J)6DG]6F#]:!-
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M>FZ1C5"9".F.H??4H+PAU1;X.6Y1(6-+L3"WS&R/ZNG10[?F0W?Q'B; !)@
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MXUCI]Q(&.S:#P@M2&9O1H=]<I$(O7-2U;&=.<(>=C/SSRB)[<QRF+']D DR
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M2Y5)V^$ :F:45J$_G<(U%"\Y*8P&*GJAR3)RZ!@J"K(>Y GT33*05Y,5S)(
M>C9OX#YQ<I:G.WJ:CLRC(I&06V&X'37&9N&%^^*3>VV6::<X7%?;[90W7!8Z
MY=PC'PZ%/Y,D &>#+Y%4+#VE3(Q__0D+_GXWOK3HT1$'Z-.3PT<Q 2; !)@
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M-8<#=*:XPS( GE])$5 &W=^J91G=I&"Q,DR "3 !)L $F  1 D0G*D#'K#S
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M%P)R#U5-35-P^X5JY;!>3( )Y$R 4RKDC) %@ #&(4@^QS%V6XRQVZ.XDI@
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MI/5CY9@ $V "3( )>$@ SGDO>UC\J$5CS%;V]G"4@U$A\9=Y12!O' YTK6*
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M""1"P'/=\!^_>-Z[.AY??6E41K,;^L59TCC_<+W^[[Z<YRW4Y[L-G<;/"""
M  ((5"K@1F$_[CC'ZJ&!LRMM:[67[W\5;F/+QYY_\>4GM!\_5R^DWZ;:=:"\
M^ @DKL/!S*[+7W5<Y];XK$(?6N*Z?]SWE<N[?<@IE%G,Z6J[0A5;%LK*%5^I
MW;(YYU:]#^B:)5N<N$?QB\5O3EV$?\]M$^9=N*[/>5X[P+-T4V%\_%I)BZHE
ML-/D[<]76<]5JSP_R]%W?U>O-WMG>^/\+]K!H9]YEYN771R[K7'>5YT^;ZEN
ME+VMW'QJN9SN]#^[Q9Z3;.CRFB4-.ZC52T(@G *S.C-/A'XX0]&IP]-^?9YS
M>Q1&.NA_(K!A_I$ZQKFYU\L]V-^I+)RKGUHA@  """ 028&TD[M5Q_GA/\8>
M&,UNV4XMH;_.8:_/4T>#4W3\\D#6R]VD@Z_](_GEH-(((!"8@!ZF"/]V-[#6
MD['/ G_Q.;] LM.UT 4:)> 7=HX?2 $^9GKWUB=MH8<YOZQ7X3Z3\YS+E/7;
M?<R>K!(JD+@.![:>]=<>R]<'E/L=UGNJ8^VA'G!>G9,Z76L^5ZY16);34=J'
M<GU]C]B.RUXE$)9Z!5T/&]*GO7'>R>IPL4R'J@\X.>_3*I-A?8*&3T#^>SQ]
MWGJ]4N;L"#=UC.?E?M9^@WN_#;]=RW;H;_0P[]Y''M+YY']%><21E)M:8*-?
MU-*2LA$(O8#KW1SZ.EH%/6?/WO7N'4LFS-\KC/6U$WP]#7B:WG/\2,[)W:!C
MG$B."A-&6^J$  ((((# 4('979D5NACXX-#/POJS=3Q<O\JY*:ROT+-W5.L)
MSF_J]7G+U='@4M7W/6&UI%X(((   O$0V.[MWIVZMQ.)!V8U2L 9>D7VI6%]
M3=(=$UOVU#7<GZU=O^$%73/YJ;XA=#2(QY])*%J1R X'X\>.N5KZZT.Q!FI<
M"=V,7[7=SMY--:Y&X,7/[FG]FZXZ_S;P@JI0@-W(LQU7;T]NN78.E^A"];NJ
M4&S5B[!.!K<UM!RMIZ4O>OZEEU]4S\#+U>%B>M4K0H&Q%V@ZRKE<%Y\>C71#
M/6]?&WY;?R^M2QJ.WZ^:;5FZ1<M!-OJ*_D9OT8'JWM4LV_>R]#V8?=9>-BI.
M31.O5*@I/X47(>"ZJ<@<.]IH*WK_X-_:)[1\_Z$=/M981/,"G<5;L"!E';04
M5ZQ=M^%E+Y>[0-O/4':("!2"S!%   $$$*B^0'2.7SSG4*^W^PF=9WW*CAVJ
M3[5IB79]1AW<YVDT@QOZG/7/Z_CJ>^IH,'G3N?@- 0000 "!8 2F/I+9H&=*
M%P>3>P"Y>L['])JDAY<TS#LJ@-Q+SM(Z,=K##NHP>->&K/.XKD%\4?OQB25G
MQ ((%!"H*S ]EI,/67EEAVYD7J_&'1?+!I;2*-?YO6VP2UDDJO.ZZ;IO.+EL
MBS:H6T6U#4/KW?\$L>=\7$\3?UP7K?^B&U27>0W.'YI79+J&SA>EG_M[\/=U
M'Z91AXY[_J57CE;=MV#TK2BMP6C6U<UDLNT3YWW#RWI_B&8+AM3:\^9EG:Q=
M"+I=[RG]A3MM[S\V+U[0-V0.7WZTX3-7+'<_HNWIF7U]SL&^9!J"3#3BSS?=
M!0LB/QI.""BI0LP%QJ1RMZ[+V<A17LTO@!=#K6.F<4[.^<;KG>L^H=?0?*VI
M:]%"&P&KF&7]F,>>;.A^8M6A.<\]9O&/'_V(ZA/)5\[X84$>"""   ((U$I
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MX:\I-40@_ +N@@4YQ_6^$_Z:4D,$$$   0000&"CP,RNRU_5TY&_P@,!!!!
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M/J)VK8];V^+8'NWW-+!!ZO/-76T7Q+%]M F!, HT=[4NTC%U)HQUHTX(((
M @@@@,!( A,G;?EMC=+TR$C3^ P!!!! H#P!S]%M8!("51"H'^.<IOWXZU4H
MBB(00""/ !T.AN"DO#&+].N&(1_%Z<>>\6/'7!VG!@7=ED-67MGA;-]PF Z-
M+@FZ+/)' ('H"#1UMEV;=E/V>H6UT:EU$FOJYC0BQ6?F=K7^.HFMI\T(U%2@
MP3M5)_N/UK0.%(X  @@@@  ""!0I,.W%"WO2Z?IC=?RRILA%F T!!!! H("
MZ^BE-20$JB P:U7F.3TX>KR*XA5)5?"F" 1&$Z##P1"9V3U7O*1?+QGR49Q^
MO+3_!GJ<6E2%MC0OOV1=<W?FDZE4Z@S=7.RK0I$4@0 "$1"8T]UZLY=RCM1V
MH2L"U4U@%=V<.HN=JA$I?IO QM-D!&HNT+PBTZ6+]A_FHGW-5P450  !!!!
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MZ>,SO5SN.!T?':M&O+W6#=&)59>VRXL=)[5HZPECKMGWE<L9RZ#6*X7R$4
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M6*D YK.1$'K7=C8Z!TY]C8N3 0"3I7/[I!.W<K/>CGU>WX[JR+*C_N!WU%.
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M#<=#FSKR&P((((   @A43\!&0TC_]>GMO+K<A%0VVY!+N8U>3L<N]J]ZE^L
MIM-+I3H]+]4Y=DQ?9\Z=V#'KM8NB\X[RZE%2$@((((   E47>&K*Z6-?6+ER
MN_K>#8W9;+I!UR.T'W<;4RFOP<NF>KU43M<@M!^OTS6(;&_GQ$E;=3#R>=57
M$P4B@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((((   @@@@  """"   ((((
M @@@@  """"   ((((   @@@@  """"   ((Q$3 C4D[: 8""""   ((((!
M^ 1.4Y72/E7K)N7SC$]YD0T""(1#P+8/;U'LI-A!,7X@QNK?M8K5BC4#_SZG
M?U<I2 @@@  """"   ((((   @@@@  "(1*@PT&(5@9500 !!!!   $$8B:P
M3NVQ&X=^I'G*).-'1N2!  (U$]A/)3<K#E#LK]A#44JGI!<U_\,#\5?]>[O"
M/B,A@  """"   ((((   @@@@  """"   ((((   @@@@$#,!*S#@>=3M,3,
MAN8@D!0!ZU3P*\4+"K^V!T/SL9%/+E%\4K&;@H0  @@@@  """"   ((((
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M>8IZ!0D!!!! H#H"=#BHCC.E(%!+@7-5>#6/ZXHIBPX'(W\CZ' PL@N?(H
M @@@@$!R!.APD)QU34NC+[! 32CF_*\:\^3K<& /.W866=<_:3Z_TR'*,*<H
MQN%AS<?(T'ZO ?+K%TCA@  ""!0A8#?ISU?<H9A1Q/QAF\6V=>]7M"H>4WQ4
M04(  000"%[ 3G9("" 07X'WJFGV*@42 @@@@  """"   ((((   DD4^)P:
M7>S(!<=HWL-]1OJ^\G.+S'.JYCNHR'F9#8&2!.AP4!(7,R.02(%MU.J;%9^-
M2>MW5SLRBF6*@V/2)IJ!  ((((   @A46V K%7BIHM@+&]6N'^4A@  """"
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M,$^I(S*,D 4?(;"Y !T.-C?A$P22+K"W +Z<4 0;3N@6Q1&*I0DUH-D(((
M @@@@$ ^@4]I(N>1^828A@ """"   ((((   @@@4*G B\K HI3T:A$S/ZIY
M[B]BOF)F*??FO8TP;1T&K%-%N:F<URE86>5VDBBWGBR7$ %[5P@) 000&"KP
M _UB.[RDIO%J^!\4>R85@'8C@  """"   *C"-CYXZ='F<;'"""   ((((
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M""" 0,T%I@50@S7*\V,*&SVA59&OLX$F.SV*>Q3_J=A7L9?B L5Z!0D!!!!
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MA9N4@3WX62CEZ[10:%FF(S"B !T.1F3A0P02)V W\8-(7U*F/_<IXV[E\\Q
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M#R!?LD0  03B*A#$_B6N5K0+@; +^'E!HM#%C[!;4#\$$$   0000  !!!!
M ('P"53[.E2A$0X&1V.^452%1AZPURKD2Q_.-U'3KAXRO=!K%0K5>TA6_(A
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M_52HPX'M9PHE^WM:HIA;:,8ATW\_Y.?1?BRFPT&A^H^6-Y\C,** W50A(8
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MFY,,_@JM A6ILR?#_@= O"NZ6SY%MVT*O[&MUW5]T;(D^S^+ FT@*!3;H4]
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M/#0=I+!IX60EZ&*%LQX^V Z:J\=W63:?@\2QVHS);_I^Y/EHEB #I;T%?I>
M3H36%.?!XW.LV*?=-8? /"C*:H&*PWIG%*2NXS>!S_&@#2"US0^'(R%>2S7!
MV$_ OHY_!2H,KW$XB8'74TJ+?:W3+_8;D>"D/HD4U\GLK^^7SPM]XAC\-?M
MEQF\H<O[V[ M;3\8K['ZQ?=0ESR\R01,P 1,P 0*$>#)C)WB;=53*#L'E2:
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M.1D;?@NI[DY?#[ZV@]Z'BAK[?]<OZ@3[7P?=+_!3!1?3(HAD,D'GQ(+/5"'
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MFPDTB8#Z&I_]5G=5 -"3B('B1"&5D94G'*AHVH\)F( )9"3@"0<9@3FY"9A
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M"[S^!_O>7F#_(KMR@@57-["90-L)*.MXKE;"B5Q5,F7[C).L8M7Q56+H6$S
M!$R@$@1< 5?B,#@($S"!" 0>0!X7!,AGZ0 ^V^)R^K84M$ YU<_JZPR%2VSN
MV[G1GTW !$R@0@3&%\?RGMA?47?J>-2\BI;/^YN "9B "80GH*S[E7>:JDJN
M/E?&Z@N]!P!N4D& GU'0!"G]38-T65=$Z.:ZK-4-AB.8DZ!8QZI;V;W-!*I"
M0%W'A[@9JP@K=1VOY%6D7-[7!$S !%I'P!=NK3OD+K )M)K P0%*/R]\3A?
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M4O&(*.6J"WF*IFRG<F+\='F":.D^RLGQB[:48:QBAZCC)T'P,>OX_9#?9P,
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M+U174[93R8"K5TY05Q@UB/M"Q!BJCO\C?+,O56VKP>&IT#"U8_AC'5^%.BQ
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M8MA,R(1:(D9F??+8%M^S'5=UNQH!/@P-AV(;VR95,@YB7@RM$3 HMN'7&U#
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MTDZ= ._9-Y"T5=E>95W =NH3D*U:!-+6\4D][SJ^6L?/T9B "9B "9B "9B
M"9B "9B "9B "9B "9B "9B "9B "9B "9B "9B "9B "9B "9B "9B "9B
M"9B "9B "9B "9B "9B "9B "9B "9B "9B "9B "9B "9B "9B "9B "9A
8 PG\/\G\P,R/N!%]     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>svb-firstamendmenttoloan001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 svb-firstamendmenttoloan001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7F6I>#-?N?C1IWC**&T-A9P& Q-<$2."DB[@-N/X^
MF>U>FT4 9.M:?++X;U&PTZ",RW,,R*K/M7?(&R2>?XF)KB/!7@S7_#7PRU/P
MU=0VDEY.)Q$\=P=A\Q-HR2N1@^QKTVB@#QW2_A%=W'PJF\*:VMJE_#.]S97<
M,A<(YZ9R 0#T(]/>NATK3/']MX<T2UNY--EU+3;L&25KEREU;B-UVL=F0WS*
M,X/(!]17H-% '!W_ (/E\1>.M$\0W.FPZ:=++/)(L@>6Y; "+\O&U>3DG/.,
M"J?Q=\%ZUXYTK3[#25M5^SW'GO)<3%0?E(P %/K7I%% $5NTKVZ--$(I,?,@
M;< ?KWK"U[3;[5]6TVW>S@FT:)S+<[IRKN^,)\N.0I);KU"^E=%10!Y3XO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX/%4+_0K&UDUK6((5CN;RQ,4^U0!)L#$,?4_,1GT ]*X']G3_DG5W_V$Y/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KSOXI>!=7\=1:7#I\]C;I93&8O<.^6. ,8"G
M^=>B44 <OJ5KXKU1K*#9I5G:+=0RW;1W,DKR1HX8HH,:@9QCGMFLMO UWHWQ
M N/%OAR2V)OXS'?V%RS(DA)!WHZAMK9 ."#GGD9KO** .$/@>[USQ]:>*O$;
MVRKIT82PL+9VD5&!)\QW95R<G. !T'/'.I:^''OM8U&]\1Z;I-WYKJMJ2/.,
M4*@83#H,?,78D=VQVKIZ* /,_"7@#6O"/CO6-5L'TU-%U(DM8+*X,9SE2OR8
MX)88]&QVKL]!L;^VLKNVU2*S*RW,\JB&1I 4D=GVL&4=-V/?VK9HH Y#P7X$
MMO!6IZZVGN!I^H2QS0P]X2 VY?IR,>W';)T?$>F:AJTEA;106,VF+.);V*YD
M8&95R50 *1C=M8YZ[<=ZWJ* /,O'_P +FUV;2;KPO#I>D7VGS^<+@)Y>>A V
MHG." 02>.?6NN-KKLNMZ5>RPZ<$@MY(KD+</DLY0DI\G0;._7/M6_10!QWB?
MP#9Z[XHT/Q'!L@U+3;F-W?'$T0.2I]QU!_#OQD>*? VNZS\2]&\56<FG+#I:
M*@@FF<-+AF.<A"%^][]*](HH X6'P'/J7CZ+Q?XBN8);BTC$=C96P)B@ S\Q
M9L%VRQ/0<_05T?B;3[_5-!EM=+NH[6],D,D4\@)5"DJOD@=>%/'>M>B@#A?$
MWA'4?&T.FV>LVNFV\-K=)<27,$SR2,%ZJ@*#8&[Y8X]^M4-?\#:]J7Q5TSQC
M:/IHAT^$0K;RS.&D'S\DA#M^_P"_2O2:* .:L]/UZ?7EEU%-,M]'CAE"VEK(
M\C23.PRSEE4$8+\8ZMWKGO#/@?6O &I:@GAR2QOM$O9/.%G>S/#);OT^5U1P
MPQ@<@'@?CZ-10!F6=MJ,\=R=7D@Q.NP6UODI$N#GYR 6)SUP!P,#J3Q'@?P=
MXG^']M?:1IYTK4-+FN6N()KBXDAEC) 4AE$;!N%'0COZ\>E44 <CKOA6]O?A
M]>^';.>"2ZO%D\VXG)1=\CEW8 !OXF.!^M<O<?"6?4OA;8>&;Z:TCU73"S65
M]"S$!BY8@Y4$ @@'&>@/;%>K44 >:^)?!GBSQ3\-H/#>H7>F-J"NAEO?-DQ(
M$Z$KL^\>,_GWQ79^'[*^TKPOI^GSI;M=6=K'!^[E;8Y10N<E<C./0X]ZUZ*
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M5 21@@Y QS22^+- ATRSU*35;9;&\)$$Y;Y'(4L>>V K=?0UYCX?BUB76?"
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M!$U_\3)#&I:2Z*.2.JBW7 /MR?SK',,4/PA^'WEHJXU'3)!@=&9P2?J<G\Z
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MO/&V@6-I97$]W+_IH+6\*6LK32 =2(@N\ >I%:.CZSIVO:>M]IETMQ;LQ7<
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ML8O<X0?O6(VDMZ\ "F'1M-:RM+(V,!MK-D>WBV#;$R?<*CMCM53_ (2O1/\
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M+\,Z4ZO8:%86[K*)U:.$ AP" 0>V S8^IK=K#T?Q?H>N?;!97AW60#7"3PO
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MPVL25<'&1D_XY7PY^(%_XDGEL==@@@NIA)/8/"I5+B%)&C8<D_,K*<CT(.*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7G7QR_Y)-JO_72#_T:E>BU6O\ 3[+5+1[34+."[MGP6AN(Q(C8.1E3
MP>1F@#C88D;XU12,@+IX:7:2.F;@YQ7%:X5C\$>-V)"HOB]6)/  WVY)KVD6
M5H+W[:+:$7?E>3YXC&_R\YV;NNW/..E02:+I<UI=VLFFVC6]XYDN8C"NV9SC
M+.,?,>!R>>!0!R,=S;Q?&B2:XFC"W.A(ME(6&UMLS&15/<\J2/2G^ '2XUSQ
MG=VC!M/FU?\ <NGW7=8D$A'K\W?VKHI_"OA^ZTN#3)]$T^2QM^8;=K="D9[[
M1CC\*T+2SM=/M8[6SMXK>WC&$BA0(BCT ' H XOXINL>F>'I'8*B>(;%F9C@
M* YY)IVG"&7XS:M.NQR-$M@CCG@RR9P?P'Y5V&H:=9:K9O9ZC:07=L^-T,\8
M=3CD<&F6>D:;IS*]EI]K;,L2P!H850B-<[4R!]T9.!TYH \.\3@#X5>(E' 7
MQ=. /0>?7=>(HY;/7=;U;0->T^*]BMH_[3TS48MT4RJA*'=D%<J2,C(/?I79
MRZ%I$]I+:S:58R6TLQN)(7MT*/*3DN1C!;/.>M1ZEX:T+6;J*YU/1["\GB&$
MDN+=791UQDCI[4 2:#>IJ/A[3+Z.V^S)<VL4JP8QY09 0OX9Q7*^*/$<E]KK
M^$]-U.#366)9-2U"215:WC;[L<0)YD8<YZ*.>I%=R    , = *R+[PEX;U.\
MDO+_ ,/Z5=W4F-\T]G&[M@ #+$9.  /PH XGQ3::,EIX/\,6DT%OX=GO&C>Z
MAD4F-HT+1JLG.UV;^('=UYYJHMM;Z)X@\7Z+I4[W=G-H#7=Q)-)Y\L4_S(J&
M4Y8@KR%8G&.,9KT8>'-#726TI='T]=.8[C:"V01$^NS&,U)IFAZ3HMJ]MI>F
MVEG YR\=O"J!C[X'/XT >7VS6UWX7^$Z!HY@ES;[@"&VLMLYY]P1^E=5  /C
M7>XXSX?A)]_W[UT%GX9T'3@@LM%T^W"3>>GE6R+MDQC>,#AL$C/I5X6=J+YK
MT6T(NVC$1GV#>4!R%W=<9)./>@#DOBRDC_##6Q&K-A(V<+U\L2(7_P#'0:SO
M%FHZ7=^,/ "VEQ;S2F^>2(Q,&Q$86YXZ G;]<>U>AR1I+&T<B*Z,"K*PR"#U
M!%95CX5\/:8RM8Z'IULRR^<IBM44J^" P('!P2,^A- 'DNNZK<ZAX';4WU/3
M["SNM641:1;6BJV4NQEG?.=_REV.!^M;WB[57\ >+[_6;="T&OZ>4C11D&_B
M&(O^^E8#WVUWA\*^'C/>3G0].,MZ"MTYMDS,"<D-QSD\\]ZP[WPWJ>M^(],C
MO;6PM/#NBSBXM(8'+23R*NV/(V@1JN2< GH* -CPAH0\->$].TG.Z6"(&9^N
M^5OF=OQ8DU@ZO)':_&+0)[UE2WETNYAM6<X'G[T) /J4_.NYJGJ>DZ=K-H;3
M4[&VO;<G=Y=Q$'7/K@]_>@#S:ZDCN;_XKW5HRO:'3$B:1#E6F6VDW@'U *@U
MUGPV_P"2:>'/^O"+_P!!K<MM'TRSTQM,MM/M8;!E9&MHX5$;*>""N,'/?UJQ
M;6MO96L=M:P1P6\2A8XHD"JBCH !P!0!GW_B/3=,UFTTN^F^SRW<4DL,DI"Q
MMLV[EW$_>PV<>@->9Z#?W']C^%;&QDL;674;S4[F'4;JW$IAC$KG]V"1\SJ_
M7/W<]:]3U31M+UNW6WU73[6]A5MZI<1+( ?4 C@TR_T#1]4L8;&_TJRN;2$@
MQ02P*R1X&!M!&!QQQ0!XS<.EWX4\5Q37T>H[_$]H'F$819@3 "VT<8.#R.#U
MKT'Q  /BKX/(&";74 ?<;8^*Z,^'-#:5Y6T?3R[B-78VR981XV \?PX&/3 Q
M5R2SM9KN&[DMH7N8 PBF9 7C#8W!3U&<#..N* /%)=2LXOV9XK9[F,7#*(!#
MN&_>+C)7'7( )/L,UTGB#4KJYU7Q@D&HZ?H]OI\,<,Y^QK)<7I:'<,DD<?/L
M4 $DY^E=K_PB/ALW-S<G0=,,UT")W-JA,N3D[N.<GFK$^@:/=:K%JL^EV<NH
M1#$=T\"F11VPQ&: /,="2&YU_P"%+L%D\O0964]<,(8Q^8YK5\9:DO@'QFGB
MLH38ZE8R6ETHZ&XB4O ?JP#)^5=S::!H]@T#6>E6-NUOO\DQ6ZJ8]_+[<#C/
M?'6L#7]!U?Q/KUE:7L5E#X=LKE+LD2%YKIT&54KM 10Q.>3D >IH D\(6</A
M'P=IEOJUS%#>W<@>X>5@IENIFW%>>K9.!]*ZRLW6M'AUJ"UAG*A;>[ANU)0,
M=T;AQ@GIDC&?0D=ZTJ //-<UJ'Q9K=[X:35+?3]%LV\K5+AIU26Y<C)MX\GA
M<'YV]\#O4DLNGZ1\4-#NEDMX=,N]$ET^TD5@(PZ2(X0'I]T''TKH[CP7X6N[
MF6YN?#6CS3RL7DEDL8F9V/)))7))]:M3^'M%N=)32IM)L9-.3&RU:W7RE],+
MC ZGI0!P]IXAT_3/$OCSQ7++YFEVR6EJ)(OF$LL:MN13T)W2*OU-:/A:*/4-
M87Q!KFIV,VMS1F.UL8+A72QB/)1<'YG.!N;OC X%=0?#^C'2!I!TFQ.FC&+0
MVZ&+@Y^YC'7GIUJO9^$/#.G7<=W8^'M)MKF,Y2:&RC1U.,<$#(XH Y?7-6TT
M?%;PNYU"T"Q6E\LC><N$)\K //!X/Y5VZZE9/?)8K=PM=/#]H6$."S1YQO _
MNY(&:RY?!'A.>9Y9?#&BR2.Q9W>PB)8GDDG;R:LKH5K'K]MJT:1QM;6364<<
M<87",RMC([#8,#H,GUH ?XB_Y%G5O^O.;_T UY7=W6GW'P#\.VEA+$;N1K"&
MWC0C?]H$J%L#KG(<FO9)8HYHGBE19(W4JZ,,A@>H([BLN#PMX?MM0BU"#1-.
MBO(D"1SQVR*Z*!@ $#C X^G% 'GOBS4KCP%XJUF:S1BOB2R!LU4?\Q!2(P /
M]H.K'UVFO0O#&AQ>&_#.G:/#@K:0*C,/XWZLWXL2?QK%NM!U?7_&%C>:O%90
M:/I$SSV<44ADDN)<81WRH"!0<X&>>]=A0!PWB#4+J3QW'IMG>Z=I#0:6;J74
M;BV625D,FWRU+$ *"NYNO\-<5H1BN]#\$*\@N /%-TQ+)MR0T[ E?X3G!QVK
MUW4M!TC6)8)=3TNSO)+<[H6N(5<QGVR..@_*ECT'1XKEKF/2K)9VG^TF06ZA
MC+@CS,X^]@D9Z\F@#S7QY%-)XE\7):@^:_A#HO5AYLF?TS4WB?4M(NM%^'4=
MI/!(SZOI[VZ1L"50#!.!T R ?<BO3?L5K]M:\^S0_:FC$+3^6-Y0'(4MUQDD
MXZ<UFVOA+PY8R-):Z#ID+F59BT=J@.]3E6Z=0>0>U &S7DGAZ_TBW\ ^/DN)
MH$9=1U(W*.P!;<6"\=\C 'J1BO6ZQI_"/ANZFCFGT'3))8W:1':U0D,QW$].
MI/)]^: /,?#EKK</B#3(AK=OI-TWA>Q"&[M!,75=V]1EUP5)!(YZBI9;6UTJ
MQ\">5K$.H6C>(I95NTB\F/+^:2%&3@!BP'->I:KH6D:[%'%JVF6E\D9W(MS"
MLFT^V1Q1>:%I&H:;'IUYIEG<6,>-EO) K1IC@84C Q[4 >6^*<V?BK6O#,1_
M=^+9+&2'8> "WEW!_P"^$!_&EM8_.\86G@7&(=/UZ?560=%M@HFB'T\R8#_@
M->J'2-,,]G.=/M#-9*4M9#"NZ!2,$(<948XXIZZ;8IJ3ZBEE;K?21^4]R(E$
MC)_=+8R1P./:@#QRSTZ[O?!>NV.H>+K'3+-M1NHKV"6P$DJ2-.Q!W>8"6.5(
M..XQTK5BM]37Q=XTB/B6QTQ=\,DZW=D)3+!]G4!\EU^7AACG!SZUZ)/X;T.Y
MU9-6GT>QEU%,%;I[=3(".AW8SD=J74_#FB:U/#/JFD6-[+#_ *M[B!9"OL"1
MT]J ."\.:=;V7CKPI:QW8OXK7PO)]GNC'LWKYD85@#G'RG'T-;?@@!?$WC=1
MP/[64X'J8(\UUWV*T^V)>?98?M21F)9O+&]4)!*ANH&0#CIQ1!9VMM+/+;VT
M,4EP^^9XT"F1L 98CJ< #)]* ,7QC=Z!!HT=KXEA633+Z=+5S(N8T9N5+M_
M,C[W8XKD!;1>#_%/A^U\.^(KN\MM1NO(FTB>Z^TJD.QF,D><L@7 [X.:]+N;
M6WO;:2VNH(IX)!M>*5 RL/0@\&L_2O#&@Z'*\NE:-864KC#/;VZHQ'ID#./:
M@#BO W_)6OB+_P!=;/\ ]%M4/P;U?3+/X>PPW.HVD$HN[@E)9U5A^\/8FO1X
M-.L;6\N;NWL[>&YNBIN)HXE5Y=O W,!EL=LUD-X%\(,Q9O"NB$DY).GQ<_\
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MTT,5Q!)!/&DL,BE'C=0RLI&""#U!%-MK:WLK:.VM8(X+>)0D<42!511T  X
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MOD^Q.A-N&.V3G_5_*N?FY.Y:V?#NKWT/BG5O"^K7!N)[=5O;*X90K36SDC#
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M,/9A^(^M<#'975MX)\.W=Y ]O+J?C"'4! XPT:RS$J".QQ@_C6E\0HI/!O\
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M1Z5'LNX4NY(5D1965"%PQ !958#Z$=Z .E'C/03X=FUUK[R["!S',9(G5XY
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M&<= "3UKC-%OK&_^-6MR6,L<JIH\$<LD9!4N)&SR.N 0/PQVK0^*R-)\+O$
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MPQZ:F^\BN+:2.6%<;LF-@&P0,C YJQH?B?2_$;7(TN669+<J&E,+HC$Y^ZQ
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M/[,P.U255=BY7)X.#U/)Q72U5TS_ )!-G_UP3_T$5:H **** "BBB@ HHHH
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M!,BNC*PR&P2,$=ZZ&]\6V.C0:?!<K>7=]<VXF%O9VS3RE !N<JHX7)ZGOTH
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MC;'SMZ =3P,\56U7QO;:CX.\4R:4UY9:II=C)(T5U;M#+$3&S(^UAT.,CZ4
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M7N_%]K>7)B'A/5KV?3M.8( 1)&!L<MW$C"0 >U 'J*JJ*%4!5 P !@ 4M%%
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M4F# R3P,GBO:P0P!!!!Y!'>JLVE:=<VD=I/86LMM&04A>%612.F%(P*M@
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M1MK3S_*638LD@4G:PP>M=77#_%.#[3X=TRW\V6'S=9LD\R)MKIF4#*GL1U%
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M_P!DC-[:SP%)X>,C*GKD<@@X-1K\0-'?3+C41!J(M4ECA@<VC?Z8[DA1 /\
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M&"_NM1C$;&"TMC*Q5\_-Q_",<D],CUKS2&WLTT37M&USQI=Z<3J-S#<:5'#
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M;2"2">-9(W'1E89!_(UYUX?51X4^(AP,G5M2S[_(*ZKP)_R3[PW_ -@RV_\
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MMY+J01B:(1!#M)Z[64@CWH Z33O&>BZK=Z9;V<[R?VE;R7%J^PA7"$!UYY#
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MU:,ZU)?1+<+IQ=HVM<_O/._AVXQR>0>E>SO&DF-Z*V.FX9H2-(QA$51_LC%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M65L&V^=,YPJY[#J2?05OUPGQ.#V=EH.N^4\EKH^K0W5V$7<5APRL^.^W<#0
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M4$B0+]IDVLZY' 8H>2* /6+'QCH.HZ??WMO?'R=/0R78EADC>%0I;<490V,
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M+M*1DHB;=S?@#6GHOB'2O$-O+-I=T)A"_ERHR-&\;>C(P#*?J*X7[1;CQ?\
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M6^@Z;%%'.+A%6V0!91T<<?>'8TW5O%VC:,ME]HN))GOE+VT5I"]P\J@ EE5
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ML['S3F3[/"J;O3.!6G7-VWCSP]=ZLFG0W<IDDF:WBF-M(())5SE%E*[&;@\
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M-O=P3:-8217DOG7*-;J1*_\ >;CD^_6M"VMH+.UBM;6%(;>% D<4:A510,
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M"[;$+M@#)PHR2?8<UP%I\0K/Q#X$U753?W.B?9G8->+9.XB3SBJ, RX<D 9
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M\1:;X>B@>_ED#W#^7!##"\LLK8R0J("3@<GCBJG_  FWA_\ L.+66U )827
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M^0",'D4 >=^+M1T[5[GP1#H]S!<32:Q!<PK P)$"(Q=L#HNTX_&F^#/^2O\
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M'(ARKJ>014U4M'TR+1M%L=+@8M%:0) K-U(50,G\JNT %%%% !1110 4444
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MCWOV/4=>TZUN>,Q2W"JR_49X_&@#;HID,T5Q"DT$J2Q2*&1T8,K ]"".HI]
M!145S<P65K+=74T<-O"A>261@JHHY))/05BV_CGPG=3K#!XFTB25SA46]C)8
M^@&: -^BBB@ HHHH **** "BBB@ HHHH **R]<\1:1X:M$NM7O4M8I'$:%@6
M+L>RJ 23]!5ZTNX;ZSAN[=B\$R"2-BI4E2,C@X(_&@":BBB@ HJO=WMM8VES
M=7$JI#;1M+,W78H&22!ST&:=:74-]9P7=L_F03QK+&^"-RL,@\^QH FHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBL]=;T]]>?1%N,ZBD'VEH
M=C<1YQG=C'4],YH T**9YL>POYB[!G+9X&.M/H ***IIJME)K$NDK.#?10K<
M/%M/$;$@'.,=5/?M0!<HJAJVM:?H5O#/J5QY$<TRP1ML9LNV<#Y0?0\]*OT
M%%%)N7?LW#=C.,\XH 6BJ>EZK9:UIZ7^GSB>UD9E60*1DJQ5N" >"I'X5<H
M***K1:C93:A/817<+WENJM- K@O&&^Z6'49[4 6:*** "BBB@ HHHH ****
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MY, _,0H^8^@I^C>$9?"OB7=H(@B\/W4 6ZLF8@Q3(H59(Q@@[@ &!(S@'DT
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MP2M($=D8%WD*@\DC@+P!W- &#-K/BNP\#6OB"_UH!=2-JTC16"LNF0."7D
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MM]1A@B"7ES)&R^6N#PJ'OGO0!T/C?7I_#7A*\U&TC22[!2&W63[OF2.J*3[
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M8F\J,OMW*<ALXYSC'&*]>H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK'+]H\OG'.=N[IVQ7G_@WPY;ZO+XLGF\0ZSIQ'B&]3RK*_,"8W#YL>O/7V%
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M(Y!(4#OQ7!>,I=,?Q'\/1;-"9#J.ZWV8_P!3Y39QC^'[GZ5Z#-_J)/\ =/\
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MES:2YV2+D=#@@@\@@CH:Y-O',&D>-?$=CK5_Y=E:I:&TB2!I'RZ,TA 12Q'
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M8 'L!6?<^&=$O-:BUBXTRVDU&)-B7)3YPN",9[\$_G6K10!GG0M*;1X])-A
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT\42+C9"Q/E@^IVX.?>NBH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJJZE9MJKZ
M6+A3?)"+AH>XC)*AOID$4 6J*** "O,/B[X2UWQ<^B)H]DLHL;AIY7DF1 0=
MN ,G.>#VKT^B@#S;Q7X+U3XAZ[I']K01Z=H6G.97@,HDFN7../E^55P,9R3R
M>*Z6WD\5_P#">74<T%D/"PME^SR*?WIEXR",^N[MC&.^:Z2B@ HHHH ****
M"O/$LO%>@^._$^J:=X?M]3L]6:V:-VU!8"OEQ!3D%6[Y_*NVU75K#0]-FU'4
M[E+:SAQYDKYPN2 .GN0*MQNLL:R(=R, RGU!H \WE\(>)-?NO$6LZG]DTV^U
M#1VTNSM;>8R"-22VZ1\#)W'' X%):Z)XC.K^%K]?#ECIUMI#M%):17*%W5XC
M&T@8#&U>,+R3D]*]+HH \]@\):M'\(M5\.M%'_:-R+P1IY@VGS)79>>G1A3;
MWX>1:[XR^U:U8P3Z;_PCZ6"L6!>.<.Q)7T(4\-7HE% '/^$+?7;#26T[7F6>
M6TD,4%ZK@FYA'W68=0^.#^>349T:\_X68NN;%^PC1S:;MW/F><'QCTQWKI**
M /,;_P &ZT8M3F2Q@O WB9=52R>956Z@$:KM)/ .1G!X^459M=+\86GB'5M8
MM=*TV%]0L85A@:?*0-$['RWP!N+*Q^8<*3W Y]%HH X?POH5]%XPN]=ET"VT
M""6S%O):P3HYN)=X;S&" *,#(!ZG<:M>--'U"^O]!U&RTZ+5$TVY>26PEE5!
M)NC*JX+?+E2<C/K72:;J5GJ]A'?6%PL]M(6"R+G!*L5/Y$$?A5J@#R/5/#&N
M?8O$UUJ TS3OM<]IJ5K<-<A8(98B@6%\@?W0-W0D_A5ZZN=<O_BCX+DU6P@T
M\(EZ5M8[@3O_ *G#.S   9*@#Z_2O1[VRM=1LIK.]@CGMIE*212+E6![$5E:
M+X.T#P]<O<Z7IRPW#IY9E:1Y&"==H+DD+[#B@#!T'P;=K\/=8\.ZGMADOY;S
M#(P;:LK,5;CZ@XI?#VGZXEWI]O?>%]&L(K6,K=7J.DC3L%P#$% *Y/)+=!QC
MO7<T4 >;:#X;UO0[>ST%/#>CS06L^T:Q,R-NMP^?]7C?YFWY>N,\YJQ#I/BC
M0M2\0V6E:=;75CK%V]Y#>O=!/LKR* ^],98 C(V]?;MZ#10!SW@;2;O0O ^D
M:7?(J75K;B.55;< 1GOWK&FT#5D^(.M7/V!+G1]<LHK::=;@(UOL5U/RD9;.
M[M766.LZ=J5Y>VEG=I-<6+B.Y1<YB8] ?RI]SJ5G9W=G:W%PL<]X[);H>LC!
M2Q _ $T ><OX<\6WW@JV\"76G6L=G&L5K+JRW0*O;QL""L>-V\JH&#QGO7IT
MBOY++"55]I"%AD ]LCN*?10!YS#H.MZOXGT>_P!2\.:?IEW92,U[J=M<*QNU
M,;(450-VUBP/S],=ZIKX<\6V_@F7P'#I]LUHRO:IK#70VBV9B<F+&[>%)7'3
M/.:](N-2L[6^L[*>X5+F\+BWC/60JNYL?0<U:H AM;=+.S@MHL^7#&L:Y] ,
M#^5>3CPAXHC\*)H<.B6"S65ZMV]Z;E=VH%9Q( .,J2.I8]L=\CUZB@#D]!T7
M4+7Q#XKU&ZA6*/5'MW@42!C\L 1@<>C BL0>#M8'PET7P]Y47]H6DML\J>8-
MH"3!VP>_ KT>B@#SNZ\/ZQI&M:V^G>'-,UB'5)_M4$]U*B&VE**K!PP)9,J&
M&WGDCWK9L]!OX/B!#J\D=N+1-#6R8P_*OFB7<0J=0N.E=710!YG>>"];-GJE
MS;1P&^B\3C6[&)Y<+,BJJ[6/\)(WC\JTK'3O$FI?$*P\0ZGIL.GV4%A-:BW%
MRLKJS,AW$@8YP1@9QMZ\X'=44 <[XUT&Z\0>'Q#821IJ%M<0WEJ9<[#)&X8!
ML=C@C\:QKS3O%/C*QU6PU>T@T73KC3WMX[<3+<.\[=)"RCA5QTZFN[HH XOP
M]::Y_:5F+WPOH^F16\9%Q=1NDCS/C ,6T H,Y)+<XXQWI?"/AG4-+\ 76B7H
MCBNIGN\8;<H$CN5.1[,*[.JMWJ5G8W%I!<SK'+=R>5 IZR/@M@?@"?PH \RL
MO#GB>+0/"D5WX=M[A_#TA1[)KQ"MTOE%%E4D;05)R ?4T^[\)^)KS3/&MM+I
M]HCZ[!');^3.-D3JH3RCD#H!][H:]1FEC@ADFE8+'&I9F/8 9)JMI>J66M:;
M#J.G7"7%I,"8Y4SAL$@]?<&@#E;#PUJ5OK/@RYDC01:5I,EK=$./ED9(@ /4
M91N:T=#T:\L/&7BG4IT46VHR6S6Y# DA(0K9';FNEHH \^\=-?Q^/O!$FFQ1
MS72/>LL,C[!(/)&Y=V#@D9P?7%5;[POX@\06WB_4KVQBL[[4]-73[&S^T*Y5
M5#'+N/ERS-VZ 5WUSI5C>:E8ZC/ 'NK'?]FDW$;-Z[6X!P<CCG-7: ..U_PU
MJ-_X2T2*R\D:KH\UM=PQRMA))(AAD+#H""PS]*99:;KFN>-+#7M9TV/2[?2[
M>6.VM_M*S2222[0S$J,!0JX Z\UVE% 'FUCX&U.#XA&601?\(S;WLVJVR;\L
M;F1%7:5[!6\QA]:TO^$<UA/BIJ?B* 0);3:*+2"21MV)@X8;E!SMXKMZJP:E
M9W6H7=A#<*]U9[/M$8SF/>,KGZB@#A].T/6;_P 9:5K-]X<L='N+(2_;;RWN
M%<WNY"NT!0"5W$-\_(P*R])^'^N6W@.6Q86\6K6VN'5K,-)F-BKAE#$=,C(]
MLUZM10!Q-MIVO:_XRTG6M8TN/2K72(IO)A^TK.\TLJA2<J,!0N?<D]*S?^$-
MUC_A1P\+>5%_:ODA-GF#;GSM_P![ITKTBB@#S_QGI&NZ['J&E2>&=,U.WG7;
MI^H/.L;69*@98$%MRMELIU&!Q7<V<+V]C!!+*9I(XU1Y&ZN0,$GZU/10!Y?'
MX>\6Z=X.O/ UEIUK+9RB:W@U5KH!8[>5F)W1XW%U5B,#@\<UK7GA&\3QSX+O
MK)%;3=%M9[>5V<!@#%L3 []*[JLBY\3Z+9V&H7UQJ$4=MITWD7<ASB*3Y?E/
M'7YU_.@#7KRC2O"/B:'P/8>&;G388SIFJPW$=RMTK+<1BX,C,%ZK@$<'K7JL
M<B2QI(C!D<!E([@U3LM9T[4;Z^LK2Z2:YL75+F-<YB8@D _D: ,'7O#=SJ_C
M+3+PJO\ 9\>GWEK<-N 8&4(!@=^ :R/#>BZ]IJZ1I,_AK1DCL"L<VK%E<SQH
M,*40 ,)#A3EC@'/6O0Z* (;N-I;.>-/O/&RCZD5YKX,B\=^$?"-AH7_"(6EU
M]D#CSO[71-VYV;[NPX^]CKVKU"B@#AKZP\1G6](\6VVD0G4([26ROM,^V#)C
M9PRE)2 I(*@\@<'%9&H>#=?U>QU[5KJSMAJ.I7EG,-*,X9&@MV!$3OC&6^8G
MMTKU"B@#S630/$EYK]UJ3:-:6EO?:+/IRVT5PI:V/WE9R  Q8Y'R\ 8]ZT+[
MPOJ<_@'POI"1QF[TZ;3WN%+C $)7?@]^A^M=U56]U*STY[5+NX6)KJ86\ ;/
MSR$$A1[X!_*@ U)[R+2[I]/A6:]6)C!&[!59\?*">PSBN&\-?"?P_;Z!:CQ!
MI-KJ&L2 RWMS*-S/*Q+-SWP3C\*]#JC8:SIVIW-[;65TDTUE+Y-RBYS&_H:
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M2L4CO+:2W9@.5#J5S^M7J* /-)-$\6:WH&E>%=3TRUMK.UDMQ>:BEV'$\<+
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MH  ;!"MD \@CC'>JEM::SX/T#7]:MM,TVQN+V\@DATN.0O#$"4C;E0H+MR<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZNL*:U-978D$9.&B1Y-NW/)4!QC/]ZN(T2SN_"_Q'UWP9;Q2#3-?07]JZ<+
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MZ9'X$C\:]5H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "L^PT33],N[JZM(I$FNWWSL9G;S&X&2&)&< #/H
M,5H44 8,?@OP_%X@.O)I^-5)R;OSI-YXQ@G=R,#&.F.*GF\,Z3-?SWPMG@NK
MA0L\MM/) 90.F_8PW$>IS6O10!@2>"?#<N@IH3:3"-+1MXM4+*A;.<D C)SZ
MYJ:[\*:)?RZ?+=6(DFT[_CTF,C^9%TZ/G/8=ZV:* ,!/!F@Q7UW>PVDT5U>?
M\?,L5W,C3?[Q#<TEQX(\.W=K86LVFAH-/.ZT02N!"V<[EPWWL]^M=!10!CCP
MMI >[<V\KR7</D3R27,KN\?]W<6) ]@:NIIMHCQ2"+][%"T"2EB9%1B"1N)S
MR57OV%6Z* ,"W\%>'K2POK&WT_R[6_)-U$LTF)B>I;YN<]_6EM_!F@VL5G##
M9N(+*19;:$W,K1Q.IR"J%MHP>>E;U% %2RTVUT]IVMED4SR&23=*SY;U^8G'
MX40:;9VMBUE;0""W9G8I$2F"[%F((Y&68GCUJW10!F:'X>TKPW9M9Z1:"UMF
M;>8E=BN>Y )./PK3HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **KWE_9Z
M?&DE[=P6R.XC5II @9CT4$]2?2K% !1110 4444 %%%% !15>SO[/486FLKN
M"YB5BA>&0. PZC([CTISW=M'=16KW$2W$JLT<3. [A<9('4@9&?K0!-1110
M444UW2*-I)&5$4%F9C@ #J2: '45#:7EM?VJ75G<17%O(,I+"X=&[<$<&IJ
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M6?S.F5!]L<=:[.#Q!XFB^(Z:'?:3;C19[8O;WL;Y=W15+DC/"[FV]!U')S0
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M9%>VF924#%F(<$J1D;:Y7P?9:U=?&+Q9<7JZ+-<6TEF+F1H')13&<>02?E.
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M%<C.X%L G@CF@#=_X2CQ5I46C:GKMMI/]F:E<0P/#:B036AE^X69B5< D X
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M2ZA\3Q:,R(K%!&2@9@<Y)^8D'TQQ74WNNW5MX[TW1(XXFMKJQGN7)!W[D9
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MV3C(XH ]!HK$\):]_P )-X8L]5:-(I)0R2HC;E61&*-@]QN4X]L5MT %%%%
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MRN3^%=->WUKIME->7LZ06T*[I)9#A5'J35>37=*B_L_??P+_ &CC['E_]?D
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M_B?SIU 'FUGH^L?\)AI&L0>$X-+T^.VGLWMHI81)%OV$2-M.TK\N  21C/?
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M&,$8.>/:2 001D&N8LOA[X8T_4(;RVT]E:"0S01-<2-#"Y_B2(L44\GH..U
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M(-?T'6[G1M8NK._:73)KZRNXK<PG?']Z-TW,#U!!!'>LR/P5KPTA=7\JV'B
M:\VM_8S-^[P1L,'F8Z[/XL8S[5J1Z'K7B7Q))J^L6":5!#ILUC:VYG6:0O+C
M?(Q7@    9)Z]* '77BW4H?AQX?UY1!]LOVL!,"AV?OF0/@9X^\<5&-6\6:W
MXG\2:3I5YI]A!I4T2Q3S6QE:0O$K[,;@ ,DY;GJ,#K6+_8/C*\\':)X;FT:V
MMETF>T\RY^V*XN4A=?N*.5X&X[L=,8.>.R\/Z->Z?XI\4W]PBK;ZC<PR6Y#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0P__ %\UGZ)X2T/P[/+/IEB(IY5"/,\KRN5'1=SDD#V!Q6U10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9?6UOE&D'G3*F57[S<GH,C)[9H M45FS>(M$M[;[3-K&GQP>6DOFO<H%V/\
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MT5R4/BF\D^*MQX5,,'V.+2A>B4 ^87,@7&<XQ@^E7/%6OW&@_P!B>1'"PO\
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ME))YS[I7,C2YSYADSNWY ^;.?PH YT6-A9?'.U^QPQ0R2Z#*TJ1*%!_?( Q
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M4Q0MNW$QINPASW'8D="15K4O >@:KJ$]Y<P7(-R0;J&*[ECAN"  #)&K!6X
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M9BQ='!W*<LW0]\=*(_!.@)H-WHKV336EXWF7)GF>229^/G:0G<6&!@YXP,4
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M%[6X0/!-XAM4D0]&4K)D'V(XKJ$\/Z8GB63Q"MN1J<EM]E:;>V#%N#8VYQU
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MAB 3M7"].U='5;3M/M-)T^"PL($@M8$"1QIT4?Y[U9H **** "BBB@ HHHH
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M'!RH.>._I5/3=:VC69]4U?1GM;.[:-7MI,?9T!P$F+' <=^E<_K^G6>F^-_
M*V5M%;A+BYA7RT"_)]G;Y?IP*X.3_D1OBY_V&I__ $8M 'M%KXBT6^U.;3;3
M5K*>^ASYEO%.K2+CKE0<\=_2F3>*- M[^:PFUK3X[N%#)+ ]R@=% R21G(P.
M3[<UROB#3K/3/%G@ 65M%!Y=W-"IC4 [#;OD9].!7*PV>FW'[/NN7E_%#]LD
M-[-/,X&_[3YSA<GKG.T?0X[T >JW_B;0=+-N-0UFPM?M*AH?.N$3S >ZY/(]
MZU 0RAE((/(([UYB^E:A'MUC28-)UE9-'M;?4-,O'VRJBHQ&QL$+N#'AA@XS
MFNXT"\M;[PCIUYI4#0VLME&]M"W5%V#:I^G H )/%?AZ*[N;237=-2XME+3Q
M-=(&B ZEAGC'?TJ*XU66W\4I;/J>DQV L6GDMY'(NL@G]X.<>6 .3CJ#S7DU
MY9:4_P"S)]KGCA^T-#YQG('F&X,V&.[KN))4^V174W*J_P ?]+1E#*WAM@01
MP1YK4 >B1W]G+IXU".Z@>R,?FBX60&,IC.[=TQCG-4;SQ3X?T^"UGO-;T^"&
M[ :WDEN4590>ZDGD<CD5Y2\UQ9>%]0^&<,C+>OJXTVV/5ELILS;_ ' CWJ:V
M8].U4_$+Q'9Z38Z)-!;65G:QQZD7^2W\L_*@53\I;=GZ"@#T6\UG2]/56O=1
MM+97C:53-,J91<989/09'/N*=IFKZ=K5I]KTN^MKVWW%?,MY ZY'49'>O+]-
MT,0>(?ASIVHS6FH?9;*_*20OYD+!3'Y>">H4;<>Z^U=+X2BCMOB)XZ@@18XO
M.LI B#"AF@RQQZGO0!J:KXWT31_$UAH5Y>V\=S=H[$O.JB+&-H;)X+;N/7!J
M[?>*- TN_2PO]:T^UNWQM@FN41SGIP3WKEM=@AD^,WA??%&VZPO"=R@Y(V8J
MCX7L]/O?"'C*;5889)I=1OUOGE4$@*2%!)Z!5VX].U 'IC.J(79@% R23P!7
MGVI_%'3YO"7B34=!N;.>]TEG5(GE#B55*CS JG)0EL ^U;GP\DN)_ASX>>[W
M-*UA%DOU(VC!/X8KS2>"&/X3_$MDB16&MWR JH!"B5,#Z4 >NV?B/1;_ %&3
M3;75K&>_B!\RVCG5I%QURH.>._I2GQ%H@U@:0=7L1J1_Y=//7S>F<;<YSCG%
M<CXATVRTSQ1X %E;10>5>2PJ8U .PV[Y&?? KD='T?Q#K/P]!7_A'+9);][A
MKZYED6XCN5N2=S';@/N&T<],"@#UF_\ $^@Z4TBZAK6GVK1.L<BS7"*58C<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5F1V D^K.& ]0R&N\\3>+[#PS/IEI/'+<7VJ7 M[2VAQEVR 222 %&X9/O7
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K)U;
MP]:ZM?6%^TUQ;7U@7^SW$# ,@< ,,,"I! '4'I6M10!E66@V]IJCZI+-/>:@
MT/V?[3<;=RQYW;0%55 SR>,GCTK5HHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***X/Q-\6M \+:K]BO;;4Y8UD\J6[@MMT$3]U+$C)'<+G'UXH [RBH[>
MXBN[:*YMY%DAE021NO1E(R"/PKG=1\>:)IOBBP\.223R:E>R;$2.([5Z\EC@
M8X(XR<]J .FHHHH **** "BFNZ11M)(P5%!9F8X  [FN4_X3ZT;09-?CTK4Y
M-%17<7B(A#(N07";M^WCJ5]S@<T =;12 Y ([TM !14<\T5M!)//(L<4:EW=
MS@*H&22?2L#7O&FG:!:Z1<RP7EU#JD\<,#6T.[&\9#-G&!C\?:@#HZ*** "B
MBB@ HKA_$OQ3T7PM?K#?6.K26OF^3)?PVI-O&_==Y(W$<Y"YZ$=017;1R)-$
MDL;!D=0RL.A!Z&@!U%<%XD^+GA_PQKD^D75IJEQ<0!?,:UMPZ D!L9+#G!%=
MO:S_ &JS@N/*DB\V-7\N489,C."!W'>@":BJNI:E9Z1ITU_?SK!;0KN=V[=@
M,=22<  <DFLO6O%^E^'-#BU36&ELUE(6*W==TSL>BA5)RWMV[XH WJ*Y6Z\;
M'3=)?5-4\.ZS96:KNWND3D>FY4=F7/N,#N1754 %%%% !16)XK\46?@_0I-8
MU""YEM(F59#;JK,NXA0<%AW('%5+SQQI]G>>'+9K2^D.OX-L\<0*Q@A3\YSQ
M]X=,]SVH Z:BJ_VZU_M'^S_.4W?E><8AU"9QN/H,\?@?2LCPQXLL_%::@UI:
MWD L;IK63[3%LW,O=>3Q^OM0!OT444 %%%% !161XE\0V_A;0[C5[RWN9K6W
M ,OV<*64$@9PS#/)[5ST'Q4T)H])GO+;4-/M-6_X\[JZC3RI#G&"49MO_ L4
M =Q1110 4444 %%%<YXD\::?X6U+2;*_M[MCJDXM[>2%59 Y(&&RP(^\.U '
M1T444 %%%5[*^M=1MOM-G,LT)=XPZ="R,5;\F4C\* +%%%5[.^M=0A::TF6:
M-9'B++TW(Q5A^!!'X4 6**** "BN*UCXE6&AZ;=ZG>:/JXT^VNWM&N1'%M=U
M<H=H,@8C*GG%:>E>+8M4O+&W_LG4K5;^V-U;33K&8W0!3U1VP<,#@@&@#HJ*
M** "BBB@ HHKG/&/C.P\$:6FI:G:WDEJT@BWVRHVUB"0""P/8T ='17'?\+(
MTF#5]-TW4K34-,EU-0UG)=1IY<V<8 9'8 \C@XZCUKL: "BN4\8>/M-\$/9C
M4[._D2\<QPO;HC L,<<N".OI741.TD2N\3Q,1RCD$CZX)'ZT /HHHH ****
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M%B(.>"N.V>Q'OD4 >=>(/#7Q%\&-J/B;1?%*ZC;++)>W.GRQ%4VDEF"J2P(
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MKD.M3W5WJ&H6]HMG;S713]S$,\*%51DY.6.3S72T >7?'M%3X6SA%"C[9$<
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MD1%QO(^G6O+-(\/Z,/CGXB4:/8,+>QM[F%/LZ827(.]>.&SSD<UG6FAZ5??
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MO:1EBD:L2 68L>22>I)J]0 4444 %%%% !1110 4444 %%%% !1110 4444
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MI0W,#026^HWSSQE6QGY6[XXSZ$U!IWP_TK3[RRG:[U.\BL#NLK:[NC)%;'&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK2;R,7L?V"7]ULX/\/.0,\9QWP<4 >TZOXQTK1KV>SE,\]Q;VQO+F.WCWF"
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M/,^FV[F.X(B.^)@0"&7KQD=/6HM/^)?AW4M6TS3H9+M9-3B\VSEEMG2.;C)
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M=$RH90P&XE2"<=P?:@#6U#QA>7GQ>\)6]A/JEG87\+23V=RK(L@VL5;:>,$
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M@AHN<%]V1QCBN?\ $>G7&JZ+XD@N]'UN_P#$_P!JG:,E9_(CMU?*&/GRR/+
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M*6"[\X$H 6C?Y5PP4YXR* .L\Q-I;>N!U.>E.!R,CI7B/AF]L].^$GC>[O\
M3TU&UBUJY,EH\A02C=&,%@#CU_"NZE\5W,+:%HWA_1H;B^O-/6\\F:Y,45M
M H&6VL3R0HP.U ':45Q.G^.[[4++7VC\.7)OM)N([4622AVED8+GD# 4$GYN
M?E&?:D;Q=KL*:S87FC6D.LV5B+Z%([PO#-$2P)WE 05*GC'/'K0!VS,JC+,
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M:)U'*,"!C/'/7BMSX>Z3>Z1X3C348?(O+FXFNY8<Y\HR2,X7([@$9]\UU-%
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M9.0<;\[?EQCVKTBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML9YM/8[6E$:J)(^HPVTM^(INC:=I]L-5OM!^'T\&RR,0%^3"]WN.7A"-N^7
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MWVJ.4,-TF3RP8!@?K5#3O#=GXO\ ">L^*K\S-K,\]V]E=B9E>S6)V6)8\'
MV ^^3F@#UNBL7PIJTFL^#=(U6X_UMS9132D#^(J"WZYKS2UT"WUCX77?CF9I
MAXFD@GU**_$K;X2A9D1><! JA=N,=: /9:*\PL+:S^(WBRY.N0?:+"PTNRDA
MLR["/S;A&D9R >2  !GI61'<7-Q9P>"'N[@V@\32Z<S^:WF-9I'YPC+YST(7
M.>@Q0!['+-%!"TTTJ1Q(,L[L H'N33@0RAE(((R".]>>6NBZ?X9^(<&AZ?;B
M/1M:TR<S6)):+S(V4;@I)QE7(/K@5>^'=Q+:+K?A>>1I/["O?(MV<Y;[,ZAX
M@3W(!(^@% ';45'/(T4$DBQM*R*6")U8@=!GN:XNQ\5>(HM;TJRUO3M-MQJZ
MR"".WN&>6VD6,R!)<C!X!&5[B@#N**X#X:ZIXCU2;Q ^L/:26\.JW,"^7*[,
MCH5&Q0PP(P,X[^U=GJ^H+I.BWVI/&TJVEO).47JP12V![G% %RBN,TKQ%XEF
ML#J-]IVER:?-8O=PSV%R7$;!0PC?<!G(/WE[@\4ZX\9W$/@#1?$8M(C-J!LP
M\.X[4\YE!P?;=0!V-1^?#]H^S^:GG;=_E[ANVYQG'7&>]<=>^*/$5[JNKP>&
MM+L;FWT=A'<-=3.KW$NP.8X@H(! (&6[G\:QKC4-8N/BK;S:3IT:7UUX:C=H
M]08HML//8G?M!)(.%P._? H ].HKG?!_B"Z\0:=>_;[6*WO]/O9;&Y2%RT9=
M,'<I/."&!YIOCZ^U'3? FLWNEM$ES#:2.'D8KL 4Y92/XAU'O0!OS7-O;&,3
MSQ1&5PD8=PN]CT SU/M4M>77VNWEEH'@1]>TO3=0NK[4[2&*1F:0P[E&V8%A
MGS!U_K6S<^*/$E[XF\0:)H6FZ>[:3Y+&>\E=5<21APN%!.XG/H ![T =Q17F
M</Q&UR?PWI?BO^QK*+0;F6&&9'G8W WN(RZX&W:'/ /) SQGC7U'Q3KTNI:Q
M'H&G6%Q:Z-A+EKJ9D>XDV!VCCV@@$*1RW<_C0!VM%4])U*#6='LM3ML^1=P)
M/'NZA64$9]^:XWXA:IXAL=9\+6VC/:I'=:B$;S973S&".=C[1]PCD]\@<4 =
MTD\4DLD22HTD>-Z!@2N>1D=LU)7F%C/XC7XC>,8M&M-/>Z*6+SRW<KK$I$'W
M5VC<23GGC 'O6E:^/K[5]#\/MIFG6ZZOK!F7RKF4B&W$)*RLQ R0&   Z[A0
M!WM%8'AC7;K53J-CJ5O#;ZGILX@N%@<M&X90Z.A(!P5;H>00:TM6TFQUS39=
M.U&#S[67&^/<RYP01RI!Z@4 7:*\>A\ ^&6^+UUHQTTG3TT1+E8/M$N!(9BI
M;.[/3CK77W%[=Z/J5IX1\)6-DK6]I]JD>]F?RX8RY55&,LS,P;OP!WH [*BO
M/+WXC7T6C:+<6VD))J%[J4FESVC3<1SIO4@-CIN4<X^Z<U:N?$WBBUUO2_#Y
MTW2Y-5O;*6X>1)I!!$R. #DC<5VGTSNP.!S0!W-%>;0^-O%UWIFM26^C:6MS
MH,LL=\9+A_+G*#=B' SRN#EO4>^.\T;4DUG0]/U2)"D=[;1W"H3DJ'4,!^M
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M8JCE) @1T<%AMY4$'I@USE_X,UV/P?X2MC9&6_C\1IJ=]'$P80*SN[<]PH8
MX[U[#10!YY-H>LM\7-8U6V@>.WF\/FVM[LXVB?>"!^'6N7LO#]Q;VWABZM/
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M'...M>GT4 <QI;GPRWASPDMJTT)L&C-V&P 854$;<<[LY]JXZ.T\1Z9X(N_
M%OH%W-.XFL[;4P4^R_9Y&;$CMNR&5&(VX)R/>O4VMX&N4N6A0SQHR)(5&Y58
M@D ]@2JY^@]*EH \^^PWW@?Q/+?6.CWNJZ7>Z?;VLBV05I8I8 54E6895E/4
M'@BLY?"VNP:-!X@^P;M;777UJ33UD7=Y;J8S"&Z%A'@^F1BO4J* .(TB/4?$
M7CJ/Q%=:3=Z986%B]K;17H5999)&!=MJDX4!0.3SFF> _P#3_$_C378^;:[U
M%+:%NSB",1EAZC.1GVKL[VV^V64]MY\T'FH4\V%@KKD8RI(.#[U%I.E6>B:5
M;:9I\(AM;9 D:#L/4GN2>2>Y- $/B&"^NO#6J6^F.8[^6TE2V<-MVR%"%.>W
M..:\OTW0WM=6\)ZEIG@:YT]-.F*:A*\48N96>%D+9W9= QR6)YR, X->Q44
M<-X"@U#2=5\2:7?:5=PK-JUU?PWA"F"2.1EV@-G.[OC';K78:BURFFW3V5O'
M<72Q,8H9&VK(V.%)[ GC-6:* /+-)T%KGQ \FA^&K_PY:SV5Q%J4=QM2"61U
M C"(K$$@Y.X #'UJDT/B.^\ Z#X:7PQJ$-SID]DMW+-L$96*103&0Q+YQNZ
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M^RC-)JWA:TL?%&O7&H>!W\0G49EN;&XCC1MK%%5HI"S#8 RYSR,,?3%>KT4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** ,\Z+9MXB372'^VI:-9@[OE\LN'/'KD#FM"BB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
F*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>svb-firstamendmenttoloan002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 svb-firstamendmenttoloan002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2WM8L;Y7Z+D@#]2* +=%%% !1110 4444 %%%% !1110 44@(8 @@@\@BEH
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M;-Q$DLTG)6,L VP8.YST48.2>AZ4 :]%<3IOB#5;KP1X@O!./MNG37<4,T\
M!98LE2Z# W8P#T^G:LNWUOQ1O\&3-JUNZZ_;;)HFM%VQ/]G\WS%(()/!R,XY
MZ"@#TJBN!L_%.J:7I'BT:C.M_<Z+=>5!.8EC\T/&C(&"X'!?!(QQ6SHK^)!J
M]]!?QS'3F@1[:YNA!YB2Y(9"L3<K]T@G!ZC)H Z6H;JYCL[66YE#^7$I=MB%
MVP/0 $G\*\TTWQ-XG;1?#VM76IP2QW6L'3I[9;55#HT\D8;=U!&!C'8<YKH;
MO4[[6]9\1:78WQLH])@C4LL:N99I$+_-N!^0+M&!@G)Y&!0!T>D:I;:WH]IJ
MEF7-M=1"6(NN#M/3([5=KS;PQJMS:^ O!.F6:S^=?60)>W$9D5$C!.WS#MSD
MKUSQGCTU)_$.O:+X*CFU>WCCUF6]6Q@+[2KF279'*P0D#Y3N*@]01QF@#HEU
MVR?Q(V@#SOMRVOVH@Q$)Y>X+PQX/)[9K3KA+*VNK7XQE;F_DO = )1Y4167]
M^,CY  1WZ9YKH_$=U=6EA ]M=16JM<QI-,PRZQD\B-<'<Y. !@YSTH V**X2
M#Q'J\OPWU_4UN%&H:8U\D<TT RXA9]I9!@!B% /;/;M2Z5K&NP^)_#UOJ&H1
M75MK.FRSF%;=4\B2,1G(8<G(D.<]QP!TH Z?7]=LO#>D3:IJ'G?9HL!C%$7/
M)P.!TY/4X%:=>3^+]3OO$OPS\0:O%?&&S2Z:"&U$:E7CCF$9+$C=N)!88( &
M!@\D^KG.#@@'L2,T +17F>G^(/$S:=X@UR[U:W-GH-_?1R6J68!N8XDX&[.4
MYQZ]\D\ ='H4_B4ZZ5OX9I-*EM!)YT_D*8[C<,J@C8DH5)(W9(QU.: .II R
ML6 8$J<$ ]#U_J*X[PEXBGUK4[FVN;^2._MD=;W3)X51[=]XVLG +1D9P<GJ
M.>:P_#,VKV^E>,[Q-:WSPZU<0B2^V+&@7RE\PD+U"#@?=X Q0!Z=2*RN,JP(
MR1D'N.#7*^&=4O=7E\0V$MY<'[%=+%;W,D"QS!'A1P64J!D%CC*CC&17*^"M
M7U*U^'WAS_2[N[N]8NY8@<1%X\-/([*6P"QV'[Q/)S@]" >JUF2Z[90^(;?0
MW\[[;<0/.G[H["BD _-T)^8<"N<F\0Z[X=\#ZMJ6MVN;NUN&BLS*8P9T9E6)
MI!&2H.7PV,?=)P,U7DM+VU^*_A\7>I/>[M+N\%XD3:VZ+=C:!\IXP#DCGDT
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MEB5&T'L,#\*T* "BBB@ HHHH **** "BBB@ J.."&$L8HD3<<MM4#)]ZDHH
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M(S6>BZ[IW]K23?VK+-)YDL"_NC*,-PN,GDGL.G'K&G@V=$\+J-43'A]=L?\
MHW^N_=F+YOGX^4]N_/M7644 <JO@J*9?$L-_=_:+?7FW31I%L,1V!!M.X]E!
MZ=1^%6_#NA:GI,##4]?FU>X5/*@EF@6,1I[A3\S' RQ.3@=.<[]% '%1> IX
M?#VF:0NKJ5L-2&HI*;7EV$IE"D;^FYC^&/K5N\\(7)\2WFLZ7K#6)U&!8;^$
MVXE67:,*ZY(VL <9Y'M7544 <2?A_)'X6T33;37;BWU'12#9ZBL*DK\I4J4Z
M%2IP03^-:6I>$$UCPG)HVH:C<2W+LLQOP L@F5@RN .!@@ #T&/>NDHH Y?3
M?"VHV_B>'7M1UTWEREB;)DCM%A1UW[L]20<@=_R'%7O$>A2:Y#8&WOVLKFQN
MTNX91&)!N 92&4D9!#']#6U10!RD/@V6'PUKNC?VO+*NK27#&62%<Q";._ &
M,GYCSTZ<>LL7A6=-6\/WSZBC'1[62V5!;X\T.$!).[@X1?UKIJ* .!O?AO/-
MI^LZ39Z_):Z/J<QN#:FU5VAD9@S;')^Z2,[<<>OKW<:.D*HTA=PN"[ ?,?4@
M8I]% ',Z/X073]/URPO;M;VUUBYGN)D\GR]IF&'4'<>/3O[T[POX:O\ 046.
M^\07&JQP1^3:++"L?E1\<,1R[<*-Q].G)KI** .>TOPU+::M:ZE?7R7EU:6;
MV<4JP>6S1LRL?,.X[B-@QTZMQS65/\/GDMM<MH=<GA@U*^&HQH(%/D3AT?<3
M_&,QCY>.">O!';44 8.A>'9]'U75;^;5)+Q]1>.61&A5 KK&J$C';"C [>_6
ML&+X;O!X7AT:'7KF-K&Z^U:9<K"H:U;<S#(_C^^P.< CL*[RB@#G+CPFNJ>$
MKW0]:U":_DO1FXNMBQL7XVLJCA=NU<#GISG)JK8^$=437=*U;4_$37L^GV\M
MN EHL7FJ^WEN3S\@R1U[8YSUM% %74;:2]TVXM8IEA>:-H_,9-X7(QG&1G\Z
MY+0_A_-HG_".*FKK+'H:3QPAK7!D67[VX[^H[8'YUV]% &)X;T&30(M01[Q;
MG[9>RWI(BV;&D.67[QR,]/ZU5\5^%9/$\^D2#4!:KIE['?1KY&_?(F< G</E
MYZ?K72T4 <G#X/N[34-9NK/7)(!J4R7)C%NI$<RA06R3DJ=@^7]36MHNB+I4
M^HW+R1R7.H7 GG,47EIN"*@PN3CA<DDG))K6HH YOQ)X7N-8U"PU32]7ETG5
M+,/&MPD*RJ\3XW(R-P1E01Z$4NK^%GU/2-.L%U%D:SNX;QIY8O,::2-]^3@@
M#+<G'X8KHZ* ,/3] ELO%.JZTUZLG]H10QM"(=NSRMVT@[C_ 'VSQZ5CV?@*
M:R\"WGA1-:=[.>.2")WMES#$Y8D<$;F^;[Q]!Q7:44 <?I7@FXTS5=$O?[62
M4:3IW]G)']EQYD7R\D[^&^1>1Q[5(W@VXB\2W>H66NW%KIM_(LU]IRQ*RS2
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MVN5F@<[BDBAQG!P001@CO7<T4 9FBZ-%HUO< 2&6XN[A[JYF*[?,D;&2!V
M  YX Y/6N=/PUTL>%+_08YYHX[J[-U',OW[<^9O14YX"]!]2>]=K10!A^(_#
MJZ[X4N/#\$ZV5O/"("RQ;]B>BC(QP*H:7X1N],U:#4!JL4CPZ4FF*AM2 50D
MJY^?KD\]OI75T4 >:Z[ID?A3P'HWAZ?6GMK<72QG4VM0T4:KND F4Y4J2 O.
M!DCT.=7P1->?:)((M>T_6]*$187%G9+ D4FX84%&*OD%B<<C SU%=J0",$9%
M(  ,   =A0!0T6ROM/TU+?4=3?4KD.Y-R\2QD@L2!M7C@$#\*T*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M':HN7,;AW.#C?MDY]2:H>-(=&T_X&W,&G,4TUI(FM_/?EU-TK;AGL<EA[$4
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MBFW,]J.7<A5!GDSDA2-H7&!QU).!J?$VZMX?$_@-99XT(UE7(9P,+C&?IDT
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M]B0"/0@'U!O^5'N+>6NXG<3CDGIFJ-GKVEW]ZUG:WD<DX5G"C/S*K;6*D\,
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M#'+ Q.[+$<#CJ".];VE>)=%URTN+K3-3MKF"W8K,Z/Q&1S\V>G'>@#2>&*1
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MF:G<O;VEVDDZ()#&058H>C@$ E3V8<>] %V6*.>,QRQI(AZJXR#^%.50JA5
M  P .U<%I>N7T/Q1\3:=J.K,VEV=E!-$)_+18=W7D ?F:V?#VK6%MX8@N9/$
MC:Q"\SQQWSJ"TS;C\BA!\Q&"!@'.* .C9$?&]%;'J,T+&B?<15^@Q7&^#_$1
MNT\4W=]JOGV5CJ;QQ3S!4$40BC8J< 8P2V<C/KS72VNLZ?>P7,UO<!EM25G!
M5E:(@!L,I (X(/3D&@"W+!%.H6:))%!R Z@@'UYIS(CXWHK8]1FN>\/>--+\
M0:&^K1RF&!99$Q(I!P)6C0XQU;:,#KDXZUKV&JV.IV;7=G<I+ K,CMTV,OW@
MP/*D=P: +)AC;&8T.!@94<4DL$4Z!)HDD4'(#J",^O-<;-XF%Y\1/#]EINJ/
M)97-M<R36X0!7VA?+D4E<L#EN02IQQ79RRQP0O--(L<4:EG=SA5 Y))/04 /
MINQ-H7:NT'(&.,YS5&QUW3-1>XCM;M&DMP&E1@49%(R&(8 [2 <'H<4:=KFF
MZM))'8W:3/&BR,H!!V-G:PR.5.#AAP<<&@"[+%'-&8Y8UD0]5<9!_"E:-' #
M(K = 1FJ=MK%A>7CV=O<AYU5FVA2,A3M8J2,, 3@D9YKDO"_BZW@DU*RU[6T
M:[.MW%G:>?M5F16"HN%  ],X&30!V\EO#*JK)#&ZJ<J&4$ U)16=9Z]I=_>M
M9VMY').%9PHS\RJVUBI/# -P2,X- %U8(EF:58D$C#!<*,D?6E\F(Y_=)SU^
M4<UB7?C7PS8O*ESK=E&T,HAD_> ['..#CIC(SZ9&<5J7NHVFG1(]U,$$C;(U
M +,[8SA5&2QP"< = : )_*C^7]VOR?=XZ?2CRHR@38NQ>BXX%<IX U>XUFRU
MJ:?4&ODAU>>""9@H_=*%VC"@#OZ5)XBU^[C\2:3X8TITBOK]7GFN&7=]F@3J
MP4\%F/RC/ Y)!Z4 =-]GA_YY1_\ ?(IS(CH4=%93_"1D5AM8ZW9ZCISP:M->
M69F(O([F*/=LV-@JR*N/GVY&#[8QS=77M+;4QIRWD9NR[1JG.&=1N90W0L!R
M5SD#M0!H!57.% R<G ZFA45%VHH4=< 8JE/K&GVUZEG-<A9W94"[21N;[JDX
MP">P)S7+7?B9=$^(>HPZMJ_E:2FE0W"1RA0J2-(ZG;@9/"9YSW[4 =H8HRQ8
MQKN)!)QR<=/RH:*-SEXU8^I&:;;W$-W;17-M*DL$R!XY$.5=2,@@]P17'7MY
MJ\WQ1CT&'6;FVL)-(:]VQ10EED$H3 +(>,'IZ]Z .S$,2ME8T!'<**<R*^-R
M@X.1D=#ZUF:1'=0"\^TZHU_")3Y4LB(K1@##*VQ5!PP/.._M3;;Q-HMY?165
MOJ$3W,P+0I@CS5 )+)D89>/O#(]Z -(P1,23$A)[E11Y$7'[I..GRBLU_$VB
MQV%S?/J,*VMK,8+B5L@0R#&5;^Z>1U]153Q3?6=N=-@F\2#1IGO(RBJ4+W/.
M/+VL"<$D<CTH WUC16+*B@GJ0*2.*.+=Y<:)N8LVU0,GU/O5&RUW3-1GNX+.
M[2>:T.VX1 28CZ,,<'VZU!+XJT2"TBNY-0C$$J-*K@,1Y:D!G.!P@)&6/ SU
MH U(X(H2QBB1"YRQ50-Q]Z<R(XPZAA[C-<G\2M1O]+^'NJ:II.H26MS;Q"2.
M2-4;<"P'\0/&#U&*T8/$6GV6F:<=2ODCFF@A9F?. 7  +'HN6R 3C)Z4 ;7D
MQ9SY:9QC[HH\F(H4\I-IY*[1@UGZAXAT?2KE+:_U*VMYW1I%CDD 8J.IQZ?U
MXJCJ7C/1K'P?/XFBN1=6$<;,C0 MYC#(VCT.1@YZ<YZ4 ;^Q,,-JX8Y(QUIO
MV>'_ )XQ_P#?(K*'BC2DTZ&\GNUCCDC,A.QCM QN)XX49')XY%;- #5C1"2J
M*">I I/)BPH\M,*=P&T<'U^M97_"5Z%]DO+O^TH?L]E)Y=U)SMA;T8XX/UZ5
M:_MG3\61^TKB]_X]L@_O>,\<>G/TYH N>6FS9L7;_=QQ31!"#D1(#_NBN(N_
M&.E:!:>)M:_X2)M8CMV0BSC"LMLY4A8U9!_$1R2>,?7,FJ^)A9^,]!E_M8QZ
M-<VEV\R.H5-T?EA3DC=G+D8SSQ@4 =JL:)G8BKGT&*=573=3LM8T^&_TZYCN
M;68$QRQG(;!P?U!%6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KRSXE:E;"7Q%IS%;2Z;P^SI((]TMX,R?NUX("IR6P,_
M/G( .?4Z0@'J!0!YI\6KVWN/@G?-',K?:8K;R0>#)^]C/R@\G@9^G-0ZYJ=A
M+\6O ,L=[;M$MK=[G64$#=$ N3VR>GK7J5% '$_%8[/ DLQ!\N&\M)9& SM1
M9T))]@*KKJFFW?Q>M+E+JW>/_A'Y2DA8#_ENIR,^J@G/<<]*[[K10!XUIE_#
M9?##PGJ4DDITRPU64WSVS'=#&QG0,=O("ET/TKT'PL^@PZ3?:AI,C#3KFY>Y
M>ZGE8K,Y"AI 7/3(QZ9!KHR 000"#VH      '04 ?/OA.[L%\$?#Z&>>W#0
M^(9'D1V&4&9<$@]!DKS[BOH!42*/$:!5&2%08]Z?BB@#R/PMK-C?>*/",\$B
MPH]G?0BQBC(2T;=$?)SC)< $MD]LX4&C5[BQ:/XN'S;<N]NBK\PRQ%FJ@#U^
M?(^OO7K> .PI: /-;G6(-+\4>#M5U*Y1-%ETJ2W2Z=OW45PPC(+-T&54@$^]
M:?PXN[:Y'B@VSAE.NW,@(& 58+AA['GFNV95888 CT(I0 .@Q0!YM\0]2MH[
M_4M.<K:W$WA^X:.<1[I+H?,/(3@C QN; S@CD8)IGCN]MYO@+.Z3*1/I\"Q9
M."YRG0'KTKTS /:B@#R36M3L'\:?"Z1;VW:...X,C"4$)N@0#)[9/ KJ?B.U
MQ!I&DWR([V=CJ]K=7P09_<*QRV!U"G:W_ <]J[*B@#BK 1:A\4Y]8TV>.;3U
MT9;>XFA<-&\IEW(,C@D+N/L&'J*S/!.H64OQ1\>B.ZA8S36?E8<?O-L1#;?7
M!X.*]'551=JJ% [ 8I: .%\?W$-AK_@R^NI!#:0ZHXDF?A4W0N!D]LGBL&_N
M["6Z^*KF:',FG1*-Q 8_Z*1C!Y^\0,>O'6O6,9HH \NO-8LM+D\'ZGJUW/#H
MTVD-;?;(9&"Q3D1, Y7H&"$?45IZ]#I6F?!75;?3XVM=/.FW"VL<['<P8,5^
M]SELY //(%=ZRJPPP!'H12T >/\ AB[TZ?Q-\/T>>VD9/#318+*2LA6(;?9L
M!QCKUKU34KH:7H]W=I%N%K;O*(UXSM4G _*KE!&1@T >5O9:-;>-M$UOP5?(
MESJ5T$U+3[9_W<L!5B\CQ_P,IQR0.3CJ>=B_U*TTCXMO)?S"!;O0TBM]P.9I
M%G<E$'\389>!SS7=!%#%@H#-U(')I2H)!(!(Z''2@#QNRFMW^$/@6>4K]EMM
M3LVN7<?)&JNV2Q/  R.3Q70RVVGWGB7Q=K"G=H<NB+;7D]N>)Y!YA<J1PS+&
M5&?4X[&O0]HV[<#&,8H"A5"J  .@% '&^"+N^6?5+*_U"VU6"S2$V^KQ8!GB
M8,0LA'&],9)'4.#WKS33=3BM+G5;_P U7TVV\<27=YY9W;8""J2D#J@<J<^H
M%>^JJJ,* !UP!00""" 0: .#\-:MIU]\3/%$]G=PS0RV5DZS1-E'"B7<0PX(
M&0,UQ.A:YIMCJ6N^;+:HL_C"5H[R0AEM04;$P'0YY0$_+ELG.,'W(*JC"@ >
MPHP#U% 'EFGWEO\ \*=\7QM.Q*/JL;&9=C%F>4J""!\QR.,=QQ6C?2Z>GP)G
MDC>V57\/^2&4@;F\@@+]=Q/'KFO0\44 >(Z%JFB6UGIUIXCNIX].U+PY96T#
MPR2;)&1766 [/X_G'R]>:ZWQ7$MA::))IFIIH^J65A,;2&](>*>%5B\R"3)R
M3PG(.?E)KT JK8R <'(R.AH95;[R@X.>10!3T>9[G1+">2V-J\EO&[6YZQ$J
M"5_#I^%7:** /,/ ^L:1<:1IGAO5;?S?$FF7C&2TDB)>.4.Q,X.,8VL6W=\X
MZD4L5W;62?$#2-==%NKNXFN((Y/O7,$D*I&(Q_&1MVX&<' [UZ;M4,6P-QX)
MQS054L&*@D="1TH \R\EM.U#X7V.KRQ_;K>*19A(P)#BU([]]V!GN:CT]],O
M/#WC6&?4OLD)\1%ENH'&8'+P^7)Z8$@!STX->I48!&,4 >7:F^O:M\*?$4#I
M#>ZC;W/EM/9)A=0B0QLSJ!W*!D('&5(K6EN;7Q'X^\*:IHES'<0V]K=/=RPL
M"%B=%"(^.A+X(4\_*WH:[I5"J%4  = *%55SM4#)R<#O0!YGH^I6,7QO\5/+
M>6Z)_9]LNYI !E1\PS[9YKC/ &K6^DZ5X(O;Z=(]*MY]0AN)6/R6TTC?NFD_
MNY7< 3ZFOH"D9592K*"#U!% 'DT&LZ=%H7Q"NU@AOK?^U1+L*DQLC1PCS#CJ
MH.6..H4\]ZWO!%];W/B_Q4(K\WIE:UF6?9@2+Y(&Y< #;G@>H'4]:[O P1@8
M/6EP!VH \3TG5(;+X;:3YCW&S1]<E?5HX PDMXFFG&6QR,%T;'7 S70ZO;6=
M]\,?%5QX/%S<?;PTK3;W<W3842%-W)R@*\=2"*]*P,$8'/6@ *    .@% 'F
MQ\2Z'KGC[P5=:5=PS1-:WB8CY,99(L(V/NGCH>E=!\1TNW\":@UG \\D30S/
M#&,M)&DJ,Z@=\J&X[UU 15^ZH'7H*=0!Q2>(?#>N:?J^N:/9KJC)ICBXECC*
MF10I98"2.6.6X'(XSU%8_@S4[2\\<PR07R7*W'A^#R_)CVQ)MD?*)Q]U<@<D
MD$X)SQ7IBJJC"@ >@%  '0 4 >>>#;B6V\1165G?Q:GHD]K/<6S,!Y^G'S$W
M0N1U4D\9Y^0CH*YF_N[$_#[QFZ7%OO;Q,7!#C)_TB(@^_ )SZ U[2%4$D* 3
MU('6EH :'5HQ(A#J1N4J<Y'M7DOA76;&]\4>$IX)%B1[*^A6QBC(2T?=$?)S
MC)< $MD]LX4$5ZY28 ["@#R35[BQ:W^+?[VW+O"JK\PRQ%HJ@#U^?(^OO6E=
M:Q!I7BKP?JNHW*)HLNE26\=T[?NHKAO+.6;H,JI )]Z]*I&56&& (]"* .(^
M&]U;7(\4&W<,IUZYD&!@%6VX(]CS5;Q4C:!\2=%\7W".=*-G)IUY,JDBVRV]
M';'12>">@[UZ" !T&** ,RVU_3-0FCBTV\@OV;EC:RK(L:_WF() 'IZ_GCS6
M76K&?Q)I)5UM3;>*)XY;&.,DHQCG7S)#@G?(3D#(!#8 .":];2-(UVHBJ/11
MBEP/04 >>:O/+8>.&N-+OXK@37UI;ZEH\X!9B0FRXA[@JN">Q"'TJ:2YL5^+
MNJF>>W&SP_&C%V'R_O9"PY]B"1Z8KO=JE@VT;AT..:6@#D?A=*LOPR\/[7#%
M+14;!S@CC!]Q6!K<^@R?&JW76)K V\>@NI^U.@19//! ^;@-C/'7%>FT4 >=
M:TUC-\.O$VD^#MMPD$#O_HC!D+2,SR1H5ZG:3P/[P%1IXCT?Q)XZ\$W.C7"S
M0+#>@[4(\O,2?(>.&'<=N/:O2:Y[4]!NKSQ9H>K02V\<&FB<-$P.Z3S0 2".
M!C&??/:@#S;Q'J5I9^%_B3I$\P749=1:XCML$NT31P8<#^[P>>GYBM[XMWUH
MVE^%7^T18.O6DXRV/W8W9;Z>]>EE%)R5&?7%+0!YWKL-]H_CN*[TA6:#Q1;"
MREDBY$-P@RDWX1;_ *[!5;QQ=6&GS76BQJEBW_".S+!*L>Z2X49 MTR",# 9
MN"<$8Q@FO3<#CCI1@'M0!YGXXO;:;X"SR),I6;3H5BR<%S\G SUZ5D0:AX?F
MN]0TGQ%-<O;ZI:6CV,<$LFR\00(C1KL."PD4\=?FKV.D*J2"0"1T..E '#^(
M);6/XF>"HYGB5T@O<*[@E24C"]>YP<>N#7-%DN_A-\0(K1EF(U#4658CN^4R
M%@0!V(YKUZB@#RWQ#JEO<V-IK.@ZS;B]M]+)-I<#=!J<'\40[[@1@%>[8]<>
MGPNTD$;NAC9E!*'JI(Z4XJIQE0<<CCI2T >;ZQIES;^.=1TB"!VT[Q99CSG4
M96!X\),WH"T3#!_O 5:^'B:C-"+?5D<2>'@^EI(W29@W^L'MY8AP?]IZ[['.
M>]& .U '@FKS0W=K\7X[61)6E:W=%C8$N%'S$8Z@8.:[J^U?2M2^(_@ZZM[N
MWFA-G?-')D8.1$ 1GUPV#WP:]!Q1B@#B_AG/#+HFJ+#*CJNLWN C @*9F(_
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M!^83J3]XL#ENX.<U0^(&H1)J-]IS(UO+/H-P8IXH"\ER>1Y"G!P!C<W?D'(
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M&L66A:='=:Q>0VZDJA<Y 9SQ@#KR:T:XKXK/&/A]>1N5R\]L%4]6Q/&3@=\
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M7FIV_P#:3QLUSN=HYCM_<1+M!(&1@ 'J:LW_ (UTJT\,:GKD)GN8M/WI-#'
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M8[V=;2[M[PRVP8"-BBIM. .3\QZYKH]-U>RU>.22R>22.-VC+M"Z*6!(."P
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M +^,]51V&,=#YG'7CT*B@"*YN8;2WDN+B01Q1C<S'L*XW0M-;Q+87VLMJUY
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M4VSB1@;A6!"XSC;DY]JZCQ&S7WQ \#3VHG$4-I>I+<K ^V!I(-J;CCY3N]:
M.Z3Q9H[W=O;_ &AP+F9H+>=HF$,L@SE%DQM)X..><'&:@U'QMH6EWEY9W$\[
M7-G&LLT,-K+(RH<_, JG(X.2.!WKAK:UN-3^&^B>%#;30:Y8W=M%+&T;#R/)
ME!:;=C&THI(8'!W #DUO22"/X@^)I7CE$3:-!&LGE-M=E,I90<8)&Y>!ZT =
MM9W=O?V4%Y:RK+;SQK+%(O1E89!'X&N)\=SWL'B;PG;6FHWEI%J%ZT%RL$N
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M/O!5EX>B^$MI8Z]X>GFU!8YA) -+D:X+&1RNTA,AL%<'/''(JUI%CXFT71_
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MP/'N5I201N S_2HO'^E7SWOA[Q)I]K)=S:'=M++;1#,DD#KMDV#NP ! [\T
M:MWX?O((('TO5]06XCGB>;S[@RK/&'4NI#9"Y4'[FW\N*M7?BC2;'4#93SN)
M%EBAD98F9(WD_P!6K,!A2V1C/J,XR*;:>)[#4U1=,\ZYE<C*&%X_+'<N64;<
M>AY/0"N$\8W<UQ?ZS;O87J/;:CI\T:VMFY6XB62%FF=U7YR,,@7)QM'&>0 >
MAZCKMCI<ACN&E++'YK^5"TGEIG 9MH. 2#^1[ XYOQ)JK:1\0_#S2WEV+.:T
MO#);1;G$C)Y>W$:@EF^8]B:I^.$F&IC4=(GNK77+>R4Q0M$7@U%"[9MG7&"V
M1QSD;\].1H:VQ'Q-\+R&.3RXK2\$D@C8HA<1[06Q@9VMCZ4 ='H^L6.O:7%J
M.G2F2VD+ %D*,"I*L"I (((((-7ZX_X=;ET?5%>.2,G5[R15DC*$HTS,K $=
M"#D&NPH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!X.#0!J45Y_X&GN3X_\ '=G+>74\%M<6JP+/.TGEAHV8A=Q.!DUZ!0 4444
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M;ZM;2M;6T#2"VB56SNV @!<@'M4VD0SR^+_'.+:Y1+H6X@DD@=$EVP;#M8@
MX;CBNWHH \ETBT2]^'GAK3;R+6M(O[!-L=_':R(UK<(I'(*_,A!(.?E.0,YZ
M>B^&I=0F\,Z;)JT2Q7[6Z&=%3: V/[O;Z=NE:M% 'G?B43?\+@\*7BV=[):V
M=O=+<3QVLCQQETPH+!2.:QM/ANH_ ?@J!].U!9[;7%EGB-E+NB022DLPVY P
MR\^]>NT4 9VOR7,/AW4Y;.T6\NDM96BMG7<)7"G"D=P3QCO7&^$'ED\;2W?V
M753#=:-;#[1>6SQ R+))N&" $QN "@#U (YKT.B@#SGP1?W=AI]KX3U#0[UM
M3T^Y93<26Q^SM'O)$ZRGCE3P.N[CUPMA?W6@Z_XBT2_T.^O3J-^UY82QVYD@
MF5U4;7?HFTKR6[?AGT6B@#B7:XT+XEWNHWL,[Z=J>GPQ1W$4+2"*6)FS&0H)
M&X/D=B<CK6!/H=_I?PV@D:SN&:/74U5K6.,M)% ;KS,!1SD)R0.G/I7JM% '
M":#>--X^\2:B;'4(K.XL;0PS2VDBB0()-V 1D'YA\I ;VKGM*@NH?!OP[MY-
M/OUFL]21[F,V<NZ%0DJDL-O RR\GUKURB@#S^82V'Q'\227&E7EU;W^E0"'R
MH&:.78)-Z%P,*>1P3DYXSQ5KP+:W6G7E]8P75Y=Z$D$+V3WT3+-;DE]T!+ %
M@H"GG[N[%=M10!Q_CBWO([[PYK-O!-<V^EZAYEU#"A=A&\;1EPHY;;NS@<XS
M4-GILVI>*O$FM6T<B6EWIT5E"9$*>?(H<EL, <#<J@]^?2NVHH \CT.XN)8?
MAQ -*U16THM;WI>RD40N+9H\'(Y&XCYAD<]:UV1K/QIXZ6]TB^N[74K*!XEB
MMW9)T2!U=-X& V?EQG)R,"O1:* .-\$0WNGMJ=H][=WVCP"(V%Q=Q,LZJ0Q:
M)B0"^SY<'&?F(ZCCSZPMM4LY]0U4:3J3P6OC&74Y(/LDBO+:NI02H"!NQNS@
M<U[G10!YJD<_B#7O&ZV5M>Q1ZIH\,%I<3VLD*,_ERJ>6 Q@NO7![]*T?!-S:
M:G-!/_PC-WIVI6MMY-W-=V[)Y;\9C1C]X$C.1Q@#/45W-% '*?$.PO[WPRDF
MG0O<3V5[;WIMD^].L4@8J!W.!D#N14$$7]N?$*PUVSCG2SM--EADEEA>+S'D
M=2J88 G 5B?0D=Z[*B@#SWP\\B_%WQ5=/9WL=K=P6B03O:2+'(R*0P#%<<$U
M)\6HI;KPS9VT%G=7<AU&WE:.WMGFPBOEB0H/&!7?44 >6^-K%==DTA?"6DW=
MOK<=Y&XU!;"2U6WB'W][LJ[@?[G.?2D\2SWMSJ]ZDNEZGNL];L9XDM;1S%)
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MT4 >?>&UDM])\:1M8ZE&LE[+-#]HAD+RH\$84C.68D@\=1T..E9^EQ7,=O\
M"Y'L;Y6L8F2Z!M)!Y!^RM'\_R_+\Y YKU&B@#QS5;'6$\>>)_$>F6M[(]A/:
M7,-K+;2>5?HD)215RO+KD[2,X/UKU?2]1CU73H;R.&Y@$B@F*YA:*1#W#*P!
MR/RJY10!Y_X@MKE/&"ZCHS7T&J)/;0SVYA9K;4("PR2<;0R!G.X'(V\]17?.
MXCC9VSM4$G )/Y#DTZB@#C-%LW\0ZAJ6N2SZK82R2_9H83&T!6",D+D.N?F)
M=^.S 'I6+X)$WA#Q;X@\-FUU)]$>87=C=FSD**[ >9'N"XZ\C''![FO3:* /
M-? $TEAIGB_[78ZA ;C6[R[A62RE!DB<+M91MYS@\=:YV&UO1^S8VB'3-2&J
M"%H_LALI?,W&<L.-OISFO;** /+=6,TWC#X<7<=CJ#06,4_VJ064N(=\*JN[
MY>.0169]HU#3_%GC6^BTG4#;WNH:<4G_ +.D<B).))8U*$,R=1P<'G!Q7LM%
M '"^#K>86?BRU^QW\/G:A++ ;Q&!D1X4"G<W)Z'/IT..E<OIS75EX*\'7=QH
M>J30:-FWU&U^RNLJ[D*[U4X+A2!DC(PW'0X]BHH XF[LM)O/!,D9T:^L-/O+
MI90MM$Z7,3%P1<%5!96# /SR!R>XK4\%G5!H+1ZK.US)%<2QPW3Q>6]Q$&^2
M1E]2._?&>]=%10!Y_P"-+:X_M\7^C->V^N06\2QA86>WU",R-F"08VY')SD%
M0^>G2WX@E?2_B-H>JRVMW+9M87-H7MK=YMLK/&RA@H)&0IY/'%=K10!Y+'9:
MA-\'KNU&F7RW46K&X:W:!O,*"^$I*C^+Y.?ESGMFNKM8/[9^(4.OVL4JV5KI
MCVIFDB:,S.\BL% 8 D*%))QC+8Z@XZ^L[6=/O-1M(X['5KC3)DE63SH8T?<!
MGY6# @@_ATH \BE@NV\4>.;RULI;X6.M6%U-:PC+S1+&P<*.[ -D#VKK[S38
MO$?P_P#$2>'](ET^348&$?VB(PRW+A>K!N0#PH)]^V">JT70;;17O9XV:6[O
MYO/NIW !D?  X'     _F<FM6@#F/#7B/_A(WAF_L.]LIXH=MR]Y:F(Q/QF)
M"W+<\Y'& ,\D50^&XGL[#5-,NK*[@GAU.[D9I8&1&5Y2RE6(PV0<_+GWQD9[
M:B@#B==$]G\4- U$V5W-:FPN;8R6\#2!9&9"H8@?*#@\G ]ZYQ=/OO\ A7.M
M^";BRN7U9[F>*!C"QCG668NLV_&W:-V3DY&WUQ7K-% $44;06B1Y,C1H%R3R
MQ KS'PS->77BCPS?7.EZG#+]BNX+I6M'B@MI2T1\M5P%50%.&_BXY8\#U.B@
M#%\7Z%_PDWA'5-&$@C>[@9$<]%?JI/MD"LGPUXG\K1;33]7L-0M-7MHEAFM_
ML<CAV48W(RJ593C((/&><5V%% '$^)TU"'Q!X4\0O:2M:V4L\=[#"IE:%9DV
MJ^%ZA2,'&<9/:J,VGS2+\0-:BM[@V^J6:06L8A;?,R0,I8)C=RS!1QSMSTP:
M]$HH \XM%G_MCX<L;.]"VVGS1W#&UD A8PHH#G;\IRI'/I1;&XL-:\?V\^GW
M^;QA/;R):NZ2)]G5>& P3N&-HY]L D>CT4 >7'3M3G^#GAL6EC=&]TEK*XFL
M7A9))/)92Z!6 )/&1ZXXK?MH?[;^(EGKUFDZ65KI<EN\LD+1>8\CJP3# $[0
MI)]"0.M=E10!YYX)6:/XC>.)Y;.\A@O9[9K:66VD1)0D;!B&( X->AT44 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4%[>
M0:=87%[=.$M[>-I9&/95&2:GKEO%!;5=1T[P^T%\+.>7S;RXA@DV!4^9$\P#
M +/M)YZ*0<9% &)X)U_6D\8:MH/B0E;F\C35;!"?N1. &A'NA 'O\QKJ=3\4
MV&ES7D<B3S&QMQ<WGD)N^SQ'.&;G)X5C@9. 3CI7'>/M NM*FT7Q+HD>JZAJ
MVFW8Q #).98&XE3OMR.Y]ZJZYJ"#Q)K3V^GZ\EOJVFPPW;P:3)<'I(N< @Q.
MJL1\P(.0<<<@'9WGCC1;'3M,OYFNQ;ZG,L-LWV20;F;.,@J,9P2.Y'0&D'C6
MQ.F->BPU0>6DDDMNUJ4EBC1B&=E8CC(.,9)P< X..<U\V][X?\%?V'9WUQ8V
M>K6K[4M9&>&&$,C;QMR"IX(/.0:G\3+_ &?XVCU*]\.76M:7?:>EI_H]KY[P
M2H[L-RGHK"3&?5>: .NEURS%C9W5MOO!>J&M4MP"TP*[LC)  V\Y) _$BL^X
M\;Z+;>$O^$E=YSIX.UMD#%T8-M*LO\)# @YP,]ZPO%%I+IP\,ZG_ ,(Z;O3[
M%)(+O3;* 2M LBK@H@X8(4 X[$XIGBVR:Y^$NHVVEZ#-:/=X:#3[>U_>#,@;
M+(@X8@%CZ9P>: -QO'.F+JD^FFUU+[8D/GPP_9&W7*9QNC'< ]<X]>G-7+#Q
M1INH^'X]:@:7[.[^4(WC(D$F_9Y97KNW_+C^E8TYE?XIZ;?K:7IM%T>:)IOL
MLFU7:2-@I.W@X4_RZUS4&FZF? -TT>CW4\]IK\NH&PF@9&N8?/9\*& R2C9'
MN,=: .]M_%.GSV&I73)<PMIC,EY;O$6EB(4-]U<Y!4@@C((JKI?CC2=6OM.M
M8$O$.HVYN+26:W*1R@*&958]6 .3VZ\U3LVM;KPKK5YIWAR?2TN;=E$3V7E7
M$[;",F->>X SSP>V#6)IUM>1GX9*^GWRFPMFCN\VDG[AOLOEX?Y>/FX_7IS0
M!TFB^*Y=6\7ZWHYT^XABTYHHQ(RC!9D+ECSP""N!^>,X&YJ6IVVE6RS7+-^\
MD6*)$&6DD8X55'<G_$G !-<MH,5W8_$OQ6)M/NQ!J#6LT%R(CY)5( K?/TR&
M&,=><XQS4_CJROG_ +!U6RMY;I=*U)+FXMXEW.\15D8JH^\RALX')YH U['Q
M'97SW\/EW$-WI^/M-K)$3*@(RI 7.X$="N<X/I5+P_XWTOQ-+;KIL-^\5Q"\
MR7#VK+%A6VE=_3=WQ_7BJ>GVS7'CK4_$ZPW,5C_9L-F@>W='F=7=V8(1NP R
M@<<\XZ4GPLM[FR^'6E65Y:7%K=6ZNLD5Q"T;*3(Q'!'/!'(H Z'4M7ATV2*(
MPSW$\D;RK# H+;$QO;!(R!N48')W# -0S^(;*VNM)@E68'53MMFV94ML+X//
M!V@FL+QYIZWSV)C.IVNH01SRV>HV$+R&"0;/W;A0<J^>AX.RJWB(:G':^"]7
MO+">::QNDDU"*RA,K1E[=T8A%R2H=NV>* +7B;6K?5O WBY;.2ZM[G3()XI"
MK-$\<JQ;QAE/(Y4]<&I/#?C/3+N;3=$<7D-Y+9J\#W-NR1W051N,;'[^.OTY
M&1S6%;66IW^B?$:W72KR&;47F>T69-GF[K9$4 DXSD8]JO6UK+KU_P"#WBL[
MN!-'5IKJ2YMGA*MY)C$8W@;B2V3C(PO7D9 +B:SX=A\?:HS3W\>IVNF^9<B7
MS%@6%6'*J>"<]U!SSZG.YIOB"UU+4+O3_*N+:]M5222"X0*QC?.UQ@D$'!'7
M((P0*\T\4:==ZK\3O$MG8(LEV_AF,Q1MT=EG#!3]<8_&NN\.&TUNUO+BS\,3
MZ%++;&WEENK002ESGY5[LJG)ST)(QWH TX/%^F7&HV-HHG5-0,@LKED'E7!0
M98*<YZ D$@ @<$U6T#Q7+K?B36]..GW$$6GS+ KNHY.S<2W/&<C ]/3I65X$
MU/4H])TOPY?>'KZVOM+C6WGN9H<6X6-=H>.3HY8 # ]3G@<V/#,5W8>//%D-
MQI]VL=[=17$%SY1\ED$*J?GZ9W#&.OMCF@#1\9>)I/#%A8RPV4MS)=WT%J"@
M!";W ).3UQG ]<5;NO$EO;.85L[RXN4@%S-;PQAI(8R2 6&1R2#@ DG!P#BL
MCXCVMU<:!82VEI/=&TU6TNI(K>,O(8TD!8A1R<#L*JV<MUHWCW5M4N["_;3M
M:M+=X9([9Y6A>(,IC=4!*DAMPSQU'7B@#L--U*SU?3;?4+"=9[2X0212+T8'
M^7TK!O\ Q5+:^.[+PZFGW,D<UI)</,BC!PR*,<]!N.3],9YI_@'1KC0?!UI9
M7:>7,7EF:+(/E>9(SA... P'U!K/UF.[M/BAHNIKI]W<6C:=/:&2WB+A)&=&
M&X]%! /)P* ,OPQXJM-"35X-0?4)H_\ A(;BV%RRO,D ,@2,/(2<#. .3VSU
MKL=9\26>B),\\5Q,MO#]HN?(CW^1%DC>W/3Y6X&3\IXX->>7MI?R^ _%-LFF
M:B;BY\0M<0Q?8Y=TD9N8W#@;>FU2?PK7UU18^-KBZO\ PQ=:WINJV4,4306@
MF,,B%\HZM]U6#@Y.!P<]Z /089H[B".:%U>*10Z.IR&!&017!W#3_P#"[[6Q
M%]?"R;16NVMA=R"(RB;:&V[L=#TZ>U=Q91>18V\/DQ0>7$J^5$,(F!C:OL.@
MKC=?M;O2OB3I7B@6=S=:>;"33[DVT32O 2X=7**"Q7/!P#B@#7\0P&37?#F+
MF[B66]>.1(;F2-9%%O,X#!2 ?F53^'I7&SZ]#H7Q>U:+4-4OS9)80/:V7VN1
MA)<.X 5$+8)/ITZG@<UU_P!J/B#7M+DM+6[2ST^22XDN+BW> ,YC:-44. S<
M2,20,#'7)KCK[PW:^)OBEKD>L:1>R:3=Z9%!%<M:R*HE5LY5]ORD9Z].M ':
M:)H=XNH7&LZI>7@N;EMR6"WLC6]JN/NA<X9NY.,9Z #J[QQ=ZC8^#-2N=+29
M[J.-6Q ,R;-P\PI_M!-Q'OBN9\,ZQXA\-ZQ/X8UVSU35+"# L]:BLY'W+V27
M Y(Z;AGW]:[76[ZYL-):[L[2:[E62+,,2Y=D,BA\ ]PI8_A0!@>$I-*U:YM]
M:\.ZQ<W6EO:O%+;RW<DNR4LA4D.2RM@,"/?/?)U;OQ3I]E?Q6TRSB*2Y6S^U
M!,Q+.WW8R<YR<@9QC)P2#Q7-:9HUI_PLR+6_#]C=65M+:2KJIDMI+>.9R5\O
M"N!E\[R2!]>3S6TZV%IXEU'1]2\)27MQ+J;WEGJ+6@>#RW?S S2'[K(21CKP
M,=: .PU?Q+9:.;A9(KBX>VM_M5RMN@8PP\_.V2/[K8 R3M. <4H\3:<U]I-J
MC2/_ &M"TUG*JY2157>>>WRD'D=ZYJ[O+_PS\0=4NIM&U'4=-UBW@$4EC!YW
ME2QAE*./X00V<GCK[XE\2"\M->\':S+IMS)#:&>.ZCL86F,)DBPORJ"2H(QG
M'I0!L-XRTI-#U/5Y!=+;:;-)!=#R&9T>/[PPN>!Z]/>LO4O&.A:EX:U9[N'6
M(=-CME:6X2UE3?'(I(:-U'(&#ENGO@U@I;:C)\/_ !];/I&H17-[>7S6T)@+
M-+YBX7:%SGGN./>MKQ!'/<_!RYM(;*\>[FTK[.EN+9_,\PQ[=I7&1SW/% !I
M_B^*/6]"T+3M/OY;&?2!>1S289V3]V$R2V3@,=Q/?'7FMO3/%=AJUGJ=U!'<
MHFF2O#<K,@1E=!EA@GL".>G/!KC-$AO[#Q#X.O9-)U%HD\/?V=+MMF!AG!B.
M'R!M'RGYCQQUJ[KNAWD?C](;$+_9OB.#;JB9P5\@J2X'^VC>4?J#0!W=C=K?
MV$%VD<D:3()%65=K 'D9';Z5P&D6;:C\4/%VGW.HZLUG9Q6;6\*:E<(L9DC)
M?&UQU('TKT>O.M'N9-.^)_B[4;G3]46SO(K-+>9=.G=9#&A#XVH>A/?K0!-9
M:KJ7AKXE6WA>]OYM0TS5;9Y["6X(,T$B9+QEOXEP,@GGH*WX_&.EO/9 B=+6
M^F,%I>L@\F>3G"J<Y&<'!( ;'!/%<XV@:GXM\;_\)!>6TNFV%A8RVFG)-@32
M22 JTK*#\H . #SWXK/M=-U#4_ .@^$Y]/N[;4]/NK:.=V@<1QI X)E63&U@
M57C!R2WL< ';ZQXKT_1?M33I<2I91K+>/ FX6R-T+<CT)PN3CG&,5.?$%D-9
MM]+ E:XNK9KJ JH*2(NW.#GK\R]<=:Y07FH>&_&VOPW&A:CJ-GK+Q7%I-:0>
M8FX1+&T<AZ)]T$%N,$U:UTW>G^./#FK2Z?=7,"V5S:S&R@:7RY7,17('(4[6
M&3P.^* -*;QQH]OX7F\0R_:A8PRM#)B!BZNKE""!T^88R>/>FMXYTQ=4GTTV
MNI?;$A\^&'[(VZY3.-T8[@'KG'KTYKB9['4Y/@UKNGG2-06^FOYS';_9V9W#
M71<$ 9XV]^E=3.97^*FG7ZVEZ;1='FB:?[+)M5VDC8*3MX.%/'X=: -FP\4:
M;J/A^/6H&E^SR/Y0C:,B3S-^SRRO][=QC^G-);^*M/GT_4KMDN83IC,EY;O$
M6EB(4-]U<Y!4@@C(([UP,&FZG_P@-PZ:/=3SV>ORZ@UA- R-<P^>S84,!DE&
MR/<8ZUT]JUK=>$]:O-.\.3Z8ES;NJQ/9>5<3ML(R8U&>X SSP>V#0!>TOQQI
M.K7VG6L"7B'4;?[1:2S6Y2.8!0S*K'JP!R>W7FJEEXW6;7_$=K=V5Q;66C*F
M^9T!'W"[,<'H1C Z_GBL/3K:[C?X9!]/OE^P6K1W>;60"!OLOEX?Y>/FX_7I
MS4OV>:U\4>/(K[0K^]L]2BAD01PDQSQK;['4,/XLC;M'/([<T =SI^I+?M<(
M;6XMI8&"O'.H!Y 8$$$@C!['V[56U[Q#9^'+6"YOHYS#-,D >)-P5V.%W<\
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MFGB]<27,$/E2([!0NX>8C%3M51QZ"G7WC/3;!;B>6*Y:PM;C[-<WR*IAADR
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M:]U*XB2&6[G"ABB9PH"@ #))Z<D_3&Q7G7C"YM+/XE>'$O\ 5)K+3[FUNC<
MW[V\3,@39G# 9Y-=#HC:9#I-[JNG7E[>Z;<,Q5?.DN3E"8V\LDL=I*YXX[]Z
M .DHK@/#'BWPYI_AOP^FD6>IC3-4N)+>R>8[_P!YYC@AF9R1DJQ&>WOQ757.
MOVUI>7EO-%.JVL*2R2A05.\E548.2Q((QCT]1D U:*R=)U^WU6]OK$07%K>V
M+()[>X"[E#C*,"I92" >A['-8WQ(T^YU#PKY-A?W-A>R75O##<6\[QE#),B'
M.TC(PU '7T5R/@3Q4=:\&_:]4807^FE[;4PYQY<L7WR?J!N_&N6\):CJ=_\
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M30!FZ]HD.OZ>MK+<W-LT<J3Q3VS[7CD4Y5AD$'Z$$5'IFB36<JSW^KWFJ7"
MB-[E8T$>>N%C51D^IR>N,9->=3:W'K/B+QNOB+1]1GTO3(8 D2F/=9IY3.[\
M2<.>N5R< #VKN=*U:PT]M#T)&OYC=V1EM;BY8.9$15)WMG.[#+V[T ='17)I
MX_L)]1N+"TTS6+J>WNQ:3"&T.(V(R&8DC:ISU./RYKDM;\3W7B;X5:CJD]G=
M6!BOE$;"4!=JW8CVG8V6.W(.1C/3/% 'K-%8FE>)[35=6O=,%M>6MU:QI,4N
MHO+\R)B0'7GIE2.<$=Q3;/Q78WFJVM@(;F(WL+3V4TJJ([I%QN*$$GHP.& .
M#F@#=HKED\>:?-K$^F6^GZM<3V]W':SF*S)6(N,AV[A.>I_E4GC;Q)<>&-'@
MN;6QDN9)[N&V!4J!'O<+DY(R>2![XS@4 =+17GEUJKZ=\4&NC9:G,TN@[_L,
M7[Q]WGX.%W;%X'J!^)KI8_%NFSZ)I>J6PFGCU1UCM(D4!Y'*EMOS$ $!6SD_
MPF@#>HKF;[QA#'X%O/$UC93W*6\4S&W;:CJT997#9.!M*G.">G&>*T_#^H3Z
MIH-E>7-O+!-+"C,)-OS$J"6&TD8.?K[4 :=%<P?'-@-/UN\-CJ 719#'>1^6
MF]<+N+ ;N5"D'/<=,\UHQZ_!*-*,=K<L-2C,D6T(=B!0VYL-TP1TSU ZD4 :
MU%>8:AXQTK0M-\:ZOH&G:A)J5K*@O/M!(192"%8*[<*.X &>.,=+VM:D]K\1
M?#EXUGJ*M+87H-D#O=F4Q;<*K% >3SD<'DT >@T5SJ>)=+U;P;<:P8KS["8Y
M4GB$3"9-NY9%(7D$8/0_C6/H7C'P_8:-H-AI5GJLD-[:/-8Q>4TCLB'D%BQY
MY'? !Y(% '=45F:!KMKXBTE-0M%FC0N\;Q3IMDC=&*LK#G!!!K3H **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N,\1V]]#\
M0O#.K0:=<W=K%!=6\IMU!\MG";=V2, [3ST%=G10!Y<FE:G;>#O$W@Z73[F6
M[N[BY%E<")FAECG8L':3&U2I8[@2#\O&<BO2+6T^S:9#9"1F\J%8MYZG"XS5
MFB@#SKP%;36B:?I%[X0^R:CI*&&75'MD$<BJI57BD^\S.,9XX&[/;)XQTW4-
M:NVU_3;.6/4/#L@:PCDMCF]/!=>F2A'RKCHP+<#!KT6B@#S[4M0U.U\2Z-XN
MAT+4[BSFL)+&\LXH<W%LS,KJVPXW#*D$CCO4WBJ/4KBQT/7'\/O>K9W;RW.E
M!%DE\ET9,A<D-(N5; [Y&>,UW=% '":SIMSJ7@*632?#T=I*MW%?1:7)$D;3
MB.1'*R*/E#,%/'NH/.:FM[,>(O"6NQ:=X>;0&U"S>V07%NL$SN4898+_  @L
M ,\_>[8SVM% 'ET%QJVH+X'BD\.:K#<:5=!+X- %2/$#Q[E8G#*2<@CC'O@5
MZC110!P:0W7_  NR74_L-X+ Z(+(7)MVV&83[\9QTP>O3WK0\>:9?W-CIVK:
M/;^?JVDWB7$$0.#*A^22//8%&/Y5UE% 'G=AX2U/3/&X129M)U&*.^U&4YPU
MY"W8=M[,C8](R*9<V<UCXPUJUO/")UB'5IDN+*]-LDL4;>6D;),S?<4% W?(
M)QSQ7H]% '(ZK%.?B9H5XMK<O:P6-U'+,D+,B,YC*@D#OL:N7GT35+[X/>)M
M+BT^Y%]/=W4L4$D91I%:X,BXSURO^%>K44 <7XRMY=;\"MJL$,MAJ&FD:E9_
M:E"NCQ?-AAG@,NY2#V;FMWPW:7%MHZ2WJ!+^[8W5TH.=LC\E<]PHP@]E%1ZG
MX9@U;6;:_N;_ %$0PH%:PCN"MM*0VX,Z8^8YQWYP <BMN@#B-;BN7^*?AN\C
MLKN2TM+:ZCGG2!BB-(%VC('/W3TZ=ZZZ18;&QF,<3!!O<I$A8EF))P!R222?
MQJS10!Y+X7\*:A=_ V'0+BUN+'6K,R3VXFC*&.=9FEB()XYX&1ZFM[4=(UC5
M/AQ<SO9(=<O)(=1ELW^Z7C>-Q"<_[$:ISWSZUWE% '->$YH+U)[V#PP^AHZH
MC+<6R0S2,,YR%_A&1@GKD_C+XN:3^S[..*VN9W_M"TE(@A9]J).CLQP.,*I/
MOVKH** /.;_P=J#_ !"DN;#">'M=@235XV&#OB(*C!Z>8"%(]-^>U2:;'<P?
M&#7-5ET^^73Y].A@BN/LKE7=3D@8&?T[5Z%10!XC%H^K_P#"F_%&C'1]0&HW
ME_+)!;FV?+JTB,#G&!P#U/:NAU6"\N?%WP]O8M-U!K?38YQ>/]ED_<EX5101
MCGD'IFO3:* /&+[0=:OM>\:7EGIMV&EO]/O[$2PLBW0M^73)& ?3.,G%=O%;
MOK?CG3O$$=K=VUI8:?-$QN(&B=Y)&4[-K $[0I).,9(P3SCL** /)DL-1'@6
MTM#I=_\ :4\2"[:+[,^X0_:S+OZ=-AS^G6O5VD5(C(0VT#. I)_(<_A3J* /
M./ 5S=:#INMQWNBZL)KC5[F[AC6S;,D;L"O)^4'ZD5GWO@37=;TGQ?K%W'';
M:WK*Q"TLQ(&$,4+*R1LPX+-M&<<#UKU>B@#BS%/XG\5>&=66QO+--+2XEN!=
M0M$5>2,((AD#=U))7*_*.>15'3XKJU^,&O:K-87RV$VGPPQ7 M7*NZ'Y@,#/
MX]#BO0J* /&?!=MKNE:!HFD7NAZJML9KPW4<411][,&B#-D8C(+9P<9 !XX.
MA?:;JDOP"MM'&DWHU)8+>$6OE9<E)$+' Z#"D\X_6O5J* .,\:6,.LPZ>PBU
M6WN$26:SU&QAD\VUE 7"LH&<,"001@[><5TVC&^.AV!U-574/LT?VD)C EVC
M=C'&,YJ[10!Q'@BV?3/%'C33YAAY-2&H1D_Q1S(,$>P*,/J#6'KEM-XJU2TD
MCTJ]M/$=J+)XI6A9!:$32><?,^ZR%,C )W<<9!QZ3-I\$U]#>X9+F$%!(AP6
M0\E#ZC@?3MBK6!G..: .,\4ZY<+JBZ8_AS6[_3E423O9VRNLS=1'EF'R]V]>
MG3(K5D\1SV^BV>HSZ#JO^D2['MH81+- ISAG4'/0#(7.,]ZWJ* .;TJT:TOM
M>\0_8IHS?"-EM0H\UQ$A )7/#-G ![!<X.0,B[DF\0?\(KXPM=/NXGTZZF6X
MLI8_WR1NK0R_*.258 X') ..>*[IE#HRG(!&#@D'\QTID$$5K D,*!(T& HH
M X-_",_B&W\;W,Z/;'7T2WM5F4JRI%%M1V'49<L<'G&.]3165]X@UCPG+<V5
MQ:KHR//>>=&5'G^7Y:HA/WQDLVY<C '/-=U10!YM<Z'J-CH'BWPS;6DTDFL7
M<TEE,L9,0CN -^]NB["7R"<D 8R375#48] O]#\.K87DD$T)ACO%0&*,QIPK
M'/!(4_E^6_4+VT,ES'<.FZ2($(23A<\$@=,XXSUP2* /-9?#>H)X)U/P+%:S
M[KF_<07(C/E"UDF\TN7Z J"Z[>I(&!@YKH;G3Y-$\>C78[:>:QNM,%G*+>)I
M&CDC?<AVJ"<%689[%1GK77T4 >:KX-U&W\$V$I@W:M;:R-=DME8$EC*6:,'I
MN",1Z$BM_3-/EU#Q_>^)FAFAMDTZ/3[831F-Y/G,CMM8 @9*@9 S@]L$]737
M4LC*&*$C 88R/?GB@#@[591\3_%.NQ6\UQ#8:7#:>7",M-+@RE%]6P5'_ A7
M6:!K"Z]HL&HK:W%H9"ZO;W"[9(G1BC*P]0RFK%KIUM9V;6L"LJ.69V#$.S-R
MS%NNXD]:F@MXK6!(((UCB0855Z"@#S.WF>9/B-I4-C<W-S>7TD,*I"S1LSVT
M:@,^-J@<$EB.#WJ_>:3=:9XA^'L$=M=7,&D0RPW-Q%"S*F;?RE)('=OR[UU.
MB^'HM%O-3N8[RYG;4;C[3*LVS"OM"_+M4$#"@<YZ5L4 <5%'=^'OB%K>H3V=
MW<Z=J]O;M%+;0M+Y4L2E3&P4$C((()XZ\TFB^"\_"UO"^J*$:ZBF,B@@^2TC
MM( ,<90L.G&5KMJ* .6\$P:NFAC4/$4135I(UAE4 L0D0*CIUW-O?C_GIBO.
MM+TG7=.:;5ET;4'^R>*[G4S:>0P>:UE39O0'AF&2=O6O;J* /-AIVH>(-1\>
M)'IU[9PZQIL,%K/=1>6&812*<@G(Y<=O7.*U_!DYO76:7P>VB7<$'E74TMLD
M9>3(RL3+RR<$YX'W>O..RHH \<^RZW9_#@^$I="U.?4;#4(B)HH=T5Q$+M9/
M,5\X/R]1U'4X&2/85;*!BI4D9*GJ/;BG44 >5P:9J-YJ_P 3$&G7D:ZU;I'8
M22V[*LI$#(>2/E^8CKCK5O3)-2OO$7@JY_L+4X(+*PN+>X>XA">6Y2(<@GIE
M3@]^V<5Z310!QG@R&Y@\2>+7GL[J".[U 3V\DL+(LB>6BY!(]5/%<G_9VKQ?
M"S5- ;1=0^VQZDS+MAW+*#=B7*$=1LR<].W6O7Z* .*>TN+WXD7TZV]U':7&
M@I:+<M RJ)/,D8C)'4*X/Z=:I^ XI8X[#3[SP?\ V?J6F0^3<Z@]LBQR;5VY
MAD'+%^">, 9![9]!HH XSPE#<P^,?%\TUG=0PWEW%+;RRPLJR*L2H2"1ZBI?
MB/8WE]X7C^PVDMU+;W]K<M#",NR)*K-M'<X'2NNHH XJ%[B3XFC59-.OHK0Z
M)Y)=K=B!)YN_;\N>=O/Z=>*Q=%36=+^'_A:S;2]1"QW31ZC%!$1<1H?,*[>A
M +%,LIX!/(YKT^B@#SG3=(U*7X2^(=%_LRXMKR0:C'!!+@%_,DE9-IR<@A@,
M]/YUUOA6::;PQIPGLKFTDCMXXC%<J%?*J >,\<Y'/I6S10!PNK^&[Z7QX[6T
M6=&URS$>K'.,&%AM_P"^T8QGV!/:I/A_H>IZ1!/;ZJ"4TQGT_3G;DO;!]X?\
M08UQ_P!,A7;44 >+:CH6KZA8?$V&#2KW?JDD4MCO@9?/5/O8R.O'0X)[5V-Q
M-<ZAX^\-ZH-+U"&UBLKM93+;G,9<Q[ V,X)V-QVXSBNXHH X#0+>[MO /B&W
MFL+Q)YKJ_>*$V[;W$KNR8&.X8?3OBL7P?I^HV4O@)+K3+^$Z=I]W!=E[9\1.
MY3:"<<YVGD5ZS10!R?@"WN+;3-42YM;BW>35KN=%FB*%HWE9E89]0:ZRBB@
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M^7:4 Q^%>S>&_P#D5](_Z\H?_0!0!IT5R5YXY6WO=;L[?0M2NI]'5'N%C\L
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M0!V5%<;IOQ$M=271IQI&HP6.JS&WANYE0*LOS80@-NYV'D C/&>N.RH *0D
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M.D:IJ&B7<,K:3+:W]U/-&S-<;XV+'#'Y#M8*!T] *](I ZLS*K E3A@#T^M
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M<L:H?8/$5SXCTN]O=#N)KFRUN=I+HS1[/LS)*D7EC=D(%9-PP#D9PQZ>F44
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M5EJ+_$TZLVG31V#:.MKYS/'Q)YI?! 8GH<9QC- '5,JNC(ZAE88((R"*\?\
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MN:Y34?&EU:ZMK&FV>@7%W/IEM'<L3.B+(C;SD'G'W#@=2>PZUD>,[RSUG2_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M508^3)^8 #MFN"^-6GZS<^%4U;3KVV>RTN5+J>QE@#B;:W4DGD#/*XYY[@4
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MVCD4,C@JRD<$'J*P_"^ERZ#I0T*13):VFY;68\AX2255O1E!V^X (ZD#>HH
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M+;ZI"-J7MI,T,H'H2I^8>QS5[3]#M-/N&N0UQ<W3+L-Q=3-*X7KM&>%' R%
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MD'FJ<<<'@<8XQQQ6WHL^IW.E0RZQ90V5\V[S((9O-5>3C#8&<C!J_0!S.E^
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MMUD633V9K<1R%%&Y=I!4<$8]>E1W>@65[K=EJ\QG^V60=8"LK!5#8W#:.#G
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M]/TNUTP3?9U<R3/OFED<N\C8 !9B23@  =@.E1KH>FK-J4HM(]^I@"\./]<
MFP ^VWC\Z ,*&*'5]-UW6HIYA#>(R6TD$[I^[C7 =2I&"7#'(ZC;7 ^$%FU7
M3?ANMU?W[+>0:@+D+=R+YNW)&<'KR>1SSUKUU=(LDT5-(CC:.Q2$6ZQQR,A"
M 8 # @]/>LJP\#>']+;339VL\7]F>9]C'VN8B+?]\ %L8/H: .3LY-4M_AGX
MNM=*NI1/IU_>V]F\DQW1Q(^=H=CG(4L 2>.*V-%TZ27QT=0LH=1M=%334'D2
MF:!#<EB,^4Q 8[,9)!YQWS4^O>&(K/PGJMGHVEO>?VA<":[MGNF+3!G!E*%V
MP'*YQR!G%4O"V@1V^L07NFZ=X@TJ"/<)X]2OC(LP*D!1&9'Y#$-NXZ8&<F@#
MK=-TB#2Y[^:&6Y=KVX-Q()IBX5B ,*#]T<=!6A6?INBV.DSW\UG$R27]P;FX
M)D9MTA !(R>.@X%:% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8J%(&1@DGTZT =A17%Z?\3=%O=)UG4Y[>]L;32',5V]RL?$@."BA78DYP!P
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNG_MFUD0BV,622ZMT.[J$Y()!PN*JCPWKHN?BB_]CWFW64Q8'R_]=\SC\/O
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M*;%D8QD;1NXC&T[<#G/<Y->G44 <!?6MX/C/9:P+"[;38=(>UDN5A8J)#(6
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M0-MXW=SCIG'.,UHT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*MSJ6H:5/8S0ZI91+,;8.K>=&V=KQL2 1D$<XP1SZT ;M%<9I?Q#AU,:'/\
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M-P8@ EU '7/L"0 =117/6WC#3KWPWINLVJ2RIJ3+%:P8 =Y&S\AYP,;6R<X
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M&"T<64;[([PN-D_J4'4C/&>AQQD<T :E%<S\0->O?#7@C4]5T^ 2W$,1VEF
M$>>-YSUP2..]67\02I<6NGKI[MJMQ"\_V8RJ D:D NS#( )8 8R23[$@ W:*
MRO#^O6WB'3WNK=)(GAF>WN()0 \,J'#(V"1D>W4$5JT %%%% !1110 4444
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M&M?7?#6G>(Q:KJ'V@K;R%U6&X>(-D8(;:1N!'8UJHB1QK'&H5% "JHP !V%
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M?F:DHH \U\$6NO>'?AM!H-[X3N[B]C696B,]OY+[W=@"WF9VX89X]>#531O
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MB2-58XX#Y/&<KQG- &)/JUU)\4]:&K:?!+86&C*S12S!DBB9B9'P5Y) Y'H
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M/X:U,"6[A$T2>3<=Y(E9AP>,@X_04 9WC/0;7P-X@MOB#I-A!]G@(BU2T5%
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M(UU&@6.1=WF#/7 .=H.>O3C(!V%%4=8U!]+TR2[CM);N161$AB!RS,P4= <
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MGCO@?I0!J+(CG".K'V.:%DC9MJNI/H#7GWPAM+>WT77##!'&?[<NTRJ@':&
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M56.5&)4+G#=#D<9SR*[?0[:\L] TZUU&X^T7L-M''<39SYD@4!FSWR<U?HH
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M&VEO[7L, X)^TI_C7EWG3?#'Q;)X9TZ>WAT;7I1)92RG(TV9SM8,.ZD [ <
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M^-O.\*_VG>6L<%ZMZVGO )24$ZRF,X?&=O&[.,XSP30!UKNL:,[L%51DL3@
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M7DZK#<3LBW2C&T@!#A@,_-[#WSL1V.L:EXD6XU>UM(]+M0'M(8K@R$S?\])
M4 R!]T D Y/)QCI** . M/"^NZ#\0-0U+18+'_A']34/>6<MPRMY_.94 0@9
MXR,\\^V.ALO"NB^'FEO-!T#3[>^,9C!C00[P2#M+ ' R >AZ5O44 <QIF@W-
M]8:C)XHM+6>^OU>&6..4O$L'.V-"5! P<DXR6)/H!C^#])\:>%M!N-(EATZ^
MA@9AIC27KADCR=J2'R^0!CD?3IBN_HH XZ?P>-6\$7NFZU;Q7&IZ@GF74@DX
M,^/E9&Q\JK@;1C@#'/.:^DP_$+3_  :FG7$>D7.L1)Y4=ZUV^TKT#,/+R6 _
M/J:[FB@#A_%/@8:MX)CT[3XQ'JUO(+JUNY)B'CN<Y,C2!222<YXYSVP,7K?P
MRGB#3K1O&VAZ1=ZI;Q^694'FHWJ1N4%<]<5U517-U;V<#3W4\4$*\M)*X51]
M2: .3UFR\4KJMK'HVF:+)I%E&HMX;FZDC^<# 8JL9&%'"C/'7KC'06G]JG0P
M;^.U;4V1B\<#D1 DG #$9P!@9QVZ4V#Q'H5U*D5OK6G32.<*L=TC%C[ 'FM.
M@#F?"6EZKX>\!6.E2PVTFHV5MY2*LQ\J1@.,MMR ?H<51T&W\;V][&-2L]#2
M*:7S+VZAN9))7XZ*I0 #@*!G@>IZ]I39)$AB:25U2- 69F. !ZDT <UK%GKN
MNVNJZ'<6-E#IUVK0+>+<EF\IAACY>S[_ "<<XZ>G/211)#"D48PB*%4>@' J
M#3]1LM6LDO=/NHKJU<L$FA8,K8)4X(Z\@BIHKB&9I$CD5VB;;(H/*GK@CMQ@
MT <]JND:C<^.-#U:WB@:SL(+B.7=*0Y,H3&T;2.-GKWK"3P?KI\*W]JDEI;:
MJNLR:M8N)"\>XR^8JO\ *#C!*G'KFO0J* ,C16UQ[*2XUJ&UBNV^Y:VTA=$
M'=R!DD^V ,>Y/GNF^ ?$^EPQWL2Z>=3L];GU2"/[0QCEBF7:\1.P%6QG!P17
MK-% '*>&]*UJU\4Z_JVI6]G##J0MS''#<-(R&./:0<H >O7VZ=ZT_%5AJ&J>
M%]0LM+G6&]FCVQ.S%0>02I(Y (R,CIFMBB@#E/#.C:MI_B#5KZ\MM/MK6]BM
M_+@M9&;RC&I79]U1@#OQ]*7P-HFJ^'=+GTN_6T-O'=3R6\L,C,TJR2,X+ J
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M/VEMOE_:/.QG9G=VZ5Z,,E02,''(I:K:AJ%GI5A-?7]S';6L*[I)9&PJCW-
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M NG,2L:SRO!#YA<01,Y*1ACUV@@5O444 %%%% !1110 4444 %%%% !1110
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M 8]P*9W'DX!XXP =-K?B;7;#Q'I6B6>E6,MQJ-K-*KR73!$DC520?DSMRPY
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M0 0^0Y&"5Z=:S9O!VMR_!Y/" >P-_P#9%M3*97$2@8YSM)/3T% %^R\57O\
MPDNB:7=6EK#9:KIYN;:9"V3(JJ6B Z# .[/H.E66U[5&MEGBM[802WLD*W;D
M^7#"@?,LG(X+)M&#CY@<\XJGK'A+4-6\(Z/:)<0V6LZ7)!)!<Q,75&3"O@E0
M2"A;@CTJYK>@W[#0!HHM#;Z7."UI=.RQN@C**<@'+(2&&1U'4'!H ET;6O\
MA)? YU.2%(VFBF1T1MRY1F0D'N"5)'L:X;X=>(9=/^&?AW3K)8VO'LY[C,L<
MCJ LS  A!G+$]>V#UX%=EX=T/5]&\&SZ5.UE/=^9<&(H[(C+)(S@L2"0?FZ
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M;[%I)NO#TC-<-OD$<\8C$H"+U5MI.220#CKGCO+"[6_TZUO$4JMQ"DH4]0&
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M-+:V[S+'(Y56VJ3@D ^E &C17!6/C+7DU/PXVKZ;8QZ7KT:K!);R,9(9C'O
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M1PA);)QD<'MBR>/KN?PCI&M6.FP^==:C%I]S;S2D&%S+Y3 $#GG."<<8..U
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2VN8DF@D&UXW&58>A'<4 <%X4T:^UKPEX):_%K'8Z=!;WB>5(S/,ZP[8P05
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M6[6WEZ>'"R!AAG8M_$1T &!D]<\=+10!Q_A+0_%&C06FF:IJ5A/IFGKY=M)
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MBJTL[;[3,MNTD,A;:/,D5#MQSU;(R:L#P;=:8OAB+1+R!(=&BD@9+J,N'#J
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M0O)$8SYJO''L !SC!X.<9[>]+XKT'4M3FTW4]#O8+75=-D=HC<H6BE1QM='
MYP< Y'<4 58_%>H0>$;6^U'33;ZM<7:V,=NZM&CRM)L1_F^8(1\_/(&1R:EL
MM8UE?&L_AZ]DL94&FB]CGA@=#N,FS:5+MD#!/7G(Z8Y36_#&HZYX5CM)M31-
M9AN([V*[2,^6DZ-N4!"2=@^[C.<<\FLK1UU1?BLW]L2VCWA\/H6%HC+&O^D-
MP-Q)/U- "VWC759O"V@:LT-F);[6!IUP@1L;3<-%N3YN#A<\YZU<\3^*=3T&
M\E?R[-+2.:VCCBD!:6Z6214D92&^0)N')4@D>XK,7P)K\>G6FE1ZGIZ6-AK
MU&U8PNTC+YS2[7Y X+$<=?48P;6O>#-;U.\UMK74K)+?4GM)E\Z%F>-H"AV
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M,JEYC* 0<'@G'TYK7\[Q)#X@T>&:XT^6VDCD^WQ0Q,&4X)5U))PH(5>>I)_
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M_0J .IL;WP_XWT47$*6VJ::TC*//@W(64X/RN.Q[XK8CC2&-8XT5(U&%51@
M>@%>1?#:_P!0LOA_8):26]O!+?7@EN9EWE&#G8BQ@@N6/IG@'CG(U/%/B+4]
M4^!XU^UF2RN;JUA><(A;AV56523\N=QYY./?F@#TNBN.UC7M9MKFXTJQ>*;4
M[6R6Z9TL)'25G9Q&FU6.P?NR"23U&.],\1>)M<T[2_#%U:V=M!/JE[;VMQ;7
M08M$TBDD9!XP00>#0!VE9NN:_I?AO37U#5[H6UJGWG*,WMT4$]2/SKD];U[Q
M5X=TBYGU"?23+;6<URDD4+D7+J25C$>_<H"#+-R!GK@'*?%F<77P:UB?;M\V
MWA?'IF1#0!U4NN:3::I86+R[+O50SVZK"W[W:H))8# P,=2*U:X:[\2:KIGC
M'P=H<2VC6&K03%R4;S5,4.[@YQ@DCMVJ2#6_$;^+['05GTRY>.$7&K/':.HM
ME(^5%/FG+L<X!' &: .S>-)-N]%;:0PW#."._P!:=7%)XIU>]U&VFTVS:XL&
MU)[*:(6C@I$KM&TWFYVG#+G&/NG'45VM !65=>)-)LM=L]%N+L)J-YN\B'8Q
MW[5+'D# P!W-8#>)]4MO%EAI]T+01WE_-:&V12SQ1K&[Q2%PQ 9@F=I .&]B
M30\8_P#)7/AW_O:A_P"B5H Z[2O$>DZU>W]GIUV)Y[!E6Y4(P\LMG R0 >AZ
M5JUYYX'_ .2F_$3_ *^;/_T4U>AT %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWVSPD&-P2?F^902,#ZUU'A^RUNV@>37]1M[R\8*@^S0F*-5&><$G+'.2>!T
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M]LG/-:NBZU9^(-,CU&P:5K=V95,L31ME20?E8 ]16A0 R$R&",S!5E*C>%Z
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MX-=Q10 BJ%4*H 4#  [5QK>$]:LO$FI7>C:U#:Z9JT@FO()("\D<FT*SPMD
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MOJHU(2_9&^8B8S;,>9_>.,YZ4 7-7U[4/^$BU+2+*:*T-EI0OTDECW><Y9@
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M_:4N(TV2!U#&1-N>5P 0>O..:N^)=!M_$WAV\T>YD>..Y0 21_>C8$,K#W#
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M4119B_E^62N3CF4 @'M5P^$;WRO"B#4H,Z#@D_9C^_Q$8O[_ ,ORDGOS3/\
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MN!MC:3<S,&4X<XQQ\O.<X$_Q2GEL/ MSJ]L=MWI<T-Y WHRR*"/H59E/LQH
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MJ%W1L6)C)4 '&>F>#C%CQSI[>(])7PS#R;Z:+[4P_P"6-NKAW8^F=NT#N3Z
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME743'/90O!%#Y(*%7^]NYR3]".E9$?PV:&[N;N'7KB.XFU3^U0ZP)\DVUE(
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MC#ARHVK(F?NN%.,\@X&1Q5W4-?@LM2CTN&":\U*2!KA;6 J&\M2 6)8@ 9(
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M'P0Q8'AMVYMP/7-=710!SM]X1MM5\)S:%J5Y<W+3X>2])"RF4$,)!@84@@8
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M .;\4ZO/9WNAZ3:RF";5KPP&< $QQJC.VW.1N.T*,C^+/:N8M;R7PSKOQ(U
MS27C65I;7$?G8R=L,C!20!D9XSUQ^==CXE\-6_B6SMXY+B>TNK2=;FUNH"-\
M,B]",@@C!((/!!JG8^#88+S6+F^U&ZU!M7@2"[CF6-4=54KP%48X8C@]^YYH
M ;H4?B&/7G>[EDETF:T#9N)(V<7 8<IL'W&4].Q QUKCEN)[7XD_$26VO8K*
M01::/M$HR$4J V!@Y8@D*,'+$<5V_ACPH?#B;'UC4-12./R;87;*?(BX^48
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M=)%EA(W(Z.'4C((X91P10!S>FRZUIGCV;P_>ZS/J-G?:<]Y!-)%&LMO(KJC
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MNH7"3W5FMF8PJ%$12S CC.<LW4]ZL^'=$C\.:!9Z/#/+/#:1B.-Y<;MHZ9P
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M8 &#GI5[1]/ETO2XK.:_N;^1"Q-Q<D&1\L3S@ <9P/8"@"]1110!POQ;W_\
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MTN;<JK"1 6.02,JQW$9_3(!$E[X>2\\1Z;K7VR:*33XI8HH552A$F-V<C/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/8 5=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLA!V*XW%!SG"X^[Z9H ]5HKSKQ(FNZ)\(M9%QK,G]I62R-'<VTQ,@3=E%9R
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M&<Y4'&<$C)&>:LZCHEOJ%W!>":>UO(4>)+BW8!_+;&Y#D$$$@'ID$ C%:=%
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M(N5*C:<<@G=D?0T 13>&+&7Q$VNI+=07KP"!_*F*HX4DJ67H2I)QGCV-4H?
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MR\TA=W8G)9F/)))))JW110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKEW64+;HZ_*3M&#W '4YSF@#TF*]MYKRXM(Y5:>W"F5!_!NR1GWP,_EZU/7
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MBF_SG7<%S@'  X]*X&;5I]*\5>//(E: WFL:99R7"'!ACD&UV![';D ]B0:
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M/U"WE)2-_*"FVE3/ +!F!Y!+#N* .NNKG5(]9L8+;3XYM/E#FZNFG"M"0/E
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB3?VA!&8HY!.X4(>2NT':02!VJY97]MJ,+RVDJRQI*\)9>FY&*L/P((_"K-
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M66CF=!*@.0D@4@.N>QS^5;]% &;>:#87^KV.JSK*;NQ#BW=9G4)N&&^4'!R
M.HJ&S\,Z;865_:6RW"17\KS7'^DR%F=_O$,3E<^V*T+V2ZBM)'LK>.XG RL<
MDIC#>V[:<?E6!X)\;67C?1GO+6(V]W"=EQ9R-EHF/(YQRI'(..?PH =;^ ]
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M![BMBB@#,T3P_IWAZ">'38I(XYYGGD#S.^78Y)^8G'X5IT44 %%%% !1110
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MD<KKY[^6[IC8Q3.TD;1@XZ@'L*9J/AC2-6U2#4KRU9[N&,Q!UE= T9.=CA2
MZYYPP(H X+1-1N9_ _@"SGN4*:EE)Y+K<ZRL(G94?D$Y(Z9Y*@<]*W&T75=.
M\$WVEV6I07]W%>AX(IBT:>7YBR?92Q9C@J2@)/1@.E:\G@?P[+X8C\./IRG2
MXB&CB,CY1AT97SN!]\U;7PWI4>AQZ/';O'91LKHJ3.K!E8.&W@[MVX9SG)-
M%'P3?VU_H<C6]G<6+QW4D<]E/RUM*#ED!Z%1D$8XP1TZ4GBD03ZAHME)NGEF
MFD9+$D"*XQ&<F4X.%7(;H>=O![;=CI]MIL#16R%0[F1V9BS.QZLS'))JMJWA
M_3-<DM)-0MC*]I(9('61D*$C!Y4C((X(/![B@#+^'<\]QX"TI[B5Y90C(7=B
MQ(5V4<GD\ "NGJAH^BZ?H%@+'3+86]L'9Q&&) +')ZD_EVJ_0 4444 %%%%
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M<#2[Y[(P73E&N70+OVL.$Y; R#G':LBTM8F^.VKVDF^6WFT%7>*61G7+2@'
M8G X' XKEM BL]/T?59DBM;<2>,IK)[B2+*QPEA\IP1\A.%(R!AB.AH ]PC9
MVB1I$V.5!9<YVGTSWIU<,VA?V-X4\5V@U%98Y(I;A+>VC:!;0F+.U,.2 2N[
M&1C/3!K%T*QAT[6?AW=VQE6?4=,D2[=I68S*+='4')Z CCTH ])M]2M;J_N[
M*"4//:;!.H_@+#(!]\<_B*FG,PMY3;JC3!#Y8<D*6QQDCH,UYIH^D:=_PD'Q
M&*VL<3I,FQXOD==UL&;#+@C)R3CKS2^$_#FGGX7V^LG[4=1N-#\N6?[5("5"
M[@,!L#! Z#^M 'H.DOJ4FE6[:O%;Q:@5_?);.6C!S_"3STQ5VO$_"5E'J5K\
M-H[J2>2.YT^_$Z>>X60+MQD _P"T<^N<'(K4L[Y])\!WMHEP(+&W\32:?YDI
M++#;?:MNT\@[<':>1P>M 'K%%<YX9T7^P;O5HQJ$$D,\B7"VD$!BBM<K@[06
M; 8KNQQ@Y]:Z)65T#HP96&00<@B@!:*\DG?^UOAWXH\03.8M>T^\NWBN <2V
MS0N?+C4]0NT*"O0[CG.36CX@L%UCQYX-AU(3JM]I]Y]KMUF=58B./Y< \<LW
M3&>] 'I1( ))P!U-9&G:M-K.ESZAIT41@=6^PF5B!/C(#G'1"1QU..>^*R_%
M]O\ V)\+-9MM+#HMII<L</SEF51&1U))) [U&MM"WPCBBC9TC31%*&*1D(Q!
MQ@J0: --IO$_]C:<ZV>F'4VE07T9F<1)'SN*'&2>F ??K5B:37?[9D2"WL#I
M@MMR2/(WFF?=]T@# 7'?DY['I7C]T&/PF^'-UYTPE;5+.-B)6 92SD@C.#R!
MU]*Z^V3R/VA+F-))3')X<,I1Y68!C<*"0">. .!Q0!VNCZO!K-DT\2M')'(T
M$\+_ 'H95.&0_0]^X((X-:%<+X0:1/B1X^MUS]E6XLY5'82- -_X\+7=4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6-KO
MA30_$K6[:OI\=R]L287+,K)GJ,J0<'N.AK9KE_$7B+4=)\1Z%I5G:VLPU9Y8
MU>:1E\LQIOYP#D$#% &O?:%IFHZ?!8W-FAM[=D:!4)C,++]TH5P5([$$4#0M
M.&F7.G>03;7.[SP97+2[A@EGSN8D #)/3CI3;"?6#?R0ZC:VJ0^6'CFMY&;+
M9P5(*C'8CUY]*TLCUH QQX6T<?V;BU<?V8,6?[^3]R,8^7YO3CZ<=*HZWX=M
M[?P[XC_LBQEDO]4M94=5F),TC(54G>V!V&?2NGR,XSS6==MK UBP%FMB=,._
M[89B_G X^3R\<=>N>U &;X4\/V^FZ-I<LUE+#?P6:0%9YC(83M 94^9E4$@?
M=XX'I5N3PMHTNL2ZM)9[[Z6(PR2M*YWQGJA&<%?]G&/:LV?Q#J.I>(M9T+0A
M:1W6E00R2R7D;.CR2AF5 %8$#"\MSUZ<5O:3-?3Z7;RZG;16U\R?OX8I/,5&
M[@-WH IZ!X6T3PO%-'HVGQVBS,&DVLS$XS@98D@#)P.@R:C'@_P]Y.I0_P!E
M0&+4F9KM&R1(6.2<$\9.#QCD ]:W,CUJG_:EI_;(TD2@WIMS<&,=50,%R?3)
M/'T/I0!%HNA:9X=T\6&DVBVUL&+;02Q)/<DDDG@#D]A27V@Z;J6HV=_=P,]U
M9DFWD$KKY1/!( ('(X/J.*TLC.,UG:0VL&&X_MH6*RBX<0_8RQ7RN-F[=_'Z
MXXH JZKX1T#6]4M=2U+3(;B\MAB*5L@XSG! .&&><'(JSJ&@Z;JD_G7D#._E
M&%MLSH'C)R48*0&4^AR*TLYZ4 @]#0!QOB71KG4_&_AB==/N)+"R6Y$UQ#,(
M_*+JH3!#A_X3G':NDCT;3HM+ETT6D;6<H<2Q2?.)-V2Q8G)8G)R3DFH?$FHW
M.C^&=3U.TBBEFM+62=4E8A6V*6P<<]JL:3>/J&C6-Y*%62>WCE=5Z LH)Q[<
MT 0Z;H&FZ3S9PN&\L1!Y)GE98QT16<DJOL.*J'P=H)L);$V3&UEN/M3Q_:),
M-+G=O/S==W/UYK=R,XSS1D9QGF@#,F\/Z9<7OVN6!WF/E[LS/M<H<H67.UB#
MR,@\U!K7A'0/$-Y:W>K:9#=7%K_JG8D$#KM."-R^QR*VJ3(]: %K%;PEH;ZC
M>7\EB)+F]C,-R[RNWG)C&U@3@KCMC%;1('4XJGJFJ6FC:?)>WTHCA0@9/5F)
MPJCU)) % %;0?#6C^&+1[71K%+6%VW, S,2?<L2<#L.U5U\&>'4TZ^T]=*@%
MI?L6N(LG#DG=QS\O/.!C!YK=HR/6@#GM0\#>&=5BL8[W289EL<^1EF!4'D@D
M'+ ]PV<]ZOZGH&F:PUHU];F0VD@EM\2N@C<=&&TCD=C6ED9QGFC(SC/-  !@
M8JLNGVB:E+J*VZ"\EB6%YL?,44DA?IEC5G(&,GK6=K+:PMG&=$6Q-SYR>9]M
M+A/+S\V-O.['3M0!-9Z99Z?IRZ?9P"WM4!"QQ$KMR23@CD<DUD)X%\-1Z6^F
MKIBBS><7!B\V3 E!SO'S9#>XP:Z*@D 9)Q0!D)X8T>.ZFN8[5HY9H!;2,DSK
MF(=$P&P ,G&/4U<TW3;32-/AL+"+R;6%=L<>XL$'H,D\>U6ZY_2-=N[[Q=K^
MD3PP)!IZ6SP/&Q+.)0Y.[/'\(X'YF@"]9:#ING:E=ZC:P,EW>$&XD,KMYI P
M,@DC@<#T%5M-\(Z!H^KW6JZ?ID-O>W1)EE3/))R<#.%R0,X S2^+-8N/#_A?
M4-8MH8IVLH6F,4C%0ZJ,D9&<&H++4O$-Q'IMS)86#6EUL:7RIW+Q*RY!P5P<
M' //?- %^WT#3;6^-Y%;L)C(\PW2NRJ[YWLJD[5)R<D =3ZFN7T7PQ]J\2>*
M;G5]+N([>^NTDAWW&(YXUC1<.B/AAE3PPZ'W-68_$VN7/C?4_#EM8Z>18P1W
M'GRSNN]7Z# 4X(P>]6=+\7O+XGD\-:SI_P#9VJ^5Y]OLF\V&ZC'4QOA3D=U(
M!^M &CKWA?1?$T,$6L6$=TMN^^(EF5D/?#*01GN.AJ74?#^DZMHO]CWUA#-I
M^U5$!&%4+]W;C[N.V.E4/&OBE/"'AJ?53;M<RJ=L5NG60X)/X!0S'V4ULV%]
M;ZGIUM?VD@DM[F)98G'=6&0?R- %.T\.Z18Z))HUO8Q+I\B,DD!RPD###;B>
M6)'<G-6-+TJRT:PCL=/@$%O&,*@)/YDDD]NOI5SH,FB@#(C\+Z)%=:A<KIL'
MFZB"+O<"1+D8;*GCD 9P.<<U)IGA_3='8-9P.K+&(D:29Y2D8YV*7)VKTX&!
MP/2M/(]:,CUH H:OHFG:[;1V^I6RSQQ2K-&"Q4HZ]&!!!!Y/YU5C\*:'#IE[
MIL.G1Q6=\[/<Q1EE$A;[P.#T/H..3Q6SD#K29''/6@#+C\.:5'>65VMN_GV,
M9BMG,\A\M#C*C+=#@=?0>E6M2TRTU>QDLKZ-I;:48>,2,H8>AVD9'M5NB@"-
M((TMQ!@O'MVD2,7)'N6R3^-95[X3T34-(MM)N;$/I]L%$5N)'5%V_=X!&<=L
M]*V,Y&1@URGA7Q/J&M>)?$VE7UM;0C2)XHHS S-O#J6R2?H.P[T :L7A?1HK
MN&Z:S\^X@.89+F1YVB/JI<G:?I4]SHEA=ZK;ZG-%(UY; B&03.NP'J  <<X&
M>.<<U!XHU^#POX9O];N8VDBM(M_EJ<%SD #/;)(&:K65QXF_M:U^UQ:9+I4\
M&^22'?'+;R8R%P2P<'ID;?IZ@%_6M"TWQ#8&QU6V^TVK$%H6=E5B#D9 (SR,
M\T_^QK Z.=):%GL3'Y1B>1F^3TR3G'XU>Z49S0!3L]*L[&.9(8F/GG,K2R-*
MTG 7YF8DG@ <FLFQ\"^&M.EM)+72HU>T<O;EG=_*)&.-Q.!Z#H,G&,UT60"!
MGK10!CS>%M&N+^>]DL_WMP5:=5E=8YBO0R1@[7(P.6!Z58N]$T^_U*SU&YA9
M[NSW?9Y!*Z^7N&&P <<C@^HXK0!R,BB@#$/A'1&M=0MFLW,.HN7NT,\A$S'@
MEOFYR !] *?J/A;1]6TZWT^_M&N+2W*F*)YI, CH?O<D=B:V*SM&;6#9/_;B
MV*W7FL%%D6*>7GY<[N=V.M #(_#FDQ:S_:ZV:_V@8Q$;AG9F90"!G)Y(!(R>
M<'&:I?\ ""^&#HMQH_\ 8\']GSOO>'+8W9)&TYRN"21@C&3CK70@YZ5S^J:[
M=V/C'0=(CA@:UU$7'F2%CO4QIN  Z=QSS0!>M] TFVT(Z)%8PC32C1M;L-RL
MIZYSR<Y.2>:I:;X+\/:3=VUW9Z<%N+:,Q0RR2O(T:'^$%F/'' [=JO!M8_X2
M%E*V/]C?9\J07^T>=N]/N[,?CFM'(/0]* *VH6%MJEE+9W:,]O*I61 [+N4C
M!!*D'!':LP>#]"73+?3ELF6UMG$ENJSR P,,X,;;LH>3]TCK6YD'//2J=MJE
MI=ZC>6$$HDGL]GGA>0A<$@'WP,X]Q0!"=!TUM)GTLVY-I<;O/3S&S+N^]O;.
MYB>^3S5G3["VTNQALK.,QVT*A(T+EMJCH 22<#TJOI#:P8;G^V5L5E%PX@^Q
MER/)XV[MW\?7..*T001D<B@#&NO"NCWFK'59K>;[>8_*^T)=2HP3.=H*L,+G
MG'3-.3PSI"6%[9"V8P7W_'T'FD9IN-N&8MN(P,8STK6R#WILID$3F$*9,':'
M. 3VR10!F1^&M)BN=/N%MG\W3HS':,9Y#Y2D8(&6Z$ #GL!Z5)9Z!IMA=?:;
M>W99,N5W2NZH7.Y]JL2%R>3@#-5/!NN3^(_"6GZM=1113W*,S1Q9VKAB.,\]
MJW: ,C_A&-)&M2ZR+>1=1EC\I[A;B0,4Z[>&Z>W2JT7@CPY#IU[IZZ:IL[YB
M]S \KLDK'&6(+?>X'S=>!S705SWB77;W1KW18;:W@E74KU;,F1B#&2K-NX'/
M"'CB@"U9>&-&T_09-$M+(0Z?(&62)7;+AN#EL[CD<<GIQTHC\+Z/%+ILB6KA
M],4I9GSY/W*D8('S=,<?3CI6O10!CR^%M%FU*[U%[%1>7D8CGE5V4NH&WL>N
M.,CG''2I;?P_IEIH?]C6]NT>G["@A69\!3U4'.0/8'%:><T9!S@]* ,*S\&Z
M#I[V+VEDT1L ZVNV>3$(?[P4;L 'N.]2Q^%M%BTR]TT6*O9WSM)<PR.SK(S<
MLQW$\D\Y]>:U9G,4,DBQM(RJ6"+U; Z#/>N8TKQ!K9\6MH6MZ7:0>=:->6TU
MG.TJA5=59'W*OS#<.1P: -&R\+Z/I/A^XT;3M.CCLID=7@,C?O-R[3N<Y;D<
M9YP/I4WA_1XM T*UTR# B@!"J"2%!8MM&><#.!GL!6+?^+YXCKES8VD<]AH1
M O&+'?(P4/(L?;*(0>>IXXZUU-O<17=M%<P.'AE02(XZ,I&0?RH S)/"^C2Z
MA->M9_OIW6295D<1RNN-K/&#M8C Y()X'I4MUH.FWNK6NJW$#/>V@(@E$KCR
MP?O  ''/?U[U=N9OLUK-.4>3RT9]B#+-@9P!W-<E9^*->MO%5AH_B'1K6UBU
M19#936ER9=K(NXQR94<[<G(XX[T ==/!%<V\D$R"2*5"CHW1E(P0?PK#TG0?
MLOAX^'+Y6GL((_(AD$A4R0=%1L$'(7Y3V( /<@5-0\6W$<^N-I]I'<6VA(&O
M"S$/*VS>R1]LJF#SU)QQUJYJ6L:I<6-G)X8L[:]>[B\]9KJ5HX4C(!!) ));
M/ QV))&.0!K^!O#KZ;::<VGDV=G();>#[1+MB<9PRC=P1DX],U.WAS2[?53K
MD5E++JBQ>4)?M#[V3.=F6;&W/.#Q57PYXGN=>\-SWW]EM#J5M-):3V1D&%G1
MMI&_^[G!SCIZTSP_K^KW6OZEH>MZ?;6]W:117"2VDK2121R%@/O $,"A'O0!
M?\/Z)_9$-W-,RO?7]RUU=2+TWG "KGG:JA5'TSWK8HHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*UMOAWX4\16".FOI?P1PS+(VZ17N"C1$9QLVECCIP3ZUU?B7[)X)\<VGBUX
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M.^NZMX2:6RTO3X]+C:SBDB#;(W>4RR1%F&U@^"3[+Z4 >GNZQH7=@J@9+,<
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M1HL[X4>PKLJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX8T26[M[N338'N;<8AF9<O$/13U'X5K44 8R^$] 0W932;53>?\ 'SA,>?\
M[_\ >ZGKZTUO!WAQ[2"T;1K-K:W;?#"8P4B;U4= ?<5MT4 9;^'-'EOOMKZ=
M UQA SE>7V?=+?WB.Q.<=JFN-'TZZU&'4)[.*2\@4K%.1\Z ]0#VSWJ]10!3
MT[2;#28Y(]/M(K9)',CK$N S'JQ]SZU<HHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %,>&*1MSQ(Q]64&GT4 -1$C&$15'HHQ3J** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
:**** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>svb-firstamendmenttoloan003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 svb-firstamendmenttoloan003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+8H=\-N;D.,KU7"C<?3//-=5<W"CXR6T\8\Q/[ DC5E^ZTAF5E3=TR0,X]*
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M,B-3$RAF/8;B!DUS.LVE[J=_\2H=+C>6YF^P2VZ+E?M B53(J'N?E*G'<XH
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MSXXKF!XC+'G!9=P&<=QU'<5>U#4;32[0W-Y+Y<>Y4'!8LS'"JH'+$D@ #DT
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M%PC$A=QP"!C.1GC- '545P)M](LO$VDW+Z]XCMVO9@MMI\TD_E2RJK E@XR
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MN&.N*IZ.+2UM;SPEXC\.:G>ZBMU,85\N5[:]1Y6D1]P.Q1R,DXQC/7BO7Z*
M/-;34V\*>+O$FGZUI=]<6NK3K<V4UO:/<),#$J-"=H."-H&#QCT%6-3F;1_'
MWAO5;S3Y[>R;2YK0K:V[3""4M&RQD1@]@0,#'%>A44 >*7RW,OPY\8VK:9J
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M"N2LM,UJ/3O$^C6E[?:OHTNCNME-?1%9XYF5U$&Y@"XQSSTR!44:Z@EK\/\
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MLI'CO8EM"9+39]XR#.  .>">,^AK<N/$-E$UG%;B2\N+V(S6\%N 6>, $O\
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M/$!A1R6&"0=^%88[8.<8P>PC<R1JY1D+ ':W4>QH =16+KOBK3/#MQ8P7YN
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M:TOM;GT62"YL]2AA%P;:Y507B)QO4J2I&>.N0>M;5 !16)_PDUJ;@K';74L
MN_L37,:*8UFW;2I^;<,-P3C&>]<;I7B2'PUKWC=[M=4O(+:]C<B)7N#!%Y*L
MS$L?E49)QGUP.* /3:*Q)_%%@DUC!:I-?7%];FZMX;8+N:$ 9?+%0!\R]3DY
MKE?&VM6VN?#[3];TJZN5AEU"UV,KO$2#.J.KJ",]P0<]* /1:*XJY,D?QGL$
M6>?RI=%G=HC*Q3<)8P"%)P#CT%=K0 45YQ<ZR-!^*VL%X]4O4?28)4M+99+A
MMQD?<53.%& /0?B:ZFP\8:1JFB6FJV,LD\=W(88853$K2C.8]IQAAM8G.  "
M<XYH WJ*R-&\1V6MW%]:1)-!>V$BQW5K<*%DB+#*DX)!!'(()!K7H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N,UN&X?X
MH>&+I+2Z>VMK:[2:=('9$:0)L!8#'.T_3O79T4 >806UY_87Q(B.G7XDU">Y
M:T4VD@,P>!47;\O.6!'Z]*72[74-%\0>&=>FL+V2P;P_'I5TB6[M):RJ0X9H
MP-V"05R >@/2O3J* /(O$OA_4+GPWX^U"VL+QGUV:W6SM%@8R,L012Y3&5W$
M,?FP< 9ZUT/CNWNYG\/^(+31Y=6M=/F=KK3_ "<RO%(FTLL;#EE.#CK7>44
M<YX5^QW'VJ_L?#9T:*?8,S6JV\\Y7/+*.=HR ,\_>XQC.[=0FYLYX Y0R1L@
M8=5R,9J:B@#SGP/J>KV&B:?X4O\ PU?IJ.G[;=KEX?\ 1#&IP)5DS@_+V'.?
M3D@T-+WPW%XIT;4--OKEKJ^N+RRE@MWE2Y289"E@"%8'@[B!WZ<UZ-10!Y=!
MX?O]!B^'&GR6]S<MI<CM>2P0O(D6Z)EY('3<V/H,U;<:O:^)OB!>6&E3S37%
ME;BQ$]NPBN'CB<,H)&#R0,9Y[5Z-10!Y;IB7LOC;PKJG]D:ZR&QG@NI[N$J4
ME;R^JD@1J,-P H/\.:98V-^/AUKGA-]*O?[5NY[R*-9+=Q#B:1BLGFXV;0&W
M=<\8QG KU6B@#SS2=/N_!OCB]EN8+N[TO4=/M(8[J"!YC%);H4V,J L-P.X'
M&,\5B7?A_4;'P^DO]GWCR7WBU=8^S10-(T$'F@_,%!P=JAL>IQUKUZB@#C?$
MEYJ"^*=(B_L_4)='EMY?,FL(29?-)7:CL,-&A').5R0,G -<;:Z7JT/PUMK8
MZ'J*3:=XA6[D@\G+M$+HN2@!)?"D'(X/8FO9** .'O!<W7Q/\/:@NGWR6R:?
M<1R2-;MMC9RA4,0" 2%/?COBL'2[#4M.^&.K>![O3+R;4U2ZM;:18':&Y$K,
M4D\W&Q1\_.X@C'TKU:B@#SW2],N='^(>DH\%W-:V7AH6#W:V[F-I1(AQNQU(
M4G].M:'PY@N+;2=5CN;2YMG?5KN=%GA:,M&\A96&X#.17944 4M9DNXM#OY-
M/MTN+U;:1K>%_NR2!3M4^Q.!7FFGIJ-QXF\$:J^C:XS0PW$5])<0%!%(\2C
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M[03^G6NUHH \FL=-U"7X5WO@U]+O%U>>6XAVRVSB%1),S"3S<;"H5MW!)R,
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MY&%#!RH/WAE@1CM^-5+R&ZT?QOJ>H:AX/N=9T[64@EB:"WCGEM95C"-&X)P
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M1;XY!*GW&.?E92,<]>W;/6^!8+JT\"Z':7MI+:W-O910R12XW!E4 ]"?3ZT
M9^@^-)-0G\1RZE8RV%CI5V\1FE:,K&B1HS;L,3DDD\ C&!G-:,?BZS%_I]K=
MV=[8C4N+.6Y10DS8SM^5B58CD!@">G7BN+NO#6KZGI?Q \/"RN()-3O7N[6Z
M; AD4I'M7=G.24(/''>M348;WQE:>%[9]-O+&YL=1@OKXW$)18?*!RJL>'+,
M0!M)X))Q0!T_BQ-_A'5R'D1TLYG1XY&1E8(2""""#FN<^&>JWHL]0\-:Q<R3
MZIHTH7SI6)>>W<;HI"3UX.#]!72^* [^%=5BBAEFFFM)8HXXD+,S,A &![]^
ME<AK_AC4]3UK0M9T4R6K75LVF:KO4HXMF7=NP<$,I! /JR]J *6C:C>ZS\:?
M.GN[@Z7-HSW=E:B5EC"K.(TD*@X)8!G!/9QZ5UB^.],>2U807?V*ZOSIT-[L
M7RFG#%=N-V\ LI .W&1]#60EG/!\98+Z'3KI-+BT+^SUG6!O+63S@P4<=-HZ
M]/>N;O(/$.IV&E7&H>']5DU:Q\00W-R$ $*0K,2/(7< 1MVY;&>NXT =Q/X\
ML(M:OM)ATS5[J[LI(4F6WM"V!+G#]?NC')]^,\XDO?'&F6,1NG@NWTU;H6;W
M\:*8EDW;"/O;B WRDA2,_C5'P]#=1_$?Q5=S6-U#;WL5F()9(B$<QHP<9Z<%
MA]>V:RO"%QK_ (:L9/"4_AZ]GG@N)?LFH*JFUDB=RX=WR""-QRH!/''- "6N
MKC0?B-XVD^R:E?A8+*006X,K*-DA8C<P 'MD>PKOM)U2UUK2+34[)R]K=1++
M&Q&#M(SR.QKD=/AN;?Q[XRO9;&\%K=VUJEO(+=B)6C1PX7CU8?7M6A\-[2YT
M_P"'NC6-[;36UU;0>7+%*A4JP)_/ZB@# ^)-I8V=HM]_PD<^G^()KB-=.=[]
MHHT.\#'EYV; ,EB1SZ]!72^/3,G@#7)[>[GMIH+&:9);=RC;E0D<CD#([51\
M27*^)M&UKP\WA_47GD5[>$W-MMA=B,+*LF2H4'#9SNXX&>*L>)--G@^&%_HT
M"S7ET=+:SB$:%FE?RB@/'3)[GB@#8\/.TGAK2G=BS-9PDL3DD[!S6E7.6^HW
M&C> K2Z32KZ[N;:TA0V44>)F8!5( ;'3D_0'K6SI]_%J6DVNHPK((;F!)T5E
M^8*RA@"/7!H \]\8^'+S1]/@U_3=8U-_$GVR!5!NG,5RSR*IB\K.T)@D@ <!
M>2>36L]TWB#XF7VB3M)_9NE6$<C0JY423RDX9L$9"J.!ZDGKC%)O%-_-J[7M
MUX*\23&W9EL8UMXPB9X\PDN/F8<9Q\H) ZDG0-A<Z)X_N/$+VLTEGJ>GQPW(
MMD:9HIXS\O"C)4J2,XX*\XS0!2\,-=^*=#U+1;W4;I5TG5Y["::*4I-<0Q\H
M"XY!(902#D[3ZFI?"%C=:)XT\0:/;7MU<Z'!#!+&MU,TIMYGW%HU9N<;0K8)
MXW#UYK:9'JW@[PSJ%XFCW=YJVLZG/?/;6Z"0V_F-QN^8 [5 X!Y/&<<U<TDG
M7M-O=!;0]>TJWN87:YO[L1QRRNQ )!!;+'GL  , 8P  4=1U2^O_ (B>#[F*
MXDCTFXGND@A4X$ZK Q\UO4$_='H,_P 7'<:S8+JFBWEB[7*K/$R$VTOER?\
M 6[&O/=8\ :@/%?A=[?7O$-Q;0RS^=<--&3:CRB%VD1@#<?EZ'CTKT"VU*6X
MUF_L&TZZACM5C*7<B@13[@20ASD[<8- '/VGA.^@O/#5Q)JE\\^F0F*X8W1,
M<R;2-K*?OMDK\QQPN>N*["BB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q-/\ #-O8:U=:
MJU]J-Y/,[M&EW<&2.V#$%EB7HHX'KP,5MT44 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!%<6\5U \$REHW&&4,1D>G';V
M[U(JJB!54*JC  & !2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDEL)G.57H1TK*G^&^FW.G:E9RZCJ#?;M0_M(S!HUD@N,CYXV"?+]T#OQGUH
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MFK-<)Y<TU^X=GCP0$X &,$_7))JIX;\%P>&V18]5U*\MK<%;.VNY0R6RGLN
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M&.TG 'S;=N>.N:M:QJ TG1+_ %$H9!:6TDY0?Q;%+8_2GZ=8IIMA%:1R2RA
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MX\]A:M:1JWE[71MN=V$SGY5Z$=* -ZN!FM9)/CA%_IUVJ#06E$:N-H_TA 5
MQP#@9[GUKOJP[[PQ!>^)K77DO;RVNX+<VS"!E"S1%@VULJ3]X \$&@#SJQFU
M+2M!EUBTU2XB6+Q5+"UHJKY4L<EX4</D$DX;@Y&,#CN>HUNZU[5]7UK3=#G:
M"YTZ*'[.PF"*)7!?=("IW*>%Q['OTN'P!:'1)-*.J:CY,FH?VB7_ '6[S?,\
MW^YC&_G&*FU;P5;ZGKL>KQ:GJ5A<F$6]U]CE""ZC!)"OQU&3R,$ GF@#H[=I
M'MHFF""4H"X0Y7..<'TJ2FHBQHJ(H55&  , "G4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445SG
MBO5);*?0]/BF: :IJ"VLDRG#*@1W(4]BVP+GJ-QQSB@#HZ*X;Q!>:EX*\(Z]
M>#5#=D31_8O/&][1)66,;F8DN%8LP+>F.:FGFO- \>Z%IT-Y=7-AJ\-PDL=Q
M(9#'+$H<2*3R,@D$#Y>F * .SIKL4C9@C.0"0JXR?89XKR2XO]<@\.:WK9\0
M:@\^E>(6MX8R5"/%]HCC*N HW#:Q] .PSG/8SWLFL^/;O06N;BWM+'3X[AA!
M*8WEDD9@#N'.%"].A+<YP* +VD>)?[;\)'7K/3KAF*S&.S++YCM&[)MSG;DE
M?7'-:-EJ'VBSLI+J!K*YND#?996!=3C)7C@XKSSP^]Y9_ 6YN+2_GM[NT@OY
MDGC"[BR2S'G((Y([8]L52T59]5\3> +N[O[UY[GP_)+*WVAAE@L1)_')SZ\>
ME 'ID6H74FO7&GMI=Q':Q0K(E\S+Y<C$\H!G.1]/Z9T:\C\0^+=8\-^+O&#+
MJ$]S!9:1%/:PS!=D4CNJYPH&0,YYYQWKI[J:]\/>,_#=K#?75W9:L)K>YCN)
M#)^\2/S%E7/W<X8$#"X/ &* .UHKR+4+[7(?#GBO5QXAU SZ/K3);)E C(#%
M\K@+\RX8C' []:Z3QAK$^DZY";][ZVT>:&-(K^U<[+6XWMGSE'\##8 2"!@]
M,YH [FBJ.M-*FAW[P3O!,MN[)*@!92%)!&01^8KS:PNM>T^P\">(7UZ]O1JS
MVUI>VDVTQ%98LAU &0P(R3DD\]!Q0!ZO17GEG;ZMK/Q \4:>_B34X+33Y+&6
M!(2BXW(69#\OW3@C'4\9)Q4OAF?Q!K3:%XC2ZB2RNT=[V&2[9PZL#L5(]FU&
M1L#@\@'))H [ZBN&BDU'Q2-?FM-8ETZZT[4S:VQ!)BB6+86WID!]^6^]T!&,
M8Y-:EUO7=9UK2]&NA;7&GV\)MI/M31!)7#,'90C>8O &#QP>,G- '<UCZ!X@
MCU\:ELM)K9K"^>R=9BI)954D_*2,?-ZUDZCJ=U<^*- \/23^2+JTEO+M[60K
MYFP* B.,$*6<MD8.%'J:YK2+VX\/>&_&#P7#O,/$OV9)YFY42FWCW%L'E0_4
M@].<T >IT5S.BZ=KEI=:O#>WP6RF5'LE6Z-Q-;G!#_-(G(R 1G..>U<;H&HZ
MTND^ M:N-;O;F74[G[+=02,/*=&CD;.W'W@4!SGU[<4 >J">(W#6XD4S*@<I
MGD*20#],@_E4E<#HMD#\8/$\AN;L[+2S<*9V*_-YO&.FT=AT'-2^-M7GTC4H
M9+U[ZVT:2WV"_M&.VSN"W#3*.2A&!DY P?7- '<U'-/%;QAYI%1"RH"QP-S$
M*!^)('XUR?B"XU'4_$<N@V$QA*:;]J5TNV@;>SLBME5)8+MZ=#NY!XK&\;6U
M_+X:\(+JEX3?KK%C%=/9RLL<CEP&88QW&1QP: /2:Y2?QJ6MI[W2]%O=5L;:
MZ:TFDM,-)N4X8I'U=0>,\=#@$<UT;V8>Q^R>=.!M"^8)")..^[KFO&/!EU-I
M7A/3$M[RZC?5/$<NGN_FDJB%V9B > Y";<]?FSUH ]O[4=!DUQNGW%]9>/\
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MCM)>JRB. J. P)R<].!_7'#^,+&Z,7@2*_U2:XNUU>&WGGMW,2RMY<FYMH.
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MWN4'SA&QNVGG!YJ[IUEKMC;:]'>7X6W91+8;+DW$UN-AW M(G(W#*YSU([4
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MX_>S32[IG?((<O\ W@0".PP !@8I=+\-1Z9I-Q9?VGJ5W+<+LDO+N8238Q@
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M]DV-;QRM$8C#MV;BH#!B<Y(YQQ776N@Z?9Z[?ZS!#MOK](TG?^\$!"_H>?7
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M"A=8P20H"J%'))Z<GKG J+1?#%CH>F7.G027$UK<222.D[AN7)+X( ZDG^E
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M_%%1JG@'1M2G6>*>:ZLBT:SNJKO8$C:#C(SUQD>M '<6&J:Q)KDNGZAH?V>
M0^;%?07(FB<Y *'*JRMSGH1CO6I=74%E!YUS*L<>Y4W-ZLP51^)('XTEI:1V
M5N((FF9 2<S3/*W_ 'TY)_6N*^*EI%<Z-HS2&4%=:LU&R5D^]* ?ND<^AZCM
MB@#H8O$#/XTG\.M9,GEV*WHN#("'!<I@+VY!ZG\*VZ\\O-%BO_BE+IYN[Z&
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M#\%)_"IJ\KU'=K^H?##4=0\]+J]1GF$4\D6";4N<!2-ISW'...E>IJ JA1G
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#7&U'5)KG0]4OWLHFO)&3"1 JC GYQTX.>G'4YZ;PSIMY'JEGJRZI&]E>Z>
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MT*XM[OP_IUQ:7#W%O+:QM%,^=TBE1AC[GO3;O0[2Z-J5:>V:U1HH3;2F/:C
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MH)I+JR;?;.MS*GE-QD@*P&>/2MBB@#G(_ ?AN.Z6Y6P8RI=&\0M<2$+*00S
M%L#=DY'1NX-6=2\*:/JVJIJ5Y;.UTL/D%DF=!)'DG:ZJ0' )) 8&MJB@#"D\
M':%+X93PX]FYTE5""W%Q( 5!R 2&R1P.II5\(Z(E_8WPM9#<V,(@@D:XD)$8
M.0K9;YP" 0&S@\U;TZ35WNK\:E;VD5NLV+-H)&9GCQU<$#!^G_USHT 4=7TB
MQUW2YM-U&'SK68#>FXJ<@@@@C!!! ((]*I6'A+1M,O9;VUMY5NYH!!).US(S
MNHSC+%LEN3\W7WK;K!\::[<^&?"=]K%I;17,ELH8QRR%1@D#/ .>O3CZT -B
M\%:##I^GV$=K,MMI\_VBUC%W-^ZDY^8?-GN>OJ?6G:EX-T/5=3DU&YMI!=2P
M^1,\-Q)$)H_[L@5@''^]FMUL[3M +8X!.!6'X2UVX\0Z1-=W5O%;RQ7D]L8X
MG+J/+D*9R0,]/04 1WG@CP]?Z#::+/8$V-F5-LJS.KPE1@%7!W#CCK5F\\+:
M-?\ A]=!N+0G3% 7R%E= 0#D9*D$\\\GD\FMBB@!D,2P0I$A<J@P"[EC^)))
M/XUE3>%M'GUB?5GMG%]/$(998YY$WJ 0,A6 R 2 V,C/!K-U7Q3J-CXTT_P[
M;:5:SF^@DGCGDO6C"A.H*B-N>1WJ;3O%3R^*Y?#6J6 LM1%M]KA,<WG13Q;M
MI*MM4@@]00/QH FB\&Z'!;Z9!%:S+%I;[[)1=2XA."./FYX)'.>"11/X-T"X
M\2+X@DL =2&TF02,%<K]UF0':Q'8D$C ]!6]10 CJ'1D)(##!VD@_@1TJAI&
MBV.AV\EO8)*D4DC2LLD\DN68DL<NQY)))]2:S=8\0W6F>+O#VD):PO;:J\RO
M,9#O0QQE\!<8YP.<^O%=%0!R6O\ @ZSD.IZWIMAYWB":T>%&ENY520$<(PW;
M=OL1BL+P[X7MX;ZRETS0O$&B2VSH97O-1+PE!]Y @E</N''W0!G.00!7I5%
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M[RV",@'GN :R=(BU36]9@UC6]$32VL(Y8K6%ITG=F<@,^Y1@#:H '?<V>@H
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M\R$_W0> O0;1CI7I>@>%=$\+PS1:-8):I,P+X9F)QG RQ) &3@=!DU2/P_\
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M'VL^([66YBUK3]8NY+*5)G&UOM1 0)G:0V<$8YS]*]KBBC@A2*)0D: *JCH
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M8E<K(Y.2Q4G&??% &G1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>Q'3K7'Q^#_%NG_"C7O J^'Y[BZ:^66"ZCEC$,L?F1G();.?E/!' /)&,5]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0M),N-;LUQ',R AI0#G!&3Z>G44 =%%X@63Q?/X>-I*DD5FMX)V9=KJSE
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M7))KW42=;$:WV)$'F!/N ?)\N!QQBM=/#T"^(HM<:[NI+R.U-I\Q3:T9(8Y
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M ;BV >*T]2U2+3OL\94R7-U)Y5O I^:1L$GZ  $D]@/H*NKDJ-P ;'(!R,T
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M&/8S;R0,=%..1WSST&.GTSPAINEFU2%[F2VLG:2SMII-T=LQ!&4XSP&(&XG
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M;P7<DZI!.EPGE/M/F(<J3QV(SBH[?PY90:QJ&IEYI9]0B2&Y65@4=%!"C;C
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MQVC)_+%7-<\+6/B"ZT^XO);E7T^87%L(I-H20=&Z<GV/'M0!R^C?\EU\3?\
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MZ?96<R36HL6#6<ME(89+<@8^1EZ#'&* )O#%KJ-CX?M[35;Y+Z\A+H\ZL6W
M,=H)(!+!< GN1FN1U"=_$L/CM;BZNHETM'M;:*&=HPF( Y<A2 Q9F(^;(PN.
MYSWNGV,&F6,5G;!A%$, NY=F.<DLQY)))))Y)-8FH^"-*U'5;S43)>VTU]!Y
M%XMK<&-;A0,#>!U(!P#Z<'(H YVPN[F;2O!&AQ?ZJ[T3SV7[6]L7:..$!0Z
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M7&9D!Z'G@GZ=J .[HKB(PFI^/-0\.7,ERMC8:;#)!$+F0-(TC/ND+;MQ(VJ
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MT<;>Y.#CTJRUQ=67A_P3XBL[VYFO-0N;2*]W3,RW*3K\^5)P"I.1@#;C XH
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M2-Q^Z!U^M6/ .G6]OXJ\9R1^=NCU7: T[L.8D)R"<$Y/4\T >@4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5GZWHMCXATJ73=1B:2VE*DA7*,"K!E(8<@@@&M"B@#$F\*:;+<
M6ETANH+NUB:%+F*X82M&QRRNQ)+@GGYLG/(YK3L;&VTRRBL[.(16\0PB DX^
MI/))/))Y)JQ10!S>H^!="U6\O;JYAN=]ZT3S".ZD12\>-CA58 ,-JC<.<"K]
MQX>L;G6++5'\X75E&T5N5E8*BMC<-O0YP.OH*OW=W!8V<UW=2K%;P(9))'.
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M86C2_9H$6.)9)"Y10,  GG&*Q[3P'H%C>6MS!!<![2XDN+=3=2%8B^=RJN[
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M5[=A=&+5V+7J_:'_ 'I(VGOQD #C'%2_\(KIOV[2KPFY,^E1M':,9V^16 #
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MY^4D<YX-4;I;CQ1K\%E>:#<6]CI-\+H75ULVSL@(C,6"3U;<20,!<=3QUU%
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MS]ECO+69!V$DD +_ ,A75VMA;:/:SFTMY)'D;S)#OWR3/@#)9CR< #DX  '
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M%VC&,4 >NTAS@XQGMFO.-2T&TUSXM7^FW\EX]E+H4<S0K=2*N_SV&1@\?='
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M4L<S1B3-H['(! !/Y\XK?^'D8M8O$>GQ,_V6RUN:&WC9RWEQ[(WVC/;+-^=
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *JZCIUKJUA+8WJ.]M,I21%D9-RD8()4@X(/2K5% '//X(\/R:7::
M:;*06MFXDME%U*#"0"!L8-N48)& <5:LO"^B:=:W]M:Z=%'!?EC=1\E9-PVD
M$$],<8'%:]% '/OX(\//I%KI?V K:VLHF@VSR*\;@8!$@;?TXZ]..E21>#]!
MM[+4+.#3UBM]0)-TD<CKYF1@@D'(!'&!Q6Y10!CS^%]&NO#@\/W%D)M+"",0
M22,VU1]T!B=PQ@8P>,<5:TG1[#0M.CL--MQ!;)DA=Q8DGJ2Q))/N35ZB@#+U
MCP]I>O&U.HVQD>UD,D#I*\;(2,'#*0<$<$=#57_A"_#PTJ]TQ=-1+*^E::YA
M21U$C$Y.<'IGL./:MZB@#,C\/Z;'JT.JK%*;V&#[.DK7$C$1]=N"V",@'GN,
MUFS_  _\,7$US))IF1<S"XEB$\BQM*"#OV!MH;(&2!D]^IKI:* ,+5O!OA[7
M;ZTO=2TR*>XM5V1/N9?ESG:P! 9?]ELC\ZM:EX?TW5KRSN[V&22>S;?;LL\B
M>6WJ K 9QQ]*TZ* "L:V\*Z-9W?VBWM"A\XW B\US$LIZNL9.Q6Y/('<^M;-
M% &8OA_35UYM<$,G]HM%Y)F\^3F/.=NW=MQGG&.O-7YH5N(7B<N%<8.QRA_
M@@C\*DHH YVR\"^'-.6R6SL7A2QD:6U5;J7$3MPQ W8YR<_4^M:6FZ)I^D37
M<ME"\;WDIFG+3.^]\8W?,3S@ <>@K0HH Q]>\+:-XGCMTU>R%P;=]\+AVC>,
MGKAE((SW&>:ENO#VDWFCQ:3-91_88MOE1)E/+*_=*E2"I'8@@UIT4 9T.A:?
M!9W5JD4A2Z_U[M,[22\8^:0G<> !UX'%58O"6BPKIBQVLBKI?_'D!<RXAXQQ
M\WIQSVXZ5MT4 8DOA+19AJ8DM9&&J<7H^TRXFXQS\WIQQVXZ4W5?!N@:WI]G
M8ZC8>?#9$&V)F</'QCAPV[ICOS@5NT4 9>H^'=(U;0_[%O;"&73@JHL&-H0+
M]W;C!7&."*+/PYI%AHDNC6]D@L)59)8F)?S PPVYB26)'&2<UJ44 <]/X'\.
MW.B0Z--8,^GPL&6$W$N,CH2=V6Q@8R3C Q4]QX3T:ZNGN9;:0RRQ"&8BXD'G
MH.BR@-B0<D?-G@XZ5M44 9UYH6G7][8WEQ QGL26MF25T$1(P<!2!R./IQ2Z
M9HFGZ/)=R6,+QM=RF><M,[[Y" "WS$\X ''H/2M"B@"MJ&GVFJZ?/87T"SVM
MPA26-NC*:;)IEE+J%M?O;H;JUC>."3',:OMW ?7:/RJW10!DZEX9TG5M2M-1
MO;>22[LR3;2"XD3RB>I4*P S@9]:JS>!_#D\>HQOIHV:C(9+M5FD42,2"3@-
MQD@$XQD@9SBN@HH S(_#^G1:O'JRQ2F^C@^SK,UQ(Q\O.=I!;!&0#SW&>M2:
MOHNGZ]:):ZE;^=$DJS)AV1D=>C*RD$$>QJ_10!C0^$]#M].O[""P6*UU!F:Z
MCC=E\S<,$9!R ?08')]32Q^%](BN=-N$MY?-TV,QVC&YD/E*1@@ MR" !SG@
M =JV** .6MHM3U_Q!!<:MH:Z?:Z3/*]LTDZ2M<.045UV_=7:6.#SDCTKJ:**
M .=/@;0#J=QJ0MKE+ZY $UQ'?3J\@ P 2'Y P*D'@OP_]GO8'L#,MZ$%PT\\
MDKOL)*?,S%A@DD8(P:WJ* ,ZWT+3K:WNH%@,JW:[+AKB1IGE7&,,SDDC!(QG
MN?6JFE^#M T:ZANK#3UBN(8/L\<AD=V$>>F6)SCH">0.!QQ6Y10!@/X+T&33
M[NP>SE:UO+C[3<1FZEQ)+G.X_-UR ?J!Z5NK&%B$8+;0-N2Q)_/KGWIU% '/
MP^"M"M[BZG@ANXI;MS)<-'?W"^:WJV'Y_&M33])T_2K+[%864%M;9),42!02
M>I/J3W)ZU<HH Q]-\+Z/I$D3V5JT?D[O(1IG=(-W7RU8E4S_ +('''2H;GP9
MX>O/$"Z[/ID;:B-I,NY@'*_=+*#M8CC!()&!Z"MZB@#)U'PUI&K:G;:C>VGF
M75NAC1Q(RY0G)5@" ZY&<-D577P7X?31;71TL"EA:R":&%)Y%VN#D-D-DD'G
MDUO44 90\.Z8NJS:F(IA>S0B"287,H)C'1?O<8R2/<YJLW@SP^_AK_A'7TY7
MTD'*V[R.P0YSE6)RO//!%;U% &./"^C+X=;0%L\:8RE6@$CC>"<G<V=QSWR>
M>]/C\.:7'J-IJ"PR_:K2$P02-<2'8AQE<%L$' Z^@]*U:* ,.7P=H$TFJ.^G
M+NU1&2\Q(X$@88;@'"D@#)&"<5L6\$5K;16\*[(HD"(N<X4# %244 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !11D#'O10 44@((R""/:EH **** "BBB@ HHHH ***,C.
M.] !1110 4444 %%%% !110"",B@ HHH) ZG% !11D9QGGTH) ZT %%%% !1
M110 4444 %%%% !1110 4444 %%&1G'>B@ HH!!&0<@T4 %%%% !1110 444
M4 %%%% !12$@#)( ]Z6@ HHHH **** "BD) &20![TM !10"#THH **** "B
MBC(.?:@ HHHH **** "BBB@ HHHH **** "BDW#=MR,]<4M !11D'I10 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7BWQML=.L-.CU.77[ZWU^2X06(%PZQQIN /RK]T!<DMU)'X5[37GNNS:KXOT
M'7O#FI>#[F&=_,BLYFD1X'Z^7+OR-I!PQ&"?3)XH [?2G:31[*1KI+MFMXR;
MB/[LIVCYQ['K^->._%KPK>Z;#:^)=.UW59/$,VH1PV\:RX0[R=L<:#[N,#N<
MX.<YKM;:+Q'X4_X1+P[I.EQZAI<<*P:A?.^TQ;0!N SQW/?/3BN;US5/'TGC
M-]2M/ AO;6S#1Z=]HND4)GAI=H;[S=/9>.,G(!ZQ;^:+:+SRIFV#S"O3=CG'
MXU)5;3C='3+0WVW[884\_:,#S,#=CVSFK- !1110!6U&R74=,NK%I'C6XA:)
MGC.&4,""0>QYKSC5=!TZW^*_AO3(H'6RGL;EY8?.<J[*!M)YY(KU"N&UBQU&
M7XKZ!JD6FW,FGV=I<0S7"A=JLX&WC.3T[#O0!GZUI=MX;\8^#FLX;J=1=WIC
MA5B[_-;N=@W'IN)P20 #U %=7I/B6+6]%O+Q-/NTEM9I+:XLF"&59$X9>&VG
M@@Y!Q@U2\16E[/XT\)W=O9336UE-</<2IC$8>%D7.3D\GMFHO"=O>Z='XGDN
MM/N8_M&K374"D*3+&RH%(P?53P<4 4/"/BC08O".G?\ "-:-=I:3175S!9!E
M\P1Q2;7/S/R2S# SW[5WL;B2-7 (# '!KQC0O">HQ?#W2='U+1-3M-7T]+J6
MTOK1E\RVG:0L@#*W*N#SGCY><<&O8;$7*Z?;"]96NQ$HF9.A? W$>V<T 5];
MU,:/H]Q>^699$ 6*(=99&(5$'NS%1^-<9\/;[4],UW6_!^OW?VF_MY/M]O.>
M/.AE.6P/17)'XX[5M:Q:SZWXGL;"YL+P:1:JUPUPC[%DN.B#*L& 4%SGIG;Z
M5S_BWPW>:5XC\/>(O#.G7U[?6DYBNXS<E_,M6!W#,K]0>0/4YH VKWQ]%:RZ
MW'%H>J7+Z,5-V(UC&$*;]X)< C;SC[Q]*L6GC:UN]8TNS_L^^BM]5C9[&\E5
M1'.53>1C=N7Y>1N SCBL,6.IR77C^;^R;M5U6",688+F4BW$9'WN/F]<>M)%
MINJ*?AWG2[G_ (E496]^[^Y/V8Q<\\_,>V>.: .AO_&5EI]ZD<L$S6IO%L7N
MU*[(YFP ",[L9(4D# )]CA-1\7"RU^;1(-'U&]ODM!=HL 0+(F[;PS, .0>N
M.G&<BL+3K'5-+\3:EITGAF.[AN[][RVU8B,I%'(=S!\_-N4[L =>.@YK4>VO
M8_BA)J?V"X:Q&C"V$Z@$&02E]H&<].^,9H NP^+].N?#.G:Y LSQ:B42U@"@
M2R2/P$P3@$8.>< *3G KG_#5RZ?$/QK.^GW$,J6]DS0;E9G.V4Y4YP0?J/PK
M)M- U^R\!>$9H]+F;4=!OO/N-/+*'EC.]6V'.TMM?(Y]>]=!H8U(^,_$>KSZ
M+?6]G>6EJ(#+Y>YFC$F5*AB0?F']<4 %O\2K*>ST>_\ ['U1-/U5Q%!<F-"!
M*<[4*ABV3M(R 1GO6MI'BNWU&?5K:ZL[G3+G2PKW,5T4.(V4LK@HS @@'OQ@
MUQ=GHNLP> ?!.G/I%U]KTW4X)KN(;"8T1F+-G=@_>'3)K8;0[[4?$WC:-[6:
MWM=6TZ&UM[IP-I98Y%;@'(P7'4<T ;FG>++:_P!:72WM;BVGEM?MEOYI4B6+
M(!^Z3AAD94X/(]\99^(]HL4UPVCZHMI;:A_9]U<,D86W?>$R?GR1N8?=S@=<
M<4[P6^I/'%%J/A9-(N+2'RKBXQ&1/(,#]T5Y*G!))QV'/)'.WFC:S-X(\3V*
M:1=FZO==:[MXODR\1GC<-G=@?*AX/- '4:IXFU"T\?Z7H,&FRRVT]K+.\B/'
ME]I4<!F& -V3W/85T>HWT&EZ9=:A=,5M[6%YI2!DA5!)_05RVM6FI+\0= UJ
MUTV>ZM5L[BVEV,BF%G*%2VXCY?E.<9/'2NEU<.VBWPCLUO7-O(!:MC$QVGY#
MGCGISZT 4I+S^U=+U*WN;&:WV0G(=U(D5E)!4J3D=OJ#]:Y3X?\ BB.W\.>$
M-'N-/O(UO;%4M[QPOE22)'N9<;MPX!P2 #CC-7O#.CW.BZ?KEM:QZ@='9%.G
M6=T=TL+%#O1<G.S.T#)]>W)R=,TC5[?2_AW!+I5RLFDMB]'R_NOW#QYZ\\L.
MF>* .KD\7VL>JK:&TN?):_\ [-^TX7:)]F_&,[MO;=CK[<US7Q"@C7QUX"G
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MJLI4]#\PXR.F>.1<\1:9K]SX0\*R3VSW^J:=?V5W?1PLH9R@_>;<D G)]0*
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MTN8DOHII;2:0+ME6)@K\ Y7[P(R.1Z'BJ&H_$&WL)=:0:+JD_P#8Q4WK1K&
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M.$42,HP"V.2/QJ6D5E=0RD,I&00<@BEH **** "BBB@ HHHH **** "BBB@
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M0,<DKU(';'O740^+&74M*MM1TY[./5U)LI3*'RP7=Y<@P-CE>0 6'!&:P&\
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M*D#:.01@YSCMC/;(\=:%XAUN76[6#3$O[6XTU8]/=[A$2WFR^_*GG>V5PV.
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M< $%#G.!GID<G*T[PQKT?PBT[1EMDMM<TUHIH8Y9%:.22*42 94GAL8YQUH
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MD$L:\2(%&T,P)QSGI^- &98ZEH>@^-M?^R^$'M-8CTS[?=RQ21DS+D95/FP
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MQ[;PMI%IXAN==BMF_M&Y^_*\K,!P!\JDX4D #( K8HH **** "BBB@ HHHH
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M+]X=Y.3EF/XF@#V*BO$OASJ-[I7C2T\,>*+">WUI$F>"^CD9H]00@L6?G#$
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M<8Z5GS_#[PY<:):Z3):3&WM'$EN_VJ7S8F P-LF[<!@ 8SC 'H*Z>B@#&O\
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MUN6_U.\B:+Q!%,8+ZUDZVA7A54=-I7D/_%GKV&F?!6@-H<&BFSD_LZWD$L4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;;Q2L-W/I\Y0#RT&^,LVS# D8PQP<9_&MC1]5DU:.Y:33+ZP\F8Q*MV@4R#
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MP=V!A<<G;GTJT\7Z;=>'9=9(FBCAF:VE@=094G5_+\K )!8M@#!P<B@#?HK
M@\3&>?5+/^RKR._T^))C;N4'FJX)4JX;;_"0<GC%1>!/$%WXF\*6>JWEH\$E
MPGF DH58%CC;@DX P/F - '245R>O>)[_3?&F@Z+;Z9-/#?+/(\B/'EPB?=
M9AC!8$DXZ8&>:GU#QI96$-[=FTNIM.L)_(O+R(*4A88W<9W,%R-Q ..>N#@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **1F"J68@ =2:6@ HHHH
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M **** "BBB@ HHHH **** "BBB@ K.U?51I:VBK;R7$]W<"WAC3@%BK-ECV
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MM)9,?O!$P5LKU4_,"/4>AXJI+XX?^WM1T>T\/:I=W.GR0+/Y?EXV2Y(<$OT
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M3&RE@ZLO7A6&.H(^E<1K7A;Q#J7B[Q9>6NF/''>6]HUC--)'LDEMW63:P#9
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M)+<O;[0L"&&++?,1N.23A<GUQQGM]:\20Z21''";JX,#7/E+*J?NU[Y8CD]
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MWAR<#W)XKE?%6F>(=2U#4T.BS7RQ7ME<:=,L\81(4>)I%568$2%@^20,COP
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M\V-0(R@<N.>?E.0!SZXXR =K14<$R7-O%/$<QR('4^H(R*DH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KD_B)IFHZQX86RTRR>ZN#=V\NU9$0!8Y5<Y+,.RFNLHH X[Q+;ZY;:_I
M7B'1]*_M'R[>2TN[!IDC?8Y1@RLQVY5DYYY!XJQKVFS:SX=M++5M$6_CGES=
MV\$BAK<88JR,2N65MHR,$\D#M74T4 >9^(K74]*^'.@6]^TMW?0:M9#$D@,C
M@7(**S="VW:"<XR"<UM3^';C7]?U;4[J"2QBN-'.DPK(59R'9F=SM)  RH S
MG@^U;^MZ'9:];P0WQF\N"9+A!'(4PZ'*DD>A&:L?VC8)9?:VOK?[,IV&<RKL
MSG;C=G&<\?6@#GO!\OB8V\%EKFC0V/V*(1/<I.L@NV  #(!RJD#)W8.<#UK.
M\+6GBGP^\GAPZ7')IL=W)+;ZM]H7:('D+E3'][>-Q'3'?/'/>T4 <5-INMV7
MQ!U;5+334N;6_P!-BB24S*JQR1ESM92<G.X8P,>I%/\ !OA^71=4U&6VLKC3
M-)N8HW73I95=8KC+>88PK$*I!7CN>P%=E4<L\4&SS94CWL$7>P&YCT ]2?2@
M#GO%5OJUQ=Z/]CL3?Z>L[_;K43+'O!0A"VX@,@;DKSGC@XQ6/I&A7\'PXAT/
M5O#\=V!.\<]DLR-OA:5FW*20 1D$#(/ Z'IWM% '/^#=+O-&T#[%=R3LD<\G
MV9;B022QP;CL1F!.2![GC [50N=-U+2?B!-KUI92W]C?V*6UQ'"Z"2*2-B4;
M#LH*D,1P<@^U=?10!QECX?OM)\!ZM9K:F?4=1:[N&@B=0%DF+$+N8@8&0"?8
MFKW@&QO])\$Z5I>I6;VMU9VZQ2*SHX)&>058\?XUT4LL<$3RRR+'&BEF=S@*
M!U)/8412QSQ)+#(LD;@,KH<A@>A!'44 <&='URUU;QNL>E&>VU=!);3I/&,G
MR!'LVD@@[AWP,9YSP4LM%UF*Z^'[2:7*JZ1:/#>MYL1\MC (QCY_F&1GCM^5
M>@44 </H5KXET;6+O1CI,,NER7\MW!JGGKA(I)#(T9C^\7!9@#TYSVYZG7-.
M_MC0-1TSS/+^V6LMOO\ [N]2N?UJ_48GB:=H%E0RHH9HPPW 'H2/0X/Y4 >;
M6]CXJN;;P=:W?AYHI=$O$^TS?:HC'(BPO&'3#;L'(." 1G&#SA^K:-XEO-:>
M=]&6[>VUN"ZMKIKJ-1]D7;\B G*D');@9Z_-P*]%N+F"T@>>YFCAA09:21@J
MK]2>!4@(8 @@@\@CO0!R6L:9JJ_$/1M;LK$75JEE/:3$3*GE%V1@QSR5^4]
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M4'C B_>;">1N4-_"2N0#V)S6/X6TK4M,UW7+R;1X;*SO(X'@A@G5F#(FTI@
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M$TW2-%U*'3KB[AU6>"&,(RJ4\W&TG)Y//3]1UI=)\6?:IM<@U6R_LR;1]KW
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M&2&XY;D$53N_'26NF2ZX+#S-!ANC;RWBS?. )/+:01[>4#Y&=V< G&*3P?\
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MZ5B^-K)]:UWPGI<(RT.J+J<Q'\$4"GD_5F11]:T/'FF7NM>!]6TO3X/.NKN
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9A%/I5UYJ9.V0J\0&1T) )_.N(U>-+SX ZV;@M,8+RY\HNY;;MNV5>I[#@4
M>DW>OSVOC/2]#^RQFWOK:><7'F'<#'MR-N/]L<Y_"MZO/M;T>SE^('A73MLB
M6AL;_=''*R[@?))!8'./Q]NG%8T&K7>E_#86Z7,ZP)XA;3&N#(2\-K]K*'YR
M<C"_*#G(R* /6J*XB.W;2/B=!INGAH],U#2Y9;BV1B$CDC=5$BC^$D/@XQG
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MVZ6*WOM0$*LY(0(H*@>@!Z#H*T([:.:Y\.^'4^SQVESH[W/E3AV6:4>4#C#
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M[F221[J8EF)R2?GK8\8:[=>'/#[ZE:VT,Y2:&-EE<K@/(J9&!R1N'''UK>H
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M"2!FM.RL+;3H6BMHRJNYD<LY=G8]2S,22?<GL* )+F22*TFDB3S)$1F5/[Q
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MF6.2RM/+\K=Y*&5V2'=][RT)*IG_ &0* /-M=TFVN1\3IIFN'>P1+BUS</\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1103@9- !1129 (&>30 M%%%
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M<'TIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %>3_&O6[YO ^K6^F2F*UMVCAO9EZNSL!Y*GZ'+'W [G'K%>._$#
MX02WF@7\F@7VL7=_<7/G"QFOU%OEI-SG:0!W)'- 'J>A_P#( TW_ *]8O_0!
M7C/QITO0]-GTV^.I7MKXCN+U"E^[RE(8LG)P,JJKQ@*-WKGDUWEI:^*_#O\
MPBFC:39QWFE*FS5+F\GW31=^#D9QDXP#T XZU1UJV\1>./"FI>'=9\*_8;J5
MPL-U]IBEMU 8$2 AM^0.P7GVR< 'H=NZRVT4B2B5&0,LB]'!'48]:DJII=A'
MI6DV>G1,S1VL"0(S=2%4*,_E5N@ HHHH ;)&DL;1R(KHPPRL,@CW%>.^"O\
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M><0JK1QGWR"7^KFK_A*X\1S0QPZYH<6G/:P^7)*DR2?:I!@;D"_=7 )^;G)
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M\S.PYP",-GMG*U[0_$!_X3O3[+1VNH]<B$EM<B>-4!\A8RC G<&RO'&.>2*
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MBAT8=P1D&GTV)62)%=@SA0&8#&3ZX[4Z@ HHHH **** "BBB@ HHHH ****
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M8W6I&U!M[O3I91#, VT[&X],@CK0!U$,T5Q"LT$J2Q,,JZ,&!^A%.9@JEF(
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M@D\ 9/<U+7(?$/5]/TC1;635="&K6LEY%&%<ILCD+85CGG\@:@U+Q_<V4GB
M0^';F=-"*M=,;A$S&4#EEZY.TY"^W..,@';45';SI<VT5Q$<QRH'4^H(R*DH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>7-U<P Y"B7C9GOA  3ZYKH8[F"6>6".>-YHL>9&K@LF>F1VS@_E4M 'EJ>
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M"1VJ[34=)(UDC961@"K*<@@]Q3J "BBB@ HHHH **** "BBB@ HHHH ****
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M6KR^6+B 9W)NZ==IP>" 0>M8MCH&M0>#_%6FS65LL^H37;6B03Y4B8'&20,
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M6\P=<J1($SV((V\$=ZQ?"WC6]E\#:3JFL"R6YU.5EMV>Z*(S$R,=Y*_(JJI
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MY0V\_-SSVX]^*DTFP\4Z-KM_IT-M:2Z)=7TE['?F?$D"R/ODB\O'S'<6P<@
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M(,3R#:NSYG;(!&1C  SC)V-$\23ZGJU]I=U8QVUY:V\%P52<R#;+NPK':"K
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M+R0M)Y?GQ*ZF2/=_#N4$?C63H&CZOIMOXG2?3K:)+ZX,]K%;S CF"./9R
M4Z]_3U &Z/X\NM2N/#K7&B&ULM=A+6\WVD.RR",R;2H7[I .&SGCD"JGCG69
M-5\'^+K6QTZ&[M;"VE@N)I9MI$OE;FV+M.[8&4DDCG('2F:?X<UJVL? 4$EB
M-VAG%X1,F/\ 4M%E>>>6SVXJ&]\.>)+*U\9:/86,%[8Z[]HN;>X:Y$9ADECV
MNC*1SR."./7'8 [K0_\ D :;_P!>L7_H J_5'1H;BVT2Q@NTC2XB@1)%C?<H
M( '!P,]/2KU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9AA;R"=U"!N&^4, <X&<CG%:-%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HI;6WG9&F
M@BD9#E2Z E?IGI4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
0% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>svb-firstamendmenttoloan004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 svb-firstamendmenttoloan004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M930R3:MJ%[+$R'-NLL<K*&_NG!'7N<5UFG03+\6M=G:)Q"^EVJK(5.TD/)D
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MJD[ ()!D^@KF(-4.A>"O%'A.>POI-9:2^%O"EK(PN$E+,L@<#;MPW.3Q@]Z
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M9/T%;<TJ6\$DTAPD:EV/H ,FO)/ MC?W?BRWT345=K;P4LL,<K=)GD)$+?\
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MR:7<1K%E6F$0#.(SW;"G&.^*NZ3:^'K^^N;G2/\ A(K^>VTZ?%U?RW#1PEP
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M;"8ODG"Q[1\^0 0?4XP"* .PHKC[#QCJDNI6]AJ?AN33[B^M9+BP4W:R>:4
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M69XA97\%\NT [FB;<%/L: .&U57\?^*X?[,MKV&TLM)O8)+FZM9(!YTZJBH
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M-S'S"-IR0 N"<YIVD:=?1^(_BI(]E<*EW'$+=C$P$V(9!\AQ\W) X]:]2HH
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M$9%9?C_3+WQ?XAT7PG&+N#3,M?ZA>1)@ )Q&@8@J6+<X.>@.*]"HH \N\8^
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MI%:BXB,;E8XE19=IY'S#<,\\5%\,&U'Q#J%UXCUB(I<V5M'HL6XYRT?,[_\
M GQS_LUWFN:=>:IIQM;+5KC2W9OFGMT1G*X(*C<"!UZCD8IVB:-9^'M&MM*T
M]"EM;KM7<<LQSDL3W))))]30!C_$:RN=1^'6O6EG"\]Q):-LBC&68CG '<\=
M*P+2Y.M>*O FH6EI>BVM[2]BF>:UDC\MO+B&&W 8R00#T.#C->CT4 >6Z]IU
M]++\4S'9W#_:M/MUM]L3'SB(&!"<?,0>.*9+;:5'X.\(6WB/2=7A:#2XO)U*
MQCF\VTF"(#&?+!=2?<8./45ZK10!SO@9]4D\)6K:NURUQOD"/=IMF:$.WEF0
M=G*;<_KS71444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4R66."%Y97"1HI9F8X"@<DFGUQGQ*75
M+[P]%H.D07#3:Q<+:37$<99;: G]X[$< ;>.>N: .(T_7-8@U2P^(EW>7(T/
M5=2>S>T=SY<%HV$@EV]%.Y,D]]WO7HOB?Q5+X?U+1K"WTQ[^?5))(HE68)M9
M4W#.0>#W/89//2L*^^$UG=>'I-&'B3Q";/R1%';R7:M$H4?("NSH"!Q[5F:/
M_;VJ7?P^FU73+V*\TVXN[>_>2%@ 5@9%D)(Z-Q@]"3Q0!L6OC?Q%>:AJ6C0>
M%8FUK3BK3QG4 (/+==R$2;,EFY 7;V.2*GA^(#:EH>@7.D:4UQJ.M"0PVDL_
MEK$(_P#6L[X/"GC@9.1Q5C0+*ZA^)/C"[EMI4M[B*P$,K(0LA5) VT]#C(SC
MIFO/['PS)#X7\&7NM:-J<UI8_;H+VVMUE6>$2REDDV(0Y'R\X[,#B@#M;KXB
M-I^A7-W>Z-(E_9:C%I]W91S!RID*X=&Q\X*N".!GIQ5NQ\7:@GB5=&U_1H]-
M,]I)=VTT=V)U94(WJWRC:P# \9'O7*7>B6\OA<2Z%X;U*S2;7;*0BY,LDT\<
M<B9E97)9% R.>PR<5T7B;2;K4O'NC&.&7[.=+OX))PA*1LXC"@GH"><?2@#E
M?&?BW5=?^&ES?MH'V?1KV2'[-<_:@TNWSTVM)'M&T-CC#$C(]<UV%YXPU5_$
M^JZ!HV@+>W6GQ0RF26\$4;*ZDX)VG#9& .<\G(QSPM]=ZK<?".#PC'X<U?\
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M^=G4DQ)'*2QP57G'4X%;6NZ?>S:#X&CBM)W>VU2QDG58R3$JQL&+#L!W)Z4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0!+163<ZQ-]DTV[TO3Y=2@O9(\O&ZIY43C/FD-@D 8XZ\UK4 %%%% !1110
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M4W,I.]VV$9QMP.<#)KH=0\%W$^HW]SIGB"]TJ/4MIOH;>-&$C!0N]"P)C8J
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M5=L[5N,*.O84 >YVTDLMK#)-#Y,K(&>(L&V,1RN1P<=,U+7EL-M'XE\0^%M
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M8)P -Q  QQ6#X[T+3=4^)_@A;VV$HN?MD<N78;E2$LHX/8DF@#L]%U]=9O\
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M<7<UFN]$^V$F:/#D&-L\Y4Y7GLHY/6MZ@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N(^)U@=3TG1
M+39,R2:Y9B0PY#*A?!;(Z8'?M7;T4 <QIW@U(-9DU75=5N]8NC;-:1&[6-5B
MB8Y8!4502<#)/)Q46D^!SI5S9+_;^J7&FZ>VZSL)&0)'P0 S*H9PH. &)QQU
MHM/B#I5YXXF\+1Q7 G0O&MR5'DR2HJL\:G.=RAN>.QKK* ,C0/#UOX?&I_9Y
MI9/[0OY;^3S,?*\F,@8'3BL_2_ VEZ=H6LZ.[2W5GJUS-<7"S$9!E # $ 8
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MW#=MR-W7&: ,OQ+H-OXG\.WNBW4LL4%V@1WBQN R#QD$=JYR7X=W%W9FQO\
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M!@20",CJ/2@L!C) SP,]Z .9OO!<-Q%I$EEJ-WI^H:5!]GM[V$(S&/:%*NK
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M;5+C[1+OQ\K;%3C Z84&L=/ %O:Z5HMMINJWMC>:/$T%M>QA&=HVQN5U92K
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M;3=8OM)O1;"TE>VV.)H@<@,)%8;ADX;KS5RQUK4=030KFWTA6L=0MA/<SFZ
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MY90/;QHK#RRK9R2,9SSZU@O\+].?3VTYM7U;[#'+YUE;B5-MF^_>&3Y,D@Y
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M);348Y\N1]H2,JJASU(.U2?7OG)KT+4? T%WJ5]>66LZII7]H ?;8K*1 DY
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M6A.6VGC=@  ]1SCJ:YG0($UC3?A[H&HYN-+>ZU(R02G<LOV=G$2MZ@#L?[M
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MF\I OF2-9'+MCJ3CK6CK=]9Z?XY\7W5]+/':Q^'8!*UL<2@%Y1A#V;D8]R*
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MNF#;97%@XC>!2 I49!!4@ $$'I3_  KXB'B+3)));?[+?VDSVM[:EL^3,O4
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M;C_2!(F-C*P "[<< #')XYH3P%IC:?JMK?W>H:C)JD(M[FYNY@TOEKG:JE5
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MV%[(5 6649"H=V-P;CY<_-7:Z!X1@TVU\/3W19M1TG35L0R-\A!50_'?E>*
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MU229HXPID;'WF(ZGW-4I-/L]?^+NH6^L6L-W!I^E0M:6]P@>,&1WWN%/&?E
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M[9U),?=>(^6B'_MKNX_V:[W0?#5CX?-U);O<W%U=L'N;N[E,DLI PN6/8#@
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M);C8J"4[)6 ' RN<UT_B?1],\/ZYX)N-%L;:SN?[46S_ -'C"%[=HGWJ<?>
MP#S]: .[&IV#7$=NM];&:1F1(Q*NYF7[P SDD=QVKG3XP71?"HU;Q'/IWF&<
M1!=-G\Q'RX4;2Q&2,Y;T -87PRT73Y+WQ+J\MI#+?IX@O8XIY$#/"@;HA/W<
M[FSCKGFN TNUM[CX V;3012,FMH%+H"5!N%!QGID<&@#Z MK^SO2PM+N"?8
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M4]K?V=[:_:;2[@N+?G][%('3CKR.*\LM].M-4U+X5V]["D]N-$F=HG&4<B&
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M_.?QJ#XCZQ9:CX>FTJVO%=%U6SLM3$9(\N.212RD^XP#]2#0!V]EJFGZEO\
ML-_:W7EG#^1,K[3[X/%27EQ]CL;BYV[_ "8VDVYQG SBN$UK3;'0_B-X,DT>
MRM[26Y-U;3);1B,2PB'=A@.H5@I'IFM1-5\27VGZI'K/AF+2[<64K+,FHK<%
MFQ]W:%&."3GV]Z ,K3?'_B?4]!AURW\#-)I\L7G*T>J1F0IW(0J,GCI77:-X
MAT_6_#EKKUO+Y=C<1>:&F(38.A#=A@@@_2O-?!/AGQ1JOPPTM+/QG)96T]IA
M+<:?&VQ3GY=_#?CD&JME>VNNZ!X$TB2PAMM*75Y;.YMD8O#*\".4&3]Y68;L
M'.3US0!Z_:ZE87ULUS:7MM<0+G=+%*KJ,=<D'%,_MC3#O_XF-I\D:RO^_7Y4
M;[K'G@'L>]>>:S9VND?$#4[?3+>*VAN_"]Q+=0P($0LCX1R!QG#,,^E8=QHN
MGZ?^S9+>P6D*WEUI<+S7.P>9)ED(!;J0. !T  H ]C74;%UN&6]MRML=LY$J
MXB/HW/R_C4<.L:9<6;WD&HVDMJAP\R3JR*?=@<"O/_$N@Z98)X.T:*SACTV^
MU2/[< @'VIUB9E$I_C+, 3G.2*A\1^&[.X\=W6A:;;0VT>K^';A;F*% B;U=
M1%(0.,@D@&@#TZ6Y@@>-)IXXVE;;&'< N?09ZF@W,"S^0TT8FV>9Y98;MN<;
ML>GO7A^H:E<^+M(T[5HMS7'AG1(M2<#J+L2KN!]]MO*/^!5:\3W3ZW#XP\0V
M9$ML7L-%@<N4#0F1&F!89PK&4*3]: /8;34["_CDDL[ZVN8XSAVAE5PI]R#Q
M21ZKITKE([^U=EB\XA9E)$?]_K]WWZ5P%IH6L6GB!]1;0]'T6T&ESV\\-C=;
M_/'RE#M\M!\I!&>>&K+\*>#;/4O@I9+9QV4.J7]O&6NKE,^=ME5EB=OO%#L5
M-H[=J /5K._L]1A,MC=P740.TO!(' /ID&K%</X.DMX/$>HV5UX:AT+6OLT4
MDJVDH>WN8@S!77;@9!W#E0W(Y-=7K$TUMHE_/;#,\=M(\>!GY@I(_6@!5U;3
MFOS8+J%J;P=;<3+Y@_X#G-.GU.PMG9)[ZVB965&6255(9ON@Y/4]O6O(;[2-
M+M/@!9ZU:VT*ZK';6]\E\$'G?:F="6W]22Q(Z^U;NF:-8:M\9?%$^HV<-R;:
MUL6BCF0.J.4;Y@#QN&.#U&3ZT =YK6KVF@:+>:M?/LMK6(R.1U..P]R< >YJ
MII6KSCPY;ZGXA^R:9),N]HVDVK"&Y569CRV,9Z<YKG_BK^\\/Z3:O_Q[W.M6
M4-P.QC,@)S[9 IOB>W@U+XH>%-/U"))K);:[N$AE4,CS*$ )!X) )(],T 69
M?%FJ76H^)K71[2TO&TF"UN+8;S_I0D5F900< X7Y3TR>:Z/0]9M/$&B6>K6+
MEK:ZC$B9ZCU!]P<@^XKCO!=C9:=\3/'5M81I% HL&\J,86-FCD) ';DYQ[U/
M\+/W>CZ[:I_Q[VVO7L, [!!)G ]LDT =!_PE6DCQ2?#IN4%^+<3D%UV\MM"=
M<[^^,=*H^%/&%MKF@V%YJ%Q9VE[>22HEMYP!;9*Z#:"<G.VL.'3;!_CO>R-9
M6S.NB13AC$I(D\YAOSC[V !GK7'Q:#I?_#/NI:F;*%K_ /TB9;ID!D1DN&"[
M6ZKC'0>I]30![5>:E8:>8Q>WMM;>:=L?G2JF\^@R>:M5Y/-;ZCK/Q \2#_A'
MM+UI8;:T@4:A<^7Y4;Q%B$'EM]YBV3Q]WVKLO#-KJFC?#RTMKQXYM0M+1E5H
MY/,5MN=@#8&?E"B@#:_M;3OM_P!@_M"U^V_\^_G+YG_?.<TZXU.PM&9;F^MH
M2A4,))57:6^[G)[]O6O'Y-(TI/V?%UI8(?[4%JM^+_://^U;PV[?UW;N.OM6
MY8:/9:U\8M7EU6SAN3#I=G(L,Z!T60[OFVGC<.0#VR: /1)-3L(;L6DM];)<
ME=PA:50Y7UVYSBDN-5TZTM([NYO[6&VDQLFDF54;/3#$X->7:=H^E:MX-\<Z
MIJEO"]__ &A?E[MU'FP>5D1[6ZKM"J1BDTE8]1L?!VGVF@66JZG;^'89]VI3
ME+>")PJYVA'R[%",XX Z\T >KM>6RI$[7$(6;_5L7&'XSQZ\<U!%J=I?6<\V
MFWMI<^6"-R3!D5@.C%<XKQO3[2+4O"_@FPNTB:V_X26ZA,,3%H_+!G^0$XRF
M..1RO&*Z>2QM-*^(_B&VT^VAM8)_#2S210($5G$DBAL#C..* .QTS6-NA6EW
MK=YI4-Q+D,]M<Y@8@G&QFQG@?GFK]OJ=A=Q22VU];31Q<R/'*K!/J0>*\L\(
M7>CZ=\!-%O=8TVWU$1B1;:UEA60RS-,X1$!!^8DXX[9JV?#=EX3^'5Q#JFF1
MWFHZW>0_:;2U801R3R2*$A!'"QKP/0@'@YQ0!Z(FMZ5+8S7T6I6DEI#_ *R:
M.961/J0<"L,>+?[9\*6NL^'IM.!G:,E=2G\L1JW56VDX?'05QMO8RP^,/$-C
M?Z3H]DDWASS9+33V,D3%9&",X**-PY'3H!S6#KEI;6W[/7AM[>WBB>:>S>5H
MT"F1LGEL=3[F@#W"]U*QTV-9+^]MK5&.%:>54!/H"34AN[98XI#<1!)B!&Q<
M8<D9 ![\>E<-:6%GK7Q:\1C5K6&Z^PV-I'9QW"!U1) [.5!XR6 !/MBN,-E!
M/I-MHI4G2[?QZ;2"('"B#:Q,8_V<LXQ]: /:+/4K'41(;&]MKH1G:Y@E5]I]
M#@\4EMJFGWEQ+;VM];3S0_ZR.*969/J <BO/-2CTKPQ\1=2GBM%M+ >%99[J
M*S01;]DO4!<?-M) -9VEV4^F^+O C#0-*T6"83QQ):W)DN'C^SLVV4[%#<A2
M3EN: .U\'>*KGQ+>^(X+BWBB&E:G)91F,GYU7H3GO7076I6%@\27E[;6[S';
M&LTJH7/H,GFN ^%7_(7\>?\ 8PW'\ZL:;IMAKGQ2\8_VM9V]X;2"RM[=+B,.
M(XGC9FP#TRQ.?I0!O^%_$AUK0[K4KX06JP7EQ;EMV%"QR%0Q)Z<"MJSO[/48
M?.L;N"ZBSC?!('7/ID&O$M!M[:YTKPGHTN)M'G\27WFK(=RS>7YC1*V?O D
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MM/ &"1[UGZ;\/]$TR]M+B,WTZV1S9V]S>22PVIQC*(QP,#@=<=JZFB@#,M-
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MN+5+J1;>:3.=SQ!MA.0,\<]\ULC1+ :^-<$)&H"U^QB3<<>5NW[=N<=>^,T
M</X<T?3[SXN^-KNZM(9I+5[$6_F(&$1, )*@]#\J\]>*RM%TS3-1^#.OZAJ=
MM!)?7']H37D\B R+,KR8.3R"NU<>F!7IUGHMA8:KJ.IV\)2[U$QFY?>3O*+M
M7@G P/2L:\^'OAR^OKBYFM9]ES+YUS:I=2I;SR?WGB#;6/ SQSWS0!Y^^LW?
MA:/^V)BXN==\*0R G[SWT2JJ_B1,OY56GTYO#^C:E\.(7*MJ-WI\<!!Y\N9
M)V'MF"4G_>KUK6?#&C^('T]M2LQ,=/G6>VPQ78XQCH1D<#@\<477AG2+SQ)9
M^()[7?J=G&8H)M[#:IR#QG!^\W4=Z /-4TC5=6U7QM!!I&@7,)NOL;R:C</'
M)#"L"; H$; * =P.1R3Z59M]$6[^)'A6RUT6^H2VWADF4_ZR*:175=W(^89.
MX9'7!KMM7\#Z%K=_+>W<-PLLZ".Y%O=20K<H.BR*C .!TY[<5H)H&F1ZS;ZK
M';!+NWM39Q,K$*D)(.T+TZ@=J //?$.E?V'/X@U2?1M,U[P[<2B:\V2!+NS"
M(JL%/0JH0, "I&37I$-A8-?_ -K16T7VR6 1&XV_.T><A<]<9YK%O_ 6@:EJ
M,]Y<07'^DN'N8([N5(+AAC!DC#!6/ ZCG'.:M1^'Q'XWE\0 HH?3UL]H8DL0
MY;)'0 <8QUR<]!0!N4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>8?&7Q/
MJ.G>#M2@T64Q/%Y:7ETI(,0=@!&I'\9!R?1<?W@: /3Z*HZ*S/H6GLS%F:VC
M)).23M%>6W/Q$L]6\9:M'J>HWFG^%]&E6V+6L<N+F<D@F26,'8@(( R-V1UY
M% 'L%%0VAMVLX6M&1K9D#1-&<J5(R"#W&*FH **** "BJ]]90:E8SV5TI>"=
M#'(JN5)4]>001^!KR?5/ OA^W^*&@Z/%;W2V%U97,LT7VZ<[F7;M.=^1C/8T
M >O-+&DB1LZAWSM4GEL=<#O3J\P\0::GACQ9X(M/#]@97$M]Y,$MRY&YH1DL
M[;B%'4]>!P*U(_'MYIUKXCCU_3H4O]$6%MEE,7CN1-Q$%+ $$M\IR* .[HKE
M=+\0ZU'X@MM'\1:=9VTM[;O/:26=PTBDIMWQMN488!@<C@\UJ^)-<C\.>'[K
M5)(6G\D*$A0X,CLP5%![99@,^] &K17(V7B'7X]7&C:QIVGP7]U:27-@]O<.
M\3LF T;DJ""-RG(R""?2J,/Q%DO;'3K2STX'Q)<W36D^FR28^RM'_K7<@?<4
M8(/?<N* .\HKBM1\6ZVUWK#Z)I%I=V&BMLNGGN&CDFD"!W2(!2,JI'+'DG'O
M3KCQC?ZGJ-GI_A6RM;J:;3TU&2:]F:...)_N#Y58EFY^@% '9T5R%IXPO9=1
M\-V-YHTEC<:JUTD\4S',+0KG*\?,K=CQP15+Q1XMU2"W\9V6FV\"3Z-I\=PD
M[RLI(D20L1@'YEV9'J>XH [F2:*'9YLJ)O8*NY@-Q]!ZFGUY;>Z]<V_A/P//
MXBTBPU"YO=2LXH7,S/Y99 5FR5'[SKD=.>M='=^)=<O_ !#J6D^&].L9QI80
M74]]<-&K2.NX1H%4\@8R3P,T =?17 ?\+&N+K3_#DVG:/YMSJ]Q/:O;2S;3!
M-&K9!;!^4,O)Q]WD#/%:_ASQ%J=[KVJ:%K=E:V]_8QQ3J]I*TD4L<F[!&X @
M@J0<T =1169KU]J&GZ;YFEZ<;^\>1(HXB^Q!N.-[M@X51R< ]*Y>7QOJ>FZ7
MXF&JZ=:#4]#MDNMMM.S0SHX8K@E00<HP((H [ND9E1"[L%51DDG  KB(O&&N
M0:KH9U31[2WTK6I?)MVCN6:>%RA=/,7:%Y"G@$X]367KOBO6]9\,>*;K3])M
M7T*UCNK,R-<,+B78K*\B+MV[0<\$Y(!^E 'I:LKHKHP96&00<@BEK$\&_P#(
MC^'_ /L&V_\ Z+6LF;Q1K=[XCU2PT'2K2YMM)*)=27%RT;2R,N_9$ I&0".6
MP,G'O0!U\<L<T8DB=70]&4Y!_&DEFB@C,DTB1QKU9V  _$UY7X&\0WEG\/O"
MNFZ19Q7&IZFUVT2W,ACCBC25R[N0">-RC ')-1?$77;C5_A!XLM=0M8[74].
MG@M[J**0NA)EB=70D E65@>1GJ* /6#/"LD<9EC#R E%+#+8]!WJ2N!O-5M+
M;QOX&TZ72;>XN;NUG,-ZY^>VVPY(7_>'!K3T/QHE[X5U35M3MUM)])EN(;Z%
M7W!&BR3@G&<KM(^M '5T5P=GXR\0:M%I5GI^CV2:M=:>-2N5NKAEBMXF8B-<
MA2Q9L'L,8-1WOQ'N8-&T:ZM]&\V^OM1?3)K,S8,5PN\%=V,$;E'/H<^U 'H%
M%<EI?B;54\56_A[Q!86EM<W-BUU!+:S,\;LKX:,;@#D*5;\35W1/$4NM>(==
MLHK918Z7*ELMSNR99MNZ1<=MN0/QH WFEC1T1G56<X52<%OIZTZO/_B#<W-I
MXJ\%365J+JY^VSK%"7V!F:!E&6P<*,Y)P> >#3;OQUKNDPZ[::AHUH^K:7:)
MJ"1VUPS17%L6(9E)4$%<-P1SB@#T*BN8USQ<MEI.BW6EPI>S:S<P0V:%MH99
M!N+G&> @)KHKF=;6UFN'SLB0NV/0#- $M%>8>$_"-EXXT"'Q-XK^T7][J6Z>
M.(W,B16L9)V)&JL ,#!SUS6P\ES\.?#$R27ESK9EO4@TJWG;$@,A"I"TA)W
M')W$9 ]<"@#MZ*Y*P\2:S:^)[/0O$=A90RZA#)+9W%C.TB,T>"\;!E!! .<]
M#6QXF9D\*:PRDJPL9R"#@@[#0!JT5\]:;=_#E/A]:W$^JW47B+[""6M[RY$O
MVC;Q@;MN=WX5Z7#XCUG1O"7A>SN;>/4/$VJ(D*H\VU-P3<\CN >%49. <GI0
M!W5%<2GC+4["76].UK3K6+5-.TUM2A^RS,\-S$ PX+*"I##!&.^:SW^(.MV_
M@&Y\8W6BVL-AY%O+;1?:&,DF]U5BPVX ^;*]21C.* /1J*XJZ\6Z]86-FEUH
MMJ-6U6\\C3K-;DX5-NXM,VW@J 20H/;%4M1\>:UH46L6FJ:/:-JNGV*ZE$+6
MX9H;BW#[9""5!5EYX(.>* /0J*XWQ!X\31];T"SM[5;FVU+;)//OQ]GB=XXT
M?WRT@'X&F:SX]?2]8UBRBT_[2NGPVR+MDVM+=7#[8XAQ@#&"3VSTH [6BN.A
M\5:O8WE]IVO:?9Q7L6GR:A;-:3L\4R)PR'<H(8$KZY#5EVGQ!UJ;PC'XEN-$
MM(+*Z2WCLT>Z(9II'5"9#MPD8+$YY.!G'- 'HM%8NA7NNSRW5OKFFVUO)%L:
M*XM)S)#,&SD#< P(QSD=QBH?%/B*70HK"WLK1;S4]2N1;6D#R;$W8+,S-@X5
M0"3@$T =!4:SPO,T*RQF51ED# L![BN2L_$OB ZO>>'KW3M.CUM;07EHT=RY
MMIX]^QLDIN4J2.,'J*Y/X&6-PVB2ZQ/I^G;KJ6</J"NS74K^9RK97[O'][L.
M* /7::)8VD:,.ID4 LH/(!Z9%</\2=7UW2E\.KHQMU%WK%O;R&29D+$ME4.%
M/R-@ACU]CFLN&Z\0Q_$_7(M.L+&749=+LFF:>=EMXB/,R 0I9LDX' X!)QC!
M /2Y9HH$#32I&I. 78 9].:?7EVO>-;>^^'=GJVI^'[:YE&JK9SV4TFY(IED
M9"RMCG!&1QWKH-2\4:Z_B'4],T'2K&[_ ++BCDN$N;LQ2S%UW!8@%(Z<98@9
M..U '8T4R%VE@CD:-HV90Q1L94D=#CO7#?$">76-3T3P7:2R1OJ<WGWSQ,5:
M.TB.YN1R-S84'ZT =Y17$_#34+G^R+SPYJ4K2:EH%P;.1W/S21=8I/H4Q_WS
M6,?B5KO_  BC>*O[!M!H]K.T5T#=-YS 2F,M&NW! XZD$G/ID@'I]%<;:>*M
M;@\5Z9I6MZ3:6MOJT4TEH\%P9'C,:ABDH*@9VG^$D9&.>M4[?QWJLEI:Z_+I
M-JGAFZNEMXYA<-]H1'D\M)F3;MVEB. <@$'F@#OJ*X1_%WB._P!0U^TT71;&
M3^Q[@QO+=7+()1L5@JA5/S<GK@#CKGA1X\N]5MO#D6@:=!)J&M6K7>V[F*QV
MT2@;BQ4$D[CM&!S0!W"RQO(\:NI=,;E!Y7/3([4ZO([7Q/?:!??$?7;O3HUO
M;(V/F6PE)1B(PN5;&2I!R. >>16]=>,O$UAKFG:?<>'[,G64D_LY4NVW1L@#
M$3Y3 ^4DG;NZ$#- '?45PD7CZ\L;#Q$NMZ;"NIZ+)#&8;.8M'<&8#RMI8 C)
M8 Y''6K=OXHUFQU*33?$&G64%S)8RWMH]I<-)')Y>-\;;E!##<IR,@@^U '8
M45YQ;_$#7FT31O$=SH=G%HE_)!%(!=,;A/-(7S NW;MW'@9R1@\9P+&@:OXE
MN_BIXET^X6S.FV:VRE!<.3&C+(R,B[<%FXW9(Q@8)Q0!W]%4=8O;G3M(N;NS
ML9+^YC3,5M&0&D;H!D]!ZGTKF[3Q3K-MJ=]I6NZ?8QWD6G-J,#64[/&Z*=K(
MVY00P)7V(- '945YS!X_UXZ/HGB&ZT.SAT349+>)P+IC<1F4A0^W;MV[CP,Y
M(P>,X&G+XJUN^UO5[?0])M+FPTAQ#<R37#))-)M#,D0"D9 (^\1DGMUH [&.
M6.:,21.KHW1E.0?QIU<9\)CGX6Z"1WA;_P!#:J=WK'B0?&6#2+=;,Z:-,^T&
M-[AUS&945G("D>8,$ =,'J,XH [R.6.5=T;JZY(RIR,CK3Z\=\-^(O$&@^"-
M4U*QTBTN-,TZ_O9;EI[EDEE43.S>6 I' [L>3GCCGM+SQ1JM]J_]F>&;"TN9
M(;2.\N9;V=HD029\M!M4DL0I/H!0!UU%97AO6X_$6@6NJ1PM!YP8/"QR8W5B
MKJ3WPRD9]JU: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ 7MHUV;074)N0-QA$@
MW@>NWK0!/1110 4444 %%%% !1110 445&\\,<T<+RQK++DQH6 9\=<#OC(H
M DKQ3XC_  UUYO#.IOIFN:KJ8N+OS_[+"*4)>3<3ZG&?TKVNB@#A;*]\1^&U
M\):%'I5UJUO/'LOM0D;!M^GW@!@8![]=N!S7"-X/UC1=+\?^'?[+NKL:S*LV
MF30Q%TDRY.&;HA7(SNQT.*]UHR,@9Y- &-X2TB;0/"&DZ3<2"2>TM8XI&!R-
MP'./;/2MFBB@ HHHH *XW5=,O9OBOX>U*.VD:R@L;J.68#Y49MNT$^^*[*B@
M#E-?T^[N?'WA"\AMW>VM&O//E4<1[H<+GZGBN:\2^$]3UO4?'4<5F62]M=.:
MU,GRI</"S.R _@!_P*O4** //?"6E:./$,5SIO@6YTCR8&,EY>+Y3(YP/+1<
MG?D;LMP.!US6Y\0-#G\1>"K[3[6%9[C,<T<+-M$ICD5]F>VX*1^-=-10!YSX
M<LM(L]4DU+3/ -]IPM;1W:XGC*2M(<?NHTR=^1G+9 Z=<U0M-!\1Z1J4/CY[
M5Y]7OY=NJ:7$ 2EHVT(B>KQA5)_O?,*]5HH \CU#PS8V'B#7Y-2\%7>NR:A<
MF[L+B!,JV]%!BD.X>7A@>2.C?A6P;6[\'>*X]5M] N[C2[K28;-[?35\YK66
M(G:N#@E-K8#>HYQFO1** /-]3E\127?A/Q3J&@SLUG<77VBQLAYDT44J%8R1
MGYF  W8]:K-IFMZY-\0KEM'N;0:MI,,-A'/@-(1',N#S@-DCC/ 89YS7J-!.
M!DT >1:I9:MKOA/P%%!H>I0S:7J]D+J*XAV,BQH TF,_<SWK>BEO_!_BWQ%.
M^B:EJ-CJTL=U;2V$0E*R",(\;C(V\J"#TP>M=Q;7MK>JS6MS#.$.UC%(&VGT
M.*5KJW6Z6U:XB%PZ[UB+C>5]0.N* /,]%\+:QI\O@N2ZLV$ZZE>WU\L9W+;^
M='(0I(]-RCZUT]AI]W'\4-:U![>1;.;3;:*.8CY696D) /J,C\ZZNB@#C_B)
M9W5YH^GK%9W5[8IJ$3ZC:VF3)-;@-E0 06&[82.X%<--X?NXH/&<.E>$KC3K
M36-'1;&&*%5RR>8") IPKMN! ],9YR*]IIDLL<$+RS2)'$@+,[L % [DGI0!
MQWB/3+ZZ'@KR+623['J<,MQM'^J00N"3[9('XUS4::YHOA3Q)X1B\/:A<W4\
MEY]CNHT!MWBF+,&+YX(W'Y<9R !UKUA65U#*0RD9!!R"*A6]M'>=%NH6:W_U
MRB0$Q<9^;TX!ZT 4/"UO-:>$-%MKB-HYX;"".1&&"K"-00?H:Y.UFU3PGXM\
M2(N@ZAJ$&JW"7=E-:(&3>8PC)(Q(V8*CD\8-=]!<0W4"SV\T<T3C*R1L&5OH
M14E 'BMGX.N8?"W@^ZUWP]/J*:=]LAOK&),RH)92RR*N06P5' YPV:O>(?#;
M7OPD\1VN@>$9M,EO)H?(M>L]PJ21G>R?PGAN,DX&?:O7*CGGAM86FN)8XHD&
M6>1@JJ/<F@#S_5-%U*;XD> +Z.RF:UL;:Y6ZE"_+$6AV@-Z9/%9OBOPMK%QX
MON],L+25]#\2O:R:C.G"P>4Q\P>Q=%0>YS7JB.DD:R1LK(P!5E.00>XIU 'F
MOB[PW9?\)M%K.I>&[C6=,ET];39:1^8]O*CLP.P$':RL1D="OO3)?#\_V3P8
MVG^&VTN*'6OM4]HC[S!&5<!W/8D;21S@G&37IM% '"_%%7T_0[/Q3;!3>:!=
M)<H"VWS(V.R2//\ M*WZ"M?P-HTVA^$K2"[YOY]UU>L>K3R'>^?H3C\*EU?P
MG9:YJUI>ZA<WLL-LRNEAYV+9G4DJ[)C+$$]SC@<5O4 <3XXM]3'B'PIJ6G:;
M-?)87<TMPD6,A#$RG&2!GDX'<X%,T.VNM?\ 'FI^(KK2KJRT_P#LU--ACOH]
MCS_.SNQ3J%Y YZUW-5=1LCJ&GS6BW=S:&08\^V<+(G.?E)! _*@#R_X?Z/>'
MQC/IUV1)IWA S6EA)NSO:9MP)]TBPN.VZO5Y8DFA>*0;D=2K#U!X-97AS1]+
MT+3GT_2Y/,"3,UQ(\OF2/,W+-(W4N<C.?:MB@#S7P[J&M^ =,'AO4?#FJZI;
M6;,MA?:;$LHFA))4.-P*,,XYXX_$OU>Q\6Z]X;BU2]T^*.]LM7@U*RTI&'F"
M&(C]VSYP7(+'V/'T]'HH X$+>>,/&^C:@='U#3],TF"Y,CW\?DO-)*@0(JYS
M@#)+=*O2>!=&T/0]:.AV$J75U830 &XEE+Y4X #L1G.*ZR.>&9Y$BEC=HFVR
M!6!*'&<'T/-24 >8>&O$.H:5X(TW0[CP+XAN;FWLTMW1K>(0R,%P069_N^Y'
MX55T[PIKWAGP_P"#M0ELWO;K1;FX>YL;9@[)#.&!6/)^8IE>,\\XKUFB@#S.
M[L=3\3:IXBUY-)O;.#_A'I=+LX;J/9-<2,2Y.S.0,A0,]:=K^AZI<_ *UT:&
MQF?4ETZQC:V5?G#(8MPQZC!_*O2J* ./\:V%\-1\/>(+"SEO6TBZ=YK:''F/
M%)&48H"1EAD''>J5C87'BOQK>:U=Z7=V.E#2&TQ([U/+DG,C[G;9G(4  <]<
MUWM% 'CFA^$=>U#PGXC@U>TEBOH-.BTK3BXY<6^YT=?9G*\_[-63X5U;7/A_
MJ=_?Z4QUB_U9=3DT^4[6>.)U582>V8T./]ZO6J* /--*T;3)$U>71O!%UI7_
M !+98EN;I3'+)(P_U:QDG(X&6R.< 9ZUHZ9:7>F_"32+&\\/MJ;QVD$5YIS@
M;RG ?"MPS#KMXSCK7=44 <'X!TZ2QU753I^G:GIGAYXXA;6>H$@K,"_F&-6)
M*I@IP>IZ5=\;Z??&]\/Z]I]G)>OI%XTLMM%CS'B=&1R@)&6&0<=^:Z^B@#B-
M'COM>^(3>))-,O-/T^UTTV4*WL?ERS2/('9MF<A0% YQDFF_"32K_1? ,%EJ
M5I+:W*W$[&*48(!<D'\J[FB@#B_B39WUQIVAW=C8SWIT[6K6]FAMUW2&-"V[
M:.YY'%/T"WO)?B!K6L26-S;6EYIUD(C.FT[AYA92.S#<,BNQHH \8UKPQK<_
MP[EL8M,N'NCXGDNA$%^;RC,S!_I@@UN^.K.+4-1NTG\(ZI-J<<0&E:MI9^?<
M5XW."I3:^>&R,<]\5Z510!4TM+N/2+)-0</>K @N&7HTFT;B/QS7GNE^#+GQ
M3XFUOQ-KKZMIDLDWV2PBM[I[=UM4Z$[3G#-\V#WKTVB@#S>'PG=>#_B%INJZ
M0=2U"QU*-K/4S<3M.\9&#%(2QS@$8]A]:SW\/:N?@)?Z,-/G_M)Y)BMMM^<@
MW1<<?[O->L44 <AXATR[O/'O@^ZBMY'M;47HN)5'$>^$*N?J>*XGP[X1T_38
M-/T6\\ SW6K6\XBEOV^6V:,/_K_,R<G;@[<9SQQUKV6B@#C_  UIMY:ZCXR>
M>VDC6[U$R6Y8?ZQ?)1<CVR"/PKD="TO6/"UOX,UF;1KZY6VTJ73[ZVMX]\T!
M9@ZMLSR,K@XZ5Z]10!X[JNDZ_K.D?$:X.B7<$FJK:&RMW4%W5% [$C=@9(SQ
MG%=IKVG7ESXZ\&7D-M(]O9M=FXD XCW0[5S]3Q7744 >6>(?"6IZQ?>/ECL#
M(MVVG36BR':ER85#,@/OC;]35G1='TJ2YO)=(\"W6E%+"5?M5VIC?S&&!&B9
M.[(SENG ZYKTJHYIX;=5::6.)68(I=@H+'@#GN: /.;K0]4?X-^']+6QF-]!
M_9_FP!?F39)&7R/8 Y^E7]-COM*^+/B"6;2[V2SUB*T\B\BC#1(8HV#!VS\O
M)XKNZ* .9^(%KJ%YX-NX--CGEE+Q&6&W;;++")%,B*<CDIN'OTKB+'11:^*I
M;W1_!]SI>EWNBW-DF+<)(TV58-*H.5! V@GDD>XKUF*>&??Y,L<FQRC[&!VL
M.H..A'I1Y\(N!;^;'YY3>(]PW%<XSCKC/>@#SJ\T/4W^$'AO3%L9C?6YT[SH
M OS)L>,OD>P!S]*ELI=6\*>(/$UFF@W]^NJ7IO;&XMT!B+.BJ5D8D;,,O4]J
M]$HH Y3X:Z?>:5\.]&L;^!X+J&)EDC<8*G>QK/U2*^T[XO6&LC2[V[L+C23I
MYEM8PXBD,X;+\C:N.]=W4;SPI/'"\L:RR E$+ ,^.N!WQD4 ><VFAZHGP?\
M$>F-8S"^N#J'E0%?F??(Y3 ]P1CZUGW_ (7M;37UU+6_"MYK5K=Z9:QK]EB\
MR2VFB4JRLH8<,"O/3*]J]7EFC@A>::1(XD&YG=@ H]23THBECGB26)UDC<!E
M=#D,#T(/<4 9/A6R33_#5G FD)I VES8I)Y@A+$DC=W/.3[D]>M;-%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 1M5RS$+Z]Q0!@:!XQ\1Z?X:\1ZQJ@L;E(=7EM80UQ(!'(9DC )886%=V?7
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M:*9)F0*Z$X(RK'@]Q3?[-U7P_JOAOQ!'I5S?)%HJZ9?6UMM,T1^1U8*2 WS
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M*S/&GA^]\8>*-%T:>WG3P];!KV]G239YDHRL<:D'(()+'_$4 <_X0L+[X?\
MBO2K34[B26/Q+:;KEY&SLU!278>P*L0/4K77:GXBUJ?Q;+H'AZSL))+2U2YN
MY[Z1U0;R0D:A03N.TG)X K#\5?"ZTDT":XT2?4SK-F1=6!GU":4"9#N&%=B,
MG!&?>I+:;6]*\7RZ\WAV]NDUK3;83V]L\?F6MQ'N!5@S ;3N^]GM0!$_Q-U!
M/"LFL/HJK/'KO]E-9^9E@-P!YZ;LY'I6M<^(O$]M+INCR6FCC7KX2SDB:0VU
MO FWEC@,S$L%P,#/-<5IVEZOK/A6Y5+02WB>-C<W"0ME4"R@N03C('/Y5UGC
MKPY%>^(M(UNZT Z[8V\,UM<VB(KR)N*LDB*Q ;!4@\YPU #CX\O1I)@-A;?\
M)!_:G]D^0)CY!EV[_,W8SY?E_-TSV]Z9>^.=5T;2?$:ZG9V+:KI%JEY']FD8
MPW$3D@$9^92"K CZ5DZAX/COO#%G<VW@F"TAM=5%V^CC9ON;?84)89VB3#;@
MN3]T#.327GAQ+WP5XIBT+P1_8S7-H(;965(Y[D]6R@)"J#C&3D\]* -6Z\8^
M*K'5M(MY]%TYX];#K8QI<.'@<*&'G$C&-N2=H.,$#/&7Q^/+_2[;Q/'K]C;&
M^T,0L!9.WEW F'[L#=RIW?*<^M7=:TF_N?$G@FYAMG>&PFF:Y<8Q$# RC/XG
M%87B+P?J>MZAX[C2U!CU"WL#:&4@).\)+E/89 !SZT ;EEXEUNTUF+2_$%KI
MJR7EK+<6LEC*S*&C +1N&'7# AAP<'BL2#X@>)&\+:9XLN-(TZ/1;AX4GB\Y
MS< .X0NO&W&X\ Y)'.1G L>'='T\ZFTVG?#[^Q#':R![JX2..02L,!(PI.X8
M+9;@=*KS^'=7;X&:=H8L9#J<4=H'M\C<"DZ,W?' !/X4 7=(U/Q+<_%S7;"6
M2S.FVMO;YB\V3Y4;S"K*N,;SQN^@ZXKT"N&MK?4=+^+.JW;Z5=SV&JVMM''=
MPA3'$T88-YF6!'7L#71^&]9DU[1EOYK)K*0S30O SARICD:,\@#NN: *7B#4
M?$<&H16NBV>GK#Y)EEO=1E98MV<"-0O.[OD\ >M8:>/;_5+#PV-*M;&WOM9C
MF?\ T^9A%&82%= 5&78L>.G )J'Q+I,DWCN2[U'PM)XALI+&.+3T*QO#;RAF
MW[PYPN<H=^#P,>U96EZ9<V7@C3M!\0^!YM4L[66XBG6!$9TD\PLDD2[A\A5B
M-P(((QC% 'I6BW&HW6F1OJUDEG?!F22..02(<,0&4_W6 !&<$9P:Q/$6L>)K
M.\N!I6GZ<MG:P"5I]0G9?M#<DQQA>A ');NPXJ7P'8W^G>&%M[^.XA'VB5K:
M"YE\R6"W+DQH[9.2%QW..F>*Y?7=!GN_&6N-?>%3K37L,,>E7,Z1R6]JH3#A
MMQ^3#Y8X!)SQ0!IS^.M0O+GPQ;Z+IT$CZ]8/=H;F0JL!54;YB!R &/0<D <9
MR*=MXP\8WL.M6T&DZ0M_H<C+=R232>3.-N]1$ ,@E>N[IQUR<5_"NC:Q'J/@
M:2ZTNYMETO2KBSNC+M^1\1J.A.0VTX-;>D:1?V^H^.));9U2_N ]J3C]Z/(5
M<C\010!$/&]]K$.@P:#:6BWVJ6']HR&^D816T7RC!V\L2S8&,=":KW'Q"U"'
M1K&1-*AEU1]:_L:YMEF.P2[6(97Q]TX0Y(X#'@XKGHO!KVFG^$[[6O"[ZS#:
MZ.+"\LE1));>0$,KA20&_B4X/&:UV\.W#:5X;.G>%X]'CC\11WLMI"5S'"%=
M?,DQP&(VY )QQ0!J0>,-4TK6-4T[Q/:V*FTTMM52:P=RK1*2K*0XSN!'T.:Y
MGQ)J_B74_#WAR]U73K"&RO\ 5K"6);:5VE@!E5E$FX8.1U(Q@X&#G(Z#Q+X9
MO];\8ZELB*6EWX8FT];@GY5F>3(![].:Q+P^)M:\-^'-&_X1>_MI]-O;)[^6
M9H_+(B=03&0Q+=-V<   ]\4 ;FH^,M<,NMW>D6&GS:7HLC13BXF99KED4-((
M\# QG SG)':K$WBW5=7U^/3/"]M8R(EC%?7%Q?.ZJ%ESY:*%!.X@$YZ 5S%Y
MX4M].UK7A>> O[?N+^\>[L;L)&4/F $I*S,"@5L\X/!XK9^RZAX1\:7&HVOA
M^ZO=-U#3K>W\O3MC&WEAW )ABOR;6X;VH G^%LTMQI?B":> P3/K]XTD);=Y
M;;AE<]\'C-5-?GU2'XPV":/;V\UW-H4J!KERL40\]"6;:"3TQ@=R.E:WPZT_
M5=/TS6#K%I]ENKK5[FZ\L,&&UR",$=1U'X55UV/5]/\ B99Z]:Z1<W^GQ:3)
M;7'V<KO!:56 4,1N/ ./3/?B@"G+\1-3T[3[J35--M4GTG5(K/5O)D8HD$@&
MV=,\X^9>#72ZMXBFM/%>AZ#901S2W_FS7#L3^Y@0#+<=RQ"BL+0_#<^NV_B^
M[UNQELH_$4@1+:;!DCA2(1JS $@,<$XSQQ6?\)K?4-16[\0:N5DN(HDT>UD5
MMP:*#(=P>^^3)_X#0!T7Q+U#4]+^'NL7FE2)%<1P-ND9F5D4@@LA'1QD8KE=
M2N?$ \4> 9'M[*XU:2TO@@65Q" 4B^=V(W<#DX')X[YKL_'VEW>M> M:TZQC
M\VZGM66*/(&YNN.?7%85G!J>J^)/!>IMH][90V-K>0W*W056C8QQA> QX)4X
M^G:@!MQXMOCX>\9VFO:7I\U[H<&^6*,LUO<QO&77AN1D @@TMMXKOY-/\*:=
MH=EI5I<ZGI8O$6Z=D@B55C_=1A1EC\_ [!:KZWX?U:YE^))ALI'&J6,$=E@C
M]\RP,I Y[$@<TDNFM%X,\-:3KW@V;6;.+38HYA;A7GMKA448P64@$9^93U%
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M(=)%RBA,[@QPV3G QWI+?X@WVJZ#X:>PM[*VU36EF9C>.?(MUA.)&.""WS8
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M5!E0AMHZDA2,X'.*M77B+Q+>^--7\.Z+;:8@L8()Q=7@<J-X;*E5())(XZ8
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MAD ,FUW5U0M@$_.2,XSBNKTVVUS4_B++K]WHTVGV#:*UI"L\B&3?YH;Y@K$
MGG !/ Y.3BNMTC1;/1(KF*R5U6YNI;N3<V<R2-N;'MGM6A0!X]HW@WQ!:_"K
MPMI$VG,E_9:W%=7$/F(2D0G9BV<X/!!X.:Z;QKX>%UXCTK7)/#T>OVD$$MK<
MV3)&[J&*LLB+(0I(*D'D'#5W=5I-1L8;^&PEO+=+R=2T5NT@$D@'4JN<D#VH
M R/!]B+/296'AVTT$33LZVENJ [. K2;/EWD#G!...:P/%&DW,GCJ'4KCPR?
M$%@=.%O;1$Q%+>?S"69ED( #*5&X D;<8KOZ* /*-!\,Z]:0>&+*YTHQ'2=;
MNIIY(V01-$XE*N@#9V_.HP0"/2NOATJ\'Q/OM5>W_P! ETB&V64D8,@E=BN,
MYZ$=L<UU%5M0LEU&PFM'FN(5E7:9+>4QR+_NL.0: /+_  'H<Z>.[^QD99-(
M\+2S1:<5.0'N"'*_5$)7VW5Z;J^GKJVBW^FNVQ;NWD@+>@=2N?UJA86>@^#-
M,M[&*:"Q@GGVH;B?YIYWYY9CEW;\3Q[5MT >5SZ?XFUGP18>!KKP_/;/&+>V
MO-1::,V_DQ,I+IAMS,P087:,9YZ5T_A_2+^S^(?C#4KBW*6=_P#8OLTNX'S-
MD15N <C!/>NMHH \F_LWQ1IG@C7?!5KX>FN&E^UK:7XFC$#PREFYRVX/\Y&,
M=<<XYJ6Y\*&QU.PU/4?"">(()=(M[26#RX9);6>('D"0@;6#8)!ZK7JE% 'G
M;^'-0:?P1-!H-IIJ65[+<7=K9E!';*R,!TP">1G&><]JZV[UB>V\4:;I(LM\
M%Y#-(;GS /+,>WY=N.<[NO;\:OWM]::;9R7=]=0VMM'@O-/($1<G R3P.2!3
MU2WFDCNU6)WV$1S  G8V"0#Z' /O@4 8OC;0I?$W@S5-'MY%2>XB_=,W3>I#
M+GVRHK*M[_Q/XDF33KSP^^D:>]K+'J,MS(CEW9-H6'8QR,DG<1TXZUUMM>6M
MYYWV6YAG\F4PR^6X;8XZJV.A&1P>:GH \HETSQ/??#^#P!+H,T4RQQV4VI^;
M&;80(P_>+\V\DJOW=HY-==H.DWEEXZ\57\T!2SO!9BVDW []D15N,Y&"1UKJ
M:* /+].T?4M+\#Z?I6K^$5UFS,]VUU:@Q/+$6F9HG4,P4@JQS@Y&1[U17P5?
M1Z9HM[>>'?[1M+"]NRFB7$D<TD5I-C8H+DJ60J#C=T.,\5Z]10!YE>^'+J^\
M'W4>E^$+717FU*TECM81$DKQ1RHQ>7:=H/WR ">/>NEUC2KVY^(7AC4H8"UG
M9P7BSR[A\A=4"\9R<X/3TKJ** /,O#EWK?@;P+K45WX>G>72Y+BZ1VGC6*Y1
MI6?Y6!)&%)/*]L=>*],4DJ"1@D=/2F3017$313Q)+&WWD=0P/X&I* /%]6\(
MZO=Z+XBTU?"4=SK5S=SW"ZS.8B)8R^^-48G>&V@(%P O7/8[%CK.IVGQ,\27
ML&@7MU'+86!GM8GB\^%BLA7(+!2/O X8XXZC->H5GVVC6=IK5_JT2N+N^2))
MR6R"(PP7 [?>- 'E-YI>LZ'9^%[B:S0ZO?>)Y]2DLA*,*9$D;RP_3.T8STS[
M<UOS:9K/B37-;UN71KC3XQH4NF6=O<O'YLTCDLS85B%&0H&3[UV^HZ-9ZI=:
M?<72N9-/N/M$&UL8?:5Y]>&-7)YXK:WDN+B5(H8E+R2.P544#)))Z #O0!P=
MSX6U6[^$>C:5%$D>L:=!9S)#(XP9H=K%"1QSM(STYJ7RM8\5^+=!O;G0KK2;
M#2&EN)3=R1EI9F0HJH$9N!DDL<9KM;6ZM[ZUCNK2>*XMY5W1RQ.&5QZ@C@BI
MJ /+KKP;J\GC][-+8?\ "*W.I1ZU-)O7 G5"#&5SD[I C'C%6=9T*\E\;ZO<
M7'A>/65OK>&+3KN?RGAL\*0X<.<J-QW?*"3G%>D44 >0VWA?Q!)I_P .(9-(
MFB?0[LK>[Y(\*J@#>,-RIQQW]J]'L-8GN_$FL:5+9>3'8+ \4_F!O/$BL3QC
MY<%2.O/6M"UO+6]61K6YAG6.1HG,3A@KJ<,IQT(/4=JD2&*.221(D624@R,J
M@%R!@9/?CB@#BOBQH6I>(O!7V#2;4W-S]KAD\L,J_*K9)R2!1J&A:E-\9-'U
MR.U+:;!IDL$L^Y<*Y9B!C.>X[5W%% 'FFAQ^+O"^AQ^$].T'S9;>Y9;;5)9$
M-K]G:4MO==P?<%8C:!U'6JMUX6_LW6==$G@*T\02ZA>/=V5[)' 54N!E)2YW
M*%;)X!R#QS7JM% '(Z=HEW9_$22_%G'#IPT."S0PD"-765R45>H !&.,8K%M
MM*U73-,UN.[\,IJ]E>Z_=7$UFS1L[V[X*2(&.TG('!(.*](HH \@_P"$(OI=
M%,\?AT_V?:ZPM[:>'[R5)#]G\K9(G+%%)8LX4G Q[UTVBQC1].US5[#P-::,
ML-N6MH,10SW1568ARF51<X R3W)KN:9+%'/"\,T:212*5='&58'@@@]10!7T
MN\;4=)L[UHO*:X@24QYSL+*#C/?&:\PUGPMJ5Y<^+;1_"T>H:CJDDALM7N#$
MT<,)B"JH+'>K*00 !U(.<<UZR %    '  I: /-+6+7M)\0Z1KP\-7US%)H2
M:;/;120^;!*DA8$Y<*5.3R#]<=*SKKPMXEN/ /B2*73%_M.YU_\ M**UCF4[
MX]\385LXZ*PYQG'3FO7** .-TZUU*^^(D/B";2[BRM'T,V[+.R%TE\_=M(5C
MSMYXX_&L"Y\):XUKJ]W!9@WEOXI76;*!Y%47,:HBXSG"Y&\#..17J-% '#6]
MOJWB;QOI>M76C7.E6&D6\ZQK=O'YLTTH53A49L*%7J3R3TJ'PQX?U6P^"AT*
MYM#'J?V"ZB\@NI.]S)M&0<<[AW[UW]% 'D<^C>)[;X9^&/#*Z)=S0NFS6$MI
MHEE6)3GR@6<#Y\X)!X /K6SXAAU/7_"MK GA2\M[6RO[=Y]+DDAS=6R=44*Y
M4@?*=I(SMQ7H=% 'E=OX=U235?$)MO#":59:SHAM;:.+R4$,BB0 2A#@,V\'
MY<\8!/!JMJ&B>(=:^'GA'3!H-U;7FD:C9"XCFDBYCBC*M(I#'*Y_'VKUVD9E
M12S$!0,DD\ 4 <,\6K^%O&>N:E;:)=:M8:PL,J_8WC#PS1IL*L'9?E( .1G'
M-9>G>$-:M(_#4]Q;*;HZ[<:IJ"QR K;^:LG&?XL;E''?VKT:QO[/4[-+S3[N
M"[MI,[)H) Z-@X.&'!Y!%6* .7ATN]7XHW>K& BQ?1XK=9MPP9!*[%<9ST(/
M2F^.=(O]1M-*OM+@%Q>Z3J$=ZMN7">>H#*R G@$AC@GN*ZJB@#@XK35O$OC&
M'7+K1[G2[+3[">"WCNWC\V:67&XX1F 4!<<GDFM7X=:7>Z+\/]&TW48#!=V\
M)66,L#M.XGJ"1WKIZ* .=\=:%+XA\'WUE:\7RJ)[-LX*SQD.F#VR1C/O7,V/
MAOQ#=>!?%5U/#]C\3:\99/*\T9B4+LBBW@X^Z.N>-U>D5 MY:O>R6:7,+74:
M"1X0X+JIS@E>H!P>?:@#S+3M%NX/$_AG5--\#_V1861DM[A%$"SDR1[?,;:W
M**1U)+')./6O:^$->C^''CW2WT]A>ZGJEU/9Q>8G[U'V;3G.!G!ZXKU._P!1
ML=+MOM.H7EO:0;@OFW$HC7)Z#).,FA]1L8]1CTY[RW6]E0R);&0"1E'5@N<D
M>] ' #2M:\/ZEX7UV#2)]0^SZ*-+O[6W=/-B/R,&7<P#?,I!YK+N_#OB?4;7
MQ9=76CLO]HZA97/V%;A-UQ;1A \6X'&[:N#S@G(!(YKURB@#S'3-#OU\8R7]
MKX371],OM)EL42,0HT+AMP>94; W=!MW$8&<9.,:\\.^)=3^#5CX:_X1^YAU
M'3Y[=&626+;*%8EF0AN@&.N/;->P07EK=23QV]S#*]N_ES+&X8QM@':P'0X(
M.#ZU/0!Q%Y;ZKX<\=ZAKMIH]SJMAJMK#',EHR>;#+%N"_*[*"I5NH/!%8L/A
M+7#8V%W/9!;V[\5IK%U;K(K?9H<%<%LX8A0N<9Y/%>HU!->6MO/!!/<PQ37#
M%88W<!I2!DA0>I !/':@#GI=*O6^*=MJX@/V!-&DMFFW# D,R,%QG/0$],4O
MCO1;[6=#MVTQ$DO]/OH+^WA=MHE:)L[,]LC(SZXKIZ* .&BAU;Q1XVT75KG1
M;K2;#1XYWQ>/&9)II$"8549OE49.2><CBF^!](U;0$\8SW5@1)=:S=7EI&9%
M_?(0"IR"<9QWZ5W=(RJZ,CJ&5A@@C((H SO#^J-K?AW3M5>W^SM>6R3F+?NV
M;E!QG SUZUI4V.-(8DBB14C0!551@*!T '84Z@ HHHH **** "BBB@ HHHH
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MU 9) Y! #+G*YX- %2;XAZOJ5OX..A6-IYWB&.X#I=;B()(E&>5(RJG?GC)
MXQ6BVM>*KWQ&?#VGRZ3'<Z?913ZC=S02.CRN3M1$#@J"%)R2:SM)\#ZGHM]\
M/8PJSQ:.EZ;^=7 "O-&>@."078C@?7%:5[::YH/CZ^UO3=&?5K/5+2&*5(9X
MXWAEB+!2=Y *D-U'(QTH XE?$-WH7PQ\4:K+IEA/=?\ "2W DM;M#-$K-*H8
M8R,X).#7=ZIKWB&7QT_AG1DT^)!IB7INKJ-W\LF1T(VJPW9PN!QCDDG@5Q^J
M>"?%-]\,-=TN2PC;5KW7'OA%'.FUD:16)#$@8Z]<'VKO(M(O5^)UQK!A_P!
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MHLR8A4L/EWD@$A5&<=ZZG4- U.?XPZ1KT=OG3;?398)9MZ_*Y9B!MSD]1VH
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MDMV\A91:1E$C0@83DDM@YYXSZ5RVK^)-<E\87^B:7J6CZ?-9PQ26]M?Q%GU
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MO;:\GN'LK\W:1I LQ)Q(A^8E2Q^Z#GCI5[2O!UYH_BOPU)"%DT_2]$:PDF+
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MV'<PQG/ ZU97P]JTU_X.O)=.L+0V%S<3WD-EA8X0\3JH']X\J"1U.3TKN:*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!  N< #)SQ
M2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'JNG2O:I'?VKM=J7ME6929E R2G/S 9&2* +=%5X[^RFOIK&*[@>[@ :6!9
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M[#R\8QQGYL8!&<U?FTBSN-:M=6EC+7=K$\,+%CA%<C=@=,G:.: +JJ%4*H
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MRPS+(WF!2."-V2,8'/04MUX'\/W6GZ?9-:2Q1Z='Y5H\%S)%)$F "H=6#$'
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M^RQB62[M':4+ARS3A2=W7[IQ],"NI\1VZZ5\1('TFWCMYSX;O0H@0+DH4*#
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M0!R+:7J<C6NN:9;Z5K;RZ+;6]_IM\^V4*%9@4?!"[MS9##!QG-=QX6N[&_\
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MT.GZ?;K!:P@A(U).,G).3R22223R2:MT %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW_W?3=[=: +O]D6']I6^HBV075O"UO"XR-D9()4#ICY1V[4ZUTNRL;R]N[:
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MJC1!GMT?DL%RP'8D<Y Y&* #4_ OAK6-0DOK[2TDN)=OG$2NBS8Z>8JL%?\
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MF,7LL;2I!GYF0'!;'IF@"2SL[;3K*&SLX(X+:% D<48PJJ.@ J>BB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "N+^)49MM$L->0?/HNH07C8ZF+=LD'TV.3^%=I4%Y9V^H64]G=P
MK-;3QM'+&XX92,$'\* /((=1CTK5XOB).?\ 1;_4[VUDD'>V$>R'\-UL"/\
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MT50, ?E6/XS_ .1%\0?]@VY_]%-6Y45U;0WMI-:W,8D@GC:.1&Z,K#!!^H-
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MV2X@WK)Y;C(W*0RG\" :S=-\)Z'X?N+B^TC2((KMXRN5)R5ZA%).%7..!@4
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M>T::";3]*A@F@+&.09+C< I^8DD\ #F@#R_2X]+_ .&:=4)$63'=&4G&?/\
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M$5M*T1F5'SEE#!<@ <\L!@<\UF/\1_"$=C#>MKEOY$I8*P#$C!P=R@97!_O
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MVLD0F1PIY0C<#CKTKE_#/Q$TCQ#;ZM.91;1:?-,&>575?)0X$A9E &?[O44
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M7;:9>:5:S65L%$$31C$0 P-O=>..*5?#.B)H9T1-*M%TQL;K41@(3D')'<Y
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MQ;H?AR6*'5+WRII5+I%'$\KE1U8J@)"^YXIEYXU\.6%G97ESJT"V]]$\MM(
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M9'?(XILWAS19]$719=,M7TQ %6U,8V*!R,#M]:U** *&D:'I>@6AM-*L8+.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KF]:U#Q58Z]:#2]#MM2T=X\7!6
MY$4\;Y/(W$*5QCCKUZ5TE% 'G]QX=\0:#I?B#4_"MK9)KFK7B7'V:1AY<: !
M2 > 6/S,>V6(YP">ZLS<FR@-X(Q=>6OG"/.T/CYL9[9SBIJ* "BBB@ HHHH
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M!M9O1B<\>U T/3!K/]L?8XSJ(C,0N6R7"'G:">@]JT* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@24!@K;BLK#/?*@$^E<Y=1Q1W&H:3&BC07\;6T,D0'[K:R!G3'3;Y@7(Z<T
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MN5G4Q@YQC=G'4@?C7(_$A;V?4O"=I:PV<RRZFQ,5Z[+ \BPNR!RH)Z@D#!Y
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MS&*JK$ G:I"].U='0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=(EMK.Z=-]L^T6R#^"8EB X[]/I5_2==TG7K=Y])U&UOHD;:S6\H<*?0XZ4
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MFLW4]KIFK65Y/!_K8X)E=DYQD@'IFFVOBC0;[5I-*M-9L9[^/(:VCG5G&.O
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M=A!8V,"06L"!(HD'"@59JGINJZ?K%J;K3;R"[M]Y3S8'#KN'49%7* "BBB@
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M:7%&WQ \%;D0D^&F/([CR\5ZD0",$9!K"OO!V@ZDVFM=6&Y]-4):.DSHT:X
MQE6!(X'!S6[0!X;/%'_PI7QKA%4G6KA<J,''VE.*[;Q!8VFG^/? "6EO% J2
MW<*B-0N$^S-\OTX%;#> O#+OJ3'3!C4SNNT$T@20[@Q.W=@'<H.0!TK8NM*L
MKV_L;ZX@#W-BSO;.6(\LLI5C@'!R"1S0!Y%X<TN/6M-\?:>U]!922^*6,$DX
M!1I5E5D1E)&X,R@8[YKM_"UY<_\ "3ZG8:SI%C9ZXMK#+)<V#EHKJ'<ZJ<$
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M[0QW#>8^V4%=IW)G:3CC.,U5B\ >&(-%.CQZ9BQ\T3K&;B4F-QP&1BVY"/\
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M;B7<?G" A.,X&-QZ>M9\W@_0)]&_LF33D-D)VN%0.X*2EBQ=6!W*<L>01UH
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MHV6DV,M]J%U%:VL0R\LK!57MU/O5JN4\=79AM]'M(;&TNKR\U***U-YGRH9
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M<5KJFKVEI/*-RQRR '&<9/H,]SQ7DL%I!!^S3;R11(LGVF.7>!SO^VA0V?7
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M[B(F20Y'XH.>E=!/XL\/VNM+H\^L6<>HLP46[2@-N/13Z$]AU-<CXR32TO\
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M8UD&Q6/O\PSZ9JM -4M_&O@"+4)-&B1H[C[-::?"ZF&/[,?E+LYW+PO89(H
M[>;QSX6MY/+EUVR5]LC;?,!("$AR?3!!'X&L*/Q_:>(/ HUK2]9T_290Z+*U
MY^]6 D_<8 CDCI5+X;V5O'X3\1W2PIY\VIWV^0CYB Q &?3V]SZUQVO8_P"&
M8-'(QUM__1IH ]EUGQ/HGAXQ#5]4MK-IL^6LKX+ =3CT'KTHU3Q1H6BV=O=Z
MCJMI;V]SS!(T@Q*,9RN.HP0<CUKBYH]>F^*WB :9)I"R#3[14&I12.3"?,SL
MVL/EWYW>^*K:1X=O[*RT"30?$&B76LV%K<HD+Y>WGMI)L_+@[DVD*NX9Z8-
M'IMI>6VH6D5W9SQW%M*H:.6)@RL/4$=:FKGO!-_!J/AB*6'3HM.*3SQ2VL)!
M1)5E99-I'!!8$Y]ZZ&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "J&L:)INOV/V+5+1+FWWB0*Q(*
ML.C @@@^X-7ZJ:GJECHVGR7^I74=M:QXWRR' &3@#W)/&* ,6X\':7:6-R^B
MZ3I\=^;)[6(7",8G4Y.V0 _,"2<DY/)KD]#\&WCZ]HLW_"*6GA^TTZ4W-PZ7
M2S-<2;&1%3&2$&]CSCZ5O>(/&UK)\/\ 6]<\-W\,\UC$V&V_ZMQCAE8 C@]Q
M6GI?C/P_JFHII=MJUO+J&TGRE)^8K][:<8;'.<$XQ0!J6&EV6E_:?L5ND/VJ
M=[F;;GYY6QN8^YP*S;'P5X;TW5O[4L](MX;L,S*ZYPA;[Q5<[5)]@*;?^.?#
M&F:D^GWNLVT-RA"R*Q.(R>@=@-JGZD5K#4K(ZH-,%PAO3!]H$/?R]VW=],\4
M 9<_@KPW=:S_ &M-I%N][Y@E+G.&<=&*YVEAZD9K3@TRRMM1N[^&W5+N\""X
ME&<R; 0N?H":Y[Q/\0-&\-Z)>:AYR7,EM<BT,"L5)FRN5S@X(#9K?M]7L+K2
M/[6@N5>Q\MI?. .-JYR?7L: *_\ PC.C?V NA?V?%_9:D$6W.T$/O'?/WN:@
MUCP=X?U^[2[U32X;B=4\O>2REESG:V"-P]CD5R%U\4(-4\&7NJZ)+'%=6U_%
M 48;_P!TUR(PYR /F7)QVS78:5XP\/ZYJ$MAIFJP7-U&N\QH3DKG&Y<C##/<
M9% %Y=)L$U&*_2UC6ZAMS;1R*,;(B0=@'3&0/RJ"?PWH]S;:E;3:?#)#J3;[
MQ&!(F; &3[X4=/2J]OXQ\.W>M'2(-6MY+X.T?E GEU^\H;H6'< Y%:>H:C9Z
M3837U_<QVUK"-TDLC851T_GQ0!A3?#WPK/:6MM)H\9CM59(L2.&56)8J6#9(
MR2<$D<U;E\-6AU;0KNWBAMXM(25(8XTQ@.@3:,<!<>W84VV\9^';O2[G4H-6
M@:TM65)W.08BQ 7<I&1DD8XK3N-1L[6]M+.>X2.XO"RV\9ZR%5W-CZ#F@"U6
M'J?@[P]K&J)J6H:5!/>*H3S&R-R@Y 8 X8>S US?AKXE:4^DQ#Q#K%K!J$EU
M/%M(VA569T3<0,+D*.3C-=%=:@T?C2PL!K5O$LML[G36@S)-C/SA\\ >F.U
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MUWW!P5,2X)RRD @8!.<<XJ.V\:^&[Q+MX-9M7CLX4N+A]V%CC894DGCD=NM
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MWEJ3\P!P2I(PP]QF@!=,\(:!H\5Y'9:9"BWB[+G>3(95QC:2Q)*X)XZ57M?
M7A>RCA2WT>%/)F6>-MS%E=00N&)S@ GC..3Q61XO^(FDZ;HFMQ:7J]L=9LH9
M-D9&X"51DKDC:6'.5SG@UM77C'0])AC75=3AM[CR(YGC()8A\X(4#)SM;IZ&
M@#4T_2K'2K>2WL;9((I)7F=%Z,['+'GU-8\7@#PK#IESIL>C0+97,BRRP;FV
MEE)((&>,$G@8%))\0O"426DC:]9[+M0T+AB0025!8@87D$?-CD'TJ[K7BK0_
M#LD4>K:E%;22J61#EF*CJV "0ON>* $UOPIH?B*2*35=/CN)(@523<R,%/5<
MJ02#Z=*9J/@[P]JEI9VUWI4!BLUV6PCS&8EQC:I4@@<#CIQ4U]XGT/38;::\
MU2VBBNHFF@<OE944 DJ1U^\OUR,5E7WQ#\/6_A34/$%K?1W<%F&4HN58RA25
MC((RI/N.] '1:?I]II5A#8V%O';VL*[8XHUPJBK-9F@:Y9^(M&@U*QD5XI%&
MX#/RM@97D#.,UIT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5RGCF]D@@T6TM[6RFO+W4XH;:2]0M
M%;R!6<28!!+ *<#(Y/6NKJCJVC:=KMB;+5+.*[MBP;RY!D!AT(]#[B@#QW6V
MNOL?Q3BO=1MKZY33K,2RVUOY*;@).-NYN0, G/;':NH\2_8FM/ATNF>7G^U;
M8VOEXSY B;?C'\.W&?PKJ_\ A"_#7E^6-$LPGV;[(5$8 ,6=VP^HSD_4FI++
MPEX?TW5GU2RTBT@OFSF9(\$9ZX],]\=: .%\./9)\)_%0U(QB9;C4AJ/F8SY
MA9_O>^W9C\*/!1GB\9>'$O25N6\&0@A^I82KD?4#K7;7W@OPUJ6J?VE>Z)93
MWA(+2O&#O(Z%AT8CWS4^M>&-#\1>0=7TRWO# 28FE7E,]0#UP?2@#R+6KF&Y
M^'GCZ>&17A/BA,.IR"!);C.?2O<ZRO\ A&=#_LR[TW^RK46-VVZ>W$8".<
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MD?A^$(Q'*YGDSC\J\Z\6@)\)?&J* %7Q5,% Z ><E>V:?H.E:5(DEC80V[I
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M95U/4&J\>BZ;"]@\=E"K:?$8;0A?]2A 4JOH,*!^% 'EWB90K?%L*, V%HQ
M]?(;)_05L,4_X3GP ]R5-N=*G%L3]WSS''T]]F<?C7=/HVFR27\CV4#-J"+'
M=EDSYZA2H#>HP2/QK/7P5X:71!HPT6T_LX2>:("F0K_WAW!]Q0!BZ!M;XM>+
M6M<>0+2S6X*]//P_7WVXS^%-U(@?&S0LG&='N0/?YTKJ])T73-"L_LFE64-I
M!N+E(EQN8]2?4^YJ+5O#>C:[-:S:IIMO=RVK;H'D7)C/'0_@/RH X#1[6#_A
M /B,_E)NFU#5O,..6QN S]*H1DMXU^$#$Y)TJ8DG_KU%>JQZ/IT-I=VD=G$M
MO>/(]Q&%XE:3[Y/KG/-1C0=*%SIUR+"#SM-C,5F^WF!2NTA?08XH X",S^&X
MK2:WGTO7?"=SJZ^4CIBXM9I9S@HW*R;9&)Y 88]J[#QMXB7PKX1O]5 W3QIL
MMH\9+S-\J#'?DC\ :DC\&^&XM:.L1Z+9KJ!<R^>(^=YZMCIN]^M:%_I5AJHM
MQ?VL5P+>99X1(,A)%Z,/<9H \EC\%^-#\-G\+/H^CEI09FNVU%_.\\MO\P_N
M\;@V._08S5FZUQ/%_A[X?7EW&#<C7HH;R)A]V>..0,".W(SCT(KUVLI/#6BQ
MS>:FF6ZR?:S?9"?\O!!!D_WL$\T <U96T/\ PN_59_*7S1HD&'QSS*X/_H(_
M*N&T^.^%MX9CL9K2W1/$NI)&UW$9(4E_>^6"H9>?O!>>I%>U+I]FFI2:BMO&
M+R2(0O,!\S("2%SZ D_G5.7PUHL^E3:7+IEL]C-(TLD#("K.QW%OKGG- 'EW
MB_2KJ#PKXWGU+5M-O+NZ;3UN;>QA:(0LLJ@%@78Y92O_ 'R*Z[Q+"D/Q$\!+
M#&J!'O8T"C "_9C@?3@?E706_A30+71I-(@TFU33Y7$DD 3AV!!#-W)R!R?0
M5?GT^TN;VUO)[>.2YM"QMY&',99=K8^HXH \;$EB/V8[L79C\WRYEE#XW?:?
M//7ONW8/TKJ]&AC?XOR3,BF2/PU;!&(Y7,KYQ^0KH9O OA:XO[F^FT&Q>YN0
MPF<Q#Y]PPQQTR03D]3DUK1:98PWYOH[6-;HPK;F4#YC&I)"Y] 2: /)(;.WB
M^"GCD)"BAKW4&.%ZE9"%_+ _*M*QCUZ;X@:M_9U]I=O*VE6)7^T+9Y6>':^=
MF'7"[]V>O)%>A_V%I0TVYT[[!!]BNF=IX=ORR%SEB1[GK5?5O">@:ZMNNJ:5
M;77V==L1=.47^Z".<>W2@#SS2M)@L]>^&MH;VUU.*!-3DBN(%_='A2NT9/"Y
MP.>U-\2J%E^+848!TZT8@=SY#\_H*]171].6:QF6R@5[!&CM2J >2K  A<=
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MR=473;&\35)+&5[9PL-U<<?,F>26ST.3D$=J .MHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !112%E7J0/J: %HI RMT(/T-+0
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MAU(R"/8BH+35K"_O+RTM+N*:XLV"7,:-DQ,>0&].AH N4444 %%%% !1110
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MT >M45SGAB7Q9)?ZT/$EO916JW.---NV2T7/+<GMMZX.<\=*Z.@#RWXI^&-
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MG?*$;CN'/!X/!S5>7Q=XQE\*:SXE@N--BM](O+B/[*ULS&Z2.0@Y;<-GR\<
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M'(76!'D9EB#'J%! S[5T5 !1110 4444 %%%% !1110 4444 %%%% !1110
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M?Q-HELUFX:VT0A7EN8@%)WMN#*S9;  XP.M,UCQ/8>&?BOJFHWA9B^AV\=O
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M5%<1X-\5/J6OZCHDNN6&N+!!'=07]F%&58LK(X4D!E(!XZAA7;'(4D#)QP*
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M.0JE3%OCP1G"B,@-WXX&>/5:* .2\>Z+JFK6NC7&D0PSW6F:I#?>1++Y8E5
MP*AL'!^:LKQ/I?BCQ#I]YIEWX<T>\AO(A]FGENL'3W9 &S\A+E6R0RXSQP*]
M"HH @LX'MK&WMY)6E>*-4:1NKD#&3]:Y3Q?H^M3>)O#6OZ-:6]Z^E-<K+;2W
M'D[UE0+D-@],>E=E10!Y9?\ @_Q/-H_BG0;6ST](M6N;BZ&IO/EW60[EB*;<
MY'";B< <@'I5^7P&WB/Q5<ZEXCTRU^RW.B1V7EB02/#*')8JV., C#"O1**
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MN]3EN8[K4I$4K&MNQ4E5;Y=SG;C/ R>*[;3="N[3QYKNM2-$;6^MK:*(*QW
MQ[]V1CC[PQS7,Z?X(UO1]"T":V%C/JVD7-VY@DD(BGAG=B5W[25;!0@XQD4
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MBBB@ HHHH **** "BBN3U[QHFE^,-(\+6L$<NHZDC2AYY-D<2*&.20"6)VD
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MBBC8 7$B 9"GN,G&>^..U '145GZ'>WFHZ'9WFH6#6%W-$'EM6;<8F/;-:%
M!11D&C- !102!UH)QUH **,@=Z* "BBB@ HK)UU_$"01?\(_#ILLVX^:+^1T
M4+CML!YS7&:-XH\?:W>ZM:VVF^&U?3+HVLQDN)P&? .5PIR.>^* /2:*XB+Q
MY::=XC\0V?B'4;&QMK&:WBMB[;2Q>%7?W;!/IP*U]9U@+#HMQ8:WIMM;WEW$
MH>?YQ=(W\$1!'S-V/- '045C7OBSP_IVK1Z5>:S907\A 6"28!LGH".V>V>M
M;- !14=Q/%:VTMQ.ZQPQ(7=VZ*H&23^%<-X&^(-UXHU6:RU'3EL#/;"_T[YB
M3/;%V3<<]&X4\=FH [VBLK5/$VAZ([IJ>JVMHZ1K*RS2!3L)*@X[Y((_ U4E
M\=>%88[.23Q!IRI>#=;L9UPXSC/L,@CGN"* .@HK*UGQ+HGAX1'5]4M;+SB?
M+$T@4MCJ0/0>M/N_$&CV,,$UUJ=I##<1M+#(\RA9$4;BP/0@ @Y]Z -*BLO2
M_$FBZU837VFZI:W-K"2)94D&(\#)W>G'/-<Y>>/]/O-6T"V\/ZI8WL=WJ'V:
MZ$;!RJ>6[ CGC)7KTZT =O16#=>-_"]C,L-UKVGPR-*T(5YP"'4[6!],'CGO
M4]OXIT&[UN31K?5[.74H\[K9)07!'48]1W':@#7HK'E\5Z!!K:Z-+K%DFI,0
MHMC*-^X]%QZGL.M-U/Q=X>T9YDU+6+.U>%E21))0&4L-P&.O(Y^E &U17*:_
M\0M T"/2)9K^VDBU.9%B=9AM$1SF7/=1C]1740S1W$$<\+K)%(H='4Y#*1D$
M4 /HK-UGQ!I'AZ".;5]2MK*.1MJ&9PNX^P[UA:SXR@L=;\,F&_LO[%U);J2>
MZ9P4V1Q;E(?. ,T =?167IGB71-9T^:_T[5+2XM(,^=*DHVQX&3N]..>:;HW
MB?0_$+3+I&JVMZT./,6&0,5!Z''I[T :U%>2+\1M=/P5U+Q9_HO]IVUT84_=
M'9M\Y4Y&?1CWKU:VD:6UAD;&YT5CCU(H EHKFO&7B"?P^NAR0O"D5WJT-K</
M,.%B97+'.>/NCFM#1O$VA^(?.&CZK:WIA($@AD#%<]"1Z'UH U:*Q].\5Z!J
M^H2V&G:Q975W%DM%%*&; ."1Z@>U;% !163JWBC0M!N(;?5=6M+.:89C2:4*
M2.F?8>YXK'\.>+X[CPQ>ZQKEY:VL$%_<6_G,0B;$E*)U/)( ^M '745FV7B#
M1]0TE]5M-3M9;",,7N%E&Q,==Q[8[YJ+3?%.@ZQ:7-UIVK6ES!:C=.\<@/EC
M&<MZ# )S[4 :]%847C3PQ/?I8Q:]I[73QB58Q.N2NW=G_OGGZ<U8T?Q-HGB#
MS_[(U2UO?(($HAD#;,],^QP>: -6BL?3/%>@:S?2V6FZQ9W=S$"7BAE#' ."
M1ZC/<5B>+/'^DZ3I&M1:?J]@^MV5M)(ELT@8[U7.",\D8Y'6@#LZ*@LI6N+"
MWF?&^2)6;'J0#4>IZK8:-8O>ZE>0VELF TLSA5R>@Y[^U %NBN6USQYHNF^"
M[KQ%::C9W,*HZVQ$HVS3!21'G^\<=.M<))\6[C3OAS)K4VLZ'?ZW<K$UO8P(
M4$!;;N5QO)8J&R>G2@#V2BN3TOQ?IMGX9@U'6_$^DW*RR-&MW;CRXW8?PJ"S
M$D=_Z5N2Z]I$.C#6)-2M5TPJ'%V91Y9!Z8;IUXH T**Y35?B'X=T_P )77B*
MWU&VO;:'*(L4PS)+@D1^S''?MS3Y/$UOJ$N@7.E:]IB6E[,R,DGSM<XQE(R"
M,,#G/6@#J**JV&I66IPO-8W45Q&DC1,T;9"NIPRGT(/:L^X\7>'K73!J4^LV
M:632F%9C*-K.#@J/4C!Z>E &U15>QOK34[**\L;F*YMI1NCEB<,K#V(I]U=0
M65I-=74J0V\*&221SA44#))/H!0!+15275+""&UEENX4CNY$CMV9L"5F&5"^
MI(Z5F7WC;PQILACO=>L('$S0%9)@"KKC<#Z8R,_6@#>HK-U3Q!I&B64=YJ>I
M6UK;R$".220 .3R-OKQZ4V'Q'HMQH_\ :\.J6DFG;@GVE904#%@H!/8Y(&/4
MT :E%8^F^*M UC49M/T[6+.ZNX02\,4H9@ <$^X!]*V* "BN8UK7KP>*M+\-
MZ3Y?VJ=3=WDLB[A!:J<9 _O,WRCTY-7IO%OAZWUI=&FUFR34F8*+9I@'W'HO
ML3V'6@#9HKF4UZ\L?'G]@ZEY9MM0A:?3)E7:24QYD3>I (8'T)]*Z:@ HKE]
M0\>Z)IOC*U\-7-W EU-$79FE \M\H$0C^\V[(^GO6;HGQ$TP17:>(=7T^RN5
MU.YM8$=PA,<<A1203[=3QF@#NJ*R]8\2:+X?CB?5M3M;-9B1'YT@!?'7 [@>
MM:%O<0W5O'<6\J30RJ'CDC8,K*>A!'44 245'//#:V\EQ<2I%#&I=Y)&"JJC
MDDD]!7&R^/;+4/$OARRT'4K*]MKVYFBN_+;<RA86=<>F2O7OS0!VU%4%UK3'
MTN;4UOH#8P[_ #+@.-B;"0V3[$$'Z57U7Q3H.AQV\FIZM:6BW S"99 -X]1[
M<CGI0!KT4R&:.XA2:&1)(I%#(Z,"K \@@CJ*?0 4444 %%%% !1110 4444
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M1@*H& !^% $E%%% !1110 5X9X@MKB[_ &FK&"UO9+*=].8)<1HK,A\F3G#
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MXKS>S*'3OA";DJ;#8H?=]WS_ ++^ZS[[LX]ZZ2':?C?<_9L8&@*+O;TW^?\
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MGD_V>) ,;QG=O/TZ54\1>#[*W\%2W]SXNU9UMK87*P7]XLUL[JNY4>,C# D
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M6(VLC2PL%^97( )W=3D #GT'I3[/Q?H%]I=WJ4.I1"UL_P#CY:4-&8>,_,K
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MZCGG(JK<V<WACP^EIX2T&VF8/M2V\X0(F0278D'/.,]SFJVG^(K2U/B.[O\
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M7P9X;GUL:S+HMF^H!Q)YYCY+CHQ'0L/7&:U+?3K.TNKJZM[=(Y[MP\[J.9&
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MDATFPAM%E;=(4'S.?5B>3^)K@YOB>FK^#4U;2)5MITU."WF5T+!86N#&#EE
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M^HZ?;75HF"L,L895(X!'H1[4V/P_H\6BG1DTNT73"I4V@A7RR"<\KC!YY^M
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M>MV^BZ7:FS-O86\1LHVCM2D8'DHV-RKZ X'Y5)_9=@9;R0V4!>]4+=$Q@^<
MNT!_[PQQSVH \XUO2=8DN=2N[CQ)IUYJR^'[R."UL;,Q221N!AB?,;(# 8]R
M:VM%O_"[>$O!:W#6\AD6W73E52[+.(L<!>1CY@2>!WKH]'\-:)X?\W^R-*M+
M(S8\PP1!2V.@)]!Z4RQ\)^'M,U234['1;&WOI,[IXH55N>N#VSWQUH \VLW4
M_"[XEIN&\:CJN5SR*FT!DBU/X6R79 MSH3I;EN@G,47'U*YQ^->A_P#"*:!]
MLOKO^Q[+[1?QM%=R>2,S(V-P;U!P,^M37?A[1[[2(M)NM,M9M/B55CMWB!1
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*]<\ '@YX .XHKSZS\6:YJ?@>RO_ #])TV[^V26M_>W1Q! (W=2ZJS#<25&
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M.* %;Q;X>76O[&;6+,:EO$?V4RCS-W7&/6MFO._B)_R.7@#_ +"K?^@5Z)0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %>7_#&"_N?AEJD.EW8L[][^
M\%O<,@<1OOX)!!!&:]0K T7P7H7AZ\>ZTNVF@D<L67[7*R$L<L=C,5SGOB@#
ME]<B\:>+/#LWAR]\,V=E]K58KC4&OTDB09&72,#<3QD XP<<U=_X12^?XK7&
ML21@Z3+H/]G^;Y@W%_,!(QUZ=Z[JB@#PW7!X@M?@P^B-#I\FGVOE6Z:I;WBR
MK=HLRJBQH!D,3@')XP>O;TW2='O+3Q[XCU66-1:7T%FD#!@2QC$@;(ZC[PHB
M\ >%H=4748])C$ZS?:%7S'\I9.N\1YV!L\Y KI: /*H?!^N:?9Z+.^D0ZG]@
MU2^N9=/:= '69F\N0%OERN<X///K3+_P;XEU#0/&NG26%I#)K7E7-L89E\M6
M4(/)(X.1LQNP >O%>L44 >?WMOXH?7="\41>'E:Y@MI[2[T[[;'O17*E75_N
MGE>1[UD:GX.\3:IX9\<0SVENM]K5Q;S6T4<X*@*(\J6..5VD9.,XR.M>KT4
M<EXST"ZU(Z-J5G8VVH7&EW#2&RN" L\;H4=06! 89!&>,BKGA:VO8Q>3WFA:
M?HRRNHAMK;:TFT#K(R_*3DG '0=S70T4 >=:U/JEK\9;>?2[)+YTT!O-MC*(
MV=#./NL>,@XZX&,\U0N?!^OWEA=ZO=:;;S7]WKD.I3:29U*O!&FQ8BY^4MT;
MTR!7H_\ 9-D=;&L>1_IXM_LHEW'_ %6[=MQG'49SC-7: /)M6\*:QJ9\2R:A
M96.E6&K:2D:N+A ED\3.RB0C&<Y!+#@<CG&2_6K_ ,0ZGJG@8ZK86MD@U>)M
ML5T)S<,(G)D7:,! ,^I^<=,<^IS0Q7,$D$\:20R*4='&592,$$=QBL'2/ WA
MO0K]+W3]-$=Q&I2)WE>3RE/4(&8A!_NXH Y2V\,ZOHSWFEVGA71]0CFO9)K;
M5+HQE8XY'+D2(1O8KN8#'!XY%>E@!5"@  #  [4M% 'EVD?#_5F^%NK^';LQ
M6M_<7TEU;L7#*")%DC)([$J,UK/9>)/%.N:%)J^C1Z39:5<?;)3]K68SS!"J
M! O106)RV#[5W=% 'F=GX-UJ'1_B/;O!&)-<GN7L1YJ_.'1@N?[O)'6I+;PM
MKNCZ7X+U&SLXKG4M$LC:7=B9PGFHZ*&VN?EW*R@\\'GFO2** .&L/#.H:W?^
M(]4\06D=D=6LETZ*S642M%" V2S#@L2Y.!TQUK#TOP1XB;X?ZS'J:1#Q'</!
M);E901FV2,0_-T&6C)/^\:]5HH X33-'U_0_!5M&FF6>H:A<74MUJMG-(!YW
MFLS,$<_+N!*CG@A3TJ/P_I&NZ!IVNWNF:#:64M[=126FC?:%\N( *LC%E^52
M1EL+QP*[^B@#SOXB?\CCX _["K?^@5Z)6!/X+T*ZUZ'6Y[6:6_AE\Z)WNY2J
M/C&0F[:/RK?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% "*JJ,* !UX%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
/!1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>svb-firstamendmenttoloan005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 svb-firstamendmenttoloan005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVE:);.]S?+_JF=MV(U;HQZ$XX )S0!M:/X^N-=DUJ.PT)WDTBZ:TF1KI5+R
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MB:!PLT7[IEP^-OS;<8SWK<U;6X?'%[X7L-)M;WS[;5(+^]\ZUDB%HD0)*N6
M&XDA0!GO0!Z77GFLZM>Z=\7HHK*QN-0EET$^7:QR!%W>?RS,QPH &,]>0.]>
MAUQQ@F_X7,+CRG\G_A'RGF;3MW?: <9Z9QVH ?:>.OM7AVZOUT6^.H6MZ=.E
MTU-KN+C(&-P^7;\P.X\8JM<?$)]/TO69]2T&YMKS2!#)=6BS))F&0X$BL.&
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MU219+&4,V"2GSKN!(Z8XY[5W7P_N-0N= G-[<7=U EW(EC<WL92::V&-C."
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M>H!-=7H?B2ZO]6N='U;2CIFI0PK<+&)Q,DL3$KN5P!T(P00,<=<T =#6/?Z
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFFBMOB7IL)/]F0"9HE'W48B5>/JJC_OD4 >IP_$WPG<:2=6CO[DZ:'\MKO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M35V/QAH3^&6\1O?+#I2EP9YE*?=<H?E(SG<" ,9/I2>"H[>+P-H*6@40?V?
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M=FRX,(^]$_5E;_:R<DGKG/.:Z&@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "D8E5)"EB!G ZFEHH Y?P_X]T?Q-K-[I.G
MI=B[L21<I-%L\H@D8.3SR,<9K2.O1_VY+I"V5X]S' +@E479L)(!W%L9)4@
M\\'M7E'C/_BWGQHTGQ:G[O2M9'V:_(X56X#$_AL?W*M7JOA]&GMYM6E4B747
M\Y0PY2$#$2^WRX8CLS-0!C:/\2-(U\W@TJSU2[-FVRX$=MRC<\8)YZ'IZ5;G
M\=:5;^$3XGDBO5TU69)28,21%9#&=R$Y'S BO&_AA-K<5SXG_LF*!H6URT%V
M[2$2+$9V#; !@\9SDCC/6O3/BREO%\)O$<5N$ 4*75>SM*CG/N=V?QH NO\
M$SP_!IECJEX+ZTTV]($%Y-;-Y1)Z9*YV]#UQTKH-6U[2]#TA]5U*]BM[%%#>
M<QR#GIC'WB>P'6OGK5M9NKWX>^"_!FHV\6F:9J4<3C6'<RIA2>-N!M()7//
M([<UN_&:S.FS_#_1BSMH\$BPL7.0VPQ*"WOMS^9H ]1N/'>FV%C;:AJ=IJ&G
MZ?<LJQW=S!B,;ON[L$L@/JP%3>*/&ND^$-/@U#5!<&RF8*EQ!'YB9() .#W
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MQO ]O=I@SFVBC@4@D&1@%7('.,G)QV!- &EINM6&K3W\-E<+*]A<&VN /X9
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M^A1OO_ NV_\ CE '0T5SW]N:Y_T*-]_X%VW_ ,<H_MS7/^A1OO\ P+MO_CE
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M7/\ H4;[_P "[;_XY1_;FN?]"C??^!=M_P#'* .AHKGO[<US_H4;[_P+MO\
MXY1_;FN?]"C??^!=M_\ '* .AHKGO[<US_H4;[_P+MO_ (Y1_;FN?]"C??\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP#NSCKQUJY0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOGKYO3/W,YZ>U %ZBH5N[9[N2T2XA:YC4.\(<%U4]"5Z@&IJ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#A_&JJ_C3P
M,CJ&5KZX!!&01]G?BN%\:,_@[PGXD\&7!/\ 9MU ;O1)&/1?,4R6^?5"=P_V
M37L=]H]CJ-_I][=0E[C3Y&EMFWD;&92I. <'@GK57Q)X5T;Q=IZ6.MV8N8$D
M$B#>R%6'&05(/<T <MJX_M3QE=P:=HFE75W8Z=$EY>:K,_EI'(7941 I'9B6
MX[#FN4T&VAU6S^$T%ZBW$)6\RC_,K!(R5!SU VKQ[5Z=J?@S1=6U1=1NH)O/
M\M89!'<21I.BDD+(JD!P"3P<]<=*2P\%Z'IDUC+:VTJFPFFFM0UP[+"THPX4
M$X"D?P]!DD=: .7\/>'M'F^)GCB.73;9X4%H$B:(%$\R$F0A>@+;5R>^*Y#P
MZ-3O-+^'-M:VMC>[+*]EBAU&5DB9T=5!X5LLJ$XX[FO:;71[&SU74-3@B*W=
M_P"7]I?>3O\ +7:O!.!@'M64_@;06T*QT=+:6*VL&+VCPW$B2P,2<E9 =PSN
M/>@#*\+>%Y!8:_I^OVFD/8WMZ)QI]I(9H8250LI#*N,LH?&.]=P!@8%<\?!&
M@MX:N?#[6CM873^9<!IW,DS[@VYI,[B<J.<]L=*Z$#  '04 %%4-3NM0M4C.
MGZ:+YF)W@SK%M'XCFLW^UO$?_0KK_P"#!/\ "@#H:*Y[^UO$?_0KK_X,$_PH
M_M;Q'_T*Z_\ @P3_  H Z&BN>_M;Q'_T*Z_^#!/\*/[6\1_]"NO_ (,$_P *
M .AHKGO[6\1_]"NO_@P3_"C^UO$?_0KK_P"#!/\ "@#H:*Y[^UO$?_0KK_X,
M$_PH_M;Q'_T*Z_\ @P3_  H Z&BN>_M;Q'_T*Z_^#!/\*/[6\1_]"NO_ (,$
M_P * .AHKGO[6\1_]"NO_@P3_"C^UO$?_0KK_P"#!/\ "@#H:*Y[^UO$?_0K
MK_X,$_PH_M;Q'_T*Z_\ @P3_  H Z&BN>_M;Q'_T*Z_^#!/\*/[6\1_]"NO_
M (,$_P * .AHKGO[6\1_]"NO_@P3_"C^UO$?_0KK_P"#!/\ "@#H:*Y[^UO$
M?_0KK_X,$_PH_M;Q'_T*Z_\ @P3_  H Z&BN>_M;Q'_T*Z_^#!/\*/[6\1_]
M"NO_ (,$_P * .AHKGO[6\1_]"NO_@P3_"C^UO$?_0KK_P"#!/\ "@#H:*Y[
M^UO$?_0KK_X,$_PH_M;Q'_T*Z_\ @P3_  H Z&BN>_M;Q'_T*Z_^#!/\*/[6
M\1_]"NO_ (,$_P * .AHKGO[6\1_]"NO_@P3_"C^UO$?_0KK_P"#!/\ "@#H
M:*Y[^UO$?_0KK_X,$_PH_M;Q'_T*Z_\ @P3_  H Z&BN>_M;Q'_T*Z_^#!/\
M*/[6\1_]"NO_ (,$_P * .AHK-TR]U2ZDD6_TD6* 95A<K+N/I@#BM*@ HHH
MH **** "BBB@ HHHH **** /(-*T"ZU;PYK.H:20FNZ5XDO[FPD/\3"3YHC_
M ++K\I_#TI=*\6:;JOB7Q'XC>.7[(OAJ.2YMP2LD91I?,CXP0P(([>M>GZ5H
M]CHL5Q'80F);BYDNI07+9D<Y8\GC)[=*S[?P5X?MM1U>_BTY%GU=#'??,Q69
M3URN<#.3G YS0!P.GVMW8>+_   )-)T?2H)1<)!!92L\WE?9F.V1BHW8.TD\
M\UEG2-/?X+>+[Y[2%[HWMZXF9 74K.=N#U&,9X[D^IKT>V^'?AVU^RLD-XTU
MK*DEO/)>S-)%M! 16+9"88C;T.>15_\ X1+1O^$?O-#^RM_9]X\CSQ>:V6,C
M;FYSD9)[&@#D-0TNQTKQ9\.VLK6*"0O/$SHH#.IMF)W'JV3SSWYKF-%T7Q%K
M?@2*>&Q\.PRRWS7?]J7%U(MRMPMP26;]V<-D;,;NG%>P7.AZ?=W>FW4T):;3
M69K5MY&PE2AXSS\IQS66W@+P\^JM?FVFRUQ]J:V%S(+=ILY\PQ;MA;/.<=>>
MM &W'IME%J4VHQVL2WLR+').%^=U'0$^@JU6?#HEA;Z[<ZU'"1?W,20RR;V(
M*+T&W.!^ K0H **P9=5\0),ZQ^&UDC#$*_V]!N'8XQQ3/[6\1_\ 0KK_ .#!
M/\* .AHKGO[6\1_]"NO_ (,$_P */[6\1_\ 0KK_ .#!/\* .AHKGO[6\1_]
M"NO_ (,$_P */[6\1_\ 0KK_ .#!/\* .AHKGO[6\1_]"NO_ (,$_P */[6\
M1_\ 0KK_ .#!/\* .AHKGO[6\1_]"NO_ (,$_P */[6\1_\ 0KK_ .#!/\*
M.AHKGO[6\1_]"NO_ (,$_P */[6\1_\ 0KK_ .#!/\* .AHKGO[6\1_]"NO_
M (,$_P */[6\1_\ 0KK_ .#!/\* .AHKGO[6\1_]"NO_ (,$_P */[6\1_\
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M?'K4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSDH#@%A[]L5RFO\ Q \4^'OA99>(99-$N=2>\\B7[.3- RG=C#(^-PVC/)H
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M]=BTVPAM&M(K*VCMF&UH4B4(1Z%<8HL=-L=,MS;V%E;VD!.?+@B6-<^N ,4
M>1^%(;;6=+T+7-*\0POJ]GH<EE#IUK$%8$1$;9!N)&U\$$@ G;ZBN!N+G3F_
M9O2W>2'^TEU9C)&Y'FB3<<DCKG:1S7TQ8Z3INF-*UAI]I:-*<R&"%8RY]3@<
MU$V@:,\TTS:18-+,P:5S;(3(1R"QQR?K0!AV/C?0+;4M%\-R7O\ Q,KRRCEA
M4(2C#;Q\W3)VG\OI63\<?^22:O\ [\'_ *.2NKO/#MI?:SIU_+% !IYWPA80
M'WX8#+?W0&)VCO@]JU)H(KA DT22*&#!74$9!R#SW! - 'B.IVAF\6?"3^QD
M07*6JRSF  8MPL98G'8CS!^)]:R[NZMK#Q%\8(KN>."2>S(B21@#(2K8VCO]
MX?G7O5II6G6$TDUGI]K;2R_ZQX850O\ 4@<TDVCZ9<7;7<VG6DMRR&-IG@5G
M*'C:6(SCVH ^??$R@_L\^"9< JE_'N;^Z/WW4U]$VLUO<6ZR6DD<D!SM:(@J
M<'!QCWS47]E:=]A:Q^P6OV1CDP>2OEG_ (#C%68XTBC6.-%1% 5548  [ 4
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M,_VN1^LE?2[:7I[23R-86I>X&V9C"N91Z,<<_C4/]@:,81$=)L/*#;@GV9,
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ME>8=^ .VP-^% 'OVGZ[I6K2/'I^HVUTZ*'98I QVG@-QU!P>>G%<[\3/&O\
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M;ZDBS,IR(\>;PWIU'7U% 'O[>(M%73X;_P#M6S:TG8I#,LRLLK#((4C[QX/
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M;;2S)=20XVK"0X4''8YP/J*K?V1>^'/B_JF@V4#'2/%D'G-MX6$@_OC[?*9
M,=Y$]* /9+>XANK>.XMY4EAD4,DB-E6!Z$$=14E(JA5"J % P .U+0 4444
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MV*U^R?9/LT/V;&/)\L;,=?N]*GKS+XE^*]=\->)_"UEI=ZL<&L7)@F62%7V
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M/N;:2%#*Q5064KDD GC/I5V::.VMY)IG"11J7=VZ  9)-><^$/%&N_$BZO\
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M@L(8^![\'CVKL[M!XWU#6$LKK39]/@A?2V63+G<P!E8;3Q_ H)[H<=:[?[-
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MC3T;5K;7=&L]5L_,^S7<2RQ^8NUL$9Y%6S%&8C$8U,9&W81QCTQZ4Y5"J%4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<#\1KZ\AU3PM8
M6^L7.E6]]>O%<SV[JC;0A(Y8$#D>E '?45Y@+O4-!\9Z!8:5XMNM?AOYF2\L
M[IHIFBB"Y\T,B@J ?7@YKMM#\1VVN7&JV\<,L%QIEVUK/%-@'( (<8)^5@<@
MT ;-%9'AKQ#;^*-)_M.SAFCM6FDCB:4#]ZJ,5WC!/RD@XK7H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *\T^*QTY-6\'S:Q"DNF1W\AN1)"94V^6?O*
M <C..U>ET4 >-ZA<>&[[4M'7X<Z>8M8%_$99["QDMXTMP?WGG':JE2.QS[5=
M^(1U#PUXFDO=(B9G\468THA/X+L$"*0_\ 9_^^:]7KF?^$6NKOQ9#K6K:M]L
M@LF=M/LDMQ&D#,,%F.278+P#QC)XH V-%TJWT/1++2K48@M($A3W"C&3[GK5
MZLO4M+OKZX62VU^_T] NTQ6\4#*3D_-^\C8Y_''%4O\ A']6_P"AQUC_ +\6
M?_QB@#H:*Y[_ (1_5O\ H<=8_P"_%G_\8H_X1_5O^AQUC_OQ9_\ QB@#H:*Y
M[_A']6_Z''6/^_%G_P#&*/\ A']6_P"AQUC_ +\6?_QB@#H:*Y[_ (1_5O\
MH<=8_P"_%G_\8H_X1_5O^AQUC_OQ9_\ QB@#H:*Y[_A']6_Z''6/^_%G_P#&
M*/\ A']6_P"AQUC_ +\6?_QB@#H:*Y[_ (1_5O\ H<=8_P"_%G_\8H_X1_5O
M^AQUC_OQ9_\ QB@#H:*Y[_A']6_Z''6/^_%G_P#&*/\ A']6_P"AQUC_ +\6
M?_QB@#H:*Y[_ (1_5O\ H<=8_P"_%G_\8H_X1_5O^AQUC_OQ9_\ QB@#H:*Y
M[_A']6_Z''6/^_%G_P#&*/\ A']6_P"AQUC_ +\6?_QB@#H:*Y[_ (1_5O\
MH<=8_P"_%G_\8H_X1_5O^AQUC_OQ9_\ QB@#H:*Y[_A']6_Z''6/^_%G_P#&
M*/\ A']6_P"AQUC_ +\6?_QB@#H:*Y[_ (1_5O\ H<=8_P"_%G_\8H_X1_5O
M^AQUC_OQ9_\ QB@#H:*Y[_A']6_Z''6/^_%G_P#&*/\ A']6_P"AQUC_ +\6
M?_QB@#H:*Y[_ (1_5O\ H<=8_P"_%G_\8H_X1_5O^AQUC_OQ9_\ QB@#H:*Y
M[_A']6_Z''6/^_%G_P#&*/\ A']6_P"AQUC_ +\6?_QB@#H:*Y[_ (1_5O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,3M7!/4C''J:Z[4O&6JI>:N='T*._L-&.V]F>Z\IW<('9(EVG<54C.2,DXH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7 ^*Q_8OQ*\)Z^/EAO#)H]TWKO
M&^(?]]@UWU<O\0]#NM?\%WEMIZ;M1A*7-GR ?-C8,N">,G!'XT <-XAOIS\4
MO^$G21A8:#>6FE28/R%9U?S6/^Z98ORKHY!_;OQKB'WK?P[II<_[-Q<' _\
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M -/Q%XBU2V\2V&@:0=,AN;FV>Y\[4F;8^UE7RT"D$MSGKP!T-9>O>(+RTO\
MP3'JN@Z?]OO[XPR"7$QM6&/GB;L3U!ZXQFM#QI +R6&UU#P@?$&DM&3F#89H
M9L^CLN 1_$IR".:Y=_"GB)K;X?+-:RROIFHO-=;YU=K>$ME%9B?F*KM7(STH
M WV\4^(K_4];DT6PL)=+T:<V\JSNXGN9$4-((R/E7&0!G.3Z=J-KX^US4;/P
M>+'3[)KSQ!;7$C>8S+'"T84YX).W!/'4G XSFBV77?#=_P"*K"ST@WD&H7DE
M];WRSQB*!I$7<)@6W#:1G@'(K.\#:3?7%A\--1BMV:TL]/NQ<29 V>8J[..I
MS@]* .BTWQ1XA=/$NG7.F6EWKFC^48TLY#'%<"5=R'YSE<8.>>W%16'BCQ ^
MKWNAW3Z'/J T]KVUGLV<P@JX5DD!).<L#D'GTK,\1^&=;N[OQQ+:V3R1:A_9
MQB1950W4<7^NC!SQE<KSC.:=H^CW4'CJVU2R\(#1])N--FL=D:0I)&^Y'$DJ
MHV #M(&-QXYQG@ J>$/%?B"R\ ^%[W4&M;O^U-2@M$D8N9 DCON9B3RPP,8X
MQ7:7GB*YMO&R:&D,1A;29;[S#G=O215 ],?-7 Z=HOB.+X<Z'IK^'[I=0\.:
ME;W31-+'B\5)'+>4P;^Z0?FQ[9KH;:WUS6/B"-=GT2XT_3_[%FM(UN'0R^89
M$;Y@K$#/.!D_=YQG% %72/B!KT_@B3QAJ.G6$>FFU'V>WB=Q-+<%P@R3\JH6
M)'<]#[5LZ/XDUB/Q);:+KW]E2/?6\DUM-IKL55H]N^-@Q/.&!#<9P>*QK3P=
MJ=U\#+;PU<6R1ZG';JWV>8@J727S C$9&#M _&M#PKIEJ-=2YM?A];: D,#!
M[J6*%93(<#;'Y9.5QNRQQGCB@#J=%DU:73@VM06L-[O<%+9BR;<G:<GOC&:T
M:S]%O;[4-.$^HZ8VFW!=U-NTHD( ) ;(XY'/XUH4 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHJ/SX?M'D>:GG;=_E[ANVYQG'7&>] $E%1F>)9EA:5!*P)5"PW$#J0*'GAC
MECB>5%DDR$5F +8ZX'>@"2BJFG:I8:Q9K>:;>0W=LQ*B6%PRD@X(R*MT %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM'6S!U.&Y9YKE&80F/80V 1GACQW..1S5+3_ !'XD%OXITR=-.O-9T9XQ#.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% %34=*T_6+86VI6-O>0!@XCN(PZAAT.#WY/YUE?\()X1
M_P"A9TC_ , X_P#"N@HH Y__ (03PC_T+.D?^ <?^%'_  @GA'_H6=(_\ X_
M\*Z"B@#G_P#A!/"/_0LZ1_X!Q_X4?\()X1_Z%G2/_ ./_"N@HH Y_P#X03PC
M_P!"SI'_ (!Q_P"%'_"">$?^A9TC_P  X_\ "N@HH Y__A!/"/\ T+.D?^ <
M?^%'_"">$?\ H6=(_P# ./\ PKH** .?_P"$$\(_]"SI'_@''_A1_P ()X1_
MZ%G2/_ ./_"N@HH Y_\ X03PC_T+.D?^ <?^%'_"">$?^A9TC_P#C_PKH**
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBH/MMI]O^P?:H?MGE^=]G\P>9LSC=MZ[<\9Z9
MH GHJN]]:1WL=D]U MW*I>.!I '=1U(7J0*6:]M+>YM[::ZACN+@L((GD :7
M:,G:#R<#DXH GHJAI&M:=KVG+J&EW27-H[%5E0$ D'!Z^]7Z "BBB@ HHHH
M**** "BJG]I6?]K#2O/7[<8/M/D\Y\O=MW>F,\4:AJ=GI4,<U]<+#')*D*,V
M>7<X4<>I.* +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !33(BG#.H/N:=6)J?@_PYK5X;S4]$L;N
MY*A3+-"&; Z#)H V/-C_ .>B?]]"CS8_^>B?]]"N;_X5SX+_ .A7TK_P&7_"
MC_A7/@O_ *%?2O\ P&7_  H Z3S8_P#GHG_?0H\V/_GHG_?0KF_^%<^#/^A7
MTK_P&7_"C_A7/@O_ *%?2O\ P&7_  H Z3S8_P#GHG_?0H\V/_GHG_?0KF_^
M%<^"_P#H5]*_\!E_PH_X5SX+_P"A7TK_ ,!E_P * .D\V/\ YZ)_WT*/-C_Y
MZ)_WT*YO_A7/@S_H5]*_\!E_PH_X5SX+_P"A7TK_ ,!E_P * .D\V/\ YZ)_
MWT*/-C_YZ)_WT*YO_A7/@O\ Z%?2O_ 9?\*/^%<^"_\ H5]*_P# 9?\ "@#I
M/-C_ .>B?]]"CS8_^>B?]]"N;_X5SX+_ .A7TK_P&7_"C_A7/@S_ *%?2O\
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MV/\ YZ)_WT*/-C_YZ)_WT*YO_A7/@O\ Z%?2O_ 9?\*/^%<^#/\ H5]*_P#
M9?\ "@#I/-C_ .>B?]]"CS8_^>B?]]"N;_X5SX+_ .A7TK_P&7_"C_A7/@O_
M *%?2O\ P&7_  H Z3S8_P#GHG_?0H\V/_GHG_?0KF_^%<^"_P#H5]*_\!E_
MPH_X5SX,_P"A7TK_ ,!E_P * .D\V/\ YZ)_WT*/-C_YZ)_WT*YO_A7/@S_H
M5]*_\!E_PH_X5SX+_P"A7TK_ ,!E_P * .E5T8X5E)]C3JQ])\)^']"NFNM*
MT:RLIV0QM)!"$8J2#C([9 _*MB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC_P"C_\ B:/^$/\ #/\ T+FD?^ 4?_Q- %K^WM'_ .@M8?\ @2G^-']O:/\
M]!:Q_P# E/\ &JO_  A_AG_H7-(_\ H__B:/^$0\,_\ 0NZ1_P" 4?\ \30!
M:_M[1_\ H+6'_@2G^-']O:/_ -!:P_\  E/\:J_\(?X9_P"A<TC_ , H_P#X
MFC_A#_#/_0N:1_X!1_\ Q- %K^WM'_Z"UA_X$I_C1_;VC_\ 06L?_ E/\:J_
M\(?X9_Z%S2/_  "C_P#B:/\ A$/#/_0NZ1_X!1__ !- %K^WM'_Z"UA_X$I_
MC1_;VC_]!:P_\"4_QJK_ ,(?X9_Z%S2/_ */_P")H_X0_P ,_P#0N:1_X!1_
M_$T 6O[>T?\ Z"UA_P"!*?XT?V]H_P#T%K#_ ,"4_P :J_\ "'^&?^A<TC_P
M"C_^)H_X0_PS_P!"YI'_ (!1_P#Q- %K^WM'_P"@M8_^!*?XT?V]H_\ T%K#
M_P "4_QJK_PB'AG_ *%W2/\ P"C_ /B:/^$/\,_]"YI'_@%'_P#$T 6O[>T?
M_H+6'_@2G^-']O:/_P!!:P_\"4_QJK_PB'AG_H7-(_\  */_ .)H_P"$/\,_
M]"YI'_@%'_\ $T 6O[>T?_H+6/\ X$I_C1_;VC_]!:P_\"4_QJK_ ,(AX9_Z
M%W2/_ */_P")H_X0_P ,_P#0N:1_X!1__$T 6O[>T?\ Z"UA_P"!*?XT?V]H
M_P#T%K#_ ,"4_P :J_\ "'^&?^A<TC_P"C_^)H_X0_PS_P!"YI'_ (!1_P#Q
M- %K^WM'_P"@M8?^!*?XT?V]H_\ T%K'_P "4_QJK_PA_AG_ *%S2/\ P"C_
M /B:/^$0\,_]"[I'_@%'_P#$T 6O[>T?_H+6'_@2G^-']O:/_P!!:P_\"4_Q
MJK_PA_AG_H7-(_\  */_ .)H_P"$/\,_]"YI'_@%'_\ $T 6O[>T?_H+6'_@
M2G^-']O:/_T%K'_P)3_&JO\ PA_AG_H7-(_\ H__ (FC_A$/#/\ T+ND?^ 4
M?_Q- %K^WM'_ .@M8?\ @2G^-']O:/\ ]!:P_P# E/\ &JO_  B'AG_H7-(_
M\ H__B:/^$/\,_\ 0N:1_P" 4?\ \30!:_M[1_\ H+6'_@2G^-']O:/_ -!:
MQ_\  E/\:J_\(?X9_P"A<TC_ , H_P#XFC_A$/#/_0NZ1_X!1_\ Q- %K^WM
M'_Z"UA_X$I_C1_;VC_\ 06L/_ E/\:J_\(AX9_Z%W2/_  "C_P#B:/\ A#_#
M/_0N:1_X!1__ !- %K^WM'_Z"UA_X$I_C2IKFDNZHFJ63,QP%%PA)/YU4_X0
M_P ,_P#0N:1_X!1__$T^/PIX<AD22/P_I22(0RLMG&"I'0@XZT :]%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3O\ P*3_ !H_X230O^@UIW_@4G^-,_X13P[_ - #2_\ P#C_ ,*/^$4\._\
M0 TO_P  X_\ "@!__"2:%_T&M._\"D_QH_X230O^@UIW_@4G^-,_X13P[_T
M-+_\ X_\*/\ A%/#O_0 TO\ \ X_\* '_P#"2:%_T&M._P# I/\ &C_A)-"_
MZ#6F_P#@4G^-,_X13P[_ - #2_\ P#C_ ,*/^$4\._\ 0 TO_P  X_\ "@!_
M_"2:%_T&M-_\"D_QH_X230O^@UIW_@4G^-,_X13P[_T -+_\ X_\*/\ A%/#
MO_0 TO\ \ X_\* '_P#"2:%_T&M._P# I/\ &C_A)-"_Z#6G?^!2?XTS_A%/
M#O\ T -+_P# ./\ PH_X13P[_P! #2__  #C_P * '_\))H7_0:T[_P*3_&C
M_A)-"_Z#6G?^!2?XTS_A%/#O_0 TO_P#C_PH_P"$4\._] #2_P#P#C_PH ?_
M ,))H7_0:TW_ ,"D_P :/^$DT+_H-:;_ .!2?XTS_A%/#O\ T -+_P# ./\
MPH_X13P[_P! #2__  #C_P * '_\))H7_0:T[_P*3_&C_A)-"_Z#6G?^!2?X
MTS_A%/#O_0 TO_P#C_PH_P"$4\._] #2_P#P#C_PH ?_ ,))H7_0:T[_ ,"D
M_P :/^$DT+_H-:=_X%)_C3/^$4\._P#0 TO_ , X_P#"C_A%/#O_ $ -+_\
M ./_  H ?_PDFA?]!K3?_ I/\:/^$DT+_H-:;_X%)_C3/^$4\._] #2__ ./
M_"C_ (13P[_T -+_ / ./_"@!_\ PDFA?]!K3O\ P*3_ !H_X230O^@UIO\
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MT+_H-:=_X%)_C3/^$4\._P#0 TO_ , X_P#"C_A%/#O_ $ -+_\  ./_  H
M?_PDFA?]!K3O_ I/\:/^$DT+_H-:;_X%)_C3/^$4\._] #2__ ./_"C_ (13
MP[_T -+_ / ./_"@!_\ PDFA?]!K3O\ P*3_ !IR>(=$D=436-/9V("JMRA)
M/H.:B_X13P[_ - #2_\ P#C_ ,*='X8T"*19(]#TQ'0AE9;2,$$="#B@#5HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
6*** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>vrna-20201231_g1.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vrna-20201231_g1.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M\@ZH;*>GVM3O( T,UP/Y=\-?Y8=95<J1^M@7*O5!AW<NC%&C4A2#MM5P.Y.
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MF5RK183%BY]@7'W:)%2/QYW<Q"S2HQW*E1\TER@%?:PL%B STE[?.'R_?#L
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MR?H1TKP<+E\X*%_TB($X/FX53K(=* XK /5XUC2'O8:QC6&)$ DA(K7#J'B
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M,@2\/+'+)VFA#+8J&*\8NOZK,1=,J?)("%K!JE/:,$>!.@W\'QP9(7NSNZ(
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MB%5)^IHNB*RC?JJYH%S6[M1.M(M)L,L8RPO'640U.JJBQ$&.?\5.%O*X G'
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M[6\\3J)73,22B>WED(]]U!=;;NA"'W5(+A>IU8?<Q2?^!2=&%1D1QJ"W)M-
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M:%,9=FQ$7<V(D0@B.Q9I4 *"-0=E-90D6!]3>7M%7FC)&^+X V+ 8]&$-,L
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M)E? <PONL"\Q*ER"8A8,4IKC$E:2&;4^@#$*89/LZDRS*1L(2;.-95DY_^*
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M$3$)NBT2P;T/V;T1-]#;-5'>S('>I9$)JGW=%-'=(P+=!A,DQZW<+\/?_>W
MG$'?SS8]W@+>TO9=WQL!  D>)#$  S0!W;8B";^]3>WM$;SMTA0>V\<QWZT]
M$?.MWOXQW,Y!(J -X-W_]-\G/G9H6-[L;1P1[MX4#A<8SA$Q8 !, @,!4!,%
M[AGF?64^[A$;;A/O_1"T?> :,=^Q73@W$ /QS38 8-HIKN+%8N(-V>'>_6#>
M_=T2 =U:#N1:'N1:;BNQK>4TT]S>S> JL>48Q]RU_=H/40]03N#=_1+S#20+
M#AI>_A  < -=;AQG#N3[,-[=S> &<-V$'A$TO@\KD.!=CN?9$0!I#A$;3N9
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MRHX[E0"X#JFZC*)I(8+&>W-1Y=;4C,Q]]HHA3]Q<<V@DYP#S$42PM*(J2[T
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M;A)78Y'H(]*3#2V/:-C-%!:SHQRK(#,",0T%"CZP#!_80C?:X= 2I)?=+'#
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MG$]E:- 8)8P'A= IJ\]/N-#U#$T,_[4QX[10"Y50PJ!.$%7,\FA1'?/-%(5
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M4,?N/"/*MTM-_8-'OU;\^?,/ZO[)SDX5U-!4*K*WD4R<#TC>RP0:+)<1[]T
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M[B&_[*^)./1AEWQ"G+N2ODFSE!U7%=S[D/PV4?L9KF/DJE*]^5(D0>R:IT'
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MFX+IG8+=:)XBA3+THP !U9F^2 41!4/."Y_JZ:DEZJ+V!:(:A2C9#VS1J4M
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MN;89,%J/4'TU",+FG-OW]EFW7]TMQHJY?"4M$WG(@3]S? ='$YR+ZW]'>52
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M?H(ZJ ^-QV]I>FK[(.6PI!8*?5MK5)6PQIKLO&JD9>'JN+BWMI\VK6\O#0E
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*L[G-;K9Q0   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>vrna-20201231_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vrna-20201231_g2.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %9I8W1O<FEA
M(%-T97=A<G0    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,Q
M-P  DI(  @    ,Q-P  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MQI"W$?V9PDD=P@5AD9!X)&#@]^U,^)$8D^&VNJV<"T9N/;G^E %O_A-?"O\
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M34=5LM1:YMM-16N"D$BE=QPH&X#))X%7_"/B[3O&FC-J6DK.D23-"Z3H%96
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M2_#]KI/]HW.H!""+GR]FYRHXVG/0GM7;T %8.I^-M T;7K?1=1OFAU"YV>3
M+>1M^]MJX*J1R1CK7.>+_BS9>'-=&BZ9ID^LZD,!X8'VA21G;D!B6QV XKS7
M7?$5QXF^,WA6[O='NM'GBGM(7MKH$,"+@MD9 )'S>@Z4 ?1=%<EXV^(6G>"_
M(@FAEOM0N>8;.#[Q&<9)[#/ ZDGMUK!T?XPK/KUMI7B;P[>:!+=,%A>X8E23
MP,[E4@$\9YH ]+HK@/%OQ6MO"/BZ'1;S2IID=$D:XCDYVMG[J8Y.1C&16-/\
M<'TW4H8M<\(ZCIMI,<I-.Q5V7^\$*#/X-0!ZQ17E&I?&][$I<IX1U(Z5(VV.
M^G8Q"0>J@H0?INKO;?Q9I,_@]/$SW'DZ:T/FM)(.4&<$$#OGC [T ;5%>33?
M')G66[TSPCJ%WI<+;7O2Y55^N$8#Z%J[+1O'FF>(/"%YKNDK)+]CB=Y;5L+(
MK*N[:>W/8]/UH Z>BO)['XY#5+.3^R_"FH7M^KG%K;,9 (P!\[,$R.<C&T],
MYK=\"?%*T\::E<:9-ITNF:A"A?R7DWA@#@C. <C/0B@#NZ*\UU?XP>3X@N=)
M\,^&[[7YK1RDS6[$ $<'&U6) /&>*O0_$74;GP+-K]OX4O)+F&Z^SMIX=BX
M )?(3.!G^[VH [.SU.PU'S/[/O;>Z\HXD\B57V'T.#Q5FOGCX/>)]5T..>ST
M_P ,WFJV]Y=QK+=P;MEOV.[",. <\D5W^N?&2Q\/>+K_ $74]+F1;-2?/64$
MR'8&4!<=\CG/% 'I%%>>>%OBL/$>@ZWJKZ)+;0Z4@;:DXE:8D'"CY1@\>_45
ME77QGU:R@^UW?@'4X+#(_P!)ED=%Q^,6/UH ]7)"J2Q  &23VJO9:E8ZBKMI
M][;W8C;:Y@E5]I]#@\&N/U/Q^+OX;KXA\/:1<ZJMP3#);)D/!PVYFPK<+CZ<
MCFO./@SXEU72(?[.L_#5YJ-G?:@B2ZA%N\NVSM4[L(1P#N.2./SH ^@**XKQ
MG\2['PGJ$.EV]E/JVK3#*V=N>5!Z9."<GL "?TS1\-?%B+5_$<>A:[H=WH.H
M3?ZJ.X8D,>P.54@GMQS0!Z'6)XC\8:%X3%N?$%]]D%SN$1\F23=MQG[JG'WA
MUK'\=?$K3?!$D%J]O)?ZA.-R6L3!<+G +'G&3P.#TKR#XJ>,;[Q38Z6FI>'+
MW0Y(&D=1<ABLJL%Y4E5]/2@#Z/AE2>".:(DI(H9201D$9'!Y%<KXG^).A>$]
M<M=*U/[2]S<JK?N(PRQ*3@%B2/0\#)_2NDT[_D%VO_7%/_017G'CG4_#J_%'
M0],UCPN-1OYS (+QK@H$5Y2HR@^\%(8X;^M 'J%%>>^*?BU:>$_&(T2^TJ>2
M,(KM<QR DAE)&U,<G/'45DS?'%]/U"&/6_".HZ=9S\QSS.0[)_>"% #^#4 >
ML5!>7]IIT'G:A=06L6=OF3R!%SZ9-20S1W$$<T+!XY%#HPZ$$9!KQ7X]Z]>2
M6\.AOI$\=I'<1W":D2?+D;8X,8&W&1NS][MTH ]KCD2:)9(G5XW 964Y# ]"
M#3J\RT;XAZU;^"[V[O/!EY:+I%I"R?:)7C%RO"L5)CXP!N[\5TW@GQM!XP\*
MR:TUN+%897CFC,OF;-H!SNP.Q!Z4 =/17!?#[XH0^.]2O;(::;"2VC$J9N/,
M\Q<X)^Z,8ROKUJSI_P 06U+XFW?A.UTHM%9JS2WWVC[N%&?DV_WF"_>]_:@#
MM**\\\1?%VRTW7'T;P_I-UK^H1,5DCMLA58=0"%8DCO@8]ZE\'?%C3O$^KG1
M[ZQFT?4^0MO.VX.1U4' (;V(% '?5A1>-- G\3?\(]#J ?5 S*;<1/P5&XY;
M;M' ]:W:\.TD ?M17>!CYI3Q_P!<* /<:*\^U_XFZCINO7>F:-X-U+63:.$D
MFAW!2< G&U&]<5-X(^*-IXOU6?2KC3IM+U*)2_D2ON# '##. 01Z$4 =W17E
MM_\ '"PTO6=7TZ_TB:.33V>-"LP/GR*X7 &WY01ELYZ"M+0_BQ9:AX)OO$NK
M:>^G6MK/Y"HLOFM,^ <+PO/(_7TH ] HKR/_ (7G<+;K?OX,OUTIFVB]\T[3
M_P".;<^VZMOX=:UXH\37%SX@U6^M!H%PLBVMG&JB2)@X +$#/"ALY8]0<4 >
M@T5YA??&=9-2N+;PKX:OM?BM3^]N("0H']X;48X]SBNG\#^/-/\ '%A-+9Q2
M6US;,%GMI2"R9Z$$=0<'GCH: .EGGBMK>2>YE2&&)2\DDC!510,DDG@ #O6/
M_P )KX5_Z&;1_P#P/B_^*I_BZ,2^"=<C)P'TZX4D>\;5X[\(/ GAKQ9X6OY]
M<L'N+N*[,:R"=TV)L4C 5@"<ENH/:@#W.SOK34+<3V%S#=0DX$D,@=3^(XK*
MT#QGH'BBXN(=!U 7;VRJTH6)U"@].6 !Z=J\A^'EN?#GQTOM"T:[DFTT>;'(
M"VX$*N1G'&5;C/U]:R?ACXLC\*7VNBWTB\U74+IXTMK6T0DE5+[LX!P.5[&@
M#Z0HKSSP=\6K?Q-XC.A:CH\^D7Y#;(Y)-^2HR5.54@X!/3M4_B?XC7^B^()]
M)T?PEJ.MR6ZJ9)+?=M&Y0V/E1NQ'I0!WE%>?^#?BM;^)_$#:'J&DW&CZEM8I
M#*^[=@9(Y52#CGD=J;XE^+$>D>))-"T/0KO7=0A'[U+<D!3U(&%8DC//% 'H
M5%<KX+\9S^*;.^FU'1IM%>R<(Z7#D]B2>57&/I7,7?QH$U_<Q>%_#%_KMM:D
MB6ZA+*H _BP$;CW.* /4:*YKP3XXT_QQI<EU8))!- X2>WDP6C)Z'(Z@X.#[
M&MC69K^WT:ZET:V2ZOTC)@@=@JN_8$DC _$4 7:S]:UW3?#NG&_UFZ%K;!@A
MD*LW)Z# !->5:E\4/'OA.X@?QCX7LHK25MNZW)&>Y <.ZYQV-;?Q;O[;5_@V
MVHVAWP7+6\T1(Y 9@1]#@XH [[2=6LM<TJ#4M+F\^TG!,<FQEW $@\, 1R#V
MJY7A_AGXJ7'A_P !Z=!8^%-0U"ULH=EQ>@F.%6R2<,$8=^Y%>F^"_&NG>-](
M:\TX/%)$P2>WD^]&W;Z@]C0!T=5K/4[#4?,_L^]M[KRCB3R)5?8?0X/%9OBW
M7KSPYH+ZAI^D3ZO*KJIMH"0VT]6X5N!]*\3^#WB?5=#CGL]/\,WFJV]Y=QK+
M=P;MEOV.[",. <\D4 ?0]5-5U.UT;2;G4=0?R[:VC,DC 9.!Z#N:X7Q!\7[+
MPUXRN=#U/3)5CMTWFZ64'=F/>H"X[DA>O4U4TOXHVWB_PMXCGO?#;?8-.MMT
MT37(<3JV?E^Z,' )[T ==X/\;:7XWL)[K2$N(UMY/+D2X0*P.,@\$C'XUT5>
M<> ==T.R^&NH:YHGA]M-M;>60M;1S&:28JJ\[FY.<XQSBLZZ^,^K64'VN[\
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M_:+66'=M\Q"F<9QD8KR/3O@=JNC^9_9'CN\L/-QYGV6V:+?C.,[91G&3^9H
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MQT16^&S%@"5NXBI(Z'D?R)K+U[_DU^+_ *\K7_T='7;^._")\:^&_P"R1?\
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M:S)<75R 265MK'G( SP!@GC-<]X.L]8MOVAI8O$MY#=:G' S3S6Z@))F!=N
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MZNL5W DZ*X 8*RA@#C/.#5F@))Q=F%%9T>M6\GB2;1%27[3#;+<LY V%68J
M#G.<CTK1H'*,H_$@HHHH)"BBB@ HHHH *R/$OA;2?%NF?8=;M_.C5MZ,K;7C
M;U4CI_*M>B@#S&/X!^$TFWM<ZHZY_P!6TZ;?T0']:[W1- TSPYIJV.C6B6MN
MO)"\ECZDGDGW-:-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:WF*EE'S,V]3M89POKCM4.NZ>QTWPY'INE/:10ZM;RM:Q1+_ *.GS%B1'E0
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MHHHJ3S@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LOPYHW
M_"/^'[;3//\ M'D;OWNS9NW.6Z9/KCK6I106IR47#H]?NO\ YL****" HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH QM4T*:ZUFUU
MC3+T6=_;Q/ 3+#YL4L3$$JR;E/# $$,/?(IEOH-U+KEOJNMW\=W-9QNEK%;V
MY@BC+\,Y!=V9B./O8 SQDYK<HIW-UB*BCRWZ6V5[>NX4444C **** "BBB@
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MB\!S>)6U^7PW:OJ+2^<TA=RC/G.XQ[MF<\_=K3O/ GAK4/%]KXHN]*C?6K4
M178D=2, @94':V >I!H \DLOB=XGF^!WAS79-80ZQ>ZZEG<2^1$"T7FL"FS;
M@?*%Y S^=0^./$/BSQ1;?$=+?Q!9:9HGA]'LWTM[17>[4H06,A(9"3G;C@],
M<<^E'X-^ /[3GU >&K<74\RSM(LL@VN&# J V$Y'.W&>AXXJQK/PJ\$^(=>D
MUK6/#]O<ZA*FV28NZ[_EVY*A@I;'1L9&!SP* //M.\=:AX LO T^LW>[PKJ/
MA2,+&8T'DW4-NK_? W?.H"@$G)/'2O0OAM=:WJ_PVT[4/%]P+B^U&)KA\1K$
M$B<DHN% Z(1SUYK)^(OPS_X2WP9H7A;1TM+;3=/N[?S//D<O%;1J4VQG!)?:
M<98_4UWS6D#6)LS&/LYC\KRQP-N,8_*@#PS2O"VA>*?B]HMW\.])MM,T#PF[
MB\U2U0(+Z;C$2MUDQC!8]F;G[N>4O],T74/@[\1=?U>&WD\1Q>(95^US >?
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M;A3(1_" 0"",5[?7%_#'X>P> /#\L<IAGU>_D-QJ-U$N%DD))"KZ(N2 /<G
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M)$H !#GECR2.W(KV^J@TK3QJBZD+"V%^D/V=;KR5\U8LY\L/C.W/.,XS5N@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O'/V7_\
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M Z#)*\4[X-Z[??\ "?2:1X=U"T\0>&I+4S76HVOAY-+6"8?=7"*-Q^OJ<=*
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M/G[DGCKSQZC7/6?@O3K+Q_J'B^&:Z.H:A:I:RQLZ^4%7;@@;<Y^4=S]*Z&@
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M)BE?"[L+ZY9>,9(Y[QKX?U*/X7:C;2ZEK.NR2O9L(F@C\V-5N(R_EBWB1B<
MGN1MXQ5M]%TKQ1X$UG0]';7(_/3*2ZPM\'CF&&C=&N_F(5T5L*< CL30!U$N
MMV\?B:WT,1S274UK)=ET4;(HT95^8D]6+\  YVMTQ6C7!^!?[<U6#5O%>J:7
M)8:OJ$<5M;V-_NB\F.!",'@D*TSS,"!RI4UTOAV_NM9\(V-[=F);NYM@SF%2
MB!R.H!)(&?<_6@!_A[6AX@TMM0C@\JW>>6.W;?N\Z-'*"3IP&V[@/0BM2O'=
M&T5==\"_"VUETZ2ZL[68QZA&$9D39:S1N),<;3(-I!X.=IR#@O/@F+3]#U"[
MTW0I8M1LO$T1TQXX7\RVM3=Q%Q /X(2CRDJF$P6.* /3-*UVVU>^U6UMDF5]
M*NQ:3F0 !G\M),K@G(Q(.N.<TSPUKG_"0:/]K>W^R7$<\MM<6Y??Y4L<A1AG
M R,KD' R"#BN8\-ZBNC>-/%5IJ%CJJ/J.LI):RII5S)#(AMX$W>:L90#<K D
ML ,'.!5[X?D2OXHN(A^XF\07)B(/#;%CC8C_ (&CT =?533-4L]9L?M>FS>=
M!YLL._:5^>.1HW&" >&1A[XXXKR&TL-1O?B'H]\WA[[%*VJW,6I!=%N!+Y!C
MF4":]=BEQ&VU" !M&4&1A0>M^%FCZ?H>F:A8PZ%_9>HQ7US]I?\ LYH!-&;F
M9H=LNT+*HC*XVL=HP.* .G\3:W_PCOA^;4_L_P!I\IXD\O?LSOD5.N#TW9Z=
MJU:\5US0EFCU^.\\-ZE>^)I=<$\&H1V$C?Z)YT;1[;C&WRUB 4Q!L[@WR=33
M_%]IJE]XQDN;706AO[/6K/R;A-&N)[A[821;I$O@_EQQD,X,(!P-^1RQ ![/
M6;K&KS:7Y"VNCZAJTLQ.(K)8QL '+,TKH@Z@ ;LG/ .#CSV'3+A?B,O@HPLV
MD07Y\3*^/D6)B2L/7K]J+2 >BUU7CKQ'J&AV-M;:/8WDMWJ#M&MY!I\UW%8J
M!\TLBQ*Q)Y^5<?,>I !( %3Q_IUSI&CWFF65_?SZR'^RV,,:)-F,'S0_F.J(
M4((.6Z\#-:^@:[;>(M*%]:1S0A99()8;A0LD,L;E'1L$C(92,@D<<$UYOK>C
MV3Z'X2T[3H/$5MX>LGF,FI6EA<C4X9E7Y>/+\Y%EW2EW5.>!E0W/7?#6WO;/
MP9':7UO+#%!<3)9M<0>3--;[R4DE3C$C Y;(!).2 2: .LHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF_ ?_ "+M
MU_V&M5_].%Q725S?@/\ Y%VZ_P"PUJO_ *<+B@#I**** "BBB@#%\2^)8_#<
M6GEM/O-0FU&\%G;V]GY>]I"COR9'10,1MSGTJ3P_XBM_$-O=&*WN;*YLKAK:
M[L[M5$L$@ (!VLRD%65@58@AASU P_B'I=]JLWA2/3I+R!HM=266ZLXE=[=/
MLTXWG>K*!D@98$?,.Y%87C+P?/INBV2Z=YVI6UQJ_P!LUV2[LFOVN\Q,J-);
MPF,RHKB+]V@ &U6VD*: /3ZQ]6U_^R_$&@Z9]F\W^V+B6#S/,V^3L@>7.,'=
MGR\8R.N?:O-_[-GL/!<=I'9C5-,N]8:1X)/#-Y':Z='Y1.T:<7\R6,R#(&=B
MN^_&4%9,'AWQ;<:!H-IHR3:7>6^MZHUK.^GR116L+03^61&23#&V[:N2=A8=
M2,$ ]U=UCC9Y&"(H)9F. !ZFN=TKQBFL26TEGHFKG3+P_P"C:HT,?DR@CY6V
MA_-53CAFC"D8.<$$U=-TR#5?A?<:1IFESZ ;FRGM#:W*,'@E965BS'F3YB6\
MS)WYW9.:3PIXD8Z7I6CWFAZO::G#"EO<PM82"&!D7:S"<@1.GRY!5B2".,Y
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MBBO =$\5:[IWPD2RU?5[V6[U"RM=2TO49;EC-(IFB6XAWYW$HS ]?N2@=%H
M]^HKAM=^(7]CZY<V'VWP;'Y+ ;=0\3_99QD _/%Y#;3S_>/&#WK&^(.NZE?7
M4 T2_GL[+1]1L$O)K28J+BXFGB'D;A@E%B<LPZ$RQ_W2* /4J*\PU@WVM_\
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M'<9JSK'@N/6C<P3:WJT&EWB+'<Z7!)$()4"A60$QF2-648(C=>I(P22>EHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_"T/[#RGV+^Q_MF-OS>9YVSKZ8[5*.R@JCYN1]'?T.CHHHI'.%%%% !1110
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MHL$\/.G)1;6O:47][3LOF6Z*Y&V\1>,9;N&.X\"^1"[JLDO]KPMY:D\M@#G
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M-R.VCOZ'24444CG"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF_ ?\
MR+MU_P!AK5?_ $X7%=)7-^ _^1=NO^PUJO\ Z<+B@#I**** "BBB@ HHHH S
MM=T&P\2:6VGZL+AK5\[TM[N6W\P%2I5C&REE(8Y4D@^G IL7AW3HO#DNA%+B
M;3Y87@>.XNY9F:-P0R^8[%\8) YX[8K3HH P-2\#^']7GCEO[)W*0I;LJ7,L
M:31*<K'*JL%E0$GY7##D^ISOT44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7-_$'1
M[W7_  )J&F:9&)+J?R]BLP4';*K'D\= :Z2LGQ1K\7A?PW=:Q/"\\=MLS&A
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M?E;/0XV@]VW#'&:E\$^-/^$TLKNX_L+5M'^S3M#LU.W\HO@D<>I&/F'8\9-
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MW4J,)039YE?$U(5'&)[?_P +H\._\^6J?]^H_P#XNC_A='AW_GRU3_OU'_\
M%UXA16GU>F8?7*I]0Z#K5OXAT2WU2R25()]VU9@ PVL5.0"1U![UHUR?PO\
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MPJ>Q_P"0A;_]=5_F*@J>Q_Y"%O\ ]=5_F*M[&<=T=C1117$>F%%%% !1110
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M.4W;Q'GY>O&<]:VZSZ'=4]G[*'+\6M_T"BBBD8!1110 4444 %%%% !1110
M45Y+9^(]5BNW\2:M9RSP3:K>V-FT.MSJ(O+,R1J]F%6(C]U@L69LMNQC 74\
M,&[L=2\(7(U34+YM?TV2;4!=73S1O)Y:2"1$)*Q89BN$"KA@,<"@#T:BBB@
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MT>'B_P",_P"N@4445L<I]#?"_P#Y)OI?_;;_ -'/765R?PO_ .2;Z7_VV_\
M1SUUE>14^-^I]#1_AQ]$%%%%0:A1110 4444 %%%% !7-^ _^1=NO^PUJO\
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M?^@M6_6!XQ_Y \7_ %W'_H+5I3^-&-;^&SBZ***]$\<*[3P=_P @>7_KN?\
MT%:XNNT\'?\ ('E_Z[G_ -!6L*_P'5A?XAOT445PGJ',:[I=[=_$#PI?V\!>
MUL?MGVB0$8CWQ!5]^3Z5T]9E]KUKI^OZ5I$T<S7&J>=Y+(H*+Y:AFW'.1P>,
M UITSHJRFX4U)626GFN9_K=?(*\$\1?\C1JO_7Y-_P"AFO>Z\$\1?\C1JO\
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M\!_\B[=?]AK5?_3A<5TE<WX#_P"1=NO^PUJO_IPN* .DHHHH **** "BBB@
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M]-_A1]I3^[+_ -^F_P *EHH YK4[6XN-1EEA@E9&Q@[".PJK_9]Y_P ^TO\
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M - :7_OXG_Q5?1=%;PKRA'E1R5,+"I)R;9\Z?\*X\6_] :7_ +^)_P#%4?\
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MUH>IV>I6Z.8VEL[A9D5@ 2I*DC."#CW%.[%9#O[(L?\ GW'YG_&E72K)6#+
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M<\B"14)>16^XRL2%(^8#.>*2^\$?;?[2_P")AL^W:"-&_P!3G9CS/WOWN?\
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MMV5!'3>";OSSKHT._DU?1XID&FW%Q>/<*[>6#(BSMN9T#_Q9;!+*/NX'944
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M "+MU_V&M5_].%Q725S?@/\ Y%VZ_P"PUJO_ *<+B@#I**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBO/?BOXK\4>%X-(;PGIOVXW-RJ3# 7GSH51-[94;][)MQN.[<
MI&QJ /0J*\L\8>-_&>D^)?#%IHVF?:;:_BB>ZD^R.GSM',77RVR[;502>6A#
MKY>UB?,%6-1\8^+;?XUVWA^VTS=H3H=UQY)/R8@+/M^\VUGV;U(0>;R"8FH
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MEXL6VZC&,E3'(^T@,IVOM.#P.#C6L_%&@:CIMSJ&GZYIMU96H)N+F"[C>.$
M9.Y@<+@<\]J -2BN>N/&%@9M .DRV^J6FM7KVB75M<J\:;899"P*Y#<Q%<9'
M7VQ6C<Z_I=KH,FM27T3Z=&A<W$)\U2 <?+MR6.>,#))X'- &A17(7WCN:PTL
M7=[X;U/3RUS:0JE^T2AEGG2+<'B>105WY*M@G]1MKXGT!]#?64US36TN-MKW
MPNXS IR%P9,[0<D#KU(H U**RKGQ3X?LK&"]O-=TVWM+B+SH9Y;R-8Y4RHWJ
MQ."N709''S+ZBC4O%/A_1H;:;5]=TVPBNU+6[W5Y'$LP&"2A8C</F7IZCUH
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MNKQ@EM!<7"1R3L2  BDY8Y(''<B@"_16:WB/1$U5-,?6-/6_D<QI:&Z02LP
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M)/ !QUP#VS7J5% 'GNMZ)X@M]7UNZT.P/D7$VGM$;86QF"QJRR-"LQ\L2 ;
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E** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>vrna-20201231_g3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vrna-20201231_g3.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %9I8W1O<FEA
M(%-T97=A<G0    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,U
M.   DI(  @    ,U.   ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M+@D*NWC''H.U7?%D7G?L_,O'&E6S<CT\L_TKG_V>T63P_K:. RM<("#W&PT
M:/\ PT#X5_Z!^L?]^8O_ (Y5O2OCAX;U?6+/3;6QU59KR=((V>&,*&9@H)Q(
M3CGTJUXLT[P/X(\-7&I7/AS27;[L$+VB,99".%&0>.Y]!FN"^#?@9]9U@^+M
M5A6*VAF+V<4:[%>7/+ #HJGH!QGCMB@#VS6=:T[P_IDFH:Q=):VT?!=^Y[
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MO)JDVH>7);;5%OY^_!9@?F^]R<''M7I7@R+PF]G/J'@I+58+HKYWV?*_,H.
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M9"ZDU:>S2686\*$%\889!"\,"...E>4_"2)V^,A;1MW]GQ_:"Y7./(P0F?\
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M4?)>SN<9]6>0_P!:P/C[*)_!FC3*"!)=!@#VS&373?#C_DC&G_\ 7I-_Z&]
M'F?[/L8/C;4),\KIS+CZR1_X5L_$*3X=3^/Y/[?AU@ZI&T<<\5HJB.;Y5V[M
MW/W2.01Q61^SY_R.&I?]>!_]&)5+XJ1>7\;5;C]X]JW ]E']* /:/%/C;1?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY@\)Z?'%-#!NDN([-805+#Y<\,><'&,<5X=92W7PK^*@:[A=TLYF5E _UT#
MC<N>O!R/<8KZ/T/PKH?AH2?V'IL-F90 [("68#L6.3BC7O"NA^)XDCUW38;P
M)PC-E77Z,""/SH \]\;?%KPGJG@C4+'3KR:XNKVW:)8A;NNPD?Q%@!^1-9_[
M.S@VFOH#\P> D>Q#_P"!KO[+X:>$=.MKF&RT6*+[3"\,DA=G<*ZE6"LQ)7@G
MI5_PYX.T+PE]I_X1^Q^R?:MOG?OG?=MSM^\QQ]X]/6@#;KYC\<Z+/X&^)[ZA
M=:?'>Z=/=-=0I.F^*9&.6C.01D9(Y]C7TY574M+L=8LFM-4M(;NW;DQS(&&?
M7GO[T >7V'COX226@N)-*T^QGVY,+:0"P..F50C]:Z'2/$/AK7/"'B"Y\+V2
MVEM!!(DSK;+")"(R>@Y. >X[U*?A#X&,OF'05SG.!<S8_+?BM^Q\,Z-IFCSZ
M5I^GPVUE<*RS1197>&&TY/7..,YS0!XC^SY_R.&I?]>!_P#1B5V?Q^D*?#ZU
M48P^I1J?^_<A_I77^'O GASPK>2W6@Z=]DFEC\MV\^1\KD'&&8CJ!5KQ#X6T
M?Q5:Q6VOV?VN&%_,1?-=,-C&<J1V- '&_#G7K+P]\"['5+\N;>T\WS1&,L,W
M# #'_ A65XF\6_"?Q78/+JLA-V5.V2*TD2=3_O!<'Z$D5Z'!X.T&V\,MX?BT
M]?[*8[C;/([ G=NZDD]>>M8P^$/@82^8-!7.<X-S-C\M^* /,O@ EY_PF&HO
M;;_[/%H1*6!QNWKL]MV-WX9JBLRM^TEO/RC^V"G/KG;_ #KZ#TS2=/T6S%II
M-G#9P*<^7"@4$^I]3[UB_P#"N_"W_"1?V[_9?_$R\_[3Y_VB7_69SNV[MO7M
MC% &!\<B1\-)<'&;J+/OR:A^ Q)^'4F>U_)C_OE*[K7= TSQ+IIT_6[;[3:E
MPYC\QDY'0Y4@TW0/#FE>%].:QT.U^RVS2&4IYCO\Q !.6)/84 >'?''PS>:?
MXN'B2*$RV=X(P[E=RI*BA=K#T(4?7FN@T'Q[\+;NPBEU?0M,TN]51YB'2E==
MW^RR(>/KBO8+BW@N[=X+N&.>&0;7CD4,K#T(/!KD)_A'X'N)3))H,88]H[B5
M!^2N!0 WP9XH\'Z]K-S!X3T^.*:&#=)<1V:P@J6'RYX8\X.,8XKR#PY(LW[1
M3R1G*/K%TRG'4$R5[[H?A70_#0D_L/38;,R@!V0$LP'8L<G%9]G\.O"MAKXU
MJTTOR]065IA-]HE/SMG)VEL=SVH 3XE2&/X::ZRXR;5EY]R!_6N%_9X8?V+K
M2YY%Q&2/^ G_  KU;5M)LM<TJ?3=4A\^TG $D>]EW $$<J01R!WJCX=\(Z'X
M3CG3P_9?9%N"IE'FN^XC./O,<=3TH \,^)TLWASXY)K4L;&/S;6[C &-ZHJJ
M0/Q0BO:_#7CSP]XMF>#0[UIYXX_,DC:!T*#..21CJ>Q-7=>\,:-XGME@UW3X
MKQ$)*%LADSUPP((_ U5T+P/X<\-"X_L335MC<IY<I\UW++Z99B: /#/@1_R4
M<_\ 7E+_ #6OI*N;T'X?>&/#.I?;]$TS[+<[#'YGVB5_E.,C#,1V%=)0!\X^
M#KE)/VC7G/RK)J5Z1G_:67 _6G_'Z17^(-JJG)CTV-6XZ'S)#_(BO9+/X=>%
M;#7QK5II?EZ@LK3";[1*?G;.3M+8[GM3]>^'WACQ-J7V_6],^U7.P1^9]HE3
MY1G PK =S0!MZ=_R"[7_ *XI_P"@BOG[X6R^9\<+EWP&D:Z./?)-?1$<:PQ)
M'&,(BA5&>@%<WI'P[\+:#K"ZKI.E^1>KNQ+]HE;&X$'AF(Z$]J /%OB]X=NO
M#OQ .O+;+/87LJ3H94WQF08W1L#P<D9P>H/L:[#1_'GPIN;))[[1=.TRZ ^:
M)M*#X/?:R(<CZXKUB\LK74+22UO[>*YMY!AXI4#*P]P:Y.3X1>!I93(V@H&)
MSA;B91^0?% #_!'B3PIXAN[X>$M/2 VRIYTR6BPA@Q.!QR?NGM785EZ'X:T?
MPW#)%H>GPV:RD&3RQR^.F2>3C)_.M2@#YG^.'_)39_\ KVB_]!KZ8KF-:^''
MA3Q%JLFI:QI7VB[D"AY/M$J9 &!PK =!Z5TJ(L<:H@PJ@ <YXH =7S9<,'_:
M.!4Y']M(/Q# &OI.N9_X5WX6_P"$B_MW^R_^)EY_VGS_ +1+_K,YW;=VWKVQ
MB@"[XPD,7@;79 ,E-.N& /M&U>4_LZ.HD\1(2-Q%L0/4#S<_S%>S:CI]KJVF
MSV&H1>;;7"&.6/<5W*>HR""/PK+\.^"O#_A.6>30+#[(]PH64^=(^X#I]YCC
MKVH ^>O!^L:59?$RZO\ XA1&7+2[S-$91'/N'++@D@#<.AP<>E:WQ@\:Z!XH
MATNT\.2-+'9M(S.(3&GS;<  X/8]J]GUOX>>%?$5\;S5]'BFN6^]*CO&S?78
M1G\:@E^%W@N6P6S;08!"K[QL=U8G!'+A@Q')X)Q0!F:#XLTSPG\(O#^I:LT@
MMVAB@!B3<0Q![>GRFN.\=:_\*_$>CW-S"Y&KF,M"]K:21R&3!(#DJ%89X).?
M8UZG+X*\/3^';?0I]-673;5MT,#R.VP\\Y)S_$>_>LF+X1>!H91(F@H2.SW$
MK#\BY% 'G?P7TB\UOP?XJTZ8LFGWL2PQ.V<+*58$CZ97/X5Q_A>\M/ GC&YL
MO&V@0WL./*FBGMTE:$YR'0,,$?3J#7U!9V5KI]I':V%O%;6\8PD42!54>P%4
M-<\*Z'XD15US3(+PH,*[KAU'H&&"!^- ' ?\)W\([>VWP6.GEFY,4>CX;\<H
M!^M>A^';VQU'P[97FD6WV6RGCWPQ>6J;5)_NKP,]?QKGH?A'X&@DWIH*$_[=
MQ*X_)G(KKK:V@L[6*VM(DA@A4)''&N%11T % $M>1ZK^S]I5PLDFF:S>PSME
MA]I5)%+=?X0N!7I6O^(--\,Z4^HZS.8+96"[A&SDL>@PH/6O-=?^/NE06[1^
M&[&>\NF&%DN%\N-3V.,[F^G'UH X?X=ZGK'@GXH1^'YI3Y4UW]CNH V48YP'
M'N#@Y].*^E*\/^%_@'5]3\4?\)EXKCDB/F-<0QS+M>:1N=Y'91G(]>.W7W"@
M#R3]H3_D5=+_ .OT_P#H#54^&OQ0\+Z!\/[+2]7O);>[M/-W)]G=@^Z1F&TJ
M".C#KBK7[0A'_"+:4,\_;2<?\ -/^'7@#POXE^&>C7>M:1%<7.)@95=XV8">
M0#)0C/'K0!YWK5S=?%OXHJ-*@D2"3;#&7',4"]7;&0.I/X@<UV7[0,"6NC^'
M((1B.)I44>@"H!7JVA^&-%\-0-%H>G0V:O\ ?* EF^K')/XFH?$?@[0O%OV;
M_A(+'[7]EW>3^^=-N[&[[K#/W1U]* *'PQ_Y)EH?_7M_[,:X_P"//AFZU/1;
M'6;&-I?[/+K<*HR1&V#OQZ KS]?:O4-,TRTT;3(-/TV'R;6W79%'N+;1]223
M^-6B,C!Y% 'BWPV^+NB:9X3@TGQ)-):36*E(I1$SK*G51\H)!'3D8X'-<?XH
MU"[^+GQ(BAT&VD$"HL$+.OW(P26D?T&6)_(=:]LO_A;X+U*Z:XNM!@$C')\F
M1X@3]$8#]*V]&\/:3X>MC;Z)I\%G&QRWEKRWU/4_C0!Y]\:+B/0_AO9:7#8Q
MW$4CI;)+,N[R J<,/1B!@'ZUY[I.F?":ZTZWDU37-9LKH1+YT13*E\?-C;$W
M&??IBN@^.7B.];Q':>'))3;Z48HYIMJY,A+$9Z=@. .^:[6S^%OPYO-/CNK;
M3X;FWV#_ $A+Z4JW'4D/C- #? .J_#C3?^)?X1U"W%Q.0&:?>DLY[#+@9^@_
M*N3_ &B_^9<_[>O_ &E7#^/?#^BV7C:#3/ DKWOF(H,44GF[)BQ&U6[\8/4X
MSUKZ"U7P/HOB>UL#XIL_M]S:PA/,\^1.2!N/RL,Y([T 'P[_ .2<:#_UY1_R
MKS3]H>>]#Z+ -XL")'./NM)P.?<#I]37LVG:?:Z3IL%AI\7E6UN@CBCW%MJC
MH,DDG\:CU;1]/UW3VL=7M(KNV<@F.09Y'0CN#[B@#RS1?B-\/M#\#Q6]@OD7
MGV3RY((K-O-:0K@DOC!Y[[JYO]GUP/&FHH3\QT\D#V$B?XBO5['X6>"]/N5G
MMM!@,BG(\Z1Y0#]'8BK6B> /#/AS56U'1=-^RW;*R-()Y&RI.2,,Q'8=J /#
M[AU?]HX%3D?VT@_$, :]G^*+A/ACKA;@?9P/Q+ #^=3?\*[\+?\ "1?V[_9?
M_$R\_P"T^?\ :)?]9G.[;NV]>V,5M:OI-EKNE3:;JL/GVDX DCWLFX @CE2#
MU [T >2?L[?\>.O?]=(/Y/6%^T$X/C33D!^8:>"1[&1_\#7M7AWPCH?A..=/
M#]E]D6X*F4>:[[B,X^\QQU/2J_B#P#X:\4Z@E[KVF_:KB.(0J_GR)A 20,*P
M'5C^= &GH7_(NZ;_ ->D7_H K$^)'AR;Q3X%OM/LQFZ&V:!<XW.ISM_$9'U(
MKIH(([:WC@@7;%$@1%SG  P!S4E 'S'\//$GAWPY<7>F^-M MKF-I,B>>S26
M2!QP5(89QQT'0YXYKT:X\?\ PFLH?]%L+*X YV6^D!?_ $)%%=OKG@;PUXDG
M\_6=(@N)B,&49C<_5E()K/L_A5X)L9A+!H$)8'(\Z224?D[$4 <%^T(R+IOA
MR-4\K)F*QXQM $?'' QD5Z%\,?\ DF6A_P#7M_[,:O\ B/P=H7BW[-_PD%C]
MK^R[O)_?.FW=C=]UAG[HZ^E:.F:9::-ID&GZ;#Y-K;KLBCW%MH^I))_&@#P#
M6Y_,_:7B>3:N-3MD'X*BC^0K3_:(_P"0IH?_ %QE_P#0EKU"7X=^%I_$0UV7
M2]VI"=;D3_:)1^\4@AMN[;U XQBI_$/@?P[XKN(9]?T_[7+"A2-O/D3:"<X^
M5A0!)X*_Y$#P_P#]@RV_]%+7F?Q]\,W=U'8^(+2-I8;:,P7.T9\M<Y5OIDD$
M]N/6O8+*S@T[3[>RLX_+M[:)88DR3M11@#)Y/ [U,Z+(C(ZAE88*D9!'I0!Y
M#X$^,F@6WA*UL?$<\MK>6,(A#"%G695&%P5!P<  YQSWKA+[[9\7_BD7TVVD
MCM&*(68?ZF!>K,>@)Y./4XKVN[^%7@F]NC<3Z!"'8Y(BEDB7_OE6 _2NATC1
M-,T&S^RZ-8PV<.<E8DQN/J3U)]S0!Y7^T$/*\-Z+#'\L8N&PH]DP/YUO_#F5
M_P#A1%M)N^9;2ZP?3$DF/Y5U?B+PGHOBN"&'7[+[7' Q>,>:Z;21@_=(J?3M
M TS2= 71=/MO)T]4=!#YC-@.26&XDGDL>_>@#PC]GYF'CR^0'Y3IKDCW$L?^
M)J#XKS+_ ,+I4GY1$;8,3] ?ZU[;X?\  /AKPMJ#WN@Z;]EN)(C"S^?(^4)!
M(PS$=5'Y5'J_P[\+:]K#:KJVE^?>MMS+]HE7.T #A6 Z =J .(_:%=1X8TE"
M?F-X2![!#_B*Z;X._P#))M&_[;_^CY*W_$7A/1?%<$,.OV7VN.!B\8\UTVDC
M!^Z15K1M&L/#^DPZ9I$'V>S@W>7'O9MNYBQY8D]23UH \#^)4O\ Q?FWWX"Q
MS68S[?*?ZUV_QZU+[)X0M+0V44_VN<@3R)GR-HS\OHQZ?3-=;J?P[\+:QKKZ
MSJ.E^=?NR.TWVB5<E0 ORA@. H[=J\L^-7B*[N/&5KX;NYC;Z,@BDFVKR^X\
MOGV&<#ZT 8VFZ7\([FR@EO\ 7=:LY_+7S863(W8YY6)N_O7JG@'5OAW8H-,\
M'W]N)IB-PEWI+.W;EP"3[#\!20?"SX<W-BMW!IT,UOM'[]+^7:1CKD/BO%O&
M6@:5;?$"'2O ,TEX'"!1%)YFR;)RJL.H "G/;GTH ^J**9"'6%!,P>0* S 8
MR<<FGT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 45%=_:?L4_V'ROM7EMY/G9
MV;\?+NQSC.,XK@=?UKXB>'="N=5O4\,206R@NL(N"QRP' ) [^M-*YU8?#2Q
M#Y8R2>VK/0Z*XVQE^(L[6TUP/"XMI"K.$^T;]AP3C/&<5V5!%:C[)VYD_1W"
MBBBD8!1110 4444 %%%8^L7.NPZKI4>C65O<64LQ&H2ROAH4XP5&X9/WNQZ#
MB@N$'.7*FEZZ&Q11100%%%% !167X@U^U\.:?'>7R321R3I !"H)W,<#J1Q6
MI06X245)K1_H%%%%! 45QGPHO[S4OA_;7.HW4UU.TTH,LTA=B QQR>:[.FU9
MV-\11="M*DW?E;7W!1112, HKSBSM=2\<>(_$$C^(M3TRWTR\-G;06$OEKE.
M"S_WLGM5KQ$^HZIXXTKPG!K%W80"P-W=7%HVR:;!V@;NW*D\>OTJK'H_4;3Y
M'-72N]'HK7^?^9WM%<LMIXCT"/2K'2I&UNW:[(O;K4)0988"1T.1N(&?7Z5U
M-(XZE-0LU)-/^M5T"BBBD9!1110 4444 %%%% !1110 4444 %%%<A\2KZZL
M/#-M+8W,UM(VH0(7A<H2I;D9'8^E-:LVH4G6JQII[G7T444C$**** "BBN%\
M43W^L>/].\+6NJ76EVK637EQ+9MLE?YBH4-VZ?K]*:5SHP]%UI\M[))MOR1W
M5%9VAZ7+H^F"SGU*ZU(JY*SW;;I,'H">^/6M&D8S24FHNZ"BLOQ!K]KX<T^.
M\ODFDCDG2 "%03N8X'4CBM2@;A)14FM'^@4444$!1110 45EZQK]KHESIL%T
MDSOJ-TMK#Y:@A6/=LD8'TS6I06X2C%2:T>P4444$!117)^(;VZ@^(_@^UAN)
M8[>Y^V^=$KD++MA!7<.AP>1GI36IM1I.K)Q79O[DW^AUE%8]W<ZZGBNPM[2R
MMY-%>)S=W+/^\C?!V@#=TSM['J>E;%(B4'%)W6JO_P /YA11100%%%% %#6M
M$T[Q#I;Z=K%L+FUD96:,NRY(.1RI!ZBJ.D^"?#6ARB72]%LX)5.5E\O<Z_1F
MR1^=;M<;KVO>)O\ A.4\/^&(])S_ &<+YY-1$G_/0H0"A^G;UYII7-Z-&5:3
MC%I65]3LJ*Y73_\ A8']H0?VI_PC7V/>/.^S?:/,V]]N[C/UJG\0/&.J^%KS
M28M'L8+S[6)Y)DD#;MD2JS;2",':6/.>G2BVMC:&#G4JJE3:;=]GIHK_ *&E
MXR\#:;XXM+:WU:>[A2V<NAMG5221CG<IJ]X8\.VOA3P_!H^GS3S6]N6*-<,I
M;YF+$9  ZD]JN:7J5MK&EVVH6+[[>YC$B'V/8^XZ'WK%\/\ B.ZU;Q;XDTNX
MBA2'2I(5A9 0S!U8G=DX/W>P%%C!4)M3=OAW^]+\V=)17/:=X@NKSQYK.B21
MPBVL(89(W4'>Q<9.3G'Z"M75[Q]/T.^O8E5I+:WDE4-T)521GVXHL$J,XS4'
MN[/[]47**Q_"6KSZ]X3T_5+Q(TGN8M[K$"%!R1QDD]O6L7Q[XOU'PY]EM]"M
M(+N\DCEN9DF#$)!&N6/!')[?0T6UL:0PM2I7]@OBU7W;G9456TZ^AU/3+:^M
MCNAN8EE0Y[,,UQ?C7Q[J/A;Q1:6EO8PW.G_9A=7A(/FJGF;"5YQQP>A_"A)L
M5#"U:]7V4%[VOX'0>)O!FA^+K=(]<LA,T6?+F5BDB9]&';V.17&'X ^%/,W?
M;-6 S]SSX\?^B\UZ9;SQ75M%<6[K)#*@>-U/#*1D$?A7/^$O$=UK]YKT-W%"
M@TW4I;2(Q C<BG +9)Y^F/I09QHSE&4UM'?YZ!X9^'_ASPFWFZ18*+G&#<S-
MODQ[$]/PQ725Q^L^,;]]?DT#PAIR:EJ,"AKF:9]L%MGH&(Y)]A_0U$VK^/=)
MD235M$TW5+4L!(=(DD$B ]]K\M^%%CH6"JM)MI-ZI-I/^NU]SM:*Y/Q=KVN:
M?KVAZ1X;CT]KG5/M&7OP^Q?*16_@.>03V/:HX_\ A97FKYO_  BOE[ANV_:<
MX[X]Z+"CA).$9N25]5=^;7YIG8444R65((7EE8)'&I9F/8#DFD<>X^BO/-8^
M(VI1MIUWHVD8TBZOHK3[9>JRF??DYC3((&%/S'\J]#IM6.FMAJM",746_P"G
M?L%%%%(Y@HHHH **** "BN0^(U]=6&DZ4]E<S6[2:M;QNT3E2RDG*G'4'TKK
MZ9M*DXTXU+_%?\ HKFO&^O:EH5AIO]B1VCW>H:C%8I]K#&-=X;D[2#U _7BJ
M7_%S?^I3_P#)FBQM#"2E!5'))/N^QV5%<YXPUZ_\,^ [G5TCMI+^W2+<I#&(
MNSJK8Y!Q\QQSZ4[P;XE?Q'I,IOH5M=3LYFM[VV7I'(#VR<X/;\>N*+:7(^K5
M/8.NOA3M_7EJCH:*YO5?$=U8^/\ 0="BBA:VU*.=I78'>I1"PVG..W.0:?K_
M (@NM*\3>'M.MXX6BU.:6.9G!+*%4$;<$8Z]\T6!86HW%?S)R7HK_P"3.AHH
MKF_"_B.ZUS6/$%I=10I'IEZ;>$Q@@LO/+9)YX[8I&<*4IPE-;1W^;L=)16+X
MNUUO#OAFYOX(UFN1MCMHFZ22L0JC Z\G/T!J#P9XAN?$.BROJ444&HVES):W
M<46=JNI[ DG&,?K3MI<M8>HZ/M[>[>QT-%<QX]\1:CX:T&"YT>"">[GNX[9$
MN 2IW9]"/0=ZN^$_$47BCP[!J*)Y4N3'<0]XI5^\O]?H11;2XWAJBH*O;W;V
M-JL#Q/X)T'Q?$BZW9"62,8CG1BDB#T!'4>QR*BF\1W4?Q-@\."*$VDNFF[,F
M#Y@?>RXSG&,#T_&G>*O%L?AW[+:VUI)J&J7S%+2RB."Y'4D]E'K_ ('!9@L+
M5<XP2UDKKT.1_P"% ^%/,W?;-6QG[GGQX_\ 1>:Z[PUX#\.^$_GT;3U2X(PU
MS*2\A'^\>GT&!66;WXE10_:7TO0)EZ_9(II!,/;<3LS5KQ!XLO\ 2_AM/XBC
MTTVE[&J?Z)> G83*$(.,$]<CIGBBQI]2J.48Q:?,TM&GJ_ZWV.LHKC?^+F_]
M2G_Y,UU&F?VA_9L/]L_9OMV/WWV3=Y6<_P .[GICK18RJT/9J_,GZ.Y:HHKC
M[O5O&U_J-S'X?T:PL[2WE>);C5I'S/M)&Y53D*>Q/4<T6N31HNJW9I6[NQV%
M%<QX4\4W>K7]_H^NV*V.KV&UI(XVW1R(W1U/I_B/PZ>EL*M1G1GR3W"BBB@R
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *Y+XI?\DSUC_KFG_HQ:ZVN2^*7_),]8_ZYI_Z,6FMSLP/
M^]TO\4?S1MFUDO?"WV6&=[>2:SV)-&Q5HV*8# CD$'FL+P/XC>Z^':WVJRN]
MSIJ2PWC.<MNBSDD]SMP2?>NFT[_D%VO_ %Q3_P!!%>3^*GGT77_$'AFT##_A
M*'MY;7'16D?9-^>#^%-:Z'7A*2Q//0>]T_E>S_!W^1L_"O7M5O;K4;'7YYI9
MYTCU&V$KEL12#HN>0H^7 Z<UI:3J\]YXZ\3:E-=SC2=(A6U6+>?++J-\C;>F
MX8QGK@U0\:2Q>"O$&@>(H8V-I!;R:;.H/5-A:,?]] _E6GX/T"8?#)K:X;;>
M:O#+<3NW]^8'D_0%?RINVYTXCV4HO%)652R7EK[WX1_\F,S1-*UOQU8+KNK>
M(=2TNUNF9K6RTN7R?+CS@%FP=Q.,_P"<"UHMWJ_AGQQ#X9UC4Y-6L]0@>:RN
M9_\ 6HR<LC'^+@$Y^GO4/@/QAI.G^&K?1->O(=*U/30;>:"\<1?=/!!; ((Q
M2VNI1>,_B?I][H[&;2]!@FW76TA))I5V[5/? P?P/MDU*J1J\]6%2%J:4K:*
MR_EL[=7;KK<] KS6\D\1ZM\4M:T32M8DL;,6\#R2$ES"NP9$2G@,Q/)]J]*K
MRY_$=AX<^-6MRZL9(K:XM8(C<!"4B;:I&XCH#ZTHG#EL9-U>2-VHZ:7UO'H6
M-8M=7^'LUCJ]OX@U+5=->X2"^MM1E\TA6.-Z''&#V^E:WC._O+3QAX0@M;J:
M&*YO)%FCCD*K* %P& ZCGO67XYUS3_%<-AX9\.7<.HW=Y=QO(ULPD2")3EG9
MAP.W'UJYX[_Y'CP1_P!?TG\EI^IW4XN4J4JT??:G?2VBB[-KUOKY$Z7]YHWQ
M:>QN[J:33];M?,M$DD++%-&/F50>F1DG'J*D\9WMW<ZYH/AW2[F:WFO;CS[F
M6!RC);Q\MR#QNZ?ABD^)5E,?#T.M6*YO=$N%O8_=0?G7Z$<GZ57\%3+XG\4:
MQXM"L;8A;#3RXY$:\N?Q8_SH\S""BZ4<9;X59_XEI'\&G\F)JEUJ_BOQG>>'
M](U.32M/TN-&O;JV'[V21QE45OX<#OZ@U1U[3];\ 68U[3?$.I:K8V\B?;++
M4YO.+1DA25;C!R?3^6#+'JEOX+^)FLC7'^S6&MK%/;7;CY Z+M9">QY_EZT>
M.O%&GZ[HK>&?#=U#JFI:HRPJ+5Q(D2[@6=F&0  *.IT4XU%5ITX0O2:C?16:
MLN9M^3OUTL5?BKI*7VCV>L1:KJ*QS7%O&MM'<8@PQX<)C[_/7-=?HOAJ30%N
MG@UK5=3EF3"+JMV9D1AG&, 8SGFL'XFVWV'X>6X16DBL+BV9R!R$4@9_E6S>
M^*K.^\/ZI+X5OK?4+ZWLFFC2!PY4[3MR!WR/NGGM1K8YY2K5,)3A#6-VO+[-
MKOH9C>!]:OXFN-4\9ZM'J#<@6$GE6\9]/+_B ]R,U=^'FLW^L>&'_M>02WEG
M=2VDLH 'F%#][CV/Z5PFEVOP[OO#4.K>+-6.I:C)&'N5N;V3S5DQEE6-2#C/
M X/05T_P@2./PK?I!$\$2ZI.$BD!#(ORX4YYR.E#V-\92:PT^>[<6K>XHI;W
ML^J^2Z#O@W_R36U_Z[2_^AFNNUC4XM&T6\U*X!:.UA:5E'5L#./QZ5R/P;_Y
M)K:_]=I?_0S72>+-+DUOPCJ>G0?ZVXMV6,'N^,J/S I/XCBQJ@\RFI[<[OZ7
M.!LI;;7K*/4O$'Q*-A=W""1;/3]2B@CMLC(0KDEB.,YP>OUK5\*ZE/XAAUOP
MO>:\]V]D8_(U?3IE626)N0=ZY 88P?K^-4O"E[\/[C0K:WUFPT.PU.UB6&[A
MO[:*-Q(HVL27 SDC/?K76^%[KPK=-=_\(C'8+Y95;AK*W$8.<E02  W?UIL[
M<7/DC./LY:;/E24==+-+;IYG!^ O"?VO5_$+?V_KD'V'6)(\0WNT7&UOO2\?
M,Q[GC-)=^$,_&&#3?^$AUX>9I1N/M7VW]^G[QAL#[>$XSC%=%\-O^0IXQ_[#
ML_\ Z$:+K_DOEG_V C_Z->G=W-IXJLL555]H>7\J$\4->:%J'@O3[34[YXVU
M%8II)9R7N%XXD(QNZ]ZM^+]4U2Y\0:9X6T&Z^PW%\CSW-X%W-#"O]T>I.1^5
M5?B%_P C-X+_ .PL/Z4SQ==KX;^(FB^([\,-,>V>QGF521"Q)92<=B?Y&D<U
M&*FJ4K7DXS:TW=W;U\D7;;P=K.DZE:76E^+-2ND65?M=OJDOG)+'GY]O'RG&
M<>_>KFL^'M9UW56#^(+C2]+10(X=-/ES2-CEFD(XYX '&*=-X^\-I=V=K:ZG
M%?7%[*D445FPE8%CC+8^Z!U.><=JXW47TG6_B%K%AX]U1[.UM/+%A9RW)MX)
M8ROS.3QDGZ]R.W!J9T8XFI/GJ*UE>_*F[72T6E_7HKZFQHIU3PS\1(_#UUJ]
MWJVG7UFUQ ]XV^6%U/(+=Q@?J/Q=J,^J^+?&M[H6F:I/I6F:5'&;N>TXFFE<
M9"JW\( _4?3'.>&H/"\'Q<L%\&0LMF+2999@TC))(!SM9R<X!&<<<UM6^K6O
M@[XGZW%KLJVMIK2Q7%K=2<(65=K*6Z#KW]/<4SJJTK57*$;SY$U>*3OS6;Y=
M5?E_SW-K2O"^L:/JC(OB2]U#29HF66*^DWSQMCADD S_ "J+X>:E>2Z=?Z/J
M]Q)<:AH]V]O)+*VYI$))1R3R<C/Y5HVGC30]1UZ/2-+O%OKAD9V>V^>., ?Q
M...?;-<QXMU$>!O'(\1%<VFJ6,D$XYP9XEW1GZG 7\ZG5Z''"-;$.5"K&TY)
M-:6;:O\ FK^MD:FCWMYK?Q,U>>.YG72])B6R6%9"(Y)S\SL5Z$KT_*NQKF_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTM_-:%X[A562-UQD$*2.A!Z]"*HWWB^^MOC'IGA)(;<V-YI<EX\I5O-#JY
M.<8P/3/O7EGP5F;P)\9O%?P]N6*V\LC7%B&/7;\RX'JT3 G_ '*[75O^3G]
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MY^U<I\'_ !!XIU71-;\0>+=<;4]#60C3+B6QBMGDBCW>9-L0<*>  2?NGIW
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MX[Z"(1?:(I%W L@X! *]/[V.V3X9\-/&VM>#/'/C"30?!U_XH:ZNBLJ61?,
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7_X&1_XU\QT4?58]P^O2['TY_P )7X=_Z#VE_P#@9'_C1_PE?AW_ *#VE_\
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M#U"BBN6M[_QFWQ+NK*XTBQ3PDML&@U 2_OWEPN5*[O4L/NC@9SVH ZFBBB@
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M;O[';B5%8Q",_O&7T.<KD>@JN?HS/V75/37\#D* <'(X-%%:&)[+\.?B-_:
MBT77YL7?"V]RY_UWHK'^]Z'O]>OIM?)H.#D<&O9?AS\1O[0$6BZ_-B[X6WN7
M/^N]%8_WO0]_KUX:U&WO1/4PV)O[DSTVBBBN,](**** "BBB@ HHHH ****
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ML8(([:WC@@7;'$@1%SG  P!S4E,@B$%O'"K,PC0*&=MS' QDGN?>GT %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XA\:/^
M1SM/^P>G_HR2O/*]#^-'_(YVG_8/3_T9)7GE>K1_AH\#$?Q9!1116I@%%%%
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MQ'N (!!QGW_&LZ_\9WJV?ANPTNV@FU[Q#;^;$)-P@MD6,/),^.2JE@ N06)
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MU_1G$ZOX3TNP\*QZY8:\U]'-+Y,2?8C'E@>026..,GISBD^&G_)1=*_WI/\
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M996_DV<E[9FUMXXF@:/HFY5!=2&P=V>F>#S1[1![%]]]ONN<71116A@%%%%
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M@_\ Z!'_ ),S?_%T?\*O\'_] C_R9F_^+H^M0[,/J-3NOZ^1\\T5]#?\*O\
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M5)!!R".U7Y]?UBZMC;W.K7TT!&#%)<NRD?0G%>O_ /"E_#O_ #^ZI_W]C_\
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M$SCYNO7C- '2>(?#_AG4%;5/%6GV-Y#90.2^HH)8H(Q\S,%?*J<#E@,X R<
M5S_P:6Y'PUM6E:<V3SS-IBW#,72RWGR%)8DXV8QG^'%)X]\-^)O%-]IMK#!I
M=SX>AVSW^GW%_+ UY,#E49EA?,2D XP-QZ@8%=;H\FJO:L-:L+&QD5ML<=E>
M-<(5QW+11X/M@_6@#0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG_"L6BCD0>UD;7]H6W_/7_QT_P"%']H6W_/7_P =/^%8M%'(@]K(VO[0MO\
MGK_XZ?\ "C^T+;_GK_XZ?\*Q:*.1![61M?VA;?\ /7_QT_X4?VA;?\]?_'3_
M (5BT4<B#VLC:_M"V_YZ_P#CI_PH_M"V_P">O_CI_P *Q:*.1![61M?VA;?\
M]?\ QT_X4?VA;?\ /7_QT_X5BT4<B#VLC:_M"V_YZ_\ CI_PH_M"V_YZ_P#C
MI_PK%HHY$'M9&U_:%M_SU_\ '3_A1_:%M_SU_P#'3_A6+11R(/:R-K^T+;_G
MK_XZ?\*EBGCG!,3;L=:P*?#,\$@>,X/\Z3@N@U5=]3H**BM[A+F/<G![KZ5+
M61ON%%%% $%Q=I;,!(CX/0@#%0_VK!_=D_(?XU;DC6:,I(,@UBW5JUM)@\J?
MNMZU<4F93<EJB_\ VK!_=D_(?XT?VK!_=D_(?XUDT5?(C/VDC6_M6#^[)^0_
MQH_M6#^[)^0_QK)HHY$'M)&M_:L']V3\A_C1_:L']V3\A_C6311R(/:2-;^U
M8/[LGY#_ !H_M6#^[)^0_P :R:YB#Q+>2_%.[\--% +.'2DO5D"GS"[2%2"<
MXQCVS[T<B'[21WO]JP?W9/R'^-']JP?W9/R'^-8EQ<P6=N]Q=S1P0QC<\DKA
M54>I)X%5=,US2=:1WT;5+/4%3[S6MPDH7Z[2<4<B#VDCI?[5@_NR?D/\:/[5
M@_NR?D/\:Y:Y\2Z%91227FM:=;I',;=VENT4)* "8R2>& (..O(J\+B$VWVD
M31F#9O\ -##;MQG.>F,=Z.2(>TD;?]JP?W9/R'^-']JP?W9/R'^-<=;>,_"]
MY>1VEIXDTB>YD;8D,5_$SNWH%#9)]JV)IH[>%YIY%BBC4N[NP"JH&223T HY
M(A[21L_VK!_=D_(?XT?VK!_=D_(?XUYSX0^(^C>++W4+.*ZL8+JWU":TMH!>
MI(]Y'& 1,B\$J1D\9'RGDUO77B+1;'4$L+W6+"VO)" EM-=(DC9Z84G)HY8A
MSR.H_M6#^[)^0_QH_M6#^[)^0_QK!N;^SLI(DO+N"W><E8EED"F0@%B%SUP
M3QV%5H?$&C7-K#=6^KV,MO<3>1#+'<HR22\_(I!P6X/ YXHY(A[21T_]JP?W
M9/R'^-']JP?W9/R'^-<Q:^(=%OOM'V+5["Y^R@FX\FY1_)QUW8/R_C4NG:MI
MVL6YGTB_M;^%6VF2UF650?3*DC-')$/:2.B_M6#^[)^0_P :/[5@_NR?D/\
M&L.ZNK>QM9+F]GBMX(QEY97"*H]23P*@TW6=,UFW:?2-1M+^%3M:2UG650?0
ME211R(/:2.C_ +5@_NR?D/\ &C^U8/[LGY#_ !KE[/Q%HFHWSV6GZQ875W'G
M?!!=(\B_50<BN%\3>-S<?$F'PQIOBZPT&V@L6N+F[)@D9I_,V"W_ 'A(5@/F
M*_>Q2Y8C4Y,]B_M6#^[)^0_QH_M6#^[)^0_QKF-0UW2=$6)=:U>QL7D&$-U<
M)%YA]@Q%9GC7QI8^#?"<VM2M;W#!0;:W:Y6,W))'"'G/!SP#P*?+$7/([K^U
M8/[LGY#_ !H_M6#^[)^0_P :Y'3_ !7H.IP6\EGK6G3&X?RHUBNXWW2;=Q08
M/+ <XZUH3WUI:SP0W5U##+<N4@CDD"M*P&2%!^\<<X%')$/:2-[^U8/[LGY#
M_&E74X&8 AUSW(&!6111R(7M)'1YSTHK)L;[RL1RGY.Q_NUK9STK)JQO&2D@
MHHHI%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!XA\:/^1SM/^P>G_HR2O/*]#^-
M'_(YVG_8/3_T9)7GE>K1_AH\#$?Q9!1116I@%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!ZS\#O^8Y_V[_^U*]9KRWX(VKII^KW9!V2RQQJ?=0Q
M/_H8KU*O+K_Q&>[A?X*_KJ%9NK?\L?\ @7]*TJS=6_Y8_P# OZ5G#XC:I\)G
M4445N<H4454U6>2UT:]GA.V2*WD=#C."%)% RW17C5MJGCZW^%\'CC_A,(;S
M;:B[ETZZTV%(W7/*AT 8''3U/%=*->N[_P"*/A7RIYX;._T26Z>T\P["QVD%
MEZ$C.,TKE<IZ!17+W_Q(\):9?RV=YK$:R0R>5,R12/'"^<;7D52J'V)%:NL>
M(](T#2?[3UC4(;6S.-LS-D/D9 7&2Q([#-.Z)LS3HK#T'QEX?\36MS<:+J4<
M\=IC[1O5HFA!R065P"!P>2,<&JFG_$;PGJFIQ6%EK$;SSN4@+12)',WHDC*$
M<^RDT7069T]%>;ZEXPMO#OQDOTU[6&M=+71(FC@DD8H93,1E(QG+D>@)P/:N
MS\/^)]&\4V#7F@7\=Y"C['*@JR-Z,K ,I^HI7&TT:M%<?)\5O!$6HFR?Q#;^
M8'\LR!',(;T\T+L_\>KKP0R@J001D$=Z8K-"T5YE!+XP\2^//%5CIGBYM(M-
M)GAC@@&G03 [X@QR6&[J/7O3M.\:ZW??!C7=:N)(8]6TQ;J%+J! 8Y6BR!*J
MMD$?ID'Z4KCY3TNBO-O%'B#Q /#/@@:3JYT^\UNZMH+F[%M'(</$68[6&WKS
MQBH]<U/QG\.H8]9UC6H?$VA+*B7P>R2WGMD8A=Z^7PP!(X(_Q!<.4]-HIJLK
MH&0Y5AD$=Q7DNB?$+7;?XI:E9:_.DOAZ?59=*LW\M5^RSJ R*2 "0X) R3R.
MW<;L"5SURBN0M]=U!_C%>Z&]P/[-BT:.Z2'8O$AE*EMV,].V<5L?\);X<_Z&
M#2__  -C_P :=Q69KT5A:TFL:S86O_"):S9V44K;I;WR1<'9V\L9VDD]SD>U
M<WX/U[7H/'6N^%_$6J0ZS%IUM'<IJ"6ZPLF[_EG(J?*#CD>PSWX5QVT/0:*\
MKTN_\>^,_#D_BO1=>M]*MI&E?3M*-@DHEC1B%\R1OF!;;_#C'7V$\GQ%U+7O
M#'A%?#2V]KJWBAW02RH9$M1$#Y[A?XL$< _C1<.5GIM%>>66J^)?"OC_ $K0
M?$VLIKMCK<4OV:Z-FEO)#-&NXJ0G!!!X[Y^ASZ'3N)JP4444"'PS/!('C.#_
M #K;M[A+F/<G![KZ5@T^&9X) \9P?YU,HW-(3Y3H**BM[A+F/<G![KZ5+6!T
M[A39(UFC*2#(-.HH P[JU:VDP>5/W6]:@KH9(UFC*2#(-8MU:M;28/*G[K>M
M;1E<YYPMJB"BBBK,@HHHH *X"S_Y.%U'_L7HO_1YKOZYG7OAWX8\3:L-3UK3
MGGO!$(?-2[FB^0$D#".!U)I,I'._$:*WU'X@>"-)UP*VB7-Q</+%)_JYITC'
ME*^>.I.!WSBH=;TS3-%^-'@__A'+6"RN[I+I;Z&TC""2 1Y5G51C 8<$]QWQ
M75_\(#X9/AD^'Y-+2;3/,,@@GE>4JQ_B#LQ8'Z&I/#W@CPYX5FEFT+3$MIYA
MMDF:1Y9&'IO<EL<#C/:E8=T<3X%\+Z)K/BCQQ=ZOIEO?RC6YH%^TQB140JI.
MU3P"<\D<G ]*YM7V?L__ -G*7EBAUW[%%:[B6NHQ=Y$(/N/7CBO:M,T33M'F
MOI=.M_)?4+@W5R=[-YDI !;DG'0<# KC_&?@0R^"X](\+:?');?VFE[>Z>]R
MR?;(]Q:2,2-G:6;:>PXQ1;0:EJ4=(TV+7/B?INMZ3X8N=%L-.L98KE[VP%L9
MG8CRT53R=N"=PX'0&NJL6\82ZH(]:LM!&EL7$AM[F9Y2N#M^5HPIR<9YZ9KB
M]'\%WP\7:1?:+X27P;;6<QDO)!J"2&Z3:1Y7EQEE()(^9L8QQ7J]"%(\U^%-
ME:I)XSEBM+?[1!XIOEA.P HN$P <9 Z]/>N0\"Z%X@\3_#JY<:-X8O9-4EN?
MMMUJ,THNC*9&!+XC.TCC !X&#P37K47@CP[!XK;Q+#IJ1ZLQ):X61P"2I4ML
MSMS@D9QGDU6O_AOX3U+4)[VZTD>=<-NG\F>6)9CZNB,%;\0:+#YD<-XE\/R/
MIWPTT+Q'.E^PNQ!<R12L5G41'C=P2I P?49]:T/BMH.EQ:-X4TJUL8;2RN_%
M-I'-#:((0P=9%;[N,$KQGK7>S^&](N&TLR62 :0P:Q5"46 A=HP 0,!>,'(J
M35=#T[6_L7]J6WG_ &&[CO;?YV7RYDSM;@C.,G@Y'M187,><>)O WAM?BIX/
MM(M(MH+2[M[Q+FVAC$<<ZPK&\8=5P& 8YYSG STK0T"PM-%^.^LV6DVT5G:W
M.BPW$D$"!$,@E*[L#@<5W-SHUA>:Q8ZI<P;[W3UE6VEWL/+$@ ?@'!R%'4'&
M.*1-$TZ/Q!)KB6^-1EMQ:O/O;F(-N"[<XZGKC-%@YM#&\>^%[GQ7H=M;V$\$
M5S9WL5[''=(7@G*9_=R@<E#G]!7-Q^+-,MO#OBZS\2^&H=/NM)MT_M.UL6!C
MNDE0[-KJ >1QS@KFNXUWPWI7B6UBM]9MFGCAD\R/9,\3(V",AD((X)[U!IO@
M[P_I.DW>FV.F0K:WN?M22$RF?(P=[.2S<>IIVU$FK'E/B&#4[:\\!WLN@:!H
MEO)KUFELNG3%KA4?.4;$:J5*]<$\[:ZE]/LY/VD"LEI ZMX6\TAH@07^U_>Z
M=??K6W:?"_P=936TUOHX$MI-'-;N]S*YA9&W+M+.=J@@':.#CD5N_P!AZ=_P
MD?\ ;WV;_B9_9/L7G[V_U._?MVYV_>YSC/O2L-R1Y1HEIKNL>//&D\.D^'=1
MN(]1-LW]L32>9' %_=JJB-@$*\]LG/7%+X@\,WGA[]GO7[#638SRP3/);):N
MTB6L;3*1&K,H(QEATKT;6O OAS7]0%_J>G;KS9L-Q!/)!(R^C-&REA['-7(/
M#>C6WAYM"@TZ!-+=&C:U"_*P;[V?4G)YZT<H^8Y/QWX>6X^&:W>A6\4.H:28
MM5M#"@&9(@&/ ZY7</RJIX>U2W^(7Q-@UVT(DTS0],C,()SBZN5W-^*Q@*?0
MFNNTGPSI?A#0[JV\,Z9M1@THMO.9C*X7 7=(QQG ')P*ROA9X2D\'^!H+.\M
MX[>_N)'NKN.,@JDC'[H()&%4*O!/2BVHKZ'944451 5=L;[RL1RGY.Q_NU2H
MI-7*3:=T='G/2BLFQOO*Q'*?D['^[6MG/2L&K'3&2D@HHHI%!1110 4444 %
M%%% !1110 45%<W,%G;/<7D\=O!&-SRRN%51ZDG@53TGQ%HNO*YT/6+#4A']
M\V=TDVWZ[2<4 :-%%% !1110 4444 %%5-5U2ST32+K4]3F\BSM(FFGEVEMB
M*,DX )/'8"H]$UO3_$>BVVK:+<"YL;I=\,P5EW#)'1@".0>HH OT444 %%%%
M !16)J/C3PMI%])9:MXET>QNX\;[>YOXHY$R 1E68$9!!^AJ_I>L:9KEG]KT
M74;34;;<4\ZTG65-PZC<I(SR.* +E%%% !16+I'B_0]>UO5-(TF^%Q?:2XCO
M8?*=?*8DC&6 #<J>A-;5 !1110 45A^'?&GA_P 5W6HVWA_45O)M,E$-VJQN
MOE,2P ^8#(RK<C(XK<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#Q#XT?\CG:?]@]/_1DE>>5[;\0?A]JOBSQ!!?:=<6<
M44=JL)$[N&R'8]E/'S"N5_X4OXB_Y_=+_P"_LG_Q%>C2JP4$FSQJ]"I*HVD>
M>45Z'_PI?Q%_S^Z7_P!_9/\ XBC_ (4OXB_Y_=+_ ._LG_Q%:>VI]S'ZO5_E
M//**]#_X4OXB_P"?W2_^_LG_ ,11_P *7\1?\_NE_P#?V3_XBCVU/N'U>K_*
M>>45Z'_PI?Q%_P _NE_]_9/_ (BC_A2_B+_G]TO_ +^R?_$4>VI]P^KU?Y3S
MRBO0_P#A2_B+_G]TO_O[)_\ $4?\*7\1?\_NE_\ ?V3_ .(H]M3[A]7J_P I
MYY17H?\ PI?Q%_S^Z7_W]D_^(H_X4OXB_P"?W2_^_LG_ ,11[:GW#ZO5_E//
M**]#_P"%+^(O^?W2_P#O[)_\11_PI?Q%_P _NE_]_9/_ (BCVU/N'U>K_*>>
M45Z'_P *7\1?\_NE_P#?V3_XBC_A2_B+_G]TO_O[)_\ $4>VI]P^KU?Y3SRB
MO0_^%+^(O^?W2_\ O[)_\11_PI?Q%_S^Z7_W]D_^(H]M3[A]7J_RGGE6=/T^
MZU6_BLK"%IKB9MJ(H_S@>]>B67P3U)Y/^)CJMK"G_3!6D)_,+7I'AKP=I'A:
M$KIL):9AA[B4[I']L]A["HGB()::FU/!U)/WM$2^%= C\->'+;38R&=!NE<#
M[[GDG^GT K8HHKSFVW=GL12BK(*S=6_Y8_\  OZ5I5FZM_RQ_P"!?TIP^(FI
M\)G4445N<H50UW_D7=1_Z]9?_0#5^FNBR1LDBAT8$,K#((]"*!GD7P^^'%AK
MWP[T*XUO5]:OK.6!)3I<MYBTR#D#8J@D CH2:Z#555/CMX<5%"JND70  P -
MRUW-K:6]C:1VMC;Q6UO$NV.&% B(/0 < 4CV-I)?1WLEK"UW$ACCG,8,B*>J
MANH!P.*5M"N;4\5UGQ1>Z[X"\47*:WH>@6"&\MAH_P!D#W$S?,,.2XVR.>X4
M\MGFK,]Q;V*_"'4M>=4T:&P"R33$>7'<-:IY3.3QU!P>Q!->JR^&M"GU"2_F
MT73I+R12KW#VB&1@1@@MC)&*L2:5I\NEKILMA;/8J@C6U:%3$$ P%V8Q@ =,
M4K!S(X;XB:E8>(/ASXJ@\)WEK?:C%:1_:39L)&$>\G:2O7Y1)QGC)XYYP)M.
M/B3PGI5M=?$C1%TYI+=K6.#34C=74C8B?OLALC;@#/7BO5].TG3M'MS!I-A:
MV,).3':PK$I/KA0!5>#PSH-KJ)U"VT33H;TG)N8[2-9"?7<!FBP<UCS^^U+1
M-*_:+>?7I[:V+:)'':SW. J2&5N QX4E01U&>1WQ5")GUSQ)\3;[P:XF@FTM
M+=)[<Y2>Z$3?<(X) .,CN1ZUZK=Z)I6H-,U_IEG<M/&(I3-;JYD0$D*V1R 2
M3@^M365A::;:):Z=:P6ENGW88(PB+] .!18.8\H@\3>#$_9]%C]ML0?[)-NU
MAO7SC<^7@KL^]OW\YQ[].:]!\#VUY9> ="MM35UNXK"%)5<_,K!!P?<=*M_\
M(UH7]J?VE_8NG?;\[OM7V5/-SZ[\9_6M.FD)L\8MM)\)ZI\3?'0\6W<=N1<6
MZQ!]2>UW*8?FX5U#=NN:@TNZ)^$GQ T[3[A[SP]IRSP:3<MSNCV$L@;^)5/0
M^_6O5;WP?X9U*\DN]1\.Z3=W,I!DFGL8W=\# RQ7)X %:!TZQ;33IYL[<V3(
M8S;&)?+*'JNW&,>U*P^8\N\33PVOASX73W,J0PQZA9,\DC!54>0>23TJW\4_
M$^EZ[X3E\*>';VWU76-9DC@AM[242[!O4L[E<A5 '4_RS7?WN@Z/J=C#9:EI
M5C=VD&/*@GMDDCCP,#:I&!@<<=J-,T'2-%W?V/I5CI^_AOLMLD6[Z[0*+,+H
MM6EN+2R@ME)80QK&">^!BO+-!\-6WBZP^(NCW1V>?K\QBE'6*0*A1Q]"!^HK
MUFJ]M8VED\[V=K#;M<2&69HHPIE<\%FQU/ Y/-.PD['D'PVUN^USXL:@-:@:
M/5K#0EL;Y'& \T<^"P]0P(;/3FM#^Q[_ /Z(AX;_ / VU_\ C->FQ:98P:C-
M?PV5O'>3J%FN4B422 = S8R0/>K5*P^;4XV_G\.1>'-+T3QA%:>'1>(3%I\=
MZ8(XS&1E%ECV#C<O (SGH>:Y'PK%8V7Q*U;PSX(OQ>Z!=:8T][ME\Y;6Y8E1
MB;DDD'H2>_I@>K:AIEAJUL;?5+*VO8"<F*YB61?R8$4FGZ7I^D6_V?2K&VL8
M<Y\NVA6-<_10!3L%]#S+X;^-]"\-_"6*UUO4+>SO]$$\-W932A90ZR,=H4\D
MGC& >>.U<YHUA+X+TSX4ZQKX:UM+-KV*[DERH@-T&:+=_=^\<YZ8KVFX\.:)
M=ZFNHW6C:?-?+@K=26J-*,=,.1G]:N75K;WUK);7L$5Q!(,/%*@=6'H0>#2L
M',CSO6=3L_%'Q=\)6N@W4-^-)%S>7TUO()$@5HPB D<9)[9S7I54M-T?3-&@
M:'1].M+")CN:.U@6)2?4A0*NTT2V%%%%,0445J6-CLQ+,/F_A4]J3=BHQ<F+
MI]FT7[V3(8CA?0>]7J**P;NSJ225D%%%&<=:0PSCK63?7GG?NX_N \GUHOK[
MS<QQ'Y.Y_O52K6,>K,)SOH@HHHK0Q"BBB@ HHHH **** "BBB@ HKF/B42/A
M?XC(.#_9TW_H!KC_ (37MQX;F@\':I,TD%U8QZGH\SG[T;J&EB^J,20/0DTK
MZV*MI<]7HKR_X9ZT-#^$,%[)8:AJ %]<IY.GVYGEYG?G:.WO6_9?$2*^U"WM
M!X5\50&>58Q+/I#I''N.-S,>BC.2>PHN'*SL:*\C^.NAWUQX'UG5[K6)_L=H
MMN+33H1LC#F5%9Y#U<_,<#@#ZUTGQ8U6[T_PA;VFFW;V=SJ^H0:<MQ&</&)&
M^8J>QVJ>:+ARG<45Y)XJ\(:7\.?[%\0^$8YK*XCU."WO!]HD<7D,AVL'#,03
MD@Y_^MBQ::%I_P 2/'_BAO% DO\ 3]'GCL;*R\YTCC(3,CD*1EB>_P#@,%QV
M6YZG17G_ ,,GN-/U+Q1X8DN);BUT6_5;-IG+LD,B;UCR>2%]_6O0*:U):LPH
MHHH$%%%% !1110 4444 %%%3VMJUS)@<*/O-Z4;#2N%K:M<R8'"C[S>E;4:"
M.-47HHP*(XUAC"1C %.K"4KG3&/*@HHHJ2PHHHH **** "BBB@ HHHH \A_:
M&T'7=:\+Z3/HUA-JME87PN-0TV$G=.@'' Y('S#C)&[...%^%GBKX9Z]K<US
MX9T2#P[X@@M'AN+0VX@;RMRE\!?E?#(O.-PQT'-=OXPU+Q?IALI_!^A6>N19
M<7EM-=BWE_AV&-V^7^]G/MCO7">'? ?B/Q!\7G\?>+M)MO#JQV;6T.GVUTL\
MDK,C(7D=1M/RL?R7CB@#!G^/VN:E;:EK7AX^$K;2+"1Q'8ZKJ!34+Q%&2T:!
M@!D= 1G/ R:Z;6_C4_\ PBOA.X\+Z4MWK/BMO+L[:XD(BA8,$?>PP2 YQVR,
MG(Q7(>&OAKXE\#1WFC3?#3P[XT@:X:2UU:ZFMXW12  '$BEB.,X'0D\FNF\;
M_#KQ)>V/@O7/#=AI,.M>&7$LFDVN(;60DJS+$3@*-RD<XR&)R".0#<N/&WBO
MP5X1UO6?B5I>EE;".)K671IWV73NQ7R]LF64@[<L>,-D9P:YC4/BC\2/#GA6
MR\9^(/#^@OX=NS&S6MI-*+N".3&QF+?)W'0=2.E;6OZ'XT^*'@'7-'\2:+9>
M&3-'$;"+[:+ES*C[B9'0;0APH&!D9/6N9U;PW\4/&7@/3O 6I^&[#2+.W$$5
MUK#:@DJS1Q8P5B7Y@3M!YZGT!H Z#Q1\5=?M?B;HGACPCI=AJ4>N:0E[:M<N
MT3!V,AW,P.-@2/<1MR>@-3>#?BAK,OC#Q)X5\?V6GVNI:%:&^>XTPN87A 4D
M@.2>DB$<\Y/ Q4%Y\/\ 6(/V@/!VN:=9&3P_HVB_89;IID!1A'<*HVD[C_K$
MY (Y]C3+?X>ZU=?'SQGK5_:>3H.M:)]@AO!*C%F:.W0C9G<,;'Z@#CWH Y?6
M?B%X[\;?"7Q'KUOX?TI/"UQ!/;(GGN+U4QM,O=&5>XP#P<>M=%X%UC7-%_9Y
M\,3^'+;3'F9766XU6[\BWMD\R3YV/4\X&!SS7/:9X.^*>D?"[5/AW;:!IKVS
M+.(]6-\N)8WRQC6/KN8D@,VT#//3-2:Q\*O%MU\)_ EC'IT-Y=>'[AIK_0YK
MI%2Z!DW!2^=AX!'7HYH Z3P%\6=6UCXC/X0\1/X=OI)+4W%OJ'AZZ:6!L<E#
MN).<9/8C'3!S61X9^+?Q%\6^(+BPT/PKI]S:V&K&WOKT%E2.WWA1@-(,R !F
M)!/&/E%-\(?#_P 3P?&_3O%=UX/TOPSI*V<D1M-.GB80'8RC?LQN<D]5&,8Y
MXKIO@OX/USPE_P )3_PD%E]D^WZJ]Q;?OD?S(SG#?*3CKT.#0!4\'_%^]N_"
M_C&?QC;6=KJ_A6203P6JLJ2* 0N S$Y+JRYSCE?6NN^&7B+6?%GP^T[7/$=M
M:VMW>AI%CM594\O<0APS,>0,]>]>&?&[PI>_\+FM=/T&X\M?&D4,-Y ASDI*
MN79>RC8C9_V6]Z^E]/L8-+TRUL+--EO:PI#$O]U% 4#\A0!\XZQ=Z59_M5>+
M)-<\)7GBNW.GPJME9Z:MZ\;>5;8D*-P  "-W^T!WKT'Q3XU3P)\%U\2^#O"T
M6A&2Y4#2]0T_[,4)<HQ>*-A@D+D'/0@UCWNA>._#?[07B'QEH/@_^WK#4+*.
MUB_XFD%M_P LX,M\Q)X:(C&!USFM'XD:3XS^(OP;N+)_"G]F:TU[&5T_^T89
MMT:D'?YF57N>.O% %;4/BKXU\.:SX=O/%&@:3;^'_$%PL4,=M.\EU;!L8,C?
M=)PV<*.Q&16EKGQ%\4ZA\4KGP5\/=-TN:?3;<7%_=:J\@C&0IV+LY!^=1GGD
MGC S5;XH>!_$/B+0_!%OHU@+B72KR"2\7SHT\I5503\S#.,'IDU#J7A3QIX2
M^-.I^,/"&BVWB"RUNV6&>WDO$MFMW 0;B6ZC* \ D@D<<&@#F/A1K.HVWC+X
ML:S>6"6>I01FXDM'?>L<J^<2N1C<,CJ,9%:5G\7/B/JOPU/C73O#NAC3K($W
M@EDE\RX"MAVA0-\JKT.YB>"<4OA7P7XM\/+\3]7\8VUNCZOI[RI-;2JT<CF.
M5G"KG< I8#Y@,^]<KX$A^(>L? '_ (1OPWH%C>Z=JIFBCU$WJQ-:H9")%>-N
M6)^;!7H#T)% 'I.M?&>5]!\)_P#"):4EYK?BI<VMO<R$16^"%8N1R0&R.,<*
M3QC!?I7Q%\5Z+\2M.\'?$73=)635HB]E?Z.\GE$@'Y663G/RD9XQD=0<UBZW
M\)/$&B:;X%U#P@;;4M4\*)LFM9Y/+6ZW'<VQCT^8L.<<$>G.A8^%/&'C3XL:
M1XO\9:/;^';'1(66VL$O5N999#GYBZ#&.0?^ @8Y)H I>%OB%<IH?Q.U&RT/
M1+"?0+B9H?LEH8Q=,OF8:;#9=OD&2,=35&X^,?Q"MOA[8>.Y/#NAC06*1W$?
MGR?:)26V&1.<(A<8 .YNG7K4^@?#KQ38^&?BI:76F!)]?FF;35^T1'SPWFX.
M0V%SN7[V.M3ZI\/O$UQ^RY:>$(=-W:[&(]UI]HC&,7&\_.6V?=YZT <Y\9]0
M\0ZE\1/AK?Z8=,6UN[J.;1!+YH;S7:W)^T8_@W%,;.<;N^*['QC\3/%?A74/
M#?AJ:+PY!K^JQ/)<W]Y++'IT)!.%!.'Y QR>I'!S5;Q]X!\47VD_#G4M!T^.
M^U'PHT,D^GM<)$9"!"2 Y.W@PXZ]\C-:GC6W\5>(M&L$U/X8Z7KT,UNS3V$F
MJ1I-8S$D?+,0 1MV\K@YSSTH [GPI=ZY>Z"DOBBULK?4-[*WV"8R0RKGY70G
MD CL>:V:\^^"O@W6O WP_P#[+\13HUP]U).D"2;UMD8+B,'OR&;CC+?C7H-
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9NK?\L?^!?TK
M2JI?6KW/E^65&W.=Q^E5'1D35XF/15W^RI_[T?YG_"C^RI_[T?YG_"M>9&')
M+L4J*N_V5/\ WH_S/^%']E3_ -Z/\S_A1S(.278I45=_LJ?^]'^9_P */[*G
M_O1_F?\ "CF0<DNQ2HJ[_94_]Z/\S_A1_94_]Z/\S_A1S(.278I45=_LJ?\
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MF_\ A ](_P"?SQ!_X4>H?_'Z/^$#TC_G\\0?^%'J'_Q^NDHH YO_ (0/2/\
MG\\0?^%'J'_Q^C_A ](_Y_/$'_A1ZA_\?KI** .;_P"$#TC_ )_/$'_A1ZA_
M\?H_X0/2/^?SQ!_X4>H?_'ZZ2B@#F_\ A ](_P"?SQ!_X4>H?_'Z/^$#TC_G
M\\0?^%'J'_Q^NDHH YO_ (0/2/\ G\\0?^%'J'_Q^C_A ](_Y_/$'_A1ZA_\
M?KI** .;_P"$#TC_ )_/$'_A1ZA_\?H_X0/2/^?SQ!_X4>H?_'ZZ2B@#F_\
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MD4,KJ1@@@]01VKE++X?IIMDFFZ;XEU^UTB/"QZ='<1E8X_\ GFLQC,ZKV&)
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M/0#^O6MZ5%U->ARU\1&EINSW2?XD>$K>0I)K,9(_YYQ.X_-5(J+_ (6AX/\
M^@O_ .2TW_Q%?/-%=/U6'=G%]>J=D?0W_"T/!_\ T%__ "6F_P#B*/\ A:'@
M_P#Z"_\ Y+3?_$5\\T4?58=V+Z]4[+^OF?0W_"T/!_\ T%__ "6F_P#B*/\
MA:'@_P#Z"_\ Y+3?_$5\\T4?58=V'UZIV7]?,^AO^%H>#_\ H+_^2TW_ ,11
M_P +0\'_ /07_P#):;_XBOGFBCZK#NP^O5.R_KYGT-_PM#P?_P!!?_R6F_\
MB*/^%H>#_P#H+_\ DM-_\17SS11]5AW8?7JG9?U\SZ&_X6AX/_Z"_P#Y+3?_
M !%'_"T/!_\ T%__ "6F_P#B*^>:*/JL.[#Z]4[+^OF?0W_"T/!__07_ /):
M;_XBC_A:'@__ *"__DM-_P#$5\\T4?58=V'UZIV7]?,^AO\ A:'@_P#Z"_\
MY+3?_$4?\+0\'_\ 07_\EIO_ (BOGFBCZK#NP^O5.R_KYGT-_P +0\'_ /07
M_P#):;_XBC_A:'@__H+_ /DM-_\ $5\\T4?58=V'UZIV7]?,^G-#\4:/XD\_
M^Q;S[3]GV^;^Z=-N[./O 9^Z>E:U>3? [_F.?]N__M2O6:XZL5";BCTJ%1U*
M:DPK#UKQEH/AZ]2TUB_^SSO&)53R9'RI)&<JI'4&MRO$/C1_R.=I_P!@]/\
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MYAC@UEWOCZWTRZM?[2T36+33KJ[6TBU.:"-8?,8D+N3?YR L-H9HP,D'H0:
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M9).60$ X;G(&&H ]/HK+\.6XMM#B46FI619F8V^IWINITY(^:0RR9!QD .<
M]N16)\/-<U'7(/$;:K<>>;+Q#>V5O\BKLAC?"+\H&<#N<D]S0!U]%>:ZKXF;
M1],^(E]H$FMW^HZ8&+QW,L3P6;BVWJ\*LPQ$."PY8G.%-2^$-=M_#OP]TR_U
M6VUXWNH);Q117]\;R?49VB!!B!F=4#?,<$Q@8)8*!F@#T6BL'1?%MOJ^L76C
MW-A>Z3JMK$L[65\(][PL<"56C=T9=P*\-D$8('&<+XI2&^M?#_AD<QZ]J\-O
M<C.-UO'F:5?Q$87Z,?H0#NZ*\\UKQ'=R_%>+PG+X@;PU9G3EGM'ACA\R_F:3
M:45ID=,* /D4;B6SG Q6GXE\0:KX:TS1-*M9;?4_$&K72V5O/<1^7'PI9YI$
M4\A57)"D9)XV@\ '845S5KX=\06LEK,WC6_O)(V4SPW5C:^1,/XP%CC1USSM
M.\X.,[AD'%EN=;UGXLZOH<'B._TNPLM-MKB..S@MB2[LX8DRQ.?X1Z4 =_17
ME^F?$G4X/@_<:_>K;:GJ,5Z^FV,\2^7#J3^=Y,<P ) 5C\S;3CY6QC@#8U?3
M?&&C>'+G6+;Q9-J&I6<+W+V,]G;K9S[06,:A4$JCLI,A(.,[N: .XHKS'QCK
M\-]X)\)?$+3U:$6E[:73 GYA!<8BEB)Z?\M!GW45Z=0 4444 %%%% !1110
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M5T\-2^*+36=-UN&6X\2W]S"8]$O)DDB>3Y7#I$5(..N:].HH \IN='U-M/\
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MSP7K&J2>*_%/AO5[Y]2_L6:W:"]EC1))(YHM^UQ&JKE2",A1D8KLZ "BO,]
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MIQD$#[R]:\A\-^(M2;Q?XH\'>&YUT_5-2\3WMRVHSQ@I! B0!_+#<22_['.
M=QXQ7:>,E:P^)'P^O4D9Y#=7-A*QP#*DD!/S8 'WHU;Z]* ._HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ^>?BA_R4C5/^V/_HE*Y.NL^*'_ "4C5/\
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M),>O/RL,<CCVKF:=.+C&S%6DI3NF%%%%:&)ZS\#O^8Y_V[_^U*]9KR;X'?\
M,<_[=_\ VI7K->97_B,]W"?P5_74*\0^-'_(YVG_ &#T_P#1DE>WUXA\:/\
MD<[3_L'I_P"C)*>'_B$8S^$>>4445Z1XH4444 7-+&FF]_XG37:VVT\VBJSY
M[?>(&*[3Q-';W'PUTX^&)3-HUG<L+CSQB=9FZ%NV/FQQZCK7+:'JVGZ<ES%J
MNBPZI#/MP&E,3QE<_=<<C.>1WP*NZSXKBO="CT71]*CTK3EE\YXUF:5Y7]68
MXS_]8>@K*2;DC>$HJ#N]_O#X?6MO>^/--M[R".XA=GW1RH&5OW;'D'@\UTVD
MWV@ZK<ZUIEUX9LDL=-M);B%H05N&$)&0TG4EO7^=<3X:UK_A'?$5KJOV?[1]
MG+'RM^S=E2O7!QU]*ETOQ!_9MYJTYMO-_M&TGMMOF;?+\S^+H<X].,T3BV[E
M4ZD8Q2?=G0376G^)? >MWG]BV&GW.ERP-"]G%LRDC[=K?WB,'DUL:?8C3V\+
MVVG>&+/4K34((9;R[GM//;<Y^<;C]W:*X33]<^P>&]8TG[/YG]I^1^]WX\OR
MW+=,<YSCJ,5ZG<C47LM.ATO2)]8L_L,4;7EOJSVL;X&""B,%&/<5E.\=.G_
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M6NYXY8XS$G.3N!9@22 % )/ )KI=!AU*W\/6$.O727>II;H+N>-0JR2[1N(
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M4L)9$G;0+&?4;^6.,HC22+Y,6%R=N3YK!<DX7KZ^@T4 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'SS\4/^2D:I_P!L?_1*5R==9\4/^2D:I_VQ_P#1
M*5R=>O3^!>A\]6_B2]6%%%%69!1110 445Z5\2-"TV475WH-G#:RZ3*L%]!
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MI8AD.P#<,#C.2#WI^T3!T6NO];G&T445H8!1110 4444 >L_ [_F.?\ ;O\
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M^+H_X5?XP_Z!'_DS#_\ %U]#44?6I]D'U&GW?]?(^>?^%7^,/^@1_P"3,/\
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M ,F8?_BZ/^%7^,/^@1_Y,P__ !=?0U%'UJ?9!]1I]W_7R/GG_A5_C#_H$?\
MDS#_ /%T?\*O\8?] C_R9A_^+KZ&HH^M3[(/J-/N_P"OD?/:_"[Q>S@'2@H)
MP6-S%@>_#5[#X-\&V?A+3?+CQ->R@?:+C'+'^Z/1171T5G.M*:LS6EAJ=)W0
M4445B=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MEW9_'-5?A;X1T'Q5\5/BE_PD6EV^HBVU:1(%N$WB,237&\J#P&.Q?FZC'!%
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MVO\ ],?_ !__ .M1_:__ $Q_\?\ _K5G44<D0]I(V+:_2X?8R[&[#.<U;KG
M<'(ZUK6-]YH$<I^?L?[U1*-M4:0G?1EVBBBLS4**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K:AIUEJVGRV.J6
ML-W:S+MDAG0.CCW!KBK3X'_#BRU!;V#PM;F93D"6:61,_P"XS%?TKOJ* *&L
M:'IFOZ--I.L6<5W83J%D@<?*0#D=.F"!@CI7-)\(? R>%9/#::$HTF2Y%V\
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M9=CS;WD<KG.W<[$@9 X!["NGHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP4;@"3D@8P:YN+PQ?0^&OAKJFIZ=K#6FD:<UIJ-O8/<0WEJ98XP'"1%96 9
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M,/\ Y)?_ &RCV]/N'U2MV_(\FHKUG_A1W_4P_P#DE_\ ;*/^%'?]3#_Y)?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;9MVY[\#'.* /IC2M=TC7H7FT/5;+4HHSM=[.X295/H2I.*C_P"$ET(ZS_9
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M711'?312066?L\CC:3)$#T0YQ@<9!KT6@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBJ%WKVCV%P8+_5;&VF !,<URB, >G!.::3>PFTMR_163_P )7X=_Z#VE_P#@
M9'_C1_PE?AW_ *#VE_\ @9'_ (T^6787/'N:U%9/_"5^'?\ H/:7_P"!D?\
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MR6I0(8'C!0KZ;>F/:J'_  E?AW_H/:7_ .!D?^-'_"5^'?\ H/:7_P"!D?\
MC1RR[!SQ[DND^'M%T%'70](L--60Y<6=LD(;Z[0,U$?"OAXZM_:AT'3#J(;<
M+S[''YV?7?C.?QH_X2OP[_T'M+_\#(_\:/\ A*_#O_0>TO\ \#(_\:.678.>
M/<MC2=-75VU5=/M1J+1>2UX(5\XQYSLWXW;<@<9Q5 ^#/"YTYM//AO2#9-*9
MVMC81>69" "Y7;C=@ 9Z\"I/^$K\._\ 0>TO_P #(_\ &C_A*_#O_0>TO_P,
MC_QHY9=@YX]S0M+2VL+6.VL;>*VMXQA(H4"(@] !P*FK)_X2OP[_ -![2_\
MP,C_ ,:/^$K\._\ 0>TO_P #(_\ &CEEV#GCW-:BLG_A*_#O_0>TO_P,C_QH
M_P"$K\._]![2_P#P,C_QHY9=@YX]S6HK)_X2OP[_ -![2_\ P,C_ ,:/^$K\
M._\ 0>TO_P #(_\ &CEEV#GCW-:BLG_A*_#O_0>TO_P,C_QH_P"$K\._]![2
M_P#P,C_QHY9=@YX]S6HK)_X2OP[_ -![2_\ P,C_ ,:/^$K\._\ 0>TO_P #
M(_\ &CEEV#GCW-:BLG_A*_#O_0>TO_P,C_QH_P"$K\._]![2_P#P,C_QHY9=
M@YX]S6HK)_X2OP[_ -![2_\ P,C_ ,:/^$K\._\ 0>TO_P #(_\ &CEEV#GC
MW-:BLG_A*_#O_0>TO_P,C_QH_P"$K\._]![2_P#P,C_QHY9=@YX]S6HK)_X2
MOP[_ -![2_\ P,C_ ,:/^$K\._\ 0>TO_P #(_\ &CEEV#GCW-:BLG_A*_#O
M_0>TO_P,C_QH_P"$K\._]![2_P#P,C_QHY9=@YX]S6HK)_X2OP[_ -![2_\
MP,C_ ,:/^$K\._\ 0>TO_P #(_\ &CEEV#GCW-:BLG_A*_#O_0>TO_P,C_QH
M_P"$K\._]![2_P#P,C_QHY9=@YX]S6HK)_X2OP[_ -![2_\ P,C_ ,:/^$K\
M._\ 0>TO_P #(_\ &CEEV#GCW-:BLG_A*_#O_0>TO_P,C_QH_P"$K\._]![2
M_P#P,C_QHY9=@YX]S6HK)_X2OP[_ -![2_\ P,C_ ,:/^$K\._\ 0>TO_P #
M(_\ &CEEV#GCW&KX4T5/%[>*%L@-9>V^RM=>8_,60=NW.WL.<9]ZYV[^"OP\
MO=9?5+GPQ;-=._F-B218V;N3&&"?I72?\)7X=_Z#VE_^!D?^-'_"5^'?^@]I
M?_@9'_C1RR[!SQ[FI%%'#"D4*+'&BA41!@*!T '85SUYX \,7_C*W\5W>EK)
MK=L%$5UYT@Q@$#Y VTD GDCT]!5W_A*_#O\ T'M+_P# R/\ QH_X2OP[_P!!
M[2__  ,C_P :.678.>/<I7G@#PQ?^,K?Q7=Z4DFMVP4171ED&W (!V!MI(SU
M(ST]!3?%?P\\*>-VB?Q1HT-])"NV.7>\<BKG.W>A!QDGC..:O_\ "5^'?^@]
MI?\ X&1_XT?\)7X=_P"@]I?_ (&1_P"-'++L'/'N5;;P)X8L_"C^&K?1+5='
MDY>T*[E<\'<2>2W ^8G/ YXJIX7^&'@WP9J$E]X;T.&SNI%*F8R22L >H!=C
MM'TQ6K_PE?AW_H/:7_X&1_XT?\)7X=_Z#VE_^!D?^-'++L'/'N8__"K/!G_"
M+W7ATZ(ATJ[NC>2P&>4DS<#>'W;E.% X(XX[FH=1^$'@35]6CU/4_#T-U>1J
MB^9)-*=X50HWC=AS@ 98$GO6]_PE?AW_ *#VE_\ @9'_ (T?\)7X=_Z#VE_^
M!D?^-'++L'/'N:J(L:*B*%51@*!@ >E+63_PE?AW_H/:7_X&1_XT?\)7X=_Z
M#VE_^!D?^-'++L'/'N:U%9/_  E?AW_H/:7_ .!D?^-'_"5^'?\ H/:7_P"!
MD?\ C1RR[!SQ[FM163_PE?AW_H/:7_X&1_XT?\)7X=_Z#VE_^!D?^-'++L'/
M'N:U%9/_  E?AW_H/:7_ .!D?^-'_"5^'?\ H/:7_P"!D?\ C1RR[!SQ[FM1
M63_PE?AW_H/:7_X&1_XT?\)7X=_Z#VE_^!D?^-'++L'/'N:U%9/_  E?AW_H
M/:7_ .!D?^-'_"5^'?\ H/:7_P"!D?\ C1RR[!SQ[FM163_PE?AW_H/:7_X&
M1_XT?\)7X=_Z#VE_^!D?^-'++L'/'N:U%9/_  E?AW_H/:7_ .!D?^-'_"5^
M'?\ H/:7_P"!D?\ C1RR[!SQ[FM163_PE?AW_H/:7_X&1_XT?\)7X=_Z#VE_
M^!D?^-'++L'/'N:U%9/_  E?AW_H/:7_ .!D?^-'_"5^'?\ H/:7_P"!D?\
MC1RR[!SQ[FM163_PE?AW_H/:7_X&1_XT?\)7X=_Z#VE_^!D?^-'++L'/'N:U
M%9/_  E?AW_H/:7_ .!D?^-'_"5^'?\ H/:7_P"!D?\ C1RR[!SQ[FM163_P
ME?AW_H/:7_X&1_XTJ^*?#[L%37=-9F. !>1DD_G1RR[!SQ[FK1114E!1110
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MCMU[U/M)]V7[&G_*ON/7O^%7^#_^@1_Y,S?_ !='_"K_  ?_ - C_P F9O\
MXNF:K\4?"?A[1M-U#Q'JL>F_VC;)<PP,K22;6 /W4!..<9QBHI_BKX2?P)?^
M*=-UJ"YL;0;&<1R$I*W"*R8WC+$#D"CVD^[#V-/^5?<6/^%7^#_^@1_Y,S?_
M !='_"K_  ?_ - C_P F9O\ XNN*^'_QAL_B'X(U*SU?58=(\1+974LQL+:8
M"UA48$RDY!*[@<!B<CI72?#S6-*TKX4PZI>^-)=?T^)I6?6M05X2WSD8(D)8
M8/RC))/;J!1[2?=A[&G_ "K[C1_X5?X/_P"@1_Y,S?\ Q='_  J_P?\ ] C_
M ,F9O_BZ;X:^*G@KQ?J9T_P]KT-U>8)$+1R1,^.NT.HW?AFH=3^+W@31I[Z'
M4_$,-O-I]Q]FN(FBD+K)W 4+EP,<E<@>M'M)]V'L:?\ *ON+'_"K_!__ $"/
M_)F;_P"+H_X5?X/_ .@1_P"3,W_Q=9/C+XN:'HOPQD\4Z%J5K>?:,PZ<6CD=
M)9P"=C!<%> ?O;:L_"WXF:=\1/#T;QW,3:Q;P(VHVT,,B) [9P 7&"/E/0FC
MVD^[#V-/^5?<7?\ A5_@_P#Z!'_DS-_\71_PJ_P?_P! C_R9F_\ BZOZ]XU\
M.^&-2LK'7]4BL)[Y)'@$JL%98QN<E\;5P/[Q&>U5/#'Q*\(>,[^>Q\-:W#>W
M4 +/#L>-BH."5#J-PZ<C(Y%'M)]V'L:?\J^XC_X5?X/_ .@1_P"3,W_Q='_"
MK_!__0(_\F9O_BZA\1?%KP-X5U5M-UWQ#!;WBG#PI'),8SZ-L5MIYZ'%:%]X
M_P#"^G>$T\37.L0G1I&55O(5:522< 80$YSP>..]'M)]V'L:?\J^XJ_\*O\
M!_\ T"/_ "9F_P#BZ/\ A5_@_P#Z!'_DS-_\74<'Q8\#77B=?#UOXCM)-2:3
MREC4-L9\XVB3&PG/& V<\5K1>+]#G\83^%HKX-K4$ N)+7RG&V,XYW8VG[PX
M!SS1[2?=A[&G_*ON,W_A5_@__H$?^3,W_P 71_PJ_P '_P#0(_\ )F;_ .+J
M+5?&VD:IH_B_3]!U-FU70[*;[2J1R1M;R;'VD,0 3E3RI.,5ROPE\<VVF_ K
M3=>\<Z\X#7$T;7E_,TCR-YC[5R<LQP#@#/ ]J/:3[L/8T_Y5]QU__"K_  ?_
M - C_P F9O\ XNC_ (5?X/\ ^@1_Y,S?_%TGASXI^"_%C7":!KL-U);1-++$
M8I(W"*,E@KJ"P'L#7"^"OV@-+\0^/]3T74[NTALI;N.WT*6&UG#W>YRHWYR%
M/W>H7K1[2?=A[&G_ "K[CN_^%7^#_P#H$?\ DS-_\71_PJ_P?_T"/_)F;_XN
ML?P--;'XB>,@GCB]UQXK@&72[B&1(]+RS_*K,=K#C&5P,+SGK5EOC;\.4U;^
MSF\56GG[MNX)(8L_]==NS'ONQ1[2?=A[&G_*ON+_ /PJ_P '_P#0(_\ )F;_
M .+H_P"%7^#_ /H$?^3,W_Q=7-=\=^&?#5Y8VNNZO!92:@CR6S2!MCJ@RQW@
M;5&".I&>V:@\+?$CPCXUNY[7PSK4-[<0#<\6QXVVYQN =02.1R,CFCVD^[#V
M-/\ E7W$7_"K_!__ $"/_)F;_P"+H_X5?X/_ .@1_P"3,W_Q=:>D^+=$US6]
M3TC2K];B^TEQ'>PB-AY3'.!D@ ]#T)Z5LT>TGW8>QI_RK[CD_P#A5_@__H$?
M^3,W_P 71_PJ_P '_P#0(_\ )F;_ .+KK**/:3[L/8T_Y5]QR?\ PJ_P?_T"
M/_)F;_XNC_A5_@__ *!'_DS-_P#%UUE%'M)]V'L:?\J^XY/_ (5?X/\ ^@1_
MY,S?_%T?\*O\'_\ 0(_\F9O_ (NNLHH]I/NP]C3_ )5]QR?_  J_P?\ ] C_
M ,F9O_BZ/^%7^#_^@1_Y,S?_ !==911[2?=A[&G_ "K[CD_^%7^#_P#H$?\
MDS-_\71_PJ_P?_T"/_)F;_XNNLHH]I/NP]C3_E7W')_\*O\ !_\ T"/_ "9F
M_P#BZ/\ A5_@_P#Z!'_DS-_\77644>TGW8>QI_RK[CD_^%7^#_\ H$?^3,W_
M ,71_P *O\'_ /0(_P#)F;_XNNLHH]I/NP]C3_E7W')_\*O\'_\ 0(_\F9O_
M (NC_A5_@_\ Z!'_ ),S?_%UUE%'M)]V'L:?\J^XY/\ X5?X/_Z!'_DS-_\
M%T?\*O\ !_\ T"/_ "9F_P#BZZRBCVD^[#V-/^5?<<G_ ,*O\'_] C_R9F_^
M+H_X5?X/_P"@1_Y,S?\ Q==911[2?=A[&G_*ON.3_P"%7^#_ /H$?^3,W_Q=
M'_"K_!__ $"/_)F;_P"+KK**/:3[L/8T_P"5?<<G_P *O\'_ /0(_P#)F;_X
MNC_A5_@__H$?^3,W_P 77644>TGW8>QI_P J^XY/_A5_@_\ Z!'_ ),S?_%T
M?\*O\'_] C_R9F_^+KK**/:3[L/8T_Y5]QR?_"K_  ?_ - C_P F9O\ XNC_
M (5?X/\ ^@1_Y,S?_%UUE%'M)]V'L:?\J^XY/_A5_@__ *!'_DS-_P#%T?\
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M /H$?^3,W_Q==911[2?=A[&G_*ON.3_X5?X/_P"@1_Y,S?\ Q='_  J_P?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFTML11DG !)X'0"I;6ZAO;.&ZM7WPSQK)&V"-RL,@X//0US?Q/\ ^23^*?\
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M);E8E905'RCRT08'N,^I-<)X*TF\7XR>/';Q!J+K;W-B9$:.VQ<@VH(#XBR
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MY5>,* N3C<=75O!7]J:/X8L/[0\K^P+^TO-_D[O/\A2-N-PV[L]><>AKJJ*
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M#-([)YC(>&*QKM7.<;F(Y-;]CX7OF^*&I>*=7EMY(5LH['288G8F&/.^5G!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\CB\N=E7=M^21FC8KD@2*IX(ZC% '445YYX;\9:[J'Q1\4Z/>:/J+6%G):)
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK7FFFT+XGS>)KC3M0N=(UG28($GMK"::6VEC9VV/"BF10ROG.W@C!P:]!HH
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M,O\ PEMI+';>#[:32=)EF0@7>YSFY7(_YXK$G&1RW3H/7** /#;3PSJ4_P
M? ^CWNB74DT6L6AO+*:T8LD7VEBYDC(R%VGG(Q@\UV&G:"W@GXJ11>'=+:'P
MYX@M6^TPV=N1!9W<0&V3"C;&KI\O8%E'>O0J* /./"$TWP[BU'P[K6F:H]HE
M]/<Z=?6-A->1SPROOVMY*LR.I8J0P .,@D5WNFWIU'3HKMK2YL_-!*PW2!)
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>>?&C_D3+3_
M +""?^BY*]#KSSXT?\B9:?\ 803_ -%R5K1_B(PQ'\*1Z'11161N%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5R7X ZXP.G>M/P!X TKX<:!/I&ASW<]O-=-=,UVZLP8JJX!55&,(.WK7444
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M4;^9@S,L60D(0@@ LQ)YSD*<#O4?CSQI'X2ATR!9[&VN=5NOL\5UJ,OEV]L
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M/^P@G_HN2O0Z\\^-'_(F6G_803_T7)6M'^(C#$?PI'H=%%%9&X4444 %%%%
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M ((JO?\ Q#LK-M1EMM*U34=/TJ1H]0U&SCC,-LR_ZP$-(KOL'+>6K8Y'4$
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M&_"^C>$-'72_#EA'8V:N7\M"6RQQEBS$DG@<DGH*Y+_A='AW_GRU3_OU'_\
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M (71X=_Y\M4_[]1__%T?\+H\._\ /EJG_?J/_P"+H]C4[!]8I?S'H=%>>?\
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M?]^H_P#XNC_A='AW_GRU3_OU'_\ %T>QJ=@^L4OYCT.BO//^%T>'?^?+5/\
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MPNCP[_SY:I_WZC_^+H]C4[!]8I?S'H=%>>?\+H\._P#/EJG_ 'ZC_P#BZ/\
MA='AW_GRU3_OU'_\71[&IV#ZQ2_F/0Z*\\_X71X=_P"?+5/^_4?_ ,71_P +
MH\._\^6J?]^H_P#XNCV-3L'UBE_,>AT5YY_PNCP[_P ^6J?]^H__ (NC_A='
MAW_GRU3_ +]1_P#Q='L:G8/K%+^8]#KSSXT?\B9:?]A!/_1<E'_"Z/#O_/EJ
MG_?J/_XNN7\?^/\ 3/%^@V^GZ7;7J3K=K+^^C4 @*RX&UB<Y85I3I34TVC&O
M6IRIM)GM=%%%<QVA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
..1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>vrna-20201231_g4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vrna-20201231_g4.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %9I8W1O<FEA
M(%-T97=A<G0    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,R
M,0  DI(  @    ,R,0  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                            ,C R,3HP,CHR-" P.3HR-CHQ-P R,#(Q
M.C R.C(T(# Y.C(V.C$W    5@!I &, = !O '( :0!A "  4P!T &4 =P!A
M '( =    /_A"R-H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A
M8VME="!B96=I;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED
M)S\^#0H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/CQR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2)U
M=6ED.F9A9C5B9&0U+6)A,V0M,3%D82UA9#,Q+60S,V0W-3$X,F8Q8B(@>&UL
M;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B\^/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ
M,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"\B/CQX;7 Z0W)E871E1&%T93XR,#(Q+3 R+3(T
M5# Y.C(V.C$W+C(Q-#PO>&UP.D-R96%T941A=&4^/"]R9&8Z1&5S8W)I<'1I
M;VX^/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M
M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO
M+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/CQD8SIC<F5A=&]R/CQR9&8Z
M4V5Q('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^/')D9CIL:3Y6:6-T;W)I82!3=&5W87)T/"]R9&8Z
M;&D^/"]R9&8Z4V5Q/@T*"0D)/"]D8SIC<F5A=&]R/CPO<F1F.D1E<V-R:7!T
M:6]N/CPO<F1F.E)$1CX\+W@Z>&UP;65T83X-"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/#]X<&%C:V5T(&5N9#TG=R<_/O_; $, !P4%!@4$!P8%!@@'!P@*
M$0L*"0D*%0\0#!$8%1H9&!48%QL>)R$;'24=%Q@B+B(E*"DK+"L:("\S+RHR
M)RHK*O_; $,!!P@("@D*% L+%"H<&!PJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*O_  !$( BT$LP,!(@ "$0$#
M$0'_Q  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,#
M @0#!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S
M8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H
M:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 #
M 0$! 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  !
M G<  0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q
M%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X
M>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(
MR<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /I&
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN2U
M/XH>#]'U.?3]1U?R;JW?9+']EF;:?J$(/X55_P"%Q>!/^@[_ .2<_P#\10!V
M]%9VA:_IGB731J&B7/VFU+E!)Y;)R.HPP!K1H **** "BBB@ HKS#5_C=IVE
M^,Y-$&ES3007'V>>[$H!5@=K83'(!]QTKTB^OK?3=/GO;V416]O&9)'/\*@9
M- $]%>-7/[0UJM\8[#P[-<0;L+))=!&89_NA&_+->QQL[1(TB;'*@LN<[3Z9
M[T .HHHH **** "BBJ5SK.EV5RMO>:E:6\S$*L4LZJQ)Q@8)SSD?G0!=HHHH
M ***\P'QOTUO&RZ''IDS6K7(MOMOF_Q;MN?+V_=S[YQV[4 >GT444 %%%% !
M1110 4444 %%%% !17F7BGXUZ?X:\52:.NES7B6[!+BX64)L/4A5P=V,^HYK
MTN.19HDDC.4=0RG'4&@!U%%% !1110 445YEXT^,B>$/$MSHYT1KMX%1A)]J
MV!MRANFPXZ^] 'IM%<]XV\7VO@GPZVJ7<+W!:00Q0H<;W() SV&%)S[52^'W
MC^#Q[IUU/'9/936L@22(R>8,,"00V!GH>W:@#KJ*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** /F;Q99P:C\?WLKR/S+>YU6WAE3)&Y
M&* C(Y'![5Z_+\&? TB831VB.?O)=S9_5C7BWQ CN9OC1?Q6$Q@NGOHEAE#%
M3&Y";6R.1@X.1S78W'PQ^*+PL)/%XG'7RSJER<_FN* /4[2PT?X?^$[C[%#+
M'I]FKW$B@F1L=6//7_ZU<_9?&CPA>6UW.]S<6J6NWB>(!IBV>$522<8YZ8R*
MZ34K5QX"N[2\.YQICQ2G.<GRB#R>M>!_!?PYI7B/Q9=1ZU:+=Q6UJ94C<G;N
MW*.1WX)X- 'IEO\ 'CPC-="&2/4H$)QYTD"[![_*Q;]*]%AO+:XL4O()XWMG
MC\Q9E8;2N,[L^F*\;^-_@W1=,\-VFK:1IUM83+="&06T8C5U96/('&05'YFM
M+PM9:GK7[-[65E\US+!.D !YD42ME?Q 9?RH T=2^.?A'3[MX(OMU\$.#+:P
MJ4/T+,N?K6_X-^(&D>./M7]CQ7<9M0IE%Q&%QNSCD$C^$_E7@_P_\1>&O#5S
M=6?C/PXEXSR8\^:W65H,<%3&XXY[CGV->]^#(O";V<^H>"DM5@NBOG?9\K\R
M@X!0_=/S'C ZT >:S+\-]0^*PW6VKR:I-J'ER6VU1;^?OP68'YOO<G!Q[5=^
M,OQ L%TS5/!\,=VM_F'S) B^45.V3&=V>F.U<C!%Y/[2)7CG6&;@>I)_K7HG
MQKT?3%\"7VIKIUH-0:6$&[$"^:1N ^_C/08Z]* .(^%_Q)\/^#O#KZ?=V%[+
M?W%R7:6&*,JP( 4%BP.!CTXR:]UUG6M.\/Z9)J&L726MM'P7?N>P ')/L*\V
M^"_A[1=0\ Q7E_I%A=72W4F)YK9'<8(Q\Q&>*XGXWZY-J7Q &CRS&*ST](U
MP2H9U#,Y Z\,!^% 'H#_ ![\)+<>6(-4=,X\T0)M^O+Y_2N\T+7],\2Z6FH:
M-=+<V['!(!!4]U8'D&O)WU/X,1>&SIB&&4^7L^TK82_:-V,;]Y0'.><9Q[5D
M_L^WTT?BS5-/5R;>6S,Q'8LCJH./HYH ]!M/C-X3NM4>RDEN;4QJY>:YB"1K
MM'(ZYSV  Y-49?CUX1CNO*2+4I4S_KDMUV_JP;]*\IT_1+'4OCE/H]]$9;)M
M6N(WCW%=RJSD#(QZ#I7K/Q'\ ^'(_A[J$^GZ1:65S91>=%-;Q!&^4@D$C[V1
MD<YH [&T\4Z5?^%I?$%A<?:;"*%YG*## ("64@XPW'0XKYR\1>,M-UCXLVWB
M>&"Y%A%<VTKQ2HOF%8]NX8W$<[3CFO0/V?T^U>'->M+J-)K1YD!BD4,K[D(8
M$'@@@ 5RVO:5IT/[146FPV%K'8&]M%-JL*B(@QQDC9C&"2<\=Z /6O#'Q0T?
MQ7'J4NGVM]%'IL'GR^?&H+#GA0K')^6J^G?&/PIJ*7L@FN;>*RB\UY)X@ X+
M!0J@$DG)'&*ZNT\/Z1IUO<0Z;IEG8I<KMF%K D6\8(&=H&<9/7U-?,?PS\+6
MGB[QI%IVI.XM5B>:18S@N%Q\N>W)% 'O'A7XJZ#XOULZ7I<%^D^QG#3Q*%*C
MJ<AC^M<+H:_#:^^*,#Z=;:M)J,UTS)!(JBWBE&6+8^]P1G&2,]J])\/?#WP[
MX6UB34="M'MI9(3"RF9G7:2"<;B3GY1WKQ;P/#]F_:*,''[J_ODXZ<)** /6
M_$?Q3\/^%]>.D:DEX;E=F3'$"H# $')8<<_H:H:O\;?".E7C6\<EWJ!0X9[.
M)63/L690?J,UYK\?(5B^(5NZ]9M.C=OKOD7^2BO7-,^&_A >'(;4Z#:.)8%W
MRNFZ4DCDAS\P/T(H O\ A/QUH?C.&5M&G?S8<&2"9=DB@]#CN/<$UH:]XATO
MPSIIOM;NTM8 =H+9)<^B@<D_2O OA%!+IOQC>RB;*Q+<02$GJJY_JHJ#XKZT
M==^*3V&H7+6^G6,J6P;!(B4X\Q\ $DY)/ )P!0!Z2/CWX2-QY?V?5 F<>:8$
MV_7[^?TKT#2-8L->TR+4-(N4N;67[KKZ]P0>0?8UX]J^I_!V7PK-IU@(!-Y1
M6&>.QE$ROCAC(4!/.,Y/X5%^SS?SB]UG3RV;<QI.%/\ "V2I(^H(_(4 >YUP
MMY\8/"^G^(I='NVNXIH9V@EE:(".,J2"2<YQQV!ZUW5?,/CBPA;XYW-G=Q[X
M)]0@\Q Q&Y7"$C(Z9#?A0!ZE/\>?",5SY4<6I3IG'G1VZA?K\S _I7<>'_$>
ME^*-,6_T6Z6XA)VMP0R-_=8'D&L/6/A?X5U/09=/M]'L[.0QD0W$$061&[$L
M.6Y]<UX_\#M1NM/^(ITU6(AO(9$FCSQN0%@?J,$?B: .A\3?\*WO/B:PU*WU
M>34VNUAGMH54022;@N6SS@\9P1FO1O%OQ T7P1);0ZNESNG0M$MO$&& <'J1
MCM7C/B2'[/\ M)0IQSJ]F_'^UY3?UKJ/VB8=UAH,^/N2S)G/]X(?_9: .BO?
MCCX0M(8'1KVZ>6)9&B@A!:+<,[6)8+N&><$UL^$_B5X=\8W!MM,GEANPN[[-
M<H$=AW(P2#^!S7/_  Q\%^&;WX=Z=>7FAV=S<7<;&:6XB$C$[V7(+?=X';%>
M3>.])'P_^)A_L)VB2%H[NU^;)CSSMSW&01]* /IZ^OK73;&6\OYX[>VA7=)+
M(V%45YW=?'GPC;W)BBCU*Y4''FQ0*%/O\S _I7)?'KQ'<3S:1H\3-';26POI
M4!^^6)50?7&UOSJQX=U+X0Z7X3@M-2-M>WKP@W4DMA*TC2$98*Q3Y<$X&".E
M 'JOACQ=HWB^Q:ZT2Z\T1G$L3KM>,^ZG^?2O"/C7!O\ BIL?A9H(<$>G3^E+
M\)[R*Q^,JVNC3.^G79N(D+Y!>(*SH2/7Y%J7XU_\E6M_^O:#_P!":@#U?XJ2
M^&U\)I%XP6[^QRW $4EHH+I*%8@@G@'&[K[UG_#R[\*:)\/K_5_#L%^-/@D=
MKF6Z56FDV*"3A3C !]N_%1?'>+S/APK<?N[V)N1[,/ZU1^%\2S_ O48G^[(M
MVK?0IB@#9LOC1X0O+:[G>YN+5+7;Q/$ TQ;/"*I).,<],9%4[?X\>$9KH0R1
MZE A./.D@78/?Y6+?I7F?P7\.:5XC\674>M6BW<5M:F5(W)V[MRCD=^">#76
M_&_P;HNF>&[35M(TZVL)ENA#(+:,1JZLK'D#C(*C\S0![+;7,-Y:Q7-I*DT$
MRAXY$.593T(-<AXF^*_A?PO?/97=Q-=7<9Q)#:1ARA]"20,^V<US'AO7[S0?
MV;3JD9Q-!'+';OU*[IS&K?@6_05YY\,[CP7;7UYJ'CRX224%1;P3P23*Q.2S
ML%4@]A@^IH ]E\.?%[PMXEU&.Q@EN+.YE.V)+R,)O/H""1GV)YKN:^7OB9>>
M#;W5+2\\"E8CAA<I# T*9&"K*"!@]0<8Z"OH[PS>RZCX2TB^N#F:YL89I#ZL
MT8)_4T :=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"HHPJJ, #TH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 445%;SBXB+J" )'3!_V6
M*_TH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **B$X-V\&#E8U?/U)'_LM2T %%%% !1110 4444 %%%%
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M/C;GNQ4^U:B^.O"7Q&^$_B'489+Q]*ALIUU"!4"7,2B(LP )QNV]#D@GOP:
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MD=3C-?1= !1110 4444 %%%% !523_D-6W_7O+_Z%'5NJDO_ "&;;_KWE_\
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M?@M[Q,[)WDDF9,C!VF1FV\$CCUH ZJ]O+?3K"XO;Z58+:VB:::5^B(HRS'V
M!-?,FI^*-/\ CEX^1->U^P\/^"=)E#);WM['!->-ZA68'+#(ST4'U)S],ZCI
M]KJVEW6G:A%YUI>0O!/'N*[T=2K#(P1D$].:\_\ ^&?/AC_T+/\ Y/W/_P <
MH [K1+K2;O1K9_#MQ:7.FH@B@>RD5X@J?+M4J2.,8]L5?K+\.>&])\):'#H_
MA^T^R6$)9HXO,=\%B6/+$D\D]ZU* "BBB@ HHHH **** *E_UM?^OA?Y&K=5
M+_K:_P#7PO\ (U;H **** "BBB@ HHHH *^1_ _@K5O&OQ6\;6NC^++[PWY-
MY,TSV8<F=3.XVG:Z<?7-?7%<_H/@7PYX8UG4M5T/31:WNJ.7NY1-(_F$L6/#
M,0O))X H X<?##1OAI\%_&5OI4DUU=7>CW375W/C=(5@?  ' 49/'OU-<=X'
MTNP_X8^UJ?['!YL]K>2RR&,;G=&8(Q/J-HQZ8KZ U'3[75M+NM.U"+SK2\A>
M">/<5WHZE6&1@C()Z<UE6'@CP]IG@Z3PK9:<(]%ECDC>U,TC960DL-Q8MSD]
M^.U 'SUI_C:X\(?LR>&&M+&QN[BYU.>.&74(1+':D22'>%/\7)P>V36)XLU#
M4[SXI^"SJWC?2O%<R7\)232XHU6V!F3Y2R 9SCC.2,=LU]+K\./"2^#D\*G1
M87T6-RZ6LKN^QB22P9B6!RQYSGFLRR^"WP^T_P"RFS\-PQ/:7*W4,@GE+B13
ME26+Y8 _PDD>U 'FGQ$L['1OB5K/BWP1X]TO1_$=O"(]0TO4F5//PB':F\?-
MN54X //\0[<I\1_%%]XV_9WT#5O[,BT^*+6)([N*TBV0M)M<B0#L"6;/^T37
MOWB#X2^!_%.LMJVN^'X;F^<@O,)9(R^  -P1@&X '.:WAX8T,>'/[ _LFS_L
MC9Y?V+R5\K&<_=Z9SSGKGGK0!\P^*;?6?&>D:-:ZEX\^'JP6LJ"Q33II!/$3
MA54(L6Y1TX('09QBOK*N%TSX*_#S2-434+'PS;K<QN'1I99955@<@A78J.?:
MNZH ^;?B)X6^$WBY];\6Q^//L^JS(9!;FYBQYB(%"B J)#G:.,UV?[-_B;6?
M$7P[G360KQ:?=?9K258EC!0(IVX4 ';GK[UT=]\$?AUJ6I-?77A>W\]FW-Y4
MTL:$YSRBL%_2NRTW3+'1M.AL-*M(;.T@7;'! @15'L!^= %JBBB@ HHHH **
M** "JFK?\@:\_P"N#_\ H)JW535O^0->?]<'_P#030!;HHHH **** "BBB@
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MNHH ^G**^8Z* /IRBOF.B@#Z<HKYCHH ^G**^8Z* /IRBOF.B@#Z<HKYCHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %7]%UJ\T'4X[W3Y-DB\,I^Z
MZ]U8=Q5"B@#Z$\->);/Q-I@N;0[)%P)H"?FB;^H]#W_,5L5\]>%[S5;/Q!;M
MH(9[MVVB(<B0=PWM_+KVKZ#C+F)#*JK(5&Y5.0#W />@!U%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 54U7_D#W?_7)OY5;JIJO_((NO^N3?RH
MMT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-WW_ "5/0O\
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MAD*$OAEX/7(]?I730SQ7$2RP2+)&W1D.0:F491W&I)[#Z***D84444 %%%%
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MG3=1V1A6K*BDVCW?_A&=!_Z FG?^ D?^%'_",Z#_ - 33O\ P$C_ ,*^=O\
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M@_\ 0$T[_P !(_\ "OG;_A*_$7_0>U3_ ,#)/\:/^$K\1?\ 0>U3_P #)/\
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MX&2?XT?\)7XB_P"@]JG_ (&2?XT?59=P^O1['T3_ ,(SH/\ T!-._P# 2/\
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M2^_UEG_U\#_T%JMU4OO]99_]? _]!:K= !1110 4444 %%%% !1110 4444
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M \@]16O110 4444 <W??\E3T+_L#:E_Z/L:Z2N;OO^2IZ%_V!M2_]'V-=)0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M - C_P F9O\ XNC_ (5?X/\ ^@1_Y,S?_%UY+_PM#QA_T%__ "6A_P#B*/\
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M - C_P F9O\ XNC_ (5?X/\ ^@1_Y,S?_%UY+_PM#QA_T%__ "6A_P#B*/\
MA:'C#_H+_P#DM#_\11[&M_-^+#ZQAOY/P1ZU_P *O\'_ /0(_P#)F;_XNJTO
MPT\)+J-O$-)PCHY8?:9>2-N/XO<UY=_PM#QA_P!!?_R6A_\ B*:WQ+\6M,DI
MU;YT!"G[-%P#C/\ #["CV-;^;\6'UC#?R?@CUS_A5_@__H$?^3,W_P 71_PJ
M_P '_P#0(_\ )F;_ .+KR7_A:'C#_H+_ /DM#_\ $4?\+0\8?]!?_P EH?\
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M4OO]99_]? _]!:K= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !535?\ D%7'^Y5NJFJ_\@N?_=_K0!;HHHH ****
M "BBB@ HHHH **** "BBB@ J*:W29<,*EHH PY_"UA/(7>"(L>^VG1>&[>'B
M,*H]!6U13N*R*=OIL5O]T#-7 ,#BBBD%K!1110,**** "BBB@ HHHH ****
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M>C9Z!O4?B/0>?7H\OO1V/7PN)Y_<EN=I1117*=X4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1&V@_P!XLW-0^$=#N-!T5K>]DCDN99WFE:(DJ2Q[9 /0"MRB@ HHHH ****
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MPI?P[_S^ZI_W]C_^(KT.BCVU3N'U>E_*>>?\*7\._P#/[JG_ ']C_P#B*/\
MA2_AW_G]U3_O['_\17H=%'MJG</J]+^4\\_X4OX=_P"?W5/^_L?_ ,11_P *
M7\._\_NJ?]_8_P#XBO0Z*/;5.X?5Z7\IYY_PI?P[_P _NJ?]_8__ (BC_A2_
MAW_G]U3_ +^Q_P#Q%>AT4>VJ=P^KTOY3SS_A2_AW_G]U3_O['_\ $4?\*7\.
M_P#/[JG_ ']C_P#B*]#HH]M4[A]7I?RGGG_"E_#O_/[JG_?V/_XBC_A2_AW_
M )_=4_[^Q_\ Q%>AT4>VJ=P^KTOY3SS_ (4OX=_Y_=4_[^Q__$4?\*7\._\
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M?]_8_P#XBC_A2_AW_G]U3_O['_\ $5Z'11[:IW#ZO2_E///^%+^'?^?W5/\
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MPI?P[_S^ZI_W]C_^(KT.BCVU3N'U>E_*>>?\*7\._P#/[JG_ ']C_P#B*/\
MA2_AW_G]U3_O['_\17H=%'MJG</J]+^4\\_X4OX=_P"?W5/^_L?_ ,14$GP=
M\/I>P0B\U+;(KDGS8\\8_P!CWKTJJD__ "%;3_<D_P#9:/;5.X?5Z7\IP_\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J:9_QZ/\
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M ,76-=>"[^+3Y;VQNK#5(8>938S^88QZD8!KGJ .Z_X6YKW_ #Z:=_WZD_\
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MU[_GTT[_ +]2?_%UPM% '=?\+<U[_GTT[_OU)_\ %T?\+<U[_GTT[_OU)_\
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M"W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9]:T>_BTQ8(]+4(D"S$AE!X&<<<<=Z -RPN-)U7QA=>&O[ L8;5VFACF2/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!535/^0;)]5_]"%6ZJ:I_P @V3ZK_P"A"@"W1110 4444 %%%% !1110 444
M4 %%%% !116!K/C;0]"NQ;:A=%9>-RHN[;GUJHQE)VBKCC%R=D;]%065[;:C
M9QW5E,LT,@RKJ>#4]3MHQ;!1110 4444 %%%% !1110 4444 %%%% !1110
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M]ZC_ -_(_P#XBC_A4>@_\_>H_P#?R/\ ^(H \>HKV'_A4>@_\_>H_P#?R/\
M^(H_X5'H/_/WJ/\ W\C_ /B* /'J*]A_X5'H/_/WJ/\ W\C_ /B*/^%1Z#_S
M]ZC_ -_(_P#XB@#QZBO8?^%1Z#_S]ZC_ -_(_P#XBC_A4>@_\_>H_P#?R/\
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M#NGBTTZ,A2<O(YR\A]2: $\/^'[+PYIBV=BO/624CYI&]3_AVK4HHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"I??Z^R_P"OC_V1JMU4OO\
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M*ZB'P]I.F:):ZCXHN;H-?#?;6MD%W[/[S%N!G(X_R(%T33=:UJQLO"]Q=/\
M:<^:MV@#08ZDE>",9/']: .>HKK'L?!$-\;*34-5=E.QKM%C\G=ZXQNQ4L/@
M=4U?5=)NYI'O(;0W-BT1 2<#U!!Z\<9['K0!QU%:WA?1AK_B&WL96=(6R\SI
MC*H!DGG\OQJT^B6#^$K_ %BUDN"8=0^SP*Y&#&0""PQ][GV^E '/T5V-UHOA
M?2=-TJ757U=IKZU6<FV:(JN1SP1FLSQ%X=BTNVM=1TN[^VZ9>9\J4KAE8=58
M>O\ @>.* ,&BGPQ-//'$F-TC!1N.!DG'6NIU3PIIMAX1EU"WU(WMY!<K!,82
M/)5B,D XRV,CG./:@#DZ*Z'2M$TX>'9-;UZ:Y6V,_P!G@AM0N^1\9)RW  &?
MRINOZ'9VFE6&KZ--/+87A9-MP!OB=3RIQP>_Y4 8%%;_ (+TR'4_$T0O%5[6
MV1KF=6Z%4&<>XSC/MFLJ2*XU&XNKJULV\O>9'6",E(@QX' X'84 5:*M7>F7
M]@J-?6-S;*_W3-"R!OID<UT.EZ3I-[XKT2S%C?1V]S"K3I=_)YIVD[D(YVG'
M!H Y2BKUWI\CZ]=66G6\DI2>1(XHE+M@,>W4\5'<:7?V<T<-W8W,$LIQ&DL+
M*SGV!'/6@"K170:UX/U#1["SNC#<RI-;B:<_9F46Q/\ "QYY^N*P8XWFE6.%
M&D=SA549+'T H ;16BGA_5?MUO:S:=>0R7#;4#V[@MZD#'.!R:M>(/"U]H6K
MO:"&XN(?,6.&X^SLJS,0#A>N3U& 3TH Q**G%C=M??8UM9C=;MOD",[\^FWK
MFBWLKN[N3;VMM--.,YBCC+,,=>!S0!!170R:%Y'@LW$]C-'J?]J+; .K!]AB
M+;=A]_;-8<EI<PW?V6:WECN-P7R60A\GH-O7- $5%=/H^FK=Z!KNFW=FL.HV
M<8O(FDBVRJ%^^I/7&"./4YKF* "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KO? ?CQM
M)9-+UB0M8L<12MR8#Z'_ &?Y5P5% 'TVK*ZAD(96&00<@BEKR#P'X\;2632]
M8D+6+'$4K<F ^A_V?Y5Z\K*ZAD(96&00<@B@!:*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@"I??Z^R_Z^/\ V1JMU4OO]?9?]?'_ +(U6Z "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MJFJ?\@]_]Y/_ $(5;JIJG_(/?_>3_P!"% %NBBB@ HHHH **** "BBB@ HHH
MH **** .9\=GR_ FKN.T9;^586H^)'L?"FDK;,HN;FVC.]NB#:.:W?'IQ\/M
M6SWA8?K7F^J,9M&T\?\ /.UBC'X(/\:]W+Z,:L$I;)O\D>CAHJ4=>YR-WX@U
M"XO+CS[N9F60C(?@\]J[GX.:Y-?^)KZSNI?,:.TWJ2>2-X']:YS3?![:O%<2
M0R+#M!P6&=[#G%3?!R"2W^*]W%)P5T]\_P#?:UZ&/]E*A-1Z6.G%.+I22Z'T
M!1117R1XH4444 %4=;OAINAWEX>L43%?KT'ZXJ]7*_$*Y\OPVML#\UU,J8'H
M/F/\A515Y)$5)<L'(\YT33GGU.)H7:*9>1*C893UX(KT >(]2TZWDBE2/4'0
M$([-Y3,>V< C\<"L#PO; 2RSD<(N16O:P?:M6M8B,@RAF^@Y/\J].I3@U>2V
M/GJ-:K&24'NSMT),:EEVL1R,YQ2T45Y1](%%%% !1145U=V]C:2W5[/%;6\*
M%Y9IG")&HY)+'@ >IH EHJ.WN(;NUBN;2:.>"9!)%+$P974C(8$<$$<Y%24
M%%%5K?4["[O;JSM;VWGNK,J+F".56> L,KO4'*Y R,]: +-%%% !15:^U*QT
MN%)=3O;>SCDD6)'N)5C#.WW5!)&2>PZFK- !1110!S=]_P E3T+_ + VI?\
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MX8U@++G4+Y5MHX]A^6(\NV[ISTQUR*P* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *]1^%>LZK<>9ILL33Z?"N5G8_P"I/9<]P?3M]*XOPKX5N_%&H^7%F*UC
M(,\Y'"CT'J3Z5[II>EVFC:='9:?$(H8QP.['N2>Y- %NBBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH J7W^OLO^OC_P!D:K=5+W_CXL?^OC_V1ZMT
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %5-4_Y![?[Z?^ABK=5-4_Y![?[Z?^AB@"W1110 4444 %%%% !1110
M4444 %%%% '(_$60CP!JJ#[V"H'ZUY]9+_:'AFSG7IY&XGZ*/\*]#\9VYN+*
M:V;[DR' ]21BO,? ]P(_#L]E<_ZS3I7AD4]<$\'Z8KZ7+_=H77?\ST\/I3T*
M>DR^(XO%EDEN%721$&<[QAP1DC'][)K=^&(CG^+FJ2Q]%T]_UE7'Z"L ZV-/
M@DMH@SR#*1R@C 7/'OGM6Q\ X)+[Q)XEUEL^4HCM(CZXRQ_E2Q<94Z$W+K_F
M&(3C3=^I[A1117S9Y@4444 %>>_$"\$VNV=DIS]GA:5A[L<#_P!!_6ND\1>.
M/#?A.,MK^L6UHP&1$6W2$>R#)_2O(=/\56OC/Q-JNKV,F^VGN%CMPPPWEJH
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M?^@7_P"3$O\ \50!X517NO\ PKGPK_T"_P#R8E_^*H_X5SX5_P"@7_Y,2_\
MQ5 'A5%>Z_\ "N?"O_0+_P#)B7_XJC_A7/A7_H%_^3$O_P 50!X517NO_"N?
M"O\ T"__ "8E_P#BJ/\ A7/A7_H%_P#DQ+_\50!X517NO_"N?"O_ $"__)B7
M_P"*H_X5SX5_Z!?_ ),2_P#Q5 'A5%>Z_P#"N?"O_0+_ /)B7_XJC_A7/A7_
M *!?_DQ+_P#%4 >%45[K_P *Y\*_] O_ ,F)?_BJ/^%<^%?^@7_Y,2__ !5
M'A5%>VI\/O#!U.:(Z9\BPQL!]HEX)9P?XO858_X5SX5_Z!?_ ),2_P#Q5 'A
M5%>Z_P#"N?"O_0+_ /)B7_XJC_A7/A7_ *!?_DQ+_P#%4 >%45[K_P *Y\*_
M] O_ ,F)?_BJ/^%<^%?^@7_Y,2__ !5 'A5%>Z_\*Y\*_P#0+_\ )B7_ .*H
M_P"%<^%?^@7_ .3$O_Q5 'A5%>Z_\*Y\*_\ 0+_\F)?_ (JC_A7/A7_H%_\
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M .+KSRBCV-/L'UBK_,>A_P#"Z/$7_/EI?_?J3_XNC_A='B+_ )\M+_[]2?\
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M .+KSRBCV-/L'UBK_,>A_P#"Z/$7_/EI?_?J3_XNC_A='B+_ )\M+_[]2?\
MQ=>>44>QI]@^L5?YCT/_ (71XB_Y\M+_ ._4G_Q='_"Z/$7_ #Y:7_WZD_\
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M@ HHHH *J:G_ ,>)_P"ND?\ Z&M6ZJ:G_P >)_ZZ1_\ H:T 6Z*** "BBB@
MHHHH **** "BBB@ J"[OK2PA$M]<PVT9;:'FD"*3Z9/?BIZX[Q<BZEXN\-Z2
MRB1#,]S*C#*E4&1D=^C"@#I+76=,OI?*LM1M+F3^Y#.KG\@:GN[VUL(?.OKF
M&VBSC?-($7/IDUR7CKP_I</A>XO[2TAL[NSVR136Z"-@=P&..O6J7B>^34%\
M(VVHR1A+J2.ZN?,(5<*JDY[ '<U ':6FL:;?R>78ZC:7+XSMAG5S^0-3F[MU
MO%M&N(A<LF\0EQO*^NWKCWK@M4CTJ_\ &VA0>%XK<W%M-YUU-9JH18@02&*\
M'/(_'WK2T;_3_B=KEX.4LX([52>Q/)_530!V%%%% %:\U&RT\(;^\M[4.<(9
MI53<?;)YJR#D9'(KSKQY:MKGB9-/4Y6QTN>Z( SAB"!G\0M=)I6OV\'@"TU>
M\;$<=HN_U9E&W ]R1^M &Q-J5C;W<=K/>6\5Q+CRX7E4.^>F%)R:9>:OINGR
MB._U"UM9&7<$FG5"1ZX)Z5YSIUA<W_C_ $>\U4$7EV'OY$R?W48!$2>V,?K6
M[I]K;ZW\2=<GN[>*Y@LH8[95F0, QY/!]PWYT =;:7]G?H7L+N"Y5>K0R!P/
MRISW=M'=1VKW$2W$@+)$7 =P.I ZFN+UW3K70?&GA^\T>)+22\N#!/'$H59%
M.!G:.._\JMP_Z?\ %NX9ONZ;8*BX_O.<\_@QH Z^BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH YN^_Y*GH7_ &!M2_\ 1]C725S=]_R5/0O^P-J7
M_H^QKI* "O!/BM_R-%O_ ->[_P#I3-7O=>"?%;_D:+?_ *]W_P#2F:NC#_Q#
MCQG\(XBI;6VEO;R&UMUW2SR+&B^K$X _,U%78?#JWBAU:[UZ\3?;:-;-<%<X
MW.00B_4\X]P*]"3Y5<\B$>:21M>+M&TB;PU>P:):P)=^')XX;B6) 'G0H S-
M@<G?GKTVGUKD=)\*76J:8VHR7MCIUF)?)6:^F,8D?&2%P#G KK?"OB70+_Q!
M-I_]BRV?]MJ]O<3R7YD#%\D?*5');@<]ZCT#2/$MK:SZ1<:#!K.D+=NKQS2*
MIC=259D;=E.G7'TZU@I.*LSJ<8U)*2U]"GX6\'6&H6FO_;[[3I9+2!U@=;EM
ML;  B8E1@ISUYZ'BK?@_1)9=&\7Z39W%K>2M# JS0R9B;ECG<0.!W^AJQHVG
MV-OXF\7Z%H,PG$^GR16:F0'>V!E QX."2/P^M4- L+K1_"_C6ROT\BYBMH Z
M;P<9+'&02.AH;;OKV_0<8I6T[_J8&M>$;S1M+BU+[78W]E))Y7GV,_F*KXSM
M/ J_!\.=4FM[*>6_TRUBOHHY+9KBX*>87&0@&W);D9[<CDU/IH#?!O6=W.W4
M8BOL<**A\=RNO_",;'8;-!M67!^Z?FY'OP*OFDW:YFXP2YK=$.C^&>MF8V\\
M^GVUV2WE6DUR!+.%[H #Q]<5CZ7X:N]3-T7GM+"*T8)-->S>6JN2<+W)/!Z#
MM79:@Q'[0*98_P#'W$.O_3-:73M%M;Z\\47UMIT&L:O!J4BP64\F%"%S\^W(
MW<YXSVJ?:22N_(KV46[);-K[CB]=\.7>@?97N);:YM[M"\%Q:R;XY #@X. >
M,CMWK(KT#XB1S0^%_#$=U:6EG.OVKS+>S_U<9WH<#D\\\\GG->?UK3DY1NS"
MK%0G9!1115F04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>D?"_Q
M;>C6++0[I9+JWRP@*C<T.1SG_9_E7!Z5I5YK6I16&FPF:>4X '0#N2>P'K7O
M'A;P=:>$19QQ8FO)=QN+C'WCMZ#T45SXB45&S.W"0FY\T=$==1117FGLA111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'QSXEOI%RD92S4$<$ ?,/S4?G7.>%--O-7NDT*]4C2]$NI'E!/\ K9-QVI]
M<G\3ZBO4Z* .0T;_ $_XF:Y>#E+.".T4GU/)_536%X0\8Z)IT&J7.HW3"]O;
MUYO*2%V)4_= P,=SWKTRB@#B],M[WQ3XKAU^^M)+/3K%2ME#,,/(QZN1V_\
MK#K@FI/ O^F:AXAU8?=NK\QH3UVIG'Z-7844 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!S=]_R5/0O^P-J7_H^QKI*YN^_P"2IZ%_V!M2_P#1
M]C724 %>"?%;_D:+?_KW?_TIFKWNL:'1-*U*-IM1TRSNY5FF4//;H[ >:YQD
MCIR?SK6E-0E=F%>FZL.5'S-17TY_PBGAW_H :7_X!Q_X4?\ "*>'?^@!I?\
MX!Q_X5U?6H]CA^HR[GS'17TY_P (IX=_Z &E_P#@''_A1_PBGAW_ * &E_\
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MIX=_Z &E_P#@''_A1]:CV#ZC+N?,=%?3G_"*>'?^@!I?_@''_A1_PBGAW_H
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ME[_R=_\ M='_  O'_J7O_)W_ .UUY-11["GV#ZU6[_D>L_\ "\?^I>_\G?\
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MH *J:G_QY#_KM%_Z,6K=5-3_ ./,?]=HO_1BT 6Z*** "BBB@ HHHH ****
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M4[.QN+.UN+5EO+%KE)%E:%B0%EC((, [GJ:C^P^-_P#H8?#_ /X(9_\ Y,H
MZ2O!/BM_R-%O_P!>[_\ I3-7O=<Q<>#=!\0M]KUBP^T3I)-$K^=(F%$SG&%8
M#J36M*:A*[,,13=6'*CYTHKZ&_X5?X/_ .@1_P"3,W_Q='_"K_!__0(_\F9O
M_BZZ_K4.S/.^HU.Z_KY'SS6GJ>O76JZ;IUA-'#%;Z=$8X5A4C.>2S9)RQ(YZ
M5[G_ ,*O\'_] C_R9F_^+H_X5?X/_P"@1_Y,S?\ Q='UFGV&L%52M=?U\CYY
MHKZ&_P"%7^#_ /H$?^3,W_Q='_"K_!__ $"/_)F;_P"+H^M0[,7U&IW7]?(^
M>:*^AO\ A5_@_P#Z!'_DS-_\71_PJ_P?_P! C_R9F_\ BZ/K4.S#ZC4[K^OD
M?/-%?0W_  J_P?\ ] C_ ,F9O_BZ/^%7^#_^@1_Y,S?_ !='UJ'9A]1J=U_7
MR/GFBOH;_A5_@_\ Z!'_ ),S?_%T?\*O\'_] C_R9F_^+H^M0[,/J-3NOZ^1
M\\T5]#?\*O\ !_\ T"/_ "9F_P#BZ/\ A5_@_P#Z!'_DS-_\71]:AV8?4:G=
M?U\CYYHKZ&_X5?X/_P"@1_Y,S?\ Q='_  J_P?\ ] C_ ,F9O_BZ/K4.S#ZC
M4[K^OD?/-%?0W_"K_!__ $"/_)F;_P"+H_X5?X/_ .@1_P"3,W_Q='UJ'9A]
M1J=U_7R/GFBOH;_A5_@__H$?^3,W_P 71_PJ_P '_P#0(_\ )F;_ .+H^M0[
M,/J-3NOZ^1\\T5]#?\*O\'_] C_R9F_^+H_X5?X/_P"@1_Y,S?\ Q='UJ'9A
M]1J=U_7R/GFBOH;_ (5?X/\ ^@1_Y,S?_%T?\*O\'_\ 0(_\F9O_ (NCZU#L
MP^HU.Z_KY'SS17T-_P *O\'_ /0(_P#)F;_XNC_A5_@__H$?^3,W_P 71]:A
MV8?4:G=?U\CYYHKWU/AIX2.IS1'2?D6&-@/M,O!+.#_%["K/_"K_  ?_ - C
M_P F9O\ XNCZU#LP^HU.Z_KY'SS17T-_PJ_P?_T"/_)F;_XNC_A5_@__ *!'
M_DS-_P#%T?6H=F'U&IW7]?(^>:*^AO\ A5_@_P#Z!'_DS-_\71_PJ_P?_P!
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MXJ-M$4L#.^K1D> O 4'A:U%U>A9M4E7YWZB$'^%?ZGO]*ZBY_P"0A9?[S_\
MH-6ZJ7/_ "$++_>?_P!!-<,I.3NSTX0C"/+$MT445)84444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!QOQ2_Y$I_^N\?
M]:\5KZ1O?^/FP_Z^#_Z+>K= 'S'17TY10!\QUI^&?^1MTC_K^A_]&"OHFB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *HV&BV&F7VH7EC!Y4^I3">Z
M?>Q\QPH0'!.!\J@8&!Q5ZB@ HHHH **** "JFI_\>:_]=X?_ $8M6ZJ:G_QY
MK_UWA_\ 1BT 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>vrna-20201231_g5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vrna-20201231_g5.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %9I8W1O<FEA
M(%-T97=A<G0    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,Y
M,@  DI(  @    ,Y,@  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M?[3)#O7. ,H"3SZU[]HK3^ OAQY_B^^-S<68EEN9Q*TIE)D)4 M@DD%1SWH
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ML6GW$T36LDQ"2$!D 9>G7!Z=L]:;_;_Q)U75+>^:ZUNWBO)U2)T62.W!9L
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M<M\2[V^T[X=ZI>:3<R6MW J.DL?4#S%W?IF@#@?A+\-?$?AOQ5)JNNQ+91)
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MJ)G=*1W8@$CZ@5J>.O@M;^'?#,FL:!?74\EFHDN(Y]IRO=E*@8QUP<\9YXH
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M&QB(]^6KZ'TQ@^D6;*<JT"$'U&T5Y#\=_".H:A<66OZ=;27,<,!M[A8E+-&
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M;0X_#POY[5!%$Z2LIP#P"@4DGMU% '*06M\?C%;6NN3I/?'6HX[J:$ *[^<
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M?6] CNKI  9$F,!/N5*MS],?2NV^'OC_ %OQGK-RE[H@T_3X;<NLNUSNDW*
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M/_R2S1?^N;_^C&KSO]HF?=?:#!\N$CG?W^8H/_9?YUZ)\)_^26:+_P!<W_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK31"!<=]Y"D?D336K-\/2]M6A3[M+[S'\/Z[\1/$NAP:M80^&H;>XW&-+@7
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M=[6)I%UXBGU[4X]7L+:VTN)L6,B/NDF&3\S88XX]AUJY:S7=CH"SZ[)"]U!
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MU)J$=WH1>&;KQ%=P73^*+"VL7$Q%O' ^XF/U8AB,_E]*VZQ/"M[>3^"=.O\
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M;\)-(33/A_:3[?W]^6N)7(Y.3A>?]T#\S57Q'_Q-/C-X9T[.8["WEO7 [$Y
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ML,%!M)R>5[ ]:F.YQ9?*,,3&<W91N_N5U^):\:7":!\-=3-N=JPV7V>,GMN
MC7\>13OA]H\>B>!-+MD0*\D"SRG')=QN.?IG'X54^)6B:GXB\-0:9I-OYWG7
MD9N#YBILB&26Y(SSC@<UUR(L<:H@"JHP .PI]"IU$L'&">LI-OY))7^]GG2V
M\>O?'J>28!XM#L$"#J!(W(_1S^(%;WQ(U#^S?AUK$P8*TD'D+[^80G'X,:K^
M#-"U'3_$'B;5-6M_(?4;W, +JY,*YVG@G'!Z>U'Q&T+4O$FE:=IFFVXEB>_C
M>[<R*HCB&<G!//7/&3QTI]4=;G3EC:47)<D%%7OIHKO\;FCX=A3P[\/;$2 [
M;/3UDD!/<)N;]<U@?!_3!;>##JDJC[5JT[SROW(#%5'Z$_\  JTOB=J']G?#
MC5G#;6FB$"X[[R%(_(FL'P];^.O"&DP:?:Z5;Z_8^6&@/VI;>2#<,E&W=0"3
MT_/L#=#IQE6PE27,DYRZNU[:O5Z;R19^*Y^WPZ!H,/-QJ&IQD#/*HH(9OPW"
MG?$A3J'B#PCHDF3;7FH&69.SB/:<'\&-7?#OAG59_$C^*/%SPG4?+,5I:0',
M=HAZ\]V.3S[G\'^//#FIZM)I.K>'VB.I:1.98HICA95;&Y<_\!'Z\T:7L51K
M4J56E1YE[JEKTYI)_@G;7YG7$A5)8@ #))[5YW\-[B/7/%WBWQ#&=\<]REO
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MD=A2CN<^ G&E5=5OX8MKUM9?BS$^%0@M=2UK3]6A_P"*G@G9KNXE8L\\9/#
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M$.O:E (H)XXK>S.]6WH ,G .1RHZXZTKZMF-/$*=:OB)/5J5O^WG;3Y-F?\
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MY.OAZD'-<[DF[M*Z2?5^;V'_ !/N8]0UKPQX95@9+O4(YYEQG$:G;D_7+?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+/<0DMY2HNYMRCY@0.<8S[4 ;=5M0U*QTBR>\U6]M[&UCQOGN95C1<G RS$
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M!% %_2=?T?7X9)="U:QU..)MLCV=RDP0]<$J3@UH5\\?LE?\@CQ-_P!=[?\
M]!>O7O%'Q,\'^#+H6WB37;>SN" WD!7ED /0E$!('U% '4T5@^&/&_AOQG;O
M-X9U>WU 1@&1$)5T!Z%D8!A^(K>H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFAT^TNW@D6W50 YC7AAM 8[F)QGCM7L?P/\ '>J>//AI+<ZHZRZK8SO:O-M
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MN+YT655-W(9)(9HC\P#G)92 W4D< CJ<_1M?+O@G_D\G5?\ K[OO_0&KZBH
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M!^8$RNP<$#I@8)]!7LOQB^&OBVW^)%O\0_A]$UU>*(VGACPTB2(NP,%/WE*
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M9'3UKFO$/AKXA_#GXX:IXH\*>'KC5X[ZYGGADCM'N(F68EF5Q'RI!..HZ>E
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MDNO/D;)?[QV%MHS["NGHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX5_Z"G_DO+_\30!T]%<Q_P +&\*_]!3_ ,EY?_B:/^%C>%?^@I_Y+R__ !-
M'3T5S'_"QO"O_04_\EY?_B:/^%C>%?\ H*?^2\O_ ,30!T]%<Q_PL;PK_P!!
M3_R7E_\ B:/^%C>%?^@I_P"2\O\ \30!T]%<Q_PL;PK_ -!3_P EY?\ XFC_
M (6-X5_Z"G_DO+_\30!T]%<Q_P +&\*_]!3_ ,EY?_B:/^%C>%?^@I_Y+R__
M !- '3T5S'_"QO"O_04_\EY?_B:/^%C>%?\ H*?^2\O_ ,30!T]%<Q_PL;PK
M_P!!3_R7E_\ B:/^%C>%?^@I_P"2\O\ \30!T]%<Q_PL;PK_ -!3_P EY?\
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MH?'\G^3#[+XF_P"@OI/_ (*I?_DBC[+XF_Z"^D_^"J7_ .2*V:*+A[>?9?\
M@*_R,;[+XF_Z"^D_^"J7_P"2*/LOB;_H+Z3_ ."J7_Y(K9HHN'MY]E_X"O\
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M^"J7_P"2*/LOB;_H+Z3_ ."J7_Y(K9HHN'MY]E_X"O\ (QOLOB;_ *"^D_\
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M3_X*I?\ Y(K9HHN'MY]E_P" K_(QOLOB;_H+Z3_X*I?_ )(H^R^)O^@OI/\
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MHHH **** "BBB@ HHHH **** "BBB@ KA/BY_P BE:_]?R?^BWKNZX3XN?\
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M*/9L/]6,9_-'[W_D?3%%?,__  MOQM_T&O\ R4A_^(H_X6WXV_Z#7_DI#_\
M$4>S8?ZL8S^:/WO_ "/IBBOF?_A;?C;_ *#7_DI#_P#$4?\ "V_&W_0:_P#)
M2'_XBCV;#_5C&?S1^]_Y'TQ17S/_ ,+;\;?]!K_R4A_^(H_X6WXV_P"@U_Y*
M0_\ Q%'LV'^K&,_FC][_ ,CZ8HKYG_X6WXV_Z#7_ )*0_P#Q%'_"V_&W_0:_
M\E(?_B*/9L/]6,9_-'[W_D?3%%?,_P#PMOQM_P!!K_R4A_\ B*/^%M^-O^@U
M_P"2D/\ \11[-A_JQC/YH_>_\CZ8HKYG_P"%M^-O^@U_Y*0__$5TWP[^(GBG
M7?'NG:=JNJ>?:3>;YD?V>)=V(G8<JH/4#O2<&C*MP[BZ-*564HVBF]WT^1[E
M1114'S@4444 %%%% !1110 4444 %%%% !1110 5C77_ "/6E_\ 8-O/_1MM
M6S6-=?\ (]:7_P!@V\_]&VU-&]#XWZ2_)FS1112, KSKXG:I?Z?XJ\ PV%[<
M6T5WKBQ7"0RL@F3'W6 /S#V/%>BUY7\:YUTN^\#ZY=@KI^G:_$UW,!D0JPQN
M/H.#S_C0!VOCVYGLOAOXENK.:2"X@TFZDBEB8JT;K"Q# CD$$9S7.^'_ !M:
M^'?@MX;USQ+=75U+<V=O&NT-/<7<[KPBCJ[MS5WXHZ]I=G\(?$%S/?0"&\TN
M>"V<2 B9Y(V5 O\ >R6'3ZUA6W@J#7O@[X-T35M0?1-8LX;6ZT^4%?-AN8X\
MC"-][ )RO^% '7>%O&EOXHFNK;^R=7TB[M51WMM5M/(<HV=K+@E6&01P>,<U
MB7_Q@T6UO+R.PTC7M8M+"0QW>H:98>=;0,/O ON&=O?:#BL_P]XH\5MXFUWP
M+XD:SOM4M-*-Y:ZG8(8Q(&^55D0\+)D@X'& :Y+X-:-XLU+X96(\/>/;73(8
M'EBFT]M#CFDMI/,;<KL9 23G=R!P10!Z]/XU\/6_@O\ X2R34HO[%\D3"Z&<
M,"<  ==V>-N,YXZUXU\9OB7IWB/X37]A_96M:1-=-!+9MJED85O$$JDF-@2#
M@<X.#CG%/\:>%8O!'P0\.Z:VJIK&DV7B.&>^N$A"1F R2%EV@L,!R!UZ_E70
M?M*:EIB?!^6VGN(#<W=Q"UDA(+2%6!9E^BD\^^.] 'K]<KXF^(.F>&M4ATH6
M>HZQJTT9F73M*MO/F6/.-[#("KGN2,]JZJO#+6P\0W7[0WC6VTKQ3#X?O9X;
M26 3Z<ET;J 1X.S<RX"GKC.2>>E 'H^D?$72M<T+5;_3[346NM(4M>Z3);^7
M>1$*6V^6Q') ..<'&,U#+\4O#D?P[M?&2/<36%V4C@MXD#7$DK-M\D)G!<$'
M(SV)SBJ7A'P;>^'O&VM>(=?\76^L7UW9Q1W*)8I:B-4SM=@';L" >.,]<<>/
M^'WLK+XH6'BRXLY8?A_?ZY<+I(>3$4%X551<%.@1F5MN?NX[;>0#T+QU\4-:
MT'XF^%]*L-%UP64IF-Y;QV43G4/W*,JPDMDF,L=V"O/=A7::EX_TS1?"]GK.
ML6FHV4E\PCM],DM\WDLA) C$2DY;C/7'3FN6^(QV_&KX7.WRI]HU!=QZ9,4>
M!]369\5X=0/QD\"/:ZQ'HBO'=16U_/:K/'%.5'!5B!N884<]3Q0!VWAWXD:7
MK^O'1+C3M6T/53&98K/5[7R'G0=60@E6Q['/7T-5M3^+.A:9XHU3PY]CU2\U
M?3C"/L=G:B62Y\R/S,Q@-T48W%MH!(YYK+7X?Z_/XZ\.ZUXI\=V^HRZ5+,UK
M;)I,=L\N],.H82$D8 )X/ [=:@\&HI_:-^([E076#3@&QR 8%R,_@/RH Z_P
MAXZTGQG:7DFGI=6=Q82^5>V5_#Y,]LW8.N3C.#SD]#Z&L?3/B[HNKZC;Q6.E
M:[)IUU<BU@UG^SS]BED+[  ^<X+?+N*@9[UB>%OLZ?'KXH+=LD=H;;3VFWMM
M0+]F^8L>@&">?K6;*VN_!73=,;2M5MO$'@ZXO4MX;*=,74"RMD>5(O$@R2>1
M_B #K1=Z3%\<+R&.;6Y=930//:U$JFR,(E ^52<^;NQUXP?6N@\(>+M-\:^%
M[?7M)$T=K,7&RX4+)&58J0P!(!X]>F*XJV_Y.OO/^Q2'_I2E<3K.MS?#>Y^(
MG@^RRL^L/'>:%$K89FNR(I OIM8\#_9- 'J]A\3_  [>^!9O%TDD]GI$<SPI
M)<1C=.5;;F-5)+;FX Z^PJOI/Q5TK4-<M-*U'2-<T"XOSBR;6+'R$N6_NJP8
MC=['!Z=S7!_%#P\_A7P/\.M*M+U+"STO5;:.>^>$2QP2;3B9T) (W;F.2!S7
M0:S\._$^NOI#>)OB-:W-I9ZE!>0*NBQ0EY5/RA7$O4@D#KUZ&@ CE:+]J>_<
M(\FSPAN$:=6Q<KP,\9KM_!_B_3/&WA>#7M(\V.VF+J8[A0LD3*Q!# $@'C/7
MH17%VW_)U]Y_V*0_]*4KB=>UJ;X:WWQ!\(V>5EUXQWN@QJV"SW3>5*%]U;D#
MT2@#VKP?XNL/&V@?VQI$5PEFTTD4;W"!3+L;:77!/RD@XS@\=!6)K,^D)\9_
M#D-S=:PNJR65P;:""519.@!W&5<Y+<G&/09Z"N@\):!%X6\'Z7H=O@K8VR0E
MA_$P'S-^+9/XUQ'B3_DY/P7_ -@R\_\ 030!JW_Q;T.R\1:GH$5CJU_J^GR+
M&;&QM1+)/E Y9 &^Z 0"6VC)[UL^#O&VE>-]/N+C2EN8);28P7=G>P^5/;2#
M^%UYP?H3W]#7&_#M%/QQ^*#E07673P&QR 8GR/T'Y4[X=<?&OXHH.%$^GD =
M,F*3)H [3QMXGA\&>"=4\07">8MC#O6,G&]R0J+GMEF49]ZX+0? 7BSQ3HEM
MKWBKQ[X@T[5;R,3QV>DSK!;6H895&CP=Y (SD^V3U.U\<M%NM>^#>N6MA&TM
MQ&B7"QJ,EA'(KL,=_E#5N>"O%ND^)_!-CJ]A>P&'[,GV@>8,V[A?F5_[I!SU
M^O2@#E/%WB7Q9X0\&:%H:WEKJ'C#6;W^S[>^$.V/&\XG9.@(0ID8(#$]0.4E
M^$_B%;0W5M\3_%']M ;A)+< VA?_ *]\8"Y[9.!ZUC_%#7=,GU+P%X]L+D7F
MAZ3K$MO=74 +(BN0C/TY ,9&1P>V<BO5KKQ%H]EH3:S=:G:QZ:J>9]K,H,97
M&>".OT'6@#QZZ\7>)_%_P%U'5K>ZFT[Q/X6OC]M%I*8Q,T!!D#!2,H48DK]T
ME3Z<>LZ=XHL;_P #P>*"_EV,E@+YS_<39O;/N.?RKA?@=8R7_A+Q!K5_;%+;
MQ-K-U?0PR+C= YP,CWPWX8]:\]CU"\T_P7J?P:BE;^U&U]=+MF)^86$K&;S?
M<;0V?9Q0!T7]J>)(OV9M?\57VJZA%J>K2/J%NPNGW6<3S*$2,Y^1=O( QPU;
M/Q5U'4T^'W@I++5K^PEU/6+"UN;BSN6BE>.2)]PWCGDX/U%:WQELX-.^ >MV
M5G&([>VLXH8D'1461 !^0K"^*G_(B_#G_L8=,_\ 13T :'B#P)XC\+Z+<ZUX
M*\;:_<7UE&9S9:S=_;(+E5Y*8894D9&0?RZCM/!'BB'QGX)TOQ!;Q^4M]#N:
M/.=C@E77/?#*PS[57\?>+M+\'^#]0O\ 5+J*-_L[BW@9AOGD((5%7J23^0R>
MU<C\/O!WBG3?@OX;TS2M=7P]J"+)<7)FT\7)(D=G"%69=I 89]P: /1M;EU2
M'1;E] M[>YU$+BWCN9"D98D#+$<X R>.3C%>8>!)?%%E\<M;TCQ1XCFU<C1X
M[HQH#';Q.TB\1QYP !QGJ>]>D>';#6-.TLP^(M:36;OS"PN4LUM@%XPNP,1Q
MSSGO7"Z3_P G/Z__ -B_!_Z,6@!/&&I:MXB^+VG> K'5KS1-._LQM2O+FQ;R
M[B?YR@C1\?* 1G(]_2H](EU7P'\7].\*7.O:CK6C:_9S2VAU.7SI[>>(%F'F
M8R5*CO[>G/4^+? .C^+]2L[VXN[[3=7L5/V>_P!,N?)N$0GE<X(*DYZ@]_4U
MYUI?ANS'[1FD)I&KZGK<N@6,\VJ7NH7AN"C2H8XXL\*I^8MM4#K[< 'N%%%%
M !6-XJ_Y \'_ &$K'_TKBK9K&\5?\@>#_L)6/_I7%36YOA_XT/5?F;-%%%(P
M"BBB@ HHHH **** "BBB@ HHHH **** "N$^+G_(I6O_ %_)_P"BWKNZX3XN
M?\BE:_\ 7\G_ *+>@#QZO8-!T/PO/\/([BXM[1@;<M<7+ ;T?'S?-U!!Z"O'
MZ* "BBB@ KMO ]M]L\*^*+<SPV_F10#S9VVHO+\D]JXFNC\/ZM96/A7Q%9W4
MVR>]CB6!-A.\@MGD# ZCK0!MW-DOA#X?WD3W2W\FLLJ));$M @7G[WJ1G\O:
MK.G>&[K3_"VGW.D:#::Q>7R>=-+>*K+$IY555B.QZ_\ UL8&@ZS8GPKJNA:S
M/Y44J^=:.49MLH[< X!P/U]:L?VEHGB+PWI]EK-_)IEYIJF*.80-*DJ=N%Y!
M  _R> "UXI\,(;W0'%DNEW&J2""YMHV!6-]RKN4 ]#NSQQT[U+J&JZ1I/BM=
M#@T"Q>Q@D2%IBG^D%N,N']0>W?'OQS-RVEZ-J=A<:'>RZA);R":21XO*0LK
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M J<$K)(GL[^[TZX\_3[J:UFQCS()"C8],CFI[_6]5U5%75-3O+U5.5%Q<-(
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M&D^"_P /9+YKH^&K<,[[VB26582?^N0;9_X[7;111P0I#!&L<4:A41%PJ@<
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M+_[!MY_Z-MJ:-Z'QOTE^3-FBBBD8!1110 4444 %%%% !1110 4444 %%%%
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M6\5ZKH'B;08='\2V4$<D[V\@ECNH<G8ROC. 6/RMTW'OD#NZ "BBB@ HHHH
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M_>G?]_)/_B* .%HKNO\ A4>O?\_>G?\ ?R3_ .(H_P"%1Z]_S]Z=_P!_)/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9YD3N^HS>5(DJK-JES(FY&#*2K2$'# 'D=JV:*+L/K%;^=_>PHHHI& 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%87B[Q+_PBNDQ7OV3[5YDXAV>9LQE6.<X/]W]: -VBO,?^%Q_]0+_R<_\
ML*/^%Q_]0+_R<_\ L* /3J*\Q_X7'_U O_)S_P"PH_X7'_U O_)S_P"PH ].
MHKS'_A<?_4"_\G/_ +"C_A<?_4"_\G/_ +"@#TZBO,?^%Q_]0+_R<_\ L*/^
M%Q_]0+_R<_\ L* /3J*\Q_X7'_U O_)S_P"PH_X7'_U O_)S_P"PH ].HKS'
M_A<?_4"_\G/_ +"C_A<?_4"_\G/_ +"@#TZBO,?^%Q_]0+_R<_\ L*/^%Q_]
M0+_R<_\ L* /3J*\Q_X7'_U O_)S_P"PH_X7'_U O_)S_P"PH ].HKS'_A<?
M_4"_\G/_ +"C_A<?_4"_\G/_ +"@#TZBO,?^%Q_]0+_R<_\ L*/^%Q_]0+_R
M<_\ L* /3J*\Q_X7'_U O_)S_P"PH_X7'_U O_)S_P"PH ].HKS'_A<?_4"_
M\G/_ +"C_A<?_4"_\G/_ +"@#TZBO,?^%Q_]0+_R<_\ L*/^%Q_]0+_R<_\
ML* /3J*\Q_X7'_U O_)S_P"PH_X7'_U O_)S_P"PH ].HKS'_A<?_4"_\G/_
M +"C_A<?_4"_\G/_ +"@#TZBO,?^%Q_]0+_R<_\ L*/^%Q_]0+_R<_\ L* /
M3J*\Q_X7'_U O_)S_P"PH_X7'_U O_)S_P"PH ].HKS'_A<?_4"_\G/_ +"C
M_A<?_4"_\G/_ +"@#TZBO,?^%Q_]0+_R<_\ L*/^%Q_]0+_R<_\ L* /3J*\
MQ_X7'_U O_)S_P"PH_X7'_U O_)S_P"PH ].HKS'_A<?_4"_\G/_ +"C_A<?
M_4"_\G/_ +"@#TZBO,?^%Q_]0+_R<_\ L*/^%Q_]0+_R<_\ L* /3J*\Q_X7
M'_U O_)S_P"PH_X7'_U O_)S_P"PH ].HKS'_A<?_4"_\G/_ +"C_A<?_4"_
M\G/_ +"@#TZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK#U8WMSXDT_3[74[BP
MBDM+F>1K=(F9V1X54?O$;C$C=,4&E.'M)<M[;_@KFY16-_8>H?\ 0TZM_P!^
MK3_XQ1_8>H?]#3JW_?JT_P#C%,OV4/YU^/\ D;-%8W]AZA_T-.K?]^K3_P",
M4?V'J'_0TZM_WZM/_C% >RA_.OQ_R-FBL;^P]0_Z&G5O^_5I_P#&*/[#U#_H
M:=6_[]6G_P 8H#V4/YU^/^1LT5C?V'J'_0TZM_WZM/\ XQ1_8>H?]#3JW_?J
MT_\ C% >RA_.OQ_R-FBL;^P]0_Z&G5O^_5I_\8H_L/4/^AIU;_OU:?\ QB@/
M90_G7X_Y&S16-_8>H?\ 0TZM_P!^K3_XQ1_8>H?]#3JW_?JT_P#C% >RA_.O
MQ_R-FBL;^P]0_P"AIU;_ +]6G_QBC^P]0_Z&G5O^_5I_\8H#V4/YU^/^1LT5
MC?V'J'_0TZM_WZM/_C%']AZA_P!#3JW_ 'ZM/_C% >RA_.OQ_P C9HK&_L/4
M/^AIU;_OU:?_ !BC^P]0_P"AIU;_ +]6G_QB@/90_G7X_P"1LT5C?V'J'_0T
MZM_WZM/_ (Q1_8>H?]#3JW_?JT_^,4![*'\Z_'_(V:*QO[#U#_H:=6_[]6G_
M ,8H_L/4/^AIU;_OU:?_ !B@/90_G7X_Y&S16-_8>H?]#3JW_?JT_P#C%']A
MZA_T-.K?]^K3_P",4![*'\Z_'_(V:*QO[#U#_H:=6_[]6G_QBC^P]0_Z&G5O
M^_5I_P#&* ]E#^=?C_D;-%8W]AZA_P!#3JW_ 'ZM/_C%']AZA_T-.K?]^K3_
M .,4![*'\Z_'_(V:*QO[#U#_ *&G5O\ OU:?_&*/[#U#_H:=6_[]6G_QB@/9
M0_G7X_Y&S16-_8>H?]#3JW_?JT_^,4?V'J'_ $-.K?\ ?JT_^,4![*'\Z_'_
M "-FBL;^P]0_Z&G5O^_5I_\ &*/[#U#_ *&G5O\ OU:?_&* ]E#^=?C_ )&S
M16-_8>H?]#3JW_?JT_\ C%']AZA_T-.K?]^K3_XQ0'LH?SK\?\C9HK&_L/4/
M^AIU;_OU:?\ QBC^P]0_Z&G5O^_5I_\ &* ]E#^=?C_D;-%8W]AZA_T-.K?]
M^K3_ .,4?V'J'_0TZM_WZM/_ (Q0'LH?SK\?\C9HK&_L/4/^AIU;_OU:?_&*
M/[#U#_H:=6_[]6G_ ,8H#V4/YU^/^1LT5C?V'J'_ $-.K?\ ?JT_^,4?V'J'
M_0TZM_WZM/\ XQ0'LH?SK\?\C9HK&_L/4/\ H:=6_P"_5I_\8H_L/4/^AIU;
M_OU:?_&* ]E#^=?C_D;-%8W]AZA_T-.K?]^K3_XQ5+5+;4])M[>Z3Q%J-Q_I
MMK$T4T5ML=9)XT8';"#]UCT(HL.-%2DHJ:N_7_(Z:BBBD<X4444 %%%% !11
M10 4444 %%%% !1110 5PGQ<_P"12M?^OY/_ $6]=W7"?%S_ )%*U_Z_D_\
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M[OEQJ6W9]CQU.!0!Z'17+>$/B!I?C&ZU"RMK34--U+3F476GZG;^3-&&^ZV
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ML?\ TKBIK<WP_P#&AZK\S9HHHI& 4444 %%%% !1110 4444 %%%% !1110
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M"\C>=OSOW,3TQQC/J:N:AXHM-6T:WM]1T=)K^WMQ;Q7HN&7"CH2@')^IZDT
M8$%Q-:SK-:S20RK]UXV*L.W!%=UX_O+G_A/X[7[1+]FW0-Y.\[,\<[>F:X&M
MCQ-X@;Q%KS:DL'V4E54()-V-HZYP* -?QM_R5*X_Z[6__H"5N2_\E\'^\O\
MZ3"L*X\<6UU<1:C/H-O)K$:*JWC2L5W#HWEXP2/KZ>E5F\8;O'W_  DOV''(
M/V;SO2/9][;^/2@!OB'Q/K,^N7D8U">***X98HH7*+&%)4;0.G'YUJ_$^^NQ
MX@6U%U,+=[6-FA$AV,<GDKT["N-O;G[9?W%SMV>=*TFW.<9.<9_&MW7?%-KK
M]BAO-(4:FL21?;5N&QA3G_5XQD\CDGK]* -WQYKVIV#Z/9V%Y+:Q?V?%,3"Q
M1F8[AR1R0,=/>K&N64&J?$KP^MXBLMW9PRSC Q(?G//UV@?2N.\1Z]_PD%S:
M3&W^S_9K1+;&_=NVDG=T&.O2I=9\3S:GJFG7]O%]DFL+>.%"'W9*$D-T'KTH
M [2ZUBUM?&$EW/XTDB6"X*/8"SF\M44X,>.G08SCKS57PS>VEOKGBV_T8+);
M1VDD\ 9"%./F VGG&:Q+GQ;H^H7/VW4O"T$]\<&25+MT1V'<H!_6L_2_$G]F
MG6=ME&1JEO)#LC;8L.[/08.0,]/UH HZCK&HZNZMJ=Y+<E"Q7S&SMSUQZ#CI
M73>$I&TSP;XAUBT'^FQ+'#%(!S&&;!(_//\ P&N,K9\.^(I-!EN5:WCN[.[C
M\NXMI#@2#G'/8C)_,T 5+K6]3OK+[)>W\]S )!*$F<OA@",@GGH37HM]_P E
MTL_^N8_]%-7"ZKK=C=Z<MCI.CQ:=!YHF<^:TLCL 0/F.. &/%:$_C4S>.H?$
M?V#'E+M^S^=U^0K][;[YZ4 ;GABYDLKKQI=0;?-@221-PR P9R#CZU5\-ZE>
MZSX7\4Q:K=2WB+:><@F8OM<;CD9Z<@=/2L.Q\4?8EUT?9-_]KHZ?ZS'E;BW/
M3YOO>U0:)X@_L;3M5M?LWG?VC;^1N\S;Y?!YQ@YZ].* ->V_Y([>?]A8?^@)
M5OQOJ-YH<FE:3I%U-9VL-BD@$#E"[$G+$CKT_G7.1Z]Y?@^;0OL^?-N_M/G[
M^GR@;=N/;KFM%/%]I=:;:6VOZ)'J<EDNR&?[0T3;1T#8!W4 3>'WU[6)-3O_
M .VAIT!6/[=?2':3CA0"!G/T(_E6OJOD7/PMNF767UO[/>J8[B6)T:,G *_/
MR>"?SK!M/&>R?4DO]+M[FPU$()+-&,2IL "[2,XP /R%%_XNM9_#,VB:=HL=
MA;R2+(&6<N<@Y)8D98G YH M>,O^13\)_P#7F_\ [)7'5L:SX@_M?2=)LOLW
MD_V="8M_F;O,SCG&!CI[UCT %%%% !1110 4444 %%%% !1110!].4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %8UU_R/6E_]@V\_P#1MM6S6-=?\CUI?_8-O/\
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M %:BK;Z3J,=XEI)I]TERXRL+0L'8>RXR:BNK.ZL9O)O;::VEQG9-&4;'K@T
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M ,<H_P"%[^)O^?'2?^_,O_QRCD8?ZNX_LOO/?J*\!_X7OXF_Y\=)_P"_,O\
M\<H_X7OXF_Y\=)_[\R__ !RCD8?ZNX_LOO/?J*\!_P"%[^)O^?'2?^_,O_QR
MC_A>_B;_ )\=)_[\R_\ QRCD8?ZNX_LOO/?J*\!_X7OXF_Y\=)_[\R__ !RC
M_A>_B;_GQTG_ +\R_P#QRCD8?ZNX_LOO/?J*\!_X7OXF_P"?'2?^_,O_ ,<H
M_P"%[^)O^?'2?^_,O_QRCD8?ZNX_LOO/?J*\!_X7OXF_Y\=)_P"_,O\ \<H_
MX7OXF_Y\=)_[\R__ !RCD8?ZNX_LOO/?J*\!_P"%[^)O^?'2?^_,O_QRC_A>
M_B;_ )\=)_[\R_\ QRCD8?ZNX_LOO/?J*\!_X7OXF_Y\=)_[\R__ !RC_A>_
MB;_GQTG_ +\R_P#QRCD8?ZNX_LOO/?J*\!_X7OXF_P"?'2?^_,O_ ,<H_P"%
M[^)O^?'2?^_,O_QRCD8?ZNX_LOO/?J*\!_X7OXF_Y\=)_P"_,O\ \<H_X7OX
MF_Y\=)_[\R__ !RCD8?ZNX_LOO/?J*\!_P"%[^)O^?'2?^_,O_QRM_P-\6==
M\3>,['2+^TTZ.WN/,WM#&X<;8V88)<CJH[4<C1G5R'&TJ<JDDK)-O7L>OT44
M5!X04444 %%%% !1110 4444 %%%% !1110 5C77_(]:7_V#;S_T;;5LUC77
M_(]:7_V#;S_T;;4T;T/C?I+\F;-%%%(P"BJ6M:K!H6@ZAJ]XLC6^GVTEU*L0
M!8HBEB "0,X'J*X)_CKX873H-32PUN;276,SZG%8[K>T9P#LD<-]X9 (7=@\
M=: /2J*\\OOC7X7L91,(-5NM'$HA?7+:R+V,;DXP9<\\\94$9[UTWB;Q=8>%
MK.VFNX+V]DNY/+MK;3[9KB69L9^55]N<D@4 ;M%<AX:^)&F>(]?ET.73M5T7
M5HX?M"V6K6ODO+'G&],,P(S[_P C6=K'QDT#2->U+0Q8:QJ&K:?*D9LM/M!-
M+,"@<NBAONJ",EL<],T >@45Y5=W:WG[2'AFZ19(HY_#4LH25=K*&<G##L?4
M5U.B_$?0M>;6Y;(SIIFB,5N-6F55M9"!EO+?=EMN.3@#IC.10!UE%>>1?&G0
M"8+B\TK7]/TFY=4@UF\TXQV<F[A3OSD YX+*!6WXQ^(>A>!9=-'B&2:*+4#*
M(YT0,B>6FX[N<\\ !0220* .HHKA1\6='C\,MK.H:3KNG9NUL[>PN]/*75W*
MRAE$48)W9!X.1TK9\+>,;?Q2UY"FEZKI-W9[#-::I:^3(%?=M8<D,#L;D$].
M: .AHK*\2^)=-\):#/J^M2M%:PX'R(7=V8X554<DDG%9OACQS;^)K^6Q;1=;
MT:[CB\Y8=7LC 98\@%E()!P2 1G(STH Z>BL'PIXOT_QA!J<NF17$:Z;J,NG
M3?:%52TD>W<5P3E?F&"<'V%1>'?'&D^)--UB_MO.M;;1KZ>RNI+L*@#0@%W!
M#'Y,'.3@]>!0!T=%>?V7QATC4)(9;30/$LFF3RB*+5AIC?96R<!LYW;<]]N*
MY>^\4V7A?]I'6IKV.[N9;C0X(;:TLH&FFN)-X.U%'L"<G  !YH ]HHKF/"'C
M[2O&4U]:VEO?:?J.G,JW>GZE!Y,\.[E25R1@@=03V]16_J%];Z7IEUJ%\_EV
MUI"\\S[2=J*"S' Y/ /2@"Q17GA^,VC6\EO)JFA^(]+TVXD6./5;[33%:Y8X
M4EBVX ^I4"M_Q9XXTWP@]C;W5O?:AJ&H.RVFGZ=!YT\VT98A<@8 .2210!TE
M%8WACQ-;>*M-EN[:TOK%X)C!/:ZA;F&:&0*K;64^S*<@D<]:SO%G@7_A*[Z"
MY_X2GQ+HODQ^7Y6CZC]G1^<[F&TY/.,^E '545X+\,O!5_XRT+4+[5/B!XVB
MDM=5N+-%M]:8*4C(P3N4\\\]O:HOB+XH\5Z#\:;W4M%OKR;3-!T^VO+S2EF;
MRI8&;;*=F<;AN!SCC&>U 'O]%>8?%?Q-*? 'A[5_#6ISP0W^KV12>VE:,R0O
MD[20>A&,@_C4?Q>;4+OQ3X'T2RUO5-(M]4OIHKF72[HP2,H12/F'X]0: /4Z
M*Y#PM\/O^$7U9K__ (2[Q3K&Z(Q?9]7U+[1",D'<%VCYAC@^YK.U#XR:!9:C
M?P6VG:UJ=KIDACO]1T^Q,MM:,/O!WR#\O?:#B@#T"BN=\/>-])\4:YJVFZ/Y
MTW]EI;O)=87R9A/'YB>6P.3\O7(&*T=>URR\-Z)<:KJC2+;6^W=Y432,2S!5
M 502268#\: -&BN$T_XLZ5<ZY8Z7JFB:_H,FHR>593:M8>1%</V16W'#'L"!
MU%7/$_Q,T'PEXBAT75EO#=W%I]I@$$'F>=\^P1(H.YI">@ Q@$DC% '7T5R7
MA;XBZ7XHUJZT86.IZ1JUK&)FL-5MO)E:(G'F* 2"N2!U[U!K_P 4-(T3Q#+H
M=KIVKZ[J5O&);JWT>S^T-;(1D%^0!D8X&3R..: .THKR'X1:S9^(/BK\2-4T
MN8S6ES)IS1L5*G_52 @@\@@@@@]"*[#XK7MUIOPI\0WFGW,UK<PV;-'- Y1T
M.1R&'(/TH ZZBO(_'NMZK9?"'P;>V>I7<%U<WFFK//%.RO*'3+!F!R0>^>M>
MN4 %%%>2Z8=9^*_B;7I_^$AU/1?#6DWK:?:PZ3-]GENI8\;Y&DQG;DC 'KVP
M<@'K5%9/AS0W\/:5]A?5M1U8"0LD^I3"68*<?*7P,@>IYYK6H *QO%7_ "!X
M/^PE8_\ I7%6S6-XJ_Y \'_82L?_ $KBIK<WP_\ &AZK\S9HHHI& 4444 %%
M<9?:=X_;4;E[#6;!+5I6,,;H,JF3M!_=]0,=S5?[-\2(O^7W3IO^ @?^RB@#
MNZ*X3^T/B-:_?TFPNE'4JP!_]#'\J/\ A.]<L/\ D,^%+I$[R0DD#]"/UH [
MNBN<T/QUHFO3+!;SM!<MTAN%VLQ] >A_.NCH **** "BBB@ KA/BY_R*5K_U
M_)_Z+>N[KA/BY_R*5K_U_)_Z+>@#QZBBB@ HHHH *[30[B72OACJNHZ>3%>3
M7BVS3IPR)A3P>WWB/Q^E<76YH/B7^R;&[TZ]LDU#3KO!DMW<H0PZ,&'0]/R%
M '06FK7VJ?"C75U"X>X,$L*I)(<M@R*<$]3^/K5UH[33? FB0+K[:']K5KB2
M2*!W>=N.K)T R!S[>E<]=^,89/#=YH=CH\5E9W&PQA)2S(RN&8L2,N3@#MC%
M0Z=XJBCT--(UO2X]4M(6+P9E,3Q$]0& /% &CXIUJRFTO26T_6I+_5;,NCWB
M1/"[(>F2><CIU/?UJU\1[FYE\506!NYDM9H(=\?F'9DL>2N<'M^5<IK&I65_
MY":;I,6FPPAN%D,CN3C[S'KC''IDUHZ[XIM=?L4-YI"C4UB2+[:MPV,*<_ZO
M&,GD<D]?I0!V'B>:UL-;CM(?%DFB)91HL5G#:2E5& <DKPV?_K>M5;&^TS4_
MC)87FCRB6.6)C*XC9 9/*<'@@=@*P)O&%CJD$!\1:!'J-W"@C%RERT+.!TW!
M1S_GI5/3_$L6G>,(M;M],ABCBR%M(7*K@H4^]@\\Y)QS0!9N-?U+5?%T$-Y=
M.UNNHH8X <1Q[7VC:O; .*ZJ*")_B_K=Q)$LKV=H;B%6&?G"1@?S-><17WE:
MPE_Y>2MP)MF>N&SC-;+^,KI?&DOB&S@6%I<!H&;>K+M"E2<#KC- &EX*\1ZM
M?>,H+>_O9KN"]+I/#,VY&&TGA>@_"K_A63^Q8_&;V(7_ $,?N=PW ;6DVGGK
MC K'C\8Z?I\DUUH/AV&POY5(%P;AI1'GJ50@ ?Y[<5F:1XB;2]+U>T:W,[:G
M$(S(9,%#SST.?O>U &KX>N?$FNW=W-'K;VT<,!%S>3R?ZJ,MG /4<@GC'3K6
MS=^3+\,]95==?7/)FA99)(G4Q$NHP"_)R,]*Y+P[XB.A-=Q36B7MG>Q>5/ S
ME-PYQAATZG\ZO77BZS;PW>Z+INB1V-O=%&W"<NP97#$L2/FS@ =,4 :E[JNH
M1_"C2[B.^N4G:^9#*LS!BN'XSG..!Q5.W);X/WA)R3JP))[_ ")5'3/%%M!X
M>&CZOI*ZE:I-YT/^D-$4;'J!R.3^=55U\+X2GT-;4!9KS[2)1)]WY0-N,>W7
M- '1>-=0O-!_LK1]'N9;.TBLDE_<.4,CL3EB1UZ?F34^K2MJ=AX.UB\ %_-/
MY4C$8:55D #'\L_\"K%C\6VEUI5K9^(=%34VLUV0S"X:%PG920#FJNI^*9]3
MU>QNFMHX+;3ROV>TB.%100<9]3@<T =/XC\0ZK!\3X[2WO)(;:&YA188VVJP
M;:6W ?>SD]:YSQY#'!XYU-(5"*9%; &.2H)/YDU6U3Q!_:7BXZY]F\O,T<OD
M^9G[H'&['?;Z5#XAU?\ M[7KG4O(\CSRI\O?NVX4#K@9Z>E '3_#^[DL-!\3
M7<&WS8+:-TW#(##>0<>QYJ;P/>S:G=ZGJFL7[R3Z?9L8)YU,OD;LDN!U.,=!
MV.*YC1O$']D:3JUE]F\[^T81%O\ ,V^7C/.,'/7VJ+0->N?#VI?:K9$E5T,<
MT,@RLJ'J#0!V-GJVD6]GJ,&J>,)=6@N[=T\B6TFX?LP+9P?R[>E4O#^IVEYX
M2CT2+6&T*_CN&E$^2J7&>@9@1CTY]!UK)NM>T-[:X%AX7AMIYD9/-DNGE$>>
MZJ0 #Z>E1Z=K>D0:?!;ZGX=AOI8"2LZW#0LP)SA\ [O3GMQ0!U?A:UU2T^)E
MY'KK^9>?8V+2#I(,* 0<#/ _R:R/A?\ \C9+_P!><G]*H_\ ":ZA_P )@-?V
M1[P-GD#.SR\8V?USZ\^U:&G^.K#2+QYM)\-PVHF#";_2"S-GH%)7Y5SS@#L*
M (_"G_(D>+?^N,'\WJU-JFH1?"6SGBOKE)O[2\OS%F8-MV-\N<].!Q7.Z5KW
M]F:'JVG"W\W^TDC7S-^/+VDGICG.?:K6D^)K>TT&31]6TI=2M#-Y\8,[1-&^
M,=0#Q^74^M &E8LS_"+5W=BS-J*$DG))^2KGB76+_3?!7AJ#3[E[87%KF1XC
MM=MNW W#G')XKFT\1+'X5O=%CLPJ75T+A9!*?W8&/EP1STZYIFL^(/[7TG2;
M+[-Y/]G0F+?YF[S,XYQ@8Z>] '2^*";V'P=>7,1NKBYA59> 6FPR<'/7.X]?
M6N@NKMK'QU+J5SXIM(],M\J]B+G+KA<%/*'?//K7%V^M'7K[PQIH46)T]UB%
MP7#;B67YL$8!^7IS747T^J7?C:2UG\'6<]L]R$-Q+8EF:/.-YEZ=.?;I0!YQ
MJ=X;_5+FZ+2,)9"RF1MS!<\ GV&!^%=AH^H7L?PHU>2.[G1X;F)(F65@8URG
M .>!R>!7-^*;2RL/%%_:Z80;6*7:@#;L<#(S['(_"G6OB#[-X1OM#^S;OM<R
MR^=YF-FTCC;CG[OK0!TV@ZK=Z=\+]7OK:4BZ-_@3-\S L$!8$]\$\^],T/4;
MR+P9KOB$W#S:HIBM4N)3N>-"5'!/.>?T%<Y;^(/(\'W6A?9MWVBX$_G^9C;C
M;QMQS]WKFG>'O$<FA&YADMH[RRNTV7%M(<!_0@]CS0!T'A#4KS6]-UW2]8GE
MN[7["\XDG<OY3KC!!/3KG_@/UI;?5+O2?A%#+I\IAEFU!H3(OWE4J2=I['Y1
MS61<^*[:+1[G3O#^D)I<=WQ<2&=IG=?[N2!@52DU[S/!\.A?9\>5=_:?/W]?
ME(V[<>_7- '67OB#4X_A7IUXMT_VN2X>V:YS^]\OYC@-U'W1S[50\1S2ZE\.
M= U&]D::Z666$RL<LRY.,GO]T5AW'B#S_!]KH7V;;]GN#/Y_F9W9W<;<<?>Z
MYHNO$'VGPE8Z)]FV_9)GE\[S,[]Q)QMQQ][UH QZ*** "BBB@#Z<HHHH \:_
M: _YE_\ [>?_ &E7C5>R_M ?\R__ -O/_M*O&JZ(?"?J&0_\BZG\_P#TIA11
M15'M!17H6L?"6\TCP/\ V\]_YEPD,<TUB(,&)6QGYMQSC/IV->>TDT]CGP^*
MHXF+E1E=)V^84444SH"BM31_#>K:_#>2Z1:&X2RC\RX/F*NQ>>?F(S]T],]*
MHV<,=S?0033K;QRR*CS,,B,$X+'V'6@CVD&VD]5OY$-%;WC#1-,T#6EM-&UB
M'5[=H5D,\3*0K$D%<J2,\ _C6#0*E4C5@IQV?R"BNDTWP]I%WX)O]7NM?M[;
M4+=RL.GL1OD QV)R<Y/0$#')ZXYN@*=6-1R4>CML%%%3V5I+?ZA;V=OCS;B5
M8DR<#<QP/U-!;:2NR"BO1_$_@[P9X5AFT^^UC4GUM+0RH$C7R6DVDJI&TD D
M>O /6LG7O"%CI7PYT/7X)KAKK4'VRH[*47AC\H SV[DTN9'#3S"C446KVD[*
MZM?2_P!VAQU%%%,[PHHHH **** "BBB@ HHHH ***L:?87.J:A!8V$1FN;AP
MD<8(&XGW/ H$VHJ[V*]%6]5TJ\T35)M.U.'R+J @21[@VW(!'()'0BJE 1DI
M)2B[IA1110,**** "BBB@ KLOA)_R5+2/^VW_HEZXVNR^$G_ "5+2/\ MM_Z
M)>E+9G%F'^YU?\,OR9],4445S'Y$%%%% !1110 4444 %%%% !1110 4444
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M/Y<H/RL.C CE3R>00>35'PSX$\->#FG?P[I4=I+<8$LS2/+(X'0%W);'MG%
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M<TJ?Q/;^(9;3=JMM;M;17'F-\L;')7;G:>>Y&: ."U7Y?VH=!*\%O#TRL1W
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M %%%% 'GWQ(M+>&\T6[A@CCN'O5#2HH#, 01D_6O0:X3XF_\P+_K^']*[N@
MHHHH **** "N$^+G_(I6O_7\G_HMZ[NN$^+G_(I6O_7\G_HMZ /'J*** "BB
MB@ HHHH **** "BBB@ HK=T70[?4O#NN7\\DJRZ?'&T00C:VXMG=Q[=L5A4
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M* /&OV@/^9?_ .WG_P!I5XU7LO[0'_,O_P#;S_[2KQJNB'PGZAD/_(NI_/\
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MEG;QRK)I\#1REP &)V_=P?;OB@#JO%'B.YTJQTC4]*@MK2_U2V6:YN4A4LV
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M;VWN'T_66DW>5@2H"S$8R<9PQIT_B#0+;PCJ.B:-:WX-T8W$]R5)9E<$Y .
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MQ*578  1PQSDG\*-&\(:?H?BG7M>M);AKK7FA:Y21E*(8E*KL  (X8YR3^%
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M45L77A_[-X1L=<^T[OM<S1>3Y>-FTGG=GG[OI0!CT444 %%%% !16QX8\/\
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MK/,_^%$>&?\ G^U;_O\ 1?\ QNC_ (41X9_Y_M6_[_1?_&Z],HHYF']KX_\
MY^L\S_X41X9_Y_M6_P"_T7_QNC_A1'AG_G^U;_O]%_\ &Z],HHYF']KX_P#Y
M^L\S_P"%$>&?^?[5O^_T7_QNC_A1'AG_ )_M6_[_ $7_ ,;KTRBCF8?VOC_^
M?K/,_P#A1'AG_G^U;_O]%_\ &Z/^%$>&?^?[5O\ O]%_\;KTRBCF8?VOC_\
MGZSS/_A1'AG_ )_M6_[_ $7_ ,;H_P"%$>&?^?[5O^_T7_QNO3**.9A_:^/_
M .?K/,_^%$>&?^?[5O\ O]%_\;H_X41X9_Y_M6_[_1?_ !NO3**.9A_:^/\
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MX<8]%AACMK>."!%CBC4(B*,!5 P /PH ?1110 4444 %8WBK_D#P?]A*Q_\
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MH1A0PFMVRISV^M4* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQC_D5_\ R!)_C73^%=5UG5;:X?7=+_L]XW CX*[QCG@\\>OO[4 ;U<)\7/\
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MW_?JT_\ C% >RA_.OQ_R-FBL;^P]0_Z&G5O^_5I_\8H_L/4/^AIU;_OU:?\
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MSR1B"1\,2C8^8X].?3I5X^$M,;Q!JZK>31Z/I"CSYV(:1FQ]U< #.X$?A[T
M<?174RZ#HNIZ#>ZAX;GOA)8 -/;WH3+(?XE*\=C^7TJ2#P[H<'A+3=<U>\NT
M%R95>" *6D8.0NW(P!@$DG/:@#DJ*Z?6-!TC3ETG4[:>\GT?4 Q88431E3AE
MS]W/^!K;^(/]A!K+SEU#[9_9D?V;84\L+EMN_C.>N<>U 'GM%6=,LFU+5;6Q
M1PC7,RQ!FZ+N.,UOZ[I7AK36O;&WN=334;0[0;B-?*E8'D# R,]03Q0!R]%=
M-9Z#I5EX?M]6\2SW:K>,1:VUF%WLHZL2W&/_ *WK3-8\,PQKI=UH,\EU9ZHW
MEP"8!9$D!"E6QQU[_P#ZZ .<HKL;_1/"6C:A_9>J7VIO=Q@":>!$\I&(ST(W
M''M5/3/#VG+H<NMZ]=7$=AYQAMDME'FSMZ_-P!P?R/X@'-45T^I^'M,E\,G7
M?#EQ<R6\,HBN8;L+OC)Q@Y7@CD?G]:MS^&_#NF:#I>IZM>7W^FP!_L]OL+LW
M&2"1@*,]\]: .-I8T:618XQEF(51ZDUT7B#PQ%8WFF'1YI+BUU5%:V\[ <$D
M#:V./XA6J^@>&-)UZ#2;K4K[^TT9-TX1?LZR'!"D?>QTY[9^M '(:CIUUI.H
M266H1>3<18WIN#8R 1R"1T(JM78^,XK.?XHWD>J7+6MH3'YDJ(7( A4X ]S@
M?C3+;0?#NN65^/#\^I)>V=NUP$O!&5E5>N-O0].I[B@#D:*ZSP]X9TK4/"US
MK&KWL]K':W.R3R\'<FT' &/O$D#T]J$\/Z'JFC:Q=Z#/?&6P1)D2Z*C,>,MD
M =1ANAQTH Y.GPQ27$Z0PH7DD8*BCJQ)P!6WI^AVTO@_4M:OI)5,,BP6J1L
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"UUXU11R1#^P<N_P"??XR_S/9?^&@/^I:_\G__ +71_P - ?\ 4M?^3_\
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M "BBB@ HHHH **** "BBB@ HHHH ^G**** /&OV@/^9?_P"WG_VE7C5>R_M
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M?_(AZ_\ ]@VY_P#134 >6:5<?$NZ^%4'C>W\=QW,PL6OGTVZTBW$4BJ"2F]
MK#@=?_UUZEX-\0_\)7X+TK73!]G:_MEF:+.0C$<@'N,YKP/^P/&*?L\:;JL7
MB>XO_#\=FLU[H,5O';LUJ#\Z+<*"^ ,DYZC/T/T#X5ETJ?PAI,OAV-8M*>TC
M-HBC[L>T;1SSD#KGG- "^(O$^B^$]+.H^(M1AL+7=L#R9)=O[JJ,ECQT )KS
M35OB%9>(_BE\/%\(Z_)-87%Q?QWUO"[Q;RL2%1+$V#QDD;A]*N>+8X;[]HWP
M7:ZJJO:PZ?=7%FDG*M<C.3CN0J@CW -5O'UI81?M"_#BZ@BA6_G-X+EUQO=%
MB'E[O;)< _7TH ])T?Q+I.O76I6VE7?GS:7<FUO(S&Z&*0=OF R/1AD'L:@_
MX3+P_P#;M9M&U.))="1'U(R*RI;!UW+ER-IR > 3CO7G^I75O\//CU/JEVP@
MTCQ1I3R3OCA;FU7<3Z?ZO/U+51\*^ IO'7P0UEM3G:QU+QE=-JCS8W>6/,#0
MJ1W3" X]&- '>Z'\4/!WB1KI-&UI;A[2!KF6,P2HWE+U=5907'NN:\O\,>-+
M#QY\5=3>\\9:_9+'J,<.BZ?8":&WFB7DF5?+Q\V.0^",GVQV7A[Q=K-CXYTS
MPI\0-#L8=6N;>7^S=4TYM\-P$7,BA2-T?RJ"1T.!QTJ+X2_\CA\1_P#L8'_E
M0!WFD^(]*UR\U&UTN[\^;2[@VUVOELOE2 9VY( /U&14=CXJT;4GU9;*]$IT
M:5H;_P#=N/)=1DCD?-QW&17#?"4_\5E\1QW_ .$@8X_"LSP%*DTWQ:>)UD0Z
MI<X93D']VU '67'QE\ 6L5K)/XC@5;N-9(R(96VJWW2X"_N\_P"WBNM?4[&/
M2CJ<EY M@(?/-T9!Y?EXSOW=,8YS7EOPLT?3E_9IC1;*$+?:?<O=?(/WS$N,
MMZ\ #Z 5Q^IW,DO[)GA2*YE86EQ>6]O>-G \@3OP3V VK^0H ]<T;XK^"=?U
MB'2]*UV.:[G)6%&@EC68CJ$9E"M^!-<EHOQ[T.^\?:UIE[=+'H\(MQI<\>GW
M/FS,Z?O XVG;AC@95>/7K7J9M["&"VC:*W2*%E%NI50$/1=OH>PQ7G'@S_DX
MKXD?]<=-_P#2<4 ='97>[XMZG:?\)3+<%=-CD_L VI"6X+ ><)>C$X(V]?F^
ME+X@^*7@SPOJCZ=K6N1PWD:[I88H9)FB'7+^6K;>.><5SND_\G/Z_P#]B_!_
MZ,6H?V?(XKCX<7&HW"*VJW^I7+ZG(PR[3;SPWX8X]_>@#T*T\1Z/?^'#KUCJ
M$-SI:PM,;F$[U"*"6/'.1@Y'7BN;N/C'X M/LOG^)(%^U1QRH1%(0JN,H7(7
M]WD'.'P:X?P?%%::3\8+'2\+I%O=77V9$_U:2&%O-5?3!"C';BM/P9H^G1?L
MM-''9PJEWHEQ-. @_>N48[B>YX'/; ]* /6HI8YH4EA=9(W4,CH<A@>A![BN
M3UV[$7Q-\,6I\4RZ>UQ'<[=&6T+KJ&U,DF3HFT<\]<<5%\()'E^#WAAI&+$6
M"*"?0< ?D!6#XS_Y.*^&_P#UQU+_ -)S0!TVO_$_P;X7U?\ LO7-<BM[T*&>
M)8I)#$#T+E%(3J/O8ZUU$,T5S;QSV\BRQ2J'1T.592,@@]P17E6L:5XH^'7B
M#Q+XIT&RLO$&AZHWVS4;&:0Q7,.Q,,48Y5UQN.T_0#U]#\+ZO8Z]X3TS5-(B
M\BQNK9)((B@7RUQPN!P,=....* *'B7XA>%O"%U':^(-8BMKJ5-Z6Z1O+*5R
M1NV(&;'!YQV/I5[P[XIT3Q9I7]H^'=1BOK4,49TR"C#LRD J?8@5R&M^*]6E
M^)%WX=\"Z!IEQK%M91RW^IZE(8DC1CE(_D4N_4GT&37.?"NTU"[\??%'3?$
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MVTLLEY>RKM50&.7('3/)Q_A4Y\(6=[I]U/X>UQ-3FM$\R6W-LT3%1U*Y)W4
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M[\'J>G>O._!WCR?PK:WEA/80ZGIEZ/WUK,=H)Q@D'!ZC@Y!Z"NATOXNVFA7
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MD D#=G%3:S\--,U;Q=_PDD&J:QI&H21I%<G3+SR5ND4_*)!@D\#'!!Q78T4
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M /\ 4R_^2'_VRC_AG_\ ZF7_ ,D/_ME'/$/[>R[_ )^?A+_(\:HKV7_AG_\
MZF7_ ,D/_ME'_#/_ /U,O_DA_P#;*.>(?V]EW_/S\)?Y'C5%>R_\,_\ _4R_
M^2'_ -LH_P"&?_\ J9?_ "0_^V4<\0_M[+O^?GX2_P CQJBO9?\ AG__ *F7
M_P D/_ME'_#/_P#U,O\ Y(?_ &RCGB']O9=_S\_"7^1XU17LO_#/_P#U,O\
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M *F7_P D/_ME'/$/[>R[_GY^$O\ (\:HKV7_ (9__P"IE_\ )#_[91_PS_\
M]3+_ .2'_P!LHYXA_;V7?\_/PE_D>-45[+_PS_\ ]3+_ .2'_P!LH_X9_P#^
MIE_\D/\ [91SQ#^WLN_Y^?A+_(\:HKV7_AG_ /ZF7_R0_P#ME'_#/_\ U,O_
M )(?_;*.>(?V]EW_ #\_"7^1XU17LO\ PS__ -3+_P"2'_VRC_AG_P#ZF7_R
M0_\ ME'/$/[>R[_GY^$O\CQJNR^$G_)4M(_[;?\ HEZ[/_AG_P#ZF7_R0_\
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MANHU;<$FC#@'IG![\F@#YJHKZ)_X1G0?^@)IW_@)'_A1_P (SH/_ $!-._\
M 2/_  H ^=J*^B?^$9T'_H":=_X"1_X4?\(SH/\ T!-._P# 2/\ PH ^=J*^
MB?\ A&=!_P"@)IW_ ("1_P"%'_",Z#_T!-._\!(_\* /G:BOHG_A&=!_Z FG
M?^ D?^%'_",Z#_T!-._\!(_\* /G:BOHG_A&=!_Z FG?^ D?^%'_  C.@_\
M0$T[_P !(_\ "@#YVHKZ)_X1G0?^@)IW_@)'_A1_PC.@_P#0$T[_ ,!(_P#"
M@#YVHKZ)_P"$9T'_ * FG?\ @)'_ (4?\(SH/_0$T[_P$C_PH ^=J*^B?^$9
MT'_H":=_X"1_X4?\(SH/_0$T[_P$C_PH ^=J*^B?^$9T'_H":=_X"1_X4?\
M",Z#_P! 33O_  $C_P * /G:BOHG_A&=!_Z FG?^ D?^%'_",Z#_ - 33O\
MP$C_ ,* /G:BOHG_ (1G0?\ H":=_P" D?\ A1_PC.@_] 33O_ 2/_"@#YVH
MKZ)_X1G0?^@)IW_@)'_A1_PC.@_] 33O_ 2/_"@#YVHKZ)_X1G0?^@)IW_@)
M'_A1_P (SH/_ $!-._\  2/_  H ^=J*^B?^$9T'_H":=_X"1_X4?\(SH/\
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M_P"#F[_^.T?\(KI__/QJW_@YN_\ X[6S11=A]8K?SO[V8W_"*Z?_ ,_&K?\
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M_P#/QJW_ (.;O_X[1_PBNG_\_&K?^#F[_P#CM;-%%V'UBM_._O9C?\(KI_\
MS\:M_P"#F[_^.T#PIIGF1.[ZC-Y4B2JLVJ7,B;D8,I*M(0<, >1VK9HHNP^L
M5OYW]["BBBD8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>vrna-20201231_g6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vrna-20201231_g6.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %9I8W1O<FEA
M(%-T97=A<G0    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,R
M-   DI(  @    ,R-   ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M44$A5)8X Y)/:L>T\8>&K_4/L%CXBTFYO,X^S0WT;R9]-H;- &Q1167J?B?0
M-$NHK76=<TW3[B8;HXKN[CB=QG&0&()YXH U**** "BBB@ HHHH **** "BB
MB@ HK-L_$FAZAJ<VG6&LZ?=7T&?-M8+I'ECQP=R Y&/<5I4 %%%% !113)IH
MK:WDGN)$BAB4O))(P544#)))Z #O0 ^BL[2/$.BZ^DKZ#J]AJ:PD"1K*Y28(
M3TSM)QG!I/\ A)-#&M?V/_;.G_VG_P ^/VI/.Z9_U>=W3GI0!I4444 %%%%
M!1110 44R::*VMY)[B1(H8E+R22,%5% R22>@ [U1TCQ#HNOI*^@ZO8:FL)
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ME=&/(5Y#*&#<\_*<'/6NV_9U^(^LW'B>[\%Z_J!U*%8Y)+.X>7S2K(?F4/\
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MW#!>QR\>?8$2#_@0KTCX(>*E\0?!S3+J[E'FZ=&UG<NS9QY0P"3_ +FPGZT
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M>QH \3_94O[2+P/KL,MS$DD5^)I%9P"J&-0&/ME3S[5A?M;?\A3PO_UQN?\
MT*.M-_V2M/.I;X_%ERMENSY+62F3;Z>9O S[[?PKN?BK\&8_B9_9&S6VTHZ9
M&\:YM?/$BMM_VUP1M]^M '0_"K_DD?A?_L%P?^@"OG;]JO\ Y*GIO_8%B_\
M1\]?4/AC0U\,^%-,T2.=KA=/M8[<2LNTOM4#..V?2O//BK\#(_B;XGM-9.OM
MIC6]HMJT7V/S@X#NP(.]<'YR._:@#-^.O_)N=K_VY?R%,_94_P"26:E_V&I?
M_1$%=WXZ^'D?C7X=KX5_M%K(1^3LN?)\S_5XQE<C.<>HIGPL^'2?#+PG-HR:
MDVI&:[>Z:<P>5RRHN NYNR#OWH ^=_C1_P G,Q_]=['^25N_M96%POB#P_J)
M#&VDM9( <?*KJ^X_B0P_+VKT3QG\"(_%_P 38O%Q\0M:;7@=[3['OW>7CH^\
M8SM]#BN_\8>#=&\<^'Y-'\0VYFMV8.C(VUXG'1U/8C)]NQ!% 'AO@7X!?#OQ
MKX/T_5[/7=8EEF@0W,4-U!^YEP-Z$>42,'/7MCK7;_#_ .$'@/P;XT^W^'M<
MNK_5K:!O]&GO89#&K?*6*(BGOC)XYKC;O]DFT>Y+6'B^>&#/"3:>)&'_  (2
M*/TKT'X7_!C3/AE?7=]:ZG=:A=W4/DLTJ*B*FX-PHR<Y YS0!T'B;XE^$/!V
MJP:;XDUN*QN[A Z1-&[_ "DD DJI"C(/)QTKJ%974,A#*PR"#D$5Y/\ $[X$
MVWQ)\66VMR:[+IQCMUMY85MA+O568Y!W#:?F(Z&O5+6VCL[.&VAR(X8UC3)R
M< 8'\J ):\!_:Q_Y%+0/^OY__1=>_5P?Q7^&$?Q0T2RL6U5M,>SG,RRB#S@V
M5P05W+^>: ,K]G/_ )(CI7_7:X_]'-7)?M8_\BEH'_7\_P#Z+KU?X=^#%\ >
M";3P\E\;_P"SM(QN#%Y>XLY;[N3CKZFLGXL?#!?BAHUC8G5FTMK.<S+(+?S@
MV5P1C<OYYH I_L^?\D)\/?\ ;S_Z4RUXK^U5I]Q#\1]-OW#&WN=-6.-CTW)(
M^Y1] ZG_ (%7TCX!\))X%\#:=X<CO&O19!\W#1[-Y>1G/RY..6(ZFF^./ >A
M_$'0O[,\0P.R(V^&>)MLD#XQN4]/P((/I0!X_P"&?V>?AMXI\.6FKZ7X@UJX
M@GA61C'=P'RR1RK#ROE(.00>F*[/X;?"GP/X)\4WE[X8UJXU+4H[?R)H9KR&
M4P([ Y*HJD$E,<^AKA9_V2;9KG=;>,)8X,_<DTX.V/\ >$@'Z5Z5\+_A'IOP
MP6^>QU&ZO[B^5%E>9550$SC:HZ?>/4GM0!\]SZOXH^-OQ8N-#N/$1TBT>658
M+:25EBC1#PHC!&]S@9SR>>@&*P?BM\,[/X:7UA9V_B6'6KFY61IX4@$36P7;
MMW#>WWLMC./NGK7N_C?]FC1/%&OW&K:/J\NBRW3F6:$6XFB+DY)4;E*Y/.,D
M?2LR3]E'1_\ A'_LL/B*X74S,KM?26H9 @# HL0<8R2#DL?NCU- '8^#4:3]
MF.V1 69M F  [GRWKR7]E&[MX?&&N6\LR)--9(T:,<%PK_-CZ9%?1WA/PW'X
M7\&:=X?\_P"V1V5N(#*\>WS?4[<G&<],FO&=:_91TF\U:2XT;Q)/IUI(Y86L
MEH)R@)^ZK[UX],@GW- &C^U/(DWPGTR2)U=&UF(JRG((\B?O6K^S5_R1FV_Z
M_)__ $*K_BOX-VOB/X5:1X)M]8ELX]*ECDBNW@$I<JCKRNY>N\G@\<5T'PW\
M#K\//!D.@)?MJ'ERO*TYB\O<6.?NY./S- 'S;J'_ ">&G_8>B_\ 9:]L_:,_
MY(CJO_7:W_\ 1RU4G^!$<_QC'CL^(6 %ZMY]A^Q]UQ\OF;^F1_=KM?B+X,7Q
M_P""+OP\U\;#[0T;"X$7F;2CAONY&>F.HH \8^">GW&J_LR^-+"R#-<7$]['
M$J]78VL6%_$\?C7EWP<\&^$_'/B*[TGQ;JEUI\QB#V7V>:.+SF!^9<NK9.,$
M <\'TKZJ^%?PZ7X9>%)]&74SJ9GO'NFF,'DX+(B[=NYNR#G/>N,\:?LT>&_$
MNK3ZEH^H7&AW%PQ>6-(Q-"7/)8*2",D] V/0"@#.U']FOX;:1;F?5O$NK6,(
M&3)<W]M&H_%H@*G_ &@])M-"^ 6F:5INXVEE=VT$)9MQ*K&X!)[GBLO3_P!D
MO38I@=5\5W5S'GE;>S6$D?4L_P#*O5/B1\/(_B#X)3P]_:+:<(YHY4G$/FXV
M C!7*YX/K0!QW[+_ /R2*3_L)3?^@I7D?Q-_Y.V_[BFF_P#HN"OH_P"&/@%/
MAOX/_L--1;42;AYVG,/E9+ # 7<<?='>N2\3? >/Q'\6T\;_ /"0M;8N;:X:
MR^Q[\F%47 ?>,9V#^$XS0!0_:I1F^%6GE5)":Q$6([#R9A_,BM/]G*_M&^"^
MGQ"YB\R&ZFBD4N,J[2$JI]R&&/7-=[XQ\):;XX\+W6A:TK_9K@ AXSAXW!RK
M*?4'\^AZUY!X?_9;L]%\56.JR^*9KF"SN4N$MUL@C,48, 7WGCCGY?RH ][K
MYF_:TL)QJ'AO4-I-NT4T!;'"L"K8_$']#7TS6+XK\)Z1XU\/S:-X@MO/M9"&
M&UMK1N.CJ>Q&?Y@Y!(H P?A)XBTS5_A+H$EG>0M]ATZ&VN5WC,+QH$8,.W*Y
MY[$&OG#QA>0^/?VGXSX<:.ZAEU&UACFBY5Q&J!WSW VL<CJ!7?7?[)5D]X6L
M/%UQ#;9XCFL5D?'^\'4?^.UZ/\./@SX=^'$CWED9;_4Y$V->W(&47N$4<*#^
M)]Z .+_:N_Y)_H__ &%!_P"BGKK?V?/^2$^'O^WG_P!*9:O_ !6^&J_$_P .
MVFF'53IAMKH7 E^S^=N^5EQMW+_>ZYK7\ >$5\">!=.\.)>&]%D)/](,?E[R
M\C.?ER<<MCJ>E '1U\@?M0_\E<A_[!</_H<E?7]>1?%#X#Q_$GQ;#K9\0MII
M2V2W>'['YNX*S'(;>N/O>AH ]$U#_D1;K_L&O_Z*-?-G[*'_ "/FM?\ 8-_]
MJI7U#<:>L^BRZ=O*I);F#?C) *[<UYM\*/@FGPPUV_U(:\VIF[M_(6/[)Y.P
M;@V<[VST'I0!X-X/O(/!?[4 EU^46T5OJMW#)+)\JKYBR(K$]E)=3GI@YKZ9
M^*GB;2M"^%NMW%]=VX^UV$L%M&S@_:))$*JJC^(9/..V3T%97Q'^"'ASXBWO
M]I7$D^FZKL"-=V^")0!@;T/!P.XP>V< 5P-A^R581W0;4_%EQ<P9YCM[)86(
M_P!XNX_2@#,_92LI;>3Q-K=Q^[L8X8X3*W0L-SM^0P3_ +PK:U[X)>!/B7!/
MXD\ ^(8K)[C,L@C(DMPQY.Y#AHB><@]/[HKVC0O"NC>&_#,>@:19)!IR(4,>
M<E]WWBQZDGN:\4U;]DW2[B^:31?$]S8VS$D0W%H)ROL&#IQ]0: .>_9Z\9>(
M+#XD2>"[W43J&FLLR*#*94B>('#1,?X3M(QT.0:Y+QIJ-MH_[44^IW[E+6RU
MZWN)F R51'1F.._ -?1_PU^#>@?#5YKNREFO]3G3RWO+@ %4X)5%'"@D ]S[
MU\X^,].MM7_:CFTV_3S+6\U^WMYD!(W([HK#(Y'!- 'TA\5?%VBVGP9UJ^74
M+:>#4["6VLVCE#"=Y4*#9CKC=GCH :\H_9+TZ<WWB34RI%N(X;=6(X9B68@'
MV '_ 'T*U+G]DS2GU8RVOBB[AL"V1;O:*\@'IYFX#_QVO9_"'A#2? _AR'1=
M!@,5M$2S,QR\KGJ['N3@?D , "@#Y5^ O_)PD'_;W_Z ]=;^ULK#4/"SD':8
MKD ^I!CS_,5W7@3X!Q>"/B'_ ,)0OB)[T+YWEVILQ'CS 1R^\YP#Z"NO^)'P
MVTGXEZ%%8:K)+;36SF2VNH0"T1(P1@]5/&1[#F@"3X97]I<?"OPGY%S%)G2K
M:(;7'+I$H=?J"""/:OF_Q5XC\3_%3XU7'A5=>;1K!;V:TMXFF:.)%C+#+ $;
MW;;T/<X&!7JOPY_9WMO 7C2V\12^(I-2EM!((85LQ"H+HR$L=[9X8^E2?$']
MG/1/&FOSZUIVIRZ+>W3;[@+ )HI'[OMW*03WYY//KD \(^*OPGL_AE!8JOBF
M#5KVY<A[1;<1/"H&=Q_>,<$\<@5[)X1_Y,NN/^P7J'_HZ:JT?[*.CIH,]NWB
M*XDU.0KY=XUJ/+B .3B(/R3TR6./2O1](^&L6E?!M_ )U-Y4>TGMS>^2%.96
M=BVS)Z%^F>W6@#QW]DG_ )"GBC_KC;?^A25R?_-W7_<R_P#M2O>_A)\'E^%L
MVJ2_VVVJOJ"QK_QZ^2(PFX_WVSG=[=*R_P#A0<7_  M__A./^$B?;_:'V_[#
M]C&=V<[?,W],_P"S0!-\??B7_P (1X1.F:7/LUO54*1%3\T$71Y/8_PK[Y/\
M-8G[-OPV_L+0#XNU:'%_JD>+16',5OUW>Q?K_N@>IK6^*7P''Q*\61ZW_P )
M&=-*6J6YA^Q>=G:S'.?,7^]TQVKB_P#AD;_J=O\ RD__ &Z@"3]K73[AK?PS
MJ*AC;1M<0.>RNP1E_$A6_P"^:I_#7X&_#[Q[X)L=577-6:^:/%[;P7,(\F4<
M,-IC) [C/8BO=+CP)I6I_#RT\(:^K:E9V]I#;&5R4=FC4*) 0<ALC/7\Q7CM
M_P#LE6,EP6TSQ;<6\.>$N+%9F'_ @Z#]* .I\&?!7X?^$?'EI?:1KMY>:Q9H
M\L5G<7T+$ KL+E$16P-_7IDBO%O%=POA/]JF74-7++;PZU%=.[#I$Q5MP]0%
M/Z5[M\,O@9I?PWUR36(=6NM0O'@: ;XUCC"L02=HR<_*._K5[XG?!K0_B6T-
MW<SRZ=JD">6EY"H;<G)"NIQN ))'(//6@!?C+XHT73/A)K NM0@W:G9/!9HC
MAFG9UP-H'4<Y)Z 5Y1^R3_R%/%'_ %QMO_0I*ZCPM^R[X?T:]^U:_JLVN,@/
MEPFW$,0/8LNYBV/3('J#73_"7X/)\+;C59EUMM4.H+&H!M?)\L(6/]]LYW>W
M2@#TNOD#]J'_ )*Y#_V"X?\ T.2OK^OD#]J'_DKD/_8+A_\ 0Y* /I73/'?A
MR3X>1^)H]4MVTR"U#R2;QE"%^X1U#YXV]<U\T?LWV<^J?&DZA%&5BM;:>>7
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M?B:PL@S7%Q]NCB5>KL85POXGC\:[K7O@W:ZO\(=/\"6^KRVL=@Z2)>/ )"S
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M**JW^J6&E1++JE];64;-M5[B98P3Z L1S0.,7)V2NRU16-_PF/AG_H8])_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M23Z"IKK3K.^T][&[M8IK5UV&%T!7'IBO-/B1#'J/Q!\(Z'<X_L]I-S0] WS
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G_P 6/#.L>(]/TO\
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MC'IGUZ>I7%O#=6[P74,<T+C#QR*&5A[@]:6&&.W@CAMXTBBC4(D:*%55 P
M.@ I\VMSI>:_O8XE4U[1::[;632Z/T=CS:TU/XFV%G%:67@O2X((5"1QI<(
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M_P +0\'_ /07_P#):;_XBOGFBCZK#NP^O5.R_KYGT-_PM#P?_P!!?_R6F_\
MB*/^%H>#_P#H+_\ DM-_\17SS11]5AW8?7JG9?U\SZ&_X6AX/_Z"_P#Y+3?_
M !%'_"T/!_\ T%__ "6F_P#B*^>:*/JL.[#Z]4[+^OF?0W_"T/!__07_ /):
M;_XBC_A:'@__ *"__DM-_P#$5\\T4?58=V'UZIV7]?,^AO\ A:'@_P#Z"_\
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MS4/_ (Q1_P )YI'_ #Y^(/\ PG-0_P#C%=)10!S?_">:1_SY^(/_  G-0_\
MC%'_  GFD?\ /GX@_P#"<U#_ .,5TE% '-_\)YI'_/GX@_\ "<U#_P",4?\
M">:1_P ^?B#_ ,)S4/\ XQ7244 <W_PGFD?\^?B#_P )S4/_ (Q1_P )YI'_
M #Y^(/\ PG-0_P#C%=)10!S?_">:1_SY^(/_  G-0_\ C%'_  GFD?\ /GX@
M_P#"<U#_ .,5TE% '-_\)YI'_/GX@_\ "<U#_P",4?\ ">:1_P ^?B#_ ,)S
M4/\ XQ7244 <W_PGFD?\^?B#_P )S4/_ (Q1_P )YI'_ #Y^(/\ PG-0_P#C
M%=)10!S?_">:1_SY^(/_  G-0_\ C%'_  GFD?\ /GX@_P#"<U#_ .,5TE%
M'-_\)YI'_/GX@_\ "<U#_P",4?\ ">:1_P ^?B#_ ,)S4/\ XQ7244 <W_PG
MFD?\^?B#_P )S4/_ (Q1_P )YI'_ #Y^(/\ PG-0_P#C%=)10!S?_">:1_SY
M^(/_  G-0_\ C%'_  GFD?\ /GX@_P#"<U#_ .,5TE% '-_\)YI'_/GX@_\
M"<U#_P",4?\ ">:1_P ^?B#_ ,)S4/\ XQ7244 <W_PGFD?\^?B#_P )S4/_
M (Q1_P )YI'_ #Y^(/\ PG-0_P#C%=)10!S?_">:1_SY^(/_  G-0_\ C%'_
M  GFD?\ /GX@_P#"<U#_ .,5TE% '-_\)YI'_/GX@_\ "<U#_P",4?\ ">:1
M_P ^?B#_ ,)S4/\ XQ7244 <W_PGFD?\^?B#_P )S4/_ (Q1_P )YI'_ #Y^
M(/\ PG-0_P#C%=)10!S?_">:1_SY^(/_  G-0_\ C%'_  GFD?\ /GX@_P#"
M<U#_ .,5TE% '-_\)YI'_/GX@_\ "<U#_P",4?\ ">:1_P ^?B#_ ,)S4/\
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M?B#_ ,)S4/\ XQ7244 <W_PGFD?\^?B#_P )S4/_ (Q1_P )YI'_ #Y^(/\
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MYI'_ #Y^(/\ PG-0_P#C%=)10!S?_">:1_SY^(/_  G-0_\ C%'_  GFD?\
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MS4/_ (Q1_P )YI'_ #Y^(/\ PG-0_P#C%=)10!S?_">:1_SY^(/_  G-0_\
MC%'_  GFD?\ /GX@_P#"<U#_ .,5TE% '-_\)YI'_/GX@_\ "<U#_P",4?\
M">:1_P ^?B#_ ,)S4/\ XQ7244 <W_PGFD?\^?B#_P )S4/_ (Q1_P )YI'_
M #Y^(/\ PG-0_P#C%=)10!S?_">:1_SY^(/_  G-0_\ C%'_  GFD?\ /GX@
M_P#"<U#_ .,5TE% '-_\)YI'_/GX@_\ "<U#_P",4?\ ">:1_P ^?B#_ ,)S
M4/\ XQ7244 <W_PGFD?\^?B#_P )S4/_ (Q1_P )YI'_ #Y^(/\ PG-0_P#C
M%=)10!S?_">:1_SY^(/_  G-0_\ C%'_  GFD?\ /GX@_P#"<U#_ .,5TE%
M'-_\)YI'_/GX@_\ "<U#_P",59TOQ=I6KZJ--MAJ$-VT+SK'>Z7<VN]$958J
M98U#8,B9 .?F%;=<W??\E3T+_L#:E_Z/L: .DHHHH **** "BBB@ HHHH **
M** "BBB@#)\5_P#(F:U_V#Y__1;5\QU].>*_^1,UK_L'S_\ HMJ^8Z[\+\+/
M*QWQ(****ZSS@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]O^"__ ")E
MW_V$'_\ 1<==9XE\5:)X/TDZGXDU".PM-X0.X+%F/954$L>"< 'H:Y/X+_\
M(F7?_80?_P!%QU=^*/PUM/B=X<ATVYOI-/FMIO.@N$C\P*<$$,N1D$'U':O*
MK?Q&>_A_X43J-&UK3O$.D0:IHMW'>65PNZ*:,\-V/N"#P0>0:O5S?@'P9:>
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M?:+6&62*23RV7:\9(<88 \$?X55;QMX=C\)P>)9=5ABTBY4-#<RAD\S/0!2
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MQ232(?E1")R1D$C@<>G% 'L5<5=?&#P%9:J^GW'B2V6:-_+=UCD:%&]#*%*
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MHHH **** "BBB@ HHHH **** "BBB@#)\5_\B9K7_8/G_P#1;5\QU].>*_\
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MN-IEGJ5]?W;0I]MB\Q(47/1?4X//O[53G9V(5*ZO?N<Y?Z+]B\.Z3JOVC?\
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M1$+;HA=VR2^6?4;@<'Z5H44 5K73K*QEGELK.WMY+@AIGBB5#*0 H+$#G
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M.M-/M\[O*M(%B3/KA0!5)O!WAE[BYG?P[I+378*W$AL8BTP/4.=N6S[ULT4
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MF2 ,D^I('XUYU%XS\>Z_XH\2:+X5TS1$71KWR1?:BTHC*E%*IL0[F<G<2W
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MCX%>'O$2VWV4WNK6FZ'=NV,MR48 ]QE3CVKVF@ HHHH **** "BBB@ HHHH
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MUV5% 'FOAS0F.O64C?"+0_#_ )+[Y;\O:,T9 X,(B4L3G')V8'Y5!::;XS\
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M)*VYB!R0YY-=#J?A_4KGXS:%KT-ONTVTTRY@FF\Q1M=V4J-N<G.#R!BNTHH
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MM34_#^IW/QGT+78;;=IMIIES!-/YBC;([*5&W.XYP>0,5VE! 92&&0>"#WH
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M7EG\2M#\/11P&TU&SNIY793YBM%LVA3G&/F.<@_A73UY%:>#]*\'_';PY;:
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MBGQ'X@^(&L:?I$6EP:+H=U%:W37*R-<7#,FYRA!"IC.!D'..W;FQX=T_X?\
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MPC/DK"NUA"S8P2[JO!Y&#ZT[XL:9>WGB3PO>&QUF;2K%[AKFYT!3]MA=D55
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ME0H  Y(VA>22<UL^'_"UCX;N]8N+&2=WUB^:^N!,P(61@ 0N ,+QWR?>JO\
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MH4#=CN<G\JV]+\*V.D^*]=\06TEPUWKGV?[2DC HODH438  1P><D\^E5O\
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MYO1O VF:'X)N/"UG-=-8W"W"O)(ZF0"8L6P0H'&XXX].M'_"QO!'_0Y>'_\
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MW!OI[%;%HRP\H1J^\$#&=V3ZX]JJ_P#"QO!'_0Y>'_\ P:0?_%4?\+&\$?\
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MZ'+P_P#^#2#_ .*H Z2BN;_X6-X(_P"AR\/_ /@T@_\ BJ/^%C>"/^AR\/\
M_@T@_P#BJ .DHKF_^%C>"/\ H<O#_P#X-(/_ (JC_A8W@C_H<O#_ /X-(/\
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MZ'+P_P#^#2#_ .*H Z2BN;_X6-X(_P"AR\/_ /@T@_\ BJ/^%C>"/^AR\/\
M_@T@_P#BJ .DHKF_^%C>"/\ H<O#_P#X-(/_ (JC_A8W@C_H<O#_ /X-(/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?OYVK7LC7NISDY,EQ)R_/?'3\,]ZZZBB@ HHHH **** "BBB@ HHHH ****
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M7#1?"G5-4U*RD\?>-;OQ-8:?,)[?3VLH[:-G'W3+M)\S'O\ R)!]*H ****
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MM;--JESEG).69CZDDD_6@#7HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[+-&"1($$:Y#@X'S[5'.:SO"_P ;?#OBGXB7_A>S.T1 "RNSYG^F%4+2_*4
MC";6&6;G''6N-\%_#[6=$\9_#W2=2L;AK;0--N]0N;D1DP+<SLP\K?C:67Y3
M@'MGI46C:9XJE\(?%+2QX>U2WUS5+RYN8[F6'9#<1.0!'&Q(W-M\SIQ@CGG%
M 'H\7QG^'T^I&PM_$L$MSYZ6ZI'#*V^1FVJ%(7##/<9 [FN>D^(NJV_B/XCW
MDNIV=OHOAU+>VLA>1$PI<N,,7,:F1AOX(&>H ]:Y71+#6/$&O?#/2U\$:GHF
MB: #/<3WMIL)N(XP<D=5!<9!;!<L3CBJ)\+>(-5^%KVMQH.II>>+_&'VB_B>
MVD5[:V+YW2#&44%0<G ^;.>E 'J=Y\7_  MX6AL;'QOKEM:ZS)9Q3SI:6=R\
M1+KG*_(2%/. W..M:FN?$_P;X;O;.TUS7K>SN+U%DAC=7)VMT9L [ ?5L5YQ
MKNK:AXI^+EOIOB3P=XFD\+Z3>+%8P6VELUM=3ABGVB9R0/*7JH&1CD]P<C5$
M\5:+JWQ.BC\%:IJFJZ[(ZV>I16V^%;3:54!N26"E<(H.2!G&* .W\4_'WPIH
M.FZ+>Z;+_:<>K3@*=LL(CMP[))/S&2=K(1MQD]JWK7QP-6\>V6FZ/J&EOI3Z
M,-5N%ECG6Z\MS\C@E1&JX920QW\GY1C-><W?A_6/#>I?"6,^'=3U+3]%M':[
MCT^#>8[J2,?>Y 4"3!)8@8W4[7/"WB?7[SXM:E8:?=07E[';Z?IHEC,?VB&/
M'G>63C<&5>"."30!Z-I7Q;\"ZWXA70]+\1VUQJ#ML2-4<+(WHKE=C'Z$YJ/4
M_C'X!T>\N+74?$<$-Q;736DT7DRLR2KC<,!3P,XW?=SWXKSK3M*U+QC?>!;&
MS\&ZIX=TCP@\=W=SZE;>4\LD84B.)>K[F7);OG/!'.1_PA^N2? ;4\^'[U/$
M7C#7 UTALW,T$9GW R#&Y$&PG)P/G]Z />W\5:*GB2ST WRG4[VV-U;P*C-O
MB&?GW ;0.#C)&<<5KUBZ3JD9U:ZT"WTO4X(M+BB5;VXM]EO."HP(W)^<@<'C
M -;5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!P
MOQJUC^Q/@WXBN Q#S6WV5<'!)E81_P F)_"O+_B?X)\/^%?@CX?6RTNUMO%0
M>SBM;FTB$=Q-<8!<EEPS="><X..^*]F\=>"-/^('AT:-JUU>VML)TG+64BH[
M%<X!+*PQSGIU K(T+X1Z#I&NP:U?WVL>(=3M?^/:ZUN]-RT'NHP #[XXH XG
M5/'?C+54\6:WH>O66C:-X0+VS12V:W!U*XC'S@L2"@+8"E?[PI=&U_6M=\6?
M#2P\036E[.=)FUS49KBQ@+JK F%E.S]V00HRFTG'.:Z/5_@+X5UB\U>66]UJ
M"'5IC<S6<%[M@28G)E6,J1NZ_>R!G@#C&_\ \*VT9=>N]7CFO([BYT<:,H61
M=L$&!R@VY#<#DDCVH \<\,^(M9T'P/8^--/N?(A\2>-C)J ,:-YEJ[%2N6!*
MX*,,C!&:]1\ ^)M8\8>,O%&HK=[O"]G<+8:;$(TQ+(@'FRA\;B,].2/F]JQ_
M&_PVNY_AGH_PZ\)6+R:<9T$^IW4T?^AQJ^\N5X+NQ)P%7'7.*]$\,^'=/\)^
M&[+1-'B\NTLXPB9ZL>I8^I)))]S0!P<'C[45^('Q :YNU&@>%["(QPE$ ,YC
M+L=^-Q.59<9QTXS7)Z9XX^(>J6OP\TFPU> ZSKMO=7NH3W-I&4$&3Y3%548P
MH)&,;B "<5VNM_ [POKVL:Q?W=WJ\2ZP0]U:07FR R@$++LV\L"21NR 3TK<
MTGX=:-H_B>PURVENWN-/TA-'MHI'4QQPH<AL!0=_J<XY/% 'BOB3Q=XOU'X+
M^,8-1\0B[EL->.D)=1V$:'4(C\CQ;1PGW@^1DX&,\YKJ)-.UCP]K?PU\ ZAJ
M%IK9\^2YE>?2X ((((EV(H(;:1AAY@(8^M=;)\&O#LO@%_"<MWJ;6SWQU!KO
MSD%P9R<[]P0+[?=K3L_AUIMIXEL-=;4=4N;ZPTPZ;%)<W D)4L6,K$KN,A+'
MG./:@#F/@KG5+WQMXH<#_B:Z]+'"W]Z&'A/_ $(C\#6;X>T32O'7QU\=ZEKV
MFV>I66EI;Z;;QWD*RHK!<N0&! (9#SU&[ZUZ3X,\(:=X%\*VV@:.\\EK;L["
M2X8-(Y9BQ)( '?' ' %<:_P(T1]0U&X/B3Q0L&J7,EU>V4>HB."=W)+;E5 2
M.?7/O0!YKX3\67'A#2_$UOX%6-[?6?%:Z7X?$S%H(F8G=(/50#'CKU7/>NHC
MUSXB6?C;7O##^+X=5DTCP]/?&ZCTV&$_:64>4C#!'RD@C& 1U!KO-9^%'AC5
M_">G>'H(;C2K72YUN+*73I?+E@D'\08@Y)R22<G//7FJVF?#VQ^'UOK^L>%;
M+4-<U74H44VMW>(3,Z@C_6/C&XL68L3[=A0!RGAKXC>(/&-_X TK1M1_TB:S
M.H^(9UAC.8D.S805PN]U(^7!&1C%=[\1;KPA8^&X[SQ[!;W-C;3B6"WG3S/-
MFVLJJL?1VPS<'([GID8OP:^%\?PX\+M]LV2:U?[9+V1>1'C[L2GT7)Y[DGMB
MK?C?X3:5XZ\1V.MW^LZWI]W81".W_LZZ2(1G<6WC*$ACG!((X4>E 'F6F_##
MQ1<_"SQG<Z)8Q:->>*[F*:VT8,(_(M5=F$9/ 1F5R".!@ '&2!)X(LYS^T)I
M=K%X-L?";Z3H\C7MK97*3;E?Y4,CH "Q+*><G!!S7I;?"^)_#*:/)XP\7,T=
MV;M-0.JG[4I*!=@DV_<QSMQU)-:W@_P+HW@FVN4TE9YKF\?S+N]NY3+/<-V+
MN>N,GC@<GUH YCQ=XG\2:K\2[7P%X*U"#29Q8'4+_4Y;9;AH8]VU51&."<D9
MS_>'I7"/\5/&D'@74[-=0M[S7[;Q2FA66HQV\:BZY))*8*C(7&0. X[\GU#Q
M9\+M'\6:_%K;:CJ^D:FD'V9[K2;SR'EBR3L;@Y'/M^E)#\)O#%K!X>M[**XM
M;?P_=F]MX8Y!MFF./GE)!+$8R,$?E@4 ;7AFTUW2M'G/B_6X=5NVE:8S0VH@
MC@0J/W:@<D*0V&/)!YKQKX?^'O#&O?"?Q3XT\::797']J7M[>_:KB)3+#$.
M$<_,IW!L8/4BO>-2L4U/2KNPEDDB2Z@>%I(2 Z!E()4D$ C/'!KS;3_@!X9M
M+6WL;W6/$>JZ7;MNCTN]U'-JISG_ %:*HZG- '!?#J^U2[M_A3X;NXH)XV6\
MU&;[9;1S/' C-Y!0NI,?W>"N#@KS@5M:#\2/%4?C#5I?%VL)IJ:7'=7-SX;G
MTSRRUK&C%)()^3(2P4<G!&2,\5Z3=?#?0KSQ--K,WV@/+HS:*+:.0)#%;DG.
MP* RM@D9#< \"LW2/@YX=TV:\FO[S5]=FNK)[#S-7O3.T-NPP8X^!M'ZCL:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ?0=JZ'PAX5MO!OAR'1K&]O[V"#A)+^?S9 N  H.  H  "@  "MRB@ HHHH
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M_P#?A/\ Y%H_X1?]H;_H>_#_ /WX3_Y%KVVB@#Q+_A%_VAO^A[\/_P#?A/\
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M_"?_ "+7MM8K^,/#\?BV+PP=4@;6I49Q9)EW4!=QWX!"?*00&(R.F: /+/\
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M=4,:'YESN88W#.,U=UGQ/I6@W%O;ZA-,US<AC%;6MK+<S.HZMY<2LVT<9;&
M2!GD4 >4?\(O^T-_T/?A_P#[\)_\BT?\(O\ M#?]#WX?_P"_"?\ R+7IO_";
MZ+)8:'J%I.UUI^N7(MK:[A ,:2,K%0^2&4ED*8QD.0I -=!0!XE_PB_[0W_0
M]^'_ /OPG_R+1_PB_P"T-_T/?A__ +\)_P#(M>VT4 >)?\(O^T-_T/?A_P#[
M\)_\BT?\(O\ M#?]#WX?_P"_"?\ R+7MM% 'B7_"+_M#?]#WX?\ ^_"?_(M'
M_"+_ +0W_0]^'_\ OPG_ ,BU[;10!XE_PB_[0W_0]^'_ /OPG_R+1_PB_P"T
M-_T/?A__ +\)_P#(M>VT4 >)?\(O^T-_T/?A_P#[\)_\BT?\(O\ M#?]#WX?
M_P"_"?\ R+7MM% 'B7_"+_M#?]#WX?\ ^_"?_(M'_"+_ +0W_0]^'_\ OPG_
M ,BU[;10!XE_PB_[0W_0]^'_ /OPG_R+1_PB_P"T-_T/?A__ +\)_P#(M>VT
M4 >)?\(O^T-_T/?A_P#[\)_\BT?\(O\ M#?]#WX?_P"_"?\ R+7MM% 'B7_"
M+_M#?]#WX?\ ^_"?_(M'_"+_ +0W_0]^'_\ OPG_ ,BU[;10!XE_PB_[0W_0
M]^'_ /OPG_R+1_PB_P"T-_T/?A__ +\)_P#(M>VT4 >)?\(O^T-_T/?A_P#[
M\)_\BT?\(O\ M#?]#WX?_P"_"?\ R+7MM% 'B7_"+_M#?]#WX?\ ^_"?_(M'
M_"+_ +0W_0]^'_\ OPG_ ,BU[;10!XE_PB_[0W_0]^'_ /OPG_R+1_PB_P"T
M-_T/?A__ +\)_P#(M>VT4 >":WIGQ_T'0-0U>\\<:&]OI]K)=2K%;QEV5%+$
M*#; 9P.,D5Z-\(/$>I>+/A1HVM:[.MQ?W(F$TJQJF_9,Z X4 #A1T%:/Q'_Y
M)9XK_P"P+>?^B'KFOV?/^2$^'O\ MY_]*9: /2:*** "BBB@ HHHH **** "
MBBJ.LZSIWA_29M3UJ[CL[*#;YL\I^5-S!1GZD@?C0!>HJ"RO;?4=/M[ZQE6>
MVN8EFAE7HZ,,JP]B"#4] !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%07M[;Z=I]Q?7TJP6UM$TTTK=$11EF/L ": )Z*HZ-K.G>(-)AU/1;
MN.\LI]WE3Q'Y7VL5./H01^%7J "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /$OCE_R5/X3?\ 8:/_ */M:]MKQ+XY?\E3^$W_ &&C
M_P"C[6O;: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH X7PM_R6'Q[_ -<]-_\ 1+U@^';F_@T3QSXJ
MO-2U+4;K1M4U;^S[1[R40QQQ%]L?EAMLG.<;@=ORA<8KTJUT6PLM8O\ 5;:W
MV7NHB(74N]CYGE@JG!.!@$] ,]Z33-#T[1X;N+3K811WMS+=W"EF<22R'<[?
M,3C)[#CT% 'FWAA/%#R^&=4LK'Q+)+=,KZQ=:GJ<$EI<P2H6=T@%PPC(<H4$
M:+A05/!(JIKOB!O,L_$'AEO$TR?V]#;MJLU\OV&=&N!#)$+;S0-@R4#"$'*!
MMQ.7/HFF>"-!TB[BGL+6=! S/;V[WL\EO;DYYBA9S'&<,0-JC ) P"155_AK
MX4DN!*^FR%5NA>1P?;)_)BF#A_,CBW[$;<.2JC(+ \,00#G?"N@6J?&GQI<>
M;J&Z#[!+&#J-P58O%(3N4OAUST5@0O10*Y2Q.LGX2:)XG7Q1K:ZQ-JZ6WGM>
MLZ+"]XT&SR6S&^%;.YU9LXYP !["_AK2W\2#7A%-%J/EK$\D-U+&LJKNVB2-
M6"28WMC<#C/TJ"/P;H,7AVVT*.PQIMK.MQ#!YTGRR++YH;=NW'Y^<$X[=.*
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M_P"P+9_^B$KI*YOX<?\ )+/"G_8%L_\ T0E=)0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7-_$?_ ))9XK_[ MY_Z(>NDKF_B/\ \DL\5_\
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M#_OF?_Y(KVVB@#Q+_A1OC?\ Z+1X@_[YG_\ DBC_ (4;XW_Z+1X@_P"^9_\
MY(KVVB@#Y;\6^!M<\%_%/X;_ -O>--0\4?:]:C\K[:'_ -'V3P9V[I'^]N&<
M8^Z.O;ZDKQ+XY?\ )4_A-_V&C_Z/M:]MH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *YO5O&2Z;XHC\/VFB:GJM^]F;TK9FW55B#[,DR
MRISNQP,]:Z2O-]8T^YU'X]P16>KWFE.OAEF,UFD+,P^U#Y3YL;C'.> #QUH
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MHH **** "BBB@ KS;]H/_DA/B'_MV_\ 2F*O2:\V_:#_ .2$^(?^W;_TIBH
MZ7X<?\DL\*?]@6S_ /1"5TE<W\./^26>%/\ L"V?_HA*Z2@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "N;^(__)+/%?\ V!;S_P!$/725S?Q'
M_P"26>*_^P+>?^B'H YK]GS_ )(3X>_[>?\ TIEKTFO-OV?/^2$^'O\ MY_]
M*9:])H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *\2^.7_)4_A-_V&C_ .C[6O;:\2^.7_)4_A-_V&C_ .C[6@#V
MVBBB@ HHHH **** "BBB@ HIKNL4;22,J(H)9F.  .Y-<!KOQF\,Z1,T%DTV
MJS+QFU \L'_?) /U7=32;-Z&&K8B7+2BV_(Y.Q^3]LG4O^FFBC_T"/\ PKVV
MOE]?'TJ?'!_'0TD?9WL?LIM?M7S9P!G.WVZ8_&O7]"^,WAC5ID@O6FTF9N,W
M8'ED^F\$@?5L4^5G74RK&TXN4J;L>@T4B.LD:O&P=& *LIR"/44M2>:%%%%
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M1_T.7A__ ,&D'_Q5 '245S?_  L?P1_T.7A__P &D'_Q5'_"Q_!'_0Y>'_\
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MK&TN+NWNI[6&6XM2Q@F>,%X=PPVUCRN1P<=16%_PL?P1_P!#EX?_ /!I!_\
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M7B#_ ,!X/_CU'_#5?@C_ *!7B#_P'@_^/4 >VT5XE_PU7X(_Z!7B#_P'@_\
MCU'_  U7X(_Z!7B#_P !X/\ X]0![;17B7_#5?@C_H%>(/\ P'@_^/4?\-5^
M"/\ H%>(/_ >#_X]0![;7FW[0?\ R0GQ#_V[?^E,5<W_ ,-5^"/^@5X@_P#
M>#_X]7(_%+]H#PKXW^&NJ>'M*L-8AN[SR?+>YAB6,;)D<Y*R$]%/;K0![O\
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MT"O$'_@/!_\ 'J/^&J_!'_0*\0?^ \'_ ,>H ]MHKQ+_ (:K\$?] KQ!_P"
M\'_QZC_AJOP1_P! KQ!_X#P?_'J /;:*\2_X:K\$?] KQ!_X#P?_ !ZC_AJO
MP1_T"O$'_@/!_P#'J /;:YOXC_\ )+/%?_8%O/\ T0]>;?\ #5?@C_H%>(/_
M  '@_P#CU9'BS]I7P?KW@O6](L]-UQ+C4-/GM8FE@A"*SQLH+$2DXR>< T =
MW^SY_P D)\/?]O/_ *4RUZ37FW[/G_)"?#W_ &\_^E,M>DT %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>)?'+_D
MJ?PF_P"PT?\ T?:U[;7B7QR_Y*G\)O\ L-'_ -'VM 'MM%%% !1110 4444
M%<U\1-,DU?X>:Q:0 M)Y'FHH'+&-@X ]SMQ72T4&E*HZ<XS6Z=_N/C4'-7]!
ME2'Q'ILLSK'&EW$S.QP% <9)-=E\3OAW<>&]3FU32K=I-&N&+GRUS]D8GE6]
M%R>#T[>F?/JZ4[H_6L/B:6-H<]-Z-?<>K7/C=(OBU?VUWJ*W_AN_<6TT;3>9
M $9 -R\[1@G)([9KS?6[&'3-<O+.TNHKNWAE*Q3Q2!UD3^$Y'!XQGWJC10E8
M6'P<,.TX/HD_.W7U G%?4OPZTR32/AWH]I."LGD>:ZD<J9&,A!]QNQ7C?PQ^
M'=QXEU.+5-4@:/1K=@X\Q?\ CZ8'[J^JY')_#UQ]$UE4=]#Y'B3'0JRCAZ;O
MRZOU[!11169\@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XE\<O\
MDJ?PF_[#1_\ 1]K7MM>)?'+_ )*G\)O^PT?_ $?:T >VT444 %%%% !1110
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M ,9KVVB@#Q+_ (94\$?]!7Q!_P"!$'_QFC_AE3P1_P!!7Q!_X$0?_&:]MHH
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MX$0?_&:/^&5/!'_05\0?^!$'_P 9KVVB@#Q+_AE3P1_T%?$'_@1!_P#&:/\
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M8QSUI=+\(:OH'FV&A:_#:Z))=27"6TFG^9<6XD<NZ1R^8%"[BQ&Z-B-V,GC
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MJFA^%_"NE6.L"SCTF&-+^(6RR"\ 3#*&/*#=DY&3VH ZRBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F_B/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M) &#R:X?Q/+J</QMT!M%M+2[N?[%O 8[NZ:W3;YL.3N6.0YZ<;?QKC9V-O\
M#W6],O(?LVJ6OC*"2]MH\&&,RW<4B>2W>,HRD9"MG=E10!Z_J7C'PQHMZ;/6
M/$>DV%TH#&"ZOHHG /0[68&M>.1)HEDB=7C=0RNIR&!Z$'N*X?PV WQF\=AA
MD&TTL$'O\D],^'$$>E^(O&FAZ:@CTBPU1&LXDX2$RP))+&@Z*H=B=HX&XX%
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MPX_Y)9X4_P"P+9_^B$KI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *YOXC_\DL\5_P#8%O/_ $0]=)7-_$?_ ))9XK_[ MY_Z(>@#FOV?/\
MDA/A[_MY_P#2F6O2:\V_9\_Y(3X>_P"WG_TIEKTF@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KQ+]E3_DEFI?\ 8:E_]$05[;7R
M?\&/C/X?^&?@^]T3Q!8:M+=R:C)<?Z+#&553'&F#N=2&RAXQZ4 ?6%%>)?\
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M2OHS>,Z25I0N_4Z;4?"_A_5K/PO;W>E:Q*/#3Q#3V:-0TLD:J/)DXP02B$L
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M?] KQ!_X#P?_ !Z@#VVBO$O^&J_!'_0*\0?^ \'_ ,>H_P"&J_!'_0*\0?\
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MBVU$4*HR>3@ <FK- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%<W\1_\ DEGBO_L"WG_HAZZ2JVIZ=;:OI-WINH1^;:7D#V\\88KN1U*L,CD9
M!/(H \__ &?/^2$^'O\ MY_]*9:])K,\.^'=,\*:!;:+H5N;:PM=WE1&1GV[
MF+GEB2?F8GK6G0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%>3?''_ )@?_;Q_[3KR:NJGA^>/-<X:N+]G-PY3ZRHKY-HJ_JOF9?7_
M .[^/_ /K*BODVBCZKYA]?\ [OX_\ ^LJ*^3:*/JOF'U_P#N_C_P#ZRHKY-H
MH^J^8?7_ .[^/_ /K*BODVBCZKYA]?\ [OX_\ ^LJ*^3:*/JOF'U_P#N_C_P
M#ZRHKY-HH^J^8?7_ .[^/_ /K*H[FY@L[66ZO)HX+>%#)++*X5(U R68G@
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M1_T.7A__ ,&D'_Q5=)10!S?_  L;P1_T.7A__P &D'_Q5'_"QO!'_0Y>'_\
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M'_0Y>'__  :0?_%4?\+&\$?]#EX?_P#!I!_\57244 <W_P +&\$?]#EX?_\
M!I!_\51_PL;P1_T.7A__ ,&D'_Q5=)10!S?_  L;P1_T.7A__P &D'_Q5'_"
MQO!'_0Y>'_\ P:0?_%5TE% '-_\ "QO!'_0Y>'__  :0?_%4?\+&\$?]#EX?
M_P#!I!_\57244 <W_P +&\$?]#EX?_\ !I!_\51_PL;P1_T.7A__ ,&D'_Q5
M=)10!S?_  L;P1_T.7A__P &D'_Q5'_"QO!'_0Y>'_\ P:0?_%5TE% '-_\
M"QO!'_0Y>'__  :0?_%4?\+&\$?]#EX?_P#!I!_\57244 <W_P +&\$?]#EX
M?_\ !I!_\51_PL;P1_T.7A__ ,&D'_Q5=)10!S?_  L;P1_T.7A__P &D'_Q
M5'_"QO!'_0Y>'_\ P:0?_%5TE% '-_\ "QO!'_0Y>'__  :0?_%4?\+&\$?]
M#EX?_P#!I!_\57244 <W_P +&\$?]#EX?_\ !I!_\51_PL;P1_T.7A__ ,&D
M'_Q5=)10!S?_  L;P1_T.7A__P &D'_Q5'_"QO!'_0Y>'_\ P:0?_%5TE% '
M-_\ "QO!'_0Y>'__  :0?_%4?\+&\$?]#EX?_P#!I!_\57244 <W_P +&\$?
M]#EX?_\ !I!_\51_PL;P1_T.7A__ ,&D'_Q5=)10!S?_  L;P1_T.7A__P &
MD'_Q5'_"QO!'_0Y>'_\ P:0?_%5TE% '-_\ "QO!'_0Y>'__  :0?_%4?\+&
M\$?]#EX?_P#!I!_\57244 <W_P +&\$?]#EX?_\ !I!_\51_PL;P1_T.7A__
M ,&D'_Q5=)10!S?_  L;P1_T.7A__P &D'_Q5'_"QO!'_0Y>'_\ P:0?_%5T
ME% '-_\ "QO!'_0Y>'__  :0?_%4?\+&\$?]#EX?_P#!I!_\57244 <W_P +
M&\$?]#EX?_\ !I!_\51_PL;P1_T.7A__ ,&D'_Q5=)10!S?_  L;P1_T.7A_
M_P &D'_Q5'_"QO!'_0Y>'_\ P:0?_%5TE% '-_\ "QO!'_0Y>'__  :0?_%4
M?\+&\$?]#EX?_P#!I!_\57244 <W_P +&\$?]#EX?_\ !I!_\51_PL;P1_T.
M7A__ ,&D'_Q5=)10!S?_  L;P1_T.7A__P &D'_Q5'_"QO!'_0Y>'_\ P:0?
M_%5TE% '-_\ "QO!'_0Y>'__  :0?_%4?\+&\$?]#EX?_P#!I!_\57244 <W
M_P +&\$?]#EX?_\ !I!_\51_PL;P1_T.7A__ ,&D'_Q5=)10!S?_  L;P1_T
M.7A__P &D'_Q5'_"QO!'_0Y>'_\ P:0?_%5TE% '-_\ "QO!'_0Y>'__  :0
M?_%4?\+&\$?]#EX?_P#!I!_\57244 <W_P +&\$?]#EX?_\ !I!_\51_PL;P
M1_T.7A__ ,&D'_Q5=)10!S?_  L;P1_T.7A__P &D'_Q5'_"QO!'_0Y>'_\
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M)'%>RU\SZ)H/B^X^!5YJ.D^([B32([BZ>ZT&*WCC:>!9G\U5G +@L-QQ[D4
M>^Z%XKT_6O!=CXE>1+&RN[99R;F0((LCD,QXX/&:NZ5KFDZ[;M/HFJ6>I0H=
MK26=PDJJ?0E217G6NZQX:;P9X(M-$\.VVLQZE)&-$L;J7RX(BL1^:0D'.U21
M@@DM[C-9O@^#4K#]I"]MM4LM'T^:;PP)98-&D9HG(N5"N^Y%._!(Z=,<\T >
MFS^+O#=K'%)<^(=*A2:1HHFDO8U$CJ=K*"6Y((P0.AXK3N+NWM+1[JZN(H+>
M-=[S2.%15]23P!7B_P -/ _AS6OA_P"(KS5])MKVZNK^_A::X0.\:+(V A/W
M,$D_+CDYK'CNEUCX4_"6RUY]VDWNHQP7JRN0DHCWB)'/<$J.#Z>U 'I6I>-%
MN_'G@JU\-:S:7FE:I/>QWAM)(YDE\NW+J-XS@AAG@CWKJM6\1:+H/E_VYK%A
MIOFG$?VRZ2'?]-Q&:\TUS0O#6B_'_P !G0[2RL=0F%[]I@M%6/=&+5]C,B\#
MJP!QST[<+X#T?1_$OCWQ[=^*;"TU'5[?5VM8XKR)9?)LU4>3M5L[0PR>!SB@
M#U&35-/ATMM2FOK:.P5/,:Z:91$%_O;\XQ[YJ"/Q%HDVK?V5#K%A)J(7<;-;
MI#-C&<[,YQCGI7AJ)!;?"/XL6.CMNT*UOYTL AS''D*71#_=#'H..?>M'QOX
M!\-VGPT\*R6>F1VURVI6 DO(?EN)?.8++NE'S'<&)//7'I0![%8Z_H^J7D]I
MIFK6-Y<VW^OAM[E)'BYQ\R@DK^-9>F:W<P7GB&;Q#K&A?V?8W($+6T^UK2/;
MG%R6.%;D'Z?6N*\1>'='\+?%OX<OX<TVVTPS27=I*+6(1B6(09"MC[V#SD\Y
M.:F\&2Z=!X@^)\VN>0-.CU0/<FY4&,((026!X(XH [O3/&'AK6[S[)HWB+2=
M0N=I;R;2^CE? ZG:K$XJ2\\3:#I^I1Z=?ZWIUK?2$!+6:[C25L],(3DUP?PS
M\.0W^J7WQ!;2+?37U&+R='LHXEB$%H.5=@H^_(?F)YP,#VKAOA[X>\2>+/AC
M=2#0_"5_)JTUU]NN]3GF%V9C(X)?;$VUEXV@-P,'@F@#Z"O;ZTTVSDN]1NH;
M2VB&9)IY B(/=CP*XZ7Q>;[XF>&['0M6MKS1K^QO)93;-'*DCQF/:0XR>-QX
M![\UQ6N:3-#J'PC\,>,[FWU*P)N%O6WEX+F:. >1DL!N!)XR/FR:U7T;P[HW
M[1NAIH%M:6=U+I5T]Y;VH" ?<V,4'"DC/.!G'M0!ZQ4-W>6UA:275]<16UO$
M-TDTSA$0>I8\"F6^HV5Y=7-M:7EO//:,$N(HI59H6(R X!RI(YYKSGXM1V]]
MXJ\!:5K(5]$O-5?[7%*<1RR+'F)&[$%B>#UH U;[QE]L^(W@VS\.ZQ:WFD:I
M'J!NC:O',DK1)&4^<9Q@L>A'7FNHU7Q'H>A/$FMZSI^FM-_JUO+I(B_TW$9K
MS?4M$\.:-^T1X0&@VMG9WLUG?->06H"?*(U\MF1> 3\XSC)V^U,^'.BZ+XF\
M0^.K_P 4Z?9ZCK2:Y/:RI>Q+*8+90!$JALX0@'GC./:@#U&ZUC3;+2CJ=YJ%
MI;V "L;N6=5B 8@*=Y..20!SSD5)=W]G8"$W]W!;">98(C-($\R1CA47/5B>
M@')KYRU1$3]G?XDV>ELTFC6OB QZ;M.Y%A%S 2$/= 2<'IUYKTWXKZC9/'X(
MB2ZA:2Z\4:=+ @<$RH),EE'<<CGW'K0!<?Q?<6/QEU/2=4U*"UT*UT**\Q/L
MC2.0S%2QD.#TP,$XKIKC6K6\\+7FJ:%?V]Y$EO(\5Q;2+*A95)X(R#S7FVH:
M/H.M?M/O#XBM[6[,>@126EO=$%7E$K<A#PQ"EC@@XY/;(CT*UM-+^(GQ-T[P
M]&D.DIIL,DT$"@0PW)B;<% X!(&2!W^E '<?#WQ!<:M\+=&USQ!>1F>>S$US
M<R!8USSECC"C]!6WI6OZ/KR2/H>K6.I+$<2-9W*3!#Z':3BO!+TWL_P@^%.F
MP16<UI>W<:SPW\K1V\SA6,:2%025)R<8.2!P:[K2_!GB>+XG:)XAO+/POHUO
M;07%M=QZ1/+YE[&R?(I5HE!V.H;KZ^E 'J->=?#CX@0WW@2ROO&>OV$-_=7=
MS%&;J6*W,H29E4*OR@X  X%=!HTOCE]50>(++P]%I^&WO8W<\DH..,!HU'7&
M>:\N^$WA;P3J7PFU6]UNQTZXG::[74+B<+));J'?;R>8\+AAC'//O0!Z!\2O
M$6I^'QX2.CW(@&I>)K.PN?W:OYD$F_>OS XS@<C!]ZV+2^U.3QUJ%E-?Z0^G
M16L;PVD3DWL;D\M(O0(<'![_ (5XQ:SWUQ\%O@_)JA<S_P#"5V*@OU,8DF$?
M_C@6N_T7_DXKQ/\ ]@6T_P#0FH ZYO&'AI%M"WB+25%[_P >I-]'^_YQ\GS?
M-SQQWK1O;ZTTVSDN]1NH;2VB&9)IY B(/=CP*\$^'G@CPYJ/[,-SJ5]I-M<7
M]U87LCW<J!Y4:-Y5CV,>5"A%P!@9SZFK=Q,GB"W^"MCXDVW&DWUN\EXDYS'/
M/':IY._/!)8G@]<F@#OY?%YOOB9X;L="U:VO-&O[&\EE-LT<J2/&8]I#C)XW
M'@'OS7<5Y.^C>'=&_:-T-- MK2SNI=*NGO+>U 0#[FQB@X4D9YP,X]J]/M]1
MLKRZN;:TO+>>>T8)<112JS0L1D!P#E21SS0 :AJ5CI%F]YJM[;V-LGWI[F58
MT7ZLQ %8'B+Q&9O ]SJW@_7O#ZLK($O[^Z!LE^=00SH>N#@>Y%4_B'X0U'Q*
M^BZAHSV,EYHMTUPEEJ:%K:YW)M(?'(89RK8.#7G?Q \06VM?L]^-+9-"CT*^
MTV^@MK^TAV-'YWVB$EE=0 P(QR0#QS0![7<:OI]A(L&HZA9V]QY)G:.294.Q
M<!GP3G:"1D]!D4:7K.F:Y:FZT74;34;<-M,MI.LJ9],J2,UYMXST/3O$/Q\\
M+66LVJ7=H-*N96@DY20JZE0R]& .#@\9 IVB6=CX:^.WB:RT>&'3;.YT"&^E
M2% L:2+(R[]@XZ<G\?6@#N+_ ,;>%=*O'L]4\3:/97,?WX+B_BC=?JK,"*P[
MOQ3>2?%SP[I>G7T<VBZEI,]V1$$=9B"NQU?&<8/&#@YKR+2-,_X2?X-Z;X<T
MGPC?-K]U<QW"Z[)8?N#^_#M<FX;KE,C:?FYQCBO3=6C2']H7PM'$BI&FB7:J
MBC 4!EP .PH [74?$V@Z1>1VFK:WIUC<RX\N&YNXXW?/HK$$UI@Y&1R*\!\"
M:3XB\1V/B2Y_L'PGJLUWJUU#?R:O<2_: 0VWRR!$VU5& H!''85WGAC1_'7A
M?X<Z#HVGR:#JM]9QR174]U>3+'M#GRA&5C).%^4Y QM'6@#O+N\M=/M)+J_N
M8;6WC&7FFD"(H]23P*@TO6M+URU-SHNI6>HP [3+:3K*H/IE217F'C>*YU7Q
MU\.=)\=0V8L;F:[DN[:!VDM9KE(QY*DL 2.> 1R21@U+\7-,T[PO\*/%MSX/
ML;33M0N;>W2]^PH(V,)EVY*K_LO(,XZ9YXH ]#L?$V@ZGJ$EAINMZ=>7D8)>
MWM[N.21,=<J#D5)>>(-&TYKA=0U:QM6M462X$]RB>2K9VLV3\H.#@GK@UY1<
M^ O$U_9: =.TOP5HT.FW=O<VM]IUU-Y@0,/E4^2-P<'&"<-GFKR>'-)U_P#:
M.UQM;L8;Y+32;62&*X7?&')8;BAX) R 2.,F@#T6X\2Z-!X=DUW^U;%M,1-P
MO/M*>2><#]YG;R2!UZG%8WP_^(6E>/O#UK>VD]G#J$L1EGTR.\2:6V 8K\P&
M"!TY*CJ*Y3P)IUC9:[\2_#]K9Q)IEO?1S16NP&-#) &("] ,J" .G'I6;X.W
MZ;^R@VJ:)#'%J2Z/=$7$* 2<-)D[@,Y&,_44 >K1>)]!GU<Z5#K>G2:BI(-F
MEW&9@1U^3.[]*FO=<TG3)'CU'5+*T>. W+K/<(A6(,%,A!/"Y(&[ID@5X=:^
M!/$FO_"/2[31]*\%V$+6T%S:ZK'=S+<1.-K^;O$/#D@Y^;J372^(-"L=>_:)
MT*VUZWCO8X?#KS-%(,QR.LW&Y>C#)S@\9 /:@#U6UN[>^M(KJQN(KFWF4/'-
M"X='4]""."*H7GBC0-/U)-/O]<TVUO9" EM-=QI(V>F%)R:O6EG;6%I':V-O
M%;6\0VQPPH$1!Z!1P*\'UV0>(_AWXPU3PUX0\.VVA_Z:9K[4;AC>3RKNW2JH
MC.&W#Y0S#G:.!0!Z=X[^(VE^!;C1H+V2U>;4]0AM9(Y;Q86MX7+!KD@@Y12O
M)X'/45T^GZE8ZO81WVE7EO?6DN?+N+:59(WP2#AE)!P01]17C'BB**]^&OP>
MN[Z..>:75]%6::50S.K0DL&)Z@GDCI7MEO;PVL"PVL,<,2YVQQJ%4<YX ]Z
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M^CE<@=3M5B<5Y#JNIBZ\*_""?5;6?6D9!/<:9%"9Y+K9:X\[:?O%"0Q'4[N
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M^%_^1B\9?]AF/_TWVE '24444 %%%% !1110 4444 %%%% !1110!Y-\<?\
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M&BN1*Z'*'<I958*V" 1N!Q@5A>)?"%UXD^,/AC4[G3D&DZ#;RW/VPNN9;AB
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M/_TWVE=)7-^%_P#D8O&7_89C_P#3?:4 =)1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*YOPO_R,7C+_ +#,?_IOM*Z2N;\+_P#(Q>,O^PS'_P"F^TH Z2BBB@ HHHH
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M))%W&/;C@J,9Y/7M7251TK1=/T2*X33+80"ZN)+J<[BS22N<LS,Q))/Z  #
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M20?E) SCGWK:5510J *JC  & !0!YM\48]6DU[01+:ZY>>%B)AJ4&A%_/:3
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MP-H;KZ5Z[10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 45G>'_$&F>*=#M]8T&Z^UV%SN\J8(R;MK%3PP!'S*1R.U:- !16+XQ\1?\
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M 4444 >3?''_ )@?_;Q_[3KR:O6?CC_S _\ MX_]IUY-7J4/X:/#Q?\ &?\
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MEBCCE5F:)A&!(J@\K[CBN]O_  5X5U6Z^TZIX:T>]GVA/-N+"*1MH& ,LI.
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M7[/,6OVOC'6-/EL;:[N-.M+*4101^7+*Q$J@9EW,&R2> 0 ..?<?!FL2^(/
MNB:O<X\^^L(9Y=HP-[("V!Z9S63X8\ #PW\)QX*&I?: +:YM_MA@V_ZYG;.S
M<>GF=,\X[5M^%=#_ .$9\(Z7HGVC[3_9]K';^=LV>9M7&[;DXSZ9- '#>"%B
MN?CQ\1+F[.^^MA8P0!QS' 8MQ"^Q(!/X'O70?%B>>V^$?B:6T9DE&GR ,G4
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M,^F30!K4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5JBPOB.27Y5 0D\@[2<Y]ZA\+^%?)EUF'4-,BO\ 7+!8C!IDTP"MNY+'!PV
M1QGVZFN#HJN1]&2JJTNK[_B>E>.([B+X;Z5'>V-GI]PM\_F6MG]R,E6(&,G!
M(()Y[UKQD?\ "\==Y_YAY_\ 1,=>/45/LM+7[_B5[?6]NWX'H/@ZTUV\T2"S
MN-"@U?0)IB1YLBJT!SM9E;=E._\ 3K7)>);.QT_Q+?6NDS>?9Q2[8GW;N,<C
M/?!R,^U9=%6HM2N9RFG%1L%%%%69!1110!]94445XI],%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"Z!UVJJDO\I!)7.,\XJO=_%[P%96-I>3>);4PWB>9$8E>5MN=NYE524&<C+
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M<$C*GD9/-<!::N_@633_ (H7BLJ^*8]2-TK<\MF:S7\1&%'IFMGQ/X9_L/\
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M"WE!<. <J<JPY_NGTK!^(-G;7WQN^&$%[!'/%OU-]DBAAN6!&4X/<,H(]P*
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MM#:ZO86M_;DY,-U"LJ$_[K BK=% %73M*T_1[06ND6%M8VX.1#:PK$@_X"H
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M?_\ !#/_ /)E'V'QO_T,/A__ ,$,_P#\F4 =)17-_8?&_P#T,/A__P $,_\
M\F4?8?&__0P^'_\ P0S_ /R90!TE%<W]A\;_ /0P^'__  0S_P#R91]A\;_]
M##X?_P#!#/\ _)E '245S?V'QO\ ]##X?_\ !#/_ /)E'V'QO_T,/A__ ,$,
M_P#\F4 =)17-_8?&_P#T,/A__P $,_\ \F4?8?&__0P^'_\ P0S_ /R90!TE
M%<W]A\;_ /0P^'__  0S_P#R91]A\;_]##X?_P#!#/\ _)E '245S?V'QO\
M]##X?_\ !#/_ /)E'V'QO_T,/A__ ,$,_P#\F4 =)17-_8?&_P#T,/A__P $
M,_\ \F4?8?&__0P^'_\ P0S_ /R90!TE%<W]A\;_ /0P^'__  0S_P#R91]A
M\;_]##X?_P#!#/\ _)E '245S?V'QO\ ]##X?_\ !#/_ /)E'V'QO_T,/A__
M ,$,_P#\F4 =)17-_8?&_P#T,/A__P $,_\ \F4?8?&__0P^'_\ P0S_ /R9
M0!TE%<W]A\;_ /0P^'__  0S_P#R91]A\;_]##X?_P#!#/\ _)E '245S?V'
MQO\ ]##X?_\ !#/_ /)E'V'QO_T,/A__ ,$,_P#\F4 =)17-_8?&_P#T,/A_
M_P $,_\ \F4?8?&__0P^'_\ P0S_ /R90!TE%<W]A\;_ /0P^'__  0S_P#R
M91]A\;_]##X?_P#!#/\ _)E '245S?V'QO\ ]##X?_\ !#/_ /)E'V'QO_T,
M/A__ ,$,_P#\F4 =)17-_8?&_P#T,/A__P $,_\ \F4?8?&__0P^'_\ P0S_
M /R90!TE%<W]A\;_ /0P^'__  0S_P#R91]A\;_]##X?_P#!#/\ _)E '245
MS?V'QO\ ]##X?_\ !#/_ /)E'V'QO_T,/A__ ,$,_P#\F4 =)17-_8?&_P#T
M,/A__P $,_\ \F4?8?&__0P^'_\ P0S_ /R90!TE%<W]A\;_ /0P^'__  0S
M_P#R91]A\;_]##X?_P#!#/\ _)E '245S?V'QO\ ]##X?_\ !#/_ /)E'V'Q
MO_T,/A__ ,$,_P#\F4 =)17-_8?&_P#T,/A__P $,_\ \F4?8?&__0P^'_\
MP0S_ /R90!TE%<W]A\;_ /0P^'__  0S_P#R91]A\;_]##X?_P#!#/\ _)E
M'245S?V'QO\ ]##X?_\ !#/_ /)E'V'QO_T,/A__ ,$,_P#\F4 =)17-_8?&
M_P#T,/A__P $,_\ \F4?8?&__0P^'_\ P0S_ /R90!TE%<W]A\;_ /0P^'__
M  0S_P#R91]A\;_]##X?_P#!#/\ _)E '245S?V'QO\ ]##X?_\ !#/_ /)E
M'V'QO_T,/A__ ,$,_P#\F4 =)17-_8?&_P#T,/A__P $,_\ \F4?8?&__0P^
M'_\ P0S_ /R90!TE%<W]A\;_ /0P^'__  0S_P#R91]A\;_]##X?_P#!#/\
M_)E '245S?V'QO\ ]##X?_\ !#/_ /)E'V'QO_T,/A__ ,$,_P#\F4 =)17-
M_8?&_P#T,/A__P $,_\ \F4?8?&__0P^'_\ P0S_ /R90!TE%<W]A\;_ /0P
M^'__  0S_P#R91]A\;_]##X?_P#!#/\ _)E '245S?V'QO\ ]##X?_\ !#/_
M /)E'V'QO_T,/A__ ,$,_P#\F4 =)17-_8?&_P#T,/A__P $,_\ \F4?8?&_
M_0P^'_\ P0S_ /R90!TE%<W]A\;_ /0P^'__  0S_P#R91]A\;_]##X?_P#!
M#/\ _)E '245S?V'QO\ ]##X?_\ !#/_ /)E'V'QO_T,/A__ ,$,_P#\F4 =
M)17-_8?&_P#T,/A__P $,_\ \F4?8?&__0P^'_\ P0S_ /R90!TE%<W]A\;_
M /0P^'__  0S_P#R91]A\;_]##X?_P#!#/\ _)E '245S?V'QO\ ]##X?_\
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M?_\ !#/_ /)E'V'QO_T,/A__ ,$,_P#\F4 =)17-_8?&_P#T,/A__P $,_\
M\F4?8?&__0P^'_\ P0S_ /R90!TE%<W]A\;_ /0P^'__  0S_P#R91]A\;_]
M##X?_P#!#/\ _)E '245S?V'QO\ ]##X?_\ !#/_ /)E'V'QO_T,/A__ ,$,
M_P#\F4 =)17-_8?&_P#T,/A__P $,_\ \F4?8?&__0P^'_\ P0S_ /R90!TE
M%<W]A\;_ /0P^'__  0S_P#R91]A\;_]##X?_P#!#/\ _)E '245S?V'QO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
? %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>vrna-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:vrna="http://veronapharma.com/20201231"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vrna-20201231.xsd" xlink:type="simple"/>
    <context id="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia1877ba50aad4b8b8bb262f25baa012d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i87a26c2d1e064e0b89d02c718f6a3154_I20210219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2021-02-19</instant>
        </period>
    </context>
    <context id="idecac34827ce472182dc1492d400ffdf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7cd52ee77a7948f196f2eb3dd03b56a8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1c68faae09684ddba54ea78663480657_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia7bb2db7aeed4fe28f6502081a2b3fb2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iad4673fe986541979acd434b04d81115_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i670b119a86454681a09079c9b183ec50_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1448e425ab1943f8ae8c4d34c3c75f39_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i89de9796f5344884bc5b430e67f6af27_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibc6502e2d84744a1a4f122e93a5bbedc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i51bd538a85ce40bb90149ddc83f13568_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7144fbaaf53a410eb5a86ca2c38da7d6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7bffa5795b9245b9b6367166015c8f55_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i218678a6acb04250abe3f3a39f5ced25_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i48d5ccc6c4d54da9843cb1e12f96b89a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9796b77433d84134a9500d1119aa6875_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia4209fc83abb4e68a86d37c119722d62_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5d652bbdead0408181aff2dd02b415f6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5cfc9b650e8f4111a9282e4577094d50_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i33ee67ddc86e47f4b9ee46c176ae9f52_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i67b3a7b2ab5743e8ab134b4311cd3357_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icc88e7e39c7041c7aec47904740a5ffa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2ee4138b94f24a3fb37c3a49fc55fbf0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id772c24a98d045f687a38be7f9204a60_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib4bdef42e0964c40a84e61be80f90c28_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icfd1b77b4c11404ab36abf3475f7fdf7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie991833e533a42c1bb4590e7c40b875d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia30de411faa549d8a507b268ebbff4e6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1ab5f2cf37f34ce1822987a9a032bfe3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2906e285538640d2ba863cc6f7be6d7f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i382c3abae01044dfaf69a5a01cfc1c00_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if62ffe34397d4178bfe3a160fb777109_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib24f80c535f0403a800a6d65d53720d3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia2cc9b6147bc414a87f7dd9652e152aa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iff1f3d0564a142dbb860c4d8ca0a33d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie91783fe6f4743229a237427eba95bbe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9dd30f2681444b31a30cecbb105a8d12_D20200717-20200717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-17</startDate>
            <endDate>2020-07-17</endDate>
        </period>
    </context>
    <context id="i84e00d94b1de4386a6170826d98862d2_D20200717-20200717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2020-07-17</startDate>
            <endDate>2020-07-17</endDate>
        </period>
    </context>
    <context id="i2f3b17ae809741d291cfb524e558c10e_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i46b0f32ad5df416e83423bbabba5a3b9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if9ab2cee3ac140aa8c75e12ed71b0cf2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i94c8c6508a314e10be6ed1a9414e5627_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87d649c393ad4d1b95b36d916dbd127f_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i06f7637896b74a8e922bb5f0526d2b57_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i9c561e8d91b04a3eb8a0bb1c609295ce_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vrna:LondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8d00a9e878d548fb96619548564db190_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i433bd94d277a4aaca4429c549dceb814_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie038220275954e62811afea2defe4cd3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i30a26c5ea22f48a09788808b52ec5291_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1934261cb6744a68b1f3c1ac28b455f2_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="ia00163949ecb43ad94978f60f9da30cc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie527217d2eb345ecb87bd45f62bc6551_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic9d34c4d3648482ca9398caf5933c3fc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vrna:MeasurementInputAnnualizedVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i15dd5dffacd24b789e1a47ff62cf2c12_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vrna:MeasurementInputAnnualizedVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic846b25fc9864471980143616fd3554b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i798475f69cfd4d4cae668edfa84dcee9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie41a5e71b1994eee9bbaacc09238aab0_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i7a160b4682334bfdb2a585dd96fe5385_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermBLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i5f6a1d485e244da9a9515d7aeca27d8b_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="if4a9630a9c2e4c549a9169a0cdb89d7c_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i11218b759beb41eeb8f443403c8f9195_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vrna:DebtPrepaymentPeriodAxis">vrna:DebtPrepaymentPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i37571b3be78b4c2bb25afe43255bbd52_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vrna:DebtPrepaymentPeriodAxis">vrna:DebtPrepaymentPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i14b92f6c922045ebb4b765d2692f0b26_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vrna:DebtPrepaymentPeriodAxis">vrna:DebtPrepaymentPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i6a56eccf381d4490ab23ba0ce2602ed8_I20201119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-19</instant>
        </period>
    </context>
    <context id="ifff034be4ded4bcb8670b2917c2d0bd5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6bcfa5910fbe4e2ca7f076edd714a549_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i52c90d5f0c46487fb88765d553f1b65b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9935563a347240e5a3824eaba4a823a6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5c70e119f5364bafabd0f2b4cf13c8cb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0c63e739a8e547e990aedd5fb7ed7cf4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia47baec57d49425a9f307369903c9687_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i15364ff1d68341ec805494f64c383003_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7bd04de9015c48df9fe3e3bef6ce4e5d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i465329a24eeb4cefbb25e840bfa5bc80_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibc6a3a52eb8741acb78a572b648649d0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i38dd4fa39df844e6af7ab7270ee1dc55_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iac60289acf4d49a68397763e265d6cf1_I20060918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:EMIOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2006-09-18</instant>
        </period>
    </context>
    <context id="i3c19fa116eb54bf28428386737d1542d_I20120724">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:PreIPOOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-07-24</instant>
        </period>
    </context>
    <context id="ia61b9dcc76d44330a7872e53c1b77d1a_D20170401-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:PreIPOOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iafc15080cb714e279a2a7b822b3d58d6_D20170401-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:EMIOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i747d51980c684daaa52f9e04f16b0666_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:PreIPOOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i210506e1747a4dcab92bcdbad863492a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:EMIOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7e33e5ffa3934ca7a4c7048a96c317a9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:A2017IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if3ed89efc5e44f55be2b1d1c803d1f72_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i75308170234746af98ca1381553d9120_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i44675776f6c54a54a40dc4ccde2d3c52_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5c77df9054424edb9685cd91224a73df_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i35514ffd7c034b0e8ce21b1da270c038_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i844f6711369540ba826df75f6b6a22dd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3bc3d048b42b479595d7e0e6de32ce57_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2c41d3b6c046482b826d8cdf888acde0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idce44936200646a39eb2e2ac020a3b66_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:RestrictedStockUnitTimeBasedVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idffe8ebf902f434a94b6fcaa44362bd1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:RestrictedStockUnitTimeBasedVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie67bf5c881684176b281b06cfe0628ed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:RestrictedStockUnitMilestoneBasedVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0cb4743b3dc645c38fc5bff065067b3c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:RestrictedStockUnitMilestoneBasedVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaed0afb2f5ac4a73bc91d4c2a32c115e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vrna:ConsultancyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia323b627bb0e4dfda11f8e943e75767d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:DrEbsworthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vrna:DirectorOrOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i14e765c2f7c2471cac03f164f5c1521e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:DrZaccardelliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vrna:DirectorOrOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9b7fe6a0bec54714ba0212643a952e53_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:MrSinhaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vrna:DirectorOrOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibf836d4ae04748dd8b1be54f7881b5a8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:DrUllmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vrna:DirectorOrOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i05bb837cdc2e4bab8740f004c4754b5d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:DrEdwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vrna:DirectorOrOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia6ee6389e25345f08e3512dcfb211a54_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:MrHahnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vrna:DirectorOrOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="gbpPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:GBP</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="subsidiary">
        <measure>vrna:subsidiary</measure>
    </unit>
    <unit id="segment">
        <measure>vrna:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="rate">
        <measure>utr:Rate</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MzkvZnJhZzo4ODA3ZThjZDlmZTI0N2Y4OWQ2OTIzY2ZlZWVlNTNiOS90YWJsZTpmMDAwZmNiYjFiNWM0ZWExODU4N2VlODM2ODIzYTRmNy90YWJsZXJhbmdlOmYwMDBmY2JiMWI1YzRlYTE4NTg3ZWU4MzY4MjNhNGY3XzMtMS0xLTEtMTQxNzc_09fa92c4-f4f4-4328-94d6-6353d565356b">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MzkvZnJhZzo4ODA3ZThjZDlmZTI0N2Y4OWQ2OTIzY2ZlZWVlNTNiOS90YWJsZTpmMDAwZmNiYjFiNWM0ZWExODU4N2VlODM2ODIzYTRmNy90YWJsZXJhbmdlOmYwMDBmY2JiMWI1YzRlYTE4NTg3ZWU4MzY4MjNhNGY3XzQtMS0xLTEtMTQxNzc_3c05f58b-8cfb-4541-9ed7-b11314262828">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MzkvZnJhZzo4ODA3ZThjZDlmZTI0N2Y4OWQ2OTIzY2ZlZWVlNTNiOS90YWJsZTpmMDAwZmNiYjFiNWM0ZWExODU4N2VlODM2ODIzYTRmNy90YWJsZXJhbmdlOmYwMDBmY2JiMWI1YzRlYTE4NTg3ZWU4MzY4MjNhNGY3XzUtMS0xLTEtMTQxNzc_3a395176-fd6f-423e-8157-6c4635e1453d">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MzkvZnJhZzo4ODA3ZThjZDlmZTI0N2Y4OWQ2OTIzY2ZlZWVlNTNiOS90YWJsZTpmMDAwZmNiYjFiNWM0ZWExODU4N2VlODM2ODIzYTRmNy90YWJsZXJhbmdlOmYwMDBmY2JiMWI1YzRlYTE4NTg3ZWU4MzY4MjNhNGY3XzYtMS0xLTEtMTQxNzc_38dc6d2a-2e3a-4dbc-883a-abe61d91b445">0001657312</dei:EntityCentralIndexKey>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i51bd538a85ce40bb90149ddc83f13568_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzMtMC0xLTEtMTk5NTI_cdbb0f1c-034b-4cc5-a4ab-bf0b4180f75c">us-gaap:AccountingStandardsUpdate201602Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if9ab2cee3ac140aa8c75e12ed71b0cf2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNjc4_366b91a1-c260-4eab-9b78-d6ac9d5b8954">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i0c63e739a8e547e990aedd5fb7ed7cf4_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcyNjkw_00bc9b5e-059e-48bb-806a-540b915c41a7">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjI4_7c2f6607-4559-41b9-a2c6-a3fe2688de61">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjM0_c505206c-440d-4bca-ad2b-15dece4310c7">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNTM0_176188d2-b281-4954-9f46-5771cad99e65">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNTM0_06599b25-6810-4dfb-8c31-148cb4c8f7c7">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjM5_c163e170-a994-4d07-bf6d-86f3bae9b378">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjQw_fef6545f-eed1-4a46-8b03-ec0b9197fd86">001-38067</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjQx_7e4bb365-bd20-4ad6-a0fa-2df933fd2e46">Verona Pharma plc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90YWJsZTozMGJiMGFhOTk5Njc0ZjQyOWM4NTZiZWQyMDUwNTkxMy90YWJsZXJhbmdlOjMwYmIwYWE5OTk2NzRmNDI5Yzg1NmJlZDIwNTA1OTEzXzAtMC0xLTEtMTg2MTU_58a3e921-7184-49bc-bc51-e30c602c857e">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90YWJsZTozMGJiMGFhOTk5Njc0ZjQyOWM4NTZiZWQyMDUwNTkxMy90YWJsZXJhbmdlOjMwYmIwYWE5OTk2NzRmNDI5Yzg1NmJlZDIwNTA1OTEzXzAtMy0xLTEtMTg2MTM_2d9f39e0-00c4-43c8-9486-1ec0a0b0e76f">98-1489389</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90YWJsZTozMGJiMGFhOTk5Njc0ZjQyOWM4NTZiZWQyMDUwNTkxMy90YWJsZXJhbmdlOjMwYmIwYWE5OTk2NzRmNDI5Yzg1NmJlZDIwNTA1OTEzXzMtMC0xLTEtMTg2MDIvdGV4dHJlZ2lvbjpiMjIwYWRiMDNhY2Y0MWEyYWFjZGQ2M2MyZmYxYTZhOV8yMDg5MDcyMDkyNzg2Mg_b12c74ae-7443-4dde-893f-623492883df6">3 More London Riverside</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90YWJsZTozMGJiMGFhOTk5Njc0ZjQyOWM4NTZiZWQyMDUwNTkxMy90YWJsZXJhbmdlOjMwYmIwYWE5OTk2NzRmNDI5Yzg1NmJlZDIwNTA1OTEzXzMtMC0xLTEtMTg2MDIvdGV4dHJlZ2lvbjpiMjIwYWRiMDNhY2Y0MWEyYWFjZGQ2M2MyZmYxYTZhOV8yMDg5MDcyMDkyNzg3MQ_a6fbcaea-a4f7-4f9b-9d07-6dd871dfc7f8">London</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90YWJsZTozMGJiMGFhOTk5Njc0ZjQyOWM4NTZiZWQyMDUwNTkxMy90YWJsZXJhbmdlOjMwYmIwYWE5OTk2NzRmNDI5Yzg1NmJlZDIwNTA1OTEzXzMtMC0xLTEtMTg2MDIvdGV4dHJlZ2lvbjpiMjIwYWRiMDNhY2Y0MWEyYWFjZGQ2M2MyZmYxYTZhOV8yMDg5MDcyMDkyNzg4MQ_9fa023d9-e900-462e-8347-6d84076106ac">SE1 2RE</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90YWJsZTozMGJiMGFhOTk5Njc0ZjQyOWM4NTZiZWQyMDUwNTkxMy90YWJsZXJhbmdlOjMwYmIwYWE5OTk2NzRmNDI5Yzg1NmJlZDIwNTA1OTEzXzMtMC0xLTEtMTg2MDIvdGV4dHJlZ2lvbjpiMjIwYWRiMDNhY2Y0MWEyYWFjZGQ2M2MyZmYxYTZhOV8yMDM0MDk2NTExNDA2Ng_87662dcc-9ca2-4cae-98a5-2a0208354725">GB</dei:EntityAddressCountry>
    <dei:CountryRegion
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTYxOTEx_8d4c97ec-ff30-4741-b7b4-09c615bbf968">44</dei:CountryRegion>
    <dei:CityAreaCode
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjQ0_2e5579ad-f987-4bf8-80ee-a6f793e859f8">203</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjQ4_2c2d82aa-b36c-4f72-a3fa-6a046edb7517">283 4200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90YWJsZTpiMDJhZTU2YTg5Zjc0NjdjYTRhZjQwZmM1MDBkYzljNS90YWJsZXJhbmdlOmIwMmFlNTZhODlmNzQ2N2NhNGFmNDBmYzUwMGRjOWM1XzEtMC0xLTEtMTY3ODI_529bf9c4-4b7e-42de-a441-01a05c58d886">Ordinary shares, nominal value &#xa3;0.05 per share*</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90YWJsZTpiMDJhZTU2YTg5Zjc0NjdjYTRhZjQwZmM1MDBkYzljNS90YWJsZXJhbmdlOmIwMmFlNTZhODlmNzQ2N2NhNGFmNDBmYzUwMGRjOWM1XzEtMS0xLTEtMTg2MTc_cea1aba3-6398-44fc-b43f-452df59c07a4">VRNA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90YWJsZTpiMDJhZTU2YTg5Zjc0NjdjYTRhZjQwZmM1MDBkYzljNS90YWJsZXJhbmdlOmIwMmFlNTZhODlmNzQ2N2NhNGFmNDBmYzUwMGRjOWM1XzEtMi0xLTEtMTg2MTcvdGV4dHJlZ2lvbjo1MGJkMDFjYjVjNWM0MDExOTBkMzc0NGQzOWY5MDMyN18yMDM0MDk2NTExMzkzMA_32e12288-33ca-49d6-a829-ced2da95a4c1">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjY0_8480c7a8-69ac-47f0-b6b7-f26fbd94a939">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjY1_27af857d-e1c3-4345-b250-aa9688f6d505">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjY2_ade9ca35-9241-4661-9d2d-6c03b1d74c7a">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjY3_010cf5b2-9b2f-402c-83b6-dda04c03ad82">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90YWJsZTphNmI2Yzc0MGU5NTI0MTAxYjVmZjFkYzQzNTAwNzVlNy90YWJsZXJhbmdlOmE2YjZjNzQwZTk1MjQxMDFiNWZmMWRjNDM1MDA3NWU3XzEtMC0xLTEtMTg2MjA_c5f093ed-b52d-4b5e-98e2-45572a99afea">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90YWJsZTphNmI2Yzc0MGU5NTI0MTAxYjVmZjFkYzQzNTAwNzVlNy90YWJsZXJhbmdlOmE2YjZjNzQwZTk1MjQxMDFiNWZmMWRjNDM1MDA3NWU3XzEtNC0xLTEtMTY4Mzc_4a4ddec7-5838-4662-89a9-00e351e105b8">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90YWJsZTphNmI2Yzc0MGU5NTI0MTAxYjVmZjFkYzQzNTAwNzVlNy90YWJsZXJhbmdlOmE2YjZjNzQwZTk1MjQxMDFiNWZmMWRjNDM1MDA3NWU3XzItNC0xLTEtMTY4NDE_dc2f5570-df7e-42c5-8ee4-6eb21abca9a6">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjc0_83787c8a-21b1-4660-bdc5-f06fdcdc42d1">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTYxODkx_3a82b628-73e8-4bc6-b52f-420d2489cb64">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjc1_df8a3e94-f848-4437-aa61-50157ffba68a">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ia1877ba50aad4b8b8bb262f25baa012d_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTYxODc4_b742d294-3da1-4c46-a6f8-802da9288071"
      unitRef="usd">37500000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i87a26c2d1e064e0b89d02c718f6a3154_I20210219"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzU0OTc1NTg2MjQ2Ng_267e2a74-d4f4-4c0c-95c8-c2cd2c62351a"
      unitRef="shares">463478446</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yMDQvZnJhZzo3MTAyMjlhNGM0YzY0ZWY1YWViMTQxOTYxODY4NDM0Mi90ZXh0cmVnaW9uOjcxMDIyOWE0YzRjNjRlZjVhZWIxNDE5NjE4Njg0MzQyXzIwMzQwOTY1MTMyNjc2_ac965a8a-d843-4d6c-ae6d-f7a9fd0565e9">Portions of the registrant&#x2019;s definitive proxy statement that the registrant intends to file with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant&#x2019;s 2021 Annual Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzUtMi0xLTEtMzg0Mw_2e59ec01-818e-41f0-9192-654f83ab58de"
      unitRef="usd">187986000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzUtNC0xLTEtMzg0Mw_af83dc9d-b146-4d54-97d2-ac40257f8cda"
      unitRef="usd">30428000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzYtMi0xLTEtMzg0Mw_64b9d5f2-4f7e-4521-b1c1-63852c82bfc8"
      unitRef="usd">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzYtNC0xLTEtMzg0Mw_2b9943a3-5157-4b72-831f-0b538c83a1dc"
      unitRef="usd">10380000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzctMi0xLTEtMzg0Mw_0cbd3eb0-496b-4e77-8791-e6408888a1fd"
      unitRef="usd">4538000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzctNC0xLTEtMzg0Mw_3c948cd7-c267-481e-9e44-f49f8204403d"
      unitRef="usd">1655000</us-gaap:PrepaidExpenseCurrent>
    <vrna:TaxCreditAndIncomeTaxesReceivableCurrent
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzgtMi0xLTEtMzg0Mw_95baeac1-c9cb-44b1-9158-f7a9a346673c"
      unitRef="usd">8260000</vrna:TaxCreditAndIncomeTaxesReceivableCurrent>
    <vrna:TaxCreditAndIncomeTaxesReceivableCurrent
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzgtNC0xLTEtMzg0Mw_62defcfb-323e-433d-be45-fdf89cd48d8b"
      unitRef="usd">9814000</vrna:TaxCreditAndIncomeTaxesReceivableCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzktMi0xLTEtMzg0Mw_bf4409b7-96d0-4721-810d-4b3149bd7618"
      unitRef="usd">1720000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzktNC0xLTEtMzg0Mw_933c730a-52b9-4bb7-beb0-cdbde6fb2a2a"
      unitRef="usd">2021000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzktMi0xLTEtNDc5Mw_8fb2da62-cc8c-467b-8946-9bde91b9c5ce"
      unitRef="usd">202504000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzktNC0xLTEtNDc5Mw_835d758f-0104-4408-92d6-b1a28d412239"
      unitRef="usd">54298000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzEyLTItMS0xLTM4NDM_a12f40e7-40e4-4cea-b9cf-34d6c7c8e157"
      unitRef="usd">107000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzEyLTQtMS0xLTM4NDM_85474781-f71c-4181-995c-33f2748c39d8"
      unitRef="usd">63000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzEzLTItMS0xLTM4NDM_c18fe2fa-f3fd-4824-b5ce-8286e62ee185"
      unitRef="usd">545000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzEzLTQtMS0xLTM4NDM_b7698176-a9f0-48ec-a94a-580d6fd230df"
      unitRef="usd">585000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzE0LTItMS0xLTM4NDM_d746f07a-6abe-4884-ad3d-6a51ee4d0635"
      unitRef="usd">1050000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzE0LTQtMS0xLTM4NDM_f08d8cca-2bf1-49c9-8da9-61b8a8db1cd4"
      unitRef="usd">1288000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetsNoncurrent
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzE1LTItMS0xLTM4NDM_3d4b3073-7698-4ad6-bc53-c5cdf4f3c27e"
      unitRef="usd">1702000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzE1LTQtMS0xLTM4NDM_3e0601bf-2c1f-49ec-864c-f164420c1bfa"
      unitRef="usd">1936000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzE2LTItMS0xLTQ3OTM_b92856ec-d507-46f7-a1f5-f3fe510236d5"
      unitRef="usd">204206000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzE2LTQtMS0xLTQ3OTM_c55ef3aa-f644-40b6-b23e-7afaf6aaadab"
      unitRef="usd">56234000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzIwLTItMS0xLTM4NDM_ae598a7b-94b7-410f-ad6c-54b2fc269361"
      unitRef="usd">178000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzIwLTQtMS0xLTM4NDM_0164023a-2ead-4028-9173-f0d834957175"
      unitRef="usd">1931000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzIxLTItMS0xLTM4NDM_99e1b8ed-7b03-4252-bb97-2f81a045267c"
      unitRef="usd">10863000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzIxLTQtMS0xLTM4NDM_3d2b0c3d-05da-4991-b4a1-b69423dd15c1"
      unitRef="usd">8971000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzIzLTItMS0xLTM4NDM_33f2cf54-73ea-426b-b3e0-8413ca2b803f"
      unitRef="usd">798000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzIzLTQtMS0xLTM4NDM_1795716f-404b-4a38-b09a-58867a302e1f"
      unitRef="usd">611000</us-gaap:OperatingLeaseLiabilityCurrent>
    <vrna:WarrantLiabilityCurrent
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzI0LTItMS0xLTExMDI4_1e3521a8-4c34-4f5a-8f97-25d7228a05d6"
      unitRef="usd">2246000</vrna:WarrantLiabilityCurrent>
    <vrna:WarrantLiabilityCurrent
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzI0LTQtMS0xLTExMDI4_f6778f44-ac89-4e7a-949f-8eafce386fec"
      unitRef="usd">1188000</vrna:WarrantLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzI0LTItMS0xLTQ3OTM_00955cd0-0733-4ae6-a48e-9981997c340d"
      unitRef="usd">118000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzI0LTQtMS0xLTQ3OTM_58fc5b3d-ae8e-4981-8707-5efcfca48dd0"
      unitRef="usd">140000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzI1LTItMS0xLTM4NDM_c84e7a9f-a7bb-4e82-b214-325e12b7f950"
      unitRef="usd">14203000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzI1LTQtMS0xLTM4NDM_787bb612-27f2-4fc3-8cdd-cc7167740987"
      unitRef="usd">12841000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMwLTItMS0xLTEyMDIw_900c8222-e994-4449-b0e3-468f4f3dcfef"
      unitRef="usd">4635000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMwLTQtMS0xLTEyMDIz_9a34d0b3-507d-472b-9aad-1eee3bedd14b"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzI5LTItMS0xLTQ3OTM_d87ebeca-bf93-4548-ac96-b7fd51d847d5"
      unitRef="usd">514000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzI5LTQtMS0xLTQ3OTM_47c34d48-be87-4509-bd71-17748c1ee691"
      unitRef="usd">652000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMwLTItMS0xLTQ3OTM_e8ee1cc1-b0d4-451a-b4b9-c6ad8d8fa916"
      unitRef="usd">5149000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMwLTQtMS0xLTQ3OTM_ec55f7eb-204f-468e-a043-3ef741404b74"
      unitRef="usd">652000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMxLTItMS0xLTQ3OTM_2491568c-1878-4d69-890c-d0cb6c043c9b"
      unitRef="usd">19352000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMxLTQtMS0xLTQ3OTM_2fac3c39-2d93-4dc1-9c34-4a108a4ff743"
      unitRef="usd">13493000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzM1LTItMS0xLTE5MDIy_354c0e7b-c6ee-4485-8bf2-1891e375c779"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzM1LTQtMS0xLTE5MDIy_e90cfe37-0897-4485-be96-b87af81e02d9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzM4LTAtMS0xLTg4MTQvdGV4dHJlZ2lvbjo4OGFlYmZmNGMyMGE0NjE5OTk4MTY4NTRjMDE3YTM5MV8yMDM0MDk2NTExNDM5NA_70554a27-7271-4830-ae31-8d0d9228b0dd"
      unitRef="gbpPerShare">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzM4LTAtMS0xLTg4MTQvdGV4dHJlZ2lvbjo4OGFlYmZmNGMyMGE0NjE5OTk4MTY4NTRjMDE3YTM5MV8yMDM0MDk2NTExNDM5NA_d6e93802-a8e5-466b-a351-2b8bdf433df1"
      unitRef="gbpPerShare">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzM4LTAtMS0xLTg4MTQvdGV4dHJlZ2lvbjo4OGFlYmZmNGMyMGE0NjE5OTk4MTY4NTRjMDE3YTM5MV8yMDM0MDk2NTExNDM2Nw_ba2a8224-3f95-44b3-ad52-5d4885df77d2"
      unitRef="shares">488304446</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7cd52ee77a7948f196f2eb3dd03b56a8_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzM4LTAtMS0xLTg4MTQvdGV4dHJlZ2lvbjo4OGFlYmZmNGMyMGE0NjE5OTk4MTY4NTRjMDE3YTM5MV81NDk3NTU4MTQ0NDc_d5560b71-702b-44a9-98d7-fd4b20ce2b4c"
      unitRef="shares">105326638</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzM4LTAtMS0xLTg4MTQvdGV4dHJlZ2lvbjo4OGFlYmZmNGMyMGE0NjE5OTk4MTY4NTRjMDE3YTM5MV82NTk3MDY5NzY3MDYz_80eeb2d7-ac35-4ec9-bf7b-1fe265c42244"
      unitRef="shares">463304446</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzM4LTAtMS0xLTg4MTQvdGV4dHJlZ2lvbjo4OGFlYmZmNGMyMGE0NjE5OTk4MTY4NTRjMDE3YTM5MV82NTk3MDY5NzY3MDY5_0ee86cb1-6302-4e3c-968f-cabed2a36c95"
      unitRef="shares">105326638</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzM4LTItMS0xLTQ3OTM_b7e459ae-b164-4fef-a8ec-233bd500928f"
      unitRef="usd">31794000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzM4LTQtMS0xLTQ3OTM_42274bc4-94d3-46b5-8f39-c820831f3389"
      unitRef="usd">7265000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzI5LTItMS0xLTM4NDM_b0fe4b93-3d1c-4329-a421-5dca5a8cf6d8"
      unitRef="usd">366411000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzI5LTQtMS0xLTM4NDM_2f20951c-e3a0-4ad1-be3d-7695bbbebd10"
      unitRef="usd">179535000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockValue
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzM5LTItMS0xLTEyMDA0_8cb0ad22-a108-4830-b87f-2c50adc95829"
      unitRef="usd">1700000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzM5LTQtMS0xLTEyMDA4_d02a0b77-7585-433c-a1de-d8a07785bf17"
      unitRef="usd">0</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMwLTItMS0xLTM4NDM_e4169321-4a5e-494d-b1ac-164c6d45e11e"
      unitRef="usd">-4601000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMwLTQtMS0xLTM4NDM_eacfc111-391f-4f16-85ab-aaaaff37524b"
      unitRef="usd">-2280000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMxLTItMS0xLTM4NDM_96034322-787e-49a8-9023-d0cfcd1209ad"
      unitRef="usd">-207050000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMxLTQtMS0xLTM4NDM_54776477-a599-4564-8737-b79fcbcbf0f4"
      unitRef="usd">-141779000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMyLTItMS0xLTM4NDM_4fe1ebcb-e9d5-4aca-80af-fa687afef6aa"
      unitRef="usd">184854000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMyLTQtMS0xLTM4NDM_8302b777-2c7a-4a6b-be32-afaca4f90e39"
      unitRef="usd">42741000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMzLTItMS0xLTM4NDM_bf73101e-1711-4275-afcc-6c8928288bb4"
      unitRef="usd">204206000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzAvZnJhZzpmNzA1ZDljZjY3ODE0N2M4YjZkYmE2Mjk5MjhlYzc2NS90YWJsZTpiNjA0M2FhNzU4MzM0Nzk4ODIxNTIwODhmOTg2NGYzZi90YWJsZXJhbmdlOmI2MDQzYWE3NTgzMzQ3OTg4MjE1MjA4OGY5ODY0ZjNmXzMzLTQtMS0xLTM4NDM_289f46c3-eb2f-4c4d-82ee-6d330d6c06ac"
      unitRef="usd">56234000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzMtMi0xLTEtMzkyOA_9b809355-daef-4d95-bbc9-5487bb594295"
      unitRef="usd">44505000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzMtNC0xLTEtMzkyOA_d5be59e3-7350-4521-a984-99da3ae1f2c8"
      unitRef="usd">42417000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzQtMi0xLTEtMzkyOA_2d4ffa7f-ae94-4e30-901f-9c1ff8db54b2"
      unitRef="usd">29772000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzQtNC0xLTEtMzkyOA_1bf59991-87a2-45ba-b731-e5ef814f8416"
      unitRef="usd">9986000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzUtMi0xLTEtMzkyOA_4c7c002a-18da-4b8d-a522-e9d9860f4275"
      unitRef="usd">74277000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzUtNC0xLTEtMzkyOA_f3dc878c-3cde-404c-bc8b-59f4046b10b0"
      unitRef="usd">52403000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzYtMi0xLTEtMzkyOA_13761d1d-3bed-4a21-9810-26065224f288"
      unitRef="usd">-74277000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzYtNC0xLTEtMzkyOA_1253d4a3-3fef-4cac-97f8-373485ef21fd"
      unitRef="usd">-52403000</us-gaap:OperatingIncomeLoss>
    <vrna:GainLossFromResearchAndDevelopmentTaxCredit
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzktMi0xLTEtODk4NA_e1a2d316-89b9-468b-be7e-b8da4481cd78"
      unitRef="usd">8267000</vrna:GainLossFromResearchAndDevelopmentTaxCredit>
    <vrna:GainLossFromResearchAndDevelopmentTaxCredit
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzktNC0xLTEtODk4NA_4d5b8e49-5bdc-4db6-bbfa-177b5da5dce9"
      unitRef="usd">9283000</vrna:GainLossFromResearchAndDevelopmentTaxCredit>
    <us-gaap:InvestmentIncomeNet
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzgtMi0xLTEtMzkyOA_bc5b33cc-39a3-4c59-8e63-44a572c97bdf"
      unitRef="usd">121000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzgtNC0xLTEtMzkyOA_576a81bf-25bc-4c41-9367-992daa9fab1c"
      unitRef="usd">964000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpense
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzktMi0xLTEtMzkyOA_bdad4dfd-6f9a-4c66-b694-8538d0c9c67c"
      unitRef="usd">35000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzktNC0xLTEtMzkyOA_d6c19bb9-576a-490d-a1f0-425735dbc530"
      unitRef="usd">0</us-gaap:InterestExpense>
    <vrna:UnrealizedGainLossOnWarrants
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzExLTItMS0xLTExMjI1_122346ff-8d15-427e-95d1-fbde581583c0"
      unitRef="usd">-1136000</vrna:UnrealizedGainLossOnWarrants>
    <vrna:UnrealizedGainLossOnWarrants
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzExLTQtMS0xLTExMjI1_6eccb012-0a73-49fc-805a-14c6761d33c2"
      unitRef="usd">2066000</vrna:UnrealizedGainLossOnWarrants>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzEwLTItMS0xLTM5Mjg_5facb47b-14c6-4c24-850c-b3513219921c"
      unitRef="usd">2060000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzEwLTQtMS0xLTM5Mjg_1a845639-6aed-4a68-b431-735533fccb34"
      unitRef="usd">-399000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzEyLTItMS0xLTM5Mjg_b329a4f7-6a74-4647-9a0a-3e4a2e687031"
      unitRef="usd">9277000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzEyLTQtMS0xLTM5Mjg_93407228-935c-4436-bc93-93493858bd66"
      unitRef="usd">11914000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzEzLTItMS0xLTM5Mjg_eff17340-60df-4e71-a970-7f74a8d18e2a"
      unitRef="usd">-65000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzEzLTQtMS0xLTM5Mjg_3589c0f8-8edb-425a-9923-67fca8152762"
      unitRef="usd">-40489000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzE0LTItMS0xLTM5Mjg_ad06c86a-6424-4f18-885b-c89774fa0a90"
      unitRef="usd">146000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzE0LTQtMS0xLTM5Mjg_8d136bde-c2c1-407f-8427-b7a7465b3109"
      unitRef="usd">72000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzE1LTItMS0xLTM5Mjg_fa5e342c-4d54-4d91-b3cd-57cdb01342ce"
      unitRef="usd">-65146000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzE1LTQtMS0xLTM5Mjg_8f872b94-ccc1-4060-8c70-bd305436d882"
      unitRef="usd">-40561000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzE3LTItMS0xLTM5Mjg_95b485eb-16dd-41d9-a93d-d0d0689f7535"
      unitRef="usd">-2321000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzE3LTQtMS0xLTM5Mjg_d1861811-591d-4b07-a770-324f208c6089"
      unitRef="usd">1348000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzE4LTItMS0xLTM5Mjg_fef8ed60-73f7-4001-bbc8-bee07a937ec1"
      unitRef="usd">-67467000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzE4LTQtMS0xLTM5Mjg_3223f51e-7f88-4e6c-988f-5c728b2d4e52"
      unitRef="usd">-39213000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzE5LTItMS0xLTM5MzI_1b72646d-e556-44e5-a75a-7974c4e8b298"
      unitRef="usdPerShare">-0.25</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zNzgvZnJhZzowNjQ0ZTA5NWQyYzg0Y2IzYmU2ZDYyMDdmNDUxYTlhNS90YWJsZTozNWJkMmY5YjYxMGM0NjIwOTE5YjgwYjVhMmYxNmRmNi90YWJsZXJhbmdlOjM1YmQyZjliNjEwYzQ2MjA5MTliODBiNWEyZjE2ZGY2XzE5LTQtMS0xLTM5MzI_31947bf6-f608-460b-96d9-a90f2cfa7481"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia7bb2db7aeed4fe28f6502081a2b3fb2_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEwLTItMS0xLTQxMDA_f3cbdd08-43a7-4681-a7c8-46fb91caffa2"
      unitRef="shares">105326638</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia7bb2db7aeed4fe28f6502081a2b3fb2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEwLTQtMS0xLTQxMDA_de3ef8da-ff0e-430b-88a4-2cf0ca5f7362"
      unitRef="usd">7265000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iad4673fe986541979acd434b04d81115_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEwLTYtMS0xLTQxMDA_c15db197-f2b1-4ba7-a6c9-713e2b5446a9"
      unitRef="usd">176416000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i670b119a86454681a09079c9b183ec50_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzItOC0xLTEtMTM0NzM_78814d3d-2fa1-4e30-b251-9b7d40e5e643"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1448e425ab1943f8ae8c4d34c3c75f39_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEwLTgtMS0xLTQxMDA_da8cf25e-2129-4476-a0c2-d45de6057255"
      unitRef="usd">-3628000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i89de9796f5344884bc5b430e67f6af27_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEwLTEwLTEtMS00MTAw_38877b67-abcd-4347-98a8-f13181c58e61"
      unitRef="usd">-101192000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibc6502e2d84744a1a4f122e93a5bbedc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEwLTEyLTEtMS00MTAw_6bf70775-1b11-4e28-bcef-f6aeec5d25ab"
      unitRef="usd">78861000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7144fbaaf53a410eb5a86ca2c38da7d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzExLTEwLTEtMS00MTAw_d4cd132e-47f4-43a7-8bb4-4bb21e555a0b"
      unitRef="usd">-26000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7bffa5795b9245b9b6367166015c8f55_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzExLTEyLTEtMS00MTAw_d0db9d21-0b74-4a9a-9a11-454200694ba5"
      unitRef="usd">-26000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i218678a6acb04250abe3f3a39f5ced25_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEyLTItMS0xLTQxMDA_c38f72a7-526f-4b4b-bd56-5bd8b92f5773"
      unitRef="shares">105326638</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i218678a6acb04250abe3f3a39f5ced25_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEyLTQtMS0xLTQxMDA_ccb43d70-cd97-4e1d-aee4-a7393a22d1f1"
      unitRef="usd">7265000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i48d5ccc6c4d54da9843cb1e12f96b89a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEyLTYtMS0xLTQxMDA_49f55738-046b-497e-b1fe-59696901e4aa"
      unitRef="usd">176416000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9796b77433d84134a9500d1119aa6875_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzQtOC0xLTEtMTM0NzM_c14e5c5b-4026-4fab-933a-f183c28c2fc0"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia4209fc83abb4e68a86d37c119722d62_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEyLTgtMS0xLTQxMDA_4133ff52-0733-4913-8a58-ce4a28176b4c"
      unitRef="usd">-3628000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5d652bbdead0408181aff2dd02b415f6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEyLTEwLTEtMS00MTAw_b86c2b27-57ee-44ba-beca-cac96fe20c40"
      unitRef="usd">-101218000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5cfc9b650e8f4111a9282e4577094d50_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEyLTEyLTEtMS00MTAw_62a4ee84-7753-4ad4-87bf-2ca58abd064f"
      unitRef="usd">78835000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i33ee67ddc86e47f4b9ee46c176ae9f52_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEzLTEwLTEtMS00MTAw_f87efa84-7bdf-44b6-936a-ee53c9d38e54"
      unitRef="usd">-40561000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzEzLTEyLTEtMS00MTAw_4cbdafb0-9edb-405d-a62d-c37672c7446d"
      unitRef="usd">-40561000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i67b3a7b2ab5743e8ab134b4311cd3357_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE1LTgtMS0xLTQxMDA_c6567cc3-56c6-454d-8117-bf40bd356a5a"
      unitRef="usd">1348000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE1LTEyLTEtMS00MTAw_6284564f-c38e-4a73-a719-d56ba4f45ee0"
      unitRef="usd">1348000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icc88e7e39c7041c7aec47904740a5ffa_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE4LTYtMS0xLTQxMDA_ed448803-db3a-4359-b590-591fd49ec401"
      unitRef="usd">3119000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE4LTEyLTEtMS00MTAw_eb8dc4b1-6784-4bad-a2b8-e56aef635802"
      unitRef="usd">3119000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7cd52ee77a7948f196f2eb3dd03b56a8_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE5LTItMS0xLTQxMDA_d5560b71-702b-44a9-98d7-fd4b20ce2b4c"
      unitRef="shares">105326638</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7cd52ee77a7948f196f2eb3dd03b56a8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE5LTQtMS0xLTQxMDA_540c8daf-946b-407f-b41c-a0c4571e1309"
      unitRef="usd">7265000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2ee4138b94f24a3fb37c3a49fc55fbf0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE5LTYtMS0xLTQxMDA_3854f2ec-9512-49e6-9d49-bc584225584d"
      unitRef="usd">179535000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id772c24a98d045f687a38be7f9204a60_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzktOC0xLTEtMTM0Nzc_08e6a74e-63eb-4b3e-97f5-d8242d8cc7ae"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib4bdef42e0964c40a84e61be80f90c28_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE5LTgtMS0xLTQxMDA_7f9bb10a-01db-419e-81eb-c16855248cbe"
      unitRef="usd">-2280000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icfd1b77b4c11404ab36abf3475f7fdf7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE5LTEwLTEtMS00MTAw_81bed40a-eb55-4254-b3fe-cffd3b8bea6c"
      unitRef="usd">-141779000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE5LTEyLTEtMS00MTAw_c9d7b1d4-5c63-451d-989b-d8698ebea87d"
      unitRef="usd">42741000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ie991833e533a42c1bb4590e7c40b875d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzIwLTEwLTEtMS00MTAw_aa7472e0-8cb2-4a40-bfc7-f71130b2787d"
      unitRef="usd">-65146000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzIwLTEyLTEtMS00MTAw_7f085370-f491-4990-b57f-37b0c407714c"
      unitRef="usd">-65146000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ia30de411faa549d8a507b268ebbff4e6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzIyLTgtMS0xLTQxMDA_dc2825bf-ad9e-482b-9350-8d33ddd8bfe4"
      unitRef="usd">-2321000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzIyLTEyLTEtMS00MTAw_298f8206-2e61-4e7c-aa33-63ea0ae0dc2e"
      unitRef="usd">-2321000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1ab5f2cf37f34ce1822987a9a032bfe3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI0LTItMS0xLTQxMDA_8d563de9-3a92-41eb-8847-30cc6bf091da"
      unitRef="shares">355831184</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1ab5f2cf37f34ce1822987a9a032bfe3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI0LTQtMS0xLTQxMDA_51932485-c9cf-447b-8de3-bd094f512df2"
      unitRef="usd">22700000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2906e285538640d2ba863cc6f7be6d7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI0LTYtMS0xLTQxMDA_cf48279b-1a68-4e0e-9648-34f52f0ab6c8"
      unitRef="usd">164660000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI0LTEyLTEtMS00MTAw_fb28faeb-4e92-4ac2-9bd0-9d6a50eb70ad"
      unitRef="usd">187360000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <vrna:StockIssuedDuringPeriodSharesHeldInTreasury
      contextRef="i1ab5f2cf37f34ce1822987a9a032bfe3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE1LTItMS0xLTEyMDM4_ee308189-97a0-4db3-8532-56c818d5900c"
      unitRef="shares">25000000</vrna:StockIssuedDuringPeriodSharesHeldInTreasury>
    <vrna:StockIssuedDuringPeriodValueHeldInTreasury
      contextRef="i1ab5f2cf37f34ce1822987a9a032bfe3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE1LTQtMS0xLTEyMDM4_852b1560-fb15-4994-acf7-04680eeb71b0"
      unitRef="usd">-1700000</vrna:StockIssuedDuringPeriodValueHeldInTreasury>
    <vrna:StockIssuedDuringPeriodValueHeldInTreasury
      contextRef="i382c3abae01044dfaf69a5a01cfc1c00_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE0LTgtMS0xLTEzNDgx_c9fd44b9-cdd5-4fb8-873e-3369ffc59379"
      unitRef="usd">1700000</vrna:StockIssuedDuringPeriodValueHeldInTreasury>
    <vrna:StockIssuedDuringPeriodValueHeldInTreasury
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE1LTEyLTEtMS0xMjAzOA_d10b02ff-86cd-49e5-ae70-5f342ddbe67a"
      unitRef="usd">0</vrna:StockIssuedDuringPeriodValueHeldInTreasury>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i1ab5f2cf37f34ce1822987a9a032bfe3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI2LTItMS0xLTQxMDA_7c5e03f6-1bc2-4359-92c7-1aa82e81f7ef"
      unitRef="shares">2146624</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i1ab5f2cf37f34ce1822987a9a032bfe3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI2LTQtMS0xLTQxMDA_c86296fb-a634-4b94-90ed-9e6e30552d8c"
      unitRef="usd">129000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i2906e285538640d2ba863cc6f7be6d7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI2LTYtMS0xLTQxMDA_290f54db-9ef5-423a-8498-a96dfac045c5"
      unitRef="usd">39000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ie991833e533a42c1bb4590e7c40b875d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI2LTEwLTEtMS00MTAw_36e2a568-c31d-4387-9b3c-32595493543b"
      unitRef="usd">-125000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI2LTEyLTEtMS00MTAw_22b51f81-64a9-40d4-ba5e-c8ad244df61d"
      unitRef="usd">43000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2906e285538640d2ba863cc6f7be6d7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI3LTYtMS0xLTQxMDA_34d4285b-508d-49e6-a320-45b677500e75"
      unitRef="usd">22177000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI3LTEyLTEtMS00MTAw_e1009bf5-11c0-4f4c-be4a-56bffcc171c1"
      unitRef="usd">22177000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if62ffe34397d4178bfe3a160fb777109_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI4LTItMS0xLTQxMDA_493342f6-bba5-41c2-b1e4-2ffc1b25da9d"
      unitRef="shares">488304446</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if62ffe34397d4178bfe3a160fb777109_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI4LTQtMS0xLTQxMDA_e86448f4-4700-42d6-928a-5aff18e4adbb"
      unitRef="usd">31794000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib24f80c535f0403a800a6d65d53720d3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI4LTYtMS0xLTQxMDA_07c2b302-6b07-4116-a567-e40c6565e6e7"
      unitRef="usd">366411000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia2cc9b6147bc414a87f7dd9652e152aa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzE3LTgtMS0xLTEzNDgx_862b9f09-47df-4818-bf65-93dba87e1f1f"
      unitRef="usd">-1700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iff1f3d0564a142dbb860c4d8ca0a33d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI4LTgtMS0xLTQxMDA_7af98a36-d2a4-4cc7-aeb7-ef6c0fadf56c"
      unitRef="usd">-4601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie91783fe6f4743229a237427eba95bbe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI4LTEwLTEtMS00MTAw_fc697b7d-09f8-41c8-a9b7-b6078955c47d"
      unitRef="usd">-207050000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zODUvZnJhZzo5NGJiOTc0ZTExYWQ0YTRkYmExYWQ2YjhlNzRkZmVhNC90YWJsZTpmZTg4OGQ5ZDc4MDI0MDAzOGM5Yzk0MDkzOWQ0NTAwNi90YWJsZXJhbmdlOmZlODg4ZDlkNzgwMjQwMDM4YzljOTQwOTM5ZDQ1MDA2XzI4LTEyLTEtMS00MTAw_ffe08f78-90f7-47d2-bf57-43a11ee61209"
      unitRef="usd">184854000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzItMi0xLTEtNDgyOQ_fb8120ad-28fa-4d35-845e-5e3d22c83ff5"
      unitRef="usd">-65146000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzItNC0xLTEtNDgyOQ_23df8b8d-05d4-4458-aca5-2816a5e0a04e"
      unitRef="usd">-40561000</us-gaap:NetIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzQtMi0xLTEtNDgyOQ_9e600696-02af-40a2-8c3d-b6500561ed3f"
      unitRef="usd">2060000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzQtNC0xLTEtNDgyOQ_8c26d6eb-23a1-4741-bc4d-cafd2c6b63c3"
      unitRef="usd">-399000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzYtMi0xLTEtMTI4MjM_58cddd78-7d00-4653-8b04-8e52f2879fd2"
      unitRef="usd">10000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzYtNC0xLTEtMTI4MjM_a204a2d5-7c2e-4b02-bd51-0f4e1d30a01c"
      unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzctMi0xLTEtMTI4MjM_9473a4ce-ed82-4698-8aed-a58633a7de72"
      unitRef="usd">8000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzctNC0xLTEtMTI4MjM_cfde3933-8a62-48d6-aee9-a2e1aebf5e09"
      unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzYtMi0xLTEtMTEyMDU_f2902be9-735d-4e94-9e49-1ba0a317e043"
      unitRef="usd">1136000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzYtNC0xLTEtMTEyMDU_8aa17878-065f-44ed-bd49-6eca24f14885"
      unitRef="usd">-2066000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzUtMi0xLTEtNTE4OQ_79ea4177-6b21-4a31-9baa-2bff11f3878b"
      unitRef="usd">289000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzUtNC0xLTEtNTE4OQ_70fc75a5-2dfd-4b0f-ace7-c6a5d1860933"
      unitRef="usd">0</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzUtMi0xLTEtNDgyOQ_3821f482-db6a-464b-b932-201fa991df76"
      unitRef="usd">22177000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzUtNC0xLTEtNDgyOQ_f42d3881-eb56-431b-9aa8-be2348192a24"
      unitRef="usd">3119000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzYtMi0xLTEtNDgyOQ_eaeb691b-4d2f-437b-a49a-c24ad079f401"
      unitRef="usd">623000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzYtNC0xLTEtNDgyOQ_59f7a60c-9877-475e-a67c-a418a710717b"
      unitRef="usd">510000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzgtMi0xLTEtNDgyOQ_da81ed9d-1638-41aa-ae08-96d294cd0ec5"
      unitRef="usd">3065000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzgtNC0xLTEtNDgyOQ_6f353225-7ff8-492f-8ca0-7df3957b360b"
      unitRef="usd">158000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzktMi0xLTEtNDgyOQ_3c87dd8d-3e7b-4474-80f7-07644625f2da"
      unitRef="usd">-768000</vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent>
    <vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzktNC0xLTEtNDgyOQ_577c15b5-a560-4204-ac76-225d4f253d27"
      unitRef="usd">3929000</vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzEwLTItMS0xLTQ4Mjk_d650ef00-6f6c-437a-8b01-8c1d7a0e2d8c"
      unitRef="usd">-187000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzEwLTQtMS0xLTQ4Mjk_cd07ba64-0531-4f29-a781-f3718185ba8b"
      unitRef="usd">289000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzE3LTItMS0xLTIxMTM5_cc55ccb9-34c1-4bed-b870-59dd1fbef7c9"
      unitRef="usd">703000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzE3LTQtMS0xLTIxMTM5_d3a96f5d-600b-4aaf-ba8c-dba38c8fcb6a"
      unitRef="usd">1325000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzExLTItMS0xLTQ4Mjk_0790c668-6bea-4a67-944b-faa380d415bb"
      unitRef="usd">-1398000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzExLTQtMS0xLTQ4Mjk_af5d4ae0-4add-4cd9-8232-3c3c316b7b45"
      unitRef="usd">-1734000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzEyLTItMS0xLTQ4Mjk_80cc249e-23c8-472a-9a02-a636e65a507e"
      unitRef="usd">1940000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzEyLTQtMS0xLTQ4Mjk_7c5da896-cc20-46f2-8597-330511af4c9e"
      unitRef="usd">2454000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <vrna:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzE0LTItMS0xLTQ4Mjk_468c0173-b204-4b21-afc5-6040aa87c007"
      unitRef="usd">110000</vrna:IncreaseDecreaseInOperatingLeaseLiabilities>
    <vrna:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzE0LTQtMS0xLTQ4Mjk_43f39439-10cc-4a06-ac91-ea863fdd90cb"
      unitRef="usd">849000</vrna:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzE1LTItMS0xLTQ4Mjk_94e4e810-0767-4809-a929-e5fc13805113"
      unitRef="usd">48000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzE1LTQtMS0xLTQ4Mjk_bc4ee346-2b4e-475d-a652-a97270cdd24f"
      unitRef="usd">-137000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzE2LTItMS0xLTQ4Mjk_250d30ae-5f18-45fb-9289-958f4273f851"
      unitRef="usd">-45076000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzE2LTQtMS0xLTQ4Mjk_75e716e3-3daf-4d33-840d-2fd05ad82039"
      unitRef="usd">-42868000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzE4LTItMS0xLTQ4Mjk_81b50cc2-2ccb-428e-8f15-751dac6504d7"
      unitRef="usd">82000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzE4LTQtMS0xLTQ4Mjk_db58e4a0-4062-47a3-9636-32ebdc7e2bca"
      unitRef="usd">53000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzIwLTItMS0xLTQ4Mjk_6cd6e8b0-9ec9-4dfc-b909-a1f27beb248b"
      unitRef="usd">0</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzIwLTQtMS0xLTQ4Mjk_a3ffea3c-c38f-40cb-9147-204fc8657492"
      unitRef="usd">9777000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzIxLTItMS0xLTQ4Mjk_b6f5fbe8-b84f-4adc-9159-df1234419479"
      unitRef="usd">9792000</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzIxLTQtMS0xLTQ4Mjk_997119f9-e646-40a4-9349-da47b66629fa"
      unitRef="usd">57144000</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzIyLTItMS0xLTQ4Mjk_433e65f2-50f5-4471-a43c-5f081188a208"
      unitRef="usd">9710000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzIyLTQtMS0xLTQ4Mjk_2071c419-c346-4d00-bd3a-05d5d631ff54"
      unitRef="usd">47314000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzI0LTItMS0xLTQ4Mjk_86b2c339-8e94-4eaf-9a91-c222f6e73428"
      unitRef="usd">200156000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzI0LTQtMS0xLTQ4Mjk_acbce34c-6f4e-415b-99d0-bdb08a6f70fb"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzI1LTItMS0xLTQ4Mjk_4f69ed02-e1eb-4038-b366-0aebd1d65931"
      unitRef="usd">12748000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzI1LTQtMS0xLTQ4Mjk_58e48738-7112-479a-897b-3f1d249f2a5a"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzI5LTItMS0xLTEyMDUx_2e2c210d-0349-4dcc-ac3b-7247fbc6d964"
      unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzI5LTQtMS0xLTEyMDUx_306fba86-cb6b-47b1-8b1e-c64214cf1d26"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzMwLTItMS0xLTEyMDUx_9a60252b-4a39-4bab-a826-6067e2fa93bf"
      unitRef="usd">108000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzMwLTQtMS0xLTEyMDUx_747b6f69-0164-4c5d-bb7f-117df4ed2dfb"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzMxLTItMS0xLTEyMDUx_cc397431-fced-473a-b4ff-dd5ee51dbef6"
      unitRef="usd">43000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzMxLTQtMS0xLTEyMDUx_7da37945-c0b1-4c81-8388-0e129594ebc3"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzI3LTItMS0xLTQ4Mjk_53f76e54-1632-437e-b714-c0a4cc2bcad9"
      unitRef="usd">192343000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzI3LTQtMS0xLTQ4Mjk_f865e34d-8c0f-40ba-a4b4-d6984c9c8356"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzI4LTItMS0xLTQ4Mjk_777f942f-e6df-44f3-aff7-41226006a6ab"
      unitRef="usd">581000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzI4LTQtMS0xLTQ4Mjk_16d1472a-ab64-4482-8700-a48daddefd91"
      unitRef="usd">739000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzI5LTItMS0xLTQ4Mjk_205ce423-3255-40ed-aeaa-596f95d17978"
      unitRef="usd">157558000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzI5LTQtMS0xLTQ4Mjk_55be8210-9712-416d-9348-8cb08af43300"
      unitRef="usd">5185000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzMwLTItMS0xLTQ4Mjk_4403b9fc-063a-410e-96ce-a4fe87a2ad9e"
      unitRef="usd">30428000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibc6502e2d84744a1a4f122e93a5bbedc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzMwLTQtMS0xLTQ4Mjk_0ce5da92-6c2f-4e49-b45b-8d2e5b1a2f24"
      unitRef="usd">25243000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzMxLTItMS0xLTQ4Mjk_06afa7dd-8b97-4be3-804f-9a553d3bf166"
      unitRef="usd">187986000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzMxLTQtMS0xLTQ4Mjk_cdaf27f8-69b4-40ee-b58e-e7f8c26a2df2"
      unitRef="usd">30428000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzMzLTItMS0xLTQ4Mjk_436fe6a0-1314-407a-b90e-9fbb5b8ed015"
      unitRef="usd">8000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzMzLTQtMS0xLTQ4Mjk_fbc024c8-3311-44f3-a697-c368ea4c5402"
      unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzQyLTItMS0xLTEyODMw_0bf5719e-70b4-403d-9321-46246e85e9b8"
      unitRef="usd">7000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zOTIvZnJhZzpjOTFlZGM3NDdmMDc0NDBiYmZlNTRiN2JmZmI3YWQxMS90YWJsZTpmNzA0NGFkMzMzYzE0MzJiOTczYmVhMmU2NjBhMTk1Ni90YWJsZXJhbmdlOmY3MDQ0YWQzMzNjMTQzMmI5NzNiZWEyZTY2MGExOTU2XzQyLTQtMS0xLTEyODMw_5fa02ec9-aabf-4ea3-9cd7-f543b47ff948"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <vrna:OrganizationAndBusinessDescriptionTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMjEvZnJhZzowMDU4MjEzMTY4Yzc0ODNiODg3YTVhMDYzNTg1ZTRhMy90ZXh0cmVnaW9uOjAwNTgyMTMxNjhjNzQ4M2I4ODdhNWEwNjM1ODVlNGEzXzIxNDQwNDc2NzU5MjI1_71ecb317-dbb1-4634-84ae-c5edfecf3174">Organization and description of business operations &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Verona Pharma plc (the "Company") is incorporated and domiciled in the United Kingdom. Verona Pharma plc has two wholly-owned subsidiaries, Verona Pharma, Inc., a Delaware corporation and Rhinopharma Limited ("Rhinopharma"), a Canadian company. The address of the registered office is 1 Central Square, Cardiff, CF10 1FS, United Kingdom.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company is a clinical-stage biopharmaceutical group focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The Company listed its American Depositary Shares ("ADSs") on Nasdaq in April, 2017, which trade under the symbol &#x201c;VRNA". The Company&#x2019;s ordinary shares were also listed on the Alternative Investment Market of the London Stock Exchange (&#x201c;AIM&#x201d;) until October 30, 2020, when the shares were delisted from AIM in an effort to enhance liquidity of trading by combining all transactions on Nasdaq and to reduce costs through removing duplicative listing and compliance fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company has incurred recurring losses and negative cashflows from operations since inception, and has an accumulated deficit of $207.1&#160;million as of December 31, 2020. The Company expects to incur additional losses and negative cash flows from operations until its products potentially gain regulatory approval and reach commercial profitability, if at all.&lt;/span&gt;&lt;/div&gt;In July, 2020, the Company raised $200&#160;million in a private placement (the "Private Placement"), with net proceeds after transaction related fees and expenses of $185.5&#160;million. Additionally, in November, 2020, the Company entered into a term loan facility with Silicon Valley Bank for up to $30&#160;million (the &#x201c;Term Loan&#x201d;). As of December 31, 2020, $5&#160;million had been drawn down.</vrna:OrganizationAndBusinessDescriptionTextBlock>
    <vrna:NumberOfWhollyOwnedSubsidiaries
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMjEvZnJhZzowMDU4MjEzMTY4Yzc0ODNiODg3YTVhMDYzNTg1ZTRhMy90ZXh0cmVnaW9uOjAwNTgyMTMxNjhjNzQ4M2I4ODdhNWEwNjM1ODVlNGEzXzIxNDQwNDc2NzU5MjMx_f46a1986-08f7-4105-84d7-258c4f0541dc"
      unitRef="subsidiary">2</vrna:NumberOfWhollyOwnedSubsidiaries>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMjEvZnJhZzowMDU4MjEzMTY4Yzc0ODNiODg3YTVhMDYzNTg1ZTRhMy90ZXh0cmVnaW9uOjAwNTgyMTMxNjhjNzQ4M2I4ODdhNWEwNjM1ODVlNGEzXzIwMzQwOTY1MTM0Nzky_c1f0da2e-b5da-482b-9e99-4ec98ddaf138"
      unitRef="usd">-207100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i9dd30f2681444b31a30cecbb105a8d12_D20200717-20200717"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMjEvZnJhZzowMDU4MjEzMTY4Yzc0ODNiODg3YTVhMDYzNTg1ZTRhMy90ZXh0cmVnaW9uOjAwNTgyMTMxNjhjNzQ4M2I4ODdhNWEwNjM1ODVlNGEzXzIwMzQwOTY1MTM0ODE4_d67b4ea1-f1eb-4ae9-aef9-d3115c2e5552"
      unitRef="usd">200000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="i84e00d94b1de4386a6170826d98862d2_D20200717-20200717"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMjEvZnJhZzowMDU4MjEzMTY4Yzc0ODNiODg3YTVhMDYzNTg1ZTRhMy90ZXh0cmVnaW9uOjAwNTgyMTMxNjhjNzQ4M2I4ODdhNWEwNjM1ODVlNGEzXzIwMzQwOTY1MTM0ODMy_1e88e6b6-3761-456d-80da-2048da0fc0d5"
      unitRef="usd">185500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2f3b17ae809741d291cfb524e558c10e_I20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMjEvZnJhZzowMDU4MjEzMTY4Yzc0ODNiODg3YTVhMDYzNTg1ZTRhMy90ZXh0cmVnaW9uOjAwNTgyMTMxNjhjNzQ4M2I4ODdhNWEwNjM1ODVlNGEzXzIwMzQwOTY1MTM0ODQ4_596e76f1-fe15-4383-b0fa-636c72e4f6a0"
      unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i46b0f32ad5df416e83423bbabba5a3b9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMjEvZnJhZzowMDU4MjEzMTY4Yzc0ODNiODg3YTVhMDYzNTg1ZTRhMy90ZXh0cmVnaW9uOjAwNTgyMTMxNjhjNzQ4M2I4ODdhNWEwNjM1ODVlNGEzXzIwMzQwOTY1MTM0ODYx_009083fa-ab07-4796-ac05-2ce9f4c3c482"
      unitRef="usd">5000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNjY0_81b0f732-900f-40c3-8c35-5ea741009086">Basis of Presentation and Summary of Significant Accounting policies&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Basis of presentation and consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The consolidated financial statements include the accounts of Verona Pharma plc and its wholly-owned subsidiaries Verona Pharma, Inc. and Rhinopharma. All inter-company balances and transactions have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. ("US GAAP") and the following accounting policies have been consistently applied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Previously, the Company prepared its consolidated financial statements in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;At the end of the second quarter of 2020, the Company determined that it no longer qualified as a Foreign Private Issuer under SEC rules. As a result, beginning January 1, 2020, the Company is required to report with the SEC on domestic forms and comply with domestic company rules in the United States. The transition to US GAAP was made retrospectively for all periods from the Company&#x2019;s inception.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses, the fair value of share-based compensation and the fair value of warrants. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Business combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company applies the acquisition method to account for business combinations. The consideration transferred for the acquisition of a subsidiary is the fair value of the assets transferred, the liabilities incurred to the former owners of the acquiree and the equity interests issued by the Company. The consideration transferred includes the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;fair value of any asset or liability resulting from a contingent consideration arrangement. The excess of the cost of acquisition over the fair value of the Company's share of the identifiable net assets acquired is recorded as goodwill. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Identifiable ass&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;ets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date. Acquisition-related costs are expensed as incurred and included in administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company considers all highly liquid investments purchased with original maturities of ninety days or less at acquisition to be cash equivalents. Cash and cash equivalents includes deposits held at call with banks, term deposits with maturities of less than three months at inception, and in money market funds investing in U.S. and U.K. government debt and liquid securities from highly rated institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Short-term investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Short-term investments include fixed term deposits held at banks with original maturities between three months and a year. They are classified as loans and receivables and are measured at amortized cost using the effective interest method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Furniture and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Furniture and equipment comprise office furniture and computer equipment and are stated at cost less accumulated depreciation, which is calculated on a straight-line basis over the expected useful economic lives, generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNjc4_366b91a1-c260-4eab-9b78-d6ac9d5b8954"&gt;two&lt;/span&gt; to five years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Goodwill consists of goodwill related to the acquisition of Rhinopharma. Goodwill is not amortized but periodically tested for impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company reviews long lived assets for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of assets may not be fully recoverable. The Company initially compares the market capitalization of the Company to the book value of its assets. If the value of the market capitalization does not support the valuation of the assets, the Company reviews estimates of the cash flows over the remaining lives of its other intangible assets, or related group of assets where applicable, in measuring whether the assets to be held and used will be realizable. In the event of impairment, the Company would discount the future cash flows using its then estimated incremental borrowing rate to estimate the amount of the impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Effective January 1, 2019, the Company adopted ASC 842, Leases (&#x201c;ASC842&#x201d;) using the modified retrospective transition approach and did not restate comparative periods. The Company determines if an arrangement is a lease at inception. Leases are classified as operating or finance leases in accordance with the recognition criteria in ASC 842-20-25. The Company&#x2019;s lease portfolio consists entirely of operating leases as of December 31, 2020. The Company&#x2019;s leases do not contain any material residual value guarantees or material restrictive covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Ligand agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In 2006 the Company acquired Rhinopharma and assumed contingent liabilities owed to Ligand UK Development Limited (&#x201c;Ligand&#x201d;) (formerly Vernalis Development Limited). The Company refers to the assignment and license agreement as the Ligand Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Ligand assigned to the Company all of its rights to certain patents and patent applications relating to ensifentrine and related compounds (the "Ligand Patents") and an exclusive, worldwide, royalty-bearing license under certain Ligand know-how to develop, manufacture and commercialize products (the "Licensed Products") developed using Ligand Patents, Ligand know-how and the physical stock of certain compounds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company is obligated to pay a milestone payment on obtaining the first approval of any regulatory authority for the commercialization of a Licensed Product, low single digit royalties based on the future sales performance of all Licensed Products and a portion equal to a mid-twenty percent of any consideration received from any sub-licensees for the Ligand Patents and for Ligand know-how. Royalties payable are based on the future sales performance so the amount payable is unlimited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;At the time each contingency is resolved, the Company will record the contingent consideration payment (or payable) in connection with the Ligand Agreement as an expense and will classify it within R&amp;amp;D expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Research and development costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) costs are expensed as incurred. Research and development expenses include salaries, share-based compensation and benefits of employees, and other costs related to the Company&#x2019;s R&amp;amp;D activities, including contracts with clinical research organizations and contract manufacturers. As part of the process of preparing financial statements the Company is required to estimate its expenses resulting from its obligation under contracts with vendors and consultants and clinical site agreements in connection with its R&amp;amp;D efforts. The financial terms of these contracts are subject to negotiations which vary contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company&#x2019;s objective is to reflect the appropriate clinical trial expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the trials and other development activities measured by patient progression and the timing of various aspects of the trial. The Company determines prepaid and accrual estimates through discussions with applicable personnel and outside service providers as to the progress of clinical trials, or other services completed. During the course of a clinical trial, the Company adjusts its rate of clinical trial expense recognition if actual results differ from its estimates. The Company makes estimates of its prepaid and accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. The Company&#x2019;s clinical trial prepaid and accrual expense is dependent upon the timely and accurate reporting of study recruitment from contract research organizations and activities carried out by other third-party vendors as well as the timely processing of any change orders from the contract research organizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company has a share-based compensation plan under which various types of equity-based awards may be granted, including stock options and restricted stock units (RSUs). The fair value of share options and RSUs, which are subject to service conditions with graded vesting, are recognized as compensation expense using the cliff vesting method; f&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;orfeitures are recognized as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company uses the fair-value based method to determine compensation for all arrangements under which employees receive shares. The fair value of each option and RSU is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatility is based on the historical volatility of the Company&#x2019;s ordinary shares over the expected term of the options. The expected term of options granted is derived using the simplified method, which computes the expected term as the average of the sum of the vesting term plus the contract term. Historically the risk-free rate has been based on the appropriate U.K. government debt yield. After delisting its Ordinary shares from AIM on October 30, 2020, the Company began using U.S. government debt yields.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Details of the assumptions used are set out in note 11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Other income - United Kingdom R&amp;amp;D tax credits &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Other operating income relates to R&amp;amp;D tax credits receivable in the UK. As a company that carries out extensive research and development activities, Verona is subject to the UK R&amp;amp;D Small and Medium Enterprise (&#x201c;SME&#x201d;) Program. Qualifying expenditures largely comprise employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which it does not receive income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Tax credits related to the SME Program are received as cash and are recorded as other income, as they are akin to grant income, in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company accounts for income taxes in accordance with ASC 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC 740&#x201d;). This Topic prescribes the use of the liability method, whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. ASC 740 establishes a single model to address accounting for uncertain tax positions. ASC 740 clarified the accounting for income taxes by prescribing the minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. The Company has no uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company accounts for comprehensive loss in accordance with ASC 220, &#x201c;Income Statement - Reporting Comprehensive Income&#x201d;. Comprehensive income represents all changes in stockholders&#x2019; equity during the period except those resulting from investments by, or distributions to, stockholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company has one operating and reportable segment, pharmaceutical development. The Company&#x2019;s long-lived assets are held in the United Kingdom.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Foreign Currencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Reporting currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company&#x2019;s reporting currency is U.S. dollars. Prior to July 1, 2020, Verona Pharma plc&#x2019;s functional currency was pounds sterling and its financial statements were translated to U.S. dollars. The statement of comprehensive income was translated at average rates for the period, assets and liabilities at the balance sheet date exchange rate and equity balances at historical rates. Translation differences were recorded in accumulated other comprehensive income / (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Functional currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company's consolidated financial statements are measured using the currency of the primary economic environment in which the entity operates, which was pounds sterling for Verona Pharma plc until June 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In the six months to June 30, 2020, management changes resulted in lower people costs being paid in pounds sterling. Following the Private Placement the Company entered into contracts to commence Phase 3 trials for ensifentrine and the majority of the costs are incurred in U.S. dollars. Management reviewed budgeted activities over the next five years and identified that the majority of costs from the second half of 2020 onwards will be incurred in U.S. dollars. Furthermore, the Private Placement in July, 2020, raised funds in U.S. dollars and having delisted from AIM any future fundraises will be in U.S. dollars. Also, the commercial focus of Company is the U.S. market.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;As a consequence, management determined the Company's functional currency changed from pounds sterling to U.S. dollars and this has been accounted for prospectively from July 1, 2020. To convert Verona Pharma plc&#x2019;s books and records into U.S. dollars income and expenses were translated at average rates, assets and liabilities at the June 30, 2020, exchange rate and equity balances at historical rates. Translation differences were recorded in accumulated other comprehensive income / (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Treasury shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In the year ended December 31, 2020, the Company incorporated a trust to facilitate the acquisition of shares, by or for the benefit of employees and former employees. The Company issued 25&#160;million ordinary shares (equivalent to 3.125&#160;million ADSs) to cover expected shares issued upon the vesting of share awards to employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company has the indirect ability to control the trust as trustees are required to act in accordance with the trust deed and because the Company controls the issuance of shares to cover awards. As a consequence, the trust is consolidated into the Company&#x2019;s consolidated financial statements. The shares that were issued to the trust that have not been issued to employees to satisfy vesting of share awards are included in the Consolidated Balance Sheet as treasury shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;US GAAP defines fair value and requires companies to establish a framework for measuring fair value and disclosure about fair value measurements using a three-tier approach. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Our financial instruments include cash equivalents, short-term investments, other assets, accounts payable and accrued expenses and other liabilities. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgement and therefore cannot be determined with precision. The carrying amounts of these instruments are considered to be representative of their fair values because of their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Concentration of credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents, bank deposits and certain receivables. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company holds cash and cash equivalents with highly rated financial institutions and in highly rated money market funds and the Company has not experienced any significant credit losses in these accounts and does not believe the Company is exposed to any significant credit risk on these instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In February 2016, the FASB issued ASU No. 2016-02, &#x201c;Leases&#x201d; (Topic 842) (&#x201c;ASC 842&#x201d;). The standard requires lessees to recognize almost all leases on the balance sheet as right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities, and requires leases to be classified as either an operating or a finance type lease. The standard excludes leases of intangible assets or inventory. The standard became effective for the Company beginning January 1, 2019. The Company adopted ASC 842 using the modified retrospective approach, by applying the new standard to all leases existing at the date of initial application. Results and disclosure requirements for reporting periods beginning after January 1, 2019, are presented under ASC 842, while prior period amounts have not been adjusted and continue to be reported in accordance with our historical accounting under ASC 840 &#x201c;Leases&#x201d;. The Company elected the package of practical expedients permitted under ASC 842, which also allowed the Company to carry forward historical lease classifications. The Company also elected the practical expedient related to treating lease and non-lease components as a single lease component for all equipment leases as well as electing a policy exclusion permitting leases with an original lease term of less than one year to be excluded from the ROU assets and lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;As a result of the adoption of ASC 842 on January 1, 2019, the Company recorded an operating lease ROU asset of $415&#160;thousand and an operating lease liability of $441&#160;thousand. The adoption increased opening accumulated losses by $26&#160;thousand but did not impact the Company's prior year financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Under ASC 842, the Company determines if an arrangement is a lease at inception. ROU ass&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;ets and liabilities are recognized at the commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;As the Company's leases do not provide an implicit rate, the Company determined the incremental borrowing rate in determining the present value of lease payments. The ROU assets also include any lease payments made prior to commencement and are recorded net of any lease incentives received. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company&#x2019;s lease terms may include options to extend or terminate the lease. When it is reasonably certain the Company will exercise such options the lease will be recognized as a liability and a corresponding ROU asset also recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Operating leases are included in operating lease ROU assets and current and non-current operating lease liabilities, on the Company's consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The FASB issued ASU 2020-04 to provide optional expedients and exceptions for applying US GAAP to contract modifications, hedging relationships, and other transactions affected by the anticipated transition away from LIBOR. There is no material impact of the adoption of ASU 2020-04 on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Recently issued accounting pronouncements, not yet adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (&#x201c;ASU 2019-10&#x201d;). The purpose of this amendment is to create a two tier rollout of major updates, staggering the effective dates between larger public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies (&#x201c;SRCs&#x201d;), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies will have an effective date for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until the earlier of fiscal periods beginning after December 15, 2022. Under the current SEC definitions, we meet the definition of an SRC as of the ASU 2019-10 issuance date and are deferring adoption for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. We are currently evaluating the impact of the adoption of ASU 2016-13 on our consolidated financial statements, but do not believe the adoption of this standard will have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNjY1_d24a4efc-39e7-4c2a-828d-75461626bb3f">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Basis of presentation and consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The consolidated financial statements include the accounts of Verona Pharma plc and its wholly-owned subsidiaries Verona Pharma, Inc. and Rhinopharma. All inter-company balances and transactions have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. ("US GAAP") and the following accounting policies have been consistently applied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Previously, the Company prepared its consolidated financial statements in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;At the end of the second quarter of 2020, the Company determined that it no longer qualified as a Foreign Private Issuer under SEC rules. As a result, beginning January 1, 2020, the Company is required to report with the SEC on domestic forms and comply with domestic company rules in the United States. The transition to US GAAP was made retrospectively for all periods from the Company&#x2019;s inception.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNjY2_0432018e-7a84-4e9c-ac89-ac3bb11cc46c">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses, the fair value of share-based compensation and the fair value of warrants. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNjY3_85387915-ef26-4f2d-beb4-2346fd86a952">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Business combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company applies the acquisition method to account for business combinations. The consideration transferred for the acquisition of a subsidiary is the fair value of the assets transferred, the liabilities incurred to the former owners of the acquiree and the equity interests issued by the Company. The consideration transferred includes the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;fair value of any asset or liability resulting from a contingent consideration arrangement. The excess of the cost of acquisition over the fair value of the Company's share of the identifiable net assets acquired is recorded as goodwill. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Identifiable ass&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;ets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date. Acquisition-related costs are expensed as incurred and included in administrative expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNjY4_98ee18d0-7410-4280-bcf4-6b2a04053da1">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company considers all highly liquid investments purchased with original maturities of ninety days or less at acquisition to be cash equivalents. Cash and cash equivalents includes deposits held at call with banks, term deposits with maturities of less than three months at inception, and in money market funds investing in U.S. and U.K. government debt and liquid securities from highly rated institutions.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNjY5_fb20f96f-2de2-4390-8cba-8bcfe9c87612">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Short-term investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Short-term investments include fixed term deposits held at banks with original maturities between three months and a year. They are classified as loans and receivables and are measured at amortized cost using the effective interest method.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNjcw_5a53147b-b0c5-4fb6-9c3e-b802db58aaa9">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Furniture and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Furniture and equipment comprise office furniture and computer equipment and are stated at cost less accumulated depreciation, which is calculated on a straight-line basis over the expected useful economic lives, generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNjc4_366b91a1-c260-4eab-9b78-d6ac9d5b8954"&gt;two&lt;/span&gt; to five years.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i94c8c6508a314e10be6ed1a9414e5627_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNjk2_689dd258-bf83-451b-bde5-d35cffe01131">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzIy_2a6a587c-2e8c-4417-94f5-906828893856">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Goodwill consists of goodwill related to the acquisition of Rhinopharma. Goodwill is not amortized but periodically tested for impairment.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzIz_e760aca7-c8aa-4394-b5de-570698801ad0">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company reviews long lived assets for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of assets may not be fully recoverable. The Company initially compares the market capitalization of the Company to the book value of its assets. If the value of the market capitalization does not support the valuation of the assets, the Company reviews estimates of the cash flows over the remaining lives of its other intangible assets, or related group of assets where applicable, in measuring whether the assets to be held and used will be realizable. In the event of impairment, the Company would discount the future cash flows using its then estimated incremental borrowing rate to estimate the amount of the impairment.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzI0_0a5a7c14-7517-4f52-84a0-5eef678091b0">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Effective January 1, 2019, the Company adopted ASC 842, Leases (&#x201c;ASC842&#x201d;) using the modified retrospective transition approach and did not restate comparative periods. The Company determines if an arrangement is a lease at inception. Leases are classified as operating or finance leases in accordance with the recognition criteria in ASC 842-20-25. The Company&#x2019;s lease portfolio consists entirely of operating leases as of December 31, 2020. The Company&#x2019;s leases do not contain any material residual value guarantees or material restrictive covenants.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzI1_e3c25a1d-2ea7-407e-b79c-70be520ae539">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Ligand agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In 2006 the Company acquired Rhinopharma and assumed contingent liabilities owed to Ligand UK Development Limited (&#x201c;Ligand&#x201d;) (formerly Vernalis Development Limited). The Company refers to the assignment and license agreement as the Ligand Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Ligand assigned to the Company all of its rights to certain patents and patent applications relating to ensifentrine and related compounds (the "Ligand Patents") and an exclusive, worldwide, royalty-bearing license under certain Ligand know-how to develop, manufacture and commercialize products (the "Licensed Products") developed using Ligand Patents, Ligand know-how and the physical stock of certain compounds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company is obligated to pay a milestone payment on obtaining the first approval of any regulatory authority for the commercialization of a Licensed Product, low single digit royalties based on the future sales performance of all Licensed Products and a portion equal to a mid-twenty percent of any consideration received from any sub-licensees for the Ligand Patents and for Ligand know-how. Royalties payable are based on the future sales performance so the amount payable is unlimited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;At the time each contingency is resolved, the Company will record the contingent consideration payment (or payable) in connection with the Ligand Agreement as an expense and will classify it within R&amp;amp;D expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzI2_707c0406-a345-4712-9956-8ff5b8124f60">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Research and development costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) costs are expensed as incurred. Research and development expenses include salaries, share-based compensation and benefits of employees, and other costs related to the Company&#x2019;s R&amp;amp;D activities, including contracts with clinical research organizations and contract manufacturers. As part of the process of preparing financial statements the Company is required to estimate its expenses resulting from its obligation under contracts with vendors and consultants and clinical site agreements in connection with its R&amp;amp;D efforts. The financial terms of these contracts are subject to negotiations which vary contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company&#x2019;s objective is to reflect the appropriate clinical trial expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the trials and other development activities measured by patient progression and the timing of various aspects of the trial. The Company determines prepaid and accrual estimates through discussions with applicable personnel and outside service providers as to the progress of clinical trials, or other services completed. During the course of a clinical trial, the Company adjusts its rate of clinical trial expense recognition if actual results differ from its estimates. The Company makes estimates of its prepaid and accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. The Company&#x2019;s clinical trial prepaid and accrual expense is dependent upon the timely and accurate reporting of study recruitment from contract research organizations and activities carried out by other third-party vendors as well as the timely processing of any change orders from the contract research organizations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzI3_b00a8528-00f7-4b76-adcf-02262dc7d2b8">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company has a share-based compensation plan under which various types of equity-based awards may be granted, including stock options and restricted stock units (RSUs). The fair value of share options and RSUs, which are subject to service conditions with graded vesting, are recognized as compensation expense using the cliff vesting method; f&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;orfeitures are recognized as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company uses the fair-value based method to determine compensation for all arrangements under which employees receive shares. The fair value of each option and RSU is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatility is based on the historical volatility of the Company&#x2019;s ordinary shares over the expected term of the options. The expected term of options granted is derived using the simplified method, which computes the expected term as the average of the sum of the vesting term plus the contract term. Historically the risk-free rate has been based on the appropriate U.K. government debt yield. After delisting its Ordinary shares from AIM on October 30, 2020, the Company began using U.S. government debt yields.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <vrna:GovernmentTaxCreditsPolicyPolicyTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzMw_0906c519-34c7-45ac-9230-4650adfda985">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Other income - United Kingdom R&amp;amp;D tax credits &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Other operating income relates to R&amp;amp;D tax credits receivable in the UK. As a company that carries out extensive research and development activities, Verona is subject to the UK R&amp;amp;D Small and Medium Enterprise (&#x201c;SME&#x201d;) Program. Qualifying expenditures largely comprise employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which it does not receive income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Tax credits related to the SME Program are received as cash and are recorded as other income, as they are akin to grant income, in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</vrna:GovernmentTaxCreditsPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzI4_287e7d0d-a48d-4852-a80f-b333a4ebdfa4">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company accounts for income taxes in accordance with ASC 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC 740&#x201d;). This Topic prescribes the use of the liability method, whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. ASC 740 establishes a single model to address accounting for uncertain tax positions. ASC 740 clarified the accounting for income taxes by prescribing the minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. The Company has no uncertain tax positions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzMx_fb66e492-ad9f-4652-bece-f9c228d6fe6f">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company accounts for comprehensive loss in accordance with ASC 220, &#x201c;Income Statement - Reporting Comprehensive Income&#x201d;. Comprehensive income represents all changes in stockholders&#x2019; equity during the period except those resulting from investments by, or distributions to, stockholders.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzMy_f7cd402e-c7d0-4ab0-b554-90e1f1ef4e80">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company has one operating and reportable segment, pharmaceutical development. The Company&#x2019;s long-lived assets are held in the United Kingdom.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzg3_813c9345-417c-4828-8089-f4977da28705"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzg3_ee5fcb2d-1e02-4b13-8112-8b66579bca9a"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzMz_162acff9-3c16-4772-94b8-84bb216ebbcc">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Foreign Currencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Reporting currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company&#x2019;s reporting currency is U.S. dollars. Prior to July 1, 2020, Verona Pharma plc&#x2019;s functional currency was pounds sterling and its financial statements were translated to U.S. dollars. The statement of comprehensive income was translated at average rates for the period, assets and liabilities at the balance sheet date exchange rate and equity balances at historical rates. Translation differences were recorded in accumulated other comprehensive income / (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Functional currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company's consolidated financial statements are measured using the currency of the primary economic environment in which the entity operates, which was pounds sterling for Verona Pharma plc until June 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In the six months to June 30, 2020, management changes resulted in lower people costs being paid in pounds sterling. Following the Private Placement the Company entered into contracts to commence Phase 3 trials for ensifentrine and the majority of the costs are incurred in U.S. dollars. Management reviewed budgeted activities over the next five years and identified that the majority of costs from the second half of 2020 onwards will be incurred in U.S. dollars. Furthermore, the Private Placement in July, 2020, raised funds in U.S. dollars and having delisted from AIM any future fundraises will be in U.S. dollars. Also, the commercial focus of Company is the U.S. market.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;As a consequence, management determined the Company's functional currency changed from pounds sterling to U.S. dollars and this has been accounted for prospectively from July 1, 2020. To convert Verona Pharma plc&#x2019;s books and records into U.S. dollars income and expenses were translated at average rates, assets and liabilities at the June 30, 2020, exchange rate and equity balances at historical rates. Translation differences were recorded in accumulated other comprehensive income / (loss).&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwODkwNzIxMDkxNjk5_76417b82-ef7e-4119-bb5b-f51ac72752f4">Treasury shares&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In the year ended December 31, 2020, the Company incorporated a trust to facilitate the acquisition of shares, by or for the benefit of employees and former employees. The Company issued 25&#160;million ordinary shares (equivalent to 3.125&#160;million ADSs) to cover expected shares issued upon the vesting of share awards to employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company has the indirect ability to control the trust as trustees are required to act in accordance with the trust deed and because the Company controls the issuance of shares to cover awards. As a consequence, the trust is consolidated into the Company&#x2019;s consolidated financial statements. The shares that were issued to the trust that have not been issued to employees to satisfy vesting of share awards are included in the Consolidated Balance Sheet as treasury shares.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <vrna:StockIssuedDuringPeriodSharesHeldInTreasury
      contextRef="i1ab5f2cf37f34ce1822987a9a032bfe3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwODkwNzIxMDkxNzI2_c9c47e73-0594-4ea8-91f0-30beb1d176d0"
      unitRef="shares">25000000</vrna:StockIssuedDuringPeriodSharesHeldInTreasury>
    <vrna:StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares
      contextRef="i1ab5f2cf37f34ce1822987a9a032bfe3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwODkwNzIxMDkxNzM4_5e71e9f5-d958-4752-84ea-759705968343"
      unitRef="shares">3125000</vrna:StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzM0_43f3caa2-a594-4ec4-b8a3-e44e80430a48">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;US GAAP defines fair value and requires companies to establish a framework for measuring fair value and disclosure about fair value measurements using a three-tier approach. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Our financial instruments include cash equivalents, short-term investments, other assets, accounts payable and accrued expenses and other liabilities. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgement and therefore cannot be determined with precision. The carrying amounts of these instruments are considered to be representative of their fair values because of their short-term nature.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzM1_5e64a9e1-461b-47c8-a7fd-4244f78a59e7">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Concentration of credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents, bank deposits and certain receivables. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company holds cash and cash equivalents with highly rated financial institutions and in highly rated money market funds and the Company has not experienced any significant credit losses in these accounts and does not believe the Company is exposed to any significant credit risk on these instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzM3_cdc601ec-0951-41ea-9771-d3be3103cb8d">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In February 2016, the FASB issued ASU No. 2016-02, &#x201c;Leases&#x201d; (Topic 842) (&#x201c;ASC 842&#x201d;). The standard requires lessees to recognize almost all leases on the balance sheet as right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities, and requires leases to be classified as either an operating or a finance type lease. The standard excludes leases of intangible assets or inventory. The standard became effective for the Company beginning January 1, 2019. The Company adopted ASC 842 using the modified retrospective approach, by applying the new standard to all leases existing at the date of initial application. Results and disclosure requirements for reporting periods beginning after January 1, 2019, are presented under ASC 842, while prior period amounts have not been adjusted and continue to be reported in accordance with our historical accounting under ASC 840 &#x201c;Leases&#x201d;. The Company elected the package of practical expedients permitted under ASC 842, which also allowed the Company to carry forward historical lease classifications. The Company also elected the practical expedient related to treating lease and non-lease components as a single lease component for all equipment leases as well as electing a policy exclusion permitting leases with an original lease term of less than one year to be excluded from the ROU assets and lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;As a result of the adoption of ASC 842 on January 1, 2019, the Company recorded an operating lease ROU asset of $415&#160;thousand and an operating lease liability of $441&#160;thousand. The adoption increased opening accumulated losses by $26&#160;thousand but did not impact the Company's prior year financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Under ASC 842, the Company determines if an arrangement is a lease at inception. ROU ass&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;ets and liabilities are recognized at the commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;As the Company's leases do not provide an implicit rate, the Company determined the incremental borrowing rate in determining the present value of lease payments. The ROU assets also include any lease payments made prior to commencement and are recorded net of any lease incentives received. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company&#x2019;s lease terms may include options to extend or terminate the lease. When it is reasonably certain the Company will exercise such options the lease will be recognized as a liability and a corresponding ROU asset also recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Operating leases are included in operating lease ROU assets and current and non-current operating lease liabilities, on the Company's consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The FASB issued ASU 2020-04 to provide optional expedients and exceptions for applying US GAAP to contract modifications, hedging relationships, and other transactions affected by the anticipated transition away from LIBOR. There is no material impact of the adoption of ASU 2020-04 on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Recently issued accounting pronouncements, not yet adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (&#x201c;ASU 2019-10&#x201d;). The purpose of this amendment is to create a two tier rollout of major updates, staggering the effective dates between larger public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies (&#x201c;SRCs&#x201d;), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies will have an effective date for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until the earlier of fiscal periods beginning after December 15, 2022. Under the current SEC definitions, we meet the definition of an SRC as of the ASU 2019-10 issuance date and are deferring adoption for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. We are currently evaluating the impact of the adoption of ASU 2016-13 on our consolidated financial statements, but do not believe the adoption of this standard will have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i87d649c393ad4d1b95b36d916dbd127f_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzU0_10a4abe2-84ee-499a-9cd9-ca7074faaecb"
      unitRef="usd">415000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i87d649c393ad4d1b95b36d916dbd127f_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzM5_42fca009-735e-4044-bd83-212596b5880d"
      unitRef="usd">441000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquity
      contextRef="i06f7637896b74a8e922bb5f0526d2b57_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNzY5_d2b2e282-aff9-4673-a728-7d32b3496c46"
      unitRef="usd">-26000</us-gaap:StockholdersEquity>
    <vrna:PrepaidExpenseDisclosureTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNzkvZnJhZzplODQ4NzQ0NGE1Mzg0ZmFjYWQxMTAzYTg4Zjc3MDc4NS90ZXh0cmVnaW9uOmU4NDg3NDQ0YTUzODRmYWNhZDExMDNhODhmNzcwNzg1XzIxNDQwNDc2NzQyNTcx_50a0b6e0-705a-4128-a392-f5f1d110fef7">Prepaid expenses &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Prepaid expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial and other development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</vrna:PrepaidExpenseDisclosureTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNzkvZnJhZzplODQ4NzQ0NGE1Mzg0ZmFjYWQxMTAzYTg4Zjc3MDc4NS90ZXh0cmVnaW9uOmU4NDg3NDQ0YTUzODRmYWNhZDExMDNhODhmNzcwNzg1XzIxNDQwNDc2NzQyNTcy_5e856a41-f5c7-467e-a5e4-e21b02e1eac5">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Prepaid expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial and other development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <vrna:PrepaidResearchAndDevelopmentFeesCurrent
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNzkvZnJhZzplODQ4NzQ0NGE1Mzg0ZmFjYWQxMTAzYTg4Zjc3MDc4NS90YWJsZTo1YzQxYmU0M2E4MGY0NzQzOWNkNjljOTAzOTdhZDhhMS90YWJsZXJhbmdlOjVjNDFiZTQzYTgwZjQ3NDM5Y2Q2OWM5MDM5N2FkOGExXzItMi0xLTEtMTIxMzk_1eb65228-99c7-4f4a-995b-190be5c6e3fa"
      unitRef="usd">2551000</vrna:PrepaidResearchAndDevelopmentFeesCurrent>
    <vrna:PrepaidResearchAndDevelopmentFeesCurrent
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNzkvZnJhZzplODQ4NzQ0NGE1Mzg0ZmFjYWQxMTAzYTg4Zjc3MDc4NS90YWJsZTo1YzQxYmU0M2E4MGY0NzQzOWNkNjljOTAzOTdhZDhhMS90YWJsZXJhbmdlOjVjNDFiZTQzYTgwZjQ3NDM5Y2Q2OWM5MDM5N2FkOGExXzItNC0xLTEtMTIxMzk_926177d3-172f-467d-b09d-cb7612cf1765"
      unitRef="usd">874000</vrna:PrepaidResearchAndDevelopmentFeesCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNzkvZnJhZzplODQ4NzQ0NGE1Mzg0ZmFjYWQxMTAzYTg4Zjc3MDc4NS90YWJsZTo1YzQxYmU0M2E4MGY0NzQzOWNkNjljOTAzOTdhZDhhMS90YWJsZXJhbmdlOjVjNDFiZTQzYTgwZjQ3NDM5Y2Q2OWM5MDM5N2FkOGExXzItMi0xLTEtODc0NA_ef92a558-d1ec-45e6-9799-e84fbe2d7b2f"
      unitRef="usd">1701000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNzkvZnJhZzplODQ4NzQ0NGE1Mzg0ZmFjYWQxMTAzYTg4Zjc3MDc4NS90YWJsZTo1YzQxYmU0M2E4MGY0NzQzOWNkNjljOTAzOTdhZDhhMS90YWJsZXJhbmdlOjVjNDFiZTQzYTgwZjQ3NDM5Y2Q2OWM5MDM5N2FkOGExXzItNC0xLTEtODc0NA_5abfd2f6-55fb-4519-a799-16dc4f3464e1"
      unitRef="usd">534000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNzkvZnJhZzplODQ4NzQ0NGE1Mzg0ZmFjYWQxMTAzYTg4Zjc3MDc4NS90YWJsZTo1YzQxYmU0M2E4MGY0NzQzOWNkNjljOTAzOTdhZDhhMS90YWJsZXJhbmdlOjVjNDFiZTQzYTgwZjQ3NDM5Y2Q2OWM5MDM5N2FkOGExXzQtMi0xLTEtNDgxMQ_c3538e20-4a58-4fc5-9462-8cd602149188"
      unitRef="usd">286000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNzkvZnJhZzplODQ4NzQ0NGE1Mzg0ZmFjYWQxMTAzYTg4Zjc3MDc4NS90YWJsZTo1YzQxYmU0M2E4MGY0NzQzOWNkNjljOTAzOTdhZDhhMS90YWJsZXJhbmdlOjVjNDFiZTQzYTgwZjQ3NDM5Y2Q2OWM5MDM5N2FkOGExXzQtNC0xLTEtNDgxMQ_7e12ced4-6cad-4a35-b1ae-cd546abd4127"
      unitRef="usd">247000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNzkvZnJhZzplODQ4NzQ0NGE1Mzg0ZmFjYWQxMTAzYTg4Zjc3MDc4NS90YWJsZTo1YzQxYmU0M2E4MGY0NzQzOWNkNjljOTAzOTdhZDhhMS90YWJsZXJhbmdlOjVjNDFiZTQzYTgwZjQ3NDM5Y2Q2OWM5MDM5N2FkOGExXzUtMi0xLTEtMzU1Ng_d72cad1f-750c-487d-abf1-78851079a980"
      unitRef="usd">4538000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNzkvZnJhZzplODQ4NzQ0NGE1Mzg0ZmFjYWQxMTAzYTg4Zjc3MDc4NS90YWJsZTo1YzQxYmU0M2E4MGY0NzQzOWNkNjljOTAzOTdhZDhhMS90YWJsZXJhbmdlOjVjNDFiZTQzYTgwZjQ3NDM5Y2Q2OWM5MDM5N2FkOGExXzUtNC0xLTEtMzU1Ng_2cd24c12-a112-4b2a-a013-0788e7b6aeac"
      unitRef="usd">1655000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV80MjEvZnJhZzo2OTA3NGIwZGY4ZWY0OTg0YTg1NWY0NWJjMWExYmIzZi90ZXh0cmVnaW9uOjY5MDc0YjBkZjhlZjQ5ODRhODU1ZjQ1YmMxYTFiYjNmXzIwMzQwOTY1MTE3NDc2_18db0d7f-c18f-4b1f-b83d-986e6995308a">Tax and tax incentive receivables&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Taxes receivable consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D tax credit receivable - U.K.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax receivable - U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <vrna:ScheduleOfNontradeReceivablesTableTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV80MjEvZnJhZzo2OTA3NGIwZGY4ZWY0OTg0YTg1NWY0NWJjMWExYmIzZi90ZXh0cmVnaW9uOjY5MDc0YjBkZjhlZjQ5ODRhODU1ZjQ1YmMxYTFiYjNmXzIwMzQwOTY1MTE3NDc3_6916da73-08f1-4a76-9f55-da886cdd2ea1">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Taxes receivable consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D tax credit receivable - U.K.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax receivable - U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</vrna:ScheduleOfNontradeReceivablesTableTextBlock>
    <vrna:ResearchAndDevelopmentTaxCreditReceivableCurrent
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV80MjEvZnJhZzo2OTA3NGIwZGY4ZWY0OTg0YTg1NWY0NWJjMWExYmIzZi90YWJsZToyNmM4NzdmMWUyMzA0NjUxYTZiOGE5ODE5MDRlMTBhZS90YWJsZXJhbmdlOjI2Yzg3N2YxZTIzMDQ2NTFhNmI4YTk4MTkwNGUxMGFlXzItMi0xLTEtNDgxNQ_d5256533-9e5a-4739-955d-07f581f1542c"
      unitRef="usd">8202000</vrna:ResearchAndDevelopmentTaxCreditReceivableCurrent>
    <vrna:ResearchAndDevelopmentTaxCreditReceivableCurrent
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV80MjEvZnJhZzo2OTA3NGIwZGY4ZWY0OTg0YTg1NWY0NWJjMWExYmIzZi90YWJsZToyNmM4NzdmMWUyMzA0NjUxYTZiOGE5ODE5MDRlMTBhZS90YWJsZXJhbmdlOjI2Yzg3N2YxZTIzMDQ2NTFhNmI4YTk4MTkwNGUxMGFlXzItNC0xLTEtNDgxNQ_27aaf064-b4dc-42b6-a35b-54d7813a46e5"
      unitRef="usd">9618000</vrna:ResearchAndDevelopmentTaxCreditReceivableCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV80MjEvZnJhZzo2OTA3NGIwZGY4ZWY0OTg0YTg1NWY0NWJjMWExYmIzZi90YWJsZToyNmM4NzdmMWUyMzA0NjUxYTZiOGE5ODE5MDRlMTBhZS90YWJsZXJhbmdlOjI2Yzg3N2YxZTIzMDQ2NTFhNmI4YTk4MTkwNGUxMGFlXzMtMi0xLTEtNDgxNQ_d8686a4a-1bbd-4d9e-a6d7-342c0a1321c2"
      unitRef="usd">58000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV80MjEvZnJhZzo2OTA3NGIwZGY4ZWY0OTg0YTg1NWY0NWJjMWExYmIzZi90YWJsZToyNmM4NzdmMWUyMzA0NjUxYTZiOGE5ODE5MDRlMTBhZS90YWJsZXJhbmdlOjI2Yzg3N2YxZTIzMDQ2NTFhNmI4YTk4MTkwNGUxMGFlXzMtNC0xLTEtNDgxNQ_9c47bc14-7755-44c0-932e-89a6e5e78bc2"
      unitRef="usd">196000</us-gaap:IncomeTaxesReceivable>
    <vrna:TaxCreditAndIncomeTaxesReceivableCurrent
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV80MjEvZnJhZzo2OTA3NGIwZGY4ZWY0OTg0YTg1NWY0NWJjMWExYmIzZi90YWJsZToyNmM4NzdmMWUyMzA0NjUxYTZiOGE5ODE5MDRlMTBhZS90YWJsZXJhbmdlOjI2Yzg3N2YxZTIzMDQ2NTFhNmI4YTk4MTkwNGUxMGFlXzQtMi0xLTEtNDgxNQ_327e14dd-4dea-41cf-92b4-a3b1ac4eab38"
      unitRef="usd">8260000</vrna:TaxCreditAndIncomeTaxesReceivableCurrent>
    <vrna:TaxCreditAndIncomeTaxesReceivableCurrent
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV80MjEvZnJhZzo2OTA3NGIwZGY4ZWY0OTg0YTg1NWY0NWJjMWExYmIzZi90YWJsZToyNmM4NzdmMWUyMzA0NjUxYTZiOGE5ODE5MDRlMTBhZS90YWJsZXJhbmdlOjI2Yzg3N2YxZTIzMDQ2NTFhNmI4YTk4MTkwNGUxMGFlXzQtNC0xLTEtNDgxNQ_8b605a08-49c0-4621-bab3-7c382db50865"
      unitRef="usd">9814000</vrna:TaxCreditAndIncomeTaxesReceivableCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90ZXh0cmVnaW9uOjk4MjgwNjE0ODNhZTRkYjg4NDM2YWY1MzI5MjgyZDBmXzIwMzQwOTY1MTIzNDM2_e5ce51e5-7e86-42fe-9600-f149efddfafa">Property leases&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The right-of-use assets (&#x201c;ROU&#x201d;) relate to rented office space in London and North Carolina, with leases ending in 2022 and 2024, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In the year ended December 31, 2019, the Company determined that it was reasonably likely to extend its existing London lease. As a consequence it modified its accounting for the lease and recorded an additional $0.7&#160;million ROU and associated liability. The Company has the option to further extend this lease but is not reasonably certain to do so and therefore has not recognized this extension as an asset and liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In the year ended December 31, 2019, the Company entered in&#160;&#160;&#160;&#160;to a lease arrangement in New York for serviced offices and recognized a right of use asset and corresponding lease liability of $0.4&#160;million. In the year ended December 31, 2020, the Company&#x2019;s New York office was closed and the related ROU asset of $290&#160;thousand was subsequently expensed in the consolidated statements of operations and comprehensive loss. The Company retains a liability of $195&#160;thousand relating to this lease arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In the year ended December 31, 2020, the Company entered into a lease arrangement in North Carolina for office space and recognized an ROU asset and corresponding lease liability of $0.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;To calculate lease liabilities the Company used a weighted average discount rate of 8%. The weighted average remaining lease term is 2.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Minimum annual payments over the remaining lease periods as of December 31, 2020 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.926%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The total operating lease expense included in general and administrative costs was $692,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Under the prior lease accounting guidance minimum rental commitments under non-cancelable leases,  for each of the five years and total thereafter as of December 31, 2019, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i9c561e8d91b04a3eb8a0bb1c609295ce_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90ZXh0cmVnaW9uOjk4MjgwNjE0ODNhZTRkYjg4NDM2YWY1MzI5MjgyZDBmXzIwMzQwOTY1MTIzMzA1_68bbf444-6418-4b54-9405-47ffb63c04e9"
      unitRef="usd">700000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i8d00a9e878d548fb96619548564db190_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90ZXh0cmVnaW9uOjk4MjgwNjE0ODNhZTRkYjg4NDM2YWY1MzI5MjgyZDBmXzIwMzQwOTY1MTIzMjkx_52de9087-b52a-45a0-ae7b-69b6d5e8fbbc"
      unitRef="usd">400000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i433bd94d277a4aaca4429c549dceb814_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90ZXh0cmVnaW9uOjk4MjgwNjE0ODNhZTRkYjg4NDM2YWY1MzI5MjgyZDBmXzIwMzQwOTY1MTIzMzM0_9ef59987-2de3-4b20-a65e-d56bbd2e76ff"
      unitRef="usd">290000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseLiability
      contextRef="ie038220275954e62811afea2defe4cd3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90ZXh0cmVnaW9uOjk4MjgwNjE0ODNhZTRkYjg4NDM2YWY1MzI5MjgyZDBmXzIwMzQwOTY1MTIzMzE5_0eb5bafb-a460-40b1-a6cd-27af3ec2fdb6"
      unitRef="usd">195000</us-gaap:OperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i30a26c5ea22f48a09788808b52ec5291_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90ZXh0cmVnaW9uOjk4MjgwNjE0ODNhZTRkYjg4NDM2YWY1MzI5MjgyZDBmXzIwMzQwOTY1MTIzMzUz_fd5797d1-b5ee-4e20-9db9-bdab24943694"
      unitRef="usd">700000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90ZXh0cmVnaW9uOjk4MjgwNjE0ODNhZTRkYjg4NDM2YWY1MzI5MjgyZDBmXzIwMzQwOTY1MTIzMzQ5_668b24df-21fd-4001-8473-b9b334507af3"
      unitRef="number">0.08</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90ZXh0cmVnaW9uOjk4MjgwNjE0ODNhZTRkYjg4NDM2YWY1MzI5MjgyZDBmXzU0OTc1NTgyNTM3OQ_e621f8d0-3a0c-4467-92d0-cb80de0e7f6d">P2Y2M12D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90ZXh0cmVnaW9uOjk4MjgwNjE0ODNhZTRkYjg4NDM2YWY1MzI5MjgyZDBmXzIwMzQwOTY1MTIzNDM4_885ae978-3746-44e8-8658-2c31fc1792e8">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Minimum annual payments over the remaining lease periods as of December 31, 2020 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.926%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90YWJsZTo1MTcyNmUxNjc0Y2Q0OTk5YjY5ZTM5OTM2NTA2NTMwMC90YWJsZXJhbmdlOjUxNzI2ZTE2NzRjZDQ5OTliNjllMzk5MzY1MDY1MzAwXzMtMi0xLTEtMzUxOQ_f7395080-8d25-4878-9d5c-79a77f8c36da"
      unitRef="usd">862000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90YWJsZTo1MTcyNmUxNjc0Y2Q0OTk5YjY5ZTM5OTM2NTA2NTMwMC90YWJsZXJhbmdlOjUxNzI2ZTE2NzRjZDQ5OTliNjllMzk5MzY1MDY1MzAwXzQtMi0xLTEtMzUxOQ_fa00269b-0b49-43af-b9b4-bb9798a32e99"
      unitRef="usd">281000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90YWJsZTo1MTcyNmUxNjc0Y2Q0OTk5YjY5ZTM5OTM2NTA2NTMwMC90YWJsZXJhbmdlOjUxNzI2ZTE2NzRjZDQ5OTliNjllMzk5MzY1MDY1MzAwXzUtMi0xLTEtMzUxOQ_052197d4-71bb-4ebc-87b8-6e281d4d2802"
      unitRef="usd">201000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90YWJsZTo1MTcyNmUxNjc0Y2Q0OTk5YjY5ZTM5OTM2NTA2NTMwMC90YWJsZXJhbmdlOjUxNzI2ZTE2NzRjZDQ5OTliNjllMzk5MzY1MDY1MzAwXzYtMi0xLTEtMzUxOQ_69c76273-c2a3-4153-879b-5c96a1b71ddb"
      unitRef="usd">44000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90YWJsZTo1MTcyNmUxNjc0Y2Q0OTk5YjY5ZTM5OTM2NTA2NTMwMC90YWJsZXJhbmdlOjUxNzI2ZTE2NzRjZDQ5OTliNjllMzk5MzY1MDY1MzAwXzgtMi0xLTEtMzUxOQ_e5226a19-fe4f-4055-b481-a6f21d0afc7d"
      unitRef="usd">1388000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90YWJsZTo1MTcyNmUxNjc0Y2Q0OTk5YjY5ZTM5OTM2NTA2NTMwMC90YWJsZXJhbmdlOjUxNzI2ZTE2NzRjZDQ5OTliNjllMzk5MzY1MDY1MzAwXzgtMi0xLTEtNTk5NQ_bc68705c-227e-47d3-b6f8-5da0c33488ea"
      unitRef="usd">76000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90YWJsZTo1MTcyNmUxNjc0Y2Q0OTk5YjY5ZTM5OTM2NTA2NTMwMC90YWJsZXJhbmdlOjUxNzI2ZTE2NzRjZDQ5OTliNjllMzk5MzY1MDY1MzAwXzktMi0xLTEtNTk5NQ_91372cc1-5397-423a-81fb-c02403afb69b"
      unitRef="usd">1312000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90ZXh0cmVnaW9uOjk4MjgwNjE0ODNhZTRkYjg4NDM2YWY1MzI5MjgyZDBmXzIwMzQwOTY1MTI2NTc3_e11acad8-50e8-4d8a-a341-787e94f5109f"
      unitRef="usd">692000</us-gaap:OperatingLeaseExpense>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90ZXh0cmVnaW9uOjk4MjgwNjE0ODNhZTRkYjg4NDM2YWY1MzI5MjgyZDBmXzI0NzM5MDExNjM4NjQ1_cf37f6e9-f057-4a95-945c-319595a27767">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Under the prior lease accounting guidance minimum rental commitments under non-cancelable leases,  for each of the five years and total thereafter as of December 31, 2019, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90YWJsZTpmOWM0YzA1YjI0Zjc0Y2IyYjMwMTJhMjM4Y2I1ODc2ZC90YWJsZXJhbmdlOmY5YzRjMDViMjRmNzRjYjJiMzAxMmEyMzhjYjU4NzZkXzEtMi0xLTEtMjUwNzE_2e7b4e8b-14c7-4918-9db8-9bc28ea6c8c7"
      unitRef="usd">680000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90YWJsZTpmOWM0YzA1YjI0Zjc0Y2IyYjMwMTJhMjM4Y2I1ODc2ZC90YWJsZXJhbmdlOmY5YzRjMDViMjRmNzRjYjJiMzAxMmEyMzhjYjU4NzZkXzEtNC0xLTEtMjQ5NDU_5a9623b6-9465-4ec6-8d4a-d263ac1b79ba"
      unitRef="usd">862000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90YWJsZTpmOWM0YzA1YjI0Zjc0Y2IyYjMwMTJhMjM4Y2I1ODc2ZC90YWJsZXJhbmdlOmY5YzRjMDViMjRmNzRjYjJiMzAxMmEyMzhjYjU4NzZkXzEtNi0xLTEtMjQ5NDI_4e8973ec-7e52-40dd-90ee-2f576457fd3d"
      unitRef="usd">281000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90YWJsZTpmOWM0YzA1YjI0Zjc0Y2IyYjMwMTJhMjM4Y2I1ODc2ZC90YWJsZXJhbmdlOmY5YzRjMDViMjRmNzRjYjJiMzAxMmEyMzhjYjU4NzZkXzEtOC0xLTEtMjQ5Mzk_3e239c69-1f93-4f4e-b107-ab33c2e2bd72"
      unitRef="usd">201000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yODQvZnJhZzo5ODI4MDYxNDgzYWU0ZGI4ODQzNmFmNTMyOTI4MmQwZi90YWJsZTpmOWM0YzA1YjI0Zjc0Y2IyYjMwMTJhMjM4Y2I1ODc2ZC90YWJsZXJhbmdlOmY5YzRjMDViMjRmNzRjYjJiMzAxMmEyMzhjYjU4NzZkXzEtMTAtMS0xLTI0OTM2_8eba82ab-0003-40cf-ae76-56979c9c9279"
      unitRef="usd">44000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNTkvZnJhZzo4NjA1NjFiNWIxZWE0MzVkOTBlMzE5ZjZkMjI0YzQxZi90ZXh0cmVnaW9uOjg2MDU2MWI1YjFlYTQzNWQ5MGUzMTlmNmQyMjRjNDFmXzIwMzQwOTY1MTE0NzI0_43462080-1aaa-4f95-90bc-ac1d9f13140c">Accrued expenses&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial and other development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees, listing and general corporate costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;People related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Other expenses include people costs, professional fees and other accrued costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNTkvZnJhZzo4NjA1NjFiNWIxZWE0MzVkOTBlMzE5ZjZkMjI0YzQxZi90ZXh0cmVnaW9uOjg2MDU2MWI1YjFlYTQzNWQ5MGUzMTlmNmQyMjRjNDFmXzIwMzQwOTY1MTE0NzI1_8c22767a-001f-486b-ab9b-c4c89247cfe2">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial and other development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees, listing and general corporate costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;People related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <vrna:AccruedResearchAndDevelopmentFeesCurrent
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNTkvZnJhZzo4NjA1NjFiNWIxZWE0MzVkOTBlMzE5ZjZkMjI0YzQxZi90YWJsZTpjZmU4ZjQxZjU4MWE0MDZhYTJkYTRlYzc5YmQzNGNkZS90YWJsZXJhbmdlOmNmZThmNDFmNTgxYTQwNmFhMmRhNGVjNzliZDM0Y2RlXzMtMi0xLTEtMzcwOA_1ecb21e8-e39d-487a-b11c-4db6cbbaabe5"
      unitRef="usd">8607000</vrna:AccruedResearchAndDevelopmentFeesCurrent>
    <vrna:AccruedResearchAndDevelopmentFeesCurrent
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNTkvZnJhZzo4NjA1NjFiNWIxZWE0MzVkOTBlMzE5ZjZkMjI0YzQxZi90YWJsZTpjZmU4ZjQxZjU4MWE0MDZhYTJkYTRlYzc5YmQzNGNkZS90YWJsZXJhbmdlOmNmZThmNDFmNTgxYTQwNmFhMmRhNGVjNzliZDM0Y2RlXzMtNC0xLTEtMzcwOA_8a5a6c71-f8de-433d-b2e7-237cd4c9e963"
      unitRef="usd">6394000</vrna:AccruedResearchAndDevelopmentFeesCurrent>
    <vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNTkvZnJhZzo4NjA1NjFiNWIxZWE0MzVkOTBlMzE5ZjZkMjI0YzQxZi90YWJsZTpjZmU4ZjQxZjU4MWE0MDZhYTJkYTRlYzc5YmQzNGNkZS90YWJsZXJhbmdlOmNmZThmNDFmNTgxYTQwNmFhMmRhNGVjNzliZDM0Y2RlXzMtMi0xLTEtMjUxNzQ_62b3ea5f-0cbf-4533-ad62-7f8526728981"
      unitRef="usd">2149000</vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent>
    <vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNTkvZnJhZzo4NjA1NjFiNWIxZWE0MzVkOTBlMzE5ZjZkMjI0YzQxZi90YWJsZTpjZmU4ZjQxZjU4MWE0MDZhYTJkYTRlYzc5YmQzNGNkZS90YWJsZXJhbmdlOmNmZThmNDFmNTgxYTQwNmFhMmRhNGVjNzliZDM0Y2RlXzMtNC0xLTEtMjUxNzQ_21b48942-866a-46d9-bce3-d037f1ca1041"
      unitRef="usd">2191000</vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNTkvZnJhZzo4NjA1NjFiNWIxZWE0MzVkOTBlMzE5ZjZkMjI0YzQxZi90YWJsZTpjZmU4ZjQxZjU4MWE0MDZhYTJkYTRlYzc5YmQzNGNkZS90YWJsZXJhbmdlOmNmZThmNDFmNTgxYTQwNmFhMmRhNGVjNzliZDM0Y2RlXzQtMi0xLTEtMzcwOA_ae1c055e-506a-4352-b76d-1df04f6b56c9"
      unitRef="usd">107000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNTkvZnJhZzo4NjA1NjFiNWIxZWE0MzVkOTBlMzE5ZjZkMjI0YzQxZi90YWJsZTpjZmU4ZjQxZjU4MWE0MDZhYTJkYTRlYzc5YmQzNGNkZS90YWJsZXJhbmdlOmNmZThmNDFmNTgxYTQwNmFhMmRhNGVjNzliZDM0Y2RlXzQtNC0xLTEtMzcwOA_305739fe-4cc5-4785-9655-6e31a8b5bd52"
      unitRef="usd">386000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNTkvZnJhZzo4NjA1NjFiNWIxZWE0MzVkOTBlMzE5ZjZkMjI0YzQxZi90YWJsZTpjZmU4ZjQxZjU4MWE0MDZhYTJkYTRlYzc5YmQzNGNkZS90YWJsZXJhbmdlOmNmZThmNDFmNTgxYTQwNmFhMmRhNGVjNzliZDM0Y2RlXzYtMi0xLTEtMzcwOA_b0a635f0-0cd1-4599-8081-ad377632d861"
      unitRef="usd">10863000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNTkvZnJhZzo4NjA1NjFiNWIxZWE0MzVkOTBlMzE5ZjZkMjI0YzQxZi90YWJsZTpjZmU4ZjQxZjU4MWE0MDZhYTJkYTRlYzc5YmQzNGNkZS90YWJsZXJhbmdlOmNmZThmNDFmNTgxYTQwNmFhMmRhNGVjNzliZDM0Y2RlXzYtNC0xLTEtMzcwOA_3d050f84-4daf-4679-a2b3-a3fd235cf030"
      unitRef="usd">8971000</us-gaap:AccruedLiabilitiesCurrent>
    <vrna:WarrantAndRightsDisclosureTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzIwMzQwOTY1MTIxMjA3_18f0508c-4d8a-44ad-a38b-b0fd37113afb">Warrants&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In 2016, the Company issued 31,115,926 units to new and existing investors at the placing price of &#xa3;1.4365 per unit. Each unit comprised one ordinary share and one warrant. The warrant holders can subscribe for 0.4 of an ordinary share at a per share exercise price of &#xa3;1.7238 until May 2, 2022. The warrant holders can opt for a cashless exercise of their warrants, whereby the warrant holders can choose to exchange the warrants held for a reduced number of warrants exercisable at nil consideration. The reduced number of warrants is calculated based on a formula considering the share price and the exercise price of the warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;At December 31, 2020, 31,003,155 warrants remain outstanding and entitle the investors to subscribe for, in aggregate, a maximum of 12,401,262 ordinary shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;If, after a transaction, should the warrants be exercisable for unlisted securities, the warrant holders may demand a cash payment instead of the delivery of the underlying securities. Accordingly, the warrants are accounted for as a liability under ASC 480 &#x201c;Distinguishing Liabilities from Equity&#x201d;.The warrants are measured at fair value, Level 3 in the fair value hierarchy, with movements recorded in finance income / (expense) in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In the years ended December 31, 2020, and 2019, no warrants were exercised or forfeited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The warrants had no intrinsic value as at December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;There have been no changes in valuation techniques or transfers between fair value measurement levels during the years ended December 31, 2020 and 2019. The warrants are valued using the Black-Scholes model and the table below presents the assumptions used:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares potentially issued under warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,401,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,401,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price in pounds sterling&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equivalent price of ordinary share (ADS price divided by eight)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term to exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.34&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Annualized volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Calculated value of the warrants, in thousands of U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows the movement of the value of the warrants (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;At January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,066)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange differences recognized in loss for the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translation differences recognized in other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;At December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;For the amount recognized at December 31, 2020, the effect when the following parameter deviates up or down is presented in the below table (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10% volatility increase&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Base case, reported fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,246&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10% volatility decrease&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</vrna:WarrantAndRightsDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i1934261cb6744a68b1f3c1ac28b455f2_I20161231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzIwMzQwOTY1MTIxMjA5_24c17df1-bfec-4875-a31e-d7914fda36c3"
      unitRef="shares">31115926</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <vrna:ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights
      contextRef="i1934261cb6744a68b1f3c1ac28b455f2_I20161231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzIwMzQwOTY1MTIxMjIx_cda85977-ae23-4885-bb27-c2dc4384e3e5"
      unitRef="gbpPerShare">1.4365</vrna:ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i1934261cb6744a68b1f3c1ac28b455f2_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzIwMzQwOTY1MTIxMjMw_bfe6e97f-a90e-4856-857a-668e2146666d"
      unitRef="shares">0.4</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i1934261cb6744a68b1f3c1ac28b455f2_I20161231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzIwMzQwOTY1MTIxMjM1_21d8ad3c-e7ef-43cb-b37d-da40526975fd"
      unitRef="gbpPerShare">1.7238</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzU0OTc1NTgxNzE0MQ_e27da514-3fdd-4386-b1ca-07f85c803c49"
      unitRef="shares">31003155</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzIwMzQwOTY1MTIxMjQ2_f8ea50bc-bdcd-416d-816d-50420fafed4b"
      unitRef="shares">12401262</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <vrna:ClassOfWarrantOrRightNumberOfExercisedOrForfeited
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzIwMzQwOTY1MTIxMjY1_42505124-86bc-4bc3-802a-d16f90608d26"
      unitRef="shares">0</vrna:ClassOfWarrantOrRightNumberOfExercisedOrForfeited>
    <vrna:ClassOfWarrantOrRightNumberOfExercisedOrForfeited
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzIwMzQwOTY1MTIxMjY1_6b985ca1-0dcd-439f-9b96-8ff6f42e91be"
      unitRef="shares">0</vrna:ClassOfWarrantOrRightNumberOfExercisedOrForfeited>
    <vrna:ClassOfWarrantOrRightIntrinsicValue
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzIwMzQwOTY1MTIzMzEz_9fda51b7-5387-4efc-9909-b03fe4a69674"
      unitRef="usd">0</vrna:ClassOfWarrantOrRightIntrinsicValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzIwMzQwOTY1MTIyODg2_7a0795a7-49a2-44d7-8459-cb14c857cd99">The warrants are valued using the Black-Scholes model and the table below presents the assumptions used:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares potentially issued under warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,401,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,401,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price in pounds sterling&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equivalent price of ordinary share (ADS price divided by eight)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term to exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.34&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Annualized volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Calculated value of the warrants, in thousands of U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzItMi0xLTEtNjkzMQ_65489030-78aa-486e-8a02-c205532adca0"
      unitRef="shares">12401262</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzItNC0xLTEtNjkzMQ_e6bcf89b-8921-476c-b64c-e5f53b31f492"
      unitRef="shares">12401262</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzMtMi0xLTEtNjkzMQ_50b199f7-5204-483d-bb39-9684ec6f0bb1"
      unitRef="gbpPerShare">1.7238</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzMtNC0xLTEtNjkzMQ_ab11031c-6167-4bc4-b6fd-9357b2f7b378"
      unitRef="gbpPerShare">1.7238</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vrna:ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzQtMi0xLTEtMTIyNDc_390ac764-495c-4153-a0e4-b445be1dc562"
      unitRef="usdPerShare">0.64</vrna:ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare>
    <vrna:ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzQtNC0xLTEtMTIyNDc_4c216e73-56fd-4bf3-b6f3-1217da66ed4a"
      unitRef="usdPerShare">0.62</vrna:ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ia00163949ecb43ad94978f60f9da30cc_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzUtMi0xLTEtMTIyNDc_d1b39aa4-d7b3-4fee-a3f0-66e7830eb5cd"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ie527217d2eb345ecb87bd45f62bc6551_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzUtNC0xLTEtMTIyNDc_80b2ebd0-8af4-457a-8f67-738922a4c2ca"
      unitRef="number">0.0054</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzYtMi0xLTEtMTIyNDc_a08864c8-af1d-49f9-b4df-7b9fb887a233">P1Y3M29D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzYtNC0xLTEtMTIyNDc_3a80b36c-a8c7-4593-b4f1-0ab76fd12813">P2Y4M2D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ic9d34c4d3648482ca9398caf5933c3fc_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzctMi0xLTEtMTIyNDc_6a4bb0c6-b09e-43e6-b934-fb6c568320b4"
      unitRef="number">1.054</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i15dd5dffacd24b789e1a47ff62cf2c12_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzctNC0xLTEtMTIyNDc_fbf5ee1b-6dfd-425b-926f-8ca5b619359e"
      unitRef="number">0.656</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ic846b25fc9864471980143616fd3554b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzQtMi0xLTEtNjkzMQ_a090d62c-2550-4658-85ec-b922851c8f7b"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i798475f69cfd4d4cae668edfa84dcee9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzQtNC0xLTEtNjkzMQ_228068b6-44df-44c0-a263-899f64bd0ac8"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <vrna:WarrantLiabilityCurrent
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzUtMi0xLTEtNjkzMQ_dcd1d22e-040e-46b8-9a5e-0ff0b11ae6f3"
      unitRef="usd">2246000</vrna:WarrantLiabilityCurrent>
    <vrna:WarrantLiabilityCurrent
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTphN2Q2MjNmNDJjZjE0YTM5OWQxNDllNWI3ZTU3ZDRiOS90YWJsZXJhbmdlOmE3ZDYyM2Y0MmNmMTRhMzk5ZDE0OWU1YjdlNTdkNGI5XzUtNC0xLTEtNjkzMQ_c5abd579-e977-4a57-bd35-7c67dc656ef6"
      unitRef="usd">1188000</vrna:WarrantLiabilityCurrent>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzIwMzQwOTY1MTIxMjU3_e4648427-2202-4a39-ae8d-73fd2fae37fc">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows the movement of the value of the warrants (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;At January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,066)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange differences recognized in loss for the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translation differences recognized in other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;At December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTowOGQwYmI1MmFkYjE0ZGViODI3MGMwYTgzMTA1OGE3OC90YWJsZXJhbmdlOjA4ZDBiYjUyYWRiMTRkZWI4MjcwYzBhODMxMDU4YTc4XzItMS0xLTEtMTIyMTU_9b049d69-389e-4a27-be3c-33f785a633e1"
      unitRef="usd">1188000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ibc6502e2d84744a1a4f122e93a5bbedc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTowOGQwYmI1MmFkYjE0ZGViODI3MGMwYTgzMTA1OGE3OC90YWJsZXJhbmdlOjA4ZDBiYjUyYWRiMTRkZWI4MjcwYzBhODMxMDU4YTc4XzItMy0xLTEtMTIyNDE_5c5caaad-f19b-40fa-ad27-4da8001a4dea"
      unitRef="usd">3180000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTowOGQwYmI1MmFkYjE0ZGViODI3MGMwYTgzMTA1OGE3OC90YWJsZXJhbmdlOjA4ZDBiYjUyYWRiMTRkZWI4MjcwYzBhODMxMDU4YTc4XzQtMS0xLTEtMTIyMzc_7c4ddcb0-df4a-4994-a156-f6538ee64767"
      unitRef="usd">1114000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTowOGQwYmI1MmFkYjE0ZGViODI3MGMwYTgzMTA1OGE3OC90YWJsZXJhbmdlOjA4ZDBiYjUyYWRiMTRkZWI4MjcwYzBhODMxMDU4YTc4XzQtMy0xLTEtMTIyNDE_3c4cd362-eec6-4a7c-8cee-3d431218add9"
      unitRef="usd">-2066000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <vrna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTowOGQwYmI1MmFkYjE0ZGViODI3MGMwYTgzMTA1OGE3OC90YWJsZXJhbmdlOjA4ZDBiYjUyYWRiMTRkZWI4MjcwYzBhODMxMDU4YTc4XzUtMS0xLTEtMTIyMzc_9150c85b-bd6c-412e-90ce-864339db13d3"
      unitRef="usd">22000</vrna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference>
    <vrna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTowOGQwYmI1MmFkYjE0ZGViODI3MGMwYTgzMTA1OGE3OC90YWJsZXJhbmdlOjA4ZDBiYjUyYWRiMTRkZWI4MjcwYzBhODMxMDU4YTc4XzUtMy0xLTEtMTIyNDE_bbc096fa-19ca-4f71-8a77-444477259eab"
      unitRef="usd">0</vrna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTowOGQwYmI1MmFkYjE0ZGViODI3MGMwYTgzMTA1OGE3OC90YWJsZXJhbmdlOjA4ZDBiYjUyYWRiMTRkZWI4MjcwYzBhODMxMDU4YTc4XzYtMS0xLTEtMTIyMzc_f94df147-a210-40db-a1db-9c2624945c96"
      unitRef="usd">-78000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTowOGQwYmI1MmFkYjE0ZGViODI3MGMwYTgzMTA1OGE3OC90YWJsZXJhbmdlOjA4ZDBiYjUyYWRiMTRkZWI4MjcwYzBhODMxMDU4YTc4XzYtMy0xLTEtMTIyNDE_b06a405f-82fc-4d9b-a4cc-c73c083a4df0"
      unitRef="usd">74000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTowOGQwYmI1MmFkYjE0ZGViODI3MGMwYTgzMTA1OGE3OC90YWJsZXJhbmdlOjA4ZDBiYjUyYWRiMTRkZWI4MjcwYzBhODMxMDU4YTc4XzUtMS0xLTEtMTIyMTA_a18459e2-b54f-45d1-a41b-876f12991769"
      unitRef="usd">2246000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTowOGQwYmI1MmFkYjE0ZGViODI3MGMwYTgzMTA1OGE3OC90YWJsZXJhbmdlOjA4ZDBiYjUyYWRiMTRkZWI4MjcwYzBhODMxMDU4YTc4XzctMy0xLTEtMTIyNDE_c9c1be7c-54d0-46d7-a38a-459b28ef66c9"
      unitRef="usd">1188000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <vrna:FairValueImpactOfIncreaseOrDecreaseInVolatilityTableTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90ZXh0cmVnaW9uOjM0ZTJkYTgxN2Q5MzRiMzI4MTdmOTI1Njk1ZWY4YTc5XzIwMzQwOTY1MTIyODg4_5a1b9c35-b899-4803-b1b5-c7a09be08d01">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;For the amount recognized at December 31, 2020, the effect when the following parameter deviates up or down is presented in the below table (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10% volatility increase&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Base case, reported fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,246&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10% volatility decrease&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</vrna:FairValueImpactOfIncreaseOrDecreaseInVolatilityTableTextBlock>
    <vrna:SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTo1Zjc3OGYyMWE0NmQ0MGFjYmJmNzQ3NTM4MGM3YjM5Zi90YWJsZXJhbmdlOjVmNzc4ZjIxYTQ2ZDQwYWNiYmY3NDc1MzgwYzdiMzlmXzEtMS0xLTEtMTIyNzA_0127a248-ed36-42c9-ac47-dfcc53333b86"
      unitRef="usd">2734000</vrna:SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate>
    <vrna:WarrantLiabilityFairValue
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTo1Zjc3OGYyMWE0NmQ0MGFjYmJmNzQ3NTM4MGM3YjM5Zi90YWJsZXJhbmdlOjVmNzc4ZjIxYTQ2ZDQwYWNiYmY3NDc1MzgwYzdiMzlmXzItMS0xLTEtMTIyNzA_2c9bc920-9766-4b77-9c25-d705e02870fb"
      unitRef="usd">2246000</vrna:WarrantLiabilityFairValue>
    <vrna:SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjQvZnJhZzozNGUyZGE4MTdkOTM0YjMyODE3ZjkyNTY5NWVmOGE3OS90YWJsZTo1Zjc3OGYyMWE0NmQ0MGFjYmJmNzQ3NTM4MGM3YjM5Zi90YWJsZXJhbmdlOjVmNzc4ZjIxYTQ2ZDQwYWNiYmY3NDc1MzgwYzdiMzlmXzMtMS0xLTEtMTIyNzA_96fba689-98f4-496a-88ed-03cf214f9e4e"
      unitRef="usd">1772000</vrna:SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTM3MTg3_ea98e98d-3b1a-4d94-8ae6-c4c0474a500e">Term loan&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In November 2020, the Company and its wholly owned subsidiary, Verona Pharma, Inc. (the &#x201c;Borrowers&#x201d;) entered into a term loan facility of up to $30.0&#160;million (the &#x201c;Term Loan&#x201d;), consisting of term loan advances in an aggregate amount of $5.0&#160;million funded at closing, a term loan advance available subject to certain terms and conditions in an aggregate amount of $10.0&#160;million (the &#x201c;Term B Loan&#x201d;) and a term loan advance available subject to certain terms and conditions in an aggregate amount of $15.0&#160;million (the &#x201c;Term C Loan&#x201d;), with Silicon Valley Bank, a California corporation (&#x201c;SVB&#x201d;), the proceeds of which will be used for general corporate and working capital purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Term Loan is governed by a loan and security agreement, dated as of November 19, 2020, between the Borrowers and SVB (the &#x201c;Loan Agreement&#x201d;). The Term B Loan will be available, subject to and customary terms and conditions, only during the period commencing upon the achievement of a specific clinical milestone relating to ensifentrine through and including June 30, 2022. The Term C Loan will be available, subject to customary terms and conditions, only during the period commencing upon the achievement of an additional specific clinical milestone relating to ensifentrine through and including June 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Term Loan will mature on November 1, 2024. Each advance under the Term Loan accrues interest at a floating per annum rate equal to the greater of (a) the sum of the prime rate reported in The Wall Street Journal plus 1.00% and (b) four and one-quarter of one percent (4.25%). The Term Loan provides for interest-only payments on a monthly basis until the payment date immediately preceding December 1, 2023. Thereafter, amortization payments will be payable monthly in equal installments of principal plus monthly payments of accrued interest. Upon repayment (whether at maturity, upon acceleration or by prepayment or otherwise), the Borrowers shall make a final payment to SVB in the amount of 10% of the aggregate Term Loans advanced (the "Final Payment"). The Borrowers may prepay the Term Loan in full but not in part provided that the Borrowers (i) provide ten days&#x2019; prior written notice to SVB, (ii) pays on the date of such prepayment (A) all outstanding principal plus accrued and unpaid interest, (B) a prepayment fee of $450,000 plus 3.0% of the Term C Loans advanced if paid on or before the first anniversary of the closing date; $300,000 plus 2.00% of the Term C Loans advanced if paid after the first anniversary of the closing date and on or before the second anniversary of the closing date; and $150,000 plus 1.00% of the Term C Loans advanced if paid thereafter and prior to maturity, (C) the Final Payment and (D) all other sums, if any, that shall become due and payable with respect to the Term Loan Advances, including interest at the Default Rate with respect to any past due amounts. Amounts outstanding during an event of default are payable upon SVB's demand and shall accrue interest at an additional rate of 3.0% per annum.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Term Loan is secured by a lien on substantially all of the assets of the Borrowers, other than the equity interests of Verona U.S. and other than intellectual property, provided that such lien on substantially all assets includes any rights to payments and proceeds from the sale, licensing or disposition of intellectual property. The Borrowers have also granted SVB a negative pledge with respect to its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Loan Agreement contains customary covenants and representations, including but not limited to financial reporting obligations and limitations on dividends, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. The Loan Agreement also contains other customary provisions, such as expense reimbursement, non-disclosure obligations as well as indemnification rights for the benefit of SVB. The Loan Agreement includes a minimum cash covenant triggered when Borrowers' consolidated cash and cash equivalents drop below $45.0&#160;million at any time after the earliest to occur of any of the following: (i) the release of negative data from Enhance 2 and/or Enhance 1, which in the reasonable business discretion Borrowers&#x2019; senior management, would be considered insufficient to support submission of an NDA to the FDA, (ii) the FDA issues a complete response letter with respect to an NDA submitted for ensifentrine, or (iii) failure to achieve a specific regulatory milestone relating to ensifentrine by June 30, 2023 (extendable to March 31, 2024 upon the Borrowers receiving a specified amount of new cash proceeds after September 8, 2020 from the sale of equity securities in one or more public financings or other bona fide equity financings, subordinated debt and/or upfront/milestone payments from one or more collaboration agreements not prohibited in the Loan Agreement). Upon such trigger, Borrowers must cash collateralize an amount equal to the outstanding obligations to SVB plus the amount of any prepayment penalty and Final Payment which would be due in the event the Loan Agreement were prepaid in full with respect to the Term Loans advanced as of such time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The events of default under the Loan Agreement include, but are not limited to, the Borrowers&#x2019; failure to make any payments of principal or interest under the Loan Agreement or other transaction documents, the Borrowers&#x2019; breach or default in the performance of any covenant under the Loan Agreement or other transaction documents, the occurrence of a material adverse change, any Borrower making a false or misleading representation or warranty in any material respect under the Loan Agreement, any Borrower&#x2019;s insolvency or bankruptcy, any attachment or judgment on any Borrower&#x2019;s assets of at least $500,000, or the occurrence of any default under any agreement or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;obligation of any Borrower involving indebtedness in excess of $500,000. If an event of default occurs, SVB is entitled to take enforcement action, including acceleration of amounts due under the Loan Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In connection with the Term Loan the Company incurred debt issuance costs totaling approximate&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;ly $400&#160;thousand &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;which were deducted from the carrying amount of the debt and are being amortized over the estimated term of the debt using the effective interest method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;As of December 31, 2020, the carrying value of the Term Loan was approximately $4.6&#160;million, of which all was due in greater than 12 months. The debt balance has been categorized within Level 3 of the fair value hierarchy. The carrying amount of the debt approximates its fair value based on prevailing interest rates as of the balance sheet date.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2f3b17ae809741d291cfb524e558c10e_I20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwNzM5_2bffa798-f730-48f6-84c3-3cd202cc4b2b"
      unitRef="usd">30000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ie41a5e71b1994eee9bbaacc09238aab0_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwNzU0_c0ece4e4-4a4d-47a8-9a83-b4c28841a200"
      unitRef="usd">5000000.0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7a160b4682334bfdb2a585dd96fe5385_I20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwNzY4_1a46e45e-0003-46c2-8ae9-5322e32e8987"
      unitRef="usd">10000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5f6a1d485e244da9a9515d7aeca27d8b_I20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwNzgz_436ba53b-035b-4959-a2c2-c9c2f32ca42e"
      unitRef="usd">15000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="if4a9630a9c2e4c549a9169a0cdb89d7c_D20201101-20201130"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwODA1_4f5ddfe8-26ac-4066-8165-5a443d94f10c"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2f3b17ae809741d291cfb524e558c10e_I20201130"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwNzk4_bf8807d3-3087-473b-afc5-569849ee63cd"
      unitRef="number">0.0425</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <vrna:DebtInstrumentFinalPaymentPercent
      contextRef="i2f3b17ae809741d291cfb524e558c10e_I20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwODEy_39977871-30a7-40df-a4a0-46ddb6966d68"
      unitRef="number">0.10</vrna:DebtInstrumentFinalPaymentPercent>
    <vrna:DebtInstrumentPrepaymentTermOfPriorWrittenNotice
      contextRef="ie41a5e71b1994eee9bbaacc09238aab0_D20201101-20201130"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwODI5_197addeb-593d-4f5c-8598-aea56b3252a3">P10D</vrna:DebtInstrumentPrepaymentTermOfPriorWrittenNotice>
    <vrna:DebtInstrumentEarlyRepaymentPenaltyAmount
      contextRef="i11218b759beb41eeb8f443403c8f9195_I20201130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwODM2_17a878ac-ec63-4e61-813c-c5290a8f7611"
      unitRef="usd">450000</vrna:DebtInstrumentEarlyRepaymentPenaltyAmount>
    <vrna:DebtInstrumentEarlyRepaymentPenaltyPercent
      contextRef="i11218b759beb41eeb8f443403c8f9195_I20201130"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwODQ2_6a06517e-7661-4636-a821-dd99d0333298"
      unitRef="number">0.030</vrna:DebtInstrumentEarlyRepaymentPenaltyPercent>
    <vrna:DebtInstrumentEarlyRepaymentPenaltyAmount
      contextRef="i37571b3be78b4c2bb25afe43255bbd52_I20201130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwODUy_cb4f4bb6-fa0a-4fe5-b125-1bee735ae601"
      unitRef="usd">300000</vrna:DebtInstrumentEarlyRepaymentPenaltyAmount>
    <vrna:DebtInstrumentEarlyRepaymentPenaltyPercent
      contextRef="i37571b3be78b4c2bb25afe43255bbd52_I20201130"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwODYy_e37c901f-6679-474c-85df-d9d23a95d9c1"
      unitRef="number">0.0200</vrna:DebtInstrumentEarlyRepaymentPenaltyPercent>
    <vrna:DebtInstrumentEarlyRepaymentPenaltyAmount
      contextRef="i14b92f6c922045ebb4b765d2692f0b26_I20201130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwODY5_ac56e6b3-b0c2-47f7-b4f3-fc9f8cc01824"
      unitRef="usd">150000</vrna:DebtInstrumentEarlyRepaymentPenaltyAmount>
    <vrna:DebtInstrumentEarlyRepaymentPenaltyPercent
      contextRef="i14b92f6c922045ebb4b765d2692f0b26_I20201130"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwODc5_9de1db7c-eb75-447e-882e-4b16a9acc5ea"
      unitRef="number">0.0100</vrna:DebtInstrumentEarlyRepaymentPenaltyPercent>
    <vrna:DebtInstrumentDebtDefaultInterestRateStatedPercentage
      contextRef="i2f3b17ae809741d291cfb524e558c10e_I20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwODg2_22a28394-10c9-4452-9a08-952f8cd85f27"
      unitRef="number">0.030</vrna:DebtInstrumentDebtDefaultInterestRateStatedPercentage>
    <vrna:DebtInstrumentCovenantCashAndCashEquivalentsMinimum
      contextRef="ie41a5e71b1994eee9bbaacc09238aab0_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwODky_32264118-66f1-4eac-8ff2-6ad7447f028b"
      unitRef="usd">45000000.0</vrna:DebtInstrumentCovenantCashAndCashEquivalentsMinimum>
    <vrna:DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold
      contextRef="ie41a5e71b1994eee9bbaacc09238aab0_D20201101-20201130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwOTA3_e0b3d21a-e5d9-4f02-8cb0-6f81b919ce72"
      unitRef="usd">500000</vrna:DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold>
    <vrna:DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness
      contextRef="ie41a5e71b1994eee9bbaacc09238aab0_D20201101-20201130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTYwOTE3_e011f38d-89f2-4b5b-9b1e-1ab2a2a994de"
      unitRef="usd">500000</vrna:DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i6a56eccf381d4490ab23ba0ce2602ed8_I20201119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTM3MTU4_d4a0c8a2-f553-4b1d-a5cd-f3bcb30e9075"
      unitRef="usd">400000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:LongTermDebt
      contextRef="i46b0f32ad5df416e83423bbabba5a3b9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV81MDgvZnJhZzpiYThjZGY0YjJlM2M0YzQ4ODZlZTk0YWI4NjcyOWIwZS90ZXh0cmVnaW9uOmJhOGNkZjRiMmUzYzRjNDg4NmVlOTRhYjg2NzI5YjBlXzIwMzQwOTY1MTQwMjQ4_e0f268bb-97aa-485a-a742-a934ff64e810"
      unitRef="usd">4600000</us-gaap:LongTermDebt>
    <us-gaap:DefinedContributionPlanTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMjkvZnJhZzo3MjRiZjBhM2Y1MGI0MzczODhmMjE3Y2E3MGM1OTg5Mi90ZXh0cmVnaW9uOjcyNGJmMGEzZjUwYjQzNzM4OGYyMTdjYTcwYzU5ODkyXzIwMzQwOTY1MTE2MTQw_a6cabd6a-d775-41bc-b921-52fc994fd616">Benefit plansThe Company maintains a 401(k) defined contribution retirement plan in the U.S. and a defined contribution plan in the U.K. for its employees and executive director. The assets of the plans are held separately from those of the Company in independently administered funds. The retirement plan cost charge represents the contributions payable by the Company to the plans during the year. Defined contribution costs during the years ended December 31, 2020 and 2019 amounted to $315 thousand and $203 thousand, respectively.</us-gaap:DefinedContributionPlanTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMjkvZnJhZzo3MjRiZjBhM2Y1MGI0MzczODhmMjE3Y2E3MGM1OTg5Mi90ZXh0cmVnaW9uOjcyNGJmMGEzZjUwYjQzNzM4OGYyMTdjYTcwYzU5ODkyXzMyOTg1MzQ4ODQyNzM_411bd366-5416-4c9b-8626-b8a8e09bc9ec"
      unitRef="usd">315000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMjkvZnJhZzo3MjRiZjBhM2Y1MGI0MzczODhmMjE3Y2E3MGM1OTg5Mi90ZXh0cmVnaW9uOjcyNGJmMGEzZjUwYjQzNzM4OGYyMTdjYTcwYzU5ODkyXzMyOTg1MzQ4ODQyODI_94f90a15-e242-4740-86c1-4674c11e2014"
      unitRef="usd">203000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI0MTcy_c7336ddc-0fea-49f1-908a-7daa00bce991">Taxation&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Verona Pharma plc operates in the United Kingdom and Verona Pharma, Inc. in the United States and they are subject to income taxes in those countries. U.K. corporation tax is charged at 19% and the U.S. Federal Income tax rate is 21%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The components of loss before income taxes are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The components of income tax expense are as follows &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;(in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total income tax expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;A reconciliation of the U.K. statutory income tax rate to our effective income tax rate is as follows (in percentages):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.K. tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development incentive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in deferred tax valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Difference in overseas statutory tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,860)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,860)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D asset&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future exercisable shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Movements in the deferred tax valuation allowance &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation allowance at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation allowance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;These relate to the difference in the tax base of the IP R&amp;amp;D asset and assumed contingent liability and the accounting base, which is nil under US GAAP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Management has reviewed cumulative tax losses and projections of future taxable losses and determined that it is not more likely than not that they will be realized. Accordingly, valuation allowances have been provided over deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;At December 31, 2020 and December 31, 2019, the Company had U.K. net operating losses (&#x201c;NOLs&#x201d;) of $95.7&#160;million and $75.5&#160;million, respectively. The NOLs can be carried forward indefinitely to be offset against future taxable profits, but this is restricted to an annual &#xa3;5&#160;million allowance after which there will be a 50% restriction in the profits that can be covered by losses brought forward.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company files separate income tax returns in the U.K. and the U.S. All necessary income tax filings have been completed for all years up to and including December 31, 2019, and there are no ongoing tax examinations in any jurisdiction. No interest or penalties were recognized in the consolidated statements of operations or consolidated balance sheets. As of December 31, 2020, the Company has no uncertain tax positions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI0MTcz_a80deb3a-0c1e-41c6-9ae7-23c3ba988980">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The components of loss before income taxes are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTpmYzRiMjFkNTdkNjM0NWI2ODY4YjMyODA1M2NlZjc1Mi90YWJsZXJhbmdlOmZjNGIyMWQ1N2Q2MzQ1YjY4NjhiMzI4MDUzY2VmNzUyXzMtMi0xLTEtMzMzMg_7917f80f-1979-46a6-afd3-a521171a9686"
      unitRef="usd">3191000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTpmYzRiMjFkNTdkNjM0NWI2ODY4YjMyODA1M2NlZjc1Mi90YWJsZXJhbmdlOmZjNGIyMWQ1N2Q2MzQ1YjY4NjhiMzI4MDUzY2VmNzUyXzMtNC0xLTEtMzMzMg_2dbdc9aa-ce6a-4ce8-81a5-866cd5df86a8"
      unitRef="usd">-198000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTpmYzRiMjFkNTdkNjM0NWI2ODY4YjMyODA1M2NlZjc1Mi90YWJsZXJhbmdlOmZjNGIyMWQ1N2Q2MzQ1YjY4NjhiMzI4MDUzY2VmNzUyXzMtMi0xLTEtMTQ1NzQ_916f731c-5b30-4b25-a463-af1afdba5483"
      unitRef="usd">-68191000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTpmYzRiMjFkNTdkNjM0NWI2ODY4YjMyODA1M2NlZjc1Mi90YWJsZXJhbmdlOmZjNGIyMWQ1N2Q2MzQ1YjY4NjhiMzI4MDUzY2VmNzUyXzMtNC0xLTEtMTQ1NzQ_41dc19c8-0a8a-48a4-9ddc-d1f01c6b6f58"
      unitRef="usd">-40291000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTpmYzRiMjFkNTdkNjM0NWI2ODY4YjMyODA1M2NlZjc1Mi90YWJsZXJhbmdlOmZjNGIyMWQ1N2Q2MzQ1YjY4NjhiMzI4MDUzY2VmNzUyXzYtMi0xLTEtMzMzMg_79aca95d-cff2-4dbf-801f-53ce28c5c7b2"
      unitRef="usd">-65000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTpmYzRiMjFkNTdkNjM0NWI2ODY4YjMyODA1M2NlZjc1Mi90YWJsZXJhbmdlOmZjNGIyMWQ1N2Q2MzQ1YjY4NjhiMzI4MDUzY2VmNzUyXzYtNC0xLTEtMzMzMg_f5aa1595-2598-4b5c-a77e-f85f03eec308"
      unitRef="usd">-40489000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI0MTc0_f3cdb9b4-9445-4d3c-bae4-7d04f851258d">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The components of income tax expense are as follows &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;(in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total income tax expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzQtMi0xLTEtMzMzOQ_3baacf26-bbc2-4300-857b-2a4ba8f6203c"
      unitRef="usd">146000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzQtNC0xLTEtMzMzOQ_c988b089-a1d4-42e7-bc8b-3ac631a11d05"
      unitRef="usd">72000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzUtMi0xLTEtMzMzOQ_abcf7734-a285-4509-9a4b-954fe173fe71"
      unitRef="usd">0</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzUtNC0xLTEtMzMzOQ_5e67d7d3-5795-4f08-9a36-41d2d0fbd3b2"
      unitRef="usd">0</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzctMi0xLTEtMzMzOQ_89113d8a-85f8-436e-bd91-130d8daf51f1"
      unitRef="usd">146000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzctNC0xLTEtMzMzOQ_da78afad-cb10-4fbe-b74c-b4d9606066ea"
      unitRef="usd">72000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzYtMi0xLTEtMTcxMTU_8a8da82f-59cd-468a-af52-351e485b16fc"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzYtNC0xLTEtMTcxMTU_6016fa0d-f27d-4c9b-989d-f7c735059a15"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzEwLTItMS0xLTMzMzk_4dd5da3e-59ab-4e4d-a17c-0d0379b191a8"
      unitRef="usd">0</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzEwLTQtMS0xLTMzMzk_05fbff4a-f4cb-49aa-bf50-07fc7bc39c5c"
      unitRef="usd">0</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzEzLTItMS0xLTMzMzk_e063a913-e617-4dd7-8ea5-97aa81b3ecd3"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzEzLTQtMS0xLTMzMzk_39c2296b-4a26-4daa-81f9-f610cce4074a"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzE0LTItMS0xLTMzMzk_77806262-26bb-4918-bdec-712c0f849cb7"
      unitRef="usd">146000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTo5YjliMzE3OTFlZjU0ZGU5OTIxNjU4YzAwZTI2YThiMS90YWJsZXJhbmdlOjliOWIzMTc5MWVmNTRkZTk5MjE2NThjMDBlMjZhOGIxXzE0LTQtMS0xLTMzMzk_8211ba4e-4345-48f9-968b-9ba7c925e497"
      unitRef="usd">72000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI0MTc1_46dd257d-f838-4b79-a4b9-527461d9dd56">A reconciliation of the U.K. statutory income tax rate to our effective income tax rate is as follows (in percentages):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.K. tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development incentive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in deferred tax valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Difference in overseas statutory tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzItMi0xLTEtMTcxMTk_fabbab7b-62c8-47a9-b271-8d2d93213dda"
      unitRef="number">0.190</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzItNC0xLTEtMTcxMTk_c469bf76-40c3-4114-a8ca-ed64705fe91f"
      unitRef="number">0.190</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzctMi0xLTEtMzM1MA_f40a87a0-6505-4947-8be6-e1b430b96c60"
      unitRef="number">-0.089</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzctNC0xLTEtMzM1MA_17d63b82-42b1-44db-9a11-8ab863297a6e"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzgtMi0xLTEtMzM1MA_049a5d2c-fc9e-4ff1-b576-e2164df5d57b"
      unitRef="number">0.048</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzgtNC0xLTEtMzM1MA_3a9cc7a6-ff71-4bf7-a375-710fa7c672d6"
      unitRef="number">0.086</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzktMi0xLTEtMzM1MA_140f86ab-1dcf-4641-99ed-cfd31e61b330"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzktNC0xLTEtMzM1MA_9b75672e-afcb-43e0-b6b8-e52b3c7433a4"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzEwLTItMS0xLTMzNTA_46534683-5798-44b1-8fad-ca4adec2609c"
      unitRef="number">-0.059</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzEwLTQtMS0xLTMzNTA_e472523b-3e07-418d-ac93-1780dec2b231"
      unitRef="number">-0.099</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzctMi0xLTEtMjQ0NTU_9aedb0e6-0de7-4fd5-9c38-deff7f44563c"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzctNC0xLTEtMjQ0NTU_37287ed6-4574-4131-80f1-3a7a618cda74"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzExLTItMS0xLTMzNTA_63a7873c-87ec-4987-b719-dd2225664205"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTplNzliZmY1ZTkzMzk0ODcyYjY3YmM5ODk2ZDViZTBmZi90YWJsZXJhbmdlOmU3OWJmZjVlOTMzOTQ4NzJiNjdiYzk4OTZkNWJlMGZmXzExLTQtMS0xLTMzNTA_df9361d2-5d9f-4f9f-8cba-8b44136dc69d"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI0MTc2_99d8a22d-7926-4567-a8b3-a2da2231f77f">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,860)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,860)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D asset&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future exercisable shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Movements in the deferred tax valuation allowance &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation allowance at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation allowance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;These relate to the difference in the tax base of the IP R&amp;amp;D asset and assumed contingent liability and the accounting base, which is nil under US GAAP.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <vrna:DeferredTaxLiabilitiesContingentLiability
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzUtMi0xLTEtMzQzOA_62453d38-8e42-4e84-8cf7-1975d192de64"
      unitRef="usd">5860000</vrna:DeferredTaxLiabilitiesContingentLiability>
    <vrna:DeferredTaxLiabilitiesContingentLiability
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzUtNC0xLTEtMzQzOA_3640ff11-a35c-4a9f-9b27-fae35d147fa0"
      unitRef="usd">95000</vrna:DeferredTaxLiabilitiesContingentLiability>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzctMi0xLTEtMzQzOA_68f15f6a-907c-4623-8fbc-f71b3ebf3c15"
      unitRef="usd">5860000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzctNC0xLTEtMzQzOA_f3a29dec-7da2-455a-9b9f-f5a06209eb4a"
      unitRef="usd">95000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzgtMi0xLTEtMTgxMTM_5074996d-4265-4e54-bbc6-f0eee86b0ec7"
      unitRef="usd">19855000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzgtNC0xLTEtMTgxMTM_4918812a-d574-40e9-8c02-a5e58b8839de"
      unitRef="usd">12835000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzEyLTItMS0xLTM0Mzg_e93ba706-243e-4d89-9f1f-b2cf29397d1c"
      unitRef="usd">5631000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzEyLTQtMS0xLTM0Mzg_0e69b34d-4134-42dd-a1c8-d6a9d5961102"
      unitRef="usd">310000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzEzLTItMS0xLTM0Mzg_356ca178-80c4-4596-ac04-cd52fc649c4e"
      unitRef="usd">10480000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzEzLTQtMS0xLTM0Mzg_a4983ec9-65aa-4c6d-853e-3aa287c79433"
      unitRef="usd">273000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzExLTItMS0xLTE4MTEz_ffc931ed-ff85-4c98-8a69-ee502b75b9e6"
      unitRef="usd">215000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzExLTQtMS0xLTE4MTEz_63f0eab6-5b4f-4b3b-a669-775bdf599ed0"
      unitRef="usd">181000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzEyLTItMS0xLTE4MTEz_d1e92b2c-f491-4a12-98d6-33ab112c65a8"
      unitRef="usd">36181000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzEyLTQtMS0xLTE4MTEz_48cb0003-d38c-4a35-bcd6-510197a8ad57"
      unitRef="usd">13599000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzEzLTItMS0xLTE4MTEz_dfb9dc6a-626c-4023-ba4f-c38be2b5809e"
      unitRef="usd">30321000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzEzLTQtMS0xLTE4MTEz_4bfdba9b-b7d1-4cd1-9c79-3fe37aaac1af"
      unitRef="usd">13504000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzE0LTItMS0xLTE4MTEz_3003ae16-8e6c-416f-ba6e-d44e6ff6953f"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzE0LTQtMS0xLTE4MTEz_404736d5-7166-4c37-9b68-7b14e80f90af"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ifff034be4ded4bcb8670b2917c2d0bd5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzE4LTItMS0xLTE4MTIx_a83f2e3b-ed03-4784-8d06-e4a68a719890"
      unitRef="usd">13504000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i6bcfa5910fbe4e2ca7f076edd714a549_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzE4LTQtMS0xLTE4MTIx_9d6e5e43-7ce2-4a53-ab92-eb9732767fcf"
      unitRef="usd">9322000</us-gaap:ValuationAllowancesAndReservesBalance>
    <vrna:SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates
      contextRef="i52c90d5f0c46487fb88765d553f1b65b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzE5LTItMS0xLTE4MTIx_90269403-f5d6-4778-9c31-29aa13e1d68f"
      unitRef="usd">1632000</vrna:SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates>
    <vrna:SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates
      contextRef="i9935563a347240e5a3824eaba4a823a6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzE5LTQtMS0xLTE4MTMw_63917326-e73b-422b-9963-018b85906a17"
      unitRef="usd">0</vrna:SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates>
    <vrna:SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance
      contextRef="i52c90d5f0c46487fb88765d553f1b65b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzIwLTItMS0xLTE4MTIx_d6db43ee-e3b0-42b1-a092-fcf63354c177"
      unitRef="usd">14815000</vrna:SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance>
    <vrna:SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance
      contextRef="i9935563a347240e5a3824eaba4a823a6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzIwLTQtMS0xLTE4MTIx_ca89f198-7ed8-4b7c-8762-fe8ae562b295"
      unitRef="usd">3802000</vrna:SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance>
    <vrna:SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments
      contextRef="i52c90d5f0c46487fb88765d553f1b65b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzIxLTItMS0xLTE4MTIx_061b539d-bb29-4115-80fc-4805444bee92"
      unitRef="usd">370000</vrna:SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments>
    <vrna:SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments
      contextRef="i9935563a347240e5a3824eaba4a823a6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzIxLTQtMS0xLTE4MTIx_1448a3ab-5efd-4b7f-80d9-6bbf220ae198"
      unitRef="usd">380000</vrna:SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i5c70e119f5364bafabd0f2b4cf13c8cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzIyLTItMS0xLTE4MTIx_7b02ea86-fa23-4a02-8393-e822f389dd01"
      unitRef="usd">30321000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ifff034be4ded4bcb8670b2917c2d0bd5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90YWJsZTozYTZiNWFmNmYyYTM0MDljOWNlZjI5MDM1MjIzMjAyNS90YWJsZXJhbmdlOjNhNmI1YWY2ZjJhMzQwOWM5Y2VmMjkwMzUyMjMyMDI1XzIyLTQtMS0xLTE4MTIx_69703363-3c0d-499c-9ad4-449a79466bff"
      unitRef="usd">13504000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI4MjUy_1977fb07-104c-4c5b-a48a-b73f50f14f2c"
      unitRef="usd">95700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI4MjY5_49bb699f-0ceb-4707-8d5c-e935b5571aea"
      unitRef="usd">75500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:IncomeTaxExaminationPenaltiesAccrued
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI0MTgy_2cf26bf2-636e-4c09-a6d3-46631d2ae0ae"
      unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAccrued>
    <us-gaap:IncomeTaxExaminationInterestAccrued
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI0MTgy_4785d40b-9e21-4622-9113-13321d533c9f"
      unitRef="usd">0</us-gaap:IncomeTaxExaminationInterestAccrued>
    <us-gaap:IncomeTaxExaminationInterestAccrued
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI0MTgy_5420d7ab-fde1-417c-b019-4d213daab429"
      unitRef="usd">0</us-gaap:IncomeTaxExaminationInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAccrued
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI0MTgy_5807b9dd-bb44-4bc8-a5e6-180be2365443"
      unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI0MTgy_b4699813-1329-4803-b087-bcbf34cb8cae"
      unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yOTkvZnJhZzowOTQwODRkYzE3ODU0NWM4ODNlYWQwZjkwOTBjNGE5ZS90ZXh0cmVnaW9uOjA5NDA4NGRjMTc4NTQ1Yzg4M2VhZDBmOTA5MGM0YTllXzIwMzQwOTY1MTI0MTgy_f8060b0c-e139-4cb6-b6b5-57b86388a862"
      unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwODkwNzIwOTg0ODUx_25d5b187-e826-432d-9fac-a287bba00ed9">Share-based compensation&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company operates various share based incentive plans for its staff and issues ordinary shares or ADSs when share-based awards are exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company records share-based compensation expense related to share options and RSUs granted to employees and directors. The expense is included in R&amp;amp;D and general and administrative costs, based on the nature of individual employees&#x2019; functions, and represents the relevant year's allocation of the expense. The costs of share-based compensation to employees are recognized in the consolidated statements of operations and comprehensive loss, together with a corresponding increase in equity over the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Options are issued with an exercise price of the market price on the day of grant and generally vest over a period of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcyNjkw_00bc9b5e-059e-48bb-806a-540b915c41a7"&gt;one&lt;/span&gt; to four years and the contractual life of all options is ten years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows the allocation of share-based compensation between R&amp;amp;D and general and administrative costs (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%"&gt;EMI Option Plan and Pre-IPO Option Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The EMI Option Plan and the Pre-IPO Option Plan were adopted by our board of directors on September 18, 2006, and July 24, 2012, respectively. The total number of shares that may be issued under these plans is the current number of outstanding options, or 114,000 ordinary shares, or 14,250 ADSs, for the EMI Option Plan and 1,860,000 ordinary shares, or 232,500 ADSs, for the Pre-IPO Option Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;No further awards have been granted since the 2017 Incentive Plan was adopted, and no further awards will be granted under them.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%"&gt;2017 Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The 2017 Incentive Plan was adopted by our board of directors and became effective on April 26, 2017, in order to grant share based compensation to certain of the Company&#x2019;s directors and employees. It provides for the grant of stock options, RSUs, and other share-based awards to Company&#x2019;s directors, officers, employees and non-employee directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In the year ended December 31, 2019, the Company modified the terms of all RSUs issued prior to January 1, 2019 to include a market based condition, which was also included in the terms of RSUs issued during 2019. The Company's stock price must be maintained above the equivalent of &#xa3;2 per ordinary share for thirty days for the RSUs to vest, in addition to the existing service condition. The RSUs vest five years after the date of grant irrespective of whether the &#xa3;2 market condition was met. This modification did not result in an increase in the fair value of the RSUs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Share option activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The number of options, the weighted average grant date fair value per stock option, and the weighted average exercise price are all shown below on a per ordinary shares basis. The Company&#x2019;s ADSs that are listed on the Nasdaq Global Market each represent eight ordinary shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows share option activity and includes the options outstanding from all three plans :&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.335%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of share options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average exercise price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate intrinsic value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,752,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,569,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121,970)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,179,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,096,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,506,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(589,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,125,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercisable at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,749,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The exercise prices relate to the equivalent price for an ordinary share, calculated as one eighth of the ADS price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Determining the fair value of share options and RSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The total fair values of the options and RSUs were estimated using the Black-Scholes option-pricing model for equity-settled compensation, amounted to $62.1&#160;million for instruments granted in the year ended December 31, 2020 (2019: $3.1&#160;million). The cost is amortized over the vesting period of the options and RSUs on a straight-line basis using the cliff-vesting method.The following assumptions were used for the Black-Scholes valuation of share options granted in 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Volatility is calculated using historical weekly averages of the Company's share price over a period that is in line with the expected life of the options and RSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Fair value of ordinary shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The fair value of ordinary shares has been based on the share price of the Company&#x2019;s shares on AIM on the evening before the date of grant, as the Company&#x2019;s primary listing was previously on this market.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The risk-free interest rate has been based on the U.K. Government debt yield for the relevant term at the time of grant, as the Company&#x2019;s primary listing was previously on AIM. Effective from the delisting from AIM the Company will use appropriate U.S Government debt yields.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The expected term is determined using the simplified method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Expected dividend&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;There are no expected dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;A summary of the weighted-average assumptions applicable to the share options granted in the applicable years is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0% - 0.21%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.39% - 0.82%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected lives (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.05 - 7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5 - 7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.83% - 75.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.98% - 68.71%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant date fair value (per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.40 - $0.62&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.31 - $0.49&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Restricted stock units activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows RSU activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of RSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,602,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,566,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,091,960)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,992,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of RSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining vesting Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Period in which the target must be achieved&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs subject to time based vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,416,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs subject to milestone based vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 - 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The intrinsic and fair value of RSUs that vested in the year ended December 31, 2020, was $1.5&#160;million (2019: $nil).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;As of December 31, 2020, total compensation cost related to share options and RSUs granted but not yet recognized was $41.8&#160;million. This cost will be amortized to expense over a weighted average remaining period of 1.5 years and will be adjusted for subsequent forfeitures.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia47baec57d49425a9f307369903c9687_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcyNjc4_93e364a0-6a9d-45ad-ae72-f45e1de096de">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i15364ff1d68341ec805494f64c383003_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcyNjcx_0c0f0557-f3bc-49da-a461-d56718af14c7">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwMzc2_8c9a7fe8-4d21-4639-9a2c-cbdd19ffb7a3">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows the allocation of share-based compensation between R&amp;amp;D and general and administrative costs (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7bd04de9015c48df9fe3e3bef6ce4e5d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo1NmM5M2ZhYzg5N2Q0ZTQxYjRjODZlNDY1NjU0OGZlNC90YWJsZXJhbmdlOjU2YzkzZmFjODk3ZDRlNDFiNGM4NmU0NjU2NTQ4ZmU0XzItMi0xLTEtMjA0MjM_5975779c-a433-4bc4-9c8f-28a591b4848b"
      unitRef="usd">9319000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i465329a24eeb4cefbb25e840bfa5bc80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo1NmM5M2ZhYzg5N2Q0ZTQxYjRjODZlNDY1NjU0OGZlNC90YWJsZXJhbmdlOjU2YzkzZmFjODk3ZDRlNDFiNGM4NmU0NjU2NTQ4ZmU0XzItNC0xLTEtMjA0MjU_46177f5a-e92a-4bc3-9855-8173dd738e09"
      unitRef="usd">1692000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibc6a3a52eb8741acb78a572b648649d0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo1NmM5M2ZhYzg5N2Q0ZTQxYjRjODZlNDY1NjU0OGZlNC90YWJsZXJhbmdlOjU2YzkzZmFjODk3ZDRlNDFiNGM4NmU0NjU2NTQ4ZmU0XzMtMi0xLTEtMjA0MjM_b72daef2-df02-44ef-a1eb-56e82c550894"
      unitRef="usd">12858000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i38dd4fa39df844e6af7ab7270ee1dc55_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo1NmM5M2ZhYzg5N2Q0ZTQxYjRjODZlNDY1NjU0OGZlNC90YWJsZXJhbmdlOjU2YzkzZmFjODk3ZDRlNDFiNGM4NmU0NjU2NTQ4ZmU0XzMtNC0xLTEtMjA0MjU_1537417f-9d26-4c76-b704-ff10d3712cc3"
      unitRef="usd">1427000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo1NmM5M2ZhYzg5N2Q0ZTQxYjRjODZlNDY1NjU0OGZlNC90YWJsZXJhbmdlOjU2YzkzZmFjODk3ZDRlNDFiNGM4NmU0NjU2NTQ4ZmU0XzQtMi0xLTEtMjA0MjM_e37a0995-8fbc-4e79-a7cf-d37caf7944da"
      unitRef="usd">22177000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo1NmM5M2ZhYzg5N2Q0ZTQxYjRjODZlNDY1NjU0OGZlNC90YWJsZXJhbmdlOjU2YzkzZmFjODk3ZDRlNDFiNGM4NmU0NjU2NTQ4ZmU0XzQtNC0xLTEtMTAzMjg_0214fbb1-61b6-4b99-9496-70f44746861e"
      unitRef="usd">3119000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="iac60289acf4d49a68397763e265d6cf1_I20060918"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwMzc4_aedca137-796c-494a-90c3-25d771f01ad8"
      unitRef="shares">114000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized
      contextRef="iac60289acf4d49a68397763e265d6cf1_I20060918"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwMzg3_880e15cd-3a14-474a-8368-4861ef694ef2"
      unitRef="shares">14250</vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i3c19fa116eb54bf28428386737d1542d_I20120724"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwMzk1_eb965709-39af-488d-b4ca-eeaf81c8c647"
      unitRef="shares">1860000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized
      contextRef="i3c19fa116eb54bf28428386737d1542d_I20120724"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNDE0_f4500176-4b3e-444a-85cc-455e17c4f777"
      unitRef="shares">232500</vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ia61b9dcc76d44330a7872e53c1b77d1a_D20170401-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNDI2_9e670cb9-ab72-455c-9fa9-18a47efa0274"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iafc15080cb714e279a2a7b822b3d58d6_D20170401-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNDI2_c05d8407-1507-447c-838a-3e6826f0843c"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i747d51980c684daaa52f9e04f16b0666_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNDM1_78f2668a-319a-44ac-a93e-32721f6f4dde"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i210506e1747a4dcab92bcdbad863492a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNDM1_fe7c3939-774b-4250-8cf3-eea6f58bf308"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired
      contextRef="i7e33e5ffa3934ca7a4c7048a96c317a9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNDcx_b02ffbe8-a69c-4cc2-bba7-98d113a69533"
      unitRef="gbpPerShare">2</vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired>
    <vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod
      contextRef="i7e33e5ffa3934ca7a4c7048a96c317a9_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNTEz_cdd16053-91ee-4c6c-aa6c-f2f3da9d42a0">P30D</vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7e33e5ffa3934ca7a4c7048a96c317a9_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNDky_b4ccfb66-290c-4bc1-bd4d-3773a6cfe6fa">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired
      contextRef="i7e33e5ffa3934ca7a4c7048a96c317a9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNDc1_a4592031-5c0d-4e97-bb00-2986b404b45d"
      unitRef="gbpPerShare">2</vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired>
    <dei:EntityListingDepositoryReceiptRatio
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwODkwNzIwOTg0ODM5_fe52a3c5-62dc-4a2e-ad13-9ad1f5f55820"
      unitRef="rate">8</dei:EntityListingDepositoryReceiptRatio>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNTE5_79c098d0-b774-4a98-adec-069c68c04c22">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows share option activity and includes the options outstanding from all three plans :&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.335%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of share options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average exercise price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate intrinsic value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,752,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,569,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121,970)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,179,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,096,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,506,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(589,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,125,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercisable at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,749,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The exercise prices relate to the equivalent price for an ordinary share, calculated as one eighth of the ADS price.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ibc6502e2d84744a1a4f122e93a5bbedc_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzEtMi0xLTEtMzY0Ng_2d036b6d-eb8d-4c25-ac94-207a59124255"
      unitRef="shares">8752114</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ibc6502e2d84744a1a4f122e93a5bbedc_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzEtNC0xLTEtMzY0Ng_8e66e596-e13a-438c-92f7-a26444ba4e9d"
      unitRef="usdPerShare">2.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzItMi0xLTEtMzY0Ng_391fe287-8021-40f0-9499-1a9755a32133"
      unitRef="shares">5569050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzItNC0xLTEtMzY0Ng_613f9cc3-837e-4e62-bdf9-677906382286"
      unitRef="usdPerShare">0.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzMtMi0xLTEtMzY0Ng_270355f2-ee4c-4580-a7ec-41f8e064a499"
      unitRef="shares">121970</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzMtNC0xLTEtMzY0Ng_19436ae2-dde4-4887-b13a-ff078052254a"
      unitRef="usdPerShare">1.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzQtMi0xLTEtMzY0Ng_1cb84cf7-108f-4218-b9b8-8f7779ddbe10"
      unitRef="shares">19998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzQtNC0xLTEtMzY0Ng_0ad207e7-ce8b-4c62-82db-d1fe645fdc17"
      unitRef="usdPerShare">2.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzUtMi0xLTEtMzY0Ng_302cfbd5-78ab-4809-a294-2a7c9b8f8ef4"
      unitRef="shares">14179196</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzUtNC0xLTEtMzY0Ng_87120c53-8d05-4fc6-90a8-0dce38fd9433"
      unitRef="usdPerShare">1.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzUtNi0xLTEtMzY0Ng_ccf5c944-d62a-4dc3-8cc5-9ffcd0cc3de7">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzUtOC0xLTEtMjA1NzI_2fd5ada0-2988-4ef6-a10b-28cf014492f9"
      unitRef="usd">933000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzYtMi0xLTEtMzY0Ng_fbfbc52f-ad48-4013-89ec-c8ecef758b2c"
      unitRef="shares">2096285</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzYtNC0xLTEtMzY0Ng_88ef8828-e012-4f20-bf3f-adad189ebff7"
      unitRef="usdPerShare">0.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzctMi0xLTEtMzY0Ng_b1763c5d-4ba7-4310-a961-6b66c9065363"
      unitRef="shares">2506017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzctNC0xLTEtMzY0Ng_4a7596ee-962e-40f1-ac9e-ebe7e47ba557"
      unitRef="usdPerShare">1.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzgtMi0xLTEtMzY0Ng_a14336e9-2b91-404d-ba59-d82dff287b8f"
      unitRef="shares">589128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzgtNC0xLTEtMzY0Ng_e1ba4bb2-079e-4c98-8d40-dd02448f415a"
      unitRef="usdPerShare">1.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzktMi0xLTEtMTIyOTE_47ee7143-f09f-458b-98ad-accf3a92bd1e"
      unitRef="shares">54664</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzktNC0xLTEtMTIyOTE_638f8fcf-90e8-41f0-ad2c-01a5a6c5c331"
      unitRef="usdPerShare">0.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzktMi0xLTEtMzY0Ng_8a3980b0-7d9a-4abb-bb06-7e93af3ffff2"
      unitRef="shares">13125672</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzktNC0xLTEtMzY0Ng_4fb5e658-7f95-4512-b236-bb9b6cd27041"
      unitRef="usdPerShare">1.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzktNi0xLTEtMzY0Ng_c7d3129e-2da0-4abc-b886-991c4a6c55c1">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzEwLTgtMS0xLTIwNTc0_8729a66b-4730-4ab9-ac92-fc992e18c374"
      unitRef="usd">914000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzEwLTItMS0xLTM2NTc_205149da-ccc2-497a-b7ef-149e4282a277"
      unitRef="shares">7749296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzEwLTQtMS0xLTM2NTc_9e664506-9e9d-4006-aa3e-017f39ac961a"
      unitRef="usdPerShare">1.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzEwLTYtMS0xLTM2NTc_c9e1bc4a-6b17-407b-a46c-031cd4bc2bcd">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTo3NzkxMTEwYWYyZTk0ZGU2YTg1OTM5ZWNlMjNkY2FhNS90YWJsZXJhbmdlOjc3OTExMTBhZjJlOTRkZTZhODU5MzllY2UyM2RjYWE1XzExLTgtMS0xLTIwNTc0_6e90e79a-7ddc-4f52-b956-dfb3e52e1fa4"
      unitRef="usd">220000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <dei:EntityListingDepositoryReceiptRatio
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwOTcx_4fee5e99-ed77-4742-8b25-cd5970cb07c0"
      unitRef="rate">8</dei:EntityListingDepositoryReceiptRatio>
    <vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNTIy_2ff1886f-17ef-4a7e-af56-6bc5c08ca5e5"
      unitRef="usd">62100000</vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue>
    <vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNTM4_4b8130e6-e97e-4f89-8bce-60ceebaf457e"
      unitRef="usd">3100000</vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwODkwNzIwOTg0ODUw_bed61fd1-0f0e-41bc-8ad2-dc534a598e6e">A summary of the weighted-average assumptions applicable to the share options granted in the applicable years is as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0% - 0.21%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.39% - 0.82%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected lives (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.05 - 7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5 - 7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.83% - 75.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.98% - 68.71%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant date fair value (per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.40 - $0.62&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.31 - $0.49&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i15364ff1d68341ec805494f64c383003_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzEtMi0xLTEtMzY4My90ZXh0cmVnaW9uOmJkMWY5MDhjZDhhYTQyZjdhMTYwMDQ1Y2MyYTNlNzQ2XzIwMzQwOTY1MTEzODcy_18210e56-6a56-4bc2-9e14-439c7952ba0a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i15364ff1d68341ec805494f64c383003_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzEtMi0xLTEtMzY4My90ZXh0cmVnaW9uOmJkMWY5MDhjZDhhYTQyZjdhMTYwMDQ1Y2MyYTNlNzQ2XzIwMzQwOTY1MTEzODgw_c957ec56-20b7-4f9f-8a6d-42e0e14d808f"
      unitRef="number">0.0021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="if3ed89efc5e44f55be2b1d1c803d1f72_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzEtNC0xLTEtMzY4My90ZXh0cmVnaW9uOjgxNzY4ZjE3NGE0YzQzYjA5Yzg0NGExOGNlZDBlZDEzXzIwMzQwOTY1MTEzODc4_974726af-712c-4463-a0f2-75dcb868c44b"
      unitRef="number">0.0039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="if3ed89efc5e44f55be2b1d1c803d1f72_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzEtNC0xLTEtMzY4My90ZXh0cmVnaW9uOjgxNzY4ZjE3NGE0YzQzYjA5Yzg0NGExOGNlZDBlZDEzXzIwMzQwOTY1MTEzODg2_584fa5fd-b764-4367-8926-c023523eec9e"
      unitRef="number">0.0082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0c63e739a8e547e990aedd5fb7ed7cf4_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzItMi0xLTEtMzY4My90ZXh0cmVnaW9uOjBhNDc5YjE2MmU3YjRlMGFiY2Q4ZWM0ZDQ5ZTM5YWMwXzIwMzQwOTY1MTEzODcy_413c0c90-bc6b-4e9a-bba9-058611125000">P5Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia47baec57d49425a9f307369903c9687_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzItMi0xLTEtMzY4My90ZXh0cmVnaW9uOjBhNDc5YjE2MmU3YjRlMGFiY2Q4ZWM0ZDQ5ZTM5YWMwXzIwMzQwOTY1MTEzODc2_a2378533-7d87-4a94-97f9-7c7562772378">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i75308170234746af98ca1381553d9120_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzItNC0xLTEtMzY4My90ZXh0cmVnaW9uOmQ1MTBlMGFhZWFhZTQ1OTg5OTUzYTlhMDIwNWU5MGIyXzIwMzQwOTY1MTEzODcw_60ea6c31-0f06-4c8a-9fc0-f9f44679fa50">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i44675776f6c54a54a40dc4ccde2d3c52_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzItNC0xLTEtMzY4My90ZXh0cmVnaW9uOmQ1MTBlMGFhZWFhZTQ1OTg5OTUzYTlhMDIwNWU5MGIyXzIwMzQwOTY1MTEzODc0_74e631cf-0afe-4968-8fe1-b60268b01d42">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i15364ff1d68341ec805494f64c383003_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzMtMi0xLTEtMzY4My90ZXh0cmVnaW9uOjEyNTk0NGE2OTE5YzQyZTc4MzJkOGI5NWFkNDQ5MzNlXzIwMzQwOTY1MTEzODgx_559b809e-814a-4c4f-afe2-ae289e6aafd3"
      unitRef="number">0.6583</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i15364ff1d68341ec805494f64c383003_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzMtMi0xLTEtMzY4My90ZXh0cmVnaW9uOjEyNTk0NGE2OTE5YzQyZTc4MzJkOGI5NWFkNDQ5MzNlXzIwMzQwOTY1MTEzODkw_f5d13401-7ba6-4f0b-9319-4293de78c8d7"
      unitRef="number">0.7540</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="if3ed89efc5e44f55be2b1d1c803d1f72_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzMtNC0xLTEtMzY4My90ZXh0cmVnaW9uOjIyNDEzMmFhMjAzNzQ2ZDA4NWI4ZjcyYmZkMDQ1MDUxXzIwMzQwOTY1MTEzODgx_5af6f56a-323b-4204-9dc2-e6b767e6b469"
      unitRef="number">0.6798</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="if3ed89efc5e44f55be2b1d1c803d1f72_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzMtNC0xLTEtMzY4My90ZXh0cmVnaW9uOjIyNDEzMmFhMjAzNzQ2ZDA4NWI4ZjcyYmZkMDQ1MDUxXzIwMzQwOTY1MTEzODkw_34e67f02-9ac9-4983-abe2-b8a6982d5f02"
      unitRef="number">0.6871</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i15364ff1d68341ec805494f64c383003_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzQtMi0xLTEtMzY4Mw_d51d87b1-00d6-4861-884d-a21ab1e951ad"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if3ed89efc5e44f55be2b1d1c803d1f72_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzQtNC0xLTEtMzY4Mw_80797c53-d6fa-4a82-91f7-cd05740998e6"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0c63e739a8e547e990aedd5fb7ed7cf4_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzUtMi0xLTEtMzY4My90ZXh0cmVnaW9uOjI2NzgxZmJkM2U1ZTRkNjY5ZjAyZmEwM2NhNTNiZTdmXzIwMzQwOTY1MTEzODc4_aeeed79b-0f6a-4429-be07-c962d33a41e5"
      unitRef="usdPerShare">0.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia47baec57d49425a9f307369903c9687_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzUtMi0xLTEtMzY4My90ZXh0cmVnaW9uOjI2NzgxZmJkM2U1ZTRkNjY5ZjAyZmEwM2NhNTNiZTdmXzIwMzQwOTY1MTEzODg2_d96e23d8-a225-48fd-aa3d-2da1ce350a67"
      unitRef="usdPerShare">0.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i75308170234746af98ca1381553d9120_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzUtNC0xLTEtMzY4My90ZXh0cmVnaW9uOjhjNzUwOTc1MDQwYzRmYjU4YmUxNDVjNDFmZjcwOGY0XzIwMzQwOTY1MTEzODc4_0daff27d-da3e-40d2-a9c4-529c8c984684"
      unitRef="usdPerShare">0.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i44675776f6c54a54a40dc4ccde2d3c52_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTplNjFmZWM4YjJlMTQ0OTYwOWQxMzk0ZGMyZjIxMmUzOS90YWJsZXJhbmdlOmU2MWZlYzhiMmUxNDQ5NjA5ZDEzOTRkYzJmMjEyZTM5XzUtNC0xLTEtMzY4My90ZXh0cmVnaW9uOjhjNzUwOTc1MDQwYzRmYjU4YmUxNDVjNDFmZjcwOGY0XzIwMzQwOTY1MTEzODg2_65f40a04-b81b-45c6-9ebb-e3950525217c"
      unitRef="usdPerShare">0.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNTUy_572354c9-9847-4706-ad04-da736ea67673">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows RSU activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of RSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,602,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,566,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,091,960)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,992,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of RSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining vesting Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Period in which the target must be achieved&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs subject to time based vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,416,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs subject to milestone based vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 - 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5c77df9054424edb9685cd91224a73df_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTphOTVjMzAyMDRhOTE0NjQ2OTQyOWFlNGRkYWEzMDJhYi90YWJsZXJhbmdlOmE5NWMzMDIwNGE5MTQ2NDY5NDI5YWU0ZGRhYTMwMmFiXzEtMi0xLTEtMTM3MjU_007db3ef-7010-4fb0-b115-31d76e8b97c8"
      unitRef="shares">862473</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i35514ffd7c034b0e8ce21b1da270c038_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTphOTVjMzAyMDRhOTE0NjQ2OTQyOWFlNGRkYWEzMDJhYi90YWJsZXJhbmdlOmE5NWMzMDIwNGE5MTQ2NDY5NDI5YWU0ZGRhYTMwMmFiXzItMi0xLTEtMTM3MjU_37c3eedf-7db9-4598-bbe1-84a30a41d1eb"
      unitRef="shares">740496</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i844f6711369540ba826df75f6b6a22dd_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTphOTVjMzAyMDRhOTE0NjQ2OTQyOWFlNGRkYWEzMDJhYi90YWJsZXJhbmdlOmE5NWMzMDIwNGE5MTQ2NDY5NDI5YWU0ZGRhYTMwMmFiXzUtMi0xLTEtMTM3MjU_b3e9bfa6-157c-438f-b11c-76608a827f77"
      unitRef="shares">1602969</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i35514ffd7c034b0e8ce21b1da270c038_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTphOTVjMzAyMDRhOTE0NjQ2OTQyOWFlNGRkYWEzMDJhYi90YWJsZXJhbmdlOmE5NWMzMDIwNGE5MTQ2NDY5NDI5YWU0ZGRhYTMwMmFiXzUtNC0xLTEtMjEzNjU_5656bca0-dea5-4d4f-84b4-acc04c82bffd">P3Y4M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i3bc3d048b42b479595d7e0e6de32ce57_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTphOTVjMzAyMDRhOTE0NjQ2OTQyOWFlNGRkYWEzMDJhYi90YWJsZXJhbmdlOmE5NWMzMDIwNGE5MTQ2NDY5NDI5YWU0ZGRhYTMwMmFiXzYtMi0xLTEtMTM3MjU_29d9a172-6764-4a08-8083-dbb9b951498c"
      unitRef="shares">62566271</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i3bc3d048b42b479595d7e0e6de32ce57_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTphOTVjMzAyMDRhOTE0NjQ2OTQyOWFlNGRkYWEzMDJhYi90YWJsZXJhbmdlOmE5NWMzMDIwNGE5MTQ2NDY5NDI5YWU0ZGRhYTMwMmFiXzctMi0xLTEtMTM3MjU_c39e0daf-c25d-4332-898e-105dcde05552"
      unitRef="shares">84920</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i3bc3d048b42b479595d7e0e6de32ce57_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTphOTVjMzAyMDRhOTE0NjQ2OTQyOWFlNGRkYWEzMDJhYi90YWJsZXJhbmdlOmE5NWMzMDIwNGE5MTQ2NDY5NDI5YWU0ZGRhYTMwMmFiXzgtMi0xLTEtMTM3MjU_e6339cbc-0a46-4322-aac8-e1e3c5267ce4"
      unitRef="shares">2091960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i2c41d3b6c046482b826d8cdf888acde0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTphOTVjMzAyMDRhOTE0NjQ2OTQyOWFlNGRkYWEzMDJhYi90YWJsZXJhbmdlOmE5NWMzMDIwNGE5MTQ2NDY5NDI5YWU0ZGRhYTMwMmFiXzktMi0xLTEtMTM3MjU_c934801b-c348-48ec-a0ab-60f530ee295c"
      unitRef="shares">61992360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i3bc3d048b42b479595d7e0e6de32ce57_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTphOTVjMzAyMDRhOTE0NjQ2OTQyOWFlNGRkYWEzMDJhYi90YWJsZXJhbmdlOmE5NWMzMDIwNGE5MTQ2NDY5NDI5YWU0ZGRhYTMwMmFiXzktNC0xLTEtMjE1MDU_1ac1f9e1-6e47-44b2-8b6c-977cc1afae93">P1Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="idce44936200646a39eb2e2ac020a3b66_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTpiZmExZTZiZmFjMDk0YmRmOThiZWM4MDFmYzAyMWI4Mi90YWJsZXJhbmdlOmJmYTFlNmJmYWMwOTRiZGY5OGJlYzgwMWZjMDIxYjgyXzEtMi0xLTEtMzY5OQ_6954ea2d-0d5b-452a-abf7-b4aa5f310205"
      unitRef="shares">61416336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod
      contextRef="idffe8ebf902f434a94b6fcaa44362bd1_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTpiZmExZTZiZmFjMDk0YmRmOThiZWM4MDFmYzAyMWI4Mi90YWJsZXJhbmdlOmJmYTFlNmJmYWMwOTRiZGY5OGJlYzgwMWZjMDIxYjgyXzEtNC0xLTEtMzY5OQ_50e0af21-9b41-43af-a7f7-60cf3860375c">P1Y6M</vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ie67bf5c881684176b281b06cfe0628ed_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTpiZmExZTZiZmFjMDk0YmRmOThiZWM4MDFmYzAyMWI4Mi90YWJsZXJhbmdlOmJmYTFlNmJmYWMwOTRiZGY5OGJlYzgwMWZjMDIxYjgyXzItMi0xLTEtMzY5OQ_2d33067c-ee33-4276-bd48-111ebf50b276"
      unitRef="shares">576024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod
      contextRef="i0cb4743b3dc645c38fc5bff065067b3c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90YWJsZTpiZmExZTZiZmFjMDk0YmRmOThiZWM4MDFmYzAyMWI4Mi90YWJsZXJhbmdlOmJmYTFlNmJmYWMwOTRiZGY5OGJlYzgwMWZjMDIxYjgyXzItNC0xLTEtMzY5OQ_beaeec8e-b652-469a-a463-f728da35242f">P2Y6M</vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i3bc3d048b42b479595d7e0e6de32ce57_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNTU1_047e3834-34da-493a-b3a8-718f059598ff"
      unitRef="usd">1500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i35514ffd7c034b0e8ce21b1da270c038_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNTcz_b961de6a-5fe6-4415-9a1b-815507b8ad2c"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="idecac34827ce472182dc1492d400ffdf_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcwNjI5_8f692089-1177-4a4a-a13f-0552a6acbb63"
      unitRef="usd">41800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzU0OTc1NTg3MDkxMg_6ac5db54-901f-4a9e-b70e-2cdb1d773abd">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90ZXh0cmVnaW9uOmNhMGRhMjE3ZjBjNTQ4MjE5YzI2YjFmZTk0MzBjNzQ0XzIwMzQwOTY1MTE5NjA0_edc81351-96c0-460e-b1f4-a6f9a7c33f8b">Net loss per share &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Net loss per share is calculated on an ordinary share basis. The Company&#x2019;s ADSs that are listed on the Nasdaq Global Market each represent eight ordinary shares.The following table shows the computation of basic and diluted earnings per share for 2020 and 2019 (net loss in thousands, loss per share in cents):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss available to ordinary shareholders - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,932,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,326,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;During the years ended December 31, 2020 and 2019, outstanding share options, RSUs and warrants of 87,519,294 and 28,183,427, respectively, were not included in the computation of diluted earnings per ordinary share, because to do so would be antidilutive.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90ZXh0cmVnaW9uOmNhMGRhMjE3ZjBjNTQ4MjE5YzI2YjFmZTk0MzBjNzQ0XzIwMzQwOTY1MTE5NjA1_a79fe95a-0690-407b-a40e-9a5cca19d126">The following table shows the computation of basic and diluted earnings per share for 2020 and 2019 (net loss in thousands, loss per share in cents):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss available to ordinary shareholders - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,932,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,326,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90YWJsZTo5MjQ3ZGY2NmQ5Mjk0YmJiODkxM2IxMzViYzc2Njk0Ny90YWJsZXJhbmdlOjkyNDdkZjY2ZDkyOTRiYmI4OTEzYjEzNWJjNzY2OTQ3XzQtMi0xLTEtMzMxNw_8fc43d04-b910-4889-8955-88156185a64d"
      unitRef="usd">-65146000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90YWJsZTo5MjQ3ZGY2NmQ5Mjk0YmJiODkxM2IxMzViYzc2Njk0Ny90YWJsZXJhbmdlOjkyNDdkZjY2ZDkyOTRiYmI4OTEzYjEzNWJjNzY2OTQ3XzQtNC0xLTEtMzMxNw_9ba2b235-1181-4e8f-a039-49ba3a507a27"
      unitRef="usd">-40561000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90YWJsZTo5MjQ3ZGY2NmQ5Mjk0YmJiODkxM2IxMzViYzc2Njk0Ny90YWJsZXJhbmdlOjkyNDdkZjY2ZDkyOTRiYmI4OTEzYjEzNWJjNzY2OTQ3XzUtMi0xLTEtMzMxNw_191abda8-7778-4b77-8975-dfbb2ed77533"
      unitRef="usd">-65146000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90YWJsZTo5MjQ3ZGY2NmQ5Mjk0YmJiODkxM2IxMzViYzc2Njk0Ny90YWJsZXJhbmdlOjkyNDdkZjY2ZDkyOTRiYmI4OTEzYjEzNWJjNzY2OTQ3XzUtMi0xLTEtMzMxNw_98542997-ccce-4b05-98bd-9f79bd01ce85"
      unitRef="usd">-65146000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90YWJsZTo5MjQ3ZGY2NmQ5Mjk0YmJiODkxM2IxMzViYzc2Njk0Ny90YWJsZXJhbmdlOjkyNDdkZjY2ZDkyOTRiYmI4OTEzYjEzNWJjNzY2OTQ3XzUtNC0xLTEtMzMxNw_4386ef0d-c03b-48c8-a6a6-fd726c889b38"
      unitRef="usd">-40561000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90YWJsZTo5MjQ3ZGY2NmQ5Mjk0YmJiODkxM2IxMzViYzc2Njk0Ny90YWJsZXJhbmdlOjkyNDdkZjY2ZDkyOTRiYmI4OTEzYjEzNWJjNzY2OTQ3XzUtNC0xLTEtMzMxNw_c0d13325-1746-4225-9324-be0de78ae19f"
      unitRef="usd">-40561000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90YWJsZTo5MjQ3ZGY2NmQ5Mjk0YmJiODkxM2IxMzViYzc2Njk0Ny90YWJsZXJhbmdlOjkyNDdkZjY2ZDkyOTRiYmI4OTEzYjEzNWJjNzY2OTQ3XzctMi0xLTEtMzMxNw_f78f6444-ab95-4ed2-a0d1-f6abcf64dd06"
      unitRef="shares">262932653</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90YWJsZTo5MjQ3ZGY2NmQ5Mjk0YmJiODkxM2IxMzViYzc2Njk0Ny90YWJsZXJhbmdlOjkyNDdkZjY2ZDkyOTRiYmI4OTEzYjEzNWJjNzY2OTQ3XzctNC0xLTEtMzMxNw_650966fc-d3a6-4971-b26f-f1b2cd80b300"
      unitRef="shares">105326638</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90YWJsZTo5MjQ3ZGY2NmQ5Mjk0YmJiODkxM2IxMzViYzc2Njk0Ny90YWJsZXJhbmdlOjkyNDdkZjY2ZDkyOTRiYmI4OTEzYjEzNWJjNzY2OTQ3XzgtMi0xLTEtMzMxNw_1b72646d-e556-44e5-a75a-7974c4e8b298"
      unitRef="usdPerShare">-0.25</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90YWJsZTo5MjQ3ZGY2NmQ5Mjk0YmJiODkxM2IxMzViYzc2Njk0Ny90YWJsZXJhbmdlOjkyNDdkZjY2ZDkyOTRiYmI4OTEzYjEzNWJjNzY2OTQ3XzgtNC0xLTEtMzMxNw_31947bf6-f608-460b-96d9-a90f2cfa7481"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90ZXh0cmVnaW9uOmNhMGRhMjE3ZjBjNTQ4MjE5YzI2YjFmZTk0MzBjNzQ0XzIwMzQwOTY1MTIyMDUz_b9d8ef38-e8a9-4fdc-be29-b0aabef2414b"
      unitRef="shares">87519294</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1c68faae09684ddba54ea78663480657_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8zMDQvZnJhZzpjYTBkYTIxN2YwYzU0ODIxOWMyNmIxZmU5NDMwYzc0NC90ZXh0cmVnaW9uOmNhMGRhMjE3ZjBjNTQ4MjE5YzI2YjFmZTk0MzBjNzQ0XzIwMzQwOTY1MTIyMDY1_6d7fbbe5-2eac-4b50-880a-58fdcad9ee14"
      unitRef="shares">28183427</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90ZXh0cmVnaW9uOjZjMTgyMGJkZGQ3NjQ2NjJhMDg5M2NkYzQ0MDVjM2U5XzIwMzQwOTY1MTE1NjU4_0e2b55a5-507c-46cb-8991-8097187535be">Related party transactions and other shareholder matters&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In the year ended December 31, 2019, Anders Ullman, a director of the Company, provided consultancy services to the Company for which the Company paid him $33&#160;thousand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In the year ended December 31, 2020, certain directors and officers participated in the Private Placement, summarized below (in thousands, except for number of shares acquired):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Participation in Private Placement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Ordinary Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Consideration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dr. Ebsworth&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dr. Zaccardelli&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mr. Sinha (through connected persons)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dr. Ullman&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dr. Edwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mr. Hahn&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="iaed0afb2f5ac4a73bc91d4c2a32c115e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90ZXh0cmVnaW9uOjZjMTgyMGJkZGQ3NjQ2NjJhMDg5M2NkYzQ0MDVjM2U5XzIwMzQwOTY1MTE1NjQ1_c22886e0-d172-4f90-9023-396515d7ec37"
      unitRef="usd">33000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90ZXh0cmVnaW9uOjZjMTgyMGJkZGQ3NjQ2NjJhMDg5M2NkYzQ0MDVjM2U5XzIwMzQwOTY1MTE1NjU5_381a1364-3825-4920-a01b-a001e0ac9e1b">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In the year ended December 31, 2020, certain directors and officers participated in the Private Placement, summarized below (in thousands, except for number of shares acquired):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Participation in Private Placement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Ordinary Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Consideration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dr. Ebsworth&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dr. Zaccardelli&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mr. Sinha (through connected persons)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dr. Ullman&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dr. Edwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mr. Hahn&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ia323b627bb0e4dfda11f8e943e75767d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90YWJsZTpmOGI3NDZkOWZlYWM0MTNjYjg3NDg2M2RmMzY5MDExNS90YWJsZXJhbmdlOmY4Yjc0NmQ5ZmVhYzQxM2NiODc0ODYzZGYzNjkwMTE1XzEtMi0xLTEtMTY0OTk_51805f37-51c1-4b53-b939-905df4ebba80"
      unitRef="shares">222216</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ia323b627bb0e4dfda11f8e943e75767d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90YWJsZTpmOGI3NDZkOWZlYWM0MTNjYjg3NDg2M2RmMzY5MDExNS90YWJsZXJhbmdlOmY4Yjc0NmQ5ZmVhYzQxM2NiODc0ODYzZGYzNjkwMTE1XzEtNC0xLTEtMTY1MDE_601e1bb1-14f4-4e06-adc5-2476c275d124"
      unitRef="gbp">100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i14e765c2f7c2471cac03f164f5c1521e_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90YWJsZTpmOGI3NDZkOWZlYWM0MTNjYjg3NDg2M2RmMzY5MDExNS90YWJsZXJhbmdlOmY4Yjc0NmQ5ZmVhYzQxM2NiODc0ODYzZGYzNjkwMTE1XzItMi0xLTEtMTY0OTk_cc856b34-4a44-44f0-9c73-9e140d31aeca"
      unitRef="shares">444440</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i14e765c2f7c2471cac03f164f5c1521e_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90YWJsZTpmOGI3NDZkOWZlYWM0MTNjYjg3NDg2M2RmMzY5MDExNS90YWJsZXJhbmdlOmY4Yjc0NmQ5ZmVhYzQxM2NiODc0ODYzZGYzNjkwMTE1XzItNC0xLTEtMTY1MDE_69bf1a86-841d-4a9c-9fca-3b80c17c27c5"
      unitRef="usd">249998</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i9b7fe6a0bec54714ba0212643a952e53_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90YWJsZTpmOGI3NDZkOWZlYWM0MTNjYjg3NDg2M2RmMzY5MDExNS90YWJsZXJhbmdlOmY4Yjc0NmQ5ZmVhYzQxM2NiODc0ODYzZGYzNjkwMTE1XzMtMi0xLTEtMTY0OTk_6e262410-0984-4702-8f95-d9939911a584"
      unitRef="shares">533328</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i9b7fe6a0bec54714ba0212643a952e53_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90YWJsZTpmOGI3NDZkOWZlYWM0MTNjYjg3NDg2M2RmMzY5MDExNS90YWJsZXJhbmdlOmY4Yjc0NmQ5ZmVhYzQxM2NiODc0ODYzZGYzNjkwMTE1XzMtNC0xLTEtMTY1MDE_8c0f6827-5a35-4b41-bb55-69f55afc19a4"
      unitRef="usd">299997</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ibf836d4ae04748dd8b1be54f7881b5a8_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90YWJsZTpmOGI3NDZkOWZlYWM0MTNjYjg3NDg2M2RmMzY5MDExNS90YWJsZXJhbmdlOmY4Yjc0NmQ5ZmVhYzQxM2NiODc0ODYzZGYzNjkwMTE1XzQtMi0xLTEtMTY0OTk_dc1d6948-20ba-48ec-a716-35262359e0d6"
      unitRef="shares">266664</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ibf836d4ae04748dd8b1be54f7881b5a8_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90YWJsZTpmOGI3NDZkOWZlYWM0MTNjYjg3NDg2M2RmMzY5MDExNS90YWJsZXJhbmdlOmY4Yjc0NmQ5ZmVhYzQxM2NiODc0ODYzZGYzNjkwMTE1XzQtNC0xLTEtMTY1MDE_e3d973ab-f0de-443e-96f0-81cceecff162"
      unitRef="usd">149983</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i05bb837cdc2e4bab8740f004c4754b5d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90YWJsZTpmOGI3NDZkOWZlYWM0MTNjYjg3NDg2M2RmMzY5MDExNS90YWJsZXJhbmdlOmY4Yjc0NmQ5ZmVhYzQxM2NiODc0ODYzZGYzNjkwMTE1XzUtMi0xLTEtMTY0OTk_48ba3753-c873-4a24-a569-ab9dc3e97a33"
      unitRef="shares">53328</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i05bb837cdc2e4bab8740f004c4754b5d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90YWJsZTpmOGI3NDZkOWZlYWM0MTNjYjg3NDg2M2RmMzY5MDExNS90YWJsZXJhbmdlOmY4Yjc0NmQ5ZmVhYzQxM2NiODc0ODYzZGYzNjkwMTE1XzUtNC0xLTEtMTY1MDE_00f14a62-9d89-45a2-b87f-7a1387064b26"
      unitRef="usd">29997</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ia6ee6389e25345f08e3512dcfb211a54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90YWJsZTpmOGI3NDZkOWZlYWM0MTNjYjg3NDg2M2RmMzY5MDExNS90YWJsZXJhbmdlOmY4Yjc0NmQ5ZmVhYzQxM2NiODc0ODYzZGYzNjkwMTE1XzYtMi0xLTEtMTY0OTk_35dbe698-3ae4-4ea4-b4da-eefa593ef6c3"
      unitRef="shares">177784</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ia6ee6389e25345f08e3512dcfb211a54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDkvZnJhZzo2YzE4MjBiZGRkNzY0NjYyYTA4OTNjZGM0NDA1YzNlOS90YWJsZTpmOGI3NDZkOWZlYWM0MTNjYjg3NDg2M2RmMzY5MDExNS90YWJsZXJhbmdlOmY4Yjc0NmQ5ZmVhYzQxM2NiODc0ODYzZGYzNjkwMTE1XzYtNC0xLTEtMTY1MDE_b64e6f72-0a50-478c-872b-b529f2bd0455"
      unitRef="usd">100004</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988423760104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 19, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Verona Pharma plc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1489389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3 More London Riverside<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">London<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">SE1 2RE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">283 4200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, nominal value &#163;0.05 per share*<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VRNA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463,478,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant&#8217;s definitive proxy statement that the registrant intends to file with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant&#8217;s 2021 Annual Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001657312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988423652872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 187,986<span></span>
</td>
<td class="nump">$ 30,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">4,538<span></span>
</td>
<td class="nump">1,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_TaxCreditAndIncomeTaxesReceivableCurrent', window );">Tax and tax incentive receivables</a></td>
<td class="nump">8,260<span></span>
</td>
<td class="nump">9,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,720<span></span>
</td>
<td class="nump">2,021<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets:</a></td>
<td class="nump">202,504<span></span>
</td>
<td class="nump">54,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Furniture and equipment, net</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">545<span></span>
</td>
<td class="nump">585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">1,050<span></span>
</td>
<td class="nump">1,288<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets:</a></td>
<td class="nump">1,702<span></span>
</td>
<td class="nump">1,936<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">204,206<span></span>
</td>
<td class="nump">56,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">1,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">10,863<span></span>
</td>
<td class="nump">8,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">798<span></span>
</td>
<td class="nump">611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_WarrantLiabilityCurrent', window );">Warrants</a></td>
<td class="nump">2,246<span></span>
</td>
<td class="nump">1,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">14,203<span></span>
</td>
<td class="nump">12,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Term loan</a></td>
<td class="nump">4,635<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating Lease, Liability, Noncurrent</a></td>
<td class="nump">514<span></span>
</td>
<td class="nump">652<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">5,149<span></span>
</td>
<td class="nump">652<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">19,352<span></span>
</td>
<td class="nump">13,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary &#163;0.05 par value shares; 488,304,446 and 105,326,638 issued, and 463,304,446 and 105,326,638 outstanding, at December 31, 2020 and 2019, respectively</a></td>
<td class="nump">31,794<span></span>
</td>
<td class="nump">7,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">366,411<span></span>
</td>
<td class="nump">179,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Ordinary shares held in treasury</a></td>
<td class="num">(1,700)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(2,280)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(207,050)<span></span>
</td>
<td class="num">(141,779)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">184,854<span></span>
</td>
<td class="nump">42,741<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 204,206<span></span>
</td>
<td class="nump">$ 56,234<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_TaxCreditAndIncomeTaxesReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit And Income Taxes Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_TaxCreditAndIncomeTaxesReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_WarrantLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_WarrantLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988424157528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - &#163; / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in pounds sterling per share)</a></td>
<td class="nump">&#163; 0.05<span></span>
</td>
<td class="nump">&#163; 0.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">488,304,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">463,304,446<span></span>
</td>
<td class="nump">105,326,638<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988426505512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 44,505<span></span>
</td>
<td class="nump">$ 42,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">29,772<span></span>
</td>
<td class="nump">9,986<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">74,277<span></span>
</td>
<td class="nump">52,403<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(74,277)<span></span>
</td>
<td class="num">(52,403)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income / (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_GainLossFromResearchAndDevelopmentTaxCredit', window );">Benefit from R&amp;D tax credit</a></td>
<td class="nump">8,267<span></span>
</td>
<td class="nump">9,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(35)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_UnrealizedGainLossOnWarrants', window );">Fair value movement on warrants</a></td>
<td class="num">(1,136)<span></span>
</td>
<td class="nump">2,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain / (loss)</a></td>
<td class="nump">2,060<span></span>
</td>
<td class="num">(399)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">9,277<span></span>
</td>
<td class="nump">11,914<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(65,000)<span></span>
</td>
<td class="num">(40,489)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(65,146)<span></span>
</td>
<td class="num">(40,561)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfOtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive (loss) / income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(2,321)<span></span>
</td>
<td class="nump">1,348<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss attributable to shareholders of the Company</a></td>
<td class="num">$ (67,467)<span></span>
</td>
<td class="num">$ (39,213)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfOtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfOtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_GainLossFromResearchAndDevelopmentTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) From Research And Development Tax Credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_GainLossFromResearchAndDevelopmentTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_UnrealizedGainLossOnWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized Gain (Loss) On Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_UnrealizedGainLossOnWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988512706184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Ordinary shares</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Ordinary shares held in treasury</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th">
<div>Cumulative Effect, Period of Adoption, Adjustment </div>
<div>Accumulated deficit</div>
</th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjusted Balance</div></th>
<th class="th">
<div>Cumulative Effect, Period of Adoption, Adjusted Balance </div>
<div>Ordinary shares</div>
</th>
<th class="th">
<div>Cumulative Effect, Period of Adoption, Adjusted Balance </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>Cumulative Effect, Period of Adoption, Adjusted Balance </div>
<div>Ordinary shares held in treasury</div>
</th>
<th class="th">
<div>Cumulative Effect, Period of Adoption, Adjusted Balance </div>
<div>Accumulated other comprehensive loss</div>
</th>
<th class="th">
<div>Cumulative Effect, Period of Adoption, Adjusted Balance </div>
<div>Accumulated deficit</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,326,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,326,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 78,861<span></span>
</td>
<td class="nump">$ 7,265<span></span>
</td>
<td class="nump">$ 176,416<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (3,628)<span></span>
</td>
<td class="num">$ (101,192)<span></span>
</td>
<td class="num">$ (26)<span></span>
</td>
<td class="num">$ (26)<span></span>
</td>
<td class="nump">$ 78,835<span></span>
</td>
<td class="nump">$ 7,265<span></span>
</td>
<td class="nump">$ 176,416<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (3,628)<span></span>
</td>
<td class="num">$ (101,218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(40,561)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,561)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Effect of foreign currency translation adjustments</a></td>
<td class="nump">1,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 3,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">105,326,638<span></span>
</td>
<td class="nump">105,326,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">$ 42,741<span></span>
</td>
<td class="nump">$ 7,265<span></span>
</td>
<td class="nump">179,535<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,280)<span></span>
</td>
<td class="num">(141,779)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(65,146)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,146)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Effect of foreign currency translation adjustments</a></td>
<td class="num">(2,321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355,831,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares, net of issuance costs</a></td>
<td class="nump">187,360<span></span>
</td>
<td class="nump">$ 22,700<span></span>
</td>
<td class="nump">164,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_StockIssuedDuringPeriodSharesHeldInTreasury', window );">Issuance of ordinary shares to treasury (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_StockIssuedDuringPeriodValueHeldInTreasury', window );">Issuance of ordinary shares to treasury</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of ordinary shares from restricted share units and share options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,146,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of ordinary shares from restricted share units and share options</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 22,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">463,304,446<span></span>
</td>
<td class="nump">488,304,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 184,854<span></span>
</td>
<td class="nump">$ 31,794<span></span>
</td>
<td class="nump">$ 366,411<span></span>
</td>
<td class="num">$ (1,700)<span></span>
</td>
<td class="num">$ (4,601)<span></span>
</td>
<td class="num">$ (207,050)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_StockIssuedDuringPeriodSharesHeldInTreasury">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Held In Treasury</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_StockIssuedDuringPeriodSharesHeldInTreasury</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_StockIssuedDuringPeriodValueHeldInTreasury">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Held In Treasury</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_StockIssuedDuringPeriodValueHeldInTreasury</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988422557368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (65,146)<span></span>
</td>
<td class="num">$ (40,561)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange (gain) / loss</a></td>
<td class="num">(2,060)<span></span>
</td>
<td class="nump">399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issue costs</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of redemption premium on debt</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment</a></td>
<td class="nump">1,136<span></span>
</td>
<td class="num">(2,066)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment of right-of-use asset</a></td>
<td class="nump">289<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">22,177<span></span>
</td>
<td class="nump">3,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">623<span></span>
</td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(3,065)<span></span>
</td>
<td class="num">(158)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent', window );">Tax and tax incentive receivables</a></td>
<td class="nump">768<span></span>
</td>
<td class="num">(3,929)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">187<span></span>
</td>
<td class="num">(289)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Non-current assets</a></td>
<td class="num">(703)<span></span>
</td>
<td class="num">(1,325)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,398)<span></span>
</td>
<td class="num">(1,734)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,940<span></span>
</td>
<td class="nump">2,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">48<span></span>
</td>
<td class="num">(137)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(45,076)<span></span>
</td>
<td class="num">(42,868)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of furniture and equipment</a></td>
<td class="num">(82)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities', window );">Purchases of short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,777)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities', window );">Sale of short-term investments</a></td>
<td class="nump">9,792<span></span>
</td>
<td class="nump">57,144<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">9,710<span></span>
</td>
<td class="nump">47,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of ordinary shares</a></td>
<td class="nump">200,156<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs in connection with the issuance of ordinary shares</a></td>
<td class="num">(12,748)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from the issuance of term loan</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Term loan issuance costs</a></td>
<td class="num">(108)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of share options</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">192,343<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">581<span></span>
</td>
<td class="nump">739<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">157,558<span></span>
</td>
<td class="nump">5,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of the year</a></td>
<td class="nump">30,428<span></span>
</td>
<td class="nump">25,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of the year</a></td>
<td class="nump">187,986<span></span>
</td>
<td class="nump">30,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121593497&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow through purchase of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Tax And Tax Credit Receivables, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988422023368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and description of business operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_OrganizationAndBusinessDescriptionTextBlock', window );">Organization And Business Description</a></td>
<td class="text">Organization and description of business operations <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Verona Pharma plc (the "Company") is incorporated and domiciled in the United Kingdom. Verona Pharma plc has two wholly-owned subsidiaries, Verona Pharma, Inc., a Delaware corporation and Rhinopharma Limited ("Rhinopharma"), a Canadian company. The address of the registered office is 1 Central Square, Cardiff, CF10 1FS, United Kingdom.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company is a clinical-stage biopharmaceutical group focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The Company listed its American Depositary Shares ("ADSs") on Nasdaq in April, 2017, which trade under the symbol &#8220;VRNA". The Company&#8217;s ordinary shares were also listed on the Alternative Investment Market of the London Stock Exchange (&#8220;AIM&#8221;) until October 30, 2020, when the shares were delisted from AIM in an effort to enhance liquidity of trading by combining all transactions on Nasdaq and to reduce costs through removing duplicative listing and compliance fees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has incurred recurring losses and negative cashflows from operations since inception, and has an accumulated deficit of $207.1&#160;million as of December 31, 2020. The Company expects to incur additional losses and negative cash flows from operations until its products potentially gain regulatory approval and reach commercial profitability, if at all.</span></div>In July, 2020, the Company raised $200&#160;million in a private placement (the "Private Placement"), with net proceeds after transaction related fees and expenses of $185.5&#160;million. Additionally, in November, 2020, the Company entered into a term loan facility with Silicon Valley Bank for up to $30&#160;million (the &#8220;Term Loan&#8221;). As of December 31, 2020, $5&#160;million had been drawn down.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_OrganizationAndBusinessDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Business Description</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_OrganizationAndBusinessDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988421772168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting policies<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Basis of presentation and consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The consolidated financial statements include the accounts of Verona Pharma plc and its wholly-owned subsidiaries Verona Pharma, Inc. and Rhinopharma. All inter-company balances and transactions have been eliminated. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. ("US GAAP") and the following accounting policies have been consistently applied.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Previously, the Company prepared its consolidated financial statements in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS").</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At the end of the second quarter of 2020, the Company determined that it no longer qualified as a Foreign Private Issuer under SEC rules. As a result, beginning January 1, 2020, the Company is required to report with the SEC on domestic forms and comply with domestic company rules in the United States. The transition to US GAAP was made retrospectively for all periods from the Company&#8217;s inception.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses, the fair value of share-based compensation and the fair value of warrants. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company&#8217;s estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Business combinations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company applies the acquisition method to account for business combinations. The consideration transferred for the acquisition of a subsidiary is the fair value of the assets transferred, the liabilities incurred to the former owners of the acquiree and the equity interests issued by the Company. The consideration transferred includes the </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">fair value of any asset or liability resulting from a contingent consideration arrangement. The excess of the cost of acquisition over the fair value of the Company's share of the identifiable net assets acquired is recorded as goodwill. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Identifiable ass</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">ets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date. Acquisition-related costs are expensed as incurred and included in administrative expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Cash and cash equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company considers all highly liquid investments purchased with original maturities of ninety days or less at acquisition to be cash equivalents. Cash and cash equivalents includes deposits held at call with banks, term deposits with maturities of less than three months at inception, and in money market funds investing in U.S. and U.K. government debt and liquid securities from highly rated institutions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Short-term investments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Short-term investments include fixed term deposits held at banks with original maturities between three months and a year. They are classified as loans and receivables and are measured at amortized cost using the effective interest method.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Furniture and equipment, net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Furniture and equipment comprise office furniture and computer equipment and are stated at cost less accumulated depreciation, which is calculated on a straight-line basis over the expected useful economic lives, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNjc4_366b91a1-c260-4eab-9b78-d6ac9d5b8954">two</span> to five years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Goodwill consists of goodwill related to the acquisition of Rhinopharma. Goodwill is not amortized but periodically tested for impairment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Impairment of long-lived assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company reviews long lived assets for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of assets may not be fully recoverable. The Company initially compares the market capitalization of the Company to the book value of its assets. If the value of the market capitalization does not support the valuation of the assets, the Company reviews estimates of the cash flows over the remaining lives of its other intangible assets, or related group of assets where applicable, in measuring whether the assets to be held and used will be realizable. In the event of impairment, the Company would discount the future cash flows using its then estimated incremental borrowing rate to estimate the amount of the impairment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Effective January 1, 2019, the Company adopted ASC 842, Leases (&#8220;ASC842&#8221;) using the modified retrospective transition approach and did not restate comparative periods. The Company determines if an arrangement is a lease at inception. Leases are classified as operating or finance leases in accordance with the recognition criteria in ASC 842-20-25. The Company&#8217;s lease portfolio consists entirely of operating leases as of December 31, 2020. The Company&#8217;s leases do not contain any material residual value guarantees or material restrictive covenants.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Ligand agreement </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In 2006 the Company acquired Rhinopharma and assumed contingent liabilities owed to Ligand UK Development Limited (&#8220;Ligand&#8221;) (formerly Vernalis Development Limited). The Company refers to the assignment and license agreement as the Ligand Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ligand assigned to the Company all of its rights to certain patents and patent applications relating to ensifentrine and related compounds (the "Ligand Patents") and an exclusive, worldwide, royalty-bearing license under certain Ligand know-how to develop, manufacture and commercialize products (the "Licensed Products") developed using Ligand Patents, Ligand know-how and the physical stock of certain compounds.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company is obligated to pay a milestone payment on obtaining the first approval of any regulatory authority for the commercialization of a Licensed Product, low single digit royalties based on the future sales performance of all Licensed Products and a portion equal to a mid-twenty percent of any consideration received from any sub-licensees for the Ligand Patents and for Ligand know-how. Royalties payable are based on the future sales performance so the amount payable is unlimited.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At the time each contingency is resolved, the Company will record the contingent consideration payment (or payable) in connection with the Ligand Agreement as an expense and will classify it within R&amp;D expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Research and development costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. Research and development expenses include salaries, share-based compensation and benefits of employees, and other costs related to the Company&#8217;s R&amp;D activities, including contracts with clinical research organizations and contract manufacturers. As part of the process of preparing financial statements the Company is required to estimate its expenses resulting from its obligation under contracts with vendors and consultants and clinical site agreements in connection with its R&amp;D efforts. The financial terms of these contracts are subject to negotiations which vary contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company&#8217;s objective is to reflect the appropriate clinical trial expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the trials and other development activities measured by patient progression and the timing of various aspects of the trial. The Company determines prepaid and accrual estimates through discussions with applicable personnel and outside service providers as to the progress of clinical trials, or other services completed. During the course of a clinical trial, the Company adjusts its rate of clinical trial expense recognition if actual results differ from its estimates. The Company makes estimates of its prepaid and accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. The Company&#8217;s clinical trial prepaid and accrual expense is dependent upon the timely and accurate reporting of study recruitment from contract research organizations and activities carried out by other third-party vendors as well as the timely processing of any change orders from the contract research organizations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Share-based compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has a share-based compensation plan under which various types of equity-based awards may be granted, including stock options and restricted stock units (RSUs). The fair value of share options and RSUs, which are subject to service conditions with graded vesting, are recognized as compensation expense using the cliff vesting method; f</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">orfeitures are recognized as they occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company uses the fair-value based method to determine compensation for all arrangements under which employees receive shares. The fair value of each option and RSU is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatility is based on the historical volatility of the Company&#8217;s ordinary shares over the expected term of the options. The expected term of options granted is derived using the simplified method, which computes the expected term as the average of the sum of the vesting term plus the contract term. Historically the risk-free rate has been based on the appropriate U.K. government debt yield. After delisting its Ordinary shares from AIM on October 30, 2020, the Company began using U.S. government debt yields.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Details of the assumptions used are set out in note 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">to the consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Other income - United Kingdom R&amp;D tax credits </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other operating income relates to R&amp;D tax credits receivable in the UK. As a company that carries out extensive research and development activities, Verona is subject to the UK R&amp;D Small and Medium Enterprise (&#8220;SME&#8221;) Program. Qualifying expenditures largely comprise employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which it does not receive income. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Tax credits related to the SME Program are received as cash and are recorded as other income, as they are akin to grant income, in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Income taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company accounts for income taxes in accordance with ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). This Topic prescribes the use of the liability method, whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. ASC 740 establishes a single model to address accounting for uncertain tax positions. ASC 740 clarified the accounting for income taxes by prescribing the minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. The Company has no uncertain tax positions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Comprehensive loss</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company accounts for comprehensive loss in accordance with ASC 220, &#8220;Income Statement - Reporting Comprehensive Income&#8221;. Comprehensive income represents all changes in stockholders&#8217; equity during the period except those resulting from investments by, or distributions to, stockholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Segment Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has one operating and reportable segment, pharmaceutical development. The Company&#8217;s long-lived assets are held in the United Kingdom.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Foreign Currencies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Reporting currency</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s reporting currency is U.S. dollars. Prior to July 1, 2020, Verona Pharma plc&#8217;s functional currency was pounds sterling and its financial statements were translated to U.S. dollars. The statement of comprehensive income was translated at average rates for the period, assets and liabilities at the balance sheet date exchange rate and equity balances at historical rates. Translation differences were recorded in accumulated other comprehensive income / (loss).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Functional currency</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company's consolidated financial statements are measured using the currency of the primary economic environment in which the entity operates, which was pounds sterling for Verona Pharma plc until June 30, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the six months to June 30, 2020, management changes resulted in lower people costs being paid in pounds sterling. Following the Private Placement the Company entered into contracts to commence Phase 3 trials for ensifentrine and the majority of the costs are incurred in U.S. dollars. Management reviewed budgeted activities over the next five years and identified that the majority of costs from the second half of 2020 onwards will be incurred in U.S. dollars. Furthermore, the Private Placement in July, 2020, raised funds in U.S. dollars and having delisted from AIM any future fundraises will be in U.S. dollars. Also, the commercial focus of Company is the U.S. market.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As a consequence, management determined the Company's functional currency changed from pounds sterling to U.S. dollars and this has been accounted for prospectively from July 1, 2020. To convert Verona Pharma plc&#8217;s books and records into U.S. dollars income and expenses were translated at average rates, assets and liabilities at the June 30, 2020, exchange rate and equity balances at historical rates. Translation differences were recorded in accumulated other comprehensive income / (loss).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Treasury shares</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the year ended December 31, 2020, the Company incorporated a trust to facilitate the acquisition of shares, by or for the benefit of employees and former employees. The Company issued 25&#160;million ordinary shares (equivalent to 3.125&#160;million ADSs) to cover expected shares issued upon the vesting of share awards to employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has the indirect ability to control the trust as trustees are required to act in accordance with the trust deed and because the Company controls the issuance of shares to cover awards. As a consequence, the trust is consolidated into the Company&#8217;s consolidated financial statements. The shares that were issued to the trust that have not been issued to employees to satisfy vesting of share awards are included in the Consolidated Balance Sheet as treasury shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Fair value of financial instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">US GAAP defines fair value and requires companies to establish a framework for measuring fair value and disclosure about fair value measurements using a three-tier approach. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our financial instruments include cash equivalents, short-term investments, other assets, accounts payable and accrued expenses and other liabilities. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgement and therefore cannot be determined with precision. The carrying amounts of these instruments are considered to be representative of their fair values because of their short-term nature.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Concentration of credit risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Financial instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents, bank deposits and certain receivables. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company holds cash and cash equivalents with highly rated financial institutions and in highly rated money market funds and the Company has not experienced any significant credit losses in these accounts and does not believe the Company is exposed to any significant credit risk on these instruments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Recently adopted accounting pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In February 2016, the FASB issued ASU No. 2016-02, &#8220;Leases&#8221; (Topic 842) (&#8220;ASC 842&#8221;). The standard requires lessees to recognize almost all leases on the balance sheet as right-of-use (&#8220;ROU&#8221;) assets and lease liabilities, and requires leases to be classified as either an operating or a finance type lease. The standard excludes leases of intangible assets or inventory. The standard became effective for the Company beginning January 1, 2019. The Company adopted ASC 842 using the modified retrospective approach, by applying the new standard to all leases existing at the date of initial application. Results and disclosure requirements for reporting periods beginning after January 1, 2019, are presented under ASC 842, while prior period amounts have not been adjusted and continue to be reported in accordance with our historical accounting under ASC 840 &#8220;Leases&#8221;. The Company elected the package of practical expedients permitted under ASC 842, which also allowed the Company to carry forward historical lease classifications. The Company also elected the practical expedient related to treating lease and non-lease components as a single lease component for all equipment leases as well as electing a policy exclusion permitting leases with an original lease term of less than one year to be excluded from the ROU assets and lease liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As a result of the adoption of ASC 842 on January 1, 2019, the Company recorded an operating lease ROU asset of $415&#160;thousand and an operating lease liability of $441&#160;thousand. The adoption increased opening accumulated losses by $26&#160;thousand but did not impact the Company's prior year financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under ASC 842, the Company determines if an arrangement is a lease at inception. ROU ass</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">ets and liabilities are recognized at the commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As the Company's leases do not provide an implicit rate, the Company determined the incremental borrowing rate in determining the present value of lease payments. The ROU assets also include any lease payments made prior to commencement and are recorded net of any lease incentives received. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s lease terms may include options to extend or terminate the lease. When it is reasonably certain the Company will exercise such options the lease will be recognized as a liability and a corresponding ROU asset also recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Operating leases are included in operating lease ROU assets and current and non-current operating lease liabilities, on the Company's consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The FASB issued ASU 2020-04 to provide optional expedients and exceptions for applying US GAAP to contract modifications, hedging relationships, and other transactions affected by the anticipated transition away from LIBOR. There is no material impact of the adoption of ASU 2020-04 on our consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Recently issued accounting pronouncements, not yet adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (&#8220;ASU 2019-10&#8221;). The purpose of this amendment is to create a two tier rollout of major updates, staggering the effective dates between larger public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies (&#8220;SRCs&#8221;), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies will have an effective date for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until the earlier of fiscal periods beginning after December 15, 2022. Under the current SEC definitions, we meet the definition of an SRC as of the ASU 2019-10 issuance date and are deferring adoption for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. We are currently evaluating the impact of the adoption of ASU 2016-13 on our consolidated financial statements, but do not believe the adoption of this standard will have a material impact on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988422012296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_PrepaidExpenseDisclosureTextBlock', window );">Prepaid expenses</a></td>
<td class="text">Prepaid expenses <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Prepaid expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and other development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,655&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_PrepaidExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expense, Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_PrepaidExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988421692152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax and tax incentive receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Tax and tax incentive receivable</a></td>
<td class="text">Tax and tax incentive receivables<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Taxes receivable consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D tax credit receivable - U.K.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax receivable - U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total tax receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,260&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,814&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988589532664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Property leases</a></td>
<td class="text">Property leases<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The right-of-use assets (&#8220;ROU&#8221;) relate to rented office space in London and North Carolina, with leases ending in 2022 and 2024, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the year ended December 31, 2019, the Company determined that it was reasonably likely to extend its existing London lease. As a consequence it modified its accounting for the lease and recorded an additional $0.7&#160;million ROU and associated liability. The Company has the option to further extend this lease but is not reasonably certain to do so and therefore has not recognized this extension as an asset and liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the year ended December 31, 2019, the Company entered in&#160;&#160;&#160;&#160;to a lease arrangement in New York for serviced offices and recognized a right of use asset and corresponding lease liability of $0.4&#160;million. In the year ended December 31, 2020, the Company&#8217;s New York office was closed and the related ROU asset of $290&#160;thousand was subsequently expensed in the consolidated statements of operations and comprehensive loss. The Company retains a liability of $195&#160;thousand relating to this lease arrangement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the year ended December 31, 2020, the Company entered into a lease arrangement in North Carolina for office space and recognized an ROU asset and corresponding lease liability of $0.7&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To calculate lease liabilities the Company used a weighted average discount rate of 8%. The weighted average remaining lease term is 2.2 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Minimum annual payments over the remaining lease periods as of December 31, 2020 are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.926%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum future lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The total operating lease expense included in general and administrative costs was $692,000.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the prior lease accounting guidance minimum rental commitments under non-cancelable leases,  for each of the five years and total thereafter as of December 31, 2019, were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.194%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988421963640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued expenses</a></td>
<td class="text">Accrued expenses<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and other development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees, listing and general corporate costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,863&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,971&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other expenses include people costs, professional fees and other accrued costs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988420445976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_WarrantAndRightsDisclosureTextBlock', window );">Warrants</a></td>
<td class="text">Warrants<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In 2016, the Company issued 31,115,926 units to new and existing investors at the placing price of &#163;1.4365 per unit. Each unit comprised one ordinary share and one warrant. The warrant holders can subscribe for 0.4 of an ordinary share at a per share exercise price of &#163;1.7238 until May 2, 2022. The warrant holders can opt for a cashless exercise of their warrants, whereby the warrant holders can choose to exchange the warrants held for a reduced number of warrants exercisable at nil consideration. The reduced number of warrants is calculated based on a formula considering the share price and the exercise price of the warrants.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At December 31, 2020, 31,003,155 warrants remain outstanding and entitle the investors to subscribe for, in aggregate, a maximum of 12,401,262 ordinary shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If, after a transaction, should the warrants be exercisable for unlisted securities, the warrant holders may demand a cash payment instead of the delivery of the underlying securities. Accordingly, the warrants are accounted for as a liability under ASC 480 &#8220;Distinguishing Liabilities from Equity&#8221;.The warrants are measured at fair value, Level 3 in the fair value hierarchy, with movements recorded in finance income / (expense) in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the years ended December 31, 2020, and 2019, no warrants were exercised or forfeited.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The warrants had no intrinsic value as at December 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">There have been no changes in valuation techniques or transfers between fair value measurement levels during the years ended December 31, 2020 and 2019. The warrants are valued using the Black-Scholes model and the table below presents the assumptions used:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares potentially issued under warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,401,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,401,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price in pounds sterling</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equivalent price of ordinary share (ADS price divided by eight)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term to exercise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.34</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Calculated value of the warrants, in thousands of U.S. dollars</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,246&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows the movement of the value of the warrants (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,066)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange differences recognized in loss for the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation differences recognized in other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At December 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,246&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For the amount recognized at December 31, 2020, the effect when the following parameter deviates up or down is presented in the below table (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10% volatility increase</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Base case, reported fair value</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10% volatility decrease</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_WarrantAndRightsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant And Rights Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_WarrantAndRightsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988421686296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term loan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Term loan</a></td>
<td class="text">Term loan<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In November 2020, the Company and its wholly owned subsidiary, Verona Pharma, Inc. (the &#8220;Borrowers&#8221;) entered into a term loan facility of up to $30.0&#160;million (the &#8220;Term Loan&#8221;), consisting of term loan advances in an aggregate amount of $5.0&#160;million funded at closing, a term loan advance available subject to certain terms and conditions in an aggregate amount of $10.0&#160;million (the &#8220;Term B Loan&#8221;) and a term loan advance available subject to certain terms and conditions in an aggregate amount of $15.0&#160;million (the &#8220;Term C Loan&#8221;), with Silicon Valley Bank, a California corporation (&#8220;SVB&#8221;), the proceeds of which will be used for general corporate and working capital purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Term Loan is governed by a loan and security agreement, dated as of November 19, 2020, between the Borrowers and SVB (the &#8220;Loan Agreement&#8221;). The Term B Loan will be available, subject to and customary terms and conditions, only during the period commencing upon the achievement of a specific clinical milestone relating to ensifentrine through and including June 30, 2022. The Term C Loan will be available, subject to customary terms and conditions, only during the period commencing upon the achievement of an additional specific clinical milestone relating to ensifentrine through and including June 30, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Term Loan will mature on November 1, 2024. Each advance under the Term Loan accrues interest at a floating per annum rate equal to the greater of (a) the sum of the prime rate reported in The Wall Street Journal plus 1.00% and (b) four and one-quarter of one percent (4.25%). The Term Loan provides for interest-only payments on a monthly basis until the payment date immediately preceding December 1, 2023. Thereafter, amortization payments will be payable monthly in equal installments of principal plus monthly payments of accrued interest. Upon repayment (whether at maturity, upon acceleration or by prepayment or otherwise), the Borrowers shall make a final payment to SVB in the amount of 10% of the aggregate Term Loans advanced (the "Final Payment"). The Borrowers may prepay the Term Loan in full but not in part provided that the Borrowers (i) provide ten days&#8217; prior written notice to SVB, (ii) pays on the date of such prepayment (A) all outstanding principal plus accrued and unpaid interest, (B) a prepayment fee of $450,000 plus 3.0% of the Term C Loans advanced if paid on or before the first anniversary of the closing date; $300,000 plus 2.00% of the Term C Loans advanced if paid after the first anniversary of the closing date and on or before the second anniversary of the closing date; and $150,000 plus 1.00% of the Term C Loans advanced if paid thereafter and prior to maturity, (C) the Final Payment and (D) all other sums, if any, that shall become due and payable with respect to the Term Loan Advances, including interest at the Default Rate with respect to any past due amounts. Amounts outstanding during an event of default are payable upon SVB's demand and shall accrue interest at an additional rate of 3.0% per annum.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Term Loan is secured by a lien on substantially all of the assets of the Borrowers, other than the equity interests of Verona U.S. and other than intellectual property, provided that such lien on substantially all assets includes any rights to payments and proceeds from the sale, licensing or disposition of intellectual property. The Borrowers have also granted SVB a negative pledge with respect to its intellectual property.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Loan Agreement contains customary covenants and representations, including but not limited to financial reporting obligations and limitations on dividends, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. The Loan Agreement also contains other customary provisions, such as expense reimbursement, non-disclosure obligations as well as indemnification rights for the benefit of SVB. The Loan Agreement includes a minimum cash covenant triggered when Borrowers' consolidated cash and cash equivalents drop below $45.0&#160;million at any time after the earliest to occur of any of the following: (i) the release of negative data from Enhance 2 and/or Enhance 1, which in the reasonable business discretion Borrowers&#8217; senior management, would be considered insufficient to support submission of an NDA to the FDA, (ii) the FDA issues a complete response letter with respect to an NDA submitted for ensifentrine, or (iii) failure to achieve a specific regulatory milestone relating to ensifentrine by June 30, 2023 (extendable to March 31, 2024 upon the Borrowers receiving a specified amount of new cash proceeds after September 8, 2020 from the sale of equity securities in one or more public financings or other bona fide equity financings, subordinated debt and/or upfront/milestone payments from one or more collaboration agreements not prohibited in the Loan Agreement). Upon such trigger, Borrowers must cash collateralize an amount equal to the outstanding obligations to SVB plus the amount of any prepayment penalty and Final Payment which would be due in the event the Loan Agreement were prepaid in full with respect to the Term Loans advanced as of such time.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The events of default under the Loan Agreement include, but are not limited to, the Borrowers&#8217; failure to make any payments of principal or interest under the Loan Agreement or other transaction documents, the Borrowers&#8217; breach or default in the performance of any covenant under the Loan Agreement or other transaction documents, the occurrence of a material adverse change, any Borrower making a false or misleading representation or warranty in any material respect under the Loan Agreement, any Borrower&#8217;s insolvency or bankruptcy, any attachment or judgment on any Borrower&#8217;s assets of at least $500,000, or the occurrence of any default under any agreement or </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">obligation of any Borrower involving indebtedness in excess of $500,000. If an event of default occurs, SVB is entitled to take enforcement action, including acceleration of amounts due under the Loan Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In connection with the Term Loan the Company incurred debt issuance costs totaling approximate</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">ly $400&#160;thousand </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">which were deducted from the carrying amount of the debt and are being amortized over the estimated term of the debt using the effective interest method.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of December 31, 2020, the carrying value of the Term Loan was approximately $4.6&#160;million, of which all was due in greater than 12 months. The debt balance has been categorized within Level 3 of the fair value hierarchy. The carrying amount of the debt approximates its fair value based on prevailing interest rates as of the balance sheet date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988516678024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">Benefits plans</a></td>
<td class="text">Benefit plansThe Company maintains a 401(k) defined contribution retirement plan in the U.S. and a defined contribution plan in the U.K. for its employees and executive director. The assets of the plans are held separately from those of the Company in independently administered funds. The retirement plan cost charge represents the contributions payable by the Company to the plans during the year. Defined contribution costs during the years ended December 31, 2020 and 2019 amounted to $315 thousand and $203 thousand, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235116<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988420402680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Taxation</a></td>
<td class="text">Taxation<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Verona Pharma plc operates in the United Kingdom and Verona Pharma, Inc. in the United States and they are subject to income taxes in those countries. U.K. corporation tax is charged at 19% and the U.S. Federal Income tax rate is 21%.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The components of loss before income taxes are as follows (in thousands): </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,489&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The components of income tax expense are as follows </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total income tax expense </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">A reconciliation of the U.K. statutory income tax rate to our effective income tax rate is as follows (in percentages):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.K. tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development incentive</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred tax valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Difference in overseas statutory tax rates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Significant components of the Company&#8217;s deferred tax assets and liabilities were as follows (in thousands): </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,860)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,860)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future exercisable shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,181&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,599&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,504)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Movements in the deferred tax valuation allowance </span></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation allowance at January 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation allowance at December 31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,321&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,504&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline"> (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">These relate to the difference in the tax base of the IP R&amp;D asset and assumed contingent liability and the accounting base, which is nil under US GAAP.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Management has reviewed cumulative tax losses and projections of future taxable losses and determined that it is not more likely than not that they will be realized. Accordingly, valuation allowances have been provided over deferred tax assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At December 31, 2020 and December 31, 2019, the Company had U.K. net operating losses (&#8220;NOLs&#8221;) of $95.7&#160;million and $75.5&#160;million, respectively. The NOLs can be carried forward indefinitely to be offset against future taxable profits, but this is restricted to an annual &#163;5&#160;million allowance after which there will be a 50% restriction in the profits that can be covered by losses brought forward.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company files separate income tax returns in the U.K. and the U.S. All necessary income tax filings have been completed for all years up to and including December 31, 2019, and there are no ongoing tax examinations in any jurisdiction. No interest or penalties were recognized in the consolidated statements of operations or consolidated balance sheets. As of December 31, 2020, the Company has no uncertain tax positions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988420513000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share based compensation</a></td>
<td class="text">Share-based compensation<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company operates various share based incentive plans for its staff and issues ordinary shares or ADSs when share-based awards are exercised.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company records share-based compensation expense related to share options and RSUs granted to employees and directors. The expense is included in R&amp;D and general and administrative costs, based on the nature of individual employees&#8217; functions, and represents the relevant year's allocation of the expense. The costs of share-based compensation to employees are recognized in the consolidated statements of operations and comprehensive loss, together with a corresponding increase in equity over the vesting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Options are issued with an exercise price of the market price on the day of grant and generally vest over a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNjkvZnJhZzo5Y2Y1Y2UxNTJmZDc0M2E3YWUzZDNhNDE5M2RiNGE3OS90ZXh0cmVnaW9uOjljZjVjZTE1MmZkNzQzYTdhZTNkM2E0MTkzZGI0YTc5XzIwMzQwOTY1MTcyNjkw_00bc9b5e-059e-48bb-806a-540b915c41a7">one</span> to four years and the contractual life of all options is ten years. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows the allocation of share-based compensation between R&amp;D and general and administrative costs (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,692&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">EMI Option Plan and Pre-IPO Option Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The EMI Option Plan and the Pre-IPO Option Plan were adopted by our board of directors on September 18, 2006, and July 24, 2012, respectively. The total number of shares that may be issued under these plans is the current number of outstanding options, or 114,000 ordinary shares, or 14,250 ADSs, for the EMI Option Plan and 1,860,000 ordinary shares, or 232,500 ADSs, for the Pre-IPO Option Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">No further awards have been granted since the 2017 Incentive Plan was adopted, and no further awards will be granted under them.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">2017 Incentive Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The 2017 Incentive Plan was adopted by our board of directors and became effective on April 26, 2017, in order to grant share based compensation to certain of the Company&#8217;s directors and employees. It provides for the grant of stock options, RSUs, and other share-based awards to Company&#8217;s directors, officers, employees and non-employee directors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the year ended December 31, 2019, the Company modified the terms of all RSUs issued prior to January 1, 2019 to include a market based condition, which was also included in the terms of RSUs issued during 2019. The Company's stock price must be maintained above the equivalent of &#163;2 per ordinary share for thirty days for the RSUs to vest, in addition to the existing service condition. The RSUs vest five years after the date of grant irrespective of whether the &#163;2 market condition was met. This modification did not result in an increase in the fair value of the RSUs. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Share option activity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The number of options, the weighted average grant date fair value per stock option, and the weighted average exercise price are all shown below on a per ordinary shares basis. The Company&#8217;s ADSs that are listed on the Nasdaq Global Market each represent eight ordinary shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows share option activity and includes the options outstanding from all three plans :</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.335%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.244%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of share options outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average exercise price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate intrinsic value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,752,114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.02&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,569,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121,970)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,998)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,179,196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096,285&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.73&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,506,017)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(589,128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,664)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,125,672&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,749,296&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline"> (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The exercise prices relate to the equivalent price for an ordinary share, calculated as one eighth of the ADS price.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Determining the fair value of share options and RSUs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The total fair values of the options and RSUs were estimated using the Black-Scholes option-pricing model for equity-settled compensation, amounted to $62.1&#160;million for instruments granted in the year ended December 31, 2020 (2019: $3.1&#160;million). The cost is amortized over the vesting period of the options and RSUs on a straight-line basis using the cliff-vesting method.The following assumptions were used for the Black-Scholes valuation of share options granted in 2020 and 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Expected volatility</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Volatility is calculated using historical weekly averages of the Company's share price over a period that is in line with the expected life of the options and RSUs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Fair value of ordinary shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The fair value of ordinary shares has been based on the share price of the Company&#8217;s shares on AIM on the evening before the date of grant, as the Company&#8217;s primary listing was previously on this market.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Risk-free interest rate</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The risk-free interest rate has been based on the U.K. Government debt yield for the relevant term at the time of grant, as the Company&#8217;s primary listing was previously on AIM. Effective from the delisting from AIM the Company will use appropriate U.S Government debt yields.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Expected term.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The expected term is determined using the simplified method.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Expected dividend</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">There are no expected dividends.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">A summary of the weighted-average assumptions applicable to the share options granted in the applicable years is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.690%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0% - 0.21%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.39% - 0.82%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected lives (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.05 - 7</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 - 7</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.83% - 75.40%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.98% - 68.71%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant date fair value (per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.40 - $0.62</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.31 - $0.49</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Restricted stock units activity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows RSU activity:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of RSUs outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602,969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,566,271&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,920)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,091,960)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,992,360&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.243%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of RSUs outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining vesting Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Period in which the target must be achieved</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs subject to time based vesting</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,416,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs subject to milestone based vesting</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 - 2024</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The intrinsic and fair value of RSUs that vested in the year ended December 31, 2020, was $1.5&#160;million (2019: $nil).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of December 31, 2020, total compensation cost related to share options and RSUs granted but not yet recognized was $41.8&#160;million. This cost will be amortized to expense over a weighted average remaining period of 1.5 years and will be adjusted for subsequent forfeitures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988421726488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net loss per share</a></td>
<td class="text">Net loss per share <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Net loss per share is calculated on an ordinary share basis. The Company&#8217;s ADSs that are listed on the Nasdaq Global Market each represent eight ordinary shares.The following table shows the computation of basic and diluted earnings per share for 2020 and 2019 (net loss in thousands, loss per share in cents):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available to ordinary shareholders - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,932,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,326,638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.39)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div>During the years ended December 31, 2020 and 2019, outstanding share options, RSUs and warrants of 87,519,294 and 28,183,427, respectively, were not included in the computation of diluted earnings per ordinary share, because to do so would be antidilutive.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988420544200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions and other shareholder matters<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related party transactions and other shareholder matters</a></td>
<td class="text">Related party transactions and other shareholder matters<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the year ended December 31, 2019, Anders Ullman, a director of the Company, provided consultancy services to the Company for which the Company paid him $33&#160;thousand.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the year ended December 31, 2020, certain directors and officers participated in the Private Placement, summarized below (in thousands, except for number of shares acquired):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"/><td style="width:58.315%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.542%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Participation in Private Placement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ordinary Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Consideration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Ebsworth</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Zaccardelli</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Sinha (through connected persons)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Ullman</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Edwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Hahn</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988423742504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of presentation and consolidation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Basis of presentation and consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The consolidated financial statements include the accounts of Verona Pharma plc and its wholly-owned subsidiaries Verona Pharma, Inc. and Rhinopharma. All inter-company balances and transactions have been eliminated. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. ("US GAAP") and the following accounting policies have been consistently applied.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Previously, the Company prepared its consolidated financial statements in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS").</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At the end of the second quarter of 2020, the Company determined that it no longer qualified as a Foreign Private Issuer under SEC rules. As a result, beginning January 1, 2020, the Company is required to report with the SEC on domestic forms and comply with domestic company rules in the United States. The transition to US GAAP was made retrospectively for all periods from the Company&#8217;s inception.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses, the fair value of share-based compensation and the fair value of warrants. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company&#8217;s estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business combinations</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Business combinations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company applies the acquisition method to account for business combinations. The consideration transferred for the acquisition of a subsidiary is the fair value of the assets transferred, the liabilities incurred to the former owners of the acquiree and the equity interests issued by the Company. The consideration transferred includes the </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">fair value of any asset or liability resulting from a contingent consideration arrangement. The excess of the cost of acquisition over the fair value of the Company's share of the identifiable net assets acquired is recorded as goodwill. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Identifiable ass</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">ets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date. Acquisition-related costs are expensed as incurred and included in administrative expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Cash and cash equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company considers all highly liquid investments purchased with original maturities of ninety days or less at acquisition to be cash equivalents. Cash and cash equivalents includes deposits held at call with banks, term deposits with maturities of less than three months at inception, and in money market funds investing in U.S. and U.K. government debt and liquid securities from highly rated institutions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short term investments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Short-term investments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Short-term investments include fixed term deposits held at banks with original maturities between three months and a year. They are classified as loans and receivables and are measured at amortized cost using the effective interest method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Furniture and equipment, net</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Furniture and equipment, net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Furniture and equipment comprise office furniture and computer equipment and are stated at cost less accumulated depreciation, which is calculated on a straight-line basis over the expected useful economic lives, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ0ZGQ5NWE2OGE2NTQxNWFhNWYyZTIxYmQ4N2QxMTg5L3NlYzpkNGRkOTVhNjhhNjU0MTVhYTVmMmUyMWJkODdkMTE4OV8yNDIvZnJhZzphNzY2ZGM3ZDMwOTI0NGU3YWNmYmU4MzBjMDYyYzgzMi90ZXh0cmVnaW9uOmE3NjZkYzdkMzA5MjQ0ZTdhY2ZiZTgzMGMwNjJjODMyXzIwMzQwOTY1MjcxNjc4_366b91a1-c260-4eab-9b78-d6ac9d5b8954">two</span> to five years.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Goodwill consists of goodwill related to the acquisition of Rhinopharma. Goodwill is not amortized but periodically tested for impairment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Impairment of long-lived assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company reviews long lived assets for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of assets may not be fully recoverable. The Company initially compares the market capitalization of the Company to the book value of its assets. If the value of the market capitalization does not support the valuation of the assets, the Company reviews estimates of the cash flows over the remaining lives of its other intangible assets, or related group of assets where applicable, in measuring whether the assets to be held and used will be realizable. In the event of impairment, the Company would discount the future cash flows using its then estimated incremental borrowing rate to estimate the amount of the impairment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Effective January 1, 2019, the Company adopted ASC 842, Leases (&#8220;ASC842&#8221;) using the modified retrospective transition approach and did not restate comparative periods. The Company determines if an arrangement is a lease at inception. Leases are classified as operating or finance leases in accordance with the recognition criteria in ASC 842-20-25. The Company&#8217;s lease portfolio consists entirely of operating leases as of December 31, 2020. The Company&#8217;s leases do not contain any material residual value guarantees or material restrictive covenants.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Ligand agreement</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Ligand agreement </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In 2006 the Company acquired Rhinopharma and assumed contingent liabilities owed to Ligand UK Development Limited (&#8220;Ligand&#8221;) (formerly Vernalis Development Limited). The Company refers to the assignment and license agreement as the Ligand Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ligand assigned to the Company all of its rights to certain patents and patent applications relating to ensifentrine and related compounds (the "Ligand Patents") and an exclusive, worldwide, royalty-bearing license under certain Ligand know-how to develop, manufacture and commercialize products (the "Licensed Products") developed using Ligand Patents, Ligand know-how and the physical stock of certain compounds.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company is obligated to pay a milestone payment on obtaining the first approval of any regulatory authority for the commercialization of a Licensed Product, low single digit royalties based on the future sales performance of all Licensed Products and a portion equal to a mid-twenty percent of any consideration received from any sub-licensees for the Ligand Patents and for Ligand know-how. Royalties payable are based on the future sales performance so the amount payable is unlimited.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At the time each contingency is resolved, the Company will record the contingent consideration payment (or payable) in connection with the Ligand Agreement as an expense and will classify it within R&amp;D expenses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Research and development costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. Research and development expenses include salaries, share-based compensation and benefits of employees, and other costs related to the Company&#8217;s R&amp;D activities, including contracts with clinical research organizations and contract manufacturers. As part of the process of preparing financial statements the Company is required to estimate its expenses resulting from its obligation under contracts with vendors and consultants and clinical site agreements in connection with its R&amp;D efforts. The financial terms of these contracts are subject to negotiations which vary contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company&#8217;s objective is to reflect the appropriate clinical trial expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the trials and other development activities measured by patient progression and the timing of various aspects of the trial. The Company determines prepaid and accrual estimates through discussions with applicable personnel and outside service providers as to the progress of clinical trials, or other services completed. During the course of a clinical trial, the Company adjusts its rate of clinical trial expense recognition if actual results differ from its estimates. The Company makes estimates of its prepaid and accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. The Company&#8217;s clinical trial prepaid and accrual expense is dependent upon the timely and accurate reporting of study recruitment from contract research organizations and activities carried out by other third-party vendors as well as the timely processing of any change orders from the contract research organizations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based compensation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Share-based compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has a share-based compensation plan under which various types of equity-based awards may be granted, including stock options and restricted stock units (RSUs). The fair value of share options and RSUs, which are subject to service conditions with graded vesting, are recognized as compensation expense using the cliff vesting method; f</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">orfeitures are recognized as they occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company uses the fair-value based method to determine compensation for all arrangements under which employees receive shares. The fair value of each option and RSU is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatility is based on the historical volatility of the Company&#8217;s ordinary shares over the expected term of the options. The expected term of options granted is derived using the simplified method, which computes the expected term as the average of the sum of the vesting term plus the contract term. Historically the risk-free rate has been based on the appropriate U.K. government debt yield. After delisting its Ordinary shares from AIM on October 30, 2020, the Company began using U.S. government debt yields.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock', window );">Other income - U.K. R&amp;D tax credits</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Other income - United Kingdom R&amp;D tax credits </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other operating income relates to R&amp;D tax credits receivable in the UK. As a company that carries out extensive research and development activities, Verona is subject to the UK R&amp;D Small and Medium Enterprise (&#8220;SME&#8221;) Program. Qualifying expenditures largely comprise employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which it does not receive income. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Tax credits related to the SME Program are received as cash and are recorded as other income, as they are akin to grant income, in the consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Income taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company accounts for income taxes in accordance with ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). This Topic prescribes the use of the liability method, whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. ASC 740 establishes a single model to address accounting for uncertain tax positions. ASC 740 clarified the accounting for income taxes by prescribing the minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. The Company has no uncertain tax positions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive loss</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Comprehensive loss</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company accounts for comprehensive loss in accordance with ASC 220, &#8220;Income Statement - Reporting Comprehensive Income&#8221;. Comprehensive income represents all changes in stockholders&#8217; equity during the period except those resulting from investments by, or distributions to, stockholders.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Segment Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has one operating and reportable segment, pharmaceutical development. The Company&#8217;s long-lived assets are held in the United Kingdom.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currencies</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Foreign Currencies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Reporting currency</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s reporting currency is U.S. dollars. Prior to July 1, 2020, Verona Pharma plc&#8217;s functional currency was pounds sterling and its financial statements were translated to U.S. dollars. The statement of comprehensive income was translated at average rates for the period, assets and liabilities at the balance sheet date exchange rate and equity balances at historical rates. Translation differences were recorded in accumulated other comprehensive income / (loss).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Functional currency</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company's consolidated financial statements are measured using the currency of the primary economic environment in which the entity operates, which was pounds sterling for Verona Pharma plc until June 30, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the six months to June 30, 2020, management changes resulted in lower people costs being paid in pounds sterling. Following the Private Placement the Company entered into contracts to commence Phase 3 trials for ensifentrine and the majority of the costs are incurred in U.S. dollars. Management reviewed budgeted activities over the next five years and identified that the majority of costs from the second half of 2020 onwards will be incurred in U.S. dollars. Furthermore, the Private Placement in July, 2020, raised funds in U.S. dollars and having delisted from AIM any future fundraises will be in U.S. dollars. Also, the commercial focus of Company is the U.S. market.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As a consequence, management determined the Company's functional currency changed from pounds sterling to U.S. dollars and this has been accounted for prospectively from July 1, 2020. To convert Verona Pharma plc&#8217;s books and records into U.S. dollars income and expenses were translated at average rates, assets and liabilities at the June 30, 2020, exchange rate and equity balances at historical rates. Translation differences were recorded in accumulated other comprehensive income / (loss).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Treasury Shares</a></td>
<td class="text">Treasury shares<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the year ended December 31, 2020, the Company incorporated a trust to facilitate the acquisition of shares, by or for the benefit of employees and former employees. The Company issued 25&#160;million ordinary shares (equivalent to 3.125&#160;million ADSs) to cover expected shares issued upon the vesting of share awards to employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has the indirect ability to control the trust as trustees are required to act in accordance with the trust deed and because the Company controls the issuance of shares to cover awards. As a consequence, the trust is consolidated into the Company&#8217;s consolidated financial statements. The shares that were issued to the trust that have not been issued to employees to satisfy vesting of share awards are included in the Consolidated Balance Sheet as treasury shares.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Fair value of financial instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">US GAAP defines fair value and requires companies to establish a framework for measuring fair value and disclosure about fair value measurements using a three-tier approach. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our financial instruments include cash equivalents, short-term investments, other assets, accounts payable and accrued expenses and other liabilities. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgement and therefore cannot be determined with precision. The carrying amounts of these instruments are considered to be representative of their fair values because of their short-term nature.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risk</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Concentration of credit risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Financial instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents, bank deposits and certain receivables. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company holds cash and cash equivalents with highly rated financial institutions and in highly rated money market funds and the Company has not experienced any significant credit losses in these accounts and does not believe the Company is exposed to any significant credit risk on these instruments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting pronouncements and Recently issued accounting pronouncements, not yet adopted</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Recently adopted accounting pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In February 2016, the FASB issued ASU No. 2016-02, &#8220;Leases&#8221; (Topic 842) (&#8220;ASC 842&#8221;). The standard requires lessees to recognize almost all leases on the balance sheet as right-of-use (&#8220;ROU&#8221;) assets and lease liabilities, and requires leases to be classified as either an operating or a finance type lease. The standard excludes leases of intangible assets or inventory. The standard became effective for the Company beginning January 1, 2019. The Company adopted ASC 842 using the modified retrospective approach, by applying the new standard to all leases existing at the date of initial application. Results and disclosure requirements for reporting periods beginning after January 1, 2019, are presented under ASC 842, while prior period amounts have not been adjusted and continue to be reported in accordance with our historical accounting under ASC 840 &#8220;Leases&#8221;. The Company elected the package of practical expedients permitted under ASC 842, which also allowed the Company to carry forward historical lease classifications. The Company also elected the practical expedient related to treating lease and non-lease components as a single lease component for all equipment leases as well as electing a policy exclusion permitting leases with an original lease term of less than one year to be excluded from the ROU assets and lease liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As a result of the adoption of ASC 842 on January 1, 2019, the Company recorded an operating lease ROU asset of $415&#160;thousand and an operating lease liability of $441&#160;thousand. The adoption increased opening accumulated losses by $26&#160;thousand but did not impact the Company's prior year financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under ASC 842, the Company determines if an arrangement is a lease at inception. ROU ass</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">ets and liabilities are recognized at the commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As the Company's leases do not provide an implicit rate, the Company determined the incremental borrowing rate in determining the present value of lease payments. The ROU assets also include any lease payments made prior to commencement and are recorded net of any lease incentives received. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s lease terms may include options to extend or terminate the lease. When it is reasonably certain the Company will exercise such options the lease will be recognized as a liability and a corresponding ROU asset also recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Operating leases are included in operating lease ROU assets and current and non-current operating lease liabilities, on the Company's consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The FASB issued ASU 2020-04 to provide optional expedients and exceptions for applying US GAAP to contract modifications, hedging relationships, and other transactions affected by the anticipated transition away from LIBOR. There is no material impact of the adoption of ASU 2020-04 on our consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Recently issued accounting pronouncements, not yet adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (&#8220;ASU 2019-10&#8221;). The purpose of this amendment is to create a two tier rollout of major updates, staggering the effective dates between larger public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies (&#8220;SRCs&#8221;), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies will have an effective date for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until the earlier of fiscal periods beginning after December 15, 2022. Under the current SEC definitions, we meet the definition of an SRC as of the ASU 2019-10 issuance date and are deferring adoption for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. We are currently evaluating the impact of the adoption of ASU 2016-13 on our consolidated financial statements, but do not believe the adoption of this standard will have a material impact on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21459-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Government Tax Credits, Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_GovernmentTaxCreditsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988420572456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Summary of Prepaid Expenses</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Prepaid expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and other development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,655&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988420593624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax and tax incentive receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_ScheduleOfNontradeReceivablesTableTextBlock', window );">Components of Taxes Receivable</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Taxes receivable consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D tax credit receivable - U.K.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax receivable - U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total tax receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,260&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,814&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ScheduleOfNontradeReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Nontrade Receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ScheduleOfNontradeReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988422475752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Minimum Annual Operating Lease Payments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Minimum annual payments over the remaining lease periods as of December 31, 2020 are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.926%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum future lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Minimum Rental Commitments Under Non-cancelable Leases</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the prior lease accounting guidance minimum rental commitments under non-cancelable leases,  for each of the five years and total thereafter as of December 31, 2019, were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.194%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988524055784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and other development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees, listing and general corporate costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,863&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,971&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988516668200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Valuation Assumptions of Warrants</a></td>
<td class="text">The warrants are valued using the Black-Scholes model and the table below presents the assumptions used:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares potentially issued under warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,401,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,401,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price in pounds sterling</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equivalent price of ordinary share (ADS price divided by eight)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term to exercise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.34</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Calculated value of the warrants, in thousands of U.S. dollars</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,246&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Movement of the Value of the Warrants</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows the movement of the value of the warrants (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,066)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange differences recognized in loss for the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation differences recognized in other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At December 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,246&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_FairValueImpactOfIncreaseOrDecreaseInVolatilityTableTextBlock', window );">Fair Value Impact Of Increase Or Decrease in Volatility</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For the amount recognized at December 31, 2020, the effect when the following parameter deviates up or down is presented in the below table (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10% volatility increase</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Base case, reported fair value</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10% volatility decrease</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_FairValueImpactOfIncreaseOrDecreaseInVolatilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Impact Of Increase Or Decrease in Volatility</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_FairValueImpactOfIncreaseOrDecreaseInVolatilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988424350280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Components of loss before income taxes</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The components of loss before income taxes are as follows (in thousands): </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,489&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of income tax expense</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The components of income tax expense are as follows </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total income tax expense </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of the U.K. statutory income tax rate</a></td>
<td class="text">A reconciliation of the U.K. statutory income tax rate to our effective income tax rate is as follows (in percentages):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.K. tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development incentive</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred tax valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Difference in overseas statutory tax rates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Deferred tax assets and liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Significant components of the Company&#8217;s deferred tax assets and liabilities were as follows (in thousands): </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,860)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,860)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future exercisable shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,181&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,599&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,504)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Movements in the deferred tax valuation allowance </span></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation allowance at January 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation allowance at December 31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,321&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,504&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline"> (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">These relate to the difference in the tax base of the IP R&amp;D asset and assumed contingent liability and the accounting base, which is nil under US GAAP.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988424281272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Allocation of Share Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows the allocation of share-based compensation between R&amp;D and general and administrative costs (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,692&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share Option Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows share option activity and includes the options outstanding from all three plans :</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.335%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.244%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of share options outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average exercise price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate intrinsic value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,752,114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.02&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,569,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121,970)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,998)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,179,196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096,285&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.73&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,506,017)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(589,128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,664)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,125,672&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,749,296&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline"> (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The exercise prices relate to the equivalent price for an ordinary share, calculated as one eighth of the ADS price.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Assumptions</a></td>
<td class="text">A summary of the weighted-average assumptions applicable to the share options granted in the applicable years is as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.690%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0% - 0.21%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.39% - 0.82%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected lives (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.05 - 7</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 - 7</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.83% - 75.40%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.98% - 68.71%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant date fair value (per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.40 - $0.62</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.31 - $0.49</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Restricted Stock Unit Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows RSU activity:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of RSUs outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602,969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,566,271&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,920)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,091,960)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,992,360&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.243%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of RSUs outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining vesting Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Period in which the target must be achieved</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs subject to time based vesting</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,416,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs subject to milestone based vesting</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 - 2024</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988420587832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Earning Per Share</a></td>
<td class="text">The following table shows the computation of basic and diluted earnings per share for 2020 and 2019 (net loss in thousands, loss per share in cents):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available to ordinary shareholders - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,932,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,326,638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.39)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988421881784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions and other shareholder matters (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Private Placement to Related Parties</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the year ended December 31, 2020, certain directors and officers participated in the Private Placement, summarized below (in thousands, except for number of shares acquired):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"/><td style="width:58.315%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.542%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Participation in Private Placement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ordinary Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Consideration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Ebsworth</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Zaccardelli</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Sinha (through connected persons)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Ullman</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Edwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Hahn</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988422545432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Consolidation and Presentation of Financial Statements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 17, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>subsidiary</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_NumberOfWhollyOwnedSubsidiaries', window );">Number of wholly owned subsidiaries | subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 207,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from sale of stock</a></td>
<td class="nump">$ 185,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_TermLoanFacilityMember', window );">Term Loan Facility | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Amount drawn down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received from sale of stock</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_NumberOfWhollyOwnedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Wholly Owned Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_NumberOfWhollyOwnedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988424674792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting policies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 1,050<span></span>
</td>
<td class="nump">$ 1,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">1,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="num">(184,854)<span></span>
</td>
<td class="num">(42,741)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (78,861)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">$ 207,050<span></span>
</td>
<td class="nump">141,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period (in shares) | shares</a></td>
<td class="nump">355,831,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="num">$ (31,794)<span></span>
</td>
<td class="num">$ (7,265)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,265)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_StockIssuedDuringPeriodSharesHeldInTreasury', window );">Issuance of ordinary shares to treasury (in shares) | shares</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares', window );">Issuance of ordinary shares to treasury as ADS equivalent (in shares) | shares</a></td>
<td class="nump">3,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Furniture and equipment, useful life</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Furniture and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_StockIssuedDuringPeriodSharesHeldInTreasury">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Held In Treasury</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_StockIssuedDuringPeriodSharesHeldInTreasury</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Held In Treasury (American Depository Shares)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988423145256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_PrepaidResearchAndDevelopmentFeesCurrent', window );">Clinical trial and other development costs</a></td>
<td class="nump">$ 2,551<span></span>
</td>
<td class="nump">$ 874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Insurance</a></td>
<td class="nump">1,701<span></span>
</td>
<td class="nump">534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 4,538<span></span>
</td>
<td class="nump">$ 1,655<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_PrepaidResearchAndDevelopmentFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Research And Development Fees, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_PrepaidResearchAndDevelopmentFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988420355224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Tax and tax incentive receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent', window );">R&amp;D tax credit receivable - U.K.</a></td>
<td class="nump">$ 8,202<span></span>
</td>
<td class="nump">$ 9,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Tax receivable - U.S.</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_TaxCreditAndIncomeTaxesReceivableCurrent', window );">Total tax receivable</a></td>
<td class="nump">$ 8,260<span></span>
</td>
<td class="nump">$ 9,814<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Credit Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_TaxCreditAndIncomeTaxesReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit And Income Taxes Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_TaxCreditAndIncomeTaxesReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988423785160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property leases - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment of right-of-use asset</a></td>
<td class="nump">$ 289<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 1,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount rate (in percent)</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Weighted average remaining lease term</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets recognized with associated liability</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vrna_LondonMember', window );">London | Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets recognized with associated liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NY', window );">New York</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment of right-of-use asset</a></td>
<td class="nump">290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NY', window );">New York | Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets recognized with associated liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121593497&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vrna_LondonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vrna_LondonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988427024936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property leases - Maturity (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum future lease payments</a></td>
<td class="nump">1,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 1,312<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988424588776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property leases Maturity Under ASC 840 (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2020</a></td>
<td class="nump">$ 680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2021</a></td>
<td class="nump">862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2022</a></td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2023</a></td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2024</a></td>
<td class="nump">$ 44<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988424294936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_AccruedResearchAndDevelopmentFeesCurrent', window );">Clinical trial and other development costs</a></td>
<td class="nump">$ 8,607<span></span>
</td>
<td class="nump">$ 6,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent', window );">Professional fees, listing and general corporate costs</a></td>
<td class="nump">2,149<span></span>
</td>
<td class="nump">2,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">People related costs</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 10,863<span></span>
</td>
<td class="nump">$ 8,971<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Professional Fees, Listing, And General Corporate Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_AccruedResearchAndDevelopmentFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Fees, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_AccruedResearchAndDevelopmentFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988423138024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,401,262<span></span>
</td>
<td class="nump">12,401,262<span></span>
</td>
<td class="nump">31,115,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights', window );">Issue price of warrants (in pounds sterling per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1.4365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of stock warrant (in pound sterling per share) | &#163; / shares</a></td>
<td class="nump">&#163; 1.7238<span></span>
</td>
<td class="nump">&#163; 1.7238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1.7238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,003,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited', window );">Number of warrants exercised and forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_ClassOfWarrantOrRightIntrinsicValue', window );">Intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ClassOfWarrantOrRightIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ClassOfWarrantOrRightIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Issue Price of Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Exercised Or Forfeited</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988426716696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants - Fair Value Assumptions (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Stock warrants (in shares) | shares</a></td>
<td class="nump">12,401,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,401,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,115,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of stock warrant (in pound sterling per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1.7238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1.7238<span></span>
</td>
<td class="nump">&#163; 1.7238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare', window );">Equivalent price of ordinary share (ADS price divided by eight) | $ / shares</a></td>
<td class="nump">$ 0.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term to exercise</a></td>
<td class="text">1 year 3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_WarrantLiabilityCurrent', window );">Calculated value of the warrants, in thousands of U.S. dollars | $</a></td>
<td class="nump">$ 2,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement Input</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=vrna_MeasurementInputAnnualizedVolatilityMember', window );">Annualized volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement Input</a></td>
<td class="nump">1.054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement Input</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Equivalent Price Per Ordinary Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_WarrantLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_WarrantLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=vrna_MeasurementInputAnnualizedVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=vrna_MeasurementInputAnnualizedVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988423509256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Movement in Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Warrant Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">At January 1</a></td>
<td class="nump">$ 1,188<span></span>
</td>
<td class="nump">$ 3,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Fair value adjustment</a></td>
<td class="nump">1,114<span></span>
</td>
<td class="num">(2,066)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference', window );">Foreign exchange differences recognized in loss for the period</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome', window );">Translation differences recognized in other comprehensive loss</a></td>
<td class="num">(78)<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">At December 31</a></td>
<td class="nump">$ 2,246<span></span>
</td>
<td class="nump">$ 1,188<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Exchange Difference</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988421750968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants - Effect of Change in Volatility (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate', window );">10% volatility increase</a></td>
<td class="nump">$ 2,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_WarrantLiabilityFairValue', window );">Base case, reported fair value</a></td>
<td class="nump">2,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate', window );">10% volatility decrease</a></td>
<td class="nump">$ 1,772<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis Of Fair Value, Warrant Liability, Impact of 10 Percent Decrease In Volatility Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis Of Fair Value, Warrant Liability, Impact of 10 Percent Increase In Volatility Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_WarrantLiabilityFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_WarrantLiabilityFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988426926200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term loan (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 19, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Funded advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Funded advances</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_DebtInstrumentFinalPaymentPercent', window );">Final payment (in percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_DebtInstrumentPrepaymentTermOfPriorWrittenNotice', window );">Term of prior written notice</a></td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage', window );">Interest rate in the event of default</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_DebtInstrumentCovenantCashAndCashEquivalentsMinimum', window );">Loan covenant, minimum cash and cash equivalents</a></td>
<td class="nump">$ 45,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold', window );">Default threshold of attachment or judgment on any of borrower&#8217;s assets</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness', window );">Default indebtedness threshold for default of any agreement or obligation</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carry value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Term Loan Facility | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Term B Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Term C Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Term C Loan | First Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_DebtInstrumentEarlyRepaymentPenaltyAmount', window );">Prepayment fee</a></td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent', window );">Prepayment fee (in percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Term C Loan | Second Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_DebtInstrumentEarlyRepaymentPenaltyAmount', window );">Prepayment fee</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent', window );">Prepayment fee (in percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Term C Loan | After Second Anniversary and Prior to Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_DebtInstrumentEarlyRepaymentPenaltyAmount', window );">Prepayment fee</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent', window );">Prepayment fee (in percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_DebtInstrumentCovenantCashAndCashEquivalentsMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Cash and Cash Equivalents, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_DebtInstrumentCovenantCashAndCashEquivalentsMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Debt Default, Attachment Or Judgment On Any Borrower&#8217;s Assets Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Debt Default, Default of Other Agreement Or Obligation, Threshold of Indebtedness</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Debt Default, Interest Rate, Stated Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_DebtInstrumentEarlyRepaymentPenaltyAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, Early Repayment Penalty, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_DebtInstrumentEarlyRepaymentPenaltyAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, Early Repayment Penalty, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_DebtInstrumentEarlyRepaymentPenaltyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_DebtInstrumentFinalPaymentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Final Payment, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_DebtInstrumentFinalPaymentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_DebtInstrumentPrepaymentTermOfPriorWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment, Term of Prior Written Notice</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_DebtInstrumentPrepaymentTermOfPriorWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_TermBLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_TermBLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_TermCLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_TermCLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_DebtPrepaymentPeriodAxis=vrna_DebtPrepaymentPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_DebtPrepaymentPeriodAxis=vrna_DebtPrepaymentPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_DebtPrepaymentPeriodAxis=vrna_DebtPrepaymentPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_DebtPrepaymentPeriodAxis=vrna_DebtPrepaymentPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_DebtPrepaymentPeriodAxis=vrna_DebtPrepaymentPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_DebtPrepaymentPeriodAxis=vrna_DebtPrepaymentPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988420500936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit plans (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Contribution cost</a></td>
<td class="nump">$ 315<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988424282104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation - Loss Before Tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">United States</a></td>
<td class="num">$ (3,191)<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United Kingdom</a></td>
<td class="nump">68,191<span></span>
</td>
<td class="nump">40,291<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="nump">$ 40,489<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988422641656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation - Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">United States</a></td>
<td class="nump">$ 146<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit', window );">United Kingdom</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">United States</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">United Kingdom</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 146<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988423769944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation - Reconciliation of Statutory Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.K. tax rate</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="num">(8.90%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development incentive</a></td>
<td class="num">(4.80%)<span></span>
</td>
<td class="num">(8.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share options exercised</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in deferred tax valuation allowance</a></td>
<td class="num">(5.90%)<span></span>
</td>
<td class="num">(9.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Difference in overseas statutory tax rates</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988419157016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation - Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_DeferredTaxLiabilitiesContingentLiability', window );">Contingent liability</a></td>
<td class="num">$ (5,860)<span></span>
</td>
<td class="num">$ (95)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(5,860)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">19,855<span></span>
</td>
<td class="nump">12,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">IPR&amp;D asset</a></td>
<td class="nump">5,631<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Future exercisable shares</a></td>
<td class="nump">10,480<span></span>
</td>
<td class="nump">273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">36,181<span></span>
</td>
<td class="nump">13,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(30,321)<span></span>
</td>
<td class="num">(13,504)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember', window );">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Valuation Allowance [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Valuation allowance at January 1</a></td>
<td class="nump">13,504<span></span>
</td>
<td class="nump">9,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates', window );">Change in tax rates</a></td>
<td class="nump">1,632<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance', window );">Increase in valuation allowance</a></td>
<td class="nump">14,815<span></span>
</td>
<td class="nump">3,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments', window );">Foreign currency translation adjustments</a></td>
<td class="nump">370<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Valuation allowance at December 31</a></td>
<td class="nump">$ 30,321<span></span>
</td>
<td class="nump">$ 13,504<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_DeferredTaxLiabilitiesContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Contingent Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_DeferredTaxLiabilitiesContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>SEC Schedule 12-09, Valuation Allowances and Reserves, Change In Tax Rates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>SEC Schedule 12-09, Valuation Allowances and Reserves, Foreign Currency Translation Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>SEC Schedule 12-09, Valuation Allowances and Reserves, Increase In Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988420388840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 95,700,000<span></span>
</td>
<td class="nump">$ 75,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Interest and penalties recognized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationInterestAccrued', window );">Interest accrued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAccrued', window );">Penalties accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988426712472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 22,177<span></span>
</td>
<td class="nump">$ 3,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">9,319<span></span>
</td>
<td class="nump">1,692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 12,858<span></span>
</td>
<td class="nump">$ 1,427<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988422762440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">45 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Rate </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Rate </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 24, 2012 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 18, 2006 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number granted (in shares)</a></td>
<td class="nump">2,096,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,569,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingDepositoryReceiptRatio', window );">Number of ordinary shares per ADS | Rate</a></td>
<td class="nump">800.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue', window );">Fair value for instruments granted during period | $</a></td>
<td class="nump">$ 62,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Cost related to share options and RSUs granted but not yet recognized | $</a></td>
<td class="nump">$ 41,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected period for recognition</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrna_EMIOptionPlanMember', window );">EMI Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrna_PreIPOOptionPlanMember', window );">Pre-IPO Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contract life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share Options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share Options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share Options | EMI Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized', window );">Number of American Depository Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Further awards to be granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share Options | Pre-IPO Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,860,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized', window );">Number of American Depository Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Further awards to be granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Intrinsic and fair value, vested | $</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | 2017 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired', window );">Minimum stock price required to vest (in pound sterling per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod', window );">Period to maintain minimum stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingDepositoryReceiptRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingDepositoryReceiptRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Minimum Stock Price Required</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Minimum Stock Price Required, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of American Depositary Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vrna_EMIOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vrna_EMIOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vrna_PreIPOOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vrna_PreIPOOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vrna_A2017IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vrna_A2017IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988528572904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation - Share Option Activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>Rate </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingDepositoryReceiptRatio', window );">Number of ordinary shares per ADS | Rate</a></td>
<td class="nump">800.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of share options outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance outstanding | shares</a></td>
<td class="nump">14,179,196<span></span>
</td>
<td class="nump">8,752,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted | shares</a></td>
<td class="nump">2,096,285<span></span>
</td>
<td class="nump">5,569,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited | shares</a></td>
<td class="num">(2,506,017)<span></span>
</td>
<td class="num">(121,970)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired | shares</a></td>
<td class="num">(589,128)<span></span>
</td>
<td class="num">(19,998)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised | shares</a></td>
<td class="num">(54,664)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance outstanding | shares</a></td>
<td class="nump">13,125,672<span></span>
</td>
<td class="nump">14,179,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable | shares</a></td>
<td class="nump">7,749,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning Balance, Weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="nump">$ 2.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weight average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">0.73<span></span>
</td>
<td class="nump">0.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, Weight average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">1.53<span></span>
</td>
<td class="nump">1.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, Weight average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">1.93<span></span>
</td>
<td class="nump">2.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, Weight average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending Balance, Weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">1.41<span></span>
</td>
<td class="nump">$ 1.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Weight average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock option activity, additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted average remaining contractual term (years)</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Aggregate intrinsic value (in dollars) | $</a></td>
<td class="nump">$ 220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate intrinsic value (in dollars) | $</a></td>
<td class="nump">$ 914<span></span>
</td>
<td class="nump">$ 933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted average remaining contractual term (years)</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingDepositoryReceiptRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingDepositoryReceiptRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988424713560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation - Weighted-Average Assumptions (Details) - Share Options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.39%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">0.21%<span></span>
</td>
<td class="nump">0.82%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">65.83%<span></span>
</td>
<td class="nump">67.98%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">75.40%<span></span>
</td>
<td class="nump">68.71%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected lives (years)</a></td>
<td class="text">5 years 18 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected lives (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 0.62<span></span>
</td>
<td class="nump">$ 0.49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988426794456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation - RSU Activity (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>RSU Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance</a></td>
<td class="nump">1,602,969<span></span>
</td>
<td class="nump">862,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">62,566,271<span></span>
</td>
<td class="nump">740,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
<td class="num">(84,920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(2,091,960)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance</a></td>
<td class="nump">61,992,360<span></span>
</td>
<td class="nump">1,602,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Outstanding, Weighted average remaining contractual term</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs outstanding</a></td>
<td class="nump">61,992,360<span></span>
</td>
<td class="nump">1,602,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vrna_RestrictedStockUnitTimeBasedVestingMember', window );">Time-Based Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>RSU Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance</a></td>
<td class="nump">61,416,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs outstanding</a></td>
<td class="nump">61,416,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod', window );">Weighted average remaining vesting Period</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vrna_RestrictedStockUnitMilestoneBasedVestingMember', window );">Milestone-Based Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>RSU Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance</a></td>
<td class="nump">576,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs outstanding</a></td>
<td class="nump">576,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod', window );">Weighted average remaining vesting Period</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Vesting Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vrna_RestrictedStockUnitTimeBasedVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vrna_RestrictedStockUnitTimeBasedVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vrna_RestrictedStockUnitMilestoneBasedVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vrna_RestrictedStockUnitMilestoneBasedVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988516466600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share - Computation (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 65,146<span></span>
</td>
<td class="nump">$ 40,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to ordinary shareholders - basic</a></td>
<td class="nump">65,146<span></span>
</td>
<td class="nump">40,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss available to ordinary shareholders - diluted</a></td>
<td class="nump">$ 65,146<span></span>
</td>
<td class="nump">$ 40,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding - basic and diluted (in shares)</a></td>
<td class="nump">262,932,653<span></span>
</td>
<td class="nump">105,326,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share (in shares)</a></td>
<td class="nump">87,519,294<span></span>
</td>
<td class="nump">28,183,427<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988523907896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions and other shareholder matters (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 17, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>GBP (&#163;) </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received from sale of stock</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director | Consultancy Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Amount paid to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vrna_DirectorOrOfficerMember', window );">Director or Officer | Private Placement | Dr. Ebsworth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in sale | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,216<span></span>
</td>
<td class="nump">222,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received from sale of stock | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vrna_DirectorOrOfficerMember', window );">Director or Officer | Private Placement | Dr. Zaccardelli</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in sale | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">444,440<span></span>
</td>
<td class="nump">444,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 249,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vrna_DirectorOrOfficerMember', window );">Director or Officer | Private Placement | Mr. Sinha</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in sale | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533,328<span></span>
</td>
<td class="nump">533,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 299,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vrna_DirectorOrOfficerMember', window );">Director or Officer | Private Placement | Dr. Ullman</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in sale | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,664<span></span>
</td>
<td class="nump">266,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vrna_DirectorOrOfficerMember', window );">Director or Officer | Private Placement | Dr. Edwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in sale | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,328<span></span>
</td>
<td class="nump">53,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vrna_DirectorOrOfficerMember', window );">Director or Officer | Private Placement | Mr. Hahn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in sale | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,784<span></span>
</td>
<td class="nump">177,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=vrna_ConsultancyServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=vrna_ConsultancyServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vrna_DirectorOrOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vrna_DirectorOrOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vrna_DrEbsworthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vrna_DrEbsworthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vrna_DrZaccardelliMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vrna_DrZaccardelliMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vrna_MrSinhaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vrna_MrSinhaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vrna_DrUllmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vrna_DrUllmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vrna_DrEdwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vrna_DrEdwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vrna_MrHahnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vrna_MrHahnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139988421653128">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
<td class="text">us-gaap:AccountingStandardsUpdate201602Member<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>84
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M!^Q%NP\"%!3&F&J8@!$9:YW5S\ &S!N)4:MTWFNE\_<R 9FP,\<F1JIVG]:
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M!O!^+J79WM@/E =F9_\!4$L#!!0    ( +9#65*][ 8T' 8  .H8   8
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M<R!RF'EQ?B="D)EJIQMZ<+Q1:!UNVPK".99 @Q0@OQ0<"O7HA+N0(H<.P&D
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M-1A64GY*/I&/'\(L_D)\HFL\TKEO4((E\LLAW56?+CJ2[AK*"8G#,Q(%47
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MDSB6G@2/[Z737C6F--R]WG@_*X(7P=SCG(Q9_#>-^/RX%_1 1&9X&?-;MOI
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M@[#02\2SR,(@_@S*#W+)/LS0F?70%/#VW8Z\WX8(0)R;8JG^SA5_48V6_M"
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MI]\JX'\C<T(!.G_UH*48\E:*!,F/.1%F?K>\O#C!,L6R.,DTB^*EX1H;ZV\
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MIV>2J@O_Z-V>/_6\<GWO=OPGFI.-QPOT?.U<'_Z! ^*WOW_Z;U!+ P04
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M3JOX+.(U9I<PBGR(PS@\@S<::APYO-&+> 4JA3FLI3;:AS5KN&$5_X6Y#[T
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MI8:7X]0#U9F_6QC9.,-MI2'[NFE)[R4J>X#V"RG-<6$O&%[@Q6]02P,$%
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MK1:ZU%ZSHUOMLM*XUC+]^VKAO 4H_O.&I5EO:18LS?Y$%M^4E)Y[[QJ5\<4
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MSA/@6+-.^CNS^8A;/6>!KS+2Q5_8#+93\EAUSANU!=->"3V\V=,V#WN \_P
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M#H]^1"OY5^OJ>EO+EN@SX$$\X%& [?;7=!1ZQ=&H/SZ)PVHR.MY7 =L@.^I
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M:&5E=#(P+GAM;,U=29/;1I;^*XB:CFXI@J2*E.1-MB-*6[?:UEBCLGH.$W,
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M96)\"[30AP86LE6MLB7L$K]7AX[?11)]6-PNB@=7'VZ+O][<O+MZR&N&+S9
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M*<L-)!E ">"S=0.C"6H\  @IB[T&Q-V!&UJ$@"W8\W4G=I@#UM9UK$5!@'W
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M(1%&K+T^=!*''$:CDWK(]8D"7S56">MU+\TM9I;--GF>L;QP.5T1>*NV1)]
MG='C_,(QSK@2DY 12;%OBL^2:#M^'6  9=4K!1M&ER'!/Q?J$\[*PE!I49E/
MWJ$E,&^*8JM8_[>:+N+S36LO$'&TV!,X1K(O'B2A7L4?GD8W;<\? V5"R+PV
M#2@PASV(FF)3Q=_[)FF/.VL$#8-N0&=(:V 8%9O6)/_NP* U_N0N!A^/6)9%
MQ3D!-.7+^E6B?,K7]55CLH;S)J-@T$V\+;9F/CG+,C7[3'O62  5I)"C4.1K
M^5K7+NU>[5+7U4I45]:D!^:<MITV"*4EKC[A-K+/1\4#U&8 4UZ/4#\Y^K_<
MIU_T A@(XX7LFJ:F\5 FJ]H[#5S!)4]).Q.5$:&S3E*K0A!HC"OP1,Z;C-%T
M-L"!(/K>LPP5=DY_\C7:Q*7),[.TY<\K6M:5TMUE@.)P^N;0*('_;#(IA(H9
MKGQY0-_0T(MS^V;3=PVH&FXL3+25HB@'CI.DT;BV!0L?D)7>82=#\=BG;BC*
M,JQA(4!0_L:E$TFO#1]4<%=\'T 0D;=Q[Z&C;=W76T6B$ .S(3C2@O,(' %L
MA67N+ :^'<>WX X7(_Z:#[Y*5^^N;#:^I1<4-H<;(UB\M.+7O44>WX-"FUV@
M+[R#BLB?KRTUHF+?$Y&-1^O?E7=X6!S!\%4:&*S  Y)""GR;!DK7.%C:3>.D
M@3$6K<!Q53TAZR1U3*8"7^42V>"OMPXT@R(DFS!EUN&<2NF8%F4.ECT,!6>@
M(85SM(L!((%"4K=]R)N'<<A4PX..(IX%WN@FE#U6#8>6!V/I$(8K$1WE&R0Y
M7SK0[T/-_#E5/!#S_V]J> H<Q$KXU73=^J^6=/"IH S!.#*XYP@2J1.-B=)=
M4/+YO'IST/@.^[* $?B,X,!Z1Q&B35GA@832XKRK@&>;49;'!ALKI219)8DO
M@\+VR/#AL!Z-NB!73[$&K:$9!O''![%%"]?V>+%,'KYY>>L>LLJE"GWOA<J[
M,GK(A?F0:TA@2*H$ZT#&U[>3,"X6]EOT@+T_[W6^:217CK0C/ (_J)!XB(X;
MAJDNU/;RR[62%L"UJDJ,.J1')7/)8F!;ONY-=AI(P#L:TTMQ)CV "2348X'V
MSX()06JR!HH9H' )W654X2O\EJ[$X*8'U2:/19;!=!&(K-N<+IZ6V,70)LDK
M3U;Z7)#<+2$Y.I1,4B8%.-;$KZ9+VU]G69M('6RTL_W%;KA_?=1P]4$-$H>E
M&$G^B'6UW(C 863-5 UQ$."+C2WW"N]8(O&-#1&#@9)[#LHUAI^3[P5!2JJ+
M4&1)00PU!TUN0[T]<0@RLU8VU*=]5_R,'AM:(]X#AS_7F"B4@/BA[QR7!,$W
MO_<&SQ4@:>5C?Y379R/LGLEPJVPX&<-GHLOV<\/$O+W27&!#(L]=0%X!X&]A
MG<^(3#SYXVSROCW?30#-H$"Z!E/;&(.17AO@W!+T%];EDZA:#O'P6;)#Y8%V
MK#SFPC0LTXBYO$7Q2V\O,(XO#QRVOF*9X%B[Y4RHYUMM0K@E%*^.%J6$"J7$
MM /\B\PS[ /"XH5DF>2AX"4H>!P%XAB\T@(PD6:(B#4#LQ@Q]=D!3TK=\A5G
MU(/!W!<GE*RXY$/8NA=M&4JW8?=8(!M#8R&("N]WTN'ODELV?D/,':KFX\G!
ME]+=E:! 4OG4RNC\ZH8=8A,T\;6XK#/72;")RUSXQ4&#NK<FX<ODJ'G?D^HP
MME>LIGLC0 -C&75RJPME1BAA.:H'__APR8U&*8E(? \&*["YU"@DO1)#RG;[
M\M#2',-%I70W%#?>7>H:GU&[<6Q"3G-029_P %68IG:7QV0VR;JW<WGV?=R^
M@SQ[=*2=W/N9>?BW2VXTJ;FV/>%K(0HBWG"/D4NN"R,#X3-C:W# U%T.6335
MTQHG\&=\>**Y:<\9?I(I8\GWZG,5VI5<NB6=9=G57Z8U*.;Q\IWPN""3BT_/
M:-<G1!<\\"B'_]O6!LC^M5I;:IQ;72^_8C#W^N;VN5_IS>V'XC_-@KZ=7Z]"
M=)M;T$+ZBS-<WSQ9/<Q284E378B]T55?$4M@2[;@LY!P*,IFC^W:&.B6#C !
MVGDLK93&G[G9S/LDK?S^EP\AK9PZA-2OEMVZE,$:F4HN>,@:Z\1P@ZW,6NS*
MT&2'%5,\P&"CU!I4Q]&Q^G+8:\HX %L^C3T-WD<UNT\[_+UCE%1'C%U&MOQV
M4"*<MT!^OL?1 RURR+"Z]N1?:-4QK@]%,!X3 0VR.?G55-)IG+9@4=L!U;$.
M(*&<!W,HI_0'UU$E>RZITN2L^9.KPLF$H9]&%5.A^1/ 4D-Q2.-+)(.)S/T(
MKM05[XE[5WH5323?I37B>QD 2DG8()&_="77H[*4GYJ2Z[0H<%I6'Z7BYX A
M01H;-6VM^8:34,)POE^$NXTSG!C-HT9DN1 J(*W1$4J7SB+C9:%*;TJ*77@P
M;K;.\\5E50S@,\5^4")M:]JYS(3=92WKS22M.O@RU,7%"Q]B<ZDO N5;7<E]
MH)L33[Y+#PL?F51)5RK7D+?Q8@^>TE=SQ6M7,(]$D1!F Q'O.L8R0?E,*IWL
M+L'0W%Y+81[\[B44?IML:HX5'NVPRS8N @?\TY/E4\SX]8[;%4??B!4%],:3
M97B#CSNLD'K'&2(#+I<[*D.82\PZJ(P_K;Z*D^)5$+XY&GO(<_#T%R?22(0=
MCP=\R'DZ)<0?:Z(6$A6CX<)!<6<70[AB.UFS9<5QHF^BDYU<.,"=TMSWDH3.
M(Y-ABL!RY/706T0W^1[C-4>FQ;)F/U1P+?GB&B[:8G*P(Y7T[7&Z*VR!&#$_
MA;S=6DHKD*)4IUAIKKR<N&U335TM )K2/QRRTD.:Y91BUDLE"I6-]S9Q]@%E
MR;L[^-QC=F!GA5&M"KV9/(HF^$YW0_BRJJG&=^Z60K_/+\C7?&)4! OJ:JK/
MY\.0F*= A/_&>A?=<1%&Z0P>UBG@^Y2\E%I0GS!UX!0'+L(T@8/B31)I07*9
ME@E1PRKL' A^,-SU$)4$D36^#*[^6=?^(#9V4>&(IT+)ARYH=__[):U#8,RT
M W;,PH09]!/.&")5#$7/KY]0 [(P+Q,KMY2<4Q!-P!@C !P? TM;V!@AB?6;
M%3M5;[E AI, ;J</67=C=NTP7P:JPHU\X*1H]/[('";W2!Q+R:?\_.;Y+^]I
M?Q3QY%B.7&,@NG/4:L3MXR>]O4^4]8\[)N@[4#KELM] /L/R\2QQJ]]$1VS^
M@CVUG]EBB OQ>/75P_G;& .D-%GV(&QN=#RIM=OVFI$8 #1,_[DD"=W%)")7
M\<2+>;CPSC1F>_*VQD-=/R(QJ >R:8D5R5;']?5#K#I+XFMG]P$'=R>I6&.-
M+OV'W"3F%Q]:2F-H0<QM6B67IDJCH=&;D2MBHUL<+5D"_J(7/PMK2%HMV'<2
MY<5 3B[PH=\Q6%65CJX":L&'O..,4<0Q%]S,;^?+ZPLL4\R+BTPS*UXJ2ON2
M_L;%_$W$U#NGRZ</9Q)7+9.7T6G]+KE(YB6%\Z(7^\$O*O=DQ4HS41%DP IK
MCSA0>2#,51B[/AH*4A<6:P!ZXFA*A1?]H>:D)4CD=JM"J5;T]>C[4*U)!=#@
MLO3K)MP''2HQ\2X,4C[$;%H%>9#^@W!_ V)Y]D/#"&D/#Y5MPS!YK1I/%,JV
MW[_P[@J2M&:.P%XRA!FP>80+++Z\4SIJ[S)FTR5Z8E'\?&&#9-[(-2O; 75(
M>6_ >839N?Q@Z!N&7.7RJ4?1<7JJYM;[X%C*/0%<'I<.RU?-YQ3V5P"+UT7A
M<VS(/%?+H@=][9+WA@+/ $FX5H6.O[2-YKO-9067W-[!UE:K5'5YB<5KQBF!
MH,5\'147>Y)_'KY@*%3 T4KS)WZ=<'],#M8^6<Z5QEA&2TORN\83R8X5Q251
MRQ)M*;_D<B7?]@L0AET->' NM</LI?O[N6&LDL HD!%)Y9+M1/KY6B3V_G'K
MLGJ 9GQUAI /3*.2NF*1SL^98-KTO4TPWWHM@#N-=J8#DX()$9=$&LZ!P7TM
M_U@4]%'R-T+V"D01_Q(*W1O==OSG0L*GX:^MW/#?&(F/\Y]J>0N2#-8%4-X&
M7KU>?/WTBD-U_I?.'.@OCJQ-UYD]_8C-%,KB _#]QIC._X(3A+]!\^/_ 5!+
M P04    " "V0UE2[GF+8ZL"  "0!0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970R,2YX;6Q]5-MNVS ,_17"Z$,+&/4E=I,%28 T[; ^# O:;L,P[$&QZ5BH
M+'F2W'3[^E&VXV9;DQ?K1AX>DCZ<[91^,B6BA9=*2#/W2FOK:1"8K,2*F4M5
MHZ270NF*63KJ;6!JC2QOG2H1Q&%X%52,2V\Q:^_6>C%3C15<XEJ#::J*Z5_7
M*-1N[D7>_N*>;TOK+H+%K&9;?$#[N5YK.@4#2LXKE(8K"1J+N;>,IM>)LV\-
MOG#<F8,]N$PV2CVYPUT^]T)'" 5FUB$P6IYQA4(X(*+QL\?TAI#.\7"_1W_?
MYDZY;)C!E1)?>6[+N3?Q(,>"-<+>J]T'[/-)'5ZFA&F_L.MLQV,/LL985?7.
MQ*#BLEO92U^' X=)>,0A[AWBEG<7J&5YPRQ;S+3:@7;6A.8V;:JM-Y'CTC7E
MP6IZY>1G%VN-->,YX NUV:"!\T>V$6@N9H$E>&<49#W4=0<5'X&*8OBHI"T-
MW,H<\[\! N(UD(OWY*[CDX@WF%W"*/(A#N/P!-YH2';4XHV.XA6H->:P4L8:
M'U:LYI8)_AMS'_I*^,!D#I]LB1J6QJ U<,--)I1I-,+WY<983;_2CQ-TDH%.
MTM))CM!YZ(0 JM@'A]N^#6]5_R28$^_4U"S#N4?J-*B?T?N_NYDB.1E+):"@
ME",42I NN=S".9=THQI#^9N+*7Q#I@%=)X'Z@-6&"K+O!7VB=[ B#CQC JSF
M]'5U4VW=<GPFM=>D74L1J=1P!K&?IA&MDW$"=Y**R62&$/GC,()TE/05CR=7
M$"=C>%34%ZC_I?\:(FNHD03/NA:=0>*GHPFMD7^5IO!6=X(#E52HM^TL<"5I
MI.T$,]P.XV;9J>S5O)M5'YG><FE 8$&NX>4X]4!W^N\.5M6MYC;*DH+;;4DC
M$[4SH/="*;L_N ##$%[\ 5!+ P04    " "V0UE2J^F@(7@"  !)!0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q]E&MOTS 4AO_*4830)HWFTJYT
MI8VT;B 0FC1U&P@A/KC)26/-EV"[Z_CW'#MM%M#:+_$EYWW.Q3Z>;;5YM#6B
M@V<IE)U'M7/--(YM4:-D=J ;5/2GTD8R1TNSCFUCD)5!)$6<)<DXEHRK*)^%
MO5N3S_3&":[PUH#=2,G,GP4*O9U':;3?6/)U[?Q&G,\:ML8[= _-K:%5W%%*
M+E%9KA48K.;193I=C+Q],/C&<6M[<_"9K+1^](LOY3Q*?$ HL'">P&AXPBL4
MPH,HC-\[9M2Y],+^?$__%'*G7%;,XI46WWGIZGDTB:#$BFV$6^KM9]SE<^YY
MA18V?&';VHZR"(J-=5KNQ!2!Y*H=V?.N#CW!)#D@R':"+,3=.@I17C/'\IG1
M6S#>FFA^$E(-:@J.*W\H=\[07TXZE]^S9V"J!$<C5P4J7R2J=H'\B:T$PLF]
M'^SI+';DSHOB8H=>M.CL #K-X$8K5UOXJ$HL_P7$%&<7;+8/=I$=)5YC,8!A
M>@99DB5'>,,N^6'@#0_PEEV:%GY>KJPS=$E^'0&/.O H@$<'P%=:-EI1,2WH
M"JC&Y.#%V6NE/,KSG3FU#2MP'E'K631/&.4MMG=4A:9>L0Y+[]35")46U'1<
MK>&$*]K1&TMG;4^G\ .9 ?3' E14E"LT76'IDU[ \BV3S8?K<#$*@R5W?5?O
MX&'P=0!O8')&$AHOSL;IQ&?ZO]7= ,XGD%Z,X5X[)@*O9Q((XR00)ND(7BM^
MW+O>$LTZ-+&E=#?*M3>]V^W>B<NV/5[,VT?FAIDU5Q8$5B1-!N_/(S!MX[8+
MIYO0+"OMJ/7"M*:W#HTWH/^5UFZ_\ ZZUS/_"U!+ P04    " "V0UE2/4KV
M@24#   W!P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6R-5=MNVS ,
M_17"R$,+='7B)&T6) %ZV; !ZQ;TLCT,>U!L.A:JBR?)3?OWHR3'2[$TV(LM
M6>3A(0]%SS;:/-H*T<&S%,K.D\JY>IJF-J]0,GNJ:U1T4FHCF:.M6:>V-LB*
MX"1%FO7[9ZED7"6+6?BV-(N9;IS@"I<&;",E,R^7*/1FG@R2[8=;OJZ<_Y N
M9C5;XQVZAWII:)=V* 67J"S7"@R6\^1B,+T<>_M@\)WCQNZLP6>RTOK1;SX7
M\Z3O":' W'D$1J\GO$(A/!#1^-UB)EU([[B[WJ)_#+E3+BMF\4J+'[QPU3R9
M)%!@R1KA;O7F$[;Y!(*Y%C8\81-MQ^,$\L8Z+5MG8B"YBF_VW-9AQV'2?\,A
M:QVRP#L&"BROF6.+F=$;,-Z:T/PBI!J\B1Q77I0[9^B4DY];+ WI:]P+"*3<
M+!S=LY5 >SQ+':%[FS1OD2XC4O8&TB"#&ZU<9>&#*K!X#9 2K8Y;MN5VF1U$
MO,;\%(:#$\CZ6?\ WK#+=1CPAF_@?8DI_KQ866>H'7X=P!QUF*. .7H#\X8K
M+AL)%THU3, W*B9S7*TA!(,E>Z$.=G9?.0\"^\LXM37+<9[0;;-HGC#IHK$8
MK6[103^A 5<A71-_$7W\H"<0':X+"XQL2J""HER1Z;:HP SZLU(+NIVD/E<$
MHQO+5&&/I]YF #V8G&5^28_)P"^&] B+$8Q&<*\=<9$MM;)Q#8&VX;<$>S X
M&4XF5!5KI\!EW3@L@"N'E)N#H_.SXQ9'=Q6,$(*S%1?<<6Q1J,\.Z#;N=!O_
MEVZW1(^B7FDIN8M<'ZA]#7S5ZEW.5(["7X@HYUX9#\;9+V.,X/6J21[39LKR
M7#<JI+YN>.%C=U4UD6:^0[,)(.HUS7B+3TA0 \CRRJONXY0T^N %F:%64 6X
M4&HZH#E>D@;[^V/P_@0V^*I#IK%M0E_$CHC=0)VPK>@_RI]-^FT/]4(#]4+W
M]'SK[!,RW1EF$LTZC&P+H39QKG5?N[_"11R&?\WC+^6&F357EBB5Y-H_/2>M
M3!S3<>-T'4;C2CL:M&%9T9\-C3>@\U)KM]WX -V_<O$'4$L#!!0    ( +9#
M65*;5#4QI@(  (T%   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;'U4
MVV[;, S]%<+H0PL$]2U-DR )D+0=MH<"0=MM&(8]*#8="Y4E3Y*;]N]+R8Z7
M;4U>=*'(PT-*1[.=TL^F1+3P6@EIYD%I;3T-0Y.56#%SJ6J4=%(H73%+6[T-
M3:V1Y3ZH$F$21:.P8EP&BYFWK?5BIAHKN,2U!M-4%=-O*Q1J-P_B8&]XX-O2
M.D.XF-5LBX]HO]9K3;NP1\EYA=)P)4%C,0^6\70U=/[>X1O'G3E8@ZMDH]2S
MVWS)YT'D"*' S#H$1M,+WJ 0#HAH_.XP@SZE"SQ<[]$_^=JIE@TS>*/$=Y[;
M<AZ, \BQ8(VP#VKW&;MZKAQ>IH3Q(^Q:WS0-(&N,55473 PJ+MN9O79]. @8
M1T<"DBX@\;S;1)[E+;-L,=-J!]IY$YI;^%)]-)'CTEW*H]5TRBG.+I99IAO,
M 5_IF@T:.']B&X'F8A9:@G=.8=9!K5JHY A4G,"]DK8T<"=SS/\&"(E73R[9
MDULE)Q%O,;N$-!Y $B71";RT+S;U>.D1O#5[\\4!DSGXRIDP\'.Y,5;3\_AU
M(L6P3S'T*89'4CR2:O)&(*@"]KV]ZWK[44M/HCE%3DW-,IP')#F#^@6#_Z\L
M4Z018\E$26V)4"A!8N-R"^=<DD4UABHV%U/X@4P#NNL!:BY6&]1]@VF()W!#
M''C&!%C-:72=4H2IZ:F_D(1K$J2EC,8:.(/Q8!1=TSP:I),AK+4JT#BY4F"!
M: 8@B)?CX6"V*%'32:9TK32SV,$D@W@X<>,DAC6JFIJG43!73^L04XYT/((G
M91VC?\L_(X?!>)1Z/I/K&#ZZQO! (A7JK?\(7.L::5NU]-;^KUFV$OOCWGY4
M]TQON30@L*#0Z/+Z*@#=BK_=6%5[P6V4)?GZ94G_)6KG0.>%4G:_<0GZ'WCQ
M#E!+ P04    " "V0UE20X\D(9($  "8"@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6R55FUOVS80_BL'K1T2P+4EV9:]U#9@YP7-L"!!G*88AGV@
MI9/%A1)5DK*3_?H=*5O1LMCHODBDR'ONN;N')TZV4CWI#-' <RX*/?4R8\JS
M7D_'&>9,=V6)!:VD4N7,T%2M>[I4R!)GE(M>Z/M1+V>\\&83]^U.S2:R,H(7
M>*= 5WG.U,L"A=Q.O<#;?[CGZ\S8#[W9I&1K7*+Y6MXIFO4:E(3G6&@N"U"8
M3KUY<+:(['ZWX9'C5K?&8"-92?ED)]?)U/,M(108&XO Z+7!<Q3" A&-[SM,
MKW%I#=OC/?J5BYUB63&-YU)\XXG)IM[8@P135@ES+[=?<!?/T.+%4FCWA&V]
M=QAY$%?:R'QG3 QR7M1O]KS+0\M@[!\P"'<&H>-=.W(L+YAALXF26U!V-Z'9
M@0O561,Y7MBB+(VB54YV9O:-*<4*H^'D@:T$ZM-)SQ"L7>S%.XA%#1$>@ A"
MN)&%R31<%@DF_P;H$9^&5+@GM0B/(EY@W(5^T('0#_TC>/TFR+[#ZQ_ NS49
M*OB-LQ47W'#4<,%U+*2N%,(?\Y4VBM3QYQ%/@\;3P'D:'/!TQ;B"1R8J=$_F
ME#?7)/G2#C7(%/8I?R_31]'M 3W3)8MQZM$)U*@VZ,T>,H3MOHJ, MI8]PE4
MFA=KH,AA(5C\]&D99Y(*#+E,4  K$K=F;-5A90\G.$R+8A=8BW2E,3F#WY$I
M0%MBH )AOJ*<[HM$C^ 76&;D7T,I#<%P)L0+<(*Q9,A,O=(,PL[ #SIA%+:'
ME\^H8JZ1B/ 8@1>$1(8:M$$E;#0__Q1$_<\0=$=A?_QF=OF]XA0Z>=[94ZJE
M2GA!O0:T908G\XOE;C'A&VXC6;V .[BG\ '\;C2H7R'<<_WT*55H:9!WU 84
M,T@^QV$0?H:/M&TXH-?E<TD-AI!H5PY& NZC"+K]/H3=_@#F15$QP?^F71LI
M2!2DPA<(_&'7(D3#;D2O"\>(RO+&S^OHG(FX(G,+XR1&$9I6]3LV92:3E68V
M:[3ZM;OL0B*%8$I39&$G'$3T#CK!> Q'Y#YLY#X\*G?2%":5<$QNY 9SF_T=
MJ\<VQ6.:/^KBL.93"DMNG<:=AG4FM[5T\S=,WDT6G+23=?HC\IX;^)51)4E/
M09/%#]"GMP_NY->>6/(7-6['@/8$ S@).WX4G0+]1TAL!4DDSEBQMBI,4Q)7
M$=.I41C+=>%$0LRH.6D*43G.)2HN$PC#1@P/%(,6=7LY#")=WXME3IG+[(]T
M@S7PR6A\"J.!C:@5Z_]12-0H)/K1AGB=4QD-W*9P7<1T@: C<JNL_WI,?!^;
MP_&>3HXZ>E\G5[L$LIP:B6EGAYG_5KGC]B)EDVAN*6%N_JJSDBF6(YUS^NUO
M.)U#ZHPE]1@Z8=N".MV^@=;)M[9U7ZWU^59O@?^QW0WX/B>V""-J&@L[B>G1
M(=ZE5!8V?1597:DW( DV($%G- K?K6"O=5O(4:W=G4B33"A%]<6A^=I<N^;U
M;>-U>WUGNV%JS>D'(3 E4[\[HK.LZGM0/3&R='>/E31TDW'#C*Z.J.P&6D\E
M_2MV$^N@N8S._@%02P,$%     @ MD-94BWJW)8M!0  'PX  !D   !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&ULK5=K;]LV%/TK%UY;.(!FZ^&'G"8!\FBW
MK&L7Y-%A&/:!EFF;FT1Z)!4G_WZ'E*S8K>*EV+Z(%,E[[KD/7I)':Z7_,DO.
M+3T4N33'G:6UJ\-^WV1+7C#34RLN,3-7NF 6OWK1-RO-V<P+%7D_#L-1OV!"
M=DZ._-B5/CE2I<V%Y%>:3%D43#^>\5RMCSM19S-P+19+ZP;Z)T<KMN WW-ZM
MKC3^^@W*3!1<&J$D:3X_[IQ&AV=CM]XO^"SXVFSUR5DR5>HO]W,Y.^Z$CA#/
M>68= D-SS\]YGCL@T/B[QNPT*IW@=G^#_M[;#ENFS/!SE?\J9G9YW$D[-.-S
M5N;V6JU_Y+4]0X>7J=SX+ZVKM<.D0UEIK"IJ83 HA*Q:]E#[84L@#9\1B&N!
MV/.N%'F6%\RRDR.MUJ3=:J"YCC?52X.<D"XH-U9C5D#.GMRR!^;=T[UETYR;
M@Z.^!:R;[&<UQ%D%$3\#$<7T44F[-/1.SOAL%Z //@VI>$/J+-Z+>,&S'B51
M0'$8AWOPDL;(Q.,ES^!=RDP5G& K70B3Y<J4FM/OIU-C-=+BCSTJ!HV*@5<Q
M>$;%N2I62G)I#:DY08.A*<>>X20JY98]<-/FW+VX;D\>FA7+^'$'F\YP?<\[
M)[=+3MF+%!+# #,T5SFVGZ&ND&27JC1,SLS!(?W&F2;NPD9P.B^F7#>.QR>:
MT)T4%K,WEEG O:)N$D23Z "]:))N9C\(N9BI@D:IFZ1!&,1H;I5E.1:.AD$8
MANA@?)!.:(^[AXV[A]_@[B>+B3^@7!G>YNB]B"]U]->J_G\71X,1ON/X2^^^
M^2Z-H_AMTU;^S4JMP6Z'TM<8-?B7$"_2@"+'H6.VHZ)]:8M[MKCL"?RH"?QH
M;^"O>:9D)G)152U$Q")&=[T//3(PL;1*/VZST#"[+1GV:SG%>?/M>L@J4B6"
M/9]S?]A\M4"8+S-EQ76&Z.'\>V&N. 8-7C3IA?1ZTWQ2\GN(EM"-4KX) /2D
MO<D!YKMA;^S::Z0WT]F2D*$([CU.YE7A4@ATT3CBW4$O]2)I;^3:FZ7+<K5R
MSC! !FMAP#+L#3"[R8'7=+YD<N'LWDV:>Y:7E2.9,YU!#W6'-:M)U5X(N V9
MG'EQ=<\U6)HM;V^L-EOZ8%+DA-\]ZW*LB&OC$[1[4G#<I.!X;W)<;%O&C.&H
M#,Z3R)4I$L:*]CJ_'_1&+*28BXPA#+L5Q^6=*W=,/GJ[QV_-KG/;*=":_]>Z
MM&/H%O0A^"!-$&B0W8P_4M>?"MUAD(Y"WYL,#]HJR#;)S6J_ML6QA_0)%U-<
M01%+*/3G',2B29 .AQ3%09H,Z?+J^@TK5F\O*B%/9!B,D@CVA/2^M.ZTKW/6
M77+(N&P&BCN.8.LXH5_@94UQ!,PT:B-=.SD9!6Y!E 3#R81^Y@8,6Y,["8,D
M!H^N6QH.6HT+2#KCYJT(KYHL?^I]Q*XH?%[X6/)_WV2?6\:8I9^8+'$%I\A5
M9T\0G0D8QUL[^&F_17!FW+# ;0K7?^/7M.F,!D$*1R9!&L:$JS,NQK(^I3+L
M8LVDR6N9V9^XX586)>.0$D3C&<9;*0JJE7>?R+N(XZP&)\WSNA)[_^S4%#?B
MC'*W^,W.NKRBW>1QVPB]LH!7L[8T=PN<),LR5?IY#QC0>BE04U'BI<BIQ,;2
M='=#/YR>7O7:JDY_Z])><+WP3Q-#'K2ZOS>CS>OGM+KT/RVOGDX?F5X(U.6<
MSR&**H^KCJZ>(]6/52O_!)@JBP>%[R[Q@N/:+<#\7"F[^7$*FC?AR3]02P,$
M%     @ MD-94F7SGG'6!0  * X  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&ULG5=M3^,X$/XK5F]9@13:Q'EK6$ JR]Z;M'<(]D6GTWTPB=OZ2.*N
M[5+X]_>,TX:R0%G=E\1V9IX9SSPSL8]7VMS8N92.W35U:T\&<^<61Z.1+>>R
M$7:H%[+%EZDVC7"8FMG(+HP4E5=JZA$/PVS4"-4.3H_]VH4Y/=9+5ZM67AAF
METTCS/V9K/7J9! --@N7:C9WM# Z/5Z(F;R2[O/BPF VZE$JU<C6*MTR(Z<G
M@TET=):3O!?XHN3*;HT9[>1:ZQN:_%:=#$)R2-:R=(0@\+J5[V5=$Q#<^+;&
M'/0F27%[O$'_V>\=>[D65K[7]5=5N?G)8#Q@E9R*9>TN]>I7N=Y/2GBEKJU_
MLE4GF^0#5BZMT\U:&1XTJNW>XFX=ARV%<?B" E\K<.]W9\A[>2Z<.#TV>L4,
M20.-!GZK7AO.J9:2<N4,OBKHN=.KN3#2[ZMBI6Z0:RM\N/8_B>M:VH/CD8,9
M$AZ5:\BS#I*_ !EQ]E&W;F[9A[:2U6. $?SKG>0;)\_X3L1S60Y9' 6,ASS<
M@1?WFXX]7KQKTX?=IB_$/3CFV,08T<ZD'_\]N;;.@##_[#"6],82;RQYP=BD
MKG79Q51/61?O,V_Z_7:\/]S16#X7[IWX5+5'=B%*>3) 65II;N7@]--<LJF&
MY95J9\Q1*IF=ZY5E#E_$(Y?L5C0>4>!:NI64+;M\*YK%NW,FVHK-9"N-J/U8
M5""DHDA194'7.LOV50L;>FDA80^.V%]2&":)" QIE,VU-'TJ\8@*=@FGA2GG
M'K.2MV@4"Y^&-ZP(8@B\85&0%9S]\K+MB ?C= RYA.?LDW:0>L,X#Z(\QR .
M(L#LR&7:YS+=F<LN>W\N?'@FU%"4NW\N9;MA7LZ.SP73BX>.!0-^PZHMZV4E
MNP1V I:ARUJ'KP0S-;JAS$+ 2,D6M8# $?MCZ4.^R?.SJE]][T*&Q"T"/)-,
MWDE3*@L4HTK)]J.#IS)&4L\G]1+53M6R1-2=- W;OT="[0&;S&9&SH23\-X9
MA4Y>LEM1+Q'"+>O"L=]%N\0O@7E>(%7C($^1O"BA+ Y#I![%2<;3(,V*($Q#
M%@YSSM"8IU+1A_V(1T&1AP<L&H8%59,R?KD(BF)\ )0L_=[J=WR$W2@!8XH@
M*C(BW3"-63XD A5QW+O @[#( CY.R85XVP4>I&$6A%%^T.GV3J1C8/(Q+1>T
MW 67/B1!EB4'L "LU_Q#O41@,D^##%LG_Y((_L7D'R*UAO5D>E8Y#_*D"/AZ
M;S"7#5-?):%/,)'R<=XM<EQ3]ISVK)/?E@KIH]+L>($S ;C)M(''E#[/L("5
MHBZ7I BR@&@M-(D[<R(AX4S.KSJ X8Z2S/J2S':7)(XIU1)[!OB&HX>3-4<G
M%H>-CO#/5>ENY,GFI++Q>[6!WY2 >(!G8K&H5>FCOP[7XWJ;K>GCVZ/<%O?%
MPI2E8'5=P?Y0VU3VYG!*I8[BDNC\CAE*5KC'#D$G'NWA&1?=;,SW_!^F)!=J
M=$S;%VDZ#%/(Y!AT[U[N5B.)JJ8.E*7#<4Q0>3I,8"'+A\68YMEXF$=;V!4Z
M5@6_V;V2=<7>_C3F$7_']K9&OI!81;Y.A3+KCK"_P Y]R% .(8P '.^,TS..
MNEE2[&!,WC,FWYE7_&_0C+RW5TZ7-^QSJ]S.;KX;[^5N?GGUN6_BVYT8ZZ\T
MX!]HKJ^UT(P'2?[0MO(D#!+4_NL],,A"'A19P>)ATJL#+<W0]O)HN^.-DZ#@
MZ+E?$-*N X8%VG 6/G'O*8DS"!8\B+.0NN7_C Z([.A](8W2U>:%&EO-%4X4
M5&E.F!DN-PW.TCC1(!]SA3-&U9FQR^M_05Q?LKAKK _"&U2XF$19$,>9=[$=
MB2=:C<(AV5&/>ZR:YO@3\ 3_G92VR\%?O)+GZ#O:.KTW$L[2'<4B\<O6=0?Y
M?K6_!DVZT_^#>'>'^HB]XC?+:CF%*OU3!LQT]Y)NXO3"WP6NM</-P@_GN,I)
M0P+X/M7:;29DH+\<GOX'4$L#!!0    ( +9#65*SS^CHR0(  #$&   9
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M69I1?EG31P&U,Z#[E5)VMW$"PV=F]AM02P,$%     @ MD-94IV'>T%8 P
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M%%UEN#.ZO1G:P*J-/XU+9?%L^V&%EREHEX#K*Z7L/G 'O+N>\]]02P,$%
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M2H,-R TK_$6 L@&X7TII/B:V"_4_G>P=4$L#!!0    ( +9#65)P$0GX60,
M &$*   9    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;)U6VV[;.!#]E8%:
M+!)@:]ULV<[:!N)+L0&V;="@VX>B#[0TMHA0HDK2<0KTXY>D9$5V9:_:%XFD
MYIPY,QR*,]ES\2A31 7/&<OEU$F5*FY<5\8I9D3V>(&Y_K+A(B-*3\76E85
MDEA0QMS \R(W(S1W9A.[=B]F$[Y3C.9X+T#NLHR([W-D?#]U?.>P\)%N4V46
MW-FD(%M\0/6IN!=ZYM8L"<TPEY3G(' S=6[]FY7O&8"U^)?B7C;&8$)9<_YH
M)G?)U/&,(F08*T-!].L)%\B88=(ZOE6D3NW3 )OC _M;&[P.9DTD+CC[3!.5
M3IV1 PENR(ZICWS_-U8!#0Q?S)FT3]B7ML.! _%.*IY58*T@HWGY)L]5(AJ
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M=Y VP.POA=!;PR;H_ACY/U!+ P04    " "V0UE2@2RKM\H"  "X"   &0
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M,-._%B"-@?X^$P(W$^.@_EF)_P-02P,$%     @ MD-94JGBZ7\H P  ) H
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M#X=^<4C-)HW,"X*3AN!DD."=-)3;B^5T@8MJA1>^0M4AU4<U;*B&;X\3+2_
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MLHM?F2S:6#'1(K>=X$EH["MVF&#K!VD"<'\IA-Y-S '5GXG17U!+ P04
M" "V0UE2 VIKQ-0%   U'   &0   'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6S-65UOVS84_2N$UPTMT,8B*<M.YQA(8J?+L+1&C&P/PQYHB[:%2J)+4G$R
M[,>/I!C1'Q+M;GEP@"26S'MT[H<.+\G^FO&O8DFI!$]9FHN+UE+*U<=V6\R6
M-"/BC*UHKKZ9,YX1J2[YHBU6G)+8&&5I&P5!U,Y(DK<&?7-OS =]5L@TR>F8
M U%D&>'/5S1EZXL6;+W<N$\62ZEOM ?]%5G0"94/JS%75^T*)4XRFHN$Y8#3
M^47K$G[\%!H#,^+WA*[%QF>@79DR]E5?W,87K4 SHBF=20U!U+]'>DW35",I
M'M\L:*MZIC;<_/R"?F.<5\Y,B:#7+/TCB>7RHM5K@9C.29'*>[;^A5J'.AIO
MQE)A_H*U'1NTP*P0DF766#'(DKS\3YYL(#8,,&PP0-8 [1B@L,$ 6P.\:]!M
M, BM07@LI8XUZ.P^H<GIR!I$QQITK4'7)*N,KDG-D$@RZ'.V!ER/5FCZ@\FO
ML58927)=BA/)U;>)LI.#R9)P:I(9@QG+5(4+8FKD _A,.">Z4,#;(94D2<6[
M?ENJ9VK+]LSB7Y7XJ $?(G#'<KD48)3'-*X!&/D!PHX'H*V\K5Q&+RY?(2_B
MD,[. (;O 0I0\# 9@K=OWMT3284.A:AA>'TT'CS_Z0<8X9]!&S2B#;\#S;)K
MQ!J]LJ<W?KQ?B_0,H-!P0XT@G_P@$[HZ ["G08*H#F0KJ;BJ8VQ0L:^./Y1U
M?+U9QY>JB/,%5>HIP?09;(X;DV=S^W)-> S^_$U!@EM),_&7AU!8$0H-H;"!
MT.<BFU(.%NKI4CWK;9+;DJA]B4JLR&#IV>-Q@(+S"/4Z_?;C9NWLC^MTHO.@
M$U3CMLAV*K*=8\BR.6 \3G(U)UFR8*5N7PXGX!^@"Z>.NA^Y%P1G0?!C7>W^
M!\,MYZ+*N<B+=$,2#AY)6E"@IFZ0Y$+R0B=>5-F)"Y[D"^ULPF+EZYLZ1\NG
M=#=B'R$8Z)^=).T/Q#OCMOSH5GYTO7Y<,R'5[)\2S5BR,D. K729"T#R&-Q/
M'IQ/TT*"G$GP3+75C"WRY&_:Z%QWCW,(>S7.C8X8N.5=K_*NY_5N]+12W8DB
M:).@4V5I:P?K./L!H?*<<!"!S$P?GD(ZKRB>^RG>W8(O)MQ@G)+<@P@#-_T&
MIZ%;<*,C@*^G7",+MBE)#94 D6. O S&RM7;\9=C@^WF"'@BDP1TLP1\Q6EB
M!/?UORG83OJA7VC+#K ,M>\M@4YO870B87;2"0]I9RZY6O: -)G7SF('[&%@
MU,0;'Z=TT*],6Q%7@GR7Y$E69#YL)U'P_#1BCYS$H<#K;@G[2(5T<VQ="@[
ME'KN8^04#OD5;B\!Y.E  I#3+H1.) %.]A!^G03X8<*#KP!RLH?\LK>;@>.G
M5N2$#75.)!-.&9&_%75]MFVO22&7C.O&K'8A%>W)/81A8ZN%G!PBOYPY'I>9
M*H<9R<&0KIA().,V( >Y=?>YA:AI(8*<."*_.-X47"X5-Z(S('2?.Z7'KJ(L
M=/WT:!?,OB';E)WF(G]?N%O,W]>^8">D^$1Z1>R4%!_5*QY9T#=XOUF$O:AY
M\8"=[&)_R_C_*_K&/F%K$8Y513=QV]B:\ OG_REI"^TK:>^0;<I.G[%?G^_5
M9*&BJ E.))M]!0]J&>;=IW&RC$]$EK&39>R7Y5O5'":Y2&9F%3VO]@O>FTFS
M>=&,]U?ZL%.W(U SL"E%3L.Q7\/K4Z2HH@!VP6T^4P'3F[>'Y,<I,^Z=2.*<
M\F*_\A[9V0P/P'0.=C:A$^G0WZ;:9AX(DY.5RA %G'XK$E[NVFBRYJ5?L4(5
MFRHOGEKRI0Z\4RD\O(M\;6G <%.NZFLJ='(>^N5\7.Z]*)KZ%$NJ7WWFL.M/
M780/ ., Q.2Y-L+MC<,+)=T+<RXEP$R%1Y:;^M7=ZNSKTISX[-R_@A^'Y0F6
M@RD/U.X(7ZCW&Z1TKB"#LZY2*%Z>4947DJW,$<F42<DR\W%)24RY'J"^GS,F
M7R[T ZJ3PL&_4$L#!!0    ( +9#65+J7S,F_@0  $P4   9    >&PO=V]R
M:W-H965T<R]S:&5E=#4Q+GAM;+586V_C*!3^*RB:E5JIC0V.;U4:*6EG+P^S
M4[7;G8?5/E";)*BVR0)I6FE__ )V[#BV:4:S?4D G\MW+IP#3'>,/XLU(1*\
MYEDAKD=K*3=7CB.2-<FQ&+,-*=27)>,YEFK*5X[8<()3PY1G#G+=P,DQ+4:S
MJ5F[X[,IV\J,%N2. ['-<\S?%B1CN^L1'.T7[NEJ+?6",YMN\(H\$/FXN>-J
MYM124IJ30E!6 $Z6UZ,YO+I!OF8P%']2LA,'8Z!->6+L64]^2Z]'KD9$,I)(
M+0*KOQ=R0[),2U(X_JF$CFJ=FO%PO)?^LS%>&?.$!;EAV3>:RO7U*!J!E"SQ
M-I/W;/<KJ0PR !.6"?,+=A6M.P+)5DB65\P*04Z+\A^_5HXX8)C  094,: C
M!B\<8/ J!L\86B(S9MUBB6=3SG: :VHE30^,;PRWLH86.HP/DJNO5/')V<,:
M<V(<D8*$Y2H[!#;^O03EIZ\;,YUK=U/Y!LYNB<0T$^?@$W" T#0"T (\%E2*
M"[6HQG^LV5;@(A531RJ,6I.35'@6)1XT@ <B\(45<BW YR(E:5N HXRK+41[
M"Q?(*O&6)&/@P0N 7.0^/MR"LT_G#?1[+$DYZL%Z<[)D&'<D]TEM&>#5(?*,
M&L\6HLLR1'?X3>TA">:<XV)%S/BO^9.07.V'ORW*)K6RB5$V&5#V^S9_(ARP
M)6 \I87:V?L8;]3R_/8!_ NTS_HB:Y<<N>[8=7^R8/1KC+[5(0U& PTPDZ("
MJ"HEI$H[6JPL6H):2V#%NR K6A1*EMH=&2X2<BA?>6$P:Q:EW,#(U67T908G
M,(QA'$R=E\/TZA)&H8\@G-1T+>1AC3RT(O]%Y894R6+#&'94(S<.4.0?0>S2
M^7X0N[[;#S&J(496B*H$+PE]#V3447Z)?#=P87B$LH<0(AB' RCC&F5L1?GY
M=4/Y.QCCKFH_BB&*CB#VT,$XCJ-^A-!MZK?[#D;"$RK>05D):<.<!,% IL&#
M]@'MZLOM\+U;I)+:VB,>1'X0HB._]5$>[Z8V=M1@1Z>X#C]EQ X6=2"$X21&
M@PB:R@[MI?V;.66HV.$7PM6I"9 JFF##:4(L50PV!1W:Z^[7)B07H"EJBS)B
M%^ =#.!,-?2491GF90\P?CI7#FM:7:_32E3Q8=S&OG<<W2X5&KMHP*]-@X#^
M*15P;]S_;5JI7/_5J-UQV+&MGVS(N*8O07MCJFOG1YD7=''WA:Z7S(T'S&N:
M%[1WKZKH?I1Q81_JN&-<#QD:!_Z <4W;@_:^5U?KCS(OZLVY(=Q-(X3V3M@J
M(E7-__ *$O>%:@*/0Q7;"TW[TM#T57127]7-X8-B50%H Q\*%6HZ,H+VZX)D
MR7-U)BYOR>K:=@%PFE*]A#.04I%D3&SMUQ/4]%%D[Z.MY.@D R?Z-4$G3*(N
M=OJ>LE48).$Y.'LCRF?GO<ZQJPR!804>R,O;(HQ BM_Z+W&GB8IJ4:A'5-LU
M38-'WNE9-%^M.%FIRY.Z(TM."T$3\(*S;2N#3-[T>J34%!Y6)#1PP$7-Z0!]
MQ^G@!P%..@#C@ZM,%8P>(F]HLS;]'MG[?<]F_?$,M*L,JK0)JK3I2Q?GX%TF
M)WQEGJN$0K$M9/F 4:_63V)S\Q!TM+Z 5S?EPU8CIGQG^X*Y.M$)D)&E$JE+
M_0CP\NFJG$BV,:\_3TQ*EIOAFN"4<$V@OB\9D_N)5E _(,[^ U!+ P04
M" "V0UE2]TO "9,#  "N#0  &0   'AL+W=O<FMS:&5E=',O<VAE970U,BYX
M;6S-5]MNVS@0_15"V (M4.MJRW9@&W"<=EM@@P8)VCX4^\!88YL():HD;<=_
MOT-*D2^0F<N^],46+^=PSLQ(,QQMA7Q0*P!-'G->J+&WTKJ\" (U7T%.E2]*
M*'!E(61.-0[E,E"E!)I94,Z#. S3(*>L\"8C.W<C)R.QUIP5<".)6N<YE;M+
MX&([]B+O:>*6+5?:3 2344F7< ?Z>WDC<10T+!G+H5!,%$3"8NQ-HXM9E!J
MW?&#P58=/!,CY5Z(!S/XFHV]T%@$'.;:4%#\V\ ,.#=,:,?OFM1KSC3 P^<G
M]L]6/(JYIPIF@O]DF5Z-O8%',EC0-=>W8OL%:D$]PS<77-E?LJWWAAZ9KY46
M>0U&"W)65/_TL7;$ 0"%M@/B&A"? OIG $D-2*S0RC(KZXIJ.AE)L272[$8V
M\V!]8]&HAA4FC'=:XBI#G)[<K:@$ZXB,S$6.V:&H]6^'_+0N@*PSW8#$D)*I
MPF"79E61]U>@*>/J VZL.+[5*QWR%PF(,G-J%&BTT9P4S&M[+BM[XC/V1#&Y
M%H5>*?*IR" [)@A07*,P?E)X&3L9KV#NDR3Z2.(P#EL,FKT8'@T=YB2-PQ/+
ME[@<WJD</CMT^%1*6BP!7Q%-[G?D<-\-W=GIZ9;*C/SZ!RG)5PVY^M=A4+<Q
MJ&L-ZIXQZ):IA\Y" A!6:,"@:2*IAH\FVUB^SMMBZ&8,_3!\U^;IYV#)\)U#
M4*\1U'NC(/IX3I";,?3CJ%70<[!![!*4-H)2)\^GQQ(_>I@'&\$Q5SC3.V=T
MW&QISQ\DK6J>P?7]X< EI]_(Z;]!SOG8N-GZ/;_;GFUN7#KP^Z=!/9(S:.0,
M7B8G8QN609&1'0.>M2EQ$YU];5X-.](Q;'0,G3S7;0EUQ!2%^Z(2_AD?N>B@
MSD4O"Q/'M@'KUPZH5!]:"Y2;J$<LE$0#DM%=6XF;O9 A);DM=2Y]\5Y?["3]
M&QVKT2(-9$&9)!O*UT#>LX)D@G-S7 FR*LOMJBOZH:4WS=\&,ZL["C9'PMHV
M)5&SZ]CV?4F,$G?JM;W\QUS[:A9U_Y#4V]>CR%T'7I%Z;J)^E3BM*?<&Y+&<
M?36*W(7@?V=:VI)$:7R::FV[NL.35 L..M\<Y-)>"!1VLNM"5RUB,]M<.J:V
MU3Z9OS27$=M1[VFJF\PUE4N&?2V'!5*&?A\]+:O+0370HK3]];W0V*W;QQ5>
MJ$":#;B^$$(_#<P!S15M\A]02P,$%     @ MD-94K?;#PNZ P  )PX  !D
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M(BM.$T:!IFD SY="Z.<+LYU3[_>-OP)02P,$%     @ MD-94FH,Q+/@ 0
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M==D<\EGWN<3D$U!+ 0(4 Q0    ( +9#65('04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ MD-94A-F
MYK+O    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ MD-94IE<G",0!@  G"<  !,              ( !S0$
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "V0UE2K)L;;KP&   \
M&P  &               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ MD-94KWL!C0<!@  ZA@  !@              ("!  \
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( +9#65+HCQ1>
M: (  .,%   8              " @5(5  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    " "V0UE23Q2H,*L$   0$   &
M@('P%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ MD-9
M4G1 -LGX!0  +AP  !@              ("!T1P  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( +9#65)B!12?! <  #0=   8
M      " @?\B  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M" "V0UE2R9EN,^($  !9"@  &               @($Y*@  >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ MD-94M>6NVFJ'@  !UP  !@
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M970Q,BYX;6Q02P$"% ,4    " "V0UE2MO3?7K,&  !,#P  &0
M    @('J6P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M +9#65*'S>D9T0L   $?   9              " @=1B  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ MD-94@]()5O3 @  4@8  !D
M             ("!W&X  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    " "V0UE2]L=7$Q4'   K$0  &0              @('F<0  >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( +9#65)(Y E;,PL
M ,$=   9              " @3)Y  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ MD-94@6R!6H% P  P@8  !D              ("!
MG(0  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "V0UE2
M;5)O:%8#  !3!P  &0              @('8AP  >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( +9#65)KB%/^\A\  (]F   9
M      " @66+  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ MD-94NYYBV.K @  D 4  !D              ("!CJL  'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "V0UE2J^F@(7@"  !)!0
M&0              @(%PK@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( +9#65(]2O:!)0,  #<'   9              " @1^Q  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ MD-94IM4-3&F
M @  C04  !D              ("!>[0  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    " "V0UE20X\D(9($  "8"@  &0
M@(%8MP  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( +9#
M65(MZMR6+04  !\.   9              " @2&\  !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ MD-94F7SGG'6!0  * X  !D
M         ("!A<$  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M    " "V0UE2L\_HZ,D"   Q!@  &0              @(&2QP  >&PO=V]R
M:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( +9#65+F O.$)0,  '(&
M   9              " @9+*  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
M4$L! A0#%     @ MD-94IV'>T%8 P  4@H  !D              ("![LT
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " "V0UE2V*FQ
MQ?<$  "'%0  &0              @(%]T0  >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;%!+ 0(4 Q0    ( +9#65(=,A',E (  (8&   9
M  " @:O6  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
MMD-94GK<-95( @  N@4  !D              ("!=MD  'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    " "V0UE2-VF%ZY\#  !2#0  &0
M            @('UVP  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    ( +9#65+'CY&S> (  (<&   9              " @<O?  !X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ MD-94@)&]N-3 @
MJ@4  !D              ("!>N(  'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    " "V0UE2LZM%DXL"  " !@  &0              @($$
MY0  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( +9#65)P
M$0GX60,  &$*   9              " @<;G  !X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @ MD-94DD6@'T+!   00X  !D
M     ("!5NL  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +9#65)4E)?N? (  #T&   9              "
M@?/\  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ MD-9
M4H$LJ[?* @  N @  !D              ("!IO\  'AL+W=O<FMS:&5E=',O
M<VAE970T-2YX;6Q02P$"% ,4    " "V0UE2J>+I?R@#   D"@  &0
M        @(&G @$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0
M   ( +9#65)?J::;.P0   </   9              " @08& 0!X;"]W;W)K
M<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ MD-94D-YH/^* @  VP8
M !D              ("!> H! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q0
M2P$"% ,4    " "V0UE22YA @-$"  !8"   &0              @($Y#0$
M>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( +9#65(#:FO$
MU 4  #4<   9              " @4$0 0!X;"]W;W)K<VAE971S+W-H965T
M-3 N>&UL4$L! A0#%     @ MD-94NI?,R;^!   3!0  !D
M ("!3!8! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " "V
M0UE2]TO "9,#  "N#0  &0              @(&!&P$ >&PO=V]R:W-H965T
M<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( +9#65*WVP\+N@,  "<.   9
M          " @4L? 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#
M%     @ MD-94J*X=>TV P  <@D  !D              ("!/",! 'AL+W=O
M<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " "V0UE2S/,YLS@$  #[
M$P  &0              @(&I)@$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM
M;%!+ 0(4 Q0    ( +9#65)J#,2SX $  %0$   9              " @1@K
M 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ MD-94H6B
MG&>1 @  )!    T              ( !+RT! 'AL+W-T>6QE<RYX;6Q02P$"
M% ,4    " "V0UE2EXJ[',     3 @  "P              @ 'K+P$ 7W)E
M;',O+G)E;'-02P$"% ,4    " "V0UE2/V@A-ZT$   $)0  #P
M    @ '4, $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ MD-94@P_D/SE
M 0  ?R$  !H              ( !KC4! 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ MD-94H_AMVG3 0  -B$  !,
M ( !RS<! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $  0 !W$0  SSD!
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>105</ContextCount>
  <ElementCount>378</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>43</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Shareholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and description of business operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations</Role>
      <ShortName>Organization and description of business operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Prepaid expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Prepaidexpenses</Role>
      <ShortName>Prepaid expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2109104 - Disclosure - Tax and tax incentive receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Taxandtaxincentivereceivable</Role>
      <ShortName>Tax and tax incentive receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112105 - Disclosure - Property leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Propertyleases</Role>
      <ShortName>Property leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117106 - Disclosure - Accrued expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Accruedexpenses</Role>
      <ShortName>Accrued expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120107 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Term loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Termloan</Role>
      <ShortName>Term loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2128109 - Disclosure - Benefit plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Benefitplans</Role>
      <ShortName>Benefit plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2130110 - Disclosure - Taxation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Taxation</Role>
      <ShortName>Taxation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2137111 - Disclosure - Share based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Sharebasedcompensation</Role>
      <ShortName>Share based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2144112 - Disclosure - Net loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Netlosspershare</Role>
      <ShortName>Net loss per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2147113 - Disclosure - Related party transactions and other shareholder matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Relatedpartytransactionsandothershareholdermatters</Role>
      <ShortName>Related party transactions and other shareholder matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Prepaid expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/PrepaidexpensesTables</Role>
      <ShortName>Prepaid expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Prepaidexpenses</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Tax and tax incentive receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/TaxandtaxincentivereceivableTables</Role>
      <ShortName>Tax and tax incentive receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Taxandtaxincentivereceivable</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Property leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/PropertyleasesTables</Role>
      <ShortName>Property leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Propertyleases</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2318304 - Disclosure - Accrued expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/AccruedexpensesTables</Role>
      <ShortName>Accrued expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Accruedexpenses</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2321305 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Warrants</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2331306 - Disclosure - Taxation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/TaxationTables</Role>
      <ShortName>Taxation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Taxation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2338307 - Disclosure - Share based compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SharebasedcompensationTables</Role>
      <ShortName>Share based compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Sharebasedcompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2345308 - Disclosure - Net loss per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/NetlosspershareTables</Role>
      <ShortName>Net loss per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Netlosspershare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2348309 - Disclosure - Related party transactions and other shareholder matters (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersTables</Role>
      <ShortName>Related party transactions and other shareholder matters (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Relatedpartytransactionsandothershareholdermatters</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails</Role>
      <ShortName>Organization, Consolidation and Presentation of Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Basis of Presentation and Summary of Significant Accounting policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Prepaid expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/PrepaidexpensesDetails</Role>
      <ShortName>Prepaid expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/PrepaidexpensesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Tax and tax incentive receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/TaxandtaxincentivereceivableDetails</Role>
      <ShortName>Tax and tax incentive receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/TaxandtaxincentivereceivableTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2414405 - Disclosure - Property leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/PropertyleasesNarrativeDetails</Role>
      <ShortName>Property leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2415406 - Disclosure - Property leases - Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/PropertyleasesMaturityDetails</Role>
      <ShortName>Property leases - Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - Property leases Maturity Under ASC 840 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/PropertyleasesMaturityUnderASC840Details</Role>
      <ShortName>Property leases Maturity Under ASC 840 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2419408 - Disclosure - Accrued expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/AccruedexpensesDetails</Role>
      <ShortName>Accrued expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/AccruedexpensesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2422409 - Disclosure - Warrants - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/WarrantsNarrativeDetails</Role>
      <ShortName>Warrants - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2423410 - Disclosure - Warrants - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails</Role>
      <ShortName>Warrants - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Warrants - Movement in Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/WarrantsMovementinValueDetails</Role>
      <ShortName>Warrants - Movement in Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Warrants - Effect of Change in Volatility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/WarrantsEffectofChangeinVolatilityDetails</Role>
      <ShortName>Warrants - Effect of Change in Volatility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Term loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/TermloanDetails</Role>
      <ShortName>Term loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Termloan</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Benefit plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/BenefitplansDetails</Role>
      <ShortName>Benefit plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Benefitplans</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2432415 - Disclosure - Taxation - Loss Before Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/TaxationLossBeforeTaxDetails</Role>
      <ShortName>Taxation - Loss Before Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - Taxation - Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails</Role>
      <ShortName>Taxation - Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Taxation - Reconciliation of Statutory Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails</Role>
      <ShortName>Taxation - Reconciliation of Statutory Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - Taxation - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Taxation - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Taxation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/TaxationNarrativeDetails</Role>
      <ShortName>Taxation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2439420 - Disclosure - Share based compensation - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share based compensation - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2440421 - Disclosure - Share based compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SharebasedcompensationNarrativeDetails</Role>
      <ShortName>Share based compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - Share based compensation - Share Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails</Role>
      <ShortName>Share based compensation - Share Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - Share based compensation - Weighted-Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails</Role>
      <ShortName>Share based compensation - Weighted-Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2443424 - Disclosure - Share based compensation - RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails</Role>
      <ShortName>Share based compensation - RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2446425 - Disclosure - Net loss per share - Computation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/NetlosspershareComputationDetails</Role>
      <ShortName>Net loss per share - Computation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2449426 - Disclosure - Related party transactions and other shareholder matters (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails</Role>
      <ShortName>Related party transactions and other shareholder matters (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="vrna-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - vrna-20201231.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - vrna-20201231.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="vrna-20201231.htm">vrna-20201231.htm</File>
    <File>consentletter-fy20vrp_sx4x.htm</File>
    <File>exhibit311.htm</File>
    <File>exhibit312.htm</File>
    <File>exhibit321.htm</File>
    <File>exhibit322.htm</File>
    <File>non-executicedirectorappoi.htm</File>
    <File>svb-firstamendmenttoloan.htm</File>
    <File>vrna-20201231.xsd</File>
    <File>vrna-20201231_cal.xml</File>
    <File>vrna-20201231_def.xml</File>
    <File>vrna-20201231_lab.xml</File>
    <File>vrna-20201231_pre.xml</File>
    <File>vrna-descriptionofsecuriti.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>vrna-20201231_g1.gif</File>
    <File>vrna-20201231_g2.jpg</File>
    <File>vrna-20201231_g3.jpg</File>
    <File>vrna-20201231_g4.jpg</File>
    <File>vrna-20201231_g5.jpg</File>
    <File>vrna-20201231_g6.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>90
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vrna-20201231.htm": {
   "axisCustom": 1,
   "axisStandard": 17,
   "contextCount": 105,
   "dts": {
    "calculationLink": {
     "local": [
      "vrna-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vrna-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "vrna-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vrna-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vrna-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "vrna-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 462,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 3,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 7
   },
   "keyCustom": 45,
   "keyStandard": 333,
   "memberCustom": 21,
   "memberStandard": 22,
   "nsprefix": "vrna",
   "nsuri": "http://veronapharma.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://veronapharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109104 - Disclosure - Tax and tax incentive receivable",
     "role": "http://veronapharma.com/role/Taxandtaxincentivereceivable",
     "shortName": "Tax and tax incentive receivable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112105 - Disclosure - Property leases",
     "role": "http://veronapharma.com/role/Propertyleases",
     "shortName": "Property leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117106 - Disclosure - Accrued expenses",
     "role": "http://veronapharma.com/role/Accruedexpenses",
     "shortName": "Accrued expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vrna:WarrantAndRightsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120107 - Disclosure - Warrants",
     "role": "http://veronapharma.com/role/Warrants",
     "shortName": "Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vrna:WarrantAndRightsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Term loan",
     "role": "http://veronapharma.com/role/Termloan",
     "shortName": "Term loan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128109 - Disclosure - Benefit plans",
     "role": "http://veronapharma.com/role/Benefitplans",
     "shortName": "Benefit plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130110 - Disclosure - Taxation",
     "role": "http://veronapharma.com/role/Taxation",
     "shortName": "Taxation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137111 - Disclosure - Share based compensation",
     "role": "http://veronapharma.com/role/Sharebasedcompensation",
     "shortName": "Share based compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144112 - Disclosure - Net loss per share",
     "role": "http://veronapharma.com/role/Netlosspershare",
     "shortName": "Net loss per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147113 - Disclosure - Related party transactions and other shareholder matters",
     "role": "http://veronapharma.com/role/Relatedpartytransactionsandothershareholdermatters",
     "shortName": "Related party transactions and other shareholder matters",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idecac34827ce472182dc1492d400ffdf_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://veronapharma.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idecac34827ce472182dc1492d400ffdf_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting policies (Policies)",
     "role": "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Prepaid expenses (Tables)",
     "role": "http://veronapharma.com/role/PrepaidexpensesTables",
     "shortName": "Prepaid expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vrna:ScheduleOfNontradeReceivablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Tax and tax incentive receivable (Tables)",
     "role": "http://veronapharma.com/role/TaxandtaxincentivereceivableTables",
     "shortName": "Tax and tax incentive receivable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vrna:ScheduleOfNontradeReceivablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Property leases (Tables)",
     "role": "http://veronapharma.com/role/PropertyleasesTables",
     "shortName": "Property leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318304 - Disclosure - Accrued expenses (Tables)",
     "role": "http://veronapharma.com/role/AccruedexpensesTables",
     "shortName": "Accrued expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321305 - Disclosure - Warrants (Tables)",
     "role": "http://veronapharma.com/role/WarrantsTables",
     "shortName": "Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331306 - Disclosure - Taxation (Tables)",
     "role": "http://veronapharma.com/role/TaxationTables",
     "shortName": "Taxation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338307 - Disclosure - Share based compensation (Tables)",
     "role": "http://veronapharma.com/role/SharebasedcompensationTables",
     "shortName": "Share based compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2345308 - Disclosure - Net loss per share (Tables)",
     "role": "http://veronapharma.com/role/NetlosspershareTables",
     "shortName": "Net loss per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348309 - Disclosure - Related party transactions and other shareholder matters (Tables)",
     "role": "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersTables",
     "shortName": "Related party transactions and other shareholder matters (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idecac34827ce472182dc1492d400ffdf_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "gbpPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idecac34827ce472182dc1492d400ffdf_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "gbpPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "vrna:NumberOfWhollyOwnedSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "subsidiary",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Details)",
     "role": "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
     "shortName": "Organization, Consolidation and Presentation of Financial Statements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "vrna:NumberOfWhollyOwnedSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "subsidiary",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Basis of Presentation and Summary of Significant Accounting policies (Details)",
     "role": "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idecac34827ce472182dc1492d400ffdf_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:PrepaidResearchAndDevelopmentFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Prepaid expenses (Details)",
     "role": "http://veronapharma.com/role/PrepaidexpensesDetails",
     "shortName": "Prepaid expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idecac34827ce472182dc1492d400ffdf_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:PrepaidResearchAndDevelopmentFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vrna:ScheduleOfNontradeReceivablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idecac34827ce472182dc1492d400ffdf_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:ResearchAndDevelopmentTaxCreditReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - Tax and tax incentive receivable (Details)",
     "role": "http://veronapharma.com/role/TaxandtaxincentivereceivableDetails",
     "shortName": "Tax and tax incentive receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vrna:ScheduleOfNontradeReceivablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idecac34827ce472182dc1492d400ffdf_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:ResearchAndDevelopmentTaxCreditReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414405 - Disclosure - Property leases - Narrative (Details)",
     "role": "http://veronapharma.com/role/PropertyleasesNarrativeDetails",
     "shortName": "Property leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idecac34827ce472182dc1492d400ffdf_I20201231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idecac34827ce472182dc1492d400ffdf_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415406 - Disclosure - Property leases - Maturity (Details)",
     "role": "http://veronapharma.com/role/PropertyleasesMaturityDetails",
     "shortName": "Property leases - Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idecac34827ce472182dc1492d400ffdf_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416407 - Disclosure - Property leases Maturity Under ASC 840 (Details)",
     "role": "http://veronapharma.com/role/PropertyleasesMaturityUnderASC840Details",
     "shortName": "Property leases Maturity Under ASC 840 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idecac34827ce472182dc1492d400ffdf_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:AccruedResearchAndDevelopmentFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419408 - Disclosure - Accrued expenses (Details)",
     "role": "http://veronapharma.com/role/AccruedexpensesDetails",
     "shortName": "Accrued expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idecac34827ce472182dc1492d400ffdf_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:AccruedResearchAndDevelopmentFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422409 - Disclosure - Warrants - Narrative (Details)",
     "role": "http://veronapharma.com/role/WarrantsNarrativeDetails",
     "shortName": "Warrants - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "i1934261cb6744a68b1f3c1ac28b455f2_I20161231",
      "decimals": "4",
      "lang": "en-US",
      "name": "vrna:ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "gbpPerShare",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idecac34827ce472182dc1492d400ffdf_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423410 - Disclosure - Warrants - Fair Value Assumptions (Details)",
     "role": "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails",
     "shortName": "Warrants - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idecac34827ce472182dc1492d400ffdf_I20201231",
      "decimals": "2",
      "lang": "en-US",
      "name": "vrna:ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "i4ddbe14bb0b74155b1ec2fe2ec3b8225_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Warrants - Movement in Value (Details)",
     "role": "http://veronapharma.com/role/WarrantsMovementinValueDetails",
     "shortName": "Warrants - Movement in Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "ibc6502e2d84744a1a4f122e93a5bbedc_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vrna:FairValueImpactOfIncreaseOrDecreaseInVolatilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idecac34827ce472182dc1492d400ffdf_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Warrants - Effect of Change in Volatility (Details)",
     "role": "http://veronapharma.com/role/WarrantsEffectofChangeinVolatilityDetails",
     "shortName": "Warrants - Effect of Change in Volatility (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vrna:FairValueImpactOfIncreaseOrDecreaseInVolatilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idecac34827ce472182dc1492d400ffdf_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Term loan (Details)",
     "role": "http://veronapharma.com/role/TermloanDetails",
     "shortName": "Term loan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "ie41a5e71b1994eee9bbaacc09238aab0_D20201101-20201130",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Benefit plans (Details)",
     "role": "http://veronapharma.com/role/BenefitplansDetails",
     "shortName": "Benefit plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432415 - Disclosure - Taxation - Loss Before Tax (Details)",
     "role": "http://veronapharma.com/role/TaxationLossBeforeTaxDetails",
     "shortName": "Taxation - Loss Before Tax (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - Taxation - Tax Expense (Benefit) (Details)",
     "role": "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails",
     "shortName": "Taxation - Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Taxation - Reconciliation of Statutory Rate (Details)",
     "role": "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails",
     "shortName": "Taxation - Reconciliation of Statutory Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idecac34827ce472182dc1492d400ffdf_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:DeferredTaxLiabilitiesContingentLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - Taxation - Deferred Tax Assets and Liabilities (Details)",
     "role": "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Taxation - Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idecac34827ce472182dc1492d400ffdf_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:DeferredTaxLiabilitiesContingentLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idecac34827ce472182dc1492d400ffdf_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Taxation - Narrative (Details)",
     "role": "http://veronapharma.com/role/TaxationNarrativeDetails",
     "shortName": "Taxation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idecac34827ce472182dc1492d400ffdf_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439420 - Disclosure - Share based compensation - Share-Based Compensation Expense (Details)",
     "role": "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails",
     "shortName": "Share based compensation - Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "ia7bb2db7aeed4fe28f6502081a2b3fb2_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Shareholders\u2019 Equity",
     "role": "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity",
     "shortName": "Consolidated Statements of Shareholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "ia7bb2db7aeed4fe28f6502081a2b3fb2_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440421 - Disclosure - Share based compensation - Narrative (Details)",
     "role": "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
     "shortName": "Share based compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idecac34827ce472182dc1492d400ffdf_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityListingDepositoryReceiptRatio",
      "reportCount": 1,
      "unitRef": "rate",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - Share based compensation - Share Option Activity (Details)",
     "role": "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails",
     "shortName": "Share based compensation - Share Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "ibc6502e2d84744a1a4f122e93a5bbedc_I20181231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "i15364ff1d68341ec805494f64c383003_D20200101-20201231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - Share based compensation - Weighted-Average Assumptions (Details)",
     "role": "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails",
     "shortName": "Share based compensation - Weighted-Average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "i15364ff1d68341ec805494f64c383003_D20200101-20201231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "i844f6711369540ba826df75f6b6a22dd_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443424 - Disclosure - Share based compensation - RSU Activity (Details)",
     "role": "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails",
     "shortName": "Share based compensation - RSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "i5c77df9054424edb9685cd91224a73df_I20181231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446425 - Disclosure - Net loss per share - Computation (Details)",
     "role": "http://veronapharma.com/role/NetlosspershareComputationDetails",
     "shortName": "Net loss per share - Computation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "i9dd30f2681444b31a30cecbb105a8d12_D20200717-20200717",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449426 - Disclosure - Related party transactions and other shareholder matters (Details)",
     "role": "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails",
     "shortName": "Related party transactions and other shareholder matters (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "iaed0afb2f5ac4a73bc91d4c2a32c115e_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vrna:OrganizationAndBusinessDescriptionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and description of business operations",
     "role": "http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations",
     "shortName": "Organization and description of business operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vrna:OrganizationAndBusinessDescriptionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting policies",
     "role": "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vrna:PrepaidExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Prepaid expenses",
     "role": "http://veronapharma.com/role/Prepaidexpenses",
     "shortName": "Prepaid expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20201231.htm",
      "contextRef": "idd7bc12ea57c419cbbb7d33d22b52857_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vrna:PrepaidExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": null,
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - vrna-20201231.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - vrna-20201231.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 43,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region",
        "terseLabel": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'.",
        "label": "Entity Listing, Depository Receipt Ratio",
        "terseLabel": "Number of ordinary shares per ADS"
       }
      }
     },
     "localname": "EntityListingDepositoryReceiptRatio",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r54",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember": {
     "auth_ref": [
      "r115",
      "r123",
      "r180",
      "r258",
      "r259",
      "r260",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjusted Balance [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjusted Balance"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r115",
      "r123",
      "r180",
      "r258",
      "r259",
      "r260",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r115",
      "r123",
      "r180",
      "r258",
      "r259",
      "r260",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r115",
      "r123",
      "r180",
      "r258",
      "r259",
      "r260",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r220",
      "r221",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r420",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails",
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r220",
      "r221",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r420",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails",
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r216",
      "r220",
      "r221",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r420",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails",
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r216",
      "r220",
      "r221",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r420",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails",
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r169",
      "r170",
      "r214",
      "r215",
      "r421",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r169",
      "r170",
      "r214",
      "r215",
      "r421",
      "r435",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_NY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW YORK",
        "terseLabel": "New York"
       }
      }
     },
     "localname": "NY",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r119",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r290",
      "r291",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible List]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Accruedexpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://veronapharma.com/role/AccruedexpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/AccruedexpensesDetails",
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r32",
      "r56",
      "r57",
      "r58",
      "r409",
      "r430",
      "r434"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r55",
      "r58",
      "r59",
      "r112",
      "r113",
      "r114",
      "r311",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r30",
      "r261"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r258",
      "r259",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r222",
      "r224",
      "r264",
      "r265"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r224",
      "r250",
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r75",
      "r88",
      "r336"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Accretion of redemption premium on debt"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r71",
      "r88",
      "r338"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issue costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r97",
      "r155",
      "r163",
      "r167",
      "r176",
      "r307",
      "r312",
      "r322",
      "r388",
      "r407"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r53",
      "r97",
      "r176",
      "r307",
      "r312",
      "r322"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets:"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r97",
      "r176",
      "r307",
      "r312",
      "r322"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r225",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails",
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r95",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r36",
      "r90"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r12",
      "r91",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r84",
      "r90",
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of the year",
        "periodStartLabel": "Cash and cash equivalents at beginning of the year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r84",
      "r327"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of stock warrant (in pound sterling per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails",
      "http://veronapharma.com/role/WarrantsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of shares called by each warrant"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/WarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Stock warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails",
      "http://veronapharma.com/role/WarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Number of outstanding warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/WarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r213",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r47",
      "r192",
      "r396",
      "r413"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r95",
      "r193",
      "r436",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Ligand agreement"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r112",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in pounds sterling per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r29",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Ordinary \u00a30.05 par value shares; 488,304,446 and 105,326,638 issued, and 463,304,446 and 105,326,638 outstanding, at December 31, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r61",
      "r63",
      "r64",
      "r69",
      "r399",
      "r416"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss attributable to shareholders of the Company"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r145",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of credit risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r95",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation and consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal, State and Local, Tax Expense (Benefit)",
        "terseLabel": "United Kingdom"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r103",
      "r285"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r285",
      "r294",
      "r296"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current tax expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Term loan"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Termloan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r21",
      "r23",
      "r24",
      "r389",
      "r391",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r24",
      "r195",
      "r391",
      "r405"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Amount drawn down"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r337",
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r46",
      "r101",
      "r204",
      "r207",
      "r208",
      "r209",
      "r336",
      "r337",
      "r339",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Summary of Prepaid Expenses"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PrepaidexpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "terseLabel": "United Kingdom"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs incurred"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r286",
      "r294"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r98",
      "r286",
      "r294",
      "r295",
      "r296"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred tax expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r26",
      "r27",
      "r276",
      "r390",
      "r404"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r277"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r283",
      "r284"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r283",
      "r284"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r282",
      "r283",
      "r284"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "IPR&amp;D asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r283",
      "r284"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Future exercisable shares"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r278"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Less: valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Contribution cost"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BenefitplansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for defined contribution plan.",
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "Benefits plans"
       }
      }
     },
     "localname": "DefinedContributionPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Benefitplans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r88",
      "r153"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share based compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Sharebasedcompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Loss per share, basic and diluted (in dollars per share)",
        "verboseLabel": "Net loss per share - basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Netlosspershare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r271"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r271",
      "r298"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.K. tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r271",
      "r298"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in deferred tax valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r271",
      "r298"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Difference in overseas statutory tax rates"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r271",
      "r298"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Non-deductible expenses"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r271",
      "r298"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "terseLabel": "Share options exercised"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r271",
      "r298"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedTerseLabel": "Research and development incentive"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://veronapharma.com/role/AccruedexpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "People related costs"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/AccruedexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r251"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Cost related to share options and RSUs granted but not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expected period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Share Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r117",
      "r125",
      "r127",
      "r140",
      "r180",
      "r203",
      "r210",
      "r258",
      "r259",
      "r260",
      "r290",
      "r291",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r88",
      "r198"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Fair value adjustment"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Fair Value Valuation Assumptions of Warrants"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/WarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Warrant Activity"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/WarrantsMovementinValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r316",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Movement of the Value of the Warrants"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/WarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Fair value adjustment"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/WarrantsMovementinValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": {
     "auth_ref": [
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "terseLabel": "Translation differences recognized in other comprehensive loss"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/WarrantsMovementinValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "At December 31",
        "periodStartLabel": "At January 1"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/WarrantsMovementinValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r95",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair value of financial instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r326"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedTerseLabel": "Foreign exchange (gain) / loss",
        "terseLabel": "Foreign exchange gain / (loss)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r95",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currencies"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r186",
      "r187",
      "r387"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r95",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r102",
      "r297"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationLossBeforeTaxDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "negatedLabel": "United Kingdom"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationLossBeforeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r67",
      "r155",
      "r162",
      "r165",
      "r166",
      "r168",
      "r386",
      "r397",
      "r401",
      "r418"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://veronapharma.com/role/TaxationLossBeforeTaxDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "negatedTotalLabel": "Total",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://veronapharma.com/role/TaxationLossBeforeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r102",
      "r297"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationLossBeforeTaxDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "negatedLabel": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationLossBeforeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r272",
      "r274",
      "r281",
      "r292",
      "r299",
      "r301",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Taxation"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Taxation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationInterestAccrued": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated interest accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Income Tax Examination, Interest Accrued",
        "terseLabel": "Interest accrued"
       }
      }
     },
     "localname": "IncomeTaxExaminationInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAccrued": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated penalties accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties Accrued",
        "terseLabel": "Penalties accrued"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Interest and penalties recognized"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r126",
      "r127",
      "r154",
      "r270",
      "r293",
      "r300",
      "r419"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax expense",
        "totalLabel": "Total income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r65",
      "r95",
      "r268",
      "r269",
      "r274",
      "r275",
      "r280",
      "r287",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r51",
      "r395",
      "r414"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxandtaxincentivereceivableDetails": {
       "order": 2.0,
       "parentTag": "vrna_TaxCreditAndIncomeTaxesReceivableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Tax receivable - U.S."
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxandtaxincentivereceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedTerseLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedTerseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r66",
      "r152",
      "r335",
      "r338",
      "r400"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r83",
      "r85",
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r73",
      "r75"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r175",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Short term investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Discount rate (in percent)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Minimum Annual Operating Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://veronapharma.com/role/PropertyleasesMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://veronapharma.com/role/PropertyleasesMaturityDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum future lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://veronapharma.com/role/PropertyleasesMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://veronapharma.com/role/PropertyleasesMaturityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://veronapharma.com/role/PropertyleasesMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://veronapharma.com/role/PropertyleasesMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://veronapharma.com/role/PropertyleasesMaturityDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Property leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Propertyleases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r42",
      "r97",
      "r164",
      "r176",
      "r308",
      "r312",
      "r313",
      "r322"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r35",
      "r97",
      "r176",
      "r322",
      "r392",
      "r411"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r44",
      "r97",
      "r176",
      "r308",
      "r312",
      "r313",
      "r322"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r24",
      "r25",
      "r97",
      "r176",
      "r308",
      "r312",
      "r313",
      "r322"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "Tax and tax incentive receivable"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Taxandtaxincentivereceivable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r24",
      "r196",
      "r391",
      "r408"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Carry value of debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Term loan"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r46",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Dividend rate"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "Valuation Allowance [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r84",
      "r86",
      "r89"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r60",
      "r62",
      "r68",
      "r89",
      "r97",
      "r116",
      "r121",
      "r122",
      "r123",
      "r124",
      "r126",
      "r127",
      "r131",
      "r155",
      "r162",
      "r165",
      "r166",
      "r168",
      "r176",
      "r322",
      "r398",
      "r415"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedTerseLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r124",
      "r128",
      "r129",
      "r132",
      "r134",
      "r155",
      "r162",
      "r165",
      "r166",
      "r168"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "negatedTerseLabel": "Net loss available to ordinary shareholders - basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r130",
      "r132",
      "r134"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "negatedTerseLabel": "Net loss available to ordinary shareholders - diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r123",
      "r138",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r288",
      "r289",
      "r290",
      "r291",
      "r371",
      "r372",
      "r373",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently adopted accounting pronouncements and Recently issued accounting pronouncements, not yet adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r155",
      "r162",
      "r165",
      "r166",
      "r168"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r343"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Impairment of right-of-use asset",
        "verboseLabel": "Impairment of right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://veronapharma.com/role/PropertyleasesMaturityDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liabilities",
        "verboseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails",
      "http://veronapharma.com/role/PropertyleasesMaturityDetails",
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating Lease, Liability, Noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails",
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesMaturityUnderASC840Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r340",
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesMaturityUnderASC840Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r340",
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesMaturityUnderASC840Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r340",
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesMaturityUnderASC840Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r340",
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesMaturityUnderASC840Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r340",
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesMaturityUnderASC840Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r282"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r305",
      "r306",
      "r310"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustments",
        "verboseLabel": "Effect of foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other income / (expense)"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r43"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r2",
      "r5",
      "r185"
     ],
     "calculation": {
      "http://veronapharma.com/role/PrepaidexpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Term loan issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payment of offering costs in connection with the issuance of ordinary shares"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireHeldToMaturitySecurities": {
     "auth_ref": [
      "r77",
      "r174"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities.",
        "label": "Payments to Acquire Held-to-maturity Securities",
        "negatedTerseLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of furniture and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r225",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r2",
      "r5",
      "r184",
      "r185"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://veronapharma.com/role/PrepaidexpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets",
      "http://veronapharma.com/role/PrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r3",
      "r5",
      "r183",
      "r185"
     ],
     "calculation": {
      "http://veronapharma.com/role/PrepaidexpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of ordinary shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from the issuance of term loan",
        "verboseLabel": "Funded advances"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Net proceeds from sale of stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities": {
     "auth_ref": [
      "r76",
      "r174"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer.",
        "label": "Proceeds from Sale of Held-to-maturity Securities",
        "terseLabel": "Sale of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r79",
      "r253"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of share options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r38",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r16",
      "r17",
      "r190",
      "r412"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Furniture and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r37",
      "r95",
      "r190",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Furniture and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r16",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Furniture and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r217",
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r217",
      "r357",
      "r358",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Amount paid to related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r217",
      "r357",
      "r360",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r355",
      "r356",
      "r358",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related party transactions and other shareholder matters"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/Relatedpartytransactionsandothershareholdermatters"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r267",
      "r450"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r95",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r31",
      "r210",
      "r261",
      "r410",
      "r429",
      "r434"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets",
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r117",
      "r125",
      "r127",
      "r180",
      "r258",
      "r259",
      "r260",
      "r290",
      "r291",
      "r425",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r351",
      "r353"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets recognized with associated liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in sale"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/AccruedexpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components of income tax expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of Basic and Diluted Earning Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/NetlosspershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of the U.K. statutory income tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r224",
      "r249",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r224",
      "r249",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Allocation of Share Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Minimum Rental Commitments Under Non-cancelable Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Components of loss before income taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r99",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of Private Placement to Related Parties"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r225",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails",
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r231",
      "r241",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Share Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Weighted-Average Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r48",
      "r96",
      "r141",
      "r142",
      "r199",
      "r200",
      "r202",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r95",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, ending balance",
        "periodStartLabel": "Outstanding, beginning balance",
        "terseLabel": "Number of RSUs outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Outstanding, Weighted average remaining contractual term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails",
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "verboseLabel": "RSU Activity"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Further awards to be granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Stock option activity, additional disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable, Weight average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted",
        "verboseLabel": "Number granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, Aggregate intrinsic value (in dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r233",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance outstanding",
        "periodStartLabel": "Beginning balance outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of share options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, Ending Balance, Weighted average exercise price (in dollars per share)",
        "periodStartLabel": "Outstanding, Beginning Balance, Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r223",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails",
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised, Weight average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired, Weight average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited, Weight average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted, Weight average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r95",
      "r225",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Intrinsic and fair value, vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Contract life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r246",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected lives (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable, Aggregate intrinsic value (in dollars)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, Weighted average remaining contractual term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, Weighted average remaining contractual term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r22",
      "r393",
      "r394",
      "r406"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r50",
      "r112",
      "r113",
      "r114",
      "r117",
      "r125",
      "r127",
      "r140",
      "r180",
      "r203",
      "r210",
      "r258",
      "r259",
      "r260",
      "r290",
      "r291",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfOtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Other Comprehensive Income [Abstract]",
        "terseLabel": "Other comprehensive (loss) / income:"
       }
      }
     },
     "localname": "StatementOfOtherComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r140",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r28",
      "r29",
      "r203",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock issued during period (in shares)",
        "verboseLabel": "Issuance of ordinary shares, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r28",
      "r29",
      "r203",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of ordinary shares from restricted share units and share options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r28",
      "r29",
      "r203",
      "r210",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r28",
      "r29",
      "r203",
      "r210"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of ordinary shares, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r203",
      "r210"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of ordinary shares from restricted share units and share options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r29",
      "r33",
      "r34",
      "r97",
      "r172",
      "r176",
      "r322"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "negatedLabel": "Total shareholders' equity",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails",
      "http://veronapharma.com/role/ConsolidatedBalanceSheets",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "auth_ref": [
      "r94",
      "r95",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Treasury Shares"
       }
      }
     },
     "localname": "StockholdersEquityPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r49",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Ordinary shares held in treasury"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r49",
      "r211",
      "r212"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Ordinary shares held in treasury"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r143",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset"
       }
      }
     },
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r104",
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Valuation allowance at December 31",
        "periodStartLabel": "Valuation allowance at January 1"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Measurement Input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Expected term to exercise"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average shares outstanding - basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vrna_A2017IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Incentive Plan",
        "label": "2017 Incentive Plan [Member]",
        "terseLabel": "2017 Incentive Plan"
       }
      }
     },
     "localname": "A2017IncentivePlanMember",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/AccruedexpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Professional Fees, Listing, And General Corporate Costs, Current",
        "label": "Accrued Professional Fees, Listing, And General Corporate Costs, Current",
        "terseLabel": "Professional fees, listing and general corporate costs"
       }
      }
     },
     "localname": "AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/AccruedexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_AccruedResearchAndDevelopmentFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/AccruedexpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research And Development Fees, Current",
        "label": "Accrued Research And Development Fees, Current",
        "terseLabel": "Clinical trial and other development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentFeesCurrent",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/AccruedexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Equivalent Price Per Ordinary Share",
        "label": "Class of Warrant or Right, Equivalent Price Per Ordinary Share",
        "terseLabel": "Equivalent price of ordinary share (ADS price divided by eight)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightEquivalentPricePerOrdinaryShare",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "vrna_ClassOfWarrantOrRightIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Intrinsic Value",
        "label": "Class Of Warrant Or Right, Intrinsic Value",
        "terseLabel": "Intrinsic value"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIntrinsicValue",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/WarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Issue Price of Warrants or Rights",
        "label": "Class of Warrant or Right, Issue Price of Warrants or Rights",
        "terseLabel": "Issue price of warrants (in pounds sterling per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/WarrantsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Number Of Exercised Or Forfeited",
        "label": "Class Of Warrant Or Right, Number Of Exercised Or Forfeited",
        "terseLabel": "Number of warrants exercised and forfeited"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfExercisedOrForfeited",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/WarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vrna_ConsultancyServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consultancy Services",
        "label": "Consultancy Services [Member]",
        "terseLabel": "Consultancy Services"
       }
      }
     },
     "localname": "ConsultancyServicesMember",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_DebtInstrumentCovenantCashAndCashEquivalentsMinimum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Cash and Cash Equivalents, Minimum",
        "label": "Debt Instrument, Covenant, Cash and Cash Equivalents, Minimum",
        "terseLabel": "Loan covenant, minimum cash and cash equivalents"
       }
      }
     },
     "localname": "DebtInstrumentCovenantCashAndCashEquivalentsMinimum",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Debt Default, Attachment Or Judgment On Any Borrower\u2019s Assets Threshold",
        "label": "Debt Instrument, Debt Default, Attachment Or Judgment On Any Borrower\u2019s Assets Threshold",
        "terseLabel": "Default threshold of attachment or judgment on any of borrower\u2019s assets"
       }
      }
     },
     "localname": "DebtInstrumentDebtDefaultAttachmentOrJudgmentOnAnyBorrowersAssetsThreshold",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Debt Default, Default of Other Agreement Or Obligation, Threshold of Indebtedness",
        "label": "Debt Instrument, Debt Default, Default of Other Agreement Or Obligation, Threshold of Indebtedness",
        "terseLabel": "Default indebtedness threshold for default of any agreement or obligation"
       }
      }
     },
     "localname": "DebtInstrumentDebtDefaultDefaultOfOtherAgreementOrObligationThresholdOfIndebtedness",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Debt Default, Interest Rate, Stated Percentage",
        "label": "Debt Instrument, Debt Default, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate in the event of default"
       }
      }
     },
     "localname": "DebtInstrumentDebtDefaultInterestRateStatedPercentage",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vrna_DebtInstrumentEarlyRepaymentPenaltyAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, Early Repayment Penalty, Amount",
        "label": "Debt instrument, Early Repayment Penalty, Amount",
        "terseLabel": "Prepayment fee"
       }
      }
     },
     "localname": "DebtInstrumentEarlyRepaymentPenaltyAmount",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_DebtInstrumentEarlyRepaymentPenaltyPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, Early Repayment Penalty, Percent",
        "label": "Debt instrument, Early Repayment Penalty, Percent",
        "terseLabel": "Prepayment fee (in percent)"
       }
      }
     },
     "localname": "DebtInstrumentEarlyRepaymentPenaltyPercent",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vrna_DebtInstrumentFinalPaymentPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Final Payment, Percent",
        "label": "Debt Instrument, Final Payment, Percent",
        "terseLabel": "Final payment (in percent)"
       }
      }
     },
     "localname": "DebtInstrumentFinalPaymentPercent",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vrna_DebtInstrumentPrepaymentTermOfPriorWrittenNotice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment, Term of Prior Written Notice",
        "label": "Debt Instrument, Prepayment, Term of Prior Written Notice",
        "terseLabel": "Term of prior written notice"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentTermOfPriorWrittenNotice",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vrna_DebtPrepaymentPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Prepayment Period",
        "label": "Debt Prepayment Period [Axis]",
        "terseLabel": "Debt Prepayment Period"
       }
      }
     },
     "localname": "DebtPrepaymentPeriodAxis",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vrna_DebtPrepaymentPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Prepayment Period",
        "label": "Debt Prepayment Period [Domain]",
        "terseLabel": "Debt Prepayment Period [Domain]"
       }
      }
     },
     "localname": "DebtPrepaymentPeriodDomain",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_DebtPrepaymentPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Prepayment Period One",
        "label": "Debt Prepayment Period One [Member]",
        "terseLabel": "First Anniversary"
       }
      }
     },
     "localname": "DebtPrepaymentPeriodOneMember",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_DebtPrepaymentPeriodThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Prepayment Period Three",
        "label": "Debt Prepayment Period Three [Member]",
        "terseLabel": "After Second Anniversary and Prior to Maturity"
       }
      }
     },
     "localname": "DebtPrepaymentPeriodThreeMember",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_DebtPrepaymentPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Prepayment Period Two",
        "label": "Debt Prepayment Period Two [Member]",
        "terseLabel": "Second Anniversary"
       }
      }
     },
     "localname": "DebtPrepaymentPeriodTwoMember",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_DeferredTaxLiabilitiesContingentLiability": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Contingent Liability",
        "label": "Deferred Tax Liabilities, Contingent Liability",
        "negatedTerseLabel": "Contingent liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesContingentLiability",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_DirectorOrOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Director Or Officer",
        "label": "Director Or Officer [Member]",
        "terseLabel": "Director or Officer"
       }
      }
     },
     "localname": "DirectorOrOfficerMember",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_DrEbsworthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr. Ebsworth",
        "label": "Dr. Ebsworth [Member]",
        "terseLabel": "Dr. Ebsworth"
       }
      }
     },
     "localname": "DrEbsworthMember",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_DrEdwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr. Edwards",
        "label": "Dr. Edwards [Member]",
        "terseLabel": "Dr. Edwards"
       }
      }
     },
     "localname": "DrEdwardsMember",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_DrUllmanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr. Ullman",
        "label": "Dr. Ullman [Member]",
        "terseLabel": "Dr. Ullman"
       }
      }
     },
     "localname": "DrUllmanMember",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_DrZaccardelliMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr. Zaccardelli",
        "label": "Dr. Zaccardelli [Member]",
        "terseLabel": "Dr. Zaccardelli"
       }
      }
     },
     "localname": "DrZaccardelliMember",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_EMIOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EMI Option Plan",
        "label": "EMI Option Plan [Member]",
        "terseLabel": "EMI Option Plan"
       }
      }
     },
     "localname": "EMIOptionPlanMember",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_FairValueImpactOfIncreaseOrDecreaseInVolatilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Impact Of Increase Or Decrease in Volatility",
        "label": "Fair Value Impact Of Increase Or Decrease in Volatility [Table Text Block]",
        "terseLabel": "Fair Value Impact Of Increase Or Decrease in Volatility"
       }
      }
     },
     "localname": "FairValueImpactOfIncreaseOrDecreaseInVolatilityTableTextBlock",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/WarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Exchange Difference",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Exchange Difference",
        "terseLabel": "Foreign exchange differences recognized in loss for the period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/WarrantsMovementinValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_GainLossFromResearchAndDevelopmentTaxCredit": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) From Research And Development Tax Credit",
        "label": "Gain (Loss) From Research And Development Tax Credit",
        "terseLabel": "Benefit from R&amp;D tax credit"
       }
      }
     },
     "localname": "GainLossFromResearchAndDevelopmentTaxCredit",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_GovernmentTaxCreditsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Tax Credits, Policy",
        "label": "Government Tax Credits, Policy [Policy Text Block]",
        "terseLabel": "Other income - U.K. R&amp;D tax credits"
       }
      }
     },
     "localname": "GovernmentTaxCreditsPolicyPolicyTextBlock",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vrna_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Liabilities",
        "label": "Increase (Decrease) In Operating Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Tax And Tax Credit Receivables, Current",
        "label": "Increase (Decrease) in Tax And Tax Credit Receivables, Current",
        "negatedTerseLabel": "Tax and tax incentive receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_LondonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "London",
        "label": "London [Member]",
        "terseLabel": "London"
       }
      }
     },
     "localname": "LondonMember",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_MeasurementInputAnnualizedVolatilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Annualized Volatility",
        "label": "Measurement Input, Annualized Volatility [Member]",
        "terseLabel": "Annualized volatility"
       }
      }
     },
     "localname": "MeasurementInputAnnualizedVolatilityMember",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_MrHahnMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mr. Hahn",
        "label": "Mr. Hahn [Member]",
        "terseLabel": "Mr. Hahn"
       }
      }
     },
     "localname": "MrHahnMember",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_MrSinhaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mr. Sinha",
        "label": "Mr. Sinha [Member]",
        "terseLabel": "Mr. Sinha"
       }
      }
     },
     "localname": "MrSinhaMember",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/RelatedpartytransactionsandothershareholdermattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_NumberOfWhollyOwnedSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Wholly Owned Subsidiaries",
        "label": "Number of Wholly Owned Subsidiaries",
        "terseLabel": "Number of wholly owned subsidiaries"
       }
      }
     },
     "localname": "NumberOfWhollyOwnedSubsidiaries",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vrna_OrganizationAndBusinessDescriptionTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Business Description",
        "label": "Organization And Business Description [Text Block]",
        "terseLabel": "Organization And Business Description"
       }
      }
     },
     "localname": "OrganizationAndBusinessDescriptionTextBlock",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vrna_PreIPOOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-IPO Option Plan",
        "label": "Pre-IPO Option Plan [Member]",
        "terseLabel": "Pre-IPO Option Plan"
       }
      }
     },
     "localname": "PreIPOOptionPlanMember",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_PrepaidExpenseDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expense, Disclosure",
        "label": "Prepaid Expense, Disclosure [Text Block]",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseDisclosureTextBlock",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/Prepaidexpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vrna_PrepaidResearchAndDevelopmentFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/PrepaidexpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Research And Development Fees, Current",
        "label": "Prepaid Research And Development Fees, Current",
        "terseLabel": "Clinical trial and other development costs"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopmentFeesCurrent",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/PrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/TaxandtaxincentivereceivableDetails": {
       "order": 1.0,
       "parentTag": "vrna_TaxCreditAndIncomeTaxesReceivableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Tax Credit Receivable, Current",
        "label": "Research And Development Tax Credit Receivable, Current",
        "terseLabel": "R&amp;D tax credit receivable - U.K."
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditReceivableCurrent",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/TaxandtaxincentivereceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_RestrictedStockUnitMilestoneBasedVestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Unit, Milestone-Based Vesting",
        "label": "Restricted Stock Unit, Milestone-Based Vesting [Member]",
        "terseLabel": "Milestone-Based Vesting"
       }
      }
     },
     "localname": "RestrictedStockUnitMilestoneBasedVestingMember",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_RestrictedStockUnitTimeBasedVestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Unit, Time-Based Vesting",
        "label": "Restricted Stock Unit, Time-Based Vesting [Member]",
        "terseLabel": "Time-Based Vesting"
       }
      }
     },
     "localname": "RestrictedStockUnitTimeBasedVestingMember",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SEC Schedule 12-09, Valuation Allowances and Reserves, Change In Tax Rates",
        "label": "SEC Schedule 12-09, Valuation Allowances and Reserves, Change In Tax Rates",
        "terseLabel": "Change in tax rates"
       }
      }
     },
     "localname": "SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SEC Schedule 12-09, Valuation Allowances and Reserves, Foreign Currency Translation Adjustments",
        "label": "SEC Schedule 12-09, Valuation Allowances and Reserves, Foreign Currency Translation Adjustments",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "SECSchedule1209ValuationAllowancesAndReservesForeignCurrencyTranslationAdjustments",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SEC Schedule 12-09, Valuation Allowances and Reserves, Increase In Valuation Allowance",
        "label": "SEC Schedule 12-09, Valuation Allowances and Reserves, Increase In Valuation Allowance",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_ScheduleOfNontradeReceivablesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Nontrade Receivables",
        "label": "Schedule Of Nontrade Receivables [Table Text Block]",
        "terseLabel": "Components of Taxes Receivable"
       }
      }
     },
     "localname": "ScheduleOfNontradeReceivablesTableTextBlock",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/TaxandtaxincentivereceivableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensitivity Analysis Of Fair Value, Warrant Liability, Impact of 10 Percent Decrease In Volatility Rate",
        "label": "Sensitivity Analysis Of Fair Value, Warrant Liability, Impact of 10 Percent Decrease In Volatility Rate",
        "terseLabel": "10% volatility decrease"
       }
      }
     },
     "localname": "SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/WarrantsEffectofChangeinVolatilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensitivity Analysis Of Fair Value, Warrant Liability, Impact of 10 Percent Increase In Volatility Rate",
        "label": "Sensitivity Analysis Of Fair Value, Warrant Liability, Impact of 10 Percent Increase In Volatility Rate",
        "terseLabel": "10% volatility increase"
       }
      }
     },
     "localname": "SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/WarrantsEffectofChangeinVolatilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Minimum Stock Price Required",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Minimum Stock Price Required",
        "terseLabel": "Minimum stock price required to vest (in pound sterling per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Minimum Stock Price Required, Period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Minimum Stock Price Required, Period",
        "terseLabel": "Period to maintain minimum stock price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Vesting Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Vesting Period",
        "terseLabel": "Weighted average remaining vesting Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Grant Date Fair Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Grant Date Fair Value",
        "terseLabel": "Fair value for instruments granted during period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of American Depositary Shares Authorized",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of American Depositary Shares Authorized",
        "terseLabel": "Number of American Depository Shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vrna_StockIssuedDuringPeriodSharesHeldInTreasury": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Held In Treasury",
        "label": "Stock Issued During Period, Shares, Held In Treasury",
        "terseLabel": "Issuance of ordinary shares to treasury (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesHeldInTreasury",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Held In Treasury (American Depository Shares)",
        "label": "Stock Issued During Period, Shares, Held In Treasury (American Depository Shares)",
        "terseLabel": "Issuance of ordinary shares to treasury as ADS equivalent (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vrna_StockIssuedDuringPeriodValueHeldInTreasury": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Held In Treasury",
        "label": "Stock Issued During Period, Value, Held In Treasury",
        "negatedTerseLabel": "Issuance of ordinary shares to treasury"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueHeldInTreasury",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_TaxCreditAndIncomeTaxesReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://veronapharma.com/role/TaxandtaxincentivereceivableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit And Income Taxes Receivable, Current",
        "label": "Tax Credit And Income Taxes Receivable, Current",
        "totalLabel": "Total tax receivable",
        "verboseLabel": "Tax and tax incentive receivables"
       }
      }
     },
     "localname": "TaxCreditAndIncomeTaxesReceivableCurrent",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets",
      "http://veronapharma.com/role/TaxandtaxincentivereceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_TermBLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term B Loan",
        "label": "Term B Loan [Member]",
        "terseLabel": "Term B Loan"
       }
      }
     },
     "localname": "TermBLoanMember",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_TermCLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term C Loan",
        "label": "Term C Loan [Member]",
        "terseLabel": "Term C Loan"
       }
      }
     },
     "localname": "TermCLoanMember",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_TermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan Facility",
        "label": "Term Loan Facility [Member]",
        "terseLabel": "Term Loan Facility"
       }
      }
     },
     "localname": "TermLoanFacilityMember",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_UnrealizedGainLossOnWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized Gain (Loss) On Warrants",
        "label": "Unrealized Gain (Loss) On Warrants",
        "terseLabel": "Fair value movement on warrants"
       }
      }
     },
     "localname": "UnrealizedGainLossOnWarrants",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_WarrantAndRightsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant And Rights Disclosure",
        "label": "Warrant And Rights Disclosure [Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantAndRightsDisclosureTextBlock",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/Warrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vrna_WarrantLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Liability, Current",
        "label": "Warrant Liability, Current",
        "terseLabel": "Warrants",
        "verboseLabel": "Calculated value of the warrants, in thousands of U.S. dollars"
       }
      }
     },
     "localname": "WarrantLiabilityCurrent",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets",
      "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_WarrantLiabilityFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Liability, Fair Value",
        "label": "Warrant Liability, Fair Value",
        "terseLabel": "Base case, reported fair value"
       }
      }
     },
     "localname": "WarrantLiabilityFairValue",
     "nsuri": "http://veronapharma.com/20201231",
     "presentation": [
      "http://veronapharma.com/role/WarrantsEffectofChangeinVolatilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(ColumnA))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/subtopic&trid=2196772"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21459-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/subtopic&trid=2235116"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121593497&loc=SL77918431-209957"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r451": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r452": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r453": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r454": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r455": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r456": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r457": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r458": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r459": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>91
<FILENAME>0001657312-21-000004-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001657312-21-000004-xbrl.zip
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MF&T0#A[&8N4#KT4>ZE/*]J()CZ DI5MM\L@W8=5O^#S-?RAW\A]02P,$%
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MM<PPC1, +'@Q:'(])6F+YU7F9$#OQ1(+(UU?W+!*3H!?D7UY_/RQ&LS0F8F
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MUAL,DL'3G,?LB1%H?&> /:L;/!QUHMBVI:#?.S1-1PNN,P$/##YWJF3&[F:
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M\JA7#N3KVW3J\I,PC?_U<5XW_)*\;KC)ZX9?@]<-D1&&_6&-ZQ?D%[<YQQ?
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M;6>"R&4R;](PLOWBG\[;(]Z3?6I.D7HKI=G9G\]D9GXX>@:"(JEX^4=?5M3
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MJ2D)_8$5($(P\*L FK& V)[';,F=6#J2NRQT' ]7P(Z6;@7LZ$=6H)6J,S8
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MPIA%OF]'\)?G$\& ;5: >QZ3IC_*NG@XS%;WY&GQ#'%=)B(BG""@A%)."7%
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MQ[&()QDC+/ ]X?CPK<4<?WG9[KMITROD6M\MG/%\ZOF2\]@-P1D@D469XS)
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MB7-B=3[MC4X^O3Z'M7,Z3F=TVC^Y/CD^[>EW/O,ZNQS^?3'JWL!X9Y^9[?"
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M/SG1=7BW">^Z*Q_>=3;/!V?SP[OU3S/AW=#Z=<.[*H[1X.>F*!!%+D%!:?L
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M9<Y,["I(;3N.DW1J/BB^)#H=7U[;Z=29+V^!)"@A!@$V $IF?OWL]:S+7AL
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M_JNHS[J;_:]\O?F>WE9%:#YG+Q1IY5U=M PN'%?K]A.==$/&;W-(!(]%*#U
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M!UWBAU$&9Q5JB]E'?TD@6%W9'HP7J^*(6I=(-00IBWW-*BG2IG!'*AT^RR7
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M'P6285KM<7CKY=\^X##*)OTZ2:[L-MP>0$]FT<ED3*'//T4_:1(W:I,'7J/
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M,V3B:*8J&I*'\^DBNR36HR^?NTKD21(8Z:3%.;-6%+)CETUD%7Q^<D"1?E[
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M:3*<-H7W3J>3,\'/4H=V"WW*&H06G.CS_!^:"^>5VK1G>2U4%3?&;'X(L?&
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M$:K9P^NB3 :!8WM^1 R!#6DW,6)BRJYY+)94WI*H_!O"1*=D'7QL $E2(I-
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M_S(FT RL1?NV6;"=6Q2*U-&DV05C]%K?0CX:,LF."0L ];^-<XK95+?_5>0
M9VUSR>SXC'+$"0W[$Q8@GBMS38BQI]?6!S_4LJ!^OX*-]2XL"9 ^-&.RF%W:
M/N]1;+)0Z J1RJ<LE&H?SFEX:R:# 'L,2^,R!B;BN);!J26:3*--($ 6/0^A
MJLHV&2^?[+P5GNEKC.%K6>MAE,C/^<%R!6%L3P7H=3,LUMY\U/3K_UHH:X:J
MS\H$4RF[[)BX1ZDU:BJYNN2WH_]1A,H-R=I=Y\FQWJ6VY(9!)0#5O&P&)55U
MKYGS??\09G$,@S7> KGJ69?B#X()(,V/#EAPWOJ"P4 027%N'<R*?"W8A_]X
M]/7Q_5D8A4H-ZW\\O'?\R/ZB, '4^&>,#Q_%T!PN P ;.0Q)3O.ZF)M22@O1
MPT-IDA)!L%O_\>#>-_'!.'R0ITY+^193*&D'U77K#DDB&2H4/[L"@!(4=:+1
M'Z+HV'<#1GC4#,VS@'M(2_$4'2 W[JB53.?L\IR<T?FVK.P\-<,83N(V9^IU
MP-)=A;I)) APM:NG7R>-LE9=47!I!S5I]@+HRJB"(96P9V0$0)O1 9CK<K(N
M\RO'D,O1Q3N7)]Q'Y"44O0Y\EH(:?QTC)Y'JT$EF^*Y4IKTN YW7]*Y__W2+
MLJ&R:7UV5!6KL+>_G;0Q_*>R)@+-OQ_1ESZ3U8'G\^A[?=O_]X\P&*Z'QU_3
M6"B?ZBO2O0T1_I"F /WP\RW-_#*9>EO$$>N$"!.1750I(*6B;;4._@SW$F$9
MW!%/\_'+5T_$([S[_6$=?,YU$&:]+Q5IH(MB8C%\P!+8A0&GE,@\^- A1K#)
M?J933;%.?[[.L]GCE_\\?7)T_[N(HXW48]W^%?'O5^%^<#,KW(>=^=^T,Z7J
MQ3[#<)OZJMA:F:FSZ=U*)O@C=]]AUC^[/98XA3N;NWZ[9#$LBE*XT*S3?IC%
MSSJ+ZF2CB1J\@]&)Y];OHQ#'LS231S=VF[)E9WS,I7F8TK^$P[QIBZ-(DRA;
M$!T;S)B8.$JY5[PC"+TWWX<I_HM-L6Y0Z7$0!+\CK8Q]!^"SM660!LM8"E59
M=!$+ZI>$!$=#J9NSMEB6*H*AEIQR+\0"86#P97A;PH$CVU'VAP7S^<W\1 9E
M%#$=YNFSSI,WP<;_3:VK3!D=E9T$6A[F;+Z5VIO/_G$"C62QCK:;@8D@C!SZ
M-N4\V)\\2QIT#ROCLZX,9;#(-/4J]KW7@B(A&H$9VW*3Q:8 350XZ5=-53:'
MZ?O,!G@AK -"1$(1+2>V"?NR;,"8I(2^VEH5O6]2*115J#(YW/N#+_9Y9S;\
MS?RKS-&49UXGVU?YI>U2$ P)@$+9FED+BH#.=5$EFK[Z1^_(>T4#7U5)?'I+
MQ3AKSS>5,LWW]/W#4OJ<2\D5U1SHH]PK=9*"&&6^ 27;1:[!VU 0?^D+=B;K
MMZ=H%WP6(?IJ2VX:J'=,4]:Q4#$@^ 43KY1=M_69*55'F@>7QVT\II8F6(N6
MV GC1^Q2*"!/!-I-.\QZ9L*W_5[!/9F2T\I# --M+GID(KL-,Z@PCV"?&AJ^
M09V5!6!HX4<[V1I66<A[E8V)L6%[BLY\,DY,2*(:,5TNXF)Q6VBUG"SNM65J
MK=$S0I-U>D<( 0]4B2TQ0O[#1"FW8)+?-L:-+2QBCBF&J$+#6(G"[V)1,*Y"
M!@I[#/-,"#;6E/1'%3YWLA1Y'[EI/))!44#$ACVI)P*69"!N5]N*>8%,(,*S
M8\=F+G_^*F,^_>?5:RFSE*J%:_:F:6?\,+>6B6/HA#M'H(=1[@Y9]7W9.AZO
M^-K5SE;JV$@ELE-IY!A5\$9Q)#" PG<6+D]TT_R+??ILT)ZX0H9/=B* -*52
M:!459#2) *9'BW$8]'4TVUWAI@V7 #<V0&-NR0V_R7PVM'#D[""J[4O_XR$-
MDO1N=<G2*VJ62FEF)"=>7 SD)6[#!O^A6.0BL$,34I,0"S6%[\.!.I%!G+![
M9#.<L>3F$J@.*@>5TT+?4.I1Z,4BEUZD,8[T->8M-$S]!Z1]N<+EC7/#;C U
M7=1)+\]B>NO".OGLR0D[8$^?GV2Q-NG7L>-OIHY,%G6TLZ@<$BH0[C:!Q$;(
MDCRYL.$P)[+Y,VCJ-Y.4X*O4+'%)]8IC3(\A$8V:LD?>_6+XL/E>PO>/76%D
M $IG).2PMV'I/_7F(1H$0Y\V.U'NC>)@FK5+3(DN-N;+G>)2HR,IMM]@<@"G
MG^==V3&.D1Q/B'TU>RYR*1AOL!!>#0?GD@#F-**M]3I$Z)13"VXP]@3IS3SP
M+T+8E]QIM=HEL2@:DJGKB/GA!("81C<BWT?CK69^_Y.2TR^TNKDJD89/9N=-
M!68I(MIR"';?)$/43@[$?C,6Y,=#J6'::CKGG(M!O(BB[FW'_H1_NM=]R 9]
M#IB4$7P#EH:ZMWH/TICVF4=99\\CY/VM*^@BHWF.1T6R5IGRE08#;'K>/#7M
M@K'V,%"9RCZ28\4>1E_LS:H8O>2 ]#!)IMR0!?:!#%>)_>]=X,V<,K6TV%D;
M<5.#&HACL8HXV):)/YW(*#&>V&!#[N>,^'R RUR!_APO+RV/CJ" (PS14#UI
M=;4Z]-CWOO;LO/0H[#'R>F(%Z4"WL27$^:HN%ZB\;P(6A-H-.Q@6*J4.?)33
MR5?A"&E]12GCTVI46#*V<>*>FWP=G2[&K0]=O@@M!^>^M*/&MN!Q;DO"#,Z3
MXX>0LH.#(^SE>;?,_S7[L6KFX5V>B]I:F K^()PIBT4#[BFB$;ST9C'BR5T&
M8LI8[EG:!\2G(3Z_NIF(S[^,?75)I@&!UX>?:P@^P*K2"ER#F-B[3SSN]B;5
M_)GG7(5;??R=?NQ9P,:Q$\YWUV@BQFN1=^>#I&87@L3^B*;,.:>2MIJ4]+JF
MT27)=PV,FJJGXEA 7H94S&(Z9P(AUI_[.4X.F@\"VA-T%X?JU/"5G;*@+Z6S
M#%PGS#U+LG8ZDFC:[[9K$8XQ:G?6%.64'N@E2"W1<K*\^C5*B)P(NHGB1! M
M !J?PQI+8G ^Z 8N@@M?Z P.W@T>ACDL^(P3PCW-3:VXWSQL9]<(JU2"\F%"
M^MIE$B^RIIZMIO!PP/%XN1)Y&_\.\07$]QJ\@82C^RXEO,ZK_*)I,6(2CUES
M,JP NM6*,QSEW#FN(&Z71YL3,?)%82ERMY9Y16J=6]DD&H,<ID-\*PP* G<Q
MG+8(L57=K@\A.ZF)-76R=EQ(=.A&^ZPEVEX$+=G%9J4?3H'%?OU1"#,.6TQX
M/8<\++HC1Z;S .SXJTRUY)HY\=4OHKRR/]F$=GL4D7K&G?VG+HLMB\?F$\[3
M6>4/.58/Z^<OL7[V6XJ8.=!E8!/_&;RPPW*Y <MEWT&2SOBS/]S >ICR_X=3
M+J&"QVB[AHTD[YU];/O&H%_#VC+V]&T<5L1G7Q%@K8U6(')!<:6NZT7[Q6&<
MD@(Z>#_9S/="#S:%?1JELJTIUY=OX/*LIDK(3UZ=<H+_^9/302%HSZETI;,[
MZD!C ^:X]GW3H? T');KYU^N5[K('P _G@9:#>L6UY4ILM%Z/BR-O\;2X(*O
M@'5@MS8Y3RISDFHO W5(<,(G[W%:T=FVT*Q24@^"B!)EM17T,MW[TM(CRE(I
M5J*VQE6GB:\?:;UM4>7ENAO&;?Q71@"5I.](-<PB\C2Q(N>*WHQ^LMUPK:J\
M^N$.B_2S+U)GN"*0S.0.2[C=F05)W,_J?3"8HT,7Y5]M6GE>&$2$N>4*@&"L
MPJPN0ZC-J?6PG8^8>MVD2CGR2N1'#\?+7VV*HX8RP0DXGQ:[Y+3=7<H7GJ?U
MT.KTUYB_][V4-0T5+K3RS#Q"!=&9TP5QN!;Q*EQ+9(H:ZQEVS]J;Z* 4K##I
M*G!\!-^S!?9?!(!']5R3$D_*@M+M@4.@E(HMU<55FZ%+@';D.X"=%[*-HCAR
M&\I9)-<\*#$33 'C+[TZ5&8$-)0KX:[I431 R3U:YKOP<D=+ZNIRH8 *=NZF
MZ9,=0%717M<100Z+H(N\IAK[V38/,],74F25.$7:D,++&%K<2L@ #UDE4U48
M&8D!^ 4HW3>]HC>VG*TGE4B2N(^:TG _\ .%8-I=][YX!-W2KPGYJ@A;9NZ&
MRRM5J.X\>*4"CLWT*ZSXHW4J0DFAGX*^BLL0U/8VK,\I'(UV7 O&"U!K4F<)
M0PQTM17'?0V&4O$1L4>],UOJ<*@RAM, '$NM/@[??#V0AI%A#,J= A3NA=9D
M]&SQC29;1C'7R=>BEI*4G@&ZK8?,VE1OV-:R W/PF=,0I(*@U,.1_G"8NF%T
M-O=;)4/ST=3=-PZ +?7[\R*_**N= A:E]>ICN()%G,4M'A;Q$:,%C6VRP%VW
M;3FC1M8K64J"!D+@<@5][LXE_'2FRT[@)V0;YJ19&\P>GH[656)E%8H=93_B
M&4NP%T G+\^#O9>]A=.9CV9W9FJ2<-C+.=X(8\AOLL>OHC-A?4OM"SY@.0W+
M^?" Y?R3;8$'><=FK250(5V3#9V848>A6O4)=0@G&ITZ"+>CT^I7=%BAG=I\
M;AN>'#KO&")18K0$C.\U-1A@;+QR#7^.WS"U%KE$B_BB7"N"$SDBN:IY71U?
M,*---+(+W/U#>LIE"%@;87^'@1NCB0/CY;Y%AFZUG:>1L5'-8C0FSR" ?ZPZ
M**+PP='/JB+O&)]0A\4SZVB<P_N"Z1\N;P$WUP/;I@]&:L4>&GYM!/^0$R I
MD,;(@2<>CWP\>SIQ-(Z LM,5-1>X4++!R%Z2&IS0NOAV:1?.3&(OZMF:>J9#
MH#C[+?RDH]Y6]M^(QF_;VBW3ZZ+LN\O& Y/M:VJ(X&*&'3O;%*%(NGCEN _S
M?\6N2UH<K5L;NB\AH"E[:5R1Y OW1*Z#BSCI[$YTK$^3GCS=ME#T;$=:OO&A
MKW1X).Q,.GC%#&SR5A6L"Q+JW(>[&AD6O2&B_(]I&MK7<!<M#HUGF%(9SV"*
M7SPY408,O$(NW2\T?R>B]\I[Y"263_07XW?U-18+$_;U,2.622R"8J^IKT=\
M'IC7$# U.H-C!0G19IUVB3\0!2N7KJKF\H")_=RY/-T-W+ 0#]DUZ=6U!E]/
MP08=R&^4VD6D3@&?C]  A8=S6VFQ3) )LJB[\,]NQ7DU8^_A94T/,KV6#\G[
MSY[\O7:.L*8FCNCDT)UB61+W):4I8.4Y+4<'DULU4CMV)_UA67SV9>'@CM=I
M>ZC-61<%.Z$5S21]C;0$J>EJN$*BW[,8DWI<OR#)'#D&5CG>#XOFLR^:#[,E
MR[)#OBDJS]9;5K"G-.<9><_A6;+8BMX2(T8%)]SB#K "2$O[8($>%L)G7PB4
M::9&V)B ;]JSO!:?N#.AG]<O51_XK@%XV@*U =<D.31 M(AZ*"PO!.BX[:GU
M3=<%[MY4VJ'(8I:5K^,0PXK4<0Z+YZ^V>#[,BM")LRI%H39$:_G_9>]-F]PX
MKJSAOX*(9V9"BBBV2<KKZ!--2;;LD<40I7'$^ZT %- E E7M6KJ)^?5OWG.7
MO)E50'>+GNG%^"*QNX%:<KEYEW//T7CXCI2#:3_OQ$G&*O8I!0[)EB$2W]3#
M]! ,2Q ONZ _"ITDLW'AL,JMGH+ENBM:[FK4Z#7."_!!%^"DIAW711G67.,6
M%T\R^)YVD8DN+3F?HZ#'/^5CPVF4J->*^,8[K$(,R]WN2(@:W5O;,$@FW\N)
M$3JH/WV>ZL<RU6DJER<XTO4(42 "E,@*W!NOFUL0!CZ(M?T)8(19,Z6;3+V4
M.0%6P26<E\D3\D+8XK,/XB2QY]S+$-F<19L>>G:9$X/3^;.Y_.#MU0-WY%(G
M.:<F2.!Z?5WWH 0'XG"HJD*_A<7 Q-HU^94C<U#VJ\MJ/4IWQ<SWD3,1EBM#
M0.TIJNT4)C;W)23D4'4BI,<VA$O]$,L<8E]<34%]T/@E\W'IV24#4W#:-Y:W
MVXU=M#B:^3O%LPZ.=FU&:ZPT2)UQU4Z H(EX#IAK>V2?PB]7Y][8A]\M]\\1
MYY26B(,6%>$=2YOEL##JK8AM,(7- ;"@'[[^[OVIA7A>#4]D-=0TA,1$NZXX
MSE[5L9Q\3"N/>(?*E7*9BR'SC2'QB\'!.J^%)[(6A)2+<>9V3EVUNWHE1T>Y
M;H,+U82'E<N<+?^#SR_[2:HZFV2[%*(@Z'=%K*#L2\3/VI29TJ)/"TG:SU<?
MEU@H)NC3G(_XO$P>V QTZ,V92:8;C-]4C96##_XGW,.<5N>Z=LV!.5IG3UG_
M] M'L&B+L=E4)4DPG5@?_WKXXM\\37SQ>9_^L\RY5->D/XFAJF7>C:?= #.M
M>!Y=FUKW>X@]>;,_+>3W;/83_1MG($Z(J-[MN#@WG3Z"I1AAPE(P:5AD(K'A
MRP.14%"-3AP-I4VG^:7^*$9.^P#AJCP H6A8-M%8XB7&M3=4\N@_Y14C24T4
M8^W+-UF!QU".T3VAF_]C#%._.=#OL?P<04;AV#%2\HL[<64PT\5SZ"1XT]!Q
M;$2VRDM#22^O&:7. ;>W"7MOW9CL =J% +R>]G0 RAL^[&IWN<[6T8;49S#"
ML2.-VL)8^6D&[7D+X+FWCI94FFU&R^@$NMN4"HI[WEP3ZJ>0X\IJ'*Y_ -3]
MY),JB[O I4]<>(:'Z[;GC8)"*>#VJ,*.DRY*UN9Q;O.>L?N6\_!$"O=\5FZ'
ME=8!G6;&=Z.W@J2+@@4MC#$'*"Q%\O(]+7\3G,(0WK>=HO&L4V5[C*2='ASY
M<7>2LZW#'/E[T 7%[*./HAI2=A]&(<.H2JM#F0K L9*)\I8GTW1*JS#O8T(?
M@1/#<:(WS\-B@#2=#"4QD,]-VLDNSD5XR<OCPB%H=/BIF/0D.\DU#O#1Y&$-
M)!>+OU\RG$((^)@%:)8PM0_QXZ[LT+_#_:YRD<++BQ#-%3?TG>[\B3TLDLCN
MI7,:/NXA02NRVAZ]VG79';+L14(FKNO(7WU;0A-%'0R!WH>UN.(?MA0JLP/A
MV.C)S6FVI%Z;6>/4X56Q,V+<,<?#UUB.-;K)^:'2?MH78CJ-26?4$]D!]^P5
MI7X8XVFE?OYJ7Z^"V5(IG$.T[=0T/0<GC+00L4>&%:RJNP1'3V1<3ZO/'AW%
M/HQ"R?UHDUV7JKOJ9H%RMND6.#'N-L)_VTCS?M=17OP)6TPZWLGJIP:$;V<1
M*+6:#D0$,BPNR7'=5V4_=I43@9K?J0+[N*R75L<2W:5M21\$8XB0"UN]DRJE
MZW 7PLUS+9H21HW"DH8N/-J.>[=L<*/50-ANST<H6?**P=G94AJ7^UA)P.\R
MS$29G(.\C LV[.N:9#SD ?B'@AXMD@!YP\/%XYLVG. =JZE %I9G;87>V/67
MTC!)Y8"ZD3\NJ_" P3YUX]5 'W'E']<42X,7/]Z//=R6]9<25NW1YTL5:/%\
MMVV[%F67JKNN5[2\8(;#0VH,J7_ACPF#;R'KM/X@':R[RE^?I_?4U7EZ^#(;
MJ!B#\,;&7[NE>"> <Y5W2F&K?$7:B6NQ&F&%U5<HZF^(04V/VXN_7EAG>OZG
M]Q<BHQY\O"H<7>VAJGHOI<UU&)JL'#G-E\K5V&@8^F'BMM9$4 *L"WU5%18$
MP62>(D@:14:3;O/ZY>N7121JI'Y8%(*EES 2E:I19>=P:E!:%2/F^X&_62@N
M"5SP27+MYR3/IR=YOCTV<7J&LJ>?FB!2_:84S0;3:*Z[(PMQSJ.8C:A&Q(D#
MM+\?/9;O>$3XXTA"(U9*7!A9>++8= ?EVR!\Z-P5^Z#K,))^Q*1SVHB^:U=@
MASBF&JV&[E33$9(/<OJ8&W&N3#Z&F0?(S('RP@Q53=?N=D)RC/RRYAG/[4!/
M8P9=+^E0Z0YE[5BSV_EWPO[OQCJ%(LC7U0VA]'-R&N#OP?G?;,Y+X6&7@AWV
M64ZT2PY_![B7:(/ZJIRR1M2ZFR:U;<$<%F *HI7RH>("4MO 3$0VMJBF$-.S
M>0$+-Q8N&.$_]L]R7E*/P;KDUJ1WCH*M(W43M9VT5^%7UZ<ZBX!)J5*<#D-8
M/N8;DSZ("YLMZM<53R$MBRSWE_75%5]-Y#?=B@>U+;2J)FW[\<'/B^Y!%QUC
M(;'J$K^355YZ1!H"F\YR!M-(*C)L*?::,]: =7"'=(R65(.&TB2&QUS<R [@
M2\W9Q;(S5?B4U2L6:%U;E:B0D&U,.4<Y"YY?>S>TVXJ2*F>05@1I_?8,TOI7
MM0Y@Z>XE5WQ9$?'YBC:@DZL.LQSYT^SHF="TY"=/>N6V!_MPSQE,BHC[H^UJ
M7+N5;[ OK)J(>G'W&.<@ZK&MJ<23"#,$CS:=9\^0J)GLF:6PV+<-ROY4\!!]
MZJS'B_/?E'KC)'87F\ZXCVY3K4%.R>VTX9JQ;D&P+<Y72Q2F&'-ML'8OD3_=
MN/R9O*#KNJ\%/L5]U^@M65,QA,LQ4HP0M)FGTW9^%-ULVPD&.;O3F:/AP1<T
M^LG@_W):M@[/%2:=DSI@IYMU9 !Z,68:\Z9N#&^0S73=:UTQY5V7M'+&DC6]
M@+? RX-2H*G)9,XC6,PE&6'"'G)!F1E7SU;S\5A-3@Y8M#A70A!KJ(5<-GVP
MC9Y6HM>V\*A==C@N4J#5Q?-*>"1I@IC\P>I0^BE46[,B IUE89)7?>S;=F<:
MSL=N %AM*ZV17$UGZT1IR)GSE3+74M!U'F$+'N@5::*-W8Y[<38>#F!%X/-"
M>CS.O9J'Z#K-3"W#'G'J1':1)6'15R/<*ZZ!>US,9BH)<KN'GAQ5%<N&$'*M
M7GUHE!S8D 2<]ZRIF2L,7&V_$962],.$D[IN:U[:)=C+:;,0A'.Q[=KQBD5T
MJ_;J5*/6>7G^'RS/R_#W:A("UHT*FQAMZZ^2TS ]W.+'U;#YE)&Z3E8UUR0Z
M\>EH"XB_H\@ 6JLP+6>VM/:W=472374CS\ /=F[R>?#EU%6;L6<ZDD]B>H<)
M<10[+/PYK;ZK],9B6Q'TXNJR_B0(T*.!4_X96:!D<-1EX)H *&,.#.IS0!F/
MCJE5 ]=OUIYSS)3#/0:R8I@AIHZF30!_I^9-'\WX</I=>R.BX9S,QMBH+M:Z
MZE[H<;=F!YHH=]#K"SIA3B*/?2\-#'8G\/?TO<EL^<8+*A!RIF(^H]VL"__Z
MA=R53L&>\MA*4B)H3K-6HDCF*$5A;4AZZ1DLM'G<;D1KT>R45_4ZO'9UW>ZN
M14 @5X\</#"5#7[_RS!8N0:!=+=X!5$]7"A'2N<7Y%<4AX-+6E>4 -O#,H,+
M$MYK0QPE!%TU\&9X=((+[)&74C.R<FA-SJ1"\YZMV7KLK/_<OWFAF; $VHN\
M5 N8/F'R66.PB-X:03]'T?^S7[J-S/=,)'23[H'P$-?!5M+W"G/]K!5273E>
MUAJ],$98MH\.&[C__=L^!TL:.TMB&;8*;]W&E;I8@LQ@8,:O]>P43_>(V 6#
M#^#((H@TX]1YX?'<W80U)\LI@<:S)4+RJICM-K!J6Y&V/T98! 5]7"2.DD?2
M4T46+KC_VHS@FB1+[O(0-<(LT27*(;SMFFI;2D.MD\'<U?\8ZW6X6(89YNP8
M7=OXQ]"UMFJ[3BPLOQ$:9[6<,85%RZ-X%N>I!N<369SW[$;Y?IQDD,)870:[
M0><?K0_08=2#6W@;$^P%RT:KM%M5+G^8!(ETRK*\T-HO71*8XKDW4HXG,M(G
MS<#[&H$&6K#)K12 Q>N7+W\30?CAD&E/2HRY(-V$S'*J ;+L]>Z6CF]*!&U"
M?-,6_C*0C77M$@4#3_5/\2Q5K5_9P=HU<5WCMMSOR+\MUR%*JL&VQC))*.%I
M"-8GLJ"F?*3ZR>O8LL,0YU>XYNO)F3VEC%B.@PTKG<4'J( ;K_(Z-TEYWW;4
M;U9PM75B7-5AEKQ<F*8S3K34%FE#K6N=>]&'2\3N60*GLRZU -5]TM;DE52\
MM;HL=QL.;)JHR.4:=NM$B2P#DKDN9FO>S2EN+A9O#,U!LF,W3NN+. J8M< :
M;</B1MM-B)?1K4/)PS+8=E*%"T?(9 ]8(Z"(2AT3/81C;.9(*R"9^[W9C;3,
MTT;;G12NM1LD?$[_21?%@X7?X?^2_2RIP;*NN!)G\E-[H0V(OM^R.K32#B/L
M_Q>+MQ1O_&.$*%\A^F:5-C Z*PDK6B[;<? FSVQEYRB)?+<WJ+Y'9@;ON1^=
MSRJ2XMKPBJ<.*Q*XJ;JI!7\BIO07M%":E#:F@\9\T+ZN YFQ54KPJ5LHCE J
MV[C951]K.7ZDGY^,7JH7*-9/R:C6U7*(*MXS"M]$-8</\9QMF+' GBNW2?QL
MU5/T.DZ+<S>+O[77%4J1L3,K#/]_5UT86+*XW;XL@F^WNEBH;(?\C3K-3+T#
M@"FXK]BUN[9LI$,N[!'$*48J]!E-AESJO^AS;_1/>K6"0[3W8?C#;E[\-_71
M'19_+)L/]@SO__N/\=-78T?I0Q>$EIAM?@Q;>HAMPH-LJ05[..L..\C9[YXF
MY.S1[*-R3ST_9%S&*UJ%__;%RXN7BW"C'1V9?L7_2.N2EKUM'1*-X(B>^4-&
MR=>16 @A>E>7HNPI]"4<E6[JCC1?^>]TXW_[C;LCX>'#N1]LW\7B>](U!ZM'
MKM%G#4OJ/H6OTZ'8  .]DZ[,-L6T<[LLPVWHU _C'L8O^#%L7Z6,R9994CB)
M2"0.3_^^B*DIJ]@<_G/Q6?TYARH4F*_M_7"9DJX@$-=EB"/##V7")B&S(%/P
MRD^!'@Q_&<,K?!'L7+!VK]GE^:R6>[)_]TFW_,TMM_SB.1P:=,;;,@81!QEY
MH4D/(6O5T)%^-')RQXL>(:]^]V6/L!/88>FA+SG]0,CF02KN5<]@&_=UGZB]
M! 743)!52$A4"?,Y$G[''Y2?1&JB<.*-F"O,\E5Y8.( ";565;7N70XC^/V%
MT*9&CG/3946!:^818\B%1/XVK$(PJOSW'TEX1G(OP7NJUEO1$**4NFS"H]'E
M<UENJ9^@J<K>61^J!S:E3DM771&L1@3CTOIV\//)A]?4"D4K3B)<8:WM<B<$
MY5)U3(OU820I>[S&I<F1K-8<CX-*D< AP'^IW'/X@R=AZ0ONU=@ WAC"O"U!
M'BG(7(75SBN%/E-^K'#)[JJ%^RG- Y0IP(*B$(3LCV1[:26'N+]D(IV9<</2
MLL$3[68;0NP1J:AH2IR"P0:,_/5^&=RLBI6X20F)"C.<KTX'B]B7L(DP,GN.
M_CCCQWM(B[XBID5;(BSSV0>.6W!!R8O]N ^N?G]ILTT!_W8+S_/FLFHT  QN
M%WBOUOQI+@2$?Y MN0[[DY;).FR1\ ADW__MU]G921N>RCX+^#DSP-')R2EE
M<9=P (KO8O$3#EX:37E4N-@W&BF:^J6\EBX>8ENBDX:/EXI8!O6L),Z&H10B
M03?PX<]D+:YV(U<RHD\BL:\8KD6845.=+['X=VK4$M%62FF/1BS!LD?#=(YN
M*E".A<O7R!E3XF9BH09_9O0$=:0*_QJX<Z%(H@&_6+QI#M(KD@\(KR&.U]A0
M6EK8H)/:\M^DR>DLHC3_Y+F81T:,HM6QVI24"&9FUYG9DAW%:3G-'T5;R!Y8
M33LH7'-U*&00I;EV&6(PJC>LH'BD!%P"6&5/:A-<.[()?%)B[9%]9$#;T<>R
ME!Y"MG6[&H4_RPFC+,N^YKNDMQ$ K>N_UZ/@V.WH(M>?9WMZ9CEQZ2Q\.GS8
M_KBO^_1X(;]GI >[KB?7Q-O[*4'JB@MP;DZHGLILN'(3?Z@PS4VX>KB\OF-\
MFN"M'Q8_C^LM!LP8#V]9!P5L!7 #JU6UX^Q&DMY6BY ?A.@K4XG-6UPZ=E?6
MYMIY(CBV?/32[%Z',:NV;21:B,-#OC1BBQTEY"*/*,=*7/NO]\3K$[Y+.6-6
MFG;9;".DY,0<+7M=UM33-D"TF$:JET?GHXH?RTRC&L4P\37?%54N/M1D)-Y\
M]7YQV>[6<I[WE^%>^C.NQ@R4;)%SU]%M-3:$ZVJU*SM;9#1E6%1BC-U^%^J3
M)-E*N9LI&C#<%E990S7Z'B/^F$ZG7E7N9:2\0>=<E67?FD-"QG(JX\;>1/;A
M$YFWNZ0"GX;IOF?Z] >IYLRD-E$0QCRM@^731G@:+5E?Q>P8"GH];1#M"-!"
MGN:EBVN 2Z]6ETUX^ZW .J=,HD]DW$\>F3\%&[2+3@?, I$&%4(=&M[6,87&
M\-"&0QE#"U<OL3A"1.[)?6FPOS41@%K34I"*V!:<'&6MFPWSP1793NH+D^#@
M_3K+U&XT<MQ)@.BQ3_=KGB*?OSD<S)OPZM1H;D'WG'5#P.'-FY'*TO($L[<
M*,P,<)G1W1B84'9(O/%S!;ZN"H]&IZF H>>D%8G6CI\AL=X(1<P61XMVL?@J
MLU5$[:H9J6)"/[VI/U;KQ<QQ:!4SP7^8+T\I<&C]4GY,#FRK>%Q7T4&)<586
M7F;E!]3R<@-:,'Y#M-MZBKD *N?%<HI>O& *C0]Q42#,"U?G1CGIWL;A4_E0
MU^8E*0!:)>=H>683W)"X#](U;,\,NV<+VKB_X.JG-@N8!F@.'35>A=;Q9*L&
M$]-5Y?Z(4:/?8L_H\/71Z3"B!2G\9?Y'SI57:3LAA=K9H@#1;CH64F'F/2S
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M5) $'M2O3UG8I&+&!&AKG7".NZ*J1; :N%>\#PY-.DK BG>$GI,9WKHM)8E
M!,D1!>8T4CY,AI/\T1Y8<4MZSUQ[6;%JRYY%3HCQK:,$08WO'"Q-/[,@BOGA
M=T/O8U\5FF#%.2FZ4C5HB8H"W 4RN##?^@[NF'7B(/AR> 'F+ :_'^Q5L$9D
M[@?->T^OI^DW7F&\)W7972R^4XI .DYSNPYR4;XX5CH\4'>@LW]A"2K4[,.?
M^$$P?2_Z,#TS/($=C1Z7)RA_3*^-:V/\Z3I[2!!=A]!$R3,]F5GIK3S?8GJ<
M(+S#"1D)SU[];O'NDM*'KS!/KV]C,(0'Z#G+"GYH>QA</R9XPQ*M=SBS]NVZ
MDJ(>KP*B2)G@8</V7I.4$Y72QVW8YS?!26*7)CS)V^_??54LFK('0^"AV8;%
MP OL\A#N.' !^#F<*3\XYNMC9(*QV'%=43IG<1DN($2SWL.IJ&E+V!UI-X35
MT3!E^%Q=%S/,1?6&=RH3CR>WA$,PCSM0+_I.1\21PTXTACK*ZK!/O4*..T8"
MB<_#I];QI"7'Y0T3/8;-/]!.Y%VYUCH/E\&H2/VB$Y+L9/M+?IK9Z66U*Q.'
MYF&'5#V(PRX2NW+\',;X #:?R/F@YW2DDE=#O;-F.K08$'VFQ3+$;IXS (NU
M[N=*2L*RJ%/2"VNH@I#N[BG/NS-%@K*P5]D=[N M>H?%680SF^&#(MB.;%!R
M:E7VR/$4MQ(0Q1,0>7#$V+*10>Z;ACX;SJ#S<CWC6A_K?.L\YBP8""/8\PW&
M1"H5T"PC6,A-B70U.30"9HU&%U%O7:'N5W7"7W1YZ.O@QJB8&#,!UV<,^^-?
M&*5DG#"UJ$U1QF]7:[E"$F/M7-:$3N@U@;3JY:A4AWIL"H$N(S2-]S+<[H>O
MOWL/5&52<I$ZE8#0IE6C\$QX>]"(GQM;'GYIS2.V1)^%IO*FS+LH>T/U$1.X
MX6X3>8U)B.4O:4;KS/WR.)>"RS<B(:E5[V9!W/7R.6+);H?J/(./9P89#32'
MI%I7@E1*^$?/T_48-YQFL[@",A^'GON+'GSV6"/M:A18+Y=.J4CX'%)@B8BQ
MI(PY2: U.2Z8Y*HW@KV,-7!'_1:+44JZ(9FPO!@G0M(L$"LY#(-:3F6U6,O+
M5Z:U#8L*%T3GR1><E!45&B_02811+E6B.H(F#TCF]8EB\NY9V_U[HI8315)4
M2"1$#JW$C)(.G.;\]@1Y#/&"3_3Y;'/9#Y?[LEB\_::(#6,.Y=U?U1W'/"$V
MH:E_%C)I[\K.P&?<:+,] "/MNUZ.C"I:WVPL9:#0V<RY>4X<]QA1'ET&ALG@
M.E%/T7><E>I,)K<<*A7^V6ZYFC*5GKH4\'U,GUJ7Y)%'B45U7F&E%?WF7YOM
M4/+RDE3FE#0OD(*3T?%-YH5^4AQ-^N!2K<OOG]R& ^\S=LRP8Z_/V+%/L@FV
M1(52/)$O3T1TO?5,L%=)LZSUQ,;B1]VDO1JJ%!:VH>9PI*NVTF**T]4%UJ';
MTP&0)(YB=2G\N5R1U'88QY6"+P!_%L-QK" R=0@8D(7^X -@/E&9REO(N*%1
M%F:[P2*')$IUNI'@^/ET4W&->E-2@TS20AYYHB8-)Z3JRU5"Z7A0#T1<F43T
M@8:2"XO6D*:;_HF<</?W)B*P.>(A$\X-<2PFDIF9B*(N"%XD>FSD"F/S%V/Q
MA7A[ZM^>9P<I[G9 6CDV5]"NUD]D(D^:I??1[4L ]*?Z72:BE]A,L7JAG?Z8
MK])3+KK2I11XG3[NXL=$H\V%RXI+3<VA7L+-]E!^H*TK^)T)'PR%!?(EK:V)
MA6(+1SB?CE*;VBX437'TK]Y-;\L+'[DS-!W-=+\CM" 3!9AKJ<3*3!C%%XRD
M%.RP&*Q >S[9,Y%>C 034RRJL)9JS1Z$;X5OEI@HJX(7"JKZ2-F^0[(QR9 F
ME/NJ=LQB6%F?J#;:%TD]/LJEL,D7*G";:"I%H]:@A0IU,O,:/E83,?IG;/YR
M.T;H& 9 .MBF3 _S'R=&><(@]!&;J:/DRF9S;;&]'W(! /-GJ):F344HJ<F;
MZ._"<4$''S=Q6!MT/'HAIVFRHH.@)#*T&TBI=J92)7BO"%<*/Y97  +^"#]:
MES#MICV5A.LA'G5"<.K,:M6PTN@<D.)(DXD1XS :LA]>1$E:YLJY6/PYF!K=
MB48ZSE8@I6-RW8F MHD/$,56I'%]I@/J8O'5I_6XWJ'-,\<!)VV><^V=,0_A
M,!K_E)[/++1Q#??G+L>']X'X\()PLF/\H_4D&V5=[LLM#JDLVULH&>W-9=68
M?O-,D"PS(SQ4&0 =\L2QDWJ:6JZIB@L?7 -G<(X#MH5GT]9J)!H$$/4T9NLV
MV=RR2R;E%!",D7SM)KA&7.RD%/F^H3]QC=TZ<50;6R=''<HB#>J2;LG"!TJ$
M)N2$1";*K!B?B\5;[KO<'6+C8=.Z-FUZ%OQV21P7R<'FET8P*5]2<:]")SP6
MCC1T@M248YNYY B8CMCF35+!4^*\PA"*<[E4[DN01RQTU/CFA2H;QU:?*3:/
MCS?^2<+/I:!W'<Z8!V7LK464AJH0<#OUZ]#OKD.<2VY:-O FF%W,-S\*LH]4
MXO,M>K%XT^BC+LIM20V<8(D*-C%8_IVP 3!0?D_N71$CC'@\ZXFZ.[#[NZF:
MM6LZR$,1A^Z:.N>21(LD#.FRT 3[' PYGC*3Q^>'QW @SP[Z/%:,+R:3)B 6
M06"> 8</K+:D'7S!HF'C9ROF7#!^8.F"G\>.PZFD^'B>EH>MX\>$P<0Y3MK>
MS_/TL"3.*!3'4U-[#2+DXCQ!#TS9"M84=CG"':037)(E?>2ND_1L^-_J#$Y^
M:-!9Q&DL]FU3#21S'8PA=<BC#IQ;09=K/<_=HP&69TGC6.(*1QDC>.,QQZ44
MA?'ZD)4A:_O6V!ZDX[EMSE/]T#SX'*!)JO ,('SP&>'"PE'Z.MM*U5-,CYY&
M%RH.:::8HL2(=2\U)L[(69<D4DW4\MZ[+%W*C<R$ HPOR7O]A0J9-H%T><\V
MUG.RZ;)>UD-"SISVZN;%@DHXK,$H,=??JXPD,_T1_##Q"2(XV.4E_5FKF104
M=MYEG5N:ZHJ)W*A_0"D?[0SC4;'!91J<I/S$I ':A^^O3>PY_26R3G0+>N=G
MNU Q&UJV/)$XSQ,FNAC354CNJYL^)9W_N"**&?ICO" R\,$/!G\ D9 T6 AA
M3:@?//TLHWF4^SCF6E,R&DX0BW815V=G,#I3 ,:?-4L\#^&S89IY+FS ,W#.
M@'-?G(%SG[0]*5G9,@J(8GLDX)?'%A^#3X1_Q%CGR:B&!=;C9#FX/6W\0657
M]XP[*CT2^DAG!AAP6:<7N2#DN(,!6'9D1P:7^.=">X,G11(BVH.6=C7L ?ML
M,Y_A^@,=A,[*+Q,14W@4URJGH84'L1HFH>?D#JS:P.RZ3P;%=,]2[(^7LVPZ
MZGE$J 58-(0%3DHL=R71H"K2KFJVP^6AX+0%:/GW6M;3TN".:!^N.FK='5AL
M#G^-&+=84(]P-UGC<^\P/7^2R=;EG_96,,?V$YGLDP:!IA:C[9M9%7HT1Z/U
MRV8W[.=LUI;C0'J0Y--188X$(AGO=:C*SK.Q3<$54S@%@T08-S9>M0VA8JJ.
M:)1FT&/>)21X3&<HC>'R&,UQ5L&+.T 4[!*RXT(!P>']./M6[HE5,GERB XT
M%>V?DBL4VV3,H<? '<!K3T8V=EQ3+J?46);UFX-"&[?_-;)-^S9<D?BO^K5D
M&R+?$CBJL 2J]9WV#&_!&;?M2.TT9_2ZT99+QB0G96S>@0TY4">V\7/8BN^Z
MF@75(FS:1GP2Z\Y,OXY;2E!*HQZ.TG)=')7<!)&U%[(1'NNX32HJ[L-;)S +
M\9N] #L&@PWG(0NM>-+D*I2)?)"PA<Z9#.'X+GCY>'86_YX]1'6X@<U0<K0H
MZZ$7E[\"$"0L:J6FPI,W)'"2 ?JGQ-C$%]3@5%<=$H8,1D93<B<O%E]32,PG
M#^7U*F'H]S=)^A)HQRN-\_2M!$:QKWMD"%G1B[YRU%<AIG%B'9RQTU.*\(E!
M^U$^:5"TE/EFAJ,@C,1D]-K;$>@*Q;JR]4U OCYL.J]P4K/OV!I.N=JI-%5&
M/.Z-FA#_/H?MG[##LF.IU-XG& VY,8/L*KOV$YRT':1GI,@C:5V/;JFWN:?M
M9?2[VOLPTTT/X5G;6431"',#=[3+P'Y#B(E^$#B[MN40X;U:7-(,0+XM@K[/
MI8O'O=CR=3%U'>,!$JF)/!61J.Z=&8D>?K8_S4; \ZY[J':P'> <:2[!QNX+
M>5'AUR_NX@C@9#JHHKOHK)$P4I50-9Y7SQ-?/3+!@I]?$]Z8VLI;2@P1?^M8
MB@/-W+U?S"T4)<XR@==U.]+ME[N:12YO2+= -2#.B^@1+B)L;XHL>8Y@*F[A
M9Z;EPWZ$QBKBPYZ,=P86G@Z14F]]28N_A5!F+@"F:'3QW7?VQZ]_*F8Y?MT%
M3R<,C=S E$+.:^_!U]XG&C")LZ230CH 4D4NRW1WE%.TN@-YZ'6W?D%PK8/[
M$O4TX# U!3^F$UT-*5F!I%&MK43$P\Y+ZL&7U"3'Z^0N)E)ZOWCII40'DO!E
M 0QT?8;O4H?R1%03QI:J7&8@P1HNSWQ>/@^^?/Z9#KEO'^\BIZRYYC,]Q6>T
MVK-;!9(VYE2+M38+<[53[G02B3G-S'/(DT(W6RK%4W5@)[]"P^Z*CL9:,*M.
M(1UU67<=D\X$[P#9U)-N893W3<$_/\X53D]EYI4];+9(*4YL_MJB("0"0"P<
M7,%8J!30W"-K;=MJ?5/HTI$2QR]Q]?^I]8UD4T5:LSFE\^>PYI/B<Q7G1/&3
M><%>%41\@;<X96G4\YUP/FVJ&Q:2@MI25&B-O'*@H[CAS''5#X7-I_>FK[IZ
M!878",@CT[2=P__1][<=\4G:^S"%Q1;5?]X!WL@!J(?^7I25(B9OCL[HS$27
M .I^?0;4?=+.G-TX#!H6Q3J6_FHK%FSS*%-C=1>D642#@)51E6V44L=!Z>[0
M<?[&Z;6'K;MM 7T)BZWLZE:1:P24ZB*D*>>_2-O<GR!4^9XXMZ_JG@0+V9,:
M9FKI49 \RI%';:'-R*G*/IA682 *7]FURS"4S)5 AFP5KJ#C?UF#?HH9#%Q?
MPV5-_ V4?:\;7@Q7N_:P^% Q2TS5D5ZL>ZY@#?LVA(N[F-NZJ:&>Q[R]1-0$
M&[YFF4\#,^/D9FXD*:L3CX217F3D!J(UKU1%$J$R=4I81"F%G^HF$15Q<'I%
M7UN!=4]D =V*G7-^I2X7%.ROZW"/2&Q480ILV 5?XC6-2P)FU96XJ%/4FEMZ
MRW&]K91GA)<<JK5$LA2"PI%.>'_:LW>(-(:F&(30*SRN5?ZRY2=B2%B!M.YL
MB?%;(?$NC&L'A>6%C4 >@RI:"@^<DT\$PL-6I^/;./(@<LHONG8<X)&,C8+5
MW@A(688:&HA^T\*+WNQ&DHT?E/*+SEH!&#K^NPS<YT9:AY=B[*,& &]&GSS.
M?QC5[E& CV1\S%U&R<25]^:%C+OWJ-?P+O5:]/(<DO)B<:O5LB<UJ ^XN :%
M?L9SA\Q\)'4SBV&N'C';A3=DRV!6@C_--1F>#A;6^Y7_T/+@[C,SC/K2-_.D
M+(GM6'Q#Q]''DA(AP>)=LPD-YVD_,-%?&$O,LM] ]&Y?_":$'(>>&4]9IK%9
M?!4>"TR*KU\7B]<O7_V>]P:DL]V#$F=S?SD.S&&FMY%U1UG<JIL$A_9N2C1M
MX0N6YR43?FW&;H>>&>(:Q$*@^:OV9/,KN7H?K%_\>UQ/S\&.OJ\H)T*0[8*W
M:7]%_(:Z/XSJG!IXJGV]*FC6OL-&>_62INSU2[?JFW:$DJ=A 4V@*00'X<)5
M6-0].6)P;323J]F8-.T?,_UBT>R^O^?[%M'JA_EJNV#")0RA.ZW-</5C=UV%
M<!OQ2G;K-:G9AGD]>N^+Q?MQR=*#H*T*3_&7,=SF/B]/EHXP];)(V^8%45/>
M^U&\[2H!_GBQ+#D?52.>%'>T/_1A0"+(D,,^& FFD:I[_VUN3\0VXV\F#8SP
M2HGWO=4N$;_'>"L<E*>O$7E=\L'AK&QKBI>W%0$%KX*)H41$&8['< SBW<@#
MTLJ?;3 _+CIZ5\:""(+6_ EJ1IO.AMAA%:"I<0K/A4E>M^$L[4-LO2N[I ,\
M5BKE]-Y7)36V]'?:)]*"$PPP.%S7WIJ1)6,R1AHM#HWKS7%O-=)(JT_ID+PG
MTUF<'&(TJ8 2:_UPYP>ZD,.C+^:O:<.,%L$YGFCQ,X=YO^RV!Z5A9,?6N6^:
M5V3^#/M>K!9GQ-6PZZ4%5ED_*&W=)^@%WS.,TJ1ABOY'BJJ?;QY6#O&4J3@L
M6D2M[7(G+ LJ%L^K,6E.X#G3R4BSN%ZCQ.&91?PD5Z@]0;#GY(2C_)!&\3ZQ
MZ[:PXVS/>))GU8S"(Y5,2L\I/JU-^W[DY+6!UQ2D=.>TK D>X^B:PRL$;W$O
M5>DG&,N?3I#.UV++.Q9<+ ':9[-_ @E0.#J/8'8^@(BT2&0ABU1#7C3<.?T=
M[L_DHO2)09+BQ@0BT=>J[=8A^JJNU(&=4NVFJX=(M\-'KH7T1S;0D?6B](_)
M&M($E0OK@ELQLM*'1G?._ $BS%A0EX](\[!U@URM>S$:AW =<2SHL;8UL*GZ
M$9 V[^J>1\M5=>+FQXZHX5%A3:_^]-V[]%TT<^9@&;/\PG]Z._/%*=>QA'J,
MY4#U+6MC(,<@7/\V$R1V![=&1GV6P'A6AR'O0_,RXF).I!8P62UH*&NYT]P_
MC=<K5'XO<=,2.T87E&HC>6PA]-X&[_:*SC\3S:4.D7(TUR57T!4O>@^<'R^S
MY=@%-P^\R\E@ E>*1"C8S2.U5;:"DTA03_I4YA6ZJ\BC(=<683ZS?3C9>4YE
M]GHWLSHFZK%%% ->X*V-USS,YMCH9TD\A+NRW$&DK2Y1&!8@?7!.:^BHDT$!
MMY>>W5?!AI%^1I1YQU[2WB8YDC"*X:'VZJ(/;4MTW\_ ^/\]4IP9R"I'8I'Q
MH,Q'?MB2]DB(":(;>K39]3;?<=\&QUZ)OYU9&J8V5BE]J5S;*Z^ZKL3Y_:PR
M'EAZLR<8F-ZO*Q9KJ]NQ1P>T\),DA[_U#L;%E9Q3>*34>XCR">$(0*6O61T*
M8=QQEQZ8.%VCQ9O+JDM(@RFGY::&<LWS;P,;L0=W<1H0-6R$[0VF)[0=*J#E
M]RD@G@3^UPK&VG-TF82$/*JIV(GW1O9O[,ET1[Z]>-O,,I/;-@JYC?/<TL3<
M:><D63(LEL@+EQ<ZT2KCM%!MX0[I=GK,G\/KKD0%<,]XD;"_-,JR\3AWA#TP
M=[ *+8B;TE4_5];XE9N#$Y#0?[VJ]6^>9M7ZO&O^&02,Z6DP<9W9,Y] /UPA
M8&3+#X9-+[U^V>Y8=\@2#QW<-1"J,:KR;#$?T]R[T[HO,I>/VZ*G@?MY"A^V
M,Y5C1?AFP;\<=F@U'H)Y/L_, W-]U]>U]*-T(4H$X8/F(L]3\^ J!LV9$_@1
MS(0/ //8<::R<9ZNAYTNZY*HZO^ALFD!C'QC"4J*CKMAL2S/&^N!9^HZ1)[-
M(-A74M+AC923JJ,D.RZI(6](,R3G^7O89J=V*).H*DV5R3P2,\RY,>VAYPHY
MP5H339. VNA-?= L#18$#DS#JJ0<\PR*"818 B:FJZ2WA-*L7+^EY0V7F+@*
M^^ F+ZD2MFRO*ZEI,?WYG:MYLY*D3IHN961#V3"!O$1Y%Y-V28!!\4IV$T5E
M1ROZ'"8M2;TKIG9E#?H.$+LY7<=QK)N .<<:G<-.^29P99QO2B8F 0@-0RXX
MJ4)+O)WHQ1X1=)TO1H*4<T6X/BIY /3+4-?Z0[6K+]MV79@ -DMN<\E^]FDS
MAF8N<$@WY(Z*AO(Q%"?SFD+UL5J-^*&4=C*A]3O-.CE3H=5.2YD:(!@!MGT7
M_L*@/ZZ)<BY<*D%Y X&0 J_#NNL.%XN_E7O@1^F*/W;C_BIY!2YW?C#4;OXR
M$]:\NN]'[2TKG=+ZU_;%[SN6NW0S+O4JOT&EO+V@\4HZ,USG#9;%23Q^U6Q+
MI@50/&D+V2?08T=HN1;SK$&<):^I(P P=1!J+[HQ_!'2[D7RFE3$9EXW-BA9
M!P.OTH3O?J=E_8O%MZCL1<U-Q@EBN6H':GC]2T:=@Q]H;759IL_F)Z:*H.M:
M#?\YV(?"ZEC58/84#,FN)*@K*[B7BS_2TLEFG0&H9@P8T%<;*A/$,6'BVSTG
M"-WRRU8/F*6EF!JMJIM$!SWTYH'WH;(W3/:W5G7I\L#D(RVFC&WENKP:I%62
M>C:8XIPQ,1/@%T"/!"258YU.ZOPSD:V8T9YR9S1KYF($SDS%BK9)&.Q:'"^'
M.0$$!<G0YP"'M/YB!WK#/5>7Z"CFPJHJ16QJ;=9^(B?3+R!3/\[0JJT:V-:$
M1:T(.[72AL&;7A9_7&)AR.!VJ.F*&#(Z53:;%]R&"#;<IS&@MR']<D++1*.9
M%F5$'.F2HV6^:4?N/,:B#!NV(U=W=U#1H'4V6C.MR3>))KD#DJ2 *EV_B[O-
M-?O?.W,-JG0>4:)"@ZB=WZK1''S/$8X!.:.\]6,]1(^#8S GAVP%>($5YPB5
M73AZ:=>=;^,$'8:^<L+=KM][[6F(6]%2.+'0"=FT$2*!.JGIQ*-0KZR(2[6;
M2HQ[1(9EAB3;H;1$!8)<@G!3R#'+2-*)I.U9=93>2WAY6 8(>,FP"X-1!B^T
M8F#2)_9F/EV%-J0\2LGZ^V7+#9[4IEK#S\G:EW9TJ-,S4>/]3+Y_0YZ5"6Z8
M<C>/Y2ZXB-7:]LT).X.+TOVJYN<6AE_]+G=)\CWAUS! U%W!+ASW#UW,.*I#
MO!H];;T>X C49H(2<$]O#&UF]D7#\X9IJR L;ZET\1P8[1>1C<F^DVIRF&<^
M@[DE=J0FFAVV#>95'/38H,W-L:RADEGD$^CRF\H YG>:\+1ESCDC)[OGN&\T
MS'>#'F]Z1<0XS^)P:!9?C[0\BVQ%UMQ]3^NV-P\MFJJO?\IEZWT\!"?8V-]7
M%8/8"+Q:#3<D<H;N?!AQ'VV1NTPN,)?2%,XCT+^151PF'X"186@I_8[<@%5P
M$[_/WX8$>3N1ZVA*$X^TFR=J#RR-(>V.\K[?<<\CXK7/^L^?R.S_PDZ4DX)=
M.2)\QHL0P_\SF9)TG0@VT/=W3B)AHIQ4M]?K6,0GZ$XEB8QPDA^ [YCUR\["
MR+N*KT;-@ "]R,.:6MT3F?3;MKP!N^7]')I6SFRFZD1M(1C)KN:N>)H3DKX(
M!TH(?^K^TD1M%*YI,C+T!]I*)[HIT @Q,G!\<C/Z4MDQ.T1LEJ@H7"Y7X>1^
MFPM0\,'#+A'UK)[!?P;^^^W3!/\]FAVCZ]-+$8+.@<_#8PI.$]K;PH>B$XI<
M%K' C8S\9E^5DH2\$QT9;5VC]I*+72S>)-QG:W3#.DTC>SS>S$CP7+<[2O5Y
M)1,^C8>*DRF\O7<4(=B!'S^=)4,E-<:] ]2<754?,KM@]7^\ RRO,]V6W9]K
M#F)4<!%S:?8J;2^])V-OQ[MUN20J+7=B9_?'Q[+2 @_\DT1]+6EJ3@P>#2Y&
M/FP;<C:ETY<G'8XX_S,FS#@#WG9)$W%-0D)2'9P<QH@(*=ED\QH&G.4')>$A
M\<8DPDR[VGIYP5Q;KEA0PSPWQ8-G(?K<:0<$STN&\E=ZP+&[369.UK+?>S88
M++JEA1E5CHWX1C0@;]IY$K_ION2: 0I8-*/K%GN/&Y/G];>2! JT3^5Q4_XX
MS<HZ)NWYS+]M6J@(F'MJGHLD9?R3N;Y5>B-3P#KRRK,7UG#L/BVSQZZU\%)<
MLMTL,RH2*;;+>2$,%%8/L==7L]9AM"7W><0_0]/,G'\VV0UZ47HS4"D^&1'"
M>SKNWX>12@E0*/-/40Q9#>WRRBB2KL(8T7:E%7)-EGU;\D>PVW=$IQE^"'9G
M3:IG;)54!PVIL[(;&BI+0,O::BY[:JSB/(!1"%@6)&$EL"<A";"L#<R3!PR$
M;^G6FLM]7@7TOW.>RVEPHRA"_8<FY?Q8IG;3E>-ZW,F-LRFFA%?*M;/X+BX%
MSAP0QQJE32L]U+6OU<A7J"^XJU8?D%\$O=(V3%)VQW#4L*M%%&NNHH<!NZY;
M2E;\Y^*S^O/C98"\T(UWB)PBMOB6K:G>J1'WI4\Z:G%]<=/8O>"REC2OXU;=
M6!5L8*NA4DJPL6,9PMCM#197"HVC)_EE>(_P(BF*Q+8$_AK^K!E,YCZBRX(K
M-JR#ZY(Z#_LJW TY,,PA/\%R3)P!9C%905EV;LAF*]=\(2I=?TDS\UE]_?FG
M#DA,MN6-\/1.P9]1#F?03]#YBVX&2U2$#\;D74?$-?'PH@=Q[ZD%<:XHSO$"
M'!D)T4QT_"X8U\)9OV+QH5Y]6):K#U1<J':;%VLZP!+F"YH"H$LD<V4< [.W
ME19YSIQQ+RDC:$JXE.#HJ1@^1EDR9E> GX,?TB&R+*L,(5(J3%(0)B:,2KN'
M1T+!*S\BI -]D_3L*(>(PY?8/76;OA=O?22H-=B 8ZN'Q,B*..%IPIHADCC'
MW>Z7A(]\0'ID:J^3=J95<!X&YB\R$R:: %+PN;-&DQJZ\'CP:,)@1]$GHF&P
M7EO?&!^C%W^R:9>I!%_TXG2,4 J%"49;8=*Y&@>IT#-T  4DA.A.0M9Q0!F_
MM3^.@PU.3Y)64 -UMU:[7)BI\^0$P4LDR6'611LJ2<S&J*3N([&4BY.CVFAX
M;U5 I5E0; !L.:?^UZR-1K_:M2H=PB5NNB&^)7606*9)#KB4 :J,E%"TZ$:(
ML W5?F\L5N6QKF.88*S45,(B9[Y1)$+*3QB/[E)8(,%K&DM+NORI0,3W8IML
MC^YMB+)7-Y0A$* =%U(H;.##0M<0#%H8"P*PK)T0O$406GITU+BDTUIM--U-
M^V=W+6%)F 2QU[0$R64!?@=0!KEE0N+DPW)%(#736HK#,\UC)\46.,REOS+J
M<$4LPG'R(<DX6!].,(#EO@1]YSZ,'_#2*-K!,F[;3FQ6$3=1]3$\!F"XK-V&
M(B_%M)+7_@ZU!J*;Y7\)QR1/7%),=,>,V<ZVF_VU!:6)PG2!<V;+/ (1P&2$
M,#G7$Q.O<>X&-LH\G;!X7GA4"J7JK^LUL=20T:W#&MT#>R=N4&Q^5_]RA(:*
MC&4T1_2:P4[1<&(&+KD@"/E#YEL%6JXRQA/8.:X'*ET.+9"X$)Z(2W_/^.Q;
MBIGK,$Z .+_\,CSR"_I4@9]??2DYGAW6-*4 33QP1JO$$$/*7XAOCYR29Q8&
MRMD(/UN"T>R9EUZI3W ;J9Z6UV%. &O"CDKM6C!/-2\]XK78&#E+3"DZ7%\\
MZHS6S2&R$+UCY\*;>QK3?3*"^R8?<BM?,6AXQV0CP(#IQ-]KPAW!+?,_DCN<
M?#V<H+M#7VM8T[R(LTE7CH>Z&E^V(ES4W;!DH)'%B0'L\T4@B\@4DJG&1ZL)
MV97J4AQF2?=*?(7W<C1)<"P,.!-9B_"BR,3!+=R3LQ$.(&&1#"- 9_Q>SXHP
M-"OSBB=/W>,.:EIX:!B^&,?"P>IP>@DR9LWY11ZK%G(:8R/I)\8IL*/65?R3
MRC4B:<W1R9M(E,SYOF-3KE.ANYF-N@C94.T\ 1QG*."^), #^ZF )T:Q=3\6
M3"I%,,W.Q1#_"-:<G$1X#W)AHDE=)8EQ3!T&9TE%>QLAMNO^[8,_\N.I=2U0
ME#VHM.YM5%)BL-1\"!>[1P?;.!@?S<D]=U-Y B"QHO1&Z3SJ)<3M3:_17VI5
M0,B<F5^-G6?T;>_RYZ:M97OT>1M!S+X9P)I/PLS@4:R11U_8::DAI')"_O5C
MAR/SMVE^X92;WO+2@"V3[647;<>!3L?^K(.2%I5_=RXJ?])V<18K^F;JEE4-
MQ<E[S>\2?:.4,&]UWBA$96JRB+_J#7B5;#[%M>U4GFI*$(P<1!+ F<3)LV#"
M^V8D*&LG<4_&?39#2Q^1^)!SH" YU9N;<UFJS&$I\A,Z>BB=],6)ECA:.^AY
M+20.@9.TGV#.[+#;'=)LDVNOH#/:[)ISO23X+!S^UDB@4WR59;>F5T@KHY*3
M-.">)UZK&VFJVV4U82YIQZ0>H3HO6_:59QSH" PJ9QW)3*;.N\PW D$>#E><
M/'9I7O<$[" >VM$2,GV<^#C=-W+.J(J<P!PEX$F:EV*:<)+MC_4/C):\9G!^
MGH-/("S#M0:_)QVQS WV+K#D'Z*GBFZ<TWLV%E"*&750OP/#^;2Z1"-56FZ>
M$8DKC*#4L(?%D7X![3L@$PJP<D)ZGIG50A,@> EYRZ@F1222OQR _.IUND3P
M\P.LD?G,R ](^OX0(\0_Q_S8?VD1Y'NDI?X+:?>WL5#\70DBI*>Q4^X+Q94.
M69=%\QAKX00F 7B1F%3\D^*'^D'!3W$MSZ-Y)VMZVG0-/S[*#T&>L%<ONZ^&
M9V&M9LJ;A<*_8XY7F4>S5.T ZE8+ERW+0$ ='K5.\"A>'&))[:.N7]:F^%K[
MU&-7H:30I';': ']I<0T+K>LNB Q+>=Z&Z8Y!9> S7N;LC?3?(M[A^05PO$[
MU'@#DU=*TN*Q0LTB7/R(?55]X 0VP7_\BS".#[B'?13(1 J#]2KB9[/FZ5K5
M9UZ_?"7*,^_$=WXG126I*[_9A%E=(UWVEN[YABHOU$.SYS*OM#VP:>*/T->^
M#L_*V_&'BDZ4<'3PC_@^O"A(OG)G(EWAS=LWQ/_=:P.\G@M.OG87IYJ^<4-=
MH:Y@W<M1P$\5MM5E6@Z3GMUK]C5ZD/N%H !83\''7=?&1&_/Q&4=:FNF0FG5
M#][=U+Q="N5'G;VF<;QLPA;='K2:SO#7J-MH"<,S@>Z#\IB4M-A)FJ! 06A=
M 40*-N4* @;8 *2M1PP>Q#9XT R<,44Z&JC>U)&678EMDC16LLJ9+)*P/$A)
M:,O%-LMFE\BPUI!^*G6)$JTVW9S;>DG20=2DN;M0.T@NN=QI#^%[]Z8EMC/=
MT<,N/?37:^TTF.'@X7^U /\ZE!'**X.JQ,"T;DP:PC.5H@>%_7GR;! F7+4A
MR'C1;EX C:N7(A-'G?W;EDXD5MU:"9$!TS%@P7=EXT3Y0EBRQ:98AG"5U+5+
M&+0U Z]X#28/SL!V/B^B=SXGIM%9AVX[#I;&<6J N*YQ-&3#=5["#VT]S>&N
MM8=1U$-9*6+<!_=ER:BX9-IYR08#*Q-+WS7TP%<$&?H!WR.WA)8^K8;77UR\
M^G>8SU=?7+S\=SVL2UEXR>59+9P6G%IB(TH*5A<+K #+D?HBYZ7T"*PA"Y&P
MYQ0.739UNH#:&W;P4M-WQ^4#MUDRCM*E(%9&^0?JYC(8RC79V W),1<,'-KQ
M[_;$XCUP,;1N?@;7P'G)/.B2D4RE""K.'RJV)G@1Q<9WQK?QT<(+(9R0T%1:
M<PY2T4#4Y=0R'!TE"(96VG45J(=#J>VV92/)X;-[]="K(SR(K@YV8'CB2:"3
M$M*P 3:/ACM;DM8U_&Y#@C)*2Q$>/8.\S<^R2Y@'1$M+//!D'5&F%511%64!
MZ&BJB+#IU1=?V%FF&8$KNM9PX'R Y!N6A]C6L[-4EX!.[K7XSTOS$9QUDG=Y
M\19%ZV!"OM>Z^@^J ?ZM(E>QVE##I!R. IH=#UG=:!Y>M"M8%@A),RO_&/08
M94M5&J>E3<L=RU/5RC?*NJ.?.G.N/OBR,8X!$U5<\-IQEBP<0M\V37LM_2&<
M:^1/]>G'_J/<7WT93<3[JKNF0! YNK??O2^074#22ZYW'04=D:_D+U +:O@3
M^?OM&JG+=A&,F@_5Z--VGUYH1(K<EEF75I8OL6\\AWSZ^QK=J8,D.QE@G">3
M57H+ _<V;,TP)+V0"5T2BEG3V]9TK#4QE[P\FFI?)H V=T% 7"FY:SJ"<C&#
MF"%#SHQ*TAM\FO#0/3[?&Y2CAR13KDGNL'K"M !'75$V+BD6UXUTU@-4R&ED
M>?<D=UOH(U\L(HRA67Q5K9BIYM6O2>V<A-=+3L!_54OGT-LV?'[QEW&]M4CV
M;RVNT,0/A?']L?I(;&/C3NFCN)AKT'&F'6=*N2@%SAV*S&#%N<52A423"<,T
M43&E(! +6E_J ;EQ'A;(G!N2<P#SZ:O?+7XL/R[>CE(1^$N[[#G9SMC6O71!
MSR:Y)?#!Z*I"ZL7B>S]D4*E_]8<B5BUXK,)%WES10T6-U-]0(:#N5F-XZ/'J
MLMHQ9C0=9/-.UM4*SW-R'.G=1]"CX2#D1;L<![P8MYM!V3V,%'65Z:K-YE5:
M=!B2X(A!S^BUB%[[_1F]]DFF_1?MM!\GO:/OQRMJY):%2YP3QL+ *'+.N-(?
M2I)VI:P^.'EK?#KLE5WPUVB1$Q[>]IB:?N(<TWXY@%#U"\2KRP%/184_/@#L
M=%"[S,U?8,VU%\.E';AJ5]X\AZ,Z)>G R/A*M-8CX[%M!6CNOFJO'!ME.L<]
MO  ;OUCZG&&Z_B,=263'T"A(AIT65;#(KXC1<#Y4W7$.H]QN"1DV"(&$=3Z9
M8R;N7,\MNV'1@E"9+O_OH+G;U#V=7H>*2M[(Q16+M1S;X[*'A.N0UN<G_H-P
M1Q>\3 3P3B3$BIQ@1NG7+[]X640L4O61P(26VADJJJX1+,I)0@ &]5UY6+PJ
MF !<K\4%[B_XUZ^(G06-\YZ-A\O<A'LK/U30ZU5'!:??7T(T37=[C;/O"W$K
M]I0Z#@LQ'+=AY,+X_!!<WVKCYN0U)I/PHIAZ<H7+&QNZN:G:L)MB%!^S<Z/4
ME\/ABBLU-ED>Z779]E<$I:%?[ID3<R6.O] 8K>C&5,MF&"W_L1#OA-/X:S]I
M0%\X:6^NZMAQ[ZJ+0"FP=##]9WYA2?.!%*DVM%YH:4W[NZG6BA^4$C]Q0+/F
M!S>M;IF[KL1)-S_GZB32S5%HZ-HTR*)I&@M.A!&)V@G>:X\^UV,)< HDB>'2
MGEP+WTF+^%UP3&EV"XL#8[I>A0^6,]U1F U/I)#Q8CI CP/*9+8PA*3">'1=
M[=HK9%!\.)J%H9&Z>!GFF0RB/3/^G@%NJ9$'9ZS&8CW;='[_BK9S@B@)(2J1
MZ',/JI8T&^8UFJO/]D3)PX56V3U6M>?N4! -HM?+(C8J2\2U?:R-%O'"GFC1
M>D 18HR7'$"\=0KF5=HD:YYY'U%(VW.%V!SR8T3 N G5[C:3YEUF3'0)@OYX
MSS^;O#4\^0E3=J9O+_0-"#CQIL]A1WT; Q[)*L_Z"VR56'H>V>.8^J7N.V,3
MN"I[I(/S#9:(.7CRC'4E9Q53'L/#F$<T :SB6.^,32/AUY&V6ZGB=U6]7U+W
MO'9M4&:@!MK%T C%1#O(!?8,FD=;OB N%:H)*&<$AG/PW(69"+$QR<K;?L#I
M!MA$3P-'/C,4W.)[AX\'HPTR'T9W#>9<9*1HPJ*R^["X&H.'@?&_8 0NDS6O
M(Z!"AQ.O9'9*]A>@<W6W?D&1_('^W':.I2$9D:/HZ".4 3.@:(5':I-*9OFV
MTK,>M['G;!1R)5VFYF1(/./6X8BUMZS7:Y/*E8[%-/H.MB5;8XG94/ ?@5$2
M?0]&SZE%J[N95.$L;X]6=LC-J"-Q(C"5M->('W$/=J#CANA**/*QV-HFP;?+
M5G@>]DBPO871/I'>!V:I6!">L]T39BT]M.5(9H_/H:*SW@'5Y4 "\!BR>BHI
MH$M5;53=C/X<P/[BD]4PWO2Q8$+$15%#X..4Y)'EL/OZ)S0;<=K+H7$S?]/S
M;B2^9ZJ3TA)X=;7S#;L&E7'L#F++V >.3HQ!>!="R63SDE*"I"4!+'^U!>X:
M>A([&AL^3'DBO96.?.)@HZ,DP9Z&5"A  -J%?ZQE!R4]#):DE,@FK%MZTN#!
ML^4AQ1C(*\E014>"GRA]2A<PX-R+S<NNW 6_FU8)M:E8K'EL^.[TVI[M61#B
M#6U,+$)ITRHH35+!!<Z@Y4N$Z264;NR< ]T#C5[&E=YK?SVM*;9H\[+D=YDE
MYML-*[4TE.=T*)&TO=II&S:]P@M7/Q8P?TX"#ZXW4Y\2//1-6&T"/E5?/)[-
M3CIDB,96.9%,O^QV!O7H%SB^(9)AZH.EU.\XECLLB%FS<Q];<X1K-!W\N&1]
MH"[-!<(CG+:,+HVTM9"Q,AK76A>#(RD2!Z*J=V"@"",ORA*K]*2D[59>U<_#
M%7X4&G7WE*5CJE@R]F/GR")!'_E@:EQ''^<^$EV)_Y.(=<V1Z=IXQV3H6:\K
MIZ*U=O'HK2OS4Z=FQ7J0)$"[K*\,-I10EJ;N[4;KPSF9Z4R4P;?4_)4ZUYZ!
M)*+ DS2#33MEYM*8GGE:I:W.B,:>R%2>M$KWG+B$6?-_<=ZXZSX9=IBDW<%/
MWR]F-4T2LLP9(CX-C%(<$)_K3-[=J)1L%6MR7BCCJTA=FU"=I0GM&VY^5IP2
M'\@@#N7$Q!IEWB6EJD\<[.^-NE!BR.,]5_]Z9=\_/,VR[QE/]D_06\\SO&]"
M=/WBKT+0"W^'*W?8LDJL>Z3FR*R>L G6J0;'BTA-)5%)KD X<)@HJX?KPBR\
M -+B7\RH!1;'3L(7#H'(\]B/C0:WGT4S07]35N$BV,&:&H@=0HC!KY]3TC%<
MG?QQ0/CUIP(Y?/GU2OZ-C.&J["^%</5#35E$QH6/G.7LJINR8ZE9W"0<  WS
M(8CWR/ ;DMC2EG*?2,,GQ<N3=&)%.0K\C]6(<!.$+\U:0WK.X&_A$&_*E6BX
MU=363"X5QWT%(G.9-BU[1,E'Z2)K=Y72R8:#II!&BB-]R7,,G5IAF07Z72S>
M.*97Z9PT%9>FJJ* H5!9T$()$>K68%%6A>QB ,2<Z/15H30'[L'I-^&*H&T>
M0!4@GPNC=P8]/RYKLPE^3Z6RI'!OH"9II+3F2(K'F6:^^,/?X!IO^1IOC%]Z
MWD2)MG;"DLN7<>2X_B[LL?!'PG7[85<M&=L:EF0(Q!9#N8_JW\HM["'_B34,
M/T1C*!S>;/XZ\%Q+5@4JJ?ACQ3;G1"6NT/';H.["6YTBU"0T0[D;(T4>FY%]
M%^YQ5,V;GV+R0) J!',&/5,I5R/KU*$C"D9"[(R4SBF4F+LK/W'!OTS.!WX&
M^U:\)EWJNJW7!>MQEGQ)8A>H,(V.\1<1"&68PBHZW#)X,Z1++I^ _ 'HGF40
M^<'= JF1[_&E3DGI.39MLSYJU&X_<!>&=D33Y-$AY#D?.UK44;LAVQ!??@(E
MV=GJ_2]8/>'+^)9H*$ D\8YJCI*N!._&"IE!_96 BU[]X0^_Q9[Y\[?OWKPQ
MNH ]3_Z,28N-;LS1-&,/CWEFU<=J-9IEHE0_T;>Q+>"_@:&E7UU6>Z&_UU S
MX>7@9G'7O)X8P/2>M,IKZ'$5NK'5$-&6!-/]E4?F;$I.#:O1@(Z\\0=F%J00
MKOU&^$T,9^8J!L7"F5",V?15^D(V??2U^B^M5#9G;8ZXU.79-SI;B6@E9%,?
M9=?YUA'D_1BY9>@ ^-H794T"5+YGR,27?RCR)$]$A532>(  0$T+*Y&H?9%0
MRC'K>T^)H0^<0X[4^%3Q[PM5KNJO5(:ZW(2'$+Y"*7.E>CP1S2':*TRAI%X5
MM0MQ!USMLI0I7V)-H.@A(1E4=23^!$HRW/UK#EI.ACL2[DR#'+D+=8&G>3S
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M44](7"<KK:6D;S5 YY%AM_9<Q G7:-*FW/'AJ!\@YSF\\QP.X[B4[9GRZ_^
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M"@%83RYP0/64F&7H/E:9VF+"6+XLY_L,_RZ[U7@)"K_ENM,B2)'J0]'^1QV
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M$YRBB $T0L<MA#X4+H\Y'IJR'J_O7SV+&/VKXZ2/U53%?DT*X3 08C,^VAQ
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M)0CUG"C>.MQ52SJN]U2JFGKF7XE.[Q)H'S2^ AP>!O-NV*O;.Z0=^AN02S2
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MVTC1O[D7L?2O9#26*5[02^80D";,B3&A"Q]K C<X6KQ,5Q13.=#$_C:!'EK
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M\TL@>WU'9NTP'*5-JK&^3AKK F([QEU0VH9#6Z"#V:0._3,+C=J.#M04<JD
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M%*"D"I5WI+EFKX[*H)L)!24&ZTVWMMM#26*F]W*MYR7%=ZLL#:QWJP?L!7Q
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MZ<36*A\= ,OS^]$O)DJ^@!73%$EV?D1;?5F90WQPIC(4_J?/5(&YH80)C,U
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M0>;6F66WKUD7+<84P4?>A!U4K>*G[XOA548<'5>$PMPX191"IWLA?%C;@'E
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M+XIHIEP)<L_P^J[8X8]7AI>;K\_]_7VJ*N739T2<4VZJF#1VIBUF0*2M+SP
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M3,'G&777=_9+# *&2BHRK,D@&3L>I>[0D+&,HS3#"GF>CD6]C@R6_BL\#/7
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M.4J;'.2(2+ 'Q3O##RF)2.ORO&K&TP^<& ^%U=ZTF%9XTR<D^?Q!(OUNM]6
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M*B^W:5('642M*!WJ_NG90?94P <ICD$P4..LX)]N")H758@JS"'V1.BT4S@
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MS[1JA.+\=K17WXX^]G84DZ4#940NO-:K<D+AFD!5Z0#EL83[HC9Z[J-!J$J
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MM(T$RLB-3\9MJ+GPK08"FM-H@M(0Q"N-BBQ51#@!O7PU%-@F<9SBXP1[A-_
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MP*,('BK#XS\I?-0R:).LPA+W5UGBTRPO#XY@F\"G66JK>LQ"1P4&D.RRD7,
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M*W0ZX6)TT=1G/QQ/(C[D08P([E_".-:\,")$LREG4:RA">0^G5"J39_7(I2
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M^7K)8O^JNF9R,S63VY=N5B>F+7"J>#361B$+ZO#LKKM*87"%IWG !TD-+_=
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M;H =L90>:]U<Z^:-ZN:+(8OX,!R!/1G_K\;_FSYUHLRNC[&AJ\W5*,+UK]7
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M;%WXKU00.]XS$T%Z\G[IWD$$;=Q]V+L!NTWW'/<7(J\@6TA,23*&7_^NK))
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MWK9R+9!V[^+IMO6=PRER9QAB@7C$&37(<DJ0"-X*JWV200,=D7*=/_S$HE)
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M]P*YLWG*XA@UEB<%(*<XXI(K9"RVB$5N:91:81!;3E<K9>(% )ZO3+P P.(
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MD+M*Y>Z'<"4(^]2P-EO2Y;WC+"B,?# *\4@"LC%R9!4SS%(:2"++7=)5 *T
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M=)8G+F+$RP?D/W#7A,[@I&O/\F#C]T&E7%FNO/N5KR?_J6F!@IP=Q/RDQR>
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M>!3KRK>+?.QA*YZ3%2(K-QM>C6C'\+79"+: V)U +!_NN3TY&9GO?/YR$*3
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ML*1D%!P1R2CB3$7D%.& _I9[G]O@!;.V00Q=9P_G;G?2GU5Q-KU*-'@BOE>
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MS3K-#YB4SA!+D*<2Y^Z%#AFG- K2>A.$TT;P<5N49I%GFOP]2#;<ZWP(J[8
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M^S( +K>9ZK&]P[5%:2W@^_YAKWT67W=@.!W;M.ALIPK0!5%Q?>?-=FAY,TH
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M=8T)C>FP.;;=38(K1W'C,+OI1+#_NH-EDJ@@I";6"94>%[Z1L?"DI"KT$I8
MVR-^TJ3$SR4F2G"'@K]/N.][Z4%A[$"4/>FF1NT,MK^I4S$X,>^'^2P,_U4-
MRJT-E_ GQV,P=NAQ&$N9<LY)R"G8(C+@).%>0'B4IC+TE<=-LO;&V[BN9P;P
M40_IPL[6Q:%B13$$_0+QHAY-[$:(551_*MQ8RG(^%M!V.LG=8#9'XW9<EJ-,
M'*YE9[..EPY1'N+DK6+H"I)PD"L.+;0/<%?4HY+M+>WM"SN7K+!D[@8C#YIO
M^C/"D-52[<3DZS1!V&A1846>(WNY28D#^\Z'P_S<(@J\\%>0$)6D*&I@J096
M.]F#U3.U['&3F&>&5L].7;[$K]\%AF+M>2(Q<13K@,>I3,*0)O!3$'(M 7]:
M&%HQ&#H[_W8<,&T2+XX(J-J"\$!X1)A(DC"1H0X,'*-4"$/7^4)*&+*S2K]/
M_<R;H?YZXGM-R:6:@Y(8BTRM2+3P4L]]G$Y5OR-I<M^7.N&:19'@0BC!.0.I
MR1.M0%I2OM3"N&=)_"S9[=33?G'TZJKX[IZ?]JZZWC'8'4&2 .T!#?I8YPZT
M%P:&Z""4$N?!A6FZ]H8EUT4SJKH_2S+%1#H%S(Z>=/T([#!Z.].S:8I/ISDB
M&95#YZO!O#@\-3>G**^^&CLF>%:(NC&9J/'=&R>-YZ/.SZ( T-&$+*94I$8P
M' G*E?8?H)G-3=#7DM]V<.P9&4B12B)XZ!'N20KDIS1AD4A]].UK&6)RQ75-
M%FKR<]Y''',Z;.I0#8G]4Z@W<P#?4&^^H\;,V*]6F9FQ=N<5F4%#!CRX N-[
M@H4J %9D*0<;*HGB./9BD(Q&!2RA-TF)5H%Y:BX^N#I.=1 ED::@P!A#.#8+
M3;1,B-1",IYP/TSX+>RHU\"A^\,.$(::6/?1+"_@U.TF;TZL>M5QM\,?OP*I
MG9B.S@KKJ^CD> _@GVO9!Z@;6/]!,DW8;;RY6^6;?8(7JSF L)^>!3X&QV$8
M ZGKE#"::A!D@$\QCWPB$^G[//!0GJV]6<SB_9=3;1:((#=] *,IH**S#+T!
MW_7AW^'D&R )I*Y^UY,<I<IMJ& ?7F4O?6?[A:CQ3W?X!][>OJ*[^R>7<$]_
M[^,QJ(\T!<.;^ (;[/$P(K#G'E$R]K3Q3)2&&E3H#3;OB[=R?'Z<^=/':&JA
MUA7C20[_7:6^+\_.W? =?AS'@3"@BA _XB$<L8E)' 8Q8<JGJ:)1PDS\.OJ^
M= %T^I,^*':#";:N%9>EE0:X5/H!9H$)2"D;Z@+=BB"J%M114#;1V55VBRE6
MMU?,8\QCCMF&%_DOI<D*WTA8^!!-5EY2>OGRE#2@7/H<Z>0_04+CZTQ,?*@2
MN^_*Y[]+,-Z:F%UX\OZ%Z7TU77B-TY?OU*S:?7;WU>5N_^#;[IGR#ME'T+7.
M@\.SP^!HOQOL[7?A?3?A_[L7W7?S"8EPS=4..]J'-5U].CO:^@C?[V6[9[U>
M]^H\Z%Z!.-]"4;]YT:S" _OU&^AP:>0G@1=[)-8LP";),5BP@2)1(J(HC94?
M:@'J>_A0C1/:4N';H3!K*X-?$VQA[[']BV&+5G="JX\+:"4\CX6)))[D">&^
M2-'/P(F4293$PF<F27 DSRJ-\OL9=$:_G17VZM#J-#<K4T+]0O#J8!ZOO(#1
M)-*<1%1*PHU4)(YD3$(#&*6Y9K'';!? 5KMZ4KSBK7;UVO#J_7"2MW!U)[@Z
MG(>K,%%1R"*?*"9\PFG@ UR!MA6H)!141E1KN?:&M[-8G[)ME&WXT"^]T^ED
M/,FK^&KEHV[[I;:] U<4SV^=DG);J&\A_DX0?S(/\29@#+ \(:GA*>%>$!#)
M8TP^2QG5GDA5I'&\CQ^W;0-7 O^1,7[O9/W19.S2V4QNBO%SZZ\_ /^KAX2_
MK)IJ>S"H4J&,WOZFX*N;??RM!;][@M\NW'_WX[%481QY@2*,18;P2/M$AFE,
M BT\Y<.IQD:LO8D6&YK]>L^99JL">JNK]'ZOR]FPXH[%?,*VY=DJ*L1MLYZG
M4I=?:XW%TPJ(\WD!D5 _8DI1$OA)1#CS!8EI*HGR&/=\D<HPD58[I@\\2&!5
MV_.\R%0^S"L>+Y4@96D6SC#L3;0KT3HQ _A2S]4Q:W2T%./<-O0!KB[&A2WP
MNDLEQ[VR51\$!\I)N#4*>"\4!1XHA176H_QC0ZE00H.6YYF8<!T+(GR.8\ C
MD_ TH%Z2KKT)$[8.5+G U4^:I#P=2OG>^OG*G-1/9@#$7#E!%FIS5FI<Y7.<
MN;=[A6.-MT%:=/GNV4=ZK%(_2D.3D-0+ ,=%$I"$@][OTR1( L&B*(Q>1]HR
MF(IE?O(HSX9Y5>@V;?IQ,LFTP,8@E0LYM]2$M:;];.QRG"?V)D#81.%7>S:9
MV#5R6>_8NC@CU&D]_Q*AT6;PNQIIUY$8&S'8UE_+$Z*Q_<"%F4F)7J$<Z*>=
ME^G[&S3A+R4[^J7-RVQ?MGU9')L:K-K8U,6OOI 9E;<:Z_F*EW^;BHA7O/S;
MI"*_XN7?)K?Q%2]_-E7JB3S/S^KIJRH!5R;)HO4XMQ[GIYFC-.=8F/%"-)(P
M5JP9_ ]ZFT?]O2]=[_!JDQZ>[7A'UN.\<WEXUKWH[O]YVCWK<OB=[FTI=C3O
M;>X?!H=7G\ZZ6_]DW;-/??0X'Y[]F76O-K]U^]N7W:M3^/V [UX=G?_?U?8T
M%^/LX&+W:ON8F4AR$TM"N8H(3R@67TGX1RH6&Q&J6$5K;\*XG:C10F8+F2\:
M,G<&^Q=#S%-^+16K3X>:U0B-[AGLQ=;!<2"2D/DR) D/ \*-"DFLN2":A;Y0
M5$:)?-"2U18U6]1L4?.Y4!/+T%K<O!=N9DW<W#D&33.)?*-(9 )&N*<U23QC
M"$N#*.1!E&I?/TCQ;(N;+6ZVN/F\N(GE<"ULW@<V]QKJ9O?J_-@WS$]4F!":
M)C[A*3=$4B\B0OJ^8H9)'3UH#6\+FP\+F\]7NK&BF/E\&[+2@)E];?7,^WDU
M]S?'W<\(FCL>YN8>QT:*F E)@)H ,3V5XEB'D 1A$B4*_I=%R4.4$3\+8#KN
M>9+QED&R=F-RU N8P!<^_@2^39?O5@!'XVEL#C3\)9\8_=>T9 1[./>&!;#_
MJJ1*[NZ?5PS.=\\VZ>[9^VSWR\ZWHR_;7O?J'[C/VQX."S@Z.SKO A,?7GW\
MMI@J><*Z6P>L^V4'&/U][W ?0.$+:"X?#JZZ^[W^;O_C)3#QV>[6^[GTV&UO
M]VK'.^8^#QDV@*-""()#[\ JE(H(17624I\"_\Z/YA.I'_N"41,DV.(Y20"6
M#96,>YRFQDOG4RO+PZC2K^\SF^_&1SY=;NXB::U4 NX*4!4]CA5C41@)$ $T
M)3P.)>C+B22*JSAA/%(@RE]' NX\;=MQ+UGA1B>Z?%F;[HJYN#]5#^"(;80T
M>D$9@R\KO9&M6GIC\C)3G Z7CY2Y2];3XR2)WEIQ7>W]O67ZZ,VK_9FVC";/
MD77W?(Z!=_ G?)'..,_*4KRA'0ZJS5?3&X[LQ"9;C=?V.FI[';W4XNVO^4#\
M7NJ+GTP!@D>=@JFZ-:7Q]\84JY9<=U][HG1#G1WU#_C1&?SM[(!W\9JM(WC6
MG^>'^Y_@750 [W>U^V'W_.CSO!MJMW^T?]I'&V-W_^0;V" 7N_WWI]W^I]/=
M#_^<[5[ULJ.MKG?(/O5F&YNKB[W-8VJ4!',Q)L9/-#8V%T12J@C7,@3[3PAI
M@K4W\7KH73><:[4:';58UV+=ZCC96ZQ[5JRK4^(<UL4B$*&**$EC;0CW?4TD
M,Q%A?J0T5XE)0G_M3;CN)P_L<U^5_D8OK:G;W_DP-05.I0=M-S589MW+"ENO
MC;IOU9)"#?/1T Y#O+_NVS8M7BW%KWGT"(%_N7,';/S@3OU==>CO\,Q;A/Q!
M;= V!/IX'#+I&Q&DQ%,R)3SP?2)TR$B4Q@$+(Q8G,07+>QU.?(6Z&[=,_C(U
MGI;)GU8-*IF<4<GCA#,2AZ$@/-0)D<KX1'M^E%(EJ,<=DR?M@)BGU';,<-0S
M;E*]T8_GQ[L5S+4#8^[0I7:[/^H-+XWYY(ZN$?)N(>L^D/5QWDLE#%5>$!@2
M>(A8?L"(C$)-J$X]GH8R"%6R]H8^F(]JA3Q1+;<^=*YCRZT/S:US?A;?"R(_
M20WA2@6$1W% DC (2&A\*F(92!VPM3=^O-A NAWG]!@YAHU>T6(AQ>SA?24W
M7==6 SWNUKP:P'^"!M&+28JM#+B/##B<U]BD)T(_2#WB*4T)#Y*$Q!X.4-%^
M%(4^TW%(46-;CT/_@8S,U:L(:A&R1<@558E;A'QRA)S7DK47>&G,"=<B)3R,
M$B*8](GP4\W\0*6>[V'F11(]E!>N;:+_\'GM>S;_KLYJ+SOF=T;.EV=]>.N=
MT7P<LY&Z5VGD]JMS;=1_J"PJY ]=%O7F?V3^VYMKT_'+?8GP'J-AD>$;_VZ]
MF=E7,TV4_]=L"4/Y)M[T$B&!]B;CZR]9R$I]>I/*)J"^)]2?.[#&OZ?Y5 TX
M,43F1IP3V_K[=]&[$)?%VF^S)P-GT-S"55_]/R8'>N[\?2I DG1&/74M8:S*
M&V.97=$9#SOOA@,+;];/_CX;B('"?-K/8_B#+75U^+KX[[+3?LDUA]'CU1S:
M.-\7D>=B,-X<Z$_XZ%4L+CRKJX=!R!]<'GW8YMU]#=>#X#[K7NYM;?M'9^>@
M9!S"._S3AW?P]S[/EX%UO2.K,)Q\@W<)NE>?LN[5#MZGO[>_ PK).3WZ<L@/
M]U4P-WOC6_=LTS^F<0JZ0(Q9E[$@G L-6D LB?12,)<HQ9$Z\\6%DD4ZY9R"
M_22XEOA/Y*=2IDJSB/.%LK'R*.Y35'CCHUZH[-X9X,2%<-V6G[T;]N$5+CM9
M4: XOE8)+P#O3#&GA]/$YRRD2H:P'R"4)4U]185BL>0!2&:KAX?S>KAW!S7\
M74\4Q5Y:GN)>;OD)SE":?"_];-0D=[JYZ/6,?GM9G7;YQ6FU_G//NED!?@N.
M&5<42)H2F1J%2<\!\!LU1$<)Y:D6?JC\M3<^7:<T6$_8HI_:DH,5)0,@153F
MS+<R,2T;?#7%>(A3/\9NX$A/*/Q@!-QFL-@118G_Q[4$=B)'?YO\,Y+9@U 9
MGT'DI72T@S3_-[Y?_4E+.8N4L_/M6&D1!TD4$6&8#Y03!T0"/!+%M.)^S(V/
MZ?)T@_MAL$@U(]#W\9PW.MLX* 9_Q $S0!D%UL$.@#QRL+1$?MFQ,./,!/CS
MA3N4C0[.["I_Z9P.>V"P%1V%R#F1A<HS:>P8FJ< KYW=]S^(4;@'L]]M::VF
MM>[%,8!3:)(H)2+Q#-!:$!)0N00)PQ@L/1["_^BU-][&8K(RH@P0Q3PQC3O"
MDJ#[U7PSN<H*\_S ]%WZV2Y?\QIXHBW-3&F&'C,*&J3V%3&120GW%2B1?J2)
M%MP+6)A$08ISRS<BYB\.+N_@+*Q>IRLN.PR'43%V/> ,1V,+-0)^*TY[IBBF
M!.4*^K.\NK!8[US@W"MY:07BLMNIT^&PP'&$<!=U*@8GIOG5HG-J>KI\7F[T
M1 %<#BRPX,/J;Y5O8 O\@=H'6<^U&="VN=%PX);SG1MD^#8]-7$96%(X6(:'
MHIX&?ZUOAP(=7]"QDN,@.^7K=!EC-9>R\<#M#)ZEF<-X?FX9\];O*'7N%]S[
M895Y;S(NQG!2<( _,7(<>'O[BJ+3>O=JV^M^/#9@XHF <N*G6@-NQ"&15 GB
M8>*WBCU?\<1JQ)[GK]-@B6Y3\U!N^B(#@)ANM%.0 5O&/<?64QT9&'Y&=5G'
M4:/BY"0W)\""Z\!Y??'-CAD!-GH1!-;:9/>07!_9<1H;$6!'):D54" --8GQ
MG\#CS$M%:C3'F<)LG7MTG2WI6CZG[KP*H-U)@07<M,C.&(BG<&M=AR4.)ST]
M*R.EF1& *"TG@Y[KL5/4U+B^5 ;W0>9K8%P<[FLE>C70!_@1;B#J+CW:]+*O
M!C:Y_-W.Q.Q=(I=/G['1P4YC>!PGO<OUV;>TFJCK0V9*D0Y_K(?67Y93-C<_
MO^OPV .=-&;,^V/+6=>3K#C%1S6BD9TT'_8[V_^9P+7VR_2/C?WY!_:-0*>C
M1JT@%:"9?!6]"<#+7UAGV?$[MN&0:7S4.<U 9\C5*;S^138^[?2'7YUK&/ -
ME^:&(J?6=VP')0_[IO-;YY<R$O1K=4O5=#47M8,9MZ^<N@Q?L !I#4%S"E?C
MX-#>L'@=%.RVP<U!7>P?4ZH.N'XW_/2.IJL*XU0(XR5AC+%P$7 CHC@, ?>]
MT/FG:5+ZIQ<#X;-@#TM4"/@7<+R%&=SL-JF@OC)1]%[^?IBG)H.S;L&]!O=#
M>LQ9X 64<1*'@/!<*I_$'A-$TS!-O-"+-0N_D_BP7+[_V/SP]NR?Z.Q#F8 *
M*2CQK&#WDY0D,@E)G*9ARIE)J#1K;P;#!8'^'1W3CDBN["R033F>I=O\UP":
M,_+K5'PG&O%029/6F_<C_+ S&(-17&3J'Q2?+0<X#KCJ7FU?'2<IVE8R(H$?
M1X2;5)$D\1(B/3\U7(1)&/&E' !*1+FKI58B;%1A08"^$IH'GCX5H/M(8P:=
MP;#C'$&85&.7[R*28Z-.!]E_)O!W8'NK%*>HP4HSOL#K&CI<J?59-;:'FE[1
MT9/:=?-=E:362#8>NR?O>WA?RS.;16'&Q>:@F6K7+?76O<$G5*YS5QR[.QSD
MU:]O19$5_U2[LU]OSFKU6GU>+H3[G[#C2'A1$@@<("@8X5Q').9!0I2D7,%9
M*9TD"T%V86*/BLB+6<Q]$R:)3^$_,55!S)GD\T'V!</#$J+N3(J*ZM[VA#HG
MGQ487D#!_2'84[7CT'4FE:8WO.B *5!80P$_ +R=]$?.5)B P/O]^T'\'^;_
MY5D -^W%ZK56]388Y8_0K93S1^A6RC8"=M\7>O+6JOBR_BMJK?H(=5EM7]5G
MW]P7VE3U&??K-AU5PU?4<\%&LXO.:#C&^(3H]>H$,.>&O*BSYJZAHEM49?]
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M)K+(=";RR_7.#%"N=W8&:J/S"]X!*TZ8]\?;89X/+TQ>V-_I'[]V+$C:^ R
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MP[W=VC$< \Y_?+GW:1MLJQ?9MNYL'I_7\K^[!QAL^,]]*H)P!(A4U%0BSFA
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M]^!W<'-ZU491)=JK'FW@ZE%U7Q@EE#(>O%S&<HX71\;KA*C.8R,<UUR[8JQ
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M$3^3G[P#%K(D7&,F'*.L(YY7&-DZ__?N0:_Z-4/)]GEMU^-]K:BQ4CK$%2N
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MW\IYA*<0X7I/"J XZPZ?UA]-X"+HJS]L-_/7B^^A+#OY R?M$)L%[F0PZEW
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M9OP! E7)CF).D,LO@BLT$U$#@5ZK;*4$H-CX 0K4:9_T13D.OU.\E.5^Y 2
MI\UFMN 5>WK::<-I\AU^6_LZ_5:6$E"OK'->EF4!T#AZ4]F AD%XXH;7W6V<
MG(+];,"+ ZZWS.L+=]. RPO+L<1@JK*]:[6OUWIX@TM! V:>E3&VW>D/8SAK
MQITTW=4=;1GTS]"-V;CV?7;SCL4N7-$?3?C@.W1W=S:/SVOYW]T#O+/Y[7S?
MQ2!)"@3AA,'=)<XC;0-%P0O&K3 ZRD'4O]$ZBV$CARD8@4536G%#+1=,6QRL
MC9%'+$*47*Q48M?;4UBW7N<,G.6-"BQ 80D'#.]\D/B"!L[%#?<4;!I 1)&.
M/MC,N-4'S6^.?#R'=KJ%M]T=N+[=#[?F=ES%M ?W5HC*#:T;"+:B(/F3&T7G
MC= ['&[\CWQKH*3X^BO6==O-L][M7QG17A\S:WG]2@!:."EH9(Y]__F,_#R\
MVOH]A25#KA/M,;()+O>#;9[;B^[*;S=!"_!I]!'.^]W_$SOMEJW\#<)V IYL
MT]\*Q_-RQ;5V#PX&2O(GZ$6NF2T<^8_@=;5\ SSXKSUXH0B"]D-3DS^GK?:8
M2O0Q,C(N?#!""J,X#3D/G5@99-(F*$7PR@SLU=03WXLUZ_]3;$./[63#$C3M
M:3=^&/[R>VAT3YOVXD.C53S(XDM3TM:OQ70-]T5U4/LS./[@[;7BK;',C/Y[
MDJPI>OO;>(T\\3V)G_;-NRZ6R#6I]0)=K'G8D[VG:FN6611FXJ-34O3Z./$Z
MV6KZ0>!1G[X/<B/IZ!6?XM1<E+N; <SW\WUHZ=R]=_N>'MD(_UBRVLOI&:/W
MQ>+>OD;@X?)T9Q;R$\E!D98X;]F\K4&IX\UM8,$D3XD$J1DGT6LLN.%)<L\T
MPYC=DX[ 9U:1=+6M.^+V9C'["%*V/1"R+R!CU4:K<7)V<K7YBQ:[.<9ILW;T
M\63O>Y77C_YJ5G<_XYW=^OG.=[B>RYSS6[W8.]K^">>]W!G/\SWY1JO?]^!Z
M#QOP_L_:)MSCT8;8V]RZS#F_]<N_3JI'6W"/57"AMT8;B?'JQ9@[?O+7<?5[
M750W#X_V-@_A7C_#><-A%:ZENOD9[JEZ4=^M-<%-IS=WG^%<F_YBGVA*<,QI
M#Q9^Y"(%9"+AB#/CE1'466Q7UB<SAO]50;=G[BV)P-J?I<#.E\ >G.][(U3T
M(*L4.X5X,@EI< P1IQ&#X :-\Q@1O$8G\R7^->9]EL9N48Q=8C%H$Y,7D?,D
MA(O4D4  0U@@2=%[<IY*8[<PV#'2&6X2.XX.?M;@];VC+0;7A^LY]@S'JE\>
M8/C[Y\ZG6G-O\X]F/O848\?WC>**2IN0(M0CSB5#%B>*E C>::D]YRYC!S,S
ML'>+)[.EO9LWF3V@^T+S9$4*R"F9:9E42!LJD<>4"<IB]"9FF=63'6.GV;LE
M:GE]ZS2_8<;7#SCJ+\4>S<08B3GJS[BDEGWJCBSVDD7%C-51<!6-P3:&())3
M,2B?^)O4R4_#QZ$4+7XY_&O!X/;=M/_H#[@^+^I'6Q2.Q>I'7YK53Q\;=?J9
MP[7A/3AV/D[]>_5\JI_*"?/8&XR<S^W<HK'(.6L0%EH20J@ H5Y9%VMXHKC^
MVG!/%4F;Y]""0Z$">*-46),85DR":#)OI'Z;U@VE2,Z]2-)]2YG2@C&D@@9/
MU!J.C$H&*:^$I$KEMU?6U3T) :5!>DN#I 3#FBC@4EQQ\ R,]I8P381@ 2@Y
MGDK22^U?#.V_DY>?? 9-_B-K_.$>/)N]W<]D!Y['SNZWR_IN\["ZN7U>^_Y-
M5#]M7TS1_O-]B:.5GA5Y3!)QKRTRR6.43 +'4AD@[85!>JP]RE\62LDDO> 6
M_N,X>.Y]B#0P+Z:[C:5$OGN)Q/N*1\F(3PC;%!$'\H)TB@0YB:G4#I/ Z</L
MT=)O@]Y5:O7& ZK>CT%>AGVCH2!=5[F5T=\GXV/U'KZ^=5';/<Y1,[JSNR7J
MEY_A>YY7+^%>/VW#L_MXG(]?O:PUIT32?NX+89S&)B)-N 6+S1,"H*3(1JI-
ME-:FP%;6I5C3DU.GEVR[\Q:Q+0/ \R:VQ^?[203".(B)<A:(9L(.&48,XM2P
M$)7V.N0.S6*-3]FEGX\=S]*V+>(>46G;9@H2=^\2;5_ ]5U63SX>5H\V+G/V
MP][F!J]]W^9[1_ZB?K)WG+,CJIO??DZW;3;))*1%C#('T( Y,L%3%*534L%/
M+@W8-K5F]+)O;9:V;4'$%FP; Y=5)4Q1;J4-+JMFR((P(:>M-)H& >^!V.HU
M];!LGO>SNSDLXNQ77+_U'-^GS469S]ZY+\'FMVL?;W9=NHR==K#=PU=!PLV!
MK'PI&BJ6 /@8 /Q\D]R?[P=!@E:.((P#T'$M"=*:!V0IL8Y$(X@-*^M%2P;Z
M^WR,E7H+]?I7"4GS[3N4D+2XD'2#DYWO:ZR,\H*A(%,>+:Z!3X$$(!^P4!R;
M7%-?0M(8)"W]'D?1=['?HVJD3]8OI['3[V_PM)RX,BKTM/D4CY\T]:1<N1<<
M.76SJ^?8*)D[FGPN:J/LUP7U;_<$D;=I[?+@YUZNGJ'?R!Y\OW94%WM'&Q=[
M)UOG50K7OUMK[.V&DZF9[S9&D!KC$$X23 2G!KF(P40820-C%GP:D;.(I\20
M*^CN]K2WB.^3\NI*\2W%=UH2?# R4A8T>%E4@-.50A[#%O)\<.(C$]A*E<57
M3B;!ESL@"V#KGI2&5X+%PH+%W4'EPZ/:Y;<\8()4-S^?UR^_G-2/OO%Z<=Q_
MCFJ;<(U'_GSG4QU/M74XV)2H"BCD28T<!XJL\1P):KSV1G.I>5'E-1E3?J*M
M>U+.7BF^I?A.LW52)(XMYLAIXA 7/@\?=0Y%9@065%"B?$'5)HL4;]L1N1J<
M--%];H:=']?_QW5^6U^,EI*/[6 <N[U.H]AWZ>:&CP4F="OYJ?^8Z-+^J@TI
M)Y)YKR^U:$VYT0ICKWS+E[XQN/)WWY[RYC2&;Q?[0E$FN#<([$2>:)0'_@90
MQF#!>8E ,Z5BX^TFYU;,[V^@?C6O8=#3[K!]WLT]\:]D^\.,%?H9O?-NGG#*
MP+3BA/VWG]]53]$UI5ZB41WG+]"HCJQ19A:EJQY<[ .?P9OT@UNH%F:U8FLH
M][GM#V\YZW5[MI6O_P'AW65]*$/&.YPE4ND,)UT7]G@PZKK?]'Q:@?@2[0U,
M/* "#7>NQ21/&/C+ B'L7%2*J51C+?%F'2RY:^OV40UR'KZI^W9[,+?ZDOT1
M(V-NI/!*A62PX)SR&)R1.O? )91R8!_]Z99$WSW=<OH\KV<[EEO%1+WMZREG
M.[W#V-D]M*V!RUEKM_(\J!AJ@[WJY7 I#^$\1]7+C8OJYA?X?0O7CC[3G=W/
M%SO?/S;S==2_;UU6-_\ZK#?&7<HMN*?J95&U]0F.O?N9UC;KHK:Y+>"<<,]?
MX)JKY]63CXT;/;-VJZQZ]&T?8Q4<BPDI< <03PXC1XA C 0EHW9&>;VRKB5=
MY6JR7.'9\YSO;DSUP-W>OM[-;YNMR0G#RYPZ^*G?QGXQ\W(6!<*9$(2G%)3'
MC#L<M8^4.!(L51A>TO=$ N<#RV^&#TLH?Q24;T] .5.>Q1@ RL&D(RZ,1LY%
M@C2W#%M. HEN95UQO,J-?-/TG"< ]@NTI'@,+ \#!?#$XMVGG;]/OM];6SH'
M:FRP;^E"O97]U9PGJ0AAT@B.G=54AJ1$DDY:2D,H7*@Y-;NE"_4<N_MMPNZ"
M^V1<LA(1H3SB3*?L0GFDI,0:)$,EI5;6R:K$=-7(R=VTTHFZ$Y#G+\'WKJVW
M)Q'SQ[35>1%(&#$S8[OX7X81S3^O YJY$T^W!(L'@<75%O[1UB7<T[Z00CIO
M,0K1"L0#3\#/'4?6>\R]I@YD)T]AY[>VSRF#"*\71!@!609(&MIG>5?Q&?QF
M'G#KH2$&YUG 7#M.'5=&&!%4Q%&&R*B/MR01S!O7*4,,ST"O^@35H2882Q1%
MLF@2;;%&&FN&@G/&&;!\1ON5=4E7A92K=$HQ]=.B# ]4PR?4![U5#.(!=_2\
MJ/'\.KK3L>ECNY-BXZF0/T./=@%Q_9=W".Q7\E)B^Y.PW4]@NV<FYI1FY*D(
MX,8RBK31$1$L@@\1"R'HRKKFJX9.%N],%/D]$IA>%+=?P$]]7UMZ_Q3AHK<F
MXXL647R/L-R7E!*3GX3)!Q.8'"5CQCN/L.42,)E29*W7*)*8ZSVD\I&OK--5
M;,BJD<^!Y7>VG[=(A/DI.T,/&]'["CM#@RSJ<2?GO>X;4<])8$YZS"77U.5]
M(^U#TEK;3++ROM&\8GNY;_0<<#^>)-R&<8V)0Q[^15Q'CRRV#DF<!,,Q4B-R
M, 60W=!5-@7=G[5Q]"S%7)1MI;OO];&;3F\.,M-WG)["&\L=IZ6%F9$=I]P0
M<Y]83Y*)!,F8*\VX [\>#! R2GE/;++1L)5U,CE 9'+'Z:J^<\ZK.9]1_#6I
M\L\O\1)FC2NY0%53"U7BM5 7RUE9CU;6H[U!/5IF[OG??F#F'3^C_@.H-%J5
M\\.&/ZP +ZGTP*;$7N4$#$C%Q8KUAXWX8RS@N40!A>D<L]"C[ID[BKY7Z;4K
M/3AXI:C['PK/G(04WEW0(/C(N6$26+SDTC(3'8W4>F#SECDIRZ#!J[/YQM[)
MUL^]W3WX]^-1=?,8UT^^G.SL'C9R6YCJYL>3>F;ZW[=Y=8+-_W52WP7&G__]
M7CW?V?W2V/M4%SN?_H)[.#BO?M^#X\']'1U<W*C7NX3/?-[/Z<;1TH!P$+EI
M"[7(NJ20X]:*Q C(@2AB!IS(5<:>7>:QE,FF#[Z;^=[VO[,#3$I11Y<,IHFS
M/#/6R>2MY1Q@Q 7RE*# CT[+OFU$X)^^'1IN+I4 \@  &>DAE0%$X(AMH@09
MQPGBS"9D%0"(Q#XQ+3%3.>AX7S2@5-JG*FWK-_N^,GG':26< K2XW9H%MWS'
MR06/8Y!1*I>$UYI(S8F2CFKBL/0I8DEU#"6#7%8#L#W.(',;9BR51S$RACA5
M$KG -2*$ %\0V,$K*^M"R55,>5DEO!A6Y2XJB+WCBC/'@I=<>*:3%RXE+ 6(
M@6.^I(+O!0G&J*"+-D:O(W)24,2E 5^22X:2HCI8)BBG:66=SH@*OE?5!)VB
M%913<OA]&VKCCWEAVSTV6KU.H]4%) (E'IT*,@S7]PYMK]*WZCD2FV.P&5XJ
ML17@E8E<IM7*N>W>W3%YMLF42#R6^DPT2)W$0?=H'-PX..C$ ]N+V\,'6O11
M[B=97A$AN:#P-\-^JF0?<Q699APQ'BSBAEGDF-5($9TP++_1*=WP:\<H#6A"
M,\O4+[DJ]\/C9.UYO7C&!V05]A8$[AP<WFYLS9NT+2KMGIVT^<M]9R0)45HD
M4I2(<R*0L<2A/$D *Z=MH!Y\_49S,B-W;3$Z5]^)\1O=C.138+K7[MDF:,>U
M8,(?W5ZE$YLV8SWX_X5_6FGW1:ZP#X5%..@7_%;<6:_2:O? '.1O^?9!"ZXK
M/!K_0;UL3JNC.4-:4:)I\(0;&N"&0%73=(?W4;"_=7+:;%_$^#5V?C1\G,Z&
MKYS70@6[N_GYC+[_)SR=6KM7CW#=PYLM@7VH:D?;8E\G:2C6!AQ4I1"W'%@J
M80EA(:B5UCLGV<HZ)VN3 Z=O(/M:!1AUMR^.Y_!2L=%[T@:B>-D7S/@SKPJ(
M)K#'BJV<W[Z7?MK?0@85F'D3]@?FY;V8[/7]J8_MSN"E_#GR[L3P&\Y3%6J[
M!PS<L9_5@WV0,Q&<X C,> (A-. T*1P1]0$,O5+,NC U:E[0VC[,70E=R. -
M@@5KG0.CW?A_9V".\Y^YHO&L$[MC-F)RG$*V&OTUX2$88:6V4H 5RIN -+./
MH%4@1)M]AOG*O;:&T)O&IOC[#:S-1,9&86U 1F.%T.OI\2\U\V#+=K)^=X?3
M5^9D8,%E=?/S0 %.C^J[?QS7X9@U6C^O9T$%_W[G>_6B=K+]<^_DFZAM5N%U
MCVM_CBG 2>VP^NG+8?5HB^T=_7$$U\CA=U&_W*;U/,YD]QA7+^'UR\_CXT+R
MB!*\'X/7A F"C/08<0G2[TCBR,IDK/*,)>WZ1AC$%# G@YB.#KYBC ?["X87
MQ-)EZ^N<L)Q&$\<''-3 Z#?;W6[E:GADY=;8PW &QJAB])?I_K/>O$IJ+'?)
MI"A<X%Q&"]R9P)]8T\SEQ,J"LK0I3S,;0-OT9WTV!@\,K@K<C$8K=^7N?P3\
MAD8W&\M8R<;"MBZ*@:[J]VYE8_/KP'7/'VPVNH.#9/>]9KO!_E_E4[/M@ %6
M;><8SAZM/P2[>0J0EA&NN+BQ\P'6O=8@DW'U!H/9\!NML-EHGL&=S-.,DGE0
M>;)O%6@!6!>$I0&5!V5 EH/>&RN\!Q4)A,IQ91(V1..I4"G 9SF!%0L*2UBR
ME&VH'5?YVZ>#9*G*GL19KZ_;0+>R;/9C2J&_9B!A_34=D?%L5K,P%)_+#G?E
ME]90$XI84_L,M"IT5R>4 YR5[!?_^N%NT'DV&$Q%K7L?W-REM2NZ)HE:H.3K
MQ<H4I_.6*6X6,^&W/CVP_)@LC)?)MW]21LO\/=^'%AL_KDW^DC^RL<Z]2Y]<
M7EA2VX-SS7\>V<S[PY0#)9XG.P/V]A+;SL]."YNO1_5?S\G,>6A&SERENTT)
M_3_%9QS9 \C2!#<+OSUB,P!D=+L%WDK\-PCJ50"?+:@7V4],:8OJT6>V]ZE.
M:R>?X?><F/)78R='1.GVS^KE/PWX/*W!Z[6+L<24H^.+&ES'WE&=[FT>7^3$
ME/K)-M_9W;JLYT:XW_\"K[.>RY_9?RX_CZ2H57_6SO=U\CSOWB-G\DPBK0W2
M1@BD-1&2:&$E#ROK4JP2OFQS+$H\6CH\(E[J9&W$1FH>@K.Y@D=I*7/W#]G'
MHSO2 TH\>GT\NDZ4*_#(.$L=90(1H@GB42=D,3.(PQO,"JPL52OK'*\".LT+
M'BV_1S&,Z=D?MM$L(F.]]EAP^;#=!";=K:#)R.%+N"&/>;9+!=[3[F\YP/OM
MR>3&4+QWVW^V3T[:K6*Z^D"RBRV,$MX?!>_?QNDFV%SK0LX55$HC[I0"NJD$
M"LDY&H-2@K%E$IK!?E<I-L\3&Z,%I\8HY '^0&RP0$:[@$Q2Q@5,?,Q;Q[=X
M*3.JRYZ7ZNO2\BV=Y7M[MZ4$L1< L3'7AC,M8\(@SY@YQ+77R$HK40J*2J^U
M<4POD]B4A&D&0N-Q((Q1\(=5[DI-X3?#*$<NXA"5MI&8=*L_/"^6;^FW339C
MJWT"SO"3-]U>ND7WO!QCZ4,EPQI:-$QE[V?>C3;->ZT0R6/:?2UW2X9G.HGC
M56-W&\BQ*NI^)X6=5*1!CA1;CV5$SDO-UX+823_N(2:ED^2<(^N,0#P&BBR8
M3I2D=1[>"0'+E74JZ2J8SU4IV+S8QE+99ZSLSV3%I;+/H;*/D6(I8'%E\B@P
M\)^X400Y*A-*Q%$?-'8,XY5U@L4JHW)5LMO*U4HB_&([1=>IWK-B.P_<S7_H
MQ(5'SYB=]J!/@%HTX[Q%SF;R".X5ZS>]]]OG?9UUP[#H9+8LD(Y$2^ZN92O1
M_CEH?S"Q9^04E5P&%(7(#0"B0%8)BY11W/.H'35Z91VOT<E^$[?.Y)J%BCS<
M ERIRFNF+Y5(^-+/9OD@\IG<N83(UX+(,4+,B.'*)0GN+M:Y8-@A(X-!UN!$
M?;**:Y(ADIGGCRU\4^R\V<EKHE;_KAK^P7T-=$3ELOO3=K?HNO"AZ)G2^!&O
M"_7^=;,2>7"W^/HKUG7;679O_<I$5<SKE_07!3 ?T4C-4/_YC/P\[%Q74QU$
MY#K1'B.;X'(_V.:YO>BN_':S"K/10J./<-[O_I_8:;=LY6\ G1-;.6WZ6^M+
MY^6*<PN&;LZO^[/=*NI1BOKQCXV6;?F&;5:^]N"%HJE4WXF=_#EMM1>RJGYZ
M]>[]/00VSSI%A?.@U5WWMEYW5V7+JS?B\S?:)JWV>R85745L[OS5ZXYTHWF=
M /1CF@-OP.,JW&R LZ_1PY/H-6)WZZ=OGL$S^-AIG_QY7>@]6:B_<0*0WUMX
M>SR;VOSMB^KFM]R!+.B8F$916X-X"AZY2 URV%H7$^6$NY5UK58%2!(UDYU\
M"^EYU2AF*3%O)S%ULB^#2LZ!HPHJ[Q%W B.ML45"@_#88&(D>9:T7B6:K7*J
M)B1FM0(B<1I]7I/FQ6KE/ (BY5YMC59_68:M/,>Z-DSMU7 S47NUXJ*W9]TB
MASNT*]UVY;Q]U@Q%OZ0145B;QJ_&;>?#&B-1;I:C,1)[^<9(7_KM^_ZVG=[%
M+IB;;E\BNIN-KF^VNV=STRH)_)6K7F&T?KD%&O)'8P^^#WX*KAW5+^J[&^"_
MU([V/E5Q;7.#U"]KS<E>87M'</Z+ZJ>_CN%:61[463OZZ["Z>2"JM'9<!PVK
M;OYS5*7?QEK6;1&X/KZ/(SQ:80426(&F2>^0-H8@C8TB6@DFW$03(A^<,Y9:
MFSSAE,/OC"EMN4V4N2#T>-^4P9)43O.:5'HCBU( >SOW]APM@J@ [@)_[#ZA
MG]*]E[:@3&[[OL;#F8-MM(H*DF_-)IQOM6(!S3H @>UB]&#ONDG2:N6TT_[1
MR$>!)]@]:P)Q\X!N_09]!7<>^731I.9Z_MSPU5/;")7#QLFC6EW:&+!-CB9A
M/;>*.6](X)Y:1CTA(CX@V_S!9OD6(-CJMT[L9KL\B@_?&[W#T:_,2^+=',#$
M9[+O*=5:1HP"410HG,'(8,H0,U*0W*_:,[6RSF[+"A@V,EJ;4.%7Z:9UFTV8
MIS9:<[#.W\0^T\02)CEBF@K$#<7(YK'O%AYUQ-:;2-PXO"\IHN8>P3YV>A:8
MXA!(!P8K)<!)^",;M(9OG-J1WO!_=QH_X._*WTWKBS##:J5[=@)/H>C=ZF*S
M?5[YY69OK_C3Q].BJ6:E=34J=I#W9OW_G<')PZ\?9MS8ZQD-NFZ>4)Q.[I_G
M$_;?'@2XC%Y3_?Y;CQY(K=<8$2_0#(OSI[78NK,9EEX3#VR&-2<7^[ G^\">
M4W.47C'AA101UK^O%+9@C*U);7W'TX9WAF[NUS[TO.-'D4/'P(\[A9R\K^Y7
MFYVURI;KGK<[O<.WSJI^KT.4P1UB3E+E'(X\I& )23H:SJ(22JHPPW#W5YL)
M<E%V="/YLKO=[8*_O]T:X<OS$J-\,E4>#+$ZV?FTS6J;>\<[W_>:]>]5.!=\
MZ^@ 7CN@5?KE) ^=JFYN_:Q]'1]B5>?U(X_S[O3>"5S?)=P#K35V-CW>V:Q?
M[GV",QT=GV<Z?6,@\FX=[^P>[PNBL4A,(4$\R6%-AIQA!EPI$1*/SEF-5]8I
MI:N4O)]QR"^( M.@]4TG;.4U9"^TAO>OW3S,_9N$P -W.A?X=\/H?P%GL/$C
MAIT2 )\!@%=I-CG&L+FU+S&)Q#F""$\<\8@ELL$+1+F2GBH1".4Y\1RO@BS.
M*0!>*='[R$C/?'#/>F_A*3:;C7+V\8O6WO"HI/ T*0\J0;SUF"4B>1*>"$KN
MBX^7Q&\N<&][@OAYKX5TC.>94/"#)XR,5PR92#@.C-CH[<HZYWR5\V?CWGMH
M$_FF3.:%.T7.)TN;TC[C3<"J9&DS1ZL)EF9<(E9+I#D)>8*81R9YBYC3V!-8
M;>4%N*G<K!KS[-+ 9Z'5,[G8HL7FJL#%OC9:A[;R2^\0[N3@,&MD*_HBNR)V
MNJ ;$_GH977T+!F:<2I%:;&+7@#H<6<Q)51R9HV@4;"2H2T"YE4G&)J,5%).
M,,)& T-3F"*=C$#!&&8,(59H\$P%8ZN,SDTY]#QWQ%L0AO:DIGB+PM#>!JQ*
MAC9SM!IG:-KC)#552%@F$'><(.>$0-(D(7+NH[$Y/]IDAC:9'/V::/4.HV7]
M_,LR4/:2-,PES63@-F*NN Y!.^*BX$EI39RPNJ1ABP!LGR=H6/ D2,,UK)JS
MB.OHD55$(B: GC%A(@Y%&RJY*N5DG5 9*)LOJE(&RMX0K$H:-G.T&J=AD06C
MF'4HX1 1YRPB(Q-&FF3.Y%,B_W][Y[(240R#X7=Q;; G39IT,VM?P(7+I!=F
MH0@BB&_O.0L'9D;!R\AAAJ[Z (6?KU_3OPFO-M,BRO3/A7E#E/UPB*V^VG/]
MW4]\0X=]D\,"NVN44@NV^7CI*A1Z"%1(F)S'I-I9)-O=$8>1ND7A"$4E AD2
M&*>\M(/6$EL66_X9X6'#+@O#+MJ&K9-5 \-.'E:'&!9"G\@20JZ:@=@0YLWM
M(#9%E9#(<3DT#AFVPG7EK6V'"OO?QP*IM10U-^1(W(.VR!/6TAV7:RL:"'8.
MJ79_A&"1J[>4%:*U95;6")RJP9P_QCFVGLJ,8)/(M>A089?#8!>MPM8)J\%@
M)T^K0P;S1"UU00C& 4BT@ HZ.&/NZ#40\\=D_[II]0F$[0HQ=_67>ZTSHPYS
MOPYS^KH.\\:?ZMN\;%\>'S;O4$L#!!0    ( +9#65(YE[6VLA   (:M   1
M    =G)N82TR,#(P,3(S,2YX<V3M7>UOX[C1_WY_A>H"#ZY O;%LY\7I90OG
M;9LB60=)MEL\7PZT1-GLR:2/I)*X?WV'E&3+ED6)=K)VJP"+C25Q?D/.#(<S
M)$7]\M?72>@\8RX(HV<-]U.KX6#J,9_0T5GCV]-U\Z3QU\\__?3+'YK-?YX_
MW#J7S(LFF$KG@F,DL>^\$#EVOOM8_.8$G$V<[XS_1IY1L_E9$UVPZ8R3T5@Z
M[5;;77W*3UN>Y[6\HUZSUSUI-;M!T&J>'+>Z31=UC]S.\<G12<O_\^BTTW/=
M$^RVFWB(>E!LV&F>#'N=)@[:\/?0"UJ'/0WZ*DZ%-\83Y$##J#A]%6>-L933
MTX.#EY>73R^=3XR/#MJMEGOPS[O;1UVTD90-"?UMJ?3KD(=I^<Z!>CQ$ J?%
MGSE%\^(@0D;1=(SX!'WRV 1(VBVWW7'3T@J+&- )%1)1;XY.&:719#V!+_F!
MG$WQ 11J0BG,B3>G*R=:)E %?#FGR=;J\"!^V'"0E)P,(XFO&9]<X@!%(9!$
M]/<(A20@V >S";$RC*4"F<<2\1&67]$$BRGR< 7!??[)<90^R63*N'1HCC1
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MKE[!OQ U>/!KQ@,,G(J[]P9([]1+]? M*C3^ 7P*> ]]Z#<8_3<8.)_()'9
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ME%EH8?F=#ZSZ? \!"> $??[I/U!+ P04    " "V0UE2$$;OT)\@   Y3P$
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MB([9<_Q'$7V3H/,FE"%YU_6TH2?+>XN^G!R,T.Z^[  ]?-3+E4G&W\#\/41
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M!0!&5(Q&HQF)[OJMREMNTNTQZ: ,9U4]:,K^.LKQQ[0#/QG_"](YSK?3];7
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M-((7C.P%LF%X*61E13)IG$HB%6N*-H^!,3>R+QX>8?91PY&)\L6@_G5EYH_
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M=SQQP&ON+I@W;KA)Y+*D(%*67$MA8C#"9A&2E$XCSZ/NZ ^3\T43CUFY:.]
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M*<&#D,A\U#0R$^L>2%]%LH!%5%Y9VRVI=LO#'Z$V^PEPZ(GYZ_SM>/H!UDB
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M=#=*2BS=(27=K8"Z[_=_[\.;;W/FG+EW[KVCI*(H(FI5AN:$\@OP_PH$ $
M !@ @   D  @   $ 8 0 ! & "( 0"0 # " 00 P! "& < ( !@)" 4 0D&
M4 @@% 8(10!"D0 X   ' > 0 !P&@", <"1@"0!8 @&6(( E&& ) 5A"_K<;
M@ 0!D!  $@9 (@#(_YK_L$$@  0$@($ B/]F("  ! 2!@! 0$ 8"(D! ) @,
M (%!(# $!(:!P @0& D*!8!"0:!0""@4!@I%@$*1(#@ ! >!X! 0' :"(T!P
M)&@) %H"@98@H"48: D!6D*"D  0$@1"0D!(& B) "'_X_'?V2 (  (!P"
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M4R073ZO1W7JR4*7UYLV;GXJL4;!A:-><"5Y359H3\$U/]\-9Y,1L8P7W8<>
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M#/6E.% \6RI]0=9NE8-!X$$!<+;-<C&AZ)C$M*&YP"%C'G/D2&6$8*<&05B
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M25-&A:TU>>_V\E8@ 704]<<F'<TQ FU"GU_EJ&EX<YI]XRDLK1\NS:/&J7Y
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MU\[,^?([A8$K<==$EV15LZ0N7.&7>5[57#[<2%GRU.4W(>=(Y,NQIWIY:M&
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MBDVU$)+8US"E5-G=58Q\&:R SF)?H75_IB31TTZF+Y+/OYF297!$F5,HW_K
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M,LJX%:C>S,?B9S(+U7[1&HO+WLT-1B^O4Y9GRUA2-IYB5%A"9NQ BQ'<VF,
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M196%+.*R(%KH9;\I*6M6(@$-]":GF9:XA3X^TMG EEBB)@Y156"9WU+,,@8
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M_M<TH.X!H^-+E>J$1CX#_N9/2:?B9#;HN)9;$%5.G"6L-!]PGX1?-]^)  ]
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M.2@_#')';W@#!8ETO!-4!HIG@E?9W2U8S:2MHRF=D=<*2ZCNV(D!Q'L1A (
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M!&(!VA\<40ZLV*2 "<526!A#AL$<HE7P]1_N&%-&WADE,N4U;@>6V,+=@(U
M_<'8!23?H)T[)!$(8=]?F6,JQI#%T=V1Z9@#+1Q=*2/5!!XGR6%ZQ6!#9>&S
M12 950XR=MWW')>W,8CD_9]^F5IEP%/F/(AIZ=^^0>/5J9EVC=<#/AMZX19Z
M[59((E^*/1DJYI1^L=Q3?>"2<8X^P--GSN:*M2!^71(1T9P,!25B'M\3XF&E
M(4G:J(+;*4]LP65<4O\&1=H,V^'-NF@6[F3(9@K/1CH0=%%EQ#4:^IE(4N8)
M#-8$(CZ%OFUB_TAG5!@"("@,'@E0RC11\T'G,HIB(@757;Z$^ QA#("%A(U7
M-B4A;SE5+-+5>L)+>Q;%51J* 8QC55QD4ICG]#&H4_@1'8U2<PZ4+63H?4[&
MA;H,/2 1] G-;'GG4;IBR'%4^S2C!@6F$^Z-@G(&%+I)%?[+4SI%,08DC=X&
M/8SBZ0!"/H(H4H@HZ2@#[\0 1$)5^^A.@=;<W,6H^/G-D?X$>>K)J^$$"3X%
M5T&GE3H%,014%E%#(6Q:D>(GFJKIY:QIFQJ.FXC2UPC4D+JI_M1IFX+IG8+=
M:)XBA3+THP !U9F^2 41!4/."Y_JZ:DEZJ+V!:(:A2C9#VS1J4M PR0$5XMA
MI/"@08I^#OKLI?M@*C5!%4_$YKSX**/FSZFBZJJRQ(WV8W.^PG6.6FS.ZOBX
M7N8 #PM.'*FVH/?L)DW$E1K^:K(X*JM23+$:*VTAZU"X0T"U)2#@Y498WCY4
MZ@3%J!7^'2W-&I7ZA( "!00=:[*"XK**JS.1ZY4FT>.0$CBUSZ<@J$/]'24]
MW&XJ@QAL&?<X7B&*7Z4:YA!-1:F*9958:N= !J=&&"76*S%-$Q.F%9[_J&JY
M)L[#0FRB2NQGB"F(+1)(O1%%->%P(9^VIL^.;!1FS>HD?.J1Y=2[NJ)V D"2
M;9\F/9SP9&7E."9Q5N3$$MRYXNP@Z6Q/ *D_LHN@DM;?-5MKLN3'YA>CY9>T
M3D*)*.WZ6)#NU.N.M>#WN9,J^E^HQBCEI!L<^6>5?"UT8>%ZW>S.4EK%FNV:
MHFUGN,-/"538@-1<:2(G-=W?G>R$[@X \)KW-!JW]EUDWJ&.7MB?<<& 3I"A
MVIU<C5_/_L3:IBTM9@:G?J;PS.9&O0O-&LG+QJRG&2AGRN),A)9%A:Z6*EF_
MOIN-?H?D8@2GLMRM]DRI-NJ-[A6'P@(XR:VT__*ED2'?Z#)+O<ZJ8'*$W\JH
M][S/BI[;K-*41>54XJ8/^3#O$ UKD3#NX[)29MR<]_S8OMV2K[D$+6E;D"0E
MY2P@<IVDMRGCDJ:/  (=*@)E8KAHQKD$[SBN<^P;]O:A7"4&EGIL>$;%].I$
MVPH4Y/Q!M!8MQQ)M#+K:2>F82LC4WPZM=TE<+6%.M-7JJW'M@ )/P(:L7&V&
M\(*)_U)OJ,QOF&@O/7$ICPTF/EDJ_U:(@P(1KZDGME'6<;93*G*$\:6D_2%E
M0W%I;K$9A="<5M[B@'*1CK8CZD+%"%^&,BR,'AF"T-:PC;XK[B*M4]TN4%JP
M _%M\ H>0XJE@&KPX/^^XH"V!':N;B9I,/3J20@75'NZ,(3.6PU[&0O;&X\&
M272!&QCZCN>P\!D?R^W%L/U-1Y3%\4K$P WH,86\,:^Y<$<94S0@\0TH5Q^7
M$)RZ[;KDT1^,V(#-)!H(Q;7F+?)=[50VV> >UQ-*+1J,935A4^4%6)3J#C1P
MX!-6B0//LBQWI[=Z:]FR\2JUIP8&(CT*,3[U;JR!(X^0)[@U,A!MTL\P(VA1
MUE7>8P[3(_AY!!)W!S!'EC#3D_[*6LR%J.PN#_9!<6YQTOIT;"@SW-*>9(2Z
M8$)1*R<9TV8"+Y%-7*?E+JAYGPEOU/CNFP=C"0CW<A59;PG/[&R*(_<Z5)6U
MN?-X4N)07H0^5. PPL31O83Q]:0.D]9!6]/J*7%2<!X<H6="[T,7*8DBGN'S
M@ DQI PIMDLJB)L8B(_/79L:J00H&Z\%O0LQH-;[/F$QD<L;K8^AKMAN)2SW
M^%)BT-(*E(BA'K5D(N1"XFV1?/1 ;\PO__,!IB+,R3,VMALE0T@B[T.G7=NM
M[4DQ=O718K,U&UO[2B6G/LCZ+?-\.-+XG?%L@MRM;2=0!D]5SXV;D"C0/K%5
MS_\@8:.27_L.B[U;AJ"U,B*7';](@0%@/.])&::PD65F N>.@!&+.J(G6HTO
M8C>HS"XV[EY$($LE,Z<IEOBIT!2"T" 1D1*V0!LVG;1G#F/=[B4E'G(.N= >
M^-JH29-6,\M$I\5$A=*=B4GC1?[V6FM'2/XJ(JJC< \7F45G;9LJ=@.2&]MP
M[M7P0C::W$EDD1BQ6>=6!X/U)8G;)0(EL6".5>JH3!EQ=WQVS56'5)DW%7/2
M1].V=E-%?R<+40M8&F)K>E_TTCX%[F3V&F-&-0^Q3SHW9#OTIV"I<2OT4AGM
MA%$4#'JI"MZ.<V>'@^=D=4%=3-!P$ONWM@!X:+"@ 4S_@FQWZW&"[$ND,T[,
M>)<"-(<5-)&$-/*=^,L9^'QX<TEW(ZY=^ S%]=QEM*O9#@Y;5'W'U(I[=[EA
M%NY<VGS+6SBGN+*(MI",[H\;!>P.>+!1<641>(R[X5&*"E;_*J<V63]S1#D6
MR5SO@U[KUM#N]51><0--X9F/[C9R:AH.>>IVMYMKA)V_<DSYM91O^5$PNF=
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M*UXSV""><6) [6G=9=K:V<:V=2"&/'C=]2KMG3:>QW9-#AX1=7$D+8]W>KC
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M*ZPSV;RG;-1/(<[-)9/_\N02;C:],U3 TS\I,4#1HK]&0V#6TJ]6YMRRZ7S
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M)CK.!TLU0I)DF3YXQ!XKV',]@UTAY5]11%WEJ7:<!9 84D0AU7KF4FV*8R-
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MHCJ()3'IO$YMS2!$80Q=PE@E&QX$).! S9HLYJPP47$?J+P3QWPF+:JDQ8P
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M%9FL-+#CS:*R/<P+MWI!T."[GGCBO.B9*N$!*CUBR6QS)@RL)*7JO@Z-B8:
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MU)F89:=^I3P?)8:NY1\,71"V$'IVGQ#QMQNQ>Z"ON"A@YB$['25I*,?R%9I
MOOR^QU^3HJGJ6="CX=,?R#[Z,5 85)=NE;B4LKH=&!M8PLG>6M6RQ)&G*^!%
MH_T;VXPRC1?4Y<MU#R0LKTM<[[K? WG/?_H_$R^^![".N"Q\',U<;T(JZAJ
M7AHU%Y<2\2N'WM2S90Q?(7%BN$=Q&;7.89@:WE?_D4K+793;PUXQKE&M$2I?
MT7%?5U39J]R:ID#BB#TV!R#]D.YV]7"^5E.2BJ09-K$F$4D?1$N ").OCWC,
M3C/%\BX^^/*#7C[<2"!V+?93SK?:AFZ'DMGA]6VJU)WG"($B[KSF>R"63R2-
M2 *^7Q&T/O%86D)Q$1[0&;S62FKCO7U1/OL82D\C-UM[E6;.>5F+;26X8_TH
MK/>--L*N.Y#188U%?L>+MB]U<*9U8V;M'BAG-;ZEIO:X$X&%P\M#[X%?,O?
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MYP[_$^)U5ZIRWB<7X30;>DT&^[K$QDOV_CTA48(SZK! ?XJA53\FHQJX^85
MLG>"K+G\; VSX68X X<X;,.MUTY+#O'<SAV30Y1UK?FUC (>5T])%Y[RP)[\
M]5;-0QH4*CW3H=<3[5.V9*Q4C/;42%'<?'X"2(R'YHB>2E*V$$SX\ORP4:4-
M;NFSFY,V/+0Z_>CKZ9N@(D+8+07'7U]M:89*C.;>:1FO7@::PFC27!VI3Y>5
MW.F\&*R1U2LF0+W@GM>0'23SS3WP*;938$YN3GSHH@[9*F!YFQZ<;FZ57PI
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MC.P.#K%:WS[\7C-9:9\V>K:R;,D_$!U(^R7Y^$)[9]B20NH.6X5^PW'OCK0
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MU]@_[KW$@'5L0!N6U3H-YGC^I/AE^8J^O O8P8$@MEZ!:>5[AM][P* H,_*
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M-=IQ>%7.82Y^C.()_N0Q..:K?YF#]W&N'I%K!4TYMC&K3S[ 8/*Y^_*2%87
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MVW/?3"&JC)M($=71RE1\;3UDHB2Z;9B15BSW YB,S$9\VWU3B.W;@1;,I@*
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MOD9_#UC7KX1,(!S5VF=J^S6@KNH \>*EM\ .EO.@<SD8$+*N"PDT,S?XS!7
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MWSRLYDCZKV2M_YC(G_:N,MS[T\]Q3[%0L112#@-Z #DSPH#*1P6+YV$;N4/
M@5PC!O9-TP&?L)CZ@C@83H#5H+@@TD<C\L9J3.0!V[WY>EWM+.EC.VVG-_!D
M]XT6<?RFD4V& -EW4"[#WHQ/,_2YG9=I0CTN)H,A9ALM$Y[J:D=- 2A )Z\^
M_/<9WL/5$ QHZ<4H;),64.L6)^'UNS \T0*75E^@0<K[Q6"_:??5K]"3VYR
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M;PL?%R:L-K@5Z2(A7P5.BU(8!$C0>E]9E[W-B>6EI$UX1U>ER%6<YG/_(+M
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M+U))".[^6S?%+F4\W"A[ZU1A:'/-'@2%!<A=6# &U*8(P '>!CN\&H=&,V-
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MJNL"NR?H?9ZOJ"B/A;\=^D.3./U#DR!<OJW]7;OG.5B<6C>H1TU;D)1*&V!
MM#8'K.^@'P1VKH.YNK\<A%\3^T&U%#4^-?UDM[^07>F^NG1D2 G#Y1L*] !Q
M+>#MCJ% !>"=YM'YNQ^(A7#>2[O?SQIMME-P!'ZJF72A^!1+ SKGGXZ^ 2.
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M=\57:G$7:9SZO"XDI.S2-0>Q@//VVHA&TY55AZOL6?6MYW ^8V79A=^QO<_
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MFBB@5_,[2^QU#E"14 L<^:]Q69<R/U^[MW/[.G)AK<+KI]MH.50M[#D]5:>
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M_$8HT"'B0)'3CZU3E[#$QKW:)^B*EJ+L7PF]2:?7]ZYQZ!*:P20]VP=1G*X
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MF")?=Y:96" JWH[S;U@_FF]VMMU*P-&N3[W2G!=;KE(M,2C))VQ9$_-BX<W
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M,"<KHF#Q+*"X+DJ/M6>(YM6PD_WM582G_P/H&&,/&NB,K"\CE,8\,&*V.5B
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M/IFHK^9_@>*>'A/73W/JT>*&AY&R;/UK:*?_*/3W?_^0_EW\+U!+ P04
M" "V0UE2\6#:G0FG 0!"!@( %    '9R;F$M,C R,#$R,S%?9S,N:G!G[+MW
M5)-=MR_Z4*1# .DM2$>:@/02BC01$ L@57KO(*&&(AU!0$!!J@(B77KO3024
M*IT0I(,)0@@MW+S?M_>WS]GG_''//7O<>\<X[\R8(W.M9V;-->>::\W?RDBN
M?UZO =3W-74T 3P\/. U[@5<PZFQ&E!G!P#0TP-N P!  A#B*0#X.(D&U[@?
MZPP0XF0\G&S^/O>O=X + *BG=]D 8EP?!:ZMC&. ;?<?G_V;_J:_Z6_ZF_ZF
MO^G_4#)RMO7S]'&VYGSL9Q]@[>.'Z[KQFN ?F((.AQT^OR;\E]R9EOH/F4!*
M%@#2TOY#_@]\09+WUYA_XXN_Z6_ZF_ZFO^EO^C^;).Y(B,O?D9 7E^,4EY:7
MO"LO*?4_[<,A$< 9L 7\ $_ !R=9 YS 8US+'@C R3[ 7\#D&D[.[>3GYR4O
M)N;A*VIMYVEC+VKKZ2X&M?82$Q>](P8H0J!>UK:N]GZ<-O:.SAY*_+_;NO@Y
MG>V4^(VE].[H>:G;.SEK!_G8/P[2?V(;Y&HK9\</4:8D4X3*0]V]W.W]K#FA
M[FX>OO)0):Y_C"Z/D__J%N-25O2Q<Y!_=$_SWS1P+26N?YM+0$" :("DJ*>/
MHYBXG)R<V!T),0D)$9R&B&^@AY\U5,3#E_O?!KAG[VOKX^SEY^SIP?E7V]K&
MT]]/B<O?W]E.WL':0<K&SDY*Q,9:TDY$7-S.6L3:3E)<Q$Y2TDY&2EQ6PD'<
MANO?S-O9_LNZE[^/VS]LV]F*V;O9N]M[^/GBHB$NQB7V7VL3%Z)_&?V?AA_G
M(TY'7MW'WMK/_AZ.E?]::)$[$B+B<D_^?:%%I63O*(K])SU%L?\TT?\/HJ6L
M:&<K;_O7G#Q]_FG^L;WW_]YJNSDK_V=X_4]/<0_^*>!,X/*/E)144>R_M?X_
MAD/LW](/)_TK67&?Y/Q_@?XV\K>1OXW\;>1O(W\;^=O(_[^,_ ?@M?? H=P
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M'+1:SBCV: H=,WPS]P)@C/"'P$!7;"8X#X"F!\#=*U;#-/6N)E!2TDI6V@.
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M%^#^)\+ UW# 3[@5>9%>NFQKX)B**WYX$69?JPAG*UOK_7 ;UXBO?*]<%/<
M,/LM><9<]G=?)XL 7541\TV[OF[!/!3H_5OUM1=F16$K@9+8C=??3W%\'17F
M&2NB$)'5<6@7YQK,$CPI-<]'/*W1 ,W454K2;KKBAOJ@E)K7PXX*K.,*O58\
M/>)N#8N :H5[K1Q=H!,W94_KEN#M4.YT &A7B:4IMTJCX-A!U<BE;%?333N[
M8WJEE5IPX)UUT%!?XI+A71E,W&\N+QBLQA_PG<QYW1*5- V1A4E2M*,J5K%.
M\K]A9-^8OZZW3HIV4??YG,9N(\8KWA]!K($.G5I5,"N+Q$I4$@?0''C<OZ9[
M-/E_APH> .NNIK?:-,^JS@W<"XI1_@)I5WP6/H:/F<>P_ $ I;NC3E;K'WL
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M\SZA:#]7OK38P.3'31[L:1)HQHGO?,9> _*; S*[='0C3,1ZXO%"8%7"*)9
M9"Z-E=!6U.#ZI7AR16J-B9(#WHI,H45F_M._M#F"ZO@BV_.K%\^"3G JWX(Z
MJ$LHU-;M#![I6;]@(3+YN-],P?3B/5+26D)XT.++>[,O3=<2Z64.]S./;!-
M=MD$6@YMXQOE!75 %+@<K;]W)(=D96(G%"])VY*Z;/60R]V&X'W]EA:\QE2
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M_3-(:4(R(PL7U5E*UQ_13@4YN/:/R$OI7_VW/Z\8/H0?&JD=G?S$[8E%X'$
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M&'I7WS_J*=FO5=*\2RN01(.1)S6EYH6Z0>\_+&?$_N+K?(=:+2SQ46Q%AH;
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MBA1Y(ME'%8?A(QWX:7=I/-+VNG,U?"A@!ZD-JK">#Q _6H/)Q[B@9 ZZG?O
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M6L:12:\_47!%;F0KE@"P"6M7'J#E1H7U0;_,'TN\M>EDCJ4*GS^54Q9Z$\]
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MK]M%9P87P"K5ZM,M-$<@(Q;PXSP-"_B8B 7$,2-24%Z84)@9YIXB1NB$D2)
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MO)YAAIUS+&_OG9[M0,N'@*)E:0],Q(;2+":+<Z.WQ+O^AWE"JX'<_O+,#]I
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M4G:8YJ)=BYX6DXX"^!!P"7R8!R&59]Q==VW^ &8BP$]W\DR)>GW$9!%7&:&
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MZTE]H063+7B4M+N=XU(V6QJO++828.=,M@0;*459PINCY4-5:Y4-&<CH>;U
M%CF,O9ZI)[/+WMU]7F8VC4V0]<9P8:^F^PXK8<R"T??Q0W!HMX32!"=;K78I
M-D <T%-K\C*4ANI/1+GO1G@;=&*$+_EA0&1_*OYG98MX?E^W:(WP[&,M]ZJ+
M?"Q@PM&H@Z?N6QO'G>VR0BS ?':L1;ZFS3[<T"QN=+C4;\5UJ3J0V<1XSOM$
MK:DM2\);*]N]IDG7;/'G>A:^D)=3QF6B)=U$34._;Q"<,TT#B8_F/-]T9.2Q
MM)$<^-SD$OBBU6=G5.,5X;H#%K >L\M\3J5Q@V-O(5/?@&B,<A)J/2*WU3;
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MA*CA6GE7_SX)8PE+^NXF7J+_PMY; ,799&W#@R=H<)<@P=T=0O#@P2U88)@
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M-"J*F9<W/#+I(RK6<\>G$7ZC$L/CK^ /DENI"<KIRO+24:FN"!GY=M@E%#N
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M2O5OB5H^M&R>J]X!6BK!".*MD2(TU&0)^Q,VE2P@C;>\#^TU*Q@?/'3PZ0X
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M (#!\TK&LTP6H1&ITYJ&-MG9C NO,L*/6Y<9.<61WNMZZ (Q8YEZ&5.'(?E
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MOW 3?RNB"?HAH>IVUHP_7EH291W>#61@\XDE9R#^5.I%@?>(\K,@-4C/@>U
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M->)_X>2S/1LPKGL"$'ELCO] O%0/54"867&<3YCPYTY?O.K%$E KV,*@S_P
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MH6=9Z^%[9,O3-58_>WI4XZ/6AVZL[3T"B#9@[3-7;S/LPJEZ07;Z'Z5=':C
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MW=&>F-(]OOK26HMG0V8@+HIG'Y/C. V^]5X%.Z ?M)J)D&\R_G&;T[SP .M
MIO*3AJ=WAG_I13UE26;W\^%@#_@5HDK12\\E.I.]E<)?!%7,Q$;T=M'!.2;W
M:BZ3-M\=XPP,%V64?NE9;G@EN@(CF1^3I-;,RS% &,)Z_)Y-T$)1U]J!"[JS
M>KH''NLQ+XF<$WZ2?I"GOP<DM#$W&&#1*"QW3A/NSLB[%^4UX-;#5(H9&V6@
M & BM"<>6'-;RCP]THPM6[:F%??%[F++*T$Q--8E,E=?2T9=.D*U*[:KE+\>
MST_N*R<'9?RP#^6O3;$(-3F:VK5*7J)2IPD>K+P_->:OHV;ZZQ!?2/"YU(=
M[MN*\SO^Q]NZ9"ZI==761!;.7UM'-^= CJFMZ_N-7M_D><E!5[SGP&=) &/8
MN=0'^T=KN*C CYVKFY+=U=7G>G,Z5F#SZ*E5RQAGAL\+03UDN-$Y0F70".!D
MMSSXQ<*VUR"H6)0R>N/GU5)FH31 9'7"\QUXN"QX^<+9O[TRP-]RZLG/:7$N
M#[4.'2*W47:+2?OU&)ZP<;F6M]KZZ?7BH'O]@H8M+4'__M7X/B=P*92"3!$:
ML &?*FBQ&%AT$UP^HRRXJ;Q-'9_IIWN=HNYM^9S90Q6G@HE5-4W_._5G(ISA
M]809F9;7PS3^JFV>$K)1R0C_G$+39,L+)F4*B5?JSQC'#ZPH[52=# CXLAO0
M )65VS-8^+YQTHA"@"W4N('E?GSDY[N6O2R,IV<;%9RG\WK>;O$TUCW[/=S$
MSP1-T(!O3\Y9-H\2,U%0)*@R4]JKP?(\\%AD:\^E2)28_?A"_*VYZO&'=30P
M?=F(:!,/*G7JQZ.D\[<]T_/6\SPX8ZN+9FH(8#[.?M>N3;(@MQN3^"#;[%=D
MS-Z:9;EB;&>*V7EI/HAG]DW2A!61-1FIX\/*IK@H0F K-U'P7!P2;;&.R.SP
M.JWCUU19M&KGM%V'U,J]R LS%0$67@@.RXEM7[]I'P.5G]7WC$F39/G_V[\X
MNQ*8K1M":, .#5RK-9LWI:ZX(WLE]I?1@+56R<PW(T34A4-FN]&,2CD[(GUE
MT;M+G+FN<6Q/?.R.3LE;E(M5"/XFN3EV%LF.BZ9#:E #7Y&21BR;N.<?9(XP
M@C^Y'"7^0C)I_!<VQE T$%F>55B*@HCWK5]%BQ]>7=*)WL['<GCHGTR1="C.
M6(0&ZL5?J!X[T4#WS.BDZEG1^:LS2M_E/S@L_YGHG%WUO: =WNO6/R@L_Z")
M[*'[DR7R*_@O])6=?Q(]$J !,B,I5=GI@EGL2:L+\$S?Y2:*!!PE\2='Y*WZ
M/^DK_PJJ)20[ME2YBJ!PX@ -E,>=C/Q!$DD._I,CTOC?Z"O_"LOWH32=;J8I
MG6K!(AHP8MC,_'N;QOX!UQ5EA/BM0\1SE!O_(+"4^'NC<OX>F.LI'[&OM>]G
M7YE,]S\(+,%_9Y3L/P#;W;)FO9J\IO\_V-=S2$ZXMR"VPH/[[2;.I-BM#PT[
M5Y:Q9A&*2L>PKIFJ@//(**?>ZYPQ:1<73>?29\4O=;6M7=)'5:5)PL?_*Y@_
MG(R(Q.FUD4)'15/EQMY%>9^E0-:A6%8X+!1[P-V$&SF2GAW#%XC6[P@GY<?6
M2U1':RDVCV[3-N5 JZ0#\JOT0?FW ?&.F7GFJ G" :S,53%CF'OEQ-G;A42*
M.?QQ'HD5/ EJ]]L\'8H=X0*2^'35\^/B_%C7P&H\KSK7/WP6]H3$5YY1!8LN
M3%QP*T6KXYJ 7%N:!K;\F7["K%&;^2.53?K7]- R#!HQD 2TKOO^7@O1*Z@$
M!D@STQ+49YRD:!&Q)EV/RVO[N4W@W6PYYY2H(#O8E$;\0FT"2I9_/5R;)!>:
M2JPF/QO6AT=,*QREI0<O5QBO*9]=5C(@[1C^)72PS_1%]W5<.'6'GTD-7CQW
M_W<"T(2/8JZ1OFQ!=XFV4E%8D*(5S2^*Y*BT[T)TB=I3KOL,KX*99OCT:/@%
M!&6;ZN6DZ"2UHV8"?>2/6B)7#@E]N!J.>M*QOCG,13GV<S3L>\ILM5SN;"8,
MF*[$:?#-*]EW+=>,A+'3UQXM98GE93/EE8>/RP9\G*405^/2''C<)Z8]BCVZ
M7[HMGY.N<R;"-_'Z4"!D]>X3YZC#X06+%BL.OGT&E180VT/-7QO['Q_S$BXP
M]#$(=B9BB[R3%1,B.;GI#3HSPD(^1$2"?E@+\\)'1)UZS7+?'<N:;DBS?W5X
M<*0.K*W@I1R*XR#%C\Z#5VGHNLY)QV\W(VO=CS?Y&_*+=>'\]53.-7B%/5B^
M0X ^HAUV8]]6ZT6'9$BZ\ID1SKN859X?FR5C"#I^P9!P>%H*QA/H<IW2:;+S
M><X[ADN]+6%Y(K5F(FXQ4$<QXI?8YC=>X9L_T7[D626UL8LAVI<*RI>D4/\=
MT].X3]!.=Q0^9^UTNZ:5H6+V^Z3=;B#AT#E2T3M.09;M8EN8.DU6JZ:0VGHP
MT=;NO5DV^V>M8>Q=U(2A;E38,2+3>4/[I8D)2X;ZG?8@R@//]<_/6<_8/>ZT
MZ!\1?.)]*'MN"I>!@//F%ZP=(C.?'T@O,AKJLK&^]CMD3(BR8!$J\(@_UUL.
M!#^P.0.%HOH;FH\/9Q=^?)'G+S3?NV.'K)[S%Q/H 3\Z6$4DK+!QW0<E)0N+
M5[K #7V_=@N_Q:3O.;I_UT[")>+4$ZGZ7?>F>E]X(Y7@-X7FX6!CM-^@GLB;
M;Q)/! 6'7T8<V=-L^9&.MEH: 9VKWGIL0DL;+SUMS>_\0.ZN5TJO$ DX3ZY0
MIG8T<(7R+<]I]9(NL=35-,WY#(#T!GE$ $S^SD["W*L5(DO,Y3U77#&U7R)#
M/ >X U98:MZ>;\)@LP'T4[CV9!YV%^K"MIEAO(V1*W+\E88]XVMNO_'!"I=@
MI>:F\18RI&Y0Q\G;!G;=7&X=T3>)CWB'8X,.R:,>;TF[T!$V\:T,<9W;CY[9
MDHYW/-3(J?$&_;Y3<J(@R6/6.]AE%HZ=15,I2=M9M@B"(S5&2_=\-'*TMXDD
M>S9E?YI>&\P_1 .\'\J@W'59Y'/*8FQ^X%LTTU3A=CZO\J1H2GJ65M>:H]_P
MQ%16LJS;FPQY3$.8%EIK6#HN^3@ZX*<.,U0A!%]-DMW U%-&P2V/1GTTX.K0
M9"2CKD%+-@?$BNC>3R4H-^,,U:^@-I-*/[L<ZD>2M! 8.(S2*,B'0""L:SIY
MH()*3GJN8/X^PR<[YW86?P\2B: FYUR/WDY"Z^GD)$LT8!$#&K \&->L8G]9
M^YJ[YL@K8'1FN.5Q((?BN11<9+F=9&)[+N$F.B^*NZ[//_Y3;/)A'<-U3S-I
M9SNE8?TU[^SVW/LYNR#/XNWS$-!B).'/1+GG554KM>^TTM(2VK<DQ2P4X*3A
M935!;Z;9^1@(B'!%<I,M9JP$2RF/EH.3'3W 4 OD4V$T$'2:SM#E=J7S?K(F
M\(Y^9Z+)!BN*H8:F-RVH#:OYUW^8EU'<\Q\.!LJJH:'(+]'JJ-]H8.M+V;MF
M+_"=4W&O.CC33D<$:S'/GR\>E(L:F=!U[=[(8%]K1A?>"UQ7J"!ZHZH1,_[R
M\RN&F*6SCC%UUB*[/[@9IQ"M79H7XGSUD[RR(1N+63%,WI'2<7HXWY%5S]K[
M>APSFJ--^LM&G$A%!D!DH5[5N?PO7@]B# MD8U&<\WV3?O",#5^#<=YW1$Z<
M92(T1KV+VR,@0?D1X#)&G"T9(#%Y;WX=YGXMZ9P!B62^30TS'J,&?OZ,E$^9
M/E>,-'XJTF7R.5Z=-3>0H)9;/YKD>8ITP[B%+W94S8"M4\\@[_@VZ9SS=KR^
MS=Q(ZZ$"61D/!G 2L-MMV@LV_NX!TJRLG$Q0:9AZ\(82)YV(_,M:$N?W)!L8
M0/WA9+S>B_7<ZOY4PJTW:KC_S9=B%G^7-R;XX*.!KYLWC6A@7^$LY80-#3S*
M.'B,8+O:(5';N=X;_W1\8>:<_KO8->$'&NB]C9X_);Z59"=XI2K5E(5+0-#
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M4>^=%$WI2 IL0#TM^ON^A,<9=BESZ,H-;J=7?FGA5JV$>>.T^<EA[HD!<G.
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M^PI"3$)";9O8V'/9DR@FJUIAR'2Z<=ZN\,(TB^WL> ERK<[& L1-;_';=$;
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M1-CD:K_"A5]Z/2>>Y>G(TVYA3+4/"A63<7  ^EFP"YH]4!#H$":,):9T_\S
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M!&PM,<2)[OB.8,#9HAY*HK9YJN5E]\KJ:G^3;,ZVERCXXYA,&>^I';%G8XQ
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M1%5B?F8]3SCH_#V!TOAO[+U55-S?EBY:!()[<"=HD.#ND" AA$!P=RC<*9Q
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M,/D:[9JQI39:TS"/D]ZUP@$Z]_4$[ 8[5L;9==;1_63Q?7RIEM[X\\6-6MS
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MMC"$75?-9.!M9<2]%&S%@0)BT]\-E<]OKYE\6<9A12O]08Z5D+M6N/+/[X/
M>X1HU^<6C-1P_Y$?%K@H;S3%5_Y"2597-?S3V6O6<U-1%+J@($G*!\)MX9B(
MRT$:>.&$H9TP$@O$X?CS#1($3:+UW&?I?N&^A'[V7CD' N+0GG:;*O:W7]59
M,)C'T,K[*@H?PL'#V'Z1CWGLCL(4O ; 42Y[P-&; BOD]?VR:J0&UJ9DJ.I'
MIC!OD8< 8+_E/LT,0JRI:$\=PN\5B)(K^&. .4OL&74JD#[FIK1A38LTKZ0W
M21CUZ!26VV.R/ACG$NM*NX_NJSPCK:NUA7YS_$Y'DE1!VM>IVQG&Y4"(TO)
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M>WBDCD'J#N*(YR^> #6_?&.LGTLDD%""TTYFQDN ;NKC*.0,,@D]1JVP'\8
M&4A6<JDT-[S9JA(2W&5NZJBM:VH,W-]'M6AQ3CH=HM%("1A"QV&31%ISKZ#K
M-SS3;*?PG_.5>S8%6?) Q]EG/ZKGTE#5_X'1"W!27"DP^=9''1I##&KO\U%D
M3#8N,&0CLIB=)/[)%4R.:2:K&B34+X#O!T-$R85[0UG'"$"OQU1GZ*)%EL\6
MEU#;-Q0(HLBY;U]\$3Q*!:R$/(Y"K[9'5X[1[.W<'W*1GIVTR=R#><M9B/1
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MC[R>?.5OZA4/BO.TZ8-QLQ=P8[FW4DZ3-+JOQF@0)W<KQ?3]]2;<*E^!W)\
M*G;O#R\<CNPD/B>1S'XN^B,=CZ0N2SM%$TSA-F(<@POO48(KYL-O[PSO]$JQ
MROMF?S;$%H!AXC/V[B?XZ]>;G/H]"$Z25&UJ?!DNRN-L\2>:37>B^$H4Z'>D
M-<==:L92HO'(7AK("176 A)$/N_SE)U:E6NJ:E-1W9GGC\V6/! 2,O)*CO2P
M&RNLA:^[;^SY;&+J%'$B52'\\Z4-@B?2N??9KHB5ACJ J]^5'OZ6QIN^+<<8
M#G4?JV1VY%^-Q+7OO_6J[NJD2-WT<2B.$ARU]Z-9!)G(-EI4-TJ8R] %^%F>
M]Y B'SJF"0YNKD6S]D*BG@"18"S8E$':Y\QN[P?[GC_A$Z_/)C56[V96(IU1
M!9$2NS;) )=IE;C ) .:JHFW]N[6PH$*#'7BNM1<IH#F)61DA&.Y>J#F*]]?
MUBW*O5FHNXAJJ?N39Z.7QQ!0[JJ(+!US;RXSR9+?[F?O\*%)-PY">&T7L0%G
MU=RBD@?/2!'PNPW&XL]<=]1:(ADZ8K1S M?^8P!=+,['7[?!.U=^*6X@HZ0U
MW>ZS&TZ 68(5DW6@Y% _LOQ.FV?]6*3;":YU!W:"3+O^Z]7>66)-XL[.^)J7
MX4Q4!NL]+_X0I%<*F=O:B:Q@S?+)GL:$^_"5&K87\KK7)ZV<66THZ#-%I=F$
MS:@E,GNB<V,!7"'BY<"*W22=AM1'\X)#-%$V630-4E+*&-'H_J:L*.HS1AW_
M>2F)"[U$CJZ>33CCP4=5GW)6S?::T 5\=Q:4*JRO%\7MO/Z#*< G@#'2$V#"
M6:/./RR2B[H[;M=5Y;V9_7^#8XZ_">HBS@$K7PVKY%5<%E -[#Z0 PNHI$7(
M.,:_(F><S'TGT9=9+Z,-DRV"=APVB>J7 N<:B 2ZSW1%[-AS%<N+I>E.4C\6
M6PQ1!'4.>!U996-3Z\#5L_7Y,]S66[$$>EJ2,GP)-S63='RL=8UO\HQ:%320
M GDTC\!8MBTQ$18=37?JC=]_HY7?E[>KHKY[[V%V/$@ZBLQ:DAL@>BX/_YQJ
MV.VKW#52)C8R6QB/D:$ACV9I0:[VXZWR[Z^:Y*WN>SH"6=B\#X9]_,)98>TC
MI=K 6\OY\KJ#4C[0I'0G>,")IAK]%[(@Y8B[VF<42IP>7]8/IZ-I4 Y,&<N<
M"&_/\DIVML,X_#.!KL_NB1#U'Q1K.P5 >&GW 53>UCSPM(R/G7M37VOY%\K9
M)J $LX@\+@A7DXZNZ;F3]4B"^*8W>ESCZ2Q*%VRE6J*&Y96P@1 /5.:MW<DJ
M,I-O]8_:CM)3WC@YL R1&\4Z_I87I(DIYD7X7@C2@8%2?*2@2I\H%3\'+I>7
M$T'&%Z4<R G?2O.T$IODL>EF Q!&+6":P4^ =1P8V$MB47RAQG/['%S)(6Y6
MSLB5,.4N?!Z^4 =NF&:#ME8UA>]#S'$(QIM<W<10C;NH/Z0&"&61PC4.>E?G
M)_=N(_F)A65S&T_KK@I=G8L/ZHI=!6_.TZ]^D:T&NCD0Z<XOP"NUIRK*V"LW
M6E-GIQ1!&GN?*=[=[22P: 6"=DCZW.L^HV!!<;X]4G74U_MC/ZLWU$V1==#^
MJ/+P8K>'578!(GW$EF^&E^XJ]JL')*-7<]K0"*5$T9LZ>@(TT#4HV)VX-C8M
M;)8RLPR+^GI0;'IIFJJ?.!Q>#']Q*5[N @+,O["=H4X3T3 /;=#'HI3P(G0+
M=.L"ZW25N,_5;)K,9OT;ZK.$E^6G=^@8/@1]BZSZTHC5_75,I_Y_3Z32*GW9
MH7K^J:2SI55Z:8MZ_,K4ZH2 +9[8Y@W!/NULS(Y7NQVP>)"R^H3?Q)7#$8:"
M'?@H[;YM7]-]*7)#C)LUI0'N6<R7^;W 1IS.3DYVPCP$9&RCE/P*K,7UO0!;
M?4)9$#5_W8.()F%919*"8:=G6:H2+.]:[D4N(H'/?S#!F,G0)+-U8R;'\1.@
MAXU(9\I$,J+X!$"_U=67Z![)WQ^V*X7;#]F:@..GAPA[#73RRN)0O@15<?9L
MR>_;-/RZ\KCR^J;,F.7V<MII<$)$BL:QH@@S/_H;%>J1),5HR=J1HD'M1']]
MQ0#?;%JYS*_DD('AJ&^>+PB4-HN%1K<MA9@: %NB3FM[HAQKU.3B4:)30+(R
M$Y7\ 02'Z@_'2+6R:@E;:\E65QM;@C3XK+-6V3A4L*663\$;E$1SZ]O-YE"$
M7X/#I3V6YF:EF.C!WXZOJFDC0V@E8S,6!Q'Y=L7Q856P^N@"VSE_6V)(XL@-
M(WN:Z,YR+:G0P,?K"\+Q9X5@&F+7BTC@Z,%UE4Z9&V#3A_M5OJ%NF[C-P]T)
M-VG2FU5(_1]*384 LYF5:X4):N/U$I@K/?DK5E5M^:Q\)4V!BAZ2[;HTKO;H
M.4B<_:@TVRTMS(@!C7!S42_ER'+[>RGVS4>6&-MD[D6 D2E.DOSG3N[-+<U(
M9HR$J %-#9CF56',>@3.$0[KW8O'R7/_A-:Q,X*HIB7^XS$#IUV;7[D!0FCW
MI,6+H CU:1^ARK<IV/75E3G>$D))[_4S;=G;WMFKX8 KN!$&/CO R;M+U[)0
M=*SP5L3V(> _M2UV%O@?SIRY/<E/T\\C3],UI=X#').S<-R0VT]I)^MW;0_O
MY1<KWZ6"DM9QDK?B*-J-$!P%,:,BTTWYK,<ZJ<V:8:(=$-WG^'Y5$S]%)2L^
MT_(RU&/EAJM1\*9E8Z65C!DQQ#!$8VQ]V4:Q>;J H_C ^4#C^G,OWN$V$.E[
M(T,0(5TE*>F:^IT_NK5'ZF/6K^<8;IQ.4URZTKAR9YSE2_R1]V$]/[;5CAZ3
M$)%^+1UOYMD:H?<T'\29J8DJLM^QDUA,W6=B#49V,ZZV5OY8Y(KI3^XR0#)$
M6;5N1/E\YP2.96_B]+287=9?H!W=: 7&-6^(.NF[_35551Q]%BQD<2L7*JJ
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M=!AG@9RH,[#5T,*)@ND3/O+YDWIVC4T]?25,9))'K4E>->D_DNA!I?@*3&*
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M@WP)I3WK#V_%Y <GR:=K(C_JUR:M1BT("0GM\"+L4+\"DZ]_<<B':TK#^B.
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MN7!15SX)(J#.0V%"SM+Q)._)(?F"Z,W<H\'F&SP#;NFWSD),R WM=$W3;C&
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MF%O7+&F2':PYRI%UI+[AMY=QJYK*T9+M&P#VI52I+0WA!_;!0@?^=Z2=KXI
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M6UW-*Y=+VN58#4T4%0H:^;(B=7!A;%=OR.'-OI,%\WNH2JQO90T=EG\A3 (
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MJ^W2_D]/OHQ.3XJI6"^*^,*A=7!5')=U@QZ'G'2,(6O-IVE*Z0<-'_%E:-M
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M/A97?=A[JZ?L1I_]?ZL9XO^SA7TS\]\ 4$L#!!0    ( +9#65*E:F;P@I@
M &W\   4    =G)N82TR,#(P,3(S,5]G-"YJ<&?L>P=85%^RYR5)%%1R!@%!
MR3E(5,D"DI. Y)Q3$YL@.8. DJ.())&<0;)(3DINFBRAR4WJWO[/S)LW_YFW
MLS-OW^SN]];JK[Y[[KWGGJHZI^J<7YU[&_D=N0+<49)3E /0T-" 1-0/0$+N
M(&1!ME8 H*("/ (   ? 1'L,H*-*=U$G2A&V ":JC(8JO\S*_NT(W > .U,[
M-  VZAH!ZEP2Q0#-SA^>_46_Z!?]HE_TBW[1_Z>D8VONX>QF:\J@Z6'I;>KF
M@;J$E8CQ!TQ!@L(.'Q,Q_UQN3T[Z0QF#CQ< DI/_O?SO^ (GY[<V?^&+7_2+
M?M$O^D6_Z/]OXN/AXQ7CX1/C$V#@$17C$Q+C%?X/KZ&0"& +F ,>@#/@ABJ9
M @R )NK,$O!&E=V WX )$H+/9./AX2+&S>WDSF5JX6QFR67N[,@-,G7AYN7B
MX0;$I4 NIN;VEAX,9I;6MDX2K <M':P,MA82K+J"*CPJ+D\M;6P5?-TL-7U5
MM<Q][<U%+5BE)&_CB8/$0(XNCI8>I@P@1P<G=S&0Q/T_M"Z&*O]VF?N^I+B;
MA968QC.Y/]5 G4G<_Y,NWM[>7-[\7,YNUMR\HJ*BW#Q\W'Q\G*@:G.X^3AZF
M($XG=Z8_-?#,TMW<S=;%P];9B>&W<U,S9T\/B?N>GK868E:F5H)F%A:"G&:F
M_!:<O+P6IIRF%OR\G!;\_!;"@KPB?%:\9O?_)-["_,_273S='/X@V\*<V]+!
MTM'2R<,=U1N\W/>Y_VMEHKKHST+_P^Y'V8BJ(_;4S=+4P_(9BB5_&VA.'CY.
M/@&M?QMH+CY> 7'NOZHGSOU7BOY?Z"U)<0MS,?/?=')V^Z-X34O7_[W1=K"5
M_&MX_4=+43?^6$")0/D?+BZN./=?2O_;[N#^D_NA2G]V5M23#/\'Z)>07T)^
M"?DEY)>07T)^"?E_2\B_ UY+)Q3*]4;!6>0\\!3 QL*ZA86)?0OK%@XV-@[>
M77P4QL C);I#<)>"E(J2@I2"G)J.E9&:EH66G.(^UWT6MH?L'.Q4#-S\W(_X
M6!^Q/_JM$31L'!P\7#P2?'R21S04-(_^:4)V G=QT#DQ:S#0[@/H=]$P[J(A
M>P!Z $##0OL#_5N.@(:.@8EU"QL'%P\?5:'N#H".AH&!CHF!A86)B;H;@+H/
M8-[%NL?(*W.+6-T4^[XK"5]P4CX.TY/J+E*-<1@SOYE;""X>&3D%)17+ U:V
MAX\$!(6$143%GCZ3E9-74%32U-+6T=73-S"WL+2RMK&U<_?P]/(&^?B&O@X+
MCXB,BDY.>9.:EO[V749!85'Q^Y(/I1\_U]36U3<T-C5_Z>[I[>L?&/PZ,3DU
M/3/[_<<<9!6ZMKZQN;6]<WAT?')Z=@Z_N/S-+C0  ^W?Z#^TZR[*+G1,3 Q,
M[-_L0D/W_JW"74PL1MY;]V34L4U=B>_S!>.0/$G*K^["9>+7@)&:N8WCD3$+
M0%@.?S/M#Y;]8X:%_*<L^[-A_V[7'$" @88:/(R[@!1P*1?-EH?^B_\3O%8G
M%4U'-'XJ>G(CKWOD5+%L47V39C47F(\C%::-!,)Z5]0N"9' 6A82N)8%O$YT
MO,*JMG-8)N7R"U[>O)]JDF%-&QS8X>FD&O^+1H]OFT"]LHOA(RIW;-U5,,GI
MK7-VE=!TL.U->0>P%SRJ%-K;&R8]+@Z<+>\:SO=9)(W"/E *H$F00G6E:@4_
M+E/LBC\6[*'^]%G1X^Y;ZZM\ZJ-A/QJ'O7L"4=5?0X:R]B3?'4@3%D2S 7_D
M8O?R;2]==F>?4@/#;SV/>CEVRA7[;N&.BM)G T9_K'*,=MBAXDS-%4'WCM^@
M;J#^RCGSVK!^<VC^W/T@RVM/FBY7EN0%VM^P3WITH. V@NI0*T-LV]V8I06S
ML5'_B8.$@G;78NQEO/T$-,DJBCEVG?;IP_X7-FA3ZK( R1_8V!*J%AL%(;JW
ML+7YS+XA6/UUKMUW:K?P[4_0JC; UY%T%#3?>]:."_MIE^[2UF6+R?LD@GHA
M1'K4-(Q5<EH9<IZP<KB?[2GNI68I6![,'#FX0<##?.<[Y9:?5QYA\_]UI_G7
M,=&[5GWK6X6'-[M53,><^YZ&(,OG24T4>4Q,25U[QAW<7;D8"F]5: M$KP:]
MA< Z@JO+=YB:,J&RUSK$%%PYERSA+WJ?.SUQ=(B7(R24%_R^X,\++X!]2NE=
M=9T=$BL>'-UHS"/2K/TTCJ"'JT)W7PS1Y5I5N=X/L7#P-!\U0=2YGYE0B3/Z
M.'H_7E@P**Y<8HV\];8>)*NAV">Z'1N]+<BN2X?>4MOZ.,LV@:1$=/ H4CRG
M;@6,=2U:#$KH35?_J1/C35I7FLKDYK6_4)BT' (20-M.0P)TXDR"8^$*IVQW
MLGPFI%NP.[[V=BB=Z#ES5G)H'.%"_:P3ONFGAD\TCNQ>FK4Z0\&A'D;\W5X9
M]4DEAGK/&YY08M6:"7I:F@_06)#2OZO@QM>W\YW=79K1,1'\]DDU$?!)>E:1
M>BUM>?T!0UX#O@FAE=Q;B=F;[2(DJ/]4^O2$8RBWPADNO'HK"9I0!S;O]::L
MP[,DOQO6MPM-5$ 07^B&7DL=DH>W"KI[6D.E"%F@XF^/-QKT#0A<M/J@\7[Q
M 7%^RZ'W89D_1C^ 'G+JX!>T>_\XZN +#7IQ,WE,QR,VAIWQK>/V*5%TMV=]
MU8-2H?SU0<<ZV8[<#JRW])D';BZN>[J!?-?2GXSXM6#^O(L5"--C9IQV=<WZ
MY]9>ON9U;CRR:X@)%M"FGM6*;S*XPI>UKXW^N0FZB9U]B<%MF>+7U-7H%T5.
M& =0B5MB)WF$3!!P3RX1_'%W5<GB=^,AL*N;47$XV]=/#%A8,1C!":I\]HN>
MV?:J,,2[!_GE1BP5M?[D@9N? #>U3U5"<&[('OD+&(%N^J5LV/3$HF+41KV\
M:PCO\=T<]BCX<J5*J;\TE7@-1?G)29QTUR/**7Y1C"H";(@T71!J%*^9&^CT
M0K4\1L3'T1TOCRYNV%O'ZF[X>YH-[*@$)Q;FJ[L8[FB=ZV GV@\N:\)YR<-'
MWH93JJ77[+&;<L\)FU.?O\$6W:3LK[- C#9,RJ\.:ZKI/E@RY.>EC6'Z&)I0
MF &<4*O%+A$W3]-]571R?&ZWOM$4R6Q?ZR:V*1&$D:)E"3^%4.RW%L5HI/(C
MFCAGG7>Z.I2.LJ6>54^UBZH5+C^S_.QHL"J<X&KTM7R-(-:7,/6GU-UK#,@
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MC&'CPRA28#O/SSI2Z,^_ZMX^[.\6S@#'1$3=?SUD#6(B7/=^I!1-;D_TA"3
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M[@&44.;8LRT;C.J"QES 7Q_6W^.50XMG&.FT8G1D8-1W[\6[/DB(#"53OLC
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M@8L8R\$_]([D/+%7__!]T4@D'B, [Y'29D%(Y7?6>M<45*_&D6X:BZ'R?F[
M7NJ'6&E;2X>V3AH^1>HWF7"YU6]Y]WA<LU82#.8C5M7"+>%^]'$6;?8!9+)F
MGU4H=9E%G^3[IBT4O;(^V@@2^\@^)"YX]11.W[/$$*,05K5KE2-#<\^XLY2F
M7!7 TJ_.F0_:89_: @I:L5>Q0Q",MLUT-:MMRJO9O4FUQ]8A7Z:7*-[)L# 1
ME.=54P .HN)^L^XP_EZJT9AV\KD=R?N)PQXU@W@+?"O?HN4HH+%'<N ?>42R
M?XDU/F8T7 <[@W\NJ=U@3C>7EH$'R,X1;<M(0$8 S>E?\6'%1]O<PRTD<'HH
MC(BS:_@=!@$,_TVKJB1):A"Y]F%_7*OYK935^0-"EK;Q8\0 S4VQ@>*MF?G[
M)UT_<^I.%]T1M##N"''6#W;"2_23LMDC[Z_V%U28+B*83ZP8?<P[.S>"1!ZC
M%M\YJ6Z38$G.ZO$Y_8VFR?=^F:61R^R8#"XB>'PN$J,/"N#<[S%O,N^G*S3H
MG5(/^<W>NW]]P).L]33W!7KP297.M$>+A+-"\Z2@B/_5X\8,RM4%75^>+DK,
MN_TN=D1$</!S6'V8<Z&-4(?%I_K%]:<;_'L+O0D<BE+\Q(,'TO3,U_Q3@A]:
MB3[:&EA'M9(6&2PJWC>:MQ\Q;WQ#@M%\9R@^B#@TAWVR%1OB3&/H3_FI!NZZ
M>D.B=E,LGFP49AVV>M5",H@K2EAT,T8(DFR/*+^F@H.K=A(^[ 12-?B5TK2T
M:@SB>+$R?RX$%"4&-IHKF.0F:V]S<0K+?@[_.G+'OY'1Z&.3J%04JV@>46X[
M)URS_P FI]_J_M'@I^YE8'FZX:XYFL;WOA=K.)/,CZU%1#"/M[=RL. M*RT'
MP';*$CQ"9;+2<8\I>G5F V+FX?F" HN9C)+F;@[[!'/<@ZC"5%*HYZ.!;L;@
M'9Q]]I#<%>MNOYAC']:PBM=%FP[N2DE(8+G.I2.<#6-4DL-N1NR@E^AUQOL4
MD<;/S5-,R91/DMI4>L17@N2ANA7@M1-N\"Z)U(F2[@?C:PE89;YGP<N7VW<O
M,C#8;4-$Z03K&<H('GW"?J,Y(/'H"XA?6HVR(X:LFVHA\8+3<U/J81!OC==2
MD#L*/<9?HW^J;82G'S[:\;,IRJ&5EJ>)#_K,/N3:BO&=MBSWI2X_K.V9Y!WX
M#^<[/PAT-%['@;3IC+ZO>*T0?6V/@"&!D!,B?#NJXOW0DIMDJ,X;%5^$1\)&
M(X=,-R_^4 ,&1D;9^VM1V/LDYTJ9$EMV F,&'2/%9T?TXCPN\AQ>2* <W!)?
MBW8LV40ZB1C(H0)A4##-%//O;4G:AJ3LI5PDF<AL(83@GC[V^8:VY)?:PYTQ
M")9ZE[!D&YS(9/3@M_%CW=EM_;[+D_ZDD$6F+];=0@8OG\HQ!M>\R]!^]4UO
MK8GYR'TV>@BEYA<3#)"AGI'N$]BUT.R HF*&/C.; L,>80\W9CRO-+W$(/3&
MNK<=XY!E*I --AOF,<&:@+C[O>(^L3'[@WV^XBBS>>]8_Q_BKCI[45+51DMJ
M*L_,YV\8[1=9X*(P1(#G:90_KXTS[7GUPBK?HOOZ_H]<^.V7)N&!=]6PI%ZG
M*_2%'_E4V)Z]\W'LJNGP0N31U:()=R=<L.20((%/G+F(2*7M1_79)7/;8D:5
MV26]:W/Z7Q)EZ%;G?]L_SDH)PC:V&_XS)M!"00(U)&!\B 2VU'1V"L #=N#+
M\P04)/!M^%V*1I/>:W+!',B&$O$2"5RB5:'#-6&!5R@(2 AI;#FL++8L&'3[
M^2 !KSHVU;EM:&_PY_GM )F/MFF^,RF>[^U<HG;W5VVL(ZN-MKHQ+>[(TZ5J
M=@=2C%\S%KQ/@<SS6IM3\Y<;FW=PN*EN,.>.!(DKGX7#-K(AW,%B9%$%/68U
MM=-0+0*WGK?6+%'[BLRY%3)7BK9>5. O8'QY<VNLYBZ/I&=,L5P]/-6/>+\G
M$D&,%U>KL&V,A28*)_W5S,]^*FP0%P7:]T?@?254#]X:7J:9%%=;22 "#2DU
M3/HKEN#/*]MB)LEOM/KIH>>M4]"]/LP CK@CZ22F.=M9MR5I)KA/3 A'YNP4
MN2,]%>XNNI7/8S0R<,D_G8ZJ-%^Y&5H('/<]F8NO<ZPDF[0Z/L77ZW%]B;9N
M$?;BED@_1I95VT$/JI?$6: L#:@T)$4V_+0B49XD<TE8F[Z[C4)(HB9:A1A2
M]5I<N/RVYM-QQL\M9'V3_DY7SY^MA137)RNL05EG@B3=FZ8@<,/B8<\5;@H;
M2598>[Y[LR/ZJ?I[QB!Z >L-B+0&:"^US.1.G8HF@HI<<0;2-.D1Q>4QP,5A
M.?OF)@<8IZ,($V&,68&&[[//[R'P_,7JIL,+B<(J),<J&K%]Z'A\D4 9A^9)
MQ0$QG+4[AZ\N?KEG3K;M4C:7,XL4=#QK7TK0U+GEAP<<@B,R+!'YAZ?B,A]!
M+5\RBJ_T!JQ#9=ZM'9.P22OB$)>^7*_IA$9?HN_L+_5-&);]6*UO",,?$ABY
MRZ0^R)( $&F^/ AKIX;+=VFV(BC'&3[GR+)-.OLPSZDJ+*PEBM!8USG995CF
MU!4MVF9D209DKZD0'#JQMU&\B@W!@3:BIM+L4RD2FWN!LW.2-71-[^O3:3/9
ME_$;O^$%#K-UI3R6&<2HTF#?^FG8XO=3H;*\)'ICR8*(9*S1(TF-(9SF3H"L
MS_(U_V8W_249^"AP$PG$ZP84;Z?Y<J78O[=-O"#S<N7@D6VL[U$/0B6!\6L;
MO\?%VHK@-7Y')/"2!0F,%:)PELD%P3QX%A=\PK:%OOB7&QJZ4^ U<D]431/4
M@BYHEK'U66X ZO:)(73A!?: "1:"RBY'"K91SNEO#L[_SO'S]G#JYQJ6,?:L
M3_?8MOL99DNO%6%"2;"K,\O96L?;%KS.#6GZ[U\9V][^QE!S!]@".G=1R];#
MWSR8;L3/!'_[2Q]UE/@/W9%DE>%8:ZZ>^,<>93D,,,2[U6P\J-QL1>"LJ7O#
M<,0WB\6Z4$*M$$E+[-"Y('&F/C&CL(9=]^):,A>Y9>N:7+<^M&/:6??-J7U1
MR5/"!FC9 1&<"1*84G*;:V+G2C6&:J04)U&O<NIYJ4,8M/0$O:WOO(N.;LJ?
MFCZ,6P#"%47BVI/6[A&*]YJ4NML)BI&U46:7B_+["I!3O\RT@)Z3QYX$IE=2
M3:.-%L!327C82;F9Y2Y-+VY#[MU@4L<:8:)QJ)T0S:6M5)]?TA-%?UD:J):(
M9<8_95WY6!L)$"L[KDB >W(>P1VA%50R[AY(8,Z8OF-^0P'R7>R1\+<5?EZ*
M^?XG?E=>2;#<+BK"XI(=*KG@VQ5+&7KS2BF*J1P\RI;M[O%\/WIEP#!KR%E)
MQ6"9"<AN27G0@F]@R2$ZOF<M.3@D*R5'%@!Q]]RX';QL@ENNXNR5>_B)EL_N
M'AKU!/8[/E+"L'R2N[@BYQIZ!(U>^%0S?:U\F/[%M[T)ZHQELC3_C4RD5CG"
MQU(6ZVMV-33/N57>X'S/_(O!K8Z"_B*[2]GBF=P[Z.Q>L5@Q&!A6O T8\;R]
MYB!GB%3P-4LI5WX>*!#?KV=D<$GQ@<5 UYR%U7P74X(!L%/ES'GR$S]F?EL'
MW]XFP[8X,#*:[UM $.;LMXS<: &4#QM+/INMNT(!(E;%-WR&2TO]F+-Q.Z1O
M:3X-C,IB3V7=\'_8/FNN3_<LL;OK,Y.>V$K<WUAYXOFHFPG3@G@RXQ@)P*U'
MPZ5..)# VLTH$J#)(_SYK'G"Z<3>&K;76SR2$7D_>+=(-_*1?XM6*5.L^3QI
MX.=K44@;ZQ<#&C&IB#W)05-<JWANWF6L*/.A>VK,YQ5* %M!])^Y%#PSBV@G
MOZ!JT.:^G$,"LU^0 )/.UN^VWJJ2KHE6*@S[.DA;'>T+X9^ON@-5UH;Y?T0\
M\.1OG/-J=CT=#G!]B0A=,2$$F>M/U1D1J9 U-!>FM[Q!H<[7U>8HA##(&L2&
M$4%/(. <GHMU;>E<K"@X/;V4X#&KZP[U"'OE#V"CR:G1W:BX+F%/[$I!$NI*
M$?W8F1(5:Y\'S*FSQ]\R$>\(Q?J:M0=->5P9&2HW3];AM/Y4'C#&A:)0IUBJ
M:5(('^[VL*4>B*E[SCJT"%:1EL4T;AFOL#0US&1IP?QI0:]!5 *^AUK_;1%"
MC;"(W4%(>&UU=4MCT]1F/*4GSK/JN23F")#F]<LLNA^"4:O#3S5;X24K-66@
M9:7#EX-@7$6!QD+M^EL6%\H,E",B(PK]#K,3/V'0+\HK:[#2<=, ,F&NM,\M
M[7W,R5UOT[ Y?$9\RH>X0Y:):I' YTRIV]W$<R\KIOAPU[F8-5-98M:#I+XH
MTDVA;>3>Y=CU<(XR&(WQOPM=Y)8_I&V]+_%4>>J=YN@7QKG,_N$F;1'@^/II
MP\-#^E[R):&;[)/;AE=\G))L=5%,+=$3G(FUF2^C@%U<J]&K9[,=H%#4LGRM
M65Y?40D/I,[<9&C]HL_$'00LW UR F@V&B+"!7@AH[M$NYE2NW$Y)M];4X^J
MLVZ6WHV*_LSQ'</^)OFP8<;?NLAFICD]09*NG.QS7K6*F"WF(7&8-DZUD_ID
M"+9,EEG[YTKRYW!VV+'"-/&+:MAP\T(?9+PX35];CR:$]/N'S;F6C\!%PRIK
M6#LQJ.FT@ZP?.EJS4\.8:)CYMGKC/A8>PR-FT3F182]P#3BJ+O>N_^-LP<0J
MLES/,WM%'998$IP2)Q+ :[.JS<-[&3.0ULX@Q<0(9+P\:K6PI#71]WI3O."3
MR40+I_#SZO':+0>!,@6'/0:CZBYT3&VZSD /-+O?Y55VRT>W6I% )1$2R,MH
MT!9TOL P!L]BHY8(E7]/K/XK^7<[QA73*OP("7I$^P,D,%XA3;;U%X'WC_*'
MW".J7$0;%*5R3L7T,R20.(5*% _H$:]/_WH#X1_@4N[K<,>.GZ]_M\T$X4:$
MT?ZGN@.]& D8FES"3=;L%K4ZKF8Z3F$= ]/-_[21C]Y7( $&^]'+%11^Q2WS
MU-1!V2FQ?./JO/Z?Z[6_QSTSUPIS<F66[^=MYL(KO'T()LN]5-!W%3($S?KT
M[WB^XT%CK2J6H8_RU$V]VWJW2JZ\D]QVEZ=P:G4M*P#M_3)X4'.L8_=V*7CK
MBFK[KP=\=F0)-=9)#;I(H&J[X\0TCZC INKM5AY1"=M__:'('-5+T_TW?KU(
M(%]1Y^>&&!O&]E?V?\'A-[?A_,UM1L0NFJ.!2[?HB_A_T4$."1P8@/^X#/W'
M%FURDANTCGF*''A<""FT\N4V_US4\R;=;Z<ZY,R-JNURM_%2:"265ALF!JMO
M^2',@H3^,0\L0WF@7\?EZO)75-CJ(J3/P:>]':G_Y;,$1F8[$D@NR0=_I]9
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M+]K)ST'77<;_HZ.D:J\\\F 6+O%%R#91E2,![(8F)'!\ PETQC:<58,65,]
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M^5@4(W$ \\_1FC2_I\$:"T&7-,KJMR^9U123:Z;3K\*OOTER+HV:Y!^.))!
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M$ZDS1P3$7O;RDAKEP>OXB5)-9KV]J&-;$3SZN]0*E<LLG+CH=CFOP1]#<)%
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MV7!Q)P7'[C^YO<7?+V?]I9]B41IXS?H>I&,J#PF,'\]=/!G A$5K4'^X:*U
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M./1_?[Z#KXI.VH$EA,$_W%K1\/UFIOG%<]W))B9)"R('_X7I=TI/L&BW$"3
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MA^4OK[.%LA5KS0W'.$B@TQ]RE@M:T#I317A!SMG94(0_HR(4=2V",R6C1C&
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MS'$N4'- Q(Y6.*\<?,1Z<WQR"LSPP,PJ>#_EQ6!YOWEQ\?',.P$W=5Z[ZP[
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M3Z^S>I^J4_74WK7/.<\N[!1V":!05511!'!P<(!W-S\ NTQQK>#G: < ZNK
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MBS3M$F,>K)T.<PI[J[3_K-\:E[KZ)[OR@&1S^WZRY=A7=7GH=)#V/FF34WW
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M:$LGK?H4D?[J1ZC2,TDM_-$C@Y^GK%R8M#+S^]_J&2=:[@J'43_[ 7\CS@K
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M56I7<BHK+3]N=:C,Z\DSP#TT^/,P.,CG=)\#EV=C9500.V)+>2CF)VS:;[$
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M!]V^-WHIAK[*<]/D$:Z:3]@- FBLI[RA>A,B]OOM'6JM#S:Z?[H62_;][%N
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M*OS/IY>A3Q,Y7]5-U@2:J?9TS\Z_X'I&#G7])L7FKE:ZJ7\NEN;];:%!6:!
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MS3SV_%[0 (DU%VS<+S>6G>9V2.Q9>KRC8.>G93M^!S_MW6/MJSPD:[7=>41
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M)?3Q:4#VPY??$Q5U$L;^U.Z$5,ZW+[%$TL(OGZ/O?"F<WF@*"7L4KS?A2D?
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M4:$/.F<?L<DX'Y\DRNN^S\@X&7SCSSIVMS:$K)@WOMIIK.FP]0,^]<L+RAO
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M16;T&)K6SES)II@FA["1VD@=YJLP:[0J9</Z\P^+QDX3U_0U)V8Q-P 1OP,
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M5TSYXP1SRB.^+"DF]ZW1N+;Y997,I_FH;W _I\7 N#Z7#QM&&(E.83!A!(N
M?>?L)$&S0HT#(:2SE=4RT\](&\.AA_N+]2S5@E=GD3\.T/V/4K04\I])?%/0
MHV,YS2Y?G>P?6S4+'KHPQOGZA-><2E*2G/9PY^/"@I'A>7IKGOZ\J.0#/G$P
MMV=-JN_"@DIJL!CT&'1W*^5ECN%#_L1O;RI_S77AN%F#RBT[%@2\5VH*?7B.
M;$;X5\+8??EC1"]<DC!PE7*EM@::@A^+T/"7DV\>FCOYAJA%WLHE)1D?@AL
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MS"1KZJP?%9\:2<-[:_O.Q2"B^-.+-X"*I./RI X@?4A'.L54]^,L>W>!P<Z
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M\->H'^).W;[!>#7?O1])K<XS6]#0!WNEI$(.6FK&/O1VB33$Q\@^_JYY9(:
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M_7YEWMKT>ZR<TX0H[CX]<<@ 'AF-8OW0Z)S;6-0%K+.%"3T4@DX0RP2B86^
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M7>C6#A#V!<'V&,*1UWR.9VF -[/+[\&2'YXE/AJ'1"UV7'N=*8_*<HEMP<3
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M0/!C+[#KS>)E#1&N*O7R4I<UGGKHRN*6@*]94<'^"E@86&"E,7]4U:5Q-<Q
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MY]#+MI4#EJSJ=1BZY@IRRVOPJR_A-X"($CV(^=FO-!IN6A7QK?ZGP+UCK]T
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M*20.(0'X135Y1]=XGCFN/(KDPA[.^A**"BJ16XP$I.3,8YI,MA-]]*L["V?
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M9USG9Y.DS&_G8M0ZK&QHIR3.XRWED:-[L(Q?&S-%H<BG&L6XBHE%@(TSURN
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MR'ZR9/.M^6$_;=T1+*IG1L<T@"D'-RK_6;#4N4RNJ8[/^O!(3D^.3-7WO5_
M#I62H]=V# 3=W6JGO11A>R!3 Y7U_;H_K]?<$>.&P>1ZK#R4?.JQ7;.;AJO6
MT8+=2+.F+^6"@R<52='Y,<_AS;@R_>?P%T5TG*K^,J3[8(.1#D\EZ#J;@GY%
MY>D%FZJ);M]=MYA%A&M.OQ(&)B5:ZD6>%&#:MF9#O* WY>)>J'94WRY#=1<Y
MN.XB-9N6QR"^T .8-X,)%! *JS846F%J$XT@;#>59H2" EVF8O+6RU_YR5>
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MN+M:?7E^I.,J! T\O+-PN;Z3=' =H:MT^&V)&4/Z,HC>$1  \.0!._^3B-2
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MC?/-QAY#A@[:$0HUF"G<$2./[U<6/3\0T#";U\2M[3\5W)M4>=+RW;/YA,!
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M:?IXNWN/W=J6H3I5[*.67@8'Z6JD#!$.(;I< ;<IHJ.S\X6W5,$+SP ?)A1
MI,VMR-8YPM89]:;8<?A0^]=-C.<$<]KWB6]BA-%?=E2;&FO\L08&0M:J]4ME
MWA0.O-@(?'R7X3<QJF[%G);Y4SVZ  4\4_XN$L5TZZ9V6A;%<11CTS/!&R=%
M^/SM-S$BXZ'C+)\\'IO<Y47]2G 9]FG%H>&[V-;+/Z+2EVQBND]+V/&'O^ P
MU/>W\].1,CCYN]/\R)]4H8RN*DIG:!J\3'@FFCG^CHNR,%I0PS"=,K0*4FPU
MGPFFSLDW6/XK.;"VU@, 22BJ_O&U#TO@UHE74VV*4HYI%QX(K(B^:BI_>*BM
M(&LR0>O.K)IU2?'Y0;1#SI*BI9#_XU)955]1#\I)0A7*L@J-1><8D7*>F ;A
MNC>#/0PA^W)%S'>J)1VVM,%ZDQF!TF/D2[V$>!_,B1*D'L4)R.G(K\>_Z?H5
M(]?'U*17.EVE^%K;N4G^M%=P ,MC7G1%/U.=A9DR@XQ53I\$HRPOKYXU=RG
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M>7LWO?$+"F'#C2A )LXT5,3<+?Z3(/4JN>%W)&XMO"3(N+RT44%X0;BWI,C
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M@?J+.5'V[*TE\]ESDJC&_<NENN#M<"[H!PF*Q1>-=?4(@4 72_.8_;YQV<U
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MIU,:&E5:;;(X,%O,0_-FIT3 <C.'U=73&[26*.9J7=9=EG$5*3\&9LM0VC.
M>?C/8:M]4;([P OJ+W]DU;:[):P*LD$XM?)#+8]%A0 DJJ(<V.7\'?92CX^7
M&GJ8?\#=B]N'QG#$N[!$WA[O[Z]JI2O%5*E]Q$[U> HXL=%%J4 D[@!E/I!;
MTHFE0!8HHA+%)%_E=@>PE&@H&^(7("N^,L2U_(!,7>K@AMM.VA3!X:P17,U:
M,VO%\_NB%_2\EJF48Y7>H \3O',@IEWU6+/&F &S$WT9M#8&7#$N"4H:&%[\
MBGE')27+))U-1K:230QR]%K\#M#[&G+]9 &RU7?(.XQKJ2.>D[=#;I,3XY+?
M5V$@O\'C7IP!^!V-2?TS X:B'&MDSZ8"OJF\9LR+W3B^Z8*DA&NM!XLF HXX
MT<!=JZTMY579%<8V1)TC]=&D&I_>6@W;]]<=#8U.WPB/'G$/=_([@=D;U5>N
M<91SCJB2NG-TMG?QXB0_]Y3;L?7QA$M<MS<%=K>B*,8;:1>)J\?241WV;87K
M9E$J&_/NGT"+:T[=I%VLU/V_EWR=SP.*O,3(>Q^.#A-&.+#6\YJ_##1G8 '"
M4G)JT[#US7@A<']8UJ16]A>1E_0B*N=D- G9^E(T-WRQ2>[6#:AG;R[A/ W[
MN#QGW30*IV1>0EF@%4\(?K]E@WIUC;5%L6C7I;%Q=(-3Y<E\Z)A X&G\D0XX
MMHBG("MG)FYSP);NOZ<%Z4A>%3]%:YLMBSC/GZ!7>A3?GG\ N![@($2_I/P@
MCI4>9KC"&H VUQGO6RU$*X .#+[9;0'A6LJOY!R]@!MK1H]H\PW_G(<UN"[4
MS5WX"G5Y;XTV"F0B??1EE*G']P[S%IKV9T_(&GNAAW]XM6Z]%LM%'T:APR@]
MS$,;:R>!*P5-H%B)2XD(]"UNB/#F#<%*KR@>@KY39[TI?SZ%1[M>$<P50)$E
MK;>*E/2"&AFT_4+:R2/F-:.VXJ"FBKMUG+:8/X>;S;LV+H.[[ 5)*9USG>\
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M\Q*R(1IP="\+.QCMN@,L:GTG?"^"GT&4L0)Y #;ODB$^8HHA6HN$Y"<YR;[
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M*%Y>26!1E>#^P7JJ90A?(IS_U,!^LQD7T_9,3G<FXDDOZ_;%'<!.-R5PU^Z
MT/B X/;0MOD4+4):IV*L"D=2NY"-HSA6A;0-2Q 3040 GY=V.;>DC6*>)^DS
MH2OWP'89!$A+&RAC:49EJHT=:G4XT!(?N%+7BCJHR;6U[4H\(N+E=Q/@ZF5L
M:BS/U#HAYV4C$,6.&N>]#A.^&G+V.QA:>6+2U;,>')LDBOU *.WIA'I#$[-J
M::B\=\Z"+CTE1B*Q!&@BQ"8UR3O7]OI1;.?4<-/:V^&:W2\21+D%SRPOXDE
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MT230L?CL#O U^N3-A#,0GR-LQ9MIHO?SM8;^D2":?X>*0O*SU/GQZ=_QL*I
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MH*=FO7W=!@]>?/GV.GRNC*GL#1;1<K#8+HP\\NA&("^ &U'\I5%#ABPO:C]
MW[FX1?MAP'B+L*VM<,^(0$<%2!HF^?GL#L!?/\2%BO+D'[@9?_YMT\)'T7.Y
M19V"Q0U/RB)PG K0A!HS#AI0[XO<-N4Z_632J-#><IN>CWP>H2JQ[2D07AC
MVW"/G@W'JHE1F;K7C)&A&^IS8_VQ(K3?R;TEE\<![X9M\ ,G)VD4[-(L$GX,
M<VRV2L?TC7)F*[G-JLNM"F2'L$^D;S:&N[KY>Q4Y4IVG^ =ZO+X0\@M$1"N\
MCVL>_-BF&*JR&M<G;H<9-E.4JX 0&M1KE_B@(YA^(6EU(HOU0>OSN\W-AQ3[
MLYA%=GM!=,CS!H3[T+O9B@!B3Z7;5\2\LT:7F29BEY&/$_A8W,0S.C3[@@BG
M ]BA7;\Y7DQQQ+CP5I3X?LT\YDNY^'P,'U+\!47Q%>IC-\T$2,,"^91LF/:]
M_<I?-F-M!W/K8>9\G,/H1QTJ(0E2Z'M-\168,_V]L"J2 VNVKYF:>&1#.?KQ
MA\HMXU7-C9F_0>FC.E\@(R.\G-T"7MFU<B"RBW^D08OM$HAEA1@HS(_>5$%,
M$(+A,$G<E3VJHKJ.[-*$WS]K?Z0]>OO)*T6T"6,U)<<C:\$E!K$ 49AWKCYJ
M5X 96\,)#D$-XA]&:&PI)N:?4&S> 61VF!DULW#..\ AS@!VL/ZFJ'[J&X@6
MPLS,25)[14/,=^00^)ALXSP+R2N5+] \S;'SA77P H^$YV*(=-D0)=N[,N23
M\SK>, SL8Y/F+JL?D!>]A(5G*^:WM1P#QEDT!!W]&4@:^^AZ]'MF0GZ,ZPN1
M(4-([&Z"D;\:YHTY=!YI&]:@_/"(:M%TI?Z=->6BJG3\%H.5#R5I[YX$(T2,
M':9*@)(>NN((JQ]=N)*M*VE4C[6/Y7<2DAWXR"M\63,K?"H.EJY#,D>Z%3E8
MF-89.:^:?QD\T YC9R=XBY>74.312M]'RR>/?-C9$%CNZ'=VF\]KH%!A<GD'
M6.-Q#P!JO')861G 3B?E_GD",@PFFW>.;%CU00S0_'(?#G_,1F@F3WG6_3T'
M/]E9R C5WJIXZ?IP.F==>.B!3O@*@U_:@P[J=XBXR,BS-0^=VC3H+H1%X4A'
M1^/[:"$0#$CMMO#;!3V=/<7W,)YWVF[V/1N9\4]-_9)?6Z;V%,"AN6 .?@,.
M):,R1[$7W.90V"@M9A^- 6C/HD6)F]NMI'A_/-U<E&W?4#^XKCKV-(9XTM&^
MW$2A@-0"[$.D\,S\PFP+*;#'&T ^->/8,-.0^]1N@3R9DI-_7%3MI#(KM^/$
M^>7;(Y)XX7WCJIA\^W6Z:>?3;*H9425JJR625U,$)6^VDQ68<A28,@!$ JDR
MU\"XX,+.^->BZ7:6VXIBB?) QK+']\M;SNT.>' A,+>740\FZN0"^6A&8==-
MW4BTAA&,>'D"3^1*I51K2"$H:FA5).**0Y8#OZI0^9W4"<=L^2?U-IQF]7#J
MS+"<D@R?8#2-72[!_0J>RCE0;5*LE;_0P+9^PEV*HWY2.L&7,FD ;'?2+QHH
M(Z]AVJ>-R([YNL4AO)\M=O,PYTVZI<66JWOTC*_MC.:Y46L,>?^18SXV7X "
M8_T5;M-<CK)WAM G_EO" 9'S#GN./F/'<5RCPMBBI_U%NF8 41_-=FYO''4O
M55 D+-O?I#X-6M6P$UZE(:L19:%1_@/ @<:[JT*EGM[(W0')^K"NZP?W1B:R
MZA6G2\4=8+6X.[N4[(E83O4\*!BC9)S%9!$X\/'^8;JD:N]#D;8.$XS66RDH
MQR-"A1EU?4+3V*\3A<(6(%H+7*>7YMS,N:5KEPL(617%?&<:[UT6&A]^#-.>
M9=G@H,?[.ASX7>=B5V+.;HF"/^S"Y.''R0H2#9F(!X8MG8_M;%!MI,]>RUQ=
M6NCBHC"ZSQ^$(.3>QJ\KX0A4$_7DR_=WQI 5ZTR%NNNZ"#FS-!Z<4E.S.POV
MXG)(X,#ASEM$ WB.X3*8 (84G3:2>'1('76-6%_1BG@%C][@B3=[DJ[7Q()=
M/4&2$*"U09P?3QAKBE_U6UM7,_D$9/PE8-+UARM6O#Q&O*B[XW>D3U\@[N!R
M8VZI8Y>#/3_JESP99< /W*W=8>JP5VI:H=Q^._F(XSYQ%BDD^?GI541EY4$Y
M401UA\GQ)(A17%L8L,UQRU$5RP#^K-&VFWLAQX::Z*ACWF:<+,'S6/23K4%Y
MBXHX-PV2KP95.]E_H,#W.NF971 ?DKD#)EWPKG4JI'.LL+TB]#T6^?,YLT1W
MO^T4U $H'=J8!!-W$V@^%A GU].[2>N:<6G_;)5P7=FC0Z]^$VZ'LNP5["0S
M3(M4FQ=@SZPM]J]4098DG>_:[3[)<Q%CI<_+PS_XQ^T+2-V;D/NN?Z0FH%,'
M# 7B8-67F#UW@#D[_2U[=,;J!N&-G5_USZ7\Z%<4_]%_B(:E?^,R! Q!H%/_
M3F@DA#8S/;N1+/+Q_!_/>O3?(X;D)O370I^<O";KCZZ-QLE3?FW9S/BNY00=
M%P&6T__N'&9(1X&X VZ8,NKT TM^KYC;^USZ7UG&6OG](R^J(5DG_;7J)]>&
MR7KX-=/8?5N[0; W:SD2%_^I+0SW2=W.V=]'<*?=DV_M4BFEVJ)SMK%)27.G
MWSW_Q8GJ7NA5_O9)^XGJZ\ZPC>L<NBT77Y6TW/AU^W7>H\O%HT7U0L9#$I$O
MQG<'2"XWW:)C[KD1I%A=]6M!9[QES+>'*MFRR7N^N3>L"7AWP.1YY1T SK\#
MMCS!O5&(R9M[X[1Q<<6%%C+Y*B-AXWA;G7 'Y%;\D42ITU'>_X(;HN\ F3M@
M<.\."">"YEZBY[N.3TUO7#IXH]_\!7:\9_B[AV*3:!*Y"/#N]=_W^4R#D:V2
MT/<@6S2XP?7ZEOP.H*[^D!]O0[^,N@,NKR;Y_J6AA'_MZ7"6M>!KY'FG)#JH
M[N<=\,^F"OZEI]-1UAWS_S/H_S/H_^V#GD4<]SKC]HG<-E:;^Y2.N+FV68R_
M(!']4C:,0R@K?MAR_P[O_WQPEF]6++#?ZXUF+1/;_%]XE[V.S&1,P!OKTAC<
MR:?VWA=%C3'VKI;ZCT^753P,=(74] U&/'S%O!'OVPK3=)^4BBN(84@13VMY
M5KHJ0IR7M][/_3YCU6ZL3_-YS!:VIYC,IRX-,WZRJQO(MF$P6S2GEKC@ME;P
MH?GP"_;'FU),E>B2,H<KEQC'\VQ+M899^)\$P0.OSWS[:0SJQ0=7+@WWY?1J
M#7,<]^4+7JE\^ZE,:@]'V;DTD1)A^49,5!--Q?M_%"X8V]KBF5WS+/CT.QGG
M&H3/N BRG^E/.W-P5C]8K3S-%5^UQ;;NE/B3E#N+!/9+*VYU^ZD$/T4OKU=;
M%I??SOJZ)SVZ<GF1VK#VDM^RO+',JM7.>/!TE27YD5OVY4HL<B&8:]I(LN\.
MB/9CB?_]M'(\+KZ(Z62 +O/\--E6BV47M^^I%MG^;(=G1L+G4_P7)Z+*AH:S
M3B[6=X#NP_%5M[9;TBCF8 '6PO4BH0AJM^RE+;J&74D2B><])0&<D#.NAZ"(
M7F-=U1,)1_W\9CL?52K:D3\8?43#>81R^=_JDHIK0A4(]+=T+(]DY!S+%DU6
M5U>63%965>V@G!;1VM[A4<,$&*.YEE)DI=\7,E+C;B \>NLKJR..+*D?$T>K
MS,%'/[!_20QE]"%EFW=[_=H[R2&>AL;O!OI5/< ?)28=H.GN/V6]LPL1_DD#
M@&>]+O86_><%":R:*4W-7-6..0'J&) +H])\S&BTU$I5,$/*4U9?89HS4DV8
M:P)='W3T, =GH9*%12UT ZY33=MKUHS7<IDN+*F> 9SZL8MP$=FE'!(6]E7H
M*93)99_;>T98#QD5^Q".UML!^<V$Y %2<_  8\*P=L(BZ>^')V_//Z\?O$L[
M5_>VQ]G>C7\DDJ#&-AGI!:;O@>'P3U+O91BE7;#NB*N^3Y;&^U @RJ0@89Z4
M)?1ATR>/8#GZ#Z48&#9)YKB<EHL8DI]]63>S*PBAZJQACZ(SOT@62-AQ\CN]
MY>.,1.+VB[C&5=R\1#(JU-9TS"5EJMXS>?W**GVYGW^Y?E6=N\"D"9429XZ&
M!9!OB4OK(].C;P2J>YP?GL=X%V_\WAME;G#[:S7",FV0+Y;P+S<-4-W Q95N
MW T[M)*8VK?**R;2OTZDSE>P)K8-CRA"G"0K-CXB6)2-/>[>EL=RG9E&=W(@
MQOL%#VWSY>P63E[\2/I9@^V\G46G2H&)K#+MZ^1$I6^]:EBZD>@D"9W],%_%
MOQU_Q9[+<]/^5(D]:=A\0F0W&CC[SAZ)<$TX.@,3FX)T!PSDI]ME+)]F]2=?
M)JZ]4Q%;S&P>H:2M.\"A'0!(=+\&**-R*U ZDYJFN" _I7W^0@4NUV.MHD*,
MQL2"1&L+2I#FH*\8D7'19-3FK-C3=<;Y('FS&O*4J$'04G,X]@D)1IV,+\L-
M"_TS:P0(6=D9ED=+TG,^/_NACGJP<1#>@]Z!=PD*GE[ .KBD%BH#Y* K^+:J
M++\A4TS(B -,O,WK^,A5M4?A_PXR_IF)I#+CGY!-V<4U$LTOKKOS;Q&5_S%&
ME. _>,,?_N/<_#_[N;-_0K7< 2]2JV_!+.@8O[^K_<=G /F?L2(\X"59*F&8
M5[:2]FQ!QS53#8F.>K)'L) 7D,QW(.X8797P8;ZB\N9AY7Z=<N/1@;P!Q?FS
M9O90WT%LS [ ">0RL3'0VK%3Q)S@D-^[2/*C09W&8U3)>;)$!?QD.K,/XI<6
M7A;GT:<CHI5V#A>O',@H!//&_G;B&99 H^='04I&]3/;G;7SVNB>LK?;/Y%X
M]8$?^_93T*#"MEDQ/D=[L43'/Z9*/RZ?#MA,WZPU\;DE&*D]0L=9/.L13,\@
MB"DY)+>1N_[8$JO$!))DU9ZD\?.8C0>5;XX9XFL.BF2LVW\F[5JR=JUM/3I1
M^;7I0D,T(<Y6'-'ZL%S?M"2JZG2E%.'R_%J4QYU 7L=$,,OSS<4]3,,]6+B"
M](^;JD<P*_E6K'X2(RXPNYG@0TT]E"0PL9=@FRN:VIWZ_?I;!MGUZQ_%S++J
M2>EB-=TLB.\&,JDYX5#12G^-FNCSO;7 ^.7'@WOSP2,VM%?T8^L5]D)H2D3'
MP$1E\8''AM%?^AS.=&N)@X;7OT'"YQ??19BKB]90%KM]:(8<)2O[SEE7[U*K
MDPT*AM)=R!]QU@>P&'I2E+1F*Y5U<6[IOKGUABU]6O*WB;>F1IA7_K/]K2X)
MB(OW<_$)]CZ!?,H4OEL/P0MT>F!* .";S2@1+"G8DZ#HF.47'1&@KGS_?=+=
MG.>%K.2G1[MB2:CK)^5E!PNZ= ^F^1=MUGP<F<;Y_7&6*4=HMK##EH,Y4<D0
MU?9I?EIW=KUZI)^):&'C!U:VQ=7RE8*@U')8INGO,?WDOCZ1P,&H\VOGX\T$
MS^^*"#@#$\)W-^Q03RBC,=-MLXMPOU:94<%1K-*+QD&:C2^EAQ'K_F\>Y[!/
M51P"=?-ULZY:=>!1QF7R\S 4>:#ZKO^FA)97'/T%.,9#N6LC@N=_>T8)Q+T[
MT$@:<B<9PG.0YZA/?#R,-KE,&+AZ)@=U-#8X5HA4F"/;&LZ@=B^GB7[[/#3T
M(VB(YNS\.Y5->>&!"9$QIG%+<O_*!YO&5OG8:+ZL<M;=EOW;-Z/S%:=*HGH0
MI7GF.1=]M/?UFV@!(S\AIEU$WI,,P\&,RC8E*]<YX3M %BN!_YS&8Z&#_<-4
MM4"(AVL52E5UUFD[)%9SI;_LM?-*5LIE_$;X1PF2>;-I,77K4N-R?NXZUR>\
M4FRZDA$>*%W30H<<BADQ!:_O8S#*XZ(67>TU1X:3GMT=)F(_@.<.. !^(BH,
MK$R>+#1PJ*I$GRZ/$4EU8R9+8?JH\<JZS6E,+ 0Q(!Y]*Y-(M[;T+9FDT*V-
M&=/5,>.6"RHYK8#SZ=0V(<B:BL<%5]K*GMM9+JIL5CW>I: A.+7/:$CM"F[H
M$+1O7%M3P)6FZ_5Y^%%5N/O>4."_>-W^"HK/NU_?IG0KI[7VRG'XIC^>)Q80
MEV<\.R^78&MMZ$ Y%JSJ+>,*%[9Y;+\:+0A8J8%G)6EIJD][W0%/]J^"ZDHE
M,GV+T_1VKD45:V7]S?T1(E?^TS!E4^G,GM:@E&]C[-1*$4R*G_CP:+I*F'8I
M[V$.?:^:C <,+DC]5[)>SD=*6FEVPG>$!BN08_[K;!LP_KZ(0&IMPV:P\5]W
M0 #]S[ZG_ISNP.E-!'8$E]ELNVK)VKID.A;?(Y\>8;IFFNDR!Z4[X+'7>HE9
M#P0^Z89+RD"T0Z89W_D%8T]7Y.'ZU](ARR+4N\'K#S$.(QX?2V>5;W?P])[Z
MG</UGZ)4/]0ASRMIYYR9TXL-,R=?=[H+1CSQW[2Z S88Q7W+*KK";Y1*:?7/
MRCQ'2H!)YY<%2A&8].Q<M%V3BF50N*W"U(T2*'A5M6"M=V%BAG5=:VN'3;QG
MJPH?\,QY!($+N#Y5IC_GB(L=PXHC:73[?0D:_8'F7+WVAPA!RT4=$[!1.?9P
M6++>BT\#C'D<E"_KZL_W1'2:(JK%6*!Q&@H0O8RSG;AIZVN^_-[F"9R#_BR"
M1R(+0I\:G$46QG1FSGQ-EC<TPK6,V,A/ECQB2[<3,D_SL%$.$\M;/6B6#']0
M81K.-Q[Y/5Q9!2>X>"M!JMM >KC8RZ(UL(W^Q@%5GKW2NLP.DQU/,#DDZ>I:
M,V].3*@ I:H_^]KKL<O1T9;I1CU>S"LLJ)9W-PO3UIN;\JJB?%18[P)54$/0
ME?-.YI=HU^=%"HSB/SH(,4\N-C'0M'6UR/28U,)9\_H(7$W^A84NMI^C4IM@
M B4"\8[#@CH$?.<'1,=O-_PU_YCMYUARP>_12.[KEN>=KJ,M@>R&TP&BL/!
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M/0 IO)AW>8!R0+HTK59GOUS"S)Y,"E5EVKQEQ<0>$$F/+$;%^5@6@7#1Q'?
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M&&/O:VD=TPA54N^KZZM$MGY;C?+-""]4:":#Y6PZCR#!ZA/%6;&O>#G)\V@
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MA'VR8(6RJLQ>$A+LA<?8JETC-7BLF.,5'HEZ341;*,X:$ZLP\@$]-XQ/Y=T
M\>H-[L[\#D5S0OW1](Z()T7IK&5\HFE5@G66_%)T\S[6QQO15,6ES33"<^W$
M+LU+NEDKEZ>SNF6?'.T "[_/&LZAJ8A\D>&_\A'"FR[W[&X)3:4]Z6ML(R@(
M6=E(@P:*)D&7-!J#5%M:[IVIOZP2[!DGB"VBLLIP2=T^947CL!3WA]X_3H"S
MIN'KFE3 $K(;&AK:G4?J?**[K\CT2N=G$TY$JYV$Q3CRT$"KF[55+271E,V/
MG(0CAXH[.5&CE^OUO<' R0Z!DLZX&,4OEJ_<&13.\N]K*TQ":T"M;:Y;/A"P
M9>=X)<^#*<M:#F39-K.\3=S*[O"%QPI>&Y,OX4K.BKX&*<8",J1ELA865,0O
MJ@!M*K-)'+CR>-6H;RFKXC8(@K^J*I=@0GH11F4IT4Y>6L_6?/OQ.(Y7;UT?
M#31<>CUO'9:DJQPO<-6#GY[]S.=ESLQ3I>$JJS8-(_6K*1U-OQ$_I AM6GV#
M2+UQ:T+UZ#N18MSJ/@OC]TM*-=YKM;AZM @H%;@W%>JJN7[026*EIFI3RU?&
MU=-H$?^A&"O4C''U,W:EVRDIQI;6ZRT8B(8[1I.XPN1-KX[WBL+JKR$/=Y00
MU(L5F0RIA, 9K?0\;$M['U>&RN(*@7CW-LRIMCV"#[=9,4MOR>QJQ';3V0/5
MU5BYYH2$K49.F$[IF4>)M2EVM3<V2CQX@_TLR,[,K$A7?UN!85::-6KB$;Z
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MUW0$00.5DV%J<HS25]C<:" 5$MKT^\SHGQIOV1$!!AI0GT3=6LFSVL-\UM5
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MJNM'G2?.<F]B380>7?II%E4FJY^!F(_5ZZI#KJ('?C=%\6&,;(..Y$Z*KW#
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MF))8>@+W=IS;WL9G[/,IZH;)_:2D #%P"E"60=U,P8>./%O,ZVOOR1$1;!1
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MWC-7F)*#]ZK_*L?Y'Q)^RL0_ 5!+ P04    " "V0UE2;\U4[_G6 0"\40(
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MK1?YI1ZA6*P\AJE9!:21@N@_3/O3LO^>82'_KRS[NV'_9M<40$M*0EP\4D8
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M,-=/6(9%O2X>BD$#G0*KD<,^Z(X(^<P.]\MK^EF-^O2F,69+0OS*S_T-NPC
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ME9\?+=/SI95>^&I(/0'XK?XP'$SJ9)):='*P";%[T:UD'<%.>V[C"*P<N5Z
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M[2;B:&J>&/1$GV0MW/7$6?,JJ5Q]3KXY%_AF.W"23SP%\47SV*D:^VZA$TT
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M/4WQKAFGSZXHH)CLW6]C!<^_7/.MO0\<-OSS?R24EV\M,TR]P=]?!F-HWA
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M@W;OP26>!K'"%/7"+2ZGW=/5KN:7F9Z57F4 )3TQ(Y^9?>^[I\JG /6!5A&
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MXI)Q_EAX=JW[G!^-)-6#MVJ/H],J$BFY$ ]!M<,R 8$!&M7C(A-W0S;D<GX
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M[#%V(GIG(&.! -#TN=7L\(2]-K[4DOV^?IV$?W*B7@_[>$KOG!*F1@!>11"
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M<=6$Z>[X4O<.ANHXN/K;7R.2 DJ-D:;4 N>WP;QCR9,2R*LGLI]V /9[6:W
M.1O^N(&8'/F$R/RY4NW\ JO]=G@%!@P2&1.:/0XQ+,PC.9IYO=Y:;\RH[Y3>
M2!?D[^4U[VN<W,=US>PU<.>B?D=6F]=$#F:9VRLN+:T<^8,$(YYP&,XK3U9P
M"-API6(K>8I)]1Z6Z%?Y]J9O%%.EKB(D8\XE,5L=]UV&F&;\B>L;5$\)#F(
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MX+[]&5_WDT63]!O2V7@SOU\.CKK6:C:E]0OH"KSMDAO0L7@ 4-8[96)G]9?
M]9$)BC4U577U!-=[W)Y,EIVF)&%4%IF2W546\,H(%#4,>*30Q6-D2TH1=!V_
M,,[<'9T.5T)OZAI7>U&IFILQ2BKAE)Z?0ZD"^OOW7A"EQJ+<C@P%EQD^ &QM
M1.R3(:7;&U?=2M2^S\EBS^9*4>\1G#6%!\W/X];3?B0W3-.^XWIK7&V!EM&Y
MYGLL+T*K?%)*L=I]R0VJWNE5.U/W%9-A.E-.#,:P &!;M2N=[%LW-VE7:?M6
MUA6K,B94J\C?F%Z=@.-J]._9)XUZ38EF^(OR"89<2 G2LC])DU\.DE3)*>U,
MIQ>/JHE"7,91V)E"4_U9N0<4XNDB)KG\#NXLNNX?<4>S!2LF!_=T+L OD+'2
MB(+Q<!]\CN-V*!ZTS,JNY=>I(F/ ?&9VH+J&:9R<WCL(^#+JKJRD2,Z%3<#*
M:MX$S.SI7I -VAB86OP+2H+.OY^B_Z'$[OB'T5/QANA@0$KDK,_&QR10U"RX
M1OK)TXBWK]]KH%C) &P=95SD(*M[PE4<U?R[RL-,\[SK=E.4G?!>'&JWO6@N
M1C*-0&[T33>.*.-AW>S%-QB_ C(V#^0\MJA<4SU7SE0??63/]).ALRP[^).^
ME;WO R![5X(&].Z@QW'5EF+IP*ET7],S&1?R6EZIWSM>B05^7E'ZH>9^;,J.
MO>$ZZVO Z]4H>VBV%76S3@E5%(+\>XF\8]1_)>UJ)>II8",XDH9J5DQ]704H
M3KAX)$BPDE^6^:60F"'0N1>WC*TQ-][=0PA^L17Z7YPN]  (OR'-@W$]:XN)
M=;B,S)(0)#C1'B0?9Y?*Z[O!S2OQ84V6KVHX<X"N+#\UFG76F/@])+0+:7,G
MUG"Q!?WYN:'VELO9>'A>%57+)R9H)9&UKLH\=B36='28$Z$]*&KP\0FOD%C$
M=BOF^K*6',(LLE* S8%Y5;.-$-KQ/Y/,@4D?L7%P1&JTXE_OV[NKB?\])./Y
M'R3CKX>)$.SQJ@P#5TE6<_A-7AJ-\SJLL-J9"E^'C:O-+D\JB?*EX80E4924
MXLR#&]E&.5%LL-B7H/I; [B8^WQ]:H)#X^^,[L\UF;Q2^VJXH#$>TV0YS(4R
M"5:0^V&"NGSF"(Q_\0$0UG!35[)/(9%6H%_FO\3S2XF!;O\5MH*D>G\9,AY,
MI7_P9:/G7;UA9CKB&=#@E_SN6OKO+PJFHED%;C,:SO?U;;E9-='E0(/%L[9[
MJ_3=>W($9\O&HADQJ'UE7IV4@.SHB,YQ*W8TZH>Z3._%^4:YR@;X)3 6-BK:
MYT= H%)DR)+(5%M&K-AZQ8@KBR^O\$TO>U(]96G^5KZDI(2Q+)FCO* %_.'4
MC,1:$K_5)N># ):1T=-0H&QA%V]2HV\GX9B1-< BQMNUHL5PDNOXGK@^V@'@
M_0 X1*X3.&@DZQA')<0,M+G]U!@A&K%5DF%]^T8T/QF2E5R9,HX456R:;L6
M['GEFVHC%G]M1W&+.JN3DU,?A,,+HS=6GWDV"X0DFWM#AMRVL898 *SI3]R/
M<2;0HQQ]@;-%N9L]M$+-R1&V]D>BT)NCRI3^@RL)\>F+:TOX7712::%B9#4F
MH_YF>%70$%MZIO<]2=9Z)18R\'8@&G9"*F=G*2*[V65COUC5S]M+*$*TM)FY
M4"F3F]A'Y9JCVHT?86=06P<\J6]S;=3#? "\6"E] &"5WH(/.Q#LM[3).]>1
M5_4;E"XMYQ7'$415P=COBUR<[_+GA](E2M='-7<VY",?C4^+:EVU=6':B$9=
MV"^T!F%)7R_<BP($D6+;O,^SHCVHMH3OTHI>,LV%R4(BV6DOKO^\JMPK_ILM
M=1OE@L0]Z"J+[X=QG+_C$*264DV+.J>W]YLOB;RX<]J J!@\^JR*]OQ4G UK
MC?S4L+"[#&-_K,N#@9T^:PW%'JB@%E3 UV$3! EQ-0OSHVAM[E#',ERU??7M
M0T.RAU/M+W$I>NF(DU:N8B3T3,<:I94-U3>X?E_V>ZQL\92;F[K%:OK Q(Y$
M34\4(1S9NSSVT_[FP&WOA HONA4#7'10?\\,+X 9'+Q;>\)X6X/6N9/IU/^B
MBR;QPSZ8M"#HL$=F:NU'=.')J&SL9?UU:%8/O%(Y-^;+YU^J,MS%+\:3[2U+
M3&J!ZD:93+DFRR@>A.7%:O3Y]7'^#.[S2C1>+A9&[("9#89 ;FXV,QAG!JR2
M7 E"B_OWKJ5G2IIZ4$-$;H?/Y>RYI4-+E)?5/*38V*C'S1YN(DLUT=@S0!^B
M2[-V41!"=K060PF:>I/W,9SBC8X..@ @ GA[!G0IV.YHBV'2,IVTJ5@T>+3<
M"N:CY0*2X?6D3H8&("Z51\/(Z%30#<AV?P 8F?2UC?U>>?5*\!T!9]7E5Q?K
M:IP08RKFPXVG&^F(S+IB.14/(2 L$>AWS&:TY^MK_W?#E&=:XC6RG_+-,8KC
M66/MSS^%; LQ,&^JCCHOO. ++I)5X['V-Q/9T_3:SUDBUBTX_VY^XCDR82)>
MJB@#&G&[%95PIFL:&=Z8@6N[(]X4BTW\[SSE^O_'\X2MI>C;-TA+L^\/:4H5
MAK6,DCS&-6<0R0BX>P(.OGOV #@U=+BGKVO5>P#0?_UG]]<_QV0;Z8VX3<M'
MV3+_[0OO54Y09IE8A=>*T3X I,&HI+3'EI=W3QH:] #8Y7H Q$^#$21GHR0=
MLY^7T[-,B_^"S?AV'9"&-'B/--=QKZ+Z .C5>"P_V:['@5\] (9L.I 1U]L1
M$J6XAQ)M6M7W[5;_Z]&)?76I%WR]()9W/N,Y'>O6(,G[P ? -8?@ X!  <6!
MA_$ F#![ # 5/@!@;#NI;V[*1'_?7*@-WUQGR?[G3&/_,S*]<7Z-"WV/SQ?[
M&<D79Q(A#X#@G+4'P W6 V"S=A4E1_N?D55F6N?M_S[N.9@5Y3K8]L7Y?\Y+
M\C]#,Q.;5'A<EM#Y$G>S^9$;RO^<%_%_1M;NF1M;TM."5ZE]V%&9<FYLAH^2
M="PXC"GV)A/B-=AM2,B6"(ZG1]L;,%4HE[PG&F6X]T%)/P"^;^<\ /K9T-<Z
M4.')X$M\\-TK:B]J)^V(J%2%8F5[1TVKQT@PM^,> !)^= ^ ;I>/#X"-QU=[
MYH/'L\(DX>DSDL@^UY_:%%2K*)94!=0U\C%$S%'9!T"4QO_[AR13&E+_ O\%
M_@O\%_@O\%_@O\!_@?\"_R\ =3*X^J"ZE271[Q9L\9=KN40&O N6H"?O+759
M+:-E/PVF ':V21J,EZ]0B>)8]YW0Y/O8JFS<^/_F'BGL+)('P&!*.7A! GQ'
M.GM&[2L,Z[@F$JB\Q1A_ .1"V\TK4%S=XVS4"+K<"+:RL\#_]CZJ-]EX#LA'
M@4MON7KW_5$YRPV86(7[Z.2"))5$LL(%7AQR"'['7:OZ*IZH33@0Z(BV"TSX
M3[B>WQN40"TR8WW0=3%MC_^ZO/ LNU$1U0EYBC\<]T/Z@KKT3SE*WAL)7G^_
MSV\'5$/@QCTOSET>\+1T;,E-Y>MQEU@+ZL+X87OAXH<&MX3X^U #L_67E)Q_
MD'ID2@<Q5 T)46-DGU\<F#!9V)-L=KQB0G1\;^4H!U7*(WI_+RZ*R5,+WG+^
M343_$[<Q8LGNU"(L<*"SO5I+B_J1A?\ 6&RX_]DG18T;D \*DDK:O^HS?6?W
M=>@38]DEOF$^V>:@"6 -X(58*;%Y +SRP2RQ1=C4F](''']-&(YTU61TKG?Z
M'O>3@0K1)5P"IN(XJ?##.2B&,,8+*4(M(D_XZ75XT1X :!@2?RO,8%GA8K05
M*"H*]1"N,H>*$[]QTFAS2_K:;FEZ.ZC_ULNHH'3SG(,(P*77EH!#^ K>Q(52
M[9V*H>(QQR!1V'J\MG_FE,A;[0=  (&)>/-@4A7[@&L P&7?:12$T=-8YP9/
MJBQ< 9W(37(RM#6;Z Y\G)K<PAU;S/A;:-(52A<7Y93P./0.0B(J=2ZC@')3
M,#4?S\FBI&S8B<)?OS2@%B[=[Q)C,XV,5:I'O+1V6<FUY;*>SWU2WOMR426I
M?Y9\(Y[MSZ.9Q*L,OL<#Z9E,"M >%8O1\GO$F?8&^$W;CH9K8Z>_C0[U"]=%
M"9;(%ALAKV VM2*)^55*0(B4%KVWBH5P)\/QX&U-EEI&$7IE-1*RUB:K$Z1>
M.\]@4V%Q6KZ<$_<EXRRZ^.W'*)>)Y\)E)T>B)T@;O,..>F.PU6/AL%S&5GN&
M_CGSFV\8^3OMOL(W3Z7W"]G12Y%4MP;&7C5#UDC'LQW)_ 'Z$JG6H*U=#SR1
M??VY1DCRS4X,VZ3D]E['\8?'_QH*.*J-)=@SO$Q^EY._[)L[1VX1H216;U))
M_KJ?#+V+=EW'J'^%.K;;$91DHDM6&YF(@S.2DS R+D7LWYM.PY-E>R89NL(]
M(<8'?W2:28;'I0Z6WE8EJ^SU\8U$A&/*P;$G[USZT8IJQXF&USL")?%TH=3B
M]ES;$5#*.U5!Z2]]9E>0I]0+@U0Q$!9BM+U4VMA6 =B[%E4&S;.O-;&CF2LJ
MGE]2B&Y7C(J^B'>>& \$2' :@"I[*>J3G0T88S7C5]5.:V^#"65*7MB0_RP1
M7%FOO]R8SX0OC\YTU'['!,.,\/"-!];W-)7*[-ZSO3KY&;: X9/I,I]#I3O>
M0ZW9/=QO*CK-Q56>W9'5ZSQ$4E9=,DQ?:RNMP\*(C[DQY2]B9P3S"#H7U[23
MU)R+%XUT?@H3LDBD8ZF-B="17'NOIX$]:;PX(-X:SLY;!-J,#F(K)G]*,$.P
MT@Y&>I!6M!/.GB^.4^\V,_5Z-*B4+.Q3&(KE_%UT:>$?;N3>).2)X74R[8"?
M*07)(+WS;.J]2O8O+R_7Y'PBZ[[**&D^5R>CPU5_XB_L*<&]=[E*4MDJZ&[B
M>F D':ZEUN2I.O@SC^NE\R\J;DKUJVA7KYW>CA=(Y\O3<<,Y3>CV2"_S]QX&
M[C/BZD^L\4MO6>R=5DF&54IL;KB.F'PYJWP=/E,/A.02*+FQ]E<3.#JC?4&3
M6)GE"CGBV+K+$P-Z,!*T]9*2LA$7. ^2XZ[A?3NB302X>:W&MO*MGU17E):P
M*GF^RGC*W<,X-41[U>M4^F[5QSQH3_>P52][GX;2SF]:I\[W+7'+<LJ[7+1Y
M=Z?:F+6UB-.4YY5 Q&U?CH\6!.D.; &^J_*5Z56__$7*2R9O^+Y_'L.1?&@G
M2AL&! -0PHBLL$^SM:OD0T[%[/.8STH*:O6>]D.<2QLWG)NZQFE:)S!\<U&*
M\*PP >OS42Y=/$_6Y)"WGY*(> /BS3E+J#Y9;8U3S0L[($+5)(D%)'&7^<J#
M6S78"0LSG*?XM_XTUQ/[!T6] UP)#!U0A.2X(+C6X;-BYGG ZO;LJ8+Z%&N&
M4Y(\R7<(!D)(]B#Y0)WK'+0B*^]^TO#JLNZB+A9:"U1G..(M\[.G#GGE1+[S
M3YX '_,$)>KM;55VX+1HHM_,""?+MWHV(7*DHVFV11??U._9I]>";%MC8Z-4
M&6I5L?W<JL[+0-A:WB#JP5L2'R1,_DGX^6\4N94=R]$S!.NQ(@/PE]8'Q0)6
M+/JZAA&T0]S9\0EM26Q7$UX\/"3B\^\&:>:.8J-V!EI^Y05MR4-_-8PV@!?U
M:EBM-QY>AON99GVD\FF2!F@*CSW/=PK/9].<VJ7/"@D>6*% R)TG&7(6,K5$
MB_4X\!-*OU8_81TL,?"DBHI 8+9#'P  "?+ENRH.]G(WZ]3]?9#8;OF,6$2\
M8A,@-]U1D5J89 6Z.VV;12 F4+S_ "!P]=4]4>=K*\A(#)1CW$4\L@?OR( ]
MMY=YK!=@]T(]DN;%9.:6 +674'Y=D[=2+K[R<3S=LWL=367_GFUTAS;9C=BP
M2PD:)) K_!P8YN"##)]>DF6<5+YK(+[-"XI7/N5)GU/H3F/3@F6%>7Q=87"\
M?YU*^C-[:9!$T?C&(B'6:_-\</ NJ=7 QH&&OB[M8\R;"<>P&M*!"1<IFJ9U
M6M*]>Z[)J3-U3X-)?#6:.7V9IH^*9CSRZ\>\XON;IG33+ BF_@#J"9&,NN:E
M87N- (*JSD^*7>1D:^D>)9FX<_S+9MU0;QO#X/+=B#F2A,,S]C3<KIY/<-]H
M)TFBNA>M.!N5N*!CC4@-G/Y$<, PP^NDUYFKK;+7C]F9ATQ3F#^^8#.AO[#_
M.G6L6@YC_7U:0*WW@V_BE%=(8,P$6:DV;P6OR,D!5965.51NA@@E=:7;6O)2
M<(QD9S\SVM[U=J^D(USUX9CRFUH<O8KV$1K1?F)0)Y_ @'BR [D56 ;>8)N2
M-2-5<V6<ZT7\OS=<_9+R$(0Y@RD 4PW('@AM!$56J'W*7/?*FR3,QXYA0^&\
M96+T4DJZGQ+@G9H'1&"IP\?[.L+PD36F(/9/=@+?["P]DFV [C9B1<DL"8&+
M"H6V??6ED-T'0*UNVUVYKYWY93G%].#MAU+:M-#/P4ORGN<0$.\85!V*!=-9
M^B$_SUWX*TY9FU0.Z/ +?8&Z-"L[&_=69OZ\@\@:OI^*<^A1KV5E4;5#3H4O
MO4FPZUEX<,\X)<8%P3KRNV=C<W>BX-M,=IG4D5>A_819P;9.4=Z>LS&L2& >
MR$5L7$T?]6RI2$T<@YJ-!=;9%@0#!U3*5]KE&4"@&RJWPQIB^,:\."T!EH#?
M3]\RFC_W%\?K:>>=\#&X#,C>QW)BJGH",F6)T*^9J+5'!SAU,3S_O8,<7L.R
M+M],ZW4L62+%"K-D<F^*2D;SDVY2?/8;3V- (&7=ER +E@=,#8UQ'771BE4&
MZM7\KE8D>V^ABWMKZ8?NR"MZJRO97<[;=X]FNWCT6M).)!2JUI7R^_3-\H$_
M(!M/9<Y'+]>:0LRPL+RH#R=]ZSWA&U[R2.PBN8\J\<)HTF4XWOT4IE7P1=W9
M<W6BH5QIVVYA 5F(XHEMUX\?G]VPG<EPL_I2-UW%6:=-D*)K;PL15"+/JSX_
M&2\T_F-.5YTC@VTO?P&5=QK<2!U'F$5>X!&A\!!;A67L5HV36RJR8 C/NRNP
MF%V3L]J+,3*+M8GGE7UXE+)6%2"C'O4*VZ2/)BK;^\F&KD2,X_BQK 1Y,GY?
M]XE^B*SIV;!$H@36:?'V5(H/]+"3/X;4WFJJB"]W?Z+N>Y*""8B*;Z*^K@#V
MTYY^O'\4T_/>67?,)+&5T6J+ER$M<3X*YNO;S9.Y*EC1,KUJ-:Q59PPR8_[<
M#K_\G:6I/++Q/E0ALD+KN+"708$]6C&^O*.,WBEQ1MQA\RXA'^RQ,405Q^LL
M!A NG=7[]5!7/X8&04&YI[+FA^P]K 671[J;/OF!XFPQ(HSN-#A(2 DMZ0(R
MXD!S:O-6<V&1G6=1B;HL<M+"J2G@Z;F8Q45)._/TM^R[6+LY+/T\=/GJ)DI\
M;&6?0JX!!*$22[LJP,U4" FQ6\>CLJ9@.WNV..CV_)W6X&0_PQ^R/]@\'#.
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MW#?:-7%T%3RD-=%QB%,,WKVE .S]=\>L#2',4.&I\W=!_]P[9F?&,S^=R?8
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M@]AMA-C!E5DMTN,; AAK^O2H[9TCC]LU\'";_(F$(D'E1<^V4P$Y9VUP!N'
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MXP]0U?Y_'E%4[DLK9[=],;>3S@IR*MP0(/Y&2J!/)RF;V/;F#V2@Y@]BM'L
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MVS@C$. ]NW4TH'_U(EMSP]8G:BRLZ16ABO#8.B\8HHT%;AUXNS]@+C@K)+H
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MS[1?&5X&QX.$RI<%BE+7-#DN-]L/Q&>1:ML[9;UCN--W]$R6GO5H^;^9$H)
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M\8@CQ[.P1]X"]/OIYD)([>@S)YONB^6[B/2((X9AI[RIOBSRC[? S/<YF<*
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MR7!#0) ;D94%M#J2Y,=)%9I#G,%JL/91#,X4 F0[4A4_(-B')^/+9%U]E)@
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M@Y':?2DH"].I>C-E%HU1&N[X/*$4"DSA0;;#7V'$) .2H[@A<B%?H%7=+;=
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MX](NN[B=#D[3$,':6S$LR]P7(-\[P0>RH\<X])0&[(0#2-;P@EM25A\?R,@
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M KOF)]"98/TYS?&U6CM/ A!5LFT47"*>DZ/#D<IG_T:Y.H3*WY.UL9=2-(*
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M'.C_"-7X;4/QSH7L]B<K<5Z$7?$B,-HA?YMP0;$"8)0 K'U!3'C+4;"?&.W
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M#-Y08+,29GG[PBWJUEJ )/4>R6;Z0[AXE?7: 8Z! =C/X%!\RB4BUE"_R"0
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MSB*/4GM[C856KP&_Q&5%_S*/<JW=6:'J2-7N-.KRM^RD/9TJD_:BJB76;C>
M-1/E] 'WK3_V]"T-1))W[&%RZ'/K ./02@>=+?#"RRX?4P>7V)?;O:A@'L/C
M=+$=_H1M3M4P&%\5A4<%^_4@Y%<%JUN[XUG+G4N0>AK7+1]/B\I8EL[M4$0E
M^%DZ,%8JO*1[WK=;\CGTA=,4)@.)>BO5%K=5$H7WF<Z$@D>!7*'18C_]AWVF
MR*EW%7/5G'W%-5J2Z/[",QF_!?_]^A;:SC3ASLMIBTR3? L\7?JU":X%O=CN
M#VUJ1Z+HL8E"35^)'[F([1A(CK*)"N2&X[ #"3Y0Z)DG:R?J?35+C)-[H?<^
M/2=#:A3-^)^<!_UNSW&FXRV\"KXLS7>V;JJZ>UDN=@YR!)$M4U$5,J1.)IV"
M"JS/2..41%E%[<CC%K7#GO3U:,TD,%20K/UY,>1 $1P$)>U%(/W:K+)Y:'9N
M^:G_&\96F-9 COK'N &WN,^ICH_BD[4S<*IWK&Q+<J;XE$HI55-5K7-4@2\7
M'VBSD_5),101'18WX=ZC6S8+_ OA?"QG[9\&RR EUA2UV5F+"W0&M9^X$AJA
M &V71 &CS]BW %2."F0]TVGFO'OBK.I.3J_,:'EGGGT QL3'#?GTBV*CC0(
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M=Q%7EF=T+8/XN]G\C[A@UI[J#)I+Y:EF$N?5"R4)K.$\:$VGV >#D'T:0;U
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MJI+_!M$9EX($AY!0"7@_21>A 4L<-/:!*N]G4]TK9HV)"SD+B84X*D;AY=<
M/+5SUV2:X)NO2[WY2J#&UOHY9Q6+E H,'Q@/]P8+%GE>DUF^%MLIFFJ6^?A-
MW.1TH\(T[SR?X*IRZ_[2\;PL:)AO&*M3GQ,UJ=#2<,<'>M7>&U_E8<GHGLFR
MFYAQ<Z(7 YP@*O.<_L<^M%VM8O"]I3!;=CYJXR4=D.YJ<ZC%H>V47'R-@<AC
M['1,P4P\]7C-B97QN6?)WZ$B-U4?E25;$-Q$GEZNT9P7,,!)0_E+KQ)P*TP?
M?+SG5&60PV-&/C*T2;:9"[8!DB[=1K+I?MMKDJYI2V.[0=5+(YWT1&(!VQ-7
MZ*R4EA*!V>F6@2/*RIC^@;IFT$;[AE*?KT&H]P86QY;<D/LMX-$,S3NT76UA
M9'21L:IUGLVT0!+_TLY*78,"#8?3$3.P?$W/\V6=\\W-D)=PW(HL/\LO\P%8
M!JHUI0QSJ8:)@MI?:?.GZ\L)P.YRL+KNMK><*\/\<T]Y%-RMF6M"9!E#I&)*
MHUL"1U2%A J;R3G2,$/$F8;+/-!5HC7Q7MEKDG7<EF(,6(YB1F^:$#5=*;4_
MVDT6"*E.D]ZT=G@P_EW(!+T06J+"H@0ALA+VS:5)\RO=FJX;QR><!M6/:T.>
MWA?B:[_D@7T5^)Y[UD4ZSGX\,_GBT,6+>57W#6E@@MM=\<NW&TRIV'@V*ZTT
M"*^N=#:$F2O=Z"6CWX-2OIFYLA.AC7LOS1A>F]@JUR1%9@J@8[ZV0O_&.K>C
MS#^BU"*[3:ED%6R>['&#'L]-].Y:+MRC%?%AI8D:2[NV>:Q\UX'QW1SOJYQH
M\FAK7&[P/!BSC:\;E/QT=)OV]N6C-9$4'\7/*4$M=NO+#<F"F+%QG^TQTKG%
M;9.G?"@[&P7V*+/R NRL+5TY$ES.$D\SZ6B=S8BI'C*(+EO23*+MD. LK-<$
MY23IS! 8&'0)*/".$.![)HK>M6C-MO!P=;:S]G 0/8T@7&7.U;;2C?!?IBID
M2 >-^+++.?BLEJ-9Z_?IC''RZ5P8/DN58PNG>2&[*_4"+&:%KGW18V*+B%R>
MD\#=(:U+EBVDR;2/+.[E5AP#6H@[I3ZO^"9G#"J8\I;+^J9*"/(<R<BK7MJ>
M/MRBY_R/^7["3M29++!'L(*6"9V=71RV])Z)T??/8([TKC4W1I,0'.%VN] 0
MI_K6R!G:_'BM^!I O'7J&56=_/6T,G=7Z>'K64D"EN 1?'^/-<%3U(1OG.:=
M8V?>=D\.RFWQO]NSKS?U BWDKGM\E + >41&P=W/\OE]@3-'@SL;NO0\\D1#
ML5$D]\1TT_U?@3;9U0DD+/U"^3T->)/YRD.P/>TG&D@)G-'NX[E@I-*D>90K
M(\H+9D5];X=R9%ES-*OG*]W Q!AX_311??Z5T!E--9K3I8F3&3Q)8]Q561'+
MZ.Z,=-@1T6XDR@1J5L0L'W]N%RQ+7M.O:8;5;!1FF<PM/DD\%-4A'6<KT--,
MO]TG.I-B0R$>6.H[<8 74KIG/^2)\4S?8 %?:YVP[CX>MG2B(-U:_!R]V-WI
M"25$*%Q !79LC1N7;,NMC'$7@VO^?8JCFB!&0!RF7R[ G1;/6\JIV)M]K :"
M;RQKF3ZD[.Q,ISLCNA[%E7U,4I<+^B[>'"?^MEAW6XF@*]+R53R&^%MKP7*,
M%H&J2SJ$1EX[2>IT4IU3"6QI8&QN:$6W)XX$(X&)B4R(SA'4.'Y)O@IN9;)*
MO]]<!6N-=+"[V5TS[_GD\#RIHM([3.NCFIMP\,[.EB1-MK$K;&T50V 1H[(5
MGMYFBG,UM3"DGE+XHH[[S8<$Z?(!7 !Z@-&M2,XH$RVI52Q./)G\E;J6R/E#
M15S!SU:3KCT>Y1P(Y14'C&V3.S4&"_:]*O5I>4U&TJN.E0KV64L.3.]A]:81
MSI 6@"=F5SF!C2\M#:&P6)^_C?&#JD\-5]"V#Q@I9^5#N#P!?>UGI>%*>RJJ
MU#:D&B9;>/DR(,I.:Z)X+\KX0?F6&U14--> ('!WR=D,[<U6O/ZB>SS7@ Z=
M%YEM&F1QIK1(0=*FJWM(%=:N:\#IS>IKP&BRO_ &_&UPK!T6.%Q!W>L:0).S
M)'>!=#KT7A(0=5JL=G HY9T3XCBA++!C_T@>9_WU=HC8%QAKNS@-F*$S.7JW
MT[G0Q)I_YMZ9]KU*L?D"&DVK1:UH,QI-9IG/9.20PF)W(J80=N3=+XAXNYYX
M'_M#8^#F(XBH6^'7 PA&(E/@S -_D7-O8X?6!V#[7NFITG)>T 5EOP7_,&K%
M]IA!'T>D"]"@'0R[DWP]R :[RUYEN_".LI>R[>>.EZ4?+DYBH._;O@@, EJF
M8J]!6\27U"N;&QMJJYOKTKUD[S@1/ROF99.5=,35C(7P FPH$J)B7YXEE^ZU
M1%;Z;.U;Z([YEG2AZ=+0P\E3/I\)UP6>'. 5L](I75QDVB9MJCT6IJD7I/FJ
M)1'BBS_IK?B=(RM;+"(IF7W"D#$Q+ZBTS/W!."U5,/E +2Z.QU(7'KX!R*1J
M*9(]7CI:NG7"(;.VK?JMF=RFST="/2-)[-N]0/1>7K0]=XK6#%/Z]H)M4K<S
M&H6T[#B+QQ6.Y# 5M]>RJE*QLDDE6\GKA8UCKI3*LO/\$^PY.RR6$RSRPQYU
M$<=B(ET2M*+L%B70W(7,\3(+*^ ZD&5;D_OX.2XN'OF-M(]Z7Q"@M;K0DFJP
MZ83MOLMMAUQY-39K^K[!MN=K^4SPDTQ<%#3H6209+Z>!:,+YHRV<:9=>KR*9
M%WR+AFZ7B+01+RK G3L;C=-\J* <N3D0MR=2U"_IRGIU>IP">W!Q07W5D3Q(
M0K] 3X>WO!FWE_C_&VUO'=1V%*V+AD*18L6E6(N6X%H<2O'BQ:TM3G -;L6M
M0(%"L>).D:!!@[M+T !%"R10( 4*CYYSYLV<-W/NG3MWWO^_/3M[[V^M]7T[
M:^W5Y>5!WWM4;QBT>7<K8?HM\NC+$#S(V2T1..ME-\,(I^J=[HM-+HGQKHCE
M(\<V!4@\ 1Q[,3X$*H4=[ZRFYE+#U=$DGF??6K9])@OJL!:^BM'0Q2(9']E+
MOT#1)\7P!/\(8*\8]ZDTDP]FJW7CA6,0-H\RO5G14WP4HD0?X9-+/7WKA0B.
M$B=**!W./VQ><!NFF+LR2.7RE\_C4-07T*#Z*8;Y3,D8<,ISRNUYH\)3>_(!
MTAQOO9LE&UWX0)/*A#I :HO<ZA-QY4:'?)B-H_;B(_G7UBH4NPRBL7MZJ$58
M#ON@UG+<L\R:G?:F4+B:48T._TXY%P9S+@9=BB*A&LKC[2R4%UG8WRQ-7-<X
M"\'_YN_9<?,$=ZG7>B6E\FYT2# Q<R\6\%OBWY)SO[-&?JL^6,Q(#C-?7S\1
M8WGK-1*>K&,.#E><S4)X$1H/S%=K6[60K1;X<B[#QU//PL/#_#87OYBB\?L6
M+XTQ9AN['MM-'31[7XDTP[WFUM_+PG[J[B3T] S@P6RSH+ET,U[W +B$J9/S
MP+.=QADGJTA@Q :UNZ$S!YB%($1YFRU$BG*[KTV(@3[5[&Z^SHF?S!5ZH^K+
MGDV\;NO"$KI8WF\9((..* ;?P!::FU*7865J).F! A)]62;OJ6O'L''IQ3C%
M8W]*XI4:+H.Z2&]E0+:D]NE7T^,4-=V6\BP8T?A3!&5,1-E^^B[AS0==]>$.
M62S\_>4\29X*?1Q8V4*9$B$3BH(7Y!B'T^ \N3P#\7?BZSEL!47A-AENF:'T
M06]/_G*"UCQ49EG %_0Z(]/;(:MMDZ[1^DP];S^1]>Z$MI<H4R 6.K%0;%W(
M)+7&Z=^UCY=>+TR9P@_KUL::25[![YQ1Q$3*8G_:4LUXHX6 ]/Z7,5/5D"/P
MJ644K%90@6G,77Q\X.<^C/V5I!4F/$1*?^%D_7H&6/DLNL9I5PLUCA^EI#L5
M]NI%F3FX4';V@F7V]&)<9.'R]2,3=1]:Y>6#"':V6F.C%4-C)9"E"P4$*N_H
MVAM*@I.OW5V+LVC%P(SVV2;4A9D_11XW1=UEV73..5.O:W*>K'&6Q2.:B;\(
M$GDG/@;X^23>,=L'/6Z9SN](F=^=N\!ULDHTZ8^H1KCWU"@S_22O90^=U#:3
MSBLW/+PDV; W2+]:2-D;;?F7F8E4?F7-0O=4:<X@'ES 41M$>\O0WIDHMIMA
M,*UO7ZPU=CB5TA-SB+>3F':<?HF$=_^ P^CX>;P':2.T)\"8ZR%B@<_Z#=J2
M'OP^*=C9+M]$G7-]P9!%P84_OD+-6:R'CN ]\4""Y<,G/OW$A&AGZFKXI'YS
M6[H]O<F8+FE8NX9;HN^03(3'-<68ODRC;1RW"XNAS9SGRDLGBB$&]WSKCYTM
M4AT)/,V2?DG'5 A_D"CI:/&!3^HZ9_8?(-.[M]O?V>LN'FC%BCFX%';MZ:%2
M!FISJC 9W7D[NZX8)L9'-,""7&+:/ _CS(OS,AEUP=8L!_N\FW9B[7.B.*GD
MIPPUFK/.T71UE1JJP>^1)I^";,3(/.7UZN!9T4ZGUY)_VAZOFESYIKBITNH1
M>'C %5 CJHOO<@,$SVI\HFB:]1KFYIZKD[ T68JFNP=TR#+*FQR*I*Z/O\](
MG[$P>2'<#W4/0SG349K^E#O.;=R'X+\\/>%ZWQZFUOZ^6JI-M40YG*#<&@>8
M36=;[;L8;Y/4DT<E*;.U7&0H=*Q/-0UY28?0.F<A\K=U!>:I;D$4YV8O_5!Y
M"=Q]R0X,'&TWNGR([0:!*N5L;Q);I(<LPYKEEA..[AS+CUFO#O&S,SZUE96U
M09:8Q%8M]Y>+Z\S30DW9#GX#>39.:;1N;I[)?^2&GYBPO"<E$ES$AE;L=9NS
M==5/$>44HX&*4>KMS:V0SMF:DO-'V(R<>2S.1$1\&L\DYW>0)ZFU=]/P(Y ^
MWT9Q2;(#2M[U^S:1&L]65)@LRR,_JRF<@D-I]BFAB%"(DXMZG4ER&Z:'#]U'
M[</VZ$G$.PBWFI8%!3B(4$)GVG*V5M\F%S]3$^X<EF\MLDG'1S/J1P1*1&E&
M"!,3H0ON ?UPQ:0B4)NE/:K'H]B<(U'-[KMN?_M3K9=T7Y@>R>Z6/S!DX].^
MKO"VDC2,YOJVIKFB,-)0R4:1F(CN3<M2.C\M'+6"6T/D2=UV@BVL"T[K*/,A
M!0Z4R#NF7G+@Y=RI @VH-I&'&.Y<'IA%1!9:5\#QJWG.UB]7Z[2%H94O2(EP
M1U($<)D6L]# M[.#@RXQ3QRKNUP]2T-\U6X:+KU9:ND\)I3\]KR<O"TB,W(E
MD>/?@3P55%I33T7'9M;X(N:#U[Z<8$Z1R3*L?"@S<DB/\RHQZ_%U[JL8=^$<
M^A0F]RR4.0Q7>JOR<)UINI%<:='+GU[8ZI4BM%59GM&ISZ82+ ^;0NOVP,TC
M7!*:1$;)^*C7T:.B6WUY ]![0,^U8O*69FRG9%X_I7Y;9+F]+ST$2I5<U:E0
MFOZ$7'\"TRI%]LX38Q5=V'_M$P4E"]QB;%J&\INH<%<*'9+NRL8/TS8%?>QW
M!>Q<5LE$B/>?1DM*,%26@3L7+7(/UVE*&IIC*6@]$]OC;4?_U O&R\B\K"'3
M:*B+Z]F@_GW,^:IHRC%H9@$W7TAK_%)?(/J&L#H11_7W1J1^^N4&_JW Y27J
MS:S=91+SB\<\ZZIG;G-3CR>?H=,"GF_F:)HNU:N!\,Y>O%=.MY&P?$ODZUZ8
M9#R&=MHZ5NH7%[XU?]'4W+@H5'G 59O?A*5(XZNOU9=3K+PGN;DHBE+3ZIB7
M]$ $$]C3OFT;AF3<.-]-X&W'Q+O1UUFU/^[YO!/F"Q>?IW]F,-\8G!2V;8P\
M'@BUW3KB)QJN^?A5Q<=9X!F_(,;7B54Z4CO,&B1.-(3;Y1TJWKAZ*)U;T#1]
M9LY1[ZQ 3X>*B>!",CO/;]_S'O 082&_TOWTFTLMS-X(LE NN@T=7.BQQ)X%
M"NK/_)8AN#6:DY2SNVKS-+X]$JXG)>CYY$#&G,\:PCY3#EK(ZDB*"V(PLP#[
MP_P(7*H&Z=L.=#-RM#]')G1Y5^ABV=HSOWJ@3B>C ^[&MSHH[[Q:AZ:%+)X,
MD!7R67HB2TR1/I=:-ED*CN[OFO6)NUGM>K5QZ4/\2GML'3 +4;R4_ ,[%$Z,
M0?P%7::BM!:KN7F=W]<U@)1Y?FS>G>Z]CXIDLGSP*TT@"7GH= #?!I46G.:6
MV9K+Q(E;8\Z>@90]1B0O8Q<.M23'.&IZL%@O*;E?0FLNZE!HDL3Q\<EVBL*@
M:9D8^<W&4SLXR)3G>^62\;-W!O]))/HBN/^32&Q!Y?N:KJNKKV#M!U Q1,>C
M!4V2I>**@]2,5L,-L80ZVO+7':Z:$H&@4DTB>_%[P#%]C4BS)>&9L;U(O3Q%
M[VF\&)<HN20IMBR+6ZHL0XQ,;( ,J!A6;GK4YBA"EBWOQ;H#(H^:-LUF[)Z_
M@C;%#JVKN9&:8)T3_-ID,F]O]ASL\&6$U4:M4V;T!8DF'BE VB)7#%(6UI]%
M]R6O]$T7U@]$?1JVG,(,P7$80';6?;!$/H.EBS=]SKK-H%TYN/9*FVO_:!_P
M1[*+/YK9(70J?"5)EA@T Y4K!%4RV_E!$HOJZ)0=3W3>1VW8OZI^@@ID6'DW
M>P^P<WKNY20J/W/"(V02@K*;$<1[RL<\MAHWQ)Q(K.EP<6.F.'()BG:LY3YA
MA:2.MB@7&]A9T,"[&;]LU^43J3U8K=<&$6_4,92?(7>Q;: L'0."Y9V ":1#
M4#/D^_WES$UX(-,4!_> IX[0E]MQ4JP;NI#TK9$K%?M'-M)&]"PLB1)[LQOD
M08)PX;][H=4ZAUOC)2@Z#A[NKWC,(S)C16$"4CU5X_)J>=V,5 &\?FT_]Z)M
M%LT:EU_,9[+DXM:UC\6D&3B$7T6*_>OA)0SJ"=RB$1XW>./_#.\>X'6I$NVO
M'.;\8J>N]P?=M6765'B?'^OX"GP%1!NPB =HL;-L4_2*#GD3(3=D^M3'<\<@
M=? >P&21\"#ZSN\!13;-MR2(0#)5-+=EF9%]TT&P5S[>+I0_,DLQ'7":23P>
MYC;@%H+S09:^ ET+J_:P=VZ[_&K;(<=:]?I,:K9\?T@P':>.0LCO+HGGQ_5;
M8TC<H;*H5,KJ]TRE\K<GC&G@5TB+J,5++?$?LTQW<^)^ZX'0&EM2(&&1LB\
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M]>?(A:2M\>>_NT@,%0)M?E$/LBE2>[Y7?)*KR10^7*W*@9D^'42+5H(U7V;
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M0A9[@[',#ZD,,L0)-%E7&E-+<SAB5B\\GCI]ZX(/>$QXF"50*/>JBWI6?=A
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MO3(S@=1?SKLZE*#)5&.K\+%F]Y7W.D/,XGAK^J5PVQON1K'F04P65PL?R5C
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M=#9U'K]'<?)."^=+@"8RI@U5$[HEUN@D;SC#S5W< (7,[*9(1,O3%477U3<
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M%Q"(*!48:USX*JD(UG!.$$,=W%8K$^M>ZI3%4\%T^];P( ,FDB&UT4YFIP=
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M4Y.C[SVWW3SXV$?8I%_GFEY/IQ\UB3MQ-B(R(S:Z73RD[8P-[!L:<_2P=VW
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M+3+I>/7$2V;@3[9$]##>)RD/X@/]%MOVW)>C9B *E*U>/S"C@=Z)NN#=KT6
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M\U%93P'[04J<->;/R@MT%K@06D096!%/Z?)[[N)%D,?SO#XVQ+!+^2A)@6A
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M'@$FOPP2J&UF -4=J4-8>*%*5)<'P(C"RI1SFXI*U<H35&[Z5LSQ*Q2H6"G
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M'@*_/? L40+C2QI+.##=E2^*4+Z2;RD?/I&_!X*^H2_05>;EEP53_FNWH6=
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M)9\IL!Q=J/RV$X(6CE4KA'8(S>69=/;B-+7;THF^%3E6W@H_D&J75/8I?4.
MD=N)%:CG$XL4[5ECAJHG%Q[^,C6WJ%<DFOV Z:'U[7EP]'':-*2[/YC^UW3P
M,P/'YO:QEA@N=B3&1QX7&#9.=)ODU"=!O((6?'P)J#E2X 471 EQ8&SP*G83
MNM624(A6+YH8P3$D'RIV28HV#4Z&R7Z^8RU_;PG#L^,T;B,!?U8\%:B]RK;*
MB3]>()M H0_,PPM1ZZ9SPKYMTU7>AZ5QVW]FBGQ&23\^LY9E'&;DK47/&D4T
M/[%O7UAI/RM2[3XW)TCXK^![UO-XAFS@#J##,/GOSTE]Z0*-4I,[?%2U3%0\
M?0Y/:9ET?5$ Q2C?.T6*!%PO4K1](-+^]UBU0C%O3'7B[#'S1\[K@#]_%-A6
MP]INBR)R^8T>6)'!$1NW8L>!2N5]5FDB"^EA]E^1O:_"QV:]L,IJZ9'L,7=T
M ;>"/87[%'J"9F..+BZ@DN5TDOO:UWFK]QO+]2I#TAZ>X_"=66JLH<27)X,M
MA#VN#S3DEZ*^/.2D'<0$0JY26)SKS.%8[G+T89L3U."001\HP6:.D61SQ$[Z
M6P$5;&D<YM"^4O>E.@@W;%6@;[,KNPHHP_VPW-36RJ=4.6PS_^#9^#>NA$^@
ME=E5@]8&:6 D?9Q7&SS5(I$9Q19W/ Z5OY4I]G7J*7!,6'S')6;_DF 2USY!
M']T6UU>V7B/2(@<C1;6R4()O\^NZ\@LA-#@U>_\Z%CC95$(FOJ;'.RA\F%))
MBX-J6-&"[(:A7>/#G@VJKW0Y4*\+L;KH/5/M@LFJ)K&S(_I*.P'R>L3"[;>+
M[)I0-PEC^&A_"'YQ4SA'+EVP)'B$D889O""0X$6)GFRIJ5KA>,,+9PWBJ0L"
M6=(-1142J7B_&:PG<O- LT*369M%6R<@WL<:L.\S=S:'NP,O)QJ<G:\EFX]7
M$SL#[*61<:.HM"?>%;)9T_%D1WX4S1F)+ )'>@LKGE$8#/VZ=>4HX /)Y8S2
MHE)L=\/==/#$[1:PF_),Y'YU!3[1)3DO.\A[S9S+]@BH)7^P"A6G,]=#[H5!
MI(O!%8^ @3IP>*^?R_2)1MN,95CSB-Q?$#VV96YTTGV=Z6XGDJ$WF K2U@@5
M_MS4UFRPI)P@(&FEMBP2J=.:4^76QHC[0U]ZLS;2WZ2YG:VT^E#BN-W%.FIW
M":K3><:]D>; E"&L2T6U)5YVGBWIU^UH3FBJB@&2[HIW9DK)9)/^JV ]PV@5
M*I'C"<.*A(B7+JX=2O2+(,WS4V>?.[)\5\80&,ROHV3^X9Z5_199&QVH6F3B
MY$]?CK=:7<;FH]E3^'MXY3.F3BCX5:NC,)WHV_N?PC2U9";R=CR-#M;3/#4+
M+ &ZR5EQ\$'XD-BX6]!!1IZW;76@)G*W=K.<N74Z*KP9JJ^WQS?F@TY/Z;;-
MCI&4EPCP3@VT0860+%7ELK8P.+U+H1E-<\*B,N=OA@G(CS,XUL2;(67B-X,X
M;U7-9_/K&EG>##,'G2K*:8I;AZH#V"#Z?6NO$6HM1QWN)6-!I:PSCAY]TDD[
M*MMMMI+J?6?D+.5X$3/BL)H/!-%-R9\SS<0L,?,<BR$$PL/]/M HTN5=DM]B
ME!CGC#^068 + ES4?V2V^7(=I*0KE;S=GQVG8B;"TO6AUA7-XK1;M'&5O .\
MF H5-=EL;92=0.BO4PP!<A+FSQ9N$+Q^O*$=]@+AD0/JI.\PWB6"7AVPW@'.
MOM RYTSEBF&KMT$NWZ^?[0CUNR^=?F,&*$%[UY9U0EZ]%P-_<WF[8G=QS@1>
M:U=HY/,,T>^&,FS*)DB$Q$B!JO[-9"HSMT71<:>IM^E]E;"%3.MCGWFMD"2;
M-4VA=+0-72$?9U!YMV:2:NJ?O%)GC6NR !A]':C>B*N;X*91,.^GF?/UA#Q"
MYR:<PP#CRLI19A#N:8748@2Z!3OW,'JRUJ%)^GUS@2]B;XM60J+#I+F#?RDT
M=2J9XP^ X0@SGT"U =6](7EO)"T"[?>!NW/E?G*V3K%*N;&T?4.4%$3=U'1"
M@_+LHP"ZU![\6AB9AWL4ZCI3SH6GOJ <-P!TJH,Q(<LPBM@[DLI ;!=.^<ZZ
MCH .L,7T^:&]_@_5](5"_C-,'6A8DE*@7E)!:=4ZG101>36N+\FR@V>; .#6
MUO2GV]6X7S[^7N^#,.(J ;Z7W6>4:A;ONRC@#%X37/80PQ6,2$AR VIHSU8U
M!HFX*.AV1(U//U_E.FO])#^3&O2'0<<$_ULEZ%8%F-(;%[[7-W^FUF@=4#4@
M+W,+OGLCFP1@C[Z3]@Y.9(L'UCY!+ YMN1:,[5^ '7EFYFY2M.[\0"V$?>S%
MNQDO4P_Q6A;MJ3X6@;>V=!ZY5C4/XEO"/>#H03VCJ\$HQ,5ZC#!<4+6N?B&V
M>,@31\7?CL/WZ\=Z@!C[MK2'TTE_CN=;)$_Q1K5L[TUD;FD5GL_2+L&OC_5"
M(H=IS*FE.VI=G>Z36XE WFOQ1)V'@6\AY_F36$%E!^3MZIG>90?$UR(9;I"S
MX<:<F#C#)$R5WUBEPB-Y\5WHU(F=L4C6EASW1J:%!P,N ;*BY29CAMY^HGW]
M!^9'P# 7TOP^#"1[K@!-70-G]J0&C_([DF?Z$ 2PI>.U[R-=2)KV=8=/NY @
MP=W5)/^]'Y-8]>#H@1N*R'<,R^WARYT]KRCU1#,,W:'.#CBT_F&?H#"":%<(
MLQ^,3E23PD?/WJ:$@\4WZ6,H62$.A/;7'\[?XE*>)C[E,#IS-21[5" GW7SZ
M3R</!Z#P8%-YSVZJ_LO)H3,>8[<5>;'?8SHH#:G,M5>H+^M+S3<SG7_1X1GN
M+[9R(!D8%5&6L];AG@F3F!/A76P*6\G1@B8KYB&VAYRE:M*SB/TS/Y%O*Q@Q
M)F1I(+Q&0;MV;M[^=KL4Q*':?-,$T9"?P_Q4W9Q]])];+<N^%S?AZZN#P'"4
M=^4^E*%!U7'2?%DE"%2X=CU?*?#=NB=-,DV<3DEKQ1\J75&];?8,)>W?GD!M
MEN=:N;=N:NR'6!Z9#,-IST"G6D%CL?BQ%P>X#,%';?5U<;;FKBO,OH.2'] ;
M^UFF8NMJ*"Z^JG2Y&A2ORGX$Q#]@S(CBK!.^2TA3P2GLX6P7X%?DJBB*Q'VQ
MHCBS,"^26#CLBU12G;LP9]@W&O]I;R^A9&MM]07RI4O H*K*)ZJ'BG),<&/^
MNS5//&PO8YHB8()P7<%M --6;N'E4.LV\CC( 5T5YMO?&DB#^'=XPY)QU2*J
M2K._4YAJP*:]WYKQ$2#"SYA!)3;HK[<20A@H\$"39Q8D#S__QW9*;YQM6&#-
MAO:R[!]5[ I_(^T#)L1T"3BQ8"\F(#&(A2[V:9;_YLU#^D$PKP8>>*NO6<,%
M-LKYFEN8LL;K7A'G6Y'!\90J1X^D"3SPJW2,$-HD*F# 2"G.(LN4>%<E Q/[
MS2B(A>MS0D)57&EIDQIOC-"?0!7,,.[Y5778:HU5Z."ZE).;LK/+'_82SW6R
MT4 I9%1YS<'29735L&6(2"R+RGUY"<FVR76<.I_*TF$"WQ-U6=V_,U@N, <;
M#RXNM-.7O.H([IW?\-,F.6=5 _CHR;!-7? 2'AC1)1Z,ECM:"?H!%.GUD.G;
M"?32V$.!^CA(WL$O&AL^G8CY6B%9*R0&.85.KQE=57U9NBBMJYF;\DBNHH;P
M;R.GDPU#H4= '$7<2-?K9&W1#RNGBUEC(4246OM9BTC9J)!?CP![$(&C49Q?
MFD;9XI@_RUY@@UJ77)"?E>Q+P'DG!<P^ O*^EHY&$>IR7(LP9-;U)@Z;_?GE
MO\",@C8X$\8;*<7D2U<:(QP#KRDR/031:@AEAT"TA:VPL%+Y3:#]?QCKD0Q]
MY2X6<>S1YDEK C&8?]9$<'_280*V%G0)7@"I9:.[WH OI'2#'$N=6D13QC"@
M]55FWGD9& %4OUY0,FY<W&AB%3OX/Z3#3-](J\IW1]V,OWT[BF-CXXWAC;5P
MIMMT0N%@1I$Z)WRO*$GBP\KW7<'%DAH4\@T7E^,DX9Q*2I\,D9C?B:1(\G8A
M#>F/N]73L7W%P_Q]7NKC_@%.".'&UE(FS+2X\ZK_)&K23)X627-;\OK5L;8>
MX8C[D9QL),";Z.X=HBB7E)[E82%.FF7$TG G<8N;S?T7,X?5BA>ZL'5?EQ#B
M:8NW6Y/?SF*<&5N/AROG4EEC%?#_J5B0:1UP8Z",/**71) ='&3<*.;AC4UW
MWJ^V9N'X+3'M4&B/B/<!5&C4U<PFSU5J9-C?5YFAKE3FO0.">!STQD<&F*R)
M;*_SG&M\HIG+#AS0 [11=1M!S$9!G)I(/(B^NVPFQPLXK=J_T^<<T8LQU0PD
MX+V^8/Q3I9@+ SA+WOTG)FI#$_^827+F=<I:,90*#(3M8(XMVW"G4;9_*7HY
M8U)2YQ+R!MO,FM/>/]><&;U@G'^I=NG R#7B]ATX-81LU7A1>C?;22@@OH6H
M/%*>Y%6#>\[=EG@^_L@RC"$2),7I"U.5MA(_K^1%76=QK&;1Y_GS=?1LNR?]
MF(^JA;DPO$4< I>J#^1+WC#?YW.*,?W!"<U/2^W+/S'SW 2Z< X\ D@>&#6*
M7QQ#I,L,Y:V]W0GX5B;J(N#,44SJV/1=UU(343PU$ W?3?.HI11'=D1-@5![
M70]:8:.D2U?%\LS#=3Z!.1(K.5!X,Z"LVKM:=;@]0U;8I3!<I7CQ'I92R4>_
M;1VA/;QECC^T<874N*P2<*@KN>J($0K%6_;GX/[Q@R@APLS863C>//%!.#'0
ML!3L<[!W5&_\"' PP$Z<:TU&'[5+$=/Y(C<A\ZWB@6F*^SPDU$PF%=J?D<MT
M&W1FJB;]%8=4Z\,$^?G+FCYQ*JFK? *C*2G@YCJQ$W3)-;I\*,#;PMVM[J>+
MF7M?2E,;Y;5*#<T65B+3C#"( .7EU)[T+;.EXB9A*5 0^WVKGJ3V.YUA"P'"
M8X _]7D0_O1:7]\E>8:FTG.(R+^Z 6JX+HT20)\(R?F@E!<=<DD=<D\ZBU:6
M*X+(^WRN^D*8.WA#B34%$FZJ_.%,%7]#8"#3W;D]M'1/)CJKPQ=)TILA0]F$
M?+[;@"OALAL\QOPS^EM$.+D4B(5HQO6])_VKAI:.^\([%M?\)!#SA_8,Z<.<
M)$K+Z-8)S$I4S>FHTGT^1+(<G&M0?9XQM1O>"]N&QW'VL1ES@;6M?U.]"I4T
MQWURJ;G\AA/1PLHGU"O)$MR)M"E[!1P;?/2HJOCN!+-G==B7M41O(U>WAM)>
M<^B.$/_FT73%<'5&7\CJ:>R>"92_531>!YN!0=;UD]OQGSH:W9 [1?0FSEOA
M*R1)K?0K6BC'X@551,1 E*JR82VO,&NK581 J %@J.LYP*?A3@?QOKD),YTW
M!BX#E7Q3,C9!OTNE:0,H3)4D)YN'1@*I7;XRU%59X1A8XQ4OF^3$8-KR4O$^
M(*4/EZL,\S2:?5F_%VJK'+MQH(]5>T]0!+Y'8M;D$L];(G;#BDR%DY??9YE,
M!$@$W1<\Z,JGC&/+)E/[M\0(3T0S$#29Z@^T)W9U>[IN.IOAF#= =A!E2?E?
M\$_]S.8F[OB1^#D;RQ.$8,D!_8PE]9^@B@EO5]<B(NY52*G'GX0%O$F$A/5A
M? CI!:<YQ1W_K*L4C3>H>K1PK<>;RR>)%6^GU4=3/_SM-G)?CMSZR<<, !/%
MO:D"0=; LOKKO$65HL'Y"O<\KC\:W^&MU$/=J+SJE3N!Z3MKYVX+%UY]57.B
MA2JGK5&"G1'2+\K;!93B5-L_]&T9!D#HPYMUU8^ 7M72ZMKT75+'V8]BX^N\
MDBTA#0E00<1HKT9%(#O4$LIMTZ1!;K9F3N,71<^QAZ;#7-<;Q: E1Z?1'T*J
MMID<[1]56<R7>O/.0.@^5.9ZAXGY#0%>^'+=.EFZ>S7P1K\?A [V/]&^?6OF
M".4N%TVCO/TX-=@MBW-ZMRAF@@^,0*@7>&^9 GO6B.>($KIP!34J*VTBI#O\
M1%9R2W/6<WS6.!X!::$(WGL_)X:;9Y.809"N)S[7;T[I>*.?F/>N?JJ&,6[M
M^33\&&N"T#JUSU<SX*HZ! M<VT^(6KKJH1<E;W#2-(I?YGX[+4AMUM/AR"K!
M&76 11<DX!'(5+,O(3L0$K.E/\=5A;-F1':KV_N^]84XLSO5$[L<0)X,WG83
M@NW<ELP2?XKDT9<00K17E7>ZS,+FE$SH5_TP0Z5MEYT$GW/)C<\=!%6.>B63
MHM9 \4MF.3 .>&.GJ/;,7FORAWCG^O>_RG186G>NI5XO21_63PIUDRZ8J_#&
M0-0<*Y:^Q57Q[;]=J-PF7(8,_OG-3'D"C=ML2B;YQXN\[<MTK-ZO=J%/\4KF
MZT@HK+/]S?WC61 'NF?_S65'6>"'.H1&U 7E>90+?Y/JZ&6+81'1=:Y1D=,Z
MCZH]2\0 [V?A>P_HT%)+.$0KA+Q<NKK(]U+_\%GOF=Q84T3A77ZEA0U:EF^B
M4-Z+ Z/=G#*G7%89^GG+%FO'(&"9$HCSMP;SWDB[S146U56-_69)'K \T 0:
MJ/+32?^FZ[M]*5M&5C&\)QON224U_%(4W6E3:>39%9T*(WUIU:$_*+JQ39C.
M]9*&4QE!;6B,SIY/7W2)GF:82X_<B[K3"1+.B"_W:W$K_78YW<-"_'F_PR:N
MJ);Y"_^8S9TV4BJ78LJKW**ESO%$6-G%JF-6QXN<JZ<[>*&'$G!%YP^E*#(U
M4[U]]P_I),,Q<R?O29_L1E?%_>X50)F)!O]:^IJ9_@GHNS^M%B&2>E;\T$VJ
M;;PR"N2RPC:=5AZ'CE2D-=*+6H,Z06,P4W("O*?[+R]2ZMRN\96-(DI^YZOT
M"^FS&3K/ 3=S+&=N^D,8V>CRVYDQV#**]4L^%S*\B$D:RK42D'6V8&AUGR?%
MP H[GFH\(6>:)2VW)8_WY/%-.DS]R? !<"(<$NLO&@MYOX$*9*J%9%\4J[8R
M"\A-O[/\DOBG1Y6)T3-<X+E_@T!AA@?9)YM4-T M,[(T!L)=?:>,P/ 7OH\J
M*!NH<!58$ABQ_MS_"'CM_8=*C$EECVK /[C-7VB=P$ETS!EJ-3]OF-B>\-VG
M0!)P-2A+#=B#/[P!OSG\%-6+Y\.6X1?XS89?F2G]++&2WYP[*0!SM^;P00HQ
M$5E+/6,^9]V0XQ(,W8&XJBI!V!315GP)11+JSF$0P<%<YEGOB<_M=@6^L&2"
M(5"0=.7R/VKO;P0OB%^_8#G#?HZU=@W8HK71_WG0G'%EWC@? ^53XC1&^3A:
M\;0M//B($BA$,<N<H\VN!<HC.J,B+*M,#Z:*<XL$[=ZY3IN$=!":;B=M@>@.
MKJ(A.H6HFG'5ZF?W/%NQ=VWZ0.;^]54O"RJ-NF>0OL$M[>;[_//*2.C1^0NV
MR5P<FN5;>2E%D"0O=?@!>CKCGK18SYB7&?H4.0$=.,(@>U B)$88)SL 7,OT
MJ\G@G:2OG_.F3<BWT+X?M"\!AQ?KQ([T5.%+03[77(7MK<8.15_H2MY6_2;&
M)+4TV-[ ]:Z:P'_:^LRX"T.O572CN.-3%AZKTU4<#K&5CJ]8](<I)D.#AP:\
MSG=$0#]B#9!L_!%SQFN*-P>]<I^2-B+B,H?XAUR0(9M5",58WKP S W^VP;0
M57!N[M<G"I$&4_H,80UL-KILH.M<YGD$- R1IBE7WN\:S,4E>\95PWACVA7S
M$/-7 _[<1Z*(>#^U'RGOSA3/,*PJ-C$_N9H0^VRUD8V@GE#%G>36!(,"K//M
MA/H\^]S2)DMGNJ7 (AF]^KRS#<>$PH MRD>H"P5"VMV^BTQ*+E<)OO$98+)[
M!"B].8ZX+6XGVH?+T<<_19 A\F QQ&KU"NO Z9(\ZWF(31;EM H)"],7P.&7
ME7)7_@EF,09"R'^T@_8&- !-NS5+/BEO#EP"J3UI!3!:M+,'W1:L!SV'M[(6
M4/I5CNV9?1KXR_M+D=6S\UGO"TW>XX[ <?SDW39HRT=^[=V63O\*9EQ<-@]T
M15D^/R*:(+]7NU0NB-H)HU(G<!MY<?4L5.(1@ L^Z3,3 *8CULKIMC.*_*:^
MK8E^/)<T08\X3-#SJ47:_[XAK^;)+D>%4Q[GNS1PN:N\Z5T<I)OZ4#!A]ZJN
MEK#G]L-R4[[R;CNBL0*>#-';<&'?OZLDV'PRP=?Y@>P9?0/4D8E1Q4#A/_/5
MM45:@B,VSADZHSMNF&@3ZLKY!.JS=X8%#C<81FL%Y3WT.2(3;)O87SX:'W_&
M2=V^?(DMK+T^]$#3CEA]Z"2[K<DIM8=KJP*%7,@!4H-_& KHL/S/>+%03IPG
MX3)D\9_FNS>I9[EK;;JG2MN\N/*DHOBTQFE) ^$3;\5+#[OX9B%*B&P86V9E
M-DW;N?)GAB4C1UG[CI6"+DV5/EY%*D82.;KS$+) (IYN\GB&&)>L2T,,Y6?=
M&>/@Q5UKNR-DBX_G@&I >77+$Z7*[*\E!1:IN"U1UG.QO+R;V W[HOCVZ, ]
M90TR-"3#A,BHO)59<@BFZ:AKG74EG\:3U6BT-9S>5OY^O[ZFR""B@E[;Z=W
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M;1_@][SXU,S$Z,L6O=&WR=:-E+,?]LR^SI-851U5#N-'3_&K3@SP%)>Q!AD
M*P>5I7TP8[OOVZ<I(\I,=N<D9*<3&W.R \" V^[/#\P1ROH!I75NY92LWT,2
M .(L-9MQFU+ZL%KT]> )M1)'_7D*S"WUI+4^M<BYO3/$,XZ$P.6(+:F 2:SB
MPS51Q%X4S_RR^9QE77KUTLZ[B@7^RN<LA/P_?J'Y_T#@\4;> 3=/J)8G1*.:
M6#K)3^IM%I 0^^9M-TI[+"K:#6A>US?S+?90QOE-E6.XE#2G;!8Z_/O;9^N:
MGF-.^W'-CX#&C#9:CC*>0&F0T+*B:/O?3R0G+?]I9_+J?]!PW?]_ZKSFXZ?^
MIP_F_V00L/WWR?E#V?].G^4#0Y]2=/R#X$/[<U(M8]J"_Y=*9ZSY3UK_39GT
MN7[=S%%CAQ:PQ$C>WI7JVWL0\6!HVA.,H&))#1HS* .!&&>.>'A!#*,MS;'%
MZ0CU6:U4-W$I_%G <J+,R,'!TL'!-'8--V43I/Y=%2*5[P.Q0%$2OJ269^GB
MF@9(>+6(9-3IP1:2VD]5X&SMD2JC$Y$0IR:JV31W7JFFJI$YW@B)9 ]7*_;]
M668KQDCT10G#KFKR.=CKEA-XF+T<(/:JO6/Q,G8K5G=WB:]C ;<9"UWZ.6MS
MCJU-6G%.3F?[RH>9CW7O*EA3NLZ:L;@"TH8KA30Q_2:%/ L3:?=%V#_B-!K2
MV)S*C;OO;+D*PM5^(8YCBU5(]K-D\FP0/Y5(C)>*[(2M<#@8<='#ODALZ-@A
M%<- E7@\6R8S5K.4&T;2*\#7,MG8$_OZH/]9+UK-9X;[ET9>'FQYCL\K5#G5
M7O40Y_M1[OS8\!AJ.P!FYO52^$</+(/(G/ <YJGM?LS?!*JFO?D+OQVF80:X
M7"MB'_CK*Q4?&IFU.;EZF7Z8T JE*S%6F=?%FGFC7-D(T+,KWZS&,4D5%^ZD
M4)\UDVV%^L2^UBBP<#?RTGPN?IXHLCO(R9DC,V]L8&@DQA)F2%@^\J7(@M"/
M/IUU/L<VB!62.>]SQ0ODR,+,8O7$24(O9]YQU6#.JGL/L'<RHYL2SHZQGSL/
MP+G.?P3HLLY5?)BZNE9]IK1IF/L&4>5?&W8G_]/AB^&BR0'B(]6EG\.9A,O:
MCJ+*ALW&#S135E*T"0=Z_.G&2FD!8"*G6I#5^#BG;[>JC0!Q#"GLK:AUW/QL
M8[6D8:-(>V=D]7V;.-_JV_H"V>-?KZJGY,B\X)P:4_#G-2F6+M:N^.]$?E4I
MRVZ\ 911]-T(.+H[QA89<'_&9XF;-&:,$\%K%2CAP]_Z$0;-FBH,Y5QUG->?
M-AX.L@=Y7-;'YCL6ZO.U;DBDRNAMGXJ7"=-A*<^SA9L:?ZCK2EULD;O2&V:*
MN2FW< /#]?_EO^Q3JZ,NF(W,:>WFN\8\'#$7&OIQM)X GQ ;%]2 -#3-<NTT
MSG(7M#=_]QG&148KT4=J8'R:U42W3GR5:!VK2P30U:5\B27W_&U6T __SRW(
M);G,M%=#K"/]&$D_"S,&E:G$R*SB ,45#NU/Y\G=5"WRG_/LY6PEU\6"XKXH
M*YERL43LC*<7&2T;#+ 0OZ?5'&1.Q'E-1^H.G6XLR\<7[0DA.+_'Z6TG:VXI
M<?3-&LQT_G7?Y#*OJ"UX1?>5C_967S_ TK'<L+/D)_#Y:F,$P=,:%>D/P,+2
MI&A*'Z:$JE^NYD\)C4I+D$MF2:IZQ:I<](:^ 4K+C&J</?38/Z]=L@/&WGU+
MEUHT/I&T\!A"9SEUU^/(?TE!C9_B6ZE08>JH)^A$B*O@RUHO5)=\:9*0_'OV
MLCTH/2&3P-;Q></J![N<@EC-429*G@4&P2?[1SX]C%MI_A+E/Z3CHCCZ=H:[
M]ELJ5'-Q,#75/W7#_J*RMG1QN.Q]"&L1@=]+(?>51KD_<?YESC;H82G_F?:P
MU)"GZ"9N<3E^+^;MU5O6,T.T/V\7ADW^K_:N+)SM=>O_U52$5&NL>2H=M%*J
M:E9%5>T00XE&M(H84C6/J6FC54T,F_W54(J:(K054E%#:V8;:@B2HH;2&-I0
M5-GDQ'/.Q=GG/-]W+O9YSODN7*RK]?N_:_W7\ZZU?N_-6M^P&1HOS30LA3I?
MF<YZ*R0G2/]L4YH/ZCW7 A=)5$Q#99W-+='-PQ!4C\HS 5B^.Z$R[PXYW>NT
M)] 0^K.JOSP24L@MQ^>J$]"G;9>DPJ[<EF5+_1YW@2#_?M9\@U\_PB$+=AFO
MZY.?<\@O?>QX'Z,I-K!7XLI V]ZOQ985=#*F 3_U_!4QN_"Q549*J8]?QT_[
MZ_A4O,@BJ97O4KW#$9G/)=%U1]<FE'@QAB[WO"Q4E7\:NI-IJ0.M(8;%\L /
MVX%B3$>ZV',$N,(%3DT(L67[3C<(#$9T$0+1^N*^,4XD[(AP)=NB9,PWCZD+
M+I[AX73O8M7'+UXXM%J@Y) JLI_K(<D1MPG6AN)D:&*@)8?6P#K&P/(HA@F\
MI!;I--8;]L*K6>7Z\YRE_B"?;:9]EDFLDN$:I.=2\R=<P/!(DLJAW%I<\;BG
M@D7U$$%UG5$1.Z@B?)NW-5,":.=1U@U(MVV:!C/Z-Z\.[@\T&(RJ;GV*(NZ
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MH&Y(,G?[LBNVQAG)L^4?0?_J,:!1=_:+<)KG9+>Z8GD+2/Q!%\?1PWK>SDE
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MN'AR1:'7[LP]X"-;#-RN=S>QG0FLJVU%,0$.=2:PYB9S:[5I%Z0OPP3>@IC
M[T\,I92$#U 'J /4 >H =8 Z0!V@_B.H?UH@@?G'CQP9DX\P19IXO_(IVA1B
M,:1@T:RVQCMTZ(C)82N"PM.4N-P)2P#]_D_LM3B0 _D3PL8<_PM02P,$%
M  @ MD-94N;@<Z)VUP  ;14) !4   !V<FYA+3(P,C Q,C,Q7VQA8BYX;6S<
MO7F3W#B6)_C_? ILMMELIED@DP=( C7=/1:ZJK2M5&@D9>?4IJVYX0RQR\,]
MFG0/2?WI%^#AM],!.L%@CEE5*J0@@?=^('YX -[QS__SV\,</,FBS)>+?_DA
M_#GX <@%7XI\<?\O/_SV^0W$/_S/?_UO_^V?_R\(__>+C^_ JR5?/\C%"KPL
M)%U) ;[FJR_@=R'+?P!5+!_ [\OB'_D3A?!?JY=>+A^_%_G]EQ6(@B@\_&WQ
MEX!S'O"40()P )%2 <19@&!(41K&&4YQ(&[N_Q*3,,0RC*!DE.C'6 PQ(S&4
M*M)_)EP%":D:G>>+?_S%_(?14@*MW**L_OHO/WQ9K1[_\LLO7[]^_?D;*^8_
M+XO[7Z(@B']IG_ZA>?S;T?-?X^KID!#R2_7;S:-E?NI!W6SXR__^]=TG_D4^
M4)@ORA5=<--!F?^EK/[QW9+3587Y1;G V2?,WV#[&#3_!#5$<?CSMU+\\*__
M#8 :CF(YEQ^E N;/WSZ^/=LE^<4\\<M"WIN1_2"+?"D^K6BQ>D>9G&OIJ]96
MWQ_EO_Q0Y@^/<]G^VY="JM/-SHMBKU4C)3%2AJF1\I_.=?;+%>(/)._J6-8!
MA*O4?3^4C%V8OA],W,^:'Z1_@7>ZN5KD^H-ZO1!C?;N;KJX6W;_$0WT6RQ6=
MC_!9;+O9$7EN_N&=_JGIQC340:95/PUU[X@JOZWD0LB:+?>:!KGXEQ_T3[-U
M">\I?9R]6)?Y0I;ER^4#RQ<5>9<?EO.<?Y]A%6<IQA(*G"B(XDRO3DD008JX
M2-((\8AFL]7FZY[)!?SM4RM(U9MM5S\X:+LZ,VL+62[7!=^N=P_S4XN87K_,
MBH=_6= '63[2Y@4MKS$-:A7^M944\!U1__F7K6)7X3H?$:WY2$#M2@EJ,<$?
MS9^?]><(7LR7_!__WUD,EWQ/QKFQ(Y;%(3Q+[@#/W@RMH%&T9)5N32,:IRCX
M1<Y79?LOT/P+#,+&VO@GB]Y^.?H6;HM6&5KP"X/4//$+7VI+ZG$%]\;+6)ZN
M6J^6KI]1C;@6Y >P+(0LM+U\0JFC#_S3%UK(%]I"$[KI1[DHJ[9OBT)_']+8
MTB^^;Q_Y0+^;?[K]2@OQ^C_7^>K[6VT]%I7-7=ZMOLCB\Q>ZN'NLQ/NK;F)5
MOEW4*] L3:(4TU!!07$&$14$XCA3,,."1Y'*:*2$"PV-)?C42*V23@HW&AMM
ME.U(<8ICYYEB*WV@V0H)L*LTV-$:L.]@][E&<U"I?@-JY<&.]J!2'ZRT_J !
MX ;4$(!\ 6H0AB/KL8=M2.H?3?91%Y*Q1^1P61J]?[=%3LA\UIX)?=:OSCA/
M4<*I-N95I!>A "-(98@@(5R*5&5<"&RS"!TV/+5%8G,09H2S6RJ.L.JF\FL0
M\$RU=LI;L]\Y3;?L5+;T5$K^\_WRZ1?]2LU,^H=#0CIJ;A3".*=$.Z'/_MY]
MPKWEJKA=BURC>;M:R7)5<<*;.;V?94F642(03*0&!!$40QH'7-N F8A%3&@0
MA+;3[WPW4YN,;U^^^0@:4<&.K, (:S\Y.W"]/%6'0<OSQ.T'E--$OHS#%=.Z
MH_'1)OEE!7>GO,73(V\KF^7_;KTRUQ+FIN?M8E7DBS+G_T[G:ZGWD30)6<B@
M%(1!A ,!69)@2!A'"*4X%H'3<98W2:=&0SN"WH#;^_NB.L#4^X1&:/!DI 8_
MZHV#6,[GM"A_&FF3>7',/>\JAQS)Z6\C-QO%O0]BHS&H5)[ IM%V5":Q2[PH
M[)]C6VB+^6#[0.L.GV<9VM^%_K58EN6,Z66&Q4$ 0V1N^R-$(!5I#..899AG
ME+. S9YDP99C+4$GI'2AK%U9_3'7^_4#DP6XKX\OJV6F-$J-O<J<&E(9*1KA
M4,%41$@/*9%Z2%4"F22,DCB1"JDQ;8HK!_3_O&/HCK$;QS:X<D3^1%;!X?&Q
M^1>M[70,@HZAF)(I<$K,/Y41T('ST,M_5U?]%OZ/<EYYO]!B]?VS;KVDO.KI
MQ??=W]Q^R\M93(@2C$=Z/5=Z/2>I@C2.8AAR&K(@0)E$5H=2[EU/C=,;^4 E
M(/C#B'C^JO]:V.UXVP^8GNG8"4=G_G2'9$A:=.A]5+9S1^60Q'JTT(^;;A^6
MQ2K_KXHC[]0KR5:O\I(OUXO5AT(^Y.N'F?["E,8@@=SX$J. 4XB)B&& 2!P(
M'&=821=*NMCCU)CHEO-"5A;,4H%""OE0+13@L187Z!^%UL*-G"[C;L=)@Z+I
MF8IV9358&FE!*R[XL1'X_!;,F9VLP1F2E"YW.BH766-P2$'V+_9CGL^%I.6Z
M^/YIM>3_^%6:#?DL#2.5,<)A&' ,4<P9Q,SX9:5"Q8B0)$%.Y^DG^I@:N]P5
M(E_0XGMS  &^R+DP&YY5([H;K9P"U8Y(KH3*,W6TTH%*//!'+>" ADR'^D.2
MPZEN1J6##CT/":#KT7Y37N^V*)O+\G8AS**ZIO/REI6K0ALWEE]I1PL3^EI;
M*0%="-#*J6WO1M(!/UL+/(;\?+NZ&_4SMM#[\'.V>:7?9VTN!^I#AOE\^=7$
MKYE./LI2%D^R?+5\H/EBEL18<<D$E"'-H-[=2Z@_'J&W]W$8(FRNBQ.7I<VF
MTZFM=9]>OP0FTD^LY_(&A!$,R W8* *VFE03I]4%_%%KX[C]MQH5.]89&FO?
M)[">8'9F)Q?<AJ0IJWY'Y2L7) Z)R^E=-P9[*A9T]G;!S4HO7\GZS[>+S_2;
M[D'_]Z7>[N:KCY++_*DBSY?KHI"+U8QFF,4I"V&4IN900(:015S_A\2QD&$2
MAXS,CH(5STZTOG)833J[",U!K57ZK9I:*_UGKL=KL<J?)"BVXMLQ6>_1Z68U
MKV"/Y)S72 ]^;.7_R>R9#.Y:A^K/6@NPH\8-:!3QC+YH7%>K.?NLH[ GR9]N
M-*R7FVNAK)<>TTJUH(11LYST;G>4I>5:K=MEYNIV^AG-[V192OG.=-8$#YJ8
MSBJD<\:0BB(F8QC&F80(,09QP D4&24I4PF-J=.1<T=?4S.1:R'=+-TN*.T,
MW($ \LSZM90WH);3;RRP!2)#6JQ=W8UJJ%KH?6B?VKPRZ,7YZV_F6E^6;[3T
MNY=CO^>K+[NOS+#$(:4JAI2)2%NI NL]=T2@(E2@),2<DF" VW1;>:;&-;</
MU<7+(\VUJ;K4]FE]4_QH9!WDJMUZH*ZZ?_<!_ZB7\CM"WX!6FSI'U*X^=0*I
MO5>]7^2[8CO"[;ZU2%.X\G?%S](/P+G9'L<"O?VHJO_\NRQ7^>+^HTEH5OZ:
M+_*']4-UD?"AR+G\*/]SG6N[<I8&61C(*($)-<ZN3!'(@BR#A/-$TD"%2%(;
MAAY-XJEQ>",H**M[L4<CJB;R6E9#ZD]:J\J_^5%SO="/R4)+<@\>95'?.%IZ
M/(_W25@<7DQMH'V?YU:>LB^Z/6I?='K45G^ 1G-0JWX#VH^GOE2MU >M_E/[
M+!Q.5:;V>8QT##.MS\3M]&;,(>L\[AE%D/'.A\;$=>] :=2.^^TN7TDE"]W,
MFWQA+E5>+LM568=Q4$RXR%@&*36W&V$:0!R+&#*"J4C2$(4B<MDWGNUI:M9$
MY9&7E^7:B FXD=-<8)@#/\?HFO/@VNWU!H',\[I<H?6V1:L2<?  E8LX#+GC
M.M_9J'NIBSH?[I(NO^#&$&6QFGTT1-5XT(4*$142!5F"$X@DE\8M,8(H%BHA
M"<4RL3I'.FAW:K/_D[%0-/%R.@>_5KY?M<W@YG]Q"%[W?+\"$M]6=U\TK.?X
M&=T[9K1^8V<VZ[\=SN3#)D>9MV?T:&?IN5_WO#?**<OG^2JOO" JH^#+<J[?
M+^LT7AN'PH2))**Q@"P0(40LQ9"%,84L$BE.HU1EH55Z+=>.IS:KW[V]??'V
MW=O/;U]_ K?O7X%/?[O]^/IO=^]>O?[XZ;__$X["['^ U__KM[>?_^YXZV0[
M$)974![@]7T?M16Y<O=H<B+Z\/-T16?0NRG;OL>]J')$Y.C6RO7]D9,^O,L7
M\NU*/I0S@B(4Q%Q!%4<"HBB.(281A\IL0S!':2S8* D!-B)-C>*N#CD'?QC=
M0*6<HYOI  -L1Y#C#MLH1YK>1VR\? !'($\B_'\KU9\CVO\(Q<&"^X];[G,E
M]OIEZU<=1@'I=LQ]^<7(5#E2?:0K6<X45:%$*8)89L8@#8G)]ZK'.^(RB3(<
MTLSAKNL:4:;&W[5\5=0;_08*(Z++]<-5HV)SW306UKY)=R<NP#HLX 8TH_.V
M]NC\..KHN-SZC#5*8UWG^!\MQSN:(0#NOGRYJH<1;U6&0&+_NF20%MWS(W^2
M?%WHW<[K;[QJ]+W^(&>IWF^$/.4P$0&'**0I9"DC$">9#*2*8L:LW&_/=3"U
MY:>5$;1" B.E?3+DDR!VKRM#0.-[M7!#Q2GS<9?J5^0\/MGL:-F.NY3:S7/<
M^=R8CEIU%L0[=?L@BYS3Q2OYN"SS%2WJY\O;]>K+LLC_2XJ9%"S"@3965:HP
M1#+1;(!2"7F(@Q21).38*GIU+(&G1C%-PLFE JWLH!%^632[7+V0;\0?P_G&
M8?1M;.1IC>G4CR]NP/DO@FZ_B-NI?A%C>&/Y^3)&=<::Q!<RDB>6^W#Y<<1R
MD.-/X(?ECNHP;E@]^NV9$Z98<BE%Y<K>^M+<J7?+Q?UG63P8%YL95W$:,QY"
M&<L8(I$R2#E-H(BIS'@6AX%RN@"YW.74S(=6XCHH9/5%;IVT-#UH"1[ ?$D7
M;C<7%L@+2K!@0L ,&??\),40,Q1!*@@-!%5$$N267GQ8[,?)%OYF;0K? BJ>
MJIWXX"C;W?\,BYQG VG_@WV[\[$:@6'UQ;[J2IKHG@G)&IY!$R)=[G7<O$C6
M*!RE1[)_LQ_1WSW*@JZJH@I\^2#?&5_0,..(R"B#E"44(I1H:C%U6&6"-,'$
M JN$SE:;JM87Y\B)/IRH_$R9[D'S_;4B:L;N<!2UAM"./*X$QC-;;#&IQ0,_
M&@$'3 3:H?Z0;'"JFU&G?X>>A_.]Z]'>V?V,^5C6R4);#JF<<6=QC .%-&),
M8081S1"D =,F12:D2B-%4,8<\@59=&GU>3]#:J#65CMPLW<T*CJ@MK0FKD1N
MM$2*E92;;,'[WO:#YE&\!,? >13/=C=V'L5+>I_(HWCQE:M=>]M<2BK,:!I+
M!B.<<HBBB$.L2 !#&<HLDS))8^QB(!QW,37[X+/I _!:.##?RMO;.]<N*]@P
M"'GF@QWA!LP?=5EU3^ZTH^:+NJQEAXOL,#F?WCX\TKPP['%7O,K+QV5)Y_4>
MXUW^),5M64I3>87/UTWQ-3WV.9O+^A=U;IG#!$<!#BD/LA"&B;$G5!1"G,D0
M"I:E+%(LS)A3CA</,D[M-&FKHEE7YV9#/C>Z 5KIX$8T/L;4CJF>>:0\4]WN
M(!6@U6]S@E*I"&I53,',1DNP57/SRR9-EM=T61['8DCN]2'FJ.3M$>=#]O?9
M50\OAU?%:V$N)LJV5 35FTBL]Y&1BA*(,-9[2TH93!'%J=EK(B&L/1(.&I\:
M8;\J?@:-@ [WP(>(6=SB7X&#9SK<@>!R]8?+6#C<7U^!R4AWS3:?A]LE\!F=
M.R]L#]\9[W+UC+1[%Z'GGNF;\;_(32Y4XW[99)(7*@U"+C,8TU"9_/X*$FU\
M0L7BF,4J($E@Q4?GNY@:*[425D[&O9/T'P%I9_Q=!X]GLG)$ID=>_7/*#YM%
M_ZB7D7/FG]/R.$/^V2>OG]]5@<B,8>-E0"!*30QFAA1D@@50R92PC,6)(H[5
M._8[F/C<[E%]\PA"]WD]L4J:3IA<-:=]U<L\ZN/9YG-7[<NSS_6;RR^7#P_Y
MJCJROEV(E\N%N?22"Y[+<I9F21JQ$$.1969NIR'$*98PE#R,I8PRX]_B,*T[
M^IK:#-\1M8H@XKO"NDWU+H3M9OU N'DF@$/(7EI!YLP$%F ,20I=W8W*#Q9Z
M'U*%S2O]6..U4I*;LBWU]7@3:O51&EWR>5[MZ-HXK#;]E"F94!U^'(=OS9(D
M4OI_&"H<)Q EA$/,(PX91QP%1 51K%R89F#Y)L=.FXA@T0A?A08_;>(?:2NY
M&U4-/:QV]/:,@^69$C>:M9X[;= IV-=N$Y>:&R?V9D2K C&5CJ<"6V_ !UGP
M02_X/(W#D&P\M(BC,K@G? ]9WU<W/3/\F-1!Q@U"BE?K0J\_^K/-E\+THV4J
M5T7.5[).,%1[ULO5G7JS+)3,5VL]%V<R(#'&:093D1CW=D$A5H&$F.JE(4D"
M&F=.18^O%6AJ:\&N]_#RH%IRY5Y<;)2J_QFL%WECHM5_7U8%VQVMVJO'U6YM
M&'.T/"\&=7[H6A=0*P-J;>K,!9K2MQHUV:3;6"=9W47OZ#5@3I^!$!XTH\^U
M,HV;SV<@!(^R^0S5;C_FKA>$39Y"E'(18T)AJ.)4F^@A@C@C&*8)B47$4H((
M=^'A_>:GQJJWGSZ]_OS)C1(/ +,CN/XP>*:KQO3TD:[QM,Y#$LA!#Z/2P6GM
M#B?WF:=&3J.XFTZ^9I=PAB2CB:04<A29B8XQ)$$D8)9PP;&DJ?[?* D53P@W
M.9JHDNT]-14A'BLA1TJ0>&KH+&VJ9QH0W_;5]3'E^P4^/G0/YWC9$SMPGT0>
MQ5/R_3DR*G8@.UANQ:X^>EIFG)O2A*8]XT%F<O0Z&AUG&YC0?-X*"5HI_5@C
M%\$8U#(YW]NX5LI%K8\LELMOC&R]U*FHWRZT%.LZZ&;U11:?O]#%77VD86:=
M%&\7];2;D8A%,4H)#(($0T15 ED4*<C2("-$9 F-11MFY]FV<13=:EKNA^OY
M=H&HY!O)UG$=:,]VD(_!^]/82$T:_QWM0:4^6&G]00/ #:@A,!<:DS&C>@[;
M)$PL5]G_'.97SQ$9S#3KV_]59ENI)3 ./&W@(2)8)8A(&,<F1$LF(<0LD#"(
M&:>IBG$JG2XX3G<SN9US(R5XK,5T/&H[#:63]7L%0.-8OB5H)/00S-F-@0>#
M]["GYS!VSVA[QM ]]W3O<HKY0E9..$7.UH9=/NA!WT;UR1B1$ O- *&)V D0
M@RR..21A%"4L2;,LLLI_;]OAU CAA5QHB0TAZ']VO(R\"*X=,0P)F6>*:$0%
MN[("(RSXPTL$HRTT ]=;[.YS[+*+5@B<J+YH]]X@1L7M0NA_*=9Z_[<-3W^5
MEWR^-"7ZMC,B5 &.4IQ"B50$$<,<TD2:O;!@&8MH)%,GNNDIQ]18J!$:R&_&
MCG1U]>T[&+WL%A\0CVS85$XH+>2[]>*V:GCBLRNQ]&@@68ORG!:4*UX73"SG
MYOIQY4>YHH:+7]-BD2_N2]WG^F$]-Z=EAJ5YOIHEDLA,:EI$7!!S^4DACC,$
M!9%QP!CC*'0*>;C<Y009L)70>!<;$=U(T )EQ*D,%)<P%"PT64D$)";]64@1
MST081S+D/?*=#03V^&G/QL#<;HT9]GOUO)RTPH)66O#C+I*-P ,F2K1'9\@%
MPJ+74=<">Q0.:=_AS2NSJ+Z3M)0?\_LOJSOU6UEGW9AE*0]D$C&8BBC3-J](
M($9)#&,FN90XB'AH5;G'JK>I\7HE'EPJN"YEKU1&W=C:T<M@B'EFEFW*U4K0
M&[!!3PM;1V5X2+_:!8J71*PG.WR>E*Q=NI]-SMKY4H\L.F\7O#!-OI+UGV\7
M^UWM6*>S+*%4QB*"),L";2XR!4D:"XCT7AJ%G)!$V->K=.AX:KQ2R>>>B=$9
M[VZ"\8FB9ZYII08_MG+_9.H3'E#0[O;8$\(.67\\(3U21J !$7=+'-0#MLZD
M0B[MC9=PJ(>6>\F(^KSO7MOQ]6)EZM@+H;^L\J4YC2B^ST0:B$1E$521I)K4
M,PFQ5"$4,2)4(<+"R+JVXZD.ID;>M8R@$?(&-&+:%W<\B6(W50^!C6=*=H7%
MJ;ICE^Y75'<\V>QHU1V[E-JM[MCY7,^\V+HE*4]3Q/<V'?>KM7POOZT^?Y7S
M)_GK<K'Z4LYHD%$B:0HE#O5VD)O\^T%29<]F*HE$B@.G0(>^@DR-%/3'%3JF
MT^X[!':[QC& ]<PHM0HWAS;&S<;(^'X#5DO )/A <W$#_BYI >X6 Q24'0K$
M09-\]Y5EW%3@5R)VE##\VO9&=J]N?.#NUJMR11<FC6U=]FZ6$D6"*-)F$3%W
MQR0BD 9I J-(BDPD<1Q@,JN#H3ZM:+&RH\_!Y729_H?2^O1SN<\7YO03,#JO
M _>W@H_D3WUV9(7 +$)"0<*YMG]C@B )355!2@1C*J!A*IJ1?;WP[2,_W+BV
MLOJT&,5$A]1NB7W60?*\]@[@]+YQ:]_1LRU!.P'/]DN#, D7]K-"_CE\U2]A
M/)A3^L6._&Z3C.7Y1L^]6<*S+#5UA40:Z^U1C!/(& IAR"A/4I4A)+QLCUH!
M)K@M0GZV11O(A]T.]0%RBML@H\/X^Z!#])YC_[.189+[GD.$^NYWCMKIF9/R
MX7&^_"[E)UD\Y5R>YM_WR\53%=-346U9E1/;_;TIU/9^N?J[7)F$:?<+4\)[
MIB<^C\. 0RG-?H?3$+*4:V),8BXCH>(8.R6O]R;IU"C3R @*6;OCZ'F]EV^L
M<O[\^.FW$MSK-=$\P=8KL%BNP'=IWFJ5<DQAZ>TKL"/G28SMB ;UQE#>&C;:
M,&[U:^WGZD-XWPSM5J<;</M@SH 'S&'I&_Y!LUEZ$W;<O):^,3_*<.F]PWXK
MT'OY=2=)0K%<Z!^YK -+BS;EYNX3^8+GCW.]*"[DVY5\*&<)%C*E"8:Q2;N$
MXC"%)$$"RBQ,.,O2"(G(9:6Y6J*IK2A:(;";&&1/)5,*;IM(=^^Q1B_PA]$,
M5*HY5FRX?G#M%I!1A\SS0C'*:#FO$8,A/.1:<+U0HW+^8!@><OMP#??P_WO]
MZ]OZ],5$Z#6UT)2IP8X1AQ$3#**0:DI61,(PXXE,6"ST>%K[^9WH8&H,JT5L
MCCNK>%('7[-3Z'5SWA"8^'8%V8>C3W6]4[@X^-I=B<](/G6VGXV;PUR'[IV.
M<:?>&\\!KD/J/4>WKN?Z6:":,+F4HGRC!?I$Y_)._4W.Q>?EKW2U+O+5]T^2
MFS^-MR=!J2#5>4:4$HBRR%SUD11*_1\1:7M3)+&+J6G?]=08STAKTFN77Y;%
M"NH>'[1!8O8.U:KC9B4Z#("=.>@'5L^DV0I=)Z!O\36"P]42/C2B@ZWLPQEW
M[G@-:<4Y]#ZJN>:.RJ%=UJ.%?A2VJ5IQ6/:<9S0QNV,HTU1!%"01I"J.8989
M=Y00I2%QVAN?ZVAJ]-24CEG1;Z[I",Y":4<]0P#DF6BV975&*N1^ 9)!J[&?
MZVO<DNH7-#ZJBW[I^2L#.U\WB3EF>D_&8L0#&%&10:32!#*,(\B1Y E-B:2"
MS%;FU,^.#HYZ<.*!33_^OO7J!!,L-S>G_5*4' -I1P97P>.9!;:WR:\O8=(_
M./-0;R\!F9M.GB<(\U#'LX&71P_VF]4OUOG<.+@TF^)8L23,4KVD\R#5^Y(@
M@(0J#M, )T&$LC!&V&6%WV]^:NMZ*YW;_#V S&[R]@?"\\QM!;M\K.(\<4_K
M/.2L/>AAU"E[6KO#^7KFJ>?Q(W_]318\+TV^G\8UE9(T"4(<0D83D_>0,TA,
MQAU!4)12' B5.94-'US"J5'&CH#CNA4?CYT=\3SKB'CFKB'=BG?TG)Y;\=E!
MF));\;&0?RJWXK,8#^U6?+ZC_O7CEXNJ"-T'6MP5GU;&V:NJ4?=!%I4H,[TM
M2QBGVII+,PI1&BJ(*8OT3P*I,$AQ&#C7D;_0Y]28NQ89E$;F&_!(BZI8LP0_
MY@OPN%PO1*E_)XMY4T:J]I0[G[FJ]U#8T?;  'LFX@;;3S6V6F#C65"+7!?6
M-"4(:AH>M@R])41#EZ._U.WH9>DM<3A5GM[VU1Z7^0<E,G];Y*O/^4--C$TY
MIF8310(<I"@CD*:I2>!#!<1A)* 481*F!%&%K#+PNW4[-8HR4L)*S+8"FL,=
MMSW8W0SD#T+/)'14NM=(?0..0>WC06"/KH-?@1>41_(VL$9[(#\$9ZPZO1/L
M6QO/9\%9PSU/!O>W>V8[%_^Q;N[E/R]OA<C-9T;G)ECH[>(E?<Q7=%XM'.S0
M0OXH_W.=E_FJ=1JN*[HTKK_F@6K=F65()@%-,4R21$*4T1#B+,X@";B0"NE?
M4:<4D;X%GMHBLKO9Y3O:..91]SW,=F;PE ;/\_)U^^'MRYO31Q6[@1V;S&G*
M..^:H(X=G0;,SCX2\(.F<?<M\[CYWD<:@:/$\&/UVV_],6W4!R[S^?*K2?5P
MIUY))8M"BL_T6UW4>W.;%7.BN("A)!@BQ5+(,BEAP((T2HA@U,U?Q:'OR:T*
MKU^"3_R+%&MSOAE&," W8*,/V"AT UJ%C$O'A3R[5P^0W2+@"7;?A]-7(.[A
M,JX'B$-RLTOWH])L#UP.&;-/$ST#K)62?'6G7G_C51S&1[J2=YJ4RR_F_Z:6
MXA.=&^;>[@;,+VX78O\?=IZ<*2)3)E@,LY@CB 3.(),)T9R)L:0QDH0[D:0'
M&:=&IK6*QJ%6-DJ"0FL)ZI]+H*<WUQI4X=75#W*KBV,LM8<!MR/=9QY&S^2\
M'<%6/V 4-"-GA+ZI_@MV9+\!.P<>+]O!/?RWUQ;C[!Y0[6\D!@VE]B#FN$'4
M_G ^"I_VV)7;RE(6J]G+N@)(_B1KN6J[_4[=BCI/1+TCD.)%G5JML=UD2H,T
M0PE,J. 0&0N;81I#*E :1SC*2,IMUHW>$DQM5=@J 6HM;IK"VX9F6DUN0*L+
M:)2Q6Q#ZCU,WW8^"ON_;QW[ #VAD7XUB!Q'KMG=(6/_MD(#[=SX*O5Z-34N>
MUS?4XPKSE62K;75R\S=MV=/U7/^CYA1-QH:ZZVM3+0LW]R[W<B9)$B98I9 1
M%4-$I'&KRS*8R4 $)%6Q90V[_B),C1Q;66M#.5^ U1<)Y),YWM235-0*.=S'
M]1L7BYM/[VA[)D,C,=@J8$X7]#\T.ICCXV8<C!HWK8_&5A/O0^!P/>I]*$:Z
M*O4U)&X7J%>AV7F9VJ_E\2Y6K])\[Y+UNI;Z1F.V@="',811@ FF:0R3U-2K
M9SB!)$H49%QQFL0H3CES"\<\T]/4%I-/)DP<7!<F?AY6N_.10<#RO!9L91PK
M-O,")L,&9Y[K;.3HS LZ'X=G7GJA9W"(<?OXLISK-TIS+K#Z?OAAAP'.E$@5
MS(@2$/$T@A@I"I&( YH)I93;==C%'J?&&Y_-S?FZ: ("' GC,KYVQ#$H:K[O
ML'9D_;]!+>TX5&*-TJ 1$!<['3>BP1:#HP@%ZQ?[44U[N67<3\K&)< D;_Q0
MR$>:B]N%N-/;NZ*^^-H6D;]EVG*BW+92[96]3&@:;2YX*U7,Y<)&&3V;:G5N
MJ@N%2J/Z#K@$6YW 'ZU6 TZQ@? =<@)>*]*HTW,@_ XG[U#-]CCL>D/SHO+1
M^;5:)RN/L]_SU9??%DM6RN+)A"R]73RNS;V$ 2F?YXWC#U\71;ZX?T'+O-PD
M&'^S+&1^OV@O.5[E2FLF-;:SU&3S3AB!@BL)D<(!Q('@,!,BQD'"B4JL[@Y&
ME7IJUDPCZ/8.6FQ$+7>2=YO#-OV)E)7#H#EUJPOR.!STC/996!S/37&P/:\>
M1N4ZBNH&[&@-OFJUP:[>H%8<[&MN;JX;W4&E_%ZIA_8CVER#;R&8XA?B<'HX
MQ2]EI /'R7TQ;B>58X]<Y^'F:,*,=QXZ-KY[1ZBC=^[N#_%)WANI_BJ7]P5]
M_))S.G^U?*#Y8F;JC(04(:CG'8$HP1PR&7$8\$"PF/),]V[K\W"VEZG9&;L2
M@C]J&2U#Y[K1O.R9, A&GI=G-WB<7 HNJG^MV\#Y#D9S#;BHX^[U_^6'KTBL
M<Q3/<)S2@1VF='C][3$OJH=K3X19$(>*LECO9RBF$)$TA(29"(0TS% <"9$Q
MZIQ09PC)IL8J+Y>+:K\*YKGJDTIGD-&R/+%]CC'P?;)[?>J<K7:-N]7 ^7*&
M1'SP/#F#"#=^?IPA,3V9%V?0#GH<8=T5]W21_U?=]4*\6)?Y0I;E*UGR(J]<
MQ';2&:LH%H&BD',I($J5@$2F"0R"2'+)>(*%5?YUUXZG1L6[H@,M.VB%!SO2
M.YP&N(R!Q9&/)V0]$ZP5J. /F\NSZQ!V.#+QA/1(IQ[7?<9N1Q0]D.H\97!I
M;[R#@AY:[NWU^[SOOEW?AM\MQ/]:4VU/?L\7]TV!HIT;DG>;,F T"W@B(P+#
M2 3:2&<!)#&.8!8K&2&,,VY'_+UZGQK[7XA3-;>26[W:(F'[EY/O7"NZ]1NV
MR^<%7@?#MT4^SC@X'4#TQO/:@PGWCD<[L.B-R>Y!1O]&^CJ'T55E@V]G4X2S
M3,A 0J7"6%N_)(0X"#%, ZD$5BFGL5-Q^>,N)L=TK817U* \ :3E(<)5\/CF
M'C=D>GASG5-^6/>MHUY&]M<ZI^6Q@];9)Z_SR&JN0S8E0)HJ 2_D0JI\-6,1
M2QB-8D@RD_R5Q@JR.%4P"C%% <9<("</4+MNI\8#)C=:E;9.#X*C$Z@ESG:4
M,#QZGFEBX\?6W@%OB_^T=3_ CXW8YS/G]G94L\/)AS_:A9Z?Q>W,#HUSWF66
M;_=CHW=+NBC?+_7L^EQ0(5N7M8^2R[RZX-VQ<+8'%2B)XXA( 2,29A!E(8.8
M2PJEB-)(89)Q[E1[I)<44^,J,[6,Z;_2?^8+$U%DPIR+C0YN]-5O8.S8S#O<
MGLFMDO\&5!K<@$J''9?<'37VMEQ>G-^O@G)(_NLGR*AT>!56A^QX76-N9"ED
M/GNMI_/J^[\OYWK71XOO;_*YII09RI2((THAPR(Q5IJ)ZPLY5#(((I9F(@BM
M=F9G>Y@:R=5"@HV4H!;3CMO.X]C-6X.@XYF37(&Q9IJ+RF]9I&QII)3\Y_OE
MTR_ZW9I!] ^'Q'&^W5%(X:):[82__& _RV?'J:UR8ONLFVF\G7@81"A%$@8$
MZ;T7R13$4<9@@ @B(J-92(2+>7.^JZE-[UT7U$I48&1U="6S0-C.3AD&-\\3
MOR]DSJ;&932&M"<Z>AO5:+BL]:%E8/'&E2>SGXU],8NYPC0-4Z@X11"I+($T
M3&-(&4EP2#&EV*H0QNGFI\8,.^>.E7Q]#V-K[!P/8IT1&>\0]@(8_<]?]W3V
M<O9:]_ \YZY[VIT]<]U_ROV^^:/Q9[K]EI>S6&4LCA.]I NLE_28"<@2%4%*
M>(IQ*N(LL'8'W[0ZQ3F:EZO*O7EW6?K#".MPW[N%[?(];B\P1IB>/7!PNF\]
MTOO:>]1M@Z/=CQ[IL'OO>?S+ODEQ-N>6]"%?-,Z#"SI?Y;+4V_8V'T]SK#E+
M:!RP- P@RTR=4V)^BK">N*$2092P-'$SOAW[G]J<WJ2<,@=<CZW<.T&CKKET
MW$;#;J'VB+%GJMB[%MG(;K)2MD@;W#>#T"@P9!Z>7L@-FYW'3821<_;TPN<X
MDT^_9OI5TI/Z#9,!^)5\DO/E8VW)?'M92)&OM@>4+]=%H7\S2V.&>!*G,-%6
M"$1<8,@8YY!1F=(,)XHDH4M!/:?>IT9W'_\[?7C\'Z^J2Q1>B;QS@P(@^.WG
M?_O9K1:<VV!T\YUWB#VS72MZY7.[(WS%?[7X.]<G-Z#1P"?@;C7XO $_7BF^
M00? N3!?+P OU>=S:W34,GV]]#VLUM>OD2OB&_N4K-Y$:]^6Y?JAK5_]*$T"
M^G]?FDS,)@C;9+W\-5_D#^N'&95<A;'$D$L:0)1P!K$,]%\S_9O*KU!:I789
M7_2IK5JML.!I(^T->*AE[1$P.<[P6Y[!37)0?1\@7!]RN4WL 78 J$(QZT]E
MBT&33?C7"]]+O]#,48=N\-C-<:0?/[ASU%$Y&?TYK@3]UL*7<UJ6=^IW:D1;
MW14?\_LO>HLF"YZ7\D.1F^I=S2_+YK=E.*,XCM,$)S ,3<94B20DBBA("(H#
MS%5 D=,!4B\IIK="U?*"1R.P2>1?5J6@O]:"@Q_S!7A<KK556FIQYB9NY5$6
MH#3?P7G_T %'S6XU\CX6GA>62GZ#?B.DG@Z@DM(L#,T(?6A'J%5D\]" E:JN
M G)(FN\GR*B,?156A^1[76,]:Q'28J%G=/E!%BVQY]SL9_+Y6E/W#(4A8T&@
MAR=&*40DRB"12A-H3%-3X9O1T*VN8'=_4^/&=R;EXH;M;@ SXE;GOJ(6N&)'
ML9S/:5'VIL5+@Q 2%$BBYPA.:*B7K2R#., !#!G. A9C+A*]K94%6S[#,.SV
MZV\@WLM5G?]R@S& SS0:=LO1@ A[7GA:24W^EWK;<E,E#*R1;>0=L!"B'3"#
M%C6\T.6X!0KM]#\J-FCY6E_WY4\/=#YO8_MG61(B'D88:G9A$-$D@IA* A6B
MJ3:8 QRIP,UY>:_]J=%\XZ%;R;A)..'JN+R/8#=+#("+;U9P@J2'R_))Q:]V
M6-YO=61WY9,J'3LKGWZLYSY8[[.7\US4UY8'I2QD@D7(L@"*# 4F%HM"D@;Z
M/S(C222#+$Z<C+>NSJ8VI:L$HV:K]*A;;6]OZEK.NUHX[E^[T+;<I@Z$H>_=
MZ*Z8XQ0+L4%FT.UE5W_C[B(M-#_:+-J\T]LMRY38D:]D_>?;Q7$IDH_:R'ZS
M+,S1WRP+>!JR@$#$$@$12A5DF6)0IDF"D IX2)R\G1W[GQKSM.*#'UL%?C+9
M^T]5X0%_&#U HXBCW[3K,-GQDT?P/5.6!]S[^&SU06]@GRTG$<;VV>J#SPF?
MK5[-]-T<O3,NPXO[5_)Q6>;Z"_A>7>T_FD*1^7*FTC#EBF60JR"#R%PH8!IK
M@XM*3!$7H:16(>^6_4V-[]ZO37EF8VII4/.%"7"LCEWJ$YC;5Y]<-U+=:-MN
MK ;#<)R-5B.N*2O;"@P:B4$E\I![+RMLKMZ+=?<R\M[,2N7CO9K=:SW]>>A<
MWJF*N>HYI/]239RW9;F6XNWB<T$7)>6U^UN@MVY,4AB06!M90F809YIS5"H)
M8@S+1+B%E#ET/EW&:8@FKV0VJWU)7;-I.(V"G0WE"UO/3&3$-J!6@M^ +<JU
M\.#M!N4=^0?T2>F!VJ!>)2[]C^L7T@.9(\^./FWT36/&5J<RT"2IT@R6I)"H
M"&OKB"!(4_V33#*)9!;3E#MY7YSI9VIL]=E4N)XOJ>-9TSD4[2AH &P\LXV1
MT'\2G@LX#)MF['17(^<5Z]3W.)%8]^/]"*!Q#"L_+V^YWHL5\F]R+CXO?Z6K
M=6'.OTT1J-R$U\S"* AC04+(9:JW3HPQ2)&FA"3,4LRI2+,PG2WD/5U)\=F>
M&:P%L)H/I)X/1V+XFQL?=$-?]+ZVK&V<9;&"*\,B^:;JN&/&0_L1L:.780$>
MAW!:F<%J"1JI@1$;KI;PH1$<;"4?CH.<P1J2E>P['Y6GG#$Y9"[W!D8N*G77
M.L%6_ELF"N1W:5RVI+A]D@6]EQ^E23RB-Y=M$:4UG1M;(9RIF"@<DPQFR&2V
MSX(88A4(&*I84R)/J%!..12?08>I&6$[*MR 5@E :RU T:IA+@=;/4!%N3]^
ME[0H'5V(GN.CL=R:3OM3\+W#O3YXXVX;K7'JBVK  !LTP X<P. Q@?I:UX_E
M)"IQ7:'&GZ-FU_7C-%AUKP%$Z;F7*.0CS443?=^&!F><1ADB"*K47+GH303$
M02!AHH*(XH#&0EKE[.GL96IK6",DD+64KEN TT!&L91*"8@45]K4H";0,Y4P
ME%&D4DJ5PMK46*[H?"P@-WUY/)$Q?1C'H#TX*^>@994GF-=R UJ6TGFK=1)G
MRVW5M>CYWD(UD#4"#AB$;H7 H/NBDQV-NP?JTO5HO]/Y<%]N77(I1?E&BV:.
M@>G"A)CHE>%A65^HSR05-*.:%(C>>D"$,@5)H(DBS+B@ @4\"8@;SU[H<7J<
M6PL,S/!5]TQ&Y!.7W:XD<0EY6\(8$$_OY+$+Y=L=*&MYZWNG(:G$$IMA:>52
MIR-3C"4&QW1C^Z*[3\VMMBJ%L2S?S.G]C >94$F20<9P8BZV8T@0%U &'&=9
MQ%F0);;>,WLM3XU*-L(!(YV]4\P^7-V\<!4(GN>_I?Y.[BPG=;W"<66_O=%<
M5$ZJL>N,<OJ!GB>:37G".W4AIJA*L;J]> QCO2F(20!%@/56@6HS@$:(P( F
M(DU3/8>5DRW04XZI36NSD5XWX05Z+3N*G .-=MOP.L>SQ)[#97D>Z'\0?)_I
M-1H8\*U"&9O$S'Z"&*[$<]!SM9ZBC'LV=AU>1^=;5S;7(ZEC$Y&OFZXC\D_Y
M;(@TS%A2!7";*'I!$"299#"3&4(A,HE(K *Q;#N<&D>V60L<L@7:P-I-<3[
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M&B.55Z*"0LOJMB9U 6RW?@P$FV>NWT?,"'<#:D&;OWQ8SG/^'?S1_.G%M+>
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MD>Y^>P/KYS+879QGNAWNC=OYZ^+^3?;,M;B]EYZ12. L,#[T H40240ADY&
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M":*H1YW2?M)8S8KQRY6>B[ T.1/T'UI+-_[H.51V/.,1^7'X:*/ 3J [,#J
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M\E$/YA=:RMO[0E;'MR^7:U,PZ9$6J^_O]>"]6C[0?#%33$0L#06,51! E(@
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MMJ>A^TU/;@(WTMD?<!Y =?D4LS\ OJ=H(]B "1//ZWOM,>1!JZ.=-9[69O=
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ME\PXXJ&Z>,&0YF/K5?FTW-(5?_DB-\\++LNF_+@0,8\*@F F$8$H3V.(8YI
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M'*(H-16R3$#&TTR[%R5%P25*L=6FE)VXJ?F385UG+:'M=B/^ 0OL1DY:R\[
M7EV[C/0A&#IP07G%<B1.J Y,/5%#6:/221'5_Y3QJ**L+3JBC+*_Z]84LLOM
MQZLNX_=5G5%I:'OK](.R?'JH_^Z$>(2+.$U(D>O)3F&(2))";'J%RSQ/1"9-
M[PVG,,^O>E-SXX>T)?^4IKFBCHWOGO6L^DV" RN&YH1Y&5*[J/+U!BKTV>S!
M&%T\IS76S4!E'V@,G(&=B8?#.!+7C,\!"),3YD7#5TH&\XGN]2PPKU(&!."G
MY.SM$C/).<&*4%C$6$%4( Y9I*-P)C(4)S&5D4,?RRM"IN:E&S5=@NQK\&42
MIRI-,KU@R6.(TB*#-(LXC#5N:29%E!?(KFNS+P#'Z=;\AB[Y4Y7#L&?=V'Z7
MX(\&VIDI:MA^7S^5="4J'K7?_OKEKT"LETNZ\0&\Q9K& YB!IZ(+/3CZ]D'L
M$7)8L7A :J1UR@#$W)8I/5!T+DZNW3O>DJ1'^Z.%2-^U[H3P[U9;T_9CI7TX
MY=O%LWQ+M[1]'7,L%4\EACE.$XBD*B#&BD.))%%%@F*&K(I0^@1-;;*I=04'
MR@*CK=N'WHMNMSOTB5E@ES@4+B=N?ALL;J#J[WS\:,S]-D8>$OE;7>^SI>=!
M0FSY\\OE +F)C=_]D!N^*&7Y85771+2+ZV9MW?[^TV;!Y;P0!96IU$$9SW.S
ME8P@C?,$2DD26C"11,*MDF%4]2?GP!KE])JX5AO09D-#-K\!CT;OJKE0$^"9
M)D.@-)!8MAEZI3?%<BMDLN,?>JOD8'ODT/3#7/82L)>N?93=#LH.!+,TJ&&8
M[3;)0+M)UEX%*BQ"MVH-/8;A6\ &LV "K65#CXY=R]K@6@S8S;GC?/,DQ6=9
M2GWC][N5>"N?Y7)=T8F^E[+<1=V4I$7!%:0\T5.A3# D0C*8Z7!;9CE.>(2L
MMW=LI4YM!GNCG[O@= FVFX7^IRGN75=\"V*O/N"F%L-AV6T]!!8[%2& #3PU
M-"J#5F>@E08'6@.C]I#M#&M<'?8W0N [TH:')YS=-D%<\>K<%;%^V'C;)*[V
M'>V;.-\\I-6Y.1?X4)9:SMNGS6+UK9Y.JLFG_%]R*3ZLOFZJYB(O=P_Z5YRN
MWLK'=;G0@UI/4>5<*,94@F*((ZR70B8W#T>F55!,\IPB(5)EU>7#ET)3FQ6,
M-52_*V9S6@_,8D4W+_6:I03;M9XK:G, +<'=VR\58?TS7<JFBVI]H4L351]C
M:C&7C#Q2H5<@U2EL;0ZH[=FM'6IE9\ 89;I3MV:!GUK#P-ZRYNJQ!\RE/?FX
M S=6*_+1!M"QZ;@_M+L;C'N0,V(S<7^H'#<.]_C<85N0'^7V#2V_?]JLGQ="
MBI]??M-+N ^K7<;K':_ZFB\.BJ!XHG"*"-<K)L;TVJE0D!5Q"@G-:)XS/<QI
MYK*-Z*["U*;,?0(WW>GZ[VX;? /&P6Z3+BRZ@:<YK3PPVH-6?;.I]I.Q "Q6
M?SD@7MY;$:2F;3B(/G>Z!F@QZF[5<)1.=YQN>)*_[-##S:[#A*1&^,M)^B#E
M69:Q+(6X("E$/"H@4XS"0D0Q%5%$$'&BC;]=I:FYR<J.9N.[_6(="X,\C)/E
MV<:HZ(]X7G&1X*\V9+8;E-$3.(=!&SIITU&K5T_4'(:B37+FP"?[/!:O)=ZM
M]#S ]4N[>):F85CY:;U<\)<Y27 :49G#G"L%42H22"..8*;7'4F$<L7M=G5N
MT&&2[K;YZOF!$3Y.GKL'XY;C8V\0OZY/!;_7&@=RH<.A"W_TVJW&!,Y/K7"R
M.P2U>]3 9O?KYZ9%]CX%?KE<_V$V9TLMTNRT;YYE^7F]7+Y?;\QYZ[R0-(]C
MAF!$< Q19"C,\H+# @O%TYBPB#NMS0?H,#4W>%"ATFH.?C?Z@D9A1X:S(<-B
MYQ #@QW:(;Y[ ]K080;B1+^",]":9');+@Q$61TZMW;9#HNSN[P!6)_N<H@:
MH[K+&W Z=9>W/&J8NVR.%W>=K'\TI:0_RY54B^V<L0A'L<"0988H)RT4Q"KC
M,.*%PC&6"5.)BVOLD3<U-_C;:F'RR2HN7,<ZRSYD[;R;1[P">[*VW4BC:L7J
MUB@+?FK4]7#>X@B,3T_4)W)4KV-I_ZF'L;W-G6#KS=.#J>'2P=P[I23?UH<R
M]^I.K.MP3_SOIW)KO%O#+24BG.$\IMJKY!(B%F.(<2Q@11RO(J4C,JLN]D.$
M3\W/[/4'M0&SYES3Y!.T1LS W@Q[0B_G<>EV3*'1#NZE'('V3" V%+I;.<:<
MY8Y&0S84D4.FLL'/&%J6]EE^6Y@CE)I =QYG,<XUZE!$.C9"B!!("YY!HI>1
M*),2YYE5E'1-P-3<55-7M5>RHG-VK3X[ ;';[_B )K!O<41E0)'99=-O+BX[
M>>S(1667C3HO)KMRW8W=:^Y5M3/_?;W4-Y=UKPO'9 &K9TWH/=WI6Y&6'&C\
MKZ#IPQ(B&\ )I2"-6#H%OTY#%ALLKC9FL;IY0+[P,4.\^=-;J>C3LOW7O:I:
M%=Y]V\A:C\T]6RZ^5=L57_7(E4:C>_5A)?2M4JQD6<YCD2.&E8(1QCKBSWD!
M69$F,$[SM.!Z_HR05; ?2L&IS;"-)6!QH"/8MKH#M3;U)O4E^B.FJQ= 6VOU
M0(/USEZ'%-40X][M0:<PFH&=[5GCB^HO&M-F[0]F$.NNK3LSP?T&[ V=@9VI
MYMI#8U]YA!V2DE]YI$=*4G[%$7?+6@XX')U9S"'DCI?5'!"UHRSGD'*&Q<QU
MEXB/&J.F:(XI(DA<'9E2_8\X$2:-+X$9)PD5.8V4:?UDW]SE5(#3I#Q:6Y?5
M>@6/VY4[9BV?X6BWS+@%G<"37-N]9:^<OW7#-;-]+A'.9(RZ&KAFX6G@?_6Z
MVSHV?5CQ]8/\2G^TY$T+6<YYFDE,40:9XOK3-OW=&,H,9ZO^;\))5.39?"6_
M&=*VK^[MFR[)M'J?2?T^GTD._=$?]7):[I4>UM#I(N1V7N!F!%^AN=.!BL$Z
M/'7A$:+/TT5YK]+MJ<OR:SV?.N^Y><O@'=TL7S[+QSK![Y-<T>7VI6YZ/H\2
MQ+,D1S"E*(6(D0@2I?^(549D4>",XWC@1D"'V*DM[RO>[CK]44G+C7-'H)U7
MWI[@&V,]O3A8755J@YW>H%%\!FK5@V [>,WK">,Q5[(^L+YE76H!F<-JL^MI
MK[6&M+"P8V5H<_< C_YWNEC]HF?J]UKSR^P4>O9XHZ>2A?;IJ50QEA@FF2K,
M8C"'F*4%C.,X2VDB$\ZL:/U=!4_-JS=)-,",-OC\+_3A\6]OJX"15^HZN"(7
M]"T<?2!, [MZHS7XR>C]%_"^@O0:;8T),M^$Q-C!X0?">B27[Q5S-[<_ +A.
MQ^_RO/%<_P KCYS_D/L#\:Q>XZ_[V%9XU$>2^ZFJO'_:EENZ$HO5M\-$?T13
MQ..H@$E",40J)I#&&8(%RE&11GJU@(0=[_WHNKM\PN.0Z7_^\MO0,N'1!MPR
MKV**@Q@Z-\.")+6'(U5;#YMR\2:=XP" &3B (%CIR.@C-RHUJC?E)U#5%W!,
MG E1O2LP\KS75'<?*-7%V&H45HT_S!!*(Y$74!329,<0# FF"!+.F%*L*/+8
M*COF]4R8VE)L1P5]F5Y\I(EQ^!L1>(8<99RG/U7NZ,0/@.BE$0^3'?EJ(SF)
MJ7.X%7^..?3F4?(VF=ZNR4#*O"=3>'&O/LO']69KB$^^R&_5)#Z/211%*L\@
M25D$$4\4)(IF4-(\BQ)$B216M.+]HJ8V2]6:FO2NS4Y74#;*.E+A7<?7;B[Q
M@UI@G[\';*\F^-('F#MS72\67AGJKDL;EXFNU^HSQKG^.P8</;Q9TK*\5TU+
ML?O-9^.?WNT8DRO']$F+;6B6*S\WISS*"Z7!39!ITX,IA201 BH1Y33A4:)B
M^X[O0S28FF_9J]MTU#ECI@8_&2KJ^I=BL6.*K*8#%VKC0>-E<6H1>A0"^ZI*
M_:IW<]-F<+T!E0DS<# V=4BIS0"M'77 &AI_AQ.-T.,PTM%&H/%P.^2X!<O.
MTXY!#Q[OV.,6NX_./VYZT$".E$LB?UFLY(>M?"CG2B8QC26!L30)DCG%IC5"
M @M1*)S$A!>1$X5IM[BI33-7ORKPN]$95$H[DD7U &X7S_J#\;7F"3L$W9E3
MK(#Q2IS2+7%<WA0KZ\]H4^SN&N9?+A_C-L0L#2F'=BMY3LV6<.5D<%$YF1BR
M-$,L%02G@KDX&0N94_,TNTP$PWYVT&S+S;?8@&WG8#Q#&-C+'*%WF,?1<C3Y
MXSD9 )!/;V,C=E27XX##J=]QN75XBVV^WNCU>T-33+?RC4D>W+R\60LYQQG/
M%,\9Q'G*(5**0Y9G*8QCC!.*4*X*J]P^2WE3<SKOV@[2!SK/:CXX,T\WF@.C
MNGOS[2[<NWU0 #0#^Q\?0 YJRVT!CX?NW%U21F_2;6'RI5[=-K<-BW!^D64I
MY:X1Q2^2Z@^WJ3QY:4XGRK=/VMMPA*(BU6$.*4QS.4X@1CR%451@ED0(%47B
M4E%J*]C)[8Q6=/:P6"T>GAZ >MH^;218&NU!D^CM>#Q@/0)VL4\(7 ,[H%KE
MV4'[FTKKV:XZ[65F.O4Q"3[1A? 7!;E"Y3,4LI8]:CSDBLAI4.1\_VWUL5_I
MC[KRMJJWG^=$_S<5D0Z(4 81S3*($YS#7)*(Y((I(JT"HFXQ4XN#*J6&%;N>
MX&?G8&Y'); [.2IP;>O?NU$:7-MZ&8005:TGDEZEGO6RM=<J6:]</7+JWWNZ
MV!C*;JEU>7JH4RP^+\K_>K^1\L-*?Z"RW'[6(=6O]8P^9YG*D61"#X703B17
M A(<FXJI!+&4YP+C=)2$/T?%I^:6C*I0:5W!HE$6Z$E!3^I-Z#12GI_K\-OY
MP"D.:F"OZB&GSQA?=4V0X,#\&3   (, :"$ GZM7Y=>>5V6\7+Z!XS:)##Y7
MW?\<>7L#1\1;MMY0^<.FOX85ON:(YR]?M7JEZ<UJ6I:M1/7'9:5YTZIGWQX0
M)X5DN4QA*C*FYS.&(96"0,'35#*:15A*E_ELL"93FZ#:;@B-)<Z,,<.'Q&Z.
M&07HP)/&"<8OX-"*ZKSCT [0M!@+VFKL9EA]^O3ARHSJI&_&[-3KWO[ @:N(
M)U8NQ,)DG]"J(:1AZ;W[L2CGE*E(8:*@C!G1;K(H(,Z0@BK/4,:%2++"K<[G
MFJ2IN4&CWHYM&OQN5'3,";D.JF4P[0.JT-&O"TKN86D? E[CR*O"Q@W\^FP^
MB]1Z;QAZS'HGA'Y7M*LIMW3Y_RT>JU.^HLBDB'@&19I1B'B10,99"A7'&-.H
MX"FW2NOH%C,U;]"<!3:JSD"M+-#:#CI(O8BL[?GIK7B-<VSJ#-6 H](N)&X^
M(;WX\)$/1KL,/#\/[;QZ6&!P4FG55D]42[^#@BR]"EQPD_&Q6#[IJ^=,B()$
MA8"<F,U"%$60,(E@'F-!BD12SJU*&VY38VI.I+4"MA6^54U#"=8'_ 80,&-$
MG3%6FP%^6JR:2RUK'&X</;OP)/R8!'949T6S^U*M+_7 '-78_KP;E\84?W'.
M;5#Z#((&:C)JA'0;6J?ATXU/\W10^U%NYU+F"%$=2HE(((A8QB"MDM?21&!2
M"*1_[9))<DG(U+)&WAZ2%-/F3'(EJUX#S[L^PK3M*'OC<:Y!>>!AKB-VKW&4
M^[&&[4+[Y8#GNP>X!#W=-7)>]VSWP-+>D]W#:X=YB.ILN.+<78@F>;9IA#K/
MXPP7B$908:)78#(I(,DIT1&6RAG-LTS[#Y?@ZKJHJ050 U(Z.G"T\P1^T GL
M#^JV+(V6;7[\K-E>]MC9H!\,GTZ@0]JHKJ#?ZE.'8'''#6[!G,AMY'?]U,6S
MK'G1KV\<'^\;[]N*:A=UK[3#^K3>5+_8;C<+]E15Q']=?Z+5%T*)S*,")S O
ML(0HH0ED$9(P8D3_)Y9)'#LECHVJ_=2<5WOFP]LSG^W>,$!WECF>MHW[0F1,
M%HDY ] S3:Q#U()#G.<Q%(E,)19IP11QH[V<["LQ#O5EW?S7A&WJ_X+7PV%&
MG>*0CS))'QD.:LL;^N(9Z#H7/CT6/NCXO8O]-19FPW53__X #I,G7@/B.1@8
M>QR]QQ>C&3!^R#+VV%R,@D978EA@]??U6ORQ6"[G:2)Y%HL$"LD2B C3JRO&
M%$RXPC(K.$H*JVXOIP^>6CC2ZN4VG^Q@LG/U0XP/[(5[[7;V@Z=&^G11NV>/
MZCU.+3K]L,]^[XLRJ]U];1G]Q/U&.PLE%^980F4Q+TB.]$)$ X4D*2 M%((1
M+RB+9<I54MS&E]4E?FK?[_ZPXH_:AG)'&"NJ4$&UFM_*R]0Y*-U^(#S4@;U%
MS71ROV<ZN=\Q,#4#H'^WL\'\]OTHL-_*A>4+_E&)L/P.@P<6+!L4W2FP.I_Z
MROQ7-A;WDU]9/65@0OA!^KG<FJS)@WZ!OTI:/FVTN-5G:=;9B]4W?<'']6K3
M_M$<\Y6[$Y2ODG]?+?[/DRR_5J'F+E,9Q2H6>81AQ*0.$JFD$"-,H,!9I*A(
MHSS+G)+'Q]!Z:C/80=G+P9G5OFK@@&#*-05]E)? +@2>W- &GC$/1K6QKBIU
M^K!Z?-K6J>W[P=Z; WZO# J4VC[F$'A-@Q]%\7%3YL<<B[/T^E&%NZ?=OFVB
MJ6H/9&&$U#3%<Q;'A#&$(4^P:4&;,,BXR&'&!>6I2O+";K[I$C*UZ:'5$^P5
M;2BT[;-MKP+:[;M]P10Z"\0=(:<DVSX(;DBQO?KHT1)L^XP[3*_MO798K/KN
MX7&Y?I'RB]P\+[B\4G*YK 9)_V1(R_GZVVKQWU)\DIO%6E]7;LM?=BRC/.8H
MIDK .*<11,AT)<!9"CG+:,)UI"H*[!*5>M9O:@[F8D7VOL!UUN91U-LI;^CC
M8DN7QKBV>? -?+&^A]XN%GW% 0WL"D<:2^?0,Q#B/H-,WRJ.&DX&PO<T< PE
MQB.[]T&N\CPG3')&%<RQJ6W/"($DRC-8$(3UIQ1C*O.;^;T/!$[-L^_WQ@]+
M*_X8M)?0"[:=Z_4)X2A[WA>[#APH')C=^P(TP?F]#V6^/L/W!02L.+XOW>>+
M3FY'8+<NRS=:ZDO3:4O'GD@[F)BE,,,)@DAPI6=CE>L%*V<L)YA(XM12P$'V
MY+R/R<79438NM;JN%!HNP-NYGT!PAE[@7F2LV[-A:M7!D>XAB>QZ 0O+;G==
M_"M3WO7BTL^#U_\(CX%2M5LWYR3"@@N]9H@Y-YR8$<0II9 E,A>8,9KD5LD$
M_:*FYIXZFG=4^OKH?%)C?$-DY(S<:\5$O:#Y"8>.\ @>"-727C\$.K+:*O@Y
MOF-HV,.V^X[=[_4+46\1S 7."\6TDXA83"$B4D(2)PIR%<><ZO\1XL2%<TW0
MU#R&T1,L=HK.@-+7 5KIZAK87('6-HJY';#@(0LSAYU[K(R6S1Z3S^BD&PB_
MH<@562/''=T6GP<9/=</2%G\\N[-%_Y=BJ>EC).([$X"=W6VYD31]#_9/,OR
M4I+S:5IS.2]HBE2689AED= N)<X@QD0OFTA2T$0A+E*K1L*!])N:)_);0Q5J
M4+N=V02&*O1F_+LWH+4.Q F,R.Q257J=#=(:>:WXY:S8Y94'UR'S\G4'>:34
MS-<:;+?TS7!#T9G?&4#L> F@X3 [RA -*.:&&NMZ9Z*E"B@P2KG,4YCF:011
M1!"D:59 7BB*XC1)\]B=<N%(Q-1FVKI8L9YGMPTSRX#2TV,8[:+\V\ )/+?5
MN+1[D6$(%B[:[KWP\5C*^-6)%ZV\6$)X^4KW]+JF.]AG^<U,W1BC+)<F6X9S
MID/O5$*6DDPO[A'7G[GI@VP5>I\]>6J?<MNHKM;./GGN&*[N;_<F$$+OW=G9
M[Y0:=]'6&_+ACI\W6A+<13,.,]\N7S!RJYK[NAZ@*1%YTN_&AU6=5C&7<88B
M6400HR*%*$DII$(DL(A2D^J0,RKB^4I^HULIOH[0G.:ZJE8?!*D_B#.%@ZZH
M7<K50HZE773P6D/SI^DF<]^VCSFP%"Q6H+9U CUC^@=B$NUA.M3\<W2"Z<?9
M6],7"U$#:1GD2F[H4J\ [X1ID%5NS4GQLSSN?HZQS.(DDY#F5,\":8P@B6@$
MLY3D'),XBI033Y65U*F%>8W2U3X+/5+;D>+!"G([9^T=R,#N]Q##8XT#-IUW
M LDKN825X'&9)URP.*.E<+IYR &0::WPH2R?I'C[9"K":A]7E93]+[D4'U9?
M-U45V<M<R@AE/(Y@@;F$*(MT8!JA'&:,Y(0D/(]IX1"8.HJ?:+!I=#<[>E5F
M[D8L5E0ORQH2].T:;!OM73;X[4?$YE3&+\ CA8Q5ZY5::U"KW<1Z]4:\G &C
M._BP E^# NQR,A($Z+%./#P"[GB*X0Q;]^F$_>-&/'5PMO'X-,']]F&1Z1WG
M9F]$2_ABLJU-MN)OCT)[TG<_MH;LC"WE+WH&FDO&4Q53[?X)3R!210[-SB,4
M29H7G-*(<J=:#$NY4XM.]VJ#G=Z@5AS\OE<=&-T=,Q!M1\(N9 V ;^ )P ^T
MSF&K(U ^ U=;T:.&KHYXG :OKK<'VH,M>Y;X?Z]*J-K5_4GSC);/Y]-FP>5<
M9$0D/!.P0&95SE$$<9XHF&>2)!E+$59.GF]$W:?F/2O-3;%JK31H&PBUC&_@
MT6A=-0H2Z^62;DKP*#=U:.W8,VC,-\33CN_KC/L$=H)+VZW@&H']+G#[(ATT
M/VIQ !40(VX3^Q^]4;>//:H_K6UE_^/BO-T<0 6W:;/<;.=OGAZ>EO4^4D76
M7@N[5W=B76E1=72-"\&RB!&82$.,G] "DDRE,"UH(1/,TE19)1/8"IS:!+77
M&=1*SQI/8[9Z6L6=NNA:0]\]B80 -'2^@@\LK?VT*T =SE4_ZL"QZC^=.E5K
M6:-X0E?+6_?E?-\-:8@U8?K=JNTB4]XQLZO-MW.&:9K2I( X%@2BC%-($\%A
M)".A78_4OW8J1NH6-S5_4Z?A+>KN"?\&?I*UOHZQ;@_$=N&I/^ "^Y4:LZ;C
MA#GA:G75OJ31UN/V@!TLWK,:KTL</\.QU_J+V8[]=]VP]&?]A_OL--@Z9$UL
MN5F-;KP^-7J(Y[G )(J2'#(I<X@(-CT3M$.*.4%**8YCPIU7^D%4G9H?:Y4#
M2SV5E."G%ZG7[D-6[&$&UF&!_NK#-8'U>,]R_( :]\#@FINL>@F,S9Y7WD&'
MQ?M".XRVXZ^K@Z)^<1D=5N* 7(FF+K\EV'W9"9L353"*40HES0Q54$;U;!'G
M,-:!:\Z+F*51:EWS>E7,U#R]V<, G)JVG)N*/%1_[\HX!-/FV#)%JP=8BPP'
M+W %]K0MQ<9.R4//Z04HATP%+X"-E)@P##BW%(1>/#HS#J[?/5Z"0:\%1_D$
M_5</B\;;%A@[[J,O\EM=8!R1)&9%E$&,=$2-5$PA3N("RCP1+,DB(:A3K>%5
M25/SD >LC3N*K[+1U2TBO@ZN74#K!;+ 7G*/UIX0[4L?6LXQ9"\2/D/ Z\)&
MC>!Z;3X-P/IO<*]5?+?:&F^S6,KZZ7/M @H2YPBFB6DY$R<,$H6TDXUS_2^>
M$)HQVW+%TX=/S1/4^@&C8-/?R;YJ\0RX[D_^5C@"?^4.2#C5+UXS^882QK-'
MCE;%>,V8PT+&J]>,7,OX[O\\:3WVS$1EM>?W]3M='=?02+&KBQ-2I04O,IC)
M&$,D]:*)*A7!'(N4)VF>LHRTJ>0.^VOC:&_U+1UGH@=V+F-7/ X8<8=MMPF-
MXI]F'ZZV_X"EK03UV<A60W!6/ZGOGU+UY/#!FT15Y0#UIY46XW]<O%5AWJ#"
MZU3TO_OQN-A4]^RKP+.B*'C")4QP2B$2L8YSXTA"R9@4DHI$8?(*%?T75!TP
MM8U19%5I.G8]_Z61##R+W3@P?YK9ZO[@F*BU=%(S4O] 3&+FZ5#SSS'#]./L
MNYZ_2]1P;N6WBY(OUZ;7HF.FS>6;)_2U5^2_>PV#Y-5T@^";^/>"I-%I?Z];
M>XGTM^/J :>8;S>_+9</=-6P'BA$4987&*99KH.3#%%(]3(<4L$Q08E*$VZU
M-W_AV5/;@WN[^2NH]7,X<CN!R^) <C@(H;_EG?W]E ^]0#@<. X'9*131HL7
MP^U(\;+%G>>()[>,=WAX6=>C$\,KEPP\)I3;-[3\_FFS?EX(*7Y^^:TTJ[?W
MBQ5=<=.AF&\7SU7[XKG*DR3BVB.IB@I-NRFHAQ+!.,$L%CB/(^.;UENZM#PW
MM!;MY+IV"@0\&I-;DVGQ'3PVNIL(6[5Z [I3W/%4T7XL+(\9@R <^MQ1@VNT
M!I\.P/W):*X7)7\!.^7!73_,[L>1SHAY/9^TES[N@:4S*F<GF.Y/&,B:4/?(
ME.+RTJ1)>9[+),GB/,*0%T4$4:H8Q(9#@5$J8A'C5+AU9[(3.[40[*OQE8Y<
M"';XVODG_ZB-N-O2U078(PF"$T1>.1#L)(]+@>"$QAD#@MO=PQQ075WQE?YX
M]X,^:/=FGOQAI;]F66[O.-\\23%GB,@LBQ*H.,40Q1&%N"#ZQ9*Y=C],T8PY
M]5&WD#DUU].JIX.E2C\W+V0#LIT+\@Q=8/_3U%:9;I4'^L[ #LV['C2=_8\#
M/CZ=CXW843V/ PZG;L?EU@'5XX;416X>Z6;[\E&_.E7)LHH%16D:0:%D#!$6
M!)(TSF$4250HI!!B5AGPUP1,S9L<Z@B,DNZ5X)=@['8A/L )["^<<7&KZNXP
M_N8J[DO/'J]JN\.RHRKMKNL&[ :;HIB??UGOMO7R1&5)FDM(HKB B.4Q9 4A
M4$I:9%*@5#(KWN%+#Y_:-VS4 S\#HZ##/N@I8A8[PC?@$/AS/8!@R)[P*18.
MF\(W8#+2KK#-Z^&V+7S%YLY]X=-[QML8OJ+MT<[PM6L&-K=>/SRL5Q7?95W5
MI%1&):,9))P(B)#AAI XACGCM! YBF7LQ+=V*F!J'NF^91#^E_\1Y^G?HK]&
M&="NOBZH:VB%_P80QK,T0C.$\HKT((ZR69KDLSS%8%'QA,ZJOT=Y>O6Z]=.V
M-*1\B]4W??$6O)6\&D&0QC-@WL+J#OTR$E/<5YH*RL6S7%KR[%X=4+LETBW#
M%#R^,:J!2K<=-VY-SNJQ7_85^[UVR3Z5,6YO["L6GG7$OG:=>_G)VV;6>+\H
M.5W^IZ2;]_IORCE6BL@X9I F/-,^)B*0244AHHE0*":"Y%813X>,J;F95DU0
MZPF,HJ#2U+XHY1J<W5^X)Y "?^0#\'$J5>E!X(:*E6M/'JUPI<>TP_J5ODN'
M?^)WJ]4377ZN:M+G6883HIB"6 ^[_KY3J7\2,2QRQF)<("KCQ/7[/A0PV8^[
M5A+46KI_V$<@VG_50Z$9ZY.V0V70YWS)= _?\M%C1_^0+QEUZ2N^>-W $]6J
M.>9'K6/='W.74QES005**21QHI<#,E60%F:^SO1?TH@22MR(YZ\(FMHGK36$
MQWUK_]WQ#/4:HG;QN ^< G_?;?O:O9)!4E7[D/!Z''I-UK@'H#T6GQUY]ET_
M,M7;+N^[HLZE;"D_K+:;Q:I<\&I%$<\1IBSG*H%Y2G*(,AW[TYC'4# :$Q2)
M-!/9*%1OO:I.S2\=:#H#=]^^;:J2(+!HM6[V+0XXW,?B@>L?=3O/-XVQ#.P[
M_5;T'+P2.Y-]\?6,-RR3X('KU_;/P0-GC;HW'CA[B4-Y3)K>[77 6[<XV3Z5
M<_VM11G" F*928A24N@0-8M@K$1$1%00KJQX0_L$36XJJ%D]&F7!3EM0J^M*
M=G(%W?YEJ"_, KO<H7 -8$3IQN)F=I0KCQ^9*:7;R'/6E)[KA\6H.R*U7ZMV
M;)6#^N=B^_VWU9J5<O-<NZ''IVWY61K+%LM%Y<_TG[0Z6HN?:;DH=[QL?Z>+
MU2_KLORPXLLG89*7W]'-2E]6S@6.<IIF'!81QQ 1D4.<I054453$,D,YSJSV
MM$;7?&INZ_V.KA)0\;^?RJVQW"U&'6_4[4+628YE8'>ZYX2<@0.SP1_:;G!H
M.*@M!\>FS\#.>%!9/SLDG#0(@)\,!G\!+0JF6KW%P5]8._K0^8QRQU-^U*!W
M]#$YC8''5V!(4;%DVT\;^5B'X'5=_=<_UDU:$"(X804W;4)%"A&NVMKKH#CC
MBA**\S2S:^S1+VIJ\\L7,R3"'#HLGK4XZM2HN!O4[MG +U2A#V<,R<!>T;8W
MD%9U4*%R)VPN=<N^X!NKC/DJC+[*FFT Z:YR[GS"B$7/-I8<UT!;W3$X[VV_
MN;$2G^5V4?OYP;PB#D^<D!_8JPE^EBNI%MLPC7P&H.,Y]<I:_-A96:ZX7$C8
M<G[$L(_FLUR:RKI/)A/^ZX9JF7S70*^(&1,X97IIG.OU<58HB"E6,".12M-$
M2"*<",<[9$TMXFA4!96NX$!9IP(5&Y#M/)$GZ()[GH&H.?L>"SQ\^IHN<:/Z
M%@N[3WV)S2TW-")LET0+60Z>9_L?-*&7O&:$/= V-+&7/3K>F^9U2QV_<9X5
M"A>;Y]G=.9R[;D^N^M5L)<PIS11*4 (3G"00\11#AG@"9802&2=Q5A1.Z1 7
M9$QMSOS"OTOQM)2F]<0OZ]4WN#6E/]5RZI!1^?=*><<9]!+$=K[E1N!")PWX
MP6P06> 55'PS!9Z*&9TF\(J=ES@"KUWJE:/KP^I9EMLC\IS=?!DE19QQ)&&<
M(P61D P22DW1%B^H_OM<4:>&F>XJ3,VK5)12:KG^HP1F>,&B5=TW75?7L-BY
MFK!@!_9$/?1=.R,.Z+N"1#O#01R!T:M+BRDP>UF@9,GP9?.DF\M3JZRCLJ[[
MFXLDC2E%R#0NB@V%:@(9CDW7X#1&*I<)1T.K5 _E3,Z_U:6095T*61>>5KF>
M=9VJ8ZKG-7"M]SMOA2RPESHN'*V5#%HY>@F'0 6D1Z)>JX[TDKT=Y:07+Q_H
M%[07NEL)\R_3K^*9+DWH>Z>]TV;SHAU17?HL<\8CFFG?$&$&$4USR 1/(2I$
M3B*1TRQUVI.TDCHYGV'F:5-97I&9RKW>CL[""G%+U^$;Q]".I(6P^N% Y:J.
MO]7:=\:U$TI>W8R5X'&=C@L69R[(Z>9A#ND@4Z3*#/F\*/_K_4;*E@/L,]W*
MYC@\SE*<,!7!A*=ZV:8(AD2@'"J6YP66-,LCY.*5[$5/S3493:'2JIKZE9K;
M;J.5=7-,#LC;>:<P> 9V48<I>)76,V#T!D;Q/7.@4;T_O\/94[DCYM-=.4@?
MU6>YHW+JN 8\84 BV:F4NJQX\=]2_&.]I-LJA:WY@#*2$Y[D>A1D&D&DXROM
MNB(,BYQSFJ"B8,*J?:RCW*GYK;VFX'FGJD.ZE /BW2XK(([C^ZL#5/>*#\E&
M<X#7(34M#,PCY:G9PNTI:\T=J\X4-H?'C9?/YF[C47+;@-L'^/9P72#O]VQF
M_Y2+;]^W4MP]RPW])C_+![HPZ<W_J#<%FT9^>59D12(%Q%3HN8,PHG\J8E@0
ME4J&,8X=:"ZG8]?4YJ96:4!KK<&F51NTF_(]/?\F_199S(?3T79"\^UX#8_O
M#VD.=V]C@Q/8 07^\7_!V^@0/DQ'ZPF&)W_:M],M+)K>.] 9=DU(W?'"N@D9
M?2ELG*!Z _-!'Z5I"KOZ]HL.A.6N5FY>R"S-56Z:I<0"(AYQ2&.:PS1-%$ED
MIC(4S;5>;&V[/WI%DHL;/)07,%FT510LC:9@V:KJMB%Z#5DB,Y)%2$))2 )1
MDB>0Q%Q'X0A'(I,XCZ53!;L'7$?K?P765[!U3@BZAJ[=WK('S ('BON7L%+Q
MH"S;8Y)R-PI>,Y.OB!HW';G;WK,<Y)[+ASE<DS%JN.--ZN*>*V[.HI0*XV\1
M-OXV5AP2D1)(%(XD22*"(Z=,FLMB)N<43.;LTKH+10^&=M_^[<@$_O2/<XH-
ML9BI5S>NH"7-^95NGS:>NW%VP^+3%UR1-*HKZ+;VU!/T7#W,$53D!/?JDWYU
MVI7=W4I\67Q;+=2"TY7I5V5:WIA(;[U<<#W:7^6/[<_:C/^:9RFB&3*[>(3$
M$*D\AE2J& HN"YRGBL:9U0F0#V6FYE0J6TQR_J$U5=[(EZ>'!]-C0O_NP#2P
MMPT\-L:Y^:.;AM+.:XTU0(%]6\?87!Z0UACPNS$'5/9X/#+W :M/WWB3/J-Z
M4!_(G?I9+\_T40_VRV(E/VSE0SFGN<B9S!#,&5$Z.$M,1QX5F0H/FD0R50K1
MX35A.SE3\Z$GU4S@=Z,IJ%2]J0IL#ZR=V_, 5V"/-@BI&VN_SG (5_^U%_6*
M-6!G]G;7@9U?/I!YVV1+?U\O]1UEO6\W+Y3,F Z]3!MSO4Q3/((XB2A,<Y3G
ME%$E(CS?FJT..W=P+L+)$^P$A=ZWJ0H;&CW_M<I>=MT.NP!FK)*81S&!42'U
MPK>(%*2,<2A%FE5MSKAD\\=JE_/+EFZV8T!Z*BY@*"2_+5;5(0>C^A?<,=_R
M IZ9C$F:YP@F"IM.M(A#JN((HBQ!$9,2\0@U>+Y;B?'0;(6%P_)=M5_N#4@L
MHS026$ ]^6.(1)% DD0I+'*LBCPM,IX5\U5%^1X61E+#>"CJ3_FEVTWVM[UK
MH4_N#Y3[U_:8\VZ[W2S8T[8BV-RN#8F*[&!1=6=[OXJ(5Y;V<RGCLJM?M?*,
M%?WZE<.F^.9H3B\ZJD>;HBCC0=ZLRVTY%RI6 B<Y1"R5IFXI@10Q!AG/"6<*
MI3'/6C?PU7X)T"5S@%?X.L)RH#WDUPOWM5*RHHOE1E_#!JM'>25KRJ"*=7;[
M758UD<:HZHZVM6=='>GF3#H'R,ZMW(SW. ZF5;/:G3**@E934*GJSZO8 .+3
MOW3*&]73V%A^ZG.L[AF2[[_YLEA]ITT&=,$%IZ204 BE5Q=*KRXP3YAV.(0A
MP6C&<RONF?-'3VUKX=?-7T&EGDLJ^1%6W9_];0@$_LAWQ@]*J#]"P25G?B@:
M8Z7%][X2CGGOE^SM3FT_NF/$[/5+FAXGJ%^\8F"Y=GUP]5[J6^C2='Z0=WIM
MIL%<?J4_WOTPB4RRX1^=YQ'.(RX2J)$2$$6QA"3&$<1,Y2+).6/8C=O!0?C4
M?-9OJX7)3_P/'?>(]8-CQ;8+Z'8132@H SN_]OBZT7M6M7R1U>E/I?L,:.U!
MHS[XJ3'@.IN&>RGW -R\5G2[R!^WL'L ,F?UW4.>,3")9I\V9@Z(SC<<*(XI
MR;3?T@NU&")3UXT+0B J4DYR'!.,8Y=]VCZ!T]RU/<BNJ[ZRV_=V>H&W<V ^
MX0SLM'XYP?!=-VKN>3>64'C-P.F3.6XNCB4"9UDYMO<-[,7,=>S[5/'P5CG:
M)M%;?SW:B2V>Y8<57S](TTWDH]S>*^W?YFF&4Y5%&20L11!13B&)D( BR3*1
M48)3'CNU:':3/[60Z4!]L*XJ0/BA 6"I=7=LY>PX(':N*"#,@3W3(<)UC<V1
M[J!6ONG?- .&+'"M3(CEL2GT,/"\]HIV5&'<%M+#\#GK+#WP,<,<7_U _9P]
MZ?(^6RTIDD0B7L""YID.K&($64H8C"C*XR1+]&+1B>RT2]C47)K6LMH(<7-;
MG7#:^2A?( 5V2(W#,8NX0WKU((E[-I#X=#.=\D;U*3:6GSH0JWMN7HH=I.*G
ME*:Y(I%)EDO,=K:"6"8QS%!&1$24C&4V</TUL)IAM$77:KV"C8+#RYLNH^J\
MN)IF?<->/QV5[#0,LJ0*7,EP4=!K+9XLZA@Z+Q[:#_Q."/UZE&_TC_>;K^L_
M5G.62\E2BB&)3?I1E.<0ISI2D"FF5,5%IFCAU@K\3,;48H-:3=#H.0-&4XTC
M,+JZM@ _![3[P_<$4^#/?A!" [I^7\7@YH;?YT\>N=?W5=/.VWQ?OW38-/_N
MX7&Y?I&RZ4QTX$F:;=\Y01GE&<U@P9GI/$92B+-"+P]BBM,,8YQ&3B5)O1*G
MY@(^R?7CTA#]U$MRWIFT,1!DNPC *W2AW4*C*VQQ.PH/WOB.#:RA\1DG] L=
M-6:PQN T?K"_<0A'6M-6YU[IV&2[H4*+X7)1=7DNJ]8N^V6SRE24H8*8RL<<
MHE@81G'%81(SFD=8"DRM]EI=!4_-Y9B-H/6JS1K3ZSM9-7AOE'<A<W( O]L'
MA80TL"O:-7:Z5Z#5^P#.MJ43L-G0N UB%T*K,%"/Q3C5 [DOQB=WD+HIF1R>
M-R)GDKN5QZ1& ^X?VL&VW&X67,\AU;&=2:\I/W_YK:4WIK%,"BXA8Z;("F<*
M$BXQQ#$F-(ESJ8C325JGM*FY]+VR319PI:YK[]HN>.UB2&^@!7;:E_$"/VE=
MR[\$(%FWPL5O']LN@2-WLK6P_;R7K<U- P+&XZ)/\Z>W4M&GY?9NNZ7\N_G+
M^\W_\R2^53^M[E8O/Z\WF_4?^B.^*TNY+;_J82I-RL!<J2*3.(I@(4BA@\K8
M;%?KR#+B19;$J10HMLIU]*S7U'Q38P?8M@J:J)/NK#*[.?^[L0M4M X5U09K
MK/N7_X&3N/A;"6AEI4/HY'&D+8+7UQF_P&[RI$Q]5O<K;0R;@;UIX'X#6N/
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MK0/JM3_+<KM9\*T4E4,S;(>_ZI5QN5VOZA#''&DN5M^:F3))F42Y*F"2R(J
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M?27^4](-^)5N38/"E\&T;:Y#9[?M%'!  L\"(XV%\W[50$1][ERYJC#J'M9
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MW,7<,WOD&33=^+<_1H$9=*,@V&@8P"6U'81A?<Y.2AK9V:S-VF,OL]:GNQ%
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M"Z@@2NEEE$4'+P= PK67[@>!GI.A!XMP;-U7Y"XQ;(P88XXPZP08F1UYR+*
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MO@S>T!*T4@1:D%Z%W&A2_;XDCEO)WAU>&^FV2]12Y$9NRODPY8GV+">A+,1
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M6E[& KG?JK!2+"NZ"=</I+.K].1#D'*_^1Y6/QW$0WNR=][D2<3"LHZ%?)Q
M+@_/ KS4"*B<01N"\[E)J?K#R!P7?$T1<Q@Z#U'?TP'GZ_G';XN:D%A-K(B8
M%$J()J::#T-PCBE@0FOCF9;,-ZEW?S"EXZ;-.X3H@4I\4BBM*=MS%GE$*PWP
M$@T%%.@A:!8!6<XUF>&B4>/B](+6<;/K?2+U,$4^):S6W.Z60Y53KH5#8'4M
MM&6>@>.:@>$B1NUC5*G)$*F'DSIN$KY+I!ZFQB<%U.G7LZ7(LRDZ^P+9;&XO
M*P9!D8<3N S<*BSJYMW\QP;J.:GCYN[[!.I!:NPU+_8LI>4I'C4-_N8C!DG?
MW$O70%D:4NNV]? \;UX79E?&+B1EO#02L*;-%2N)=(L&T$;E EI1VO2MNH>F
M8PT5/:\>!JS.7G'^!L+A6:9WNGL035 F*IXB:&;)'NMBR-W5!H)!([ESFO,F
M'N"!](Y\A7<@3-TT3X^AO"=BHP[O7KO[02WL5</^M?<A+,>$*FQ:#&1=3VJJ
MMFDK9,5[BT%XU\8#;FBU+EM0W@;\S4:I 0.O"\K[3-M_*K4'="WP\,F6&'/P
MOLFYX/XD]FN;'H*<N[N$#JJB)V*.CC@1N^-)+0Q2R].N^W 5A:=M+<:SOEHL
M)J 8+F_N?@BN"@K;I"RN@47:- T[$^O/)W+'Z**7=:?EJ=8 )0%1B0"1VV(X
M83Y(\3-\/.B-_=J6AV#@6H>V)L(>NTO?&5/OEHN"JQ6I)\PJ*V^FJQI]$H]_
MP3F%HK/GB^67!86DN)V?>SXK22H1!==0BJ>8$^NDMH :2)#2EJ2]9^HAL#J,
MC''/!%IB[1'4TD'.ZB7M3HL?2)O>K)9L7=FO+V;D6&&+#@Q<D12KV(3@G8@0
MF151R\A,:E)4^E/*QDWR#PV]-@KI &&W/<$+6XT4>@9:)5HI6BJ"/$UOF %K
MK&1&!,RA28QR)T7C)N-;(6H8!?0Z_NH?M97]?'V0UWWQNX/XV;LI&<BSWLR)
MWIGAN<2(9LH&D4 $67>>6BA14STVL6"\\#'E-F<)/R7M*"_I3*RT*C8=G7;F
MMB3?9-DE6!YK"P%/,6M@&81P9! 3IG"S9> =OM >+QNY4&=8'%QS?(:6=*]A
M^_E"/3Q]>.,)@YJ/A@G#/< CO!?::H3BN"#PR%)[0@I(13M'BB=/H\E=CG9&
MY/P-K\)T^?<P.]VV@ZN[[)77_15#?5=^.W^/B7;'K:/_^V*^//_G;V$U7=7?
MWZCV(Z;/\^E_GMY*:T5?L-91@$ZE@#(^@M<DORP#CU*B46V&OSX*=]V;OH>@
M]Z:;U!\^.G#>+X1RORPVS/]MOH@K7&X&K+Z>?SFM\YT7\T2_=2:2<QD87=N4
M4=C"Z@F]DK2;1%T2<,PYU@(D'YJT9VW!S,@UD8^T),;2_M@9N@L!U$:.:?VV
MO)ZG9:T*>;M\@=NO7L__OJ!(?7,_ZL9:3U:1&^8B+7.]F23!*48W 7S@-AL4
MKJC]$K]'D3%R+60;A#ZR=GKW9(>80G?GLP;U;A]E\MP>H.-9,YX*0MI<K]'U
M^!%IR\@>([=:"F':%-TW]W.?S\)J];:<"?SM<A/+_7Y:^[R_+1^JS=[F@,)L
MAOFW'^>*.?O@:A)8Y#EKNYV:O.G[Z)D18*/1,9@<E6U2[W0DW=W[I@]!W,V-
M^#%U.O:>NY/7UZO5*;Y;3A->_.22.\&9YMPYVC9"J;.Y$T0L'(J7W/"L-!:[
MUS[[X%=W[_T= KI'T$('D<T#E]3+D#Y?_^S$DSB],9$,&2J2K4T03 R 28IB
M/2NL-*F&/)KR[CW"1S251^JU5R"__([+-%W=M5CY)$CK#&,.3&T,H3C6B2]:
MU4QQ\DPGIFX6I30$[\^H'?F2S B '51_O8+T[>EZM0[S.H=HPE&84"]/<%?O
M3SJ2H,_>@Q71H,],J_AX7N<5PD:^]C("] [52I=^X[GA/U]/^>WRU6)9<+K&
M/)$L%QL2KQ7Q-0,0ZAUS$:'(G#/C6EJ4A_N-][UZW"94C^XW#J:%+C'V>KY>
M3N>K:=KDHB9%"^YDD* 0-P-)(_AB+63B@^N0I-$_S<7L^[)Q&TX]?OQQN*1[
MS^!=/7TZ/=ETS#^FGGR?QPZ:U]N;_L=+\5FO@O7"@U)H*T8<!:39T@Y6-&JM
M%8]->@&/E.+;3O+S7&2*O1F(8 VHDCWXX#7$DF2IM\YLF[.UNTGJ/C'W$)SL
MY4$]7!,=>.AGYWJUGGYS?'<QK-8FY[,A%K"$.@=(*G!9<C!.A6!*<=DUZ>E^
M%T'CXFDHA2\:2+]3%)V-JRVY1%^X @SU_FE,)!YB )S3*'V@GY8F=_+N)FE<
M) VC\CUP=(#\.T32^^GJGZ^6B.0#(FEJ,Z/L;'IQ)I--"\U#DIM9!L5#%$Q"
M$1Y3":E(WJ2.?'\2^T/:(:#X"=8&TM#8,=Y-MI[-YZ=A-OTOS)>E!&=LN>A8
MYI:!+H8L/J8,P7,.2#\(*++Q,?W,4W_@.\<]<1H822WEW:$)J^/*TAKSB^G7
M::8@Z,H"D58EE8RB9<%I@4C)@!:, 1N%3L4)G5V3<H3]21SWT.B13-A &NH
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MU,$GI8INLUQY6#[&Q7!_$>*8,.G 2C:<Y?1DW6:")M5WX*;N\8AD^Y&#BZP
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M0$D7P>E(HLZ\&,&M+JR)^QV&_'&]<I.8<P2]=A" /L7U'::W:@F3:+,L*69
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M*C$&(5H2D8I6)%>2DJ=,]G<^$MO-<.DEN]];/?TB;6.)16GA2^&0@Q2@0O:
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M-)GS.9PB-<YU,!G8SIK)BZ/%-$NFT51=:WB_ACW8CJ$=V!R3+(?7+C(X;CC
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MGK[\[?+)Z[>O+O_\IQ<G+X]/CH].GA^=GHQ.^4O^WZ&0+__OM')WV)5^,JY
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M$SW42[A(L1UTBL('S:*,9M#;J0W#V%>-(E0Y\KJ\A=[AN@$'#:9GPMM8>GP
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M6+1<B7X2?LF:D.2),P8I,S%&/W#()!F(HV[O3O;^J<QK#PN5\;*#312P#L.
MGEBQJ?.JIF+/^-]YA;G#"85B),<7]67*/2/M%]=P42)9 .)O.9/?YNO[Z/!
M?K'Z'$<U)GM**-M%]AV7CJ0\3]I:Y5@>_8K3"X1K U6.VBLU0C][W)B82P]'
M\@_&%'\2*F:+!KP*25,@QN5O@J.^CS$_-%IMB.UGJ%: Y-K9=#8X6D3\M11^
M'5QV@E#SE'2AY7@T82T-9-=A@#H_%(I+4("I8<4G4&C" L),97E_6/SRJ20"
MB(+>V# .9$6'O*P2? +-Y2G\YUI4?-)LKD5<L(BJ,>^%DE0Z,)<N)&75%*X
MX=T L1O>8[<%ZOUBA59WL]X78N_!>>Y456%B,4^[D;.85B^I#+V=19Q8MU^
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M.$':U&&W-9<7%A*S$8@3"9PD2S.KK77J2[M=V9V_6;UK)4L3UJDQ.TT<W60
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ME@.&T@K;NO: YY*"@B$-[Q6L$1,)/&'+A00%P?>5;I8<3Y()P[?8 6!)"FS
M]S)NM\?IA"[#6WN<3HY&+SX# .ST?/3\^6:^H=LV^^*>H5J;1?(?A2%_D]G+
M>VIS.7NO>ES'4+LW1]>V#>KK6;*-!H7%+'7UV1PP+VY266@@*.:Y@&<:_:Y
MH7L$8S)WV5>_^>3V)35R#MW$<')D^K<?\8Z-^'YW\&<[D\/C^<5">FU%D2UV
M7F\VIO4H$AO0[N6,(3B$*R^90'&S\$MV&./#P: [Q!%84^FC*_/822^15#<N
MK60*%C\_.3Y_6:\RVV_C[][FM?"MF)B&[\RV@6E'A)DK-+!FUKU:5IO,.WDW
MEVCV#B ?=_4$O],SJA3Z%1WAP#G%]&DP!]HO3V&H')BV2$C@!K*P#J0L26W
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M!>R8)C+'C!QBJ5=;X8"$Q<$D</4%O)!C56=U/%!E$]?7:A"/!P7TH(R.KZ@
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M%X.:Q-MX+2XK.9MCU%G@ D1]!E20^N$I?8<5 #K[!Q2):>7B=915(AL.I42
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M>S?90]P6B@X.>GVV;U\,:],;J<];MI<O6*SY2S7$FN<+1D2;XU8/74#6<C^
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MJ[*^KM_'\V"C_GQ93<._O@%02P$"% ,4    " "V0UE2J;<!F*D"  #*!@
M'@              @ $     8V]N<V5N=&QE='1E<BUF>3(P=G)P7W-X-'@N
M:'1M4$L! A0#%     @ MD-94DY1ZXLH"   @R<   X              ( !
MY0(  &5X:&EB:70S,3$N:'1M4$L! A0#%     @ MD-94C@7UIH<"   E2<
M  X              ( !.0L  &5X:&EB:70S,3(N:'1M4$L! A0#%     @
MMD-94K*K3_P*!0  J!0   X              ( !@1,  &5X:&EB:70S,C$N
M:'1M4$L! A0#%     @ MD-94H2[7!C]!   XA0   X              ( !
MMQ@  &5X:&EB:70S,C(N:'1M4$L! A0#%     @ MD-94K -14_:'P  6-<
M !X              ( !X!T  &YO;BUE>&5C=71I8V5D:7)E8W1O<F%P<&]I
M+FAT;5!+ 0(4 Q0    ( +9#65(_,0R+_!   +,S   <              "
M ?8]  !S=F(M9FER<W1A;65N9&UE;G1T;VQO86XN:'1M4$L! A0#%     @
MMD-94E16'?.I,P, D?09 !$              ( !+$\  '9R;F$M,C R,#$R
M,S$N:'1M4$L! A0#%     @ MD-94CF7M;:R$   AJT  !$
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M2P$"% ,4    " "V0UE25G>ZTZ/K   %'P$ %               @ $6T 0
M=G)N82TR,#(P,3(S,5]G,BYJ<&=02P$"% ,4    " "V0UE2\6#:G0FG 0!"
M!@( %               @ 'KNP4 =G)N82TR,#(P,3(S,5]G,RYJ<&=02P$"
M% ,4    " "V0UE2I6IF\(*8  !M_   %               @ $F8P< =G)N
M82TR,#(P,3(S,5]G-"YJ<&=02P$"% ,4    " "V0UE28=_?R+28 0"( @(
M%               @ ':^P< =G)N82TR,#(P,3(S,5]G-2YJ<&=02P$"% ,4
M    " "V0UE2;\U4[_G6 0"\40( %               @ ' E D =G)N82TR
M,#(P,3(S,5]G-BYJ<&=02P$"% ,4    " "V0UE2YN!SHG;7  !M%0D %0
M            @ 'K:PL =G)N82TR,#(P,3(S,5]L86(N>&UL4$L! A0#%
M  @ MD-94NH+K!.'>0  -8L% !4              ( !E$,, '9R;F$M,C R
M,#$R,S%?<')E+GAM;%!+ 0(4 Q0    ( +9#65(O(<>Q;7P  %2S P >
M          "  4Z]# !V<FYA+61E<V-R:7!T:6]N;V9S96-U<FET:2YH=&U0
52P4&     !0 %  T!0  ]SD-

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
